PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Nalvarte, I; Damdimopoulos, AE; Nystom, C; Nordman, T; Miranda-Vizuete, A; Olsson, JM; Eriksson, L; Bjornstedt, M; Arner, ESJ; Spyrou, G				Nalvarte, I; Damdimopoulos, AE; Nystom, C; Nordman, T; Miranda-Vizuete, A; Olsson, JM; Eriksson, L; Bjornstedt, M; Arner, ESJ; Spyrou, G			Overexpression of enzymatically active human cytosolic and mitochondrial thioredoxin reductase in HEK-293 cells - Effect on cell growth and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE INSERTION-SEQUENCE; ALTERNATIVE SPLICING VARIANT; MAMMALIAN THIOREDOXIN; GLUTATHIONE-PEROXIDASE; REDOX REGULATION; BINDING PROTEIN; LEUKEMIA-CELLS; RNA; MECHANISM; EXPRESSION	The mammalian thioredoxin reductases (TrxR) are selenoproteins containing a catalytically active selenocysteine residue ( Sec) and are important enzymes in cellular redox control. The cotranslational incorporation of Sec, necessary for activity, is governed by a stem-loop structure in the 3'-untranslated region of the mRNA and demands adequate selenium availability. The complicated translation machinery required for Sec incorporation is a major obstacle in isolating mammalian cell lines stably overexpressing selenoproteins. In this work we report on the development and characterization of stably transfected human embryonic kidney 293 cells that overexpress enzymatically active selenocysteine-containing cytosolic TrxR1 or mitochondrial TrxR2. We demonstrate that the overexpression of selenium-containing TrxR1 results in lower expression and activity of the endogenous selenoprotein glutathione peroxidase and that the activity of overexpressed TrxRs, rather than the protein amount, can be increased by selenium supplementation in the cell growth media. We also found that the TrxR-overexpressing cells grew slower over a wide range of selenium concentrations, which was an effect apparently not related to increased apoptosis nor to fatally altered intracellular levels of reactive oxygen species. Most surprisingly, the TrxR1- or TrxR2-overexpressing cells also induced novel expression of the epithelial markers CK18, CK-Cam5.2, and BerEP4, suggestive of a stimulation of cellular differentiation.	Karolinska Inst, Ctr Biotechnol, Novum, Dept Biosci, SE-14157 Huddinge, Sweden; Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Pathol, Dept Lab Med, SE-14186 Huddinge, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Acad Athens, Inst Biomed Res, Athens 11527, Greece	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Academy of Athens	Spyrou, G (corresponding author), Karolinska Inst, Ctr Biotechnol, Novum, Dept Biosci, SE-14157 Huddinge, Sweden.	giannis.spyrou@cbt.ki.se	Nalvarte, Ivan/V-3849-2019; Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012; IBIS, REDOX/J-7473-2017; Miranda-Vizuete, Antonio/D-6927-2012	Nalvarte, Ivan/0000-0001-6828-2583; Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114; Miranda-Vizuete, Antonio/0000-0002-6856-5396; Damdimopoulos, Anastasios/0000-0003-4425-1189				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; BEHNE D, 1993, AM J CLIN NUTR, V57, P310, DOI 10.1093/ajcn/57.2.310S; Berry MJ, 2002, METHOD ENZYMOL, V347, P17; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Copeland PR, 2001, BIOFACTORS, V14, P11, DOI 10.1002/biof.5520140103; Damdimopoulos AE, 2004, J BIOL CHEM, V279, P38721, DOI 10.1074/jbc.M402753200; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Ding SJ, 2004, PROTEOMICS, V4, P982, DOI 10.1002/pmic.200300653; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; Fletcher JE, 2001, RNA, V7, P1442; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 2002, J BIOL CHEM, V277, P9701, DOI 10.1074/jbc.M109234200; HAINAUT P, 1993, CANCER RES, V53, P4469; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Karimpour S, 2002, ONCOGENE, V21, P6317, DOI 10.1038/sj.onc.1205749; Kim MR, 2003, BIOCHEM BIOPH RES CO, V304, P119, DOI 10.1016/S0006-291X(03)00547-3; Koishi R, 1997, J BIOL CHEM, V272, P2570; Krol A, 2002, BIOCHIMIE, V84, P765, DOI 10.1016/S0300-9084(02)01405-0; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7; Lescure A, 2002, CURR PROTEIN PEPT SC, V3, P143, DOI 10.2174/1389203023380783; Low SC, 2000, EMBO J, V19, P6882, DOI 10.1093/emboj/19.24.6882; Ma XR, 2002, J BIOL CHEM, V277, P22460, DOI 10.1074/jbc.M202286200; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Miranda-Vizuete A, 2002, MOL CELLS, V13, P488; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Muller C, 2003, BIOL CHEM, V384, P11, DOI 10.1515/BC.2003.002; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nalvarte I, 2004, FREE RADICAL BIO MED, V36, P1270, DOI 10.1016/j.freeradbiomed.2004.02.072; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Oertel Martin, 1993, American Journal of Clinical Nutrition, V57, p313S, DOI 10.1093/ajcn/57.2.313S; Patenaude A, 2004, J BIOL CHEM, V279, P27302, DOI 10.1074/jbc.M402496200; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Powis G, 1997, ONCOL RES, V9, P303; Rundlof AK, 2004, FREE RADICAL BIO MED, V36, P641, DOI 10.1016/j.freeradbiomed.2003.12.004; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakurai A, 2004, J CELL PHYSIOL, V198, P22, DOI 10.1002/jcp.10377; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Schutze N, 1999, BIOFACTORS, V10, P329, DOI 10.1002/biof.5520100403; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Soini Y, 2001, CLIN CANCER RES, V7, P1750; Spyrou G, 1996, CANCER RES, V56, P4407; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; Sun XJ, 2000, DIFFERENTIATION, V66, P181, DOI 10.1111/j.1432-0436.2000.660404.x; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Walczak R, 1996, RNA, V2, P367; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Xia L, 2003, J BIOL CHEM, V278, P2141, DOI 10.1074/jbc.M210456200; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Zavacki AM, 2003, MOL CELL, V11, P773, DOI 10.1016/S1097-2765(03)00064-9; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	75	53	54	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54510	54517		10.1074/jbc.M408494200	http://dx.doi.org/10.1074/jbc.M408494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471857	hybrid			2022-12-25	WOS:000225793600075
J	Pei, ZT; Fraisl, P; Berger, J; Jia, ZZ; Forss-Petter, S; Watkins, PA				Pei, ZT; Fraisl, P; Berger, J; Jia, ZZ; Forss-Petter, S; Watkins, PA			Mouse very long-chain acyl-CoA synthetase 3/fatty acid transport protein 3 catalyzes fatty acid activation but not fatty acid transport in MA-10 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; PHOSPHOLIPID-BILAYERS; BETA-OXIDATION; CDNA CLONING; FLIP-FLOP; FAMILY; RAT; BUBBLEGUM; MEMBRANE; EXPRESSION	The family of proteins that includes very long-chain acyl-CoA synthetases (ACSVL) consists of six members. These enzymes have also been designated fatty acid transport proteins. We cloned full-length mouse Acsvl3 cDNA and characterized its protein product ACSVL3/fatty acid transport protein 3. The predicted amino acid sequence contains two highly conserved motifs characteristic of acyl-CoA synthetases. Northern blot analysis revealed that the mouse Acsvl3 mRNA is highly expressed in adrenal gland, testis, and ovary, with lower expression in the brain of adult mice. A developmental Northern blot revealed that Acsvl3 mRNA levels were significantly higher in embryonic mouse brain (embryonic days 12-14) than in newborn or adult mice, suggesting a possible role in nervous system development. Immunohistochemistry revealed high ACSVL3 expression in adrenal cortical cells, spermatocytes and interstitial cells of the testis, theca cells of the ovary, cerebral cortical neurons, and cerebellar Purkinje cells. Endogenous ACSVL3 was found primarily in mitochondria of MA-10 and Neuro2a cells by both Western blot analysis of subcellular fractions and immunofluorescence analysis. In MA-10 cells, loss-of-function studies using RNA interference confirmed that endogenous ACSVL3 is an acyl-CoA synthetase capable of activating both long-chain (C16:0) and very long-chain (C24:0) fatty acids. However, despite decreased acyl-CoA synthetase activity, initial rates of fatty acid uptake were unaffected by knockdown of Acsvl3 expression in MA-10 cells. These studies cast doubt on the designation of ACSVL3 as a fatty acid transport protein.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Res Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Med Univ Vienna, Ctr Brain Res, A-1090 Vienna, Austria	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Medical University of Vienna	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Res Inst, 707 N Broadway, Baltimore, MD 21205 USA.	watkins@kennedykrieger.org	Berger, Johannes/A-9122-2014	Berger, Johannes/0000-0003-0182-2658; Watkins, Paul A./0000-0002-3246-1405	NICHD NIH HHS [HD24061] Funding Source: Medline; NINDS NIH HHS [NS37355] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Berger J, 1998, FEBS LETT, V425, P305, DOI 10.1016/S0014-5793(98)00255-5; Berger J, 1998, BIOCHEM BIOPH RES CO, V247, P255, DOI 10.1006/bbrc.1998.8770; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Fraisl P, 2004, BIOCHEM J, V377, P85, DOI 10.1042/BJ20031062; Gould SJ., 2001, METABOLIC MOL BASES, P3181; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Hui T.Y., 1997, FRONT BIOSCI, V2, P222; Jia ZZ, 2004, MOL GENET METAB, V83, P117, DOI 10.1016/j.ymgme.2004.06.015; Kamp F, 2003, J BIOL CHEM, V278, P7988, DOI 10.1074/jbc.M206648200; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mashek DG, 2004, J LIPID RES, V45, P1958, DOI 10.1194/jlr.E400002-JLR200; Mihalik SJ, 2002, J BIOL CHEM, V277, P24771, DOI 10.1074/jbc.M203295200; Min KT, 1999, SCIENCE, V284, P1985, DOI 10.1126/science.284.5422.1985; Moriya-Sato A, 2000, BIOCHEM BIOPH RES CO, V279, P62, DOI 10.1006/bbrc.2000.3897; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pei ZT, 2003, J BIOL CHEM, V278, P47070, DOI 10.1074/jbc.M310075200; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Spector D. L., 1998, CELLS LAB MANUAL; Stahl A, 2004, PFLUG ARCH EUR J PHY, V447, P722, DOI 10.1007/s00424-003-1106-z; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Steinberg SJ, 2000, J BIOL CHEM, V275, P35162, DOI 10.1074/jbc.M006403200; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; Trotter PJ, 1996, J LIPID RES, V37, P336; Uchida Y, 1996, J BIOCHEM, V119, P565; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; *US NAT RES COUNC, 1996, NIH GUID CAR US LAB; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Wanders R.J., 2001, METABOLIC MOL BASES, P3219; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; Watkins PA, 1999, PROSTAG LEUKOTR ESS, V60, P323, DOI 10.1016/S0952-3278(99)80007-6; WATKINS PA, 1995, AM J HUM GENET, V57, P292; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2	47	58	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54454	54462		10.1074/jbc.M410091200	http://dx.doi.org/10.1074/jbc.M410091200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15469937	hybrid			2022-12-25	WOS:000225793600068
J	Shahied, LS; Tang, Y; Alpaugh, RK; Somer, R; Greenspon, D; Weiner, LM				Shahied, LS; Tang, Y; Alpaugh, RK; Somer, R; Greenspon, D; Weiner, LM			Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN FV; METASTATIC BREAST-CANCER; NON-HODGKINS-LYMPHOMA; FC-GAMMA-RIII; ANTI-CD20 MONOCLONAL-ANTIBODY; IN-VIVO; PHASE-I; NK CELLS; 1ST-LINE TREATMENT; CHEMOTHERAPY	Unconjugated monoclonal antibodies have emerged as important therapeutic agents for selected malignancies. One mechanism by which antibodies can exert cytotoxic effects is antibody-dependent cellular cytotoxicity (ADCC). In an effort to increase the efficiency of ADCC at tumor sites, we have focused on the construction of bispecific antibodies specific for the tumor antigen HER2/neu and the FcgammaRIII-activating receptor (CD16) found on NK cells, mononuclear phagocytes, and neutrophils. Here, we describe the production of bispecific minibodies in two distinct binding formats. The parent minibody was constructed such that the IgG1 C(H)3 constant domain serves as the oligomerization domain and is attached to an anti-CD16 and an anti-HER2/neu single-chain Fv via 19- and 29-amino acid linkers, respectively. This molecule can be expressed in mammalian cells from a dicistronic vector and has been purified using sequential affinity purification techniques. Analysis by surface plasmon resonance shows that the bispecific minibody can bind to HER2/neu and CD16, both individually and simultaneously. Furthermore, cytotoxicity studies show that the minibody can induce significant tumor cell lysis at a concentration as low as 20 nM. A trimeric, bispecific minibody (TriBi) that binds dimerically to HER2/neu and monomerically to CD16 induces equivalent cytotoxicity at lower antibody concentrations than either the parent minibody or the corresponding single-chain dimer. Both minibody constructs are stable in mouse and human serum for up to 72 h at 37degreesC. These minibodies have the potential to target solid tumors and promote tumor lysis by natural killer cells and mononuclear phagocytes.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Weiner, LM (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Louis.Weiner@fccc.edu	Alpaugh, R. Katherine/AAO-6697-2021	Alpaugh, R. Katherine/0000-0002-6775-5323	NCI NIH HHS [CA009035, CA07125, CA50633] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050633] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS GP, 1993, CANCER RES, V53, P4026; Adams GP, 1998, BRIT J CANCER, V77, P1405, DOI 10.1038/bjc.1998.233; Atwell JL, 1999, PROTEIN ENG, V12, P597, DOI 10.1093/protein/12.7.597; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Clark JI, 1997, CANCER IMMUNOL IMMUN, V44, P265, DOI 10.1007/s002620050382; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Coiffier B, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.32749; Curnow RT, 1997, CANCER IMMUNOL IMMUN, V45, P210, DOI 10.1007/s002620050435; DEPALAZZO IG, 1990, CANCER RES, V50, P7123; Figlin R, 2002, P AN M AM SOC CLIN, V21, P35; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Goldstein J, 1997, J IMMUNOL, V158, P872; Heijnen I A, 1997, Int Rev Immunol, V16, P29, DOI 10.3109/08830189709045702; HOMBACH A, 1993, INT J CANCER, V55, P830, DOI 10.1002/ijc.2910550523; HSIEHMA ST, 1992, CANCER RES, V52, P6832; Hu SZ, 1996, CANCER RES, V56, P3055; James ND, 2001, BRIT J CANCER, V85, P152, DOI 10.1054/bjoc.2001.1878; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; Kortt AA, 2001, BIOMOL ENG, V18, P95, DOI 10.1016/S1389-0344(01)00090-9; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P105, DOI 10.1002/eji.1830170118; Le Gall F, 1999, FEBS LETT, V453, P164, DOI 10.1016/S0014-5793(99)00713-9; Leonard JP, 2002, SEMIN ONCOL, V29, P81, DOI 10.1053/sonc.2002.30149; LI S, 1986, J IMMUNOL, V137, P3378; Lundin J, 2002, BLOOD, V100, P768, DOI 10.1182/blood-2002-01-0159; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; McCall AM, 1999, MOL IMMUNOL, V36, P433, DOI 10.1016/S0161-5890(99)00057-7; McCall AM, 2001, J IMMUNOL, V166, P6112, DOI 10.4049/jimmunol.166.10.6112; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; OEGEN JG, 2002, NAT IMMUNOL, V3, P611; PERISIC O, 1994, STRUCTURE, V2, P1217, DOI 10.1016/S0969-2126(94)00123-5; Pullarkat V, 1999, CANCER IMMUNOL IMMUN, V48, P9, DOI 10.1007/s002620050543; RENNER C, 1995, EUR J IMMUNOL, V25, P2027, DOI 10.1002/eji.1830250734; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; Schiedt K., 1995, ISOLATION ANAL, V1A, P81; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; Schoonjans R, 2001, BIOMOL ENG, V17, P193, DOI 10.1016/S1389-0344(01)00066-1; SCONOCCHIA G, 1994, J IMMUNOL, V153, P5473; SEGAL DM, 1988, CANCER INVEST, V6, P83, DOI 10.3109/07357908809077031; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAVINCHIORINI DC, 1993, INT J CANCER, V53, P97, DOI 10.1002/ijc.2910530119; STEPLEWSKI Z, 1983, SCIENCE, V221, P865, DOI 10.1126/science.6879183; Sulica A, 2001, Int Rev Immunol, V20, P371, DOI 10.3109/08830180109054414; TITUS JA, 1987, J IMMUNOL, V139, P3153; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; VALONE FH, 1995, J CLIN ONCOL, V13, P2281, DOI 10.1200/JCO.1995.13.9.2281; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; WEINER GJ, 1994, J IMMUNOL, V152, P2385; WEINER LM, 1995, CANCER RES, V55, P4586; Weiner LM, 1996, CANCER IMMUNOL IMMUN, V42, P141, DOI 10.1007/s002620050264; WEINER LM, 1993, CANCER RES, V53, P94; WEINER LM, 1993, J IMMUNOL, V151, P2877; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Xie ZG, 2003, BIOCHEM BIOPH RES CO, V311, P307, DOI 10.1016/j.bbrc.2003.09.211; Yusa S, 2002, J IMMUNOL, V168, P5047, DOI 10.4049/jimmunol.168.10.5047	62	97	117	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53907	53914		10.1074/jbc.M407888200	http://dx.doi.org/10.1074/jbc.M407888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471859	hybrid			2022-12-25	WOS:000225793600003
J	Neuendorf, E; Weber, A; Saalmueller, A; Schatzl, H; Reifenberg, K; Pfaff, E; Groschup, MH				Neuendorf, E; Weber, A; Saalmueller, A; Schatzl, H; Reifenberg, K; Pfaff, E; Groschup, MH			Glycosylation deficiency at either one of the two glycan attachment sites of cellular prion protein preserves susceptibility to bovine spongiform encephalopathy and scrapie infections	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE NEUROBLASTOMA-CELLS; CULTURED-CELLS; STRAIN VARIATION; RESISTANT PRP; LINKED GLYCOSYLATION; MOLECULAR ANALYSIS; MASS-SPECTROMETRY; N-GLYCOSYLATION; TRANSGENIC MICE; CONVERSION	The conversion into abnormally folded prion protein (PrP) plays a key role in prion diseases. PrPC carries two N-linked glycan chains at amino acid residues 180 and 196 ( mouse). Previous in vitro data indicated that the conversion process may not require glycosylation of PrP. However, it is conceivable that these glycans function as intermolecular binding sites during the de novo infection of cells on susceptible organisms and/or play a role for the interaction of both PrP isoforms. Such receptor-like properties could contribute to the formation of specific prion strains. However, in earlier studies, mutations at the glycosylation sites of PrP led to intracellular trafficking abnormalities, which made it impossible to generate PrP glycosylation-deficient mice that were susceptible to bovine spongiform encephalopathy (BSE) or scrapie. We have now tested more than 25 different mutations at both consensus sites and found one nonglycosylated (T182N/T198A) and two monoglycosylated (T182N and T198A) mutants that rather retained authentic cellular trafficking properties. In vitro all three mutants were converted into PrPres. PrP mutant T182N/T198A also provoked a strong dominant-negative inhibition on the endogenous wild type PrP conversion reaction. By using the two monoglycosylated mutants, we generated transgenic mice overexpressing PrPC in their brains at levels of 2 - 4 times that of nontransgenic mice. Most interestingly, such mice proved readily susceptible to a challenge with either scrapie ( Chandler and Me7) or with BSE. Incubation times were comparable or in some instances even significantly shorter than those of nontransgenic mice. These data indicate that diglycosylation of PrPC is not mandatory for prion infection in vivo.	Fed Res Ctr Virus Dis Anim, Inst Novel & Emerging Infect Dis, Boddenblick 5A, D-17943 Greifswald, Isle Of Riems, Germany; Fed Res Ctr Virus Dis Anim, Inst Immunol, D-72076 Tubingen, Germany; Tech Univ Munich, Inst Virol, D-80802 Munich, Germany; Johannes Gutenberg Univ Mainz, Centralized Anim Facil, D-55101 Mainz, Germany	Technical University of Munich; Johannes Gutenberg University of Mainz	Groschup, MH (corresponding author), Fed Res Ctr Virus Dis Anim, Inst Novel & Emerging Infect Dis, Boddenblick 5A, D-17943 Greifswald, Isle Of Riems, Germany.	martin.groschup@rie.bfav.de	Schatzl, Hermann/G-4958-2011; Saalmüller, Armin/AAN-9058-2020	Saalmuller, Armin/0000-0002-7703-3252; Schatzl, Hermann/0000-0003-4972-8740				Ali BRS, 2000, GLYCOBIOLOGY, V10, P383, DOI 10.1093/glycob/10.4.383; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Caughey B, 1999, MOL BIOTECHNOL, V13, P45, DOI 10.1385/MB:13:1:45; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DeArmond SJ, 1999, J NEUROPATH EXP NEUR, V58, P1000, DOI 10.1097/00005072-199909000-00010; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FUKUSHIMA Y, 1995, BIOCHEM J, V310, P553, DOI 10.1042/bj3100553; GROSCHUP MH, 1993, J GEN VIROL, V74, P1451, DOI 10.1099/0022-1317-74-7-1451; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Herrmann LM, 1998, NEUROREPORT, V9, P2457, DOI 10.1097/00001756-199808030-00006; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Holscher C, 1998, J VIROL, V72, P1153; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KASCSAK RJ, 1985, J GEN VIROL, V66, P1715, DOI 10.1099/0022-1317-66-8-1715; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Korth C, 2000, J GEN VIROL, V81, P2555, DOI 10.1099/0022-1317-81-10-2555; KOZAK SL, 1990, J VIROL, V64, P3500, DOI 10.1128/JVI.64.7.3500-3508.1990; Kuczius T, 1998, J INFECT DIS, V178, P693, DOI 10.1086/515337; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200; LYNCH CM, 1991, J VIROL, V65, P3887, DOI 10.1128/JVI.65.7.3887-3890.1991; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McFarlane I, 2000, NEUROREPORT, V11, P1543, DOI 10.1097/00001756-200005150-00035; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NEARY K, 1991, J VIROL, V65, P1031, DOI 10.1128/JVI.65.2.1031-1034.1991; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; Priola SA, 1999, BIOMED PHARMACOTHER, V53, P27, DOI 10.1016/S0753-3322(99)80057-2; PRIOLA SA, 1995, J VIROL, V69, P7754, DOI 10.1128/JVI.69.12.7754-7758.1995; PRIOLA SA, 1994, J VIROL, V68, P4873, DOI 10.1128/JVI.68.8.4873-4878.1994; Priola SA, 2001, EMBO J, V20, P6692, DOI 10.1093/emboj/20.23.6692; Roberts SJ, 1998, ARCH BIOCHEM BIOPHYS, V351, P227, DOI 10.1006/abbi.1997.0551; ROBERTSON MN, 1992, J VIROL, V66, P3271, DOI 10.1128/JVI.66.6.3271-3277.1992; RODRIGUEZ CG, 1995, J BIOL CHEM, V270, P25178, DOI 10.1074/jbc.270.42.25178; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Scott MR, 1997, P NATL ACAD SCI USA, V94, P14279, DOI 10.1073/pnas.94.26.14279; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stimson E, 1999, BIOCHEMISTRY-US, V38, P4885, DOI 10.1021/bi982330q; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Zulianello L, 2000, J VIROL, V74, P4351, DOI 10.1128/JVI.74.9.4351-4360.2000	68	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53306	53316		10.1074/jbc.M410796200	http://dx.doi.org/10.1074/jbc.M410796200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15448157	hybrid			2022-12-25	WOS:000225680600062
J	Rafaeloff-Phail, R; Ding, LY; Conner, L; Yeh, WK; McClure, D; Guo, HH; Emerson, K; Brooks, H				Rafaeloff-Phail, R; Ding, LY; Conner, L; Yeh, WK; McClure, D; Guo, HH; Emerson, K; Brooks, H			Biochemical regulation of mammalian AMP-activated protein kinase activity by NAD and NADH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; RAT-LIVER; GLUCOSE; SUBFAMILY; ISOFORMS; LKB1	AMP-activated protein kinase ( AMPK) serves as an energy-sensing protein kinase that is activated by a variety of metabolic stresses that lower cellular energy levels. When activated, AMPK modulates a network of metabolic pathways that result in net increased substrate oxidation, generation of reduced nucleotide co-factors, and production of ATP. AMPK is activated by a high AMP: ATP ratio and phosphorylation on threonine 172 by an upstream kinase. Recent studies suggest that mechanisms that do not involve changes in adenine nucleotide levels can activate AMPK. Another sensor of the metabolic state of the cell is the NAD/NADH redox potential. To test whether the redox state might have an effect on AMPK activity, we examined the effect of beta-NAD and NADH on this enzyme. The recombinant T172D-AMPK, which was mutated to mimic the phosphorylated state, was activated by beta-NAD in a dose-dependent manner, whereas NADH inhibited its activity. We explored the effect of NADH on AMPK by systematically varying the concentrations of ATP, NADH, peptide substrate, and AMP. Based on our findings and established activation of AMPK by AMP, we proposed a model for the regulation by NADH. Key features of this model are as follows. ( a) NADH has an apparent competitive behavior with respect to ATP and uncompetitive behavior with respect to AMP resulting in improved binding constant in the presence of AMP, and (b) the binding of the peptide is not significantly altered by NADH. In the absence of AMP, the binding constant of NADH becomes higher than physiologically relevant. We conclude that AMPK senses both components of cellular energy status, redox potential, and phosphorylation potential.	Lilly Corp Ctr, Lilly Res Labs, Endocrine Discovery Res, Indianapolis, IN 46285 USA	Eli Lilly	Rafaeloff-Phail, R (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Endocrine Discovery Res, DC0424, Indianapolis, IN 46285 USA.	PHAIL_RONIT_R@Lilly.com						Barron JT, 1999, MOL CELL BIOCHEM, V194, P283, DOI 10.1023/A:1006928516648; Beauloye C, 2001, FEBS LETT, V505, P348, DOI 10.1016/S0014-5793(01)02788-0; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Frederich M, 2002, J BIOL CHEM, V277, P1928, DOI 10.1074/jbc.M107128200; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gamble J, 1997, METABOLISM, V46, P1270, DOI 10.1016/S0026-0495(97)90229-8; Hardie D. G., 1999, ASSAY PURIFICATION P, P201; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Henin N, 1996, BBA-GEN SUBJECTS, V1290, P197, DOI 10.1016/0304-4165(96)00021-9; Kahn AM, 2002, AM J HYPERTENS, V15, P273, DOI 10.1016/S0895-7061(01)02289-0; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Makinde AO, 1998, MOL CELL BIOCHEM, V188, P49, DOI 10.1023/A:1006860104840; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SEGEL IH, 1975, ENZYME KINETICS BEHA, P330; TRUS MD, 1978, LIFE SCI, V22, P809, DOI 10.1016/0024-3205(78)90251-5; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Xavier GD, 2003, BIOCHEM J, V371, P761; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	30	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52934	52939		10.1074/jbc.M409574200	http://dx.doi.org/10.1074/jbc.M409574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465812	hybrid			2022-12-25	WOS:000225680600017
J	Rivera, MA; Blackburn, EH				Rivera, MA; Blackburn, EH			Processive utilization of the human telomerase template - Lack of a requirement for template switching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY IN-VITRO; REPEAT ADDITION PROCESSIVITY; TETRAHYMENA-TELOMERASE; RNA TEMPLATE; REVERSE-TRANSCRIPTASE; SECONDARY STRUCTURE; CHROMOSOME SEPARATION; BINDING PROTEIN; END PROTECTION; DNA	The ribonucleoprotein telomerase is a specialized reverse transcriptase minimally composed of an RNA, TER, and a protein catalytic subunit, TERT. The TER and TERT subunits of telomerase associate to form a dimeric enzyme in several organisms, including human. A small portion of TER, the template domain, is used by telomerase for the synthesis of tandem repeats of telomeric DNA. We studied some of the requirements for processive template usage by human telomerase. A blunt-ended duplex DNA primer was not utilized by telomerase. With a duplex telomeric DNA primer, a single-stranded 3' overhang with a minimum length of similar to6 bases was required for efficient priming activity. Large substitutions in the human TER templating domain did not abolish enzymatic activity, although insertion of two residues into this sequence reduced processivity, as did a template mutation that results in a mismatch between the template region used for copying DNA and the region used for alignment of the substrate primer. Finally, by using a complementary pair of catalytically inactive telomerase RNA pseudoknot mutants in combination with a marked template, we demonstrated that processive synthesis by an obligatory dimer of human telomerase does not require template switching. These results indicate that processive template usage by human telomerase, like that of Tetrahymena telomerase, is strongly dependent on the base identities in the template domain and that a dimeric human telomerase can processively utilize a single template.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Blackburn, EH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	telomer@itsa.ucsf.edu						Aigner S, 2004, RNA, V10, P1108, DOI 10.1261/rna.7400704; Autexier C, 1998, NUCLEIC ACIDS RES, V26, P787, DOI 10.1093/nar/26.3.787; AUTEXIER C, 1995, GENE DEV, V9, P2227, DOI 10.1101/gad.9.18.2227; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Bhattacharyya A, 1997, P NATL ACAD SCI USA, V94, P2823, DOI 10.1073/pnas.94.7.2823; Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Chen JL, 2003, EMBO J, V22, P304, DOI 10.1093/emboj/cdg024; Collins K, 1999, ANNU REV BIOCHEM, V68, P187, DOI 10.1146/annurev.biochem.68.1.187; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; COOKE H, 1995, TELOMERES, P219; de Lange T, 2001, SCIENCE, V292, P1075; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gavory G, 2002, NUCLEIC ACIDS RES, V30, P4470, DOI 10.1093/nar/gkf575; Gilley D, 1999, P NATL ACAD SCI USA, V96, P6621, DOI 10.1073/pnas.96.12.6621; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; Gilley D, 1996, MOL CELL BIOL, V16, P66; Grandin N, 2001, EMBO J, V20, P1173, DOI 10.1093/emboj/20.5.1173; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Lai CK, 2003, MOL CELL, V11, P1673, DOI 10.1016/S1097-2765(03)00232-6; Lai CK, 2002, GENE DEV, V16, P415, DOI 10.1101/gad.962602; LEE MS, 1993, COLD SPRING HARB SYM, V58, P707, DOI 10.1101/SQB.1993.058.01.078; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LERMAN LS, 1984, ANNU REV BIOPHYS BIO, V13, P399; Lin J, 2004, P NATL ACAD SCI USA, V101, P14713, DOI 10.1073/pnas.0405879101; Lin J, 2004, MOL BIOL CELL, V15, P1623, DOI 10.1091/mbc.E03-10-0740; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lue NF, 2004, BIOESSAYS, V26, P955, DOI 10.1002/bies.20093; Ly H, 2003, MOL CELL BIOL, V23, P6849, DOI 10.1128/MCB.23.19.6849-6856.2003; Ly H, 2003, GENE DEV, V17, P1078, DOI 10.1101/gad.1060803; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Martin-Rivera L, 2001, J BIOL CHEM, V276, P5856, DOI 10.1074/jbc.M008419200; Mason DX, 2003, MOL CELL BIOL, V23, P5606, DOI 10.1128/MCB.23.16.5606-5613.2003; MCCORMICKGRAHAM M, 1995, NUCLEIC ACIDS RES, V23, P1091, DOI 10.1093/nar/23.7.1091; Melek M, 1996, MOL CELL BIOL, V16, P3437; Moriarty TJ, 2004, MOL CELL BIOL, V24, P3720, DOI 10.1128/MCB.24.9.3720-3733.2004; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Seto AG, 2003, RNA, V9, P1323, DOI 10.1261/rna.5570803; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Tatematsu K, 1996, ONCOGENE, V13, P2265; TENDAM E, 1991, NUCLEIC ACIDS RES, V19, P6951; Tesmer VM, 1999, MOL CELL BIOL, V19, P6207; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; Wang H, 1998, EMBO J, V17, P1152, DOI 10.1093/emboj/17.4.1152; Wang H, 1997, EMBO J, V16, P866, DOI 10.1093/emboj/16.4.866; Wang LB, 2002, NUCLEIC ACIDS RES, V30, P4032, DOI 10.1093/nar/gkf513; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	74	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53770	53781		10.1074/jbc.M407768200	http://dx.doi.org/10.1074/jbc.M407768200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456773	hybrid			2022-12-25	WOS:000225680600115
J	Agniswamy, J; Lei, BF; Musser, JM; Sun, PD				Agniswamy, J; Lei, BF; Musser, JM; Sun, PD			Insight of host immune evasion mediated by two variants of group A Streptococcus Mac protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RECEPTOR; CRYSTAL-STRUCTURE; COMPLEX; BINDING; SURFACE; IGG; IDENTIFICATION	Group A Streptococcus has evolved numerous mechanisms to evade the host immune system to survive, disseminate, and cause disease. Recently a secreted protein named Mac-1 was identified and shown to enhance survival of the pathogen. A new variant of Mac-1 (designated Mac-2) also was recently described and shown to differ from Mac-1 by similar to50% amino acid sequence divergence in the middle one-third of the molecule. To gain new information about the role of Mac-1 and Mac-2 in host-pathogen interactions, solution binding experiments were performed using surface plasmon resonance and purified Mac proteins. Mac-1 bound the same lower hinge region of human IgG as Fc receptors with 2.5 muM affinity, which lead to proteolytic cleavage of the antibody. Similar K-m (6.8-18.9 muM) and k(cat) (0.02-0.13 s(-1)) values of the Mac-1 endopeptidase activity were obtained for IgG(1), IgG(2), IgG(3), and IgG(4). Mac-2 variant, in contrast, bound human IgG poorly (K-D = 16 mM) and had weak endopeptidase activity against IgG. Instead, Mac-2 bound FcgammaRII and FcgammaRIII with 5 and 75 muM affinity, respectively. This binding competitively blocked IgG from recognition by Fc receptors. Taken together, Mac proteins block immunoglobulin recognition by Fc receptors and degrade immunoglobulins, thereby enhancing survival of the pathogen through the inhibition of phagocytosis, endocytosis of IgG-opsonized particles, and antibody-dependent cell-mediated cytotoxicity. Consequently, these proteins may be potential therapeutic targets.	NIAAA, Struct Immunol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA; NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Montana State University System; Montana State University Bozeman; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine	Sun, PD (corresponding author), NIAAA, Struct Immunol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA.	psun@nih.gov		Agniswamy, Johnson/0000-0002-3053-5677; Lei, Benfang Lei/0000-0001-8133-6021				Berge A, 1997, J BIOL CHEM, V272, P20774, DOI 10.1074/jbc.272.33.20774; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dale JB, 1996, INFECT IMMUN, V64, P1495, DOI 10.1128/IAI.64.5.1495-1501.1996; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Fernie-King BA, 2001, IMMUNOLOGY, V103, P390, DOI 10.1046/j.1365-2567.2001.01249.x; Fischetti VA, 2000, GRAM-POSITIVE PATHOGENS, P11; Frank MM, 2001, NAT MED, V7, P1285, DOI 10.1038/nm1201-1285; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Lei BF, 2001, NAT MED, V7, P1298, DOI 10.1038/nm1201-1298; Lei BF, 2003, INFECT IMMUN, V71, P2881, DOI 10.1128/IAI.71.5.2881-2884.2003; Lei BF, 2002, INFECT IMMUN, V70, P6880, DOI 10.1128/IAI.70.12.6880-6890.2002; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; MUSSER JM, 1988, EMERG INFECT DIS, P185; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Perez-Caballero D, 2000, EUR J IMMUNOL, V30, P1243, DOI 10.1002/(SICI)1521-4141(200004)30:4<1243::AID-IMMU1243>3.0.CO;2-D; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Radaev S, 2001, J BIOL CHEM, V276, P16478, DOI 10.1074/jbc.M100351200; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; von Pawel-Rammingen U, 2002, EMBO J, V21, P1607, DOI 10.1093/emboj/21.7.1607	23	51	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52789	52796		10.1074/jbc.M410698200	http://dx.doi.org/10.1074/jbc.M410698200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466462	hybrid			2022-12-25	WOS:000225493400126
J	Arokium, H; Camougrand, N; Vallette, FM; Manon, S				Arokium, H; Camougrand, N; Vallette, FM; Manon, S			Studies of the interaction of substituted mutants of BAX with yeast mitochondria reveal that the C-terminal hydrophobic alpha-helix is a second ART sequence and plays a role in the interaction with anti-apoptotic BCL-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 PROTEIN FAMILY; CYTOCHROME-C; CELL-DEATH; MEMBRANE ANCHOR; INTRACELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; RELEASE; SIGNAL; PERMEABILITY; CONFORMATION	The role of the two ends of the pro-apoptotic protein BAX in its interaction with mitochondria was challenged by assaying substituted mutants in yeast cells for the ability to bind and insert into the mitochondrial membrane and to promote the release of cytochrome c. Mutations at the N-terminal end confirmed the inhibitory function of this zone, known as apoptotic regulation of targeting ( ART). On the other hand, mutations at the C-terminal end of the protein support the hypothesis that the hydrophobic helix alpha9 is not required for the insertion of BAX. In addition, three mutations ( a T174D single substitution in the helix alpha9, a K189E/K190E double substitution at the end of the protein, and a P168A mutation in the loop before alpha9) exhibited a strong binding capacity, a strong insertion, as well as high ability to induce cytochrome c release. Considering the positions of these mutations and their potential effect on the movement of helix alpha9, we propose that the C-terminal end of the protein behaves like a second ART. Also, opposite to a mutation that changes the conformation of the N-terminal ART, the mutations in the C-terminal part of the protein impaired the inhibitory effect of antiapoptotic BCL-x(L) over BAX insertion, suggesting that the conformation of the alpha9-helix plays a significant role in BAX/BCL-x(L) interaction.	Univ Bordeaux 2, CNRS, UMR5095, F-33077 Bordeaux, France; Univ Nantes, INSERM, UMR601, F-44035 Nantes, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Manon, S (corresponding author), Univ Bordeaux 2, CNRS, UMR5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	manon@ibgc.u-bordeaux2.fr	Manon, Stéphen/C-7088-2017; Vallette, Francois/N-2361-2018; Vallette, Francois M/K-9047-2015	Vallette, Francois M/0000-0002-3296-8572; Manon, Stephen/0000-0002-5792-1084; Vallette, Francois/0000-0003-0802-0519				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Clow A, 1998, EUR J BIOCHEM, V258, P19, DOI 10.1046/j.1432-1327.1998.2580019.x; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kissova I, 2000, FEBS LETT, V471, P113, DOI 10.1016/S0014-5793(00)01379-X; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; Lewis S, 1998, PROTEIN EXPRES PURIF, V13, P120, DOI 10.1006/prep.1997.0871; Ligr M, 1998, FEBS LETT, V438, P61, DOI 10.1016/S0014-5793(98)01227-7; Manon S, 2001, BIOCHEM BIOPH RES CO, V289, P1314, DOI 10.1006/bbrc.2001.6120; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Martinez-Senac MD, 2001, BIOCHEMISTRY-US, V40, P9983; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Oliver L, 2000, FEBS LETT, V487, P161, DOI 10.1016/S0014-5793(00)02330-9; Polcic P, 2003, BIOCHEM J, V374, P393, DOI 10.1042/BJ20030690; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Priault M, 1999, FEBS LETT, V443, P225, DOI 10.1016/S0014-5793(98)01661-5; Priault M, 2003, FEMS YEAST RES, V4, P15, DOI 10.1016/S1567-1356(03)00143-0; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Zha HB, 1996, MOL CELL BIOL, V16, P6494	40	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52566	52573		10.1074/jbc.M408373200	http://dx.doi.org/10.1074/jbc.M408373200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459197	hybrid			2022-12-25	WOS:000225493400103
J	Boue-Grabot, E; Toulme, E; Emerit, MB; Garret, M				Boue-Grabot, E; Toulme, E; Emerit, MB; Garret, M			Subunit-specific coupling between gamma-aminobutyric acid type A and P2X(2) receptor channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-GATED CHANNELS; GABA(A) RECEPTORS; CROSS-TALK; GUINEA-PIG; IONOTROPIC RECEPTORS; INTERNATIONAL UNION; SUBMUCOSAL NEURONS; NMDA RECEPTORS; DORSAL-HORN; TRAFFICKING	ATP and gamma-aminobutyric acid (GABA) are two fast neurotransmitters co-released at central synapses, where they co-activate excitatory P2X and inhibitory GABA(A) (GABA type A) receptors. We report here that co-activation of P2X(2) and various GABA(A) receptors, coexpressed in Xenopus oocytes, leads to a functional cross-inhibition dependent on GABA(A) subunit composition. Sequential applications of GABA and ATP revealed that alphabeta- or alphabetagamma-containing GABA(A) receptors inhibited P2X2 channels, whereas P2X2 channels failed to inhibit gamma-containing GABA(A) receptors. This functional crosstalk is independent of membrane potential, changes in current direction, and calcium. Non-additive responses observed between cation-selective GABA(A) and P2X(2) receptors further indicate the chloride independence of this process. Overexpression of minigenes encoding either the C-terminal fragment of P2X(2) or the intracellular loop of the beta3 subunit disrupted the functional cross-inhibition. We previously demonstrated functional and physical cross-talk between rho1 and P2X(2) receptors, which induced a retargeting of rho1 channels to surface clusters when co-expressed in hippocampal neurons (Boue-Grabot, E., Emerit, M. B., Toulme, E., Seguela, P., and Garret, M. ( 2004) J. Biol. Chem. 279, 6967 - 6975). Co-expression of P2X(2) and chimeric rho1 receptors with the C-terminal sequences of alpha2, beta3, or gamma2 subunits indicated that only rho1-beta3 and P2X(2) channels exhibit both functional cross-inhibition in Xenopus oocytes and coclustering/ retargeting in hippocampal neurons. Therefore, the C-terminal domain of P2X(2) and the intracellular loop of beta GABA(A) subunits are required for the functional interaction between ATP- and GABA-gated channels. This gamma subunit-dependent cross-talk may contribute to the regulation of synaptic activity.	Univ Bordeaux 2, Neurophysiol Lab, CNRS, UMR 5543, F-33076 Bordeaux, France; Hop La Pitie Salpetriere, INSERM, U288, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Boue-Grabot, E (corresponding author), Univ Bordeaux 2, Neurophysiol Lab, CNRS, UMR 5543, F-33076 Bordeaux, France.	eric.boue-grabot@umr5543.u-bordeaux2.fr	Boué-Grabot, Eric/AAQ-2061-2020	Boué-Grabot, Eric/0000-0003-2187-9037				Barajas-Lopez C, 2002, AM J PHYSIOL-GASTR L, V283, pG1238, DOI 10.1152/ajpgi.00054.2002; Barajas-Lopez C, 1998, J PHYSIOL-LONDON, V513, P671, DOI 10.1111/j.1469-7793.1998.671ba.x; Bardoni R, 1997, J NEUROSCI, V17, P5297; Barnard EA, 1998, PHARMACOL REV, V50, P291; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Boue-Grabot E, 2004, J BIOL CHEM, V279, P6967, DOI 10.1074/jbc.M307772200; Boue-Grabot E, 2003, J NEUROSCI, V23, P1246, DOI 10.1523/JNEUROSCI.23-04-01246.2003; Boue-Grabot E, 1998, J NEUROCHEM, V70, P899; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Bray D, 2004, ANNU REV BIOPH BIOM, V33, P53, DOI 10.1146/annurev.biophys.33.110502.132703; Brunig I, 2002, J NEUROSCI, V22, P4805, DOI 10.1523/JNEUROSCI.22-12-04805.2002; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Cheng Q, 2001, J NEUROPHYSIOL, V86, P2605, DOI 10.1152/jn.2001.86.5.2605; Cotrina ML, 2000, J NEUROSCI, V20, P2835; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Fisher JL, 1997, J PHYSIOL-LONDON, V505, P283, DOI 10.1111/j.1469-7793.1997.283bb.x; Fritschy JM, 2003, PHARMACOL THERAPEUT, V98, P299, DOI 10.1016/S0163-7258(03)00037-8; GRAHAM B, 1994, J NEUROPHYSIOL, V71, P538, DOI 10.1152/jn.1994.71.2.538; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Illes P, 2004, CURR TOP MED CHEM, V4, P831, DOI 10.2174/1568026043451032; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Jo YH, 2002, J NEUROSCI, V22, P4794, DOI 10.1523/JNEUROSCI.22-12-04794.2002; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Keller CA, 2004, J NEUROSCI, V24, P5881, DOI 10.1523/JNEUROSCI.1037-04.2004; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; Khakh BS, 2001, PHARMACOL REV, V53, P107; Kittler JT, 2003, CURR OPIN NEUROBIOL, V13, P341, DOI 10.1016/S0959-4388(03)00064-3; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Lee FS, 2003, EXP NEUROL, V183, P269, DOI 10.1016/S0014-4886(03)00249-8; Li Y, 2003, J BIOL CHEM, V278, P38637, DOI 10.1074/jbc.M303735200; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Lorez Matthias, 2000, Journal of Physiology (Cambridge), V527, P11, DOI 10.1111/j.1469-7793.2000.t01-1-00011.x; MacDermott AB, 1999, ANNU REV NEUROSCI, V22, P443, DOI 10.1146/annurev.neuro.22.1.443; Nedergaard M, 2002, NAT REV NEUROSCI, V3, P748, DOI 10.1038/nrn916; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Nusser Z, 1998, J NEUROSCI, V18, P1693; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Salter MW, 2003, TRENDS NEUROSCI, V26, P235, DOI 10.1016/S0166-2236(03)00081-X; Searl TJ, 1998, J PHYSIOL-LONDON, V510, P783, DOI 10.1111/j.1469-7793.1998.783bj.x; Sokolova E, 2001, J NEUROSCI, V21, P4958, DOI 10.1523/JNEUROSCI.21-14-04958.2001; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Zhou XP, 1998, J PHYSIOL-LONDON, V513, P685, DOI 10.1111/j.1469-7793.1998.685ba.x	43	59	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52517	52525		10.1074/jbc.M410223200	http://dx.doi.org/10.1074/jbc.M410223200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456793	hybrid			2022-12-25	WOS:000225493400097
J	Jiang, CL; Jin, SG; Pfeifer, GP				Jiang, CL; Jin, SG; Pfeifer, GP			MBD3L1 is a transcriptional repressor that interacts with methyl-CpG-binding protein 2 (MBD2) and components of the NuRD complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; CHROMOSOMAL-PROTEIN; DNA METHYLATION; MAMMALIAN PROTEIN; CHROMATIN; MECP2; DOMAIN; IDENTIFICATION; SITES; MCPG	Methyl-CpG-binding domain proteins 2 and 3 (MBD2 and MBD3) are transcriptional repressors that contain methyl-CpG binding domains and are components of a CpG-methylated DNA binding complex named MeCP1. Methyl-CpG-binding protein 3-like 1 ( MBD3L1) is a protein with substantial homology to MBD2 and MBD3, but it lacks the methyl-CpG binding domain. MBD3L1 interacts with MBD2 and MBD3 in vitro and in yeast two-hybrid assays. Gel shift experiments with a CpG-methylated DNA probe indicate that recombinant MBD3L1 can supershift an MBD2-methylated DNA complex. In vivo, MBD3L1 associates with and colocalizes with MBD2 but not with MBD3 and is recruited to 5-methylcytosine-rich pericentromeric heterochromatin in mouse cells. In glutathione S-transferase pull-down assays MBD3L1 is found associated with several known components of the MeCP1 . NuRD complex, including HDAC1, HDAC2, MTA2, MBD2, RbAp46, and RbAp48, but MBD3 is not found in the MBD3L1-bound fraction. MBD3L1 enhances transcriptional repression of methylated DNA by MBD2. The data are consistent with a role of MBD3L1 as a methylation-dependent transcriptional repressor that may interchange with MBD3 as an MBD2-interacting component of the NuRD complex. MBD3L1 knockout mice were created and were found to be viable and fertile, indicating that MBD3L1 may not be essential or there is functional redundancy ( through MBD3) in this pathway. Overall, this study reveals additional complexities in the mechanisms of transcriptional repression by the MBD family proteins.	City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	gpfeifer@coh.org		Jin, Seung-Gi/0000-0001-5041-0559	NCI NIH HHS [CA104967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Feng Q, 2001, GENE DEV, V15, P827; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Jiang CL, 2002, GENOMICS, V80, P621, DOI 10.1006/geno.2002.7001; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kiefer SM, 2002, J BIOL CHEM, V277, P14869, DOI 10.1074/jbc.M200052200; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	32	45	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52456	52464		10.1074/jbc.M409149200	http://dx.doi.org/10.1074/jbc.M409149200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456747	hybrid			2022-12-25	WOS:000225493400090
J	Scarlett, GP; Elgar, SJ; Cary, PD; Noble, AM; Orford, RL; Kneale, GG; Guille, MJ				Scarlett, GP; Elgar, SJ; Cary, PD; Noble, AM; Orford, RL; Kneale, GG; Guille, MJ			Intact RNA-binding domains are necessary for structure-specific DNA binding and transcription control by CBTF122 during Xenopus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; HEMATOPOIETIC DEFECT; PROTEIN; GATA-2; IDENTIFICATION; EXPRESSION	CBTF122 is a subunit of the Xenopus CCAAT box transcription factor complex and a member of a family of double-stranded RNA-binding proteins that function in both transcriptional and post-transcriptional control. Here we identify a region of CBTF122 containing the double-stranded RNA-binding domains that is capable of binding either RNA or DNA. We show that these domains bind A-form DNA in preference to B-form DNA and that the -59 to -31 region of the GATA-2 promoter ( an in vivo target of CCAAT box transcription factor) adopts a partial A-form structure. Mutations in the RNA-binding domains that inhibit RNA binding also affect DNA binding in vitro. In addition, these mutations alter the ability of CBTF122 fusions with engrailed transcription repressor and VP16 transcription activator domains to regulate transcription of the GATA-2 gene in vivo. These data support the hypothesis that the double-stranded RNA-binding domains of this family of proteins are important for their DNA binding both in vitro and in vivo.	Univ Portsmouth, Inst Biomed & Biomol Sci, Portsmouth PO1 2DT, Hants, England; Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, S Glam, Wales; Natl Inst Med Res, Ridgeway, London NW7 1AA, England	University of Portsmouth; Cardiff University	Guille, MJ (corresponding author), Univ Portsmouth, Inst Biomed & Biomol Sci, Portsmouth PO1 2DT, Hants, England.	matthew.guille@port.ac.uk		Guille, Matthew/0000-0001-6865-4519; Scarlett, Garry/0000-0001-8338-2398				BASHAM B, 1995, P NATL ACAD SCI USA, V92, P6464, DOI 10.1073/pnas.92.14.6464; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BREWER AC, 1995, EMBO J, V14, P757, DOI 10.1002/j.1460-2075.1995.tb07054.x; Brzostowski J, 2000, EMBO J, V19, P3683, DOI 10.1093/emboj/19.14.3683; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYCROFT M, 1995, EMBO J, V14, P4385; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; Connolly KM, 1998, NAT STRUCT BIOL, V5, P546, DOI 10.1038/799; Coolidge CJ, 2000, NUCLEIC ACIDS RES, V28, P1407, DOI 10.1093/nar/28.6.1407; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; ELGAR SJ, 2001, THESIS U PORTSMOUTH; Fleenor DE, 1996, GENE, V179, P219, DOI 10.1016/S0378-1119(96)00355-1; Green J, 1999, METH MOL B, V127, P1, DOI 10.1385/1-59259-678-9:1; Guille M, 1999, METH MOL B, V127, P111, DOI 10.1385/1-59259-678-9:111; Guille MJ, 1997, MOL BIOTECHNOL, V8, P35, DOI 10.1007/BF02762338; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Krovat BC, 1996, J BIOL CHEM, V271, P28112, DOI 10.1074/jbc.271.45.28112; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Liberati C, 1999, J MOL BIOL, V285, P1441, DOI 10.1006/jmbi.1998.2384; Liu WC, 2003, MOL CELL BIOL, V23, P4083, DOI 10.1128/MCB.23.12.4083-4093.2003; Maniatis T., 1982, MOL CLONING LAB MANU; Maxam A M, 1980, Methods Enzymol, V65, P499; Meagher MJ, 1999, GENE, V228, P197, DOI 10.1016/S0378-1119(98)00615-5; Minegishi N, 1998, J BIOL CHEM, V273, P3625, DOI 10.1074/jbc.273.6.3625; Moore W, 1999, METH MOL B, V127, P99, DOI 10.1385/1-59259-678-9:99; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Orford RL, 1998, MOL CELL BIOL, V18, P5557, DOI 10.1128/MCB.18.9.5557; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Reichman TW, 2003, RNA, V9, P543, DOI 10.1261/rna.2181103; Reichman TW, 2002, MOL CELL BIOL, V22, P343, DOI 10.1128/MCB.22.1.343-356.2002; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Robinson C, 1999, METH MOL B, V127, P89, DOI 10.1385/1-59259-678-9:89; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Saunders LR, 2001, GENOMICS, V71, P256, DOI 10.1006/geno.2000.6423; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; Steinbach OC, 1999, METH MOL B, V127, P41, DOI 10.1385/1-59259-678-9:41; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Sykes TG, 1998, DEVELOPMENT, V125, P4595; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Zhou YH, 1998, EMBO J, V17, P6689, DOI 10.1093/emboj/17.22.6689	45	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52447	52455		10.1074/jbc.M406107200	http://dx.doi.org/10.1074/jbc.M406107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452137	hybrid			2022-12-25	WOS:000225493400089
J	Shi, Q; Bao, SD; Maxwell, JA; Reese, ED; Friedman, HS; Bigner, DD; Wang, XF; Rich, JN				Shi, Q; Bao, SD; Maxwell, JA; Reese, ED; Friedman, HS; Bigner, DD; Wang, XF; Rich, JN			Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING EF-HAND; IN-VITRO; PROGNOSTIC-SIGNIFICANCE; MATRICELLULAR PROTEIN; MALIGNANT GLIOMAS; SIGNALING PATHWAY; ENHANCED GROWTH; TUMOR-GROWTH; NULL MICE; EXPRESSION	Secreted protein acidic, rich in cysteine (SPARC), is an extracellular matrix protein expressed in many advanced cancers, including malignant gliomas. We and others have previously shown that human glioma cell lines engineered to overexpress SPARC adopt an invasive phenotype. We now show that SPARC expression increases cell survival under stress initiated by serum withdrawal through a decrease in apoptosis. Phosphatidylinositol 3-OH kinase/AKT is a potent pro-survival pathway that contributes to the malignancy of gliomas. Cells expressing SPARC display increased AKT activation with decreased caspase 3/7 activity. Exogenous SPARC rapidly induces AKT phosphorylation, an effect that is blocked by a neutralizing SPARC antibody. Furthermore, AKT activation is essential for the anti-apoptotic effects of SPARC as the decreased apoptosis and caspase activity associated with SPARC expression can be blocked with dominant-negative AKT or a specific AKT inhibitor. As tumor cells face stressful microenvironments particularly during the process of invasion, these results suggest that SPARC functions, in part, to promote tumor progression by enabling tumor cells to survive under stressful conditions.	Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University	Rich, JN (corresponding author), Duke Univ, Med Ctr, Div Neurol, Box 2900, Durham, NC 27710 USA.	rich0001@mc.duke.edu	Rich, Jeremy/AAM-1445-2021		NINDS NIH HHS [NS047409] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS047409] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Aycock RL, 2004, J INVEST DERMATOL, V123, P592, DOI 10.1111/j.0022-202X.2004.23316.x; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bogler O, 2002, FRONT BIOSCI, V7, pE339, DOI 10.2741/bogler; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Bradshaw Amy D., 2000, Molecular Cell Biology Research Communications, V3, P345, DOI 10.1006/mcbr.2000.0237; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Chakravarti A, 2004, J CLIN ONCOL, V22, P1926, DOI 10.1200/JCO.2004.07.193; Choe G, 2003, CANCER RES, V63, P2742; Davies MA, 1998, CANCER RES, V58, P5285; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Golembieski WA, 1999, INT J DEV NEUROSCI, V17, P463, DOI 10.1016/S0736-5748(99)00009-X; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heesters MAAM, 1999, J NEURO-ONCOL, V44, P255, DOI 10.1023/A:1006398613605; Joy AM, 2003, J CELL SCI, V116, P4409, DOI 10.1242/jcs.00712; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kaufmann B, 2004, GLYCOBIOLOGY, V14, P609, DOI 10.1093/glycob/cwh063; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Kubiatowski T, 2001, J NEUROSURG, V95, P480, DOI 10.3171/jns.2001.95.3.0480; Kuriyama H, 2002, NEURO-ONCOLOGY, V4, P179, DOI 10.1093/neuonc/4.3.179; Loging WT, 2000, GENOME RES, V10, P1393, DOI 10.1101/gr.138000; Menon PM, 2000, INT J ONCOL, V17, P683; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Rich JN, 2001, CANCER RES, V61, P3556; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001; Schultz C, 2002, CANCER RES, V62, P6270; Scott CB, 1998, INT J RADIAT ONCOL, V40, P51, DOI 10.1016/S0360-3016(97)00485-9; Shingu T, 2003, J NEUROSURG, V98, P154, DOI 10.3171/jns.2003.98.1.0154; Sweetwyne MT, 2004, J HISTOCHEM CYTOCHEM, V52, P723, DOI 10.1369/jhc.3A6153.2004; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; Vadlamuri SV, 2003, NEURO-ONCOLOGY, V5, P244, DOI 10.1093/neuonc/5.4.244; Vaquero J, 2002, ACTA NEUROCHIR, V144, P151, DOI 10.1007/s007010200018; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343	48	95	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52200	52209		10.1074/jbc.M409630200	http://dx.doi.org/10.1074/jbc.M409630200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15469933	hybrid			2022-12-25	WOS:000225493400060
J	Thomas, LR; Johnson, RL; Reed, JC; Thorburn, A				Thomas, LR; Johnson, RL; Reed, JC; Thorburn, A			The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT APOPTOSIS; EFFECTOR DOMAIN; CASPASE-8; INITIATION; BINDING; FAMILY; DR4	Members of the tumor necrosis factor (TNF) superfamily of receptors such as Fas/CD95 and the TNF-related apoptosis-inducing ligand (TRAIL) receptors DR4 and DR5 induce apoptosis by recruiting adaptor molecules and caspases. The central adaptor molecule for these receptors is a death domain-containing protein, FADD, which binds to the activated receptor via death domain-death domain interactions. Here, we show that in addition to the death domain, the C-terminal tails of DR4 and DR5 positively regulate FADD binding, caspase activation and apoptosis. In contrast, the corresponding region in the Fas receptor has the opposite effect and inhibits binding to the receptor death domain. Replacement of wild-type or mutant DR5 molecules into DR5-deficient BJAB cells indicates that some agonistic antibodies display an absolute requirement for the C-terminal tail for FADD binding and signaling while other antibodies can function in the absence of this mechanism. These data demonstrate that regions outside the death domains of DR4 and DR5 have opposite effects to that of Fas in regulating FADD recruitment and show that different death receptor agonists can use distinct molecular mechanisms to activate signaling from the same receptor.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, UCHSC Fitzsimmons, Aurora, CO 80045 USA; Burnham Inst, La Jolla, CA 92037 USA; Human Genome Sci Inc, Rockville, MD 20850 USA; Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Sanford Burnham Prebys Medical Discovery Institute; GlaxoSmithKline; Human Genome Sciences Inc; Wake Forest University; Wake Forest University	Thorburn, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, UCHSC Fitzsimmons, POB 6508,Mail Stop 8303, Aurora, CO 80045 USA.	Andrew.Thorburn@uchsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061694] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; Mori E, 2004, CELL DEATH DIFFER, V11, P203, DOI 10.1038/sj.cdd.4401331; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Thomas LR, 2004, J BIOL CHEM, V279, P32780, DOI 10.1074/jbc.M401680200; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	27	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52479	52486		10.1074/jbc.M409578200	http://dx.doi.org/10.1074/jbc.M409578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452120	hybrid			2022-12-25	WOS:000225493400093
J	Zheng, W; Xie, YX; Li, G; Kong, J; Feng, JQ; Li, YC				Zheng, W; Xie, YX; Li, G; Kong, J; Feng, JQ; Li, YC			Critical role of calbindin-D28k in calcium homeostasis revealed by mice lacking both vitamin D receptor and calbindin-D28k	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,25-DIHYDROXYVITAMIN D-3; GENE-EXPRESSION; KNOCKOUT MICE; PARATHYROID-HORMONE; BINDING PROTEINS; CA2+ TRANSPORT; KIDNEY; CELLS; ABSORPTION; CHANNEL	Calbindin (CaBP)-D28k and CaBP-D9k are cytosolic vitamin D-dependent calcium-binding proteins long thought to play an important role in transepithelial calcium transport. However, recent genetic studies suggest that CaBP-D28k is not essential for calcium metabolism. Genetic ablation of this gene in mice leads to no calcemic abnormalities. Genetic inactivation of the vitamin D receptor (VDR) gene leads to hypocalcemia, secondary hyperparathyroidism, rickets, and osteomalacia, accompanied by 90% reduction in renal CaBP-D9k expression but little change in CaBP-D28k. To address whether the role of CaBP-D28k in calcium homeostasis is compensated by CaBP-D9k, we generated VDR/CaBP-D28k double knockout ( KO) mice, which expressed no CaBP-D28k and only 10% of CaBP-D9k in the kidney. On a regular diet, the double KO mice were more growth-retarded and 42% smaller in body weight than VDRKO mice and died prematurely at 2.5 - 3 months of age. Compared with VDRKO mice, the double KO mice had higher urinary calcium excretion and developed more severe secondary hyperparathyroidism and rachitic skeletal phenotype, which were manifested by larger parathyroid glands, higher serum parathyroid hormone levels, much lower bone mineral density, and more distorted growth plate with more osteoid formation in the trabecular region. On high calcium, high lactose diet, blood-ionized calcium levels were normalized in both VDRKO and the double KO mice; however, in contrast to VDRKO mice, the skeletal abnormalities were not completely corrected in the double KO mice. These results directly demonstrate that CaBP-D28k plays a critical role in maintaining calcium homeostasis and skeletal mineralization and suggest that its calcemic role can be mostly compensated by CaBP-D9k.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Queens Univ Belfast, Musgrave Pk Hosp, Sch Med, Dept Traumat & Orthopaed Surg, Belfast BT9 7JB, Antrim, North Ireland	University of Chicago; University of Missouri System; University of Missouri Kansas City; Queens University Belfast	Li, YC (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 4076, Chicago, IL 60637 USA.	cyan@medicine.bsd.uchicago.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059327] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR51587] Funding Source: Medline; NIDDK NIH HHS [DK59327] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; AN YH, 2003, HDB HISTOLOGY METHOD, P295; Beamer WG, 1996, BONE, V18, P397, DOI 10.1016/8756-3282(96)00047-6; Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200; Breslau Neil A., 1996, P49; Bronner F, 1999, J NUTR, V129, P9, DOI 10.1093/jn/129.1.9; BUSHINSKY DA, 1999, PRIMER METABOLIC BON, P67; Cao LP, 2002, ARCH BIOCHEM BIOPHYS, V400, P118, DOI 10.1006/abbi.2002.2775; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; Faucheux C, 1998, BIOCHEM J, V333, P817, DOI 10.1042/bj3330817; Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822; FERRARI S, 1992, EXP CELL RES, V200, P528, DOI 10.1016/0014-4827(92)90205-M; FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429; FULLMER CS, 1992, J NUTR, V122, P644, DOI 10.1093/jn/122.suppl_3.644; GAGNON AM, 1994, KIDNEY INT, V45, P95, DOI 10.1038/ki.1994.11; Hoenderop JGJ, 2000, AM J PHYSIOL-RENAL, V278, pF352, DOI 10.1152/ajprenal.2000.278.3.F352; Hoenderop JGJ, 2002, BBA-PROTEINS PROTEOM, V1600, P6, DOI 10.1016/S1570-9639(02)00438-7; Hoenderop JGJ, 2002, FASEB J, V16, P1398, DOI 10.1096/fj.02-0225com; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HUANG YC, 1989, J BIOL CHEM, V264, P17454; JOHNSON JA, 1994, SEMIN NEPHROL, V14, P119; Lee CT, 2002, KIDNEY INT, V62, P2055, DOI 10.1046/j.1523-1755.2002.00670.x; LI H, 1991, ENDOCRINOLOGY, V128, P2844, DOI 10.1210/endo-128-6-2844; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; Li YC, 2001, AM J PHYSIOL-ENDOC M, V281, pE558, DOI 10.1152/ajpendo.2001.281.3.E558; Peng JB, 2002, CURR OPIN NEPHROL HY, V11, P555, DOI 10.1097/00041552-200209000-00012; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; SILVER J, 1986, J CLIN INVEST, V78, P1296, DOI 10.1172/JCI112714; Silver J, 2001, J CLIN INVEST, V107, P1079, DOI 10.1172/JCI12824; Song YR, 2003, ENDOCRINOLOGY, V144, P3885, DOI 10.1210/en.2003-0314; Sooy K, 2000, CURR OPIN NEPHROL HY, V9, P341, DOI 10.1097/00041552-200007000-00004; Sooy K, 1999, J BIOL CHEM, V274, P34343, DOI 10.1074/jbc.274.48.34343; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; VARGHESE S, 1988, J BIOL CHEM, V263, P9776; VARGHESE S, 1989, MOL ENDOCRINOL, V3, P495, DOI 10.1210/mend-3-3-495; Weber K, 2001, BIOCHEM BIOPH RES CO, V289, P1287, DOI 10.1006/bbrc.2001.6121; Zeitz U, 2003, FASEB J, V17, P509, DOI 10.1096/fj.02-0424fje	39	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52406	52413		10.1074/jbc.M405562200	http://dx.doi.org/10.1074/jbc.M405562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456794	hybrid			2022-12-25	WOS:000225493400085
J	Fueger, PT; Hess, HS; Posey, KA; Bracy, DP; Pencek, RR; Charron, MJ; Wasserman, DH				Fueger, PT; Hess, HS; Posey, KA; Bracy, DP; Pencek, RR; Charron, MJ; Wasserman, DH			Control of exercise-stimulated muscle glucose uptake by GLUT4 is dependent on glucose phosphorylation capacity in the conscious mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; TRANSGENIC MICE; HEXOKINASE-II; INSULIN-RESISTANCE; KNOCKOUT MICE; TRANSPORT; OVEREXPRESSION; GENE; HOMEOSTASIS; LIMITATIONS	Previous work suggests that normal GLUT4 content is sufficient for increases in muscle glucose uptake (MGU) during exercise because GLUT4 overexpression does not increase exercise-stimulated MGU. Instead of glucose transport, glucose phosphorylation is a primary limitation of exercise-stimulated MGU. It was hypothesized that a partial ablation of GLUT4 would not impair exercise-stimulated MGU when glucose phosphorylation capacity is normal but would do so when glucose phosphorylation capacity was increased. Thus, C57BL/6J mice with hexokinase II (HKII) overexpression (HKTg), a GLUT4 partial knock-out (G4(+/-)), or both (HKTg + G4(+/-)) and wild-type (WT) littermates were implanted with carotid artery and jugular vein catheters for sampling and infusions at 4 months of age. After a 7-day recovery, 5-h fasted mice remained sedentary or ran on a treadmill at 0.6 mph for 30 min ( n = 9 - 12 per group) and received a bolus of 2-deoxy[H-3] glucose to provide an index of MGU (R-g). Arterial blood glucose and plasma insulin concentrations were similar in WT, G4(+/-), HKTg, and HKTg + G4(+/-) mice. Sedentary R-g values were the same in all genotypes in all muscles studied, confirming that glucose transport is a significant barrier to basal glucose uptake. Gastrocnemius and soleus Rg were greater in exercising compared with sedentary mice in all genotypes. During exercise, G4(+/-) mice had a marked increase in blood glucose that was corrected by the addition of HK II overexpression. Exercise R-g (mumol/100g/min) was not different between WT and G4(+/-) mice in the gastrocnemius ( 24 +/- 5 versus 21 +/- 2) or the soleus ( 54 +/- 6 versus 70 +/- 7). In contrast, the enhanced exercise R-g observed in HKTg mice compared with that in WT mice was absent in HKTg + G4(+/-) mice in both the gastrocnemius (39 +/- 7 versus 22 +/- 6) and the soleus ( 98 +/- 13 versus 65 +/- 13). Thus, glucose transport is not a significant barrier to exercise-stimulated MGU despite a 50% reduction in GLUT4 content when glucose phosphorylation capacity is normal. However, when glucose phosphorylation capacity is increased by HK II overexpression, GLUT4 availability becomes a marked limitation to exercise-stimulated MGU.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Mouse Metab Phenotyping Ctr, Nashville, TN 37232 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Vanderbilt University; Yeshiva University; Albert Einstein College of Medicine	Fueger, PT (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, 4321 Med Pk Dr,Suite 200, Durham, NC 27704 USA.	patrick.fueger@duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059637, R01DK047425, R01DK054902] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-54902, R01 DK-47425, U24 DK-59637] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Allen DL, 2001, AM J PHYSIOL-CELL PH, V280, pC637, DOI 10.1152/ajpcell.2001.280.3.C637; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; DOUEN AG, 1989, ENDOCRINOLOGY, V124, P449, DOI 10.1210/endo-124-1-449; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; FERNANDO P, 1993, CAN J PHYSIOL PHARM, V71, P854, DOI 10.1139/y93-128; Fueger PT, 2004, AM J PHYSIOL-ENDOC M, V286, pE77, DOI 10.1152/ajpendo.00309.2003; Fueger PT, 2003, AM J PHYSIOL-ENDOC M, V285, pE958, DOI 10.1152/ajpendo.00190.2003; GOODYEAR LJ, 1990, J APPL PHYSIOL, V68, P193, DOI 10.1152/jappl.1990.68.1.193; GULVE EA, 1994, J BIOL CHEM, V269, P18366; Halseth AE, 1999, AM J PHYSIOL-ENDOC M, V276, pE70, DOI 10.1152/ajpendo.1999.276.1.E70; Halseth AE, 2001, AM J PHYSIOL-ENDOC M, V280, pE994, DOI 10.1152/ajpendo.2001.280.6.E994; Halseth AE, 1998, J APPL PHYSIOL, V85, P2305, DOI 10.1152/jappl.1998.85.6.2305; Halseth AE, 2000, AM J PHYSIOL-ENDOC M, V279, pE1064, DOI 10.1152/ajpendo.2000.279.5.E1064; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hansen PA, 2000, J BIOL CHEM, V275, P22381, DOI 10.1074/jbc.M001946200; Heikkinen S, 1999, J BIOL CHEM, V274, P22517, DOI 10.1074/jbc.274.32.22517; HONIG CR, 1980, AM J PHYSIOL, V238, pH31, DOI 10.1152/ajpheart.1980.238.1.H31; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P3096, DOI 10.1073/pnas.92.8.3096; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P865, DOI 10.1073/pnas.92.3.865; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE361, DOI 10.1152/ajpendo.1999.277.2.E361; Kelley DE, 1996, J CLIN INVEST, V97, P2705, DOI 10.1172/JCI118724; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; Li J, 2000, FASEB J, V14, P1117, DOI 10.1096/fasebj.14.9.1117; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; Lombardi AM, 1997, FASEB J, V11, P1137, DOI 10.1096/fasebj.11.13.9367348; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MARSHALL BA, 1994, AM J PHYSIOL-ENDOC M, V267, pE738, DOI 10.1152/ajpendo.1994.267.5.E738; MORGAN CR, 1965, DIABETES, V14, P669, DOI 10.2337/diab.14.10.669; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; PALM T, 1983, CLIN PHYSIOL, V3, P445, DOI 10.1111/j.1475-097X.1983.tb00852.x; REN JM, 1993, J BIOL CHEM, V268, P16113; Rottman JN, 2002, AM J PHYSIOL-ENDOC M, V283, pE116, DOI 10.1152/ajpendo.00545.2001; Rudich A, 2003, DIABETOLOGIA, V46, P649, DOI 10.1007/s00125-003-1080-1; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; Tsao TS, 1999, DIABETES, V48, P775, DOI 10.2337/diabetes.48.4.775	39	49	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50956	50961		10.1074/jbc.M408312200	http://dx.doi.org/10.1074/jbc.M408312200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456776	hybrid			2022-12-25	WOS:000225355800039
J	Pruett, ND; Tkatchenko, TV; Jave-Suarez, L; Jacobs, DF; Potter, CS; Tkatchenko, AV; Schweizer, J; Awgulewitsch, A				Pruett, ND; Tkatchenko, TV; Jave-Suarez, L; Jacobs, DF; Potter, CS; Tkatchenko, AV; Schweizer, J; Awgulewitsch, A			Krtap16, characterization of a new hair keratin-associated protein (KAP) gene complex on mouse chromosome 16 and evidence for regulation by Hoxc13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-TYROSINE; MAMMARY-GLAND; EXPRESSION; FOLLICLE; MICE; DOMAIN; CATALOG; CLUSTER; MEMBERS; GROWTH	Intermediate filament (IF) keratins and keratin- associated proteins (KAPs) are principal structural components of hair and encoded by members of multiple gene families. The severe hair growth defects observed upon aberrant expression of certain keratin and KAP genes in both mouse and man suggest that proper hair growth requires their spatio-temporally coordinated activation. An essential prerequisite for studying these cis-regulatory mechanisms is to define corresponding gene families, their genomic organization, and expression patterns. This work characterizes eight recently identified high glycine/tyrosine (HGT)-type KAP genes collectively designated Krtap16-n. These genes are shown to be integrated into a larger KAP gene domain on mouse chromosome 16 (MMU16) that is orthologous to a recently described HGT- and high sulfur (HS)-type KAP gene complex on human chromosome 21q22.11. All Krtap16 genes exhibit strong expression in a narrowly defined pattern restricted to the lower and middle cortical region of the hair shaft in both developing and cycling hair. During hair follicle regression (catagen), expression levels decrease until expression is no longer detectable in follicles at resting stage (telogen). Since isolation of the Krtap16 genes was based on their differential expression in transgenic mice overexpressing the Hoxc13 transcriptional regulator in hair, we examined whether bona fide Hoxc13 binding sites associated with these genes might be functionally relevant by performing electrophoretic mobility shift assays (EMSAs). The data provide evidence for sequence-specific interaction between Hoxc13 and Krtap16 genes, thus supporting the concept of a regulatory relationship between Hoxc13 and these KAP genes.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; German Canc Res Inst, Sect Normal & Neoplast Epidermal Differentiat, D-69120 Heidelberg, Germany; Med Univ S Carolina, Dept Dermatol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Awgulewitsch, A (corresponding author), Med Univ S Carolina, Dept Med, 96 Jonathan Lucas St,Suite CSB 912, Charleston, SC 29425 USA.	awgulewa@musc.edu	Jave-Suarez, Luis Felipe/T-7036-2018	Jave-Suarez, Luis Felipe/0000-0001-6209-5031	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047204] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47204] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abzhanov A, 2003, DEVELOPMENT, V130, P4567, DOI 10.1242/dev.00673; Aoki N, 1997, J BIOL CHEM, V272, P30512, DOI 10.1074/jbc.272.48.30512; Aoki N, 1998, J INVEST DERMATOL, V111, P804, DOI 10.1046/j.1523-1747.1998.00387.x; Awgulewitsch A, 2003, NATURWISSENSCHAFTEN, V90, P193, DOI 10.1007/s00114-003-0417-4; AWGULEWITSCH A, 1991, METHODS NUCLEIC ACID, P359; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FRATINI A, 1993, J BIOL CHEM, V268, P4511; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; Hesse M, 2004, EUR J CELL BIOL, V83, P19, DOI 10.1078/0171-9335-00354; HUH N, 1994, J INVEST DERMATOL, V102, P716, DOI 10.1111/1523-1747.ep12375385; Jave-Suarez LF, 2002, J BIOL CHEM, V277, P3718, DOI 10.1074/jbc.M101616200; KEOUGH R, 1995, J CELL SCI, V108, P957; Kirfel J, 2003, CELL MOL LIFE SCI, V60, P56, DOI 10.1007/s000180300004; KOZAK M, 1983, CELL, V34, P971, DOI 10.1016/0092-8674(83)90554-8; Kuhn F, 1997, FEBS LETT, V413, P65, DOI 10.1016/S0014-5793(97)00836-3; Kuhn F, 1999, MECH DEVELOP, V86, P193, DOI 10.1016/S0925-4773(99)00115-X; Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874; Langbein L, 2001, J BIOL CHEM, V276, P35123, DOI 10.1074/jbc.M103305200; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McGowan KM, 2002, GENE DEV, V16, P1412, DOI 10.1101/gad.979502; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; PINKUS H., 1958, BIOL HAIR GROWTH, P1; Powell B C, 1997, EXS, V78, P59; POWELL BC, 1991, ANN NY ACAD SCI, V642, P1; POWELL BC, 1990, EMBO J, V9, P1485, DOI 10.1002/j.1460-2075.1990.tb08266.x; ROGERS GE, 1993, J INVEST DERMATOL, V101, pS50, DOI 10.1111/1523-1747.ep12362626; Rogers MA, 2004, J INVEST DERMATOL, V122, P147, DOI 10.1046/j.0022-202X.2003.22128.x; Rogers MA, 2002, J BIOL CHEM, V277, P48993, DOI 10.1074/jbc.M206422200; Rogers MA, 2001, J BIOL CHEM, V276, P19440, DOI 10.1074/jbc.M100657200; Rogers MA, 2000, J INVEST DERMATOL, V114, P464, DOI 10.1046/j.1523-1747.2000.00910.x; Shang L, 2002, MECH DEVELOP, V113, P207, DOI 10.1016/S0925-4773(02)00022-9; Tkatchenko AV, 2001, DEVELOPMENT, V128, P1547; Tkatchenko AV, 2000, BBA-MOL BASIS DIS, V1500, P17, DOI 10.1016/S0925-4439(99)00084-8; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; Wojcik SM, 1999, DIFFERENTIATION, V65, P97, DOI 10.1046/j.1432-0436.1999.6520097.x	42	40	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51524	51533		10.1074/jbc.M404331200	http://dx.doi.org/10.1074/jbc.M404331200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385554	hybrid			2022-12-25	WOS:000225355800106
J	Barros, MH; Bandy, B; Tahara, EB; Kowaltowski, AJ				Barros, MH; Bandy, B; Tahara, EB; Kowaltowski, AJ			Higher respiratory activity decreases mitochondrial reactive oxygen release and increases life span in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALORIE RESTRICTION; OXIDATIVE STRESS; SPECIES PRODUCTION; STATIONARY-PHASE; DNA-DAMAGE; SHORT-TERM; YEAST; LONGEVITY; SUPEROXIDE; GENERATION	Increased replicative longevity in Saccharomyces cerevisiae because of calorie restriction has been linked to enhanced mitochondrial respiratory activity. Here we have further investigated how mitochondrial respiration affects yeast life span. We found that calorie restriction by growth in low glucose increased respiration but decreased mitochondrial reactive oxygen species production relative to oxygen consumption. Calorie restriction also enhanced chronological life span. The beneficial effects of calorie restriction on mitochondrial respiration, reactive oxygen species release, and replicative and chronological life span could be mimicked by uncoupling agents such as dinitrophenol. Conversely, chronological life span decreased in cells treated with antimycin (which strongly increases mitochondrial reactive oxygen species generation) or in yeast mutants null for mitochondrial superoxide dismutase (which removes superoxide radicals) and for RTG2 (which participates in retrograde feedback signaling between mitochondria and the nucleus). These results suggest that yeast aging is linked to changes in mitochondrial metabolism and oxidative stress and that mild mitochondrial uncoupling can increase both chronological and replicative life span.	Univ Estadual Paulista, Inst Biociencias Botucatu, Dept Genet, BR-18618000 Sao Paulo, Brazil; Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5C9, Canada; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil	Instituto de Botanica - Sao Paulo; Universidade Estadual Paulista; University of Saskatchewan; Universidade de Sao Paulo	Kowaltowski, AJ (corresponding author), Av Prof Lineu Prestes 748,Cidade Univ, BR-05508900 Sao Paulo, Brazil.	alicia@iq.usp.br	Kowaltowski, Alicia J/H-8698-2012; Barros, Mario/Q-6358-2019; Barros, Mario H/B-8118-2012	Barros, Mario/0000-0003-2977-9815; 				Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Barger JL, 2003, EXP GERONTOL, V38, P1343, DOI 10.1016/j.exger.2003.10.017; Barja G, 2004, BIOL REV, V79, P235, DOI 10.1017/S1464793103006213; Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9; Barros MH, 2003, FREE RADICAL BIO MED, V35, P179, DOI 10.1016/S0891-5849(03)00307-1; Bevilacqua L, 2004, AM J PHYSIOL-ENDOC M, V286, pE852, DOI 10.1152/ajpendo.00367.2003; Borghouts C, 2004, GENETICS, V166, P765, DOI 10.1534/genetics.166.2.765; Fabrizio P, 2003, AGING CELL, V2, P73, DOI 10.1046/j.1474-9728.2003.00033.x; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Ferranti R, 2003, FEBS LETT, V536, P51, DOI 10.1016/S0014-5793(03)00007-3; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; Gredilla R, 2001, J BIOENERG BIOMEMBR, V33, P279, DOI 10.1023/A:1010603206190; Harris N, 2003, FREE RADICAL BIO MED, V34, P1599, DOI 10.1016/S0891-5849(03)00210-7; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Lambert AJ, 2004, AM J PHYSIOL-REG I, V286, pR71, DOI 10.1152/ajpregu.00341.2003; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Merry BJ, 2004, AGING CELL, V3, P7, DOI 10.1046/j.1474-9728.2003.00074.x; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Millard PJ, 1997, APPL ENVIRON MICROB, V63, P2897, DOI 10.1128/AEM.63.7.2897-2905.1997; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Reverter-Branchat G, 2004, J BIOL CHEM, V279, P31983, DOI 10.1074/jbc.M404849200; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Sinclair D, 1998, ANNU REV MICROBIOL, V52, P533, DOI 10.1146/annurev.micro.52.1.533; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P37, DOI 10.1016/S0891-5849(02)00856-0; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Speakman JR, 2004, AGING CELL, V3, P87, DOI 10.1111/j.1474-9728.2004.00097.x; Starkov AA, 1997, BIOSCIENCE REP, V17, P273, DOI 10.1023/A:1027380527769; Talbot DA, 2004, FEBS LETT, V556, P111, DOI 10.1016/S0014-5793(03)01386-3; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641	40	240	256	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49883	49888		10.1074/jbc.M408918200	http://dx.doi.org/10.1074/jbc.M408918200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383542	hybrid			2022-12-25	WOS:000225229500042
J	Mizukami, Y; Iwamatsu, A; Aki, T; Kimura, M; Nakamura, K; Nao, T; Okusa, T; Matsuzaki, M; Yoshida, K; Kobayashi, S				Mizukami, Y; Iwamatsu, A; Aki, T; Kimura, M; Nakamura, K; Nao, T; Okusa, T; Matsuzaki, M; Yoshida, K; Kobayashi, S			ERK1/2 regulates intracellular ATP levels through alpha-enolase expression in cardiomyocytes exposed to ischemic hypoxia and reoxygenation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVATION; MAP KINASE; NUCLEAR TRANSLOCATION; CELL-DEATH; C-MYC; SIGNALING PATHWAY; CARDIAC MYOCYTES; COUPLED RECEPTOR; GENE-EXPRESSION; DOMAIN PROTEIN	Extracellular signal-regulated kinase 1/2 (ERK1/2) is known to function in cell survival in response to various stresses; however, the mechanism of cell survival by ERK1/2 remains poorly elucidated in ischemic heart. Here we applied functional proteomics by two-dimensional electrophoresis to identify a cellular target of ERK1/2 in response to ischemic hypoxia. Approximately 1500 spots were detected by Coomassie Brilliant Blue staining of a sample from unstimulated cells. The staining intensities of at least 50 spots increased at 6-h reoxygenation after 2-h ischemic hypoxia. Of the 50 spots that increased, at least 4 spots were inhibited in the presence of PD98059, a MEK inhibitor. A protein with a molecular mass of 52 kDa that is strongly induced by ERK1/2 activation in response to ischemic hypoxia and reoxygenation was identified as alpha-enolase, a rate-limiting enzyme in the glycolytic pathway, by liquid chromatography-mass spectrometry and amino acid sequencing. The expressions of the alpha-enolase mRNA and protein are inhibited during reoxygenation after ischemic hypoxia in the cells containing a dominant negative mutant of MEK1 and treated with a MEK inhibitor, PD98059, leading to a decrease in ATP levels. alpha-Enolase expression is also observed in rat heart subjected to ischemia-reperfusion. The induction of alpha-enolase by ERK1/2 appears to be mediated by c-Myc. The introduction of the alpha-enolase protein into the cells restores ATP levels and prevents cell death during ischemic hypoxia and reoxygenation in these cells. These results show that alpha-enolase expression by ERK1/2 participates in the production of ATP during reoxygenation after ischemic hypoxia, and a decrease in ATP induces apoptotic cell death. Furthermore, alpha-enolase improves the contractility of cardiomyocytes impaired by ischemic hypoxia. Our results reveal that ERK1/2 plays a role in the contractility of cardiomyocytes and cell survival through alpha-enolase expression during ischemic hypoxia and reoxygenation.	Yamaguchi Univ, Ctr Gene Res, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Mol Physiol, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Cardiovasc Med, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Biochem, Yamaguchi 7558505, Japan; Univ Tokyo, Sch Med, Dept Legal Med, Tokyo 1130033, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Tokyo 2360004, Japan	Yamaguchi University; Yamaguchi University; Yamaguchi University; Yamaguchi University; University of Tokyo; Kirin Brewery Company Limited	Mizukami, Y (corresponding author), Yamaguchi Univ, Ctr Gene Res, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.	mizukami@yamaguchi-u.ac.jp	Kobayashi, Sei/E-7175-2010	Mizukami, Yoichi/0000-0002-3290-0754				AARONSON RM, 1995, J BIOL CHEM, V270, P27752, DOI 10.1074/jbc.270.46.27752; Abas L, 2000, BIOCHEM J, V349, P119, DOI 10.1042/0264-6021:3490119; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Di Lisa F, 1998, BBA-BIOENERGETICS, V1366, P69, DOI 10.1016/S0005-2728(98)00121-2; Eguchi Y, 1997, CANCER RES, V57, P1835; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; ESUMI K, 1991, AM J PHYSIOL, V260, pH1743, DOI 10.1152/ajpheart.1991.260.6.H1743; Feldenberg LR, 1999, AM J PHYSIOL-RENAL, V276, pF837, DOI 10.1152/ajprenal.1999.276.6.F837; Feo S, 2000, FEBS LETT, V473, P47, DOI 10.1016/S0014-5793(00)01494-0; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Fujimoto K, 2001, BBA-GENE STRUCT EXPR, V1518, P173, DOI 10.1016/S0167-4781(00)00309-2; GORG A, 1988, ELECTROPHORESIS, V9, P37, DOI 10.1002/elps.1150090108; Guerra S, 1999, CIRC RES, V85, P856, DOI 10.1161/01.RES.85.9.856; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Kang PM, 2000, CIRC RES, V86, P1107; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; Kawata H, 2001, CIRC RES, V88, P696, DOI 10.1161/hh0701.088842; Kimura M, 2001, J BIOL CHEM, V276, P26453, DOI 10.1074/jbc.M101289200; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Mallat Z, 1996, NEW ENGL J MED, V335, P1190, DOI 10.1056/NEJM199610173351604; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; Mizukami Y, 2000, J BIOL CHEM, V275, P19921, DOI 10.1074/jbc.M907901199; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Morris MC, 1999, J BIOL CHEM, V274, P24941, DOI 10.1074/jbc.274.35.24941; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Noshita N, 2002, J NEUROSCI, V22, P7923; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Saraste A, 1999, EUR J CLIN INVEST, V29, P380; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang XQ, 2003, J CELL SCI, V116, P2099, DOI 10.1242/jcs.00420; Webster KA, 2000, ADV EXP MED BIOL, V475, P161; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang BS, 1996, MOL CELL BIOL, V16, P538; YAO A, 1995, J CLIN INVEST, V96, P69, DOI 10.1172/JCI118081; Yonemochi H, 2000, CIRCULATION, V101, P2625, DOI 10.1161/01.CIR.101.22.2625; Yoshida K, 1996, BBA-MOL BASIS DIS, V1317, P36, DOI 10.1016/0925-4439(96)00035-X	67	77	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50120	50131		10.1074/jbc.M402299200	http://dx.doi.org/10.1074/jbc.M402299200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15459207	hybrid			2022-12-25	WOS:000225229500071
J	Robichaud, GA; Nardini, M; Laflamme, M; Cuperlovic-Culf, M; Ouellette, RJ				Robichaud, GA; Nardini, M; Laflamme, M; Cuperlovic-Culf, M; Ouellette, RJ			Human Pax-5 C-terminal isoforms possess distinct transactivation properties and are differentially modulated in normal and malignant B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; DNA-BINDING; BSAP PAX-5; PAIRED DOMAIN; TRANSCRIPTION ACTIVATION; GENE-EXPRESSION; AMINO-ACIDS; SEQUENCE; PROTEINS; MOUSE	The transcription factor Pax-5 occupies a central role in B cell differentiation and has been implicated in the development of B cell lymphoma. The transcriptional activation function of Pax-5 requires an intact N-terminal DNA-binding domain and is strongly influenced by the C-terminal transactivation domain. We report the identification and characterization of five human Pax-5 isoforms, which occur through the alternative splicing of exons that encode for the C-terminal transactivation domain. These isoforms arise from the inclusion or exclusion of exon 7, exon 8, and/or exon 9. Three of the Pax-5 isoforms generate novel protein sequences rich in proline, serine, and threonine amino acids that are the hallmarks of transactivation domains. The Pax-5 isoforms are expressed in peripheral blood mononuclear cells, cancerous and non-cancerous B cell lines, as well as in primary B cell lymphoma tissue. Electrophoretic mobility shift assays demonstrate that the isoforms possess specific DNA binding activity and recognize the PAX-5 consensus binding sites. In reporter assays using the CD19 promoter, the transactivation properties of the various isoforms were significantly influenced by the changes in the C-terminal protein sequence. Finally, we demonstrate, for the first time, that human Pax-5 isoform expression is modulated by specific signaling pathways in B lymphocytes.	Inst Rech Med Beausejour, Moncton, NB E1C 8X3, Canada; Univ Moncton, Dept Chim & Biochim, Moncton, NB E1C 8X3, Canada	University of Moncton	Ouellette, RJ (corresponding author), Inst Rech Med Beausejour, 35 Providence St, Moncton, NB E1C 8X3, Canada.	rodneyo@health.nb.ca	Cuperlovic-Culf, Miroslava/C-7876-2016	Cuperlovic-Culf, Miroslava/0000-0002-9483-8159; Laflamme, Mark/0000-0001-5955-7098				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Baranova A, 2003, GENE, V321, P103, DOI 10.1016/j.gene.2003.08.007; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; Barr FG, 1997, INT J BIOCHEM CELL B, V29, P1449, DOI 10.1016/S1357-2725(97)00095-2; Borson ND, 2002, BLOOD, V100, P4629, DOI 10.1182/blood.V100.13.4629; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; Fitzsimmons D, 2001, NUCLEIC ACIDS RES, V29, P4154, DOI 10.1093/nar/29.20.4154; Hagman J, 2000, CURR TOP MICROBIOL, V245, P169; Hardy MP, 2004, J BIOL CHEM, V279, P27699, DOI 10.1074/jbc.M403068200; Jaworski C, 1997, BIOCHEM BIOPH RES CO, V240, P196, DOI 10.1006/bbrc.1997.7623; Johnson K, 2003, CURR OPIN GENET DEV, V13, P522, DOI 10.1016/j.gde.2003.08.004; Kovac CR, 2000, J BIOL CHEM, V275, P16752, DOI 10.1074/jbc.M001551200; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; KOZMIK Z, 1995, P NATL ACAD SCI USA, V92, P5709, DOI 10.1073/pnas.92.12.5709; Kumar MB, 2001, J BIOL CHEM, V276, P42302, DOI 10.1074/jbc.M104798200; Lai EC, 2003, CURR BIOL, V13, pR285, DOI 10.1016/S0960-9822(03)00203-3; Lechner MS, 1996, J BIOL CHEM, V271, P21088, DOI 10.1074/jbc.271.35.21088; Lowen M, 2001, J BIOL CHEM, V276, P42565, DOI 10.1074/jbc.M106536200; Lynch KW, 2000, MOL CELL BIOL, V20, P70, DOI 10.1128/MCB.20.1.70-80.2000; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Morrison AM, 1998, SEMIN IMMUNOL, V10, P133, DOI 10.1006/smim.1998.0115; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; Nurtdinov RN, 2003, HUM MOL GENET, V12, P1313, DOI 10.1093/hmg/ddg137; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Reen RK, 2002, ARCH BIOCHEM BIOPHYS, V408, P93, DOI 10.1016/S0003-9861(02)00518-0; Ruscher K, 2000, J BIOTECHNOL, V78, P163, DOI 10.1016/S0168-1656(00)00207-8; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Sgambato V, 2003, J NEUROCHEM, V86, P153, DOI 10.1046/j.1471-4159.2003.01816.x; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; Szostak JW, 2002, NATURE, V419, P890, DOI 10.1038/419890a; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; Underhill DA, 2000, BIOCHEM CELL BIOL, V78, P629, DOI 10.1139/bcb-78-5-629; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Vitreschak AG, 2004, TRENDS GENET, V20, P44, DOI 10.1016/j.tig.2003.11.008; Weg-Remers S, 2001, EMBO J, V20, P4194, DOI 10.1093/emboj/20.15.4194; Zwollo P, 1997, J BIOL CHEM, V272, P10160, DOI 10.1074/jbc.272.15.10160	49	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49956	49963		10.1074/jbc.M407171200	http://dx.doi.org/10.1074/jbc.M407171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15385562	hybrid			2022-12-25	WOS:000225229500051
J	Wessells, J; Baer, M; Young, HA; Claudio, E; Brown, K; Siebenlist, U; Johnson, PF				Wessells, J; Baer, M; Young, HA; Claudio, E; Brown, K; Siebenlist, U; Johnson, PF			BCL-3 and NF-kappa B p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; CANDIDATE PROTOONCOGENE BCL-3; IL-10 GENE-EXPRESSION; ONCOPROTEIN BCL-3; NUCLEAR TRANSLOCATION; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; THERAPEUTIC TARGET; IMMUNE-RESPONSES	Lipopolysaccharide (LPS) induces expression of tumor necrosis factor alpha (TNFalpha) and other pro-inflammatory cytokines in macrophages. Following its induction, TNFalpha gene transcription is rapidly attenuated, in part due to the accumulation of NF-kappaB p50 homodimers that bind to three kappaB sites in the TNFalpha promoter. Here we have investigated the inhibitory role of BCL-3, an IkappaB-like protein that interacts exclusively with p50 and p52 homodimers. BCL-3 was induced by LPS with delayed kinetics and was associated with p50 in the nucleus. Forced expression of BCL-3 suppressed LPS-induced transcription from the TNFalpha promoter and inhibited two artificial promoters composed of TNFalpha kappaB sites that preferentially bind p50 dimers. BCL-3-mediated repression was reversed by trichostatin A and was enhanced by overexpression of HDAC-1, indicating that transcriptional attenuation involves recruitment of histone deacetylase. Analysis of macrophages from p50 and BCL-3 knock-out mice revealed that both transcription factors negatively regulate TNFalpha expression and that BCL-3 inhibits IL-1alpha and IL-1beta. In contrast, induction of the anti-inflammatory cytokine IL-10 was reduced in BCL-3 null macrophages. BCL-3 was not required for the production of p50 homodimers but BCL-3 expression was severely diminished in p50-deficient cells. Together, these findings indicate that p50 and BCL-3 function as anti-inflammatory regulators in macrophages by attenuating transcription of pro-inflammatory cytokines and activating IL-10 expression.	NCI Frederick, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA; NCI Frederick, Expt Immunol Lab, Frederick, MD 21702 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Johnson, PF (corresponding author), NCI Frederick, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA.	johnsopf@ncifcrf.gov	Young, Howard/A-6350-2008; Johnson, Peter/A-1940-2012	Young, Howard/0000-0002-3118-5111; Johnson, Peter/0000-0002-4145-4725	NATIONAL CANCER INSTITUTE [ZIABC010328, Z01BC010328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000723] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baer M, 1998, BLOOD, V92, P4353, DOI 10.1182/blood.V92.11.4353.423k21_4353_4365; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; BHATIA K, 1991, ONCOGENE, V6, P1569; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; CERAMI A, 1993, BLOOD PURIFICAT, V11, P108, DOI 10.1159/000170104; DE WMR, 1991, J EXP MED, V174, P1209; Feldmann M, 1995, ANN NY ACAD SCI, V766, P272, DOI 10.1111/j.1749-6632.1995.tb26675.x; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gerondakis S, 2001, NAT IMMUNOL, V2, P377, DOI 10.1038/87669; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; SCHATTNER A, 1994, CLIN IMMUNOL IMMUNOP, V70, P177, DOI 10.1006/clin.1994.1027; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; TRACEY KJ, 1991, CIRC SHOCK, V35, P123; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	45	160	167	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49995	50003		10.1074/jbc.M404246200	http://dx.doi.org/10.1074/jbc.M404246200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15465827	hybrid			2022-12-25	WOS:000225229500056
J	Mongroo, PS; Johnstone, CN; Naruszewicz, I; Leung-Hagesteijn, C; Sung, RK; Carnio, L; Rustgi, AK; Hannigan, GE				Mongroo, PS; Johnstone, CN; Naruszewicz, I; Leung-Hagesteijn, C; Sung, RK; Carnio, L; Rustgi, AK; Hannigan, GE			beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer	ONCOGENE			English	Article						parvin; ILK; tumor suppression; PKB/GSK3b; EGF; breast cancer	CALPONIN HOMOLOGY DOMAINS; GLYCOGEN-SYNTHASE KINASE; FOCAL ADHESION PROTEIN; TUMOR-SUPPRESSOR PTEN; CYCLIN D1 GENE; CAENORHABDITIS-ELEGANS; EXPRESSION INCREASES; CHROMOSOME 22Q13; PROSTATE-CANCER; BINDING PROTEIN	We analysed breast tumors and breast cancer cell lines for the expression of beta-parvin (ParvB), an adaptor protein that binds to the integrin-linked kinase (ILK). Quantitative RT-PCR indicated that ParvB mRNA was downregulated, by at least 60%, in four of nine breast tumors, relative to patient-matched normal mammary gland tissue. We also found that ParvB protein levels were reduced by greater than or equal to90% in five of seven advanced tumors, relative to matched normal breast tissue. Conversely, ILK protein and kinase activity levels were elevated in these tumors, suggesting that downregulation of ParvB stimulates ILK signaling. Western blot analyses indicated very low levels of ParvB protein in MDA-MB-231 and MCF7 breast cancer cells, facilitating functional studies of the effects of ParvB on ILK signaling. Expression of ParvB in MDA-MB-231 and MCF7 cells increased cell adhesion to collagen. ParvB inhibited ILK kinase activity, anchorage-independent cell growth and in vitro matrigel invasion by MDA-MB-231 cells. EGF-induced phosphorylation of two ILK targets, PKB (Ser473) and glycogen synthase kinase 3beta (Ser9), was also inhibited by ParvB. These results indicated that ParvB inhibits ILK signaling downstream of receptor tyrosine kinases. Our results suggest that loss of ParvB expression is a novel mechanism for upregulating ILK activity in tumors.	Hosp Sick Children, Res Inst, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Div Gastroenterol, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Hannigan, GE (corresponding author), Hosp Sick Children, Res Inst, Canc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hannigan@sickkids.ca	Hannigan, Greg/A-5092-2009					Ahmed N, 2003, J PATHOL, V201, P229, DOI 10.1002/path.1441; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Barker N, 2000, BIOESSAYS, V22, P961; Cairns P, 1997, CANCER RES, V57, P4997; Castells A, 1999, GASTROENTEROLOGY, V117, P831, DOI 10.1016/S0016-5085(99)70341-0; Castells A, 2000, CANCER RES, V60, P2836; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Coffer PJ, 1998, BIOCHEM J, V335, P1; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Edwards Lincoln A, 2004, Cancer Treat Res, V119, P59; Fukuda T, 2003, J CELL BIOL, V160, P1001, DOI 10.1083/jcb.200212113; Gimona M, 1998, CURR BIOL, V8, pR674; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HRESKO MC, 1994, J CELL BIOL, V124, P491, DOI 10.1083/jcb.124.4.491; Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Korenbaum E, 2001, GENE, V279, P69, DOI 10.1016/S0378-1119(01)00743-0; Kumar AS, 2004, ONCOGENE, V23, P3454, DOI 10.1038/sj.onc.1207473; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lin XY, 2003, CURR BIOL, V13, P922, DOI 10.1016/S0960-9822(03)00372-5; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marotta A, 2003, BRIT J CANCER, V88, P1755, DOI 10.1038/sj.bjc.6600939; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Olski TM, 2001, J CELL SCI, V114, P525; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Price JT, 1999, CANCER RES, V59, P5475; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Youssoufian H, 1998, BIOTECHNIQUES, V24, P198, DOI 10.2144/98242bm05; Yu X, 2000, J CELL SCI, V113, P2139; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	57	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8959	8970		10.1038/sj.onc.1208112	http://dx.doi.org/10.1038/sj.onc.1208112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467740				2022-12-25	WOS:000225354600011
J	Iwanaga, R; Komori, H; Ohtani, K				Iwanaga, R; Komori, H; Ohtani, K			Differential regulation of expression of the mammalian DNA repair genes by growth stimulation	ONCOGENE			English	Article						DNA repair gene; cell growth; gene expression; E2F	CELL-CYCLE PROGRESSION; TRANSCRIPTION FACTOR E2F; MISMATCH REPAIR; DEPENDENT EXPRESSION; MICROARRAY ANALYSIS; DAMAGE RESPONSE; PROTEIN; RAD51; REPLICATION; PROMOTER	During DNA replication, DNA becomes more vulnerable to certain DNA damages. DNA repair genes involved in repair of the damages may be induced by growth stimulation. However, regulation of DNA repair genes by growth stimulation has not been analysed in detail. In this report, we analysed the regulation of expression of mammalian MSH2, MSH3 and MLH1 genes involved in mismatch repair, and Rad51 and Rad50 genes involved in homologous recombination repair, in relation to cell growth. Unexpectedly, we found a clear difference in regulation of these repair gene expression by growth stimulation even in the same repair system. The expression of MSH2, MLH1 and Rad51 genes was clearly growth regulated, whereas MSH3 and Rad50 genes were constitutively expressed, suggesting differential requirement of the repair gene products for cell proliferation. MSH3 gene is located in a bidirectionally divergent manner with DHFR gene that is regulated by growth stimulation, indicating that bidirectionally divergent promoters are not necessarily coordinately regulated. Promoter analysis showed that the growth-regulated expression of MLH1 and Rad51 genes was mainly mediated by E2F that plays crucial roles in regulation of DNA replication, suggesting close relation between some of the repair genes and DNA replication.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kiyo.gene@cmn.tmd.ac.jp						Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Claij N, 2002, ONCOGENE, V21, P2873, DOI 10.1038/sj.onc.1205395; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; HAWN MT, 1995, CANCER RES, V55, P3721; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ito E, 1999, BIOCHEM BIOPH RES CO, V256, P488, DOI 10.1006/bbrc.1999.0368; Iwahashi Y, 1998, GENE, V213, P141, DOI 10.1016/S0378-1119(98)00187-5; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Lin WC, 2001, GENE DEV, V15, P1833; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Meyers M, 1997, CANCER RES, V57, P206; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; WILSON TM, 1995, CANCER RES, V55, P5146; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	36	42	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8581	8590		10.1038/sj.onc.1207976	http://dx.doi.org/10.1038/sj.onc.1207976			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467751				2022-12-25	WOS:000224988800003
J	Rong, R; Jin, WX; Zhang, J; Sheikh, MS; Huang, Y				Rong, R; Jin, WX; Zhang, J; Sheikh, MS; Huang, Y			Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G(2)/M arrest	ONCOGENE			English	Article						RASSF1A; microtubules; apoptosis; cell cycle arrest	FREQUENT EPIGENETIC INACTIVATION; POLYPOSIS-COLI PROTEIN; CELL-CYCLE; CPG ISLAND; PROMOTER HYPERMETHYLATION; BREAST CANCERS; GENE-PRODUCT; LUNG-CANCER; ALLELE LOSS; SPINDLE	RASSF1A is a putative tumor suppressor gene that is inactivated in a variety of human tumors. Expression of exogenous RASSF1A has been shown to inhibit tumor growth in vitro and in animals. However, the molecular mechanisms by which RASSF1A mediates its tumor suppressive effects remain to be elucidated. Here, we report that RASSF1A is a microtubule-binding protein that interacts with and stabilizes microtubules. We have identified the RASSF1A region harboring a basic domain that appears to mediate the interactions between RASSF1A and microtubules. The basic domain-containing RASSF1C isoform also interacts with and stabilizes microtubules. We further show that in addition to G(1) arrest, RASSF1A promotes growth arrest in the G(2)/M phase of the cell cycle and endogenous RASSF1A also interacts with microtubules. Based on our results, we propose that RASSF1A may mediate its tumor suppressive effects by inducing growth arrest in the G(1) and G(2)/M phases. Together, these results provide important new insights into the molecular mechanisms by which this novel tumor suppressor mediates its biological effects.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			NCI NIH HHS [CA86945] Funding Source: Medline; NIDDK NIH HHS [DK62136-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Alberts B., 2002, MOL BIOL CELL, P907; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Bosc C, 1996, P NATL ACAD SCI USA, V93, P2125, DOI 10.1073/pnas.93.5.2125; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; ERIMANN JDR, 2002, NATURE, V416, P850; Goedert M, 1996, J CELL SCI, V109, P2661; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Huang Y, 2001, CANCER RES, V61, P6918; IRMINGERFINGER I, 1990, J CELL BIOL, V111, P2563, DOI 10.1083/jcb.111.6.2563; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Lo KW, 2001, CANCER RES, V61, P3877; Lodish H, 2000, MOL CELL BIOL, P795; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Mimori-Kiyosue Y, 2001, J CELL BIOL, V154, P1105, DOI 10.1083/jcb.200106113; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Morrissey C, 2001, CANCER RES, V61, P7277; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Nogales E, 2001, ANNU REV BIOPH BIOM, V30, P397, DOI 10.1146/annurev.biophys.30.1.397; Oliferenko S, 2002, NAT CELL BIOL, V4, P816, DOI 10.1038/ncb861; Reese EL, 2000, J CELL BIOL, V151, P155, DOI 10.1083/jcb.151.1.155; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Schuyler SC, 2001, J CELL SCI, V114, P247; Shimoda SL, 2002, CELL, V109, P9, DOI 10.1016/S0092-8674(02)00712-2; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; SMITH KJ, 1994, CANCER RES, V54, P3672; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Szalay J, 2001, J HISTOCHEM CYTOCHEM, V49, P49, DOI 10.1177/002215540104900106; Tanaka TU, 2002, CURR OPIN CELL BIOL, V14, P365, DOI 10.1016/S0955-0674(02)00328-9; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Wistuba II, 2000, CANCER RES, V60, P1949; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	55	75	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	2004	23	50					8216	8230		10.1038/sj.onc.1207901	http://dx.doi.org/10.1038/sj.onc.1207901			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378022				2022-12-25	WOS:000224749500004
J	Wang, KY; Shen, CKJ				Wang, KY; Shen, CKJ			DNA methyltransferase Dnmt1 and mismatch repair	ONCOGENE			English	Article						Dnmt1; microsatellite instability; mismatch repair	EMBRYONIC STEM-CELLS; MICROSATELLITE INSTABILITY; CANCER SUSCEPTIBILITY; MAMMALIAN DEVELOPMENT; REPLICATION FOCI; METHYLATION; MUTATION; GENES; PCNA; HYPOMETHYLATION	We have examined the relationship between DNA mismatch repair and deficiency of DNA methylation in a mouse embryonic cell line, Dnmt1(-/-) ES, with homologous deletion of the gene coding for the maintenance DNA methyltransferase Dnmt1. With the use of a sensitive PCR for the assay of two mononucleotide- and three dinucleotide microsatellite markers that exhibited instabilities in mismatch repair-deficient cells, significantly higher frequencies of instability were detected at three of the five markers in Dnmt1(-/-) ES than the wildtype ES. The data suggest that Dnmt1 enzyme plays an integrating role in DNA replication and/or repair. The implication that Dnmt1 enzyme and/or cytosine methylation may participate in the strand discrimination of mismatch repair during eukaryotic DNA replication is discussed.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Genet, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Shen, CKJ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	ckshen@ccvax.sinica.edu.tw	shen, Che-Kun James/L-1343-2015					BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guo G, 2004, NATURE, V429, P891, DOI 10.1038/nature02653; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kabbarah O, 2003, MOL CARCINOGEN, V38, P155, DOI 10.1002/mc.10157; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Luria SE, 1943, GENETICS, V28, P491; Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vertino PM, 2002, CELL CYCLE, V1, P416, DOI 10.4161/cc.1.6.270; Wong E, 2002, P NATL ACAD SCI USA, V99, P14937, DOI 10.1073/pnas.232579299	34	36	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7898	7902		10.1038/sj.onc.1208111	http://dx.doi.org/10.1038/sj.onc.1208111			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15378011				2022-12-25	WOS:000224331600016
J	Ji, LL; Gomez-Cabrera, MC; Steinhafel, N; Vina, J				Ji, LL; Gomez-Cabrera, MC; Steinhafel, N; Vina, J			Acute exercise activates nuclear factor (NF)-kappa B signaling pathway in rat skeletal muscle	FASEB JOURNAL			English	Article						ROS; nuclear protein kappa B; redox signaling	NF-KAPPA-B; DISMUTASE GENE-EXPRESSION; FREE-RADICAL GENERATION; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; PROTEIN-KINASE; TRANSCRIPTION FACTOR; REDOX REGULATION; ANTIOXIDANT; DAMAGE	Two studies were performed to investigate the effects of an acute bout of physical exercise on the nuclear protein kappaB (NF-kappaB) signaling pathway in rat skeletal muscle. In Study 1, a group of rats (n = 6) was run on the treadmill at 25 m/min, 5% grade, for 1 h or until exhaustion ( Ex), and compared with a second group ( n = 6) injected with two doses of pyrrolidine dithiocarbamate ( PDTC, 100 mg/kg, i.p.) 24 and 1 h prior to the acute exercise bout. Three additional groups of rats ( n = 6) were injected with either 8 mg/kg (i.p.) of lipopolysaccharide (LPS), 1 mmol/kg (i.p.) t-butylhydroperoxide (tBHP), or saline ( C) and killed at resting condition. Ex rats showed higher levels of NF-kappaB binding and P50 protein content in muscle nuclear extracts compared with C rats. Cytosolic IkappaBalpha and IkappaB kinase (IKK) contents were decreased, whereas phospho-IkappaBalpha and phospho-IKK contents were increased, comparing Ex vs. C. The exercise-induced activation of NF-kappaB signaling cascade was partially abolished by PDTC treatment. LPS, but not tBHP, treatment mimicked and exaggerated the effects observed in Ex rats. In Study 2, the time course of exercise-induced NF-kappaB activation was examined. Highest levels of NF-kappaB binding were observed at 2 h postexercise. Decreased cytosolic IkappaBalpha and increased phosphor-IkappaBalpha content were found 0 - 1 h postexercise whereas P65 reached peak levels at 2 - 4 h. These data suggest that the NF-kappaB signaling pathway can be activated in a redox-sensitive manner during muscular contraction, presumably due to increased oxidant production. The cascade of intracellular events may be the overture to elevated gene expression of manganese superoxide dismutase reported earlier Pfluegers Arch. 442, 426 - 434, 2001).	Univ Wisconsin, Biodynam Lab, Dept Kinesiol, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Univ Valencia, Sch Med, Valencia, Spain	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Valencia	Ji, LL (corresponding author), Univ Wisconsin, Biodynam Lab, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA.	ji@education.wisc.edu	Gomez-Cabrera, Maria Carmen/H-6911-2018; Gomez-Cabrera, Mari Carmen/O-3109-2019; Vina, Jose/AAB-3069-2021	Gomez-Cabrera, Maria Carmen/0000-0003-4000-1684; Gomez-Cabrera, Mari Carmen/0000-0003-4000-1684; Vina, Jose/0000-0001-9709-0089				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bejma J, 2000, ACTA PHYSIOL SCAND, V169, P343; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; BROOKS GA, 1978, J APPL PHYSIOL, V45, P1009, DOI 10.1152/jappl.1978.45.6.1009; Cannon JG, 1998, MOL CELL BIOCHEM, V179, P159, DOI 10.1023/A:1006828425418; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; DAVIES KJA, 1982, BIOCHEM BIOPH RES CO, V107, P1198, DOI 10.1016/S0006-291X(82)80124-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HIGUCHI M, 1985, J GERONTOL, V40, P281, DOI 10.1093/geronj/40.3.281; Hollander J, 1999, AM J PHYSIOL-REG I, V277, pR856, DOI 10.1152/ajpregu.1999.277.3.R856; Hollander J, 2001, PFLUG ARCH EUR J PHY, V442, P426, DOI 10.1007/s004240100539; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JACKSON MJ, 1985, BIOCHIM BIOPHYS ACTA, V847, P185, DOI 10.1016/0167-4889(85)90019-9; Ji LL, 2002, ANN NY ACAD SCI, V959, P82, DOI 10.1111/j.1749-6632.2002.tb02085.x; Ji LL, 1999, P SOC EXP BIOL MED, V222, P283, DOI 10.1046/j.1525-1373.1999.d01-145.x; KAWAI M, 1995, J IMMUNOL, V154, P2333; LAUGHLIN MH, 1990, J APPL PHYSIOL, V68, P2337, DOI 10.1152/jappl.1990.68.6.2337; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Pedersen BK, 1998, CAN J PHYSIOL PHARM, V76, P505, DOI 10.1139/cjpp-76-5-505; Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x; Powers S. K., 1994, AM J PHYSIOL, V266, P375; Ramires P. R., 2000, Medicine and Science in Sports and Exercise, V32, pS106; Ranganathan AC, 2001, J BIOL CHEM, V276, P14264, DOI 10.1074/jbc.M100199200; Regula KM, 2002, J BIOL CHEM, V277, P38676, DOI 10.1074/jbc.M206175200; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; SANDRI M, 1995, FEBS LETT, V373, P291, DOI 10.1016/0014-5793(95)00908-R; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SEN CK, 1995, J APPL PHYSIOL, V79, P675, DOI 10.1152/jappl.1995.79.3.675; Smith JA, 1996, AM J PHYSIOL-REG I, V270, pR838, DOI 10.1152/ajpregu.1996.270.4.R838; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000	41	216	233	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1499	1506		10.1096/fj.04-1846com	http://dx.doi.org/10.1096/fj.04-1846com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466358				2022-12-25	WOS:000224849900033
J	Agou, F; Courtois, G; Chiaravalli, J; Baleux, F; Coic, YM; Traincard, F; Israel, A; Veron, M				Agou, F; Courtois, G; Chiaravalli, J; Baleux, F; Coic, YM; Traincard, F; Israel, A; Veron, M			Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (NEMO) oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-GAMMA; ECTODERMAL DYSPLASIA; KINASE COMPLEX; COILED-COIL; THERAPEUTIC PEPTIDES; PROTEIN; RECEPTOR; DOMAIN; APOPTOSIS; EXPRESSION	NF-kappaB essential modulator/IKK-gamma (NEMO/IKK-gamma) plays a key role in the activation of the NF-kappaB pathway in response to proinflammatory stimuli. Previous studies suggested that the signal-dependent activation of the IKK complex involves the trimerization of NEMO. The minimal oligomerization domain of this protein consists of two coiled-coil subdomains named Coiled-coil 2 (CC2) and leucine zipper (LZ) (Agou, F., Traincard, F., Vinolo, E., Courtois, G., Yamaoka, S., Israel, A., and Veron, M. (2004) J. Biol. Chem. 279, 27861-27869). To search for drugs inhibiting NF-kappaB activation, we have rationally designed cell-permeable peptides corresponding to the CC2 and LZ subdomains that mimic the contact areas between NEMO subunits. The peptides were tagged with the Antennapedia/Penetratin motif and delivered to cells prior to stimulation with lipopolysaccharide. Peptide transduction was monitored by fluorescence-activated cell sorter, and their effect on lipopolysaccharide-induced NF-kappaB activation was quantified using an NF-kappaB-dependent beta-galactosidase assay in stably transfected pre-B 70Z/3 lymphocytes. We show that the peptides corresponding to the LZ and CC2 subdomains inhibit NF-kappaB activation with an IC50 in the muM range. Control peptides, including mutated CC2 and LZ peptides and a heterologous coiled-coil peptide, had no inhibitory effect. The designed peptides are able to induce cell death in human retinoblastoma Y79 cells exhibiting constitutive NF-kappaB activity. Our results provide the "proof of concept" for a new and promising strategy for the inhibition of NF-kappaB pathway activation through targeting the oligomerization state of the NEMO protein.	Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Act Cellulaires, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2582, Unite Biol Mol Express Genet, F-75724 Paris, France; Inst Pasteur, CNRS, URA 2128, Unite Chim Organ, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Agou, F (corresponding author), Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Act Cellulaires, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	fagou@pasteur.fr	, AGOU/GXA-2760-2022	COURTOIS, Gilles/0000-0003-3117-9595				Agou F, 1999, J BIOL CHEM, V274, P19630, DOI 10.1074/jbc.274.28.19630; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRONSTEIN I, 1989, J BIOLUM CHEMILUM, V4, P99, DOI 10.1002/bio.1170040116; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016/S0014-5793(02)03590-1; Inohara N, 2000, J BIOL CHEM, V275, P27823; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Latham PW, 1999, NAT BIOTECHNOL, V17, P755, DOI 10.1038/11686; Lien S, 2003, TRENDS BIOTECHNOL, V21, P556, DOI 10.1016/j.tibtech.2003.10.005; Liu WK, 2004, BIOCHEM J, V378, P867, DOI 10.1042/BJ20031736; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mousson F, 2002, BIOCHEMISTRY-US, V41, P13611, DOI 10.1021/bi026274b; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Poulaki V, 2002, AM J PATHOL, V161, P2229, DOI 10.1016/S0002-9440(10)64499-9; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Schwamborn K, 2000, J BIOL CHEM, V275, P22780, DOI 10.1074/jbc.M001500200; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	49	59	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54248	54257		10.1074/jbc.M406423200	http://dx.doi.org/10.1074/jbc.M406423200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15466857	hybrid			2022-12-25	WOS:000225793600045
J	Heitmeier, MR; Kelly, CB; Ensor, NJ; Gibson, KA; Mullis, KG; Corbett, JA; Maziasz, TJ				Heitmeier, MR; Kelly, CB; Ensor, NJ; Gibson, KA; Mullis, KG; Corbett, JA; Maziasz, TJ			Role of cyclooxygenase-2 in cytokine-induced beta-cell dysfunction and damage by isolated rat and human islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; INSULIN-SECRETION; INDUCED INHIBITION; EXPRESSION; COX-2; LANGERHANS; INTERLEUKIN-1; DESTRUCTION; PATHOGENESIS; SENSITIVITY	Type I diabetes mellitus is an autoimmune disease characterized by the selective destruction of the insulin-secreting beta-cell found in pancreatic islets of Langerhans. Cytokines such as interleukin-1 (IL-1), interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha) mediate beta-cell dysfunction and islet degeneration, in part, through the induction of the inducible isoform of nitric-oxide synthase and the production of nitric oxide by beta-cells. Cytokines also stimulate the expression of the inducible isoform of cyclooxygenase, COX-2, and the production of prostaglandin E-2 (PGE(2)) by rat and human islets; however, the role of increased COX-2 expression and PGE(2) production in mediating cytokine-induced inhibition of islet metabolic function and viability has been incompletely characterized. In this study, we have shown that treatment of rat islets with IL-1beta or human islets with a cytokine mixture containing IL-1beta + IFN-gamma +/- TNF-alpha stimulates COX-2 expression and PGE(2) formation in a time-dependent manner. Co-incubation of rat and human islets with selective COX-2 inhibitors SC-58236 and Celecoxib, respectively, attenuated cytokine-induced PGE(2) formation. However, these inhibitors failed to prevent cytokine-mediated inhibition of insulin secretion or islet degeneration. These findings indicate that selective inhibition of COX-2 activity does not protect rat and human islets from cytokine-induced beta-cell dysfunction and islet degeneration and, furthermore, that islet production of PGE(2) does not mediate these inhibitory and destructive effects.	Pfizer Global Res & Dev, Dept Cardiovasc & Metab Dis, St Louis, MO 63017 USA; Pfizer Global Res & Dev, Dept Arthrit & Inflammat, St Louis, MO 63017 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Pfizer; Pfizer; Saint Louis University	Heitmeier, MR (corresponding author), Pfizer Global Res & Dev, Dept Cardiovasc & Metab Dis, 700 Chesterfield Pkwy W,Mail Code T2C, St Louis, MO 63017 USA.	Monique.R.Heitmeier@Pfizer.com			NIDDK NIH HHS [DK 52194, DK 68839] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK068839, R01DK052194] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; Corbett JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1581, DOI 10.1152/ajpcell.1996.270.6.C1581; CORBETT JA, 1993, BIOCHEMISTRY-US, V32, P13767, DOI 10.1021/bi00213a002; CORBETT JA, 1994, BIOCHEM J, V299, P719, DOI 10.1042/bj2990719; Cosentino F, 2003, CIRCULATION, V107, P1017, DOI 10.1161/01.CIR.0000051367.92927.07; DAYERMETROZ MD, 1989, J AUTOIMMUN, V2, P163, DOI 10.1016/0896-8411(89)90152-2; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; Flodstrom M, 1999, DIABETES, V48, P706, DOI 10.2337/diabetes.48.4.706; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Heitmeyer M. R, 2000, NITRIC OXIDE BIOL PA, P785; HUGHES JH, 1989, DIABETES, V38, P1251, DOI 10.2337/diabetes.38.10.1251; Kwon G, 1998, DIABETES, V47, P583, DOI 10.2337/diabetes.47.4.583; Kwon G, 1997, MOL PHARMACOL, V52, P398, DOI 10.1124/mol.52.3.398; LACY PE, 1991, AM J PATHOL, V138, P1183; Lee SH, 2000, LIFE SCI, V68, P57, DOI 10.1016/S0024-3205(00)00920-6; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; MANDRUPPOULSEN T, 1993, DIABETOLOGIA, V36, P470, DOI 10.1007/BF00402286; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Persaud SJ, 2004, DIABETES, V53, pS190, DOI 10.2337/diabetes.53.2007.S190; ROBERTSON R P, 1986, Diabetes Metabolism Reviews, V2, P261; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Scarim AL, 1997, ENDOCRINOLOGY, V138, P5301, DOI 10.1210/en.138.12.5301; Shanmugam N, 2004, DIABETES, V53, P795, DOI 10.2337/diabetes.53.3.795; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; Tabatabaie T, 2000, BIOCHEM BIOPH RES CO, V273, P699, DOI 10.1006/bbrc.2000.2959; Tran POT, 2002, DIABETES, V51, P1772, DOI 10.2337/diabetes.51.6.1772; Tran POT, 1999, J BIOL CHEM, V274, P31245, DOI 10.1074/jbc.274.44.31245; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; WRIGHT PH, 1971, DIABETES, V20, P33, DOI 10.2337/diab.20.1.33; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	41	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53145	53151		10.1074/jbc.M410978200	http://dx.doi.org/10.1074/jbc.M410978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471850	hybrid			2022-12-25	WOS:000225680600043
J	Sarg, B; Helliger, W; Talasz, H; Koutzamani, E; Lindner, HH				Sarg, B; Helliger, W; Talasz, H; Koutzamani, E; Lindner, HH			Histone H4 hyperacetylation precludes histone H4 lysine 20 trimethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHILIC-INTERACTION CHROMATOGRAPHY; INTERACTION LIQUID-CHROMATOGRAPHY; DNA METHYLATION; ERYTHROLEUKEMIC CELLS; HORMONE-RECEPTOR; ACTIVE GENES; ACETYLATION; H3; HETEROCHROMATIN; CHROMATIN	Posttranslational modification of histones is a common means of regulating chromatin structure and thus diverse nuclear processes. Using a hydrophilic interaction liquid chromatographic separation method in combination with mass spectrometric analysis, the present study investigated the alterations in histone H4 methylation/ acetylation status and the interplay between H4 methylation and acetylation during in vitro differentiation of mouse erythroleukemia cells and how these modifications affect the chromatin structure. Independently of the type of inducer used ( dimethyl sulfoxide, hexamethylenebisacetamide, butyrate, and trichostatin A), we observed a strong increase in non- and monoacetylated H4 lysine 20 (H4-Lys(20)) trimethylation. An increase in H4-Lys(20) trimethylation, however, to a clearly lesser extent, was also found when cells accumulated in the stationary phase. Since we show that trimethylated H4-Lys(20) is localized to heterochromatin, the increase in H4-Lys(20) trimethylation observed indicates an accumulation of chromatin-dense and transcriptionally silent regions during differentiation and during the accumulation of control cells in the stationary phase, respectively. When using the deacetylase inhibitors butyrate or trichostatin A, we found that H4 hyperacetylation prevents H4-Lys(20) trimethylation, but not mono- or dimethylation, and that the nonacetylated unmethylated H4-Lys(20) is therefore the most suitable substrate for H4-Lys(20) trimethylase. Summarizing, histone H4-Lys(20) hypotrimethylation correlates with H4 hyperacetylation and H4-Lys(20) hypertrimethylation correlates with H4 hypoacetylation. The results provide a model for how transcriptionally active euchromatin might be converted to the compacted, transcriptionally silent heterochromatin.	Med Univ Innsbruck, Dept Med Chem & Biochem, A-6020 Innsbruck, Austria; Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden	Medical University of Innsbruck; Linkoping University	Lindner, HH (corresponding author), Med Univ Innsbruck, Dept Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	herbert.lindner@uibk.ac.at	Koutzamani, Elisavet/N-4112-2015	Koutzamani, Elisavet/0000-0003-3059-5191				ALPERT AJ, 1990, J CHROMATOGR, V499, P177, DOI 10.1016/S0021-9673(00)96972-3; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; Czermin B, 2003, GENETICA, V117, P159, DOI 10.1023/A:1022927725945; FRIEND C, 1987, CANCER RES, V47, P378; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HELLIGER W, 1992, BIOCHEM J, V288, P747, DOI 10.1042/bj2880747; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kristjuhan A, 2003, P NATL ACAD SCI USA, V100, P7551, DOI 10.1073/pnas.1332299100; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Lindner H, 1996, J CHROMATOGR A, V743, P137, DOI 10.1016/0021-9673(96)00131-8; Lindner H, 1997, J CHROMATOGR A, V782, P55, DOI 10.1016/S0021-9673(97)00468-8; LINDNER H, 1988, J CHROMATOGR, V450, P309, DOI 10.1016/S0021-9673(01)83585-8; Lindner H, 1998, J BIOL CHEM, V273, P13324, DOI 10.1074/jbc.273.21.13324; Lindner Herbert, 2004, Methods Mol Biol, V251, P75; Marks PA, 2001, CLIN CANCER RES, V7, P759; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Sarg B, 1999, ARCH BIOCHEM BIOPHYS, V372, P333, DOI 10.1006/abbi.1999.1503; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Van Holde KE., 1988, SPRINGER SERIES MOL, P111; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Xin ZH, 2003, J BIOL CHEM, V278, P14996, DOI 10.1074/jbc.M211753200; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	45	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53458	53464		10.1074/jbc.M409099200	http://dx.doi.org/10.1074/jbc.M409099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456746	hybrid			2022-12-25	WOS:000225680600080
J	Srivastava, S; Spite, M; Trent, JO; West, MB; Ahmed, Y; Bhatnagar, A				Srivastava, S; Spite, M; Trent, JO; West, MB; Ahmed, Y; Bhatnagar, A			Aldose reductase-catalyzed reduction of aldehyde phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; LOW-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; FACTOR-ACETYLHYDROLASE; OXIDIZED PHOSPHOLIPIDS; LIPID-PEROXIDATION; OXIDATIVE STRESS; STRUCTURAL-CHARACTERIZATION; METABOLISM; PRODUCTS	Oxidation of unsaturated phospholipids results in the generation of aldehyde side chains that remain esterified to the phospholipid backbone. Such "core" aldehydes elicit immune responses and promote inflammation. However, the biochemical mechanisms by which phospholipid aldehydes are metabolized or detoxified are not well understood. In the studies reported here, we examined whether aldose reductase (AR), which reduces hydrophobic aldehydes, metabolizes phospholipid aldehydes. Incubation with AR led to the reduction of 5-oxovaleroyl, 7-oxo-5-heptenoyl, 5-hydroxy-6-oxo-caproyl, and 5-hydroxy-8-oxo-6-octenoyl phospholipids generated upon oxidation of 1-palmitoyl-2-arachidonoyl-sn- glycero-3-phosphocholine (PAPC). The enzyme also catalyzed the reduction of phospholipid aldehydes generated from the oxidation of 1-alkyl, and 1-alkenyl analogs of PAPC, and 1-palmitoyl-2-arachidonoyl phosphatidic acid or phosphoglycerol. Aldose reductase catalyzed the reduction of chemically synthesized 1-palmitoyl-2-( 5-oxovaleroyl)-sn-glycero-3-phosphatidylcholine (POVPC) with a K-m of 10 muM. Addition of POVPC to the culture medium led to incorporation and reduction of the aldehyde in COS-7 and THP-1 cells. Reduction of POVPC in these cells was prevented by the AR inhibitors sorbinil and tolrestat and was increased in COS-7 cells overexpressing AR. Together, these observations suggest that AR may be a significant participant in the metabolism of several structurally diverse phospholipid aldehydes. This metabolism may be a critical regulator of the pro-inflammatory and immunogenic effects of oxidized phospholipids.	Univ Louisville, Dept Med, Div Cardiol, Inst Mol Cardiol, Louisville, KY 40202 USA; Univ Louisville, Dept Med, James Graham Brown Canc Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Bhatnagar, A (corresponding author), Univ Louisville, Dept Med, Div Cardiol, Inst Mol Cardiol, Delia Baxter Bldg,580 S Preston St,Room 421F, Louisville, KY 40202 USA.	aruni@louisville.edu	Srivastava, Sanjay/D-3921-2012; Bhatnagar, Aruni/H-7791-2013; Spite, Matthew/B-3337-2010	trent, John/0000-0002-7346-4231	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055477, R01HL065618, R01HL059378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011860] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BHATNAGAR A, 1989, MOL PHARMACOL, V36, P825; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; Burczynski ME, 2001, J BIOL CHEM, V276, P2890, DOI 10.1074/jbc.M006655200; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CARPER DA, 1995, BBA-PROTEIN STRUCT M, V1246, P67, DOI 10.1016/0167-4838(94)00182-G; Chan H., 1987, AUTOXIDATION UNSATUR; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Dixit BL, 2000, J BIOL CHEM, V275, P21587, DOI 10.1074/jbc.M909235199; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1982, BIOCHEM J, V208, P129, DOI 10.1042/bj2080129; Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200; Gaut JP, 2001, TRENDS CARDIOVAS MED, V11, P103, DOI 10.1016/S1050-1738(01)00101-3; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Goyal J, 1997, J BIOL CHEM, V272, P16231, DOI 10.1074/jbc.272.26.16231; Harman D, 2001, ANN NY ACAD SCI, V928, P1, DOI 10.1111/j.1749-6632.2001.tb05631.x; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; Hoff HF, 2003, ARTERIOSCL THROM VAS, V23, P275, DOI 10.1161/01.ATV.0000051407.42536.73; Itabe H, 1999, J BIOCHEM-TOKYO, V126, P153, DOI 10.1093/oxfordjournals.jbchem.a022416; JAGT DLV, 1995, BBA-PROTEIN STRUCT M, V1249, P117; KAMIDO H, 1995, J LIPID RES, V36, P1876; KAYGANICHHARRISON KA, 1994, ANAL BIOCHEM, V221, P16, DOI 10.1006/abio.1994.1372; Keightley JA, 2004, MOL CELL PROTEOMICS, V3, P167, DOI 10.1074/mcp.M300119-MCP200; Khaselev N, 2000, FREE RADICAL BIO MED, V29, P620, DOI 10.1016/S0891-5849(00)00361-0; Khaselev N, 2000, J LIPID RES, V41, P564; KINOSHITA JH, 1990, EXP EYE RES, V50, P567, DOI 10.1016/0014-4835(90)90096-D; Kloner RA, 2001, CIRCULATION, V104, P2981, DOI 10.1161/hc4801.100038; Lamensdorf I, 2000, BRAIN RES, V868, P191, DOI 10.1016/S0006-8993(00)02309-X; Lee YS, 1998, BIOPHYS CHEM, V70, P203, DOI 10.1016/S0301-4622(97)00115-4; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Maack C, 2003, CIRCULATION, V108, P1567, DOI 10.1161/01.CIR.0000091084.46500.BB; Marathe GK, 2003, J BIOL CHEM, V278, P3937, DOI 10.1074/jbc.M211126200; Marathe GK, 2001, TRENDS CARDIOVAS MED, V11, P139, DOI 10.1016/S1050-1738(01)00100-1; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; Meijers R, 2001, J BIOL CHEM, V276, P9316, DOI 10.1074/jbc.M010870200; Mezzetti A, 2000, CARDIOVASC RES, V47, P475, DOI 10.1016/S0008-6363(00)00118-8; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; NAKAMURA Y, 1994, B CHEM SOC JPN, V67, P2151, DOI 10.1246/bcsj.67.2151; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Quarck R, 2001, CIRCULATION, V103, P2495; Ramana KV, 2000, BIOCHEMISTRY-US, V39, P12172, DOI 10.1021/bi000796e; Ramana KV, 2002, J BIOL CHEM, V277, P32063, DOI 10.1074/jbc.M202126200; Rittner HL, 1999, J CLIN INVEST, V103, P1007, DOI 10.1172/JCI4711; Ruef J, 2000, ARTERIOSCL THROM VAS, V20, P1745, DOI 10.1161/01.ATV.20.7.1745; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shinmura K, 2002, CIRC RES, V91, P240, DOI 10.1161/01.RES.0000029970.97247.57; Spycher SE, 1997, FASEB J, V11, P181, DOI 10.1096/fasebj.11.2.9039961; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; Srivastava S, 2002, AM J PHYSIOL-HEART C, V283, pH2612, DOI 10.1152/ajpheart.00592.2002; Srivastava S, 2001, BIOCHEM J, V358, P111, DOI 10.1042/0264-6021:3580111; Srivastava S, 2001, CHEM-BIOL INTERACT, V130, P563, DOI 10.1016/S0009-2797(00)00299-4; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; Srivastava S, 1998, BIOCHEM J, V329, P469, DOI 10.1042/bj3290469; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; Steckelbroeck S, 2004, J BIOL CHEM, V279, P10784, DOI 10.1074/jbc.M313308200; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248; Subbanagounder G, 2000, FREE RADICAL BIO MED, V28, P1751, DOI 10.1016/S0891-5849(00)00233-1; Subramanian VS, 1999, BBA-MOL CELL BIOL L, V1439, P95, DOI 10.1016/S1388-1981(99)00072-4; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Watson AD, 1999, J BIOL CHEM, V274, P24787, DOI 10.1074/jbc.274.35.24787; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; West M, 2003, PROG EXP CARDIOL, V6, P465; WILSON DK, 1995, BIOCHEMISTRY-US, V34, P14323, DOI 10.1021/bi00044a009; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; Zacarias A, 2002, ANAL BIOCHEM, V308, P152, DOI 10.1016/S0003-2697(02)00209-9	80	63	66	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53395	53406		10.1074/jbc.M403416200	http://dx.doi.org/10.1074/jbc.M403416200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465833	Green Accepted, hybrid			2022-12-25	WOS:000225680600073
J	Al-Anouti, F; Tomavo, S; Parmley, S; Ananvoranich, S				Al-Anouti, F; Tomavo, S; Parmley, S; Ananvoranich, S			The expression of lactate dehydrogenase is important for the cell cycle of Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED GENES; DOUBLE-STRANDED-RNA; DIFFERENTIAL EXPRESSION; STAGE CONVERSION; IDENTIFICATION; INTERFERENCE; BRADYZOITES; ENZYMES; MEDIATE; CLONING	In Toxoplasma gondii, lactate dehydrogenase is encoded by two independent and developmentally regulated genes LDH1 and LDH2. These genes and their products have been implicated in the control of a metabolic flux during parasite differentiation. To investigate the significance of LDH1 and LDH2 in this process, we generated stable transgenic parasite lines in which the expression of these two expressed isoforms of lactate dehydrogenase was knocked down in a stage-specific manner. These LDH knockdown parasites exhibited variable growth rates in either the tachyzoite or the bradyzoite stage, as compared with the parental parasites. Their differentiation processes were impaired when the parasites were grown under in vitro conditions. In vivo studies in a murine model system revealed that tachyzoites of these parasite lines were unable to form significant numbers of tissue cysts and to establish a chronic infection. Most importantly, all mice that were initially infected with tachyzoites of either of the four LDH knockdown lines survived a subsequent challenge with tachyzoites of the parental parasites ( 104), a dose that usually causes 100% mortality, suggesting that live vaccination of mice with the LDH knockdown tachyzoites can confer protection against T. gondii. Thus, we conclude that LDH expression is essential for parasite differentiation. The knockdown of LDH1 and LDH2 expression gave rise to virulence-attenuated parasites that were unable to exhibit a significant brain cyst burden in a murine model of chronic infection.	Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada; Univ Sci & Technol Lille, CNRS UMR 8576, Equip Parasitol Mol, Lab Chim Biol,UGSF, F-59655 Villeneuve Dascq, France; Palo Alto Med Fdn, Dept Immunol & Infect Dis, Palo Alto, CA 94305 USA	University of Windsor; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Palo Alto Medical Foundation Research Institute	Ananvoranich, S (corresponding author), Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada.	anans@uwindsor.ca	Al Anouti, Fatme/ADY-7764-2022	Al Anouti, Fatme/0000-0002-1993-6656				Al-Anouti F, 2003, BIOCHEM BIOPH RES CO, V302, P316, DOI 10.1016/S0006-291X(03)00172-4; Al-Anouti F, 2002, ANTISENSE NUCLEIC A, V12, P275, DOI 10.1089/108729002320351593; Black MW, 2000, MICROBIOL MOL BIOL R, V64, P607, DOI 10.1128/MMBR.64.3.607-623.2000; Black MW, 1998, J BIOL CHEM, V273, P3972, DOI 10.1074/jbc.273.7.3972; BOHNE W, 1995, MOL MICROBIOL, V16, P1221, DOI 10.1111/j.1365-2958.1995.tb02344.x; Boothroyd JC, 1997, PHILOS T ROY SOC B, V352, P1347, DOI 10.1098/rstb.1997.0119; Cleary MD, 2002, EUKARYOT CELL, V1, P329, DOI 10.1128/EC.1.3.329-340.2002; Dando C, 2001, MOL BIOCHEM PARASIT, V118, P23, DOI 10.1016/S0166-6851(01)00360-7; Denton H, 1996, FEMS MICROBIOL LETT, V137, P103, DOI 10.1111/j.1574-6968.1996.tb08090.x; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; DUBEY JP, 1994, J AM VET MED ASSOC, V205, P1593; Dzierszinski F, 2001, J MOL BIOL, V309, P1017, DOI 10.1006/jmbi.2001.4730; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Freyre A, 1995, J PARASITOL, V81, P1008, DOI 10.2307/3284058; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jijakli H, 1996, ARCH BIOCHEM BIOPHYS, V327, P260, DOI 10.1006/abbi.1996.0119; Kavanagh KL, 2004, BIOCHEMISTRY-US, V43, P879, DOI 10.1021/bi035108g; Manger ID, 1998, INFECT IMMUN, V66, P1632, DOI 10.1128/IAI.66.4.1632-1637.1998; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; PARMLEY SF, 1995, MOL BIOCHEM PARASIT, V73, P253, DOI 10.1016/0166-6851(95)00100-F; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SOETE M, 1993, EXP PARASITOL, V76, P259, DOI 10.1006/expr.1993.1031; Soldati D, 1995, MOL BIOCHEM PARASIT, V74, P87, DOI 10.1016/0166-6851(95)02487-5; Tomavo S, 2001, INT J PARASITOL, V31, P1023, DOI 10.1016/S0020-7519(01)00193-X; Ullu E, 2004, CELL MICROBIOL, V6, P509, DOI 10.1111/j.1462-5822.2004.00399.x; Voinnet O, 2002, CURR OPIN PLANT BIOL, V5, P444, DOI 10.1016/S1369-5266(02)00291-1; Winter VJ, 2003, MOL BIOCHEM PARASIT, V131, P1, DOI 10.1016/S0166-6851(03)00170-1; Yahiaoui B, 1999, MOL BIOCHEM PARASIT, V99, P223, DOI 10.1016/S0166-6851(99)00019-5; Yang SM, 1997, GENE, V184, P1, DOI 10.1016/S0378-1119(96)00566-5; Zhang YW, 2001, INFECT IMMUN, V69, P501, DOI 10.1128/IAI.69.1.501-507.2001	32	50	54	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52300	52311		10.1074/jbc.M409175200	http://dx.doi.org/10.1074/jbc.M409175200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459194	hybrid			2022-12-25	WOS:000225493400071
J	Bailey, MJ; Beremand, PD; Hammer, R; Reidel, E; Thomas, TK; Cassone, VM				Bailey, MJ; Beremand, PD; Hammer, R; Reidel, E; Thomas, TK; Cassone, VM			Transcriptional profiling of circadian patterns of mRNA expression in the chick retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; PINEAL-GLAND; SUPRACHIASMATIC NUCLEUS; MELATONIN SYNTHESIS; PIGMENT-EPITHELIUM; MICROARRAY ANALYSIS; MAMMALIAN RETINA; BIOLOGICAL CLOCK; BINDING-PROTEIN; COLUMBA-LIVIA	Previous transcriptome analyses have identified candidate molecular components of the avian pineal clock, and herein we employ high density cDNA microarrays of pineal gland transcripts to determine oscillating transcripts in the chick retina under daily and constant darkness conditions. Subsequent comparative transcriptome analysis of the pineal and retinal oscillators distinguished several transcriptional similarities between the two as well as significant differences. Rhythmic retinal transcripts were classified according to functional categories including phototransductive elements, transcription/translation factors, carrier proteins, cell signaling molecules, and stress response genes. Candidate retinal clock transcripts were also organized relative to time of day mRNA abundance, revealing groups accumulating peak mRNA levels across the circadian day but primarily reaching peak values at subjective dawn or subjective dusk. Comparison of the chick retina transcriptome to the pineal transcriptome under constant conditions yields an interesting group of conserved genes. This group includes putative clock elements cry1 and per3 in addition to several previously unidentified and uninvestigated genes exhibiting profiles of mRNA abundance that varied markedly under daily and constant conditions. In contrast, many transcripts were differentially regulated, including those believed to be involved in both melatonin biosynthesis and circadian clock mechanisms. Our results indicate an intimate transcriptional relationship between the avian pineal and retina in addition to providing previously uncharacterized molecular elements that we hypothesize to be involved in circadian rhythm generation.	Texas A&M Univ, Ctr Biol Clocks Res, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Texas A&M Univ, Lab Funct Genom, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Cassone, VM (corresponding author), Texas A&M Univ, Ctr Biol Clocks Res, College Stn, TX 77843 USA.	vmc@mail.bio.tamu.edu	Cassone, Vincent/AAD-5191-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039546] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS39546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi A, 2002, GLIA, V39, P268, DOI 10.1002/glia.10109; Akhmedov NB, 1998, INVEST OPHTH VIS SCI, V39, P1775; Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Allen G, 2001, J NEUROSCI, V21, P7937, DOI 10.1523/JNEUROSCI.21-20-07937.2001; Bailey MJ, 2003, MOL ENDOCRINOL, V17, P2084, DOI 10.1210/me.2003-0121; Bailey MJ, 2002, FEBS LETT, V513, P169, DOI 10.1016/S0014-5793(02)02276-7; Beaule C, 2003, NEUROSCIENCE, V121, P253, DOI 10.1016/S0306-4522(03)00420-2; BERMAN P, 1987, CELL, V51, P135, DOI 10.1016/0092-8674(87)90018-3; Bernard M, 1997, J NEUROCHEM, V68, P213; BESHARSE JC, 1983, NATURE, V305, P133, DOI 10.1038/305133a0; BINKLEY S, 1971, SCIENCE, V174, P311, DOI 10.1126/science.174.4006.311; CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S; Cassone VM, 1988, J BIOL RHYTHM, V3, P71, DOI 10.1177/074873048800300106; CASSONE VM, 1984, J EXP ZOOL, V232, P539, DOI 10.1002/jez.1402320321; Cassone VM, 1998, CHRONOBIOL INT, V15, P457, DOI 10.3109/07420529808998702; Chong NW, 2000, J BIOL CHEM, V275, P32991, DOI 10.1074/jbc.M005671200; Chong NW, 2003, J NEUROCHEM, V85, P851, DOI 10.1046/j.1471-4159.2003.01723.x; Chong NW, 1998, MOL BRAIN RES, V61, P243, DOI 10.1016/S0169-328X(98)00219-8; Coon SL, 1999, AM J PHYSIOL-ENDOC M, V277, pE792, DOI 10.1152/ajpendo.1999.277.5.E792; CRABB JW, 1991, J BIOL CHEM, V266, P16674; Cyran SA, 2003, CELL, V112, P329, DOI 10.1016/S0092-8674(03)00074-6; Doyle SE, 2002, VISUAL NEUROSCI, V19, P593, DOI 10.1017/S0952523802195058; Dudley CA, 2003, SCIENCE, V301, P379, DOI 10.1126/science.1082795; Duffield GE, 2002, CURR BIOL, V12, P551, DOI 10.1016/S0960-9822(02)00765-0; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EBIHARA S, 1984, J COMP PHYSIOL, V154, P59, DOI 10.1007/BF00605391; Fagan T, 1999, BIOCHEMISTRY-US, V38, P7689, DOI 10.1021/bi9826005; GASTON S, 1968, SCIENCE, V160, P1125, DOI 10.1126/science.160.3832.1125; Glossop NRJ, 2002, J CELL SCI, V115, P3369; Haeseleer F, 2000, METHOD ENZYMOL, V316, P372; Haque R, 2003, MOL VIS, V9, P52; Haque R, 2002, NEUROREPORT, V13, P2247, DOI 10.1097/00001756-200212030-00016; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; Hinterhuber G, 2004, J INVEST DERMATOL, V122, P406, DOI 10.1046/j.0022-202X.2004.22216.x; Iuvone PM, 1997, BIOL SIGNAL, V6, P217; JIANG M, 1993, INVEST OPHTH VIS SCI, V34, P3669; Ko GYP, 2003, J NEUROSCI, V23, P3145; Ko GYP, 2001, NEURON, V29, P255, DOI 10.1016/S0896-6273(01)00195-7; LU J, 1995, J COMP PHYSIOL A, V177, P299, DOI 10.1007/BF00192419; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; McGoogan JM, 1999, AM J PHYSIOL-REG I, V277, pR1418, DOI 10.1152/ajpregu.1999.277.5.R1418; MENAKER M, 1972, SCI AM, V226, P22, DOI 10.1038/scientificamerican0372-22; Morin F, 2001, J NEUROCHEM, V78, P88, DOI 10.1046/j.1471-4159.2001.00407.x; Morre DJ, 2002, BIOCHEMISTRY-US, V41, P11941, DOI 10.1021/bi020392h; Natesan A, 2002, CELL TISSUE RES, V309, P35, DOI 10.1007/s00441-002-0571-6; Niki T, 1998, BIOCHEM BIOPH RES CO, V248, P115, DOI 10.1006/bbrc.1998.8916; NYCE J, 1977, PHOTOCHEM PHOTOBIOL, V25, P529, DOI 10.1111/j.1751-1097.1977.tb09123.x; Okano T, 2001, GENES CELLS, V6, P825, DOI 10.1046/j.1365-2443.2001.00462.x; PETERS JL, 2003, 33 ANN M SOC NEUR NO; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rosbash Michael, 2003, Novartis Found Symp, V253, P223; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893; Tan Y, 2004, CURR BIOL, V14, P433, DOI 10.1016/j.cub.2004.02.035; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7; UNDERWOOD H, 1984, J EXP ZOOL, V232, P557, DOI 10.1002/jez.1402320323; UNDERWOOD H, 1988, J BIOL RHYTHM, V3, P323, DOI 10.1177/074873048800300402; Wu WQ, 2000, J BIOL RHYTHM, V15, P317, DOI 10.1177/074873000129001422; Yamazaki S, 2002, J BIOL RHYTHM, V17, P315, DOI 10.1177/074873040201700405; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; ZAWILSKA JB, 1992, NEUROSCI LETT, V135, P71, DOI 10.1016/0304-3940(92)90138-W; Zhuang MH, 2000, MOL BRAIN RES, V82, P52, DOI 10.1016/S0169-328X(00)00177-7	69	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52247	52254		10.1074/jbc.M405679200	http://dx.doi.org/10.1074/jbc.M405679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15448147	hybrid			2022-12-25	WOS:000225493400065
J	Carrier, JC; Deblois, GV; Champigny, C; Levy, E; Giguere, V				Carrier, JC; Deblois, GV; Champigny, C; Levy, E; Giguere, V			Estrogen-related receptor alpha (ERR alpha) is a transcriptional regulator of apolipoprotein A-IV and controls lipid handling in the intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; DIETARY-FAT ABSORPTION; GENE-EXPRESSION; COACTIVATOR-1-ALPHA PGC-1-ALPHA; PANCREATIC LIPASE; NUCLEAR RECEPTORS; GAMMA; LIVER; IDENTIFICATION; OVEREXPRESSION	The estrogen-related receptor alpha (ERRalpha) is an orphan member of the superfamily of nuclear receptors involved in the control of energy metabolism. In particular, ERRalpha induces a high energy expenditure in the presence of the coactivator PGC-1alpha. However, ERRalpha knockout mice have reduced fat mass and are resistant to diet-induced obesity. ERRalpha is expressed in epithelial cells of the small intestine, and because the intestine is the first step in the energy chain, we investigated whether ERRalpha plays a function in dietary energy handling. Gene expression profiling in the intestine identified a subset of genes involved in oxidative phosphorylation that were down-regulated in the absence of ERRalpha. In support of the physiological role of ERRalpha in this pathway, isolated enterocytes from ERRalpha knockout mice display lower capacity for beta-oxidation. Microarray results also show altered expression of genes involved in dietary lipid digestion and absorption, such as pancreatic lipase-related protein 2 (PLRP2), fatty acid-binding protein 1 and 2 ( L-FABP and I-FABP), and apolipoprotein A-IV (apoA-IV). In agreement, we found that ERRalpha(-/-) pups exhibit significant lipid malabsorption. We further show that the apoA-IV promoter is a direct target of ERRalpha and that its presence is required to maintain basal level but not feeding-induced regulation of the apoA-IV gene in mice. ERRalpha, in cooperation with PGC-1alpha, activates the apoA-IV promoter via interaction with the apoC-III enhancer in both human and mouse. Our results demonstrate that apoA-IV is a direct ERRalpha target gene and suggest a function for ERRalpha in intestinal fat transport, a crucial step in energy balance.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Univ Montreal, Hop St Justine, Ctr Rech, Dept Nutr, Montreal, PQ H3C 1C5, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; Universite de Montreal; McGill University; McGill University; McGill University	Giguere, V (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Room H5-21,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	vincent.giguere@mcgill.ca		Giguere, Vincent/0000-0001-9567-3694; Deblois, Genevieve/0000-0002-3067-2807				Ariazi EA, 2002, CANCER RES, V62, P6510; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; Bonnelye E, 2002, ENDOCRINOLOGY, V143, P3658, DOI 10.1210/en.2002-220095; Bonnelye E, 2001, J CELL BIOL, V153, P971, DOI 10.1083/jcb.153.5.971; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Claudel T, 2003, GASTROENTEROLOGY, V125, P544, DOI 10.1016/S0016-5085(03)00896-5; D'Agostino D, 2004, J NUTR, V134, P132, DOI 10.1093/jn/134.1.132; Darimont C, 2000, J LIPID RES, V41, P84; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Ek-von Mentzer BA, 2001, J BIOL CHEM, V276, P15575, DOI 10.1074/jbc.M011623200; FUJIMOTO K, 1993, J CLIN INVEST, V91, P1830, DOI 10.1172/JCI116395; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Jove M, 2004, J LIPID RES, V45, P113, DOI 10.1194/jlr.M300208-JLR200; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Laganiere J, 2003, METHOD ENZYMOL, V364, P339; Laganiere J, 2004, J BIOL CHEM, V279, P18504, DOI 10.1074/jbc.M313543200; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; Levy E, 1996, CLIN INVEST MED, V19, P317; Liang Y, 2004, MOL ENDOCRINOL, V18, P2000, DOI 10.1210/me.2003-0477; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Liu M, 2003, EXP BIOL MED, V228, P1181, DOI 10.1177/153537020322801013; Lowe ME, 1998, J BIOL CHEM, V273, P31215, DOI 10.1074/jbc.273.47.31215; Lu S, 2002, J BIOL CHEM, V277, P31929, DOI 10.1074/jbc.M201418200; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Murase T, 2002, J LIPID RES, V43, P1312, DOI 10.1194/jlr.M200094-JLR200; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poirier H, 1997, AM J PHYSIOL-GASTR L, V273, pG289, DOI 10.1152/ajpgi.1997.273.2.G289; Poirier H, 2001, BIOCHEM J, V355, P481, DOI 10.1042/0264-6021:3550481; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Stan S, 2003, BBA-MOL CELL BIOL L, V1631, P177, DOI 10.1016/S1388-1981(03)00004-0; Suzuki T, 2004, CANCER RES, V64, P4670, DOI 10.1158/0008-5472.CAN-04-0250; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Vassileva G, 2000, FASEB J, V14, P2040, DOI 10.1096/fj.99-0959com; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Weinstock PH, 1997, J LIPID RES, V38, P1782; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis	50	84	88	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52052	52058		10.1074/jbc.M410337200	http://dx.doi.org/10.1074/jbc.M410337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466464	hybrid			2022-12-25	WOS:000225493400042
J	Dobransky, T; Doherty-Kirby, A; Kim, AR; Brewer, D; Lajoie, G; Rylett, RJ				Dobransky, T; Doherty-Kirby, A; Kim, AR; Brewer, D; Lajoie, G; Rylett, RJ			Protein kinase C isoforms differentially phosphorylate human choline acetyltransferase regulating its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; NERVE GROWTH-FACTOR; BASAL FOREBRAIN; HIERARCHICAL PHOSPHORYLATION; TYROSINE-HYDROXYLASE; MYASTHENIC SYNDROME; NEURONS; ACETYLCHOLINE; ACTIVATION; MUTATIONS	Choline acetyltransferase ( ChAT) synthesizes acetylcholine in cholinergic neurons; regulation of its activity or response to physiological stimuli is poorly understood. We show that ChAT is differentially phosphorylated by protein kinase C (PKC) isoforms on four serines (Ser-440, Ser-346, Ser-347, and Ser-476) and one threonine (Thr-255). This phosphorylation is hierarchical, with phosphorylation at Ser-476 required for phosphorylation at other serines. Phosphorylation at some, but not all, sites regulates basal catalysis and activation. Ser-476 with Ser-440 and Ser-346/347 maintains basal ChAT activity. Ser-440 is targeted by Arg-442 for phosphorylation by PKC. Arg-442 is mutated spontaneously (R442H) in congenital myasthenic syndrome, rendering ChAT inactive and causing neuromuscular failure. This mutation eliminates phosphorylation of Ser-440, and Arg-442, not phosphorylation of Ser-440, appears primarily responsible for ChAT activity, with Ser-440 phosphorylation modulating catalysis. Finally, basal ChAT phosphorylation in neurons is mediated predominantly by PKC at Ser-476, with PKC activation increasing phosphorylation at Ser-440 and enhancing ChAT activity.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Cell Biol Res Grp, London, ON N6A 5C1, Canada; Robarts Res Inst, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Rylett, RJ (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.	jane.rylett@fmd.uwo.ca	Rylett, Rebecca Jane/K-3597-2013	Rylett, Rebecca Jane/0000-0002-9158-9599				Battaini F, 2001, PHARMACOL RES, V44, P353, DOI 10.1006/phrs.2001.0893; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENOREPARSONS M, 1989, ARCH BIOCHEM BIOPHYS, V272, P274, DOI 10.1016/0003-9861(89)90220-8; Blusztajn JK, 2000, METAB BRAIN DIS, V15, P45, DOI 10.1007/BF02680013; Boissiere F, 1997, NEUROSCI LETT, V225, P169, DOI 10.1016/S0304-3940(97)00210-3; BRUCE G, 1989, NEUROCHEM RES, V14, P613, DOI 10.1007/BF00964869; Cai YY, 2004, EMBO J, V23, P2047, DOI 10.1038/sj.emboj.7600221; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Cronin CN, 1998, J BIOL CHEM, V273, P24465, DOI 10.1074/jbc.273.38.24465; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dettwiler S, 1999, J VIROL, V73, P7410, DOI 10.1128/JVI.73.9.7410-7420.1999; Dobransky T, 2003, J BIOL CHEM, V278, P5883, DOI 10.1074/jbc.M212080200; Dobransky T, 2001, J BIOL CHEM, V276, P22244, DOI 10.1074/jbc.M011702200; Dobransky T, 2000, BIOCHEM J, V349, P141, DOI 10.1042/0264-6021:3490141; Engel AG, 2003, NAT REV NEUROSCI, V4, P339, DOI 10.1038/nrn1101; FONNUM F, 1969, BIOCHEM J, V115, P465, DOI 10.1042/bj1150465; Gingras AC, 2001, GENE DEV, V15, P2852; HABERT E, 1992, J NEUROCHEM, V58, P1447, DOI 10.1111/j.1471-4159.1992.tb11362.x; HIGGINS GA, 1989, NEURON, V3, P247, DOI 10.1016/0896-6273(89)90038-X; Jicha GA, 1999, J NEUROCHEM, V72, P214, DOI 10.1046/j.1471-4159.1999.0720214.x; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOLIATSOS VE, 1990, J NEUROSCI, V10, P3801, DOI 10.1523/JNEUROSCI.10-12-03801.1990; Kumer SC, 1996, J NEUROCHEM, V67, P443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Merrer J, 2000, PHARMACOL RES, V41, P503; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Maselli RA, 2003, MUSCLE NERVE, V27, P180, DOI 10.1002/mus.10300; McMillan PJ, 1996, J NEUROSCI, V16, P1860; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohno K, 2001, P NATL ACAD SCI USA, V98, P2017, DOI 10.1073/pnas.98.4.2017; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pongrac JL, 1996, J NEUROCHEM, V66, P804; RYLETT RJ, 1993, J NEUROCHEM, V61, P1388, DOI 10.1111/j.1471-4159.1993.tb13632.x; SCHMIDT BM, 1993, J NEUROCHEM, V61, P1774, DOI 10.1111/j.1471-4159.1993.tb09815.x; Schreiber KL, 2001, AM J PHYSIOL-HEART C, V281, pH2062, DOI 10.1152/ajpheart.2001.281.5.H2062; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi BT, 1998, J NEUROSCI, V18, P9326; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; Tandon A, 1996, J NEUROCHEM, V66, P1033; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	46	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52059	52068		10.1074/jbc.M407085200	http://dx.doi.org/10.1074/jbc.M407085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15381704	hybrid			2022-12-25	WOS:000225493400043
J	Hanisch, UK; van Rossum, D; Xie, YH; Gast, K; Misselwitz, R; Auriola, S; Goldsteins, G; Koistinaho, J; Kettenmann, H; Moller, T				Hanisch, UK; van Rossum, D; Xie, YH; Gast, K; Misselwitz, R; Auriola, S; Goldsteins, G; Koistinaho, J; Kettenmann, H; Moller, T			The microglia-activating potential of thrombin - The protease is not involved in the induction of proinflammatory cytokines and chemokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIGRAL DOPAMINERGIC-NEURONS; CENTRAL-NERVOUS-SYSTEM; SERINE PROTEASES; TYROSINE KINASE; EDEMA FORMATION; ALPHA-THROMBIN; RAT ASTROCYTES; IN-VIVO; RECEPTORS; BRAIN	The serine protease thrombin is known as a blood coagulation factor. Through limited cleavage of proteinase-activated receptors it can also control growth and functions in various cell types, including neurons, astrocytes, and microglia ( brain macrophages). A number of previous studies indicated that thrombin induces the release of proinflammatory cytokines and chemokines from microglial cells, suggesting another important role for the protease beyond hemostasis. In the present report, we provide evidence that this effect is not mediated by any proteolytic or non-proteolytic mechanism involving thrombin proper. Inhibition of the enzymatic thrombin activity did not affect the microglial release response. Instead the cyto-/chemokine-inducing activity solely resided in a high molecular weight protein fraction that could be isolated in trace amounts even from apparently homogenous alpha- and gamma-thrombin preparations. High molecular weight material contained thrombin-derived peptides as revealed by mass spectrometry but was devoid of thrombin-like enzymatic activity. Separated from the high molecular weight fraction by fast protein liquid chromatography, enzymatically intact alpha- and gamma-thrombin failed to trigger any release. Our findings may force a revision of the notion that thrombin itself is a direct proinflammatory release signal for microglia. In addition, they could be relevant for the study of other cellular activities and their assignment to this protease.	Univ Gottingen, Inst Neuropathol, D-37075 Gottingen, Germany; Max Delbruck Ctr Mol Med, Dept Cellular Neurosci, D-13092 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Biopolymer Spect, D-13092 Berlin, Germany; Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Univ Potsdam, Dept Phys Biochem, D-14476 Potsdam, Germany; Univ Kuopio, Dept Pharmaceut Chem, FIN-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Oncol, FIN-70211 Kuopio, Finland	University of Gottingen; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Washington; University of Washington Seattle; University of Potsdam; University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital	Hanisch, UK (corresponding author), Univ Gottingen, Inst Neuropathol, Robert Koch Str 40, D-37075 Gottingen, Germany.	ukhanisch@med.uni-goettingen.de	Goldsteins, Gundars/X-1240-2019; Kettenmann, Helmut/AAJ-5142-2021	Kettenmann, Helmut/0000-0001-8208-0291	NINDS NIH HHS [R01 NS044337-02, NS44337] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044337] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Balcaitis S, 2003, NEUROREPORT, V14, P2373, DOI 10.1097/00001756-200312190-00017; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; BISCHOFF R, 1989, J CHROMATOGR, V476, P245, DOI 10.1016/S0021-9673(01)93873-7; BODE W, 1992, PROTEIN SCI, V1, P426; Carreno-Muller E, 2003, J NEUROCHEM, V84, P1201, DOI 10.1046/j.1471-4159.2003.01634.x; Choi SH, 2003, J NEUROSCI, V23, P5877; Cocks TM, 2000, TRENDS PHARMACOL SCI, V21, P103, DOI 10.1016/S0165-6147(99)01440-6; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CROMACK DT, 1992, J SURG RES, V53, P117, DOI 10.1016/0022-4804(92)90022-R; DECRISTOFARO R, 1995, J MOL BIOL, V245, P447; DODT J, 1988, FEBS LETT, V229, P87, DOI 10.1016/0014-5793(88)80803-2; Dong JF, 1997, BLOOD, V89, P4355, DOI 10.1182/blood.V89.12.4355; Donovan FM, 1997, J NEUROSCI, V17, P5316; Friedmann I, 2001, J NEUROIMMUNOL, V121, P12, DOI 10.1016/S0165-5728(01)00397-6; Furman MI, 1998, P NATL ACAD SCI USA, V95, P3082, DOI 10.1073/pnas.95.6.3082; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Grandaliano G, 1999, EXP NEPHROL, V7, P20; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hanisch UK, 2001, EUR J IMMUNOL, V31, P2104, DOI 10.1002/1521-4141(200107)31:7<2104::AID-IMMU2104>3.0.CO;2-3; Hausler KG, 2002, EUR J NEUROSCI, V16, P2113, DOI 10.1046/j.1460-9568.2002.02287.x; Kim KY, 2002, NEUROREPORT, V13, P849, DOI 10.1097/00001756-200205070-00022; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Nakamura Y, 2000, J NEUROCHEM, V75, P2309, DOI 10.1046/j.1471-4159.2000.0752309.x; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Ohyama H, 2001, BRAIN RES, V902, P264, DOI 10.1016/S0006-8993(01)02354-X; Prinz M, 1999, J NEUROPATH EXP NEUR, V58, P1078, DOI 10.1097/00005072-199910000-00006; Ryu J, 2002, J IMMUNOL, V168, P5805, DOI 10.4049/jimmunol.168.11.5805; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; Shikamoto Y, 1999, FEBS LETT, V463, P387, DOI 10.1016/S0014-5793(99)01657-9; Si QS, 2000, EXP NEUROL, V162, P89, DOI 10.1006/exnr.2000.7334; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Suidan HS, 1996, SEMIN THROMB HEMOST, V22, P125, DOI 10.1055/s-2007-998999; Suo Z., 2004, Current Drug Targets - Inflammation and Allergy, V3, P105, DOI 10.2174/1568010043483953; Suo ZM, 2003, J BIOL CHEM, V278, P31177, DOI 10.1074/jbc.M302137200; Tomimatsu Y, 2002, LIFE SCI, V72, P355, DOI 10.1016/S0024-3205(02)02285-3; Turgeon VL, 1997, BRAIN RES REV, V25, P85, DOI 10.1016/S0165-0173(97)00015-5; Ubl JJ, 2000, J PHYSIOL-LONDON, V525, P319, DOI 10.1111/j.1469-7793.2000.00319.x; VANROSSUM D, 2004, BRAIN DAMAGE REPAIR, P181; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; Wagner KR, 2002, DEV NEUROSCI-BASEL, V24, P154, DOI 10.1159/000065703; Wang H, 2003, BIOL CHEM, V384, P193, DOI 10.1515/BC.2003.021; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; Weinstein JR, 1998, J NEUROCHEM, V71, P1034; Xue MZ, 2001, STROKE, V32, P2164, DOI 10.1161/hs0901.095408; Yamazaki Y, 1999, J BIOCHEM-TOKYO, V126, P655, DOI 10.1093/oxfordjournals.jbchem.a022499; Zoubine MN, 1996, DEV BIOL, V179, P447, DOI 10.1006/dbio.1996.0274	53	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51880	51887		10.1074/jbc.M408318200	http://dx.doi.org/10.1074/jbc.M408318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452111	hybrid			2022-12-25	WOS:000225493400021
J	Kim, KH; Song, MJ; Yoo, EJ; Choe, SS; Park, SD; Kim, JB				Kim, KH; Song, MJ; Yoo, EJ; Choe, SS; Park, SD; Kim, JB			Regulatory role of glycogen synthase kinase 3 for transcriptional activity of ADD1/SREBP1c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1C; STIMULATED GLUCOSE-METABOLISM; INSULIN-RECEPTOR SUBSTRATE-1; RABBIT SKELETAL-MUSCLE; GENE-EXPRESSION; IN-VITRO; NUTRITIONAL REGULATION; STEROL REGULATION; RAT HEPATOCYTES; BETA-CATENIN	Adipocyte determination- and differentiation-dependent factor 1 (ADD1) plays important roles in lipid metabolism and insulin-dependent gene expression. Because insulin stimulates carbohydrate and lipid synthesis, it would be important to decipher how the transcriptional activity of ADD1/SREBP1c is regulated in the insulin signaling pathway. In this study, we demonstrated that glycogen synthase kinase (GSK)-3 negatively regulates the transcriptional activity of ADD1/SREBP1c. GSK3 inhibitors enhanced a transcriptional activity of ADD1/ SREBP1c and expression of ADD1/ SREBP1c target genes including fatty acid synthase (FAS), acetyl-CoA carboxylase 1 (ACC1), and steroyl-CoA desaturase 1 (SCD1) in adipocytes and hepatocytes. In contrast, overexpression of GSK3beta down-regulated the transcriptional activity of ADD1/ SREBP1c. GSK3 inhibitor-mediated ADD1/ SREBP1c target gene activation did not require de novo protein synthesis, implying that GSK3 might affect transcriptional activity of ADD1/ SREBP1c at the level of post-translational modification. Additionally, we demonstrated that GSK3 efficiently phosphorylated ADD1/ SREBP1c in vitro and in vivo. Therefore, these data suggest that GSK3 inactivation is crucial to confer stimulated transcriptional activity of ADD1/ SREBP1c for insulin-dependent gene expression, which would coordinate lipid and glucose metabolism.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Int Vaccine Inst, Seoul 151742, South Korea	Seoul National University (SNU); International Vaccine Institute	Kim, JB (corresponding author), Seoul Natl Univ, Sch Biol Sci, San 56-1 Sillim Dong, Seoul 151742, South Korea.	jaebkim@snu.ac.kr	Song, Minsun/I-5701-2015	KIM, Jae Bum/0000-0003-2337-6935; Min, Jeong-Ki/0000-0003-4924-8739				Aiston S, 2003, EUR J BIOCHEM, V270, P2773, DOI 10.1046/j.1432-1033.2003.03648.x; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Bene H, 2001, BIOCHEM BIOPH RES CO, V284, P1194, DOI 10.1006/bbrc.2001.5102; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CHESNOKOV V N, 1990, Biokhimiya, V55, P1276; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Cline GW, 2002, DIABETES, V51, P2903, DOI 10.2337/diabetes.51.10.2903; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Eldar-Finkelman H, 1999, DIABETES, V48, P1662, DOI 10.2337/diabetes.48.8.1662; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Guillet-Deniau I, 2002, DIABETES, V51, P1722, DOI 10.2337/diabetes.51.6.1722; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Iynedjian PB, 2000, BIOCHEM J, V351, P621, DOI 10.1042/0264-6021:3510621; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Lan H, 2003, DIABETES, V52, P688, DOI 10.2337/diabetes.52.3.688; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Matsumoto M, 2002, DIABETES, V51, P1672, DOI 10.2337/diabetes.51.6.1672; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TABATA I, 1994, DIABETES, V43, P903, DOI 10.2337/diabetes.43.7.903; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Tsakiridis T, 2001, BIOCHEM BIOPH RES CO, V288, P205, DOI 10.1006/bbrc.2001.5762; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Zhen XC, 2002, PSYCHOPHARMACOLOGY, V162, P379, DOI 10.1007/s00213-002-1126-y	64	79	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51999	52006		10.1074/jbc.M405522200	http://dx.doi.org/10.1074/jbc.M405522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466874	hybrid			2022-12-25	WOS:000225493400036
J	Sugioka, R; Shimizu, S; Tsujimoto, Y				Sugioka, R; Shimizu, S; Tsujimoto, Y			Fzo1, a protein involved in mitochondrial fusion, inhibits apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; CYTOCHROME-C RELEASE; OUTER-MEMBRANE; CELL-DEATH; FISSION; MORPHOLOGY; BCL-2; CARDIOLIPIN; YEAST; BAX	Mitochondrial morphology and physiology are regulated by the processes of fusion and fission. Some forms of apoptosis are reported to be associated with mitochondrial fragmentation. We showed that overexpression of Fzo1A/B ( rat) proteins involved in mitochondrial fusion, or silencing of Dnm1 (rat)/Drp1 (human) (a mitochondrial fission protein), increased elongated mitochondria in healthy cells. After apoptotic stimulation, these interventions inhibited mitochondrial fragmentation and cell death, suggesting that a process involved in mitochondrial fusion/fission might play a role in the regulation of apoptosis. Consistently, silencing of Fzo1A/B or Mfn1/2 (a human homolog of Fzo1A/B) led to an increase of shorter mitochondria and enhanced apoptotic death. Overexpression of Fzo1 inhibited cytochrome c release and activation of Bax/Bak, as assessed from conformational changes and oligomerization. Silencing of Mfn or Drp1 caused an increase or decrease of mitochondrial sensitivity to apoptotic stimulation, respectively. These results indicate that some of the proteins involved in mitochondrial fusion/fission modulate apoptotic cell death at the mitochondrial level.	Osaka Univ, Sch Med, Dept Postgenom & Dis, Genet Mol Lab, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Postgenom & Dis, Genet Mol Lab, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp						Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fernandez MG, 2002, CELL GROWTH DIFFER, V13, P449; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; KJER P, 1983, ACTA OPHTHALMOL, V61, P300; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Malisan F, 2003, CURR MED CHEM, V10, P1573, DOI 10.2174/0929867033457188; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Messerschmitt M, 2003, J CELL BIOL, V160, P553, DOI 10.1083/jcb.200211113; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nomura M, 1999, CANCER RES, V59, P5542; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Santel A, 2001, J CELL SCI, V114, P867; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123; Shimizu S, 1996, ONCOGENE, V12, P2251; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang XD, 2001, GENE DEV, V15, P2922; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	38	275	291	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52726	52734		10.1074/jbc.M408910200	http://dx.doi.org/10.1074/jbc.M408910200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459195	hybrid			2022-12-25	WOS:000225493400119
J	Davidson, MK; Shandilya, HK; Hirota, K; Ohta, K; Wahls, WP				Davidson, MK; Shandilya, HK; Hirota, K; Ohta, K; Wahls, WP			Atf1-Pcr1-M26 complex links stress-activated MAPK and cAMP-dependent protein kinase pathways via chromatin remodeling of cgs2(+)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; MEIOTIC RECOMBINATION HOTSPOT; ATF1 TRANSCRIPTION FACTOR; FISSION YEAST; SEXUAL DEVELOPMENT; OXIDATIVE STRESS; HOT-SPOT; BINDING PROTEIN; GENE-EXPRESSION; OSMOTIC-STRESS	Although co-ordinate interaction between different signal transduction pathways is essential for developmental decisions, interpathway connections are often obscured and difficult to identify due to cross-talk. Here signals from the fission yeast stress-activated MAPK Spc1 are shown to regulate Cgs2, a negative regulator of the cAMP-dependent protein kinase ( protein kinase A) pathway. Pathway integration is achieved via Spc1-dependent binding of Atf1-Pcr1 heterodimer to an M26 DNA site in the cgs2(+) promoter, which remodels chromatin to regulate expression of cgs2(+) and targets downstream of protein kinase A. This direct interpathway connection co-ordinates signals of nitrogen and carbon source depletion to affect a G(0) cell-cycle checkpoint and sexual differentiation. The Atf1-Pcr1-M26 complex-dependent chromatin remodeling provides a molecular mechanism whereby Atf1-Pcr1 heterodimer can function differentially as either a transcriptional activator, or as a transcriptional repressor, or as an inducer of meiotic recombination. We also show that the Atf1-Pcr1-M26 complex functions as both an inducer and repressor of chromatin remodeling, which provides a way for various chromatin remodeling-dependent effector functions to be regulated.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Inst Phys & Chem Res, Genet Dynam Res Unit Lab, Wako, Saitama 3510198, Japan	University of Arkansas System; University of Arkansas Medical Sciences; RIKEN	Wahls, WP (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham St,Slot 516, Little Rock, AR 72205 USA.	wahlswaynep@uams.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062801, R01GM062244] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062801-03, GM62801, R01 GM062244-05, R01 GM062244-03, R01 GM062801, R01 GM062244, GM62244] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; DalSanto P, 1996, J CELL SCI, V109, P1919; Degols G, 1996, MOL CELL BIOL, V16, P2870; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; DEVOTI J, 1991, EMBO J, V10, P3759, DOI 10.1002/j.1460-2075.1991.tb04945.x; Fox ME, 2000, GENETICS, V156, P59; Gaits F, 1997, J BIOL CHEM, V272, P17873, DOI 10.1074/jbc.272.28.17873; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Higuchi T, 2002, MOL CELL BIOL, V22, P1, DOI 10.1128/MCB.22.1.1-11.2002; Hirota K, 2004, NUCLEIC ACIDS RES, V32, P855, DOI 10.1093/nar/gkh251; Jia ST, 2004, SCIENCE, V304, P1971, DOI 10.1126/science.1099035; Kanoh J, 1996, GENES CELLS, V1, P391, DOI 10.1046/j.1365-2443.1996.d01-247.x; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; KIM J, 1995, NUCLEIC ACIDS RES, V23, P2531, DOI 10.1093/nar/23.13.2531; Kitamura K, 2001, DEV CELL, V1, P389, DOI 10.1016/S1534-5807(01)00037-5; Kon N, 1998, MOL CELL BIOL, V18, P7575, DOI 10.1128/MCB.18.12.7575; Kon N, 1997, P NATL ACAD SCI USA, V94, P13765, DOI 10.1073/pnas.94.25.13765; Krawchuk MD, 1999, GENETICS, V153, P57; Madrid M, 2004, J BIOL CHEM, V279, P41594, DOI 10.1074/jbc.M405509200; MAEDA T, 1994, J BIOL CHEM, V269, P9632; MATVIW H, 1993, BIOCHEM BIOPH RES CO, V194, P79, DOI 10.1006/bbrc.1993.1787; MCLEOD M, 1986, EMBO J, V5, P3665, DOI 10.1002/j.1460-2075.1986.tb04697.x; Mizuno K, 2001, GENETICS, V159, P1467; Mizuno K, 1997, GENE DEV, V11, P876, DOI 10.1101/gad.11.7.876; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; Nakagawa CW, 1998, J BIOCHEM-TOKYO, V123, P1048; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; Peng Z, 2003, CURR GENET, V43, P178, DOI 10.1007/s00294-003-0384-5; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; Sato M, 2002, CURR BIOL, V12, P141, DOI 10.1016/S0960-9822(01)00654-6; Sharif Wallace D, 2002, Cell Chromosome, V1, P1, DOI 10.1186/1475-9268-1-1; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Soto T, 2002, EUR J BIOCHEM, V269, P5056, DOI 10.1046/j.1432-1033.2002.03214.x; Stettler S, 1996, J CELL SCI, V109, P1927; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; WAHLS WP, 1991, NUCLEIC ACIDS RES, V19, P3269, DOI 10.1093/nar/19.12.3269; WAHLS WP, 1994, GENE DEV, V8, P1693, DOI 10.1101/gad.8.14.1693; Watanabe Y, 1996, MOL CELL BIOL, V16, P704; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WATANABE Y, 1988, EMBO J, V7, P761, DOI 10.1002/j.1460-2075.1988.tb02873.x; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; WU SY, 1995, MOL CELL BIOL, V15, P1479; Yamada T, 2004, EMBO J, V23, P1792, DOI 10.1038/sj.emboj.7600138; Yamamoto M, 1996, CELL STRUCT FUNCT, V21, P431, DOI 10.1247/csf.21.431; YU G, 1994, GENE, V151, P215, DOI 10.1016/0378-1119(94)90659-9	50	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50857	50863		10.1074/jbc.M409079200	http://dx.doi.org/10.1074/jbc.M409079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448137	Green Accepted, hybrid			2022-12-25	WOS:000225355800028
J	Kukkonen, A; Perakyla, M; Akerman, KEO; Nasman, J				Kukkonen, A; Perakyla, M; Akerman, KEO; Nasman, J			Muscarinic toxin 7 selectivity is dictated by extracellular receptor loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMBA DENDROASPIS-ANGUSTICEPS; GREEN MAMBA; ACETYLCHOLINE-RECEPTORS; CRYSTAL-STRUCTURE; NONCOMPETITIVE ANTAGONISM; ADENOSINE RECEPTOR; SNAKE-VENOM; BINDING; M-1; PROTEINS	Muscarinic toxin 7 (MT7) is a mamba venom protein antagonist with extremely high selectivity for the M1 muscarinic acetylcholine receptor. To map the sites for the interaction of MT7 with muscarinic receptors we have used chimeric M1: M3 receptors and site-directed mutagenesis of the M3 and M4 receptor subtypes. Two Glu residues in M1, one in extracellular loop 2 and one in extracellular loop 3, were found to be important for the high affinity binding of MT7. Substitution of the corresponding Lys residues in the M3 receptor with Glu converted the M3 mutant to an MT7 binding receptor, albeit with lower affinity compared with M1. A Phe --> Tyr substitution in extracellular loop 2 of M3 together with the 2 Glu mutations generated a receptor with an increased MT7 affinity (apparent K-i = 0.26 nM in a functional assay) compared with the M1 receptor (apparent K-i = 1.31 nM). The importance of the identified amino acid residues was confirmed with a mutated M4 receptor constructs. The results indicate that the high selectivity of MT7 for the M1 receptor depends on very few residues, thus providing good prospects for future design and synthesis of muscarinic receptor-selective ligands.	AI Virtanen Inst Mol Sci, Dept Neurobiol, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland	University of Eastern Finland	Nasman, J (corresponding author), AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	Johnny.Nasman@uku.fi						ADEM A, 1988, BIOCHIM BIOPHYS ACTA, V968, P340, DOI 10.1016/0167-4889(88)90025-0; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Bradley KN, 2000, PHARMACOL THERAPEUT, V85, P87, DOI 10.1016/S0163-7258(99)00064-9; Carsi JM, 2000, TOXICON, V38, P187, DOI 10.1016/S0041-0101(99)00141-5; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; Christopoulos A, 1999, EUR J PHARMACOL, V382, P217, DOI 10.1016/S0014-2999(99)00550-6; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DEWEILLE JR, 1991, P NATL ACAD SCI USA, V88, P2437, DOI 10.1073/pnas.88.6.2437; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HARVEY AL, 1980, N-S ARCH PHARMACOL, V312, P1, DOI 10.1007/BF00502565; HARVEY AL, 1984, J PHYSIOL-PARIS, V79, P222; Hulme EC, 2003, BIOCHEM SOC T, V31, P29, DOI 10.1042/bst0310029; JANSSON CC, 1995, EUR J PHARM-MOLEC PH, V290, P75, DOI 10.1016/0922-4106(95)90019-5; Jerusalinsky D, 2000, TOXICON, V38, P747, DOI 10.1016/S0041-0101(99)00196-8; JOLKKONEN M, 1995, EUR J BIOCHEM, V234, P579, DOI 10.1111/j.1432-1033.1995.579_b.x; JOLKKONEN M, 1994, FEBS LETT, V352, P91, DOI 10.1016/0014-5793(94)00933-3; JOLKKONEN M, 1996, THESIS UPPSALA U UPP; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; Karlsson E, 2000, BIOCHIMIE, V82, P793, DOI 10.1016/S0300-9084(00)01176-7; Kim JH, 1996, MOL PHARMACOL, V49, P683; Krajewski JL, 2001, MOL PHARMACOL, V60, P725; KUKKONEN J, 1992, BIOCHEM BIOPH RES CO, V189, P919, DOI 10.1016/0006-291X(92)92291-5; Kukkonen JP, 1998, BIOCHEM BIOPH RES CO, V243, P41, DOI 10.1006/bbrc.1997.8054; Kukkonen JP, 1996, J PHARMACOL EXP THER, V279, P593; Liang JS, 1996, TOXICON, V34, P1257, DOI 10.1016/S0041-0101(96)00109-2; Marchot P, 1998, TOXICON, V36, P1613, DOI 10.1016/S0041-0101(98)00154-8; Marchot P, 1997, J BIOL CHEM, V272, P3502, DOI 10.1074/jbc.272.6.3502; MAX SI, 1993, J NEUROSCI, V13, P4293; MAX SI, 1993, MOL PHARMACOL, V44, P1171; MAX SI, 1993, J PHARMACOL EXP THER, V267, P480; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; Milligan G, 1999, TRENDS PHARMACOL SCI, V20, P118, DOI 10.1016/S0165-6147(99)01320-6; Mourier G, 2003, MOL PHARMACOL, V63, P26, DOI 10.1124/mol.63.1.26; NAKAMURA F, 1995, J BIOL CHEM, V270, P6246, DOI 10.1074/jbc.270.11.6246; Nasman J, 2000, BIOCHEM BIOPH RES CO, V271, P435, DOI 10.1006/bbrc.2000.2657; OLAH ME, 1994, J BIOL CHEM, V269, P18016; Olianas MC, 2000, BRIT J PHARMACOL, V131, P447, DOI 10.1038/sj.bjp.0703606; Olianas MC, 2004, EUR J PHARMACOL, V487, P65, DOI 10.1016/j.ejphar.2004.01.029; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; SCHWEITZ H, 1994, P NATL ACAD SCI USA, V91, P878, DOI 10.1073/pnas.91.3.878; SEGALAS I, 1995, BIOCHEMISTRY-US, V34, P1248, DOI 10.1021/bi00004a019; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; SHUTTLEWORTH TJ, 1991, J BIOL CHEM, V266, P1410; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; TUCEK S, 1995, TRENDS PHARMACOL SCI, V16, P205, DOI 10.1016/S0165-6147(00)89023-9; VANDERMEERS A, 1995, TOXICON, V33, P1171, DOI 10.1016/0041-0101(95)00057-S; Wurch T, 2000, J NEUROCHEM, V75, P1180, DOI 10.1046/j.1471-4159.2000.0751180.x; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; Zhao MM, 1996, MOL PHARMACOL, V50, P1118	51	28	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50923	50929		10.1074/jbc.M406424200	http://dx.doi.org/10.1074/jbc.M406424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452105	hybrid			2022-12-25	WOS:000225355800035
J	Walsh, EJ; O'Brien, LM; Liang, XW; Hook, M; Foster, TJ				Walsh, EJ; O'Brien, LM; Liang, XW; Hook, M; Foster, TJ			Clumping factor B, a fibrinogen-binding MSCRAMM (microbial surface components recognizing adhesive matrix molecules) adhesin of Staphylococcus aureus, also binds to the tail region of type I cytokeratin 10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASAL CARRIAGE; PROTEIN-A; CLEAVAGE; DOMAIN; KERATIN-10; MUTATION; MODEL; CLFB	The primary habitat of Staphylococcus aureus in humans is the moist squamous epithelium of the anterior nares. We showed previously that S. aureus adheres to desquamated epithelial cells and that clumping factor B (ClfB), a surface-located MSCRAMM ( microbial surface components recognizing adhesive matrix molecules) known for its ability to bind to the alpha-chain of fibrinogen, is partly responsible (O'Brien, L. M., Walsh, E. J., Massey, R. C., Peacock, S. J., and Foster, T. J. ( 2002) Cell. Microbiol. 4, 759 - 770). We identified cytokeratin 10 (K10) as the ligand recognized by ClfB. Here we have shown that purified recombinant human and murine K10 immobilized on a plastic surface supports adherence of S. aureus in a ClfB-dependent manner. Furthermore, the recombinant A domain of ClfB (rClfB 45 - 542) bound to immobilized K10 dose-dependently and saturably. Subdomains of human and murine K10 were expressed and purified. The N-terminal head domain ( residues 1 - 145) did not support the binding of rClfB or adherence of S. aureus ClfB(+). In contrast, the C-terminal tail domains ( human rHK10 452 - 593, mouse rMK10 454 - 570) promoted avid binding and adherence. Isothermal titration microcalorimetry and intrinsic tryptophan fluorescence experiments gave dissociation constants for rClfB 45 - 542 binding to rMK10 454 - 570 of 1.4 and 1.7 muM, respectively. The tail region of K10 is composed largely of quasi-repeats of Tyr-(Gly/Ser)(n). A synthetic peptide corresponding to a typical glycine loop (YGGGSSGGGSSGGY; Y-Y loop peptide) inhibited the adherence of S. aureus ClfB(+) to immobilized MK10 to a level of 80%, whereas control peptides had no effect. The K-D of rClfB 45-542 for the Y-Y loop peptide was 5.3 muM by intrinsic tryptophan fluorescence. Thus ClfB binds to the glycine loop region of the tail domain of keratin 10 where there are probably multiple binding sites. Binding is discussed in the context of the dock-lock-latch model for MSCRAMM-ligand interactions. We provide an explanation for the molecular basis for S. aureus adherence to the squamous epithelium and suggest that nasal colonization might be prevented by reagents that inhibit this interaction.	Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland; Texas A&M Univ, Hlth Sci Syst, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Syst, Dept Biochem & Biophys, Inst Biosci & Technol, Houston, TX 77030 USA	Trinity College Dublin; Texas A&M University System; Texas A&M University System	Foster, TJ (corresponding author), Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland.	tfoster@tcd.ie		Liang, Xiaowen/0000-0002-6174-2951	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carlson SA, 2002, LIFE SCI, V70, P1415, DOI 10.1016/S0024-3205(01)01512-0; Cole AM, 2001, CLIN DIAGN LAB IMMUN, V8, P1064, DOI 10.1128/CDLI.8.6.1064-1069.2001; Deivanayagam CCS, 2002, EMBO J, V21, P6660, DOI 10.1093/emboj/cdf619; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079; Hartleib J, 2000, BLOOD, V96, P2149; KARTASOVA T, 1993, J CELL BIOL, V120, P1251, DOI 10.1083/jcb.120.5.1251; Kirfel J, 2003, CELL MOL LIFE SCI, V60, P56, DOI 10.1007/s000180300004; Kluytmans J, 1998, J HOSP INFECT, V40, pS25, DOI 10.1016/S0195-6701(98)90201-8; KORGE BP, 1992, P NATL ACAD SCI USA, V89, P910, DOI 10.1073/pnas.89.3.910; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; McAleese FM, 2001, J BIOL CHEM, V276, P29969, DOI 10.1074/jbc.M102389200; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; NI ED, 1998, MOL MICROBIOL, V30, P245; O'Brien LM, 2002, CELL MICROBIOL, V4, P759, DOI 10.1046/j.1462-5822.2002.00231.x; OBrien L, 2002, MOL MICROBIOL, V44, P1033, DOI 10.1046/j.1365-2958.2002.02935.x; PARRY DAD, 1995, INTERMEDIATE FILAMEN, P20; Peacock SJ, 2001, TRENDS MICROBIOL, V9, P605, DOI 10.1016/S0966-842X(01)02254-5; Perkins S, 2001, J BIOL CHEM, V276, P44721, DOI 10.1074/jbc.M106741200; Ponnuraj K, 2003, CELL, V115, P217, DOI 10.1016/S0092-8674(03)00809-2; Roche FM, 2004, J BIOL CHEM, V279, P38433, DOI 10.1074/jbc.M402122200; Sajjan U, 2002, CELL MICROBIOL, V4, P73, DOI 10.1046/j.1462-5822.2002.00171.x; Sojar HT, 2002, INFECT IMMUN, V70, P96, DOI 10.1128/IAI.70.1.96-101.2002; Sprecher E, 2001, J INVEST DERMATOL, V116, P511, DOI 10.1046/j.1523-1747.2001.01292.x; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863; Whittock NV, 2002, J INVEST DERMATOL, V118, P838, DOI 10.1046/j.1523-1747.2002.01750.x; WILLIAMS RE, 1963, BACTERIOL REV, V27, P56, DOI 10.1128/MMBR.27.1.56-71.1963; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	31	96	103	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50691	50699		10.1074/jbc.M408713200	http://dx.doi.org/10.1074/jbc.M408713200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385531	hybrid			2022-12-25	WOS:000225355800010
J	Fanara, P; Turner, S; Busch, R; Killion, S; Awada, M; Turner, H; Mahsut, A; LaPrade, KL; Stark, JM; Hellerstein, MK				Fanara, P; Turner, S; Busch, R; Killion, S; Awada, M; Turner, H; Mahsut, A; LaPrade, KL; Stark, JM; Hellerstein, MK			In vivo measurement of microtubule dynamics using stable isotope Labeling with heavy water - Effect of taxanes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CYCLE-DEPENDENT CHANGES; CELL-CYCLE; MITOTIC SPINDLE; INDIVIDUAL MICROTUBULES; TUBULIN SYNTHESIS; MORPHOLOGICAL EVIDENCE; SUPPRESSES DYNAMICS; DEUTERIUM-OXIDE; DNA-SYNTHESIS; BETA-TUBULIN	Microtubules are dynamic polymers with central roles in the mitotic checkpoint, mitotic spindle assembly, and chromosome segregation. Agents that block mitotic progression and cell proliferation by interfering with microtubule dynamics (microtubule-targeted tubulin-polymerizing agents (MTPAs)) are powerful antitumor agents. Effects of MTPAs (e.g. paclitaxel) on microtubule dynamics have not yet been directly demonstrated in intact animals, however. Here we describe a method that measures microtubule dynamics as an exchange of tubulin dimers into microtubules in vivo. The incorporation of deuterium (H-2) from heavy water ((H2O)-H-2) into tubulin dimers and polymers is measured by gas chromatography/mass spectrometry. In cultured human lung and breast cancer cell lines, or in tumors implanted into nude mice, tubulin dimers and polymerized microtubules exhibited nearly identical label incorporation rates, reflecting their rapid exchange. Administration of paclitaxel during 24 h of (H2O)-H-2 labeling in vivo reduced H-2 labeling in polymers while increasing H-2 in dimers, indicating diminished flux of dimers into polymers (i.e. inhibition of microtubule dynamic equilibrium). In vivo inhibition of microtubule dynamics was dose-dependent and correlated with inhibition of DNA replication, a stable isotopic measure of tumor cell growth. In contrast, microtubule polymers from sciatic nerve of untreated mice were not in dynamic equilibrium with tubulin dimers, and paclitaxel increased label incorporation into polymers. Our results directly demonstrate altered microtubule dynamics as an important action of MTPAs in vivo. This sensitive and quantitative in vivo assay of microtubule dynamics may prove useful for pre-clinical and clinical development of the next generation of MTPAs as anticancer drugs.	KineMed Inc, Emeryville, CA 94608 USA; Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA	University of California System; University of California Berkeley; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Fanara, P (corresponding author), KineMed Inc, 5980 Horton St,Ste 470, Emeryville, CA 94608 USA.	pfanara@kinemed.com		Busch, Robert/0000-0002-4132-0751				AMINHANJANI S, 1991, CELL MOTIL CYTOSKEL, V20, P136, DOI 10.1002/cm.970200206; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Barlow SB, 2002, J CELL SCI, V115, P3469; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BENZEEV A, 1979, CELL, V17, P319, DOI 10.1016/0092-8674(79)90157-0; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; BLACK MM, 1987, J NEUROSCI, V7, P3695; BRANDT R, 1993, J BIOL CHEM, V268, P3414; BRANDT R, 1996, FRONT BIOSCI, V1, P118; Brooks TA, 2004, ANTICANCER RES, V24, P409; Busch R, 2004, J IMMUNOL METHODS, V286, P97, DOI 10.1016/j.jim.2003.12.012; CABRAL F, 1989, FASEB J, V3, P1593, DOI 10.1096/fasebj.3.5.2646163; CABRAL F, 1981, P NATL ACAD SCI-BIOL, V78, P4388, DOI 10.1073/pnas.78.7.4388; Cabral F, 2001, DRUG RESIST UPDATE, V4, P3, DOI 10.1054/drup.2000.0172; CARON JM, 1985, J CELL BIOL, V101, P1763, DOI 10.1083/jcb.101.5.1763; Cavaletti G, 1997, NEUROTOXICOLOGY, V18, P137; Chakrabarti G, 1999, BIOCHEMISTRY-US, V38, P3067, DOI 10.1021/bi982461r; Checchi PM, 2003, TRENDS PHARMACOL SCI, V24, P361, DOI 10.1016/S0165-6147(03)00161-5; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P10, DOI 10.1016/S0955-0674(89)80030-4; CLEVELAND DW, 1981, CELL, V25, P537, DOI 10.1016/0092-8674(81)90072-6; Collins ML, 2003, J APPL PHYSIOL, V94, P2203, DOI 10.1152/japplphysiol.00691.2002; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2; Dabydeen DA, 2004, CANCER CHEMOTH PHARM, V53, P397, DOI 10.1007/s00280-003-0755-0; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; Derry WB, 1998, CANCER RES, V58, P1177; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DHAMODHARAN R, 1995, MOL BIOL CELL, V6, P1215, DOI 10.1091/mbc.6.9.1215; Fanara P, 1999, EMBO J, V18, P565, DOI 10.1093/emboj/18.3.565; FANARA P, 1997, BRAIN MICROTUBULE AS, P259; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Gluck S, 1998, EUR J CANCER, V34, P1008, DOI 10.1016/S0959-8049(97)10168-X; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Grego S, 2001, BIOPHYS J, V81, P66, DOI 10.1016/S0006-3495(01)75680-9; Gupta Y. K., 2001, Indian Journal of Physiology and Pharmacology, V45, P253; Hamel E, 2003, CELL BIOCHEM BIOPHYS, V38, P1, DOI 10.1385/CBB:38:1:1; HAYDEN JH, 1990, J CELL BIOL, V111, P1039, DOI 10.1083/jcb.111.3.1039; Hellerstein MK, 2004, CURR OPIN MOL THER, V6, P249; Hellerstein MK, 2004, METAB ENG, V6, P85, DOI 10.1016/j.ymben.2003.10.005; Hellerstein MK, 2003, J CLIN INVEST, V112, P956, DOI 10.1172/JCI200317533; Hellerstein MK, 2002, FASEB J, V16, pA256; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Horwitz Susan Band, 1993, Journal of the National Cancer Institute Monographs, V0, P55; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; HUMPHREY TJ, 1976, BIOCHEM J, V156, P561, DOI 10.1042/bj1560561; Ilschner S, 1996, GLIA, V18, P129, DOI 10.1002/(SICI)1098-1136(199610)18:2<129::AID-GLIA5>3.3.CO;2-G; Jordan M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P1, DOI 10.2174/1568011023354290; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Katsetos CD, 2003, CELL MOTIL CYTOSKEL, V55, P77, DOI 10.1002/cm.10116; KATZ JJ, 1957, JNCI-J NATL CANCER I, V18, P641; Kim SJ, 2004, AM J PHYSIOL-CELL PH, V286, pC1464, DOI 10.1152/ajpcell.00139.2003; LAMPRECHT J, 1991, J CELL SCI, V98, P463; Lauria G, 2003, NEUROLOGY, V61, P631, DOI 10.1212/01.WNL.0000070781.92512.A4; LOPES NM, 1993, CANCER CHEMOTH PHARM, V32, P235, DOI 10.1007/BF00685842; McCune JM, 2000, J CLIN INVEST, V105, pR1, DOI 10.1172/JCI8647; Michalides R, 2002, BREAST CANCER RES TR, V74, P55, DOI 10.1023/A:1016074309582; MILAS L, 1995, CANCER CHEMOTH PHARM, V35, P297, DOI 10.1007/BF00689448; Mimura Y, 2000, NEUROTOXICOLOGY, V21, P513; MISELL LM, 2004, IN PRESS BREAST CANC; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Nakata T, 1999, NEUROSCI RES, V35, P113, DOI 10.1016/S0168-0102(99)00074-7; Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499; Neese RA, 2001, ANAL BIOCHEM, V298, P189, DOI 10.1006/abio.2001.5375; Newton CN, 2002, J BIOL CHEM, V277, P42456, DOI 10.1074/jbc.M207134200; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; Panda D, 2000, BIOCHEMISTRY-US, V39, P5075, DOI 10.1021/bi992217f; PENG SK, 1972, ARCH PATHOL, V94, P81; PEPPERKOK R, 1990, J CELL BIOL, V111, P3003, DOI 10.1083/jcb.111.6.3003; Pignata S, 2000, ANN ONCOL, V11, P455, DOI 10.1023/A:1008379922120; Previs SF, 1996, J MASS SPECTROM, V31, P639, DOI 10.1002/(SICI)1096-9888(199606)31:6<639::AID-JMS336>3.0.CO;2-S; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; ROBERTS JR, 1990, CANCER RES, V50, P710; Rodionov VI, 1997, SCIENCE, V275, P215, DOI 10.1126/science.275.5297.215; ROMIJN JC, 1988, PROSTATE, V12, P99, DOI 10.1002/pros.2990120112; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; Rusan NM, 2001, MOL BIOL CELL, V12, P971, DOI 10.1091/mbc.12.4.971; Rutten T, 1997, P NATL ACAD SCI USA, V94, P4469, DOI 10.1073/pnas.94.9.4469; SAHENK Z, 1987, CELL MOTIL CYTOSKEL, V8, P155, DOI 10.1002/cm.970080207; SALMON ED, 1984, J CELL BIOL, V99, P1066, DOI 10.1083/jcb.99.3.1066; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; STARGELL LA, 1992, MOL CELL BIOL, V12, P1443, DOI 10.1128/MCB.12.4.1443; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; Strawford A, 2004, AM J PHYSIOL-ENDOC M, V286, pE577, DOI 10.1152/ajpendo.00093.2003; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; Tanner KD, 1998, J COMP NEUROL, V395, P481; TAY KY, 1999, BIOCHEM BIOPH RES CO, V263, P398; Theiss C, 2000, CELL TISSUE RES, V299, P213, DOI 10.1007/s004419900120; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; Turner SM, 2003, AM J PHYSIOL-ENDOC M, V285, pE790, DOI 10.1152/ajpendo.00402.2002; Van Bree C, 2000, INT J ONCOL, V16, P739; Vredenburg MR, 2001, JNCI-J NATL CANCER I, V93, P1234, DOI 10.1093/jnci/93.16.1234; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WatermanStorer CM, 1997, CURR BIOL, V7, pR369, DOI 10.1016/S0960-9822(06)00177-1; WILSON L, 1985, BIOCHEMISTRY-US, V24, P5254, DOI 10.1021/bi00340a045; Wood Kenneth W., 2001, Current Opinion in Pharmacology, V1, P370, DOI 10.1016/S1471-4892(01)00064-9; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201; ZHAI Y, 1994, J CELL SCI, V107, P881; Zhou BB, 1999, CELL MOTIL CYTOSKEL, V43, P43; Zhou J, 2002, J CELL SCI, V115, P3547, DOI 10.1242/jcs.00029	105	25	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49940	49947		10.1074/jbc.M409660200	http://dx.doi.org/10.1074/jbc.M409660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15385549	hybrid			2022-12-25	WOS:000225229500049
J	Hagihara, A; Miyamoto, K; Furuta, J; Hiraoka, N; Wakazono, K; Seki, S; Fukushima, S; Tsao, MS; Sugimura, T; Ushijima, T				Hagihara, A; Miyamoto, K; Furuta, J; Hiraoka, N; Wakazono, K; Seki, S; Fukushima, S; Tsao, MS; Sugimura, T; Ushijima, T			Identification of 27 5 ' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers	ONCOGENE			English	Article						methylation; pancreatic cancer; CpG island; silencing	REPRESENTATIONAL DIFFERENCE ANALYSIS; TUMOR-SUPPRESSOR GENE; REDUCED EXPRESSION; HUMAN BREAST; ADENOCARCINOMA; CARCINOMA; CELLS; LUNG; RAS; INACTIVATION	Aberrantly methylated DNA fragments were searched for in human pancreatic cancers, using the genome scanning technique: methylation-sensitive-representational difference analysis (MS-RDA). MS-RDA isolated 111 DNA fragments derived from CpG islands (CGIs), and 35 of them were from CGIs in the 5' regions of known genes. Methylation-specific PCR (MSP) of the CGIs in seven pancreatic cancer cell lines and two pancreatic ductal epithelial cell lines showed that 27 CGIs in the 5' regions were aberrantly methylated in at least one of the cancer cell lines. Quantitative reverse-transcription-PCR analysis showed that downstream genes of all the CGIs were either not expressed or only very weakly expressed in cancer cell lines with the aberrant methylation. In the pancreatic ductal epithelial cell lines, 18 genes were expressed at various levels, and nine genes were not expressed at all. Treatment of a cancer cell line with a demethylating agent, 5-aza-2'-deoxycytidine, restored the expression of 13 genes, RASGRF2, ADAM23, NEF3, NKX2-8, HAND1, EGR4, PRG2, FBN2, CDH2, TLL1, NPTX1, NTSR1 and THBD, showing their silencing by methylation of their 5' CGIs. MSP of 24 primary pancreatic cancers showed that all these genes, except for THBD, were methylated in at least one cancer. Some of those were suggested to be potentially involved in pancreatic cancer development and progression.	Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 1040045, Japan; Osaka City Univ, Grad Sch Med, Dept Pathol, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Internal Med, Abeno Ku, Osaka 5458585, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	National Cancer Center - Japan; Osaka Metropolitan University; Osaka Metropolitan University; National Cancer Center - Japan; University of Toronto	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022; Ushijima, Toshikazu/AAP-5742-2021	Tsao, Ming Sound/0000-0002-9160-5405; Ushijima, Toshikazu/0000-0003-3405-7817				Agathanggelou A, 2003, CANCER RES, V63, P5344; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Arozarena I, 2004, MOL CELL BIOL, V24, P1516, DOI 10.1128/MCB.24.4.1516-1530.2004; Asada K, 2003, ONCOLOGY-BASEL, V64, P380, DOI 10.1159/000070297; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Clark TG, 1999, DEVELOPMENT, V126, P2631; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Furukawa T, 1996, AM J PATHOL, V148, P1763; GRIFFIN CA, 1994, GENE CHROMOSOME CANC, V9, P93, DOI 10.1002/gcc.2870090204; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HERMAN JG, 1995, CANCER RES, V55, P4525; Horikoshi N, 1999, BIOCHEM BIOPH RES CO, V261, P864, DOI 10.1006/bbrc.1999.1123; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; Kaneda A, 2003, ANN NY ACAD SCI, V983, P131, DOI 10.1111/j.1749-6632.2003.tb05968.x; Kaneda A, 2002, CANCER RES, V62, P6645; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mitchell MS, 2000, CANCER RES, V60, P6448; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Omeis IA, 1996, GENOMICS, V36, P543, DOI 10.1006/geno.1996.0503; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Qiu CP, 2003, ONCOGENE, V22, P1253, DOI 10.1038/sj.onc.1206233; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Rozenblum E, 1997, CANCER RES, V57, P1731; Sato N, 2003, CANCER RES, V63, P3735; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940; Tourtellotte WG, 1999, DEVELOPMENT, V126, P5061; Toyota M, 1999, CANCER RES, V59, P2307; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Wilentz RE, 2000, CANCER RES, V60, P2002	36	94	107	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8705	8710		10.1038/sj.onc.1207783	http://dx.doi.org/10.1038/sj.onc.1207783			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467763				2022-12-25	WOS:000224988800018
J	Niida, A; Hiroko, T; Kasai, M; Furukawa, Y; Nakamura, Y; Suzuki, Y; Sugano, S; Akiyama, T				Niida, A; Hiroko, T; Kasai, M; Furukawa, Y; Nakamura, Y; Suzuki, Y; Sugano, S; Akiyama, T			DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway	ONCOGENE			English	Article						DKK1; Wnt; beta-catenin; TCF; TCF-binding element; negative feedback	CYCLIN D1; TRANSCRIPTION; ACTIVATION; GENE; HEPATOBLASTOMAS; IDENTIFICATION; EXPRESSION; DICKKOPF-1; MUTATIONS; PROTEINS	Wnt signaling plays an important role in embryonic development and tumorigenesis. These biological effects are exerted by activation of the beta-catenin/TCF transcription complex and consequent regulation of a set of downstream genes. TCF-binding elements have been found in the promoter regions of many TCF target genes and characterized by a highly conserved consensus sequence. Utilizing this consensus sequence, we performed an in silico screening for new TCF target genes. Through computational screening and subsequent experimental analysis, we identified a novel TCF target gene, DKK1, which has been shown to be a potent inhibitor of Wnt signaling. Our finding suggests the existence of a novel feedback loop in Wnt signaling.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Database,Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp						Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; HE TC, 1998, SCIENCE, V278, P1606; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Koch A, 1999, CANCER RES, V59, P269; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Polakis P, 2000, GENE DEV, V14, P1837; Sekiya T, 2004, J BIOL CHEM, V279, P6840, DOI 10.1074/jbc.M310876200; Shinya M, 2000, MECH DEVELOP, V98, P3, DOI 10.1016/S0925-4773(00)00433-0; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; Tago K, 2000, GENE DEV, V14, P1741; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498	32	413	436	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8520	8526		10.1038/sj.onc.1207892	http://dx.doi.org/10.1038/sj.onc.1207892			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378020				2022-12-25	WOS:000224870700012
J	Treff, NR; Dement, GA; Adair, JE; Britt, RL; Nie, R; Shima, JE; Taylor, WE; Reeves, R				Treff, NR; Dement, GA; Adair, JE; Britt, RL; Nie, R; Shima, JE; Taylor, WE; Reeves, R			Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells	ONCOGENE			English	Article						high mobility group A1; stem cell factor; malignant transformation; chromatin; MCF-7; OCC1	C-KIT; IN-VIVO; EXPRESSION; PROTEIN; COEXPRESSION; RECEPTOR; GENE; ACTIVATION; APOPTOSIS; SEQUENCE	KIT ligand (KL) and its receptor, c-kit, are coexpressed in many types of cancer cells and have been implicated in tumor growth and angiogenesis. While Sertoli cell-specific regulation of the KL promoter has been well characterized, regulation in cancer cells remains to be elucidated. We recently reported microarray results demonstrating that increased high-mobility group (HMG) A1a protein expression correlates with increased KL transcription in MCF-7 human breast cancer cells. Sequence analysis indicates a potential for multiple HMGA1 binding sites within the human KL promoter. In order to better de. ne the underlying molecular mechanisms that HMGA1 uses to facilitate malignant transformation of cancer cells, we have used a variety of methods to determine whether HMGA1a directly regulates the human KL promoter in breast and ovarian cancer cells. Our results indicate that: (i) KL promoter activity is significantly higher in MCF-7 cells overexpressing HMGA1a; (ii) HMGA1a protein binds to AT-rich regions of the KL promoter DNA both in vitro and in vivo; (iii) mutation of the AT-rich regions inhibits HMGA1a binding in vitro; and (iv) HMGA1a-specific inhibition significantly decreases transcription of KL in OCC1 human ovarian cancer cells. In addition, MCF-7 cells with transgenic HMGA1 overexpression stained positive for the KL protein by immunocytochemistry and immunohistochemistry, and were growth-inhibited by KL neutralization. The cumulative evidence indicates that HMGA1 positively regulates the human KL promoter in breast and ovarian cancer cells and implicates serum KL as a diagnostic marker for HMGA1-positive carcinomas.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Charles R Drew Univ Med & Sci, Div Endocrinol Metab & Mol Med, Los Angeles, CA 90059 USA	Washington State University; Charles R. Drew University of Medicine & Science	Reeves, R (corresponding author), Washington State Univ, Sch Mol Biosci, POB 644660, Pullman, WA 99164 USA.	reevesr@mail.wsu.edu		Adair, Jennifer/0000-0003-4599-016X	NIGMS NIH HHS [GM-46352, T-32 GM008336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352, T32GM008336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Bellone G, 2001, CANCER RES, V61, P2200; Bokemeyer C, 1996, J CANCER RES CLIN, V122, P301, DOI 10.1007/BF01261407; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Caceres-Cortes JR, 2001, CANCER RES, V61, P6281; ELTON T, 1987, P NATL ACAD SCI USA, V84, P6531; Flohr AM, 2003, HISTOL HISTOPATHOL, V18, P999, DOI 10.14670/HH-18.999; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Grimaldi P, 2003, BIOL REPROD, V69, P1979, DOI 10.1095/biolreprod.103.019471; Hassan S, 1998, DIGEST DIS SCI, V43, P8, DOI 10.1023/A:1018851415704; HIBI K, 1991, ONCOGENE, V6, P2291; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Hines SJ, 1999, BREAST CANCER RES TR, V58, P1, DOI 10.1023/A:1006272527435; Huss R, 1996, ANN HEMATOL, V72, P253, DOI 10.1007/s002770050168; INOUE M, 1994, CANCER RES, V54, P3049; Jiang CY, 1997, GENE, V185, P285, DOI 10.1016/S0378-1119(96)00668-3; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Langelotz C, 2003, BRIT J CANCER, V88, P1406, DOI 10.1038/sj.bjc.6600935; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Liu J, 2003, MOL REPROD DEV, V66, P81, DOI 10.1002/mrd.10323; Parrott JA, 2000, BIOL REPROD, V62, P1600, DOI 10.1095/biolreprod62.6.1600; Pedulla ML, 2001, GENE, V271, P51, DOI 10.1016/S0378-1119(01)00500-5; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; RYAN JJ, 1994, J NEUROSCI RES, V37, P415, DOI 10.1002/jnr.490370314; Simak R, 2000, HISTOL HISTOPATHOL, V15, P365, DOI 10.14670/HH-15.365; Taylor WE, 1996, ENDOCRINOLOGY, V137, P5407, DOI 10.1210/en.137.12.5407; Timeus F, 1997, EXP HEMATOL, V25, P1253; TOYOTA M, 1993, TUMOR BIOL, V14, P295, DOI 10.1159/000217842; Treff NR, 2004, ONCOGENE, V23, P777, DOI 10.1038/sj.onc.1207167; Zhang W, 2000, CANCER RES, V60, P6757	34	29	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8557	8562		10.1038/sj.onc.1207926	http://dx.doi.org/10.1038/sj.onc.1207926			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378028				2022-12-25	WOS:000224870700017
J	Martin-Caballero, J; Flores, JM; Garcia-Palencia, P; Collado, M; Serrano, M				Martin-Caballero, J; Flores, JM; Garcia-Palencia, P; Collado, M; Serrano, M			Different cooperating effect of p21 or p27 deficiency in combination with INK4a/ARF deletion in mice	ONCOGENE			English	Article						INK4a; ARF; p21Cip1; p27Kip1; tumorigenesis	DEPENDENT KINASE INHIBITOR; TUMOR SUPPRESSION; SUBCELLULAR-LOCALIZATION; PROGNOSTIC-SIGNIFICANCE; CELL LYMPHOMAS; CYCLIN-E; P27(KIP1); EXPRESSION; RB; TUMORIGENESIS	The control exerted by the INK4a/ARF locus on cellular proliferation is crucial to restrict tumor development. In agreement with this, mice with defects in this locus are highly tumor prone. However, the potential contribution of other pathways in modulating tumorigenesis in the absence of INK4a/ARF is largely unexplored. In the present study, we investigated the consequences of the combined loss of either of two cyclin-dependent kinase inhibitors, p21 and p27, in cooperation with deletion of the INK4a/ARF locus. Our results show a clear differential effect in tumorigenesis depending on the CKI that is absent. The absence of p21 produced no overt alteration of the lifespan of the INK4a/ARF-null mice, although it modified their tumor spectrum, causing a significant increase in the incidence of fibrosarcomas and the appearance of a small number of rhabdomyosarcomas. In contrast, deficiency of p27 resulted in a significant increase in lethality due to accelerated tumor development, especially in the case of T-cell lymphomas. Finally, combined deficiency of INK4a/ARF and p27 resulted in a significant increase in the number of metastatic tumors. These results demonstrate genetically the oncogenic cooperation between defects on INK4a/ARF and p27, which are common alterations in human cancer.	Spanish Natl Canc Ctr, Mol Oncol Program, E-28029 Madrid, Spain; Univ Complutense Madrid, Fac Vet, Anim Surg & Med Dept, E-28040 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid	Serrano, M (corresponding author), Spanish Natl Canc Ctr, Mol Oncol Program, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	mserrano@cnio.es	Collado, Manuel/K-8140-2014; Serrano, Manuel/H-2634-2015	Collado, Manuel/0000-0002-0330-0880; Serrano, Manuel/0000-0001-7177-9312; Garcia Palencia, Pilar/0000-0002-4077-3732				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bearss DJ, 2002, CANCER RES, V62, P2077; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Carneiro C, 2003, ONCOGENE, V22, P361, DOI 10.1038/sj.onc.1206163; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Ciaparrone M, 1998, CANCER RES, V58, P114; Cipriano SC, 2001, MOL ENDOCRINOL, V15, P985, DOI 10.1210/me.15.6.985; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Erlanson M, 1998, BLOOD, V92, P770; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; Hurteau JA, 2001, GYNECOL ONCOL, V83, P292, DOI 10.1006/gyno.2001.6376; Jackson RJ, 2003, CANCER RES, V63, P3021; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lebel M, 2001, CANCER RES, V61, P1816; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Myung N, 2000, CANCER LETT, V153, P129, DOI 10.1016/S0304-3835(00)00359-1; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Quintanilla-Martinez L, 1998, AM J PATHOL, V153, P175, DOI 10.1016/S0002-9440(10)65558-7; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Sanchez-Beato M, 2001, AM J PATHOL, V159, P205, DOI 10.1016/S0002-9440(10)61686-0; SanchezBeato M, 1997, AM J PATHOL, V151, P151; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Singh SP, 1998, CANCER RES, V58, P1730; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tsihlias J, 1999, ANNU REV MED, V50, P401; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1999, CANCER RES, V59, P2050; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Yang WC, 2001, CANCER RES, V61, P565; Zhang W, 2002, RARE METALS, V21, P48; Zirbes TK, 2000, INT J CANCER, V89, P14, DOI 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L	57	29	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8231	8237		10.1038/sj.onc.1207863	http://dx.doi.org/10.1038/sj.onc.1207863			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378017	Bronze			2022-12-25	WOS:000224749500005
J	Tomita, M; Choe, J; Tsukazaki, T; Mori, N				Tomita, M; Choe, J; Tsukazaki, T; Mori, N			The Kaposi's sarcoma-associated herpesvirus K-bZIP protein represses transforming growth factor beta signaling through interaction with CREB-binding protein	ONCOGENE			English	Article						KSHV; K-bZIP; TGF-beta; Smad; CBP	FACTOR-KAPPA-B; MULTICENTRIC CASTLEMANS-DISEASE; EPSTEIN-BARR-VIRUS; TGF-BETA; DNA-SEQUENCES; TRANSCRIPTIONAL ACTIVATION; COACTIVATORS CBP/P300; NUCLEAR INTEGRATION; GENE-EXPRESSION; SMAD PROTEINS	Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is involved in the pathogenesis of KS, primary effusion lymphoma, and multicentric Castleman's disease. K-bZIP, the protein encoded by the open reading frame K8 of KSHV, is a member of the basic region-leucine zipper family of transcription factors. We studied the mechanisms that underlie KSHV-induced oncogenesis by investigating whether K-bZIP perturbs signaling through transforming growth factor beta (TGF-beta), which inhibits proliferation of a wide range of cell types. K-bZIP repressed TGF-beta-induced, Smad-mediated transcriptional activity and antagonized the growth-inhibitory effects of TGF-beta. Since both K-bZIP and Smad are known to interact with CREB-binding protein (CBP), the effect of CBP on inhibition of Smad-mediated transcriptional activation by K-bZIP was examined. K-bZIP mutants, which lacked the CBP-binding site, could not repress TGF-beta-induced or Smad3-mediated transcriptional activity. Overexpression of CBP restored K-bZIP-induced inhibition of Smad3-mediated transcriptional activity. Competitive interaction studies showed that K-bZIP inhibited the interaction of Smad3 with CBP. These results suggest that K-bZIP, through its binding to CBP, disrupts TGF-beta signaling by interfering with the recruitment of CBP into transcription initiation complexes on TGF-beta-responsive elements. We propose a possibility that K-bZIP may contribute to oncogenesis through its ability to promote cell survival by repressing TGF-beta signaling.	Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Nagasaki Univ, Grad Sch Biomed Sci, Div Orthopaed Pathomech, Nagasaki 8528588, Japan	University of the Ryukyus; Korea Advanced Institute of Science & Technology (KAIST); Nagasaki University	Mori, N (corresponding author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.	n-mori@med.u-ryukyu.ac.jp	Choe, Joonho/F-3066-2011					Alkan S, 1997, BRIT J HAEMATOL, V96, P412, DOI 10.1046/j.1365-2141.1997.d01-2040.x; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chan HM, 2001, J CELL SCI, V114, P2363; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Hwang S, 2001, J VIROL, V75, P9509, DOI 10.1128/JVI.75.19.9509-9516.2001; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Katano H, 2000, VIROLOGY, V269, P335, DOI 10.1006/viro.2000.0196; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lin SF, 1999, J VIROL, V73, P1909, DOI 10.1128/JVI.73.3.1909-1917.1999; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Memar OM, 1995, J MOL MED-JMM, V73, P603; Miyazono Kohei, 1994, Seminars in Cell Biology, V5, P389, DOI 10.1006/scel.1994.1046; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Mori N, 2003, INT J CANCER, V105, P661, DOI 10.1002/ijc.11146; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; Mori N, 2000, BLOOD, V95, P3915; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Park J, 2000, J VIROL, V74, P11977, DOI 10.1128/JVI.74.24.11977-11982.2000; Portes-Sentis S, 2001, J GEN VIROL, V82, P507, DOI 10.1099/0022-1317-82-3-507; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	52	34	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8272	8281		10.1038/sj.onc.1208059	http://dx.doi.org/10.1038/sj.onc.1208059			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15467747				2022-12-25	WOS:000224749500009
J	Massimi, P; Gammoh, N; Thomas, M; Banks, L				Massimi, P; Gammoh, N; Thomas, M; Banks, L			HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation	ONCOGENE			English	Article						transformation; human papillomavirus; E6; PDZ domains	HUMAN HOMOLOG; PROTEINS TARGET; CANCER-CELLS; RECOGNITION; INDUCTION; POLARITY; BINDING; GROWTH; APC	The high-risk HPV E6 proteins have been shown to directthe degradation of a variety of cellular proteins that contain PDZ domains. Although some of these proteins are involved in regulating processes of cell growth and polarity in Drosophila, little is known about their function in higher eukaryotic epithelial cells. In HPV-containing cells derived from cervical tumours, we find that the patterns of expression of the E6 targets hDlg (discs large), hScrib (Scribble), and MUPP1 are consistent with their being substrates for E6-induced degradation. It is also clear that, in the case of hDlg, E6 is specifically targeting nuclear pools of the protein rather than membrane-bound forms. We have also analysed the activity of a subset of E6 target proteins in the suppression of oncogene-induced cell transformation. Interestingly, Dlg, MAGI-1 and MUPP1 efficiently suppressed cell transformation, while MAGI-2 and MAGI-3 were ineffective in this assay. These results suggest that in the context of HPV-induced transformation Dlg, MAGI-1 and MUPP1 can function as tumour suppressors.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org						Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Banks L, 2003, TRENDS BIOCHEM SCI, V28, P452, DOI 10.1016/S0968-0004(03)00141-5; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Mantovani F, 2003, J BIOL CHEM, V278, P42477, DOI 10.1074/jbc.M302799200; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Reuver SM, 1998, J CELL SCI, V111, P1071; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	36	96	106	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8033	8039		10.1038/sj.onc.1207977	http://dx.doi.org/10.1038/sj.onc.1207977			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15378012				2022-12-25	WOS:000224692500001
J	Cantara, S; Donnini, S; Morbidelli, L; Giachetti, A; Schulz, R; Memo, M; Ziche, M				Cantara, S; Donnini, S; Morbidelli, L; Giachetti, A; Schulz, R; Memo, M; Ziche, M			Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2	FASEB JOURNAL			English	Article						angiogenesis; endothelial cells; beta-amyloid; basic fibroblast growth factor; Alzheimer's disease	FIBROBLAST-GROWTH-FACTOR; NITRIC-OXIDE; ENDOTHELIAL-CELLS; ALZHEIMERS-DISEASE; RELEASE; PATHWAYS; DYSFUNCTION; ACTIVATION; MECHANISMS; INTEGRINS	Amyloid beta peptides (Abeta) form insoluble aggregates in Alzheimer's disease. Accumulation of misfolded amyloid fibrils is generally believed to be a key pathogenic event in several brain disorders. Here we show that small amounts of Abeta peptides activate angiogenesis by promoting endothelial cell proliferation and migration as well as pseudocapillary formation. Abeta peptides functionally synergize with fibroblast growth factor (FGF-2) to promote c-Raf and ERK1/2 activation and angiogenesis in vivo. Thus, Abeta peptides at nanomolar concentrations prime FGF-2 effects on the endothelium, enhancing survival and sustaining angiogenesis. The angiogenesis promoted by Abeta peptides via FGF-2 might have implications for understanding the initial stages of Alzheimer's disease and for the design of therapies targeting beta amyloid.	Univ Siena, Dept Mol Biol, Pharmacol Sect, I-53100 Siena, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, I-25121 Brescia, Italy	University of Siena; University of Brescia	Ziche, M (corresponding author), Univ Siena, Dept Mol Biol, Pharmacol Sect, Via A Moro 2, I-53100 Siena, Italy.	ziche@unisi.it	Schulz, Richard/M-3518-2019; Cantara, Silvia/J-8808-2016; Schulz, Richard/A-8739-2012; Donnini, Sandra/K-9252-2019; Memo, Maurizio/C-2555-2011; Morbidelli, Lucia/K-4053-2016; Memo, Maurizio/AAK-7197-2020; Morbidelli, Lucia/AAC-7858-2020	Schulz, Richard/0000-0002-5045-3193; Schulz, Richard/0000-0002-5045-3193; Donnini, Sandra/0000-0001-6617-1644; Morbidelli, Lucia/0000-0001-8148-7049; MEMO, Maurizio/0000-0002-7543-0289				Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; Barillari G, 1999, BLOOD, V94, P663; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Esteban JA, 2004, TRENDS NEUROSCI, V27, P1, DOI 10.1016/j.tins.2003.10.008; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748; Genersch E, 2000, J CELL SCI, V113, P4319; HAASS C, 1992, NATURE, V359, P325; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Kalaria RN, 1998, MOL BRAIN RES, V62, P101, DOI 10.1016/S0169-328X(98)00190-9; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729; Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61; Li QX, 1998, LAB INVEST, V78, P461; Lindahl B, 1999, J BIOL CHEM, V274, P30631, DOI 10.1074/jbc.274.43.30631; Mandriota SJ, 1997, J CELL SCI, V110, P2293; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; Morbidelli L, 2003, CLIN CANCER RES, V9, P5358; MORBIDELLI L, 1996, AM J PHYSIOL, V270, P411; Parenti A, 2001, FASEB J, V15, P1487, DOI 10.1096/fj.00-0503fje; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Price JM, 2001, NEUROL RES, V23, P506, DOI 10.1179/016164101101198758; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Suo ZM, 1997, BRAIN RES, V762, P144, DOI 10.1016/S0006-8993(97)00383-1; Taraboletti G, 2000, FASEB J, V14, P1674; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Xu J, 2001, J CEREBR BLOOD F MET, V21, P702, DOI 10.1097/00004647-200106000-00008; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziche M, 1997, CIRC RES, V80, P845, DOI 10.1161/01.res.80.6.845; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	40	47	49	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1943	+		10.1096/fj.04-2114fje	http://dx.doi.org/10.1096/fj.04-2114fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15448110				2022-12-25	WOS:000224243200011
J	Tschope, C; Spillmann, F; Rehfeld, U; Koch, M; Westermann, D; Altmann, C; Dendorfer, A; Walther, T; Bader, M; Paul, M; Schultheiss, HP; Vetter, R				Tschope, C; Spillmann, F; Rehfeld, U; Koch, M; Westermann, D; Altmann, C; Dendorfer, A; Walther, T; Bader, M; Paul, M; Schultheiss, HP; Vetter, R			Improvement of defective sarcoplasmic reticulum Ca2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene	FASEB JOURNAL			English	Article						bradykinin; cardiomyopathy; diabetes mellitus; phospholamban phosphorylation	CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; CALCIUM-TRANSPORT; DEPENDENT PHOSPHORYLATION; MYOCARDIAL-INFARCTION; CARDIAC MYOCYTES; BRADYKININ; PHOSPHOLAMBAN; CARDIOMYOPATHY; DYSFUNCTION; CA2+-ATPASE	The bradykinin-forming enzyme kallikrein-1 is expressed in the heart. To examine whether contractile performance and sarcoplasmic reticulum Ca2+ transport of the diabetic heart can be rescued by targeting the kallikrein-kinin system, we studied left ventricular function and sarcoplasmic reticular Ca2+ uptake after induction of streptozotocin-induced diabetes mellitus in transgenic rats expressing the human tissue kallikrein-1 gene. Six weeks after a single injection of either streptozotocin ( 70 mg/kg ip) or vehicle, left ventricular performance was determined using a Millar-Tip catheter system. The Ca2+-transporting activity of reticulum-derived membrane vesicles was determined in left ventricular homogenates as oxalate-supported Ca-45(2+) uptake. Western blot analysis was used to quantify the reticular Ca2+-ATPase SERCA2a, phospholamban, and the phosphorylation status of the latter. Contractile performance and Ca2+ uptake activity were similar in nondiabetic wild-type and transgenic rats. Severely diabetic wild-type animals exhibited impaired left ventricular performance and decreased reticular Ca2+ uptake (-39% vs. wild-type rats, P<0.05, respectively). These changes were attenuated in diabetic transgenic rats that, in addition, exhibited a markedly increased phospholamban phosphorylation at the Ca2+/calmodulin kinase-specific site threonine17 (2.2-fold vs. diabetic wild-type rats, P<0.05). These transgene-related effects were abolished after treatment with the bradykinin B-2 receptor antagonist icatibant (Hoe 140). The SERCA2-to-phospholamban ratio, phosphoserine(16)-phospholamban levels, and the apparent affinity for Ca2+ of the uptake reaction did not differ between the groups. Increasing the activity of the kallikrein-kinin system by expressing a human kallikrein-1 transgene protects rat heart against diabetes-induced contractile and reticular Ca2+ transport dysfunctions. An increased phosphorylation of the SERCA2 regulatory protein phospholamban at threonine(17) via a B-2 receptor-mediated mechanism is thereby involved.	Charite Univ Med Berlin, Dept Cardiol & Pneumol, D-12220 Berlin, Germany; Charite Univ Med Berlin, Inst Clin Pharmacol & Toxicol, D-12220 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Med Univ Lubeck, Inst Expt & Clin Pharmacol & Toxicol, D-23538 Lubeck, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Lubeck	Tschope, C (corresponding author), Charite Univ Med Berlin, Dept Cardiol & Pneumol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12220 Berlin, Germany.	ctschoepe@yahoo.com	Paul, Martin/K-5425-2015; Bader, Michael/K-2124-2013; Westermann, Dirk/D-1344-2011	Tschope, Carsten/0000-0001-5243-8985; Bader, Michael/0000-0003-4780-4164; Spillmann, Frank/0000-0003-0002-5745; Westermann, Dirk/0000-0002-7542-1956				Antipenko AY, 1997, J BIOL CHEM, V272, P2852, DOI 10.1074/jbc.272.5.2852; Bidasee KR, 2004, DIABETES, V53, P463, DOI 10.2337/diabetes.53.2.463; Bischoff A, 1999, PFLUG ARCH EUR J PHY, V438, P797, DOI 10.1007/s004240051109; DHALLA NS, 1992, MOL CELL BIOCHEM, V116, P3, DOI 10.1007/BF01270562; DIXON IMC, 1990, MOL CELL BIOCHEM, V99, P125; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; Emanueli C, 2002, CIRCULATION, V106, P993, DOI 10.1161/01.CIR.0000027104.33206.C8; Fujii M, 2002, HYPERTENSION, V39, P952, DOI 10.1161/01.HYP.0000015613.78314.9E; GANGULY PK, 1983, AM J PHYSIOL, V244, pE528, DOI 10.1152/ajpendo.1983.244.6.E528; GO LO, 1995, J CLIN INVEST, V95, P888, DOI 10.1172/JCI117739; KAWAGUCHI H, 1993, CIRC RES, V72, P966, DOI 10.1161/01.RES.72.5.966; Koch M, 2003, AM J PHYSIOL-HEART C, V285, pH418, DOI 10.1152/ajpheart.00677.2002; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Kotsanas G, 2000, CARDIOVASC RES, V46, P450, DOI 10.1016/S0008-6363(00)00062-6; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; Kudoh A, 2002, J CARDIOVASC PHARM, V39, P621, DOI 10.1097/00005344-200205000-00001; Kuwahara Y, 1997, BASIC RES CARDIOL, V92, P214, DOI 10.1007/BF00788516; Maier LS, 2002, J MOL CELL CARDIOL, V34, P919, DOI 10.1006/jmcc.2002.2038; MATTIAZZI A, 1994, AM J PHYSIOL, V267, pH812, DOI 10.1152/ajpheart.1994.267.2.H812; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; Netticadan T, 2001, DIABETES, V50, P2133, DOI 10.2337/diabetes.50.9.2133; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; PENPARGKUL S, 1981, J MOL CELL CARDIOL, V13, P303, DOI 10.1016/0022-2828(81)90318-7; PENPARGKUL S, 1980, CIRC RES, V47, P911, DOI 10.1161/01.RES.47.6.911; Pierce GN, 1997, CARDIOVASC RES, V34, P41, DOI 10.1016/S0008-6363(97)00010-2; PIERCE GN, 1983, P NATL ACAD SCI-BIOL, V80, P5412, DOI 10.1073/pnas.80.17.5412; Pinto YM, 2000, FASEB J, V14, P1861; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; Rett K, 1997, AM J CARDIOL, V80, pA143, DOI 10.1016/S0002-9149(97)00470-0; Schannwell CM, 2002, CARDIOLOGY, V98, P33, DOI 10.1159/000064682; Sharma JN, 1996, IMMUNOPHARMACOLOGY, V33, P341, DOI 10.1016/0162-3109(96)00104-X; Sharma JN, 1998, INT J CARDIOL, V63, P229, DOI 10.1016/S0167-5273(97)00329-X; Shiuchi T, 2002, HYPERTENSION, V40, P329, DOI 10.1161/01.HYP.0000028979.98877.0C; Silva JA, 2000, FASEB J, V14, P1858; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Spillmann F, 2002, INT IMMUNOPHARMACOL, V2, P1823, DOI 10.1016/S1567-5769(02)00174-1; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; Tschope C, 2004, FASEB J, V18, P828, DOI 10.1096/fj.03-0736com; Tschope C, 2004, CARDIOVASC RES, V61, P559, DOI 10.1016/j.cardiores.2003.10.018; Tschope C, 1999, IMMUNOPHARMACOLOGY, V44, P35, DOI 10.1016/S0162-3109(99)00109-5; Vetter R, 2002, FASEB J, V16, P1657, DOI 10.1096/fj.01-1019fje; Vetter R, 1998, MOL CELL BIOCHEM, V188, P177, DOI 10.1023/A:1006850724830; Vittone L, 1998, J BIOL CHEM, V273, P9804, DOI 10.1074/jbc.273.16.9804; XU A, 1993, J BIOL CHEM, V268, P8394; Yoshida H, 2000, HYPERTENSION, V35, P25, DOI 10.1161/01.HYP.35.1.25	45	27	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1967	+		10.1096/fj.04-1614fje	http://dx.doi.org/10.1096/fj.04-1614fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15448111				2022-12-25	WOS:000224243200012
J	Drisaldi, B; Coomaraswamy, J; Mastrangelo, P; Strome, B; Yang, J; Watts, JC; Chishti, MA; Marvi, M; Windl, O; Ahrens, R; Major, F; Sy, MS; Kretzschmar, H; Fraser, PE; Mount, HTJ; Westaway, D				Drisaldi, B; Coomaraswamy, J; Mastrangelo, P; Strome, B; Yang, J; Watts, JC; Chishti, MA; Marvi, M; Windl, O; Ahrens, R; Major, F; Sy, MS; Kretzschmar, H; Fraser, PE; Mount, HTJ; Westaway, D			Genetic mapping of activity determinants within cellular prion proteins - N-terminal modules in PrPC offset pro-apoptotic activity of the Doppel helix B/B ' region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURKINJE-CELLS; COPPER-BINDING; MICE DEFICIENT; TRUNCATED PRP; KNOCKOUT MICE; GRANULE CELLS; NMR STRUCTURE; SCRAPIE; EXPRESSION; IDENTIFICATION	The PrP-like Doppel (Dpl) protein causes apoptotic death of cerebellar neurons in transgenic mice, a process prevented by expression of the wild type (wt) cellular prion protein, PrPC. Internally deleted forms of PrPC resembling Dpl such as PrPDelta32-121 produce a similar PrPC-sensitive pro-apoptotic phenotype in transgenic mice. Here we demonstrate that these phenotypic attributes of wt Dpl, wt PrPC, and PrPDelta132-121 can be accurately recapitulated by transfected mouse cerebellar granule cell cultures. This system was then explored by mutagenesis of the co-expressed prion proteins to reveal functional determinants. By this means, neuroprotective activity of wt PrPC was shown to be nullified by a deletion of the N-terminal charged region implicated in endocytosis and retrograde axonal transport (PrPDelta23-28), by deletion of all five octarepeats (PrPDelta51-90), or by glycine replacement of four octarepeat histidine residues required for selective binding of copper ions (Prnp"H/G"). In the case of Dpl, overlapping deletions defined a requirement for the gene interval encoding helices B and B' (DplDelta101-125). These data suggest contributions of copper binding and neuronal trafficking to wt PrPC function in vivo and place constraints upon current hypotheses to explain Dpl/PrPC antagonism by competitive ligand binding. Further implementation of this assay should provide a fuller understanding of the attributes and subcellular localizations required for activity of these enigmatic proteins.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Vet Labs Agcy, Weybridge KT15 3NB, Surrey, England; Univ Montreal, Dept Informat & Rech Operat, Montreal, PQ H3C 3J7, Canada; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Univ Munich, D-81377 Munich, Germany	University of Toronto; University of Toronto; University of Toronto; University of Toronto; Veterinary Laboratories Agency; Universite de Montreal; Case Western Reserve University; University of Munich	Westaway, D (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	david.westaway@utoronto.ca	Mount, Howard/B-4097-2013; Windl, Otto/C-6760-2011	Watts, Joel/0000-0002-2604-2925				Adler V, 2003, J MOL BIOL, V332, P47, DOI 10.1016/S0022-2836(03)00919-7; Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Anderson L, 2004, P NATL ACAD SCI USA, V101, P3644, DOI 10.1073/pnas.0308681101; Atarashi R, 2003, J BIOL CHEM, V278, P28944, DOI 10.1074/jbc.M303655200; Behrens A, 2002, TRENDS NEUROSCI, V25, P150, DOI 10.1016/S0166-2236(00)02089-0; Behrens A, 2001, EMBO REP, V2, P347, DOI 10.1093/embo-reports/kve088; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Chesebro Bruce, 2002, EMBO Reports, V3, P1123, DOI 10.1093/embo-reports/kvf256; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Cui T, 2003, MOL CELL NEUROSCI, V23, P144, DOI 10.1016/S1044-7431(03)00017-4; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Flechsig E, 2003, EMBO J, V22, P3095, DOI 10.1093/emboj/cdg285; FONCIN JF, 1982, REV NEUROL, V138, P123; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Gu YP, 2003, NEUROBIOL DIS, V12, P133, DOI 10.1016/S0969-9961(02)00014-1; Hachiya NS, 2004, BIOCHEM BIOPH RES CO, V315, P802, DOI 10.1016/j.bbrc.2004.01.126; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Legname G, 2002, P NATL ACAD SCI USA, V99, P16285, DOI 10.1073/pnas.242611999; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; Levkovitz Y, 2001, J NEUROSCI, V21, P5893, DOI 10.1523/JNEUROSCI.21-16-05893.2001; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Liu T, 2002, J BIOL CHEM, V277, P47671, DOI 10.1074/jbc.M207458200; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; Luck R, 1996, J MOL BIOL, V258, P813, DOI 10.1006/jmbi.1996.0289; Luhrs T, 2003, J MOL BIOL, V326, P1549, DOI 10.1016/S0022-2836(02)01471-7; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Mastrangelo P, 2001, GENE, V275, P1, DOI 10.1016/S0378-1119(01)00627-8; Miller TM, 1996, J NEUROSCI, V16, P7487; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Mo HP, 2001, P NATL ACAD SCI USA, V98, P2352, DOI 10.1073/pnas.051627998; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moore RC, 2001, P NATL ACAD SCI USA, V98, P15288, DOI 10.1073/pnas.251550798; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson EM, 2002, J MOL BIOL, V316, P807, DOI 10.1006/jmbi.2001.5347; Nishida N, 1999, LAB INVEST, V79, P689; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Perrier V, 2002, P NATL ACAD SCI USA, V99, P13079, DOI 10.1073/pnas.182425299; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Qin KF, 2003, J BIOL CHEM, V278, P8888, DOI 10.1074/jbc.M210875200; Qin KF, 2002, J BIOL CHEM, V277, P1981, DOI 10.1074/jbc.M108744200; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Sakudo A, 2003, BIOCHEM BIOPH RES CO, V308, P660, DOI 10.1016/S0006-291X(03)01459-1; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; Silverman GL, 2000, J BIOL CHEM, V275, P26834; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; Supattapone S, 2004, PRIONS AND PRION DISEASES: CURRENT PERSPECTIVES, P83; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Walmsley AR, 2003, J BIOL CHEM, V278, P37241, DOI 10.1074/jbc.M302036200; WESTAWAY D, 1994, P NATL ACAD SCI USA, V91, P6418, DOI 10.1073/pnas.91.14.6418; Westaway D, 2002, TRENDS BIOCHEM SCI, V27, P301, DOI 10.1016/S0968-0004(02)02106-0; Westaway David, 2004, VVolume 41, P283; WILLS PR, 1992, J THEOR BIOL, V159, P523, DOI 10.1016/S0022-5193(05)80696-4; WILLS PR, 1990, J ACQ IMMUN DEF SYND, V3, P95; Wong BS, 2001, MOL CELL NEUROSCI, V17, P768, DOI 10.1006/mcne.2001.0963; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zulianello L, 2000, J VIROL, V74, P4351, DOI 10.1128/JVI.74.9.4351-4360.2000	85	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55443	55454		10.1074/jbc.M404794200	http://dx.doi.org/10.1074/jbc.M404794200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15459186	hybrid			2022-12-25	WOS:000225960800059
J	Hsieh, TJ; Farh, L; Huang, WM; Chan, NL				Hsieh, TJ; Farh, L; Huang, WM; Chan, NL			Structure of the topoisomerase IVC-terminal domain - A broken beta-propeller implies a role as geometry facilitator in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II DNA TOPOISOMERASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GYRASE-A; BINDING PROTEIN; SINGLE-MOLECULE; REPLICATION; MECHANISM; CHROMOSOME; UNLINKING	Bacteria possess two closely related yet functionally distinct essential type IIA topoisomerases (Topos). DNA gyrase supports replication and transcription with its unique supercoiling activity, whereas Topo IV preferentially relaxes (+) supercoils and is a decatenating enzyme required for chromosome segregation. Here we report the crystal structure of the C-terminal domain of Topo IV ParC subunit (ParC-CTD) from Bacillus stearothermophilus and provide a structure-based explanation for how Topo IV and DNA gyrase execute distinct activities. Although the topological connectivity of ParC-CTD is similar to the recently determined CTD structure of DNA gyrase GyrA subunit (GyrA-CTD), ParC-CTD surprisingly folds as a previously unseen broken form of a six-bladed beta-propeller. Propeller breakage is due to the absence of a DNA gyrase-specific GyrA box motif, resulting in the reduction of curvature of the proposed DNA binding region, which explains why ParC-CTD is less efficient than GyrA-CTD in mediating DNA bending, a difference that leads to divergent activities of the two homologous enzymes. Moreover, we found that the topology of the propeller blades observed in ParC-CTD and GyrA-CTD can be achieved from a concerted beta-hairpin invasion-induced fold change event of a canonical six-bladed beta-propeller; hence, we proposed to name this new fold as "hairpin-invaded beta-propeller" to highlight the high degree of similarity and a potential evolutionary linkage between them. The possible role of ParC-CTD as a geometry facilitator during various catalytic events and the evolutionary relationships between prokaryotic type IIA Topos have also been discussed according to these new structural insights.	Natl Chung Hsing Univ, Coll Life Sci, Inst Biochem, Taichung 402, Taiwan; Natl Pingtung Teachers Coll, Dept Nat Sci Educ, Pingtung 900, Taiwan; Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA	National Chung Hsing University; Utah System of Higher Education; University of Utah	Chan, NL (corresponding author), Natl Chung Hsing Univ, Coll Life Sci, Inst Biochem, Taichung 402, Taiwan.	nlchan@dragon.nchu.edu.tw	huang, wen/GXW-0661-2022	CHAN, NEI-LI/0000-0003-0139-6513				Adachi N, 1997, NUCLEIC ACIDS RES, V25, P3135, DOI 10.1093/nar/25.15.3135; ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BATES AD, 1993, DNA TOPOLOGY, P26; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Charvin G, 2003, P NATL ACAD SCI USA, V100, P9820, DOI 10.1073/pnas.1631550100; *COLL COMP PROJ, 1994, ACTA CRYSTALLOGR D, V50, P764; Corbett KD, 2004, P NATL ACAD SCI USA, V101, P7293, DOI 10.1073/pnas.0401595101; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21335; Crisona NJ, 2000, GENE DEV, V14, P2881, DOI 10.1101/gad.838900; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Edwards TA, 2003, GENE DEV, V17, P2508, DOI 10.1101/gad.1119403; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; Espeli O, 2004, MOL MICROBIOL, V52, P925, DOI 10.1111/j.1365-2958.2004.04047.x; Espeli O, 2003, J BIOL CHEM, V278, P44639, DOI 10.1074/jbc.M308926200; Fulop V, 1999, CURR OPIN STRUC BIOL, V9, P715, DOI 10.1016/S0959-440X(99)00035-4; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Gadelle D, 2003, BIOESSAYS, V25, P232, DOI 10.1002/bies.10245; Grishin NV, 2001, J STRUCT BIOL, V134, P167, DOI 10.1006/jsbi.2001.4335; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hsieh TJ, 2004, ACTA CRYSTALLOGR D, V60, P564, DOI 10.1107/S0907444903029779; Jawad Z, 2002, STRUCTURE, V10, P447, DOI 10.1016/S0969-2126(02)00750-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; Kang SH, 2003, J BIOL CHEM, V278, P48779, DOI 10.1074/jbc.M308843200; KATO J, 1992, J BIOL CHEM, V267, P25676; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P9419, DOI 10.1073/pnas.97.17.9419; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; Knight SW, 1999, EMBO J, V18, P4875, DOI 10.1093/emboj/18.17.4875; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MILLER WG, 1993, MOL MICROBIOL, V10, P675, DOI 10.1111/j.1365-2958.1993.tb00939.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paoli M, 2001, PROG BIOPHYS MOL BIO, V76, P103, DOI 10.1016/S0079-6107(01)00007-4; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; Postow L, 2001, P NATL ACAD SCI USA, V98, P8219, DOI 10.1073/pnas.111006998; Prescott L., 1996, MICROBIOLOGY, V3rd ed; Qi Y, 2002, PROTEINS, V47, P258, DOI 10.1002/prot.10090; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; Stone MD, 2003, P NATL ACAD SCI USA, V100, P8654, DOI 10.1073/pnas.1133178100; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Ward D, 1997, MOL MICROBIOL, V26, P897, DOI 10.1046/j.1365-2958.1997.6242005.x; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103	56	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55587	55593		10.1074/jbc.M408934200	http://dx.doi.org/10.1074/jbc.M408934200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15466871	hybrid			2022-12-25	WOS:000225960800076
J	Cipollo, JF; Awad, AM; Costello, CE; Hirschberg, CB				Cipollo, JF; Awad, AM; Costello, CE; Hirschberg, CB			srf-3, a mutant of Caenorhabditis elegans, resistant to bacterial infection and to biofilm binding, is deficient in glycoconjugates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCANS; LINKED GLYCANS; HOST; PATHOGEN; ADHESIN; MODEL; GLYCOSYLATION; EXPRESSION; TOXIN; GENES	srf-3 is a mutant of C. elegans that is resistant to infection by Microbacterium nematophilum and to binding of the biofilm produced by Yersinia pseudotuberculosis and Yersinia pestis. Recently, SRF-3 was characterized as a nucleotide sugar transporter of the Golgi apparatus occurring exclusively in hypodermal seam cells, pharyngeal cells, and spermatheca. Based on the above observations, we hypothesized that srf-3 may have altered glyconjugates that may enable the mutant nematode to grow unaffected in the presence of the above pathogenic bacteria. Following analyses of N- and O-linked glycoconjugates of srf-3 and wild type nematodes using a combination of enzymatic degradation, permethylation, and mass spectrometry, we found in srf-3 a 65% reduction of acidic O-linked glycoconjugates containing glucuronic acid and galactose as well as a reduction of N- linked glycoconjugates containing galactose and fucose. These results are consistent with the specificity of SRF-3 for UDP-galactose and strongly suggest that the above glycoconjugates play an important role in allowing adhesion of M. nematophilum or Y. pseudotuberculosis biofilm to wild type C. elegans. Furthermore, because seam cells as well as pharyngeal cells secrete their glycoconjugates to the cuticle and surrounding surfaces, the results also demonstrate the critical role of these cells and their secreted glycoproteins in nematode-bacteria interactions and offer a mechanistic basis for strategies to block such recognition processes.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Mass Spectrometry Resource, Boston, MA 02118 USA	Boston University; Boston University	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, 715 Albany St,Evans 437, Boston, MA 02118 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721; Costello, Catherine/0000-0003-1594-5122	NCRR NIH HHS [P41 RR10888, S10 RR15942] Funding Source: Medline; NIGMS NIH HHS [F32 GM66486, R01 GM30365] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888, S10RR015942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM066486, R01GM030365] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; Chen SH, 1999, J BIOL CHEM, V274, P288, DOI 10.1074/jbc.274.1.288; Chen SH, 2002, BBA-GEN SUBJECTS, V1573, P271, DOI 10.1016/S0304-4165(02)00393-8; Cipollo JF, 2002, J BIOL CHEM, V277, P49143, DOI 10.1074/jbc.M208020200; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Couillault C, 2002, INFECT IMMUN, V70, P4705, DOI 10.1128/IAI.70.8.4705-4707.2002; Darby C, 1999, P NATL ACAD SCI USA, V96, P15202, DOI 10.1073/pnas.96.26.15202; Darby C, 2002, NATURE, V417, P243, DOI 10.1038/417243a; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Ewbank JJ, 2002, MICROBES INFECT, V4, P247, DOI 10.1016/S1286-4579(01)01531-3; Garsin DA, 2001, P NATL ACAD SCI USA, V98, P10892, DOI 10.1073/pnas.191378698; Gemmill TR, 1998, GLYCOBIOLOGY, V8, P1087, DOI 10.1093/glycob/8.11.1087; Griffitts JS, 2003, J BIOL CHEM, V278, P45594, DOI 10.1074/jbc.M308142200; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Harvey DJ, 1999, MASS SPECTROM REV, V18, P349, DOI 10.1002/(SICI)1098-2787(1999)18:6<349::AID-MAS1>3.3.CO;2-8; Haslam SM, 2003, BIOCHIMIE, V85, P25, DOI 10.1016/S0300-9084(03)00041-5; Haslam SM, 2002, BIOCHEM SOC SYMP, V69, P117; HEMMER RM, 1991, J CELL BIOL, V115, P1237, DOI 10.1083/jcb.115.5.1237; Hirabayashi J, 2001, PROTEOMICS, V1, P295, DOI 10.1002/1615-9861(200102)1:2<295::AID-PROT295>3.0.CO;2-C; Hodgkin J, 2000, CURR BIOL, V10, P1615, DOI 10.1016/S0960-9822(00)00867-8; Hoeflich J, 2004, J BIOL CHEM; Joshua GWP, 2003, MICROBIOL-SGM, V149, P3221, DOI 10.1099/mic.0.26475-0; Karlsson KA, 2001, ADV EXP MED BIOL, V491, P431; KRAMER JM, 1997, C ELEGANS, V2, P471; Kurz CL, 2000, TRENDS MICROBIOL, V8, P142, DOI 10.1016/S0966-842X(99)01691-1; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Marroquin LD, 2000, GENETICS, V155, P1693; Natsuka S, 2002, J BIOCHEM, V131, P807, DOI 10.1093/oxfordjournals.jbchem.a003169; O'Quinn AL, 2001, CELL MICROBIOL, V3, P381, DOI 10.1046/j.1462-5822.2001.00118.x; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Peterson C, 2000, J HISTOCHEM CYTOCHEM, V48, P877, DOI 10.1177/002215540004800616; Rad R, 2002, J IMMUNOL, V168, P3033, DOI 10.4049/jimmunol.168.6.3033; Rajamohan F, 1998, PROG NUCLEIC ACID RE, V60, P1, DOI 10.1016/S0079-6603(08)60887-9; Schachter H, 2002, BIOCHEM SOC SYMP, V69, P1; Schurks N, 2002, INT J BIOL MACROMOL, V30, P105, DOI 10.1016/S0141-8130(02)00002-8; Silverman MA, 1997, J NEMATOL, V29, P296; Verostek MF, 2000, ANAL BIOCHEM, V278, P111, DOI 10.1006/abio.1999.4433; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931	39	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52893	52903		10.1074/jbc.M409557200	http://dx.doi.org/10.1074/jbc.M409557200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15452127	hybrid			2022-12-25	WOS:000225680600013
J	Foster, DB; Huang, RJ; Hatch, V; Craig, R; Graceffa, P; Lehman, W; Wang, CLA				Foster, DB; Huang, RJ; Hatch, V; Craig, R; Graceffa, P; Lehman, W; Wang, CLA			Modes of caldesmon binding to actin - Sites of caldesmon contact and modulation of interactions by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; ACTIVATED PROTEIN-KINASE; LIGHT-CHAIN KINASE; FILAMENT-ASSOCIATED PROTEINS; ERK MAP KINASES; THIN-FILAMENTS; CALMODULIN-BINDING; CROSS-LINKING; F-ACTIN; SIGNAL-TRANSDUCTION	Smooth muscle caldesmon binds actin and inhibits actomyosin ATPase activity. Phosphorylation of caldesmon by extracellular signal-regulated kinase (ERK) reverses this inhibitory effect and weakens actin binding. To better understand this function, we have examined the phosphorylation-dependent contact sites of caldesmon on actin by low dose electron microscopy and three-dimensional reconstruction of actin filaments decorated with a C-terminal fragment, hH32K, of human caldesmon containing the principal actin-binding domains. Helical reconstruction of negatively stained filaments demonstrated that hH32K is located on the inner portion of actin subdomain 1, traversing its upper surface toward the C-terminal segment of actin, and forms a bridge to the neighboring actin monomer of the adjacent long pitch helical strand by connecting to its subdomain 3. Such lateral binding was supported by cross-linking experiments using a mutant isoform, which was capable of cross-linking actin subunits. Upon ERK phosphorylation, however, the mutant no longer cross-linked actin to polymers. Three-dimensional reconstruction of ERK-phosphorylated hH32K indeed indicated loss of the interstrand connectivity. These results, together with fluorescence quenching data, are consistent with a phosphorylation-dependent conformational change that moves the C-terminal end segment of caldesmon near the phosphorylation site but not the upstream region around Cys(595), away from F-actin, thus neutralizing its inhibitory effect on actomyosin interactions. The binding pattern of hH32K suggests a mechanism by which unphosphorylated, but not ERK-phosphorylated, caldesmon could stabilize actin filaments and resist F-actin severing or depolymerization in both smooth muscle and nonmuscle cells.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	Boston Biomedical Research Institute; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Wang, CLA (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	wang@bbri.org	Foster, D. Brian/S-9108-2019; Foster, D. Brian/C-6350-2009	Foster, D. Brian/0000-0002-9290-9590; Foster, D. Brian/0000-0002-9290-9590; Lehman, William/0000-0002-9430-9521	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062468, R01HL036153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL62468, R01-HL36153] Funding Source: Medline; NIAMS NIH HHS [P01-AR41637] Funding Source: Medline; NIDDK NIH HHS [DK32520] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM LP, 1992, FEBS LETT, V302, P223, DOI 10.1016/0014-5793(92)80446-N; ADAM LP, 1989, J BIOL CHEM, V264, P7698; ADAMS S, 1990, J BIOL CHEM, V265, P19652; AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BARANY M, 1996, BIOCH SMOOTH MUSCLE, P321; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BOGATCHEVA NV, 1993, BIOCHEM J, V290, P437, DOI 10.1042/bj2900437; CASTELLINO F, 1995, J CELL BIOL, V131, P1223, DOI 10.1083/jcb.131.5.1223; Chalovich JM, 1998, ACTA PHYSIOL SCAND, V164, P427; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; CHILDS TJ, 1993, BIOCHEM CELL BIOL, V71, P544, DOI 10.1139/o93-078; Cook AK, 2000, AM J PHYSIOL-GASTR L, V278, pG429, DOI 10.1152/ajpgi.2000.278.3.G429; CROSBIE R, 1991, J BIOL CHEM, V266, P20001; D'Angelo G, 1999, J BIOL CHEM, V274, P30115, DOI 10.1074/jbc.274.42.30115; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; Earley JJ, 1998, CIRC RES, V83, P661, DOI 10.1161/01.RES.83.6.661; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; Franklin MT, 1997, AM J PHYSIOL-CELL PH, V273, pC1819, DOI 10.1152/ajpcell.1997.273.6.C1819; FUJII T, 1987, J BIOL CHEM, V262, P2757; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; Geguchadze R, 2004, FEBS LETT, V557, P121, DOI 10.1016/S0014-5793(03)01456-X; Gerthoffer WT, 1996, J PHYSIOL-LONDON, V495, P597, DOI 10.1113/jphysiol.1996.sp021619; Graceffa P, 1999, BIOCHEMISTRY-US, V38, P11984, DOI 10.1021/bi9825495; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1995, J BIOL CHEM, V270, P30187; Guo HQ, 1999, J MUSCLE RES CELL M, V20, P725, DOI 10.1023/A:1005537132581; Hatch V, 2001, J CELL BIOL, V154, P611, DOI 10.1083/jcb.200105079; HAYASHI K, 1991, J BIOL CHEM, V266, P355; Hedges JC, 2000, AM J PHYSIOL-CELL PH, V278, pC718, DOI 10.1152/ajpcell.2000.278.4.C718; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; HETTASCH JM, 1991, J BIOL CHEM, V266, P11876; Hnath EJ, 1996, BIOPHYS J, V71, P1920, DOI 10.1016/S0006-3495(96)79391-8; Hodgkinson JL, 1997, BIOPHYS J, V72, P2398, DOI 10.1016/S0006-3495(97)78885-4; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; Huang RJ, 2003, BIOCHEMISTRY-US, V42, P2513, DOI 10.1021/bi0268605; Hulvershorn J, 2001, AM J PHYSIOL-HEART C, V280, pH1422, DOI 10.1152/ajpheart.2001.280.3.H1422; IKEBE M, 1991, ARCH BIOCHEM BIOPHYS, V288, P538, DOI 10.1016/0003-9861(91)90232-8; IKEBE M, 1990, J BIOL CHEM, V265, P17607; Isotani E, 2004, P NATL ACAD SCI USA, V101, P6279, DOI 10.1073/pnas.0308742101; KHALIL RA, 1995, CIRC RES, V76, P1101, DOI 10.1161/01.RES.76.6.1101; KOLAKOWSKI J, 1992, FEBS LETT, V309, P65, DOI 10.1016/0014-5793(92)80740-8; Krueger JK, 2000, BIOCHEMISTRY-US, V39, P3979, DOI 10.1021/bi992638x; Lehman W, 1997, J MOL BIOL, V274, P310, DOI 10.1006/jmbi.1997.1422; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; Lehrer S S, 1978, Methods Enzymol, V49, P222; LI Y, 2004, J CELL SCI, P29; Li YH, 2000, J BIOL CHEM, V275, P10989, DOI 10.1074/jbc.275.15.10989; Li YP, 2003, AM J PHYSIOL-REG I, V284, pR192, DOI 10.1152/ajpregu.00290.2002; MAK AS, 1991, J BIOL CHEM, V266, P19971; MAK AS, 1991, J BIOL CHEM, V266, P6678; Marston S, 1998, ACTA PHYSIOL SCAND, V164, P401, DOI 10.1111/j.1365-201X.1998.tb10696.x; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; Morgan KG, 2001, J APPL PHYSIOL, V91, P953, DOI 10.1152/jappl.2001.91.2.953; NISHIDA W, 1990, FEBS LETT, V268, P165, DOI 10.1016/0014-5793(90)80999-Y; NIXON GF, 1995, J PHYSIOL-LONDON, V487, P283, DOI 10.1113/jphysiol.1995.sp020879; Owen CH, 1996, J STRUCT BIOL, V116, P167, DOI 10.1006/jsbi.1996.0027; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Patchell VB, 2002, BBA-PROTEIN STRUCT M, V1596, P121, DOI 10.1016/S0167-4838(02)00210-8; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; SUTHERLAND C, 1994, J MUSCLE RES CELL M, V15, P440, DOI 10.1007/BF00122118; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; Tran QK, 2003, J BIOL CHEM, V278, P24247, DOI 10.1074/jbc.C300165200; TSURUDA TS, 1995, BIOCHEM J, V309, P951, DOI 10.1042/bj3090951; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VIBERT P, 1993, J CELL BIOL, V123, P313, DOI 10.1083/jcb.123.2.313; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1990, BIOPHYS J, V57, pA162; WANG CLA, 1991, J BIOL CHEM, V266, P13958; Wang Z, 1997, P NATL ACAD SCI USA, V94, P11899, DOI 10.1073/pnas.94.22.11899; Wang Z, 1997, J BIOL CHEM, V272, P16896, DOI 10.1074/jbc.272.27.16896; Watts SW, 1996, J PHARMACOL EXP THER, V279, P1541; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; Yamboliev IA, 2001, AM J PHYSIOL-CELL PH, V280, pC1680, DOI 10.1152/ajpcell.2001.280.6.C1680; ZHAN Q, 1991, J BIOL CHEM, V266, P21810; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964	86	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53387	53394		10.1074/jbc.M410109200	http://dx.doi.org/10.1074/jbc.M410109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456752	hybrid			2022-12-25	WOS:000225680600072
J	Lemieux, AM; Pare, ME; Audet, B; Legault, E; Lefort, S; Boucher, N; Landry, S; van Opijnen, T; Berkhout, B; Naghavi, MH; Tremblay, MJ; Barbeau, B				Lemieux, AM; Pare, ME; Audet, B; Legault, E; Lefort, S; Boucher, N; Landry, S; van Opijnen, T; Berkhout, B; Naghavi, MH; Tremblay, MJ; Barbeau, B			T-cell activation leads to poor activation of the HIV-1 clade E long terminal repeat and weak association of nuclear factor-kappa B and NFAT with its enhancer region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTION FACTOR; TYPE-1 SUBTYPES; DIFFERENTIAL REGULATION; REGULATORY ELEMENTS; GENE-EXPRESSION; IN-VIVO; ALPHA; REPLICATION; PROTEINS	The enhancer region in the human immunodeficiency virus type 1 (HIV-1) 5'-long terminal repeat (LTR) is very important for viral transcription. This promoter sequence binds both nuclear factor-kappaB and NFAT, two important modulators of HIV-1 gene expression. Previous studies have indicated that the enhancer regions of the different HIV-1 clade LTRs differ in their number of NF-kappaB-binding sites. In this study, we have compared the activation potential of the different HIV-1 clade and HIV-2 LTRs and assessed their interaction with NFAT and NF-kappaB. In T-cell lines and primary CD4(+) T-cells, the results showed that the HIV-1 clade LTR (with a single NF-kappaB-binding site) was the weakest LTR regardless of the tested activators, whereas the HIV-2 LTR was the most responsive LTR. The clade E enhancer region was also demonstrated to be the weakest enhancer region in transfection experiments with luciferase reporter-based vectors. Electrophoretic mobility shift assays with extracts from activated CD4(+) T-cells indicated that, although NF-kappaB and NFAT bound all enhancers, HIV-1 clade E and HIV-2 LTR enhancers were poor binding targets for these two factors. Weak NFAT binding to clade E enhancers was also confirmed using NFAT1-expressing 293T cells in competition experiments. We have also shown the absence of interaction of NF-kappaB or NFAT with the third NF-kappaB repeat present in clade C. However, the clade C enhancer bound NFAT more efficiently than all other enhancer regions tested. Our results hence demonstrate for the first time that differences in the binding of NF-kappaB and NFAT to the enhancer regions could be responsible for some of the observed variation in HIV-1 clade LTR activation, whereas HIV-2 LTR activation seems mostly independent of these interactions.	Ctr Hosp Univ Quebec, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1V 4G2, Canada; Univ Amsterdam, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Laval University; Laval University; University of Amsterdam; Columbia University; Howard Hughes Medical Institute	Barbeau, B (corresponding author), Ctr Hosp Univ Quebec, Ctr Rech Infectiol, RC709,Pavillon CHUL,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	benoit.barbeau@crchul.ulaval.ca	Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155; Lefort, Sylvain/0000-0001-7320-4256; van Opijnen, Tim/0000-0001-6895-6795				ARYA S K, 1990, New Biologist, V2, P57; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Barbeau B, 2001, J IMMUNOL, V167, P2700, DOI 10.4049/jimmunol.167.5.2700; Berry N, 2001, AIDS RES HUM RETROV, V17, P263, DOI 10.1089/088922201750063197; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Fortin JF, 2001, BLOOD, V97, P2390, DOI 10.1182/blood.V97.8.2390; Fortin JF, 1999, VIROLOGY, V257, P228, DOI 10.1006/viro.1999.9687; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Giffin MJ, 2003, NAT STRUCT BIOL, V10, P800, DOI 10.1038/nsb981; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HANNIBAL MC, 1993, J VIROL, V67, P5035, DOI 10.1128/JVI.67.8.5035-5040.1993; HANNIBAL MC, 1994, BLOOD, V83, P1839; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; MARKOVITZ DM, 1990, P NATL ACAD SCI USA, V87, P9098, DOI 10.1073/pnas.87.23.9098; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Montano MA, 1997, J VIROL, V71, P8657, DOI 10.1128/JVI.71.11.8657-8665.1997; Montano MA, 1998, J VIROL, V72, P8446, DOI 10.1128/JVI.72.10.8446-8452.1998; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Naghavi MH, 1999, AIDS RES HUM RETROV, V15, P1293, DOI 10.1089/088922299310197; Navarro J, 1998, J VIROL, V72, P4712, DOI 10.1128/JVI.72.6.4712-4720.1998; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Robichaud GA, 2002, J BIOL CHEM, V277, P23733, DOI 10.1074/jbc.M201563200; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roof P, 2002, VIROLOGY, V296, P77, DOI 10.1006/viro.2001.1397; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH SD, 1984, CANCER RES, V44, P5657; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TONGSTARKSEN SE, 1990, J IMMUNOL, V145, P4348; TRAENCKER E, 1995, EMBO J, P2876; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; van Opijnen T, 2004, J VIROL, V78, P3675, DOI 10.1128/JVI.78.7.3675-3683.2004; Verhoef K, 1999, J VIROL, V73, P1331, DOI 10.1128/JVI.73.2.1331-1340.1999; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; West MJ, 2001, J VIROL, V75, P8524, DOI 10.1128/JVI.75.18.8524-8537.2001	53	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52949	52960		10.1074/jbc.M409896200	http://dx.doi.org/10.1074/jbc.M409896200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466412	hybrid			2022-12-25	WOS:000225680600019
J	Adams, CM; Reitz, J; De Brabander, JK; Feramisco, JD; Li, L; Brown, MS; Goldstein, JL				Adams, CM; Reitz, J; De Brabander, JK; Feramisco, JD; Li, L; Brown, MS; Goldstein, JL			Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and insigs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; LOW-DENSITY-LIPOPROTEIN; A REDUCTASE-ACTIVITY; HUMAN FIBROBLASTS; MEMBRANE-PROTEIN; CDNA CLONING; STEROL; CLEAVAGE; RECEPTOR; CELLS	The current paper demonstrates that cholesterol and its hydroxylated derivative, 25-hydroxycholesterol (25-HC), inhibit cholesterol synthesis by two different mechanisms, both involving the proteins that control sterol regulatory element-binding proteins (SREBPs), membrane-bound transcription factors that activate genes encoding enzymes of lipid synthesis. Using methyl-beta-cyclodextrin as a delivery vehicle, we show that cholesterol enters cultured Chinese hamster ovary cells and elicits a conformational change in SREBP cleavage-activating protein (SCAP), as revealed by the appearance of a new fragment in tryptic digests. This change causes SCAP to bind to Insigs, which are endoplasmic reticulum retention proteins that abrogate movement of the SCAP.SREBP complex to the Golgi apparatus where SREBPs are normally processed to their active forms. Direct binding of cholesterol to SCAP in intact cells was demonstrated by showing that a photoactivated derivative of cholesterol cross-links to the membrane domain of SCAP. The inhibitory actions of cholesterol do not require the isooctyl side chain or the Delta5-double bond of cholesterol, but they do require the 3beta-hydroxyl group. 25-HC is more potent than cholesterol in eliciting SCAP binding to Insigs, but 25-HC does not cause a detectable conformational change in SCAP. Moreover, a photoactivated derivative of 25-HC does not cross-link to SCAP. These data imply that cholesterol interacts with SCAP directly by inducing it to bind to Insigs, whereas 25-HC works indirectly through a putative 25-HC sensor protein that elicits SCAP-Insig binding.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, MS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mike.brown@utsouthwestern.edu; joe.goldstein@utsouthwestern.edu		Adams, Christopher/0000-0002-5795-7212	NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM-08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 2003, P NATL ACAD SCI USA, V100, P10647, DOI 10.1073/pnas.1534833100; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1974, J BIOL CHEM, V249, P7306; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DAWSON PA, 1989, J BIOL CHEM, V264, P9046; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; GOLDSTEIN JL, 1975, LIPIDS LIPOPROTEINS, P77; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KRIEGER M, 1978, P NATL ACAD SCI USA, V75, P5052, DOI 10.1073/pnas.75.10.5052; LEVANON D, 1990, GENOMICS, V7, P65, DOI 10.1016/0888-7543(90)90519-Z; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Matyash V, 2001, MOL BIOL CELL, V12, P1725, DOI 10.1091/mbc.12.6.1725; Mintzer EA, 2002, FEBS LETT, V510, P181, DOI 10.1016/S0014-5793(01)03271-9; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Olkkonen VM, 2004, CURR OPIN LIPIDOL, V15, P321, DOI 10.1097/00041433-200406000-00013; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; TAVARES R, 1993, TETRAHEDRON, V49, P5079, DOI 10.1016/S0040-4020(01)81873-1; TAYLOR FR, 1985, CHEM PHYS LIPIDS, V38, P187, DOI 10.1016/0009-3084(85)90066-0; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	41	311	330	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52772	52780		10.1074/jbc.M410302200	http://dx.doi.org/10.1074/jbc.M410302200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452130	hybrid			2022-12-25	WOS:000225493400124
J	Luciano, BS; Hsu, S; Channavajhala, PL; Lin, LL; Cuozzo, JW				Luciano, BS; Hsu, S; Channavajhala, PL; Lin, LL; Cuozzo, JW			Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot is necessary but not sufficient for kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; T-CELL LYMPHOMAS; PROTEIN-KINASE; FACTOR-ALPHA; TNF-ALPHA; RHEUMATOID-ARTHRITIS; NF-KAPPA-B1 P105; CROHNS-DISEASE; B-RAF; TPL-2	Cot/Tpl2/MAP3K8 is a serine/threonine kinase known to activate the ERK, p38, and JNK kinase pathways. Studies of Tpl2 knock-out mice reveal a clear defect in tumor necrosis factor-alpha production, although very little detail is known about its regulation and the signaling events involved. In the present study we demonstrated that phosphorylation of Cot was required for its maximal activity as phosphatase treatment of Cot decreased its kinase activity. The Cot sequence contains a conserved threonine at position 290 in the activation loop of the kinase domain. We found that mutation of this residue to alanine eliminated its ability to activate MEK/ ERK and NF-kappaB pathways, whereas a phosphomimetic mutation to aspartic acid could rescue the ability to activate MEK. Thr-290 was also required for robust autophosphorylation of Cot. Antibody generated to phospho-Thr-290-Cot recognized both wild-type and kinase-dead Cot, suggesting that phosphorylation of Thr-290 did not occur through autophosphorylation but via another kinase. We showed that Cot was constitutively phosphorylated at Thr-290 in transfected human embryonic kidney 293T cells as well as human monocytes as this residue was phosphorylated in unstimulated and lipopolysaccharide-stimulated cells to the same degree. Treatment with herbimycin A inhibited Cot activity in the MEK/ ERK pathway but did not inhibit phosphorylation at Thr-290. Together these results showed that phosphorylation of Cot at Thr-290 is necessary but not sufficient for full kinase activity in the MEK/ ERK pathway.	Wyeth Ayerst Res, Dept Mol Inflammat Inflammat Signaling, Cambridge, MA 02140 USA	Pfizer	Cuozzo, JW (corresponding author), Wyeth Ayerst Res, Dept Mol Inflammat Inflammat Signaling, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.	jcuozzo@wyeth.com		Cuozzo, John/0000-0002-6229-0395				Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bondeson J, 2001, INT J CLIN PRACT, V55, P211; Caivano M, 2003, J BIOL CHEM, V278, P52124, DOI 10.1074/jbc.M306583200; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Channavajhala PL, 2003, J BIOL CHEM, V278, P47089, DOI 10.1074/jbc.M306002200; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Creange A, 1996, J NEUROIMMUNOL, V68, P95, DOI 10.1016/0165-5728(96)00075-6; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Feldman M, 1998, TRANSPLANT P, V30, P4126, DOI 10.1016/S0041-1345(98)01365-7; Gandara ML, 2003, MOL CELL BIOL, V23, P7377, DOI 10.1128/MCB.23.20.7377-7390.2003; Hu FB, 2004, DIABETES, V53, P693, DOI 10.2337/diabetes.53.3.693; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Kapp Alexander, 1993, Journal of Dermatological Science, V5, P133, DOI 10.1016/0923-1811(93)90760-M; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Lang V, 2004, MOL CELL BIOL, V24, P5235, DOI 10.1128/MCB.24.12.5235-5248.2004; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MAURY CPJ, 1989, ARTHRITIS RHEUM, V32, P146, DOI 10.1002/anr.1780320206; MAURY CPJ, 1989, INT J TISSUE REACT, V11, P189; Mizutani H, 1997, J DERMATOL SCI, V14, P145, DOI 10.1016/S0923-1811(96)00562-2; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Rask-Madsen C, 2003, CIRCULATION, V108, P1815, DOI 10.1161/01.CIR.0000091406.72832.11; Raza A, 2000, MICROSC RES TECHNIQ, V50, P229, DOI 10.1002/1097-0029(20000801)50:3<229::AID-JEMT6>3.0.CO;2-H; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955	40	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52117	52123		10.1074/jbc.M403716200	http://dx.doi.org/10.1074/jbc.M403716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466476	hybrid			2022-12-25	WOS:000225493400050
J	Tang, DD; Gunst, SJ				Tang, DD; Gunst, SJ			The small GTPase Cdc42 regulates actin polymerization and tension development during contractile stimulation of smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; LENGTH-DEPENDENT MODULATION; FORCE DEVELOPMENT; CELL-ADHESION; ACTIVATION; PROTEIN; RHO; PHOSPHORYLATION; CYTOCHALASIN; NUCLEATION	Contractile stimulation induces actin polymerization in smooth muscle tissues and cells, and the inhibition of actin polymerization depresses smooth muscle force development. In the present study, the role of Cdc42 in the regulation of actin polymerization and tension development in smooth muscle was evaluated. Acetylcholine stimulation of tracheal smooth muscle tissues increased the activation of Cdc42. Plasmids encoding wild type Cdc42 or a dominant negative Cdc42 mutant, Asn-17 Cdc42, were introduced into tracheal smooth muscle strips by reversible permeabilization, and tissues were incubated for 2 days to allow for protein expression. Expression of recombinant proteins was confirmed by immunoblot analysis. The expression of the dominant negative Cdc42 mutant inhibited contractile force and the increase in actin polymerization in response to acetylcholine stimulation but did not inhibit the increase in myosin light chain phosphorylation. The expression of wild type Cdc42 had no significant effect on force, actin polymerization, or myosin light chain phosphorylation. Contractile stimulation increased the association of neuronal Wiskott-Aldrich syndrome protein with Cdc42 and the Arp2/3 (actin-related protein) complex in smooth muscle tissues expressing wild type Cdc42. The agonist-induced increase in these protein interactions was inhibited in tissues expressing the inactive Cdc42 mutant. We conclude that Cdc42 activation regulates active tension development and actin polymerization during contractile stimulation. Cdc42 may regulate the activation of neuronal Wiskott-Aldrich syndrome protein and the actin related protein complex, which in turn regulate actin filament polymerization initiated by the contractile stimulation of smooth muscle.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Gunst, SJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	sgunst@iupui.edu	T, Dale/AAE-9643-2020	T, Dale/0000-0002-7339-9249; Gunst, Susan/0000-0001-9836-4782	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075388, R23HL029289, R01HL029289, R01HL074099] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL029289, HL-75388, R01 HL074099, R01 HL029289-19, HL-74099, HL-29289, R01 HL074099-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER KB, 1983, CELL MOTIL CYTOSKEL, V3, P545, DOI 10.1002/cm.970030521; Allen WE, 1997, J CELL SCI, V110, P707; Barany M, 2001, J BIOL CHEM, V276, P48398, DOI 10.1074/jbc.M106227200; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; Gong MC, 2001, AM J PHYSIOL-CELL PH, V281, pC257, DOI 10.1152/ajpcell.2001.281.1.C257; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Herrera AM, 2004, AM J PHYSIOL-LUNG C, V286, pL1161, DOI 10.1152/ajplung.00298.2003; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Hirshman CA, 1999, AM J PHYSIOL-LUNG C, V277, pL653, DOI 10.1152/ajplung.1999.277.3.L653; Hirshman CA, 1998, AM J PHYSIOL-LUNG C, V275, pL911, DOI 10.1152/ajplung.1998.275.5.L911; Jones KA, 1999, J PHYSIOL-LONDON, V519, P527, DOI 10.1111/j.1469-7793.1999.0527m.x; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; Mehta D, 1999, J PHYSIOL-LONDON, V519, P829, DOI 10.1111/j.1469-7793.1999.0829n.x; Mehta D, 1996, AM J PHYSIOL-CELL PH, V270, pC243, DOI 10.1152/ajpcell.1996.270.1.C243; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Murthy KS, 2003, BIOCHEM J, V374, P145, DOI 10.1042/BJ20021274; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OBARA K, 1994, EUR J PHARMACOL, V255, P139, DOI 10.1016/0014-2999(94)90092-2; OPAZO SA, 2004, AM J PHYSIOL-CELL PH, V286, pC433; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Ridley A J, 1999, Prog Mol Subcell Biol, V22, P1; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Tang DD, 2003, HYPERTENSION, V42, P858, DOI 10.1161/01.HYP.0000085333.76141.33; Tang DD, 2003, AM J PHYSIOL-HEART C, V285, pH1528, DOI 10.1152/ajpheart.00188.2003; Tang DD, 2002, J PHYSIOL-LONDON, V542, P501, DOI 10.1113/jphysiol.2002.021006; Tang DD, 2001, AM J PHYSIOL-CELL PH, V280, pC874, DOI 10.1152/ajpcell.2001.280.4.C874; Tang DD, 2003, J PHYSIOL-LONDON, V553, P21, DOI 10.1113/jphysiol.2003.045047; Wirth A, 2003, J PHYSIOL-LONDON, V549, P489, DOI 10.1113/jphysiol.2002.033167; Yang CS, 2000, J CELL BIOL, V150, P1001, DOI 10.1083/jcb.150.5.1001; Youn T, 1998, AM J PHYSIOL-CELL PH, V274, pC1601, DOI 10.1152/ajpcell.1998.274.6.C1601; Zhang WW, 2004, FASEB J, V18, pA1086; Zigmond SH, 2000, J CELL BIOL, V150, pF117, DOI 10.1083/jcb.150.6.F117	34	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51722	51728		10.1074/jbc.M408351200	http://dx.doi.org/10.1074/jbc.M408351200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456777	hybrid			2022-12-25	WOS:000225493400003
J	Choi, HJ; Smithgall, TE				Choi, HJ; Smithgall, TE			HIV-1 Nef promotes survival of TF-1 macrophages by inducing Bcl-X-L expression in an extracellular signal-regulated kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; VIRUS TYPE-1 NEF; NF-KAPPA-B; SH3 DOMAIN; SERINE PHOSPHORYLATION; CRYSTAL-STRUCTURE; TRANSGENIC MICE; GM-CSF; CELL; STAT3	The Nef protein of human immunodeficiency virus-1 (HIV-1) is essential for the progression from human and simian immunodeficiency virus infection to full-blown AIDS. Recent studies indicate that Nef generates antiapoptotic signals in HIV-infected T cells, suppressing cell death early in infection to allow productive viral replication. Previous work from our laboratory has shown that Nef also promotes proliferation of myeloid cells through a signal transducer and activator of transcription 3-dependent pathway. Here we demonstrate that Nef suppresses cell death induced by cytokine deprivation in the human macrophage precursor cell line, TF-1. Nef selectively induced up-regulation of Bcl-X-L, an anti-apoptotic gene that is also regulated by granulocyte/ macrophage-colony stimulating factor in this cell line. Activation of the extracellular signal-regulated kinase (Erk) mitogen-activated protein kinase pathway also correlated with the survival of TF-1/Nef cells. Using the selective mitogen-activated protein kinase kinase inhibitor PD98059, we found that Nef-induced Erk signaling is essential for Bcl-X-L up-regulation and cell survival. In contrast, expression of Bcl-X-L and TF-1 survival was not affected by dominant-negative signal transducer and activator of transcription 3. These data suggest that Nef produces survival signals in myeloid cells through Erk-mediated Bcl-X-L induction, a pathway distinct from Nef survival pathways recently reported in T lymphocytes.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057083] Funding Source: NIH RePORTER; NCI NIH HHS [CA81398] Funding Source: Medline; NIAID NIH HHS [AI57083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arold S, 1997, STRUCTURE, V5, P1361, DOI 10.1016/S0969-2126(97)00286-4; Arold S, 2000, PROTEIN SCI, V9, P1137, DOI 10.1110/ps.9.6.1137; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Biggs TE, 1999, J MOL BIOL, V290, P21, DOI 10.1006/jmbi.1999.2849; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Briggs SD, 2001, J BIOL CHEM, V276, P25605, DOI 10.1074/jbc.M103244200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hanna Z, 2001, J VIROL, V75, P9378, DOI 10.1128/JVI.75.19.9378-9392.2001; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MOSIER DE, 1993, SCIENCE, V260, P689, DOI 10.1126/science.8097595; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Orenstein JM, 2001, IMMUNOBIOLOGY, V204, P598, DOI 10.1078/0171-2985-00098; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Rivat C, 2004, ONCOGENE, V23, P3317, DOI 10.1038/sj.onc.1207437; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; SCHUITEMAKER H, 1993, J INFECT DIS, V168, P1140, DOI 10.1093/infdis/168.5.1140; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walk SF, 2001, J VIROL, V75, P834, DOI 10.1128/JVI.75.2.834-843.2001; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Yang XY, 1999, J VIROL, V73, P3460, DOI 10.1128/JVI.73.4.3460-3466.1999; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	49	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51688	51696		10.1074/jbc.M410068200	http://dx.doi.org/10.1074/jbc.M410068200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15459189	hybrid			2022-12-25	WOS:000225355800125
J	Eichacker, LA; Granvogl, B; Mirus, O; Muller, BC; Miess, C; Schleiff, E				Eichacker, LA; Granvogl, B; Mirus, O; Muller, BC; Miess, C; Schleiff, E			Hiding behind hydrophobicity - Transmembrane segments in mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN COMPLEXES; SACCHAROMYCES-CEREVISIAE; PROTEOMIC ANALYSIS; IDENTIFICATION; ELECTROPHORESIS; IMPORT; PHOSPHORYLATION; CHLOROPLASTS; CHALLENGES; DISCOVERY	Proteomics of membrane proteins is essential for the understanding of cellular function. However, mass spectrometric analysis of membrane proteomes has been less successful than the proteomic determination of soluble proteins. To elucidate the mystery of transmembrane proteins in mass spectrometry, we present a detailed statistical analysis of experimental data derived from chloroplast membranes. This approach was further accomplished by the analysis of the Arabidopsis thaliana proteome after in silico digestion. We demonstrate that both the length and the hydrophobicity of the proteolytic fragments containing transmembrane segments are major determinants for detection by mass spectrometry. Based on a comparative analysis, we discuss possibilities to overcome the problem and provide possible protocols to shift the hydrophobicity of transmembrane segment-containing peptides to facilitate their detection.	Univ Munich, Dept Biol 1, D-80368 Munich, Germany; Hoffmann La Roche AG, Roche Ctr Med Genom, CH-4070 Basel, Switzerland	University of Munich; Roche Holding	Eichacker, LA (corresponding author), Univ Munich, Dept Biol 1, Menzinger Str 67, D-80368 Munich, Germany.	eichacker@lrz.uni-muenchen.de; schleiff@lrz.uni-muenchen.de	Schleiff, Enrico/C-5105-2017	Schleiff, Enrico/0000-0002-0518-3489				Aebersold R, 2001, CHEM REV, V101, P269, DOI 10.1021/cr990076h; Anderson NL, 2000, CURR OPIN BIOTECH, V11, P408, DOI 10.1016/S0958-1669(00)00118-X; BLACK SD, 1991, ANAL BIOCHEM, V193, P72, DOI 10.1016/0003-2697(91)90045-U; Blonder J, 2004, PROTEOMICS, V4, P31, DOI 10.1002/pmic.200300543; Canovas FM, 2004, PROTEOMICS, V4, P285, DOI 10.1002/pmic.200300602; Cash P, 2003, ADV BIOCHEM ENG BIOT, V83, P93; Cooper R. A., 2004, Current Drug Targets - Infectious Disorders, V4, P41, DOI 10.2174/1568005043480989; Devreese B, 2002, ELECTROPHORESIS, V23, P2525, DOI 10.1002/1522-2683(200208)23:15<2525::AID-ELPS2525>3.0.CO;2-I; Eckart K, 2002, EMBO REP, V3, P557, DOI 10.1093/embo-reports/kvf110; EICHACKER L, 2001, Patent No. 100119597; Eichacker LA, 1996, J BIOL CHEM, V271, P32174, DOI 10.1074/jbc.271.50.32174; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fukao Y, 2002, PLANT CELL PHYSIOL, V43, P689, DOI 10.1093/pcp/pcf101; Hippler M, 2001, PLANT J, V28, P595, DOI 10.1046/j.1365-313X.2001.01175.x; Hixson KK, 2002, ELECTROPHORESIS, V23, P3224, DOI 10.1002/1522-2683(200209)23:18<3224::AID-ELPS3224>3.0.CO;2-#; Kashino Y, 2003, J CHROMATOGR B, V797, P191, DOI 10.1016/S1570-0232(03)00428-8; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kuchler M, 2002, EMBO J, V21, P6136, DOI 10.1093/emboj/cdf621; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lister R, 2004, PLANT PHYSIOL, V134, P777, DOI 10.1104/pp.103.033910; Onyango P, 2004, CURR CANCER DRUG TAR, V4, P111, DOI 10.2174/1568009043481588; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; Rachakonda S, 2004, CURR MED CHEM, V11, P775, DOI 10.2174/0929867043455774; Rowley A, 2000, METHODS, V20, P383, DOI 10.1006/meth.2000.0951; Santoni V, 1999, ELECTROPHORESIS, V20, P705, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<705::AID-ELPS705>3.3.CO;2-H; Santoni V, 2000, ELECTROPHORESIS, V21, P3329, DOI 10.1002/1522-2683(20001001)21:16<3329::AID-ELPS3329>3.0.CO;2-F; Schafer H, 2001, ELECTROPHORESIS, V22, P2955, DOI 10.1002/1522-2683(200108)22:14<2955::AID-ELPS2955>3.0.CO;2-U; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schleiff E, 2003, PROTEIN SCI, V12, P748, DOI 10.1110/ps.0237503; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Thidholm E, 2002, FEBS LETT, V513, P217, DOI 10.1016/S0014-5793(02)02314-1; Turck N, 2004, PROTEOMICS, V4, P93, DOI 10.1002/pmic.200300480; Ulmschneider MB, 2001, BBA-BIOMEMBRANES, V1512, P1, DOI 10.1016/S0005-2736(01)00299-1; van Wijk KJ, 2001, PLANT PHYSIOL, V126, P501, DOI 10.1104/pp.126.2.501; Veenstra TD, 2003, ADV PROTEIN CHEM, V65, P161; Venter H, 2002, BIOCHEM J, V363, P243, DOI 10.1042/0264-6021:3630243; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Whelan SA, 2003, CIRC RES, V93, P1047, DOI 10.1161/01.RES.0000103190.20260.37; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wimley WC, 2002, PROTEIN SCI, V11, P301, DOI 10.1110/ps.29402; Wu CC, 2003, NAT BIOTECHNOL, V21, P262, DOI 10.1038/nbt0303-262; Zhu H, 2003, ANNU REV BIOCHEM, V72, P783, DOI 10.1146/annurev.biochem.72.121801.161511; Zolg JW, 2004, MOL CELL PROTEOMICS, V3, P345, DOI 10.1074/mcp.M400007-MCP200	44	83	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50915	50922		10.1074/jbc.M405875200	http://dx.doi.org/10.1074/jbc.M405875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452135	hybrid			2022-12-25	WOS:000225355800034
J	Fewell, SW; Smith, CM; Lyon, MA; Dumitrescu, TP; Wipf, P; Day, BW; Brodsky, JL				Fewell, SW; Smith, CM; Lyon, MA; Dumitrescu, TP; Wipf, P; Day, BW; Brodsky, JL			Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN-VIRUS-40 LARGE-T; HEAT-SHOCK-PROTEIN; YEAST ENDOPLASMIC-RETICULUM; PEPTIDE-BINDING DOMAIN; ANTIGEN J-DOMAIN; SACCHAROMYCES-CEREVISIAE; CYSTIC-FIBROSIS; IN-VITRO; IMMUNOSUPPRESSANT 15-DEOXYSPERGUALIN; DIFFERENTIAL EXPRESSION	The molecular chaperone and cytoprotective activities of the Hsp70 and Hsp40 chaperones represent therapeutic targets for human diseases such as cancer and those that arise from defects in protein folding; however, very few Hsp70 and no Hsp40 modulators have been described. Using an assay for ATP hydrolysis, we identified and screened small molecules with structural similarity to 15-deoxyspergualin and NSC 630668-R/1 for their effects on endogenous and Hsp40-stimulated Hsp70 ATPase activity. Several of these compounds modulated Hsp70 ATPase activity, consistent with the action of NSC 630668-R/1 observed previously (Fewell, S. W., Day, B. W., and Brodsky, J. L. ( 2001) J. Biol. Chem. 276, 910 - 914). In contrast, three compounds inhibited the ability of Hsp40 to stimulate Hsp70 ATPase activity but did not affect the endogenous activity of Hsp70. Two of these agents also compromised the Hsp70/Hsp40-mediated post-translational translocation of a secreted pre-protein in vitro. Together, these data indicate the potential for continued screening of small molecule Hsp70 effectors and that specific modulators of Hsp70-Hsp40 interaction can be obtained, potentially for future therapeutic use.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Brodsky, JL (corresponding author), Univ Pittsburgh, Dept Biol Sci, 274 Crawford Hall, Pittsburgh, PA 15260 USA.	jbrodsky@pitt.edu	Wipf, Peter/AAG-1771-2021	Wipf, Peter/0000-0001-7693-5863; Day, Billy/0000-0001-6208-9950	NCI NIH HHS [CA78039, CA099024] Funding Source: Medline; NIGMS NIH HHS [GM067082] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078039, R21CA099024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM067082] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbanti-Brodano G, 1998, ADV VIRUS RES, V50, P69, DOI 10.1016/S0065-3527(08)60806-4; Beck J, 2003, J BIOL CHEM, V278, P36128, DOI 10.1074/jbc.M301069200; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Brodsky JL, 2001, AM J PHYSIOL-LUNG C, V281, pL39, DOI 10.1152/ajplung.2001.281.1.L39; Brodsky JL, 1999, BIOCHEM PHARMACOL, V57, P877, DOI 10.1016/S0006-2952(98)00376-1; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Cantalupo P, 1999, METHOD ENZYMOL, V306, P297; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Castellino AM, 1997, J VIROL, V71, P7549, DOI 10.1128/JVI.71.10.7549-7559.1997; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; CYR DM, 1992, J BIOL CHEM, V267, P20927; Davis JE, 1999, P NATL ACAD SCI USA, V96, P9269, DOI 10.1073/pnas.96.16.9269; Domling A, 2000, ANGEW CHEM INT EDIT, V39, P3168, DOI 10.1002/1521-3773(20000915)39:18<3168::AID-ANIE3168>3.0.CO;2-U; Ferber D, 2002, SCIENCE, V296, P1012, DOI 10.1126/science.296.5570.1012; Fewell SW, 2002, P NATL ACAD SCI USA, V99, P2002, DOI 10.1073/pnas.042670999; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Fewell SW, 2001, J BIOL CHEM, V276, P910, DOI 10.1074/jbc.M008535200; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; Gelman MS, 2002, J CLIN INVEST, V110, P1591, DOI 10.1172/JCI200216786; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; JIANG C, 2000, AM J PHYSIOL, V278, pC259; Jiang CW, 1998, AM J PHYSIOL-CELL PH, V275, pC171, DOI 10.1152/ajpcell.1998.275.1.C171; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kaur J, 1995, INT J CANCER, V63, P774, DOI 10.1002/ijc.2910630604; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Lambert C, 2003, P NATL ACAD SCI USA, V100, P5199, DOI 10.1073/pnas.0930813100; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Le Gac NT, 2002, J BIOL CHEM, V277, P5660, DOI 10.1074/jbc.M108316200; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lin BY, 2002, MOL CELL BIOL, V22, P6592, DOI 10.1128/MCB.22.18.6592-6604.2002; Liu QL, 2001, J BIOL CHEM, V276, P6112, DOI 10.1074/jbc.M009519200; Mamelak D, 2001, J BIOL CHEM, V276, P449, DOI 10.1074/jbc.M006732200; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McClellan AJ, 2000, GENETICS, V156, P501; McClellan AJ, 1998, MOL BIOL CELL, V9, P3533, DOI 10.1091/mbc.9.12.3533; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; NADLER SG, 1995, THER DRUG MONIT, V17, P700, DOI 10.1097/00007691-199512000-00026; Nadler SG, 1998, BIOCHEM BIOPH RES CO, V253, P176, DOI 10.1006/bbrc.1998.9775; Neckers L, 2003, CURR MED CHEM, V10, P733, DOI 10.2174/0929867033457818; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Rajesh D, 2003, J BIOL CHEM, V278, P35968, DOI 10.1074/jbc.M303280200; Ralhan R, 1995, CLIN CANCER RES, V1, P1217; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; Santarosa M, 1997, EUR J CANCER, V33, P873, DOI 10.1016/S0959-8049(97)00002-6; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Sock E, 1999, MOL CELL BIOL, V19, P2455; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Studer A, 1997, J ORG CHEM, V62, P2917, DOI 10.1021/jo970095w; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2001, VIROLOGY, V287, P1, DOI 10.1006/viro.2001.1038; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Tanabe K, 2000, TRANSPLANT P, V32, P1745, DOI 10.1016/S0041-1345(00)01427-5; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; WANG TF, 1993, J BIOL CHEM, V268, P26049; Whetstone H, 2003, BIOCHEMISTRY-US, V42, P1611, DOI 10.1021/bi026735t; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; Wipf P, 1997, BIOORGAN MED CHEM, V5, P165, DOI 10.1016/S0968-0896(96)00199-X; WIPF P, 1995, TETRAHEDRON LETT, V36, P7819, DOI 10.1016/0040-4039(95)01660-A; Yang H, 2003, J BIOL CHEM, V278, P35079, DOI 10.1074/jbc.M303098200; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	85	163	172	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51131	51140		10.1074/jbc.M404857200	http://dx.doi.org/10.1074/jbc.M404857200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448148	Green Accepted, hybrid			2022-12-25	WOS:000225355800059
J	Kempna, P; Reiter, E; Arock, M; Azzi, A; Zingg, JM				Kempna, P; Reiter, E; Arock, M; Azzi, A; Zingg, JM			Inhibition of HMC-1 mast cell proliferation by vitamin E - Involvement of the protein kinase B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; MAMMARY EPITHELIAL-CELLS; ALPHA-TOCOPHEROL; C-KIT; PHOSPHATIDYLINOSITOL 3-KINASE; SCAVENGER RECEPTOR; SIGNALING PATHWAY; GAMMA-TOCOPHEROL; GENE-EXPRESSION; DOWN-REGULATION	The effects of four natural tocopherols on the proliferation and signaling pathways were examined in the human mastocytoma cell line (HMC-1). The four tocopherols inhibited HMC-1 cell proliferation with different potency (delta > alpha = gamma > beta). Growth inhibition correlated with the reduction of PKB ( protein kinase B) phosphorylation by the different tocopherols. The reduction of PKB phosphorylation led to a decrease of its activity, as judged from a parallel reduction of GSKalpha/beta phosphorylation. The translocation of PKB to the membrane, as a response to receptor stimulation by NGFbeta, is also prevented by treatment with tocopherols. In the presence of PKC or PP2A inhibitors, the reduction of PKB phosphorylation by tocopherols was still observed, thus excluding the direct involvement of these enzymes. Other pathways, such as the Ras-stimulated ERK1/2 ( extracellular signal responsive kinase) pathway, were not affected by tocopherol treatment. The tocopherols did not significantly change oxidative stress in HMC-1 cells, suggesting that the observed effects are not the result of a general reduction of oxidative stress. Thus, the tocopherols interfere with PKB phosphorylation and reduce proliferation of HMC-1 cells, possibly by modulating either phosphatidylinositol 3-kinase, a kinase phosphorylating PKB (PDK1/2), or a phosphatase that dephosphorylates it. Inhibition of proliferation and PKB signaling in HMC-1 cells by vitamin E suggests a role in preventing diseases with mast cell involvement, such as allergies, atherosclerosis, and tumorigenesis.	Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland; Fac Pharm, CNRS, Unit FRE 2444, F-75006 Paris, France	University of Bern; Centre National de la Recherche Scientifique (CNRS)	Zingg, JM (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Buhlstr 28, CH-3012 Bern, Switzerland.	zingg@mci.unibe.ch	Zingg, Jean-Marc/H-6960-2019					Akazawa A, 2002, JPN J PHARMACOL, V89, P417, DOI 10.1254/jjp.89.417; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARITA M, 1995, BIOCHEM J, V306, P437, DOI 10.1042/bj3060437; Azzi A, 1998, BIOFACTORS, V7, P3, DOI 10.1002/biof.5520070102; Barella L, 2004, BBA-MOL BASIS DIS, V1689, P66, DOI 10.1016/j.bbadis.2004.02.002; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; Boscoboinik D, 1992, EXS, V62, P164; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; Cachia O, 1998, J BIOL CHEM, V273, P32801, DOI 10.1074/jbc.273.49.32801; Chandra V, 2002, J MOL BIOL, V320, P215, DOI 10.1016/S0022-2836(02)00473-4; Chun KH, 2003, JNCI-J NATL CANCER I, V95, P291, DOI 10.1093/jnci/95.4.291; Clement S, 1997, EUR J BIOCHEM, V246, P745, DOI 10.1111/j.1432-1033.1997.t01-2-00745.x; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; DOUGLAS CE, 1986, BIOCHIM BIOPHYS ACTA, V876, P639, DOI 10.1016/0005-2760(86)90053-6; Egger T, 2001, J NEUROCHEM, V79, P1169, DOI 10.1046/j.1471-4159.2001.00641.x; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Galli S J, 1994, Curr Opin Hematol, V1, P33; GOODE N, 1992, J BIOL CHEM, V267, P16878; Gueck T, 2002, VET DERMATOL, V13, P301, DOI 10.1046/j.1365-3164.2002.00307.x; Gysin R, 2002, FASEB J, V16, P1952, DOI 10.1096/fj.02-0362fje; Haider UGB, 2002, MOL PHARMACOL, V62, P772, DOI 10.1124/mol.62.4.772; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; JacobsHelber SM, 1997, J BIOL CHEM, V272, P6850, DOI 10.1074/jbc.272.11.6850; Jiang Q, 2000, P NATL ACAD SCI USA, V97, P11494, DOI 10.1073/pnas.200357097; KAARTINEN M, 1994, CIRCULATION, V90, P1669, DOI 10.1161/01.CIR.90.4.1669; KANAKURA Y, 1994, LEUKEMIA, V8, pS18; Karlsson R, 2003, J LEUKOCYTE BIOL, V74, P923, DOI 10.1189/jlb.0403142; Kempna P, 2003, FREE RADICAL BIO MED, V34, P1458, DOI 10.1016/S0891-5849(03)00173-4; Kovanen PT, 1996, CURR OPIN LIPIDOL, V7, P281, DOI 10.1097/00041433-199610000-00004; Landes N, 2003, BIOCHEM PHARMACOL, V65, P269, DOI 10.1016/S0006-2952(02)01520-4; Letiges M, 2002, MOL ENDOCRINOL, V16, P847, DOI 10.1210/me.16.4.847; Ludowyke RI, 2000, J BIOL CHEM, V275, P6144, DOI 10.1074/jbc.275.9.6144; McIntyre BS, 2000, P SOC EXP BIOL MED, V224, P292, DOI 10.1046/j.1525-1373.2000.22434.x; McNally AK, 2003, AM J PATHOL, V163, P1147, DOI 10.1016/S0002-9440(10)63474-8; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Neuzil J, 2002, BIOCHEM J, V362, P709, DOI 10.1042/0264-6021:3620709; Nilsson G, 1997, EUR J IMMUNOL, V27, P2295, DOI 10.1002/eji.1830270925; Pal S, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-3; Pozo-Guisado E, 2004, INT J CANCER, V109, P167, DOI 10.1002/ijc.11720; Qin SF, 2003, BIOCHEMISTRY-US, V42, P2995, DOI 10.1021/bi0205911; Ricciarelli R, 2000, CIRCULATION, V102, P82, DOI 10.1161/01.CIR.102.1.82; Ricciarelli R, 1998, BIOCHEM J, V334, P243, DOI 10.1042/bj3340243; Ricciarelli R, 2001, FASEB J, V15, P2314, DOI 10.1096/fj.01-0258rev; Rossi G, 2003, MODERN PATHOL, V16, P1041, DOI 10.1097/01.MP.0000089780.30006.DE; Sattler M, 2004, LEUKEMIA RES, V28, pS11, DOI 10.1016/j.leukres.2003.10.004; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Shi DY, 2003, FEBS LETT, V542, P60, DOI 10.1016/S0014-5793(03)00338-7; Shivakrupa R, 2003, CANCER RES, V63, P4412; Spencer JPE, 2003, J BIOL CHEM, V278, P34783, DOI 10.1074/jbc.M305063200; Sylvester PW, 2002, ASIA PAC J CLIN NUTR, V11, pS452, DOI 10.1046/j.1440-6047.11.s.7.9.x; Tasinato A, 1995, P NATL ACAD SCI USA, V92, P12190, DOI 10.1073/pnas.92.26.12190; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Venugopal SK, 2004, ATHEROSCLEROSIS, V175, P213, DOI 10.1016/j.atherosclerosis.2004.03.012; Wen HC, 2003, CELL SIGNAL, V15, P37, DOI 10.1016/S0898-6568(02)00047-5; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P7408, DOI 10.1073/pnas.102014399; Zingg JM, 2004, CURR MED CHEM, V11, P1113, DOI 10.2174/0929867043365332	66	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50700	50709		10.1074/jbc.M410800200	http://dx.doi.org/10.1074/jbc.M410800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385541	hybrid			2022-12-25	WOS:000225355800011
J	Kim, YJ; Lee, MH; Wozney, JM; Cho, JY; Ryoo, HM				Kim, YJ; Lee, MH; Wozney, JM; Cho, JY; Ryoo, HM			Bone morphogenetic protein-2-induced alkaline phosphatase expression is stimulated by Dlx5 and repressed by Msx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCALCIN GENE-EXPRESSION; GROWTH-FACTOR BETA-1; OSTEOBLAST DIFFERENTIATION; HOMEODOMAIN PROTEINS; MOLECULAR-BASIS; HOMEOBOX GENES; UP-REGULATION; DNA-BINDING; CELL-LINE; RUNX2	Alkaline phosphatase ( ALP) is a widely accepted bone marker. Its expression is stimulated by bone morphogenetic protein (BMP)-2 treatment, the activation of BMP receptors and R-Smads, and the expression of Dlx5 and Runx2. However, how BMP-2 induces ALP expression is not clearly understood. We dissected the murine ALP promoter and found within it a Dlx5-binding cis-acting element by electrophoretic mobility shift assays and site-directed mutagenesis of the element. Dlx5 and the product of its target gene, Runx2, stimulated ALP promoter activity in an additive manner. However, because Dlx5 continued to stimulate ALP expression in Runx2(-/-) cells, the ALP stimulatory activity of Dlx5 is independent of Runx2. We also found that overexpression of Msx2 suppressed the mRNA level and enzyme activity of ALP that were induced by BMP-2 stimulation, and suppressed the Dlx5-stimulated ALP promoter activity by competing with Dlx5 for the cis-acting element in the ALP promoter. Moreover, Msx2 levels are constitutively high in C2C12 myogenic cells but decrease over time after BMP-2 treatment. This may explain why BMP-2 treatment of these cells results in immediate Dlx5 expression yet ALP expression commences only 1 - 2 days later. In other words, Msx2 in high levels counteracts initially the transcriptional activity of Dlx5 in low levels until a threshold Dlx5: Msx2 ratio is reached to the levels that allow the ALP stimulatory activity of Dlx5 to prevail. Thus, Dlx5 transactivates ALP expression, directly by binding to its cognate response element and/or indirectly by stimulating Runx2 expression, and Msx2 counteracts the direct transactivation of Dlx5.	Kyungpook Natl Univ, Sch Dent, Dept Biochem, Taegu 700422, South Korea; Kyungpook Natl Univ, Skeletal Dis Genome Res Ctr, Taegu 700422, South Korea; Wyeth Inc, Cambridge, MA 02140 USA	Kyungpook National University; Kyungpook National University; Pfizer	Ryoo, HM (corresponding author), Kyungpook Natl Univ, Sch Dent, Dept Biochem, 101 Dong In Dong, Taegu 700422, South Korea.	hmryoo@knu.ac.kr	Ryoo, Hyun-Mo/D-5839-2012	Ryoo, Hyun-Mo/0000-0001-6769-8341; Lee, Mi-Hye/0000-0002-5484-3383				Barnes GL, 2003, CANCER RES, V63, P2631; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; BILEZIKIAN JP, 1996, PRINCIPLES BONE BIOL; Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925-4773(96)00503-5; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Ferrari D, 2002, DEV BIOL, V252, P257, DOI 10.1006/dbio.2002.0862; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Qiu MS, 1997, DEV BIOL, V185, P165, DOI 10.1006/dbio.1997.8556; Robison R, 1923, BIOCHEM J, V17, P286, DOI 10.1042/bj0170286; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; SAKANO S, 1993, CLIN ORTHOP RELAT R, P337; Semba I, 2000, DEV DYNAM, V217, P401, DOI 10.1002/(SICI)1097-0177(200004)217:4<401::AID-DVDY7>3.0.CO;2-D; SEMENZA GL, 1995, BIOCHEM BIOPH RES CO, V209, P257, DOI 10.1006/bbrc.1995.1497; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060; Stock DW, 1996, P NATL ACAD SCI USA, V93, P10858, DOI 10.1073/pnas.93.20.10858; Takahashi K, 2001, DEV DYNAM, V222, P252, DOI 10.1002/dvdy.1185; TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006-291X(91)90490-X; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920	38	159	169	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50773	50780		10.1074/jbc.M404145200	http://dx.doi.org/10.1074/jbc.M404145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15383550	hybrid			2022-12-25	WOS:000225355800019
J	Revollo, JR; Grimm, AA; Imai, S				Revollo, JR; Grimm, AA; Imai, S			The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-ENHANCING FACTOR; DEPENDENT HISTONE DEACETYLASE; LIFE-SPAN EXTENSION; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; PROTEIN DEACETYLASES; NMN ADENYLYLTRANSFERASE; TRANSCRIPTION FACTORS; ADENINE-DINUCLEOTIDE; HAEMOPHILUS-DUCREYI	Recent studies have revealed new roles for NAD and its derivatives in transcriptional regulation. The evolutionarily conserved Sir2 protein family requires NAD for its deacetylase activity and regulates a variety of biological processes, such as stress response, differentiation, metabolism, and aging. Despite its absolute requirement for NAD, the regulation of Sir2 function by NAD biosynthesis pathways is poorly understood in mammals. In this study, we determined the kinetics of the NAD biosynthesis mediated by nicotinamide phosphoribosyltransferase (Nampt) and nicotinamide/nicotinic acid mononucleotide adenylyltransferase (Nmnat), and we examined its effects on the transcriptional regulatory function of the mouse Sir2 ortholog, Sir2alpha, in mouse fibroblasts. We found that Nampt was the rate-limiting component in this mammalian NAD biosynthesis pathway. Increased dosage of Nampt, but not Nmnat, increased the total cellular NAD level and enhanced the transcriptional regulatory activity of the catalytic domain of Sir2alpha recruited onto a reporter gene in mouse fibroblasts. Gene expression profiling with oligonucleotide microarrays also demonstrated a significant correlation between the expression profiles of Nampt- and Sir2alpha-overexpressing cells. These findings suggest that NAD biosynthesis mediated by Nampt regulates the function of Sir2alpha and thereby plays an important role in controlling various biological events in mammals.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Imai, S (corresponding author), Campus Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	imaishin@molecool.wustl.edu		Revollo, Javier/0000-0003-0518-2096				Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; BERNOFSKY C, 1980, MOL CELL BIOCHEM, V33, P135; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; Emanuelli M, 1996, J CHROMATOGR B, V676, P13, DOI 10.1016/0378-4347(95)00408-4; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Gallo CA, 2004, MOL CELL BIOL, V24, P1301, DOI 10.1128/MCB.24.3.1301-1312.2004; Ghislain M, 2002, YEAST, V19, P215, DOI 10.1002/yea.810; GREENGARD P, 1964, J BIOL CHEM, V239, P1887; Guarente L, 2000, GENE DEV, V14, P1021; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Imai S, 2000, COLD SPRING HARB SYM, V65, P297, DOI 10.1101/sqb.2000.65.297; JACOBSON EL, 1995, BIOCHIMIE, V77, P394, DOI 10.1016/0300-9084(96)88152-1; Jia SH, 2004, J CLIN INVEST, V113, P1318, DOI [10.1172/JCI19930, 10.1172/JCI200419930]; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KAPLAN NO, 1956, J BIOL CHEM, V219, P287; Kitani T, 2003, FEBS LETT, V544, P74, DOI 10.1016/S0014-5793(03)00476-9; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2003, CURR OPIN CELL BIOL, V15, P241, DOI 10.1016/S0955-0674(03)00006-1; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; Marcotte PA, 2004, ANAL BIOCHEM, V332, P90, DOI 10.1016/j.ab.2004.05.039; Martin PR, 2001, J BACTERIOL, V183, P1168, DOI 10.1128/JB.183.4.1168-1174.2001; Micheli V, 1997, METHOD ENZYMOL, V280, P211; Miller ES, 2003, J BACTERIOL, V185, P5220, DOI 10.1128/JB.185.17.5220-5233.2003; Miller LD, 2002, CANCER CELL, V2, P353, DOI 10.1016/S1535-6108(02)00181-2; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Munson RS, 2004, INFECT IMMUN, V72, P1143, DOI 10.1128/IAI.72.2.1143-1146.2004; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; NEUBERT D, 1964, BIOCHIM BIOPHYS ACTA, V92, P610, DOI 10.1016/0926-6569(64)90023-9; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Rongvaux A, 2003, BIOESSAYS, V25, P683, DOI 10.1002/bies.10297; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431; Sandmeier JJ, 2002, GENETICS, V160, P877; Scearce LM, 2002, DIABETES, V51, P1997, DOI 10.2337/diabetes.51.7.1997; Schmidt MT, 2004, J BIOL CHEM, V279, P40122, DOI 10.1074/jbc.M407484200; Schweiger M, 2001, FEBS LETT, V492, P95, DOI 10.1016/S0014-5793(01)02180-9; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	60	716	760	1	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50754	50763		10.1074/jbc.M408388200	http://dx.doi.org/10.1074/jbc.M408388200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15381699	hybrid			2022-12-25	WOS:000225355800017
J	Belikov, S; Holmqvist, PH; Astrand, C; Wrange, O				Belikov, S; Holmqvist, PH; Astrand, C; Wrange, O			Nuclear factor 1 and octamer transcription factor 1 binding preset the chromatin structure of the mouse mammary tumor virus promoter for hormone induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME POSITIONING SEQUENCES; GLUCOCORTICOID RESPONSE ELEMENT; MMTV PROMOTER; IN-VIVO; RECEPTOR-BINDING; GENE-EXPRESSION; FACTOR ACCESS; POU PROTEINS; DNA; ACCESSIBILITY	When the mouse mammary tumor virus ( MMTV) is integrated into the genome of a mammalian cell, its long terminal repeat (LTR) harbors six specifically positioned nucleosomes. Transcription from the MMTV promoter is regulated by the glucocorticoid hormone via the glucocorticoid receptor (GR). The mechanism of the apparently constitutive nucleosome arrangement has remained unclear. Previous in vitro reconstitution of nucleosome(s) on small segments of the MMTV LTR suggested that the DNA sequence was decisive for the nucleosome arrangement. However, microinjection of MMTV LTR DNA in Xenopus oocytes rendered randomly distributed nucleosomes. This indicated that oocytes lack factor( s) that induces nucleosome positioning at the MMTV LTR in other cells. Here we demonstrate that specific and concomitant binding of nuclear factor 1 (NF1) and octamer factor 1 (Oct1) to their cognate sites within the MMTV promoter induce a partial nucleosome positioning that is an intermediary state between the randomly organized inactive promoter and the hormone and GR-activated promoter containing distinctly positioned nucleosomes. Oct1 and NF1 reciprocally facilitate each other's binding to the MMTV LTR in vivo. The NF1 and Oct1 binding also facilitate hormone-dependent GR-DNA interaction and result in a faster and stronger hormone response. Since NF1 and Oct1 generate an intermediary state of nucleosome positioning and enhance the hormone-induced response, we refer to this as a preset chromatin structure. We propose that this state of NF1 and Oct1-induced chromatin presetting mimics the early step(s) of chromatin remodeling involved in tissue-specific gene expression.	Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Wrange, O (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, POB 285, SE-17177 Stockholm, Sweden.	orjan.wrange@cmb.ki.se	Holmqvist, Per-Henrik/A-2804-2016	Holmqvist, Per-Henrik/0000-0001-8074-2749				ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bachurski CJ, 2003, MOL CELL BIOL, V23, P9014, DOI 10.1128/MCB.23.24.9014-9024.2003; Beato M, 1996, J MOL MED, V74, P711, DOI 10.1007/s001090050076; Beato M, 1997, NUCLEIC ACIDS RES, V25, P3559, DOI 10.1093/nar/25.18.3559; Belikov S, 2004, MOL CELL BIOL, V24, P3036, DOI 10.1128/MCB.24.7.3036-3047.2004; Belikov S, 2001, EMBO J, V20, P2802, DOI 10.1093/emboj/20.11.2802; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUETTI E, 1994, MOL CELL BIOL, V14, P1191, DOI 10.1128/MCB.14.2.1191; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; CARTWRIGHT IL, 1983, P NATL ACAD SCI-BIOL, V80, P3213, DOI 10.1073/pnas.80.11.3213; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fu XH, 2002, EXP CELL RES, V278, P1, DOI 10.1006/excr.2002.5555; Gelius B, 2001, EXP CELL RES, V265, P319, DOI 10.1006/excr.2001.5184; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; Hager GL, 2001, PROG NUCLEIC ACID RE, V66, P279; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; Huber MC, 1996, NUCLEIC ACIDS RES, V24, P1443, DOI 10.1093/nar/24.8.1443; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Lefevre P, 2003, MOL CELL BIOL, V23, P4386, DOI 10.1128/MCB.23.12.4386-4400.2003; LI Q, 1995, MOL CELL BIOL, V15, P4375; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LU Q, 1995, EMBO J, V14, P4738, DOI 10.1002/j.1460-2075.1995.tb00155.x; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; Nagaich AK, 2004, MOL CELL, V14, P163, DOI 10.1016/S1097-2765(04)00178-9; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; Prado F, 2002, J BIOL CHEM, V277, P4911, DOI 10.1074/jbc.M110094200; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Roulet E, 2000, J MOL BIOL, V297, P833, DOI 10.1006/jmbi.2000.3614; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; Spangenberg C, 1998, J MOL BIOL, V278, P725, DOI 10.1006/jmbi.1998.1718; TANAKA S, 1992, EMBO J, V11, P1187, DOI 10.1002/j.1460-2075.1992.tb05159.x; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; Venditti P, 1998, NUCLEIC ACIDS RES, V26, P3657, DOI 10.1093/nar/26.16.3657; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WHITFIELD T, 1993, DEV BIOL, V155, P361, DOI 10.1006/dbio.1993.1035; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; ZernickaGoetz M, 1996, DEVELOPMENT, V122, P3719; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	58	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49857	49867		10.1074/jbc.M409713200	http://dx.doi.org/10.1074/jbc.M409713200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15381691	hybrid			2022-12-25	WOS:000225229500039
J	Buddha, MR; Tao, T; Parry, RJ; Crane, BR				Buddha, MR; Tao, T; Parry, RJ; Crane, BR			Regioselective nitration of tryptophan by a complex between bacterial nitric-oxide synthase and tryptophanyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE NITRATION; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; PEROXYNITRITE; TETRAHYDROBIOPTERIN; PROTEIN; MECHANISM; MYELOPEROXIDASE; NITROTYROSINE; DERIVATIVES	Bacterial nitric-oxide synthase proteins (NOSs) from certain Streptomyces strains have been shown to participate in biosynthetic nitration of tryptophanyl moieties in vivo (Kers, J.A., Wach, M.J., Krasnoff, S. B., Cameron, K. D., Widom, J., Bukhaid, R. A., Gibson, D. M., and Crane, B. R., and Loria, R. (2004) Nature 429, 79-82). We report that the complex between Deinococcus radiodurans NOS (deiNOS) and an unusual tryptophanyl-tRNA synthetase (TrpRS II) catalyzes the regioselective nitration of tryptophan (Trp) at the 4-position. Unlike non-enzymatic Trp nitration, and similar reactions catalyzed by globins and peroxidases, deiNOS only produces the otherwise unfavorable 4-nitro-Trp isomer. Although deiNOS alone will catalyze 4-nitro-Trp production, yields are significantly enhanced by TrpRS II and ATP. 4-Nitro-Trp formation exhibits saturation behavior with Trp (but not tyrosine) and is completely inhibited by the addition of the mammalian NOS cofactor (6R)-5,6,7,8-tetrahydro-L-biopterin (H4B). Trp stimulates deiNOS oxidation of substrate L-arginine (Arg) to the same degree as H4B. These observations are consistent with a mechanism where Trp or a derivative thereof binds in the NOS pterin site, participates in Arg oxidation, and becomes nitrated at the 4-position.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA	Cornell University; Rice University	Crane, BR (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	bc69@cornell.edu						Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; BONNETT R, 1977, HETEROCYCLES, V7, P637, DOI 10.3987/S-1977-01-0637; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; BUDDHA MR, 2004, IN PRESS P NATL ACAD; CASTRO A, 1986, J CHEM SOC P2, V2, P1165; DA SETTIMO ANTONIO, 1962, ANN CHIM, V52, P17; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Gorren ACF, 2001, NITRIC OXIDE-BIOL CH, V5, P176, DOI 10.1006/niox.2001.0332; Healy FG, 2000, MOL MICROBIOL, V38, P794, DOI 10.1046/j.1365-2958.2000.02170.x; Herold S, 2004, FREE RADICAL BIO MED, V36, P565, DOI 10.1016/j.freeradbiomed.2003.10.014; Herold S, 2002, BIOCHEMISTRY-US, V41, P13460, DOI 10.1021/bi026046h; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; Ischiropoulos H, 2002, FREE RADICAL BIO MED, V33, P727, DOI 10.1016/S0891-5849(02)00889-4; Kato Y, 1997, BIOCHEM BIOPH RES CO, V234, P82, DOI 10.1006/bbrc.1997.6587; Kers JA, 2004, NATURE, V429, P79, DOI 10.1038/nature02504; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; MELHADO LL, 1988, J ORG CHEM, V53, P3852, DOI 10.1021/jo00251a037; Padmaja S, 1996, REDOX REP, V2, P173, DOI 10.1080/13510002.1996.11747045; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sala A, 2004, EUR J BIOCHEM, V271, P2841, DOI 10.1111/j.1432-1033.2004.04219.x; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Tommos C, 1999, BIOCHEMISTRY-US, V38, P9495, DOI 10.1021/bi990609g; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350	31	53	56	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49567	49570		10.1074/jbc.C400418200	http://dx.doi.org/10.1074/jbc.C400418200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15466862	hybrid			2022-12-25	WOS:000225229500004
J	Vieira, KF; Levings, PP; Hill, MA; Crusselle, VJ; Kang, SHL; Engel, JD; Bungert, JR				Vieira, KF; Levings, PP; Hill, MA; Crusselle, VJ; Kang, SHL; Engel, JD; Bungert, JR			Recruitment of transcription complexes to the beta-globin gene locus in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; RNA-POLYMERASE-II; CONTROL REGION; HYPERSENSITIVE SITES; TARGETED DELETION; TRANSGENIC MICE; CHROMATIN; ACTIVATION; PROMOTER; ELEMENTS	Erythroid-specific, high level expression of the beta-globin genes is regulated by the locus control region (LCR), composed of multiple DNase I-hypersensitive sites and located far upstream of the genes. Recent studies have shown that LCR core elements recruit RNA polymerase II (pol II). In the present study we demonstrate the following: 1) pol II and other basal transcription factors are recruited to LCR core hypersensitive elements; 2) pol II dissociates from and re-associates with the globin gene locus during replication; 3) pol II interacts with the LCR but not with the beta-globin gene prior to erythroid differentiation in embryonic stem cells; and 4) the erythroid transcription factor NF-E2 facilitates the transfer of pol II from immobilized LCR constructs to a beta-globin gene in vitro. The data are consistent with the hypothesis that the LCR serves as the primary attachment site for the recruitment of macromolecular complexes involved in chromatin structure alterations and transcription of the globin genes.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Gene Therapy, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Mammalian Genet, Gainesville, FL 32610 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Michigan System; University of Michigan	Bungert, JR (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Gene Therapy, POB 100245,1600 SW Archer Rd, Gainesville, FL 32610 USA.	jbungert@college.med.ufl.edu			NIDDK NIH HHS [R01 DK052356, R01 DK052356-15A1, DK0522356, R01 DK058209, R01 DK052356-10, DK058209] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058209, R01DK052356] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; Bungert J, 1999, MOL CELL BIOL, V19, P3062; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Elefanty AG, 1997, BLOOD, V90, P1435, DOI 10.1182/blood.V90.4.1435.1435_1435_1447; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; Gilbert DM, 2002, CURR OPIN CELL BIOL, V14, P377, DOI 10.1016/S0955-0674(02)00326-5; GREENBERG ME, 1997, CURRENT PROTOCOLS MO; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; Hug BA, 1996, MOL CELL BIOL, V16, P2906; Johnson KD, 2003, MOL CELL BIOL, V23, P6484, DOI 10.1128/MCB.23.18.6484-6493.2003; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Kang SHL, 2003, MOL CELL BIOL, V23, P4150, DOI 10.1128/MCB.23.12.4150-4161.2003; Kim A, 2004, P NATL ACAD SCI USA, V101, P7028, DOI 10.1073/pnas.0307985101; Kitajima K, 2003, METHOD ENZYMOL, V365, P72; Leach KM, 2003, NUCLEIC ACIDS RES, V31, P1292, DOI 10.1093/nar/gkg209; Leach KM, 2001, MOL CELL BIOL, V21, P2629, DOI 10.1128/MCB.21.8.2629-2640.2001; Levings PP, 2002, EUR J BIOCHEM, V269, P1589, DOI 10.1046/j.1432-1327.2002.02797.x; Long QM, 1998, GENOMICS, V54, P542, DOI 10.1006/geno.1998.5608; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; McDowell JC, 1999, MOL CELL BIOL, V19, P7600; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Molete JM, 2001, MOL CELL BIOL, V21, P2969, DOI 10.1128/MCB.21.9.2969-2980.2001; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; MULLER HP, 1990, TRENDS GENET, V6, P300, DOI 10.1016/0168-9525(90)90236-Y; Navas PA, 1998, MOL CELL BIOL, V18, P4188, DOI 10.1128/MCB.18.7.4188; Onishi Y, 2003, J BIOL CHEM, V278, P8163, DOI 10.1074/jbc.M209612200; Routledge SJE, 2002, J MOL BIOL, V323, P601, DOI 10.1016/S0022-2836(02)01011-2; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Scherer CA, 1996, CELL GROWTH DIFFER, V7, P1393; Schreiber R, 2001, BRAZ J MED BIOL RES, V34, P489, DOI 10.1590/S0100-879X2001000400008; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Spicuglia S, 2002, MOL CELL, V10, P1479, DOI 10.1016/S1097-2765(02)00791-8; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TUAN D, 1992, P NATL ACAD SCI USA, V89, P11219, DOI 10.1073/pnas.89.23.11219; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x	45	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50350	50357		10.1074/jbc.M408883200	http://dx.doi.org/10.1074/jbc.M408883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15385559	hybrid, Green Accepted			2022-12-25	WOS:000225229500099
J	Gondi, CS; Lakka, SS; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS				Gondi, CS; Lakka, SS; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS			RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas	ONCOGENE			English	Article						gliomas; invasion; cathepsin and uPAR; RNA interference; angiogenesis	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN GLIOBLASTOMA CELLS; CYSTEINE PROTEINASE-INHIBITORS; IN-VIVO; UROKINASE RECEPTOR; CYSTATIN-C; TISSUE INHIBITORS; COLORECTAL-CANCER; MICE; LOCALIZATION	RNA interference (RNAi) provides a powerful method for gene silencing in eukaryotic cells, including proliferating mammalian cells. Here, we determined whether RNAi could be utilized to inhibit the expression of proteases implicated in the extracellular matrix degradation, which is characteristic of tumor progression. We have previously shown that antisense stable clones of uPAR and cathepsin B were less invasive and did not form tumors when injected intracranially ex vivo. Since antisense-mediated gene silencing does not completely inhibit the translation of target mRNA and high molar concentrations of antisense molecules are required to achieve gene silencing, we used the RNAi approach to silence uPAR and cathepsin B in this study. We found that the expression of double-stranded RNA leads to the efficient and specific inhibition of endogenous uPAR and cathepsin B protein expression in glioma cell lines as determined by Western blotting. We also found the RNAi of uPAR and cathepsin B reduces glioma cell invasion and angiogenesis in in vitro and in vivo models. Intratumoral injections of plasmid vectors expressing hpRNA for uPAR and cathepsin B resulted in the regression of pre-established intracranial tumors. Further, RNAi for uPAR and cathepsin B inhibited cell proliferation and reduced the levels of pERK and pFAK compared to controls. Taken together, our findings indicate for the first time that RNAi operates in human glioma cells with potential application for cancer gene therapy.	Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NATIONAL CANCER INSTITUTE [R01CA075557, R01CA085216, R01CA092393] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75557, CA 85216, CA 92393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Alonso DF, 1998, ANTICANCER RES, V18, P4499; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Bervar A, 2003, BIOL CHEM, V384, P447, DOI 10.1515/BC.2003.050; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Creemers LB, 1998, MATRIX BIOL, V16, P575, DOI 10.1016/S0945-053X(98)90068-3; Evens DM, 1998, CLIN EXP METASTAS, V16, P353; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; GLADSON CL, 1995, AM J PATHOL, V146, P1150; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; Gutierrez LS, 2000, CANCER RES, V60, P5839; Hazen LGM, 2000, J HISTOCHEM CYTOCHEM, V48, P1421, DOI 10.1177/002215540004801012; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; Kisker O, 2001, CANCER RES, V61, P7669; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; KOBAYASHI H, 1993, JPN J CANCER RES, V84, P633, DOI 10.1111/j.1349-7006.1993.tb02023.x; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; Kos J, 2000, CLIN CANCER RES, V6, P505; Kostoulas G, 1999, FEBS LETT, V455, P286, DOI 10.1016/S0014-5793(99)00897-2; Kruger S, 1999, CANCER RES, V59, P6010; LEUNIG M, 1992, CANCER RES, V52, P6553; Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McGuire PG, 2003, INVEST OPHTH VIS SCI, V44, P2736, DOI 10.1167/iovs.02-1160; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Min HY, 1996, CANCER RES, V56, P2428; Mohan PM, 1999, CANCER RES, V59, P3369; Mohanam S, 2002, ONCOGENE, V21, P7824, DOI 10.1038/sj.onc.1205893; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MOHANAM S, 1993, CANCER RES, V53, P4143; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Planus E, 1997, J CELL SCI, V110, P1091; REDWOOD SM, 1992, CANCER, V69, P1212; REMPEL SA, 1994, CANCER RES, V54, P6027; Reuning U, 1998, INT J ONCOL, V13, P893; Sato S, 2002, FEBS LETT, V528, P212, DOI 10.1016/S0014-5793(02)03311-2; SCHMITT M, 1992, BIOL CHEM H-S, V373, P611, DOI 10.1515/bchm3.1992.373.2.611; SINHA AA, 1995, PROSTATE, V26, P171, DOI 10.1002/pros.2990260402; SIVAPARVATHI M, 1995, CLIN EXP METASTAS, V13, P49, DOI 10.1007/BF00144018; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Szpaderska AM, 2001, CANCER RES, V61, P3493; Vallera DA, 2002, J NATL CANCER I, V94, P597; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; YAMAMOTO M, 1994, CANCER RES, V54, P5016; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	57	121	138	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8486	8496		10.1038/sj.onc.1207879	http://dx.doi.org/10.1038/sj.onc.1207879			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378018				2022-12-25	WOS:000224870700009
J	Mano, N; Kasuga, K; Kobayashi, N; Goto, J				Mano, N; Kasuga, K; Kobayashi, N; Goto, J			A nonenzymatic modification of the amino-terminal domain of histone H3 by bile acid acyl adenylate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; MASS-SPECTROMETRY; LITHOCHOLIC ACID; LYSINE RESIDUES; GENE-EXPRESSION; CORE HISTONES; SWISS-MODEL; PROTEIN; COLON; ACETYLATION	Although it has been proposed that the secondary bile acids, deoxycholic acid and lithocholic acid, increase the number of aberrant crypt foci in the colon and may act as colon tumor promoters, there is little evidence detailing their mechanism of action. Histones play an important role in controlling gene expression, and the posttranslational modification of histones plays a role in regulation of intracellular signal transduction. In particular, the amino-terminal tail domain of histone H3 is sensitive to several posttranslational modifications, and acetylation of this domain changes its electrostatic environment and results in the loss of native folding. Therefore, we studied the modification of epsilon-amino groups on human histone H3 by deoxycholyl adenylate, which is an active intermediate in deoxycholyl thioester biosynthesis. After incubation of recombinant human histone H3 with a smaller amount of acyl adenylate, followed by enzymatic digestion, the peptide fragment mixtures were analyzed by matrix-assisted laser desorption ionization mass spectrometry. These data showed the formation of only one adduct fragment, which corresponded to amino acids 3-8 with a deoxycholate adduct, suggesting that the epsilon-amino group of Lys(4) had the highest reactivity. This novel modification, formation of a bile acid adduct on the histone H3 amino-terminal tail domain through an active acyl adenylate, may relate to the carcinogenesis-promoting effects of secondary bile acids.	Tohoku Univ Hosp, Dept Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Kobe Pharmaceut Univ, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Tohoku University; Tohoku University; Kobe Pharmaceutical University	Goto, J (corresponding author), Tohoku Univ Hosp, Dept Pharmaceut Sci, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	jun-goto@mail.pharm.tohoku.ac.jp	Mano, Nariyasu/AAS-9994-2020; Kasuga, Kie/D-2308-2013	Kasuga, Kie/0000-0003-0489-194X; Mano, Nariyasu/0000-0003-1679-9024				Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; BERG P, 1956, J BIOL CHEM, V222, P991; BIEMANN K, 1989, BIOCHEM SOC T, V17, P237, DOI 10.1042/bst0170237; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Fabrizi L, 2003, CHEM RES TOXICOL, V16, P266, DOI 10.1021/tx025565i; Falany CN, 2002, J LIPID RES, V43, P2062, DOI 10.1194/jlr.M200260-JLR200; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gassler N, 2003, HUM PATHOL, V34, P1048, DOI 10.1053/S0046-8177(03)00431-3; Goto J, 2001, RAPID COMMUN MASS SP, V15, P104, DOI 10.1002/1097-0231(20010130)15:2<104::AID-RCM198>3.3.CO;2-E; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Ikegawa S, 1999, ANAL BIOCHEM, V266, P125, DOI 10.1006/abio.1998.2944; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson-Saliba M, 2000, FEBS LETT, V467, P169, DOI 10.1016/S0014-5793(00)01142-X; Kimura A, 1998, FEBS LETT, V431, P131, DOI 10.1016/S0014-5793(98)00752-2; Kobayashi N, 2000, ANAL SCI, V16, P1133, DOI 10.2116/analsci.16.1133; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Mano N, 2004, BIOCHEMISTRY-US, V43, P2041, DOI 10.1021/bi035855d; Martinez JD, 1998, NUTR CANCER, V31, P111, DOI 10.1080/01635589809514689; Milovic V, 2000, INT J COLORECTAL DIS, V15, P264; NAIR PP, 1994, STEROIDS, V59, P212, DOI 10.1016/0039-128X(94)90030-2; NAIR PP, 1978, LIPIDS, V13, P966, DOI 10.1007/BF02533857; NARISAWA T, 1974, JNCI-J NATL CANCER I, V53, P1093, DOI 10.1093/jnci/53.4.1093; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; REDDY BS, 1976, J NATL CANCER I, V56, P441, DOI 10.1093/jnci/56.2.441; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUTHERLAND LAM, 1994, CANCER LETT, V76, P101, DOI 10.1016/0304-3835(94)90384-0; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; TALASZ H, 1993, BIOCHEMISTRY-US, V32, P1188, DOI 10.1021/bi00055a025; TURJMAN N, 1981, CANCER RES, V41, P3761; Wiekowski M, 1997, J CELL SCI, V110, P1147	40	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55034	55041		10.1074/jbc.M409205200	http://dx.doi.org/10.1074/jbc.M409205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15465822	hybrid			2022-12-25	WOS:000225960800008
J	Kataoka, K; Yamaguchi, K; Kobayashi, M; Mori, T; Bokui, N; Suzuki, S				Kataoka, K; Yamaguchi, K; Kobayashi, M; Mori, T; Bokui, N; Suzuki, S			Structure-based engineering of Alcaligenes xylosoxidans copper-containing nitrite reductase enhances intermolecular electron transfer reaction with pseudoazurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTION; ACHROMOBACTER-CYCLOCLASTES; ELECTROCHEMICAL PROPERTIES; FAECALIS; SITE; BLUE; COMPLEX; MUTANT; AZURINS; BINDING	The intermolecular electron transfer from Achromobacter cycloclastes pseudoazurin (AcPAZ) to wildtype and mutant Alcaligenes xylosoxidans nitrite reductases (AxNIRs) was investigated using steady-state kinetics and electrochemical methods. The affinity and the electron transfer reaction constant (k(ET)) are considerably lower between AcPAZ and AxNIR (K-m = 1.34 mM and k(ET) = 0.87 x 10(5) M-1 s(-1)) than between AcPAZ and its cognate nitrite reductase (AcNIR) (K-m = 20 muM and k(ET) = 7.3 x 10(5) M-1 s(-1)). A negatively charged hydrophobic patch, comprising seven acidic residues around the type 1 copper site in AcNIR, is the site of protein-protein interaction with a positively charged hydrophobic patch on AcPAZ. In AxNIR, four of the negatively charged residues (Glu-112, Glu-133, Glu-195, and Asp-199) are conserved at the corresponding positions of AcNIR, whereas the other three residues are not acidic amino acids but neutral amino acids (Ala-83, Ala-191, and Gly-198). Seven mutant AxNIRs with additional negatively charged residues surrounding the hydrophobic patch of AxNIR (A83D, A191E, G198E, A83D/A191E, A93D/G198E, A191E/G198E, and A83D/A191E/G198E) were prepared to enhance the specificity of the electron transport reaction between AcPAZ and AxNIR. The kET values of these mutants become progressively larger as the number of mutated residues increases. The Km and k(ET) values of A83D/A191E/G198E (K-m = 88 muM and k(ET) = 4.1 x 10(5) M-1 s(-1)) are 15-fold smaller and 4.7-fold larger than those of wild-type AxNIR, respectively. These results suggest that the introduction of negatively charged residues into the docking surface of AxNIR facilitates both the formation of electron transport complex and the electron transfer reaction.	Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan; Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Sci Mat, Kanazawa, Ishikawa 9201192, Japan	Osaka University; Kanazawa University	Suzuki, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan.	bic@ch.wani.osaka-u.ac.jp	KATAOKA, Kunishige/J-8457-2015					ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Bendall DS., 1996, PROTEIN ELECT TRANSF; CLARKE MJ, 1991, LONG RANGE ELECT TRA, V75; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Deligeer, 2002, J INORG BIOCHEM, V91, P132, DOI 10.1016/S0162-0134(02)00442-7; Deligeer, 2000, B CHEM SOC JPN, V73, P1839, DOI 10.1246/bcsj.73.1839; Dodd FE, 1997, ACTA CRYSTALLOGR D, V53, P406, DOI 10.1107/S0907444997002667; Dodd FE, 1998, J MOL BIOL, V282, P369, DOI 10.1006/jmbi.1998.2007; DODD FE, 1995, BIOCHEMISTRY-US, V34, P10180, DOI 10.1021/bi00032a011; Higuchi R., 1989, PCR TECHNOLOGY, P61; Impagliazzo A, 2004, J AM CHEM SOC, V126, P5658, DOI 10.1021/ja049619h; Inoue T, 1998, J BIOCHEM, V124, P876, DOI 10.1093/oxfordjournals.jbchem.a022201; Jansson H, 2003, BBA-BIOENERGETICS, V1607, P203, DOI 10.1016/j.bbabio.2003.09.011; Kataoka K, 2003, BIOCHEM BIOPH RES CO, V303, P519, DOI 10.1016/S0006-291X(03)00381-4; Kataoka K, 2000, J INORG BIOCHEM, V82, P79, DOI 10.1016/S0162-0134(00)00146-X; Kataoka K, 2000, J BIOCHEM-TOKYO, V127, P345, DOI 10.1093/oxfordjournals.jbchem.a022613; KOHZUMA T, 1993, CHEM LETT, P149, DOI 10.1246/cl.1993.149; Kukimoto M, 1996, J BIOL CHEM, V271, P13680, DOI 10.1074/jbc.271.23.13680; KUKIMOTO M, 1995, PROTEIN ENG, V8, P153, DOI 10.1093/protein/8.2.153; Kukimoto M, 1996, FEBS LETT, V394, P87, DOI 10.1016/0014-5793(96)00934-9; Murphy LM, 2002, J MOL BIOL, V315, P859, DOI 10.1006/jmbi.2001.5253; Murphy MEP, 1997, J BIOL CHEM, V272, P28455, DOI 10.1074/jbc.272.45.28455; MURPHY MEP, 1998, NATO SCI SERIES, P115; NICHOLSON RS, 1964, ANAL CHEM, V36, P706, DOI 10.1021/ac60210a007; SIGEL H, 1991, ELECT TRANSFER REACT, V27; Suzuki S, 1999, COORDIN CHEM REV, V190, P245, DOI 10.1016/S0010-8545(99)00069-7; Suzuki S, 1997, J BIOL INORG CHEM, V2, P265, DOI 10.1007/s007750050132; Suzuki S, 1999, J BIOL INORG CHEM, V4, P749, DOI 10.1007/s007750050347; Suzuki S, 2000, ACCOUNTS CHEM RES, V33, P728, DOI 10.1021/ar9900257; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; Yamaguchi K, 2003, BIOCHEM BIOPH RES CO, V300, P36, DOI 10.1016/S0006-291X(02)02764-X; ZUMFT WG, 1987, EUR J BIOCHEM, V168, P301, DOI 10.1111/j.1432-1033.1987.tb13421.x; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	34	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53374	53378		10.1074/jbc.M410198200	http://dx.doi.org/10.1074/jbc.M410198200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475344	hybrid			2022-12-25	WOS:000225680600070
J	Shi, HF; Ullu, E; Tschudi, C				Shi, HF; Ullu, E; Tschudi, C			Function of the trypanosome argonaute 1 protein in RNA interference requires the N-terminal RGG domain and arginine 735 in the Piwi domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PAZ DOMAIN; BINDING; BRUCEI; GENE	Argonaute proteins are central components of RNA interference (RNAi) and related phenomena in a wide variety of eukaryotes, including the early diverging protozoan Trypanosoma brucei. The single T. brucei Argonaute protein (TbAGO1) is in a complex with small interfering RNAs (siRNAs), and a fraction of this ribonucleoprotein particle is associated with polyribosomes. In this study, we generated a panel of insertion, deletion, and single point mutants of TbAGO1 and assayed them in vivo for their function in RNAi. In addition to the signature domains of Argonaute proteins, PAZ and Piwi, TbAGO1 has an N-terminal domain with a high abundance of RGG repeats. Deletion of the N-terminal domain blocked association of AGO1 with polyribosomes and severely affected mRNA cleavage. Nevertheless, the mutant protein was in a complex with siRNAs. In contrast, deletion of the Piwi domain led to a loss of siRNAs but did not abolish polyribosome association. Site-directed mutagenesis of conserved amino acids in the Piwi domain identified arginine 735 as essential for RNAi. Although the R735A mutant bound siRNAs and associated with polyribosomes, it displayed a severe defect in the cleavage of target mRNA.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06536 USA	Yale University; Yale University; Yale University	Tschudi, C (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 295 Congress Ave, New Haven, CT 06536 USA.	christian.tschudi@yale.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028798, R01AI028798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Djikeng A, 2003, RNA, V9, P802, DOI 10.1261/rna.5270203; Djikeng A, 2001, RNA, V7, P1522; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Lingel A, 2003, NATURE, V426, P465, DOI 10.1038/nature02123; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Murchison EP, 2004, CURR OPIN CELL BIOL, V16, P223, DOI 10.1016/j.ceb.2004.04.003; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Shi HF, 2004, MOL CELL BIOL, V24, P420, DOI 10.1128/MCB.24.1.420-427.2004; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Ullu E, 2002, PHILOS T ROY SOC B, V357, P65, DOI 10.1098/rstb.2001.0952; Yan KS, 2003, NATURE, V426, P469, DOI 10.1038/nature02129	22	32	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49889	49893		10.1074/jbc.M409280200	http://dx.doi.org/10.1074/jbc.M409280200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383544	hybrid			2022-12-25	WOS:000225229500043
J	Meurer, S; Pioch, S; Wagner, K; Muller-Esterl, W; Gross, S				Meurer, S; Pioch, S; Wagner, K; Muller-Esterl, W; Gross, S			AGAP1, a novel binding partner of nitric oxide-sensitive guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; FULL-LENGTH HUMAN; ACTIVITY REQUIRES; KINASE-C; EXPRESSION; PHOSPHORYLATION; PURIFICATION; CYTOHESINS; CENTAURINS; INHIBITOR	Nitric oxide (NO)-sensitive soluble guanylyl cyclase (sGC) is the major cytosolic receptor for NO, catalyzing the conversion of GTP to cGMP. In a search for proteins specifically interacting with human sGC, we have identified the multidomain protein AGAP1, the prototype of an ArfGAP protein with a GTPase-like domain, Ankyrin repeats, and a pleckstrin homology domain. AGAP1 binds through its carboxyl terminal portion to both the alpha(1) and beta(1) subunits of sGC. We demonstrate that AGAP1 mRNA and protein are co-expressed with sGC in human, murine, and rat cells and tissues and that the two proteins interact in vitro and in vivo. We also show that AGAP1 is prone to tyrosine phosphorylation by Src-like kinases and that tyrosine phosphorylation potently increases the interaction between AGAP1 and sGC, indicating that complex formation is modulated by reversible phosphorylation. Our findings may hint to a potential role of AGAP1 in integrating signals from Arf, NO/cGMP, and tyrosine kinase signaling pathways.	Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Muller-Esterl, W (corresponding author), Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, Theodor Stern Kai 7,Bldg 75, D-60590 Frankfurt, Germany.	office@biochem2.de						Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Barnstable CJ, 2004, NEUROCHEM INT, V45, P875, DOI 10.1016/j.neuint.2004.03.018; Bauersachs J, 1998, CARDIOVASC RES, V37, P772, DOI 10.1016/S0008-6363(97)00250-2; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Budworth J, 1999, BIOCHEM BIOPH RES CO, V263, P696, DOI 10.1006/bbrc.1999.1444; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; Chen LH, 2000, CIRC RES, V86, P520, DOI 10.1161/01.RES.86.5.520; Crottet P, 2002, MOL BIOL CELL, V13, P3672, DOI 10.1091/mbc.E02-05-0309; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Dedio J, 2001, FASEB J, V15, P79, DOI 10.1096/fj.00-0078com; Gibb BJ, 2003, BRIT J PHARMACOL, V139, P1032, DOI 10.1038/sj.bjp.0705318; Gupta G, 1997, J CLIN INVEST, V100, P1488, DOI 10.1172/JCI119670; Hanafy KA, 2004, J BIOL CHEM, V279, P46946, DOI 10.1074/jbc.M404134200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; Hawadle MA, 2002, BIOL RES, V35, P247, DOI 10.4067/S0716-97602002000200017; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KIM TD, 1994, J BIOL CHEM, V269, P15540; Koglin M, 2004, BIOCHEM PHARMACOL, V67, P1579, DOI 10.1016/j.bcp.2004.01.007; LOUIS JC, 1993, BIOCHIM BIOPHYS ACTA, V1177, P299, DOI 10.1016/0167-4889(93)90126-A; Mergia E, 2003, CELL SIGNAL, V15, P189, DOI 10.1016/S0898-6568(02)00078-5; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Munzel T, 2003, CIRCULATION, V108, P2172, DOI 10.1161/01.CIR.0000094403.78467.C3; Nedvetsky PI, 2002, P NATL ACAD SCI USA, V99, P16510, DOI 10.1073/pnas.262701999; Nie ZZ, 2003, DEV CELL, V5, P513, DOI 10.1016/S1534-5807(03)00234-X; Nie ZZ, 2002, J BIOL CHEM, V277, P48965, DOI 10.1074/jbc.M202969200; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Ruetten H, 1999, CIRC RES, V85, P534, DOI 10.1161/01.RES.85.6.534; Russwurm M, 2001, J BIOL CHEM, V276, P44647, DOI 10.1074/jbc.M105587200; Rybalkin SD, 2003, CIRC RES, V93, P280, DOI 10.1161/01.RES.0000087541.15600.2B; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Venema RC, 2003, AM J PHYSIOL-HEART C, V285, pH669, DOI 10.1152/ajpheart.01025.2002; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Xia CZ, 2003, MOL CELL BIOL, V23, P2476, DOI 10.1128/MCB.23.7.2476-2488.2003; Yoon HY, 2004, CELL SIGNAL, V16, P1033, DOI 10.1016/j.cellsig.2004.02.008; Zabel U, 1999, J BIOL CHEM, V274, P18149, DOI 10.1074/jbc.274.26.18149; Zhou ZM, 2004, J BIOL CHEM, V279, P24935, DOI 10.1074/jbc.M402105200; ZWILLER J, 1985, J BIOL CHEM, V260, P1350; ZWILLER J, 1981, BIOCHEM BIOPH RES CO, V101, P1381, DOI 10.1016/0006-291X(81)91600-4	44	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49346	49354		10.1074/jbc.M410565200	http://dx.doi.org/10.1074/jbc.M410565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15381706	hybrid			2022-12-25	WOS:000225098100104
J	Zanetti, L; Ristoratore, F; Bertoni, A; Cariello, L				Zanetti, L; Ristoratore, F; Bertoni, A; Cariello, L			Characterization of sea urchin transglutaminase, a protein regulated by guanine/adenine nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE; CROSS-LINKING; LIVER TRANSGLUTAMINASE; EMBRYONIC-DEVELOPMENT; EGG FERTILIZATION; SEQUENCE-ANALYSIS; STRUCTURAL BASIS; BINDING-PROTEIN; GTP HYDROLYSIS; CDNA CLONING	Transglutaminases (TGs) are calcium-dependent enzymes that catalyze the transamidation of glutamine residues to form intermolecular isopeptide bonds. Nine distinct TGs have been identified in mammals, and three of them (types 2, 3, and 5) are regulated by GTP/ATP and are able to hydrolyze GTP, working as bifunctional enzymes. We have isolated a cDNA clone encoding a TG from a cDNA library prepared from the blastula stage of sea urchin Paracentrotus lividus (PlTG). The cDNA sequence has an open reading frame coding for a protein of 738 amino acids, including a Cys active site and two other residues critical for catalytic activity, His and Asp. We have studied its expression pattern by in situ hybridization and have also demonstrated that the in vitro expressed PlTG had GTP- and ATP-hydrolyzing activity; moreover, GTP inhibited the transamidating activity of this enzyme as it does that of human TG2, TG3, and TG5.	Staz Zool Anton Dohrn, Biochem & Mol Biol Lab, I-80121 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli	Cariello, L (corresponding author), Staz Zool Anton Dohrn, Biochem & Mol Biol Lab, I-80121 Naples, Italy.	lcariel@szn.it						Ahvazi B, 2004, J BIOL CHEM, V279, P7180, DOI 10.1074/jbc.M312310200; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Aniello F, 1996, GENE, V178, P57, DOI 10.1016/0378-1119(96)00334-4; Arenas-Mena C, 2000, DEVELOPMENT, V127, P4631; BATTAGLIA DE, 1988, J CELL BIOL, V107, P2447, DOI 10.1083/jcb.107.6.2447; Candi E, 2004, BIOCHEM J, V381, P313, DOI 10.1042/BJ20031474; CARIELLO L, 1994, BIOCHEM BIOPH RES CO, V205, P565, DOI 10.1006/bbrc.1994.2702; Cariello L, 1997, FEBS LETT, V408, P171, DOI 10.1016/S0014-5793(97)00342-6; CARIELLO L, 1990, BIOCHEMISTRY-US, V29, P5103, DOI 10.1021/bi00473a015; CARIELLO L, 1984, BIOCHEMISTRY-US, V23, P6843, DOI 10.1021/bi00321a087; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Fraij BM, 1996, BIOCHEM BIOPH RES CO, V218, P45, DOI 10.1006/bbrc.1996.0009; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; Huang CC, 2004, DEV COMP IMMUNOL, V28, P279, DOI 10.1016/j.dci.2003.08.005; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; Iismaa SE, 2003, P NATL ACAD SCI USA, V100, P12636, DOI 10.1073/pnas.1635052100; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; LORAND L, 1988, P NATL ACAD SCI USA, V85, P1057, DOI 10.1073/pnas.85.4.1057; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MISRA S, 2002, GENOME BIOL; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; Murthy SNP, 2000, P NATL ACAD SCI USA, V97, P7744, DOI 10.1073/pnas.140210197; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Sano K, 1996, BIOSCI BIOTECH BIOCH, V60, P1790, DOI 10.1271/bbb.60.1790; SINGER MA, 1992, DEV BIOL, V154, P143, DOI 10.1016/0012-1606(92)90055-L; Sugino H, 2002, EUR J BIOCHEM, V269, P1957, DOI 10.1046/j.1432-1033.2002.02847.x; TAKEUCHI K, 1982, FED PROC, V41, P1453; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; Wada F, 2002, EUR J BIOCHEM, V269, P3451, DOI 10.1046/j.1432-1033.2002.03026.x; Wang R, 2001, FISH SHELLFISH IMMUN, V11, P623, DOI 10.1006/fsim.2001.0341; YASUEDA H, 1995, EUR J BIOCHEM, V232, P411, DOI 10.1111/j.1432-1033.1995.tb20826.x; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	40	4	4	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49289	49297		10.1074/jbc.M405926200	http://dx.doi.org/10.1074/jbc.M405926200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15381689	hybrid			2022-12-25	WOS:000225098100097
J	Tanami, H; Imoto, I; Hirasawa, A; Yuki, Y; Sonoda, I; Inoue, J; Yasui, K; Misawa-Furihata, A; Kawakami, Y; Inazawa, J				Tanami, H; Imoto, I; Hirasawa, A; Yuki, Y; Sonoda, I; Inoue, J; Yasui, K; Misawa-Furihata, A; Kawakami, Y; Inazawa, J			Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines	ONCOGENE			English	Article						malignant melanoma; BRAF; mutation; gene amplification; comparative genomic hybridization	COMPARATIVE GENOMIC HYBRIDIZATION; B-RAF; CUTANEOUS MELANOMAS; POTENTIAL TARGET; MUTATIONS; AMPLIFICATION; CANCER; IDENTIFICATION; ACTIVATION; PATHWAY	Comparative genomic hybridization (CGH) using 40 cell lines derived from malignant melanomas (MMs) revealed frequent amplification at 7q33-q34 containing BRAF gene, which often is mutated in MM. We found this gene to be amplified to a remarkable degree in the MM cell lines that exhibited high-level gains at 7q33-q34 in CGH. Among 40 cell lines, the eight lines that revealed neither BRAF nor NRAS mutations showed even higher levels of BRAF mRNA expression than the 32 mutated lines, although DNA amplification at 7q33-q34 was not detected in every lines overexpressing BRAF. MM cells that carried wild-type BRAF and NRAS showed constitutive overexpression of B-Raf protein and phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), even after serum starvation. Not only downregulation of the endogenously overexpressed wild-type B-Raf by antisense oligonucleotide but also a treatment with an inhibitor of mitogen-activated protein kinase kinase (MAPKK, MEK) reduced phosphorylated ERK1/2 and cell growth, whereas the exogenously expressed wild-type B-Raf promoted cell growth in MM cells. Our results provide the evidence that overexpression of wild-type B-Raf, in part but not always as a result of gene amplification, is one of the mechanisms underlying constitutive activation of the MAPK pathway that stimulates growth of MM cells.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Saitama, Japan; Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Keio University	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Imoto, Issei/AAD-5799-2020; Kawakami, Yutaka/E-7429-2013	Kawakami, Yutaka/0000-0003-4836-2855; Imoto, Issei/0000-0002-4150-7938				Ariyama Y, 1998, J HUM GENET, V43, P187, DOI 10.1007/s100380050067; Balazs M, 2001, CYTOMETRY, V46, P222, DOI 10.1002/cyto.1131; Bastian BC, 1998, CANCER RES, V58, P2170; Brose MS, 2002, CANCER RES, V62, P6997; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Edmunds SC, 2003, BRIT J CANCER, V88, P1403, DOI 10.1038/sj.bjc.6600919; Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Hoa M, 2002, CANCER RES, V62, P7154; Imoto I, 2003, CANCER RES, V63, P5691; Imoto I, 2001, CANCER RES, V61, P6629; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KUKITA A, 1989, Journal of Investigative Dermatology, V92, p210S, DOI 10.1111/1523-1747.ep13075564; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Metzelaar-Blok JAW, 1999, HUM IMMUNOL, V60, P962, DOI 10.1016/S0198-8859(99)00067-1; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sauter ER, 1998, MOL CARCINOGEN, V23, P132, DOI 10.1002/(SICI)1098-2744(199811)23:3<132::AID-MC2>3.0.CO;2-1; Sauter ER, 2002, CANCER RES, V62, P3200; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Yasui K, 2002, HEPATOLOGY, V35, P1476, DOI 10.1053/jhep.2002.33683	32	69	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8796	8804		10.1038/sj.onc.1208152	http://dx.doi.org/10.1038/sj.onc.1208152			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467732				2022-12-25	WOS:000225165100009
J	Tchevkina, E; Agapova, L; Dyakova, N; Martinjuk, A; Komelkov, A; Tatosyan, A				Tchevkina, E; Agapova, L; Dyakova, N; Martinjuk, A; Komelkov, A; Tatosyan, A			The small G-protein RalA stimulates metastasis of transformed cells	ONCOGENE			English	Article						Ras; Ral; metastasis; signal transduction	ROUS-SARCOMA VIRUS; RAS ONCOGENES; CANCER-CELLS; N-RAS; KINASE; TUMORIGENICITY; FIBROBLASTS; GROWTH; ACTIVATION; MECHANISMS	RAS oncogenes play a critical role in oncogenic transformation and metastases formation. Here we show that Ha-ras greatly stimulates spontaneous metastatic activity of transformed cells through the Ras/RalGDS/RalA intracellular signaling pathway. Introduction of RalA alone leads to a drastic increase of metastatic activity of transformed cells. We demonstrate that metastatic ability of cells could be dramatically enhanced by RalA stimulation or, conversely, hampered by RalA suppression. Furthermore, we found that during in vivo selection cells acquire high metastatic properties as a result of endogenous RalA activation. The ability of RalA to induce metastasis was demonstrated in spontaneously transformed as well as in virus transformed fibroblasts.	Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia	Russian Academy of Medical Sciences	Tatosyan, A (corresponding author), Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia.	tatosyan@space.ru	Komelkov, Andrei/E-4567-2012; Tchevkina, Elena/R-8909-2019	Komelkov, Andrei/0000-0003-0766-163X; 				Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BOS JL, 1989, CANCER RES, V49, P4682; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; DEICHMAN GI, 1989, INT J CANCER, V44, P908, DOI 10.1002/ijc.2910440527; DEICHMAN GI, 1992, INT J CANCER, V51, P903, DOI 10.1002/ijc.2910510612; Deichman GI, 1996, INT J CANCER, V66, P747, DOI 10.1002/(SICI)1097-0215(19960611)66:6<747::AID-IJC7>3.0.CO;2-#; DEICHMAN GI, 1989, INT J CANCER, V44, P904, DOI 10.1002/ijc.2910440526; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gildea JJ, 2002, CANCER RES, V62, P982; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Mizenina O, 2001, J BIOL CHEM, V276, P34006, DOI 10.1074/jbc.M011320200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; TOPOL LZ, 1993, MOL CARCINOGEN, V8, P167, DOI 10.1002/mc.2940080307; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Yamazaki Y, 2001, BIOCHEM BIOPH RES CO, V280, P868, DOI 10.1006/bbrc.2000.4233; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961	31	32	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					329	335		10.1038/sj.onc.1208094	http://dx.doi.org/10.1038/sj.onc.1208094			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15467745				2022-12-25	WOS:000226279700004
J	Puri, S; Magenheimer, BS; Maser, RL; Ryan, EM; Zien, CA; Walker, DD; Wallace, DP; Hempson, SJ; Calvet, JP				Puri, S; Magenheimer, BS; Maser, RL; Ryan, EM; Zien, CA; Walker, DD; Wallace, DP; Hempson, SJ; Calvet, JP			Polycystin-1 activates the Calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C BETA; N-TERMINAL KINASE; KIDNEY-DISEASE; SYNTHASE KINASE-3-BETA; TARGETED DISRUPTION; MOLECULAR-GENETICS; CYCLOSPORINE-A; RENAL-FAILURE; ALPHA-SUBUNIT; G-PROTEINS	Regulation of intracellular Ca2+ mobilization has been associated with the functions of polycystin-1 (PC1) and polycystin-2 (PC2), the protein products of the PKD1 and PKD2 genes. We have now demonstrated that PC1 can activate the calcineurin/NFAT ( nuclear factor of activated T-cells) signaling pathway through Galpha(q)-mediated activation of phospholipase C ( PLC). Transient transfection of HEK293T cells with an NFAT promoter-luciferase reporter demonstrated that membrane-targeted PC1 constructs containing the membrane proximal region of the C-terminal tail, which includes the heterotrimeric G protein binding and activation domain, can stimulate NFAT luciferase activity. Inhibition of glycogen synthase kinase-3beta by LiCl treatment further increased PC1-mediated NFAT activity. PC1-mediated activation of NFAT was completely inhibited by the calcineurin inhibitor, cyclosporin A. Cotransfection of a construct expressing the Galpha(q) subunit augmented PC1-mediated NFAT activity, whereas the inhibitors of PLC (U73122) and the inositol trisphosphate and ryanodine receptors (xestospongin and 2-aminophenylborate) and a nonspecific Ca2+ channel blocker (gadolinium) diminished PC1-mediated NFAT activity. PC2 was not able to activate NFAT. An NFAT-green fluorescent protein nuclear localization assay demonstrated that PC1 constructs containing the C-tail only or the entire 11-transmembrane spanning region plus C-tail induced NFAT-green fluorescent protein nuclear translocation. NFAT expression was demonstrated in the M-1 mouse cortical collecting duct cell line and in embryonic and adult mouse kidneys by reverse transcriptase-PCR and immunolocalization. These data suggest a model in which PC1 signaling leads to a sustained elevation of intracellular Ca2+ mediated by PC1 activation of Galpha(q) followed by PLC activation, release of Ca2+ from intracellular stores, and activation of store-operated Ca2+ entry, thus activating calcineurin and NFAT.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Kidney Inst, Kansas City, KS 66160 USA; Panjab Univ, Dept Biochem, Chandigarh 160014, India	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Panjab University	Calvet, JP (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3030,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	jcalvet@kumc.edu		Puri, Sanjeev/0000-0002-3967-987X; Puri, Sanjeev/0000-0002-4314-9871; Wallace, Darren/0000-0003-4616-7669	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053763, P50DK057301] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53763, DK 57301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Arnaout MA, 2000, KIDNEY INT, V58, P2599, DOI 10.1046/j.1523-1755.2000.00446.x; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098; Calvet JP, 2001, SEMIN NEPHROL, V21, P107, DOI 10.1053/snep.2001.20929; Clapham DE, 2002, J GEN PHYSIOL, V120, P217, DOI 10.1085/jgp.20028618; COWLEY BD, 1993, KIDNEY INT, V43, P522, DOI 10.1038/ki.1993.79; Cuozzo FP, 2002, BBA-MOL BASIS DIS, V1587, P99, DOI 10.1016/S0925-4439(02)00072-8; Dare E, 1998, J MOL ENDOCRINOL, V21, P7, DOI 10.1677/jme.0.0210007; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Emmons SW, 1999, NATURE, V401, P339, DOI 10.1038/43810; Fellner SK, 2002, KIDNEY INT, V61, P2132, DOI 10.1046/j.1523-1755.2002.00383.x; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Geng L, 1997, AM J PHYSIOL-RENAL, V272, pF451, DOI 10.1152/ajprenal.1997.272.4.F451; Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; Gieteling EW, 2003, J NEUROL, V250, P418, DOI 10.1007/s00415-003-0997-0; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Gooch JL, 2001, J BIOL CHEM, V276, P42492, DOI 10.1074/jbc.M102994200; GRANTHAM JJ, 1995, NEW ENGL J MED, V333, P56, DOI 10.1056/NEJM199507063330113; Grantham JJ, 2003, KIDNEY INT, V64, P1157, DOI 10.1046/j.1523-1755.2003.00242.x; Gregory RB, 2003, BIOCHEM J, V370, P695, DOI 10.1042/BJ20021671; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Harris PC, 2002, CURR OPIN NEPHROL HY, V11, P309, DOI 10.1097/00041552-200205000-00007; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; HOSSACK KF, 1988, NEW ENGL J MED, V319, P907, DOI 10.1056/NEJM198810063191404; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; Igarashi P, 2002, J AM SOC NEPHROL, V13, P2384, DOI 10.1097/01.ASN.0000028643.17901.42; Johnson CM, 1997, J NEUROSCI, V17, P6189; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; Kim SJ, 2003, J BIOL CHEM, V278, P15550, DOI 10.1074/jbc.M210210200; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Lanoix J, 1996, ONCOGENE, V13, P1153; Le NH, 2004, J BIOL CHEM, V279, P27472, DOI 10.1074/jbc.M312183200; LEE CH, 1992, J BIOL CHEM, V267, P16044; Liu Bo, 2003, V237, P99; Lohning C, 1997, MAMM GENOME, V8, P307, DOI 10.1007/s003359900429; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Maser RL, 2003, METH MOLEC MED, V86, P205; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Munaron L, 2002, INT J MOL MED, V10, P671; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nims N, 2003, BIOCHEMISTRY-US, V42, P13035, DOI 10.1021/bi035074c; Oka T, 2002, BRIT J PHARMACOL, V135, P1959, DOI 10.1038/sj.bjp.0704662; Ong ACM, 2000, EXP NEPHROL, V8, P208; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Peters DJM, 2001, LANCET, V358, P1439, DOI 10.1016/S0140-6736(01)06531-X; Pirson Y, 2002, J AM SOC NEPHROL, V13, P269, DOI 10.1681/ASN.V131269; Prakriya M, 2003, CELL CALCIUM, V33, P311, DOI 10.1016/S0143-4160(03)00045-9; Qian Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/hmg/ddg190; Qian Q, 2001, KIDNEY INT, V59, P2005, DOI 10.1046/j.1523-1755.2001.00716.x; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rubera I, 2000, AM J PHYSIOL-RENAL, V279, pF102, DOI 10.1152/ajprenal.2000.279.1.F102; Rundle DR, 2004, J BIOL CHEM, V279, P29728, DOI 10.1074/jbc.M400544200; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Schaefer A, 1998, BIOCHEM J, V335, P505, DOI 10.1042/bj3350505; SCHEFF RT, 1980, ANN INTERN MED, V92, P202, DOI 10.7326/0003-4819-92-2-202; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schwiebert EM, 2002, AM J PHYSIOL-RENAL, V282, pF763, DOI 10.1152/ajprenal.0337.2000; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Somlo S, 2001, CURR BIOL, V11, pR356, DOI 10.1016/S0960-9822(01)00193-2; STOOS BA, 1991, KIDNEY INT, V39, P1168, DOI 10.1038/ki.1991.148; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; Sutters M, 2003, J LAB CLIN MED, V141, P91, DOI 10.1067/mlc.2003.13; Sutters M, 2001, KIDNEY INT, V60, P484, DOI 10.1046/j.1523-1755.2001.060002484.x; TAKAHASHI H, 1991, J AM SOC NEPHROL, V1, P980; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; van Adelsberg JS, 1999, PEDIATR NEPHROL, V13, P454, DOI 10.1007/s004670050639; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Weston BS, 2003, FEBS LETT, V538, P8, DOI 10.1016/S0014-5793(03)00130-3; Wildman SS, 2003, AM J PHYSIOL-RENAL, V285, pF1168, DOI 10.1152/ajprenal.00171.2003; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; WOO D, 1995, NEW ENGL J MED, V333, P18, DOI 10.1056/NEJM199507063330104; WU DQ, 1992, J BIOL CHEM, V267, P1811; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; YULE DI, 1992, J BIOL CHEM, V267, P13830	97	76	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55455	55464		10.1074/jbc.M402905200	http://dx.doi.org/10.1074/jbc.M402905200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15466861	hybrid			2022-12-25	WOS:000225960800060
J	Sandler, B; Webb, P; Apriletti, JW; Huber, BR; Togashi, M; Lima, STC; Juric, S; Nilsson, S; Wagner, R; Fletterick, RJ; Baxter, JD				Sandler, B; Webb, P; Apriletti, JW; Huber, BR; Togashi, M; Lima, STC; Juric, S; Nilsson, S; Wagner, R; Fletterick, RJ; Baxter, JD			Thyroxine-thyroid hormone receptor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND BINDING DOMAIN; RETINOID-X-RECEPTOR; NUCLEAR RECEPTORS; L-TRIIODOTHYRONINE; MOLECULAR-BASIS; AFFINITY; ANALOGS; DESIGN; KIDNEY; ASSOCIATION	Thyroid hormone (TH) actions are mediated by nuclear receptors (TRs alpha and beta) that bind triiodothyronine (T-3, 3,5,3'-triiodo-L-thyronine) with high affinity, and its precursor thyroxine (T-4, 3,5,3',5'-tetraiodo-L-thyronine) with lower affinity. T-4 contains a bulky 5' iodine group absent from T-3. Because T-3 is buried in the core of the ligand binding domain (LBD), we have predicted that TH analogues with 5' substituents should fit poorly into the ligand binding pocket and perhaps behave as antagonists. We therefore examined how T-4 affects TR activity and conformation. We obtained several lines of evidence (ligand dissociation kinetics, migration on hydrophobic interaction columns, and non-denaturing gels) that TR-T-4 complexes adopt a conformation that differs from TR-T-3 complexes in solution. Nonetheless, T-4 behaves as an agonist in vitro (in effects on coregulator and DNA binding) and in cells, when conversion to T-3 does not contribute to agonist activity. We determined x-ray crystal structures of the TRbetaLBD in complex with T-3 and T-4 at 2.5-Angstrom and 3.1-Angstrom resolution. Comparison of the structures reveals that TRbeta accommodates T-4 through subtle alterations in the loop connecting helices 11 and 12 and amino acid side chains in the pocket, which, together, enlarge a niche that permits helix 12 to pack over the 5' iodine and complete the coactivator binding surface. While T-3 is the major active TH, our results suggest that T-4 could activate nuclear TRs at appropriate concentrations. The ability of TR to adapt to the 5' extension should be considered in TR ligand design.	Univ Calif San Francisco, Sch Med, Metab Res Unit, San Francisco, CA 94122 USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94122 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94122 USA; KaroBio AB, Novum, S-14157 Huddinge, Sweden	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Karolinska Institutet	Baxter, JD (corresponding author), Univ Calif San Francisco, Sch Med, Metab Res Unit, HSW1210,513 Parnassus Ave, San Francisco, CA 94122 USA.	Jbaxter918@aol.com	Togashi, Marie/L-3092-2018	Togashi, Marie/0000-0002-0886-8766	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064148, P01DK058390, R01DK041842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58390, DK 64148, DK 41842] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRILETTI JW, 1981, J BIOL CHEM, V256, P2094; APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; Baxter JD, 2002, ENDOCRINOLOGY, V143, P517, DOI 10.1210/en.143.2.517; Borngraeber S, 2003, P NATL ACAD SCI USA, V100, P15358, DOI 10.1073/pnas.2136689100; BRAVERMAN LE, 2000, WERNERS INGBARS THYR; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chiellini G, 2002, BIOORGAN MED CHEM, V10, P333, DOI 10.1016/S0968-0896(01)00284-X; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Davis PJ, 2002, J ENDOCRINOL INVEST, V25, P377, DOI 10.1007/BF03344022; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Glass CK, 2000, GENE DEV, V14, P121; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; ICHIKAWA K, 1986, METABOLISM, V35, P861, DOI 10.1016/0026-0495(86)90229-5; Kohrle J, 1999, MOL CELL ENDOCRINOL, V151, P103, DOI 10.1016/S0303-7207(99)00040-4; Nguyen NH, 2002, J MED CHEM, V45, P3310, DOI 10.1021/jm0201013; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Ribeiro RCJ, 1998, J STEROID BIOCHEM, V65, P133, DOI 10.1016/S0960-0760(98)00029-6; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Ribeiro RCJ, 2001, J BIOL CHEM, V276, P14987, DOI 10.1074/jbc.M010195200; SAMUELS HH, 1979, J CLIN INVEST, V63, P1229, DOI 10.1172/JCI109418; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SILVA JE, 1978, J CLIN INVEST, V61, P1247, DOI 10.1172/JCI109041; SURKS MI, 1977, J CLIN INVEST, V60, P555, DOI 10.1172/JCI108807; SWILLENS S, 1995, MOL PHARMACOL, V47, P1197; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wagner RL, 2001, MOL ENDOCRINOL, V15, P398, DOI 10.1210/me.15.3.398; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Watkins RE, 2003, J MOL BIOL, V331, P815, DOI 10.1016/S0022-2836(03)00795-2; Watkins RE, 2003, BIOCHEMISTRY-US, V42, P1430, DOI 10.1021/bi0268753; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Webb P, 2002, J STEROID BIOCHEM, V83, P59, DOI 10.1016/S0960-0760(02)00270-4; Ye L, 2003, J MED CHEM, V46, P1580, DOI 10.1021/jm021080f; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	38	94	99	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55801	55808		10.1074/jbc.M410124200	http://dx.doi.org/10.1074/jbc.M410124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15466465	Green Published, hybrid			2022-12-25	WOS:000225960800102
J	Heydorn, A; Sondergaard, BP; Ersboll, B; Holst, B; Nielsen, FC; Haft, CR; Whistler, J; Schwartz, TW				Heydorn, A; Sondergaard, BP; Ersboll, B; Holst, B; Nielsen, FC; Haft, CR; Whistler, J; Schwartz, TW			A library of 7TM receptor C-terminal tails - Interactions with the proposed post-endocytic sorting proteins ERM-binding phosphoprotein 50 (EBP50), N-ethylmaleimide-sensitive factor (NSF), sorting nexin 1 (SNX1), and G protein-coupled receptor-associated sorting protein (GASP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							EXCHANGER REGULATORY FACTOR; METABOTROPIC GLUTAMATE RECEPTORS; 3RD INTRACELLULAR LOOP; GROWTH-FACTOR RECEPTOR; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; BETA(1)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; SYNAPTIC-TRANSMISSION; OPIOID RECEPTORS	Adaptor and scaffolding proteins determine the cellular targeting, the spatial, and thereby the functional association of G protein-coupled seven-transmembrane receptors with co-receptors, transducers, and downstream effectors and the adaptors determine post-signaling events such as receptor sequestration through interactions, mainly with the C-terminal intracellular tails of the receptors. A library of tails from 59 representative members of the super family of seven-transmembrane receptors was probed as glutathione S-transferase fusion proteins for interactions with four different adaptor proteins previously proposed to be involved in post-endocytotic sorting of receptors. Of the two proteins suggested to target receptors for recycling to the cell membrane, which is the route believed to be taken by a majority of receptors, ERM (ezrin-radixin-moesin)binding phosphoprotein 50 (EBP50) bound only a single receptor tail, i.e. the beta(2)-adrenergic receptor, whereas N-ethylmaleimide-sensitive factor bound 11 of the tail-fusion proteins. Of the two proteins proposed to target receptors for lysosomal degradation, sorting nexin 1 (SNX1) bound 10 and the C-terminal domain of G protein-coupled receptor-associated sorting protein bound 23 of the 59 tail proteins. Surface plasmon resonance analysis of the binding kinetics of selected hits from the glutathione S-transferase pull-down experiments, i.e. the tails of the virally encoded receptor US28 and the delta-opioid receptor, confirmed the expected nanomolar affinities for interaction with SNX1. Truncations of the NK1 receptor revealed that an extended binding epitope is responsible for the interaction with both SNX1 and G protein-coupled receptor-associated sorting protein as well as with N-ethylmaleimide-sensitive factor. It is concluded that the tail library provides useful information on the general importance of certain adaptor proteins, for example, in this case, ruling out EBP50 as being a broad spectrum-recycling adaptor.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; Tech Univ Denmark, DK-2800 Lyngby, Denmark; Rigshosp, Dept Clin Biochem, DK-2200 Copenhagen, Denmark; NIDDK, NIH, Bethesda, MD 20892 USA; Univ Calif San Francisco, Ernest Gallo Res Ctr, San Francisco, CA 94608 USA; 7TM Pharma AS, DK-2970 Horsholm, Denmark	University of Copenhagen; Technical University of Denmark; Rigshospitalet; University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Schwartz, TW (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark.	schwartz@molpharm.dk	Nielsen, Finn Cilius/AAA-4926-2020	Ersboll, Bjarne Kjaer/0000-0003-1262-7890; Holst, Birgitte/0000-0001-7432-097X; Schwartz, Thue W./0000-0002-0261-6904; Nielsen, Finn Cilius/0000-0002-9829-1031				Alexander S., 1999, TRENDS PHARMACOL SCI, V19, P1; Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Bachner D, 2002, FEBS LETT, V526, P124, DOI 10.1016/S0014-5793(02)03115-0; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bennett VJ, 2002, J PHARMACOL EXP THER, V303, P1155, DOI 10.1124/jpet.102.040378; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Brady AE, 2003, J BIOL CHEM, V278, P32405, DOI 10.1074/jbc.M304195200; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; Brdickova N, 2001, FEBS LETT, V507, P133, DOI 10.1016/S0014-5793(01)02955-6; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Brunger AT, 2001, ANNU REV BIOPH BIOM, V30, P157, DOI 10.1146/annurev.biophys.30.1.157; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cen B, 2001, MOL PHARMACOL, V59, P758, DOI 10.1124/mol.59.4.758; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Csaba Z, 2001, NEUROPEPTIDES, V35, P1, DOI 10.1054/npep.2001.0848; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; Dev KK, 2000, J NEUROSCI, V20, P7252; FAGNI L, 2002, SCI STKE; Feng GJ, 2003, J BIOL CHEM, V278, P33400, DOI 10.1074/jbc.M305866200; Feniger-Barish R, 1999, CYTOKINE, V11, P996, DOI 10.1006/cyto.1999.0510; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Fraile-Ramos A, 2002, TRAFFIC, V3, P218, DOI 10.1034/j.1600-0854.2002.030307.x; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; Garland AM, 1996, MOL PHARMACOL, V49, P438; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; Gray JA, 2002, SCIENCE, V297, P529, DOI 10.1126/science.1075453; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Han SY, 2000, BIOCHEM J, V352, P165, DOI 10.1042/0264-6021:3520165; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; He L, 2001, NAT GENET, V27, P40, DOI 10.1038/83741; Hegedus T, 2003, BIOCHEM BIOPH RES CO, V302, P454, DOI 10.1016/S0006-291X(03)00196-7; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; Heydorn A, 2004, FEBS LETT, V556, P276, DOI 10.1016/S0014-5793(03)01431-5; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hu LYA, 2003, J BIOL CHEM, V278, P26295, DOI 10.1074/jbc.M212352200; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Jenkinson KM, 2000, NEUROSCIENCE, V100, P191, DOI 10.1016/S0306-4522(00)00259-1; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; Krudewig R, 2000, J NEUROCHEM, V74, P1721, DOI 10.1046/j.1471-4159.2000.0741721.x; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kurten RC, 2001, J CELL SCI, V114, P1743; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LUIS J, 1988, BIOCHIMIE, V70, P1311, DOI 10.1016/0300-9084(88)90002-8; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2003, J MOL ENDOCRINOL, V30, P117, DOI 10.1677/jme.0.0300117; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; May AP, 2001, J BIOL CHEM, V276, P21991, DOI 10.1074/jbc.R100013200; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Muller JMM, 2002, J CELL BIOL, V157, P1161, DOI 10.1083/jcb.200202082; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Ouali R, 1997, ENDOCRINOLOGY, V138, P725, DOI 10.1210/en.138.2.725; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Perroy J, 2002, EMBO J, V21, P2990, DOI 10.1093/emboj/cdf313; Phillips SA, 2001, J BIOL CHEM, V276, P5074, DOI 10.1074/jbc.M004671200; Pushkin A, 2003, AM J PHYSIOL-CELL PH, V284, pC667, DOI 10.1152/ajpcell.00225.2002; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; RAIL RA, 1998, NATURE, V392, P626; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Rochdi MD, 2002, J BIOL CHEM, V277, P40751, DOI 10.1074/jbc.M207910200; Roche KW, 1999, J BIOL CHEM, V274, P25953, DOI 10.1074/jbc.274.36.25953; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; Schmidlin F, 2003, AM J PHYSIOL-CELL PH, V285, pC945, DOI 10.1152/ajpcell.00541.2002; SCHWARTZ TW, 2003, TXB RECEPTOR PHARM, P81; Schwarz DG, 2002, MOL BIOL CELL, V13, P3588, DOI 10.1091/mbc.E02-03-0145; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; TAXT T, 1991, PATTERN RECOGN LETT, V12, P731, DOI 10.1016/0167-8655(91)90070-3; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 2003, J PHARMACOL EXP THER, V307, P437, DOI 10.1124/jpet.103.052100; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; van Koppen CJ, 2001, BIOCHEM SOC T, V29, P505, DOI 10.1042/BST0290505; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; WIDMANN C, 1995, BIOCHEM J, V310, P203, DOI 10.1042/bj3100203; Wong SKF, 2003, NEUROSIGNALS, V12, P1, DOI 10.1159/000068914; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Xia ZQ, 2003, J BIOL CHEM, V278, P21901, DOI 10.1074/jbc.M301905200; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	112	136	141	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54291	54303		10.1074/jbc.M406169200	http://dx.doi.org/10.1074/jbc.M406169200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15452121	hybrid			2022-12-25	WOS:000225793600050
J	Bostrom, K; Zebboudj, AF; Yao, YC; Lin, TS; Torres, A				Bostrom, K; Zebboudj, AF; Yao, YC; Lin, TS; Torres, A			Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta 1 activity in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BONE MORPHOGENETIC PROTEIN-2; GENE-EXPRESSION; KEUTEL SYNDROME; MICROARRAY ANALYSIS; MESSENGER-RNA; CALCIFICATION; TRANSCRIPTION; ANGIOGENESIS; MGP	Matrix GLA protein (MGP) is expressed in endothelial cells (EC), and MGP deficiency results in developmental defects suggesting involvement in EC function. To determine the role of MGP in EC, we cultured bovine aortic EC with increasing concentrations of human MGP (hMGP) for 24 h. The results showed increased proliferation, migration, tube formation, and increased release of vascular endothelial growth factor-A (VEGF-A) and basic fibroblast growth factor (bFGF). HMGP, added endogenously or transiently expressed, increased VEGF gene expression dose-dependently as determined by real-time PCR. To determine the mechanism by which hMGP increased VEGF expression, we studied the effect of MGP on the activity of transforming growth factor (TGF)-beta1 compared with that of bone morphogenetic protein (BMP)-2 using transfection assays with TGF-beta and BMP-response element reporter genes. Our results showed a strong enhancement of TGF-beta1 activity by hMGP, which was paralleled by increased VEGF expression. BMP-2 activity, on the other hand, was inhibited by hMGP. Neutralizing antibodies to TGF-beta blocked the effect of MGP on VEGF expression. The enhanced TGF-beta1 activity specifically activated the Smad1/5 pathway indicating that the TGF-beta receptor activin-like kinase 1 (ALK1) had been stimulated. It occurred without changes in expression of TGF-beta1 or ALK1 and was mimicked by transfection of constitutively active ALK1, which increased VEGF expression. Expression of VEGF and MGP was induced by TGF-beta1, but the induction of MGP preceded that of VEGF, consistent with a promoting effect on VEGF expression. Together, the results suggest that MGP plays a role in EC function, altering the response to TGF-beta superfamily growth factors.	Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Bostrom, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Box 951679,Rm 47-123 CHS, Los Angeles, CA 90095 USA.	kbostrom@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004270, P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL04270, HL030568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Azhar M, 2003, CYTOKINE GROWTH F R, V14, P391, DOI 10.1016/S1359-6101(03)00044-3; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Benckert C, 2003, CANCER RES, V63, P1083; Bostrom K, 2001, J BIOL CHEM, V276, P14044, DOI 10.1074/jbc.M008103200; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; CORMODE EJ, 1986, AM J MED GENET, V24, P289, DOI 10.1002/ajmg.1320240209; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; deMello DE, 2000, PEDIATR DEVEL PATHOL, V3, P439, DOI 10.1007/s100240010090; Engelse MA, 2001, CARDIOVASC RES, V52, P281, DOI 10.1016/S0008-6363(01)00375-3; Fan CW, 2001, CANCER LETT, V165, P63, DOI 10.1016/S0304-3835(01)00416-5; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Gilbert KA, 2004, AM J PHYSIOL-LUNG C, V286, pL1179, DOI 10.1152/ajplung.00188.2003; Gilbert KA, 2003, AM J PHYSIOL-LUNG C, V285, pL569, DOI 10.1152/ajplung.00426.2002; Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432-1327.2000.01325.x; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Grainger DJ, 2000, J CELL SCI, V113, P2355; Gray PC, 2001, MOL CELL ENDOCRINOL, V180, P47, DOI 10.1016/S0303-7207(01)00515-9; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; Hirschi KK, 2002, ANN NY ACAD SCI, V961, P223, DOI 10.1111/j.1749-6632.2002.tb03090.x; Hough CD, 2001, CANCER RES, V61, P3869; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; King KE, 2003, J BIOL CHEM, V278, P11661, DOI 10.1074/jbc.M211337200; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; LEVEDAKOU EN, 1992, INT J CANCER, V52, P534, DOI 10.1002/ijc.2910520406; Lum RM, 2000, INT J MOL MED, V5, P635; LUO GB, 1995, J BONE MINER RES, V10, P325; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Meier M, 2001, EUR RESPIR J, V17, P566, DOI 10.1183/09031936.01.17305660; Molin DGM, 2003, DEV DYNAM, V227, P431, DOI 10.1002/dvdy.10314; Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003; Munroe PB, 1999, NAT GENET, V21, P142, DOI 10.1038/5102; Newman B, 2001, J CELL BIOL, V154, P659, DOI 10.1083/jcb.200106040; *PE APPL BIOS, 1997, US B PE APPL BIOS, V2; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Renner U, 2002, ENDOCRINOLOGY, V143, P3759, DOI 10.1210/en.2002-220283; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shin V, 2004, J VASC RES, V41, P193, DOI 10.1159/000077394; Simes DC, 2003, J BONE MINER RES, V18, P244, DOI 10.1359/jbmr.2003.18.2.244; Sugi Y, 2004, DEV BIOL, V269, P505, DOI 10.1016/j.ydbio.2004.01.045; Sweatt A, 2003, J THROMB HAEMOST, V1, P178, DOI 10.1046/j.1538-7836.2003.00023.x; Teebi AS, 1998, AM J MED GENET, V78, P182, DOI 10.1002/(SICI)1096-8628(19980630)78:2<182::AID-AJMG18>3.3.CO;2-K; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Vargesson N, 2003, J ANAT, V202, P93, DOI 10.1046/j.1469-7580.2003.00133.x; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Wallin R, 2000, THROMB HAEMOSTASIS, V84, P1039; Warburton D, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-5; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Weston GC, 2002, MOL HUM REPROD, V8, P855, DOI 10.1093/molehr/8.9.855; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200; Zebboudj AF, 2003, J CELL BIOCHEM, V90, P756, DOI 10.1002/jcb.10669; Zeng X, 2001, DEV DYNAM, V221, P289, DOI 10.1002/dvdy.1140; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; Zhao JS, 1999, EUR J CELL BIOL, V78, P715, DOI 10.1016/S0171-9335(99)80040-5; Zhao JS, 1997, AM J PHYSIOL-LUNG C, V273, pL282, DOI 10.1152/ajplung.1997.273.1.L282; ZHOU H, 1993, J CELL PHYSIOL, V155, P112, DOI 10.1002/jcp.1041550115; Zhu Hong-Jian, 2001, Molecular Cell Biology Research Communications, V4, P321, DOI 10.1006/mcbr.2001.0301; ZIEREISEN F, 1993, PEDIATR RADIOL, V23, P314, DOI 10.1007/BF02010925	65	92	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52904	52913		10.1074/jbc.M406868200	http://dx.doi.org/10.1074/jbc.M406868200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456771	hybrid			2022-12-25	WOS:000225680600014
J	Martin-Clemente, B; Alvarez-Castelao, B; Mayo, I; Sierra, AB; Diaz, V; Milan, M; Farinas, I; Gomez-Isla, T; Ferrer, I; Castano, JG				Martin-Clemente, B; Alvarez-Castelao, B; Mayo, I; Sierra, AB; Diaz, V; Milan, M; Farinas, I; Gomez-Isla, T; Ferrer, I; Castano, JG			alpha-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; LEWY BODIES; MULTICATALYTIC PROTEINASE; SUBSTANTIA-NIGRA; MUTANT; INHIBITION; INCLUSIONS; DEMENTIA; SYSTEM; ACCUMULATION	alpha-Synuclein (alpha-syn) is a small protein of unknown function that is found aggregated in Lewy bodies, the histopathological hallmark of sporadic Parkinson disease and other synucleinopathies. Mutations in the alpha-syn gene and a triplication of its gene locus have been identified in early onset familial Parkinson disease. alpha-Syn turnover can be mediated by the proteasome pathway. A survey of published data may lead to the suggestion that overexpression of alpha-syn wild type, and/or their variants (A53T and A30P), may produce a decrease in proteasome activity and function, contributing to alpha-syn aggregation. To investigate the relationship between synuclein expression and proteasome function we have studied proteasome peptidase activities and proteasome subunit expression (alpha, beta-constitutive, and inducible) in mice either lacking alpha-syn (knockout mice) or transgenic for human alpha-syn A30P (under control of PrP promoter, at a time when no clear gliosis can be observed). Similar studies are presented in PC12 cells overexpressing enhanced yellow fluorescent protein fusion constructs of human wild type, A30P, and A53T alpha-syn. In these cell lines we have also analyzed the assembly of 20 S proteasome complex and the degradation rate of a well known substrate of the proteasome pathway, Ikappabalpha. Overall the data obtained led us to the conclusion that alpha-synuclein expression levels by themselves have no significant effect on proteasome peptidase activity, subunit expression, and proteasome complex assembly and function. These results strengthen the suggestion that other mechanisms resulting in synuclein aggregation ( not simply expression levels) may be the key to understand the possible effect of aggregated synuclein on proteasome function.	Univ Autonoma Madrid, Consejo Super Invest Cient, Fac Med UAM, Dept Bioquim, Madrid 28029, Spain; Univ Autonoma Madrid, Consejo Super Invest Cient, Fac Med UAM, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Univ Valencia, Fac Biol, Dept Biol Celular, Valencia 46100, Spain; Univ Navarra Clin, Dept Neurociencias, Pamplona 31008, Spain; Hosp Univ Bellvitge, Serv Anat Patol, Inst Neuropatol, Lhospitalet De Llobregat 08907, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Valencia; University of Navarra; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital	Castano, JG (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Fac Med UAM, Dept Bioquim, Madrid 28029, Spain.	joseg.castano@uam.es	alvarez-castelao, beatriz/W-1707-2018; Mayo, Isabel Cantón/AAB-2429-2019; Alvarez-castelao, Beatriz/ABG-8826-2021; Farinas, Isabel/L-7118-2014	alvarez-castelao, beatriz/0000-0001-7505-1855; Mayo, Isabel Cantón/0000-0002-9757-8233; Farinas, Isabel/0000-0003-2903-4960; G. Castano, Jose/0000-0002-6579-8442				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; ARRIBAS J, 1994, J BIOL CHEM, V269, P12858; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Dawson VL, 2000, SCIENCE, V288, P631, DOI 10.1126/science.288.5466.631; Foltynie T, 2002, J NEUROL, V249, P138, DOI 10.1007/PL00007856; Gomez-Isla T, 2003, NEUROBIOL AGING, V24, P245, DOI 10.1016/S0197-4580(02)00091-X; Gomez-Tortosa E, 2000, ANN NY ACAD SCI, V920, P9; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; Kingsbury AE, 2004, MOVEMENT DISORD, V19, P162, DOI 10.1002/mds.10683; Lehmensiek V, 2002, NEUROREPORT, V13, P1279, DOI 10.1097/00001756-200207190-00013; Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; NIETO A, 1990, BIOCHEM J, V267, P317, DOI 10.1042/bj2670317; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Rodriguez-Vilarino S, 2000, J BIOL CHEM, V275, P6592, DOI 10.1074/jbc.275.9.6592; Sawada H, 2004, J BIOL CHEM, V279, P10710, DOI 10.1074/jbc.M308434200; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Takeda A, 1998, AM J PATHOL, V152, P367; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	40	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52984	52990		10.1074/jbc.M409028200	http://dx.doi.org/10.1074/jbc.M409028200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466467	Green Published, hybrid			2022-12-25	WOS:000225680600023
J	Roebroek, AJM; Taylor, NA; Louagie, E; Pauli, I; Smeijers, L; Snellinx, A; Lauwers, A; Van de Ven, WJM; Hartmann, D; Creemers, JWM				Roebroek, AJM; Taylor, NA; Louagie, E; Pauli, I; Smeijers, L; Snellinx, A; Lauwers, A; Van de Ven, WJM; Hartmann, D; Creemers, JWM			Limited redundancy of the proprotein convertase furin in mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; IN-VIVO; PROHORMONE CONVERTASES; INSULIN-RECEPTOR; PROCESSING SITE; MICE DEFICIENT; CELL STRAIN; PRECURSOR; CLEAVAGE; EXPRESSION	Furin is an endoprotease of the family of mammalian proprotein convertases and is involved in the activation of a large variety of regulatory proteins by cleavage at basic motifs. A large number of substrates have been attributed to furin on the basis of in vitro and ex vivo data. However, no physiological substrates have been confirmed directly in a mammalian model system, and early embryonic lethality of a furin knock-out mouse model has precluded in vivo verification of most candidate substrates. Here, we report the generation and characterization of an interferon inducible Mx-Cre/loxP furin knock-out mouse model. Induction resulted in near-complete ablation of the floxed fur exon in liver. In sharp contrast with the general furin knock-out mouse model, no obvious adverse effects were observed in the transgenic mice after induction. Histological analysis of the liver did not reveal any overt deviations from normal morphology. Analysis of candidate substrates in liver revealed complete redundancy for the processing of the insulin receptor. Variable degrees of redundancy were observed for the processing of albumin, alpha(5) integrin, lipoprotein receptor-related protein, vitronectin and alpha(1)-microglobulin/bikunin. None of the tested substrates displayed a complete block of processing. The absence of a severe phenotype raises the possibility of using furin as a local therapeutic target in the treatment of pathologies like cancer and viral infections, although the observed redundancy may require combination therapy or the development of a more broad spectrum convertase inhibitor.	Katholieke Univ Leuven VIB, Dept Human Genet, Mol Cell Biol Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Neuronal Cell Biol, Dept Human Genet, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Mol Oncol Lab, Dept Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; KU Leuven	Creemers, JWM (corresponding author), Katholieke Univ Leuven VIB, Dept Human Genet, Mol Cell Biol Lab, Gasthuisberg O-N 6,Box 602,Herestr 49, B-3000 Louvain, Belgium.	john.creemers@med.kuleuven.ac.be						Bailyes EM, 1997, BIOCHEM J, V327, P209, DOI 10.1042/bj3270209; Beck S, 2002, NAT CELL BIOL, V4, P981, DOI 10.1038/ncb890; BRATT T, 1994, FEBS LETT, V354, P57, DOI 10.1016/0014-5793(94)01087-0; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNAN SO, 1989, MOL BIOL MED, V6, P87; BRENNAN SO, 1994, FEBS LETT, V338, P147, DOI 10.1016/0014-5793(94)80353-6; Constam DB, 2000, GENE DEV, V14, P1146; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Holyoak T, 2004, BIOCHEMISTRY-US, V43, P2412, DOI 10.1021/bi035849h; Jackson RS, 2003, J CLIN INVEST, V112, P1550, DOI 10.1172/JCI18784; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Ko KWS, 1998, J BIOL CHEM, V273, P27779, DOI 10.1074/jbc.273.43.27779; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; Li M, 1999, NEUROENDOCRINOLOGY, V69, P217, DOI 10.1159/000054422; Li M, 2000, ENDOCRINOLOGY, V141, P3723, DOI 10.1210/en.141.10.3723; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; Mori K, 1999, J BIOCHEM-TOKYO, V125, P627, DOI 10.1093/oxfordjournals.jbchem.a022329; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Sarac MS, 2004, INFECT IMMUN, V72, P602, DOI 10.1128/IAI.72.1.602-605.2004; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; Seger D, 2000, FEBS LETT, V480, P169, DOI 10.1016/S0014-5793(00)01917-7; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Sucic JF, 1999, BIOCHEM J, V339, P639, DOI 10.1042/0264-6021:3390639; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Torres RM, 1997, LAB PROTOCOLS CONDIT; Umans L, 1999, NEUROSCIENCE, V94, P315, DOI 10.1016/S0306-4522(99)00242-0; Villeneuve P, 2002, J NEUROCHEM, V82, P783, DOI 10.1046/j.1471-4159.2002.00988.x; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Wouters S, 1998, BIOCHEM J, V336, P311, DOI 10.1042/bj3360311; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	45	95	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53442	53450		10.1074/jbc.M407152200	http://dx.doi.org/10.1074/jbc.M407152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471862	hybrid			2022-12-25	WOS:000225680600078
J	Shcherbik, N; Kee, Y; Lyon, N; Huibregtse, J; Haines, DS				Shcherbik, N; Kee, Y; Lyon, N; Huibregtse, J; Haines, DS			A single PXY motif located within the carboxyl terminus of Spt23p and Mga2p mediates a physical and functional interaction with ubiquitin ligase Rsp5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NF-KAPPA-B1 PRECURSOR PROTEIN; REL HOMOLOGY DOMAIN; GLYCINE-RICH REGION; RSP5P-DEPENDENT UBIQUITINATION; TRANSCRIPTION FACTOR; NUCLEAR EXPORT; MESSENGER-RNA; P105; DEGRADATION	Proteasome-dependent processing of the endoplasmic reticulum localized transcription factor Spt23p of Saccharomyces cerevisiae generates its transcriptionally competent form and requires the WW domain containing Rsp5p ubiquitin ligase. Although previous studies documented an Rsp5p-Spt23p association in cells, very little is known about the nature of this interaction. We report here the identification of an imperfect type I WW domain-binding site (LPKY) within the carboxyl-terminal region of Spt23p that is required for Rsp5p binding in vitro and in vivo. Deletion of this motif abrogates Rsp5p-induced ubiquitination of Spt23p in vitro and reduces ubiquitination of the Spt23p precursor in yeast. In addition, the Spt23pDeltaLPKY mutant is inefficiently processed and is defective at up-regulating target gene (OLE1) expression in cells. Deletion of the corresponding LPKY site within Mga2p, an Spt23p homologue, also abrogates Rsp5p binding and Rsp5p-dependent ubiquitination in vitro as well as Rsp5p binding and Mga2p polyubiquitination in cells. However, the Mga2pDeltaLPKY mutant undergoes efficient proteasome-dependent processing. These experiments indicate that the LPKY motif of Spt23p is required for Rsp5p binding, Rsp5-induced ubiquitination, proteasome-dependent processing, and its OLE1 inducing function. They also suggest that the LPKY motif of Mga2p is required for Rsp5p binding and ubiquitination, and Rsp5p regulates Mga2p function by a mechanism that is independent of providing the partial degradation signal.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Texas System; University of Texas Austin	Haines, DS (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	dhaines@temple.edu	Kee, Younghoon/J-4107-2019					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Haynes CM, 2002, J CELL BIOL, V158, P91, DOI 10.1083/jcb.200201053; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jiang YD, 2001, MOL CELL BIOL, V21, P6161, DOI 10.1128/MCB.21.18.6161-6169.2001; Kaminska J, 2002, MOL CELL BIOL, V22, P6946, DOI 10.1128/MCB.22.20.6946-6958.2002; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 2003, J BIOL CHEM, V278, P31479, DOI 10.1074/jbc.M304140200; Neumann S, 2003, EMBO REP, V4, P1156, DOI 10.1038/sj.embor.7400026; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Rodriguez MS, 2003, TRAFFIC, V4, P566, DOI 10.1034/j.1600-0854.2003.00115.x; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Shcherbik N, 2003, CURR BIOL, V13, P1227, DOI 10.1016/S0960-9822(03)00457-3; Shcherbik N, 2002, J CELL SCI, V115, P1041; Zhang SR, 1999, GENETICS, V151, P473	31	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53892	53898		10.1074/jbc.M410325200	http://dx.doi.org/10.1074/jbc.M410325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466864	hybrid			2022-12-25	WOS:000225680600128
J	Wang, Y; Kedei, N; Wang, M; Wang, QJ; Huppler, AR; Toth, A; Tran, R; Blumberg, PM				Wang, Y; Kedei, N; Wang, M; Wang, QJ; Huppler, AR; Toth, A; Tran, R; Blumberg, PM			Interaction between protein kinase C mu and the vanilloid receptor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION LOOP SER(744); DIRECT PHOSPHORYLATION; D PKD; EPSILON; CELLS; VR1; IDENTIFICATION; EXPRESSION; SUBSTRATE; NEURONS	The capsaicin receptor VR1 is a polymodal nociceptor activated by multiple stimuli. It has been reported that protein kinase C plays a role in the sensitization of VR1. Protein kinase D/PKCmu is a member of the protein kinase D serine/threonine kinase family that exhibits structural, enzymological, and regulatory features distinct from those of the PKCs, with which they are related. As part of our effort to optimize conditions for evaluating VR1 pharmacology, we found that treatment of Chinese hamster ovary (CHO) cells heterologously expressing rat VR1 (CHO/rVR1) with butyrate enhanced rVR1 expression and activity. The expression of PKCmu and PKCbeta1, but not of other PKC isoforms, was also enhanced by butyrate treatment, suggesting the possibility that these two isoforms might contribute to the enhanced activity of rVR1. In support of this hypothesis, we found the following. 1) Overexpression of PKCmu enhanced the response of rVR1 to capsaicin and low pH, and expression of a dominant negative variant of PKCmu reduced the response of rVR1. 2) Reduction of endogenous PKCmu using antisense oligonucleotides decreased the response of exogenous rVR1 expressed in CHO cells as well as of endogenous rVR1 in dorsal root ganglion neurons. 3) PKCmu localized to the plasma membrane when overexpressed in CHO/rVR1 cells. 4) PKCmu directly bound to rVR1 expressed in CHO cells as well as to endogenous rVR1 in dorsal root ganglia or to an N-terminal fragment of rVR1, indicating a direct interaction between PKCmu and rVR1. 5) PKCmu directly phosphorylated rVR1 or a longer N-terminal fragment ( amino acids 1-118) of rVR1 but not a shorter one (amino acids 1-99). 6) Mutation of S116A in rVR1 blocked both the phosphorylation of rVR1 by PKCmu and the enhancement by PKCmu of the rVR1 response to capsaicin. We conclude that PKCmu functions as a direct modulator of rVR1.	Peking Univ, Dept Neurobiol, Neurosci Res Inst, Beijing 100083, Peoples R China; NCI, NIH, Bethesda, MD 20892 USA	Peking University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, Y (corresponding author), Peking Univ, Dept Neurobiol, Neurosci Res Inst, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	wangy66@bjmu.edu.cn; blumberp@dc37a.nci.nih.gov	Huppler, Anna R/F-1842-2018; Wang, Qiming Jane/B-6064-2012; Tóth, Attila/F-4859-2010	Huppler, Anna R/0000-0003-1263-6623; Wang, Qiming Jane/0000-0002-9502-4851; Tóth, Attila/0000-0001-6503-3653	NATIONAL CANCER INSTITUTE [Z01BC005270, ZIABC005270] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTS J, 1995, BIOCHEM J, V310, P171, DOI 10.1042/bj3100171; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Chandrasekher G, 1998, EXP EYE RES, V67, P603, DOI 10.1006/exer.1998.0555; Chen JS, 2003, CURR CANCER DRUG TAR, V3, P219, DOI 10.2174/1568009033481994; Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Olah Z, 2002, J BIOL CHEM, V277, P35752, DOI 10.1074/jbc.M201551200; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Szallasi A, 1999, MOL PHARMACOL, V56, P581, DOI 10.1124/mol.56.3.581; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Zhang J, 2002, MOL CELL BIOL, V22, P8144, DOI 10.1128/MCB.22.23.8144-8154.2002; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	23	56	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53674	53682		10.1074/jbc.M410331200	http://dx.doi.org/10.1074/jbc.M410331200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471852	hybrid			2022-12-25	WOS:000225680600104
J	Yoo, YG; Yeo, MG; Kim, DK; Park, H; Lee, MO				Yoo, YG; Yeo, MG; Kim, DK; Park, H; Lee, MO			Novel function of orphan nuclear receptor Nur77 in stabilizing hypoxia-inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; SERUM GROWTH-FACTORS; FACTOR-L-ALPHA; FACTOR 1-ALPHA; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; NGFI-B; MEDIATED INDUCTION; STEROID-RECEPTOR; ACTIVATION	Hypoxia-inducible factor-1alpha (HIF-1alpha) plays a central role in oxygen homeostasis by inducing the expression of a broad range of genes in a hypoxia-dependent manner. Here, we show that the orphan nuclear receptor Nur77 is an important regulator of HIF-1alpha. Under hypoxic conditions, Nur77 protein and transcripts were induced in a time-dependent manner. When Nur77 was exogenously introduced, it enhanced the transcriptional activity of HIF-1, whereas the dominant negative Nur77 mutant abolished the function of HIF-1. The HIF-1alpha protein was greatly increased and completely localized in the nucleus when coexpressed with Nur77. The N-terminal transactivation domain of Nur77 was required and sufficient for the activation of HIF-1alpha. The association of HIF-1alpha with von Hippel-Lindau protein was not affected, whereas that with mouse double minute 2 (MDM2) was greatly reduced in the presence of Nur77. Further we found that the expression of MDM2 was repressed at transcription level in the presence of Nur77 as well as under hypoxic conditions. Finally, PD98059 decreased Nur77-induced HIF-1alpha stability and recovered MDM2 expression, indicating that the extracellular signal-regulated kinase pathway is critical in the Nur77-induced activation of HIF-1alpha. Together, our results demonstrate a novel function for Nur77 in the stabilization of HIF-1alpha and suggest a potential role for Nur77 in tumor progression and metastasis.	Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea; Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea	Sejong University; Chung Ang University; University of Seoul	Lee, MO (corresponding author), Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea.	molee@sejong.ac.kr						Alarcon R, 1999, CANCER RES, V59, P6046; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bras A, 2000, CELL DEATH DIFFER, V7, P262, DOI 10.1038/sj.cdd.4400653; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Choi JW, 2004, CANCER RES, V64, P35, DOI 10.1158/0008-5472.CAN-03-0145; Chun YS, 2003, CANCER RES, V63, P8700; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Erez N, 2003, CANCER RES, V63, P8777; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lee MO, 2001, BIOCHEM BIOPH RES CO, V288, P1162, DOI 10.1006/bbrc.2001.5910; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Song KH, 2001, ENDOCRINOLOGY, V142, P5116, DOI 10.1210/en.142.12.5116; Suzuki S, 2003, P NATL ACAD SCI USA, V100, P8276, DOI 10.1073/pnas.0932598100; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; Winoto A, 1997, Semin Immunol, V9, P51, DOI 10.1006/smim.1996.0053; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	56	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53365	53373		10.1074/jbc.M408554200	http://dx.doi.org/10.1074/jbc.M408554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15385570	hybrid			2022-12-25	WOS:000225680600069
J	Bernhard, OK; Lai, J; Wilkinson, J; Sheil, MM; Cunningham, AL				Bernhard, OK; Lai, J; Wilkinson, J; Sheil, MM; Cunningham, AL			Proteomic analysis of DC-SIGN on dendritic cells detects tetramers required for ligand binding but no association with CD4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE RECOGNITION; VIRUS; ENTRY; HIV; INFECTION; RECEPTORS; MECHANISM; SUBUNIT; PROTEIN; CIS	DC-SIGN ( dendritic cell specific intracellular adhesion molecule 3 grabbing non-integrin) or CD209 is a type II transmembrane protein and one of several C-type lectin receptors expressed by dendritic cell subsets, which bind to high mannose glycoproteins promoting their endocytosis and potential degradation. DC-SIGN also mediates attachment of HIV to dendritic cells and binding to this receptor can subsequently lead to endocytosis or enhancement of CD4/CCR5-dependent infection. The latter was proposed to be facilitated by an interaction between DC-SIGN and CD4. Endocytosis of HIV virions does not necessarily lead to their complete degradation. A proportion of the virions remain infective and can be later presented to T cells mediating their infection in trans. Previously, the extracellular domain of recombinant DC-SIGN has been shown to assemble as tetramers and in the current study we use a short range covalent cross-linker and show that DC-SIGN exists as tetramers on the surface of immature monocyte-derived dendritic cells. There was no evidence of direct binding between DC-SIGN and CD4 either by cross-linking or by fluorescence resonance energy transfer measurements suggesting that there is no constitutive association of the majority of these proteins in the membrane. Importantly we also show that the tetrameric complexes, in contrast to DC-SIGN monomers, bind with high affinity to high mannose glycoproteins such as mannan or HIV gp120 suggesting that such an assembly is required for high affinity binding of glycoproteins to DC-SIGN, providing the first direct evidence that DC-SIGN tetramers are essential for high affinity interactions with pathogens like HIV.	Westmead Hosp, Ctr Virus Res, Westmead Millennium Inst, Sydney, NSW 2145, Australia; Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia; Univ Sydney, Sydney, NSW 2006, Australia	University of Sydney; Westmead Institute for Medical Research; University of Wollongong; University of Sydney	Cunningham, AL (corresponding author), Westmead Millennium Inst, Ctr Virus Res, Darcy Rd, Sydney, NSW 2145, Australia.	tony_cunningham@wmi.usyd.edu.au	Sheil, Margaret/F-2949-2015	Cunningham, Anthony/0000-0002-6744-5667; wilkinson, john/0000-0001-8728-4146				Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bernhard OK, 2004, BIOCHEMISTRY-US, V43, P256, DOI 10.1021/bi034847u; Bernhard OK, 2003, PROTEOMICS, V3, P139, DOI 10.1002/pmic.200390022; Cambi A, 2004, J CELL BIOL, V164, P145, DOI 10.1083/jcb.200306112; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Lee B, 2001, J VIROL, V75, P12028, DOI 10.1128/JVI.75.24.12028-12038.2001; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Moris A, 2004, BLOOD, V103, P2648, DOI 10.1182/blood-2003-07-2532; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Nobile C, 2003, J VIROL, V77, P5313, DOI 10.1128/JVI.77.9.5313-5323.2003; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Szollosi Janos, 2002, J Biotechnol, V82, P251, DOI 10.1016/S1389-0352(01)00041-1; Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841; Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0	24	47	48	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51828	51835		10.1074/jbc.M402741200	http://dx.doi.org/10.1074/jbc.M402741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15385553	hybrid			2022-12-25	WOS:000225493400015
J	Inou, Y; Taguchi, H; Kishimoto, A; Yoshida, M				Inou, Y; Taguchi, H; Kishimoto, A; Yoshida, M			Hsp104 binds to yeast Sup35 prion fiber but needs other factor(s) to sever it	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PSI+ PRION; PROTEIN; ELIMINATION	The interaction of Hsp104 with yeast prion fibers made of Sup35NM, a prion-inducing domain of Sup35, was tested. When fluorescently labeled Hsp104 was added to the preformed fibers, individual fibers were fluorescently decorated uniformly along the fiber length. However, the density of fluorescence differed from one fiber to another, indicating the presence of subspecies of Sup35NM fibers. The time course of fiber formation from monomer Sup35NM was delayed by Hsp104. Hsp104-mediated fragmentation of fibers was tested using bead-tethered fibers. In contrast with the recent report (Shorter, J., and Lindquist, S. (2004) Science 304, 1793-1797), Hsp104 alone was unable to sever the fibers. Yeast cell lysate or the Hsp104-deficient cell lysate plus Hsp104 caused ATP-dependent, guanidine hydrochloride-sensitive fragmentation of the fibers. Thus, in our experimental setup, Hsp104 plus other factor(s) in the yeast cytosol are required for severing yeast prion fiber. The reason of discrepancy from the above report is unknown but is possibly caused by different conformational subspecies of prion fibers.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Univ Tokyo, Dept Med Genome Sci, Grad Sch Frontier Sci, Chiba 2778562, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Tokyo Institute of Technology; University of Tokyo; Osaka University	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R1-7,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021	Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339				CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; Ferreira PC, 2001, MOL MICROBIOL, V40, P1357, DOI 10.1046/j.1365-2958.2001.02478.x; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Grimminger V, 2004, J BIOL CHEM, V279, P7378, DOI 10.1074/jbc.M312403200; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; Inoue Y, 2001, J BIOL CHEM, V276, P35227, DOI 10.1074/jbc.C100304200; INOUE Y, 2004, COLD SPRING HARB LAB; Kawai R, 1999, CELL STRESS CHAPERON, V4, P46, DOI 10.1054/csac.1999.0076; Kishimoto A, 2004, BIOCHEM BIOPH RES CO, V315, P739, DOI 10.1016/j.bbrc.2004.01.117; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kushnirov VV, 1998, CELL, V94, P13, DOI 10.1016/S0092-8674(00)81216-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; TUITE MF, 1981, GENETICS, V98, P691; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; YOSHIDA M, 2003, EURESCO C FEBS ADV C	25	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52319	52323		10.1074/jbc.M408159200	http://dx.doi.org/10.1074/jbc.M408159200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15448141	hybrid			2022-12-25	WOS:000225493400073
J	Liu, XKK; Lin, X; Gaffen, SL				Liu, XKK; Lin, X; Gaffen, SL			Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTORS; ANTIGEN RECEPTOR; IN-VITRO; IL-17; FAMILY; CYTOKINE; EXPRESSION; KINASE	The biological activities of the inflammatory cytokine interleukin (IL)-17 have been widely studied. However, comparatively little is known about how IL-17 expression is controlled. Here, we examined the basis for transcriptional regulation of the human IL-17 gene. IL-17 secretion was induced in peripheral blood mononuclear cells following anti-CD3 cross-linking to activate the T cell receptor (TCR), and costimulatory signaling through CD28 strongly enhanced CD3-induced IL-17 production. To define cis-acting elements important for IL-17 gene regulation, we cloned 1.25 kb of genomic sequence upstream of the transcriptional start site. This putative promoter was active in Jurkat T cells following CD3 and CD28 cross-linking, and its activity was inhibited by cyclosporin A and MAPK inhibitors. The promoter was also active in Hut102 T cells, which we have shown to secrete IL-17 constitutively. Overexpression of nuclear factor of activated T cells (NFAT) or Ras enhanced IL-17 promoter activity, and studies in Jurkat lines deficient in specific TCR signaling pathways provided supporting evidence for a role for NFAT. To delineate the IL-17 minimal promoter, we created a series of 5' truncations and identified a region between -232 and -159 that was sufficient for inducible promoter activity. Interestingly, two NFAT sites were located within this region, which bound to NFATc1 and NFATc2 in nuclear extracts from Hut102 and Jurkat cells. Moreover, mutations of these sites dramatically reduced both specific DNA binding and reporter gene activity, and chromatin immunoprecipitation assays showed occupancy of NFAT at this region in vivo. Together, these data show that NFAT is the crucial sensor of TCR signaling in the IL-17 promoter.	SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol & Immunol, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gaffen, SL (corresponding author), SUNY Buffalo, Sch Dent Med, Dept Oral Biol, 36 Foster Hall,3435 Main St, Buffalo, NY 14214 USA.	sgaffen@buffalo.edu	Gaffen, Sarah L/B-1560-2009	Gaffen, Sarah L/0000-0001-8511-2041	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049329, R21AI049329, R01AI050848] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49329, AI50848] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aarvak T, 1999, J IMMUNOL, V162, P1246; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Astoul E, 2001, TRENDS IMMUNOL, V22, P490, DOI 10.1016/S1471-4906(01)01973-1; Bert AG, 2000, PLASMID, V44, P173, DOI 10.1006/plas.2000.1474; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Gaffen Sarah L., 1998, P73; Gaffen SL, 2004, CYTOKINE, V28, P109, DOI 10.1016/j.cyto.2004.06.010; Gaffen SL, 2004, ARTHRITIS RES THER, V6, P240, DOI 10.1186/ar1444; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; Ghilardi N, 2004, J IMMUNOL, V172, P2827, DOI 10.4049/jimmunol.172.5.2827; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; Happel KI, 2003, J IMMUNOL, V170, P4432, DOI 10.4049/jimmunol.170.9.4432; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang SH, 2004, ALLERGY ASTHMA PROC, V25, P17; Infante-Duarte C, 2000, J IMMUNOL, V165, P6107, DOI 10.4049/jimmunol.165.11.6107; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Johnson RB, 2004, J PERIODONTOL, V75, P37, DOI 10.1902/jop.2004.75.1.37; Kane LP, 2002, TRENDS IMMUNOL, V23, P413, DOI 10.1016/S1471-4906(02)02264-0; Linden A, 2002, ALLERGY, V57, P769, DOI 10.1034/j.1398-9995.2002.02164.x; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luzza F, 2000, J IMMUNOL, V165, P5332, DOI 10.4049/jimmunol.165.9.5332; Mao C, 1996, ONCOGENE, V12, P863; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Miossec P, 2003, ARTHRITIS RHEUM-US, V48, P594, DOI 10.1002/art.10816; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100; Oda T, 2003, ORAL MICROBIOL IMMUN, V18, P30, DOI 10.1034/j.1399-302X.2003.180105.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; SCHWARZENBERGER P, 2002, MOD ASPECTS IMMUNOBI, V2, P176; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200; Shin HCK, 1998, CYTOKINE, V10, P841, DOI 10.1006/cyto.1998.0375; Shin HCK, 1999, CYTOKINE, V11, P257, DOI 10.1006/cyto.1998.0433; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Van Bezooijen RL, 1999, J BONE MINER RES, V14, P1513, DOI 10.1359/jbmr.1999.14.9.1513; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Ye P, 2001, AM J RESP CELL MOL, V25, P335, DOI 10.1165/ajrcmb.25.3.4424; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200; Ziolkowska N, 2000, J IMMUNOL, V164, P2832, DOI 10.4049/jimmunol.164.5.2832	52	128	133	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52762	52771		10.1074/jbc.M405764200	http://dx.doi.org/10.1074/jbc.M405764200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459204	hybrid			2022-12-25	WOS:000225493400123
J	Martins, RP; Ostermeier, GC; Krawetz, SA				Martins, RP; Ostermeier, GC; Krawetz, SA			Nuclear matrix interactions at the human protamine domain - A working model of potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE CHROMATIN HUB; I SENSITIVE DOMAIN; BETA-GLOBIN LOCUS; GENE-EXPRESSION; ATTACHMENT REGIONS; REGULATORY REGIONS; MOUSE; DNA; SITES; TRANSCRIPTION	The compact eukaryotic genome must be selectively opened to grant trans-factor access to cis-regulatory elements to overcome the primary barrier to gene transcription. The mechanism that governs the selective opening of chromatin domains (i.e. potentiation) remains poorly understood. In the absence of a well defined locus control region, the nuclear matrix is considered the primary candidate regulating the opening of the multigenic PRM1 --> PRM2 --> TNP2 human protamine domain. To directly examine its role, four lines of transgenic mice with different configurations of flanking nuclear matrix attachment regions (MARs) encompassing the protamine domain were created. We show that upon removal of the MARs, the locus becomes subject to position effects. The 3' MAR alone may be sufficient to protect against silencing. In concert, the MARs bounding this domain likely synergize to regulate the expression of the various members of this gene cluster. Interestingly, the MARs may convey a selective reproductive advantage, such that constructs bearing both 5' and 3' MARs are passed to their offspring with greater frequency. Thus, the MARs bounding the PRM1 --> PRM2 --> TNP2 protamine domain have many and varied functions.	Wayne State Univ, Sch Med, Inst Comp Sci, Dept Obstet & Gynecol Mol Med & Genet, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University	Krawetz, SA (corresponding author), Wayne State Univ, Sch Med, Inst Comp Sci, Dept Obstet & Gynecol Mol Med & Genet, Detroit, MI 48201 USA.	steve@compbio.med.wayne.edu	Ostermeier, G. Charles/Y-1172-2019; krawetz, stephen/GQQ-3308-2022	Ostermeier, G. Charles/0000-0002-3951-512X; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036512] Funding Source: NIH RePORTER; NICHD NIH HHS [HD36512] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALEVY MC, 1984, BIOCHEMISTRY-US, V23, P2309, DOI 10.1021/bi00305a034; Alvarez JD, 2000, GENE DEV, V14, P521; Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; BALHORN R, 1992, ARCH BIOCHEM BIOPHYS, V296, P384, DOI 10.1016/0003-9861(92)90588-N; Bode J, 2003, CHROMOSOME RES, V11, P435, DOI 10.1023/A:1024918525818; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Braun RE, 2001, NAT GENET, V28, P10, DOI 10.1038/88194; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Cai ST, 1999, METHODS, V19, P394, DOI 10.1006/meth.1999.0875; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; CHOUDHARY SK, 1995, J BIOL CHEM, V270, P8755, DOI 10.1074/jbc.270.15.8755; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P213; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P143; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Farrell CM, 2002, MOL CELL BIOL, V22, P3820, DOI 10.1128/MCB.22.11.3820-3831.2002; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; Georgel PT, 2003, GENE DEV, V17, P1617, DOI 10.1101/gad.1097603; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Heng HHQ, 2001, CYTOGENET CELL GENET, V93, P155, DOI 10.1159/000056977; Ishiguro K, 2004, EUR J BIOCHEM, V271, P2379, DOI 10.1111/j.1432-1033.2004.04157.x; Jackson DA, 2000, J CELL BIOCHEM, P69; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; KEENE MA, 1980, EUR J CELL BIOL, V22, P95; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kieffer LJ, 2002, J IMMUNOL, V168, P3915, DOI 10.4049/jimmunol.168.8.3915; Kramer JA, 1998, DEVELOPMENT, V125, P4749; Kramer JA, 1997, GENET TEST, V1, P125, DOI 10.1089/gte.1997.1.125; Kramer JA, 2000, MOL REPROD DEV, V56, P254, DOI 10.1002/(SICI)1098-2795(200006)56:2+<254::AID-MRD9>3.0.CO;2-#; Kramer JA, 1996, J BIOL CHEM, V271, P11619, DOI 10.1074/jbc.271.20.11619; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; LAWSON GM, 1982, J BIOL CHEM, V257, P1501; Li QL, 2002, BLOOD, V100, P3077, DOI 10.1182/blood-2002-04-1104; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Ma H, 1999, J CELL BIOL, V146, P531, DOI 10.1083/jcb.146.3.531; Martins RP, 2004, ANAL BIOCHEM, V329, P337, DOI 10.1016/j.ab.2004.02.041; MCPHERSON S, 1993, EUR J HISTOCHEM, V37, P109; NELSON JE, 1994, J BIOL CHEM, V269, P31067; NELSON JE, 1995, DNA SEQUENCE, V5, P163, DOI 10.3109/10425179509029356; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; Ostermeier GC, 2003, NUCLEIC ACIDS RES, V31, P3257, DOI 10.1093/nar/gkg424; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; Patrinos GP, 2004, GENE DEV, V18, P1495, DOI 10.1101/gad.289704; Rastegar M, 2004, MOL CELL BIOL, V24, P8090, DOI 10.1128/MCB.24.18.8090-8103.2004; ROSE SM, 1984, J BIOL CHEM, V259, P8534; Samuel SK, 1997, CANCER RES, V57, P147; Samuel SK, 1997, J CELL BIOCHEM, V66, P9; SCHOLER HR, 1985, EMBO J, V4, P3005, DOI 10.1002/j.1460-2075.1985.tb04036.x; SCOTT WA, 1978, CELL, V15, P1511, DOI 10.1016/0092-8674(78)90073-9; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Spencer VA, 2001, J BIOL CHEM, V276, P34810, DOI 10.1074/jbc.M104886200; Sun JM, 2001, J BIOL CHEM, V276, P49435, DOI 10.1074/jbc.M108364200; VARSHAVSKY AJ, 1979, CELL, V16, P453, DOI 10.1016/0092-8674(79)90021-7; Vassetzky Y, 2000, GENE DEV, V14, P1541; VICKERS MA, 1993, P NATL ACAD SCI USA, V90, P3437, DOI 10.1073/pnas.90.8.3437; Ward WS, 1999, BIOL REPROD, V60, P702, DOI 10.1095/biolreprod60.3.702; WARD WS, 1989, CHROMOSOMA, V98, P153, DOI 10.1007/BF00329678; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; Wolffe AP, 2000, BIOCHEM SOC T, V28, P379, DOI 10.1042/0300-5127:0280379; WU C, 1979, CELL, V16, P797, DOI 10.1016/0092-8674(79)90095-3; Wykes SM, 2003, MOL BIOTECHNOL, V25, P131, DOI 10.1385/MB:25:2:131; Wykes SM, 2003, J BIOL CHEM, V278, P29471, DOI 10.1074/jbc.M304545200; WYKES SM, 2004, IN PRESS RES TRENDS; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; ZAMBROWICZ BP, 1994, BIOL REPROD, V50, P65, DOI 10.1095/biolreprod50.1.65; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071	73	63	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51862	51868		10.1074/jbc.M409415200	http://dx.doi.org/10.1074/jbc.M409415200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452126	hybrid			2022-12-25	WOS:000225493400019
J	Mazina, OM; Mazin, AV				Mazina, OM; Mazin, AV			Human Rad54 protein stimulates DNA strand exchange activity of hRad51 protein in the presence of Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; INTRACELLULAR CA2+; REPAIR PROTEIN; RECA PROTEIN; REPLICATION; CHROMATIN; CALCIUM; BINDING; TRANSLOCATION; IRRADIATION	Rad51 and Rad54 proteins play a key role in homologous recombination in eukaryotes. Recently, we reported that Ca2+ is required in vitro for human Rad51 protein to form an active nucleoprotein filament that is important for the search of homologous DNA and for DNA strand exchange, two critical steps of homologous recombination. Here we find that Ca2+ is also required for hRad54 protein to effectively stimulate DNA strand exchange activity of hRad51 protein. This finding identifies Ca2+ as a universal cofactor of DNA strand exchange promoted by mammalian homologous recombination proteins in vitro. We further investigated the hRad54-dependent stimulation of DNA strand exchange. The mechanism of stimulation appeared to include specific interaction of hRad54 protein with the hRad51 nucleoprotein filament. Our results show that hRad54 protein significantly stimulates homology-independent coaggregation of dsDNA with the filament, which represents an essential step of the search for homologous DNA. The results obtained indicate that hRad54 protein serves as a dsDNA gateway for the hRad51-ssDNA filament, promoting binding and an ATP hydrolysis-dependent translocation of dsDNA during the search for homologous sequences.	Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19102 USA	Drexel University	Mazin, AV (corresponding author), Drexel Univ, Coll Med, Dept Biochem, 245 N 15th St,MS 497,NCB,Rm 10103, Philadelphia, PA 19102 USA.	avmazin@drexel.edu			NCI NIH HHS [CA100839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100839, R56CA100839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adzuma K, 1998, J BIOL CHEM, V273, P31565, DOI 10.1074/jbc.273.47.31565; Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Bugreev DV, 2004, P NATL ACAD SCI USA, V101, P9988, DOI 10.1073/pnas.0402105101; CARROLL J, 1994, DEVELOPMENT, V120, P3507; CHOW SA, 1985, P NATL ACAD SCI USA, V82, P5646, DOI 10.1073/pnas.82.17.5646; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Gafter U, 1997, J LAB CLIN MED, V130, P33, DOI 10.1016/S0022-2143(97)90056-1; Game JC, 2000, MUTAT RES-FUND MOL M, V451, P277, DOI 10.1016/S0027-5107(00)00055-5; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; NEGRESALVAYRE A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P207, DOI 10.1016/0005-2760(92)90113-A; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RADDING CM, 1993, CURR BIOL, V3, P358, DOI 10.1016/0960-9822(93)90200-8; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; SAKAI H, 1994, BBA-GEN SUBJECTS, V1201, P259, DOI 10.1016/0304-4165(94)90049-3; Sambrook J., 2001, MOL CLONING LAB MANU; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; SIGURDSSON S, 2002, J BIOL CHEM; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; SPIELBERG H, 1991, EXP HEMATOL, V19, P742; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wolner B, 2003, MOL CELL, V12, P221, DOI 10.1016/S1097-2765(03)00242-9; Wyman C, 2004, DNA REPAIR, V3, P827, DOI 10.1016/j.dnarep.2004.03.037; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	55	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52042	52051		10.1074/jbc.M410244200	http://dx.doi.org/10.1074/jbc.M410244200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466868	hybrid			2022-12-25	WOS:000225493400041
J	Suresh, MV; Singh, SK; Agrawal, A				Suresh, MV; Singh, SK; Agrawal, A			Interaction of calcium-bound c-reactive protein with fibronectin is controlled by pH - In vivo implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PNEUMONIAE INFECTION; PHOSPHOCHOLINE-BINDING SITE; IMMUNOHISTOCHEMICAL EXPRESSION; 3-DIMENSIONAL STRUCTURE; COMPLEMENT ACTIVATION; INFLAMMATORY LESIONS; DIRECTED MUTAGENESIS; APOPTOTIC CELLS; MICE; PHOSPHORYLCHOLINE	C-reactive protein (CRP) binds with high affinity to fibronectin (Fn), a major component of the extracellular matrix (ECM), but at physiological pH the binding is inhibited by calcium ions (Ca2+). Because CRP circulates in the blood in Ca2+-bound form, the occurrence of CRP-Fn interactions in vivo has been doubtful. To define the basis of inhibition of CRP-Fn interaction by Ca2+ at pH 7.0, we hypothesized that Fn-binding site on CRP consisted of amino acids co-ordinating Ca2+. Site-directed mutagenesis of amino acids co-ordinating Ca2+ drastically decreased the binding of CRP to Fn, indicating that the Ca2+-binding site indeed formed the Fn-binding site. To determine the requirements for possible interaction between Ca2+-bound CRP and Fn, we investigated inhibition of CRP-Fn interaction by Ca2+ as a function of pH. Ca2+ did not inhibit binding of CRP to Fn at pH 6.5 and lower. The contrasting Fn binding properties of CRP at physiological and mildly acidic pH indicated that the interaction of Ca2+-bound CRP with Fn was controlled by pH. We conclude that the inhibition of binding of CRP to Fn by Ca2+ at pH 7.0 is a mechanism to prevent CRP-Fn interactions under normal conditions. CRP, in its Ca2+-bound state, is capable of binding Fn but only at the inflammatory sites and tumors with low pH. CRP, Fn, and the ECM all have been implicated in cancer. Taken together our data raise the possibility that CRP-Fn interactions may change the architecture of ECM to modify the development of tumors.	E Tennessee State Univ, James H Quillen Coll Med, Dept Pharm, Johnson City, TN 37614 USA	East Tennessee State University	Agrawal, A (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Pharm, POB 70577, Johnson City, TN 37614 USA.	agrawal@etsu.edu	madathilparambil, suresh/L-6791-2019		NHLBI NIH HHS [HL071233, R01 HL071233] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071233] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agrawal A, 2002, J IMMUNOL, V169, P3217, DOI 10.4049/jimmunol.169.6.3217; AGRAWAL A, 1992, J BIOL CHEM, V267, P25352; Agrawal A, 1997, J IMMUNOL, V158, P345; BARNA BP, 1993, CANCER IMMUNOL IMMUN, V36, P171, DOI 10.1007/BF01741088; BERMAN MA, 1988, HUM PATHOL, V19, P784, DOI 10.1016/S0046-8177(88)80261-2; Bhakdi S, 2004, CIRCULATION, V109, P1870, DOI 10.1161/01.CIR.0000124228.08972.26; Black S, 2003, MOL IMMUNOL, V39, P1045, DOI 10.1016/S0161-5890(03)00031-2; Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699; DAVID L, 1994, CANCER, V73, P518, DOI 10.1002/1097-0142(19940201)73:3<518::AID-CNCR2820730305>3.0.CO;2-T; DEODHAR SD, 1982, CANCER RES, V42, P5084; DICAMELLI R, 1980, J IMMUNOL, V125, P1933; DUCLOS TW, 1981, CLIN EXP IMMUNOL, V43, P565; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Goerges AL, 2004, J BIOL CHEM, V279, P2307, DOI 10.1074/jbc.M308482200; GOTSCHLICH EC, 1965, P NATL ACAD SCI USA, V54, P558, DOI 10.1073/pnas.54.2.558; Hack CE, 1997, IMMUNOL TODAY, V18, P111, DOI 10.1016/S0167-5699(97)01002-5; Hirschfield GM, 2003, QJM-INT J MED, V96, P793, DOI 10.1093/qjmed/hcg134; HURLIMANN J, 1991, AM J SURG PATHOL, V15, P280, DOI 10.1097/00000478-199103000-00008; Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1; Jialal I, 2004, HYPERTENSION, V44, P6, DOI 10.1161/01.HYP.0000130484.20501.df; KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044; Kresl JJ, 1999, TUMOR BIOL, V20, P72, DOI 10.1159/000030050; KUSHNER I, 1961, J EXP MED, V114, P961, DOI 10.1084/jem.114.6.961; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; Lee RT, 2002, J BIOL CHEM, V277, P225, DOI 10.1074/jbc.M106039200; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; MIYAZAWA K, 1990, J IMMUNOL, V145, P650; Mold C, 2002, J IMMUNOL, V168, P6375, DOI 10.4049/jimmunol.168.12.6375; MORTENSEN RF, 1975, J EXP MED, V141, P821; MULLENIX MC, 1994, MOL IMMUNOL, V31, P615, DOI 10.1016/0161-5890(94)90169-4; Nozoe T, 2003, CANCER LETT, V192, P89, DOI 10.1016/S0304-3835(02)00630-4; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; POTEMPA LA, 1981, J IMMUNOL, V127, P1509; Ramadan MAM, 2002, ACTA CRYSTALLOGR D, V58, P992, DOI 10.1107/S0907444902005693; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SALONEN EM, 1984, J BIOL CHEM, V259, P1496; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; Szalai AJ, 2003, ARTHRITIS RHEUM-US, V48, P1602, DOI 10.1002/art.11026; Tan MH, 2004, BLOOD, V104, P11, DOI 10.1182/blood-2003-09-3363; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; TSENG J, 1988, MOL IMMUNOL, V25, P679, DOI 10.1016/0161-5890(88)90103-4; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; Wagner C, 2000, J MOL MED-JMM, V78, P337, DOI 10.1007/s001090000107; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; WOO P, 1985, J BIOL CHEM, V260, P3384; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620; YOTHER J, 1982, J IMMUNOL, V128, P2374	48	43	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52552	52557		10.1074/jbc.M409054200	http://dx.doi.org/10.1074/jbc.M409054200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456743	Green Accepted, hybrid			2022-12-25	WOS:000225493400101
J	Balasubramanyam, K; Varier, RA; Altaf, M; Swaminathan, V; Siddappa, NB; Ranga, U; Kundu, TK				Balasubramanyam, K; Varier, RA; Altaf, M; Swaminathan, V; Siddappa, NB; Ranga, U; Kundu, TK			Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUBINSTEIN-TAYBI-SYNDROME; VIRUS TYPE-1 PROMOTER; LONG TERMINAL REPEAT; THERAPEUTIC STRATEGIES; GENE-EXPRESSION; P300; HIV-1; TAT; CELLS; CBP	Acetylation of histones and non-histone proteins is an important post-translational modification involved in the regulation of gene expression in eukaryotes and all viral DNA that integrates into the human genome ( e. g. the human immunodeficiency virus). Dysfunction of histone acetyltransferases (HATs) is often associated with the manifestation of several diseases. In this respect, HATs are the new potential targets for the design of therapeutics. In this study, we report that curcumin (diferuloylmethane), a major curcumanoid in the spice turmeric, is a specific inhibitor of the p300/CREB-binding protein (CBP) HAT activity but not of p300/CBP-associated factor, in vitro and in vivo. Furthermore, curcumin could also inhibit the p300-mediated acetylation of p53 in vivo. It specifically represses the p300/CBP HAT activity-dependent transcriptional activation from chromatin but not a DNA template. It is significant that curcumin could inhibit the acetylation of HIV-Tat protein in vitro by p300 as well as proliferation of the virus, as revealed by the repression in syncytia formation upon curcumin treatment in SupT1 cells. Thus, nontoxic curcumin, which targets p300/CBP, may serve as a lead compound in combinatorial HIV therapeutics.	Jawaharlal Nehru Ctr Adv Sci Res, Transcript & Dis Lab, Bangalore 560064, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Mol Virol Lab, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Kundu, TK (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Transcript & Dis Lab, Bangalore 560064, Karnataka, India.	tapas@jncasr.ac.in		Byrareddy, Siddappa/0000-0002-7423-1763; Varier, Radhika/0000-0003-1302-3159; Venkatesh, Swaminathan/0000-0001-9837-1501; Kundu, Tapas/0000-0001-7790-214X				Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074/jbc.M402839200; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Barthelemy S, 1998, RES VIROLOGY, V149, P43, DOI 10.1016/S0923-2516(97)86899-9; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Cebrat M, 2003, BIOORGAN MED CHEM, V11, P3307, DOI 10.1016/S0968-0896(03)00265-7; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; Coull JJ, 2002, J VIROL, V76, P12349, DOI 10.1128/JVI.76.23.12349-12354.2002; Demonte D, 2004, BIOCHEM PHARMACOL, V68, P1231, DOI 10.1016/j.bcp.2004.05.040; GERA A, 1986, METHOD ENZYMOL, V119, P729; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gusterson RJ, 2003, J BIOL CHEM, V278, P6838, DOI 10.1074/jbc.M211762200; He GC, 2002, MOL CELL BIOL, V22, P2965, DOI 10.1128/MCB.22.9.2965-2973.2002; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; JAPOUR AJ, 1994, J CLIN MICROBIOL, V32, P2291, DOI 10.1128/JCM.32.9.2291-2294.1994; Kalkhoven E, 2003, HUM MOL GENET, V12, P441, DOI 10.1093/hmg/ddg039; Kanamoto T, 2001, ANTIMICROB AGENTS CH, V45, P1225, DOI 10.1128/AAC.45.4.1225-1230.2001; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Lin Jen-Kun, 2001, Proceedings of the National Science Council Republic of China Part B Life Sciences, V25, P59; MAZUMDER A, 1995, BIOCHEM PHARMACOL, V49, P1165, DOI 10.1016/0006-2952(95)98514-A; MCKEATING JA, 1989, J GEN VIROL, V70, P3327, DOI 10.1099/0022-1317-70-12-3327; McKinsey TA, 2004, TRENDS GENET, V20, P206, DOI 10.1016/j.tig.2004.02.002; Muraoka M, 1996, ONCOGENE, V12, P1565; Murata T, 2001, HUM MOL GENET, V10, P1071, DOI 10.1093/hmg/10.10.1071; Neely KE, 2002, MOL GENET METAB, V76, P1, DOI 10.1016/S1096-7192(02)00014-8; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Pan MH, 2001, J AGR FOOD CHEM, V49, P1464, DOI 10.1021/jf001129v; Phillips AC, 2000, BREAST CANCER RES, V2, P244, DOI 10.1186/bcr63; Quivy V, 2002, J VIROL, V76, P11091, DOI 10.1128/JVI.76.21.11091-11103.2002; Quivy V, 2002, BIOCHEM PHARMACOL, V64, P925, DOI 10.1016/S0006-2952(02)01152-8; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; RYAN CA, 2001, CURRENT PROTOCOLS MO; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Taher MM, 2003, MOL CELL BIOCHEM, V254, P289, DOI 10.1023/A:1027393719610; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252	49	614	634	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51163	51171		10.1074/jbc.M409024200	http://dx.doi.org/10.1074/jbc.M409024200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15383533	hybrid			2022-12-25	WOS:000225355800063
J	Jeimy, SB; Woram, RA; Fuller, N; Quinn-Allen, MA; Nicolaes, GAF; Dahlback, B; Kane, WH; Hayward, CPM				Jeimy, SB; Woram, RA; Fuller, N; Quinn-Allen, MA; Nicolaes, GAF; Dahlback, B; Kane, WH; Hayward, CPM			Identification of the MMRN1 binding region within the C2 domain of human factor V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; FACTOR-VIII; PROTHROMBINASE COMPLEX; B-DOMAIN; PHOSPHOLIPID-VESICLES; PARTIAL GLYCOSYLATION; ALPHA-GRANULES; CDNA SEQUENCE; FACTOR XA; PROTEIN	In platelets, coagulation cofactor V is stored in complex with multimerin 1 in alpha-granules for activation- induced release during clot formation. The molecular nature of multimerin 1 factor V binding has not been determined, although multimerin 1 is known to interact with the factor V light chain. We investigated the region in factor V important for multimerin 1 binding using modified enzyme-linked immunoassays and recombinant factor V constructs. Factor V constructs lacking the C2 region or entire light chain had impaired and absent multimerin 1 binding, respectively, whereas the B domain deleted construct had modestly reduced binding. Analyses of point mutated constructs indicated that the multimerin 1 binding site in the C2 domain of factor V partially overlaps the phosphatidylserine binding site and that the factor V B domain enhances multimerin 1 binding. Multimerin 1 did not inhibit factor V phosphatidylserine binding, and it bound to phosphatidylserine independently of factor V. There was a reduction in factor V in complex with multimerin 1 after activation, and thrombin cleavage significantly reduced factor V binding to multimerin 1. In molar excess, multimerin 1 minimally reduced factor V procoagulant activity in prothrombinase assays and only if it was added before factor V activation. The dissociation of factor V-multimerin 1 complexes following factor V activation suggests a role for multimerin 1 in delivering and localizing factor V onto platelets prior to prothrombinase assembly.	McMaster Univ, Med Ctr, Hlth Sci Ctr 2N31, Hamilton, ON L8N 3Z5, Canada; Duke Univ, Med Ctr, Durham, NC 27710 USA; Maastricht Univ, Dept Biochem, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands; Lund Univ, S-20502 Malmo, Sweden	McMaster University; Duke University; Maastricht University; Lund University	Hayward, CPM (corresponding author), McMaster Univ, Med Ctr, Hlth Sci Ctr 2N31, Room 2N31,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	haywrdc@mcmaster.ca	Nicolaes, Gerry A.F./A-8421-2016; Jeimy, Samira/S-1135-2019	Nicolaes, Gerry A.F./0000-0002-2482-0412; Hayward, Catherine/0000-0002-2843-0817; Dahlback, Bjorn/0000-0003-1546-0328; Jeimy, Samira/0000-0002-3425-1874	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043106] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43106, HL54939] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; DAHLBACK B, 1984, SEMIN THROMB HEMOST, V10, P139, DOI 10.1055/s-2007-1004416; Guasch JF, 1998, BRIT J HAEMATOL, V101, P32, DOI 10.1046/j.1365-2141.1998.00664.x; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; Hayward CPM, 2004, THROMB HAEMOSTASIS, V92, P1349, DOI 10.1160/TH03-02-0123; HAYWARD CPM, 1991, J BIOL CHEM, V266, P7114; HAYWARD CPM, 1995, J BIOL CHEM, V270, P19217, DOI 10.1074/jbc.270.33.19217; Hayward CPM, 2001, BRIT J HAEMATOL, V113, P871, DOI 10.1046/j.1365-2141.2001.02833.x; HAYWARD CPM, 1993, J CLIN INVEST, V91, P2630, DOI 10.1172/JCI116502; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; KALAFATIS M, 2003, J BIOL CHEM, V279, P2383; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; Kim SW, 1999, BIOCHEMISTRY-US, V38, P11448, DOI 10.1021/bi991275y; Kim SW, 2000, BIOCHEMISTRY-US, V39, P1951, DOI 10.1021/bi992256r; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; MILETICH JP, 1978, J CLIN INVEST, V62, P824, DOI 10.1172/JCI109194; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; Nicolaes GAF, 1999, BIOCHEMISTRY-US, V38, P13584, DOI 10.1021/bi991165r; Nicolaes GAF, 2000, BLOOD COAGUL FIBRIN, V11, P89, DOI 10.1097/00001721-200011010-00010; Nicolaes GAF, 2002, ARTERIOSCL THROM VAS, V22, P530, DOI 10.1161/01.ATV.0000012665.51263.B7; ORTEL TL, 1994, J BIOL CHEM, V269, P15898; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; Peng WM, 2004, BIOCHEMISTRY-US, V43, P4385, DOI 10.1021/bi035763o; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; ROSING J, 1980, J BIOL CHEM, V255, P274; Salzman, 2001, HEMOSTASIS THROMBOSI, P157; Steen M, 2002, SCAND J CLIN LAB INV, V62, P5, DOI 10.1080/003655102762377439; Thompson AR, 2003, SEMIN THROMB HEMOST, V29, P11, DOI 10.1055/s-2003-37935; Thorelli E, 1998, J BIOL CHEM, V273, P16140, DOI 10.1074/jbc.273.26.16140; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; Toso R, 2004, J BIOL CHEM, V279, P21643, DOI 10.1074/jbc.M402107200; Yang TL, 1998, BLOOD, V91, P4593, DOI 10.1182/blood.V91.12.4593.412a02_4593_4599	37	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51466	51471		10.1074/jbc.M409866200	http://dx.doi.org/10.1074/jbc.M409866200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452129	hybrid			2022-12-25	WOS:000225355800099
J	Kuramochi, Y; Cote, GM; Guo, XX; Lebrasseur, NK; Cui, L; Liao, R; Sawyer, DB				Kuramochi, Y; Cote, GM; Guo, XX; Lebrasseur, NK; Cui, L; Liao, R; Sawyer, DB			Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1 beta/erbB4 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; EPIDERMAL GROWTH-FACTOR; HYDROGEN-PEROXIDE; DILATED CARDIOMYOPATHY; DEPENDENT ACTIVATION; CONTRACTILE ACTIVITY; NEUREGULIN RECEPTOR; KINASE ACTIVATION; AORTIC-STENOSIS; HEART-FAILURE	Neuregulin (NRG)-1beta has a prosurvival effect on cardiac myocytes via the phosphatidylinositol-3-kinase/Akt pathway, but the physiological regulators of this system in the intact heart are unknown. In this study, we tested the hypothesis that reactive oxygen species regulate NRG/erbB signaling. We used isolated adult rat ventricular myocytes (ARVMs) or cardiac microvascular endothelial cells (CMECs) in monoculture, or together in coculture. H2O2 induced NRG-1beta release from CMECs in a concentration-dependent manner, and conditioned medium from H2O2-treated CMEC activated ARVM erbB4. NRG-1beta release occurred via proteolytic cleavage of 115-kDa transmembrane NRG-1beta and was inhibited by the metalloproteinase inhibitor 1,10-phenanthroline. In myocyte monoculture, H2O2 induced erbB4-dependent, but NRG-independent, activation of Akt. To elucidate the bioactivity of CMEC-derived NRG-1beta on ARVMs, we examined H2O2-induced myocyte apoptosis in co-culture using an antibody to NRG-1beta. The percentages of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells were significantly higher in the anti-NRG-1beta group than in the control group. The change in apoptosis induced by anti-NRG-1beta in co-culture was similar in magnitude to the protection of myocytes by addition of recombinant NRG-1beta to ARVM monocultures. Activation of NRG/erbB paracrine signaling was also seen in the intact heart subjected to oxidative stress by ischemia-reperfusion injury. Isolated perfused mouse hearts subjected to 15 min of ischemia, followed by 30 min of reperfusion, showed complete proteolytic cleavage of 115-kDa NRG-1beta, with concomitant erbB4 phosphorylation. These results demonstrate that reactive oxygen species activate NRG-1beta/erbB4 paracrine signaling in the heart and suggest that this system is involved in cardiac adaptation to oxidative stress.	Boston Univ, Med Ctr, Dept Med, Whitaker Cardiovasc Inst,Ctr Mol Stress Response, Boston, MA 02118 USA	Boston University	Sawyer, DB (corresponding author), Boston Univ, Med Ctr, Dept Med, Whitaker Cardiovasc Inst,Ctr Mol Stress Response, EBRC Rm 329,650 Albany St, Boston, MA 02118 USA.	Douglas.Sawyer@bmc.org		Cote, Gregory/0000-0003-0181-886X; LeBrasseur, Nathan/0000-0002-2002-0418	NHLBI NIH HHS [HL68144, R01 HL068144] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068144] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Canto C, 2004, J BIOL CHEM, V279, P12260, DOI 10.1074/jbc.M308554200; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; Cote GM, 2001, FASEB J, V15, pA762; Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396; Crone SA, 2002, NAT MED, V8, P459, DOI 10.1038/nm0502-459; DEBONO DP, 1995, ATHEROSCLEROSIS, V114, P235, DOI 10.1016/0021-9150(94)05488-5; Erickson SL, 1996, MOL BIOL CELL, V7, P669; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Fujino T, 1998, CARDIOVASC RES, V38, P365, DOI 10.1016/S0008-6363(98)00010-8; Fukazawa R, 2003, J MOL CELL CARDIOL, V35, P1473, DOI 10.1016/j.yjmcc.2003.09.012; Fukazawa R, 2000, CIRCULATION, V102, P138; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Jain M, 2004, CIRCULATION, V109, P898, DOI 10.1161/01.CIR.0000112605.43318.CA; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Kuramochi Y, 2004, AM J PHYSIOL-CELL PH, V286, pC222, DOI 10.1152/ajpcell.00312.2003; Kwon SH, 2003, J MOL CELL CARDIOL, V35, P615, DOI 10.1016/S0022-2828(03)00084-1; Lebrasseur NK, 2003, AM J PHYSIOL-CELL PH, V284, pC1149, DOI 10.1152/ajpcell.00487.2002; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lemmens K, 2004, CIRCULATION, V109, P324, DOI 10.1161/01.CIR.0000114521.88547.5E; Li JM, 2002, HYPERTENSION, V40, P477, DOI 10.1161/01.HYP.0000032031.30374.32; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; Ozcelik C, 2002, P NATL ACAD SCI USA, V99, P8880, DOI 10.1073/pnas.122249299; Remondino A, 2003, CIRC RES, V92, P136, DOI 10.1161/01.RES.0000054624.03539.B4; Rohrbach S, 1999, CIRCULATION, V100, P407, DOI 10.1161/01.CIR.100.4.407; Sawyer DB, 2002, CIRCULATION, V105, P1551, DOI 10.1161/01.CIR.0000013839.41224.1C; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Snabaitis AK, 2002, CARDIOVASC RES, V53, P470, DOI 10.1016/S0008-6363(01)00464-3; Wei S, 2001, AM J PHYSIOL-CELL PH, V281, pC1542, DOI 10.1152/ajpcell.2001.281.5.C1542; Yan XH, 2003, CIRCULATION, V108, P260; Yan XH, 2000, CIRCULATION, V102, P71; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261; Zhou SY, 2001, TOXICOL LETT, V121, P151, DOI 10.1016/S0378-4274(01)00329-0; Zhougang SG, 2004, AM J PHYSIOL-RENAL, V286, pF858, DOI 10.1152/ajprenal.00282.2003	39	152	169	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51141	51147		10.1074/jbc.M408662200	http://dx.doi.org/10.1074/jbc.M408662200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385548	hybrid			2022-12-25	WOS:000225355800060
J	Liu, D; O'Connor, MS; Qin, J; Songyang, Z				Liu, D; O'Connor, MS; Qin, J; Songyang, Z			Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RAP1; LENGTH; TIN2; TRF2; POT1; END; ELONGATION; REGULATOR; TANKYRASE	In mammalian cells, telomere-binding proteins TRF1 and TRF2 play crucial roles in telomere biology. They interact with several other telomere regulators including TIN2, PTOP, POT1, and RAP1 to ensure proper maintenance of telomeres. TRF1 and TRF2 are believed to exert distinct functions. TRF1 forms a complex with TIN2, PTOP, and POT1 and regulates telomere length, whereas TRF2 mediates t-loop formation and end protection. However, whether cross-talk occurs between the TRF1 and TRF2 complexes and how the signals from these complexes are integrated for telomere maintenance remain to be elucidated. Through gel filtration and co-immunoprecipitation experiments, we found that TRF1 and TRF2 are in fact subunits of a telomere-associated high molecular weight complex (telosome) that also contains POT1, PTOP, RAP1, and TIN2. We demonstrated that the TRF1-interacting protein TIN2 binds TRF2 directly and in vivo, thereby bridging TRF2 to TRF1. Consistent with this multi-protein telosome model, stripping TRF1 off the telomeres by expressing tankyrase reduced telomere recruitment of not only TIN2 but also TRF2. These results help to unify previous observations and suggest that telomere maintenance depends on the multi-subunit telosome.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine	Songyang, Z (corresponding author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	songyang@bcm.tmc.edu						Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; Chiang YJ, 2004, MOL CELL BIOL, V24, P6631, DOI 10.1128/mcb.24.15.6631-6634.2004; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dubrana K, 2001, CURR OPIN CELL BIOL, V13, P281, DOI 10.1016/S0955-0674(00)00210-6; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Iwano T, 2004, J BIOL CHEM, V279, P1442, DOI 10.1074/jbc.M309138200; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; O'Connor MS, 2004, J BIOL CHEM, V279, P28585, DOI 10.1074/jbc.M312913200; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wei C, 2003, CELL MOL LIFE SCI, V60, P2283, DOI 10.1007/s00018-003-3244-z; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Ye JZS, 2004, NAT GENET, V36, P618, DOI 10.1038/ng1360; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	30	316	339	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51338	51342		10.1074/jbc.M409293200	http://dx.doi.org/10.1074/jbc.M409293200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15383534	hybrid			2022-12-25	WOS:000225355800084
J	Okuda, M; Tanaka, A; Arai, Y; Satoh, M; Okamura, H; Nagadoi, A; Hanaoka, F; Ohkuma, Y; Nishimura, Y				Okuda, M; Tanaka, A; Arai, Y; Satoh, M; Okamura, H; Nagadoi, A; Hanaoka, F; Ohkuma, Y; Nishimura, Y			A novel zinc finger structure in the large subunit of human general transcription factor TFIIE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ELONGATION-FACTOR TFIIS; 2-DIMENSIONAL NMR EXPERIMENTS; INITIATION COMPLEX-FORMATION; TERMINAL DOMAIN; EUCARYAL TRANSCRIPTION; C-13-LABELED PROTEINS; PREINITIATION COMPLEX; BASAL TRANSCRIPTION; SCALAR COUPLINGS	The zinc finger domain in the large subunit of TFIIE (TFIIEalpha) is phylogenetically conserved and is essential for transcription. Here, we determined the solution structure of this domain by using NMR. It consisted of one alpha-helix and five beta-strands, showing novel features distinct from previously determined zinc-binding structures. We created point mutants of TFIIEalpha in this domain and examined their binding abilities to other general transcription factors as well as their transcription activities. Four Zn2+-ligand mutants, in which each of cysteine residues at positions 129, 132, 154, and 157 was replaced by alanine, possessed no transcription activities on a linearized template, whereas, on a supercoiled template, interesting functional asymmetry was observed: although the C-terminal two mutants abolished transcription activity (< 5%), the N-terminal two mutants retained about 20% activities. The N-terminal two mutants bound stronger to the small subunit of TFIIF than the wild type and the C-terminal two mutants were impaired in their binding abilities to the XPB subunits of TFIIH. These suggest that the structural integrity of the zinc finger domain is essential for the TFIIE function, particularly in the transition from the transcription initiation to elongation and the conformational tuning of this domain for appropriate positioning of TFIIF, TFIIH, and polymerase II would be needed depending on the situation and timing.	Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Kihara Mem Yokohama Fdn Advancement Life Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Osaka Univ, Grad Sch Frontier Biosci, Osaka 5650871, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Osaka 5650871, Japan; RIKEN, Cellular Physiol Lab, Wako, Saitama 3510198, Japan	Yokohama City University; Osaka University; Osaka University; RIKEN	Nishimura, Y (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	nisimura@tsurumi.yokohama-cu.ac.jp		Nishimura, Yoshifumi/0000-0002-5148-3458; Okuda, Masahiko/0000-0001-5834-0559				Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; Brunger A.T., 1993, X PLOR VERSION 3 1 S; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chen HT, 2000, PROTEIN SCI, V9, P1743, DOI 10.1110/ps.9.9.1743; Cordier F, 1999, J AM CHEM SOC, V121, P1601, DOI 10.1021/ja983945d; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krichna N.R., 1998, BIOL MAGNETIC RESONA, V16; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUI A, 2000, J BIOMOL NMR, V17, P79; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; MAXON ME, 1994, P NATL ACAD SCI USA, V91, P9529, DOI 10.1073/pnas.91.20.9529; Meinhart A, 2003, J BIOL CHEM, V278, P48267, DOI 10.1074/jbc.M307874200; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; Okamoto T, 1998, J BIOL CHEM, V273, P19866, DOI 10.1074/jbc.273.31.19866; Okuda M, 2000, EMBO J, V19, P1346, DOI 10.1093/emboj/19.6.1346; Olmsted VK, 1998, J BIOL CHEM, V273, P22589, DOI 10.1074/jbc.273.35.22589; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PETERSON MG, 1991, NATURE, V354, P369; Prompers JJ, 1998, J MAGN RESON, V130, P68, DOI 10.1006/jmre.1997.1277; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TONG X, 1995, MOL CELL BIOL, V15, P4735; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; Watanabe T, 2003, MOL CELL BIOL, V23, P2914, DOI 10.1128/MCB.23.8.2914-2926.2003; Yamamoto S, 2001, MOL CELL BIOL, V21, P1, DOI 10.1128/MCB.21.1.1-15.2001; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; Yang J, 2002, EMBO J, V21, P4950, DOI 10.1093/emboj/cdf463; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	53	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51395	51403		10.1074/jbc.M404722200	http://dx.doi.org/10.1074/jbc.M404722200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385556	hybrid			2022-12-25	WOS:000225355800091
J	Sala, A; Campagnoli, M; Perani, E; Romano, A; Labo, S; Monzani, E; Minchiotti, L; Galliano, M				Sala, A; Campagnoli, M; Perani, E; Romano, A; Labo, S; Monzani, E; Minchiotti, L; Galliano, M			Human alpha-1-microglobulin is covalently bound to kynurenine-derived chromophores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; PROTEIN MODIFICATION; ALPHA(1)-MICROGLOBULIN; 3-HYDROXYKYNURENINE; NEUROTOXIN; PRODUCTS; RELEVANCE; OXIDATION; TARGETS; FILTER	alpha-1-Microglobulin carries a set of covalently linked chromophores that give it a peculiar yellow-brown color, fluorescence properties, and both charge and size heterogeneity. In this report it is shown that these features are due to the adducts with the tryptophan metabolite, 3-hydroxykynurenine, and its autoxidation products and that the modification is more pronounced in the protein isolated from urine of hemodialyzed patients. The light yellow amniotic fluid alpha-1-microglobulin acquires the optical properties and charge heterogeneity of the urinary counterpart following incubation with kynurenines. The colored amino acid adducts of urinary and amniotic fluid alpha-1-microglobulins were separated by chromatography after acid hydrolysis and analyzed by mass spectrometry. Human serum albumin samples, native and treated with 3-hydroxykynurenine in the presence of oxygen, were used as a control. The retention times and mass fragmentation products were compared, and a lysyl adduct with hydroxantommathin was identified in the urinary alpha-1-microglobulin and in the modified albumin samples. The more extensive modification of the urinary protein appears to be correlated with uremia, a condition in which the catabolism of tryptophan via the kynurenine pathway is increased, and the consequent rise in the concentration of its derivatives is accompanied by the oxidative processes due to the hemodialysis treatment. The oxidative derivatives of 3-hydroxykynurenine, which are known to act as protein cross-linking agents, are the likely cause of the propensity of urinary alpha-1-microglobulin to form dimers and oligomers. This process, as well as the redox properties of these metabolites, may contribute to the toxic effects of the kynurenine species.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Univ Pavia, Ctr Grandi Strumenti, I-27100 Pavia, Italy; Univ Pavia, Dept Gen Chem, I-27100 Pavia, Italy	University of Pavia; University of Pavia; University of Pavia	Galliano, M (corresponding author), Univ Pavia, Dept Biochem, Viale Taramelli 3B, I-27100 Pavia, Italy.	galliano@unipv.it		MONZANI, ENRICO/0000-0002-8791-6446				Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P172, DOI 10.1016/S0167-4838(00)00157-6; Allhorn M, 2002, BLOOD, V99, P1894, DOI 10.1182/blood.V99.6.1894; Amoresano A, 2000, EUR J BIOCHEM, V267, P2105, DOI 10.1046/j.1432-1327.2000.01217.x; Aquilina JA, 1999, BIOCHEMISTRY-US, V38, P11455, DOI 10.1021/bi990458h; Aquilina JA, 1997, EXP EYE RES, V64, P727, DOI 10.1006/exer.1996.0258; Aquilina JA, 2000, BIOCHEMISTRY-US, V39, P16176, DOI 10.1021/bi001230t; Beaulieu JM, 1999, J CELL BIOL, V147, P531, DOI 10.1083/jcb.147.3.531; Berggard T, 1998, J HISTOCHEM CYTOCHEM, V46, P887, DOI 10.1177/002215549804600803; Berggard T, 1999, PROTEIN SCI, V8, P2611; CHURCHICH JE, 1972, BIOCHIM BIOPHYS ACTA, V285, P91, DOI 10.1016/0005-2795(72)90183-3; ESCRIBANO J, 1991, J BIOL CHEM, V266, P15758; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; GALLIANO M, 1990, P NATL ACAD SCI USA, V87, P8721, DOI 10.1073/pnas.87.22.8721; Garner B, 2000, BBA-PROTEIN STRUCT M, V1476, P265, DOI 10.1016/S0167-4838(99)00234-4; GIANAZZA E, 1985, ELECTROPHORESIS, V6, P332, DOI 10.1002/elps.1150060706; GRUBB A, 1992, CLIN NEPHROL, V38, pS20; Hood BD, 1999, J BIOL CHEM, V274, P32547, DOI 10.1074/jbc.274.46.32547; ISHII T, 1992, ARCH BIOCHEM BIOPHYS, V294, P616, DOI 10.1016/0003-9861(92)90733-D; Iwahashi H, 1997, J CHROMATOGR A, V773, P23, DOI 10.1016/S0021-9673(97)00271-9; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindqvist A, 1999, GENE, V234, P329, DOI 10.1016/S0378-1119(99)00191-2; Liu ZF, 2003, CHEM RES TOXICOL, V16, P901, DOI 10.1021/tx0300030; MENDEZ E, 1986, P NATL ACAD SCI USA, V83, P1472, DOI 10.1073/pnas.83.5.1472; OGAWA T, 1992, NEUROLOGY, V42, P1702, DOI 10.1212/WNL.42.9.1702; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Okuda S, 1996, P NATL ACAD SCI USA, V93, P12553, DOI 10.1073/pnas.93.22.12553; Pawlak D, 2003, J PHYSIOL PHARMACOL, V54, P175; Pawlak D., 2001, International Urology and Nephrology, V33, P399, DOI 10.1023/A:1015238418500; PEARSON SJ, 1992, NEUROSCI LETT, V144, P199, DOI 10.1016/0304-3940(92)90749-W; Salier JP, 2000, BBA-PROTEIN STRUCT M, V1482, P25, DOI 10.1016/S0167-4838(00)00144-8; SARDAR AM, 1995, J NEUROCHEM, V64, P932; Schwarcz R, 2002, J PHARMACOL EXP THER, V303, P1, DOI 10.1124/jpet.102.034439; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; TRUSCOTT RJW, 1994, FEBS LETT, V348, P173, DOI 10.1016/0014-5793(94)00601-6; Tyagi S, 2004, J BIOL CHEM, V279, P29308, DOI 10.1074/jbc.M402017200; Vazquez S, 2000, FREE RADICAL RES, V32, P11, DOI 10.1080/10715760000300021; Vazquez S, 2002, J BIOL CHEM, V277, P4867, DOI 10.1074/jbc.M107529200; Vazquez S, 2001, J AM SOC MASS SPECTR, V12, P786, DOI 10.1016/S1044-0305(01)00255-0	40	30	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51033	51041		10.1074/jbc.M408242200	http://dx.doi.org/10.1074/jbc.M408242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452109	hybrid			2022-12-25	WOS:000225355800048
J	Gu, F; Nguyen, DT; Stuible, M; Dube, N; Tremblay, ML; Chevet, E				Gu, F; Nguyen, DT; Stuible, M; Dube, N; Tremblay, ML; Chevet, E			Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ER STRESS; INSULIN SENSITIVITY; CELL-DEATH; KINASE; ATF6; GENE; DEPHOSPHORYLATION; TRANSCRIPTION; ACTIVATION	Protein-tyrosine phosphatase 1B (PTP-1B) is the prototypic tyrosine phosphatase whose function in insulin signaling and metabolism is well established. Although the role of PTP-1B in dephosphorylating various cell surface receptor tyrosine kinases is clear, the mechanisms by which it modulates receptor function from the endoplasmic reticulum (ER) remains an enigma. Here, we provide evidence that PTP-1B has an essential function in regulating the unfolded protein response in the ER compartment. The absence of PTP-1B caused impaired ER stress-induced IRE1 signaling. More specifically, JNK activation, XBP-1 splicing, and EDEM (ER degradation-enhancing alpha-mannosidase-like protein) gene induction, as well as ER stress-induced apoptosis, were attenuated in PTP-1B knock-out mouse embryonic fibroblasts in response to two ER stressors, tunicamycin and azetidine-2 carboxylic acid. We demonstrate that PTP-1B is not just a passive resident of the ER but on the contrary has an essential role in potentiating IRE1-mediated ER stress signaling pathways.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Royal Victoria Hosp, Dept Surg, Organelle Signaling Lab, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; Royal Victoria Hospital	Tremblay, ML (corresponding author), McGill Univ, Ctr Canc, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	Michel.Tremblay@mcgill.ca; Eric.Chevet@mcgill.ca	Longo, Kenneth A/A-5631-2010; chevet, eric/E-4992-2016	chevet, eric/0000-0001-5855-4522				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Gu F, 2003, MOL CELL BIOL, V23, P3753, DOI 10.1128/MCB.23.11.3753-3762.2003; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Romsicki Y, 2004, J BIOL CHEM, V279, P12868, DOI 10.1074/jbc.M309600200; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	29	163	172	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49689	49693		10.1074/jbc.C400261200	http://dx.doi.org/10.1074/jbc.C400261200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15465829	hybrid			2022-12-25	WOS:000225229500019
J	Minami, T; Horiuchi, K; Miura, M; Abid, MR; Takabe, W; Noguchi, N; Kohro, T; Ge, XJ; Aburatani, H; Hamakubo, T; Kodama, T; Aird, WC				Minami, T; Horiuchi, K; Miura, M; Abid, MR; Takabe, W; Noguchi, N; Kohro, T; Ge, XJ; Aburatani, H; Hamakubo, T; Kodama, T; Aird, WC			Vascular endothelial growth factor-and thrombin-induced termination factor, down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED T-CELLS; DEPENDENT TRANSCRIPTIONAL PATHWAY; GLYCOGEN-SYNTHASE KINASE-3; NUCLEAR-FACTOR; ADHESION MOLECULE-1; STRIATED-MUSCLES; TYROSINE KINASE; CYCLOSPORINE-A; POTENTIAL ROLE	Activation and dysfunction of the endothelium underlie many vascular disorders including atherosclerosis, tumor growth, and inflammation. Endothelial cell activation is mediated by many different extra-cellular signals, which result in overlapping yet distinct patterns of gene expression. Here we show, in DNA microarray analyses, that vascular endothelial growth factor ( VEGF) and thrombin result in dramatic and rapid upregulation of Down syndrome critical region (DSCR)-1 gene encoding exons 4 - 7, a negative feedback regulator of calcium-calcineurin-NF-AT signaling. VEGF- and thrombin-mediated induction of DSCR-1 involves the cooperative binding of NF-ATc and GATA-2/3 to neighboring consensus motifs in the upstream promoter. Constitutive expression of DSCR-1 in endothelial cells markedly impaired NF-ATc nuclear localization, proliferation, and tube formation. Under in vivo conditions, overexpression of DSCR-1 reduced vascular density in matrigel plugs and melanoma tumor growth in mice. Taken together, these findings support a model in which VEGF- and thrombin-mediated induction of endothelial cell proliferation triggers a negative feedback loop consisting of DSCR-1 gene induction and secondary inhibition of NF-AT signaling. As a natural brake in the angiogenic process, this negative pathway may lend itself to therapeutic manipulation in pathological states.	Univ Tokyo, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Mol & Vasc Med, Boston, MA 02215 USA	University of Tokyo; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Minami, T (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan.	minami@med.rcast.u-tokyo.ac.jp; kodama@lsbm.org	Ge, Xijin/AAP-6237-2021; Ge, Steven/ABF-1186-2021; 興梠, 貴英/F-9724-2012	Ge, Steven/0000-0001-7406-3782; HORIUCHI, KEIKO/0000-0003-4811-5133				Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Boss V, 1998, MOL PHARMACOL, V54, P264, DOI 10.1124/mol.54.2.264; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; COCKERILL GW, 1995, BLOOD, V86, P2689; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Hesser BA, 2004, BLOOD, V104, P149, DOI 10.1182/blood-2004-01-0273; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Isner JM, 1999, NAT MED, V5, P491, DOI 10.1038/8374; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; Minami T, 2004, J BIOL CHEM, V279, P20626, DOI 10.1074/jbc.M308730200; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wang YL, 2002, AM J PHYSIOL-HEART C, V283, pH533, DOI 10.1152/ajpheart.00002.2002; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Yellaturu CR, 2002, BIOCHEM J, V368, P183, DOI 10.1042/BJ20020347	45	189	195	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50537	50554		10.1074/jbc.M406454200	http://dx.doi.org/10.1074/jbc.M406454200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15448146	hybrid			2022-12-25	WOS:000225229500119
J	Peshenko, IV; Olshevskaya, EV; Dizhoor, AM				Peshenko, IV; Olshevskaya, EV; Dizhoor, AM			Ca2+-dependent conformational changes in guanylyl cyclase-activating protein 2 (GCAP-2) revealed by site-specific phosphorylation and partial proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING PROTEINS; CALCIUM-CONCENTRATION; 3-DIMENSIONAL STRUCTURE; PHOTORECEPTORS; BINDING; KINASE; RECOVERIN; PHOSDUCIN; RODS; PHOTOTRANSDUCTION	Guanylyl cyclase-activating proteins (GCAPs) are calcium sensor proteins of the EF-hand superfamily that inhibit retinal photoreceptor membrane guanylyl cyclase (retGC) in the dark when they bind Ca2+ but activate retGC when Ca2+ dissociates from GCAPs in response to light stimulus. We addressed the difference in exposure of GCAP-2 structure to protein kinase and a protease as indicators of conformational change caused by binding and release of Ca2+. We have found that unlike its homolog, GCAP-1, the C terminus of GCAP-2 undergoes phosphorylation by cyclic nucleotide-dependent protein kinases (CNDPK) present in the retinal extract and rapid dephosphorylation by the protein phosphatase PP2C present in the retina. Inactivation of the CNDPK phosphorylation site in GCAP-2 by substitutions S201G or S201D, as well as phosphorylation or thiophosphorylation of Ser(201), had little effect on the ability of GCAP-2 to regulate retGC in reconstituted membranes in vitro. At the same time, Ca2+ strongly inhibited phosphorylation of the wild-type GCAP-2 by retinal CNDPK but did not affect phosphorylation of a constitutively active Ca2+-insensitive GCAP-2 mutant. Partial digestion of purified GCAP-2 with Glu-C protease revealed at least two sites that become exposed or constrained in a Ca2+-sensitive manner. The Ca2+-dependent conformational changes in GCAP-2 affect the areas around Glu(62) residue in the entering helix of EF-hand 2, the areas proximal to the exiting helix of EF-hand 3, and Glu(136)-Glu(138) between EF-hand 3 and EF-hand 4. These changes also cause the release of the C-terminal Ser(201) from the constraint caused by the Ca2+-bound conformation.	Penn Coll Optometry, Hafter Res Labs, Elkins Pk, PA 19027 USA		Dizhoor, AM (corresponding author), Penn Coll Optometry, Hafter Res Labs, 8360 Old York Rd, Elkins Pk, PA 19027 USA.	adizhoor@pco.edu		Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER; NEI NIH HHS [EY11522] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 2002, ADV EXP MED BIOL, V514, P333; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Aparicio JG, 1996, J BIOL CHEM, V271, P27083, DOI 10.1074/jbc.271.43.27083; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; Burgoyne RD, 2001, BIOCHEM J, V353, P1; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; Dizhoor AM, 2000, CELL SIGNAL, V12, P711, DOI 10.1016/S0898-6568(00)00134-0; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; Ermilov AN, 2001, J BIOL CHEM, V276, P48143, DOI 10.1074/jbc.M107539200; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Gamm DM, 2000, INVEST OPHTH VIS SCI, V41, P2766; GERGELY P, 1976, BIOCHIM BIOPHYS ACTA, V429, P809, DOI 10.1016/0005-2744(76)90327-2; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Hughes RE, 1998, PROTEIN SCI, V7, P2675, DOI 10.1002/pro.5560071222; Hurley JB, 2000, METHOD ENZYMOL, V315, P708; Klumpp S, 1998, J NEUROSCI RES, V51, P328, DOI 10.1002/(SICI)1097-4547(19980201)51:3<328::AID-JNR6>3.0.CO;2-I; Krylov DM, 1999, J BIOL CHEM, V274, P10833, DOI 10.1074/jbc.274.16.10833; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; LEE RH, 1990, J BIOL CHEM, V265, P15860; Li N, 2001, BIOL CHEM, V382, P1179, DOI 10.1515/BC.2001.148; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; Olshevskaya EV, 1999, J BIOL CHEM, V274, P25583, DOI 10.1074/jbc.274.36.25583; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; Olshevskaya EV, 1999, J BIOL CHEM, V274, P10823, DOI 10.1074/jbc.274.16.10823; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; PAGHROEHL K, 1995, J NEUROSCI, V15, P6475; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Peshenko IV, 2004, J BIOL CHEM, V279, P16903, DOI 10.1074/jbc.C400065200; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sampath AP, 1999, J GEN PHYSIOL, V113, P267, DOI 10.1085/jgp.113.2.267; Sokal I, 2001, J BIOL CHEM, V276, P43361, DOI 10.1074/jbc.M103614200; Sokal I, 1999, J BIOL CHEM, V274, P19829, DOI 10.1074/jbc.274.28.19829; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Tucker CL, 1997, BIOCHEMISTRY-US, V36, P11995, DOI 10.1021/bi971212k; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 2003, J BIOL CHEM, V278, P33150, DOI 10.1074/jbc.M303678200	49	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50342	50349		10.1074/jbc.M408683200	http://dx.doi.org/10.1074/jbc.M408683200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15448139	hybrid			2022-12-25	WOS:000225229500098
J	Schonfeld, C; Wobbe, L; Borgstadt, R; Kienast, A; Nixon, PJ; Kruse, O				Schonfeld, C; Wobbe, L; Borgstadt, R; Kienast, A; Nixon, PJ; Kruse, O			The nucleus-encoded protein MOC1 is essential for mitochondrial light acclimation in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION FACTOR; DOMINANT SELECTABLE MARKER; STATE TRANSITIONS; ALTERNATIVE OXIDASE; PLANT-MITOCHONDRIA; ELECTRON-TRANSFER; GENE-EXPRESSION; PHOTOSYSTEM-I; COMPLEX-I; DNA	Mitochondrial respiration plays an important role in optimizing photosynthetic efficiency in plants. As yet, the mechanisms by which plant mitochondria sense and respond to changes in the environment are unclear, particularly when exposed to light. Here we describe the characterization of the Chlamydomonas reinhardtii mutant stm6, which was identified on the basis of impaired state transitions, a mechanism that regulates light harvesting in the chloroplast. The gene disrupted in stm6, termed Moc1, encodes a homologue of the human mitochondrial transcription termination factor (mTERF). MOC1 is targeted to the mitochondrion, and its expression is up-regulated in response to light. Loss of MOC1 causes a high light-sensitive phenotype and disrupts the transcription and expression profiles of the mitochondrial respiratory complexes causing, as compared with wild type, light-mediated changes in the expression levels of nuclear and mitochondrial encoded cytochrome c oxidase subunits and ubiquinone-NAD subunits. The absence of MOC1 leads to a reduction in the levels of cytochrome c oxidase and of rotenone-insensitive external NADPH dehydrogenase activities of the mitochondrial respiratory electron transfer chain. Overall, we have identified a novel mitochondrial factor that regulates the composition of the mitochondrial respiratory chain in the light so that it can act as an effective sink for reductant produced by the chloroplast.	Univ Bielefeld, Mol Cell Physiol Grp, Dept Biol, D-33501 Bielefeld, Germany; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England	University of Bielefeld; Imperial College London	Kruse, O (corresponding author), Univ Bielefeld, Mol Cell Physiol Grp, Dept Biol, D-33501 Bielefeld, Germany.	olaf.kruse@uni-bielefeld.de	Kruse, Olaf/O-1127-2015	Nixon, Peter/0000-0003-1952-6937; Kruse, Olaf/0000-0001-9874-382X				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; Baurain D, 2003, PLANT PHYSIOL, V131, P1418, DOI 10.1104/pp.013409; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; Cardol P, 2003, PLANT PHYSIOL, V133, P2010, DOI 10.1104/pp.103.028076; DAGA A, 1993, J BIOL CHEM, V268, P8123; DAY A, 1988, EMBO J, V7, P1917, DOI 10.1002/j.1460-2075.1988.tb03029.x; de Vitry C, 1999, PLANT CELL, V11, P2031, DOI 10.1105/tpc.11.10.2031; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; Depege N, 2003, SCIENCE, V299, P1572, DOI 10.1126/science.1081397; Duby F, 1999, PLANT CELL, V11, P115; Dutilleul C, 2003, PLANT PHYSIOL, V131, P264, DOI 10.1104/pp.011155; Dyer T. A., 1981, The biochemistry of plants. A comprehensive treatise. Volume 6. Proteins and nucleic acids., P111; FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066; Finazzi G, 2002, EMBO REP, V3, P280, DOI 10.1093/embo-reports/kvf047; Finazzi G, 1999, BBA-BIOENERGETICS, V1413, P117, DOI 10.1016/S0005-2728(99)00089-4; Fleischmann MM, 1999, J BIOL CHEM, V274, P30987, DOI 10.1074/jbc.274.43.30987; Flugge UI, 1998, CURR OPIN PLANT BIOL, V1, P201, DOI 10.1016/S1369-5266(98)80105-2; GANS P, 1995, BBA-BIOENERGETICS, V1228, P51, DOI 10.1016/0005-2728(94)00159-3; GRAY MW, 1988, PHILOS T R SOC B, V319, P135, DOI 10.1098/rstb.1988.0038; GU JY, 1993, PLANT CELL, V5, P963, DOI 10.1105/tpc.5.8.963; Gumpel Nicola J., 1994, Trends in Cell Biology, V4, P299, DOI 10.1016/0962-8924(94)90222-4; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Hoefnagel MHN, 1998, BBA-BIOENERGETICS, V1366, P235, DOI 10.1016/S0005-2728(98)00126-1; HORTON P, 1981, FEBS LETT, V125, P193, DOI 10.1016/0014-5793(81)80716-8; Huertas IE, 2002, PLANT PHYSIOL, V130, P284, DOI 10.1104/pp.004598; HUSIC DW, 1987, P NATL ACAD SCI USA, V84, P1555, DOI 10.1073/pnas.84.6.1555; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; KROMER S, 1991, PLANT PHYSIOL, V95, P1270, DOI 10.1104/pp.95.4.1270; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; Kruse O, 1999, PHOTOSYNTH RES, V61, P43, DOI 10.1023/A:1006229308606; LAMATTINA L, 1993, EUR J BIOCHEM, V217, P831, DOI 10.1111/j.1432-1033.1993.tb18311.x; Lown FJ, 2001, BIOCHEM SOC T, V29, P452, DOI 10.1042/BST0290452; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Michalecka AM, 2004, PLANT J, V37, P415, DOI 10.1046/j.1365-313X.2003.01970.x; Michalecka AM, 2003, PLANT PHYSIOL, V133, P642, DOI 10.1104/pp.103.024208; Michel KP, 1999, MICROBIOL-SGM, V145, P1473, DOI 10.1099/13500872-145-6-1473; Millar AH, 1996, FEBS LETT, V398, P155, DOI 10.1016/S0014-5793(96)01230-6; Millenaar FF, 2003, PLANT BIOLOGY, V5, P2, DOI 10.1055/s-2003-37974; MURATA N, 1969, BIOCHIM BIOPHYS ACTA, V172, P242, DOI 10.1016/0005-2728(69)90067-X; NELSON JAE, 1994, MOL CELL BIOL, V14, P4011, DOI 10.1128/MCB.14.6.4011; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Nurani G, 1997, PLANT MOL BIOL, V35, P973, DOI 10.1023/A:1005878614878; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; Polosa PL, 1999, NUCLEIC ACIDS RES, V27, P1890, DOI 10.1093/nar/27.8.1890; PURTON S, 1995, EUR J PHYCOL, V30, P141, DOI 10.1080/09670269500650901; Raghavendra AS, 2003, TRENDS PLANT SCI, V8, P546, DOI 10.1016/j.tplants.2003.09.015; RASMUSSON AG, 1991, PHYSIOL PLANTARUM, V83, P357, DOI 10.1111/j.1399-3054.1991.tb00106.x; REBEILLE F, 1988, PLANT PHYSIOL, V88, P973, DOI 10.1104/pp.88.4.973; Rintamaki E, 2000, P NATL ACAD SCI USA, V97, P11644, DOI 10.1073/pnas.180054297; Roberti M, 2003, NUCLEIC ACIDS RES, V31, P1597, DOI 10.1093/nar/gkg272; Selwood SP, 2000, BIOCHEM SOC T, V28, P154, DOI 10.1042/bst0280154; SINGH DP, 1995, PHOTOCHEM PHOTOBIOL, V62, P314, DOI 10.1111/j.1751-1097.1995.tb05274.x; Snyders S, 2001, J BIOL CHEM, V276, P32169, DOI 10.1074/jbc.M102539200; Stevens DR, 1996, MOL GEN GENET, V251, P23; Strauss C, 2001, PHOTOSYNTH RES, V70, P311, DOI 10.1023/A:1014713612509; Svensson AS, 2001, PLANT J, V28, P73, DOI 10.1046/j.1365-313X.2001.01128.x; TAM LW, 1993, GENETICS, V135, P375; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; Vener AV, 1999, BIOCHEMISTRY-US, V38, P14955, DOI 10.1021/bi990971v; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623; Zerges W, 1998, J CELL BIOL, V140, P101, DOI 10.1083/jcb.140.1.101; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961; Zottini M, 2002, FEBS LETT, V515, P75, DOI 10.1016/S0014-5793(02)02438-9	66	78	78	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50366	50374		10.1074/jbc.M408477200	http://dx.doi.org/10.1074/jbc.M408477200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15448140	hybrid			2022-12-25	WOS:000225229500101
J	Vedhachalam, C; Liu, LJ; Nickel, M; Dhanasekaran, P; Anantharamaiah, GM; Lund-Katz, S; Rothblat, GH; Phillips, MC				Vedhachalam, C; Liu, LJ; Nickel, M; Dhanasekaran, P; Anantharamaiah, GM; Lund-Katz, S; Rothblat, GH; Phillips, MC			Influence of ApoA-I structure on the ABCA1-mediated efflux of cellular lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; REVERSE CHOLESTEROL TRANSPORT; C-TERMINAL DOMAIN; PLASMA-MEMBRANE MICROSOLUBILIZATION; AMPHIPATHIC HELICAL PEPTIDES; BINDING; ABCA1; AFFINITY; HDL	The influence of apolipoprotein (apo) A-I structure on ABCA1-mediated efflux of cellular unesterified (free) cholesterol (FC) and phospholipid (PL) is not well understood. To address this issue, we used a series of apoA-I mutants to examine the contributions of various domains in the molecule to ABCA1-mediated FC and PL efflux from mouse J774 macrophages and human skin fibroblasts. Irrespective of the cell type, deletion or disruption of the C-terminal lipid-binding domain of apoA-I drastically reduced the FC and PL efflux (similar to90%), indicating that the C-terminal amphipathic alpha-helix is required for high affinity microsolubilization of FC and PL. Deletion in the N-terminal region of apoA-I also reduced the lipid efflux (similar to30%) and increased the K-m about 2-fold compared with wild type apoA-I, whereas deletion of the central domain (Delta123-166) had no effect on either K-m or V-max. These results indicate that ABCA1-mediated lipid efflux is relatively insensitive to the organization of the apoA-I N-terminal helix-bundle domain. Alterations in apoA-I structure caused parallel changes in its ability to bind to a PL bilayer and to induce efflux of FC and PL. Overall, these results are consistent with a two-step model for ABCA1-mediated lipid efflux. In the first step, apoA-I binds to ABCA1 and hydrophobic alpha-helices in the C-terminal domain of apoA-I insert into the region of the perturbed PL bilayer created by the PL transport activity of ABCA1, thereby allowing the second step of lipidation of apoA-I and formation of nascent high density lipoprotein particles to occur.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Div GI Nutr,Abramson Res Ctr, Philadelphia, PA 19104 USA; Univ Alabama, Dept Med Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Arteriosclerosis Res Unit, Birmingham, AL 35294 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Phillips, MC (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Div GI Nutr,Abramson Res Ctr, Suite 1102,3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	Phillipsmi@email.chop.edu		Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brewer HB, 2003, AM J CARDIOL, V91, p3E, DOI 10.1016/S0002-9149(02)03382-9; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; Chroni A, 2004, BIOCHEMISTRY-US, V43, P2126, DOI 10.1021/bi035813p; Chroni A, 2003, J BIOL CHEM, V278, P6719, DOI 10.1074/jbc.M205232200; Favari E, 2002, BIOCHEM BIOPH RES CO, V299, P801, DOI 10.1016/S0006-291X(02)02745-6; Fitzgerald ML, 2004, J LIPID RES, V45, P287, DOI 10.1194/jlr.M300355-JLR200; Gillotte KL, 1998, J LIPID RES, V39, P1918; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Gillotte-Taylor K, 2002, J BIOL CHEM, V277, P11811, DOI 10.1074/jbc.M108268200; Liu LJ, 2003, J BIOL CHEM, V278, P42976, DOI 10.1074/jbc.M308420200; Lund-Katz S, 2003, FRONT BIOSCI-LANDMRK, V8, pD1044, DOI 10.2741/1077; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; Natarajan P, 2004, J BIOL CHEM, V279, P24044, DOI 10.1074/jbc.M400561200; Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Oram JF, 1996, J LIPID RES, V37, P2473; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Rader DJ, 2003, AM J CARDIOL, V92, p42J, DOI 10.1016/S0002-9149(03)00615-5; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Rye KA, 2004, ARTERIOSCL THROM VAS, V24, P421, DOI 10.1161/01.ATV.0000104029.74961.f5; Saito H, 2004, J BIOL CHEM, V279, P20974, DOI 10.1074/jbc.M402043200; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; Schulman BA, 1996, NAT STRUCT BIOL, V3, P682, DOI 10.1038/nsb0896-682; Schultz Joshua R., 1994, Current Opinion in Lipidology, V5, P126, DOI 10.1097/00041433-199404000-00009; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; Sviridov D, 2002, ATHEROSCLEROSIS, V161, P245, DOI 10.1016/S0021-9150(01)00677-3; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD	41	71	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49931	49939		10.1074/jbc.M406924200	http://dx.doi.org/10.1074/jbc.M406924200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383537	hybrid			2022-12-25	WOS:000225229500048
J	Perry, E; Tsruya, R; Levitsky, P; Pomp, O; Taller, M; Weisberg, S; Parris, W; Kulkarni, S; Malovani, H; Pawson, T; Shpungin, S; Nir, U				Perry, E; Tsruya, R; Levitsky, P; Pomp, O; Taller, M; Weisberg, S; Parris, W; Kulkarni, S; Malovani, H; Pawson, T; Shpungin, S; Nir, U			TMF/ARA160 is a BC-box-containing protein that mediates the degradation of Stat3	ONCOGENE			English	Article						TMF/AR160; Stat3; ubiquitination; degradation	TYROSINE KINASE FER; ELEMENT MODULATORY FACTOR; IN-VIVO; CARCINOMA CELLS; UBIQUITIN; PHOSPHORYLATION; INDUCTION; NUCLEAR; COMPLEX; GROWTH	TMF/ARA160 is a Golgi resident protein whose cellular functions have not been conclusively revealed. Herein we show that TMF/ARA160 can direct the proteasomal degradation of the key cell growth regulator-Stat3. TMF/ARA160 was dispersed in the cytoplasm of myogenic C2C12 cells that were grown under low-serum conditions. The cytoplasmic distribution of TMF/ARA160 was accompanied by its transient association with the tyrosine kinase Fer and with Stat3, which underwent proteasomal degradation under those conditions. Moreover, serum deprivation induced the association of ubiquitinated proteins, with the TMF/ARA160 complex. However, TMF/ARA160 did not bind Stat1, whose cellular levels were increased in serum-starved C2C12 cells. Amino-acid sequence analysis identified a BC-box element in TMF/ARA160 that mediated the binding of this protein to elongin C. Ectopic expression of TMF/ARA160 in serum-starved C2C12 cells drove the ubiquitination and proteasomal degradation of Stat3, an effect that was not caused by TMF/ARA160 devoid of the BC-box motif. Thus, the Golgi apparatus harbors a novel BC-box-containing protein that can direct Stat3 to proteasomal degradation. Interestingly, the level of TMF/ARA160 was significantly decreased in malignant brain tumors, implying a suppressive role of that protein in tumor progression.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Rabin Med Ctr, Dept Oncol, Petah Tiqwa, Israel; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Bar Ilan University; Rabin Medical Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Nir, U (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	nir@mail.biu.ac.il						Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Ben-Dor I, 1999, CELL GROWTH DIFFER, V10, P113; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chapman JR, 1999, MOL UROL, V3, P11; Colanzi A, 2003, CURR OPIN CELL BIOL, V15, P462, DOI 10.1016/S0955-0674(03)00067-X; Conaway JW, 1998, BBA-REV CANCER, V1377, pM49, DOI 10.1016/S0304-419X(97)00035-8; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Daino H, 2000, BLOOD, V95, P2577; DEAN BL, 1990, RADIOLOGY, V174, P411, DOI 10.1148/radiology.174.2.2153310; DEPREZ RHL, 1995, J NEUROPATH EXP NEUR, V54, P224, DOI 10.1097/00005072-199503000-00009; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Fridmann-Sirkis Y, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-18; GARCIA JA, 1992, P NATL ACAD SCI USA, V89, P9372, DOI 10.1073/pnas.89.20.9372; Halachmy S, 1997, ONCOGENE, V14, P2871, DOI 10.1038/sj.onc.1201145; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kamura Takumi, 2002, Prog Mol Subcell Biol, V29, P1; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; Kronfeld-Kinar Y, 1999, CELL GROWTH DIFFER, V10, P201; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; LETWIN K, 1988, ONCOGENE, V3, P621; Lu ZM, 2001, MOL BIOL CELL, V12, P795, DOI 10.1091/mbc.12.4.795; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Magrassi L, 1999, J NEUROSURG, V91, P440, DOI 10.3171/jns.1999.91.3.0440; Mori K, 2002, FEBS LETT, V520, P127, DOI 10.1016/S0014-5793(02)02803-X; Orlovsky K, 2000, BIOCHEMISTRY-US, V39, P11084, DOI 10.1021/bi0005153; Orlovsky K, 2002, ONCOGENE, V21, P4997, DOI 10.1038/sj.onc.1205624; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Priel-Halachmi S, 2000, J BIOL CHEM, V275, P28902, DOI 10.1074/jbc.M003402200; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5; Schwartz Y, 1998, FEBS LETT, V434, P339, DOI 10.1016/S0014-5793(98)01003-5; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Taler M, 2003, MOL ENDOCRINOL, V17, P1580, DOI 10.1210/me.2002-0328; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Weisberg S, 2001, AM J PATHOL, V159, P1193, DOI 10.1016/S0002-9440(10)62504-7; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.neuro.11.1.423; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhou YH, 2001, ONCOLOGY-BASEL, V60, P330, DOI 10.1159/000058529	55	46	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8908	8919		10.1038/sj.onc.1208149	http://dx.doi.org/10.1038/sj.onc.1208149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467733				2022-12-25	WOS:000225354600006
J	Hughey, RP; Bruns, JB; Kinlough, CL; Kleyman, TR				Hughey, RP; Bruns, JB; Kinlough, CL; Kleyman, TR			Distinct pools of epithelial sodium channels are expressed at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; NA+ CHANNEL; SUBUNIT STOICHIOMETRY; SERINE PROTEASES; XENOPUS-OOCYTES; GAMMA-SUBUNIT; A6 CELLS; ENAC; ACTIVATION; FURIN	The epithelial Na+ channel ( ENaC) is assembled in the endoplasmic reticulum from three structurally related subunits (alpha, beta, and gamma). Channel maturation within the biosynthetic pathway involves cleavage of the alpha and gamma subunits by furin and processing of N-linked glycans on alpha, beta, and gamma to complex type. Both mature and immature subunits have been observed at the surface of stably transfected Madin-Darby canine kidney cells. We have examined whether channel maturation is an all-or-none event or whether heterogeneous processing of channel subunits occurs within an individual channel complex. Using an immobilized lectin to isolate proteins with complex type N-glycans, we found that individual channel complexes with mature subunits lack immature subunits. Furthermore, terminal processing of N-glycans on ENaC subunits was not dependent on cleavage of ENaC subunits, and proteolysis of channel subunits was not dependent on prior processing of N-glycans. Our results suggest that processing of subunits within an individual channel complex is an all-or-none event such that channels present on the cell surface contain either all mature or all immature subunits. The presence of immature channel complexes at the plasma membrane provides epithelial cells with a reserve of poorly functional channels that can be activated by proteases in post-Golgi compartments.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kleyman, TR (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054787, R01DK054354, R01DK065161, R56DK065161] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK65161, DK54354, DK54787] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Baldwin TA, 2002, J BIOL CHEM, V277, P50333, DOI 10.1074/jbc.M209075200; Bonnon C, 2003, J BIOL CHEM, V278, P48339, DOI 10.1074/jbc.M309120200; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Deryugina EI, 2004, TRAFFIC, V5, P627, DOI 10.1111/j.1600-0854.2004.00206.x; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Guipponi M, 2002, HUM MOL GENET, V11, P2829, DOI 10.1093/hmg/11.23.2829; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kobata A, 2000, GLYCOCONJUGATE J, V17, P443, DOI 10.1023/A:1011006122704; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rossier Bernard C, 2004, Proc Am Thorac Soc, V1, P4, DOI 10.1513/pats.2306007; Shah N, 2003, BIOCHEMISTRY-US, V42, P13812, DOI 10.1021/bi034742r; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Weisz OA, 2003, AM J PHYSIOL-RENAL, V285, pF833, DOI 10.1152/ajprenal.00088.2003; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200	34	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48491	48494		10.1074/jbc.C400460200	http://dx.doi.org/10.1074/jbc.C400460200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15466477	hybrid			2022-12-25	WOS:000225098100003
J	Wiederhold, T; Lee, MF; James, M; Neujahr, R; Smith, N; Murthy, A; Hartwig, J; Gusella, JF; Ramesh, V				Wiederhold, T; Lee, MF; James, M; Neujahr, R; Smith, N; Murthy, A; Hartwig, J; Gusella, JF; Ramesh, V			Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2	ONCOGENE			English	Article						NF2; merlin; tumor suppressor; Grb2; cytoskeleton	ALDRICH-SYNDROME PROTEIN; HUMAN SCHWANNOMA CELLS; TYPE-2 GENE-PRODUCT; NEUROFIBROMATOSIS TYPE-2; TERMINAL DOMAIN; SH3 DOMAINS; F-ACTIN; N-WASP; NHE-RF; MEMBRANE	Neurofibromatosis 2 (NF2) is a dominantly inherited disorder characterized by bilateral vestibular schwannomas and meningiomas. Merlin, the neurofibromatosis 2 tumor suppressor protein, is related to the ERM ( ezrin, radixin, moesin) proteins and, like its family members, is thought to play a role in plasma membrane-cytoskeletal interactions. We report a novel protein as a merlin-specific binding partner that we have named magicin ( merlin and Grb2 interacting cytoskeletal protein) and show that the two proteins interact in vitro and in vivo as well as colocalize beneath the plasma membrane. Magicin is a 24 kDa protein that is expressed in many cell lines and tissues. Magicin, similar to merlin, associates with the actin cytoskeleton as determined by cofractionation, immunofluorescence and electron microscopy. Analysis of the magicin sequence reveals binding motifs for the adaptor protein Grb2. Employing affinity binding, blot overlay and co-immunoprecipitation assays, we demonstrate an interaction between Grb2 and magicin. In addition, merlin is capable of forming a ternary complex with magicin and Grb2. These results support a role for merlin in receptor-mediated signaling at the cell surface, and may have implications in the regulation of cytoskeletal reorganization.	Massachusetts Gen Hosp, Mol Neurosci Unit, Charlestown, MA 02129 USA; Brigham & Womens Hosp, Div Expt Med, Longwood Med Res Ctr, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Ramesh, V (corresponding author), Massachusetts Gen Hosp, Mol Neurosci Unit, Bldg 149,13th St,Rm6222, Charlestown, MA 02129 USA.	ramesh@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Brault E, 2001, J CELL SCI, V114, P1901; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gronholm M, 2003, J BIOL CHEM, V278, P41167, DOI 10.1074/jbc.M306149200; Gronholm M, 1999, J CELL SCI, V112, P895; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; JANNATIPOUR M, 2001, J BIOL CHEM, V29, P29; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Liu CH, 2002, BIOCHEM BIOPH RES CO, V290, P602, DOI 10.1006/bbrc.2001.6119; Maeda M, 1999, ONCOGENE, V18, P4788, DOI 10.1038/sj.onc.1202871; Mayer BJ, 2001, J CELL SCI, V114, P1253; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Neill GW, 2001, BIOCHEM J, V358, P727, DOI 10.1042/0264-6021:3580727; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Stokowski RP, 2000, AM J HUM GENET, V66, P873, DOI 10.1086/302812; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251	47	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8815	8825		10.1038/sj.onc.1208110	http://dx.doi.org/10.1038/sj.onc.1208110			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467741				2022-12-25	WOS:000225165100011
J	Irimia, M; Fraga, MF; Sanchez-Cespedes, M; Esteller, M				Irimia, M; Fraga, MF; Sanchez-Cespedes, M; Esteller, M			CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer	ONCOGENE			English	Article						K-ras; methylation; NORE1A; lung cancer	TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; EPIGENETIC INACTIVATION; CELL-LINES; MUTATIONS; METHYLATION; RASSF1A; IDENTIFICATION; TUMORIGENESIS; PROTEIN	Imbalance of the Ras signaling pathway is a major hallmark of human cancer. In this context, activating point mutations of the K-ras oncogene are a common feature of many tumor types. The discovery of methylation-mediated silencing of the Ras-effector homologue RASSF1A has revealed another way by which this cellular pathway may be altered. Inactivation by hypermethylation of a RASSF1A homologue, NORE1A, has recently been observed in human cancers. If both K-ras and NORE1A act in the same pathway, simultaneous molecular lesions in the two genes in the same tumor should be a rare event. To test whether this inverse association exists, we have analysed the K-ras mutational status and NORE1A CpG island hypermethylation of 61 non-small-cell lung carcinomas and the methylation status of the two other Ras effectors, RASSF1A and HRASLS. No association was found between the methylation status of NORE1A, RASSF1A and HRASLS or the status of K-ras with respect to the latter two genes. However, our results demonstrate that the epigenetic alteration of NORE1A is confined to lung tumors with a wild-type K-ras: 88% (15 of 17) of the tumors with NORE1 hypermethylation did not harbor a K-ras mutation (P=0.008, Fisher's exact test). Thus, the mutual exclusivity of the epigenetic and genetic alterations in the two genes of the Ras pathway suggests that they play a critical and cooperative role in human tumorigenesis.	Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, Madrid 28029, Spain; Spanish Natl Canc Ctr CNIO, Lung Canc Res Grp, Mol Pathol Program, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Esteller, M (corresponding author), Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	Sanchez-Cespedes, Montse/H-8485-2012; Irimia, Manuel/E-3040-2010; Esteller, Manel/L-5956-2014; Fraga, Mario F/H-7824-2017	Sanchez-Cespedes, Montse/0000-0002-6045-5627; Irimia, Manuel/0000-0002-2179-2567; Esteller, Manel/0000-0003-4490-6093; Fraga, Mario F/0000-0001-8450-2603				Akiyama H, 1999, J BIOL CHEM, V274, P32192, DOI 10.1074/jbc.274.45.32192; AOYAMA Y, 2004, ONCOGENE        0308; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Dammann R, 2003, ONCOGENE, V22, P3806, DOI 10.1038/sj.onc.1206582; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 2001, CANCER RES, V61, P2816; Esteller M, 2000, CANCER RES, V60, P129; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Ito H, 2001, CYTOGENET CELL GENET, V93, P36, DOI 10.1159/000056944; Kaneda A, 2002, CANCER RES, V62, P6645; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim DH, 2003, CANCER RES, V63, P6206; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Ramirez JL, 2003, CANCER LETT, V193, P207, DOI 10.1016/S0304-3835(02)00740-1; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Schimanski CC, 1999, CANCER RES, V59, P5169; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Sparks AB, 1998, CANCER RES, V58, P1130; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242; Zhu Kuichun, 2003, Curr Opin Investig Drugs, V4, P1428	37	45	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8695	8699		10.1038/sj.onc.1207914	http://dx.doi.org/10.1038/sj.onc.1207914			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15378027				2022-12-25	WOS:000224988800016
J	Muyrers-Chen, I; Rozovskaia, T; Lee, N; Kersey, JH; Nakamura, T; Canaani, E; Paro, R				Muyrers-Chen, I; Rozovskaia, T; Lee, N; Kersey, JH; Nakamura, T; Canaani, E; Paro, R			Expression of leukemic MLL fusion proteins in Drosophila affects cell cycle control and chromosome morphology	ONCOGENE			English	Article						Mixed -Lineage Leukemia; trithorax; chromatin; Drosophila	ALL-1 GENE; TRITHORAX; TRANSLOCATIONS; DOMAINS; LINEAGE; MUTANTS; MICE; METHYLTRANSFERASE; PHENOTYPES; HOMOLOG	The Mixed Lineage Leukemia (MLL) gene is involved in lymphoblastic and myeloid leukemia through chromosome translocations leading to fusion of MLL to partner genes, or through internal MLL rearrangements. MLL is the mammalian counterpart of the Drosophila trithorax (trx) gene, involved in maintaining active gene expression states. We have used transgenic Drosophila to assess the molecular targets and cellular processes affected by MLL and two of its leukemic fusion proteins. We find that whereas expression of normal human MLL in flies does not result in phenotypic alterations, overexpressing the human MLL-AF9 and MLL-AF4 proteins causes larval to pupal lethality, which interestingly resembles the phenotypes displayed by certain Drosophila trx mutant alleles. MLL-AF9 and MLL-AF4 transgenic flies exhibit antagonistic alterations in cell cycle progression. Additionally, flies expressing MLL-AF9 display impairment in higher order chromatin integrity, evidenced in decondensation of mitotic figures. The effects of MLL fusion proteins in Drosophila suggest that alteration of chromatin structure by MLL fusion proteins may contribute to the lethal phenotype. Our results indicate that the mode(s) of action of MLL-AF9 in Drosophila varies from that of MLL-AF4. Taken together, the expression of MLL fusion proteins in Drosophila provides a new and powerful system to reveal and characterize biological activities associated with MLL fusion proteins.	Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany; Weizmann Inst Sci, IL-76100 Rehovot, Israel; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Ruprecht Karls University Heidelberg; Weizmann Institute of Science; University of Minnesota System; University of Minnesota Twin Cities; Jefferson University	Paro, R (corresponding author), Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany.	paro@sun0.urz.uni-heidelberg.de						Asha H, 2003, GENETICS, V163, P203; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bernardoni R, 1997, DEV BIOL, V191, P118; BRAND AH, 1993, DEVELOPMENT, V118, P401; BREEN TR, 1993, DEVELOPMENT, V117, P119; Breen TR, 1999, GENETICS, V152, P319; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; Collins EC, 2002, MOL CELL BIOL, V22, P7313, DOI 10.1128/MCB.22.20.7313-7324.2002; Collins EC, 2002, TRENDS MOL MED, V8, P436, DOI 10.1016/S1471-4914(02)02397-3; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CRONMILLER C, 1993, MECH DEVELOP, V42, P159, DOI 10.1016/0925-4773(93)90005-I; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HIDALGO A, 1995, DEVELOPMENT, V121, P3703; Isnard P, 2000, BLOOD, V96, P705; Ito K, 1997, DEVELOPMENT, V124, P761; Kimbrell DA, 2002, GENESIS, V34, P23, DOI 10.1002/gene.10134; Krause SA, 2001, MOL CELL BIOL, V21, P5156, DOI 10.1128/MCB.21.15.5156-5168.2001; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Loupart ML, 2000, CURR BIOL, V10, P1547, DOI 10.1016/S0960-9822(00)00844-7; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MURRAY MA, 1995, DEV BIOL, V168, P150, DOI 10.1006/dbio.1995.1068; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Pflumm MF, 2001, DEVELOPMENT, V128, P1697; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; WILDER EL, 1995, DEVELOPMENT, V121, P477; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	39	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8639	8648		10.1038/sj.onc.1207904	http://dx.doi.org/10.1038/sj.onc.1207904			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15378024				2022-12-25	WOS:000224988800010
J	Enkvetchakul, D; Bhattacharyya, J; Jeliazkova, I; Groesbeck, DK; Cukras, CA; Nichols, CG				Enkvetchakul, D; Bhattacharyya, J; Jeliazkova, I; Groesbeck, DK; Cukras, CA; Nichols, CG			Functional characterization of a prokaryotic Kir channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNELS; POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; PH; RECTIFICATION; MECHANISM	The Kir gene family encodes inward rectifying K+ ( Kir) channels that are widespread and critical regulators of excitability in eukaryotic cells. A related gene family (KirBac) has recently been identified in prokaryotes. While a crystal structure of one member, KirBac1.1, has been solved, there has been no functional characterization of any KirBac gene products. Here we present functional characterization of KirBac1.1 reconstituted in liposomes. Utilizing a Rb-86(+) uptake assay, we demonstrate that KirBac1.1 generates a K+-selective permeation path that is inhibited by extraliposomal Ba2+ and Ca2+ ions. In contrast to KcsA ( an acid-activated bacterial potassium channel), KirBac1.1 is inhibited by extraliposomal acid (pK(a) similar to 6). This characterization of KirBac1.1 activity now paves the way for further correlation of structure and function in this model Kir channel.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Renal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	cnichols@cellbio.wustl.edu	Nichols, Colin/D-6336-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK060086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54171, R01 HL054171] Funding Source: Medline; NIDDK NIH HHS [K08 DK060086, DK60086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bevans CG, 1999, J BIOL CHEM, V274, P3711, DOI 10.1074/jbc.274.6.3711; Bhattacharyya J, 2003, BIOPHYS J, V84, p78A; Bichet D, 2003, NAT REV NEUROSCI, V4, P957, DOI 10.1038/nrn1244; Casamassima M, 2003, J BIOL CHEM, V278, P43533, DOI 10.1074/jbc.M306596200; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 2001, BMC EVOL BIOL, V1, DOI 10.1186/1471-2148-1-14; Enkvetchakul D, 2003, J GEN PHYSIOL, V122, P471, DOI 10.1085/jgp.200308878; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; HILLE B, 1992, ION CHANNELS EXCITAB, P352; Jiang C, 2002, TRENDS CARDIOVAS MED, V12, P5, DOI 10.1016/S1050-1738(01)00132-3; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jin WL, 1998, BIOCHEMISTRY-US, V37, P13291, DOI 10.1021/bi981178p; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Ruta V, 2003, NATURE, V422, P180, DOI 10.1038/nature01473; Sackin H, 2003, BIOPHYS J, V84, P910, DOI 10.1016/S0006-3495(03)74908-X; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Schulte U, 2000, EUR J BIOCHEM, V267, P5837, DOI 10.1046/j.1432-1327.2000.01671.x; Thompson GA, 2000, J PHYSIOL-LONDON, V526, P231, DOI 10.1111/j.1469-7793.2000.00231.x; Wu JP, 2002, J PHYSIOL-LONDON, V543, P495, DOI 10.1113/jphysiol.2002.025247	26	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47076	47080		10.1074/jbc.C400417200	http://dx.doi.org/10.1074/jbc.C400417200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15448150	hybrid, Green Accepted			2022-12-25	WOS:000224832400093
J	Xu, XM; Wang, D; Shen, Q; Chen, YQ; Wang, MH				Xu, XM; Wang, D; Shen, Q; Chen, YQ; Wang, MH			RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells	ONCOGENE			English	Article						colon cancer; oncogenic phenotype; receptor tyrosine kinase; RNA interference	MACROPHAGE-STIMULATING PROTEIN; SPLICING VARIANT; POINT MUTATIONS; INVASIVE GROWTH; TUMOR-FORMATION; BETA-CATENIN; C-MET; IDENTIFICATION; EXPRESSION; CANCER	Altered expression of receptor tyrosine kinases contributes to tumorigenic behaviors of epithelial cancers. In this study, the pathogenic roles of receptor tyrosine kinase RON (recepteur d'origine nantais) in regulating oncogenic phenotypes in colorectal epithelial cells were studied. Increased expression of RON and its variants resulted in colony formation and motile activities of colonic epithelial AA/C1 cells as evident in soft-agar and migration assays, respectively. These results suggest that overexpression of wild-type RON mediates the transformed phenotypes in immortalized colon epithelial cells. In colorectal cancer cells (HT-29, HCT116, and SW620) that naturally express RON, the RON gene expression was silenced by RNA interference. The introduction of RON-specific small interfering ( si) RNA significantly affected cancer cell proliferation, motility, and led to increased apoptotic cell death. Focus-forming activities and anchorage-independent growth of colon cancer cells were also dramatically reduced. Moreover, it was demonstrated in tumor growth assays that silencing RON gene expression significantly reduces tumorigenic activities of SW620 cells in vivo. By analysing signaling proteins involved in colon carcinogenesis, we found that the effect of RON-specific siRNA is associated with diminished expression of beta-catenin, a critical component in the Wnt signaling pathway. Taken together, our results demonstrate that altered expression of RON in colon cancer cells is required to maintain tumorigenic phenotypes. Thus, silencing RON gene expression could have potential to reverse malignant activities of colon tumors in vivo.	Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA; Zhejiang Univ, Coll Med, Affiliated Hosp 1,Inst Infect Dis, Lab Cheung Kong Scholars Program Biomed Sci, Hangzhou 310027, Peoples R China	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Zhejiang University	Wang, MH (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 1300 S Coulter Dr, Amarillo, TX 79106 USA.	minghai.wang@ttuhsc.edu			NCI NIH HHS [R01 CA91980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Bright-Thomas RM, 2003, EUR J SURG ONCOL, V29, P107, DOI 10.1053/ejso.2002.1331; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Chen YQ, 2002, CARCINOGENESIS, V23, P1811, DOI 10.1093/carcin/23.11.1811; Chen YQ, 2002, ONCOGENE, V21, P6382, DOI 10.1038/sj.onc.1205783; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Crawford J., 1994, GASTROINTESTINAL TRA; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Dorudi Sina, 1993, Current Opinion in Oncology, V5, P130; Earp H Shelton 3rd, 2003, Trans Am Clin Climatol Assoc, V114, P315; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kinzler KW, 1998, GENETIC BASIS HUMAN, P565; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Montero-Julian FA, 1998, HYBRIDOMA, V17, P541, DOI 10.1089/hyb.1998.17.541; Okino T, 1999, INT J ONCOL, V15, P709; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Portera CA, 1998, SURG ONCOL, V7, P183, DOI 10.1016/S0960-7404(99)00020-1; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WILLIAMS AC, 1990, CANCER RES, V50, P4724; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	45	61	72	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8464	8474		10.1038/sj.onc.1207907	http://dx.doi.org/10.1038/sj.onc.1207907			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378025				2022-12-25	WOS:000224870700007
J	Liu, YM; Lu, CH; Shen, Q; Munoz-Medellin, D; Kim, H; Brown, PH				Liu, YM; Lu, CH; Shen, Q; Munoz-Medellin, D; Kim, H; Brown, PH			AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity	ONCOGENE			English	Article						AP-1; breast cancer; proliferation; apoptosis	DOMINANT-NEGATIVE MUTANT; C-JUN; RETINOIC-ACID; DISTINCT MECHANISMS; E OVEREXPRESSION; FAMILY-MEMBERS; APOPTOSIS; GROWTH; D1; ACTIVATION	The AP-1 transcription factor is a central component of signal transduction pathways in many cells, although the exact role of AP-1 in controlling cell growth and malignant transformation is unknown. We have previously shown that AP-1 complexes are activated by peptide and steroid growth factors in both normal and malignant breast cells, and that blocking AP-1 by overexpressing a dominant-negative form of cJun (cJun-DN, TAM67) inhibits breast cancer cell growth both in vivo and in vitro. We hypothesized that TAM67 inhibits cell growth by altering the expression of cell cycle regulatory proteins, thus causing a cell cycle block. In the present study, we used clones of MCF7 breast cancer cells that express TAM67 under the control of an inducible promoter. First, we determined the effect of AP-1 blockade on cell growth, then we performed H-3-thymidine incorporation and flow cytometry assays to investigate whether TAM67 inhibits the cell cycle. We observed that in the presence of serum TAM67 inhibited cell growth and caused a block in the G1 phase of the cell cycle. Next, we performed Western-blotting and CDK kinase assays to determine the effects of TAM67 on retinoblastoma (Rb) phosphorylation, the expression of cell cycle regulatory proteins, and CDK activity. We discovered that TAM67 inhibited Rb phosphorylation and reduced E2F activity. We also found that TAM67 decreased the expression of D and E cyclins, reduced CDK2 and CDK4 activity, and increased the CDK inhibitor p27. The studies of gene expression at the RNA level showed that TAM67 decreased cyclin Ds mRNA expression. Our study suggests that in the presence of serum, TAM67 inhibits breast cancer growth predominantly by inducing inhibitors of cyclin-dependent kinases ( such as p27) and by reducing the expression of the cyclins involved in transitioning from G1 into S phase of the cell cycle. These studies lay the foundation for future attempt to develop new agents for the treatment and prevention of breast cancer.	Baylor Coll Med, Baylor Breast Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Baylor Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio	Brown, PH (corresponding author), Baylor Coll Med, Baylor Breast Ctr, Dept Med, 1 Baylor Plaza,MS 600, Houston, TX 77030 USA.	pbrown@breastcenter.tmc.edu		Shen, Qiang/0000-0002-1491-5434; Brown, Powel/0000-0002-3398-163X				Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hennigan RF, 2001, MOL BIOL CELL, V12, P2352, DOI 10.1091/mbc.12.8.2352; HERBER, 1994, ONCOGENE, V9, P2105; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Kim HK, 2001, EUR J SURG ONCOL, V27, P464, DOI 10.1053/ejso.2001.1137; Lin F, 2000, CANCER RES, V60, P3271; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Preston GA, 1996, MOL CELL BIOL, V16, P211; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Sauter ER, 1999, CANCER RES, V59, P4876; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHULE R, 1991, COLD SH Q B, V56, P119; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SMITH MJ, 1992, BLOOD, V79, P2107; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang LM, 1997, CANCER RES, V57, P4652; Yang LM, 2001, ONCOGENE, V20, P8025, DOI 10.1038/sj.onc.1204911; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhao BH, 1997, MOL CARCINOGEN, V19, P180, DOI 10.1002/(SICI)1098-2744(199707)19:3<180::AID-MC6>3.3.CO;2-O	38	56	60	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8238	8246		10.1038/sj.onc.1207889	http://dx.doi.org/10.1038/sj.onc.1207889			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378019				2022-12-25	WOS:000224749500006
J	Mura, C; Le Gac, G; Jacolot, S; Ferec, C				Mura, C; Le Gac, G; Jacolot, S; Ferec, C			Transcriptional regulation of the human HFE gene indicates high liver expression and erythropoiesis coregulation	FASEB JOURNAL			English	Article						HFE promoter; iron homeostasis; hemochromatosis	TRANSFERRIN RECEPTOR; IRON OVERLOAD; HEREDITARY HEMOCHROMATOSIS; MESSENGER-RNA; HLA-H; MUTATIONS; PROTEIN; PHENOTYPE; MOUSE; ABSORPTION	The human HFE gene is clearly involved in hereditary hemochromatosis, a common autosomal recessive genetic disorder of iron homeostasis. However, the precise role of the HFE protein is still undefined. Here, to obtain new insight, we analyzed the transcriptional regulation of HFE gene and defined the functional organization of the HFE promoter. Both in vitro transcription and reporter gene assay in transient transfection evidenced a high liver expression of the HFE mRNA. The 5' end analysis of mRNA showed two major initiation sites localized at - 265 and 195 directed by TATA-like sequences and a window of initiation within the - 120 to - 10 GC-rich region upstream of the first coding nucleotide. Positive cis-regulating elements were characterized within the - 1057/ -8 region, and a negative one extending upstream ( -1485/ -1057) was identified. DNase I footprinting analysis and gel shift assay revealed several protein binding sites, and subsequent functional analysis evidenced transactivation of HFE by liver-enriched C/EBPalpha, erythropoietic-specific GATA-1, and ubiquitous Sp1 transcription factors. These data bring some evidence of a role of HFE in the liver and a coregulation with erythropoiesis as other genes involved in iron homeostasis.	INSERM, U613, F-29200 Brest, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale	Mura, C (corresponding author), INSERM, U613, UBO 46 Rue Felix Le Dantec, F-29200 Brest, France.	Catherine.Mura@univ-brest.fr	Ferec, Claude/ABG-9699-2020; Le Gac, Gérald/AFQ-1679-2022	Ferec, Claude/0000-0002-2325-0710; LE GAC, Gerald/0000-0003-3236-7280				AIRD WC, 1994, J BIOL CHEM, V269, P883; Ajioka RS, 2002, BLOOD, V100, P1465, DOI 10.1182/blood-2001-11-0037; AUGERON C, 1984, CANCER RES, V44, P3961; Barton JC, 1999, BLOOD CELL MOL DIS, V25, P146; Beutler E, 1997, AM J HUM GENET, V61, P762; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534; Carella M, 1997, AM J HUM GENET, V60, P828; Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7; de Villiers JNP, 1999, HUM MOL GENET, V8, P1517, DOI 10.1093/hmg/8.8.1517; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming RE, 2000, P NATL ACAD SCI USA, V97, P2214, DOI 10.1073/pnas.040548097; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Grover J, 2000, J BIOL CHEM, V275, P40967, DOI 10.1074/jbc.M004134200; Holmstrom P, 2003, J HEPATOL, V39, P308, DOI 10.1016/S0168-8278(03)00293-9; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kawabata H, 2001, BLOOD, V98, P1949, DOI 10.1182/blood.V98.6.1949; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LANS MS, 1994, J BIOL CHEM, V269, P14170; Le Gac G, 2003, BLOOD CELL MOL DIS, V30, P231, DOI 10.1016/S1079-9796(03)00036-6; Levy JE, 2000, J CLIN INVEST, V105, P1209, DOI 10.1172/JCI9635; Mattman A, 2002, BLOOD, V100, P1075, DOI 10.1182/blood-2002-01-0133; MCLAREN GD, 1991, J LAB CLIN MED, V117, P390; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468; Mura C, 1999, BLOOD, V93, P2502, DOI 10.1182/blood.V93.8.2502.408k27_2502_2505; Mura C, 1997, HUM GENET, V101, P271, DOI 10.1007/s004390050628; Njajou OT, 2001, NAT GENET, V28, P213, DOI 10.1038/90038; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Piperno A, 2000, GASTROENTEROLOGY, V119, P441, DOI 10.1053/gast.2000.9369; Pointon JJ, 2000, GENET TEST, V4, P151, DOI 10.1089/10906570050114867; Ponka P, 1997, BLOOD, V89, P1; POWELL LW, 1970, GUT, V11, P727, DOI 10.1136/gut.11.9.727; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Riedel HD, 1999, BLOOD, V94, P3915, DOI 10.1182/blood.V94.11.3915.423k27_3915_3921; Risch N, 1997, NAT GENET, V17, P375, DOI 10.1038/ng1297-375; Roetto A, 2001, BLOOD, V97, P2555, DOI 10.1182/blood.V97.9.2555; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; Salter-Cid L, 1999, P NATL ACAD SCI USA, V96, P5434, DOI 10.1073/pnas.96.10.5434; Sanchez M, 1998, GENE, V225, P77, DOI 10.1016/S0378-1119(98)00519-8; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; TUGORES A, 1994, J BIOL CHEM, V269, P30789; Wallace DF, 2002, J HEPATOL, V36, P474, DOI 10.1016/S0168-8278(01)00304-X; Wallace DF, 1999, GASTROENTEROLOGY, V116, P1409, DOI 10.1016/S0016-5085(99)70505-6; Zhang AS, 2004, BLOOD, V103, P1509, DOI 10.1182/blood-2003-07-2378; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	52	20	23	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1922	+		10.1096/fj.04-2520fje	http://dx.doi.org/10.1096/fj.04-2520fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15467009				2022-12-25	WOS:000224849900028
J	Mandolesi, G; Madeddu, F; Bozzi, Y; Maffei, L; Ratto, GM				Mandolesi, G; Madeddu, F; Bozzi, Y; Maffei, L; Ratto, GM			Acute physiological response of mammalian central neurons to axotomy: ionic regulation and electrical activity	FASEB JOURNAL			English	Article						calcium; imaging; membrane potential; patch clamp; regeneration; trauma	SPINAL-CORD-INJURY; WHITE-MATTER INJURY; SODIUM-CALCIUM EXCHANGE; TRAUMATIC AXONAL INJURY; RETINAL GANGLION-CELLS; IN-VITRO; HIPPOCAMPAL-NEURONS; NA+-CA2+ EXCHANGER; GENE-EXPRESSION; NEURITE TRANSECTION	The transection of the axon of central neurons has dramatic consequences on the damaged cells and nerves. Injury activates molecular programs leading to a complex repertoire of responses that, depending on the cellular context, include activation of sprouting, axonal degeneration, and cell death. Although the cellular mechanisms started at the time of lesion are likely to shape the changes affecting injured cells, the acute physiological reaction to trauma of mammalian central neurons is not completely understood yet. To characterize the physiology of the acute response to axonal transection, we have developed a model of in vitro axotomy of neurons cultured from the rodent cortex. Imaging showed that axotomy caused an increase of calcium in the soma and axon. Propagation of the response to the soma required the activation of voltage-dependent sodium channels, since it was blocked by tetrodotoxin. The electrophysiological response to axotomy was recorded in patched neurons kept in the current clamp configuration: injury was followed by vigorous spiking activity that caused a sodium load and the activation of transient calcium currents that were opened by each action potential. The decrease of the electrochemical gradient of sodium caused inversion of the Na-Ca exchanger that provided an additional mean of entry for calcium. Finally, we determined that inhibition of the physiological response to axotomy hindered the regeneration of a new neurite. These data provide elements of the framework required to link the axotomy itself to the downstream molecular machinery that contributes to the determination of the long-term fate of injured neurons and axons.	CNR, Inst Neurosci, I-56100 Pisa, Italy; Scuola Normale Super Pisa, I-56100 Pisa, Italy; IRCCS Santa Lucia Fdn, I-00179 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); Scuola Normale Superiore di Pisa; IRCCS Santa Lucia	Ratto, GM (corresponding author), CNR, Inst Neurosci, I-56100 Pisa, Italy.	gimmi@in.cnr.it	Ratto, Gian Michele/AAX-8514-2020; Mandolesi, Georgia/G-6595-2011; Ratto, Gian Michele/AAB-8719-2021	Ratto, Gian Michele/0000-0001-9632-7769; Mandolesi, Georgia/0000-0003-3612-6820				Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 2000, NEUROSCIENCE, V99, P179, DOI 10.1016/S0306-4522(00)00165-2; Ambron RT, 1996, MOL NEUROBIOL, V13, P61, DOI 10.1007/BF02740752; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bradke F, 2000, CURR BIOL, V10, P1467, DOI 10.1016/S0960-9822(00)00807-1; Brown AM, 2001, J NEUROPHYSIOL, V85, P900, DOI 10.1152/jn.2001.85.2.900; Buki A, 2000, J NEUROSCI, V20, P2825; CACERES A, 1986, J NEUROSCI, V6, P714; Caroni P, 1997, BIOESSAYS, V19, P767, DOI 10.1002/bies.950190906; Caroni P, 1998, ESSAYS BIOCHEM, V33, P53, DOI 10.1042/bse0330053; Chu GKT, 2001, NEUROSCIENCE, V102, P945, DOI 10.1016/S0306-4522(00)00514-5; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Deisseroth K, 2002, NEURON, V34, P179, DOI 10.1016/S0896-6273(02)00664-5; Diamond JS, 1997, J NEUROSCI, V17, P4672; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; DOTTI CG, 1987, NATURE, V330, P254, DOI 10.1038/330254a0; Eddleman CS, 1998, NEUROSCI LETT, V256, P123, DOI 10.1016/S0304-3940(98)00709-5; Eddleman CS, 2000, BIOPHYS J, V79, P1883, DOI 10.1016/S0006-3495(00)76438-1; FAWCETT JW, 1992, TRENDS NEUROSCI, V15, P5, DOI 10.1016/0166-2236(92)90338-9; Fishman HM, 2003, NEWS PHYSIOL SCI, V18, P115, DOI 10.1152/nips.01429.2002; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; GILL A, 1992, AM J CARDIOL, V69, pD11; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; Godell CM, 1997, P NATL ACAD SCI USA, V94, P4751, DOI 10.1073/pnas.94.9.4751; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Goldberg JL, 2002, NEURON, V33, P689, DOI 10.1016/S0896-6273(02)00602-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanz S, 2003, NEURON, V40, P1095, DOI 10.1016/S0896-6273(03)00770-0; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 1998, BIOMETALS, V11, P345, DOI 10.1023/A:1009257909785; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hayashi K, 2002, NEUROSCIENCE, V110, P7, DOI 10.1016/S0306-4522(01)00592-9; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Lehning EJ, 1996, J NEUROCHEM, V66, P493; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Lin H, 2003, J NEUROBIOL, V57, P204, DOI 10.1002/neu.10275; Liu XZ, 1997, J NEUROSCI, V17, P5395; LoPachin RM, 1999, J NEUROPHYSIOL, V82, P2143, DOI 10.1152/jn.1999.82.5.2143; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Lusardi TA, 2003, BIORHEOLOGY, V40, P401; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Perlson E, 2004, J NEUROBIOL, V58, P287, DOI 10.1002/neu.10316; Perlson E, 2004, MOL CELL PROTEOMICS, V3, P510, DOI 10.1074/mcp.M400004-MCP200; RABACCHI SA, 1994, J NEUROSCI, V14, P5292; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; REHDER V, 1992, NEUROSCIENCE, V51, P565, DOI 10.1016/0306-4522(92)90296-E; Rose CR, 1996, J PHYSIOL-LONDON, V491, P291, DOI 10.1113/jphysiol.1996.sp021216; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Rosenberg LJ, 2001, J NEUROSCI RES, V66, P191, DOI 10.1002/jnr.1211; Rutherford LC, 1997, J NEUROSCI, V17, P4527; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sattler R, 1996, BRAIN RES, V719, P239, DOI 10.1016/0006-8993(96)00125-4; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763, DOI 10.1152/jn.2000.84.4.1763; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Steffensen I, 1997, BRAIN RES, V776, P1, DOI 10.1016/S0006-8993(97)00868-8; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; STYS PK, 1992, J NEUROSCI, V12, P430; Teng YD, 1997, J NEUROSCI, V17, P4359; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Vanhoutte P, 2003, CURR OPIN NEUROBIOL, V13, P366, DOI 10.1016/S0959-4388(03)00073-4; Verbny Y, 2002, J NEUROPHYSIOL, V88, P802, DOI 10.1152/jn.2002.88.2.802; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; XIE XY, 1991, J NEUROSCI, V11, P3257; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yu SP, 1997, EUR J NEUROSCI, V9, P1273, DOI 10.1111/j.1460-9568.1997.tb01482.x; Zhang XP, 2000, J NEUROBIOL, V45, P84, DOI 10.1002/1097-4695(20001105)45:2<84::AID-NEU3>3.0.CO;2-4; Ziv NE, 1997, J NEUROSCI, V17, P3568	75	74	74	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1934	+		10.1096/fj.04-1805fje	http://dx.doi.org/10.1096/fj.04-1805fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15451889				2022-12-25	WOS:000224243200009
J	Van Laethem, A; Van Kelst, S; Lippens, S; Declercq, W; Vandenabeele, P; Janssens, S; Vandenheede, JR; Garmyn, M; Agostinis, P				Van Laethem, A; Van Kelst, S; Lippens, S; Declercq, W; Vandenabeele, P; Janssens, S; Vandenheede, JR; Garmyn, M; Agostinis, P			Activation of p38 MAPK is required for Bax translocation to mitochondria, cytochrome c release and apoptosis induced by UVB irradiation in human keratinocytes	FASEB JOURNAL			English	Article						skin equivalents; skin organ cultures; photocarcinogenesis; HaCaT cells	RADIATION-INDUCED APOPTOSIS; ULTRAVIOLET-B RADIATION; EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE; CELL-DEATH; INDEPENDENT PATHWAY; RECEPTOR ACTIVATION; PHOSPHORYLATION; BCL-2; PROMOTES	This study establishes that activation of p38 MAPK by UVB represents a crucial signal required for the conformational change and translocation of Bax to the mitochondria in human keratinocytes. UVB-induced Bax translocation and mitochondrial cytochrome c release, which precede caspase activation and other endpoints of the apoptotic program such as chromatin fragmentation and loss of mitochondrial transmembrane potential, are blocked by genetic or pharmacological inhibition of the p38alpha MAPK. Inhibition of p38 MAPK strongly reduces the UVB-induced formation of sunburn cells and blocks Bax conformational change both in cultured human keratinocytes and in human skin, providing clear evidence for the physiological role of the p38 MAPK-Bax pathway in the removal of precancerous, UVB-damaged keratinocytes. Furthermore, we show that Bcl-2 overexpression, but not the pan-caspase inhibitor zVAD-fmk, blocks Bax conformational change and its subsequent translocation downstream of p38 MAPK. These data indicate that the activation of p38 MAPK by UVB engages a caspase-independent death signal leading to mitochondrial membrane permeabilization and apoptosis in human keratinocytes and suggest that p38 MAPK might have a preventive role in the process of photocarcinogenesis.	Catholic Univ Louvain, Div Biochem, B-3000 Louvain, Belgium; Catholic Univ Louvain, Dermatol Lab, B-3000 Louvain, Belgium; State Univ Ghent VIB, Dept Mol Biomed Res, Ghent, Belgium; Catholic Univ Louvain, Fac Med, Dept Cardiol, B-3000 Louvain, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Flanders Institute for Biotechnology (VIB); Ghent University; Universite Catholique Louvain	Agostinis, P (corresponding author), Catholic Univ Louvain, Div Biochem, Herestr 49, B-3000 Louvain, Belgium.	patricia.agostinis@med.kuleuven.ac.be	Agostinis, Patrizia/AAO-2468-2020; Vandenabeele, Peter/AAD-5793-2022; Lippens, Saskia/C-1343-2009; Vandenabeele, Peter/C-8597-2009; Agostinis, Patrizia/ABI-1177-2020	Vandenabeele, Peter/0000-0002-6669-8822; Agostinis, Patrizia/0000-0003-1314-2115; Lippens, Saskia/0000-0002-8261-3462				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Assefa Z, 2003, FEBS LETT, V540, P125, DOI 10.1016/S0014-5793(03)00238-2; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Bode Ann M, 2003, Sci STKE, V2003, pRE2, DOI 10.1126/stke.2003.167.re2; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deacon K, 2003, MOL BIOL CELL, V14, P2071, DOI 10.1091/mbc.e02-10-0653; DECRAENE D, IN PRESS J INVEST DE; Delehedde M, 2001, J INVEST DERMATOL, V116, P366, DOI 10.1046/j.1523-1747.2001.01260.x; Desbiens KM, 2003, BIOCHEM J, V372, P631, DOI 10.1042/BJ20021565; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; GILCHREST BA, 1983, J INVEST DERMATOL, V81, pS184, DOI 10.1111/1523-1747.ep12541084; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Hildesheim J, 2004, J INVEST DERMATOL, V122, P497, DOI 10.1111/j.1523-1747.2004.22229.x; Hildesheim J, 2002, CANCER RES, V62, P7305; Jost M, 2001, J INVEST DERMATOL, V116, P860, DOI 10.1046/j.1523-1747.2001.01356.x; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Kulms D, 2002, ONCOGENE, V21, P5844, DOI 10.1038/sj.onc.1205743; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li SP, 2003, CANCER RES, V63, P3473; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Muller-Rover S, 2000, AM J PATHOL, V156, P1395, DOI 10.1016/S0002-9440(10)65008-0; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; Nickoloff BJ, 2002, J INVEST DERM SYMP P, V7, P27, DOI 10.1046/j.1523-1747.2002.19633.x; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Paramio JM, 2000, MOL CARCINOGEN, V29, P251, DOI 10.1002/1098-2744(200012)29:4<251::AID-MC1007>3.0.CO;2-O; Pfundt R, 2001, J PATHOL, V193, P248; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Shou Y, 2003, TOXICOL SCI, V75, P99, DOI 10.1093/toxsci/kfg157; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wang XD, 2001, GENE DEV, V15, P2922; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200	55	131	138	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1946	+		10.1096/fj.04-2285fje	http://dx.doi.org/10.1096/fj.04-2285fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15388671	Green Published			2022-12-25	WOS:000224243200013
J	Falasca, C; Perrier, NL; Massoulie, J; Bon, S				Falasca, C; Perrier, NL; Massoulie, J; Bon, S			Determinants of the t peptide involved in folding, degradation, and secretion of acetylcholinesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAINS; QUATERNARY ASSOCIATIONS; ATTACHMENT DOMAIN; CAUDATE-NUCLEUS; DISULFIDE BONDS; MOLECULAR-FORMS; COLLAGEN TAIL; CHOLINESTERASES; SUBUNITS; TORPEDO	The C-terminal 40-residue t peptide of acetylcholinesterase (AChE) forms an amphiphilic alpha helix with a cluster of seven aromatic residues. It allows oligomerization and induces a partial degradation of AChE subunits through the endoplasmic reticulum-associated degradation pathway. We show that the t peptide induces the misfolding of a fraction of AChE subunits, even when mutations disorganized the cluster of aromatic residues or when these residues were replaced by leucines, indicating that this effect is due to hydrophobic residues. Mutations in the aromatic-rich region affected the cellular fate of AChE in a similar manner, with or without mutations that prevented dimerization. Degradation was decreased and secretion was increased when aromatic residues were replaced by leucines, and the opposite occurred when the amphiphilic alpha helix was disorganized. The last two residues (Asp-Leu) somewhat resembled an endoplasmic reticulum retention signal and caused a partial retention but only in mutants possessing aromatic residues in their t peptide. Our results suggested that several "signals" in the catalytic domain and in the t peptide act cooperatively for AChE quality control.	Ecole Normale Super, Neurobiol Cellulaire & Mol Lab, CNRS, UMR 8544, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Bon, S (corresponding author), Ecole Normale Super, Neurobiol Cellulaire & Mol Lab, CNRS, UMR 8544, 46 Rue Ulm, F-75005 Paris, France.	jean.massoulie@biologie.ens.fr						Belbeoc'h S, 2004, EUR J BIOCHEM, V271, P1476, DOI 10.1111/j.1432-1033.2004.04052.x; Belbeoc'h S, 2003, EMBO J, V22, P3536, DOI 10.1093/emboj/cdg360; Bon S, 2004, EUR J BIOCHEM, V271, P33, DOI 10.1046/j.1432-1033.2003.03892.x; Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; BON S, 1988, J NEUROCHEM, V51, P786, DOI 10.1111/j.1471-4159.1988.tb01813.x; Coussen F, 2001, J BIOL CHEM, V276, P27881, DOI 10.1074/jbc.M010817200; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GENNARI K, 1987, J NEUROCHEM, V49, P12, DOI 10.1111/j.1471-4159.1987.tb03386.x; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SL, 1982, J BIOL CHEM, V257, P12282; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; Massoulie J, 1998, J PHYSIOLOGY-PARIS, V92, P183, DOI 10.1016/S0928-4257(98)80007-7; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morel N, 2001, J BIOL CHEM, V276, P37379, DOI 10.1074/jbc.M103192200; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3550, DOI 10.1021/bi00635a008; Rost B, 1996, METHOD ENZYMOL, V266, P525; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELAN B, 1994, J BIOL CHEM, V269, P22719	29	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					878	886		10.1074/jbc.M409201200	http://dx.doi.org/10.1074/jbc.M409201200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15452125	hybrid			2022-12-25	WOS:000226195200006
J	Acharjee, S; Do-Rego, JL; Oh, DY; Ahn, RS; Choe, H; Vaudry, H; Kim, K; Seong, JY; Kwon, HB				Acharjee, S; Do-Rego, JL; Oh, DY; Ahn, RS; Choe, H; Vaudry, H; Kim, K; Seong, JY; Kwon, HB			Identification of amino acid residues that direct differential ligand selectivity of mammalian and nonmammalian V1a type receptors for arginine vasopressin and vasotocin - Insights into molecular coevolution of V1a type receptors and their ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FROG ADRENAL-GLAND; PHARMACOLOGICAL CHARACTERIZATION; SIGNAL-TRANSDUCTION; BINDING DOMAINS; AGONIST; CLONING; ANTAGONIST; ACTIVATION; EXPRESSION; PEPTIDE	Arginine vasotocin (VT) is the ortholog in all nonmammalian vertebrates of arginine vasopressin (AVP) in mammals. We have previously cloned an amphibian V1a-type vasotocin receptor (VT1R) that exhibited higher sensitivity for VT than AVP, while the mammalian V1a type receptor (V1aR) responded better to AVP than VT. In the present study, we identified the amino acid residues that confer differential ligand selectivity for AVP and VT between rat V1aR and bullfrog VT1R (bfVT1R). A chimeric rat V1aR having transmembrane domain (TMD) VI to the carboxyl-terminal tail (C-tail) of bfVT1R showed a reverse ligand preference for AVP and VT, whereas a chimeric VT1R with TMD VI to the C-tail of rat V1aR showed a great increase in sensitivity for AVP. A single mutation (Ile(315(6.53)) to Thr) in TMD VI of V1aR increased the sensitivity for VT, while a single mutation (Phe(313(6.51)) to Tyr or Pro(334(7.33)) to Thr) reduced sensitivity toward AVP. Interestingly the triple mutation (Phe(313(6.51)) to Tyr, Ile(6.53) to Thr, and Pro(7.33) to Thr) of V1aR increased sensitivity to VT but greatly reduced sensitivity to AVP, behaving like bfVT1R. Further, like V1aR, a double mutant (Tyr(306(6.51)) to Phe and Thr(327(7.33)) to Pro) of bfVT1R showed an increased sensitivity to AVP. These results suggest that Phe/Tyr(6.51), Ile/Thr(6.53), and Pro/Thr(7.33) are responsible for the differential ligand selectivity between rat V1aR and bfVT1R. This information regarding the molecular interaction of VT/AVP with their receptors may have important implications for the development of novel AVP analogs.	Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea; Univ Rouen, European Inst Peptide Res IFRMP 23, Lab Cellular & Mol Neuroendocrinol, INSERM,U413, F-76821 Mont St Aignan, France; Univ Ulsan, Coll Med, Dept Physiol, Seoul 138736, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Chonnam National University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; University of Ulsan; Seoul National University (SNU)	Seong, JY (corresponding author), Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea.	jyseong@jnu.ac.kr; kwonhb@jnu.ac.kr	Ahn, Ryun S./D-1218-2011; Seong, Jae Young/A-5794-2012; choe, han/A-5679-2010	Seong, Jae Young/0000-0002-3312-6924; choe, han/0000-0003-4604-647X				Acharjee S, 2004, J MOL ENDOCRINOL, V33, P293, DOI 10.1677/jme.0.0330293; Alescio-Lautier B, 1998, PROG BRAIN RES, V119, P501; Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223; Burbach JPH, 1995, CELL MOL NEUROBIOL, V15, P573, DOI 10.1007/BF02071318; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Chen SH, 1999, J BIOL CHEM, V274, P16320, DOI 10.1074/jbc.274.23.16320; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Cotte N, 2000, EUR J BIOCHEM, V267, P4253, DOI 10.1046/j.1432-1033.2000.01472.x; Dahia PLM, 1996, J CLIN ENDOCR METAB, V81, P1768, DOI 10.1210/jc.81.5.1768; deKeyzer Y, 1996, J CLIN INVEST, V97, P1311, DOI 10.1172/JCI118547; DEWIED D, 1993, FRONT NEUROENDOCRIN, V14, P251, DOI 10.1006/frne.1993.1009; ELALOUF JM, 1986, P NATL ACAD SCI USA, V83, P2276, DOI 10.1073/pnas.83.7.2276; Eugenin EA, 1998, AM J PHYSIOL-GASTR L, V274, pG1109, DOI 10.1152/ajpgi.1998.274.6.G1109; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; GILLIES GE, 1982, NATURE, V299, P355, DOI 10.1038/299355a0; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; GONZALEZ A, 1992, J COMP NEUROL, V315, P53, DOI 10.1002/cne.903150105; Hawtin SR, 2002, MOL ENDOCRINOL, V16, P600, DOI 10.1210/me.16.3.600; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; JOHNSTON CI, 1985, J HYPERTENS, V3, P557, DOI 10.1097/00004872-198512000-00001; Kenakin T, 1996, TRENDS PHARMACOL SCI, V17, P190, DOI 10.1016/0165-6147(96)20026-4; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; LARCHER A, 1989, ENDOCRINOLOGY, V125, P2691, DOI 10.1210/endo-125-5-2691; LARCHER A, 1992, ENDOCRINOLOGY, V130, P475, DOI 10.1210/en.130.1.475; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; Moore FL, 2000, GEN COMP ENDOCR, V117, P281, DOI 10.1006/gcen.1999.7424; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; Oh DY, 2003, MOL CELL ENDOCRINOL, V205, P89, DOI 10.1016/S0303-7207(03)00204-1; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; PANG PKT, 1978, AM J PHYSIOL, V235, pF151, DOI 10.1152/ajprenal.1978.235.2.F151; Phalipou S, 1999, J BIOL CHEM, V274, P23316, DOI 10.1074/jbc.274.33.23316; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; Rose JD, 2002, FRONT NEUROENDOCRIN, V23, P317, DOI 10.1016/S0091-3022(02)00004-3; RUGGLES BT, 1985, J CLIN ENDOCR METAB, V60, P914, DOI 10.1210/jcem-60-5-914; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Seong JY, 2003, ENDOCRINOLOGY, V144, P454, DOI 10.1210/en.2002-220683; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; Tan FI, 2000, BIOL REPROD, V62, P8, DOI 10.1095/biolreprod62.1.8; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; Thibonnier M, 2000, J PHARMACOL EXP THER, V294, P195; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang CB, 2004, MOL ENDOCRINOL, V18, P105, DOI 10.1210/me.2003-0101; WARBURG MR, 1995, ZOOL SCI, V12, P1, DOI 10.2108/zsj.12.1	48	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54445	54453		10.1074/jbc.M408909200	http://dx.doi.org/10.1074/jbc.M408909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475353	hybrid			2022-12-25	WOS:000225793600067
J	Richard, D; Leprohon, P; Drummelsmith, J; Ouellette, M				Richard, D; Leprohon, P; Drummelsmith, J; Ouellette, M			Growth phase regulation of the main folate transporter of Leishmania infantum and its role in methotrexate resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; SYNTHETASE-DIHYDROFOLATE REDUCTASE; VISCERAL LEISHMANIASIS; MEMBRANE-PROTEIN; GENE; AMPLIFICATION; METABOLISM; BIOPTERIN; PURIFICATION; MILTEFOSINE	The protozoan parasite Leishmania relies on the uptake of folate and pterin from the environment to meet its nutritional requirements. We show here that a novel gene ( folate transporter 1 (FT1)) deleted in a Leishmania infantum methotrexate-resistant mutant corresponds to the main folate transporter (K-m, 410 nM). FT1 was established as the main folate transporter by both gene transfection and by targeted gene deletion. Modulation of the expression of FT1 by these manipulations altered the susceptibility of Leishmania cells to methotrexate. Folate transport was stage-regulated with higher activity in the logarithmic phase and less in the stationary phase. FT1 fused to green fluorescent protein led to the observation that FT1 was located in the plasma membrane in the logarithmic phase but was re-targeted to an intracellular organelle followed by a degradation of the protein in stationary phase. Leishmania has several folate transporters with different characteristics, and the growth stage-related activity of at least one transporter is regulated post-translationally.	Univ Laval, Ctr Hosp, Ctr Rech, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Div Microbiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Ouellette, M (corresponding author), CHUQ, Ctr Rech Infectiol, Pavillon CHUL,2705 Boul Laurier, Ste Foy, PQ G1V 4G2, Canada.	Marc.Ouellette@crchul.ulaval.ca	Leprohon, Philippe/U-5474-2019; Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646				CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; Cunningham ML, 2001, MOL BIOCHEM PARASIT, V113, P199, DOI 10.1016/S0166-6851(01)00213-4; Cunningham ML, 2001, SCIENCE, V292, P285, DOI 10.1126/science.1057740; Dodge MA, 2004, MOL MICROBIOL, V51, P1563, DOI 10.1111/j.1365-2958.2003.03927.x; El Fadili A, 2004, J BIOL CHEM, V279, P18575, DOI 10.1074/jbc.M400652200; El Fadili A, 2002, MOL BIOCHEM PARASIT, V124, P63, DOI 10.1016/S0166-6851(02)00163-9; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P10053; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P13501; Ghedin E, 2001, TRAFFIC, V2, P175, DOI 10.1034/j.1600-0854.2001.020304.x; Gilbert IH, 2002, BBA-MOL BASIS DIS, V1587, P249, DOI 10.1016/S0925-4439(02)00088-1; Guimond C, 2003, NUCLEIC ACIDS RES, V31, P5886, DOI 10.1093/nar/gkg806; HARLOW E, 1988, ANTIBODIES LAB MANUA, P377; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; KAUR K, 1988, J BIOL CHEM, V263, P7020; KUMAR HP, 1987, J BIOL CHEM, V262, P7171; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; LEGARE D, 1994, MOL BIOCHEM PARASIT, V68, P81, DOI 10.1016/0166-6851(94)00156-1; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Lemley C, 1999, MOL BIOCHEM PARASIT, V104, P93, DOI 10.1016/S0166-6851(99)00132-2; LO RS, 1991, P ROY SOC B-BIOL SCI, V246, P161, DOI 10.1098/rspb.1991.0139; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; Mullin KA, 2001, MOL BIOL CELL, V12, P2364, DOI 10.1091/mbc.12.8.2364; NARE B, 1997, PARASITOLOGY, V114, P101; Ouellette M, 2002, INT J PARASITOL, V32, P385, DOI 10.1016/S0020-7519(01)00346-0; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; Papadopoulou B, 2002, INFECT IMMUN, V70, P62, DOI 10.1128/IAI.70.1.62-68.2002; PAPADOPOULOU B, 1993, NUCLEIC ACIDS RES, V21, P4305, DOI 10.1093/nar/21.18.4305; Perez-Victoria FJ, 2003, J BIOL CHEM, V278, P49965, DOI 10.1074/jbc.M308352200; Richard D, 2002, J BIOL CHEM, V277, P29460, DOI 10.1074/jbc.M204796200; Roy G, 2001, EXP PARASITOL, V97, P161, DOI 10.1006/expr.2001.4595; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P1168, DOI 10.1128/AAC.45.4.1168-1173.2001; SHANE B, 1975, J BIOL CHEM, V250, P2243; Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Zhao RB, 2003, ONCOGENE, V22, P7431, DOI 10.1038/sj.onc.1206946	40	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54494	54501		10.1074/jbc.M409264200	http://dx.doi.org/10.1074/jbc.M409264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15466466	hybrid			2022-12-25	WOS:000225793600073
J	Guo, DL; Hu, K; Lei, Y; Wang, YC; Ma, TL; He, DC				Guo, DL; Hu, K; Lei, Y; Wang, YC; Ma, TL; He, DC			Identification and characterization of a novel cytoplasm protein ICF45 that is involved in cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA CLONING; SCLERODERMA; SEQUENCE; LOCALIZATION; AUTOANTIBODY; ANTINUCLEAR; CENTROSOME; EXPRESSION; ANTIBODIES; CANCER	A novel cytoplasm protein, interphase cytoplasm foci protein 45 kDa (ICF45), was identified by screening the cDNA expression library for HeLa cells with serum from an autoimmune patient. The complete cDNA sequence of ICF45 was determined to be 1.32 kb and to encode 298 amino acids with an apparent molecular mass of 45 kDa. The ICF45 transcripts were detected in different tissues and were relatively rich in human liver and lung tissues but scarce in brain tissue. Immunofluorescence with anti-ICF45-specific antibodies demonstrated that ICF45 is strongly expressed in interphase and cannot be seen in mitosis. The subcellular localization of ICF45 and fusion proteins GFP-ICF45, ICF45-GFP, and HA-ICF45 showed ICF45 centralized into 1 - 2 dots in the cytoplasm and always near the nuclear membrane. The staining foci of ICF45 appeared to be slightly larger than centrosomes and in some cases were found to colocalize with centrosomes. After effectively silencing the ICF45 by RNAi, the growth and proliferation of the cells were significantly inhibited, and p53 was detected to be up-regulated. The silencing of ICF45 also resulted in an appearance of polycentrosome and multinuclear cells, which finally went to apoptosis. Our results suggest that ICF45 is a highly conserved novel protein, which is expressed in a cell cycle-dependent manner and seemed to be involved in cell cycle progression and cell proliferation.	Beijing Normal Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Regulat Biol, Beijing 100875, Peoples R China; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Beijing Normal University; Fox Chase Cancer Center	He, DC (corresponding author), Beijing Normal Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Regulat Biol, Beijing 100875, Peoples R China.	dhe@bnu.edu.cn	Guo, Deliang/I-3735-2014	Guo, Deliang/0000-0002-8359-390X				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; CHAN EKL, 1992, RHEUM DIS CLIN N AM, V18, P551; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Ditzel HJ, 2000, IMMUNOL RES, V21, P185, DOI 10.1385/IR:21:2-3:185; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; He DC, 1998, CHROMOSOMA, V107, P189, DOI 10.1007/s004120050296; KIPNIS RJ, 1990, ARTHRITIS RHEUM, V33, P1431, DOI 10.1002/art.1780330917; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; POLLARD KM, 1989, CLIN EXP RHEUMATOL, V7, pS57; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHEETS M, 1992, NUCLEIC ACIDS RES, V18, P5799; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Watson M, 1996, ARTHRITIS RHEUM, V39, P341, DOI 10.1002/art.1780390226; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314	25	21	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53498	53505		10.1074/jbc.M406737200	http://dx.doi.org/10.1074/jbc.M406737200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15459185	hybrid			2022-12-25	WOS:000225680600085
J	Corcoran, JA; Syvitski, R; Top, D; Epand, RM; Epand, RF; Jakeman, D; Duncan, R				Corcoran, JA; Syvitski, R; Top, D; Epand, RM; Epand, RF; Jakeman, D; Duncan, R			Myristoylation, a protruding loop, and structural plasticity are essential features of a nonenveloped virus fusion peptide motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; FATTY ACYLATION SITES; SEMLIKI-FOREST-VIRUS; CELL-CELL FUSION; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; CIRCULAR-DICHROISM; NMR-SPECTROSCOPY; CONFORMATIONAL-CHANGE; DISTANCE GEOMETRY	Members of the fusion-associated small transmembrane ( FAST) protein family are a distinct class of membrane fusion proteins encoded by nonenveloped fusogenic reoviruses. The 125-residue p14 FAST protein of reptilian reovirus has an similar to38-residue myristoylated N-terminal ectodomain containing a moderately apolar N-proximal region, termed the hydrophobic patch. Mutagenic analysis indicated sequence-specific elements in the N-proximal portion of the p14 hydrophobic patch affected cell-cell fusion activity, independent of overall effects on the relative hydrophobicity of the motif. Circular dichroism ( CD) of a myristoylated peptide representing the majority of the p14 ectodomain suggested this region is mostly disordered in solution but assumes increased structure in an apolar environment. From NMR spectroscopic data and simulated annealing, the soluble nonmyristoylated p14 ectodomain peptide consists of an N-proximal extended loop flanked by two proline hinges. The remaining two-thirds of the ectodomain peptide structure is disordered, consistent with predictions based on CD spectra of the myristoylated peptide. The myristoylated p14 ectodomain peptide, but not a nonmyristoylated version of the same peptide nor a myristoylated scrambled peptide, mediated extensive lipid mixing in a liposome fusion assay. Based on the lipid mixing activity, structural plasticity, environmentally induced conformational changes, and kinked structures predicted for the p14 ectodomain and hydrophobic patch ( all features associated with fusion peptides), we propose that the majority of the p14 ectodomain is composed of a fusion peptide motif, the first such motif dependent on myristoylation for membrane fusion activity.	Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 1X5, Canada; Dalhousie Univ, Coll Pharm, Halifax, NS B3H 4H7, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	Dalhousie University; Dalhousie University; McMaster University	Duncan, R (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, Tupper Med Bldg,Rm 7S, Halifax, NS B3H 1X5, Canada.	roy.duncan@dal.ca	, Richard/R-2316-2019	, Richard/0000-0002-9602-9558; Jakeman, David/0000-0003-3002-3388; Duncan, Roy/0000-0002-5162-5081; Top, Deniz/0000-0002-1042-8460				AHNE W, 1987, ARCH VIROL, V94, P135, DOI 10.1007/BF01313731; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064; Chicharro C, 2001, ANTIMICROB AGENTS CH, V45, P2441, DOI 10.1128/AAC.45.9.2441-2449.2001; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Corcoran JA, 2004, J VIROL, V78, P4342, DOI 10.1128/JVI.78.8.4342-4351.2004; Cross KJ, 2001, EMBO J, V20, P4432, DOI 10.1093/emboj/20.16.4432; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Davies SMA, 1998, FEBS LETT, V425, P415, DOI 10.1016/S0014-5793(98)00274-9; Dawe S, 2002, J VIROL, V76, P2131, DOI 10.1128/JVI.76.5.2131-2140.2002; Epand RM, 2001, BIOCHEMISTRY-US, V40, P8800, DOI 10.1021/bi0107187; Epand RM, 2003, BBA-BIOMEMBRANES, V1614, P116, DOI 10.1016/S0005-2736(03)00169-X; Gibbons DL, 2004, NATURE, V427, P320, DOI 10.1038/nature02239; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Han X, 2000, J MOL BIOL, V304, P953, DOI 10.1006/jmbi.2000.4251; Hsu CH, 2002, J BIOL CHEM, V277, P22725, DOI 10.1074/jbc.M200089200; IUPAC-IUB, 1970, BIOCHEMISTRY-US, V9, P3471; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 2002, CURR OPIN CELL BIOL, V14, P488, DOI 10.1016/S0955-0674(02)00356-3; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOSEPH M, 1995, J BIOL CHEM, V270, P19439, DOI 10.1074/jbc.270.33.19439; JOSEPH M, 1995, J BIOL CHEM, V270, P16749, DOI 10.1074/jbc.270.28.16749; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LUNEBERG J, 1995, J BIOL CHEM, V270, P27606; MARTIN I, 1993, BIOCHIM BIOPHYS ACTA, V1145, P124, DOI 10.1016/0005-2736(93)90389-H; Martin I, 1996, J VIROL, V70, P298, DOI 10.1128/JVI.70.1.298-304.1996; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; Pecheur EI, 2000, J BIOL CHEM, V275, P3936, DOI 10.1074/jbc.275.6.3936; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Sham S, 2002, BIOCHEMISTRY-US, V41, P12498, DOI 10.1021/bi020347+; Shmulevitz M, 2004, J VIROL, V78, P2808, DOI 10.1128/JVI.78.6.2808-2818.2004; Shmulevitz M, 2000, EMBO J, V19, P902, DOI 10.1093/emboj/19.5.902; Shome SG, 2001, VIROLOGY, V279, P146, DOI 10.1006/viro.2000.0688; Skehel JJ, 2001, BIOCHEM SOC T, V29, P623, DOI 10.1042/BST0290623; Sowadski JM, 1996, J BIOENERG BIOMEMBR, V28, P7; Sreerama N, 1999, PROTEIN SCI, V8, P370; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Tamm LK, 2003, BBA-BIOMEMBRANES, V1614, P14, DOI 10.1016/S0005-2736(03)00159-7; Tang C, 2004, P NATL ACAD SCI USA, V101, P517, DOI 10.1073/pnas.0305665101; Wang PL, 1996, BIOCHEMISTRY-US, V35, P11319, DOI 10.1021/bi960783u; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WHITT MA, 1990, J VIROL, V64, P4907, DOI 10.1128/JVI.64.10.4907-4913.1990; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; WISHART DS, 1991, FEBS LETT, V293, P72, DOI 10.1016/0014-5793(91)81155-2; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Yang J, 2001, BIOCHEMISTRY-US, V40, P8126, DOI 10.1021/bi0100283; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	61	40	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51386	51394		10.1074/jbc.M406990200	http://dx.doi.org/10.1074/jbc.M406990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448165	hybrid			2022-12-25	WOS:000225355800090
J	Martin, SS; Boucard, AA; Clement, M; Escher, E; Leduc, R; Guillemette, G				Martin, SS; Boucard, AA; Clement, M; Escher, E; Leduc, R; Guillemette, G			Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; BINDING-SITE CREVICE; CONSTITUTIVE ACTIVATION; AT(1) RECEPTOR; CONFORMATIONAL-CHANGES; ACCESSIBILITY METHOD; LIGAND-BINDING; CONTACT POINTS; RHODOPSIN	Activation of G protein-coupled receptors by agonists involves significant movement of transmembrane domains (TMD) following agonist binding. The underlying structural mechanism by which receptor activation takes place is largely unknown but can be inferred by detecting variability within the environment of the ligand-binding pocket, which is a water-accessible crevice surrounded by the seven TMD helices. Using the substituted-cysteine accessibility method, we identified the residues within the third TMD of the wild-type angiotensin II (AT(1)) receptor that contribute to the formation of the binding site pocket. Each residue within the Ile(103) - Tyr(127) region was mutated one at a time to a cysteine. Treating the A104C, N111C, and L112C mutant receptors with the charged sulfhydryl-specific alkylating agent methanethiosulfonate-ethylammonium ( MTSEA) strongly inhibited ligand binding, which suggests that these residues orient themselves within the water-accessible binding pocket of the AT(1) receptor. Interestingly, this pattern of acquired MTSEA sensitivity was altered for TMD3 reporter cysteines engineered in a constitutively active AT(1) receptor. Indeed, two additional mutants (S109C and V116C) were found to be sensitive to MTSEA treatment. Our results suggest that constitutive activation of the AT(1) receptor causes a minor counterclockwise rotation of TMD3, thereby exposing residues, which are not present in the inactive state, to the binding pocket. This pattern of accessibility of residues in the TMD3 of the AT1 receptor parallels that of homologous residues in rhodopsin. This study identified key elements of TMD3 that contribute to the activation of class A G protein-coupled receptors through structural rearrangements.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Guillemette, G (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.	Gaetan.Guillemette@USherbrooke.ca	Boucard, Antony/CAJ-3093-2022; Boucard, Antony/ABA-9769-2020	BOUCARD, Antony Jr/0000-0002-5538-0464; Escher, Emanuel/0000-0001-6601-987X				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; BALLA T, 1986, P NATL ACAD SCI USA, V83, P9323, DOI 10.1073/pnas.83.24.9323; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; Boucard AA, 2000, BIOCHEMISTRY-US, V39, P9662, DOI 10.1021/bi000597v; Boucard AA, 2003, J BIOL CHEM, V278, P36628, DOI 10.1074/jbc.M305952200; Burnier M, 2001, CIRCULATION, V103, P904, DOI 10.1161/01.CIR.103.6.904; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; GUILLEMETTE G, 1983, BIOCHEMISTRY-US, V22, P5591, DOI 10.1021/bi00293a021; Inoue Y, 1997, J HYPERTENS, V15, P703, DOI 10.1097/00004872-199715070-00001; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 2002, METHOD ENZYMOL, V343, P137; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; JOSEPH MP, 1995, J PROTEIN CHEM, V14, P381, DOI 10.1007/BF01886795; KOJIMA I, 1984, J BIOL CHEM, V259, P4448; Lagerstrom MC, 2003, J BIOL CHEM, V278, P51521, DOI 10.1074/jbc.M307683200; Laporte SA, 1999, MOL ENDOCRINOL, V13, P578, DOI 10.1210/me.13.4.578; Miura S, 2002, J BIOL CHEM, V277, P24299, DOI 10.1074/jbc.M202743200; Miura S, 2003, HYPERTENS RES, V26, P937, DOI 10.1291/hypres.26.937; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perodin J, 2002, BIOCHEMISTRY-US, V41, P14348, DOI 10.1021/bi0258602; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0	37	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51415	51423		10.1074/jbc.M407965200	http://dx.doi.org/10.1074/jbc.M407965200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452107	hybrid			2022-12-25	WOS:000225355800093
J	Nandini, CD; Mikami, T; Ohta, M; Itoh, N; Akiyama-Nambu, F; Sugahara, K				Nandini, CD; Mikami, T; Ohta, M; Itoh, N; Akiyama-Nambu, F; Sugahara, K			Structural and functional characterization of oversulfated chondroitin sulfate/dermatan sulfate hybrid chains from the notochord of hagfish - Neuritogenic and binding activities for growth factors and neurotrophic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; DERMATAN SULFATE; NEURITE OUTGROWTH; HEPARAN-SULFATE; FACTOR VEGF; IDURONIC ACID; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; BRAIN; OLIGOSACCHARIDES	Oversulfated chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chains were purified from the notochord of hagfish. The chains ( previously named CS-H for hagfish) have an average molecular mass of 18 kDa. Composition analysis using various chondroitinases demonstrated a variety of D-glucuronic acid ( GlcUA)and L-iduronic acid (IdoUA)-containing disaccharides variably sulfated with a higher proportion of GlcUA/ IdoUA-GalNAc 4,6-O-disulfate, revealing complex CS/DS hybrid features. The hybrid chains showed neurite outgrowth-promoting activity of an axonic nature, which resembled the activity of squid cartilage CS-E and which was abolished fully by chondroitinase ABC digestion and partially by chondroitinase AC-I or B digestion, suggesting the involvement of both GlcUA and IdoUA in neuritogenic activity. Purified CS-H exhibited interactions in a BIAcore system with various heparin-binding proteins and neurotrophic factors ( viz. fibroblast growth factor-2, - 10, - 16, and - 18; midkine; pleiotrophin; heparin-binding epidermal growth factor-like growth factor; vascular endothelial growth factor; brain-derived neurotrophic factor; and glial cell line-derived neurotrophic factor), most of which are expressed in the brain, although fibroblast growth factor-1 and ciliary neurotrophic factor showed no binding. Kinetic analysis revealed high affinity binding of these growth factors and, for the first time, of the neurotrophic factors. Competitive inhibition revealed the involvement of both IdoUA and GlcUA in the binding of these growth factors, suggesting the importance of the hybrid nature of CS-H for the efficient binding of these growth factors. These findings, together with those from the recent analysis of brain CS/DS chains from neonatal mouse and embryonic pig (Bao, X., Nishimura, S., Mikami, T., Yamada, S., Itoh, N., and Sugahara, K. ( 2004) J. Biol. Chem. 279, 9765 9776), suggest physiological roles of the hybrid chains in the development of the brain.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Kobe Pharmaceut Univ, Dept Clin Chem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan; Ochanomizu Univ, Fac Sci, Dept Chem, Tokyo 1128610, Japan	Kobe Pharmaceutical University; Kobe Pharmaceutical University; Kyoto University; Ochanomizu University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp						ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Barnett MW, 2002, J CELL SCI, V115, P4495, DOI 10.1242/jcs.00114; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BRUCKNER J, 1955, BIOCHEM J, V60, P200; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Danilenko DM, 1999, ARCH BIOCHEM BIOPHYS, V361, P34, DOI 10.1006/abbi.1998.0967; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Fuller M, 2004, GLYCOBIOLOGY, V14, P443, DOI 10.1093/glycob/cwh049; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; GREGOIRE PE, 1972, BIOCHIM BIOPHYS ACTA, V279, P102, DOI 10.1016/0304-4165(72)90245-0; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; HIYAMA K, 1976, J BIOCHEM-TOKYO, V80, P1201, DOI 10.1093/oxfordjournals.jbchem.a131390; ICHIJO H, 2003, CONNECT TISSUE, V35, P11; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Lommatzsch M, 1999, AM J PATHOL, V155, P1183, DOI 10.1016/S0002-9440(10)65221-2; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; OHTA K, 1995, BIOCHEM MOL BIOL INT, V35, P283; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Rickard SM, 2003, GLYCOBIOLOGY, V13, P419, DOI 10.1093/glycob/cwg046; SAITO H, 1968, J BIOL CHEM, V243, P1536; Sakai S, 2003, CARBOHYD RES, V338, P263, DOI 10.1016/S0008-6215(02)00442-1; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Tully SE, 2004, J AM CHEM SOC, V126, P7736, DOI 10.1021/ja0484045; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Ueoka C, 1999, GLYCOCONJUGATE J, V16, P291, DOI 10.1023/A:1007022229813; Vacherot F, 1999, J BIOL CHEM, V274, P7741, DOI 10.1074/jbc.274.12.7741; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yamada Shuhei, 2003, Methods Mol Biol, V213, P71; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; Zhang JY, 2000, EUR J NEUROSCI, V12, P4171, DOI 10.1046/j.1460-9568.2000.01312.x	58	111	116	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50799	50809		10.1074/jbc.M404746200	http://dx.doi.org/10.1074/jbc.M404746200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385557	hybrid			2022-12-25	WOS:000225355800022
J	Zhang, YM; Frank, MW; Virga, KG; Lee, RE; Rock, CO; Jackowski, S				Zhang, YM; Frank, MW; Virga, KG; Lee, RE; Rock, CO; Jackowski, S			Acyl carrier protein is a cellular target for the antibacterial action of the pantothenamide class of pantothenate antimetabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CONTENT; ESCHERICHIA-COLI; BIOSYNTHESIS; KINASE; ACID; GENE; ADENYLYLTRANSFERASE; PHOSPHODIESTERASE; IDENTIFICATION; PURIFICATION	Pantothenate is the precursor of the essential cofactor coenzyme A (CoA). Pantothenate kinase (CoaA) catalyzes the first and regulatory step in the CoA biosynthetic pathway. The pantothenate analogs N-pentylpantothenamide and N-heptylpantothenamide possess antibiotic activity against Escherichia coli. Both compounds are substrates for E. coli CoaA and competitively inhibit the phosphorylation of pantothenate. The phosphorylated pantothenamides are further converted to CoA analogs, which were previously predicted to act as inhibitors of CoA-dependent enzymes. Here we show that the mechanism for the toxicity of the pantothenamides is due to the inhibition of fatty acid biosynthesis through the formation and accumulation of the inactive acyl carrier protein (ACP), which was easily observed as a faster migrating protein using conformationally sensitive gel electrophoresis. E. coli treated with the pantothenamides lost the ability to incorporate [1-C-14] acetate to its membrane lipids, indicative of the inhibition of fatty acid synthesis. Cellular CoA was maintained at the level sufficient for bacterial protein synthesis. Electrospray ionization time-of-flight mass spectrometry confirmed that the inactive ACP was the product of the transfer of the inactive phosphopantothenamide moiety of the CoA analog to apo-ACP, forming the ACP analog that lacks the sulfhydryl group for the attachment of acyl chains for fatty acid synthesis. Inactive ACP accumulated in pantothenamide-treated cells because of the active hydrolysis of regular ACP and the slow turnover of the inactive prosthetic group. Thus, the pantothenamides are pro-antibiotics that inhibit fatty acid synthesis and bacterial growth because of the covalent modification of ACP.	St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Zhang, YM (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, 332 N Lauderdale St, Memphis, TN 38105 USA.	yongmei.zhang@stjude.org	Lee, Richard/J-4997-2013; Lee, Richard/AAX-3996-2021; Jackowski, Suzanne/N-8168-2018	Lee, Richard/0000-0002-2397-0443; Lee, Richard/0000-0002-2397-0443; Jackowski, Suzanne/0000-0002-6855-1429; Frank, Matthew/0000-0002-4914-1440	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 62896, GM 34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM062896, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buchanan SK, 2001, TRENDS BIOCHEM SCI, V26, P3, DOI 10.1016/S0968-0004(00)01733-3; Choudhry AE, 2003, ANTIMICROB AGENTS CH, V47, P2051, DOI 10.1128/AAC.47.6.2051-2055.2003; CLIFTON G, 1970, ARCH BIOCHEM BIOPHYS, V137, P523, DOI 10.1016/0003-9861(70)90470-4; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; FISCHL AS, 1990, J BACTERIOL, V172, P5445, DOI 10.1128/jb.172.9.5445-5449.1990; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Ivey RA, 2004, J BIOL CHEM, V279, P35622, DOI 10.1074/jbc.M403152200; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; JACKOWSKI S, 1984, J BIOL CHEM, V259, P1891; JACKOWSKI S, 1996, ESCHERICHIA COLI SAL, V1, P687; Keating DH, 1996, J BACTERIOL, V178, P2662, DOI 10.1128/jb.178.9.2662-2667.1996; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; LACKS S, 1960, BIOCHIM BIOPHYS ACTA, V39, P508, DOI 10.1016/0006-3002(60)90205-5; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; Nakanishi M, 2001, J BIOL CHEM, V276, P46394, DOI 10.1074/jbc.M104483200; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; POLACCO ML, 1981, J BIOL CHEM, V256, P5750; POWELL GL, 1969, J BIOL CHEM, V211, P5610; ROCK CO, 1981, J BIOL CHEM, V256, P2669; Strauss E, 2002, J BIOL CHEM, V277, P48205, DOI 10.1074/jbc.M204560200; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; VALLARI DS, 1985, J BACTERIOL, V162, P1156, DOI 10.1128/JB.162.3.1156-1161.1985; VALLARI DS, 1985, J BACTERIOL, V164, P136, DOI 10.1128/JB.164.1.136-142.1985; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988	33	71	74	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50969	50975		10.1074/jbc.M409607200	http://dx.doi.org/10.1074/jbc.M409607200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15459190	hybrid			2022-12-25	WOS:000225355800041
J	Buss, H; Dorrie, A; Schmitz, ML; Frank, R; Livingstone, M; Resch, K; Kracht, M				Buss, H; Dorrie, A; Schmitz, ML; Frank, R; Livingstone, M; Resch, K; Kracht, M			Phosphorylation of serine 468 by GSK-3 beta negatively regulates basal p65 NF-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; SPOT-SYNTHESIS; ZETA-PKC; ACTIVATION; TRANSCRIPTION; ALPHA; INHIBITORS; APOPTOSIS; SURVIVAL; SUBUNIT	The activity of NF-kappaB is controlled at several levels including the phosphorylation of the strongly transactivating p65 (RelA) subunit. However, the overall number of phosphorylation sites, the signaling pathways and protein kinases that target p65 NF-kappaB and the functional role of these phosphorylations are still being uncovered. Using a combination of peptide arrays with in vitro kinase assays we identify serine 468 as a novel phosphorylation site of p65 NF-kappaB. Serine 468 lies within a GSK-3beta consensus site, and recombinant GSK-3beta specifically phosphorylates a GST-p65-(354-551) fusion protein at Ser(468) in vitro. In intact cells, phosphorylation of endogenous Ser(468) of p65 is induced by the PP1/PP2A phosphatase inhibitor calyculin A and this effect is inhibited by the GSK-3beta inhibitor LiCl. Reconstitution of p65-deficient cells with a p65 protein where serine 468 was mutated to alanine revealed a negative regulatory role of serine 468 for NF-kappaB activation. Collectively our results suggest that a GSK-3beta-PP1-dependent mechanism regulates phosphorylation of p65 NF-kappaB at Ser(468) in unstimulated cells and thereby controls the basal activity of NF-kappaB.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; German Res Ctr Biotechnol, Dept Biol Chem, D-38124 Braunschweig, Germany; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Hannover Medical School; University of Bern; Helmholtz Association; Helmholtz-Center for Infection Research	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	kracht.michael@MH-hannover.de	Schmitz, M. Lienhard/D-9328-2017; Livingstone, Mark/H-1709-2011	Schmitz, M. Lienhard/0000-0002-6984-7192; Kracht, Michael/0000-0002-8501-043X; Livingstone, Mark/0000-0002-2757-7008				Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hu J, 2004, CARCINOGENESIS, V25, P1991, DOI 10.1093/carcin/bgh198; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 2004, IN PRESS BLOOD; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; SUGANUMA M, 1990, CANCER RES, V50, P3521; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	37	201	211	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49571	49574		10.1074/jbc.C400442200	http://dx.doi.org/10.1074/jbc.C400442200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15465828	hybrid			2022-12-25	WOS:000225229500005
J	Cole, AR; Knebel, A; Morrice, NA; Robertson, LA; Irving, AJ; Connolly, CN; Sutherland, C				Cole, AR; Knebel, A; Morrice, NA; Robertson, LA; Irving, AJ; Connolly, CN; Sutherland, C			GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; HIPPOCAMPAL-NEURONS; RAT-BRAIN; TRANSGENIC MICE; BETA-CATENIN; TAU; GROWTH; CRMP-2; INACTIVATION; EXPRESSION	Elevated glycogen synthase kinase-3 (GSK-3) activity is associated with Alzheimer disease. We have found that collapsin response mediator proteins (CRMP) 2 and 4 are physiological substrates of GSK-3. The amino acids targeted by GSK-3 comprise a hyperphosphorylated epitope first identified in plaques isolated from Alzheimer brain. Expression of wild type CRMP2 in primary hippocampal neurons or SH-SY5Y neuroblastoma cells promotes axon elongation. However, a GSK-3-insensitive CRMP2 mutant has dramatically reduced ability to promote axon elongation, a similar effect to pharmacological inhibition of GSK-3. Hence, we propose that phosphorylation of CRMP proteins by GSK-3 regulates axon elongation. This work provides a direct connection between hyperphosphorylation of these residues and elevated GSK-3 activity, both of which are observed in Alzheimer brain.	Univ Dundee, Ninewells Hosp, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, Lab 4 21, Kinasource, Dundee DD1 4HN, Scotland; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland	University of Dundee; University of Dundee; University of Dundee	Sutherland, C (corresponding author), Univ Dundee, Ninewells Hosp, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland.	c.d.sutherland@dundee.ac.uk	Cole, Adam/B-9785-2011	Knebel, Axel/0000-0002-9197-6054; Sutherland, Calum/0000-0003-4398-7434; Connolly, Christopher/0000-0002-0445-8874	Biotechnology and Biological Sciences Research Council [C18727] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Arimura N, 2004, J NEUROBIOL, V58, P34, DOI 10.1002/neu.10269; Campbell David G, 2002, J Biomol Tech, V13, P119; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fukata Y, 2002, NEUROSCI RES, V43, P305, DOI 10.1016/S0168-0102(02)00062-7; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Jamsa A, 2004, BIOCHEM BIOPH RES CO, V319, P993, DOI 10.1016/j.bbrc.2004.05.075; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Leroy K, 1999, J CHEM NEUROANAT, V16, P279, DOI 10.1016/S0891-0618(99)00012-5; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Owen R, 2003, MOL CELL NEUROSCI, V23, P626, DOI 10.1016/S1044-7431(03)00095-2; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Rae MG, 2000, J NEUROSCI, V20, P8628; Spittaels K, 2002, NEUROSCIENCE, V113, P797, DOI 10.1016/S0306-4522(02)00236-1; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takahashi M, 2000, BRAIN RES, V857, P193, DOI 10.1016/S0006-8993(99)02424-5; TAKAHASHI M, 1994, J NEUROCHEM, V63, P245; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Wang JZ, 1998, FEBS LETT, V436, P28, DOI 10.1016/S0014-5793(98)01090-4; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yao HB, 2002, J CHEM NEUROANAT, V23, P291, DOI 10.1016/S0891-0618(02)00014-5; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	31	205	215	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50176	50180		10.1074/jbc.C400412200	http://dx.doi.org/10.1074/jbc.C400412200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15466863	Green Accepted, hybrid			2022-12-25	WOS:000225229500077
J	Bowie, ML; Dietze, EC; Delrow, J; Bean, GR; Troch, MM; Marjoram, RJ; Seewaldt, VL				Bowie, ML; Dietze, EC; Delrow, J; Bean, GR; Troch, MM; Marjoram, RJ; Seewaldt, VL			Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells	ONCOGENE			English	Article						IRF-1; tamoxifen; CBP; breast cancer	CREB-BINDING PROTEIN; GAMMA INHIBITS GROWTH; RETINOIC-ACID; BREAST-CANCER; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; STIMULATED GENES; CARCINOMA-CELLS; UP-REGULATION; BETA	Unlike estrogen receptor-positive (ER(+)) breast cancers, normal human mammary epithelial cells (HMECs) typically express low nuclear levels of ER ( ER poor). We previously demonstrated that 1.0 muM tamoxifen (Tam) promotes apoptosis in acutely damaged ER-poor HMECs through a rapid, 'nonclassic' signaling pathway. Interferon-regulatory factor-1 (IRF-1), a target of signal transducer and activator of transcription-1 transcriptional regulation, has been shown to promote apoptosis following DNA damage. Here we show that 1.0 muM Tam promotes apoptosis in acutely damaged ER-poor HMECs through IRF-1 induction and caspase-1/3 activation. Treatment of acutely damaged HMEC-E6 cells with 1.0 muM Tam resulted in recruitment of CBP to the gamma-IFN-activated sequence element of the IRF-1 promoter, induction of IRF-1, and sequential activation of caspase-1 and -3. The effects of Tam were blocked by expression of siRNA directed against IRF-1 and caspase-1 inhibitors. These data indicate that Tam induces apoptosis in HMEC-E6 cells through a novel IRF-1-mediated signaling pathway that results in activated caspase-1 and -3.	Duke Univ, Med Ctr, Div Med Oncol, Durham, NC 27710 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98120 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Fred Hutchinson Cancer Center; Duke University	Seewaldt, VL (corresponding author), Duke Univ, Med Ctr, Div Med Oncol, Box 2628, Durham, NC 27710 USA.	seewa001@mc.duke.edu			NATIONAL CANCER INSTITUTE [R01CA088799, P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA88799, 2P30CA14236-26, R01CA984441] Funding Source: Medline; NIDDK NIH HHS [2P30DK 35816-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiba-Masago S, 2001, CELL SIGNAL, V13, P617, DOI 10.1016/S0898-6568(01)00183-8; Anderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Aubele MM, 2000, DIAGN MOL PATHOL, V9, P14, DOI 10.1097/00019606-200003000-00003; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Coradini D, 1997, TUMOR BIOL, V18, P22, DOI 10.1159/000218012; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Detjen KM, 2002, INT J ONCOL, V21, P1133; Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251; Dietze EC, 2004, ONCOGENE, V23, P3851, DOI 10.1038/sj.onc.1207480; Dietze EC, 2001, J BIOL CHEM, V276, P5384, DOI 10.1074/jbc.M007915200; Doherty GM, 2001, ANN SURG, V233, P623, DOI 10.1097/00000658-200105000-00005; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GIBSON DFC, 1993, BREAST CANCER RES TR, V25, P141, DOI 10.1007/BF00662139; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Gjermandsen IM, 2000, CYTOKINE, V12, P233, DOI 10.1006/cyto.1999.0549; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Henderson YC, 1997, BRIT J HAEMATOL, V96, P566, DOI 10.1046/j.1365-2141.1997.d01-2057.x; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Hoshiya Y, 2003, J BIOL CHEM, V278, P51703, DOI 10.1074/jbc.M307626200; Iacopino F, 1997, INT J CANCER, V71, P1103, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1103::AID-IJC29>3.0.CO;2-C; Jiang B, 2004, TOXICON, V43, P53, DOI 10.1016/j.toxicon.2003.10.017; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; Karlsen AE, 2000, J CLIN ENDOCR METAB, V85, P830, DOI 10.1210/jc.85.2.830; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kim EJ, 2002, J CELL BIOCHEM, V85, P369, DOI 10.1002/jcb.10142; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kovacs KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kumar-Sinha C, 2002, J BIOL CHEM, V277, P575, DOI 10.1074/jbc.M107795200; Lindner DJ, 1997, J INTERF CYTOK RES, V17, P681, DOI 10.1089/jir.1997.17.681; Lindner DJ, 1997, MOL CELL BIOCHEM, V167, P169, DOI 10.1023/A:1006854110122; Lininger RA, 1998, HUM PATHOL, V29, P1113, DOI 10.1016/S0046-8177(98)90422-1; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1994, EMBO J, V16, P406; RASMUSSEN UB, 1993, CANCER RES, V53, P4096; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 2001, CANCER RES, V61, P616; Seewaldt VL, 1999, EXP CELL RES, V249, P70, DOI 10.1006/excr.1999.4462; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAMPFER M, 1985, J TISSUE CULT METHOD, V9, P109; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tsuda H, 1998, JPN J CLIN ONCOL, V28, P5, DOI 10.1093/jjco/28.1.5; Tzoanopoulos D, 2002, BRIT J HAEMATOL, V119, P46, DOI 10.1046/j.1365-2141.2002.03829.x; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Widschwendter M, 1996, ANTICANCER RES, V16, P369; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yim JH, 1997, J IMMUNOL, V158, P1284; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang SP, 2003, J BIOL CHEM, V278, P52810, DOI 10.1074/jbc.M308244200	83	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8743	8755		10.1038/sj.onc.1208120	http://dx.doi.org/10.1038/sj.onc.1208120			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467738				2022-12-25	WOS:000225165100004
J	Moodie, FM; Marwick, JA; Anderson, CS; Szulakowski, P; Biswas, SK; Bauter, MR; Kilty, I; Rahman, I				Moodie, FM; Marwick, JA; Anderson, CS; Szulakowski, P; Biswas, SK; Bauter, MR; Kilty, I; Rahman, I			Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappa B activation and proinflammatory cytokine release in alveolar epithelial cells	FASEB JOURNAL			English	Article						oxidants; histone acetylation; deacetylation; A549 cells; COPD; HDAC2	HISTONE DEACETYLASE; GENE-TRANSCRIPTION; ACETYLATION; INHIBITION; GLUTATHIONE; ALPHA; EXPRESSION; KINASE; INFLAMMATION; DEGRADATION	Oxidative stress is implicated in lung inflammation due to its effect on proinflammatory gene transcription. Changes in gene transcription depend on chromatin remodeling and the relative activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Alterations in the nuclear histone acetylation: deacetylation balance may result in uncontrolled transcription of specific proinflammatory genes. We studied the effect of hydrogen peroxide (H2O2) and cigarette smoke condensate (CSC) on histone acetylation: deacetylation in human alveolar epithelial cells (A549). H2O2 and CSC significantly increased acetylation of histone H4 proteins and were associated with decreased HDAC activity and HDAC2 levels in A549 cells. Also, the decreased HDAC2 activity was due to protein modification by aldehydes and nitric oxide products. Pretreatment of A549 cells with N-acetyl-L-cysteine attenuated the oxidant-mediated reduction in HDAC activity. Treatment of A549 cells with CSC did not cause nuclear factor-kappaB (NF-kappaB) activation or expression and release of either interleukin (IL)-8 or IL-6. However, H2O2, tumor necrosis factor-alpha (TNF-alpha), and IL-1beta significantly increased NF-kappaB activation and expression of IL-8 compared with control cells. Interestingly, CSC dose dependently inhibited TNF-alpha- and IL-1beta-mediated NF-kappaB activation and IL-8 expression. Thus, H2O2 and CSC enhance acetylation of histone proteins and decrease histone deacetylase activity but differentially regulate proinflammatory cytokine release in alveolar epithelial cells.	Univ Edinburgh, Sch Med, MRC, Ctr Inflammat Res,ELEGI & Colt Res Labs, Edinburgh, Midlothian, Scotland; Pfizer Global Res & Dev, Sandwich, Kent, England; Univ Rochester, Med Ctr, Dept Environm Med, Div Lung Biol & Dis, Rochester, NY 14642 USA	University of Edinburgh; Pfizer; University of Rochester	Rahman, I (corresponding author), Univ Rochester, Med Ctr, Dept Environm Med, Div Lung Biol, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.	irfan_rahman@urmc.rochester.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES01247] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Doorn JA, 2002, CHEM RES TOXICOL, V15, P1445, DOI 10.1021/tx025590o; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fusunyan RD, 1999, MOL MED, V5, P631, DOI 10.1007/BF03402075; Gebel S, 2001, TOXICOL SCI, V59, P75, DOI 10.1093/toxsci/59.1.75; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Horton ND, 1999, J BIOL CHEM, V274, P9200, DOI 10.1074/jbc.274.14.9200; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2000, METH MOLEC MED, V44, P309, DOI 10.1385/1-59259-072-1:309; Ito K., 2001, FASEB Journal, V15, P1110; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; LANNAN S, 1994, AM J PHYSIOL, V266, pL92, DOI 10.1152/ajplung.1994.266.1.L92; Ng KW, 1997, EMBO J, V16, P2072, DOI 10.1093/emboj/16.8.2072; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pender SLF, 2000, AM J PHYSIOL-GASTR L, V279, pG918, DOI 10.1152/ajpgi.2000.279.5.G918; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; RAGIONE FD, 2001, FEBS LETT, V499, P199; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067, DOI 10.1152/ajplung.1999.277.6.L1067; Rahman I, 2004, BIOCHEM PHARMACOL, V68, P1255, DOI 10.1016/j.bcp.2004.05.042; Rahman I, 1996, FEBS LETT, V396, P21, DOI 10.1016/0014-5793(96)01027-7; Rahman I, 1999, J BIOL CHEM, V274, P5088, DOI 10.1074/jbc.274.8.5088; Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101; Rahman I, 1998, THORAX, V53, P601, DOI 10.1136/thx.53.7.601; Rahman I, 2002, MOL CELL BIOCHEM, V234, P239, DOI 10.1023/A:1015905010086; Rahman I, 2001, BIOCHEM PHARMACOL, V62, P787, DOI 10.1016/S0006-2952(01)00702-X; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; RAHMAN I, 1995, AM J PHYSIOL-LUNG C, V269, pL285, DOI 10.1152/ajplung.1995.269.3.L285; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sternglanz R, 1996, TRENDS BIOCHEM SCI, V21, P357, DOI 10.1016/S0968-0004(96)90120-6; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Tomita K, 2003, BIOCHEM BIOPH RES CO, V301, P572, DOI 10.1016/S0006-291X(02)03029-2; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Vayssier M, 1998, BIOCHEM BIOPH RES CO, V252, P249, DOI 10.1006/bbrc.1998.9586; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516; Witherden IR, 2004, AM J RESP CELL MOL, V30, P500, DOI 10.1165/rcmb.4890; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	54	231	246	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1897	+		10.1096/fj.04-1506fje	http://dx.doi.org/10.1096/fj.04-1506fje			35	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456740				2022-12-25	WOS:000224243200004
J	Ferrari, S; Simmen, KC; Dusserre, Y; Muller, K; Fourel, G; Gilson, E; Mermod, N				Ferrari, S; Simmen, KC; Dusserre, Y; Muller, K; Fourel, G; Gilson, E; Mermod, N			Chromatin domain boundaries delimited by a histone-binding protein in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; SACCHAROMYCES-CEREVISIAE; ACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; TELOMERIC HETEROCHROMATIN; DNA-REPLICATION; SUBTELOMERIC REGIONS; SIR2/SIR4 COMPLEX; SILENT CHROMATIN; SIR3	When located next to chromosomal elements such as telomeres, genes can be subjected to epigenetic silencing. In yeast, this is mediated by the propagation of the SIR proteins from telomeres toward more centromeric regions. Particular transcription factors can protect downstream genes from silencing when tethered between the gene and the telomere, and they may thus act as chromatin domain boundaries. Here we have studied one such transcription factor, CTF-1, that binds directly histone H3. A deletion mutagenesis localized the barrier activity to the CTF-1 histone-binding domain. A saturating point mutagenesis of this domain identified several amino acid substitutions that similarly inhibited the boundary and histone binding activities. Chromatin immunoprecipitation experiments indicated that the barrier protein efficiently prevents the spreading of SIR proteins, and that it separates domains of hypoacetylated and hyperacetylated histones. Together, these results suggest a mechanism by which proteins such as CTF-1 may interact directly with histone H3 to prevent the propagation of a silent chromatin structure, thereby defining boundaries of permissive and silent chromatin domains.	Univ Lausanne, EPFL, UNIL,Ctr Biotechnol, Inst Biotechnol,ISP,FSB,Lab Mol Biotechnol, CH-1015 Lausanne, Switzerland; Ecole Normale Super Lyon, Biol Cellulaire & Mol Lab, CNRS, UMR5665, F-69364 Lyon 07, France	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Mermod, N (corresponding author), Univ Lausanne, EPFL, UNIL,Ctr Biotechnol, Inst Biotechnol,ISP,FSB,Lab Mol Biotechnol, CH-1015 Lausanne, Switzerland.	Nicolas.Mermod@unil.ch						Adams A, 1997, METHODS YEAST GENETI; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; Arnold BA, 1998, BIOTECHNIQUES, V25, P98, DOI 10.2144/98251st06; Bi X, 1999, GENE DEV, V13, P1089, DOI 10.1101/gad.13.9.1089; Bi X, 2001, CURR OPIN GENET DEV, V11, P199, DOI 10.1016/S0959-437X(00)00179-9; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRAUNSTEIN M, 1997, NUCL ORG CHROMATIN S, P250; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Chiu YH, 2003, GENETICS, V165, P115; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Defossez PA, 2002, NUCLEIC ACIDS RES, V30, P5136, DOI 10.1093/nar/gkf629; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Donze D, 2002, BIOESSAYS, V24, P344, DOI 10.1002/bies.10072; Erkine AM, 2003, J BIOL CHEM, V278, P7755, DOI 10.1074/jbc.M211703200; Fourel G, 2002, BIOESSAYS, V24, P828, DOI 10.1002/bies.10139; Fourel G, 2001, EMBO REP, V2, P124, DOI 10.1093/embo-reports/kve024; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ishii K, 2003, MOL CELL, V11, P237, DOI 10.1016/S1097-2765(03)00010-8; Ishii K, 2002, CELL, V109, P551, DOI 10.1016/S0092-8674(02)00756-0; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; Kristjuhan A, 2003, P NATL ACAD SCI USA, V100, P7551, DOI 10.1073/pnas.1332299100; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lebrun E, 2001, GENETICS, V158, P167; Li R, 1999, J BIOL CHEM, V274, P30310, DOI 10.1074/jbc.274.42.30310; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; Memedula S, 2003, CURR BIOL, V13, P241, DOI 10.1016/S0960-9822(03)00048-4; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Muller K, 2000, J BIOL CHEM, V275, P1645, DOI 10.1074/jbc.275.3.1645; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Oki M, 2004, MOL CELL BIOL, V24, P1956, DOI 10.1128/MCB.24.5.1956-1967.2004; PANKIEWICZ R, 2004, IN PRESS J GENE MED, V6; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; SMITH MM, 1983, J MOL BIOL, V169, P641, DOI 10.1016/S0022-2836(83)80163-6; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; van Leeuwen F, 2002, CURR OPIN CELL BIOL, V14, P756, DOI 10.1016/S0955-0674(02)00393-9; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	69	24	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55520	55530		10.1074/jbc.M410346200	http://dx.doi.org/10.1074/jbc.M410346200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15471882	Green Published, hybrid			2022-12-25	WOS:000225960800068
J	Loretz, CA; Pollina, C; Hyodo, S; Takei, Y; Chang, WH; Shoback, D				Loretz, CA; Pollina, C; Hyodo, S; Takei, Y; Chang, WH; Shoback, D			CDNA cloning and functional expression of a Ca2+-sensing receptor with truncated C-terminal tail from the Mozambique tilapia (Oreochromis mossambicus)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; HUMAN CA2+ RECEPTOR; IDENTIFICATION; PROTEIN; KIDNEY; LOCALIZATION; FILAMIN; DOMAIN; ACTIVATION; PHOSPHATE	The complete cDNA sequence of the tilapia extracellular Ca2+-sensing receptor (CaR) was determined. The transcript length of tilapia CaR (tCaR) is 3.4 kbp and encodes a 940-amino acid, 7-transmembrane domain protein that is consistent in its structural features with known mammalian and piscine CaRs. The tCaR extracellular domain includes a characteristic hydrophobic segment, conserved cysteine residues that are implicated in receptor dimerization (Cys(129) and Cys(131)) and in coupling to the transmembrane domain ( nine conserved cysteine residues), and conserved serine residues (Ser(147) and Ser(169 - 171)) that are linked to receptor binding of Ca2+ and L-amino acid-mediated potentiation of function. mRNA expression of tCaR was strong in kidney, brain, and gill. Weaker expression was observed in pituitary, stomach, intestine, urinary bladder, and heart. This distribution is consistent with possible physiological roles in endocrine cells, excitable tissues, and ion-transporting barrier epithelia. Expression of tCaR mRNA in kidney and intestine was salinity-dependent, suggesting a role for the receptor in iono-/osmoregulation in this euryhaline teleost species. Human embryonic kidney-293 cells transiently transfected with tCaR cDNA demonstrated dose-dependent phospholipase C activation in response to elevations in the extracellular Ca2+ concentration ([Ca2+](o)). Functional activation of the mitogen-activated protein kinase cascade by high [Ca2+](o) was also confirmed in these cells despite the naturally occurring truncation of the receptor's intracellular tail, which removes segments variably linked in mammalian CaRs to filamin-coupled activation of mitogen-activated protein kinase cascades. Sensitivity of phospholipase C activation to [Ca2+](o) was dependent on the ionic strength of the bathing medium, supporting a role in salinity sensing.	Amer Embassy, Natl Sci Fdn Tokyo Reg Off, Minato Ku, Tokyo 1078420, Japan; Univ Tokyo, Ocean Res Inst, Nakano Ku, Tokyo 1648639, Japan; Univ Calif San Francisco, Dept Med, Dept Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA	University of Tokyo; University of California System; University of California San Francisco	Loretz, CA (corresponding author), Amer Embassy, Natl Sci Fdn Tokyo Reg Off, Minato Ku, 1-10-5 Akasaka, Tokyo 1078420, Japan.	cloretz@nsf.gov	; Takei, Yoshio/R-2368-2017	Hyodo, Susumu/0000-0001-8146-2386; Takei, Yoshio/0000-0003-3004-8905	NIA NIH HHS [R01 AG21353] Funding Source: Medline; NIDDK NIH HHS [R01 DK55846] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021353] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Ba JM, 2004, CELL CALCIUM, V35, P229, DOI 10.1016/j.ceca.2003.10.016; Ba JM, 2003, AM J PHYSIOL-RENAL, V285, pF1233, DOI 10.1152/ajprenal.00249.2003; Bai M, 2004, CELL CALCIUM, V35, P197, DOI 10.1016/j.ceca.2003.10.018; Bieter RN, 1935, J PHARMACOL EXP THER, V53, P347; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brown Edward M., 1996, American Journal of the Medical Sciences, V312, P99; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Chang WH, 2004, CELL CALCIUM, V35, P183, DOI 10.1016/j.ceca.2003.10.012; Chang WH, 1998, J BONE MINER RES, V13, P570, DOI 10.1359/jbmr.1998.13.4.570; Chang WH, 2001, J BIOL CHEM, V276, P44129, DOI 10.1074/jbc.M104834200; Chattopadhyay N, 1998, AM J PHYSIOL-GASTR L, V274, pG122, DOI 10.1152/ajpgi.1998.274.1.G122; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; Chen RA, 2004, AM J PHYSIOL-RENAL, V286, pF1005, DOI 10.1152/ajprenal.00013.2004; Cheng SX, 2002, AM J PHYSIOL-GASTR L, V283, pG240, DOI 10.1152/ajpgi.00500.2001; Cima RR, 1997, AM J PHYSIOL-GASTR L, V273, pG1051, DOI 10.1152/ajpgi.1997.273.5.G1051; Fellner SK, 2002, J EXP BIOL, V205, P1889; Flanagan JA, 2002, GEN COMP ENDOCR, V127, P117, DOI 10.1016/S0016-6480(02)00035-7; Flik Gert, 1995, V14, P317; Gama L, 1997, AM J PHYSIOL-CELL PH, V273, pC1168, DOI 10.1152/ajpcell.1997.273.4.C1168; Hebert SC, 1997, J EXP BIOL, V200, P295; Hebert SC, 2004, CELL CALCIUM, V35, P239, DOI 10.1016/j.ceca.2003.10.015; Hentschel H, 2003, AM J PHYSIOL-RENAL, V285, pF430, DOI 10.1152/ajprenal.00081.2002; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Hubbard PC, 2000, J EXP BIOL, V203, P3821; Hyodo S, 2004, GEN COMP ENDOCR, V138, P97, DOI 10.1016/j.ygcen.2004.05.009; Ingleton PM, 2002, J ANAT, V200, P487, DOI 10.1046/j.1469-7580.2002.00036.x; Loretz C.A., 1995, CELLULAR MOL APPROAC, P25, DOI [10.1016/s1546-5098(08)60241-1, DOI 10.1016/S1546-5098(08)60241-1]; LORETZ CA, 1981, GEN COMP ENDOCR, V43, P325, DOI 10.1016/0016-6480(81)90291-4; LORETZ CA, 1981, NEUROSECRETION MOL C, P319; Lund O., 2002, CASP5 C, pA102; Naito T, 1998, P NATL ACAD SCI USA, V95, P5178, DOI 10.1073/pnas.95.9.5178; Nearing J, 2002, P NATL ACAD SCI USA, V99, P9231, DOI 10.1073/pnas.152294399; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pi M, 2002, ENDOCRINOLOGY, V143, P3830, DOI 10.1210/en.2002-220240; Radman DP, 2002, MOL CELL ENDOCRINOL, V186, P111, DOI 10.1016/S0303-7207(01)00643-8; RAMNEEK G, 2002, EUR C COMP BIOL 2002; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Riccardi D, 1998, AM J PHYSIOL-RENAL, V274, pF611, DOI 10.1152/ajprenal.1998.274.3.F611; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Rutten MJ, 1999, AM J PHYSIOL-GASTR L, V277, pG662, DOI 10.1152/ajpgi.1999.277.3.G662; Sands JM, 1997, J CLIN INVEST, V99, P1399, DOI 10.1172/JCI119299; Sasayama Y, 1999, ZOOL SCI, V16, P857, DOI 10.2108/zsj.16.857; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Uchida K, 2002, CAN J ZOOL, V80, P1100, DOI 10.1139/Z02-090; Wagner Graham F., 1994, P273; Yano S, 2004, CELL CALCIUM, V35, P257, DOI 10.1016/j.ceca.2003.10.008; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200	54	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53288	53297		10.1074/jbc.M410098200	http://dx.doi.org/10.1074/jbc.M410098200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456780	hybrid			2022-12-25	WOS:000225680600060
J	Manguikian, AD; Barbour, SE				Manguikian, AD; Barbour, SE			Cell cycle dependence of group VIA calcium-independent phospholipase A(2) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ARACHIDONIC-ACID RELEASE; PHOSPHATIDYLCHOLINE SYNTHESIS; PROTEIN PHOSPHATASE-1; SR PROTEINS; FATTY-ACIDS; METABOLISM; CERAMIDE; GENE; DEPHOSPHORYLATION	Homeostasis of phosphatidylcholine (PC) is regulated by the opposing actions between CTP: phosphocholine cytidylyltransferase (CT) and the group VIA Ca2+-independent phospholipase A(2) (iPLA(2)). We investigated this process during the cell cycle. PC mass doubles during late G(1) and early S phase when its rate of catabolism is lowest. We show that iPLA(2) activity is cell cycle-dependent with peak activity during G(2)/M and late S phase. iPLA(2) activity declines during G(1) and is lowest at the G(1)/S transition and early S phase. The accumulation of PC correlates with decreased iPLA(2) activity, suggesting that regulation of this enzyme contributes to phospholipid accumulation. The levels of 80 kDa iPLA(2) protein do not change and thus cannot account for changes in enzyme activity. Reverse transcriptase and real-time PCR experiments show that splice variant iPLA(2) mRNAs are preferentially expressed during G(2)/M. Immunoblot analyses with an antibody directed against the N terminus of iPLA(2) revealed a similar to50 kDa protein that is of appropriate size to be the truncated protein encoded by the ankyrin-iPLA(2)-1 splice variant mRNA. The levels of truncated iPLA(2) protein were high in cells in late G(1) and S phase cells that had low iPLA(2) activity and low in G(2)/M cells that had high iPLA(2) activity. The truncated protein co- immunoprecipitated with full-length iPLA(2), indicating a physical interaction between the two proteins. Together, these data suggest that truncated iPLA(2) proteins associate with active iPLA(2) and down-regulate its activity during G(1). This down-regulation may contribute to phospholipid accumulation during the cell cycle.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA	Virginia Commonwealth University	Barbour, SE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Box 980614, Richmond, VA 23298 USA.	sbarbour@hsc.vcu.edu						ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; BERGERON JJ, 1970, BIOCHEM J, V119, P489, DOI 10.1042/bj1190489; Blencowe BJ, 2003, CURR BIOL, V13, pR149, DOI 10.1016/S0960-9822(03)00079-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chiu CH, 2001, BIOCHEM BIOPH RES CO, V287, P600, DOI 10.1006/bbrc.2001.5632; CORNELL R, 1977, EXP CELL RES, V109, P299, DOI 10.1016/0014-4827(77)90009-X; Cremona O, 2001, J CELL SCI, V114, P1041; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Forsell PKAL, 1998, FEBS LETT, V434, P295, DOI 10.1016/S0014-5793(98)00999-5; Forsell PKAL, 1999, EUR J BIOCHEM, V262, P575, DOI 10.1046/j.1432-1327.1999.00418.x; Fuentes L, 2003, J BIOL CHEM, V278, P44683, DOI 10.1074/jbc.M307209200; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; Jackowski S, 2000, BBA-MOL CELL BIOL L, V1483, P301, DOI 10.1016/S1388-1981(99)00203-6; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Jenkins GM, 2002, J BIOL CHEM, V277, P42572, DOI 10.1074/jbc.M207346200; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; Steed P. M., 2001, Current Pharmaceutical Biotechnology, V2, P241, DOI 10.2174/1389201013378644; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; TERCE F, 1994, J LIPID RES, V35, P2130; TONES MA, 1988, BIOCHEM J, V249, P51, DOI 10.1042/bj2490051; Tseu I, 2002, AM J RESP CELL MOL, V26, P506, DOI 10.1165/ajrcmb.26.4.4702; Venable ME, 1999, BBA-MOL CELL BIOL L, V1439, P291, DOI 10.1016/S1388-1981(99)00101-8; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	46	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52881	52892		10.1074/jbc.M410659200	http://dx.doi.org/10.1074/jbc.M410659200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15385540	hybrid			2022-12-25	WOS:000225680600012
J	Namekata, K; Enokido, Y; Ishii, I; Nagai, Y; Harada, T; Kimura, H				Namekata, K; Enokido, Y; Ishii, I; Nagai, Y; Harada, T; Kimura, H			Abnormal lipid metabolism in cystathionine beta-synthase-deficient mice, an animal model for hyperhomocysteinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; LOW-DENSITY-LIPOPROTEIN; ENDOPLASMIC-RETICULUM STRESS; SITE-DIRECTED MUTAGENESIS; ENDOTHELIAL DYSFUNCTION; RAT-LIVER; A-I; PLASMA-LIPOPROTEINS; APOLIPOPROTEIN-E; HOMOCYSTEINE	Hyperhomocysteinemia (HHCY) is a consequence of impaired methionine/cysteine metabolism and is caused by deficiency of vitamins and/or enzymes such as cystathionine beta-synthase (CBS). Although HHCY is an important and independent risk factor for cardiovascular diseases that are commonly associated with hepatic steatosis, the mechanism by which homocysteine promotes the development of fatty liver is poorly understood. CBS-deficient (CBS-/-) mice were previously generated by targeted deletion of the Cbs gene and exhibit pathological features similar to HHCY patients, including endothelial dysfunction and hepatic steatosis. Here we show abnormal lipid metabolism in CBS-/- mice. Triglyceride and nonesterified fatty acid levels were markedly elevated in CBS-/- mouse liver and serum. The activity of thiolase, a key enzyme in beta-oxidation of fatty acids, was significantly impaired in CBS-/- mouse liver. Hepatic apolipoprotein B100 levels were decreased, whereas serum apolipoprotein B100 and very low density lipoprotein levels were elevated in CBS-/- mice. Serum levels of cholesterol/phospholipid in high density lipoprotein fractions but not of total cholesterol/phospholipid were decreased, and the activity of lecithin-cholesterol acyltransferase was severely impaired in CBS-/- mice. Abnormal high density lipoprotein particles with higher mobility in polyacrylamide gel electrophoresis were observed in serum obtained from CBS-/- mice. Moreover, serum cholesterol/triglyceride distribution in lipoprotein fractions was altered in CBS-/- mice. These results suggest that hepatic steatosis in CBS-/- mice is caused by or associated with abnormal lipid metabolism.	Natl Inst Neurosci, Natl Ctr Neurol & Psychiat, Tokyo 1878551, Japan; Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, Tokyo 1838526, Japan	National Center for Neurology & Psychiatry - Japan; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Kimura, H (corresponding author), Natl Inst Neurosci, Natl Ctr Neurol & Psychiat, Ogawahigashi 4-1-1, Tokyo 1878551, Japan.	kimura@ncnp.go.jp	Kimura, Hideo/AGK-0606-2022; Kimura, Hideo/J-6811-2016	Kimura, Hideo/0000-0002-6069-0475; Enokido, Yasushi/0000-0003-3252-504X; Ishii, Isao/0000-0002-5367-205X				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOMHOFF JP, 1978, SCAND J CLIN LAB INV, V38, P177, DOI 10.3109/00365517809104922; CHEUNG MC, 1986, J LIPID RES, V27, P1135; Conde-Knape K, 2002, J LIPID RES, V43, P2136, DOI 10.1194/jlr.M200210-JLR200; Cravo ML, 1996, AM J CLIN NUTR, V63, P220, DOI 10.1093/ajcn/63.2.220; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FRANCONE OL, 1991, BIOCHEMISTRY-US, V30, P10074, DOI 10.1021/bi00106a002; FRAUSCHER G, 1995, LIFE SCI, V57, P813, DOI 10.1016/0024-3205(95)02009-8; GAULL G, 1974, J PEDIATR-US, V84, P381, DOI 10.1016/S0022-3476(74)80721-3; Halsted CH, 1996, HEPATOLOGY, V23, P497, DOI 10.1002/hep.510230314; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; Herrmann Wolfgang, 2002, Clin Lab, V48, P471; HULTBERG B, 1993, ALCOHOL CLIN EXP RES, V17, P687, DOI 10.1111/j.1530-0277.1993.tb00820.x; Ishii I, 2004, BIOCHEM J, V381, P113, DOI 10.1042/BJ20040243; JONES BG, 1994, ATHEROSCLEROSIS, V105, P165, DOI 10.1016/0021-9150(94)90046-9; Kanani PM, 1999, CIRCULATION, V100, P1161, DOI 10.1161/01.CIR.100.11.1161; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; Magoori K, 2003, J BIOL CHEM, V278, P11331, DOI 10.1074/jbc.M211987200; MARINETTI GV, 1958, BIOCHIM BIOPHYS ACTA, V30, P642, DOI 10.1016/0006-3002(58)90117-3; Mathieu M, 1997, J MOL BIOL, V273, P714, DOI 10.1006/jmbi.1997.1331; MIYAZAWA S, 1980, EUR J BIOCHEM, V103, P589, DOI 10.1111/j.1432-1033.1980.tb05984.x; Ng DS, 2004, J BIOL CHEM, V279, P7636, DOI 10.1074/jbc.M309439200; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; OSUMI T, 1979, BIOCHIM BIOPHYS ACTA, V574, P258; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; QU SJ, 1993, BIOCHEMISTRY-US, V32, P8732, DOI 10.1021/bi00085a002; Sakai N, 1997, J BIOL CHEM, V272, P7506, DOI 10.1074/jbc.272.11.7506; Stead LM, 2000, BIOCHEM J, V350, P685, DOI 10.1042/0264-6021:3500685; Usui S, 2002, J LIPID RES, V43, P805; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; Wang MH, 2004, CHEM REV, V104, P119, DOI 10.1021/cr020466v; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1989, J BIOL CHEM, V264, P11373	41	126	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52961	52969		10.1074/jbc.M406820200	http://dx.doi.org/10.1074/jbc.M406820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466479	hybrid			2022-12-25	WOS:000225680600020
J	Storch, S; Pohl, S; Braulke, T				Storch, S; Pohl, S; Braulke, T			A dileucine motif and a cluster of acidic amino acids in the second cytoplasmic domain of the Batten disease-related CLN3 protein are required for efficient lysosomal targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; TYROSINE-BASED SIGNAL; SORTING SIGNALS; MEDIUM CHAINS; DI-LEUCINE; MEMBRANE-GLYCOPROTEINS; INVARIANT CHAIN; AP-3 ADAPTER; HIV-1 NEF; LIMP-II	The juvenile form of ceroid lipofuscinosis ( Batten disease) is a neurodegenerative lysosomal storage disorder caused by mutations in the CLN3 gene. CLN3 encodes a multimembrane-spanning protein of unknown function, which is mainly localized in lysosomes in non-neuronal cells and in endosomes in neuronal cells. For this study we constructed chimeric proteins of three CLN3 cytoplasmic domains fused to the lumenal and transmembrane domains of the reporter proteins LAMP-1 and lysosomal acid phosphatase to identify lysosomal targeting motifs and to determine the intracellular transport and subcellular localization of the chimera in transfected cell lines. We report that a novel type of dileucine-based sorting motif, EEEX8LI, present in the second cytoplasmic domain of CLN3, is sufficient for proper targeting to lysosomes. The first cytoplasmic domain of CLN3 and the mutation of the dileucine motif resulted in a partial mis-sorting of chimeric proteins to the plasma membrane. At equilibrium, 4-13% of the different chimera are present at the cell surface. Analysis of lysosome-specific proteolytic processing revealed that lysosomal acid phosphatase chimera containing the second cytoplasmic domain of CLN3 showed the highest rate of lysosomal delivery, whereas the C terminus of CLN3 was found to be less efficient in lysosomal targeting. However, none of these cytosolic CLN3 domains was able to interact with AP-1, AP-3, or GGA3 adaptor complexes. These data revealed that lysosomal sorting motifs located in an intramolecular cytoplasmic domain of a multimembrane-spanning protein have different structural requirements for adaptor binding than sorting signals found in the C-terminal cytoplasmic domains of single- or dual-spanning lysosomal membrane proteins.	Univ Hamburg Hosp, Childrens Hosp, Dept Biochem, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Braulke, T (corresponding author), Univ Hamburg Hosp, Childrens Hosp, Dept Biochem, Martinistr 52,Bldg W 23, D-20246 Hamburg, Germany.	braulke@uke.uni-hamburg.de	Pohl, Sandra/AAF-1943-2020; Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532; Storch, Stephan/0000-0002-8807-5917; Pohl, Sandra/0000-0001-7409-7042				Blumstein J, 2001, J NEUROSCI, V21, P8034, DOI 10.1523/JNEUROSCI.21-20-08034.2001; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; Cherqui S, 2001, J BIOL CHEM, V276, P13314, DOI 10.1074/jbc.M010562200; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Ezaki J, 2003, J NEUROCHEM, V87, P1296, DOI 10.1046/j.1471-4159.2003.02132.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; Geyer M, 2002, MOL BIOL CELL, V13, P2045, DOI 10.1091/mbc.02-02-0026; GOEBEL HH, 1999, NEURONAL CEROID LIPO, V33; Golabek AA, 2000, MOL GENET METAB, V70, P203, DOI 10.1006/mgme.2000.3006; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Huizing M, 2001, MOL BIOL CELL, V12, P2075, DOI 10.1091/mbc.12.7.2075; Janes RW, 1996, FEBS LETT, V399, P75, DOI 10.1016/S0014-5793(96)01290-2; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Jarvela I, 1998, HUM MOL GENET, V7, P85, DOI 10.1093/hmg/7.1.85; Johnson AO, 2001, MOL BIOL CELL, V12, P367, DOI 10.1091/mbc.12.2.367; Kida E, 1999, MOL GENET METAB, V66, P265, DOI 10.1006/mgme.1999.2837; Kim Y, 2003, P NATL ACAD SCI USA, V100, P15458, DOI 10.1073/pnas.2136651100; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; Kyttala A, 2004, MOL BIOL CELL, V15, P1313, DOI 10.1091/mbc.E03-02-0120; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Le Borgne R, 2001, J CELL SCI, V114, P2831; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; Luiro K, 2001, HUM MOL GENET, V10, P2123, DOI 10.1093/hmg/10.19.2123; Mao QW, 2003, FEBS LETT, V555, P351, DOI 10.1016/S0014-5793(03)01274-2; Mao QW, 2003, FEBS LETT, V541, P40, DOI 10.1016/S0014-5793(03)00284-9; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Obermuller S, 2002, J CELL SCI, V115, P185; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; Pearce DA, 1999, NAT GENET, V22, P55, DOI 10.1038/8861; Persaud-Sawin DANW, 2002, HUM MOL GENET, V11, P2129, DOI 10.1093/hmg/11.18.2129; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rodionov DG, 2002, J BIOL CHEM, V277, P47436, DOI 10.1074/jbc.M207149200; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409; Salazar G, 2004, J BIOL CHEM, V279, P25430, DOI 10.1074/jbc.M402331200; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; Simmen T, 1999, J CELL SCI, V112, P45; Stephens DJ, 1998, BIOCHEM J, V335, P567, DOI 10.1042/bj3350567; Storch S, 2001, J BIOL CHEM, V276, P4298, DOI 10.1074/jbc.M005548200; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Taschner PEM, 1997, NEUROPEDIATRICS, V28, P18, DOI 10.1055/s-2007-973658; Tikkanen R, 2000, TRAFFIC, V1, P631, DOI 10.1034/j.1600-0854.2000.010807.x; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	62	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53625	53634		10.1074/jbc.M410930200	http://dx.doi.org/10.1074/jbc.M410930200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15469932	hybrid			2022-12-25	WOS:000225680600099
J	Ellis, MA; Miedel, MT; Guerriero, CJ; Weisz, OA				Ellis, MA; Miedel, MT; Guerriero, CJ; Weisz, OA			ADP-ribosylation factor 1-independent protein sorting and export from the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLARIZED MDCK CELLS; CLATHRIN-MEDIATED ENDOCYTOSIS; INFLUENZA-VIRUS HEMAGGLUTININ; VESICULAR STOMATITIS-VIRUS; GTP-GAMMA-S; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; EPITHELIAL-CELLS; APICAL MEMBRANE	Polarized epithelial cells efficiently sort newly synthesized apical and basolateral proteins into distinct transport carriers that emerge from the trans-Golgi network (TGN), and this sorting is recapitulated in nonpolarized cells. While the targeting signals of basolaterally destined proteins are generally cytoplasmically disposed, apical sorting signals are not typically accessible to the cytosol, and the transport machinery required for segregation and export of apical cargo remains largely unknown. Here we investigated the molecular requirements for TGN export of the apical marker influenza hemagglutinin (HA) in HeLa cells using an in vitro reconstitution assay. HA was released from the TGN in intact membrane-bound compartments, and export was dependent on addition of an ATP-regenerating system and exogenous cytosol. HA release was inhibited by guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS) as well as under conditions known to negatively regulate apical transport in vivo, including expression of the acid-activated proton channel influenza M2. Interestingly, release of HA was unaffected by depletion of ADP-ribosylation factor 1, a small GTPase that has been implicated in the recruitment of all known adaptors and coat proteins to the Golgi complex. Furthermore, regulation of HA release by GTPgammaS or M2 expression was unaffected by cytosolic depletion of ADP-ribosylation factor 1, suggesting that HA sorting remains functionally intact in the absence of the small GTPase. These data suggest that TGN sorting and export of influenza HA does not require classical adaptors involved in the formation of other classes of exocytic carriers and thus appears to proceed via a novel mechanism.	Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Lab Epithelial Cell Biol, 3550 Terrace St, Pittsburgh, PA 15261 USA.	weisz@pitt.edu		Guerriero, Christopher/0000-0002-1046-2300; Miedel, Mark/0000-0002-0132-6032	NIDDK NIH HHS [R01 DK54407] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054407] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Altschuler Y, 2003, CURR OPIN CELL BIOL, V15, P423, DOI 10.1016/S0955-0674(03)00084-X; Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; Banting G, 1998, J CELL SCI, V111, P3451; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bruns JR, 2002, J BIOL CHEM, V277, P2012, DOI 10.1074/jbc.M108571200; Chen JL, 2004, FEBS LETT, V566, P281, DOI 10.1016/j.febslet.2004.04.061; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; CIAMPOR F, 1992, VIROLOGY, V188, P14, DOI 10.1016/0042-6822(92)90730-D; Folsch H, 2003, J CELL BIOL, V163, P351, DOI 10.1083/jcb.200309020; Fucini RV, 2002, MOL BIOL CELL, V13, P621, DOI 10.1091/mbc.01-11-0547; Gleeson PA, 1996, J CELL SCI, V109, P2811; GRAMBAS S, 1992, VIROLOGY, V190, P11, DOI 10.1016/0042-6822(92)91187-Y; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Happe S, 1998, J CELL BIOL, V140, P511, DOI 10.1083/jcb.140.3.511; Henkel JR, 1998, MOL BIOL CELL, V9, P2477, DOI 10.1091/mbc.9.9.2477; Henkel JR, 2000, J CELL BIOL, V148, P495, DOI 10.1083/jcb.148.3.495; Henkel JR, 1998, J BIOL CHEM, V273, P6518, DOI 10.1074/jbc.273.11.6518; Hu JS, 1997, BIOCHEMISTRY-US, V36, P5045, DOI 10.1021/bi963010e; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; Jacob R, 2004, J BIOL CHEM, V279, P3680, DOI 10.1074/jbc.C300503200; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Ling WLW, 1998, METHODS, V16, P141, DOI 10.1006/meth.1998.0661; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LOW SH, 1991, J BIOL CHEM, V266, P17729; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McLauchlan HJ, 2001, CELL BIOL INT, V25, P705, DOI 10.1006/cbir.2001.0717; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Nelson WJ, 2001, TRENDS CELL BIOL, V11, P483, DOI 10.1016/S0962-8924(01)02145-6; Nishimura N, 2002, P NATL ACAD SCI USA, V99, P6755, DOI 10.1073/pnas.092150699; Pauloin A, 1999, J CELL SCI, V112, P4089; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Polishchuk EV, 2003, MOL BIOL CELL, V14, P4470, DOI 10.1091/mbc.E03-01-0033; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Potter BA, 2004, MOL BIOL CELL, V15, P1407, DOI 10.1091/mbc.E03-08-0550; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; REAVES B, 1994, FEBS LETT, V345, P61, DOI 10.1016/0014-5793(94)00437-4; Reaves BJ, 1998, MOL BIOL CELL, V9, P1107, DOI 10.1091/mbc.9.5.1107; Rodriguez-Boulan E, 2004, CURR OPIN CELL BIOL, V16, P436, DOI 10.1016/j.ceb.2004.06.013; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Rustom A, 2002, TRAFFIC, V3, P279, DOI 10.1034/j.1600-0854.2002.030405.x; Scheiffele P, 2000, ESSAYS BIOCHEM, V36, P27, DOI 10.1042/bse0360027; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; Simon JP, 1998, P NATL ACAD SCI USA, V95, P1073, DOI 10.1073/pnas.95.3.1073; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; SPIRO DJ, 1995, J BIOL CHEM, V270, P13693, DOI 10.1074/jbc.270.23.13693; Stumber M, 2002, EUR J BIOCHEM, V269, P3270, DOI 10.1046/j.1432-1033.2002.03003.x; Takeda T, 2003, AM J PHYSIOL-CELL PH, V284, pC1105, DOI 10.1152/ajpcell.00514.2002; Tall RD, 2003, TRAFFIC, V4, P838, DOI 10.1046/j.1398-9219.2003.0138.x; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; WAGNER M, 1994, J CELL SCI, V107, P933; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; Wylie FG, 2003, TRAFFIC, V4, P175, DOI 10.1034/j.1600-0854.2003.00106.x; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	70	7	7	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52735	52743		10.1074/jbc.M410533200	http://dx.doi.org/10.1074/jbc.M410533200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459187	hybrid			2022-12-25	WOS:000225493400120
J	Madsen, M; Moller, HJ; Nielsen, MJ; Jacobsen, C; Graversen, JH; van den Berg, T; Moestrup, SK				Madsen, M; Moller, HJ; Nielsen, MJ; Jacobsen, C; Graversen, JH; van den Berg, T; Moestrup, SK			Molecular characterization of the haptoglobin center dot hemoglobin receptor CD163 - Ligand binding properties of the scavenger receptor cysteine-rich domain region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE CD163; HUMAN MACROPHAGES; IN-VITRO; PROTEIN; PLASMA; IDENTIFICATION; SUPERFAMILY; OXYGENASE-1; ANCIENT; RELEASE	CD163 is the macrophage receptor for endocytosis of haptoglobin . hemoglobin complexes. The extracellular region consisting of nine scavenger receptor cysteine-rich ( SRCR) domains also circulates in plasma as a soluble protein. By ligand binding analysis of a broad spectrum of soluble CD163 truncation variants, the amino-terminal third of the SRCR region was shown to be crucial for the binding of haptoglobin . hemoglobin complexes. By Western blotting of the CD163 variants, a panel of ten monoclonal antibodies was mapped to SRCR domains 1, 3, 4, 6, 7, and 9, respectively. Only the two antibodies binding to SRCR domain 3 exhibited effective inhibition of ligand binding. Furthermore, analysis of purified native CD163 revealed that proteolytic cleavage in SRCR domain 3 inactivates ligand binding. Calcium protects against cleavage in this domain. Analysis of the calcium sensitivity of ligand binding to CD163 demonstrated that optimal ligand binding requires physiological plasma calcium concentrations, and an immediate ligand release occurs at the low calcium concentrations measured in acidifying endosomes. In conclusion, SRCR domain 3 of CD163 is an exposed domain and a critical determinant for the calcium-sensitive coupling of haptoglobin . hemoglobin complexes.	Univ Aarhus, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Dept Clin Biochem, DK-8000 Aarhus C, Denmark; VU Med Ctr, Dept Mol Cell Biol, NL-1007 MB Amsterdam, Netherlands	Aarhus University; Aarhus University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Moestrup, SK (corresponding author), Univ Aarhus, Dept Med Biochem, DK-8000 Aarhus C, Denmark.	skm@biokemi.au.dk	van den Berg, Timo K/AAC-2479-2022; Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014	Moestrup, Søren Kragh/0000-0003-3862-2107; Graversen, Jonas Heilskov/0000-0001-7119-2108; Graversen, Jonas Heilskov/0000-0002-2411-9933; Madsen, Mette/0000-0001-7241-6505; Moller, Holger Jon/0000-0001-7687-5995				Ahn JS, 2002, J LEUKOCYTE BIOL, V72, P382; Bowen MA, 2000, PROTEINS, V40, P420; BUNN HF, 2001, HARRISONS PRINCIPLES, P681; Dati F, 1996, EUR J CLIN CHEM CLIN, V34, P517; Frings W, 2002, FEBS LETT, V526, P93, DOI 10.1016/S0014-5793(02)03142-3; Gburek J, 2002, J AM SOC NEPHROL, V13, P423, DOI 10.1681/ASN.V132423; Gerasimenko JV, 1998, CURR BIOL, V8, P1335, DOI 10.1016/S0960-9822(07)00565-9; Graversen JH, 2002, INT J BIOCHEM CELL B, V34, P309, DOI 10.1016/S1357-2725(01)00144-3; Gronlund J, 2000, J IMMUNOL, V165, P6406, DOI 10.4049/jimmunol.165.11.6406; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; Moestrup SK, 2004, ANN MED, V36, P347, DOI 10.1080/07853890410033171; Moller HJ, 2004, EUR J HAEMATOL, V72, P135, DOI 10.1046/j.0902-4441.2003.00193.x; Moller HJ, 2002, SCAND J CLIN LAB INV, V62, P293, DOI 10.1080/003655102760145852; Moller HJ, 2002, BLOOD, V99, P378, DOI 10.1182/blood.V99.1.378; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9; Ritter M, 2001, EUR J IMMUNOL, V31, P999, DOI 10.1002/1521-4141(200104)31:4<999::AID-IMMU999>3.0.CO;2-R; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; SCHAER DJ, 2004, IN PRESS EUR J HAEMA; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; Sulahian TH, 2001, J IMMUNOL METHODS, V252, P25, DOI 10.1016/S0022-1759(01)00328-3; Van den Heuvel MM, 1999, J LEUKOCYTE BIOL, V66, P858, DOI 10.1002/jlb.66.5.858	28	113	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51561	51567		10.1074/jbc.M409629200	http://dx.doi.org/10.1074/jbc.M409629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448162	hybrid			2022-12-25	WOS:000225355800111
J	Ripaud, L; Maillet, L; Immel-Torterotot, F; Durand, F; Cullin, C				Ripaud, L; Maillet, L; Immel-Torterotot, F; Durand, F; Cullin, C			The [URE3] yeast prion results from protein aggregates that differ from amyloid filaments formed in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; STRUCTURAL-CHARACTERIZATION; MAMMALIAN PRIONS; SCRAPIE; DOMAIN; CELLS; DETERMINANT; PROPAGATION; PRODUCTS; FIBERS	The [URE3] yeast prion is a self-propagating inactive form of the Ure2 protein. Ure2p is composed of two domains, residues 1 - 93, the prion-forming domain, and the remaining C-terminal part of the protein, which forms the functional domain involved in nitrogen catabolite repression. In vitro, Ure2p forms amyloid filaments that have been proposed to be the aggregated prion form found in vivo. Here we showed that the biochemical characteristics of these two species differ. Protease digestions of Ure2p filaments and soluble Ure2p are comparable when analyzed by Coomassie staining as by Western blot. However, this finding does not explain the pattern specifically observed in [ URE3] strains. Antibodies raised against the C-terminal part of Ure2p revealed the existence of proteolysis sites efficiently cleaved when [ URE3], but not wild-type crude extracts, were submitted to limited proteolysis. The same antibodies lead to an equivalent digestion pattern when recombinant Ure2p ( either soluble or amyloid) was analyzed in the same way. These results strongly suggest that aggregated Ure2p in [ URE3] yeast cells is different from the amyloid filaments generated in vitro.	Univ Bordeaux 2, CNRSI, UMR 5095, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Cullin, C (corresponding author), Univ Bordeaux 2, CNRSI, UMR 5095, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	Christophe.Cullin@ibgc.u-bordeaux2.fr	Immel, Françoise/GNP-4167-2022; cullin, christophe/AAM-2179-2020; MAILLET, Laurent/K-7959-2015; Immel, Françoise/N-7079-2019	Immel, Françoise/0000-0002-2028-902X; cullin, christophe/0000-0003-4110-4677; MAILLET, Laurent/0000-0002-8169-060X; 				AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; Bach S, 2003, NAT BIOTECHNOL, V21, P1075, DOI 10.1038/nbt855; Baxa U, 2003, J BIOL CHEM, V278, P43717, DOI 10.1074/jbc.M306004200; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bousset L, 2004, BIOCHEMISTRY-US, V43, P5022, DOI 10.1021/bi049828e; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Fernandez-Bellot E, 2000, EMBO J, V19, P3215, DOI 10.1093/emboj/19.13.3215; Fernandez-Bellot E, 2002, EMBO REP, V3, P76, DOI 10.1093/embo-reports/kvf011; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Ripaud L, 2003, EMBO J, V22, P5251, DOI 10.1093/emboj/cdg488; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Schlumpberger M, 2000, PROTEIN SCI, V9, P440; Schlumpberger M, 2001, MOL CELL BIOL, V21, P7035, DOI 10.1128/MCB.21.20.7035-7046.2001; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Speransky VV, 2001, J CELL BIOL, V153, P1327, DOI 10.1083/jcb.153.6.1327; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; TUROSCY V, 1987, J BACTERIOL, V169, P2598, DOI 10.1128/jb.169.6.2598-2600.1987; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	39	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50962	50968		10.1074/jbc.M408792200	http://dx.doi.org/10.1074/jbc.M408792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456789	Green Published, hybrid			2022-12-25	WOS:000225355800040
J	Wadhwa, R; Yaguchi, T; Kaur, K; Suyama, E; Kawasaki, H; Taira, K; Kaul, SC				Wadhwa, R; Yaguchi, T; Kaur, K; Suyama, E; Kawasaki, H; Taira, K; Kaul, SC			Use of a randomized hybrid ribozyme library for identification of genes involved in muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE WITHDRAWAL; SEX-DETERMINING GENE; IN-VIVO; CAENORHABDITIS-ELEGANS; HAMMERHEAD RIBOZYME; MAMMALIAN-CELLS; MESSENGER-RNA; APOPTOTIC PATHWAY; CLEAVAGE ACTIVITY; SKELETAL-MUSCLE	We have employed the hybrid hammerhead ribozyme-based gene discovery system for identification of genes functionally involved in muscle differentiation using in vitro myoblast differentiation assay. The major muscle regulatory genes (MyoD1, Mylk, myosin, myogenin, and Myf5) were identified endorsing the validity of this method. Other gene targets included tumor suppressors and cell cycle regulators (p19(ARF) and p21(WAF1)), FGFR-4, fibronectin, Prkg2, Pdk4, fem, and six novel proteins. Functional involvement of three of the identified targets in myoblast differentiation was confirmed by their specific knockdown using ribozymes and siRNA. Besides demonstrating a simple and an effective method of isolation of gene functions involved in muscle differentiation, we report for the first time that overexpression of Fem, a member of the sex-determining family of proteins, caused accelerated myotube formation, and its targeting deferred myoblast differentiation. This functional gene screening is not only helpful in understanding the molecular pathways of muscle differentiation but also to design molecular strategies for myopathologic therapies.	Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan; Univ Tokyo, Dept Chem & Biotechnol, Sch Engn, Tokyo 1138656, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Kaul, SC (corresponding author), Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, 1-1-1 Higashi, Tsukuba, Ibaraki 3058562, Japan.	s-kaul@aist.go.jp	Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916				Adams GR, 1999, J APPL PHYSIOL, V87, P1705, DOI 10.1152/jappl.1999.87.5.1705; Akashi H, 2002, J BIOCHEM, V131, P687, DOI 10.1093/oxfordjournals.jbchem.a003152; Amack JD, 2004, DEV BIOL, V265, P294, DOI 10.1016/j.ydbio.2003.07.021; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Bouzeghrane F, 2004, J MOL CELL CARDIOL, V36, P343, DOI 10.1016/j.yjmcc.2003.11.007; Cabane C, 2003, AM J PHYSIOL-CELL PH, V284, pC658, DOI 10.1152/ajpcell.00078.2002; Cech TR, 2002, BIOCHEM SOC T, V30, P1162, DOI 10.1042/BST0301162; ChinSang ID, 1996, GENE DEV, V10, P2314, DOI 10.1101/gad.10.18.2314; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; Endesfelder S, 2003, J MOL MED-JMM, V81, P355, DOI 10.1007/s00109-003-0439-6; Franchini Massimo, 2003, Recenti Progressi in Medicina, V94, P478; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Garcia AJ, 1999, MOL BIOL CELL, V10, P785, DOI 10.1091/mbc.10.3.785; Goodchild John, 2002, Expert Opin Ther Targets, V6, P235, DOI 10.1517/14728222.6.2.235; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HAWKE TJ, 2003, AM J PHYSIOL-CELL PH, V285, P25; Iyo Mayu, 2004, Methods Mol Biol, V252, P257; Kato Y, 2000, Nucleic Acids Symp Ser, P283; Kato Y, 2001, J BIOL CHEM, V276, P15378, DOI 10.1074/jbc.M010570200; Kawasaki H, 2002, NAT BIOTECHNOL, V20, P376, DOI 10.1038/nbt0402-376; Kawasaki H, 2002, EMBO REP, V3, P443, DOI 10.1093/embo-reports/kvf098; KAWASAKI H, 2002, NUCL ACIDS RES S, V2, P275; KAWASAKI H, 2001, NUCL ACIDS RES S, V1, P133; Kawasaki Hiroaki, 2004, Methods Mol Biol, V252, P237; Kawasaki K, 2002, NUCLEIC ACIDS RES, V30, P3682, DOI 10.1093/nar/gkf487; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; Koseki S, 1999, J VIROL, V73, P1868, DOI 10.1128/JVI.73.3.1868-1877.1999; Kruger M, 2000, P NATL ACAD SCI USA, V97, P8566, DOI 10.1073/pnas.97.15.8566; Kuwabara T, 2000, TRENDS BIOTECHNOL, V18, P462, DOI 10.1016/S0167-7799(00)01498-0; Kuwabara T, 2002, J BIOCHEM, V132, P149, DOI 10.1093/oxfordjournals.jbchem.a003193; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; MARCELLE C, 1995, DEV BIOL, V172, P100, DOI 10.1006/dbio.1995.0008; Marics I, 2002, DEVELOPMENT, V129, P4559; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; Mehra A, 1999, GENE DEV, V13, P1453, DOI 10.1101/gad.13.11.1453; Michienzi A, 2003, ANN NY ACAD SCI, V1002, P63, DOI 10.1196/annals.1281.008; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Miyagishi M, 2001, CANCER CHEMOTH PHARM, V48, pS96, DOI 10.1007/s002800100314; Morla AO, 2000, BIOCHEM BIOPH RES CO, V272, P298, DOI 10.1006/bbrc.2000.2769; Onuki R, 2004, EMBO J, V23, P959, DOI 10.1038/sj.emboj.7600049; Onuki R, 2003, ANTISENSE NUCLEIC A, V13, P75, DOI 10.1089/108729003321629629; Osses N, 2002, AM J PHYSIOL-CELL PH, V282, pC383, DOI 10.1152/ajpcell.00322.2001; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; Rossi JJ, 1999, CURR OPIN MOL THER, V1, P316; Sano M, 2002, ANTISENSE NUCLEIC A, V12, P341, DOI 10.1089/108729002761381311; SANO M, 2000, NUCL ACIDS S SER, V44, P203; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; Sioud Mouldy, 2001, Current Molecular Medicine (Hilversum), V1, P575, DOI 10.2174/1566524013363366; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; Stage-Zimmermann TK, 1998, RNA, V4, P875, DOI 10.1017/S1355838298980876; Suyama E, 2003, P NATL ACAD SCI USA, V100, P5616, DOI 10.1073/pnas.1035850100; Suyama E, 2003, CANCER RES, V63, P119; Takagi Y, 2002, BIOCHEM SOC T, V30, P1145; Taylor MV, 2003, CURR BIOL, V13, pR964, DOI 10.1016/j.cub.2003.11.044; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; Ventura-Holman T, 2003, GENE, V314, P133, DOI 10.1016/S0378-1119(03)00712-1; Ventura-Holman T, 2000, BIOCHEM BIOPH RES CO, V267, P317, DOI 10.1006/bbrc.1999.1942; Verma S, 1997, CURR OPIN CHEM BIOL, V1, P532, DOI 10.1016/S1367-5931(97)80049-X; Wadhwa R, 2003, EMBO REP, V4, P595, DOI 10.1038/sj.embor.embor855; Warashina M, 2001, P NATL ACAD SCI USA, V98, P5572, DOI 10.1073/pnas.091411398; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; Welch PJ, 2000, GENOMICS, V66, P274, DOI 10.1006/geno.2000.6230; Zhao JJ, 1998, MOL CELL NEUROSCI, V11, P92, DOI 10.1006/mcne.1998.0669	65	15	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51622	51629		10.1074/jbc.M407428200	http://dx.doi.org/10.1074/jbc.M407428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448151	hybrid			2022-12-25	WOS:000225355800118
J	Liu, JH; Chang, TW; Huang, CY; Chen, SU; Wu, HN; Chang, MC; Hsiao, CD				Liu, JH; Chang, TW; Huang, CY; Chen, SU; Wu, HN; Chang, MC; Hsiao, CD			Crystal structure of PriB, a primosomal DNA replication protein of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHI X174-TYPE PRIMOSOME; STRAND BINDING-PROTEIN; X-RAY-DIFFRACTION; COPY NUMBER; IN-VITRO; IDENTIFICATION; BACTERIAL; DOMAIN; SSB; PURIFICATION	PriB is one of the Escherichia coli phiX-type primosome proteins that are required for assembly of the primosome, a mobile multi-enzyme complex responsible for the initiation of DNA replication. Here we report the crystal structure of the E. coli PriB at 2.1 Angstrom resolution by multi-wavelength anomalous diffraction using a mercury derivative. The polypeptide chain of PriB is structurally similar to that of single-stranded DNA-binding protein (SSB). However, the biological unit of PriB is a dimer, not a homotetramer like SSB. Electrophoretic mobility shift assays demonstrated that PriB binds single-stranded DNA and single-stranded RNA with comparable affinity. We also show that PriB binds single-stranded DNA with certain base preferences. Based on the PriB structural information and biochemical studies, we propose that the potential tetramer formation surface and several other regions of PriB may participate in protein-protein interaction during DNA replication. These findings may illuminate the role of PriB in phiX-type primosome assembly.	Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Surg, Tainan 701, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan	National Cheng Kung University; National Cheng Kung University; National Defense Medical Center; Academia Sinica - Taiwan	Chang, MC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan.	mcchang@mail.ncku.edu.tw; mbhsiao@ccvax.sinica.edu.tw	Wu, Huey Nan/ABA-4484-2021; Hsiao, Chwan-Deng/AAZ-8869-2021; Liu, Jyung-Hurng/C-1340-2010; Hsiao, Chwan-Deng/D-7327-2013	Wu, Huey Nan/0000-0002-1538-7776; Hsiao, Chwan-Deng/0000-0002-7012-1532; Liu, Jyung-Hurng/0000-0002-7173-0372; 				ALLEN GC, 1993, J BIOL CHEM, V268, P19204; ALLEN GC, 1991, J BIOL CHEM, V266, P11610; ARAI K, 1981, J BIOL CHEM, V256, P5281; BASHFORD D, 1992, J MOL BIOL, V224, P473, DOI 10.1016/0022-2836(92)91009-E; Berges H, 1997, J BACTERIOL, V179, P956, DOI 10.1128/jb.179.3.956-958.1997; BOBST EV, 1991, BIOCHIM BIOPHYS ACTA, V1078, P199, DOI 10.1016/0167-4838(91)99010-P; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Curth U, 1996, NUCLEIC ACIDS RES, V24, P2706, DOI 10.1093/nar/24.14.2706; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; DEVRIES J, 1994, EUR J BIOCHEM, V224, P613; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; Fairall L, 2000, PRACT APPROACH SER, P65; Flores MJ, 2002, MOL MICROBIOL, V44, P783, DOI 10.1046/j.1365-2958.2002.02913.x; Greipel J., 1989, PROTEIN NUCL ACID IN, P61, DOI [10.1007/978-1-349-09871-2_4, DOI 10.1007/978-1-349-09871-2_4]; Harinarayanan R, 2004, GENETICS, V166, P1165, DOI 10.1534/genetics.166.3.1165; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Jordan IK, 2001, GENOME RES, V11, P555, DOI 10.1101/gr.GR-1660R; KORNBERG A, 1992, DNA REPLICATION, P275; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOW RL, 1982, J BIOL CHEM, V257, P6242; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Marians KJ, 2000, PROG NUCLEIC ACID RE, V63, P39; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; Matsumoto T, 2000, J BIOCHEM, V127, P329, DOI 10.1093/oxfordjournals.jbchem.a022611; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; Ng JY, 1996, J BIOL CHEM, V271, P15649, DOI 10.1074/jbc.271.26.15649; Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; Ponomarev VA, 2003, J MOL MICROB BIOTECH, V5, P225, DOI 10.1159/000071074; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652; Saikrishnan K, 2003, J MOL BIOL, V331, P385, DOI 10.1016/S0022-2836(03)00729-0; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sandler SJ, 1999, MOL MICROBIOL, V34, P91, DOI 10.1046/j.1365-2958.1999.01576.x; Sandler SJ, 2001, MOL MICROBIOL, V41, P697, DOI 10.1046/j.1365-2958.2001.02547.x; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SCHEKMAN R, 1974, SCIENCE, V186, P987, DOI 10.1126/science.186.4168.987; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; TOUGU K, 1994, J BIOL CHEM, V269, P4675; Webster G, 1997, FEBS LETT, V411, P313, DOI 10.1016/S0014-5793(97)00747-3; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; Xu LW, 2003, MOL CELL, V11, P817, DOI 10.1016/S1097-2765(03)00061-3; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZAVITZ KH, 1991, J BIOL CHEM, V266, P13988	59	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50465	50471		10.1074/jbc.M406773200	http://dx.doi.org/10.1074/jbc.M406773200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383524	hybrid			2022-12-25	WOS:000225229500112
J	Staruschenko, A; Nichols, A; Medina, JL; Camacho, P; Zheleznova, NN; Stockand, JD				Staruschenko, A; Nichols, A; Medina, JL; Camacho, P; Zheleznova, NN; Stockand, JD			Rho small GTPases activate the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE; TRANSLOCATION; KINASE; ALDOSTERONE; AQUAPORIN-2; ACTIN; RAC1	Small G proteins in the Rho family are known to regulate diverse cellular processes, including cytoskeletal organization and cell cycling, and more recently, ion channel activity and activity of phosphatidylinositol 4-phosphate 5-kinase (PI(4)P 5-K). The present study investigates regulation of the epithelial Na+ channel ( ENaC) by Rho GTPases. We demonstrate here that RhoA and Rac1 markedly increase ENaC activity. Activation by RhoA was suppressed by the C3 exoenzyme. Inhibition of the downstream RhoA effector Rho kinase, which is necessary for RhoA activation of PI(4)P 5-K, abolished ENaC activation. Similar to RhoA, overexpression of PI(4)P 5-K increased ENaC activity suggesting that production of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) in response to RhoA-Rho kinase signaling stimulates ENaC. Supporting this idea, inhibition of phosphatidylinositol 4-kinase, but not the RhoA effector phosphatidylinositol 3-kinase and MAPK cascades, markedly attenuated RhoA-dependent activation of ENaC. RhoA increased ENaC activity by increasing the plasma membrane levels of this channel. We conclude that RhoA activates ENaC via Rho kinase and subsequently activates PI(4)P 5-K with concomitant increases in PI(4,5)P-2 levels promoting channel insertion into the plasma membrane.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Staruschenko, A (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	staruschenko@uthscsa.edu		Staruschenko, Alexander/0000-0002-5190-8356; Stockand, James/0000-0002-3817-4319	NIDDK NIH HHS [R01-DK-59594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Booth RE, 2003, J BIOL CHEM, V278, P41367, DOI 10.1074/jbc.M305400200; Cachero TG, 1998, CELL, V93, P1077, DOI 10.1016/S0092-8674(00)81212-X; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Kanzaki M, 2004, J BIOL CHEM, V279, P30622, DOI 10.1074/jbc.M401443200; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Klussmann E, 2001, J BIOL CHEM, V276, P20451, DOI 10.1074/jbc.M010270200; Li LB, 2002, MOL PHARMACOL, V62, P602, DOI 10.1124/mol.62.3.602; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Staruschenko A, 2004, J BIOL CHEM, V279, P37771, DOI 10.1074/jbc.M402176200; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Storey NM, 2002, CURR BIOL, V12, P27, DOI 10.1016/S0960-9822(01)00625-X; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tamma G, 2001, AM J PHYSIOL-RENAL, V281, pF1092, DOI 10.1152/ajprenal.0091.2001; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Tong QS, 2004, AM J PHYSIOL-RENAL, V286, pF1232, DOI 10.1152/ajprenal.00345.2003; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Weernink PAO, 2004, J BIOL CHEM, V279, P7840, DOI 10.1074/jbc.M312737200; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094; Yang SA, 2004, J BIOL CHEM, V279, P42331, DOI 10.1074/jbc.M404335200; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200	32	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49989	49994		10.1074/jbc.M409812200	http://dx.doi.org/10.1074/jbc.M409812200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15448132	hybrid			2022-12-25	WOS:000225229500055
J	Tamguney, G; Van Snick, J; Fickenscher, H				Tamguney, G; Van Snick, J; Fickenscher, H			Autocrine stimulation of rhadinovirus-transformed T cells by the chemokine CCL1/I-309	ONCOGENE			English	Article						autocrine loop; growth transformation; rhadinovirus; suppressive subtractive hybridization T lymphocyte	VIRUS TYPE-I; DEXAMETHASONE-INDUCED APOPTOSIS; SAIMIRI PROTEIN TIP; SUBGROUP-C STRAINS; HERPESVIRUS-SAIMIRI; MOLECULAR-CLONING; RECEPTOR CCR8; MONOCYTE CHEMOATTRACTANT; GROWTH TRANSFORMATION; ONCOPROTEIN STP-C488	The rhadinovirus herpesvirus saimiri transforms human T lymphocytes to stable growth in culture. Besides the viral oncogenes stpC and tip, little is understood about the transformation process at the cellular level. To identify cellular factors that might contribute to growth transformation, we compared cellular gene expression in pairs of herpesvirus saimiri-transformed and nontransformed human T-cell clones. Using cDNA arrays and suppressive subtractive hybridization, we were able to identify the chemokine CCL1/I-309 as one of the few cellular genes that are strongly overexpressed in T cells after growth transformation with herpesvirus saimiri. The transformed T cells expressed CCR8, the receptor for CCL1, which rapidly induced intracellular calcium ion levels. Neutralizing antibodies to CCL1 led to reduced secretion of interferon-gamma and tumor necrosis factor-alpha as well as to reduced proliferation rates in transformed T cells. Thus, we propose that growth transformation of human T cells with herpesvirus saimiri gives rise to an autocrine loop where the proliferation of transformed T cells is supported by the endogenous production of the chemokine CCL1.	Univ Heidelberg, Dept Virol, D-69120 Heidelberg, Germany; Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Expt Med Unit, B-1200 Brussels, Belgium	Ruprecht Karls University Heidelberg; University of California System; University of California San Francisco; Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	Fickenscher, H (corresponding author), Univ Heidelberg, Dept Virol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	helmut.fickenscher@med.uni-heidelberg.de	Fickenscher, Helmut/A-3004-2010; Tamgüney, Gültekin/T-6333-2019; Fickenscher, Helmut/J-9655-2019	Tamgüney, Gültekin/0000-0002-6933-5154; Fickenscher, Helmut/0000-0003-0043-1153				BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BROKER BM, 1993, J IMMUNOL, V151, P1184; BURD PR, 1987, J IMMUNOL, V139, P3126; Colantonio L, 2002, EUR J IMMUNOL, V32, P3506, DOI 10.1002/1521-4141(200212)32:12<3506::AID-IMMU3506>3.0.CO;2-#; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; DECARLI M, 1993, J IMMUNOL, V151, P5022; DELPRETE G, 1994, J IMMUNOL, V153, P4872; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; Fickenscher H, 2002, METHOD MICROBIOL, V32, P657; Fickenscher H, 1997, J VIROL, V71, P2252, DOI 10.1128/JVI.71.3.2252-2263.1997; Fickenscher H, 1996, J VIROL, V70, P6012, DOI 10.1128/JVI.70.9.6012-6019.1996; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Fickenscher H, 2001, PHILOS T R SOC B, V356, P545, DOI 10.1098/rstb.2000.0780; Goya I, 1998, J IMMUNOL, V160, P1975; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Hartley DA, 2000, J BIOL CHEM, V275, P16925, DOI 10.1074/jbc.M000709200; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; INATSUKI A, 1989, J IMMUNOL, V143, P1327; Inngjerdingen M, 2000, J IMMUNOL, V164, P4048, DOI 10.4049/jimmunol.164.8.4048; JUNG JU, 1991, J VIROL, V65, P6953, DOI 10.1128/JVI.65.12.6953-6960.1991; JUNG JU, 1995, J BIOL CHEM, V270, P20660, DOI 10.1074/jbc.270.35.20660; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Knappe A, 1997, J VIROL, V71, P9124, DOI 10.1128/JVI.71.12.9124-9133.1997; Kraft MS, 1998, J VIROL, V72, P3138, DOI 10.1128/JVI.72.4.3138-3145.1998; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; Louahed J, 2003, EUR J IMMUNOL, V33, P494, DOI 10.1002/immu.200310025; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Mackewicz CE, 1997, CLIN IMMUNOL IMMUNOP, V82, P274, DOI 10.1006/clin.1996.4292; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; MILLER MD, 1992, P NATL ACAD SCI USA, V89, P2950, DOI 10.1073/pnas.89.7.2950; MILLER MD, 1989, J IMMUNOL, V143, P2907; MITTRUCKER HW, 1993, INT IMMUNOL, V5, P985, DOI 10.1093/intimm/5.8.985; MITTRUCKER HW, 1992, J EXP MED, V176, P909, DOI 10.1084/jem.176.3.909; MURPHY C, 1994, ONCOGENE, V9, P221; Napolitano M, 1996, J IMMUNOL, V157, P2759; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; Samson M, 1996, EUR J IMMUNOL, V26, P3021, DOI 10.1002/eji.1830261230; Schrum S, 1996, J IMMUNOL, V157, P3598; Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996; Spinetti G, 2003, J LEUKOCYTE BIOL, V73, P201, DOI 10.1189/jlb.0302105; VanSnick J, 1996, J IMMUNOL, V157, P2570; Wehner LE, 2001, DNA CELL BIOL, V20, P81, DOI 10.1089/104454901750070283; Wiese N, 1996, J BIOL CHEM, V271, P847, DOI 10.1074/jbc.271.2.847; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YASUKAWA M, 1995, J VIROL, V69, P8114, DOI 10.1128/JVI.69.12.8114-8117.1995; YSSEL H, 1989, J IMMUNOL, V142, P2279; Zaballos A, 1996, BIOCHEM BIOPH RES CO, V227, P846, DOI 10.1006/bbrc.1996.1595; Zingoni A, 1998, J IMMUNOL, V161, P547	56	6	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8475	8485		10.1038/sj.onc.1207903	http://dx.doi.org/10.1038/sj.onc.1207903			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378023				2022-12-25	WOS:000224870700008
J	Ishikawa, F; Yasukawa, M; Yoshida, S; Nakamura, K; Nagatoshi, Y; Kanemaru, T; Shimoda, K; Shimoda, S; Miyamoto, T; Okamura, J; Shultz, LD; Harada, M				Ishikawa, F; Yasukawa, M; Yoshida, S; Nakamura, K; Nagatoshi, Y; Kanemaru, T; Shimoda, K; Shimoda, S; Miyamoto, T; Okamura, J; Shultz, LD; Harada, M			Human cord blood- and bone marrow-derived CD34(+) cells regenerate gastrointestinal epithelial cells	FASEB JOURNAL			English	Article						stem cell; plasticity; fusion; epithelium	STEM-CELLS; HEPATOCYTES	In the present study, we aimed to clarify the capacity of human cord blood- and bone marrow-derived progenitor cells to generate gastrointestinal epithelial cells in clinical and experimental transplantation settings. First, in a clinical transplantation setting, gastrointestinal tissues derived from female pediatric or juvenile recipients of allogeneic sex-mismatched bone marrow and cord blood transplantation were examined for the presence of donor-derived epithelial cells. Gastrointestinal specimens of allogeneic recipients included Y chromosome(+) cytokeratin(+) epithelial cells at a frequency of 0.4 - 1.9%. To further determine the capacity of purified human progenitor cells, human cord blood- or bone marrow-derived CD34(+) cells were transplanted into newborn NOD/SCID/beta2-microglobulin(null) mice as an experimental transplantation assay. When gastrointestinal tissues derived from recipient mice were subjected to FISH and immunofluorescence analyses, human epithelial cells were identified at a frequency of 0.24 - 0.58% at 3 months posttransplantation. Finally, double FISH analyses using species-specific probes revealed that human chromosome+ epithelial cells did not possess any murine chromosomes, indicating that donor-derived epithelial cells were not generated only by cell fusion. On the basis of these findings, it is concluded that purified human cord blood and bone marrow CD34(+) progenitor cells can generate gastrointestinal epithelial cells across allogeneic and xenogeneic histocompatibility barriers.	Kyushu Univ, Grad Sch Med, Dept Med & Biosystem Sci, Higashi Ku, Fukuoka 8128582, Japan; Ehime Univ, Sch Med, Dept Internal Med 1, Shigenobu, Ehime 79102, Japan; Kurume Univ, Dept Anat 2, Kurume, Fukuoka 830, Japan; Kyushu Natl Canc Ctr, Sect Pediat, Fukuoka, Japan; Kyushu Univ, Fukuoka 812, Japan; Jackson Lab, Bar Harbor, ME 04609 USA	Kyushu University; Ehime University; Kurume University; Kyushu University; Jackson Laboratory	Ishikawa, F (corresponding author), Kyushu Univ, Grad Sch Med, Dept Med & Biosystem Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	f_ishika@intmed1.med.kyushu-u.ac.jp	石川, 文彦/L-4488-2014					Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Bianchi DW, 2002, NEW ENGL J MED, V346, P1410; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Ishikawa F, 2002, EXP HEMATOL, V30, P488, DOI 10.1016/S0301-472X(02)00784-1; Ishikawa F, 2003, LEUKEMIA, V17, P960, DOI 10.1038/sj.leu.2402878; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KAUR P, 1986, CELL TISSUE KINET, V19, P601, DOI 10.1111/j.1365-2184.1986.tb00761.x; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Meignin V, 2004, BLOOD, V103, P360, DOI 10.1182/blood-2003-06-1843; Morrison SJ, 2001, CURR BIOL, V11, pR7, DOI 10.1016/S0960-9822(00)00033-6; Okamoto R, 2002, NAT MED, V8, P1011, DOI 10.1038/nm755; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Podolsky DK, 2003, J GASTROENTEROL, V38, P63; Sandborn WJ, 2002, GASTROENTEROLOGY, V122, P1592, DOI 10.1053/gast.2002.33426; Singh B, 2001, IMMUNOL REV, V182, P190, DOI 10.1034/j.1600-065X.2001.1820115.x; Stappenbeck TS, 2003, P NATL ACAD SCI USA, V100, P1004, DOI 10.1073/pnas.242735899; Suzuki A, 2002, J CELL BIOL, V156, P173, DOI 10.1083/jcb.200108066; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Van den Brande JMH, 2002, ANN NY ACAD SCI, V973, P166; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wirtz S, 2003, GENE THER, V10, P854, DOI 10.1038/sj.gt.3302013; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	29	24	28	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1958	+		10.1096/fj.04-2396fje	http://dx.doi.org/10.1096/fj.04-2396fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15467008				2022-12-25	WOS:000224849900027
J	Kumar, A; Murphy, R; Robinson, P; Wei, L; Boriek, AM				Kumar, A; Murphy, R; Robinson, P; Wei, L; Boriek, AM			Cyclic mechanical strain inhibits skeletal myogenesis through activation of focal adhesion kinase, Rac-1 GTPase, and NF-kappa B transcription factor	FASEB JOURNAL			English	Article						skeletal myogenesis; C2C12 cells; cyclic stretch; FAK; Rac-1; NF-kappa B	FIBROBLAST-GROWTH-FACTOR; MUSCLE SATELLITE CELLS; RHO-FAMILY GTPASES; PROTEIN-KINASE; SIGNALING PATHWAYS; BINDING PROTEIN; TERMINAL KINASE; GENE-EXPRESSION; DIFFERENTIATION; STRETCH	Myogenesis is a multistep developmental program that generates and regenerates skeletal muscles. Several extracellular factors have been identified that participate in the regulation of myogenesis. Although skeletal muscles are always subjected to mechanical stress in vivo, the role of mechanical forces in the regulation of myogenesis remains unknown. We have investigated the molecular mechanisms by which cyclic mechanical strain modulates myogenesis. Application of cyclic mechanical strain using the computer-controlled Flexcell Strain Unit increased the proliferation of C2C12 cells and inhibited their differentiation into myotubes. Cyclic strain increased the activity of cyclin-dependent kinase 2 (cdk2) and the cellular level of cyclin A, and inhibited the expression of myosin heavy chain and formation of myotubes in C2C12 cultures. The activity of nuclear factor-kappa B (NF-kappaB) transcription factor and the expression of NF-kappaB-regulated genes, cyclin D1 and IL-6, were augmented in response to mechanical strain. Cyclic strain also increased the activity of Rho GTPases, especially Rac-1. The inhibition of Rho GTPases activity, by overexpression of Rho GDP dissociation inhibitor (Rho-GDI), inhibited the strain-induced activation of NF-kappaB in C2C12 cells. Overexpression of either NF-kappaB inhibitory protein IkappaBalphaDeltaN (a degradation resistant mutant IkappaBalpha) or Rho-GDI blocked the strain-induced proliferation of C2C12 cells. Furthermore, overexpression of FRNK, a dominant negative mutant of focal adhesion kinase (FAK), inhibited the strain-induced proliferation of C2C12 cells. Our study demonstrates that cyclic mechanical strain inhibits myogenesis through the activation of FAK, Rac-1, and NF-kappaB.	Baylor Coll Med, Dept Med, Pulm & Crit Care Sect, Houston, TX 77030 USA	Baylor College of Medicine	Kumar, A (corresponding author), Baylor Coll Med, Dept Med, Pulm & Crit Care Sect, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	axkumar@bcm.tmc.edu		Kumar, Ashok/0000-0002-2444-9529; Robinson, Prema/0000-0002-6798-4839; Kumar, Ashok/0000-0001-8571-2848	NHLBI NIH HHS [R01 HL63134] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063134] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto T, 2001, MAT SCI ENG C-BIO S, V17, P75, DOI 10.1016/S0928-4931(01)00340-X; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bassel-Duby R, 2003, BIOCHEM BIOPH RES CO, V311, P1133, DOI 10.1016/j.bbrc.2003.09.020; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BISCHOFF R, 1986, DEV BIOL, V115, P129, DOI 10.1016/0012-1606(86)90234-4; Bischoff R., 1994, MYOLOGY, VVolume 1, P97; Bruce-Staskal PJ, 2002, J CELL SCI, V115, P2689; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carson JA, 2000, J APPL PHYSIOL, V88, P337, DOI 10.1152/jappl.2000.88.1.337; CARY LA, 1999, FRONT BIOSCI, V4, P102; Chen Jennifer C J, 2003, Reprod Biol Endocrinol, V1, P101, DOI 10.1186/1477-7827-1-101; Clark CB, 2004, EXP CELL RES, V292, P265, DOI 10.1016/j.yexcr.2003.09.017; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; DELGADO I, 2003, INT J BIOCHEM CELL B, V35, P1151; DUCKETT CS, 1995, J BIOL CHEM, V270, P18836, DOI 10.1074/jbc.270.32.18836; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Granet C, 2001, BIOCHEM BIOPH RES CO, V284, P622, DOI 10.1006/bbrc.2001.5023; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Hughes SM, 2001, CURR BIOL, V11, pR237, DOI 10.1016/S0960-9822(01)00114-2; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; Ilic D, 1997, J CELL SCI, V110, P401; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; JAMES RS, 1995, J EXP BIOL, V198, P491; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2003, J BIOL CHEM, V278, P18868, DOI 10.1074/jbc.M212777200; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 1998, J IMMUNOL, V161, P776; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lew AM, 1999, BIOCHEM J, V341, P647, DOI 10.1042/0264-6021:3410647; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Marinari B, 2002, EUR J IMMUNOL, V32, P447, DOI 10.1002/1521-4141(200202)32:2<447::AID-IMMU447>3.0.CO;2-5; Martineau LC, 2001, J APPL PHYSIOL, V91, P693, DOI 10.1152/jappl.2001.91.2.693; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Morgan JE, 2003, INT J BIOCHEM CELL B, V35, P1151, DOI 10.1016/S1357-2725(03)00042-6; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nikolovski J, 2003, FASEB J, V17, P455, DOI 10.1096/fj.02-0459fje; Nobe K, 2001, CIRC RES, V88, P1283, DOI 10.1161/hh1201.092035; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Proske U, 2001, J PHYSIOL-LONDON, V537, P333, DOI 10.1111/j.1469-7793.2001.00333.x; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Robinson P, 2003, J INFECT DIS, V188, P290, DOI 10.1086/376836; Roy R R, 1991, Exerc Sport Sci Rev, V19, P269; Ruoslahti E, 1997, SCIENCE, V276, P1345, DOI 10.1126/science.276.5317.1345; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Sakamoto K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1081, DOI 10.1152/ajpendo.00228.2003; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Smith PG, 2003, AM J RESP CELL MOL, V28, P436, DOI 10.1165/rcmb.4754; Sorci G, 2004, MOL CELL BIOL, V24, P4880, DOI 10.1128/MCB.24.11.4880-4894.2004; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200; Tatsumi R, 2002, MOL BIOL CELL, V13, P2909, DOI 10.1091/mbc.E02-01-0062; Tidball JG, 1998, AM J PHYSIOL-CELL PH, V275, pC260, DOI 10.1152/ajpcell.1998.275.1.C260; Tidball JG, 1999, J BIOL CHEM, V274, P33155, DOI 10.1074/jbc.274.46.33155; VAN AL, 1997, GENE DEV, V11, P2295; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wei L, 2002, DEVELOPMENT, V129, P1705; Wretman C, 2000, ACTA PHYSIOL SCAND, V170, P45; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	95	94	102	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1524	1535		10.1096/fj.04-2414com	http://dx.doi.org/10.1096/fj.04-2414com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466361				2022-12-25	WOS:000224849900036
J	Khatib, L; Golan, DE; Cho, M				Khatib, L; Golan, DE; Cho, M			Physiologic electrical stimulation provokes intracellular calcium increase mediated by phospholipase C activation in human osteoblasts	FASEB JOURNAL			English	Article						calcium homeostasis; stretch-activated cation receptors	FIELD INDUCED REDISTRIBUTION; NONSELECTIVE CATION CHANNEL; GROWTH-FACTOR; CELLS; RECEPTORS; EPITHELIALIZATION; RELAXATION; EXPRESSION; WOUNDS; ALPHA	Strong exogenous electrical stimulation (ES) can induce changes in intracellular calcium ion concentration ([Ca2+](i)). It remains to be elucidated, however, whether physiologically relevant ES (e.g., 1-2 V/cm) could alter [Ca2+](i). We have used fluorescence microscopy to quantify [Ca2+](i) changes in response to direct current (dc) ES in human fetal osteoblasts. Increases in [Ca2+](i) in response to 2 V/cm ES show a noticeable (20-min) time delay, followed by a 45-fold rise from the baseline of 40 nM to 1.8 muM. Treatment of cells with verapamil does not affect ES-induced [Ca2+](i) increases, but inhibition of phospholipase C ( PLC) does prevent such increases, which suggests that receptor-regulated release of Ca2+ from intracellular stores is likely to be involved. Treatment of cells with the stretch-activated cation channel (SACC) blocker Gd3+ partially inhibits ES-induced [Ca2+](i) increases, as does chelation of intracellular Ca2+. These results are consistent with a model in which physiologically relevant ES does not activate voltage-gated Ca2+ channels (VGCCs) directly, but rather stimulates PLC-coupled cell surface receptors that induce [Ca2+](i) increases by activating IP3-dependent intracellular processes. The Ca2+ influx that follows PLC activation is likely mediated by activation of mechanically operated SACCs.	Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Cho, M (corresponding author), Univ Illinois, Dept Bioengn, 851 S Morgan St M-C 063, Chicago, IL 60607 USA.	mcho@uic.edu		Cho, Myoung Rae/0000-0002-8191-8045	NHLBI NIH HHS [HL-70819, HL-32854] Funding Source: Medline; NIGMS NIH HHS [GM-60741] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL070819, R01HL032854, R37HL032854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; BECKER RO, 1977, CLIN ORTHOP RELAT R, V124, P75; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLACK J, 1988, TISSUE ENG, P195; Black J., 1987, ELECT STIMULATION IT; BRIGHTON CT, 1981, J BONE JOINT SURG AM, V63, P847, DOI 10.2106/00004623-198163050-00030; BRIGHTON CT, 1995, CLIN ORTHOP RELAT R, V321, P223; Caldwell RA, 1998, AM J PHYSIOL-CELL PH, V275, pC619, DOI 10.1152/ajpcell.1998.275.2.C619; CHEN N, AM J PHYSL, V278, pC989; CHIANG M, 1991, DEV BIOL, V146, P377, DOI 10.1016/0012-1606(91)90239-Y; CHIANG MC, 1992, EXP EYE RES, V54, P999, DOI 10.1016/0014-4835(92)90164-N; Cho M, 2002, J INEQUAL APPL, V7, P1, DOI 10.1080/10755830290013362; Cho MR, 2002, IEEE T PLASMA SCI, V30, P1504, DOI 10.1109/TPS.2002.804200; Cho MR, 1999, FASEB J, V13, P677, DOI 10.1096/fasebj.13.6.677; CHO MR, 1994, FASEB J, V8, P771, DOI 10.1096/fasebj.8.10.8050677; Cukjati D, 2001, MED BIOL ENG COMPUT, V39, P542, DOI 10.1007/BF02345144; Di Sario A, 2002, J HEPATOL, V36, P179, DOI 10.1016/S0168-8278(01)00242-2; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; GIUGNI TD, 1987, J CELL BIOL, V104, P1291, DOI 10.1083/jcb.104.5.1291; Iglesia DDS, 1996, J EXP ZOOL, V274, P56, DOI 10.1002/(SICI)1097-010X(19960101)274:1<56::AID-JEZ6>3.0.CO;2-E; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013; LAUFFENBURGER DA, 1993, RECEPTORY MODELS BIN; Lee MJ, 2002, EXP MOL MED, V34, P265, DOI 10.1038/emm.2002.37; Malhi GS, 2002, J PSYCHOSOM RES, V53, P709, DOI 10.1016/S0022-3999(02)00423-3; Masur K, 2001, MOL BIOL CELL, V12, P1973, DOI 10.1091/mbc.12.7.1973; McGinnis M E, 1986, Prog Clin Biol Res, V210, P231; MCLAUGHLIN S, 1981, BIOPHYS J, V34, P85, DOI 10.1016/S0006-3495(81)84838-2; ONUMA EK, 1988, J CELL BIOL, V106, P2067, DOI 10.1083/jcb.106.6.2067; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; Potts RO, 2002, DIABETES-METAB RES, V18, pS49, DOI 10.1002/dmrr.210; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Rink TJ, 1990, CURR OPIN CELL BIOL, V2, P198, DOI 10.1016/0955-0674(90)90007-2; Ryder KD, 2001, J BONE MINER RES, V16, P240, DOI 10.1359/jbmr.2001.16.2.240; Shen MR, 2002, J BIOL CHEM, V277, P45776, DOI 10.1074/jbc.M207993200; Sperelakis N., 2001, CELL PHYSL SOURCEBOO, Vthird; TANK DW, 1985, J CELL BIOL, V101, P148, DOI 10.1083/jcb.101.1.148; TITUSHKIN I, 2004, IN PRESS MODE CELL T; Trollinger DR, 2002, J CELL PHYSIOL, V193, P1, DOI 10.1002/jcp.10144; TSONG TY, 1988, METHOD ENZYMOL, V157, P240; TSONG TY, 1988, ANNU REV PHYSIOL, V50, P273; WESTKAMP M, 2000, J MEMBRANE BIOL, V178, P11	42	61	62	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1903	+		10.1096/fj.04-1814fje	http://dx.doi.org/10.1096/fj.04-1814fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15385433				2022-12-25	WOS:000224243200016
J	Chen, JF; Takagi, J; Xie, C; Xiao, T; Luo, BH; Springer, TA				Chen, JF; Takagi, J; Xie, C; Xiao, T; Luo, BH; Springer, TA			The relative influence of metal ion binding sites in the I-like domain and the interface with the hybrid domain on rolling and firm adhesion by integrin alpha(4)beta(7)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; INTEGRIN; ACTIVATION; AFFINITY; COMPLEX; CONFORMATION; SUBUNIT; TRANSDUCTION; ASSOCIATION	We examined the effect of conformational change at the beta(7) I-like/hybrid domain interface on regulating the transition between rolling and firm adhesion by integrin alpha(4)beta(7). An N-glycosylation site was introduced into the I-like/hybrid domain interface to act as a wedge and to stabilize the open conformation of this interface and hence the open conformation of the alpha(4)beta(7) headpiece. Wild-type alpha(4)beta(7) mediates rolling adhesion in Ca2+ and Ca2+/Mg2+ but firm adhesion in Mg2+ and Mn2+. Stabilizing the open headpiece resulted in firm adhesion in all divalent cations. The interaction between metal binding sites in the I-like domain and the interface with the hybrid domain was examined in double mutants. Changes at these two sites can either counterbalance one another or be additive, emphasizing mutuality and the importance of multiple interfaces in integrin regulation. A double mutant with counterbalancing deactivating ligand-induced metal ion binding site ( LIMBS) and activating wedge mutations could still be activated by Mn2+, confirming the importance of the adjacent to metal ion-dependent adhesion site (ADMIDAS) in integrin activation by Mn2+. Overall, the results demonstrate the importance of headpiece allostery in the conversion of rolling to firm adhesion.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Osaka Univ, Inst Prot Res, Lab Prot Synth & Express, Suita, Osaka 5650871, Japan	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Osaka University	Springer, TA (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu	Xiao, Tsan Sam/A-8590-2010; Xiao, Tsan/I-7616-2013	Xiao, Tsan Sam/0000-0001-9688-475X; Xiao, Tsan/0000-0001-9688-475X; Xie, Can/0000-0002-7412-3236	NHLBI NIH HHS [HL 48675, P01 HL048675] Funding Source: Medline; NIAID NIH HHS [R01 AI072765] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072765] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDNARCZYK JL, 1992, J BIOL CHEM, V267, P25274; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; de Chateau M, 2001, BIOCHEMISTRY-US, V40, P13972, DOI 10.1021/bi011582f; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LAZAROVITS AI, 1984, J IMMUNOL, V133, P1857; Lu CF, 1998, J BIOL CHEM, V273, P15138, DOI 10.1074/jbc.273.24.15138; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Luo BH, 2004, J BIOL CHEM, V279, P27466, DOI 10.1074/jbc.M404354200; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; MCINTYRE BW, 1989, J BIOL CHEM, V264, P13745; Mould AP, 2003, J BIOL CHEM, V278, P39993, DOI 10.1074/jbc.M304627200; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; PARKER CM, 1993, J BIOL CHEM, V268, P7028; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; Salas A, 2002, J BIOL CHEM, V277, P50255, DOI 10.1074/jbc.M209822200; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; Springer TA, 2004, ADV PROTEIN CHEM, V68, P29; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; Tidswell M, 1997, J IMMUNOL, V159, P1497; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang W, 2004, P NATL ACAD SCI USA, V101, P2333, DOI 10.1073/pnas.0307291101	36	36	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55556	55561		10.1074/jbc.M407773200	http://dx.doi.org/10.1074/jbc.M407773200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15448154	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000225960800072
J	Chu, JJH; Ng, ML				Chu, JJH; Ng, ML			Interaction of West Nile virus with alpha(v)beta(3) integrin mediates virus entry into cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; HUMAN DENDRITIC CELLS; ENVELOPE PROTEIN; DOMAIN-III; ENCEPHALITIS-VIRUS; JAPANESE ENCEPHALITIS; VIRAL ENTRY; INFECTION; BINDING; GLYCOPROTEIN	The functional receptor for the flavivirus West Nile (WNV) infection has been characterized in this study with a combination of biochemical and molecular approaches. A 105-kDa protease-sensitive glycoprotein that binds WNV was isolated from the plasma membrane of cells permissive to WNV infection. The protein was subjected to peptide sequencing, and this glycoprotein was identified as a member of the integrin superfamily. Infection of WNV was shown to be markedly inhibited in Vero cells pretreated with blocking antibodies against alpha(v)beta(3) integrin and its subunits by receptor competition assay. It was also noted that cells pretreated with antibodies against alpha(v)beta(3) integrin can effectively inhibit flavivirus Japanese encephalitis but to a lesser extent flavivirus dengue infections. West Nile virus entry is independent of divalent cations and is not highly blocked by arginine-glycine-aspartic acid (RGD) peptides, suggesting that the interaction between the virus and alpha(v)beta(3) integrin is not highly dependent on the classical RGD binding motif. In addition, gene silencing of the beta(3) integrin subunit in cells has resulted in cells largely resistant to WNV infection. In contrast, expression of recombinant human beta(3) integrin substantially increased the permissiveness of CS-1 melanoma cells for WNV infection. Soluble alpha(v)beta(3) integrin can also effectively block WNV infection in a dose-dependent manner. Furthermore, WNV infection also triggered the outside-in signaling pathway via the activation of integrin-associated focal adhesion kinase. The identification of alpha(v)beta(3) integrin as a receptor for WNV provides insight into virus-receptor interaction, hence creating opportunities in the development of anti-viral strategies against WNV infection.	Natl Univ Singapore, Dept Microbiol, Flavivirol Lab, Singapore 117597, Singapore	National University of Singapore	Ng, ML (corresponding author), Natl Univ Singapore, Dept Microbiol, Flavivirol Lab, 5 Sci Dr 2, Singapore 117597, Singapore.	micngml@nus.edu.sg	Chu, Justin Jang Hann/ABA-8297-2021; Ng, Mei Li/Q-3704-2016	Chu, Justin Jang Hann/0000-0002-1673-6819; Ng, Mei Li/0000-0001-9917-4534				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Aplin JD, 1996, MOL HUM REPROD, V2, P527, DOI 10.1093/molehr/2.7.527; BAI M, 1993, J VIROL, V67, P5198, DOI 10.1128/JVI.67.9.5198-5205.1993; Beasley DWC, 2002, J VIROL, V76, P13097, DOI 10.1128/JVI.76.24.13097-13100.2002; Brinton MA, 2001, ANN NY ACAD SCI, V951, P207; Burke RD, 1999, INT REV CYTOL, V191, P257, DOI 10.1016/S0074-7696(08)60161-8; CASTLE E, 1987, ARCH VIROL, V92, P309, DOI 10.1007/BF01317487; Chu JJH, 2004, J VIROL, V78, P10543, DOI 10.1128/JVI.78.19.10543-10555.2004; Chu JJH, 2003, VIROLOGY, V312, P458, DOI 10.1016/S0042-6822(03)00261-7; Chu JJH, 2002, J GEN VIROL, V83, P2427, DOI 10.1099/0022-1317-83-10-2427; Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001; Filardo EJ, 1996, J CELL SCI, V109, P1615; Gavrilovskaya IN, 1998, P NATL ACAD SCI USA, V95, P7074, DOI 10.1073/pnas.95.12.7074; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Greber UF, 2002, CELL MOL LIFE SCI, V59, P608, DOI 10.1007/s00018-002-8453-3; HEINZ FX, 1994, ARCH VIROL, V9, P339; Hung JJ, 2004, J VIROL, V78, P378, DOI 10.1128/JVI.78.1.378-388.2004; Hurrelbrink RJ, 2001, J VIROL, V75, P7692, DOI 10.1128/JVI.75.16.7692-7702.2001; Jindadamrongwech S, 2004, ARCH VIROL, V149, P915, DOI 10.1007/s00705-003-0263-x; Joki-Korpela P, 2001, J VIROL, V75, P1958, DOI 10.1128/JVI.75.4.1958-1967.2001; KIMURA T, 1994, ARCH VIROL, V139, P239, DOI 10.1007/BF01310788; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Ni HL, 2000, J VIROL, V74, P2903, DOI 10.1128/JVI.74.6.2903-2906.2000; O'Leary DR, 2004, VECTOR-BORNE ZOONOT, V4, P61, DOI 10.1089/153036604773083004; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Rey FA, 2003, P NATL ACAD SCI USA, V100, P6899, DOI 10.1073/pnas.1332695100; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; RICE CM, 1996, VIROLOGY, P931; RIEDER E, 1994, J VIROL, V68, P5296, DOI 10.1128/JVI.68.8.5296-5299.1994; ROIVAINEN M, 1991, J VIROL, V65, P4735, DOI 10.1128/JVI.65.9.4735-4740.1991; Ruoslahti E, 1997, KIDNEY INT, V51, P1413, DOI 10.1038/ki.1997.193; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Solomon T, 2002, CURR TOP MICROBIOL, V267, P171; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Thullier P, 2001, J GEN VIROL, V82, P1885, DOI 10.1099/0022-1317-82-8-1885; van der Most RG, 1999, VIROLOGY, V265, P83, DOI 10.1006/viro.1999.0026; Volk DE, 2004, J BIOL CHEM, V279, P38755, DOI 10.1074/jbc.M402385200	39	167	183	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54533	54541		10.1074/jbc.M410208200	http://dx.doi.org/10.1074/jbc.M410208200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475343	hybrid			2022-12-25	WOS:000225793600078
J	Lim, KP; Hong, WJ				Lim, KP; Hong, WJ			Human nischarin/imidazoline receptor antisera-selected protein is targeted to the endosomes by a combined action of a PX domain and a coiled-coil region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORTING NEXIN; FYVE DOMAIN; BINDING; FAMILY; IDENTIFICATION; INTERACTS; NISCHARIN; SMART; IRAS	Around 50 mammalian and 15 yeast proteins are known to contain the phox (PX) domain, the majority ( about 30) of which is classified as sorting nexins (SNXs). The PX domain, a hallmark of these proteins, is a conserved stretch of about 120 amino acids and is recently shown to mediate phosphoinositide binding. A few PX domain proteins (including some SNXs) have been shown to participate in diverse cellular processes such as protein sorting, signal transduction, and vesicle fusion. In this report, we present our results supporting a role of human IRAS to act as a SNX. The mouse homologue, previously identified as Nischarin, has been shown to interact with the alpha(5) subunit of integrin and inhibit cell migration (Alahari, S. K., Lee J. W., and Juliano R. L. (2000) J. Cell Biol. 51, 1141-1154). Its human homologue (imidazoline receptor antisera-selected ( IRAS)), on the other hand, contains an NH2-terminal extension and is a larger protein of 1504 amino acids consisting of an NH2-terminal PX domain, 5 putative leucine-rich repeats, a predicted coiled-coil domain, and a long COOH-terminal region. We show that it has the ability to homo-oligomerize via its coiled-coil region. The PX domain of IRAS is essential for association with phosphatidylinositol 3-phosphate-enriched endosomal membranes. However, the PX domain of IRAS alone is insufficient for its localization to endosomes, unless the coiled-coil domain was included or it is artificially dimerized by glutathione S-transferase. Interaction of human IRAS with alpha(5) integrin is not affected by the NH2-terminal extension, and overexpression of IRAS could cause a redistribution of surface alpha(5) integrin to intracellular endosomal structures.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, Proteos Bldg,Rm 5-21B,61 Biopolis Dr, Singapore 138673, Singapore.	mcbhwj@imcb.a-star.edu.sg	HONG, Wanjin/E-9927-2010					Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Alahari SK, 2004, BIOCHEM J, V377, P449, DOI 10.1042/BJ20030411; Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; BUCK CA, 1987, J CELL SCI, P231; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Dontenwill M, 2003, CELL DEATH DIFFER, V10, P933, DOI 10.1038/sj.cdd.4401275; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; EKENA K, 1995, MOL CELL BIOL, V15, P1671; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hanson BJ, 2003, J BIOL CHEM, V278, P34617, DOI 10.1074/jbc.M300143200; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lowe SL, 1996, J CELL SCI, V109, P209; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nishida M, 1998, J MOL BIOL, V281, P135, DOI 10.1006/jmbi.1998.1927; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Patterson CE, 2000, MOL BIOL CELL, V11, P3925, DOI 10.1091/mbc.11.11.3925; Pierini LM, 2000, BLOOD, V95, P2471; Piletz JE, 2000, DNA CELL BIOL, V19, P319, DOI 10.1089/10445490050043290; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Raiborg C, 2001, J CELL SCI, V114, P2255; Sano H, 2002, J BIOL CHEM, V277, P19439, DOI 10.1074/jbc.M111838200; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; XU Y, 2001, BIOCHEM J, V15, P513; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	39	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54770	54782		10.1074/jbc.M411315200	http://dx.doi.org/10.1074/jbc.M411315200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15475348	hybrid			2022-12-25	WOS:000225793600105
J	Deneke, J; Burgin, AB; Wilson, SL; Chaconas, G				Deneke, J; Burgin, AB; Wilson, SL; Chaconas, G			Catalytic residues of the telomere resolvase ResT - A pattern similar to, but distinct from, tyrosine recombinases and type IB topoisomerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR PLASMID PROPHAGE; LYME-DISEASE SPIROCHETE; DNA TOPOISOMERASE; ACTIVE-SITE; INTEGRASE FAMILY; BIDIRECTIONAL REPLICATION; RESOLUTION; RECOGNITION; MECHANISM; SEQUENCE	ResT is a member of the telomere resolvases, a newly discovered class of DNA breakage and reunion enzymes. These enzymes are involved in the formation of covalently closed hairpin DNA ends that are found in linear prokaryotic chromosomes and plasmids. The hairpins are generated by telomere resolution, where the replicated linear DNA ends are processed by DNA breakage followed by joining of DNA free ends to the complementary strand of the same molecule. Previous studies have shown that ResT catalyzes hairpin formation through a two-step transesterification similar to tyrosine recombinases and type IB topoisomerases. In the present study we have probed the reaction mechanism of ResT. The enzyme was found to efficiently utilize a substrate with a 5'-bridging phosphorothiolate at each cleavage site, similar to tyrosine recombinases/type IB topoisomerases. Using such a substrate to trap the covalent protein-DNA intermediate, coupled with affinity purification and mass spectroscopy, we report a new, non-radioactive approach to directly determine the position of the amino acid in the protein, which is linked to the DNA. We report that tyrosine 335 is the active site nucleophile in ResT, strengthening the link between ResT and tyrosine recombinases/type IB topoisomerases. However, a distinct pattern of catalytic residues with similarities, but distinct differences from the above enzymes was suggested. The differences include the apparent absence of a general acid catalyst, as well as the dispensability of the final histidine in the RKHRHY hexad. Finally, two signature motifs (GRR(2X)E(6X)F and LGH(4-6X)T(3X)Y) near the catalytic residues of aligned telomere resolvases are noted.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 1N4, Canada; deCode BioStruct, Bainbridge Isl, WA 98110 USA	University of Calgary; University of Calgary	Chaconas, G (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 1N4, Canada.	chaconas@ucalgary.ca						Bankhead T, 2004, P NATL ACAD SCI USA, V101, P13768, DOI 10.1073/pnas.0405762101; BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; Burgin AB, 2000, METH MOL B, V95, P119; Byram R, 2004, J BACTERIOL, V186, P3561, DOI 10.1128/JB.186.11.3561-3569.2004; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; Casjens S, 2000, MOL MICROBIOL, V35, P490, DOI 10.1046/j.1365-2958.2000.01698.x; Chaconas G, 2001, EMBO J, V20, P3229, DOI 10.1093/emboj/20.12.3229; Chaconas George, 2005, P525; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen Y, 2003, J BIOL CHEM, V278, P24800, DOI 10.1074/jbc.M300853200; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Deneke J, 2002, J BIOL CHEM, V277, P10410, DOI 10.1074/jbc.M111769200; Deneke J, 2000, P NATL ACAD SCI USA, V97, P7721, DOI 10.1073/pnas.97.14.7721; DENEKE J, 2002, THESIS FACHBEREICH C; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Gopaul Deshmukh N., 1999, Current Opinion in Structural Biology, V9, P14, DOI 10.1016/S0959-440X(99)80003-7; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; Hertwig S, 2003, MOL MICROBIOL, V48, P989, DOI 10.1046/j.1365-2958.2003.03458.x; HINNEBUSCH J, 1993, MOL MICROBIOL, V10, P917, DOI 10.1111/j.1365-2958.1993.tb00963.x; Huang WM, 2004, J MOL BIOL, V337, P77, DOI 10.1016/j.jmb.2004.01.012; Kobryn K, 2002, MOL CELL, V9, P195, DOI 10.1016/S1097-2765(01)00433-6; Kobryn K, 2001, CURR OPIN MICROBIOL, V4, P558, DOI 10.1016/S1369-5274(00)00251-4; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; KROGH BO, 2001, J BIOL CHEM, V5, P5; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; Picardeau M, 1999, MOL MICROBIOL, V32, P437, DOI 10.1046/j.1365-2958.1999.01368.x; Ravin NV, 2003, NUCLEIC ACIDS RES, V31, P6552, DOI 10.1093/nar/gkg856; Ravin NV, 2003, FEMS MICROBIOL LETT, V221, P1, DOI 10.1016/S0378-1097(03)00125-3; Rybchin VN, 1999, MOL MICROBIOL, V33, P895, DOI 10.1046/j.1365-2958.1999.01533.x; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; Stewart P, 2004, PLASMID BIOLOGY, P291; SVARCHEVSKY AN, 1986, THESIS LENINGRAD STA; Tian LG, 2004, STRUCTURE, V12, P31, DOI 10.1016/j.str.2003.11.025; Tourand Y, 2003, MOL MICROBIOL, V48, P901, DOI 10.1046/j.1365-2958.2003.03485.x; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; ZIEGELIN G, 1993, EMBO J, V12, P3703, DOI 10.1002/j.1460-2075.1993.tb06045.x	42	34	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53699	53706		10.1074/jbc.M409001200	http://dx.doi.org/10.1074/jbc.M409001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471873	hybrid			2022-12-25	WOS:000225680600107
J	Ring, G; Eichler, J				Ring, G; Eichler, J			In the archaea Haloferax volcanii, membrane protein biogenesis and protein synthesis rates are affected by decreased ribosomal binding to the translocon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM; BOUND RIBOSOMES; IN-VIVO; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FUSION PROTEINS; SRP RNA; COMPONENTS; BACTERIOOPSIN	In the haloarchaea Haloferax volcanii, ribosomes are found in the cytoplasm and membrane-bound at similar levels. Transformation of H. volcanii to express chimeras of the translocon components SecY and SecE fused to a cellulose-binding domain substantially decreased ribosomal membrane binding, relative to non-transformed cells, likely due to steric hindrance by the cellulose-binding domain. Treatment of cells with the polypeptide synthesis terminator puromycin, with or without low salt washes previously shown to prevent in vitro ribosomal membrane binding in halophilic archaea, did not lead to release of translocon-bound ribosomes, indicating that ribosome release is not directly related to the translation status of a given ribosome. Release was, however, achieved during cell starvation or stationary growth, pointing at a regulated manner of ribosomal release in H. volcanii. Decreased ribosomal binding selectively affected membrane protein levels, suggesting that membrane insertion occurs co-translationally in Archaea. In the presence of chimera-incorporating sterically hindered translocons, the reduced ability of ribosomes to bind in the transformed cells modulated protein synthesis rates over time, suggesting that these cells manage to compensate for the reduction in ribosome binding. Possible strategies for this compensation, such as a shift to a post-translational mode of membrane protein insertion or maintained ribosomal membrane-binding, are discussed.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University	Eichler, J (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, POB 653, IL-84105 Beer Sheva, Israel.	jeichler@bgumail.bgu.ac.il	EICHLER, JERRY/F-2351-2012	EICHLER, JERRY/0000-0001-9409-8026				Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bardy SL, 2003, PROTEIN SCI, V12, P1833, DOI 10.1110/ps.03148703; Bernstein HD, 2000, CURR OPIN MICROBIOL, V3, P203, DOI 10.1016/S1369-5274(00)00076-X; Bhuiyan SH, 2000, NUCLEIC ACIDS RES, V28, P1365, DOI 10.1093/nar/28.6.1365; CHANT J, 1986, SYST APPL MICROBIOL, V7, P106, DOI 10.1016/S0723-2020(86)80132-1; CHRISTIAN JHB, 1962, BIOCHIM BIOPHYS ACTA, V65, P506, DOI 10.1016/0006-3002(62)90453-5; Dale H, 2000, P NATL ACAD SCI USA, V97, P7847, DOI 10.1073/pnas.140216497; Dale H, 1999, J BIOL CHEM, V274, P22693, DOI 10.1074/jbc.274.32.22693; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; DYALLSMITH M, 2004, HALOHANDBOOK PROTOCO; Eichler J, 2001, TRENDS MICROBIOL, V9, P130, DOI 10.1016/S0966-842X(01)01954-0; Eichler J, 2000, ARCH MICROBIOL, V173, P445, DOI 10.1007/s002030000152; GINZBURG M, 1970, Journal of General Physiology, V55, P187, DOI 10.1085/jgp.55.2.187; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GROPP R, 1992, P NATL ACAD SCI USA, V89, P1204, DOI 10.1073/pnas.89.4.1204; Hainzl T, 2002, NATURE, V417, P767, DOI 10.1038/nature00768; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Herskovits AA, 2000, P NATL ACAD SCI USA, V97, P4621, DOI 10.1073/pnas.080077197; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Irihimovitch V, 2003, J BIOL CHEM, V278, P12881, DOI 10.1074/jbc.M210762200; Irihimovitch V, 2003, EXTREMOPHILES, V7, P71, DOI 10.1007/s00792-002-0297-0; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Lerner RS, 2003, RNA, V9, P1123, DOI 10.1261/rna.5610403; Lichi T, 2004, EUR J BIOCHEM, V271, P1382, DOI 10.1111/j.1432-1033.2004.04050.x; Maeshima H, 2001, FEBS LETT, V507, P336, DOI 10.1016/S0014-5793(01)02996-9; Moll RG, 2004, J BIOENERG BIOMEMBR, V36, P47, DOI 10.1023/B:JOBB.0000019597.36170.5f; Moll RG, 2003, BIOCHEM J, V374, P247, DOI 10.1042/BJ20030475; MUECKLER MM, 1981, J CELL BIOL, V90, P495, DOI 10.1083/jcb.90.2.495; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Ortenberg R, 2000, J BIOL CHEM, V275, P22839, DOI 10.1074/jbc.M908916199; Oubridge C, 2002, MOL CELL, V9, P1251, DOI 10.1016/S1097-2765(02)00530-0; Pohlschroder M, 2004, FEMS MICROBIOL REV, V28, P3, DOI 10.1016/j.femsre.2003.07.004; Potter MD, 2000, J BIOL CHEM, V275, P33828, DOI 10.1074/jbc.M005294200; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; RANDALL LL, 1977, EUR J BIOCHEM, V75, P43, DOI 10.1111/j.1432-1033.1977.tb11502.x; Rapoport TA, 1999, BIOL CHEM, V380, P1143, DOI 10.1515/BC.1999.145; Ring G, 2004, J BIOENERG BIOMEMBR, V36, P35, DOI 10.1023/B:JOBB.0000019596.76554.7a; Ring G, 2004, J MOL BIOL, V336, P997, DOI 10.1016/j.jmb.2004.01.008; Rose RW, 2002, J BACTERIOL, V184, P3260, DOI 10.1128/JB.184.12.3260-3267.2002; Rosendal KR, 2003, P NATL ACAD SCI USA, V100, P14701, DOI 10.1073/pnas.2436132100; Seiser RM, 2000, J BIOL CHEM, V275, P33820, DOI 10.1074/jbc.M004462200; Tozik I, 2002, NUCLEIC ACIDS RES, V30, P4166, DOI 10.1093/nar/gkf548; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Zaigler A, 2003, MOL MICROBIOL, V48, P1089, DOI 10.1046/j.1365-2958.2003.03497.x; Zito CR, 2003, J BIOL CHEM, V278, P40640, DOI 10.1074/jbc.M308025200; Zwieb Christian, 2002, Archaea, V1, P27, DOI 10.1155/2002/729649	49	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53160	53166		10.1074/jbc.M410590200	http://dx.doi.org/10.1074/jbc.M410590200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475349	hybrid, Green Published			2022-12-25	WOS:000225680600045
J	Adkins, MW; Tyler, JK				Adkins, MW; Tyler, JK			The histone chaperone Asf1p mediates global chromatin disassembly in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; CELL-CYCLE; YEAST; NUCLEOSOME; TRANSCRIPTION; IDENTIFICATION; SENSITIVITY; PROTEIN; REPAIR	The packaging of the eukaryotic genome into chromatin is likely to be mediated by chromatin assembly factors, including histone chaperones. We investigated the function of the histone H3/H4 chaperones anti-silencing function 1 (Asf1p) and chromatin assembly factor 1 (CAF-1) in vivo. Analysis of chromatin structure by accessibility to micrococcal nuclease and DNase I digestion demonstrated that the chromatin from CAF-1 mutant yeast has increased accessibility to these enzymes. In agreement, the supercoiling of the endogenous 2mu plasmid is reduced in yeast lacking CAF-1. These results indicate that CAF-1 mutant yeast globally under-assemble their genome into chromatin, consistent with a role for CAF-1 in chromatin assembly in vivo. By contrast, asf1 mutants globally over-assemble their genome into chromatin, as suggested by decreased accessibility of their chromatin to micrococcal nuclease and DNase I digestion and increased supercoiling of the endogenous 2mu plasmid. Deletion of ASF1 causes a striking loss of acetylation on histone H3 lysine 9, but this is not responsible for the altered chromatin structure in asf1 mutants. These data indicate that Asf1p may have a global role in chromatin disassembly and an unexpected role in histone acetylation in vivo.	Univ Colorado, Hlth Sci Ctr Fitzsimons, Dept Biochem & Mol Genet, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Tyler, JK (corresponding author), Univ Colorado, Hlth Sci Ctr Fitzsimons, Dept Biochem & Mol Genet, Aurora, CO 80045 USA.	Jessica.tyler@uchsc.edu		Tyler, Jessica/0000-0001-9765-1659	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064475] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064475, GM64475] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Chimura T, 2002, P NATL ACAD SCI USA, V99, P9334, DOI 10.1073/pnas.142627899; Gregory PD, 1999, METHOD ENZYMOL, V304, P365; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUTTER LC, 1992, MOL CELL BIOL, V12, P5004, DOI 10.1128/MCB.12.11.5004; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Moshkin YM, 2002, GENE DEV, V16, P2621, DOI 10.1101/gad.231202; Munakata T, 2000, GENES CELLS, V5, P221, DOI 10.1046/j.1365-2443.2000.00319.x; Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004; Prado F, 2004, EMBO REP, V5, P497, DOI 10.1038/sj.embor.7400128; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Singer MS, 1998, GENETICS, V150, P613; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Sutton A, 2001, GENETICS, V158, P587; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Umehara T, 2002, GENES CELLS, V7, P59, DOI 10.1046/j.1356-9597.2001.00493.x; WANG JC, 1993, CURR OPIN GENET DEV, V3, P764, DOI 10.1016/S0959-437X(05)80096-6; WANG JC, 1982, CELL, V29, P724, DOI 10.1016/0092-8674(82)90433-0	26	84	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52069	52074		10.1074/jbc.M406113200	http://dx.doi.org/10.1074/jbc.M406113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452122	hybrid			2022-12-25	WOS:000225493400044
J	Bonini, MG; Miyamoto, S; Di Mascio, P; Augusto, O				Bonini, MG; Miyamoto, S; Di Mascio, P; Augusto, O			Production of the carbonate radical anion during xanthine oxidase turnover in the presence of bicarbonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC SUPEROXIDE-DISMUTASE; SINGLET MOLECULAR-OXYGEN; NITRIC-OXIDE; PEROXIDASE-ACTIVITY; CU,ZN-SUPEROXIDE DISMUTASE; HYDROXYL RADICALS; IN-VITRO; PEROXYNITRITE; OXIDATION; MECHANISM	Xanthine oxidase is generally recognized as a key enzyme in purine catabolism, but its structural complexity, low substrate specificity, and specialized tissue distribution suggest other functions that remain to be fully identified. The potential of xanthine oxidase to generate superoxide radical anion, hydrogen peroxide, and peroxynitrite has been extensively explored in pathophysiological contexts. Here we demonstrate that xanthine oxidase turnover at physiological pH produces a strong one-electron oxidant, the carbonate radical anion. The radical was shown to be produced from acetaldehyde oxidation by xanthine oxidase in the presence of catalase and bicarbonate on the basis of several lines of evidence such as oxidation of both dihydrorhodamine 123 and 5,5-dimethyl-1-pyrroline-N-oxide and chemiluminescence and isotope labeling/mass spectrometry studies. In the case of xanthine oxidase acting upon xanthine and hypoxanthine as substrates, carbonate radical anion production was also evidenced by the oxidation of 5,5-dimethyl-1-pyrroline-N-oxide and of dihydrorhodamine 123 in the presence of uricase. The results indicated that Fenton chemistry occurring in the bulk solution is not necessary for carbonate radical anion production. Under the conditions employed, the radical was likely to be produced at the enzyme active site by reduction of a peroxymonocarbonate intermediate whose formation and reduction is facilitated by the many xanthine oxidase redox centers. In addition to indicating that the carbonate radical anion may be an important mediator of the pathophysiological effects of xanthine oxidase, the results emphasize the potential of the bicarbonate-carbon dioxide pair as a source of biological oxidants.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil	Universidade de Sao Paulo	Augusto, O (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Caixa Postal 26077, BR-05513970 Sao Paulo, Brazil.	oaugusto@iq.usp.br	Miyamoto, Sayuri/A-2144-2008; Di Mascio, Paolo/D-1264-2014; Augusto, Ohara/D-3839-2012	Miyamoto, Sayuri/0000-0002-5714-8984; Di Mascio, Paolo/0000-0003-4125-8350; Augusto, Ohara/0000-0002-7220-4286				ALVAREZ MN, 2004, FREE RADIC BIOL M S1, V36, P57; Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4; AVIS PG, 1956, J CHEM SOC, P1219, DOI 10.1039/jr9560001219; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bonini MG, 2004, BIOCHEMISTRY-US, V43, P344, DOI 10.1021/bi035606p; Bonini MG, 2001, J BIOL CHEM, V276, P9749, DOI 10.1074/jbc.M008456200; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; BOUNDS PL, 1991, FREE RADICAL BIO MED, V11, P447, DOI 10.1016/0891-5849(91)90060-G; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; BUXTON GV, 1986, RADIAT PHYS CHEM, V27, P241; CADENAS E, 1984, METHOD ENZYMOL, V105, P221; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; ERIKSEN TE, 1985, RADIAT PHYS CHEM, V26, P197, DOI 10.1016/0146-5724(85)90185-2; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GILBERT DL, 1999, REACTIVE OXYGEN SPEC, P680; Giulivi Cecilia, 1999, P77; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Guo Q, 2003, J AM SOC MASS SPECTR, V14, P862, DOI 10.1016/S1044-0305(03)00336-2; HALLIWELL B, 1998, FREE RADICAL BIO MED, P36; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; Hodges GR, 2000, FREE RADICAL BIO MED, V29, P434, DOI 10.1016/S0891-5849(00)00298-7; HODGSON EK, 1976, ARCH BIOCHEM BIOPHYS, V172, P202, DOI 10.1016/0003-9861(76)90067-9; Koide T, 2000, ANAL SCI, V16, P1029, DOI 10.2116/analsci.16.1029; KUROSE I, 1994, ANN NY ACAD SCI, V723, P158, DOI 10.1111/j.1749-6632.1994.tb36724.x; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Liochev SI, 2002, J BIOL CHEM, V277, P34674, DOI 10.1074/jbc.M204726200; Liochev SI, 2004, P NATL ACAD SCI USA, V101, P743, DOI 10.1073/pnas.0307635100; Liochev SI, 1999, IUBMB LIFE, V48, P157, DOI 10.1080/152165499307161; LLOYD RV, 1990, J BIOL CHEM, V265, P16733; Massey V, 1997, BIOCHEM SOC T, V25, P750, DOI 10.1042/bst0250750; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Millar TM, 2002, REDOX REP, V7, P65, DOI 10.1179/135100002125000280; Miyamoto S, 2003, J AM CHEM SOC, V125, P6172, DOI 10.1021/ja029115o; MORPETH FF, 1983, BIOCHIM BIOPHYS ACTA, V744, P328, DOI 10.1016/0167-4838(83)90207-8; Nakao LS, 1999, CHEM RES TOXICOL, V12, P1010, DOI 10.1021/tx990055i; Nakao LS, 2000, FREE RADICAL BIO MED, V29, P721, DOI 10.1016/S0891-5849(00)00374-9; NETA P, 1980, J PHYS CHEM-US, V84, P532, DOI 10.1021/j100442a017; Oettl K, 1997, BIOCHEM BIOPH RES CO, V234, P774, DOI 10.1006/bbrc.1997.6712; Parks Dale A., 1999, P397; Radi R., 2000, BIOL CHEM PEROXYNITR, P57; REUVERS AP, 1973, INT J RADIAT BIOL, V24, P533, DOI 10.1080/09553007314551431; Richardson DE, 2000, J AM CHEM SOC, V122, P1729, DOI 10.1021/ja9927467; ROSS D, 1985, BIOCHIM BIOPHYS ACTA, V841, P278, DOI 10.1016/0304-4165(85)90069-8; Shafirovich V, 2001, J BIOL CHEM, V276, P24621, DOI 10.1074/jbc.M101131200; Stoyanovsky DA, 1996, ARCH BIOCHEM BIOPHYS, V330, P3, DOI 10.1006/abbi.1996.0219; TAN S, 1993, PEDIATR RES, V34, P303, DOI 10.1203/00006450-199309000-00013; Wadhawan JD, 2001, J PHYS CHEM B, V105, P10659, DOI 10.1021/jp012160i; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Yao HR, 2003, J AM CHEM SOC, V125, P6211, DOI 10.1021/ja0274756; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038; Zhang H, 2003, J BIOL CHEM, V278, P24078, DOI 10.1074/jbc.M302051200; Zhang HB, 2002, J BIOL CHEM, V277, P49767, DOI 10.1074/jbc.M204005200; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226	60	65	67	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51836	51843		10.1074/jbc.M406929200	http://dx.doi.org/10.1074/jbc.M406929200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15448145	hybrid			2022-12-25	WOS:000225493400016
J	Hirata, T; Furukawa, Y; Yang, BG; Hieshima, K; Fukuda, M; Kannagi, R; Yoshie, O; Miyasaka, M				Hirata, T; Furukawa, Y; Yang, BG; Hieshima, K; Fukuda, M; Kannagi, R; Yoshie, O; Miyasaka, M			Human P-selectin glycoprotein ligand-1 (PSGL-1) interacts with the skin-associated chemokine CCL27 via sulfated tyrosines at the PSGL-1 amino terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; HIGH-AFFINITY BINDING; HUMAN LYMPH-NODES; MEMORY T-CELLS; SIALYL-LEWIS-X; MOLECULAR-BASIS; CUTTING EDGE; HIV-1 ENTRY; O-GLYCANS; IN-VIVO	P-selectin glycoprotein ligand-1 (PSGL-1), a sialomucin expressed on leukocytes, is a major ligand for P-selectin and mediates leukocyte rolling on the endothelium. Here we show that human PSGL-1 interacts with CCL27 (CTACK/ILC/ESkine), a skin-associated chemokine that attracts skin-homing T lymphocytes. A recombinant soluble form of PSGL-1 (rPSGL-Ig) preferentially bound CCL27 among several chemokines tested. This interaction was abrogated by arylsulfatase treatment of rPSGL-Ig, suggesting that sulfated tyrosines play a critical role. In contrast, removal of either N-glycans or O-glycans by glycosidase treatment of rPSGL-Ig did not affect the interaction. The binding of CCL27 to a recombinant PSGL-1 synthesized in the presence of a sulfation inhibitor was lower than that produced in normal medium. Moreover, mutation of the tyrosines at the amino terminus of PSGL-1 to phenylalanine abolished the binding, further supporting the role of sulfated tyrosines in the CCL27-PSGL-1 interaction. Functionally, rPSGL-Ig reduced the chemotaxis of L1.2 cells expressing CCR10, the receptor for CCL27. In addition, the expression of human PSGL-1 on CCR10-expressing L1.2 cells resulted in reduced chemotaxis to CCL27. These findings suggest a role for PSGL-1 in regulating chemokine-mediated responses, in addition to its role as a selectin ligand.	Osaka Univ, Grad Sch Med C8, Lab Mol & Cellular Recognit, Suita, Osaka 5650871, Japan; Aichi Canc Ctr, Res Inst, Program Mol Pathol, Aichi 4648681, Japan; Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA; Kinki Univ, Sch Med, Dept Microbiol, Osaka 5898511, Japan; Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan	Osaka University; Aichi Cancer Center; Sanford Burnham Prebys Medical Discovery Institute; Kindai University (Kinki University); Osaka University	Hirata, T (corresponding author), Osaka Univ, Grad Sch Med C8, Lab Mol & Cellular Recognit, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	thirata@orgctl.med.osaka-u.ac.jp	Hieshima, Kunio/AAF-7040-2019; Kannagi, Reiji/Q-6459-2018	Hieshima, Kunio/0000-0002-7786-4646; Kannagi, Reiji/0000-0003-4202-2921; Yang, Bo-Gie/0000-0002-1538-8488; Yoshie, Osamu/0000-0003-4353-5809; Hirata, Takako/0000-0002-1740-6168	NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [CA71932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Bernimoulin MP, 2003, J BIOL CHEM, V278, P37, DOI 10.1074/jbc.M204360200; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Davenpeck KL, 2000, J IMMUNOL, V165, P2764, DOI 10.4049/jimmunol.165.5.2764; Dulkanchainun TS, 1998, ANN SURG, V227, P832, DOI 10.1097/00000658-199806000-00006; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Fong AM, 2002, J BIOL CHEM, V277, P19418, DOI 10.1074/jbc.M201396200; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; Hayward R, 1999, CARDIOVASC RES, V41, P65, DOI 10.1016/S0008-6363(98)00266-1; Hicks AER, 2003, BLOOD, V101, P3249, DOI 10.1182/blood-2002-07-2329; Hieshima K, 2003, J IMMUNOL, V170, P1452, DOI 10.4049/jimmunol.170.3.1452; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hirata T, 2000, J EXP MED, V192, P1669, DOI 10.1084/jem.192.11.1669; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Jarmin DI, 2000, J IMMUNOL, V164, P3460, DOI 10.4049/jimmunol.164.7.3460; Johnston B, 2002, SEMIN IMMUNOL, V14, P83, DOI 10.1006/smim.2001.0345; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4; Kumar A, 1999, CIRCULATION, V99, P1363, DOI 10.1161/01.CIR.99.10.1363; Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; MCEVER RP, 1997, J CLIN INVEST, V100, P97; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA M, 1993, BIOCHEM BIOPH RES CO, V193, P337, DOI 10.1006/bbrc.1993.1629; Scalia R, 1999, CIRC RES, V84, P93; Scalia R, 1999, J EXP MED, V189, P931, DOI 10.1084/jem.189.6.931; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Sperandio M, 2003, J EXP MED, V197, P1355, DOI 10.1084/jem.20021854; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Xia LJ, 2002, J CLIN INVEST, V109, P939; Yanaba K, 2004, ANN RHEUM DIS, V63, P583, DOI 10.1136/ard.2003.011122; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769	48	30	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51775	51782		10.1074/jbc.M409868200	http://dx.doi.org/10.1074/jbc.M409868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466853	hybrid			2022-12-25	WOS:000225493400010
J	Kenis, H; van Genderen, H; Bennaghmouch, A; Rinia, HA; Frederik, P; Narula, J; Hofstra, L; Reutelingsperger, CPM				Kenis, H; van Genderen, H; Bennaghmouch, A; Rinia, HA; Frederik, P; Narula, J; Hofstra, L; Reutelingsperger, CPM			Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ASYMMETRY; ANTICOAGULANT PROTEIN; IN-VIVO; APOPTOSIS; DEATH; CLEARANCE; BINDING; INHIBITION; BILAYERS; RECEPTOR	Expression of phosphatidylserine (PtdSer) at the cell surface is part of the membrane dynamics of apoptosis. Expressed phosphatidylserine functions as an "eat me" flag toward phagocytes. Here, we report that the expressed phosphatidylserine forms part of a hitherto undescribed pinocytic pathway. Annexin A5, a phosphatidylserine-binding protein, binds to and polymerizes through protein-protein interactions on membrane patches expressing phosphatidylserine. The two-dimensional protein network of annexin A5 at the surface prevents apoptotic body formation without interfering with the progression of apoptosis as demonstrated by activation of caspase-3, PtdSer exposure, and DNA fragmentation. The annexin A5 protein network bends the membrane patch nanomechanically into the cell and elicits budding, endocytic vesicle formation, and cytoskeleton-dependent trafficking of the endocytic vesicle. Annexin A1, which binds to PtdSer without forming a two-dimensional protein network, does not induce the formation of endocytic vesicles. This novel pinocytic pathway differs from macropinocytosis, which is preceded by membrane ruffling and actin polymerization. We clearly showed that actin polymerization is not involved in budding and endocytic vesicle formation but is required for intracellular trafficking. The phosphatidylserine-annexin A5-mediated pinocytic pathway is not restricted to cells in apoptosis. We demonstrated that living tumor cells can take up substances through this novel portal of cell entry. This opens new avenues for targeted drug delivery and cell entry.	Univ Limburg, Cardiovasc Res Inst Maastricht, Dept Biochem, NL-6200 MD Maastricht, Netherlands; Univ Limburg, Cardiovasc Res Inst Maastricht, Dept Cardiol, NL-6200 MD Maastricht, Netherlands; Univ Limburg, Cardiovasc Res Inst Maastricht, Dept Electron Microscopy, NL-6200 MD Maastricht, Netherlands; Leiden Inst Phys, NL-2333 CA Leiden, Netherlands; Univ Calif Irvine, Dept Med Cardiol, Irvine, CA 92612 USA	Hasselt University; Maastricht University; Hasselt University; Maastricht University; Hasselt University; Maastricht University; Leiden University; University of California System; University of California Irvine	Reutelingsperger, CPM (corresponding author), Univ Limburg, Cardiovasc Res Inst Maastricht, Dept Biochem, POB 616, NL-6200 MD Maastricht, Netherlands.	c.reutelingsperger@bioch.unimaas.nl						ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Blankenberg FG, 1999, J NUCL MED, V40, P184; Boersma HH, 2004, ANAL BIOCHEM, V327, P126, DOI 10.1016/j.ab.2004.01.004; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Dumont EA, 2001, NAT MED, V7, P1352, DOI 10.1038/nm1201-1352; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; FREDERICK PM, 2005, IN PRESS METHODS ENZ; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gidon-Jeangirard C, 1999, J IMMUNOL, V162, P5712; GOVORUKHINA N, 2002, ANNEXINS BIOL IMPORT, P40; Hammill AK, 1999, EXP CELL RES, V251, P16, DOI 10.1006/excr.1999.4581; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hofstra L, 2000, LANCET, V356, P209, DOI 10.1016/S0140-6736(00)02482-X; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; Kuijpers TW, 2004, BLOOD, V103, P3915, DOI 10.1182/blood-2003-11-3940; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mira JP, 1997, J BIOL CHEM, V272, P10474; MOSSER G, 1991, J MOL BIOL, V217, P241, DOI 10.1016/0022-2836(91)90538-H; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Narula J, 2001, NAT MED, V7, P1347, DOI 10.1038/nm1201-1347; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; Ran S, 2002, INT J RADIAT ONCOL, V54, P1479, DOI 10.1016/S0360-3016(02)03928-7; Reviakine I, 1998, J STRUCT BIOL, V121, P356, DOI 10.1006/jsbi.1998.4003; Rinia HA, 2001, FEBS LETT, V501, P92, DOI 10.1016/S0014-5793(01)02636-9; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; TAIT JF, 1989, J BIOL CHEM, V264, P7944; van den Eijnde SM, 1998, APOPTOSIS, V3, P9, DOI 10.1023/A:1009650917818; van den Eijnde SM, 2001, J CELL SCI, V114, P3631; vandenEijnde SM, 1997, CYTOMETRY, V29, P313, DOI 10.1002/(SICI)1097-0320(19971201)29:4<313::AID-CYTO8>3.0.CO;2-A; VandenEijnde SM, 1997, CELL DEATH DIFFER, V4, P311, DOI 10.1038/sj.cdd.4400241; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M	36	125	134	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52623	52629		10.1074/jbc.M409009200	http://dx.doi.org/10.1074/jbc.M409009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15381697	hybrid			2022-12-25	WOS:000225493400109
J	Morimoto, A; Irie, K; Murakami, K; Masuda, Y; Ohigashi, H; Nagao, M; Fukuda, H; Shimizu, T; Shirasawa, T				Morimoto, A; Irie, K; Murakami, K; Masuda, Y; Ohigashi, H; Nagao, M; Fukuda, H; Shimizu, T; Shirasawa, T			Analysis of the secondary structure of beta-amyloid (A beta 42) fibrils by systematic proline replacement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; PHORBOL ESTER-BINDING; ALZHEIMERS-DISEASE; SENILE PLAQUES; DUTCH-TYPE; PEPTIDE; PROTEIN; NEUROTOXICITY; AGGREGATION; CONSTRAINTS	Amyloid fibrils in Alzheimer's disease mainly consist of 40- and 42-mer beta-amyloid peptides (Abeta40 and Abeta42) that exhibit aggregative ability and neurotoxicity. Although the aggregates of Abeta peptides are rich in intermolecular beta-sheet, the precise secondary structure of Abeta in the aggregates remains unclear. To identify the amino acid residues involved in the beta-sheet formation, 34 proline-substituted mutants of Abeta42 were synthesized and their aggregative ability and neurotoxicity on PC12 cells were examined. Prolines are rarely present in beta-sheet, whereas they are easily accommodated in beta-turn as a Pro-X corner. Among the mutants at positions 15-32, only E22P-Abeta42 extensively aggregated with stronger neurotoxicity than wild-type Abeta42, suggesting that the residues at positions 15-21 and 24-32 are involved in the beta-sheet and that the turn at positions 22 and 23 plays a crucial role in the aggregation and neurotoxicity of Abeta42. The C-terminal proline mutants (A42P-, I41P-, and V40P-Abeta42) hardly aggregated with extremely weak cytotoxicity, whereas the C-terminal threonine mutants (A42T- and I41T-Abeta42) aggregated potently with significant cytotoxicity. These results indicate that the hydrophobicity of the C-terminal two residues of Abeta42 is not related to its aggregative ability and neurotoxicity, rather the C-terminal three residues adopt the beta-sheet. These results demonstrate well the large difference in aggregative ability and neurotoxicity between Abeta42 and Abeta40. In contrast, the proline mutants at the N-terminal 13 residues showed potent aggregative ability and neurotoxicity similar to those of wild-type Abeta42. The identification of the beta-sheet region of Abeta42 is a basis for designing new aggregation inhibitors of Abeta peptides.	Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Kyoto 6068502, Japan; Univ Tokyo, Inst Med Sci, Tokyo 1088539, Japan; Tokyo Metropolitan Inst Gerontol, Dept Mol Gerontol, Tokyo 1730015, Japan	Kyoto University; Kyoto University; University of Tokyo; Tokyo Metropolitan Institute of Gerontology	Irie, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kitashirakawa Oiwake Cho, Kyoto 6068502, Japan.	irie@kais.kyoto-u.ac.jp	Irie, Kazuhiro/A-6121-2014; Murakami, Kazuma/GQA-7062-2022	Irie, Kazuhiro/0000-0001-7109-8568; Murakami, Kazuma/0000-0003-3152-1784; Masuda, Yuichi/0000-0002-8067-5897				Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Antzutkin ON, 2002, BIOCHEMISTRY-US, V41, P15436, DOI 10.1021/bi0204185; BURDICK D, 1992, J BIOL CHEM, V267, P546; CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Fukuda H, 1999, BIOORG MED CHEM LETT, V9, P953, DOI 10.1016/S0960-894X(99)00121-3; Fukuda H, 1999, BIOORGAN MED CHEM, V7, P1213, DOI 10.1016/S0968-0896(99)00037-1; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; KANSKI J, 2001, BIOCHIM BIOPHYS ACTA, V1586, P190; Lakdawala AS, 2002, J AM CHEM SOC, V124, P15150, DOI 10.1021/ja0273290; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Morimoto A, 2002, BIOCHEM BIOPH RES CO, V295, P306, DOI 10.1016/S0006-291X(02)00670-8; Murakami K, 2002, BIOCHEM BIOPH RES CO, V294, P5, DOI 10.1016/S0006-291X(02)00430-8; Murakami K, 2003, J BIOL CHEM, V278, P46179, DOI 10.1074/jbc.M301874200; Naiki H, 1999, METHOD ENZYMOL, V309, P305; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Shimizu T, 2002, J NEUROSCI RES, V70, P451, DOI 10.1002/jnr.10350; Tagliavini F., 1999, ALZHEIMERS REP, V2, pS28; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Tycko R, 2003, BIOCHEMISTRY-US, V42, P3151, DOI 10.1021/bi027378p; WEINREB PH, 1994, J AM CHEM SOC, V116, P10835, DOI 10.1021/ja00102a079; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003	29	151	154	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52781	52788		10.1074/jbc.M406262200	http://dx.doi.org/10.1074/jbc.M406262200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459202	hybrid			2022-12-25	WOS:000225493400125
J	Nguyen, TA; Takemoto, LJ; Takemoto, DJ				Nguyen, TA; Takemoto, LJ; Takemoto, DJ			Inhibition of gap junction activity through the release of the C1B domain of protein kinase c gamma (PKC gamma) from 14-3-3 - Identification of PKC gamma-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; ACTIVATION; 14-3-3-PROTEINS; RECEPTOR; BRAIN; MECHANISMS; ISOFORMS; AFFINITY; CELLS; LEDGF	We have shown previously that insulin-like growth factor-I or lens epithelium-derived growth factor increases the translocation of protein kinase Cgamma (PKCgamma) to the membrane and the phosphorylation of Cx43 by PKCgamma and causes a subsequent decrease of gap junction activity (Nguyen, T. A., Boyle, D. L., Wagner, L. M., Shinohara, T., and Takemoto, D. J. (2003) Exp. Eye Res. 76, 565-572; Lin, D., Boyle, D. L., and Takemoto, D. J. ( 2003) Investig. Ophthalmol. Vis. Sci. 44, 1160-1168). Gap junction activity in lens epithelial cells is regulated by PKCgamma-mediated phosphorylation of Cx43. PKCgamma activity is stimulated by growth factor-regulated increases in the synthesis of diacylglycerol but is inhibited by cytosolic docking proteins such as 14-3-3. Here we have identified two sites on the PKCgamma-C1B domain that are responsible for its interaction with 14-3-3epsilon. Two sites, C1B1 (residues 101-112) and C1B5 (residues 141-151), are located within the C1 domain of PKCgamma. C1B1 and/or C1B5 synthetic peptides can directly compete for the binding of 14-3-3epsilon, resulting in the release of endogenous cellular PKCgamma from 14-3-3epsilon, in vivo or in vitro, in activation of PKCgamma enzyme activity, phosphorylation of PKCgamma, in the subsequent translocation of PKCgamma to the membrane, and in inhibition of gap junction activity. Gap junction activity was decreased by at least 5-fold in cells treated with C1B1 or C1B5 peptides when compared with a control. 100 muM of C1B1 or C1B5 peptides also caused a 10- or 4-fold decrease of Cx43 plaque formation compared with control cells. The uptake of these synthetic peptides into cells was verified by using high pressure liquid chromatography and matrix-assisted laser desorption ionization time-of-flight-mass spectrometry. We have demonstrated that the activity and localization of PKCgamma are regulated by its binding to 14-3-3epsilon at the C1B domain of PKCgamma. Synthetic peptides corresponding to these regions of PKCgamma successfully competed for the binding of 14-3-3epsilon to endogenous PKCepsilon, resulting in inhibition of gap junction activity. This demonstrates that synthetic peptides can be used to exogenously regulate gap junctions.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University; Kansas State University	Takemoto, DJ (corresponding author), Kansas State Univ, Dept Biochem, 103 Willard Hall, Manhattan, KS 66506 USA.	dtak@ksu.edu			NATIONAL EYE INSTITUTE [R01EY002932, R01EY013421] Funding Source: NIH RePORTER; NEI NIH HHS [EY13421, EY02932] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Aronowski J, 2000, J CEREBR BLOOD F MET, V20, P343, DOI 10.1097/00004647-200002000-00016; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Beyer EC, 2002, CURR DRUG TARGETS, V3, P409, DOI 10.2174/1389450023347245; Bowers BJ, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-21-j0004.2001; Craparo A, 1997, J BIOL CHEM, V272, P11663; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 2000, ANN REV PHARM TOXICO, V40, P619; Garcia-Dorado D, 2002, CARDIOVASC RES, V55, P456, DOI 10.1016/S0008-6363(02)00441-8; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hurley JH, 1997, PROTEIN SCI, V6, P477; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Irie K, 1997, BIOORGAN MED CHEM, V5, P1725, DOI 10.1016/S0968-0896(97)00116-8; Kowara R, 1999, ACTA BIOCHIM POL, V46, P405, DOI 10.18388/abp.1999_4173; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Le ACN, 1998, DEV BIOL, V204, P80, DOI 10.1006/dbio.1998.9030; Lin D, 2004, MOL VIS, V10, P688; Lin DB, 2003, INVEST OPHTH VIS SCI, V44, P1160, DOI 10.1167/iovs.02-0737; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P1168; Narita M, 2001, J BIOL CHEM, V276, P15409, DOI 10.1074/jbc.M009716200; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Nguyen TA, 2003, EXP EYE RES, V76, P565, DOI 10.1016/S0014-4835(03)00049-6; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Saltman AE, 2002, J THORAC CARDIOV SUR, V124, P371, DOI 10.1067/mtc.2002.124239; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Shindo M, 2001, BIOORGAN MED CHEM, V9, P2073, DOI 10.1016/S0968-0896(01)00100-6; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wagner LM, 2002, MOL VIS, V8, P59; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	48	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52714	52725		10.1074/jbc.M403040200	http://dx.doi.org/10.1074/jbc.M403040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459208	hybrid			2022-12-25	WOS:000225493400118
J	Rajkovic, M; Middendorff, R; Wetzel, MG; Frkovic, D; Damerow, S; Seitz, HJ; Weitzel, JM				Rajkovic, M; Middendorff, R; Wetzel, MG; Frkovic, D; Damerow, S; Seitz, HJ; Weitzel, JM			Germ cell nuclear factor relieves cAMP-response element modulator tau-mediated activation of the testis-specific promoter of human mitochondrial glycerol-3-phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; MULTIPLE PROMOTERS; ORPHAN RECEPTOR; DIFFERENTIAL EXPRESSION; MICE LACKING; DNA-BINDING; GENE; CREM; TISSUE; TARGETS	Mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH) is an essential component of the glycerol phosphate shuttle that transfers reduction equivalents from the cytosol into the mitochondrion. Within the testis, immunohistological analysis localized human mGPDH to late spermatids and to the midpiece of spermatozoa. The expression of human mGPDH is regulated by two somatic promoters, and here, we describe a third testis-specific promoter of human mGPDH. The usage of this testis-specific promoter correlates with the expression of a shortened mGPDH transcript of similar to2.4 kb in length, which is solely detectable from testicular RNA. Within the testis-specific promoter, we detected a cAMP-response element (CRE) site at -51, which binds the testis-specific transcriptional activator CRE modulator tau (CREMtau) in electrophoretic mobility shift assays. This recognition site overlaps with a nuclear receptor binding half-site at - 49, which binds the testis-specific transcriptional repressor germ cell nuclear factor ( GCNF). Both factors compete for binding to the same DNA response element. Ectopic expression of CREMtau in HepG2 cells activated a promoter-driven luciferase construct in transient transfection experiments. Additional cotransfection of GCNF relieved this activity, suggesting a down-regulation of CREMtau-mediated activation by GCNF. This effect was preserved by introducing the CRE/nuclear receptor-binding element into a heterologous promoter context. Our data suggest a down-regulation of CREMtau-mediated gene expression by GCNF, which might be a general regulation mechanism for several postmeiotically expressed genes with a temporal expression peak during early spermatid development.	Univ Hamburg, Klinikum Eppendorf, Inst Biochem & Mol Biol, D-20246 Hamburg, Germany; Univ Hamburg, Klinikum Eppendorf, Inst Anat, Zentrum Expt Med, D-20246 Hamburg, Germany; Fac Med Belgrade, Inst Biochem, YU-11000 Belgrade, Serbia; Univ Giessen, Inst Anat & Zellbiol, D-35385 Giessen, Germany	University of Hamburg; University of Hamburg; University of Belgrade; Justus Liebig University Giessen	Weitzel, JM (corresponding author), Univ Hamburg, Klinikum Eppendorf, Inst Biochem & Mol Biol, Martinistr 52, D-20246 Hamburg, Germany.	weitzel@uke.uni-hamburg.de		Weitzel, Joachim/0000-0002-4073-6691				Behr R, 2001, INT J ANDROL, V24, P126, DOI 10.1046/j.1365-2605.2001.00277.x; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Brown LJ, 2002, J BIOL CHEM, V277, P32892, DOI 10.1074/jbc.M202408200; BUCHER T, 1958, ANGEW CHEM INT EDIT, V70, P552, DOI 10.1002/ange.19580701707; Chung ACK, 2001, MOL CELL BIOL, V21, P663, DOI 10.1128/MCB.21.2.663-677.2001; Cooney AJ, 1998, BIOCHEM BIOPH RES CO, V245, P94, DOI 10.1006/bbrc.1998.8391; Cooney AJ, 2001, TRENDS ENDOCRIN MET, V12, P247, DOI 10.1016/S1043-2760(01)00424-6; DAWSON AG, 1979, TRENDS BIOCHEM SCI, V4, P171, DOI 10.1016/0968-0004(79)90417-1; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; Don J, 2002, MOL CELL ENDOCRINOL, V187, P115, DOI 10.1016/S0303-7207(01)00696-7; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Ferrer J, 1996, DIABETES, V45, P262, DOI 10.2337/diabetes.45.2.262; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; Gong DW, 1998, DNA CELL BIOL, V17, P301, DOI 10.1089/dna.1998.17.301; Gong QM, 2000, J BIOL CHEM, V275, P38012, DOI 10.1074/jbc.M004078200; Ha H, 1997, J CELL BIOCHEM, V64, P94, DOI 10.1002/(SICI)1097-4644(199701)64:1<94::AID-JCB12>3.3.CO;2-H; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; Hummelke GC, 1998, MOL REPROD DEV, V50, P396, DOI 10.1002/(SICI)1098-2795(199808)50:4<396::AID-MRD3>3.0.CO;2-D; Ivell R, 2004, MOL CELL ENDOCRINOL, V216, P65, DOI 10.1016/j.mce.2003.10.079; Katz D, 1997, ENDOCRINOLOGY, V138, P4364, DOI 10.1210/en.138.10.4364; Koza RA, 1996, ARCH BIOCHEM BIOPHYS, V336, P97, DOI 10.1006/abbi.1996.0536; Lan ZJ, 2003, BIOL REPROD, V68, P282, DOI 10.1095/biolreprod.102.008151; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Russell L. D., 1990, HISTOLOGICAL HISTOPA; San Agustin JT, 2001, BIOL REPROD, V65, P151, DOI 10.1095/biolreprod65.1.151; Schmitz TP, 1999, BBA-GENE STRUCT EXPR, V1446, P173, DOI 10.1016/S0167-4781(99)00079-2; SIBONY M, 1994, BIOL REPROD, V50, P1015, DOI 10.1095/biolreprod50.5.1015; Susens U, 1997, DEV NEUROSCI-BASEL, V19, P410, DOI 10.1159/000111238; Urcelay E, 2000, EUR J BIOCHEM, V267, P7209, DOI 10.1046/j.1432-1327.2000.01832.x; Weitzel JM, 2000, BIOL CHEM, V381, P611, DOI 10.1515/BC.2000.078; Weitzel JM, 2003, BIOL REPROD, V68, P699, DOI 10.1095/biolreprod.102.008540; Weitzel JM, 2001, NUCLEIC ACIDS RES, V29, P5148, DOI 10.1093/nar/29.24.5148; Weitzel JM, 2001, EUR J BIOCHEM, V268, P4095, DOI 10.1046/j.1432-1327.2001.02332.x; Yan ZH, 1997, J BIOL CHEM, V272, P10565; Yan ZJ, 2000, J BIOL CHEM, V275, P35077, DOI 10.1074/jbc.M005566200; Yang GY, 2003, BIOL REPROD, V68, P1620, DOI 10.1095/biolreprod.102.012013; Zhang YL, 1998, MOL REPROD DEV, V50, P93, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;93::AID-MRD12&gt;3.0.CO;2-Z; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P12262, DOI 10.1073/pnas.93.22.12262	39	20	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52493	52499		10.1074/jbc.M404467200	http://dx.doi.org/10.1074/jbc.M404467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456763	hybrid			2022-12-25	WOS:000225493400095
J	Yu, DH; Khan, E; Khaleque, MA; Lee, J; Laco, G; Kohlhagen, G; Kharbanda, S; Cheng, YC; Pommier, Y; Bharti, A				Yu, DH; Khan, E; Khaleque, MA; Lee, J; Laco, G; Kohlhagen, G; Kharbanda, S; Cheng, YC; Pommier, Y; Bharti, A			Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; N-TERMINAL DOMAIN; CATALYTIC-ACTIVITY; APOPTOTIC RESPONSE; CLEAVAGE COMPLEXES; STRESS-RESPONSE; CYTO-TOXICITY; STRAND BREAKS; SH3 DOMAINS; WILD-TYPE	DNA topoisomerase I ( topo I) is involved in the regulation of DNA supercoiling, gene transcription, recombination, and DNA repair. The anticancer agent camptothecin specifically targets topo I. The mechanisms responsible for the regulation of topo I in cells, however, are not known. This study demonstrates that c-Abl-dependent phosphorylation up-regulates topo I activity. The c-Abl SH3 domain bound directly to the N-terminal region of topo I. The results demonstrate that c-Abl phosphorylated topo I at Tyr(268) in core subdomain II. c-Abl-mediated phosphorylation of topo I Tyr(268) in vitro and in cells conferred activation of the topo I isomerase function. Moreover, activation of c-Abl by treatment of cells with ionizing radiation was associated with c-Abl-dependent phosphorylation of topo I and induction of topo I activity. The functional significance of the c-Abl/topo I interaction is supported by the findings that (i) mutant topo I(Y268F) exhibited loss of c-Abl-induced topo I activity, and (ii) c-Abl(-/-) cells were deficient in the accumulation of protein-linked DNA breaks. In addition, loss of topo I phosphorylation in c-Abl-deficient cells conferred resistance to camptothecin-induced apoptosis. These findings collectively support a model in which c-Abl-mediated phosphorylation of topo I is functionally important to topo I activity and sensitivity to topo I poisons.	Boston Univ, Sch Med, Dept Med, Ctr Mol Stress Response, Boston, MA 02118 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Mol Biol Core Facil, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Boston University; Yale University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Bharti, A (corresponding author), Boston Univ, Sch Med, Dept Med, Ctr Mol Stress Response, 650 Albany St,EBRC-311, Boston, MA 02118 USA.	Bharti@bu.edu		Khaleque, Md Abdul/0000-0002-6873-9165; Bharti, Ajit/0000-0001-7972-6688	NATIONAL CANCER INSTITUTE [ZIABC006161, Z01BC006150, ZIABC006150, Z01BC006161] Funding Source: NIH RePORTER; NCI NIH HHS [CA55241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Albor A, 1998, CANCER RES, V58, P2091; ALSNER J, 1992, J BIOL CHEM, V267, P12408; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Champoux JJ, 2000, METH MOL B, V95, P81; CHANG JY, 1992, BIOCHEM PHARMACOL, V43, P2443, DOI 10.1016/0006-2952(92)90325-D; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; COVEY JM, 1989, CANCER RES, V49, P5016; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; David-Cordonnier MH, 1999, NUCLEIC ACIDS RES, V27, P2265, DOI 10.1093/nar/27.11.2265; David-Cordonnier MH, 1998, BIOCHEMISTRY-US, V37, P6065, DOI 10.1021/bi973030w; DEFFIE AM, 1989, CANCER RES, V49, P58; Edwards TK, 2000, J BIOL CHEM, V275, P36181, DOI 10.1074/jbc.M006628200; ENG WK, 1988, MOL PHARMACOL, V34, P755; ENG WK, 1989, J BIOL CHEM, V264, P13373; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GANGLOFF S, 1994, EXPERIENTIA, V50, P261, DOI 10.1007/BF01924009; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; GOGA A, 1995, ONCOGENE, V11, P791; Gong JG, 1999, NATURE, V399, P806; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JAXEL C, 1991, J BIOL CHEM, V266, P20418; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; KANZAWA F, 1990, CANCER RES, V50, P5919; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Labourier E, 1998, NUCLEIC ACIDS RES, V26, P2955, DOI 10.1093/nar/26.12.2955; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MADDEN KR, 1992, CANCER RES, V52, P525; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Pommier Y, 1999, DRUG RESIST UPDATE, V2, P307, DOI 10.1054/drup.1999.0102; POMMIER Y, 1990, J BIOL CHEM, V265, P9418; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Rossi F, 1998, NUCLEIC ACIDS RES, V26, P2963, DOI 10.1093/nar/26.12.2963; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; RUBIN E, 1994, J BIOL CHEM, V269, P2433; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shykind BM, 1997, GENE DEV, V11, P397, DOI 10.1101/gad.11.3.397; Simmons DT, 1998, J BIOL CHEM, V273, P20390, DOI 10.1074/jbc.273.32.20390; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; SOLARY E, 1993, BLOOD, V81, P1359; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Subramanian D, 1998, CANCER RES, V58, P976; SUGIMOTO Y, 1990, CANCER RES, V50, P6925; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Urasaki Y, 2001, CANCER RES, V61, P1964; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEISBROD ST, 1982, NUCLEIC ACIDS RES, V10, P2017, DOI 10.1093/nar/10.6.2017; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; YEH YC, 1994, J BIOL CHEM, V269, P15498; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHANG H, 1990, CANCER CELL-MON REV, V2, P23	91	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51851	51861		10.1074/jbc.M404396200	http://dx.doi.org/10.1074/jbc.M404396200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15448168	hybrid			2022-12-25	WOS:000225493400018
J	Akgoz, M; Kalyanaraman, V; Gautam, N				Akgoz, M; Kalyanaraman, V; Gautam, N			Receptor-mediated reversible translocation of the G protein beta gamma complex from the plasma membrane to the Golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; PHOSPHOLIPASE-C; SUBUNIT; CELLS; RAS	Heterotrimeric G proteins have been thought to function on the plasma membrane after activation by transmembrane receptors. Here we show that, after activation by receptors, the G protein betagamma complex selectively translocates to the Golgi. Receptor inactivation results in Gbetagamma translocating back to the plasma membrane. Both translocation processes occur rapidly within seconds. The efficiency of translocation is influenced by the type of gamma subunit present in the G protein. Distinctly different receptor types are capable of inducing the translocation. Receptor-mediated translocation of Gbetagamma can spatially segregate G protein signaling activity.	Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Genet, Box 8054, St Louis, MO 63110 USA.	gautam@morpheus.wustl.edu	Akgoz, Muslum/A-6234-2015; Akgoz, Muslum/AAG-4598-2019	Akgoz, Muslum/0000-0001-5065-8087; Akgoz, Muslum/0000-0001-5065-8087	NIGMS NIH HHS [GM69027, R01 GM046963, GM46963, R01 GM069027] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069027] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azpiazu I, 2004, J BIOL CHEM, V279, P27709, DOI 10.1074/jbc.M403712200; Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Carroll RC, 1998, EMBO J, V17, P3036, DOI 10.1093/emboj/17.11.3036; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Dascal N, 2001, TRENDS ENDOCRIN MET, V12, P391, DOI 10.1016/S1043-2760(01)00475-1; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; Liang W, 2000, J ANIM SCI, V78, P2329; Morishita R, 1998, FEBS LETT, V428, P85, DOI 10.1016/S0014-5793(98)00498-0; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Weiss TS, 2001, P NATL ACAD SCI USA, V98, P14961, DOI 10.1073/pnas.261572098; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	22	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51541	51544		10.1074/jbc.M410639200	http://dx.doi.org/10.1074/jbc.M410639200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448129	hybrid			2022-12-25	WOS:000225355800108
J	Hansson, CA; Frykman, S; Farmery, MR; Tjernberg, LO; Nilsberth, C; Pursglove, SE; Ito, A; Winblad, B; Cowburn, RF; Thyberg, J; Ankarcrona, M				Hansson, CA; Frykman, S; Farmery, MR; Tjernberg, LO; Nilsberth, C; Pursglove, SE; Ito, A; Winblad, B; Cowburn, RF; Thyberg, J; Ankarcrona, M			Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-APP; APOPTOSIS; TRAFFICKING; MATURATION; INHIBITORS; SIGNAL; BRAIN	Mitochondria are central in the regulation of cell death. Apart from providing the cell with ATP, mitochondria also harbor several death factors that are released upon apoptotic stimuli. Alterations in mitochondrial functions, increased oxidative stress, and neurons dying by apoptosis have been detected in Alzheimer's disease patients. These findings suggest that mitochondria may trigger the abnormal onset of neuronal cell death in Alzheimer's disease. We previously reported that presenilin 1 (PS1), which is often mutated in familial forms of Alzheimer's disease, is located in mitochondria and hypothesized that presenilin mutations may sensitize cells to apoptotic stimuli at the mitochondrial level. Presenilin forms an active gamma-secretase complex together with Nicastrin (NCT), APH-1, and PEN-2, which among other substrates cleaves the beta-amyloid precursor protein (beta-APP) generating the amyloid beta-peptide and the beta-APP intracellular domain. Here we have identified dual targeting sequences ( for endoplasmic reticulum and mitochondria) in NCT and showed expression of NCT in mitochondria by immunoelectron microscopy. We also showed that NCT together with APH-1, PEN-2, and PS1 form a high molecular weight complex located in mitochondria. gamma-Secretase activity in isolated mitochondria was demonstrated using C83 ( alpha-secretase-cleaved C-terminal 83-residue beta-APP fragment from BD8 cells lacking presenilin and thus gamma-secretase activity) or recombinant C100-Flag (C-terminal 100-residue beta-APP fragment) as substrates. Both systems generated an APP intracellular domain, and the activity was inhibited by the gamma-secretase inhibitors L-685,458 or Compound E. This novel localization of NCT, PS1, APH-1, and PEN-2 expands the role and importance of gamma-secretase activity to mitochondria.	Huddinge Hosp, Karolinska Inst, KASPAC, SE-14157 Huddinge, Sweden; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Sumitomo Pharmaceut Co Ltd, Osaka 5418510, Japan; Karolinska Inst, Dept Cell & Mol Biol, Med Nobel Inst, SE-17177 Stockholm, Sweden	Karolinska Institutet; University of Sydney; Karolinska Institutet	Ankarcrona, M (corresponding author), Huddinge Hosp, Karolinska Inst, KASPAC, 5th Floor, SE-14157 Huddinge, Sweden.	ankarcrona@neurotec.ki.se		Ankarcrona, Maria/0000-0002-7022-3694				Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Ankarcrona M, 2002, BIOCHEM BIOPH RES CO, V295, P766, DOI 10.1016/S0006-291X(02)00735-0; Bagshaw RD, 2003, BIOCHEM BIOPH RES CO, V300, P615, DOI 10.1016/S0006-291X(02)02865-6; Brookes PS, 2002, PROTEOMICS, V2, P969, DOI 10.1002/1615-9861(200208)2:8<969::AID-PROT969>3.0.CO;2-3; Butterfield DA, 2003, CNS DRUGS, V17, P641, DOI 10.2165/00023210-200317090-00004; Chen FS, 2003, J BIOL CHEM, V278, P19974, DOI 10.1074/jbc.M210049200; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Keller JN, 1998, J NEUROSCI, V18, P4439; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Mecocci P, 2002, ARCH NEUROL-CHICAGO, V59, P794, DOI 10.1001/archneur.59.5.794; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; REICHMANN H, 1993, J NEUROL, V240, P377, DOI 10.1007/BF00839971; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Siman R, 2003, J NEUROCHEM, V84, P1143, DOI 10.1046/j.1471-4159.2003.01616.x; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	41	202	218	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51654	51660		10.1074/jbc.M404500200	http://dx.doi.org/10.1074/jbc.M404500200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456764	hybrid			2022-12-25	WOS:000225355800121
J	Schubert, SW; Kardash, E; Khan, MA; Cheusova, T; Kilian, K; Wegner, M; Hashemolhosseini, S				Schubert, SW; Kardash, E; Khan, MA; Cheusova, T; Kilian, K; Wegner, M; Hashemolhosseini, S			Interaction, cooperative promoter modulation, and renal colocalization of GCMa and Pitx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR; RIEGER-SYNDROME; GENE; DROSOPHILA; PROTEIN; EXPRESSION; HOMOLOG; FAMILY; SWITCH	The transcription factor GCMa is a member of a new small family of transcription factors with a conserved zinc-containing DNA-binding domain. All members of this transcription factor family play crucial roles as master regulators during development. GCMa is restricted to placenta during development and to kidney and thymus at postnatal stages. It is essential for the formation of the placental labyrinth and as a consequence for survival of the embryo from mid-embryogenesis onwards. Here, we identify Pitx transcription factors as GCMa-interacting proteins. We show that Pitx proteins interact via their conserved homeodomain with the DNA-binding domain of GCMa. As a consequence, Pitx proteins and GCMa exhibit cooperative DNA binding. Furthermore, Pitx proteins influence GCMa-dependent promoter activation in a cell-specific manner. One of the three Pitx paralogues in mice, Pitx2, is the predominant Pitx member present in the placenta and colocalizes on the cellular level with GCMa in the kidney. This is the first description of a regulatory cross-talk between a transcription factor of the GCM family and a homeodomain protein.	Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Hashemolhosseini, S (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.	sh@biochem.uni-erlangen.de	Hashemolhosseini, Said/N-2464-2013	Hashemolhosseini, Said/0000-0002-6564-5649; Wegner, Michael/0000-0002-4586-3294; Kardash, Elena/0000-0002-7425-9862				Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Alfonso TB, 2002, DEV BIOL, V248, P369, DOI 10.1006/dbio.2002.0740; Amendt BA, 1999, MOL CELL BIOL, V19, P7001; Amendt BA, 1998, J BIOL CHEM, V273, P20066, DOI 10.1074/jbc.273.32.20066; Amendt BA, 2000, CELL MOL LIFE SCI, V57, P1652, DOI 10.1007/PL00000647; Anson-Cartwright L, 2000, NAT GENET, V25, P311, DOI 10.1038/77076; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Bernardoni R, 1997, DEV BIOL, V191, P118; Cohen SX, 2003, EMBO J, V22, P1835, DOI 10.1093/emboj/cdg182; Cohen SX, 2002, FEBS LETT, V528, P95, DOI 10.1016/S0014-5793(02)03257-X; Correa P, 2002, CLIN ENDOCRINOL, V57, P501, DOI 10.1046/j.1365-2265.2002.01627.x; Cox CJ, 2002, J BIOL CHEM, V277, P25001, DOI 10.1074/jbc.M201737200; FEINGOLD M, 1969, PEDIATRICS, V44, P564; Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088; Gage PJ, 1999, MAMM GENOME, V10, P197, DOI 10.1007/s003359900970; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Graham A, 1999, CURR BIOL, V9, pR368, DOI 10.1016/S0960-9822(99)80229-2; Gunther T, 2000, NATURE, V406, P199, DOI 10.1038/35018111; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Hashemolhosseini S, 2004, J MOL BIOL, V336, P441, DOI 10.1016/j.jmb.2003.12.029; Hashemolhosseini S, 2003, FEBS LETT, V553, P315, DOI 10.1016/S0014-5793(03)01037-8; Hashemolhosseini S, 2002, MECH DEVELOP, V118, P175, DOI 10.1016/S0925-4773(02)00239-3; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kammerer M, 2001, EMBO J, V20, P4664, DOI 10.1093/emboj/20.17.4664; Kanemura Y, 1999, FEBS LETT, V442, P151, DOI 10.1016/S0014-5793(98)01650-0; Kitamura K, 1999, DEVELOPMENT, V126, P5749; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Lanctot C, 1999, DEVELOPMENT, V126, P1805; Lanctot C, 1997, DEVELOPMENT, V124, P2807; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Ransick A, 2002, DEV BIOL, V246, P132, DOI 10.1006/dbio.2002.0607; Reifegerste R, 1999, MECH DEVELOP, V82, P141, DOI 10.1016/S0925-4773(99)00027-1; Rieger H, 1935, Z AUGENHEILKD, V86, P333; Schreiber J, 2000, MOL CELL BIOL, V20, P2466, DOI 10.1128/MCB.20.7.2466-2474.2000; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Schweickert A, 2000, MECH DEVELOP, V90, P41, DOI 10.1016/S0925-4773(99)00227-0; Semina EV, 1998, NAT GENET, V19, P167, DOI 10.1038/527; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Smidt MP, 1997, P NATL ACAD SCI USA, V94, P13305, DOI 10.1073/pnas.94.24.13305; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Tremblay KD, 2000, DEVELOPMENT, V127, P3079; Tuerk EE, 2000, J BIOL CHEM, V275, P4774, DOI 10.1074/jbc.275.7.4774; Vincent S, 1996, DEVELOPMENT, V122, P131; Weatherbee SD, 1999, CELL, V97, P283, DOI 10.1016/S0092-8674(00)80737-0; Yamada K, 1999, J BIOL CHEM, V274, P32279, DOI 10.1074/jbc.274.45.32279; Yu CC, 2002, J BIOL CHEM, V277, P50062, DOI 10.1074/jbc.M209316200; Zakaria MM, 2002, MOL ENDOCRINOL, V16, P1840, DOI 10.1210/me.2002-0088	50	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50358	50365		10.1074/jbc.M404587200	http://dx.doi.org/10.1074/jbc.M404587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15385555	hybrid			2022-12-25	WOS:000225229500100
J	Shiozawa, T; Miyamoto, T; Kashima, H; Nakayama, K; Nikaido, T; Konishi, I				Shiozawa, T; Miyamoto, T; Kashima, H; Nakayama, K; Nikaido, T; Konishi, I			Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence	ONCOGENE			English	Article						endometrium; endometrial carcinoma; estrogen; cyclin; AP-1	BREAST-CANCER CELLS; GENE-EXPRESSION; IMMUNOHISTOCHEMICAL ANALYSIS; PROMOTER; PROTEIN; GROWTH; FOS; RECEPTOR; ELEMENT; PROTOONCOGENE	To explore the mechanism of estrogen-induced growth of normal endometrium, the transactivation system of the cyclin D1 gene was analysed using cultured normal endometrial glandular cells. Estradiol (E2) treatment of cultured normal endometrial glandular cells induced upregulation of c-Jun, and then cyclin D1 proteins, followed by serial expressions of cyclins E, A and B1 proteins. Increase in the mRNA expression of cyclin D1 preceded the protein expression of cyclin D1 under E2 treatment. A luciferase assay using deletion constructs of the cyclin D1 promoter indicated that E2-induced increase in transcriptional activity was observed in reporters containing AP-1-binding site sequence, and that in the absence of E2, cotransfection of c-Jun also showed increase of transcriptional activity in the same reporters with AP-1 sequence. A gel shift assay using nuclear extract from E2-treated endometrial glandular cells and AP-1 sequences of the cyclin D1 promoter indicated specific binding between c-Jun protein and the promoter. Transfection of c-jun antisense oligonucleotides to the glandular cells resulted in the suppression of the E2-induced upregulation of cyclin D1 mRNA and protein. These findings suggest that E2-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to the AP-1 sequences.	Shinshu Univ, Sch Med, Dept Obstet & Gynecol, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Anat 2, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Grad Sch Med, Dept Organ Regenerat, Matsumoto, Nagano 3908621, Japan	Shinshu University; Shinshu University; Shinshu University	Shiozawa, T (corresponding author), Shinshu Univ, Sch Med, Dept Obstet & Gynecol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	tanri@hsp.md.shinshu-u.ac.jp	Miyamoto, Tsutomu/ADW-0798-2022	Miyamoto, Tsutomu/0000-0002-1513-9473				Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Altucci L, 1996, ONCOGENE, V12, P2315; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; GIUDICE LC, 1994, FERTIL STERIL, V61, P1; GRONROOS M, 1987, ANN CHIR GYNAECOL FE, V76, P76; HERBER B, 1994, ONCOGENE, V9, P1295; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; Kaneuchi M, 2003, INT J ONCOL, V22, P159; Kawasaki S, 1999, BIOCHEM BIOPH RES CO, V263, P560, DOI 10.1006/bbrc.1999.1402; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LESSEY BA, 1988, J CLIN ENDOCR METAB, V67, P334, DOI 10.1210/jcem-67-2-334; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Li SF, 1996, CANCER, V77, P321, DOI 10.1002/(SICI)1097-0142(19960115)77:2<321::AID-CNCR15>3.0.CO;2-3; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; LURAIN JR, 2002, UTERINE CANC NOVAKS, P1143; Miao ZH, 2003, CANCER RES, V63, P4527; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; Nikaido T, 1996, CANCER, V78, P1248, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1248::AID-CNCR12>3.3.CO;2-U; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Salmi A, 1998, J CLIN ENDOCR METAB, V83, P1788, DOI 10.1210/jc.83.5.1788; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shiozawa T, 2001, CANCER, V92, P3005, DOI 10.1002/1097-0142(20011215)92:12<3005::AID-CNCR10153>3.0.CO;2-6; Shiozawa T, 1997, CANCER, V80, P2250, DOI 10.1002/(SICI)1097-0142(19971215)80:12<2250::AID-CNCR5>3.0.CO;2-Y; Shiozawa T, 2001, ENDOCRINOLOGY, V142, P4182, DOI 10.1210/en.142.10.4182; Shiozawa T, 1996, MOL HUM REPROD, V2, P745, DOI 10.1093/molehr/2.10.745; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SPEROFF L, 1999, FEMALE INFERTILITY C, P1014; STRAUSS J, 1999, ENDOMETRIUM MYOMETRI, P218; Takano Y, 2000, AM J PATHOL, V156, P585, DOI 10.1016/S0002-9440(10)64763-3; TSENG L, 1980, CYCLIC CHANGE ESTRAD, P211; WEBB DK, 1993, ENDOCRINOLOGY, V133, P20, DOI 10.1210/en.133.1.20; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181	44	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8603	8610		10.1038/sj.onc.1207849	http://dx.doi.org/10.1038/sj.onc.1207849			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467760	Bronze			2022-12-25	WOS:000224988800006
J	Meininger, CJ; Cai, SJ; Parker, JL; Channon, KM; Kelly, KA; Becker, EJ; Wood, MK; Wade, LA; Wu, GY				Meininger, CJ; Cai, SJ; Parker, JL; Channon, KM; Kelly, KA; Becker, EJ; Wood, MK; Wade, LA; Wu, GY			GTP cyclohydrolase I gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats	FASEB JOURNAL			English	Article						endothelial dysfunction; nitric oxide synthase; diabetes; vascular complications	DEPENDENT VASODILATION; BB RAT; SYNTHASE; DYSFUNCTION; METABOLISM; MELLITUS; ANALOGS	Nitric oxide ( NO) synthesis in endothelial cells is impaired in diabetes. We previously showed that impaired NO synthesis in the spontaneously diabetic BB (BBd) rat is due to decreased levels of tetrahydrobiopterin (BH4), secondary to decreased expression of GTP cyclohydrolase I (GTPCH). The aim of this study was to utilize adenoviral GTPCH gene transfer to reverse BH4 deficiency and repair the ability of endothelial cells to produce NO. GTPCH gene transfer increased BH4 levels in BBd endothelial cells from 0.17 +/- 0.02 ( mean +/- SE) to 73.37 +/- 14.42 pmol/million cells and NO production from 0.77 +/- 0.07 to 18.74 +/- 5.52 nmol/24 h/million cells. To demonstrate a functional effect of increasing BH4 concentrations in tissues, we transferred GTPCH into aortic rings from BBd and Zucker diabetic fatty (ZDF) rats, models of human type I and type II diabetes, respectively. GTPCH gene transfer led to a dose-dependent increase in acetylcholine-induced vasorelaxation, preventable by inhibiting NO synthase. Maximal relaxation of virus-treated rings (10(10) virus particles/ml) to acetylcholine was significantly higher than sham-treated rings (BBd 64% vs. 37%, P< 0.005; ZDF 80% vs. 44%, P< 0.05). This study demonstrates that GTPCH gene transfer can reverse BH4 deficiency in both type I and type II diabetes and provides an experimental basis for using gene therapy to treat cardiovascular complications in diabetic patients.	Texas A&M Univ Syst HSC, Inst Cardiovasc Res, Dept Med Physiol, Temple, TX 76504 USA; Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England; Univ Mary Hardin Baylor, Dept Biol, Belton, TX 76513 USA; Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Oxford; Texas A&M University System; Texas A&M University College Station	Meininger, CJ (corresponding author), Texas A&M Univ Syst HSC, Inst Cardiovasc Res, Dept Med Physiol, 702 SW HK Dodgen Loop,MRB 110G, Temple, TX 76504 USA.	cjm@tamu.edu		channon, keith/0000-0002-1043-4342				Alp NJ, 2003, J CLIN INVEST, V112, P725, DOI 10.1172/JCI200317786; Cai S, 2002, CARDIOVASC RES, V55, P838, DOI 10.1016/S0008-6363(02)00460-1; Chan NN, 2000, DIABETOLOGIA, V43, P137, DOI 10.1007/s001250050022; De Vriese AS, 2000, BRIT J PHARMACOL, V130, P963, DOI 10.1038/sj.bjp.0703393; Etgen GJ, 2000, METABOLISM, V49, P684, DOI 10.1016/S0026-0495(00)80049-9; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P175; Griffin KL, 1999, J APPL PHYSIOL, V87, P1948, DOI 10.1152/jappl.1999.87.5.1948; Harding CO, 2004, MOL GENET METAB, V81, P52, DOI 10.1016/j.ymgme.2003.10.002; Heitzer T, 2000, DIABETOLOGIA, V43, P1435, DOI 10.1007/s001250051551; Hynes SO, 2004, AM J PHYSIOL-HEART C, V286, pH570, DOI 10.1152/ajpheart.00669.2003; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; Kohli R, 2004, J NUTR, V134, P600, DOI 10.1093/jn/134.3.600; Li H, 2000, J CHROMATOGR B, V746, P199, DOI 10.1016/S0378-4347(00)00328-5; Marinos RS, 2001, AM J PHYSIOL-HEART C, V281, pH482, DOI 10.1152/ajpheart.2001.281.2.H482; Meininger CJ, 2000, BIOCHEM J, V349, P353, DOI 10.1042/0264-6021:3490353; Mitchell BM, 2003, AM J PHYSIOL-HEART C, V285, pH2165, DOI 10.1152/ajpheart.00253.2003; Pannirselvam M, 2002, BRIT J PHARMACOL, V136, P255, DOI 10.1038/sj.bjp.0704683; Pieper GM, 1997, J CARDIOVASC PHARM, V29, P8, DOI 10.1097/00005344-199701000-00002; PIEPER GM, 1996, LIFE SCI, V58, P147; Tiefenbacher CP, 2003, PFLUG ARCH EUR J PHY, V447, P1, DOI 10.1007/s00424-003-1131-y; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 2002, BIOCHEM J, V362, P733, DOI 10.1042/0264-6021:3620733; Vasquez-Vivar J, 2002, ARTERIOSCL THROM VAS, V22, P1655, DOI 10.1161/01.ATV.0000029122.79665.D9; WU GY, 1995, AM J PHYSIOL-HEART C, V269, pH1312, DOI 10.1152/ajpheart.1995.269.4.H1312; Zheng JS, 2003, CIRCULATION, V108, P1238, DOI 10.1161/01.CIR.0000089082.40285.C3	25	69	74	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1900	+		10.1096/fj.04-1702fje	http://dx.doi.org/10.1096/fj.04-1702fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15467010				2022-12-25	WOS:000224849900029
J	Nilsson, I; Rolny, C; Wu, Y; Pytowski, B; Hicklin, D; Alitalo, K; Claesson-Welsh, L; Wennstrom, S				Nilsson, I; Rolny, C; Wu, Y; Pytowski, B; Hicklin, D; Alitalo, K; Claesson-Welsh, L; Wennstrom, S			Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development	FASEB JOURNAL			English	Article						embryoid body; endothelial cell; hypoxia; VEGFR-3	EMBRYONIC STEM-CELLS; IN-VITRO; TYROSINE KINASE; VEGF-C; FLT-1; ANGIOGENESIS; EXPRESSION; MOUSE; GENE; VASCULOGENESIS	Reduced tissue oxygen tension ( hypoxia) is appreciated as an efficient stimulus for neovascularization. The effect of hypoxia on the very first stages of vascular development is, however, less well characterized. Here we show that hypoxic conditions (1% O-2) potently stimulated formation of an extensive vascular network during a discrete stage of mouse embryonal stem cell differentiation. The morphological changes correlated with an expanding pool of endothelial cells and with activation of the vascular endothelial growth factor-d (Vegf-d) and Vegf receptor-3 genes. VEGF receptor-3 expression was confined to vascular endothelial cells and analysis of the lymphatic marker Prox-1 revealed no expansion of lymphatic endothelial cells. Administration of neutralizing antibodies against either VEGF receptor-3 or VEGF receptor-2 impaired vascular network formation, whereas neutralizing antibodies against VEGF receptor-1 potentiated development of immature vascular structures. In addition, sequestering of VEGF receptor-3 ligands reduced vascularization in a manner similar to neutralization of VEGF receptor-3. We conclude that hypoxia-driven vascular development requires the activity of VEGF receptor-3.	Uppsala Univ, Dept Genet & Pathol, Vasc Biol Unit, Rudbeck Lab, S-75185 Uppsala, Sweden; ImClone Syst Inc, Dept Immunol, New York, NY USA; Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, Helsinki, Finland	Uppsala University; Eli Lilly; University of Helsinki	Wennstrom, S (corresponding author), Uppsala Univ, Dept Genet & Pathol, Vasc Biol Unit, Rudbeck Lab, S-75185 Uppsala, Sweden.	Stefan.Wennstrom@genpat.uu.se	Rolny, Charlotte/AET-0493-2022; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Rolny, Charlotte/0000-0003-4979-9266				Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Baldwin ME, 2002, BIOESSAYS, V24, P1030, DOI 10.1002/bies.10173; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; BURRI PH, 1990, ANAT REC, V228, P35, DOI 10.1002/ar.1092280107; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Flamme I, 1997, J CELL PHYSIOL, V173, P206, DOI 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; HIRASHIMA M, 2002, BLOOD; Hiratsuka S, 2001, CANCER RES, V61, P1207; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kearney JB, 2002, BLOOD, V99, P2397, DOI 10.1182/blood.V99.7.2397; Keller G, 1999, NAT MED, V5, P151, DOI 10.1038/5512; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kubo H, 2000, BLOOD, V96, P546; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; MAGNUSSON P, 2004, IN PRESS J CELL SCI; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Maltepe E, 1998, J MOL MED-JMM, V76, P391, DOI 10.1007/s001090050231; Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809; Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3; PARK JE, 1994, J BIOL CHEM, V269, P25646; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROSSANT J, 1993, PHILOS T R SOC B, V339, P207, DOI 10.1098/rstb.1993.0018; Saaristo A, 2000, AM J PATHOL, V157, P7, DOI 10.1016/S0002-9440(10)64510-5; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Teng XW, 2002, CHEST, V121, p82S, DOI 10.1378/chest.121.3_suppl.82S-a; Torii MA, 1999, DEVELOPMENT, V126, P443; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; WANG R, 1992, DEVELOPMENT, V114, P303; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; Wartenberg M, 1998, LAB INVEST, V78, P1301; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	57	35	36	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1507	1515		10.1096/fj.03-1276com	http://dx.doi.org/10.1096/fj.03-1276com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466359				2022-12-25	WOS:000224849900034
J	Massaad, CA; Portier, BP; Taglialatela, G				Massaad, CA; Portier, BP; Taglialatela, G			Inhibition of transcription factor activity by nuclear compartment-associated Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; MITOCHONDRIAL OUTER-MEMBRANE; ANTI-APOPTOTIC FUNCTION; PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; BH4 DOMAIN; SIGNALING PATHWAYS; OXIDATIVE-STRESS; FAMILY PROTEINS	Using a reporter gene assay in PC12, HEK293, HeLa, and NIH-3T3 cells, we show that the anti-apoptotic protein Bcl-2 significantly inhibits transcriptional activation of various transcription factors, including NFkappaB, AP1, CRE, and NFAT. A Bcl-2 mutant lacking its BH4 domain (DeltaBH4) also inhibited transcription, whereas a Bcl-2 mutant lacking its transmembrane domain (DeltaTM) was ineffective. Furthermore, Bcl-2 chimeric proteins containing transmembrane domains from the mitochondrial protein monoamine oxidase B ( MaoB) or the endoplasmic reticulum protein cytochrome b(5) showed no effect on transcription factor activity. Subcellular localization studies showed that under conditions of transient transfection, the active Bcl-2 forms ( wild type and DeltaBH4) were predominantly found in the nuclear fraction, whereas the non-active forms (DeltaTM, MaoB, and cytochrome b(5)) were in the non-nuclear fraction. Additionally, stably expressed Bcl-2 loses its ability to inhibit transcriptional activation and localizes predominantly to the non-nuclear fraction. Expression of FKBP38 ( a chaperone that shuttles Bcl-2 to the mitochondria) removes co-expressed Bcl-2 from the nuclear fraction and reverses its effect on transcription factor activity. Finally, using an inducible gene expression system, we show that nuclear compartment-associated Bcl-2 prevents entry of NFkappaB subunits to the nucleus without affecting NFkappaB release from its cytosolic inhibitory subunit IkappaBalpha. These results suggest that (a) Bcl-2 suppresses transcriptional activity of multiple transcription factors; (b) Bcl-2 does not interfere with NFkappaB activation but prevents entrance of its active subunits to the nucleus; ( c) membrane anchoring is required for this function of Bcl-2; and (d) association of Bcl-2 with the nuclear compartment is also necessary. We speculate that nuclear compartment-associated Bcl-2 may affect nuclear trafficking of multiple factors necessary for transcriptional activity.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Taglialatela, G (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.	gtaglial@utmb.edu						Abidi P, 2004, J NUTR BIOCHEM, V15, P210, DOI 10.1016/j.jnutbio.2003.11.007; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Distelhorst CW, 2004, ONCOGENE, V23, P2875, DOI 10.1038/sj.onc.1207519; Frasca D, 2004, MECH AGEING DEV, V125, P111, DOI 10.1016/j.mad.2003.11.004; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; Giardina C, 2002, CELL STRESS CHAPERON, V7, P207, DOI 10.1379/1466-1268(2002)007<0207:GOWNFB>2.0.CO;2; Gosselin K, 2003, EXP GERONTOL, V38, P1271, DOI 10.1016/j.exger.2003.09.007; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hour TC, 2000, EUR J CELL BIOL, V79, P121, DOI 10.1078/S0171-9335(04)70014-X; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Jang JH, 2003, BIOCHEM PHARMACOL, V66, P1371, DOI 10.1016/S0006-2952(03)00487-8; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; Kaufmann JA, 2003, J NEUROCHEM, V87, P981, DOI 10.1046/j.1471-4159.2003.02092.x; Kaufmann JA, 2001, J NEUROCHEM, V76, P1099, DOI 10.1046/j.1471-4159.2001.00118.x; Kaufmann JA, 2002, NEUROREPORT, V13, P1917, DOI 10.1097/00001756-200210280-00017; Kirshenbaum LA, 2000, CLIN INVEST MED, V23, P322; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Massaad CA, 2003, NEUROREPORT, V14, P1167, DOI 10.1097/00001756-200306110-00013; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Sheikh MS, 2004, VITAM HORM, V67, P169; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Song YS, 2004, NEUROSCI RES, V49, P69, DOI 10.1016/j.neures.2004.01.010; Sorenson CM, 2004, J BIOL CHEM, V279, P11368, DOI 10.1074/jbc.M310079200; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Taglialatela G, 1998, NEUROREPORT, V9, P489, DOI 10.1097/00001756-199802160-00024; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; TANAKA S, 1993, J BIOL CHEM, V268, P10920; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200	55	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54470	54478		10.1074/jbc.M407659200	http://dx.doi.org/10.1074/jbc.M407659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471874	hybrid			2022-12-25	WOS:000225793600070
J	Ahn, B; Harrigan, JA; Indig, FE; Wilson, DM; Bohr, VA				Ahn, B; Harrigan, JA; Indig, FE; Wilson, DM; Bohr, VA			Regulation of WRN helicase activity in human base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; DNA-POLYMERASE-BETA; HUMAN APURINIC ENDONUCLEASE; AAA-ATPASE P97/VCP; FLAP ENDONUCLEASE-1; MAJOR HUMAN; BIOCHEMICAL-CHARACTERIZATION; FUNCTIONAL INTERACTION; SUBSTRATE-SPECIFICITY; AP ENDONUCLEASE-1	Werner syndrome patients are deficient in the Werner protein (WRN), which is a multifunctional nuclear protein possessing 3'- 5' exonuclease and ATP-dependent helicase activities. Studies of Werner syndrome cells and biochemical studies of WRN suggest that WRN plays a role in several DNA metabolic pathways. WRN interacts with DNA polymerase beta(pol beta) and stimulates pol beta strand displacement synthesis on a base excision repair (BER) intermediate in a helicase-dependent manner. In this report, we examined the effect of the major human apurinic/apyrimidinic endonuclease (APE1) and of pol beta on WRN helicase activity. The results show that WRN alone is able to unwind several single strand break BER intermediates. However, APE1 inhibits WRN helicase activity on these intermediates. This inhibition is likely due to the binding of APE1 to nicked apurinic/apyrimidinic sites, suggesting that APE1 prevents the promiscuous unwinding of BER intermediates. This inhibitory effect was relieved by the presence of pol beta. A model involving the pol beta-mediated hand-off of WRN protein is proposed based on these results.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Ulsan, Dept Life Sci, Ulsan 680749, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Ulsan	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA.	vbohr@nih.gov	Wilson, David M/AAK-5409-2021; Bohr, Vilhelm/AAP-5931-2020	Wilson, David M/0000-0002-8945-0395; 	NATIONAL INSTITUTE ON AGING [ZIAAG000727, ZIAAG000726, Z01AG000726, Z01AG000727] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bhakat KK, 2003, METHOD ENZYMOL, V371, P292; Bohr VA, 2001, ENVIRON MOL MUTAGEN, V38, P227, DOI 10.1002/em.1076; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2002, BIOCHEMISTRY-US, V41, P12204, DOI 10.1021/bi026031j; Brosh RM, 2001, EMBO J, V20, P5791; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Erzberger JP, 1999, J MOL BIOL, V290, P447, DOI 10.1006/jmbi.1999.2888; Erzberger JP, 1998, NUCLEIC ACIDS RES, V26, P2771, DOI 10.1093/nar/26.11.2771; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Indig FE, 2004, J STRUCT BIOL, V146, P251, DOI 10.1016/j.jsb.2003.11.009; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Matsumoto Y, 2001, PROG NUCLEIC ACID RE, V68, P129; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Nguyen LH, 2000, J MOL BIOL, V298, P447, DOI 10.1006/jmbi.2000.3653; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Opresko PL, 2004, J BIOL CHEM, V279, P18099, DOI 10.1074/jbc.R300034200; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Partridge JJ, 2003, MOL BIOL CELL, V14, P4221, DOI 10.1091/mbc.E03-02-0111; Podlutsky AJ, 2001, EMBO J, V20, P1477, DOI 10.1093/emboj/20.6.1477; Poot M, 2002, FASEB J, V16, P757, DOI 10.1096/fj.01-0906fje; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Ranalli TA, 2002, J BIOL CHEM, V277, P41715, DOI 10.1074/jbc.M207207200; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SALK D, 1982, HUM GENET, V62, P1, DOI 10.1007/BF00295598; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sokhansanj BA, 2002, NUCLEIC ACIDS RES, V30, P1817, DOI 10.1093/nar/30.8.1817; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; von Kobbe C, 2003, MOL CELL BIOL, V23, P8601, DOI 10.1128/MCB.23.23.8601-8613.2003; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Yannone SM, 2001, J BIOL CHEM, V276, P38242	45	70	77	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53465	53474		10.1074/jbc.M409624200	http://dx.doi.org/10.1074/jbc.M409624200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15385537	hybrid			2022-12-25	WOS:000225680600081
J	Pauw, B; Hilliou, FAO; Martin, VS; Chatel, G; de Wolf, CJF; Champion, A; Pre, M; van Duijn, B; Kijne, JW; van der Fits, L; Memelink, J				Pauw, B; Hilliou, FAO; Martin, VS; Chatel, G; de Wolf, CJF; Champion, A; Pre, M; van Duijn, B; Kijne, JW; van der Fits, L; Memelink, J			Zinc finger proteins act as transcriptional repressors of alkaloid biosynthesis genes in Catharanthus roseus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET-SEQUENCE RECOGNITION; SIGNALING PATHWAYS; INDUCED EXPRESSION; SUPERMAN PROTEIN; DNA RECOGNITION; JASMONATE; ELICITOR; PROMOTER; CELL; CULTURES	In Catharanthus roseus cell suspensions, the expression of several terpenoid indole alkaloid biosynthetic genes, including two genes encoding strictosidine synthase (STR) and tryptophan decarboxylase (TDC), is coordinately induced by fungal elicitors such as yeast extract. To identify molecular mechanisms regulating the expression of these genes, a yeast one-hybrid screening was performed with an elicitor-responsive part of the TDC promoter. This screening identified three members of the Cys(2)/His(2)-type (transcription factor IIIA-type) zinc finger protein family from C. roseus, ZCT1, ZCT2, and ZCT3. These proteins bind in a sequence-specific manner to the TDC and STR promoters in vitro and repress the activity of these promoters in trans-activation assays. In addition, the ZCT proteins can repress the activating activity of APETALA2/ethylene response-factor domain transcription factors, the ORCAs, on the STR promoter. The expression of the ZCT genes is rapidly induced by yeast extract and methyljasmonate. These results suggest that the ZCT proteins act as repressors in the regulation of elicitor-induced secondary metabolism in C. roseus.	Leiden Univ, Clusius Lab, Inst Biol, NL-2333 AL Leiden, Netherlands; Netherlands Org Appl Sci Res, Dept Appl Plant Sci, NL-2333 CK Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Netherlands Organization Applied Science Research	Memelink, J (corresponding author), Leiden Univ, Clusius Lab, Inst Biol, Wassenaarseweg 64, NL-2333 AL Leiden, Netherlands.	memelink@rulbim.leidenuniv.nl	Hilliou, Frédérique/T-5714-2019; Champion, Antony/E-4148-2015; Sandonís, Virginia/K-2884-2014	Champion, Antony/0000-0002-3731-1510; Sandonís, Virginia/0000-0001-5762-7531; hilliou, frederique/0000-0002-3020-2987; Memelink, Johan/0000-0002-4767-506X				Barolo S, 2002, GENE DEV, V16, P1167, DOI 10.1101/gad.976502; Chen WQ, 2002, PLANT CELL, V14, P559, DOI 10.1105/tpc.010410; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; Dathan N, 2002, NUCLEIC ACIDS RES, V30, P4945, DOI 10.1093/nar/gkf613; Gantet P, 2002, TRENDS PHARMACOL SCI, V23, P563, DOI 10.1016/S0165-6147(02)02098-9; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARPER JW, 1993, CELL, V75, P805; Hiratsu K, 2003, PLANT J, V34, P733, DOI 10.1046/j.1365-313X.2003.01759.x; Hiratsu K, 2002, FEBS LETT, V514, P351, DOI 10.1016/S0014-5793(02)02435-3; Kazuoka T, 2000, PLANT J, V24, P191, DOI 10.1046/j.1365-313x.2000.00864.x; Kim JC, 2001, PLANT J, V25, P247, DOI 10.1046/j.1365-313x.2001.00947.x; Kubo K, 1998, NUCLEIC ACIDS RES, V26, P608, DOI 10.1093/nar/26.2.608; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; Meijer AH, 1998, YEAST, V14, P1407, DOI 10.1002/(SICI)1097-0061(199811)14:15<1407::AID-YEA325>3.0.CO;2-M; Meissner R, 1997, PLANT MOL BIOL, V33, P615, DOI 10.1023/A:1005746803089; Memelink J, 2001, TRENDS PLANT SCI, V6, P212, DOI 10.1016/S1360-1385(01)01924-0; Menke FLH, 1999, EMBO J, V18, P4455, DOI 10.1093/emboj/18.16.4455; Menke FLH, 1999, PLANT PHYSIOL, V119, P1289, DOI 10.1104/pp.119.4.1289; MORENO PRH, 1995, PLANT CELL TISS ORG, V42, P1, DOI 10.1007/BF00037677; Nimchuk Z, 2003, ANNU REV GENET, V37, P579, DOI 10.1146/annurev.genet.37.110801.142628; Ohta M, 2001, PLANT CELL, V13, P1959, DOI 10.1105/tpc.13.8.1959; Ouwerkerk PBF, 1999, MOL GEN GENET, V261, P610, DOI 10.1007/s004380050003; Ouwerkerk PBF, 1999, PLANT MOL BIOL, V39, P129, DOI 10.1023/A:1006138601744; PASQUALI G, 1992, PLANT MOL BIOL, V18, P1121, DOI 10.1007/BF00047715; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Roberts SGE, 2000, CELL MOL LIFE SCI, V57, P1149, DOI 10.1007/PL00000755; ROEWER IA, 1992, PLANT CELL REP, V11, P86, DOI 10.1007/BF00235259; Sakamoto H, 2000, GENE, V248, P23, DOI 10.1016/S0378-1119(00)00133-5; Siberil Y, 2001, PLANT MOL BIOL, V45, P477, DOI 10.1023/A:1010650906695; SILVA ODE, 1993, PLANT J, V4, P125, DOI 10.1046/j.1365-313X.1993.04010125.x; Singh KB, 1998, PLANT PHYSIOL, V118, P1111, DOI 10.1104/pp.118.4.1111; Sugano S, 2003, PLANT J, V36, P830, DOI 10.1046/j.1365-313X.2003.01924.x; Takatsuji H, 1999, PLANT MOL BIOL, V39, P1073, DOI 10.1023/A:1006184519697; Takatsuji H, 1996, J BIOL CHEM, V271, P23368, DOI 10.1074/jbc.271.38.23368; Tiwari SB, 2004, PLANT CELL, V16, P533, DOI 10.1105/tpc.017384; van der Fits L, 2000, PLANT MOL BIOL, V44, P675, DOI 10.1023/A:1026526522555; van der Fits L, 2000, SCIENCE, V289, P295, DOI 10.1126/science.289.5477.295; van der Fits L, 2001, PLANT J, V25, P43, DOI 10.1046/j.1365-313x.2001.00932.x; van der Krol AR, 1999, PLANT PHYSIOL, V121, P1153, DOI 10.1104/pp.121.4.1153; vanderFits L, 1997, PLANT MOL BIOL, V33, P943, DOI 10.1023/A:1005763605355; Yoshioka K, 2001, J BIOL CHEM, V276, P35802, DOI 10.1074/jbc.M104079200	43	126	141	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52940	52948		10.1074/jbc.M404391200	http://dx.doi.org/10.1074/jbc.M404391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465826	Green Published, hybrid			2022-12-25	WOS:000225680600018
J	Lecut, C; Arocas, V; Ulrichts, H; Elbaz, A; Villeval, JL; Lacapere, JJ; Deckmyn, H; Jandrot-Perrus, M				Lecut, C; Arocas, V; Ulrichts, H; Elbaz, A; Villeval, JL; Lacapere, JJ; Deckmyn, H; Jandrot-Perrus, M			Identification of residues within human glycoprotein VI involved in the binding to collagen - Evidence for the existence of distinct binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; INTEGRIN ALPHA(2)BETA(1); IMMUNOGLOBULIN SUPERFAMILY; TYROSINE PHOSPHORYLATION; PLATELET ACTIVATION; CRYSTAL-STRUCTURE; LIGAND-BINDING; RECEPTOR; CONVULXIN; ADHESION	Glycoprotein VI (GPVI) has a crucial role in platelet responses to collagen. Still, little is known about its interaction with its ligands. In binding assays using soluble or cell-expressed human GPVI, we observed that (i) collagen, and the GPVI-specific ligands collagen-related peptides (CRP) and convulxin, competed with one another for the binding to GPVI and (ii) monoclonal antibodies directed against the extracellular part of the human receptor displayed selective inhibitory properties on GPVI interaction with its ligands. Monoclonal antibody 9E18 strongly reduced the binding of GPVI to collagen/CRP, 3F8 inhibited its interaction with convulxin, whereas 9O12 prevented all three interactions. These observations suggest that ligand-binding sites are distinct, exhibiting specific features but at the same time also sharing some common residues participating in the recognition of these ligands. The epitope of 9O12 was mapped by phage display, along with molecular modeling of human GPVI, which allowed the identification of residues within GPVI potentially involved in ligand recognition. Site-directed mutagenesis revealed that valine 34 and leucine 36 are critical for GPVI interaction with collagen and CRP. The loop might thus be part of a collagen/CRP-binding site.	Univ Paris 07, INSERM, E348, F-75870 Paris 18, France; Univ Paris 07, INSERM, U410, F-75870 Paris 18, France; Katholieke Univ Leuven, Interdisciplinary Res Ctr, Lab Thrombosis Res, B-8500 Kortrijk, Belgium; Millennium Pharmaceut Inc, Cambridge, MA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; KU Leuven; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Jandrot-Perrus, M (corresponding author), Univ Paris 07, INSERM, E348, BP416,16 Rue Henri Huchard, F-75870 Paris 18, France.	mjandrot@bichat.inserm.fr	Arocas, Veronique/M-7075-2017; Deckmyn, Hans/N-8932-2019; Jandrot-Perrus, Martine/GZM-1526-2022; Deckmyn, Hans/L-9434-2015	Deckmyn, Hans/0000-0003-3952-5501; Deckmyn, Hans/0000-0003-3952-5501; JANDROT-PERRUS, Martine/0000-0002-8450-9247; Arocas, Veronique/0000-0002-2872-8058; Villeval, Jean-Luc/0000-0002-0562-925X				Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Chapman TL, 2000, IMMUNITY, V13, P727, DOI 10.1016/S1074-7613(00)00071-6; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Fan QR, 2001, NAT IMMUNOL, V2, P452, DOI 10.1038/87766; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Heemskerk JWM, 1999, THROMB HAEMOSTASIS, V81, P782; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Kehrel B, 1998, BLOOD, V91, P491; Lagrue-Lak-Hal AH, 2001, J BIOL CHEM, V276, P15316, DOI 10.1074/jbc.M009117200; Lecut C, 2003, J THROMB HAEMOST, V1, P2653, DOI 10.1111/j.1538-7836.2003.00495.x; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; SILJANDER PR, 2003, BLOOD; SMETHURST PA, 2003, BLOOD; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ulrichts H, 2001, THROMB HAEMOSTASIS, V86, P630, DOI 10.1055/s-0037-1616097; Vanhoorelbeke K, 2003, J BIOL CHEM, V278, P37815, DOI 10.1074/jbc.M304289200; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Wines BD, 2001, J IMMUNOL, V166, P1781, DOI 10.4049/jimmunol.166.3.1781	28	49	58	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52293	52299		10.1074/jbc.M406342200	http://dx.doi.org/10.1074/jbc.M406342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466473	Green Published, hybrid			2022-12-25	WOS:000225493400070
J	Jasuja, R; Allen, BL; Pappano, WN; Rapraeger, AC; Greenspan, DS				Jasuja, R; Allen, BL; Pappano, WN; Rapraeger, AC; Greenspan, DS			Cell-surface heparan sulfate proteoglycans potentiate chordin antagonism of bone morphogenetic protein signaling and are necessary for cellular uptake of chordin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; TWISTED GASTRULATION; EXPRESSION PATTERNS; DROSOPHILA EMBRYO; XENOPUS CHORDIN; BINDING; RECEPTOR; METALLOPROTEASES; REQUIREMENT; GLYPICAN-1	Signaling by bone morphogenetic proteins (BMPs) plays a central role in early embryonic patterning, organogenesis, and homeostasis in a broad range of species. Chordin, an extracellular antagonist of BMP signaling, is thought to readily diffuse in tissues, thus forming gradients of BMP inhibition that result in reciprocal gradients of BMP signaling. The latter determine cell fates along the embryonic dorsoventral axis. The secreted protein Twisted Gastrulation (TSG) is thought to help shape BMP signaling gradients by acting as a cofactor that enhances Chordin inhibition of BMP signaling. Here, we demonstrate that mammalian Chordin binds heparin with an affinity similar to that of factors known to functionally interact with heparan sulfate proteoglycans (HSPGs) in tissues. We further demonstrate that Chordin binding in mouse embryonic tissues was dependent upon its interaction with cell-surface HSPGs and that Chordin bound to cell-surface HSPGs (e.g. syndecans), but not to basement membranes containing the HSPG perlecan. Surprisingly, mammalian TSG did not bind heparin unless prebound to Chordin and/or BMP-4, although Drosophila TSG has been reported to bind heparin on its own. Results are also presented that indicate that Chordin-HSPG interactions strongly potentiate the antagonism of BMP signaling by Chordin and are necessary for the retention and uptake of Chordin by cells. These data and others regarding Chordin diffusion have implications for the paradigm of how Chordin is thought to regulate BMP signaling in the extracellular space and how gradients of BMP signaling are formed.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Program Mol & Cellular Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rapraeger, AC (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.	acraprae@wisc.edu; dsgreens@wisc.edu		Pappano, William/0000-0003-2848-2219; Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [GM63471, GM48850, R01 GM048850] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR047746, R01AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048850, R01GM063471] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Blitz IL, 2000, DEV BIOL, V223, P120, DOI 10.1006/dbio.2000.9740; Burbach BJ, 2003, MATRIX BIOL, V22, P163, DOI 10.1016/S0945-053X(03)00009-X; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; Chang CB, 2001, NATURE, V410, P483, DOI 10.1038/35068583; Cho KWY, 1998, CURR OPIN GENET DEV, V8, P443, DOI 10.1016/S0959-437X(98)80116-0; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Friedl A, 1997, AM J PATHOL, V150, P1443; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006-291X(03)01500-6; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Larrain J, 2003, EMBO REP, V4, P813, DOI 10.1038/sj.embor.embor902; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Mason ED, 1997, MECH DEVELOP, V64, P61, DOI 10.1016/S0925-4773(97)00049-X; Massague J, 2000, GENE DEV, V14, P627; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Pappano WN, 1998, GENOMICS, V52, P236, DOI 10.1006/geno.1998.5474; Paria BC, 1999, DEVELOPMENT, V126, P1997; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Ross JJ, 2001, NATURE, V410, P479, DOI 10.1038/35068578; Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432-1033.1996.0295n.x; Sakata H, 1997, J BIOL CHEM, V272, P9457; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 2000, DEV DYNAM, V217, P449, DOI 10.1002/(SICI)1097-0177(200004)217:4<449::AID-DVDY12>3.0.CO;2-8; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Sergeant N, 2000, J BIOL CHEM, V275, P17094, DOI 10.1074/jbc.M000237200; Srinivasan S, 2002, DEV CELL, V2, P91, DOI 10.1016/S1534-5807(01)00097-1; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Takada T, 2003, J BIOL CHEM, V278, P43229, DOI 10.1074/jbc.M300937200; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Wardle FC, 1999, MECH DEVELOP, V86, P75, DOI 10.1016/S0925-4773(99)00114-8; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200; Zimmermann P, 1999, FASEB J, V13, pS91	62	60	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51289	51297		10.1074/jbc.M408129200	http://dx.doi.org/10.1074/jbc.M408129200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15381701	hybrid			2022-12-25	WOS:000225355800078
J	Liu, M; Barth, A				Liu, M; Barth, A			Phosphorylation of the sarcoplasmic reticulum Ca2+-ATPase from ATP and ATP analogs studied by infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; MEMBRANE-PROTEIN STRUCTURE; CHAIN PLEATED SHEET; AMIDE-ONE VIBRATION; CALCIUM-PUMP; RESONANCE INTERACTION; DIFFERENCE SPECTRA; REACTION-MECHANISM; STRUCTURAL-CHANGES; CRYSTAL-STRUCTURE	Phosphorylation of the sarcoplasmic reticulum Ca2+-ATPase (SERCA1a) was studied with time-resolved Fourier transform infrared spectroscopy. ATP and ATP analogs (ITP, 2'- and 3'-dATP) were used to study the effect of the adenine ring and the ribose hydroxyl groups on ATPase phosphorylation. All modifications of ATP altered conformational changes and phosphorylation kinetics. The differences compared with ATP increased in the following order: 3'-dATP>ITP>2'-dATP. Enzyme phosphorylation with ITP results in larger absorbance changes in the amide I region, indicating larger conformational changes of the Ca2+-ATPase. The respective absorbance changes obtained with 3'-dATP are significantly different from the others with different band positions and amplitudes in the amide I region, indicating different conformational changes of the protein backbone. ATPase phosphorylation with 3'-dATP is also much (similar to30 times) slower than with ATP. Our results indicate that modifications to functional groups of ATP (the ribose 2'- and 3'-OH and the amino group in the adenine ring) affect gamma-phosphate transfer to the phosphorylation site of the Ca2+-ATPase by changing the extent of conformational change and the phosphorylation rate. ADP binding to the ADP-sensitive phosphoenzyme (Ca(2)E1P) stabilizes the closed conformation of Ca(2)E1P.	Goethe Univ Frankfurt, Inst Biophys, D-60596 Frankfurt, Germany; Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, S-10691 Stockholm, Sweden	Goethe University Frankfurt; Stockholm University	Liu, M (corresponding author), Goethe Univ Frankfurt, Inst Biophys, D-60596 Frankfurt, Germany.	liu@dbb.su.se	Liu, Man/GXH-3184-2022; Barth, Andreas/N-8872-2013	Liu, Man/0000-0002-1390-7862; Barth, Andreas/0000-0001-5784-7673				ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; Barth A, 1998, BIOPHYS J, V75, P538, DOI 10.1016/S0006-3495(98)77543-5; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P466; Cepus V, 1998, BIOCHEMISTRY-US, V37, P10263, DOI 10.1021/bi973183j; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P627, DOI 10.1002/bip.1976.360150403; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P607, DOI 10.1002/bip.1976.360150402; COAN C, 1993, J BIOL CHEM, V268, P6917; Colthup N. B., 1990, INTRO INFRARED RAMAN; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; de Meis L, 1973, J Biol Chem, V248, P3691; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; Granjon T, 2001, BIOCHEMISTRY-US, V40, P2988, DOI 10.1021/bi002553s; Griffiths P., 1986, FOURIER TRANSFORM IN; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HASSELBACH W, 1974, ENZYMES, P431; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Jung C, 2000, J MOL RECOGNIT, V13, P325, DOI 10.1002/1099-1352(200011/12)13:6<325::AID-JMR507>3.0.CO;2-C; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; KENDREW J, 1994, ENCY MOL BIOL, P624; Kubelka J, 2001, J AM CHEM SOC, V123, P12048, DOI 10.1021/ja0116627; KUBO K, 1990, BIOCHIM BIOPHYS ACTA, V1040, P251, DOI 10.1016/0167-4838(90)90084-S; LACAPERE JJ, 1990, J BIOL CHEM, V265, P8583; LADNER WE, 1985, J ORG CHEM, V50, P1076, DOI 10.1021/jo00207a032; Liu M, 2003, BIOPHYS J, V85, P3262, DOI 10.1016/S0006-3495(03)74744-4; Liu M, 2003, J BIOL CHEM, V278, P10112, DOI 10.1074/jbc.M212403200; Liu M, 2002, BIOPOLYMERS, V67, P267, DOI 10.1002/bip.10113; MAKINOSE M, 1965, BIOCHEM Z, V343, P383; McIntosh DB, 2000, NAT STRUCT BIOL, V7, P532, DOI 10.1038/76735; MEIS LD, 1971, J BIOL CHEM, V246, P4759; PETRETSKI JH, 1989, J BIOL CHEM, V264, P20339; Resnick SM, 2000, APPL ENVIRON MICROB, V66, P2045, DOI 10.1128/AEM.66.5.2045-2051.2000; Reuter N, 2003, BIOPHYS J, V85, P2186, DOI 10.1016/S0006-3495(03)74644-X; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; SIEBERT F, 1995, METHOD ENZYMOL, V246, P501; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; SOUZA DOG, 1976, J BIOL CHEM, V251, P6355; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Wharton CW, 2000, NAT PROD REP, V17, P447, DOI 10.1039/b002066o	50	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49902	49909		10.1074/jbc.M408062200	http://dx.doi.org/10.1074/jbc.M408062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15381702	hybrid			2022-12-25	WOS:000225229500045
J	Zhu, YX; Li, XM; Kyazike, J; Zhou, Q; Thurberg, BL; Raben, N; Mattaliano, RJ; Cheng, SH				Zhu, YX; Li, XM; Kyazike, J; Zhou, Q; Thurberg, BL; Raben, N; Mattaliano, RJ; Cheng, SH			Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in Pompe mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE TYPE-II; ENZYME REPLACEMENT THERAPY; GROWTH-FACTOR-II; MALTASE DEFICIENCY; RABBIT MILK; STORAGE; ADULT; INFANTILE; EXPRESSION; RECEPTOR	Clinical studies of enzyme replacement therapy for Pompe disease have indicated that relatively high doses of recombinant human acid alpha-glucosidase (rhGAA) may be required to reduce the abnormal glycogen storage in cardiac and skeletal muscles. This may be because of inefficient cation-independent mannose 6-phosphate receptor (CI-MPR)-mediated endocytosis of the enzyme by the affected target cells. To address this possibility, we examined whether the addition of a high affinity ligand to rhGAA would improve its delivery to these cells. Chemical conjugation of high mannose oligosaccharides harboring mono- and bisphosphorylated mannose 6-phosphates onto rhGAA (neo-rhGAA) significantly improved its uptake characteristics by muscle cells in vitro. Infusion of neo-rhGAA into Pompe mice also resulted in greater delivery of the enzyme to muscle tissues when compared with the unmodified enzyme. Importantly, this increase in enzyme levels was associated with significantly improved clearance of glycogen (similar to5-fold) from the affected tissues. These results suggest that CI-MPR-mediated endocytosis of rhGAA is an important pathway by which the enzyme is delivered to the affected lysosomes of Pompe muscle cells. Hence, the generation of rhGAA containing high affinity ligands for the CI-MPR represents a strategy by which the potency of rhGAA and therefore the clinical efficacy of enzyme replacement therapy for Pompe disease may be improved.	Genzyme Corp, Framingham, MA 01701 USA; NIH, Bethesda, MD 20892 USA	Sanofi-Aventis; Genzyme Corporation; National Institutes of Health (NIH) - USA	Cheng, SH (corresponding author), Genzyme Corp, 31 New York Ave, Framingham, MA 01701 USA.	seng.cheng@genzyme.com	zhou, qun/AAU-7592-2020; Cheng, Seng H/AAC-6564-2022	zhou, qun/0000-0001-6271-3143; 				Amalfitano A, 1999, P NATL ACAD SCI USA, V96, P8861, DOI 10.1073/pnas.96.16.8861; Amalfitano A, 2001, GENET MED, V3, P132, DOI 10.1097/00125817-200103000-00008; ANDERSON RF, 1960, ARCH BIOCHEM BIOPHYS, V89, P289, DOI 10.1016/0003-9861(60)90056-4; Ausems MGEM, 1999, EUR J HUM GENET, V7, P713, DOI 10.1038/sj.ejhg.5200367; Ausems MGEM, 2001, NEUROLOGY, V57, P1938, DOI 10.1212/WNL.57.10.1938; Bijvoet AGA, 1996, BBA-GENE STRUCT EXPR, V1308, P93, DOI 10.1016/0167-4781(96)00093-0; Bijvoet AGA, 1999, HUM MOL GENET, V8, P2145, DOI 10.1093/hmg/8.12.2145; Bijvoet AGA, 1998, HUM MOL GENET, V7, P1815, DOI 10.1093/hmg/7.11.1815; Brady RO, 2001, J INHERIT METAB DIS, V24, P18, DOI 10.1023/A:1012451320105; BRETTHAU.RK, 1973, BIOCHEMISTRY-US, V12, P1251, DOI 10.1021/bi00731a002; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; FELICE KJ, 1995, MEDICINE, V74, P131, DOI 10.1097/00005792-199505000-00002; FUNK B, 1992, J CLIN ENDOCR METAB, V75, P424, DOI 10.1210/jc.75.2.424; FURBISH FS, 1981, BIOCHIM BIOPHYS ACTA, V673, P425, DOI 10.1016/0304-4165(81)90474-8; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; Haley SM, 2003, DEV MED CHILD NEUROL, V45, P618, DOI 10.1017/S0012162203001129; Hirschhorn R, 2001, METABOLIC MOL BASES, P3389; Kikuchi T, 1998, J CLIN INVEST, V101, P827, DOI 10.1172/JCI1722; Laforet P, 2000, NEUROLOGY, V55, P1122, DOI 10.1212/WNL.55.8.1122; LeBowitz JH, 2004, P NATL ACAD SCI USA, V101, P3083, DOI 10.1073/pnas.0308728100; LI M, 1991, Glycobiology, V1, P511, DOI 10.1093/glycob/1.5.511; LIGHTMAN NI, 1977, CHEST, V72, P250, DOI 10.1378/chest.72.2.250; Martiniuk F, 2000, BIOCHEM BIOPH RES CO, V276, P917, DOI 10.1006/bbrc.2000.3555; Martiniuk F, 1998, AM J MED GENET, V79, P69, DOI 10.1002/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K; Raben N, 2003, MOL GENET METAB, V80, P159, DOI 10.1016/j.ymgme.2003.08.022; Raben N, 2002, MOL THER, V6, P601, DOI 10.1006/mthe.2002.0716; Raben N, 1998, J BIOL CHEM, V273, P19086, DOI 10.1074/jbc.273.30.19086; Raben Nina, 2002, Current Molecular Medicine (Hilversum), V2, P145, DOI 10.2174/1566524024605789; Reuser AJJ, 2002, EUR J PEDIATR, V161, pS106, DOI 10.1007/s00431-002-1015-8; Sands MS, 2001, J BIOL CHEM, V276, P43160, DOI 10.1074/jbc.M107778200; Slonim AE, 2000, J PEDIATR-US, V137, P283, DOI 10.1067/mpd.2000.107112; SRIVASTAVA OP, 1987, CARBOHYD RES, V161, P195, DOI 10.1016/S0008-6215(00)90077-6; TOLVANEN M, 1986, J BIOL CHEM, V261, P9546; TONG PY, 1989, J BIOL CHEM, V264, P7962; TOWNSEND R R, 1991, Glycobiology, V1, P139, DOI 10.1093/glycob/1.2.139; VALENZANO KJ, 1995, J BIOL CHEM, V270, P16441, DOI 10.1074/jbc.270.27.16441; Van den Hout H, 2000, LANCET, V356, P397, DOI 10.1016/S0140-6736(00)02533-2; van den Hout HMP, 2003, PEDIATRICS, V112, P332, DOI 10.1542/peds.112.2.332; Van den Hout JMP, 2004, PEDIATRICS, V113, pE448, DOI 10.1542/peds.113.5.e448; VANDERPLOEG AT, 1991, J CLIN INVEST, V87, P513, DOI 10.1172/JCI115025; VanHove JLK, 1996, P NATL ACAD SCI USA, V93, P65, DOI 10.1073/pnas.93.1.65; VARKI A, 1980, J BIOL CHEM, V255, P847; Vorgerd M, 1998, NEUROGENETICS, V1, P205, DOI 10.1007/s100480050030; WENK J, 1991, BIOCHEM INT, V23, P723; Winkel LPF, 2004, ANN NEUROL, V55, P495, DOI 10.1002/ana.20019; Yang HW, 1998, PEDIATR RES, V43, P374, DOI 10.1203/00006450-199803000-00011; Zhou Q, 2002, ANAL BIOCHEM, V306, P163, DOI 10.1006/abio.2002.5703	47	61	82	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50336	50341		10.1074/jbc.M409676200	http://dx.doi.org/10.1074/jbc.M409676200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383547	hybrid			2022-12-25	WOS:000225229500097
J	Giordanengo, V; Ollier, L; Lanteri, M; Lesimple, J; March, D; Thyss, S; Lefebvre, JC				Giordanengo, V; Ollier, L; Lanteri, M; Lesimple, J; March, D; Thyss, S; Lefebvre, JC			Epigenetic reprogramming of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) in HIV-1-infected CEM T cells	FASEB JOURNAL			English	Article						sialic acid; promoter; methylation; bisulfite	ALTERED GLYCOSYLATION; IMMUNE RESTORATION; SIALIC ACIDS; METHYLATION; EXPRESSION; INFECTION; GENE; LYMPHOCYTES; PROMOTER; CD43	Sialylated glycoconjugates mediate several key lymphocyte functions. We previously reported that hyposialylation occurred in latently HIV-1-infected CEM T cells, despite the fully preserved catalytic activity of several sialyltransferases. We show now that these cells are affected by a down-regulation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE), which leads to a dramatic decrease in the synthesis of CMP-sialic acid, the donor substrate of all sialyltransferases. The GNE gene promoter was found to be located in a CpG island with several regulatory motifs CREB, SP1, and AP-2. De novo hypermethylation of this promoter was observed in HIV-1-infected CEM cells. This phenomenon might explain some immunological disorders that persist in infected individuals despite long-term therapeutically controlled viral replication. Indeed, an overall decrease in sialic acid engraftment can affect glycoproteins, notably those in which the sialylation status is crucial to ensure homing, recirculation, and survival of lymphocytes.	Fac Med, INSERM, U50, Virol Lab, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Lefebvre, JC (corresponding author), Fac Med, INSERM, U50, Virol Lab, IFR 50,Ave Valombrose, F-06107 Nice 2, France.	lefebvre@unice.fr		giordanengo, valerie/0000-0002-5114-1124				ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; BEDNARIK DP, 1990, EMBO J, V9, P1157, DOI 10.1002/j.1460-2075.1990.tb08222.x; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Carcelain G, 2001, CURR OPIN IMMUNOL, V13, P483, DOI 10.1016/S0952-7915(00)00245-4; CHELUCCI C, 1995, BLOOD, V85, P1181, DOI 10.1182/blood.V85.5.1181.bloodjournal8551181; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; Fang JY, 2001, J VIROL, V75, P9753, DOI 10.1128/JVI.75.20.9753-9761.2001; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; Giordanengo V, 1999, AIDS, V13, P1141, DOI 10.1097/00002030-199906180-00020; Giordanengo V, 1997, EUR J BIOCHEM, V247, P558, DOI 10.1111/j.1432-1033.1997.00558.x; GIORDANENGO V, 1995, BLOOD, V86, P2302, DOI 10.1182/blood.V86.6.2302.bloodjournal8662302; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; JAHNER D, 1985, NATURE, V315, P594, DOI 10.1038/315594a0; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Lanteri M, 2003, GLYCOBIOLOGY, V13, P909, DOI 10.1093/glycob/cwg110; Lederman MM, 2001, AIDS, V15, pS11, DOI 10.1097/00002030-200102002-00003; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; LEFEBVRE JC, 1994, VIROLOGY, V199, P265, DOI 10.1006/viro.1994.1124; Li XD, 1996, VIROLOGY, V225, P196, DOI 10.1006/viro.1996.0588; Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764; Mikovits JA, 1998, MOL CELL BIOL, V18, P5166, DOI 10.1128/MCB.18.9.5166; OBRIEN MC, 1995, BIOCHEM BIOPH RES CO, V207, P903, DOI 10.1006/bbrc.1995.1271; Oetke C, 2003, BIOCHEM BIOPH RES CO, V308, P892, DOI 10.1016/S0006-291X(03)01471-2; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; REMOLDODONNELL E, 1987, BLOOD, V70, P104; Rossi D, 2003, BRIT J HAEMATOL, V123, P475, DOI 10.1046/j.1365-2141.2003.04644.x; Ruiz ME, 1998, J IMMUNOL, V161, P4169; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; SMITH DF, 1990, J BIOL CHEM, V265, P6225; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tanaka J, 2003, AIDS, V17, P167, DOI 10.1097/00002030-200301240-00005; Valdez H, 2002, AIDS, V16, P1859, DOI 10.1097/00002030-200209270-00002; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Zhao SF, 1998, J INFECT DIS, V178, P1623, DOI 10.1086/314506	39	20	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1961	+		10.1096/fj.04-2467fje	http://dx.doi.org/10.1096/fj.04-2467fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15469965				2022-12-25	WOS:000224849900025
J	Bhonde, MR; Hanski, ML; Magrini, R; Moorthy, D; Muller, A; Sausville, EA; Kohno, K; Wiegand, P; Daniel, PT; Zeitz, M; Hanski, C				Bhonde, MR; Hanski, ML; Magrini, R; Moorthy, D; Muller, A; Sausville, EA; Kohno, K; Wiegand, P; Daniel, PT; Zeitz, M; Hanski, C			The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein	ONCOGENE			English	Article						colon carcinoma; chemotherapy; UCN-01; apoptosis; cell cycle arrest	LUNG-CANCER CELLS; 7-HYDROXYSTAUROSPORINE UCN-01; SELECTIVE INHIBITOR; ANTITUMOR-ACTIVITY; UP-REGULATION; CONSTITUTIVE ACTIVATION; CHECKPOINT FUNCTION; GROWTH-INHIBITION; LEUKEMIA-CELLS; BCL-X	The broad-range cyclin-dependent kinase inhibitor 7-hydroxystaurosporine (UCN-01) is known to induce both a G1 cell cycle arrest and apoptosis. The mechanism of UCN-01-induced apoptosis is largely unknown. We analysed the mechanism of cytotoxicity of UCN-01 in four established colon carcinoma cell lines. The cell lines SW48 and LS513 responded to UCN-01 treatment by undergoing apoptosis in a concentration-dependent manner while the cell lines HT-29 and WiDr were completely resistant. Apoptosis in LS513 and SW48 cell lines was concomitant with the suppression of Bcl-x(L) on mRNA and protein level. In contrast, in the apoptosis-resistant cell lines, Bcl-x(L) expression was not affected by UCN-01. Stable overexpression of the Bcl-x(L) protein abrogated UCN-01-triggered apoptosis, but only partially restored growth, indicating that both cell cycle arrest and apoptosis exert the anticancer effect in a coordinated manner. The inhibition of Akt phosphorylation did not correlate with the apoptotic phenotype. UCN-01 inhibited the activating STAT3 phosphorylations on Ser727 and, notably, on Tyr705, but STAT3 did not contribute to Bcl-x(L) expression in colon carcinoma cells. Moreover, we show for the first time that UCN-01 induces apoptosis by suppression of Bcl-x(L) expression. The inhibition of this pathway is a new aspect of cytotoxic and modulatory potential of UCN-01.	Charite Univ Med Berlin, Dept Gastroenterol, D-12200 Berlin, Germany; Dept Clin & Mol Oncol, Berlin, Germany; NCI, Rockville, MD USA; Univ Occupat & Environm Hlth, Sch Med, Kitakyushu, Fukuoka 807, Japan; Inst Forens Med, Ulm, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Occupational & Environmental Health - Japan	Hanski, C (corresponding author), Charite Univ Med Berlin, Dept Gastroenterol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	christoph.hanski@charite.de	Moorthy, Dhatchana/AAD-7680-2019	Moorthy, Dhatchana/0000-0002-0071-4762				Abe S, 2000, JPN J CANCER RES, V91, P1192, DOI 10.1111/j.1349-7006.2000.tb00904.x; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Akinaga S, 2000, ANTI-CANCER DRUG DES, V15, P43; AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1991, CANCER RES, V51, P4888; Akiyama T, 1999, ANTI-CANCER DRUG, V10, P67, DOI 10.1097/00001813-199901000-00009; Akiyama T, 1999, JPN J CANCER RES, V90, P1364, DOI 10.1111/j.1349-7006.1999.tb00721.x; Alas S, 2003, CLIN CANCER RES, V9, P316; Amundson SA, 2000, CANCER RES, V60, P6101; Bredel M, 1999, J NEURO-ONCOL, V41, P9, DOI 10.1023/A:1006047025425; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Byrd JC, 2001, EXP HEMATOL, V29, P703, DOI 10.1016/S0301-472X(01)00649-X; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chan UPF, 2003, ANTI-CANCER DRUG, V14, P761, DOI 10.1097/01.cad.0000094782.62385.7a; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Dai Y, 2001, CANCER RES, V61, P5106; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; HANSKI C, 1992, INT J CANCER, V50, P924, DOI 10.1002/ijc.2910500618; Hirose Y, 2001, CANCER RES, V61, P5843; Husain A, 1997, CLIN CANCER RES, V3, P2089; Kato K, 2000, BBA-GENE STRUCT EXPR, V1493, P91, DOI 10.1016/S0167-4781(00)00168-8; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Koh Junichi, 2002, Breast Cancer, V9, P50, DOI 10.1007/BF02967547; Kruger EA, 1999, INVAS METAST, V18, P209, DOI 10.1159/000024514; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Mack PC, 1999, CLIN CANCER RES, V5, P2596; Mora LB, 2002, CANCER RES, V62, P6659; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; Patel V, 2002, CLIN CANCER RES, V8, P3549; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; POWELL SN, 1995, CANCER RES, V55, P1643; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Sugiyama K, 1999, CANCER RES, V59, P4406; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; Usuda J, 2000, INT J CANCER, V85, P275, DOI 10.1002/(SICI)1097-0215(20000115)85:2<275::AID-IJC20>3.0.CO;2-5; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Yu Q, 2002, CANCER RES, V62, P5743	51	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					148	156		10.1038/sj.onc.1207842	http://dx.doi.org/10.1038/sj.onc.1207842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15467762				2022-12-25	WOS:000226125800017
J	Zhu, L; Jang, GF; Jastrzebska, B; Filipek, S; Pearce-Kelling, SE; Aguirre, GD; Stenkamp, RE; Acland, GM; Palczewski, K				Zhu, L; Jang, GF; Jastrzebska, B; Filipek, S; Pearce-Kelling, SE; Aguirre, GD; Stenkamp, RE; Acland, GM; Palczewski, K			A naturally occurring mutation of the opsin gene (T4R) in dogs affects glycosylation and stability of the G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; VITAMIN-A SUPPLEMENTATION; RHODOPSIN GENE; TRANSDUCIN ACTIVATION; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; MOUSE MODEL; MUTANTS; DEGENERATION; PHOTOTRANSDUCTION	Rho ( rhodopsin; opsin plus 11-cis-retinal) is a prototypical G protein-coupled receptor responsible for the capture of a photon in retinal photoreceptor cells. A large number of mutations in the opsin gene associated with autosomal dominant retinitis pigmentosa have been identified. The naturally occurring T4R opsin mutation in the English mastiff dog leads to a progressive retinal degeneration that closely resembles human retinitis pigmentosa caused by the T4K mutation in the opsin gene. Using genetic approaches and biochemical assays, we explored the properties of the T4R mutant protein. Employing immunoaffinity-purified Rho from affected RHOT4R/T4R dog retina, we found that the mutation abolished glycosylation at Asn(2), whereas glycosylation at Asn(15) was unaffected, and the mutant opsin localized normally to the rod outer segments. Moreover, we found that T4R Rho* lost its chromophore faster as measured by the decay of meta-rhodopsin II and that it was less resistant to heat denaturation. Detergent-solubilized T4R opsin regenerated poorly and interacted abnormally with the G protein transducin (G(t)). Structurally, the mutation affected mainly the "plug" at the intradiscal (extracellular) side of Rho, which is possibly responsible for protecting the chromophore from the access of bulk water. The T4R mutation may represent a novel molecular mechanism of degeneration where the unliganded form of the mutant opsin exerts a detrimental effect by losing its structural integrity.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Cornell Univ, Coll Vet Med, James A Baker Inst Anim Hlth, Ithaca, NY 14853 USA; Univ Penn, Sch Vet Med, Dept Clin Studies, Philadelphia, PA 19104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Cornell University; University of Pennsylvania	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, 1957 NE Pacific St,POB 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R01EY013385, R29EY008061, U01EY006855, P30EY001730, U10EY013729, R01EY013132, R01EY008061, R01EY006855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063020] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdulaev NG, 2003, TRENDS BIOCHEM SCI, V28, P399, DOI 10.1016/S0968-0004(03)00164-6; ACLAND GM, 1987, EXP EYE RES, V44, P491, DOI 10.1016/S0014-4835(87)80160-4; Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Aguirre G D, 1998, Mol Vis, V4, P23; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1456, DOI 10.1001/archopht.1993.01090110014001; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Chapple JP, 2003, J BIOL CHEM, V278, P19087, DOI 10.1074/jbc.M212349200; Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FLIESLER SJ, 1985, J CELL BIOL, V100, P574, DOI 10.1083/jcb.100.2.574; FLIESLER SJ, 1984, NATURE, V311, P575, DOI 10.1038/311575a0; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FUJIKI K, 1995, JPN J HUM GENET, V40, P271, DOI 10.1007/BF01876186; Gross AK, 2003, BIOCHEMISTRY-US, V42, P2009, DOI 10.1021/bi020613j; Gross AK, 2003, BIOCHEMISTRY-US, V42, P2002, DOI 10.1021/bi020612r; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7; Janz JM, 2004, J BIOL CHEM, V279, P29767, DOI 10.1074/jbc.M402567200; Janz JM, 2003, VISION RES, V43, P2991, DOI 10.1016/j.visres.2003.08.010; Janz JM, 2003, J BIOL CHEM, V278, P16982, DOI 10.1074/jbc.M210567200; Jin SN, 2003, NAT NEUROSCI, V6, P731, DOI 10.1038/nn1070; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Kijas JW, 2003, J HERED, V94, P27, DOI 10.1093/jhered/esg007; Kijas JW, 2002, P NATL ACAD SCI USA, V99, P6328, DOI 10.1073/pnas.082714499; Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Noorwez SM, 2004, J BIOL CHEM, V279, P16278, DOI 10.1074/jbc.M312101200; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PLANTNER JJ, 1980, ARCH BIOCHEM BIOPHYS, V201, P527, DOI 10.1016/0003-9861(80)90541-X; PRASAD AVK, 1992, EXP EYE RES, V54, P913, DOI 10.1016/0014-4835(92)90155-L; Ramon E, 2003, J BIOL CHEM, V278, P6427, DOI 10.1074/jbc.M210929200; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; ROOF DJ, 1994, INVEST OPHTH VIS SCI, V35, P4049; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Saliba RS, 2002, J CELL SCI, V115, P2907; SULLIVAN LJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P1512, DOI 10.1001/archopht.1993.01090110078029; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1994, J NEUROSCI, V14, P5818; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Teller DC, 2003, FEBS LETT, V555, P151, DOI 10.1016/S0014-5793(03)01152-9; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; VANDENBORN LI, 1994, OPHTHALMIC GENET, V15, P51, DOI 10.3109/13816819409098864; Yang T, 1997, P NATL ACAD SCI USA, V94, P13559, DOI 10.1073/pnas.94.25.13559; Yoshii M, 1998, OPHTHALMIC RES, V30, P1	72	53	60	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53828	53839		10.1074/jbc.M408472200	http://dx.doi.org/10.1074/jbc.M408472200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15459196	hybrid, Green Submitted, Green Accepted			2022-12-25	WOS:000225680600121
J	Bruey, JM; Bruey-Sedano, N; Newman, R; Chandler, S; Stehlik, C; Reed, JC				Bruey, JM; Bruey-Sedano, N; Newman, R; Chandler, S; Stehlik, C; Reed, JC			PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-kappa B and caspase-1 activation in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR; CONTAINING APAF1-LIKE PROTEIN; DEATH-DOMAIN-FOLD; PYRIN DOMAIN; CUTTING EDGE; RECRUITMENT DOMAIN; APOPTOSIS; ASC; CANCER; FAMILY	Genes encoding proteins with PYRIN/PAAD/DAPIN domains, a nucleotide binding fold (NACHT), and leucine rich repeats have recently been recognized as important mediators in autoimmune inflammatory disorders. Here we characterize the expression and function of a member of the PYRIN and NACHT domain (PAN) family, PAN1 (also known as NALP2 and PYPAF2). PAN1 protein expression is regulated by lipopolysaccharide (LPS) and interferons (IFNbeta and IFNgamma) in THP-1 macrophage cells. In gene transfection studies PAN1 manifests an inhibitory influence on NF-kappaB activation induced by various pro-inflammatory stimuli, including tumor necrosis factor TNFalpha and interleukin1beta (IL-1beta). Gene transfer-mediated elevations in PAN1 protein also suppressed activation of IkappaB kinases induced by inflammatory cytokines. Conversely, reducing endogenous levels of PAN1 using small interfering RNA enhanced LPS-induced production of ICAM-1 (intercellular adhesion molecule 1), an NF-kappaB-dependent gene. We also show here that PAN1 binds via its PYRIN domain to ASC, an adapter protein involved in caspase-1 activation. This binding is disrupted by mutation of the alpha1 helix of ASC. In gene transfer experiments PAN1 enhances caspase-1 activation and IL-1beta secretion in collaboration with ASC. Conversely, reducing endogenous levels of PAN1 using small interfering RNA significantly reduced LPS-induced secretion of IL-1beta in monocytes. We propose that PAN1 functions as a modulator of the activation of NF-kappaB and procaspase-1 in macrophages.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org	Stehlik, Christian/AAG-2132-2021	Stehlik, Christian/0000-0002-3782-2484	NIAID NIH HHS [R01 AI-56324] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056324] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Applequist SE, 2002, INT IMMUNOL, V14, P1065, DOI 10.1093/intimm/dxf069; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Fiorentino L, 2002, J BIOL CHEM, V277, P35333, DOI 10.1074/jbc.M200446200; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hertzog PJ, 2003, TRENDS IMMUNOL, V24, P534, DOI 10.1016/j.it.2003.08.006; Hiller S, 2003, STRUCTURE, V11, P1199, DOI 10.1016/j.str.2003.08.009; Hoshino K, 1999, J IMMUNOL, V162, P3749; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liepinsh E, 2003, J MOL BIOL, V332, P1155, DOI 10.1016/j.jmb.2003.07.007; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154; Stehlik C, 2003, BIOCHEM J, V373, P101, DOI 10.1042/BJ20030304; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027	45	123	132	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51897	51907		10.1074/jbc.M406741200	http://dx.doi.org/10.1074/jbc.M406741200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456791	hybrid			2022-12-25	WOS:000225493400023
J	Fukuda, M; Kanno, E; Satoh, M; Saegusa, C; Yamamoto, A				Fukuda, M; Kanno, E; Satoh, M; Saegusa, C; Yamamoto, A			Synaptotagmin VII is targeted to dense-core vesicles and regulates their Ca2+-dependent exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT OLIGOMERIZATION; CONSERVED WHXL MOTIF; TANDEM C2 DOMAINS; NEUROTRANSMITTER RELEASE; INSULIN EXOCYTOSIS; BETA-CELLS; ANTIBODY INJECTION; MOLECULAR-CLONING; RNA INTERFERENCE; DISTINCT CA2+	It has recently been proposed that synaptotagmin (Syt) VII functions as a plasma membrane Ca2+ sensor for dense-core vesicle exocytosis in PC12 cells based on the results of transient overexpression studies using green fluorescent protein (GFP)-tagged Syt VII; however, the precise subcellular localization of Syt VII is still a matter of controversy ( plasma membrane versus secretory granules). In this study we established a PC12 cell line "stably expressing" the Syt VII-GFP molecule and demonstrated by immunocytochemical and immunoelectron microscopic analyses that the Syt VII-GFP protein is localized on dense-core vesicles as well as in other intracellular membranous structures, such as the trans-Golgi network and lysosomes. Syt VII-GFP forms a complex with endogenous Syts I and IX, but not with Syt IV, and it colocalize well with Syts I and IX in the cellular processes (where dense-core vesicles are accumulated) in the PC12 cell line. We further demonstrated by an N-terminal antibody-uptake experiment that Syt VII-GFP-containing dense-core vesicles undergo Ca2+-dependent exocytosis, the same as endogenous Syt IX-containing vesicles. Moreover, silencing of Syt VII-GFP with specific small interfering RNA dramatically reduced high KCl-dependent neuropeptide Y secretion from the stable PC12 cell line (similar to60% of the control cells), whereas the same small interfering RNA had little effect on neuropeptide Y secretion from the wild-type PC12 cells (similar to85-90% of the control cells), indicating that the level of endogenous expression of Syt VII molecules must be low. Our results indicate that the targeting of Syt VII-GFP molecules to specific membrane compartment(s) is affected by the transfection method ( transient expression versus stable expression) and suggested that Syt VII molecule on dense-core vesicles functions as a vesicular Ca2+ sensor for exocytosis in endocrine cells.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan; Nagahama Inst Biosci & Technol, Shiga 5260829, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Adolfsen B, 2001, CELL MOL LIFE SCI, V58, P393, DOI 10.1007/PL00000865; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Chakrabarti S, 2003, J CELL BIOL, V162, P543, DOI 10.1083/jcb.200305131; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Chieregatti E, 2004, MOL BIOL CELL, V15, P1918, DOI 10.1091/mbc.E03-09-0684; Craxton M, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-43; Dasgupta S, 2003, J CELL SCI, V116, P1327, DOI 10.1242/jcs.00290; Eaton BA, 2000, J NEUROSCI, V20, P7334; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fukuda M, 2000, NEUROSCI LETT, V295, P33, DOI 10.1016/S0304-3940(00)01585-8; Fukuda M, 2004, J BIOL CHEM, V279, P13065, DOI 10.1074/jbc.M306812200; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 2004, J BIOCHEM, V136, P245, DOI 10.1093/jb/mvh116; Fukuda M, 2004, BIOCHEM J, V380, P875, DOI 10.1042/BJ20040096; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2003, BIOCHEM BIOPH RES CO, V306, P64, DOI 10.1016/S0006-291X(03)00911-2; Fukuda M, 2003, J BIOCHEM, V133, P641, DOI 10.1093/jb/mvg082; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2003, J BIOL CHEM, V278, P3220, DOI 10.1074/jbc.M208323200; Fukuda M, 2002, BIOCHEM J, V365, P173, DOI 10.1042/BJ20011877; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2001, J BIOL CHEM, V276, P41112, DOI 10.1074/jbc.M106209200; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; Fukuda M, 2000, J BIOCHEM, V128, P637, DOI 10.1093/oxfordjournals.jbchem.a022796; FUKUDA M, 2003, RECENT RES DEV CHEM, V1, P15; Gao ZY, 2000, J BIOL CHEM, V275, P36079, DOI 10.1074/jbc.M004284200; Gut A, 2001, J CELL SCI, V114, P1709; Han WP, 2004, NEURON, V41, P85, DOI 10.1016/S0896-6273(03)00820-1; Ibata K, 2000, J NEUROCHEM, V74, P518, DOI 10.1046/j.1471-4159.2000.740518.x; Iezzi M, 2004, J CELL SCI, V117, P3119, DOI 10.1242/jcs.01179; Kreft M, 2003, AM J PHYSIOL-CELL PH, V284, pC547, DOI 10.1152/ajpcell.00333.2002; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Michaut M, 2001, DEV BIOL, V235, P521, DOI 10.1006/dbio.2001.0316; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; Moss EG, 2001, CURR BIOL, V11, pR772, DOI 10.1016/S0960-9822(01)00467-5; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; Rao SK, 2004, J BIOL CHEM, V279, P20471, DOI 10.1074/jbc.M400798200; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rickman C, 2004, BIOCHEM J, V378, P681, DOI 10.1042/BJ20031407; Roy D, 2004, SCIENCE, V304, P1515, DOI 10.1126/science.1098371; Saegusa C, 2002, J BIOL CHEM, V277, P24499, DOI 10.1074/jbc.M202767200; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Shin OH, 2002, NAT NEUROSCI, V5, P649, DOI 10.1038/nn869; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Tucker WC, 2003, J CELL BIOL, V162, P199, DOI 10.1083/jcb.200302060; Voets T, 2001, P NATL ACAD SCI USA, V98, P11680, DOI 10.1073/pnas.201398798; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; Zhang Q, 2004, P NATL ACAD SCI USA, V101, P9441, DOI 10.1073/pnas.0401960101; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2	67	69	72	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52677	52684		10.1074/jbc.M409241200	http://dx.doi.org/10.1074/jbc.M409241200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456748	hybrid			2022-12-25	WOS:000225493400114
J	O'Brien, KM; Dirmeier, R; Engle, M; Poyton, RO				O'Brien, KM; Dirmeier, R; Engle, M; Poyton, RO			Mitochondrial protein oxidation in yeast mutants lacking manganese- (MnSOD) or copper- and zinc-containing superoxide dismutase (CuZnSOD) - Evidence that MnSOD and CuZnSOD have both unique and overlapping functions in protecting mitochondrial proteins from oxidative damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ELECTRON-TRANSPORT CHAIN; SACCHAROMYCES-CEREVISIAE; CU,ZN-SUPEROXIDE DISMUTASE; STATIONARY-PHASE; RAT-LIVER; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; IN-VIVO; CELLS	Saccharomyces cerevisiae expresses two forms of superoxide dismutase (SOD): MnSOD, encoded by SOD2, which is located within the mitochondrial matrix, and CuZnSOD, encoded by SOD1, which is located in both the cytosol and the mitochondrial intermembrane space. Because two different SOD enzymes are located in the mitochondrion, we examined the relative roles of each in protecting mitochondria against oxidative stress. Using protein carbonylation as a measure of oxidative stress, we have found no correlation between overall levels of respiration and the level of oxidative mitochondrial protein damage in either wild type or sod mutant strains. Moreover, mitochondrial protein carbonylation levels in sod1, sod2, and sod1sod2 mutants are not elevated in cells harvested from mid-logarithmic and early stationary phases, suggesting that neither MnSOD nor CuZnSOD is required for protecting the majority of mitochondrial proteins from oxidative damage during these early phases of growth. During late stationary phase, mitochondrial protein carbonylation increases in all strains, particularly in sod1 and sod1sod2 mutants. By using matrix-assisted laser desorption ionization time-of-flight mass spectrometry, we have found that specific proteins become carbonylated in sod1 and sod2 mutants. We identified six mitochondrial protein spots representing five unique proteins that become carbonylated in a sod1 mutant and 19 mitochondrial protein spots representing 11 unique proteins that become carbonylated in a sod2 mutant. Although some of the same proteins are carbonylated in both mutants, other proteins are not. These findings indicate that MnSOD and CuZnSOD have both unique and overlapping functions in the mitochondrion.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Poyton, RO (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	Poyton@spot.colorado.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030228] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal S, 1995, MECH AGEING DEV, V85, P55, DOI 10.1016/0047-6374(95)01655-4; Aguilaniu H, 2001, J BIOL CHEM, V276, P35396, DOI 10.1074/jbc.M101796200; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Costa Vitor, 2001, Molecular Aspects of Medicine, V22, P217, DOI 10.1016/S0098-2997(01)00012-7; Costa WMV, 2002, FREE RADICAL BIO MED, V33, P1507, DOI 10.1016/S0891-5849(02)01086-9; Dirmeier R, 2004, METHOD ENZYMOL, V381, P589; Dirmeier R, 2002, J BIOL CHEM, V277, P34773, DOI 10.1074/jbc.M203902200; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; Fortuniak A, 1996, BIOCHEM MOL BIOL INT, V38, P1271; GELLER BL, 1982, J BIOL CHEM, V257, P8945; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRALLA EB, 1997, OXIDATIVE STRESS MOL, P495; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; Hawkins CL, 2001, BBA-BIOENERGETICS, V1504, P196, DOI 10.1016/S0005-2728(00)00252-8; Higgins CMJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-06-j0001.2002; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Jung CW, 2002, J NEUROCHEM, V83, P535, DOI 10.1046/j.1471-4159.2002.01112.x; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; Koeck T, 2004, J BIOL CHEM, V279, P27257, DOI 10.1074/jbc.M401586200; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Menzies FM, 2002, BRAIN, V125, P1522, DOI 10.1093/brain/awf167; Norbeck J, 1997, YEAST, V13, P1519, DOI 10.1002/(SICI)1097-0061(199712)13:16<1519::AID-YEA211>3.0.CO;2-U; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Poyton RO, 1998, NAT GENET, V20, P316, DOI 10.1038/3778; Prokisch H, 2004, PLOS BIOL, V2, P795, DOI 10.1371/journal.pbio.0020160; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V376, P59, DOI 10.1006/abbi.1999.1680; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; SHERMAN F, 1983, METHODS YEAST GENETI, P62; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Wallace MA, 2004, J BIOL CHEM, V279, P32055, DOI 10.1074/jbc.M403590200; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	52	100	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51817	51827		10.1074/jbc.M405958200	http://dx.doi.org/10.1074/jbc.M405958200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15385544	hybrid			2022-12-25	WOS:000225493400014
J	Ozbek, S; Pokidysheva, E; Schwager, M; Schulthess, T; Tariq, N; Barth, D; Milbradt, AG; Moroder, L; Engel, J; Holstein, TW				Ozbek, S; Pokidysheva, E; Schwager, M; Schulthess, T; Tariq, N; Barth, D; Milbradt, AG; Moroder, L; Engel, J; Holstein, TW			The glycoprotein NOWA and minicollagens are part of a disulfide-linked polymer that forms the cnidarian nematocyst wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDRA NEMATOCYSTS; MINI-COLLAGENS; PROTEIN; DISCHARGE; CAPSULES; LINKAGE; SWITCH; RICH	The nematocyst is a unique extrusive organelle involved in the defense and capture of prey in cnidarians. Minicollagens and the glycoprotein NOWA are major components of the nematocyst capsule wall, which resists osmotic pressure of 15 MPa. Here we present the recombinant expression of NOWA, which spontaneously assembles to globular macromolecular particles that are sensitive to reduction as the native wall structure. Ultrastructural analysis showed that the Hydra nematocyst wall is composed of several layers of globular particles, which are interconnected via radiating rodlike protrusions. Evidence is presented that native wall particles contain NOWA and minicollagen, supposed to be linked via disulfide bonds between their homologous cysteine-rich domains. Our data suggest a continuous suprastructure of the nematocyst wall, assembled from wall proteins that share a common oligomerization motif.	Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Tech Univ Darmstadt, Inst Zool, D-64287 Darmstadt, Germany	University of Basel; Max Planck Society; Technical University of Darmstadt	Ozbek, S (corresponding author), Univ Basel, Bioctr, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Suat.Oezbek@unibas.ch	Özbek, Suat/D-3701-2014	Moroder, Luis/0000-0001-9570-5713; Ozbek, Suat/0000-0003-2569-3942; Holstein, Thomas/0000-0003-0480-4674				BLANQUET R, 1966, SCIENCE, V154, P152, DOI 10.1126/science.154.3745.152; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; Engel U, 2002, J CELL SCI, V115, P3923, DOI 10.1242/jcs.00084; Engel U, 2001, EMBO J, V20, P3063, DOI 10.1093/emboj/20.12.3063; HOLSTEIN T, 1984, SCIENCE, V223, P830, DOI 10.1126/science.6695186; HOLSTEIN T, 1981, J ULTRA MOL STRUCT R, V75, P276, DOI 10.1016/S0022-5320(81)80085-8; HOLSTEIN TW, 1994, SCIENCE, V265, P402, DOI 10.1126/science.265.5170.402; KURZ EM, 1991, J CELL BIOL, V115, P1159, DOI 10.1083/jcb.115.4.1159; LENHOFF HM, 1957, BIOCHIM BIOPHYS ACTA, V26, P204, DOI 10.1016/0006-3002(57)90074-4; MARISCAL RN, 1969, EXPERIENTIA, V25, P330, DOI 10.1007/BF02034427; Mascarenhas JB, 2003, EMBO J, V22, P529, DOI 10.1093/emboj/cdg041; Ozbek S, 2002, J BIOL CHEM, V277, P49200, DOI 10.1074/jbc.M209401200; Ozbek S, 2002, J STRUCT BIOL, V137, P11, DOI 10.1006/jsbi.2002.4436; POKIDYSHEVA E, 2004, J BIOL CHEM; SLAUTTERBACK DB, 1963, J CELL BIOL, V18, P367, DOI 10.1083/jcb.18.2.367; WATSON GM, 1985, TISSUE CELL, V17, P199, DOI 10.1016/0040-8166(85)90089-8; WEBER J, 1990, J BIOL CHEM, V265, P9664; Zelensky AN, 2003, PROTEINS, V52, P466, DOI 10.1002/prot.10626	18	28	31	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52016	52023		10.1074/jbc.M407613200	http://dx.doi.org/10.1074/jbc.M407613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466471	hybrid			2022-12-25	WOS:000225493400038
J	Arai, H; Furuya, T; Yasuda, T; Miura, M; Mizuno, Y; Mochizuki, H				Arai, H; Furuya, T; Yasuda, T; Miura, M; Mizuno, Y; Mochizuki, H			Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1 beta, and expression of caspase-11 in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE INTRANIGRAL INJECTION; GROWTH-FACTOR-ALPHA; PARKINSONS-DISEASE; INNATE IMMUNITY; MOUSE MODEL; CELL-DEATH; RAT-BRAIN; SYSTEM; NEURODEGENERATION; DEGENERATION	The endotoxin lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall, selectively induces degeneration of substantia nigral (SN) dopaminergic neurons via activation of microglial cells in rats and mice. Caspase-11 plays a crucial role in LPS-induced septic shock in mice. We examined the mechanism of LPS neurotoxicity on SN dopaminergic neurons in C57BL/6 mice and caspase-11 knockout mice. Mice were stereotaxically injected with LPS into the SN on one side and vehicle into the SN of the other side. Immunohistochemistry, Western blotting analysis, enzyme-linked immunosorbent assay, and reverse transcriptase-PCR were performed to evaluate damage of SN dopaminergic neurons and activation of microglial cells. Intranigral injection of LPS at 1 or 3 mug/mul/site decreased tyrosine hydroxylase-positive neurons and increased microglial cells in the SN compared with the contralateral side injected with vehicle at days 7 and 14 post-injection in C57BL/6 mice. Intranigral injection of LPS at 3 mug/mul/ site induced the expression of caspase-11 mRNA in the ventral midbrain at 6, 8, and 12 h postinjection, and the expression of caspase-11-positive cells in the SN at 8 and 12 h post-injection. Moreover, LPS at 3 mug/mul/ site increased interleukin-1beta content in the ventral midbrain at 12 and 24 h post-injection. LPS failed to elicit these responses in caspase-11 knockout mice. Our results indicate that the neurotoxic effects of LPS on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and caspase-11 expression in mice.	Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Res Inst Dis Old Ages, Bunkyo Ku, Tokyo 1138421, Japan; Univ Tokyo, Dept Genet, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan	Juntendo University; Juntendo University; University of Tokyo	Mochizuki, H (corresponding author), Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	hideki@med.juntendo.ac.jp						Castano A, 1998, J NEUROCHEM, V70, P1584; Castano A, 2002, J NEUROCHEM, V81, P150, DOI 10.1046/j.1471-4159.2002.00799.x; Duan YL, 2003, J NEUROBIOL, V57, P183, DOI 10.1002/neu.10262; Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717; Furuya T, 2004, J NEUROSCI, V24, P1865, DOI 10.1523/JNEUROSCI.3309-03.2004; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Herrera AJ, 2000, NEUROBIOL DIS, V7, P429, DOI 10.1006/nbdi.2000.0289; Hunot S, 2003, ANN NEUROL, V53, pS49, DOI 10.1002/ana.10481; Imai Y, 2002, GLIA, V40, P164, DOI 10.1002/glia.10149; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Kang SJ, 2002, CELL DEATH DIFFER, V9, P1115, DOI 10.1038/sj.cdd.4401087; Kim NG, 2003, MOL BRAIN RES, V114, P107, DOI 10.1016/S0169-328X(03)00135-9; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Mochizuki H, 2001, P NATL ACAD SCI USA, V98, P10918, DOI 10.1073/pnas.191107398; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; Teismann P, 2003, MOVEMENT DISORD, V18, P121, DOI 10.1002/mds.10332; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5	33	95	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51647	51653		10.1074/jbc.M407328200	http://dx.doi.org/10.1074/jbc.M407328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15383538	hybrid			2022-12-25	WOS:000225355800120
J	Jana, A; Pahan, K				Jana, A; Pahan, K			Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase - Implications for Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR-PROTEIN; TRANSGENIC MICE; CELL-DEATH; CERAMIDE PRODUCTION; ADOPTIVE TRANSFER; APOPTOSIS; CHOLESTEROL; INVOLVEMENT; ASTROCYTES; PATHWAY	Alzheimer's disease is a major illness of dementia characterized by the presence of amyloid plaques, neurofibrillary tangles, and extensive neuronal apoptosis. However, the mechanism behind neuronal apoptosis in the Alzheimer's-diseased brain is poorly understood. This study underlines the importance of neutral sphingomyelinase in fibrillar Abeta peptide-induced apoptosis and cell death in human primary neurons. Abeta1-42 peptides induced the activation of sphingomyelinases and the production of ceramide in neurons. Interestingly, neutral (N-SMase), but not acidic (A-SMase), sphingomyelinase was involved in Abeta1-42-mediated neuronal apoptosis and cell death. Abeta1-42-induced production of ceramide was redox-sensitive, as reactive oxygen species were involved in the activation of N-SMase but not A-SMase. Abeta1-42 peptides induced the NADPH oxidase-mediated production of superoxide radicals in neurons that was involved in the activation of N-SMase, but not A-SMase, via hydrogen peroxide. Consistently, superoxide radicals generated by hypoxanthine and xanthine oxidase also induced the activation of N-SMase, but not A-SMase, through a catalase-sensitive pathway. Furthermore, antisense knockdown of p22phox, a subunit of NADPH oxidase, inhibited Abeta1-42-induced neuronal apoptosis and cell death. These studies suggest that fibrillar Abeta1-42 peptides induce neuronal apoptosis through the NADPH oxidase-superoxide-hydrogen peroxide-NS-Mase-ceramide pathway.	Univ Nebraska, Med Ctr, Dept Oral Biol, Sect Neurosci, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, Sect Neurosci, 40th & Holdrege, Lincoln, NE 68583 USA.	kpahan@unmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG019487] Funding Source: NIH RePORTER; NIA NIH HHS [AG19487, R03 AG019487-01] Funding Source: Medline; NINDS NIH HHS [R01 NS039940, NS39940, R01 NS039940-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; BLOOMFIELD M, 1992, Biochemical Society Transactions, V20, p293S; Brugg B, 1996, J NEUROCHEM, V66, P733; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Dasgupta S, 2004, J IMMUNOL, V173, P1344, DOI 10.4049/jimmunol.173.2.1344; Dasgupta S, 2003, J IMMUNOL, V170, P3874, DOI 10.4049/jimmunol.170.7.3874; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee JT, 2004, J CELL BIOL, V164, P123, DOI 10.1083/jcb.200307017; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; Masliah E, 1996, J NEUROSCI, V16, P5795; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 2000, J NEUROCHEM, V75, P576, DOI 10.1046/j.1471-4159.2000.0750576.x; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	28	154	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51451	51459		10.1074/jbc.M404635200	http://dx.doi.org/10.1074/jbc.M404635200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452132	Green Accepted, hybrid			2022-12-25	WOS:000225355800097
J	Mackey, AT; Sproul, LR; Sontag, CA; Satterwhite, LL; Correia, JJ; Gilbert, SP				Mackey, AT; Sproul, LR; Sontag, CA; Satterwhite, LL; Correia, JJ; Gilbert, SP			Mechanistic analysis of the Saccharomyces cerevisiae kinesin Kar3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							END-DIRECTED MOTOR; MITOTIC SPINDLE; SEDIMENTATION-VELOCITY; KINETIC MECHANISM; PROTEIN CIK1P; BUDDING YEAST; MEIOSIS-I; MICROTUBULE; NCD; ATPASE	Kar3 is a minus-end-directed microtubule motor that is implicated in meiotic and mitotic spindle function in Saccharomyces cerevisiae. To date, the only truncated protein of Kar3 that has been reported to promote unidirectional movement in vitro is GSTKar3. This motor contains an NH2-terminal glutathione S-transferase (GST) tag followed by the Kar3 sequence that is predicted to form an extended alpha-helical coiled-coil. The alpha-helical domain leads into the neck linker and COOH-terminal motor domain. Kar3 does not homodimerize with itself but forms a heterodimer with either Cik1 or Vik1, both of which are non-motor polypeptides. We evaluated the microtubule-GSTKar3 complex in comparison to the microtubule-Kar3 motor domain complex to determine the distinctive mechanistic features required for GSTKar3 motility. Our results indicate that ATP binding was significantly faster for GSTKar3 than that observed previously for the Kar3 motor domain. In addition, microtubule-activated ADP release resulted in an intermediate that bound ADP weakly in contrast to the Kar3 motor domain, suggesting that after ADP release, the microtubule-GSTKar3 motor binds ATP in preference to ADP. The kinetics also showed that GSTKar3 readily detached from the microtubule rather than remaining bound for multiple ATP turnovers. These results indicate that the extended alpha-helical domain NH2-terminal to the catalytic core provides the structural transitions in response to the ATPase cycle that are critical for motility and that dimerization is not specifically required. This study provides the foundation to define the mechanistic contributions of Cik1 and Vik1 for Kar3 force generation and function in vivo.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Mississippi; University of Mississippi Medical Center; Duke University	Gilbert, SP (corresponding author), Univ Pittsburgh, Dept Biol Sci, 518 Langley Hall, Pittsburgh, PA 15260 USA.	spg1@pitt.edu		Hoverman, Lisa/0000-0002-3396-6982	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR047841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054141] Funding Source: NIH RePORTER; NIAMS NIH HHS [K02 AR047841, K02-AR47841] Funding Source: Medline; NIGMS NIH HHS [R37 GM054141, R01 GM054141, GM54141] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett JG, 2000, MOL BIOL CELL, V11, P2373, DOI 10.1091/mbc.11.7.2373; BascomSlack CA, 1997, J CELL BIOL, V139, P459, DOI 10.1083/jcb.139.2.459; Cochran JC, 2004, J BIOL CHEM, V279, P38861, DOI 10.1074/jbc.M404203200; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Correia JJ, 1992, ANAL ULTRACENTRIFUGA, P231; Cottingham FR, 1999, J CELL BIOL, V147, P335, DOI 10.1083/jcb.147.2.335; Crevel IMTC, 2004, EMBO J, V23, P23, DOI 10.1038/sj.emboj.7600042; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Foster KA, 2000, BIOCHEMISTRY-US, V39, P1784, DOI 10.1021/bi991500b; Foster KA, 2001, J BIOL CHEM, V276, P19259, DOI 10.1074/jbc.M008347200; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; Hildebrandt ER, 2000, BBA-MOL CELL RES, V1496, P99, DOI 10.1016/S0167-4889(00)00012-4; HOYT MA, 1993, GENETICS, V135, P35; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Huyett A, 1998, J CELL SCI, V111, P295; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Klumpp LM, 2004, P NATL ACAD SCI USA, V101, P3444, DOI 10.1073/pnas.0307691101; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Mackey AT, 2000, BIOCHEMISTRY-US, V39, P1346, DOI 10.1021/bi991918+; Mackey AT, 2003, J BIOL CHEM, V278, P3527, DOI 10.1074/jbc.M206219200; Maddox PS, 2003, CURR BIOL, V13, P1423, DOI 10.1016/S0960-9822(03)00547-5; Maddox PS, 2000, NAT CELL BIOL, V2, P36, DOI 10.1038/71357; Manning BD, 1999, J CELL BIOL, V144, P1219, DOI 10.1083/jcb.144.6.1219; Manning BD, 2000, TRENDS CELL BIOL, V10, P281, DOI 10.1016/S0962-8924(00)01774-8; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MIDDLETON K, 1994, P NATL ACAD SCI USA, V91, P7212, DOI 10.1073/pnas.91.15.7212; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; PAGE BD, 1992, GENE DEV, V6, P1414, DOI 10.1101/gad.6.8.1414; PAGE BD, 1994, J CELL BIOL, V124, P507, DOI 10.1083/jcb.124.4.507; Pechatnikova E, 1999, BIOPHYS J, V77, P1003, DOI 10.1016/S0006-3495(99)76951-1; Pechatnikova E, 1997, J BIOL CHEM, V272, P30735, DOI 10.1074/jbc.272.49.30735; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Saunders W, 1997, MOL BIOL CELL, V8, P1025, DOI 10.1091/mbc.8.6.1025; Saunders W, 1997, J CELL BIOL, V137, P417, DOI 10.1083/jcb.137.2.417; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shanks RMQ, 2004, CELL CYCLE, V3, P363; Shanks RMQ, 2001, GENETICS, V159, P939; Song H, 1996, BIOCHEMISTRY-US, V35, P11203, DOI 10.1021/bi960997b; Stafford WF, 2004, BIOPHYS CHEM, V108, P231, DOI 10.1016/j.bpc.2003.10.028	46	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51354	51361		10.1074/jbc.M406268200	http://dx.doi.org/10.1074/jbc.M406268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385545	hybrid, Green Accepted			2022-12-25	WOS:000225355800086
J	Hsu, GW; Kiefer, JR; Burnouf, D; Becherel, OJ; Fuchs, RPP; Beese, LS				Hsu, GW; Kiefer, JR; Burnouf, D; Becherel, OJ; Fuchs, RPP; Beese, LS			Observing translesion synthesis of an aromatic amine DNA adduct by a high-fidelity DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATTACHED AMINOFLUORENE RING; C-8-MODIFIED SYN GUANINE; ESCHERICHIA-COLI; DAMAGED DNA; OPPOSITE DC; STRUCTURAL-CHARACTERIZATION; SOLUTION CONFORMATION; NUCLEOTIDE INSERTION; BASE DISPLACEMENT; COVALENT BINDING	Aromatic amines have been studied for more than a half-century as model carcinogens representing a class of chemicals that form bulky adducts to the C8 position of guanine in DNA. Among these guanine adducts, the N-(2'-deoxyguanosin-8-yl)-aminofluorene (G-AF) and N-2-(2'-deoxyguanosin-8-yl)-acetylaminofluorene (G-AAF) derivatives are the best studied. Although G-AF and G-AAF differ by only an acetyl group, they exert different effects on DNA replication by replicative and high-fidelity DNA polymerases. Translesion synthesis of G-AF is achieved with high-fidelity polymerases, whereas replication of G-AAF requires specialized bypass polymerases. Here we have presented structures of G-AF as it undergoes one round of accurate replication by a high-fidelity DNA polymerase. Nucleotide incorporation opposite G-AF is achieved in solution and in the crystal, revealing how the polymerase accommodates and replicates past G-AF, but not G-AAF. Like an unmodified guanine, G-AF adopts a conformation that allows it to form Watson-Crick hydrogen bonds with an opposing cytosine that results in protrusion of the bulky fluorene moiety into the major groove. Although incorporation opposite G-AF is observed, the C: G-AF base pair induces distortions to the polymerase active site that slow translesion synthesis.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; CNRS, Unite Propre Rech 9003, F-67400 Strasbourg, France	Duke University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Beese, LS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	lsb@biochem.duke.edu	Classen, Scott/AAY-8176-2020; beese, lorena/G-4993-2010	Kiefer, James/0000-0001-6317-0902	NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA92584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMAN RA, 1993, Q REV BIOPHYS, V26, P225, DOI 10.1017/S0033583500002869; BELGUISEVALLADIER P, 1994, J MOL BIOL, V236, P151, DOI 10.1006/jmbi.1994.1125; BELGUISEVALLADIER P, 1995, J MOL BIOL, V249, P903, DOI 10.1006/jmbi.1995.0347; BICHARA M, 1985, J MOL BIOL, V183, P341, DOI 10.1016/0022-2836(85)90005-1; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; BRIEBA LG, 2004, EMBO J; BROYDE S, 1983, BIOPOLYMERS, V22, P2423, DOI 10.1002/bip.360221109; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHO BP, 1994, BIOCHEMISTRY-US, V33, P1373, DOI 10.1021/bi00172a013; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; DAUNE MP, 1981, NATL CANCER I MONOGR, V58, P201; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ECKEL LM, 1994, NAT STRUCT BIOL, V1, P89, DOI 10.1038/nsb0294-89; ECKEL LM, 1994, BIOCHEMISTRY-US, V33, P13611, DOI 10.1021/bi00250a012; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Freisinger E, 2004, EMBO J, V23, P1494, DOI 10.1038/sj.emboj.7600158; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; FUCHS R, 1973, FEBS LETT, V34, P295, DOI 10.1016/0014-5793(73)80815-4; FUCHS R, 1972, BIOCHEMISTRY-US, V11, P2659, DOI 10.1021/bi00764a017; FUCHS RPP, 1976, BIOCHEMISTRY-US, V15, P3347, DOI 10.1021/bi00660a027; FUCHS RPP, 1974, BIOCHEMISTRY-US, V13, P4435, DOI 10.1021/bi00718a028; FUCHS RPP, 1975, NATURE, V257, P151, DOI 10.1038/257151a0; FUCHS RPP, 1984, EMBO J, V3, P757, DOI 10.1002/j.1460-2075.1984.tb01880.x; Fujii S, 2004, J MOL BIOL, V341, P405, DOI 10.1016/j.jmb.2004.06.017; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Gu ZT, 1999, BIOCHEMISTRY-US, V38, P10855, DOI 10.1021/bi991266p; HEFLICH RH, 1994, MUTAT RES-REV GENET, V318, P73, DOI 10.1016/0165-1110(94)90025-6; Hoffmann GR, 1997, CHEM RES TOXICOL, V10, P347, DOI 10.1021/tx960128n; Hogg M, 2004, EMBO J, V23, P1483, DOI 10.1038/sj.emboj.7600150; Hsu GW, 2004, NATURE, V431, P217, DOI 10.1038/nature02908; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson SJ, 2004, CELL, V116, P803, DOI 10.1016/S0092-8674(04)00252-1; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KOEHL P, 1989, J MOL BIOL, V207, P355, DOI 10.1016/0022-2836(89)90259-3; KoffelSchwartz N, 1996, P NATL ACAD SCI USA, V93, P7805, DOI 10.1073/pnas.93.15.7805; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; LANG MCE, 1979, CHEM-BIOL INTERACT, V28, P171, DOI 10.1016/0009-2797(79)90159-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEFEVRE JF, 1978, BIOCHEMISTRY-US, V17, P2561, DOI 10.1021/bi00606a016; Lehmann AR, 2002, MUTAT RES-FUND MOL M, V509, P23, DOI 10.1016/S0027-5107(02)00227-0; Lenne-Samuel N, 2000, MOL MICROBIOL, V38, P299, DOI 10.1046/j.1365-2958.2000.02116.x; Li Y, 2004, NAT STRUCT MOL BIOL, V11, P784, DOI 10.1038/nsmb792; LINDSLEY JE, 1994, BIOCHEMISTRY-US, V33, P764, DOI 10.1021/bi00169a018; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Mao B, 1995, BIOCHEMISTRY-US, V34, P16641, DOI 10.1021/bi00051a012; MAO B, 1995, BIOCHEMISTRY-US, V34, P6226, DOI 10.1021/bi00018a027; Mao B, 1998, BIOCHEMISTRY-US, V37, P81, DOI 10.1021/bi972257o; Mao B, 1998, BIOCHEMISTRY-US, V37, P95, DOI 10.1021/bi972258g; MICHAELS ML, 1987, J BIOL CHEM, V262, P14648; Miller H, 1997, BIOCHEMISTRY-US, V36, P15336, DOI 10.1021/bi971927n; MOORE PD, 1982, P NATL ACAD SCI-BIOL, V79, P7166, DOI 10.1073/pnas.79.23.7166; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; NORMAN D, 1989, BIOCHEMISTRY-US, V28, P7462, DOI 10.1021/bi00444a046; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; Ohashi E, 2000, GENE DEV, V14, P1589; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pages V, 2003, SCIENCE, V300, P1300, DOI 10.1126/science.1083964; Pages V, 2002, ONCOGENE, V21, P8957, DOI 10.1038/sj.onc.1206006; SAGE E, 1979, FEBS LETT, V108, P66, DOI 10.1016/0014-5793(79)81180-1; SAGE E, 1979, BIOCHEMISTRY-US, V18, P1328, DOI 10.1021/bi00574a032; SALLES B, 1983, NUCLEIC ACIDS RES, V11, P5235, DOI 10.1093/nar/11.15.5235; SHIBUTANI S, 1990, J AM CHEM SOC, V112, P5667, DOI 10.1021/ja00170a056; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; STRAUSS BS, 1990, CARCINOGENESIS, V11, P2103, DOI 10.1093/carcin/11.12.2103; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400; Yang W, 2003, CURR OPIN STRUC BIOL, V13, P23, DOI 10.1016/S0959-440X(02)00003-9; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928	82	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50280	50285		10.1074/jbc.M409224200	http://dx.doi.org/10.1074/jbc.M409224200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15385534	hybrid			2022-12-25	WOS:000225229500090
J	Jung, J; Kim, M; Kim, MJ; Kim, J; Moon, J; Lim, JS; Kim, M; Lee, K				Jung, J; Kim, M; Kim, MJ; Kim, J; Moon, J; Lim, JS; Kim, M; Lee, K			Translationally controlled tumor protein interacts with the third cytoplasmic domain of Na,K-ATPase alpha subunit and inhibits the pump activity in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE; STIMULATION; MECHANISMS; OUABAIN; ANKYRIN; IDENTIFICATION; NA+,K+-ATPASE; POLYPEPTIDE; SEQUENCE; FORTILIN	Translationally controlled tumor protein (TCTP) is a growth-related protein under transcriptional as well as translational control. We screened a rat skeletal muscle cDNA library using yeast two-hybrid system and found that TCTP interacts with the third large cytoplasmic domain of alpha1 as well as alpha2 isoforms of Na,K-ATPase, believed involved in the regulation of Na,K-ATPase activity. Interaction between TCTP and Na,K-ATPase was confirmed by coimmunoprecipitation in yeast and mammalian cells. We also showed, using Rb-86(+) uptake assay, that overexpression of TCTP inhibited Na,K-ATPase activity in HeLa cells. Northern and Western blotting studies of HeLa cells transiently transfected with GFP-tagged TCTP showed that overexpression of TCTP did not change mRNA and protein levels of Na,K-ATPase. Recombinant TCTP protein purified from an Escherichia coli expression system inhibited purified HeLa cell plasma membrane Na,K-ATPase in a dose-dependent manner. Using deletion analysis, we also found that the C-terminal 102-172-amino-acid region of rat TCTP that contains the TCTP homology region 2 is essential for its association with, and inhibition of, Na,K-ATPase.	Ewha Womans Univ, Coll Pharm, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	Ewha Womans University; Ewha Womans University	Lee, K (corresponding author), Ewha Womans Univ, Coll Pharm, Ctr Cell Signaling Res, Seoul 120750, South Korea.	klyoon@ewha.ac.kr						BERTORELLO AM, 1993, AM J PHYSIOL, V265, pF743, DOI 10.1152/ajprenal.1993.265.6.F743; BOMMER UA, 1994, CELL MOL BIOL RES, V40, P633; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; Coppi MV, 1997, ARCH BIOCHEM BIOPHYS, V346, P312, DOI 10.1006/abbi.1997.0332; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; FEHLMANN M, 1981, J BIOL CHEM, V256, P7449; Ferrandi M, 1999, AM J PHYSIOL-HEART C, V277, pH1338, DOI 10.1152/ajpheart.1999.277.4.H1338; Fiske CH, 1925, J BIOL CHEM, V66, P375; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Gachet Y, 1999, J CELL SCI, V112, P1257; GROSS B, 1989, NUCLEIC ACIDS RES, V17, P8367, DOI 10.1093/nar/17.20.8367; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; JORDAN C, 1995, J BIOL CHEM, V270, P29971; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Jung JH, 2002, J BIOL CHEM, V277, P48931, DOI 10.1074/jbc.M208806200; KAPLOWITZ PB, 1976, CELL DIFFER DEV, V5, P109, DOI 10.1016/0045-6039(76)90004-X; KOOB R, 1990, EUR J CELL BIOL, V53, P93; KORT JJ, 1990, J CELL PHYSIOL, V145, P253, DOI 10.1002/jcp.1041450209; Lee K, 2001, BIOCHEM J, V353, P377, DOI 10.1042/0264-6021:3530377; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; LINGHAM RB, 1982, BIOCHIM BIOPHYS ACTA, V688, P475, DOI 10.1016/0005-2736(82)90359-5; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; Murata Y, 1996, JPN J PHARMACOL, V72, P347, DOI 10.1254/jjp.72.347; Nestor NB, 1997, ANN NY ACAD SCI, V834, P579, DOI 10.1111/j.1749-6632.1997.tb52324.x; Sanchez JC, 1997, ELECTROPHORESIS, V18, P150, DOI 10.1002/elps.1150180127; Thaw P, 2001, NAT STRUCT BIOL, V8, P701, DOI 10.1038/90415; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; ULLRICH KJ, 1979, ANNU REV PHYSIOL, V41, P181, DOI 10.1146/annurev.ph.41.030179.001145; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x; Xu AM, 1999, BIOCHEM J, V342, P683, DOI 10.1042/0264-6021:3420683; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoon T, 2000, ARCH BIOCHEM BIOPHYS, V384, P379, DOI 10.1006/abbi.2000.2108; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200	34	70	77	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49868	49875		10.1074/jbc.M400895200	http://dx.doi.org/10.1074/jbc.M400895200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383549	hybrid			2022-12-25	WOS:000225229500040
J	Porlan, E; Vega, S; Iglesias, T; Rodriguez-Pena, A				Porlan, E; Vega, S; Iglesias, T; Rodriguez-Pena, A			Unliganded thyroid hormone receptor beta 1 inhibits proliferation of murine broblasts by delaying the onset of the G1 cell-cycle signals	ONCOGENE			English	Article						thyroid hormone; thyroid hormone receptors; TR beta 1; cell cycle; cell proliferation; E2F transcription factor	OLIGODENDROCYTE DIFFERENTIATION; NEURONAL DIFFERENTIATION; GENE-EXPRESSION; MOLECULAR-BASIS; REPRESSION; MICE; RESISTANCE; REGULATOR; CARCINOMA; ALPHA	Thyroid hormone receptors (TRs) are members of the ligand-inducible transcription factor superfamily. The two major functional TRs (alpha1 and beta1) have different spatial and temporal expression patterns and specific physiological functions for these isoforms are now starting to emerge. By expressing these TR isoforms individually in Swiss 3T3 fibroblasts, we found that TRbeta1 expression, in the absence of hormone, provokes a proliferation arrest in G0/G1, lengthening the cycling time. Upon serum stimulation TRbeta1-expressing cells showed a marked delay in the induction of cyclins D and E, in the phosphorylation of retinoblastoma protein, and in the activation of cyclin-dependent kinase 2, accompanied by increased levels of cyclin-dependent kinase inhibitor p27(Kip1). Accordingly, serum-stimulated E2F-1 transcriptional activity was repressed by TRbeta1 in transient transfection experiments. Analysis of the receptor domains required for this effect confirmed that there is no need for a functional ligand-binding domain while the DNA-binding domain is essential. In this work, we demonstrate for the first time that TRbeta1 participates in the molecular mechanisms that control cell proliferation. The unliganded TRbeta1 impairs the normal induction of the G1/S cycle regulators preventing progression into the S phase.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Rodriguez-Pena, A (corresponding author), CSIC, Inst Cajal, Dr Arce 37, E-28002 Madrid, Spain.	arodriguez@iib.uam.es	Vacas, Teresa Iglesias/ABF-8663-2020; porlan, Eva/AAE-6561-2022; Vega, Sonia/R-1883-2018	Vacas, Teresa Iglesias/0000-0002-4326-9005; porlan, Eva/0000-0003-0934-9711; Vega, Sonia/0000-0002-3895-6265; Rodriguez-Pena, Angeles/0000-0002-2515-4626				Barrera-Hernandez G, 1998, DNA CELL BIOL, V17, P743, DOI 10.1089/dna.1998.17.743; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Billon N, 2001, DEV BIOL, V235, P110, DOI 10.1006/dbio.2001.0293; BROWN DD, 1995, RECENT PROG HORM RES, V50, P309; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Carre JL, 1998, J NEUROSCI RES, V54, P584; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Durand B, 2000, BIOESSAYS, V22, P64; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Gonzalez-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6; Hashimoto K, 2001, P NATL ACAD SCI USA, V98, P3998, DOI 10.1073/pnas.051454698; HAYASHI Y, 1994, J CLIN INVEST, V94, P607, DOI 10.1172/JCI117376; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; MARKOWITZ S, 1989, J CLIN INVEST, V84, P1683, DOI 10.1172/JCI114349; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nygard M, 2003, MOL ENDOCRINOL, V17, P79, DOI 10.1210/me.2002-0107; O'Shea PJ, 2002, J ENDOCRINOL, V175, P553, DOI 10.1677/joe.0.1750553; Oberste-Berghaus C, 2000, J BIOL CHEM, V275, P1787, DOI 10.1074/jbc.275.3.1787; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; PAAVONEN T, 1982, SCAND J IMMUNOL, V15, P211, DOI 10.1111/j.1365-3083.1982.tb00640.x; PASTOR R, 1994, ONCOGENE, V9, P1081; Perez-Juste G, 1999, J BIOL CHEM, V274, P5026, DOI 10.1074/jbc.274.8.5026; Qi JS, 1997, MOL CELL BIOL, V17, P7195, DOI 10.1128/MCB.17.12.7195; RODRIGUEZ ER, 1994, BIOCHEM BIOPH RES CO, V205, P652, DOI 10.1006/bbrc.1994.2715; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SHERR CJ, 1994, COLD SPRING HARB SYM, V59, P11, DOI 10.1101/SQB.1994.059.01.004; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Tokumoto YM, 2002, DEV BIOL, V245, P224, DOI 10.1006/dbio.2002.0626; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; YEN PM, 1995, ENDOCRINOLOGY, V136, P2845, DOI 10.1210/en.136.7.2845; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0	39	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8756	8765		10.1038/sj.onc.1208126	http://dx.doi.org/10.1038/sj.onc.1208126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467737	Bronze			2022-12-25	WOS:000225165100005
J	Wu, DQ; Thakore, CU; Wescott, GG; McCubrey, JA; David, MT				Wu, DQ; Thakore, CU; Wescott, GG; McCubrey, JA; David, MT			Integrin signaling links protein kinase C epsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells	ONCOGENE			English	Article						PI3K; Src kinase; integrin-linked kinase; beta-catenin; fibronectin	GLYCOGEN-SYNTHASE KINASE; BETA-CATENIN; ANDROGEN RECEPTOR; CYCLIN D1; INTRAEPITHELIAL NEOPLASIA; PKC-EPSILON; INHIBITION; ACTIVATION; EXPRESSION; APOPTOSIS	Failure of hormone therapy often involves an outgrowth of protein kinase Cepsilon (PKCepsilon)-positive cells in recurrent prostate cancer. Our previous investigations have uncovered evidence of a complex signaling network operating downstream of this oncogenic protein kinase to actively advance the survival and proliferation of prostate cancer cells. In this study, we present evidence of a functional interplay among integrin receptors, PKCe, and protein kinase B (PKB/Akt) in recurrent CWR-R1 prostate cancer cells. Flow cytometry and confocal microscopy provided evidence that PKCepsilon signaling promoted the assembly of matrix adhesions containing an abundance of colocalized actin filaments and beta1 integrins that exhibited an exposed activation epitope on the surface of live CWR-R1 cells. Reciprocal coimmunoprecipitations provided evidence of signaling complexes containing PKCepsilon, beta1 integrins, Src, and PKB/Akt in CWR-R1 cell cultures. An investigation into the functional significance of these interactions, and of their positive influence on beta1 integrins, demonstrated that PKCepsilon and several key components of the PKB/Akt signaling pathway remain constitutively phosphorylated/activated in adherent but not suspension cultures of PTEN-positive CWR-R1 cells. Gene transfer, antisense and pharmacological experiments provided additional support for the hypothesis that a mutually reinforcing signaling loop sustains the activation of beta1 integrins, PKCepsilon, and PKB/Akt in adherent prostate cancer cells.	E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo W Jenkins Canc Ctr, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	David, MT (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA.	terriand@mail.ecu.edu		McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01 CA98195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Bernard D, 2003, J CLIN INVEST, V112, P1724; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chen S, 1998, MOL ENDOCRINOL, V12, P1558, DOI 10.1210/me.12.10.1558; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chun JS, 1996, J BIOL CHEM, V271, P13008, DOI 10.1074/jbc.271.22.13008; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; Eder IE, 2000, CANCER GENE THER, V7, P997, DOI 10.1038/sj.cgt.7700202; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; FONARO M, 2001, CANCER METAST REV, V20, P321; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Graff Jeremy R, 2002, Expert Opin Ther Targets, V6, P103, DOI 10.1517/14728222.6.1.103; Gregory CW, 2001, CANCER RES, V61, P2892; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Koren R, 2004, ONCOL REP, V11, P321; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Linja MJ, 2001, CANCER RES, V61, P3550; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Mackay HJ, 2003, ENDOCR-RELAT CANCER, V10, P389, DOI 10.1677/erc.0.0100389; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; McMenamin ME, 1999, CANCER RES, V59, P4291; Meuillet EJ, 2003, MOL CANCER THER, V2, P389; Moro L, 2004, J BIOL CHEM, V279, P1692, DOI 10.1074/jbc.M307857200; Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Orchard S, 2002, CURR OPIN DRUG DI DE, V5, P713; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tucker GC, 2002, CURR OPIN PHARMACOL, V2, P394, DOI 10.1016/S1471-4892(02)00175-3; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wescott G G, 1999, Methods Mol Med, V22, P125, DOI 10.1385/0-89603-612-X:125; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wu Daqing, 2003, Methods Mol Biol, V218, P143; Wu DQ, 2002, J BIOL CHEM, V277, P40449, DOI 10.1074/jbc.M206270200; Wu DQ, 2002, CANCER RES, V62, P2423; Xie ZH, 2003, CANCER RES, V63, P5370; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	71	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8659	8672		10.1038/sj.onc.1207900	http://dx.doi.org/10.1038/sj.onc.1207900			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467757				2022-12-25	WOS:000224988800012
J	Rozanov, DV; Savinov, AY; Golubkov, VS; Postnova, TI; Remacle, A; Tomlinson, S; Strongin, AY				Rozanov, DV; Savinov, AY; Golubkov, VS; Postnova, TI; Remacle, A; Tomlinson, S; Strongin, AY			Cellular membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves C3b, an essential component of the complement system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; HUMAN-MELANOMA CELLS; INTEGRIN ALPHA(V) SUBUNIT; DECAY-ACCELERATING FACTOR; 3RD COMPONENT; TUMOR-GROWTH; CYSTEINE PROTEINASE; REGULATORY PROTEINS; BONE SIALOPROTEIN; TISSUE INHIBITOR	Neoplasms have developed numerous strategies to protect themselves against the host immune system. Membrane type-1 matrix metalloproteinase (MT1-MMP) is strongly associated with many cancer types and is up-regulated in the aggressive, metastatic neoplasms. During the past few years, there has been an increasing appreciation of the important, albeit incompletely understood, role of MT1-MMP in cancer. We have discovered, using cell-free and cell-based assays in vitro, that MT1-MMP proteolysis specifically targets C3b, an essential component of the complement propagation pathway. MT1-MMP proteolysis liberates the deposited C3 activation fragments from the cell surface. The shedding of these cell-deposited opsonins by MT1-MMP inhibits the complement cascade and protects breast carcinoma MCF7 cells from direct complement-mediated injury in the in vitro tests. The functional link associating MT1-MMP with the host immune system, heretofore unrecognized, may empower tumors with an escape mechanism that contributes to the protection against the host antitumor immunity as well as to the survival of invading and metastatic malignant cells in the bloodstream.	Burnham Inst, La Jolla, CA 92037 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA	Sanford Burnham Prebys Medical Discovery Institute; Medical University of South Carolina	Strongin, AY (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019; Golubkov, Vladislav/L-6828-2017	Strongin, Alex/0000-0003-3765-3016; 	NCI NIH HHS [CA83017, CA77470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARA S, 1987, J IMMUNOL, V138, P1303; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bernardo MM, 2003, BIOCHEM J, V374, P739, DOI 10.1042/BJ20030557; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Caragine TA, 2002, CANCER RES, V62, P1110; Carroll MC, 1997, CURR OPIN IMMUNOL, V9, P64, DOI 10.1016/S0952-7915(97)80160-4; Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362; Dachs GU, 1997, ONCOL RES, V9, P313; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DELIBRIAS C, 1997, COMPLEMENT SYSTEM, P211; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; Fedarko NS, 2000, J BIOL CHEM, V275, P16666, DOI 10.1074/jbc.M001123200; Frade R, 1998, CANCER RES, V58, P2733; Gorter A, 1999, IMMUNOL TODAY, V20, P576, DOI 10.1016/S0167-5699(99)01537-6; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Jean D, 1996, CANCER RES, V56, P254; Jean D, 1995, BIOCHEM J, V312, P961, DOI 10.1042/bj3120961; Jurianz K, 1999, MOL IMMUNOL, V36, P316; Jurianz K, 1999, IMMUNOPHARMACOLOGY, V42, P209, DOI 10.1016/S0162-3109(99)00006-5; Jurianz K, 1999, MOL IMMUNOL, V36, P929, DOI 10.1016/S0161-5890(99)00115-7; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; KIM SH, 1987, J IMMUNOL, V138, P1530; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lhotak S, 2001, CLIN EXP METASTAS, V18, P463, DOI 10.1023/A:1011800919981; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; Maenpaa A, 1996, AM J PATHOL, V148, P1139; Morgan B P, 2000, Methods Mol Biol, V150, P1; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Morgan BP., 1999, COMPLEMENT REGULATOR; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nielsen CH, 2002, J LEUKOCYTE BIOL, V72, P249; Nuttall RK, 2003, MOL CANCER RES, V1, P333; OLLERT MW, 1993, CANCER RES, V53, P592; Pulyaeva H, 1997, CLIN EXP METASTAS, V15, P111, DOI 10.1023/A:1018444609098; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Rousselet N, 2004, CANCER RES, V64, P146, DOI 10.1158/0008-5472.CAN-03-1717; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Rus HG, 2001, IMMUNOL REV, V180, P49, DOI 10.1034/j.1600-065X.2001.1800104.x; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Ueno H, 1997, CANCER RES, V57, P2055; Yu J, 1999, CLIN EXP IMMUNOL, V115, P13; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	55	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46551	46557		10.1074/jbc.M405284200	http://dx.doi.org/10.1074/jbc.M405284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15381670	hybrid			2022-12-25	WOS:000224832400027
J	de Melker, AA; van der Horst, G; Borst, J				de Melker, AA; van der Horst, G; Borst, J			Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTORS; ENDOCYTIC PATHWAY; TYROSINE KINASES; PLASMA-MEMBRANE; RING FINGER; MEDIATED ENDOCYTOSIS; INTERACTING MOTIF; DOWN-REGULATION; BINDING DOMAIN; CELL BIOLOGY	We have demonstrated previously that c-Cbl requires the presence of a functional ubiquitin interacting motif (UIM) in Eps15 to mediate epidermal growth factor receptor ( EGFR) endocytosis. Both the ubiquitin ligase activity of c-Cbl and the UIM of Eps15 were necessary for plasma membrane recruitment of Eps15 and entry of ligand-bound EGFR into coated pits and vesicles containing Eps15. This is consistent with a scenario in which ubiquitin moieties appended to activated EGFR complexes act as docking sites for Eps15 and thereby recruit receptors into clathrin coated pits. Here, we have investigated which additional structural features of c-Cbl are required for this process. We find that c-Cbl can guide ligand-bound EGFR into the Eps15 internalization route by two distinct mechanisms. These are either dependent on the phosphotyrosine binding domain of c-Cbl that directly binds to the EGFR or on the region C-terminal of the Ring finger, which allows for indirect binding to an alternative site on the receptor. No strict requirement exists for either ubiquitin modified EGFR or the Cbl binding ubiquitination substrate CIN85 as docking site for the UIM of Eps15. Only in the phosphotyrosine binding-dependent pathway, the EGFR is ubiquitinated and may serve as a site of recruitment for Eps15. Only in this pathway, Eps15 is tyrosine-phosphorylated, but this appears unrelated to its capacity to participate in EGFR internalization.	Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl	Borst, Jan Willem/B-1259-2011					Belleudi F, 2003, FEBS LETT, V553, P262, DOI 10.1016/S0014-5793(03)01020-2; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; BLAKE TJ, 1991, ONCOGENE, V6, P653; Carbone R, 1997, CANCER RES, V57, P5498; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; de Melker AA, 2004, J CELL SCI, V117, P5001, DOI 10.1242/jcs.01354; de Melker AA, 2001, J CELL SCI, V114, P2167; Dikic I, 2003, CELL MOL LIFE SCI, V60, P1805, DOI 10.1007/s00018-003-3029-4; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feshchenko EA, 2004, ONCOGENE, V23, P4690, DOI 10.1038/sj.onc.1207627; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Morgan JR, 2003, J BIOL CHEM, V278, P33583, DOI 10.1074/jbc.M304346200; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Riezman H, 2002, NATURE, V416, P381, DOI 10.1038/416381a; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Sorkina T, 1999, J CELL SCI, V112, P317; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	63	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55465	55473		10.1074/jbc.M409765200	http://dx.doi.org/10.1074/jbc.M409765200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15465819	hybrid			2022-12-25	WOS:000225960800061
J	Ananthanarayanan, M; Li, SD; Balasubramaniyan, N; Suchy, FJ; Walsh, MJ				Ananthanarayanan, M; Li, SD; Balasubramaniyan, N; Suchy, FJ; Walsh, MJ			Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; PROTEIN METHYLTRANSFERASE; COACTIVATOR; CHROMATIN; GENE; ACID; ENHANCEMENT; ACETYLATION; REQUIREMENT; MODULATION	In this study we demonstrate that the class II nuclear hormone receptor, farnesoid X-receptor (FXR), incorporates histone methyltransferase activity within the gene locus for bile salt export pump (BSEP), a well established FXR target gene that functions as an ATP-dependent canalicular bile acid transporter. This methyltransferase activity is directed specifically to arginine 17 of histone H3. We demonstrate that FXR is directly associated with (c) under baro-activator- (a) under bar ssociated (a) under bar rginine (m) under bar ethyltransferase 1 (CARM1) activity. Furthermore, we show by chromatin immunoprecipitation that the ligand-dependent activation of the human BSEP locus is associated with a simultaneous increase of FXR and CARM1 occupation. The increased occupation of the BSEP locus by CARM1 also corresponds with the increased deposition of Arg-17 methylation and Lys-9 acetylation of histone H3 within the FXR DNA-binding element of BSEP. Consistent with these findings, CARM1 led to increased BSEP promoter activity with an intact FXR regulatory element, whereas CARM1 failed to transactivate the BSEP promoter with a mutated FXRE. Induction of endogenous BSEP mRNA and Arg-17 methylation by FXR regulatory element ligand, CDCA, requires CARM1 activity. Therefore, histone methylation at Arg-17 by CARM1 is a downstream target of signaling through ligand-mediated activation of FXR. Our studies provide evidence that FXR directly recruits specific chromatin modifying activity of CARM1 necessary for full potentiation of the BSEP locus in vivo.	Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Pediat, New York, NY 10027 USA	Icahn School of Medicine at Mount Sinai	Ananthanarayanan, M (corresponding author), Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Pediat, Box 1664,1 Gustave L Levy Pl, New York, NY 10027 USA.	meena.ananth@mssm.edu; martin.walsh@mssm.edu			NHLBI NIH HHS [HL67099] Funding Source: Medline; NICHD NIH HHS [HD20632] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020632, R37HD020632] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067099] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; Fitzgerald ML, 2002, J MOL MED, V80, P271, DOI 10.1007/s00109-001-0318-y; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Grant PA, 2001, GENOME BIOL, V2; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Lee KC, 2001, TRENDS ENDOCRIN MET, V12, P191, DOI 10.1016/S1043-2760(01)00392-7; Lee YH, 2004, MOL CELL BIOL, V24, P2103, DOI 10.1128/MCB.24.5.2103-2117.2004; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Plass JRM, 2002, HEPATOLOGY, V35, P589, DOI 10.1053/jhep.2002.31724; Redinger RN, 2003, AM J SURG, V185, P168, DOI 10.1016/S0002-9610(02)01212-6; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Sedkov Y, 2003, NATURE, V426, P78, DOI 10.1038/nature02080; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Teyssier C, 2002, J BIOL CHEM, V277, P46066, DOI 10.1074/jbc.M207623200; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; Wagner M, 2003, GASTROENTEROLOGY, V125, P825, DOI 10.1016/S0016-5085(03)01068-0; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wang LH, 2004, NAT MED, V10, P40, DOI 10.1038/nm969; Xu W, 2003, METHOD ENZYMOL, V364, P205; Zollner G, 2003, J HEPATOL, V39, P480, DOI 10.1016/S0168-8278(03)00228-9	37	57	59	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54348	54357		10.1074/jbc.M410021200	http://dx.doi.org/10.1074/jbc.M410021200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471871	hybrid			2022-12-25	WOS:000225793600057
J	Hu, YM; Leo, C; Yu, S; Huang, BCB; Wang, H; Shen, M; Luo, Y; Daniel-Issakani, S; Payan, DG; Xu, X				Hu, YM; Leo, C; Yu, S; Huang, BCB; Wang, H; Shen, M; Luo, Y; Daniel-Issakani, S; Payan, DG; Xu, X			Identification and functional characterization of a novel human Misshapen/Nck interacting kinase-related kinase, hMINK beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; MOLECULAR-CLONING; CELL-SURFACE; PATHWAY; NCK; ADAPTER; RECEPTOR; FAMILY	Misshapen/NIKs-related kinase (MINK) is a member of the germinal center family of kinases that are homologous to the yeast sterile 20 (Ste20) kinases and regulate a wide variety of cellular processes, including cell morphology, cytoskeletal rearrangement, and survival. Here, we present the cloning and functional characterization of a novel human Misshapen/NIKs-related kinase beta (hMINKbeta) that encodes a polypeptide of 1312 amino acids. hMINKbeta is ubiquitously expressed in most tissues with at least five alternatively spliced isoforms. Similar to Nck interacting kinase (NIK) and Traf2 and Nck-interacting kinase (TNIK), hMINKbeta moderately activates c-Jun N-terminal kinase (JNK) and associates with Nck via the intermediate domain in the yeast two-hybrid system and in a glutathione S-transferase (GST) pull-down assay. Interestingly, overexpression of the kinase domain deleted and kinase-inactive mutants of hMINKbeta in human fibrosarcoma HT1080 cells enhanced cell spreading, actin stress fiber formation, and adhesion to extracellular matrix, as well as decreased cell motility and cell invasion. Furthermore, these mutants also promoted cell-cell adhesion in human breast carcinoma MCF7 cells, evidenced with cell growth in clusters and increased membrane localization of beta-catenin, a multifunctional protein involved in E-cadherin-mediated cell adhesion. Finally, hMINKbeta protein was found to colocalize with the Golgi apparatus, implicating that hMINKbeta might exert its functions, at least in part, through the modulation of intracellular protein transport. Taken together, these results suggest that hMINKbeta plays an important role in cytoskeleton reorganization, cell adhesion, and cell motility.	Rigel Pharmaceut Inc, San Francisco, CA 94080 USA		Xu, X (corresponding author), Rigel Pharmaceut Inc, San Francisco, CA 94080 USA.	xxu@rigel.com						Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; Caplan S, 2001, J CELL BIOL, V154, P109, DOI 10.1083/jcb.200102142; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COLIGAN JE, 1999, CURR PROTOCOLS IMM S, V31; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; GRENZ H, 1993, J CELL SCI, V105, P739; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Gupta S, 2000, MOL CELL BIOL, V20, P9294, DOI 10.1128/MCB.20.24.9294-9306.2000; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Klingelhofer J, 2003, ONCOGENE, V22, P1181, DOI 10.1038/sj.onc.1206245; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Machida N, 2004, J BIOL CHEM, V279, P15711, DOI 10.1074/jbc.C300542200; Paricio N, 1999, EMBO J, V18, P4669, DOI 10.1093/emboj/18.17.4669; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Poinat P, 2002, CURR BIOL, V12, P622, DOI 10.1016/S0960-9822(02)00764-9; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Qu KB, 2004, CURR MED CHEM, V11, P569, DOI 10.2174/0929867043455873; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Rivera GM, 2004, CURR BIOL, V14, P11, DOI 10.1016/j.cub.2003.12.033; Ruan WJ, 1999, NEURON, V24, P595, DOI 10.1016/S0896-6273(00)81115-0; Shi CS, 1999, J IMMUNOL, V163, P3279; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Su YC, 2000, MOL CELL BIOL, V20, P4736, DOI 10.1128/MCB.20.13.4736-4744.2000; Wright JH, 2003, MOL CELL BIOL, V23, P2068, DOI 10.1128/MCB.23.6.2068-2082.2003; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717; Xue YZ, 2001, DEVELOPMENT, V128, P1559; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	42	46	51	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54387	54397		10.1074/jbc.M404497200	http://dx.doi.org/10.1074/jbc.M404497200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15469942	hybrid			2022-12-25	WOS:000225793600061
J	Pearce, AC; Senis, YA; Billadeau, DD; Turner, M; Watson, SP; Vigorito, E				Pearce, AC; Senis, YA; Billadeau, DD; Turner, M; Watson, SP; Vigorito, E			Vav1 and Vav3 have critical but redundant roles in mediating platelet activation by collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; EXCHANGE FACTOR VAV; TYROSINE PHOSPHORYLATION; GAMMA-CHAIN; DIFFERENTIAL REQUIREMENT; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; GLYCOPROTEIN-VI; DEFICIENT MICE; FAMILY	Vav family proteins are guanine nucleotide exchange factors for the Rho/Rac family of small GTP-binding proteins. In addition, they have domains that mediate protein-protein interactions, including one Src homology 2 (SH2) and two Src homology 3 (SH3) domains. Vav1, Vav2, and Vav3 play a crucial role in the regulation of phospholipase Cgamma (PLCgamma) isoforms by immuno-tyrosine-based activation motif (ITAM)-coupled receptors, including the T- and B-cell antigen receptors. We have reported in platelets, however, that Vav1 and Vav2 are not required for activation of PLCgamma2 in response to stimulation of the ITAM-coupled collagen receptor glycoprotein VI (GPVI). Here we report that Vav3 is tyrosine-phosphorylated upon activation of GPVI but that Vav3-deficient platelets also exhibit a normal response upon activation of the ITAM receptor. In sharp contrast, platelets deficient in both Vav1 and Vav3 show a marked inhibition of aggregation and spreading upon activation of GPVI, which is associated with a reduction in tyrosine phosphorylation of PLCgamma2. The phenotype of Vav1/2/3 triple-deficient platelets is similar to that of Vav1/3 double-deficient cells. These results demonstrate that Vav3 and Vav1 play crucial but redundant roles in the activation of PLCgamma2 by GPVI. This is the first time that absolute redundancy between two protein isoforms has been observed with respect to the regulation of PLCgamma2 in platelets.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Babraham Inst, Lab Lymphocyte Signalling & Dev, Mol Immunol Programme, Cambridge CB2 4AT, England; Mayo Clin, Dept Immunol, Mayo Grad Sch, Rochester, MN 55905 USA; Univ Birmingham, Ctr Cardiovasc Studies, Inst Biomed Res, Div Med Sci, Birmingham B15 2TT, W Midlands, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Mayo Clinic; University of Birmingham	Pearce, AC (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	a.c.pearce@bham.ac.uk	Senis, Yotis/AAD-7183-2021; Watson, Stephen P/Q-6292-2016; Turner, Martin/N-9976-2014	Watson, Stephen P/0000-0002-7846-7423; Turner, Martin/0000-0002-3801-9896; Senis, Yotis/0000-0002-0947-9957	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000M050] Funding Source: Medline; Medical Research Council [G117/424] Funding Source: Medline; MRC [G117/424] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abtahian F, 2003, SCIENCE, V299, P247, DOI 10.1126/science.1079477; Atkinson BT, 2003, BLOOD, V102, P3592, DOI 10.1182/blood-2003-04-1142; Best D, 2003, BLOOD, V102, P2811, DOI 10.1182/blood-2003-01-0231; Billadeau DD, 2000, J EXP MED, V192, P381, DOI 10.1084/jem.192.3.381; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gulbranson-Judge A, 1999, EUR J IMMUNOL, V29, P477, DOI 10.1002/(SICI)1521-4141(199902)29:02&lt;477::AID-IMMU477&gt;3.0.CO;2-V; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Judd BA, 2002, J EXP MED, V195, P705, DOI 10.1084/jem.20011583; Judd BA, 2001, ONCOGENE, V20, P6291, DOI 10.1038/sj.onc.1204772; Kato K, 2003, BLOOD, V102, P1701, DOI 10.1182/blood-2003-03-0717; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Mangin P, 2003, FEBS LETT, V542, P53, DOI 10.1016/S0014-5793(03)00337-5; Movilla N, 1999, MOL CELL BIOL, V19, P7870; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; Pearce AC, 2003, BLOOD, V102, p208A; Pearce AC, 2002, BLOOD, V100, P3561, DOI 10.1182/blood.V100.10.3561; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Quek LS, 2000, BLOOD, V96, P4246; Reynolds LF, 2004, J BIOL CHEM, V279, P18239, DOI 10.1074/jbc.M400257200; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Suzuki-Inoue K, 2003, BLOOD, V102, P1367, DOI 10.1182/blood-2003-01-0029; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; WENG WK, 1994, J BIOL CHEM, V269, P32514	40	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53955	53962		10.1074/jbc.M410355200	http://dx.doi.org/10.1074/jbc.M410355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15456756	hybrid			2022-12-25	WOS:000225793600009
J	Carter, S; Urbe, S; Clague, MJ				Carter, S; Urbe, S; Clague, MJ			The Met receptor degradation pathway - Requirement for Lys(48)-linked polyubiquitin independent of proteasome activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; UBIQUITIN-BINDING; HUMAN CANCER; DYNAMICS; PROTEINS; MUTATION; ENDOCYTOSIS; EXPRESSION; TRANSPORT	Acute stimulation of the receptor for the hepatocyte growth factor/scatter factor Met leads to receptor ubiquitination and down-regulation through the lysosomal degradation pathway. We have determined that the Met receptor undergoes multiple monoubiquitination as opposed to the appendage of polyubiquitin chains. Nevertheless, overexpression of ubiquitin in HEK293T cells enhances the rate of Met receptor degradation, in contrast to a point mutant of ubiquitin (K48R) that cannot form Lys(48)-linked polyubiquitin chains. Furthermore, an enhancement of Met degradation is also seen under conditions where the proteasome is inhibited by lactacystin. We propose that this reflects polyubiquitin-dependent sorting of Met, as the overexpression of ubiquitin but not K48R ubiquitin also restores hepatocyte growth factor-dependent phosphorylation of the endosomal coat protein Hrs from inhibition by lactacystin. Our data indicate a requirement for K48-R-linked polyubiquitin for Met endosomal trafficking independent of its canonical function of targeting for proteasomal degradation.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Clague, MJ (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	clague@liv.ac.uk	Clague, Michael J/A-7199-2008	Clague, Michael J/0000-0003-3355-9479; Urbe, Sylvie/0000-0003-4735-9814				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Colledge M, 2003, NEURON, V40, P595, DOI 10.1016/S0896-6273(03)00687-1; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; HAAS AL, 1987, J BIOL CHEM, V262, P345; Haddad R, 2001, ANTICANCER RES, V21, P4243; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hammond DE, 2004, CURR TOP MICROBIOL, V286, P21; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; POLO S, 2003, SCI STKE; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; Tsirigotis M, 2001, J BIOL CHEM, V276, P46073, DOI 10.1074/jbc.M109023200; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169	31	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52835	52839		10.1074/jbc.M407769200	http://dx.doi.org/10.1074/jbc.M407769200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466866	hybrid			2022-12-25	WOS:000225680600007
J	Lovmar, M; Tenson, T; Ehrenberg, M				Lovmar, M; Tenson, T; Ehrenberg, M			Kinetics of macrolide action - The josamycin and erythromycin cases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BOND FORMATION; CELL-FREE SYSTEMS; RIBOSOMAL COMPLEX; TRANSFER-RNA; STRUCTURAL BASIS; POLYPEPTIDE-SYNTHESIS; BACTERIAL-RIBOSOMES; PROTEIN-SYNTHESIS; VIRGINIAMYCIN-S; ANTIBIOTICS	Members of the macrolide class of antibiotics inhibit peptide elongation on the ribosome by binding close to the peptidyltransferase center and blocking the peptide exit tunnel in the large ribosomal subunit. We have studied the modes of action of the macrolides josamycin, with a 16-membered lactone ring, and erythromycin, with a 14-membered lactone ring, in a cell-free mRNA translation system with pure components from Escherichia coli. We have found that the average lifetime on the ribosome is 3 h for josamycin and less than 2 min for erythromycin and that the dissociation constants for josamycin and erythromycin binding to the ribosome are 5.5 and 11 nM, respectively. Josamycin slows down formation of the first peptide bond of a nascent peptide in an amino acid-dependent way and completely inhibits formation of the second or third peptide bond, depending on peptide sequence. Erythromycin allows formation of longer peptide chains before the onset of inhibition. Both drugs stimulate the rate constants for drop-off of peptidyl-tRNA from the ribosome. In the josamycin case, drop-off is much faster than drug dissociation, whereas these rate constants are comparable in the erythromycin case. Therefore, at a saturating drug concentration, synthesis of full-length proteins is completely shut down by josamycin but not by erythromycin. It is likely that the bacteriotoxic effects of the drugs are caused by a combination of inhibition of protein elongation, on the one hand, and depletion of the intracellular pools of aminoacyl-tRNAs available for protein synthesis by drop-off and incomplete peptidyl-tRNA hydrolase activity, on the other hand.	Uppsala Univ, BMC, Program Mol Biol, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Univ Tartu, Inst Technol, EE-51010 Tartu, Estonia	Uppsala University; University of Tartu	Ehrenberg, M (corresponding author), Uppsala Univ, BMC, Program Mol Biol, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.	ehrenberg@xray.bmc.uu.se	Tenson, Tanel/I-6431-2015	Tenson, Tanel/0000-0002-0260-3601				ANDERSSON S, 1987, BIOCHIMIE, V69, P901, DOI 10.1016/0300-9084(87)90218-5; ANTOUN A, 2004, BIOL PROCED ONLINE; Berisio R, 2003, J BACTERIOL, V185, P4276, DOI 10.1128/JB.185.14.4276-4279.2003; Berisio R, 2003, NAT STRUCT BIOL, V10, P366, DOI 10.1038/nsb915; BRENNAN RJ, 1994, J CHEM SOC CHEM COMM, P1615, DOI 10.1039/c39940001615; CHINALI G, 1988, BIOCHIM BIOPHYS ACTA, V951, P42, DOI 10.1016/0167-4781(88)90023-1; CHINALI G, 1988, BIOCHIM BIOPHYS ACTA, V949, P71, DOI 10.1016/0167-4781(88)90056-5; CONTRERAS A, 1977, EUR J BIOCHEM, V74, P539, DOI 10.1111/j.1432-1033.1977.tb11422.x; DIGIAMBATTISTA M, 1987, J BIOL CHEM, V262, P8591; DINOS G, 1993, BIOCHEMISTRY-US, V32, P10638, DOI 10.1021/bi00091a014; Dinos GP, 2000, BIOCHEMISTRY-US, V39, P11621, DOI 10.1021/bi000811f; Dinos GP, 2003, MOL PHARMACOL, V63, P617, DOI 10.1124/mol.63.3.617; Dinos GP, 2001, MOL PHARMACOL, V59, P1441, DOI 10.1124/mol.59.6.1441; Ehrenberg M, 1990, RIBOSOMES PROTEIN SY, P101; Elf J, 2003, GENOME RES, V13, P2475, DOI 10.1101/gr.1196503; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Heurgue-Hamard V, 2000, EMBO J, V19, P2701, DOI 10.1093/emboj/19.11.2701; HeurgueHamard V, 1996, EMBO J, V15, P2826, DOI 10.1002/j.1460-2075.1996.tb00643.x; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; MAO JCH, 1968, J BACTERIOL, V95, P1111, DOI 10.1128/JB.95.3.1111-1117.1968; MAO JCH, 1971, BIOCHEMISTRY-US, V10, P2054, DOI 10.1021/bi00787a014; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P441; MENNINGER JR, 1982, ANTIMICROB AGENTS CH, V21, P811, DOI 10.1128/AAC.21.5.811; Moore PB, 2002, NATURE, V418, P229, DOI 10.1038/418229a; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; OTAKA T, 1975, P NATL ACAD SCI USA, V72, P2649, DOI 10.1073/pnas.72.7.2649; Pavlov MY, 1996, ARCH BIOCHEM BIOPHYS, V328, P9, DOI 10.1006/abbi.1996.0136; Petropoulos AD, 2004, J BIOL CHEM, V279, P26518, DOI 10.1074/jbc.M313634200; Poulsen SM, 2000, J MOL BIOL, V304, P471, DOI 10.1006/jmbi.2000.4229; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Schlunzen F, 2003, STRUCTURE, V11, P329, DOI 10.1016/S0969-2126(03)00022-4; Schlunzen F, 2001, NATURE, V413, P814, DOI 10.1038/35101544; Schmeing TM, 2002, NAT STRUCT BIOL, V9, P225, DOI 10.1038/nsb758; Tenson T, 1999, J BACTERIOL, V181, P1617, DOI 10.1128/JB.181.5.1617-1622.1999; Tenson T, 2003, J MOL BIOL, V330, P1005, DOI 10.1016/S0022-2836(03)00662-4; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; VAZQUEZ D, 1979, MOL BIOL BIOCH BIOPH, V30, P169; VESTER B, 1987, BIOCHIMIE, V69, P891, DOI 10.1016/0300-9084(87)90217-3; WALSH C, 2003, ANTIBIOTICS ACTIONS, P57; WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P797, DOI 10.1128/AAC.39.4.797	42	56	69	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53506	53515		10.1074/jbc.M401625200	http://dx.doi.org/10.1074/jbc.M401625200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15385552	hybrid			2022-12-25	WOS:000225680600086
J	Gu, LB; Zhu, NX; Findley, HW; Woods, WG; Xhou, MX				Gu, LB; Zhu, NX; Findley, HW; Woods, WG; Xhou, MX			Identification and characterization of the IKK alpha promoter - Positive and negative regulation by ETS-1 and p53, respectively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; ACUTE LYMPHOBLASTIC-LEUKEMIA; INDUCED APOPTOSIS; GENE-EXPRESSION; DNA-BINDING; KINASE-ALPHA; TRANSCRIPTIONAL REPRESSION	IKKalpha, a subunit of IkBalpha kinase (IKK) complex, has an important role in the activation of nuclear factor-kB (NF-kB), a key regulator of normal and tumor cell proliferation, apoptosis, and response to chemotherapy. However, little is known about the transcriptional regulation of the IKKalpha gene itself. The present study revealed that the transcriptional induction of the IKKalpha gene is positively regulated by binding ETS-1, the protein product of the ETS-1 proto-oncogene. Furthermore, ETS-1 mediated activation of IKKalpha is negatively regulated by p53 binding to ETS-1. By analyzing the genomic DNA sequence, we identified the putative IKKalpha promoter sequence in the 5'-flanking untranslated region of the IKKalpha gene. Transfection of EU-4, an acute lymphoblastic leukemia (ALL) cell line, with plasmids containing the IKKalpha 5'-untranslated region sequence upstream of the luciferase reporter showed that this region possessed major promoter activity. Induction or enforced overexpression of p53 represses IKKalpha mRNA and protein expression as well as IKKalpha promoter activity. Deletion and mutation analyses as well as chromatin immunoprecipitation and electrophoretic mobility shift assay indicated that ETS-1 binds to the core IKKalpha promoter and strongly induces its activity. Although p53 does not directly bind to the IKKalpha promoter, it physically interacts with ETS-1 and specifically inhibits ETS-1-induced IKKalpha promoter activity. These results suggest that the proximal 5'-flanking region of the IKKalpha gene contains a functional promoter reciprocally regulated by p53 and ETS-1. Furthermore, loss of p53-mediated control over ETS-1-dependent transactivation of IKKalpha may represent a novel pathway for the constitutive activation of NF-kB-mediated gene expression and therapy resistance in cancer.	Emory Univ, Sch Med, Div Pediat Hematol Oncol BMT, Dept Pediat, Atlanta, GA 30322 USA	Emory University	Xhou, MX (corresponding author), Emory Univ, Sch Med, Div Pediat Hematol Oncol BMT, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	mzhou@emory.edu			NCI NIH HHS [R01 CA82323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FISHER RJ, 1991, ONCOGENE, V6, P2249; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Post A, 1998, J NEUROSCI, V18, P8236; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VAN AD, 1996, SCIENCE, V274, P787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao CW, 2001, ENDOCRINOLOGY, V142, P557, DOI 10.1210/en.142.2.557; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	52	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52141	52149		10.1074/jbc.M407915200	http://dx.doi.org/10.1074/jbc.M407915200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15469934	hybrid			2022-12-25	WOS:000225493400053
J	Lee, CY; Bai, HB; Houle, R; Wilson, GM; Lu, AL				Lee, CY; Bai, HB; Houle, R; Wilson, GM; Lu, AL			An Escherichia coli MutY mutant without the six-helix barrel domain is a dimer in solution and assembles cooperatively into multisubunit complexes with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; MISMATCH REPAIR; STRUCTURAL BASIS; DAMAGED BASE; GLYCOSYLASE; ADENINE; 8-OXOGUANINE; RECOGNITION; SPECIFICITY; MUTAGENESIS	Escherichia coli MutY is an adenine and weak guanine DNA glycosylase involved in reducing the mutagenic effects of 7,8-dihydro-8-oxoguanine (GO). MutY contains three structural domains: an iron-sulfur module, a six-helix barrel module with the helix-hairpin-helix motif, and a C-terminal domain. Here, we demonstrate that the mutant MutY(Delta26-134), which lacks the six-helix barrel domain, cannot complement the mutator phenotype of a mutY mutant in vivo. However, the mutant can still bind DNA and has weak catalytic activity at high enzyme concentrations. The mutant is a dimer in solution and assembled into two and multiple (up to five) complexes with 20- and 44-bp DNA fragments, respectively, in a concentration-dependent manner. Higher order complexes with DNA substrates containing A/GO mismatches were formed at lower protein concentrations than with the A/G mismatch and homoduplex DNA. Measurement of equilibrium binding using fluorescence anisotropy showed that the mutant protein retains some specificity for A/GO-containing DNA substrates and that the binding event is highly cooperative. This is consistent with the MutY structure determined, which indicates that GO specificity is contributed by both the six-helix barrel and C-terminal domains. The nonspecific binding of MutY(Delta26-134) to DNA suggests a model in which the specific binding of mismatched DNA by MutY involves sequential interactions, in which one MutY molecule scans the DNA and enhances binding of another MutY molecule to the A/GO mismatch.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Combined PhD Program Biochem, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Fluorescence Sepct, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	aluchang@umaryland.edu	Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507	NCI NIH HHS [CA102428] Funding Source: Medline; NCRR NIH HHS [P41 RR 08119] Funding Source: Medline; NIGMS NIH HHS [GM35132] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102428, R56CA102428] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breuer W, 2001, ANAL BIOCHEM, V299, P194, DOI 10.1006/abio.2001.5378; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Dandliker W B, 1981, Methods Enzymol, V74 Pt C, P3; Fromme JC, 2004, NATURE, V427, P652, DOI 10.1038/nature02306; Fromme JC, 2003, EMBO J, V22, P3461, DOI 10.1093/emboj/cdg311; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; Li L, 2003, NUCLEIC ACIDS RES, V31, P3038, DOI 10.1093/nar/gkg434; Li XH, 2000, J BIOL CHEM, V275, P8448, DOI 10.1074/jbc.275.12.8448; Lu AL, 2003, BIOCHEMISTRY-US, V42, P3742, DOI 10.1021/bi0269198; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; Lu AL, 2000, METH MOL B, V152, P3; Lu AL, 2001, CELL BIOCHEM BIOPHYS, V35, P141, DOI 10.1385/CBB:35:2:141; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Norman DG, 2000, BIOCHEMISTRY-US, V39, P6317, DOI 10.1021/bi992944a; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; VANHOLDE KE, 1998, PRINCIPLES PHYSICAL, P216; Volk DE, 2000, BIOCHEMISTRY-US, V39, P7331, DOI 10.1021/bi000416p; WEBER G, 1952, BIOCHEM J, V51, P155, DOI 10.1042/bj0510155; Williams SD, 1999, BIOCHEMISTRY-US, V38, P15417, DOI 10.1021/bi992013z; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Wong I, 2003, J BIOL CHEM, V278, P2411, DOI 10.1074/jbc.M209802200; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Wright PM, 1999, J BIOL CHEM, V274, P29011, DOI 10.1074/jbc.274.41.29011; Zhang QM, 1998, NUCLEIC ACIDS RES, V26, P4669, DOI 10.1093/nar/26.20.4669; Zhao JY, 2000, J BACTERIOL, V182, P5025, DOI 10.1128/JB.182.17.5025-5028.2000; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 2000, BIOCHEMISTRY-US, V39, P14768, DOI 10.1021/bi001538k	53	13	14	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52653	52663		10.1074/jbc.M405271200	http://dx.doi.org/10.1074/jbc.M405271200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456766	hybrid			2022-12-25	WOS:000225493400112
J	Pacheco-Alvarez, D; Solorzano-Vargas, RS; Gravel, RA; Cervantes-Roldan, R; Velazquez, A; Leon-Del-Rio, A				Pacheco-Alvarez, D; Solorzano-Vargas, RS; Gravel, RA; Cervantes-Roldan, R; Velazquez, A; Leon-Del-Rio, A			Paradoxical regulation of biotin utilization in brain and liver and implications for inherited multiple carboxylase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONYL-COA CARBOXYLASE; HOLOCARBOXYLASE SYNTHETASE; PYRUVATE-CARBOXYLASE; MESSENGER-RNA; FUNCTIONAL EXPRESSION; GUANYLATE-CYCLASE; RAT-LIVER; BIOTINYLATION; CELLS; GLUCOKINASE	Holocarboxylase synthetase (HCS) catalyzes the biotinylation of five carboxylases in human cells, and mutations of HCS cause multiple carboxylase deficiency (MCD). Although HCS also participates in the regulation of its own mRNA levels, the relevance of this mechanism to normal metabolism or to the MCD phenotype is not known. In this study, we show that mRNA levels of enzymes involved in biotin utilization, including HCS, are down-regulated during biotin deficiency in liver while remaining constitutively expressed in brain. We propose that this mechanism of regulation is aimed at sparing the essential function of biotin in the brain at the expense of organs such as liver and kidney during biotin deprivation. In MCD, it is possible that some of the manifestations of the disease may be associated with down-regulation of biotin utilization in liver because of the impaired activity of HCS and that high dose biotin therapy may in part be important to overcoming the adverse regulatory impact in such organs.	Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Biol Mol & Biotecnol, Mexico City 04510, DF, Mexico; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Unidad Genet Nutr, Mexico City 04530, DF, Mexico	Universidad Nacional Autonoma de Mexico; University of Calgary; Universidad Nacional Autonoma de Mexico	Leon-Del-Rio, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Biol Mol & Biotecnol, Mexico City 04510, DF, Mexico.	leon@biomedicas.unam.mx	Solorzano-Vargas, R Sergio/D-4869-2016; Leon-Del-Rio, Alfonso/L-5932-2019	Leon-Del-Rio, Alfonso/0000-0001-7683-5109; Pacheco-Alvarez, Diana/0000-0001-5454-9267				Balamurugan K, 2003, AM J PHYSIOL-GASTR L, V285, pG73, DOI 10.1152/ajpgi.00059.2003; BHAGAVAN HN, 1970, J NEUROCHEM, V17, P289, DOI 10.1111/j.1471-4159.1970.tb02213.x; Borboni P, 1996, ACTA DIABETOL, V33, P154; BOWERSKOMRO DM, 1984, NUTR REV, V42, P360; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; CHAUHAN J, 1991, J BIOL CHEM, V266, P10035; CHIANG GS, 1974, P SOC EXP BIOL MED, V146, P21, DOI 10.3181/00379727-146-38035; COLLINS JC, 1988, J BIOL CHEM, V263, P11280; DAKSHINAMURTI K, 1970, CAN J BIOCHEM CELL B, V48, P493, DOI 10.1139/o70-079; Das UG, 1999, AM J PHYSIOL-REG I, V276, pR809, DOI 10.1152/ajpregu.1999.276.3.R809; De la Vega LA, 2000, AM J PHYSIOL-CELL PH, V279, pC2037, DOI 10.1152/ajpcell.2000.279.6.C2037; DEODHAR AD, 1970, LIFE SCI 2-BIOCH GEN, V9, P581, DOI 10.1016/0024-3205(70)90166-9; Dupuis L, 1999, MOL GENET METAB, V66, P80, DOI 10.1006/mgme.1998.2785; Hassel B, 2000, MOL NEUROBIOL, V22, P21, DOI 10.1385/MN:22:1-3:021; HYMES J, 1995, BIOCHEM MOL MED, V56, P76, DOI 10.1006/bmme.1995.1059; Hymes J, 1996, CLIN CHIM ACTA, V255, P1, DOI 10.1016/0009-8981(96)06396-6; LEONDELRIO A, 1995, P NATL ACAD SCI USA, V92, P4626, DOI 10.1073/pnas.92.10.4626; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LO W, 1991, J NUTR SCI VITAMINOL, V37, P567, DOI 10.3177/jnsv.37.567; Maeda Y, 1996, J NUTR, V126, P61, DOI 10.1093/jn/126.1.61; Morita J, 1998, MOL GENET METAB, V64, P250, DOI 10.1006/mgme.1998.2700; NARANG MA, 2003, HUM MOL GENET; Pacheco-Alvarez D, 2002, ARCH MED RES, V33, P439, DOI 10.1016/S0188-4409(02)00399-5; PETRELLI F, 1978, MOL BIOL REP, V4, P87, DOI 10.1007/BF00775966; Prasad PD, 1999, ARCH BIOCHEM BIOPHYS, V366, P95, DOI 10.1006/abbi.1999.1213; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; Rodriguez-Melendez R, 2001, J NUTR, V131, P1909, DOI 10.1093/jn/131.7.1909; Rodriguez-Melendez R, 1999, MOL GENET METAB, V66, P16, DOI 10.1006/mgme.1998.2777; RODRIGUEZPOMBO P, 1992, J NEUROCHEM, V58, P1460, DOI 10.1111/j.1471-4159.1992.tb11364.x; Salto R, 1999, MOL CELL BIOCHEM, V200, P111, DOI 10.1023/A:1007091116952; SANDER JE, 1982, NEUROLOGY, V32, P878, DOI 10.1212/WNL.32.8.878; SINGH IN, 1988, MOL CELL BIOCHEM, V79, P47, DOI 10.1007/BF00229397; Solorzano-Vargas RS, 2002, P NATL ACAD SCI USA, V99, P5325, DOI 10.1073/pnas.082097699; SPENCE JT, 1984, J BIOL CHEM, V259, P6393; Stanley JS, 2001, EUR J BIOCHEM, V268, P5424, DOI 10.1046/j.0014-2956.2001.02481.x; Suormala T, 2002, INT J VITAM NUTR RES, V72, P278, DOI 10.1024/0300-9831.72.4.278; VESELY DL, 1982, SCIENCE, V216, P1329, DOI 10.1126/science.6123152; Wang HP, 1999, J BIOL CHEM, V274, P14875, DOI 10.1074/jbc.274.21.14875; Watson RT, 2001, RECENT PROG HORM RES, V56, P175, DOI 10.1210/rp.56.1.175; WEINER D, 1991, BIOCHEM MED METAB B, V46, P344, DOI 10.1016/0885-4505(91)90083-W; WOLF B, 1985, J INHERIT METAB DIS, V8, P53, DOI 10.1007/BF01800660; Wolf B., 2001, METABOLIC MOL BASES, V3935, P3962, DOI DOI 10.1097/MAO.0000000000002044; Zempleni J, 1999, ARCH BIOCHEM BIOPHYS, V371, P83, DOI 10.1006/abbi.1999.1431	43	33	36	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52312	52318		10.1074/jbc.M407056200	http://dx.doi.org/10.1074/jbc.M407056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456772	hybrid			2022-12-25	WOS:000225493400072
J	Peng, JM; Liang, SM; Liang, CM				Peng, JM; Liang, SM; Liang, CM			VP1 of foot-and-mouth disease virus induces apoptosis via the Akt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; MUSCLE-CELLS; ACTIVATION; RECEPTOR; CANCER; ATTACHMENT; INHIBITION	Foot-and-mouth disease virus (FMDV) binds to cellular integrins through an RGD motif in its capsid protein, VP1. It is unclear, however, what kind of cellular event(s) are triggered after the binding of VP1 to the cells. In this study, we show that aqueous soluble recombinant DNA-derived VP1 (rVP1) of FMDV induced apoptosis of BHK-21 cells after binding to integrins. In addition, treatment of BHK-21 cells with rVP1 resulted in deactivation of Akt and enhancement of several proapoptotic responses such as dephosphorylation of glycogen synthase kinase-3beta and cleavage of procaspase-3, -7, and -9. Additional studies revealed that the rVP1 treatment caused apoptosis of cancer cells, including MCF-7 (a breast carcinoma cell line with a functional deletion of the caspase-3 gene) and PC-3 (a sphingosine 1-phosphate receptor subtype 3-deficient androgen-independent prostate cancer cell line). These results suggest that rVP1 of FMDV may be used selectively as a potent apoptotic agent for human cancer by modulating the Akt signaling pathway and that its effect is not primarily dependent on either activation of procaspase-3 or deactivation of sphingosine 1-phosphate receptor subtype 3.	Acad Sinica, Inst Bioagr Sci, Taipei 11529, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan	Liang, SM (corresponding author), Acad Sinica, Inst Bioagr Sci, No 128,Acad Rd,Sect 2, Taipei 11529, Taiwan.	smyang@gate.sinica.edu.tw; cmliang@gate.sinica.edu.tw		Liang, Shu-Mei/0000-0001-8926-4747				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; Baudhuin LM, 2003, FASEB J, V17, P341, DOI 10.1096/fj.03-0302fje; BAXT B, 1984, J VIROL, V51, P298, DOI 10.1128/JVI.51.2.298-305.1984; Bayry J, 1999, MICROBIOL IMMUNOL, V43, P765, DOI 10.1111/j.1348-0421.1999.tb02468.x; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BELSHAM GJ, 1993, PROG BIOPHYS MOL BIO, V60, P241, DOI 10.1016/0079-6107(93)90016-D; Benetti L, 2003, J VIROL, V77, P6567, DOI 10.1128/JVI.77.11.6567-6573.2003; Brognard J, 2001, CANCER RES, V61, P3986; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DU ZJ, 1995, BIOTECHNIQUES, V18, P376; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jackson T, 2000, J GEN VIROL, V81, P1383, DOI 10.1099/0022-1317-81-5-1383; Jackson T, 2002, J VIROL, V76, P935, DOI 10.1128/JVI.76.3.935-941.2002; Jackson T, 2000, J VIROL, V74, P4949, DOI 10.1128/JVI.74.11.4949-4956.2000; Kiaris H, 1999, P SOC EXP BIOL MED, V221, P87, DOI 10.1046/j.1525-1373.1999.d01-59.x; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Li MO, 2003, SCIENCE, V302, P1560, DOI 10.1126/science.1087621; Loberg RD, 2002, J BIOL CHEM, V277, P41667, DOI 10.1074/jbc.M206405200; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Mateu MG, 1996, J BIOL CHEM, V271, P12814, DOI 10.1074/jbc.271.22.12814; Nishida K, 2004, J HISTOCHEM CYTOCHEM, V52, P843, DOI 10.1369/jhc.4C6315.2004; Patil PK, 2002, VACCINE, V20, P1163, DOI 10.1016/S0264-410X(01)00431-5; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; ROIVAINEN M, 1991, J VIROL, V65, P4735, DOI 10.1128/JVI.65.9.4735-4740.1991; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Ruoslahti E, 2003, MATRIX BIOL, V22, P459, DOI 10.1016/S0945-053X(03)00083-0; SaCarvalho D, 1997, J VIROL, V71, P5115, DOI 10.1128/JVI.71.7.5115-5123.1997; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shieh JJ, 2001, VACCINE, V19, P4002, DOI 10.1016/S0264-410X(01)00114-1; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; STANWAY G, 1994, J VIROL, V68, P8232, DOI 10.1128/JVI.68.12.8232-8238.1994; Stoeltzing O, 2003, INT J CANCER, V104, P496, DOI 10.1002/ijc.10958; SUROVOI AY, 1988, SOVIET J BIOORG CHEM, V14, P965; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; Wang JH, 2003, VACCINE, V21, P3721, DOI 10.1016/S0264-410X(03)00363-3; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Woolhouse M, 2001, NATURE, V411, P258, DOI 10.1038/35077149; Wu WH, 2000, J BIOL CHEM, V275, P40113, DOI 10.1074/jbc.M004108200; Zhang HFM, 2003, J BIOL CHEM, V278, P33011, DOI 10.1074/jbc.M305352200	56	42	54	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52168	52174		10.1074/jbc.M403686200	http://dx.doi.org/10.1074/jbc.M403686200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466859	hybrid			2022-12-25	WOS:000225493400056
J	Rose, A; Froment, P; Perrot, V; Quon, MJ; LeRoith, D; Dupont, J				Rose, A; Froment, P; Perrot, V; Quon, MJ; LeRoith, D; Dupont, J			The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary alpha T3 cells by protein kinase C alpha-mediated negative regulation of Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PLECKSTRIN HOMOLOGY DOMAIN; GENE-EXPRESSION; IGF-I; PROSTATE-CANCER; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; COUPLED RECEPTORS; TRANSGENIC MICE	The luteinizing hormone-releasing hormone (LHRH) receptor is a G protein-coupled receptor involved in the synthesis and release of pituitary gonadotropins and in the proliferation and apoptosis of pituitary cells. Insulinlike growth factor-1 receptor (IGF-1R) is a tyrosine kinase receptor that has a mitogenic effect on pituitary cells. In this study, we used the alphaT3 gonadotrope cell line as a model to characterize the IGF-1R signaling pathways and to investigate whether this receptor interacts with the LHRH cascade. We found that IGF-1 activated the IGF-1R, insulin receptor substrate (IRS)-1, phosphatidylinositol 3-kinase, and Akt in a time-dependent manner in alphaT3 cells. The MAPK (ERK1/2, p38, and JNK) pathways were only weakly activated by IGF-1. In contrast, LHRH strongly stimulated the MAPK pathways but had no effect on Akt activation. Cotreatment with IGF-1 and LHRH had various effects on these signaling pathways. 1) It strongly increased IGF-1-induced tyrosine phosphorylation of IRS-1 and IRS-1-associated phosphatidylinositol 3-kinase through activation of the epidermal growth factor receptor. 2) It had an additive effect on ERK1/2 activation without modifying the phosphorylation of p38 and JNK1/2. 3) It strongly reduced IGF-1 activation of Akt. 3-(4,5-Dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide assays and cell cycle analysis revealed that, in addition to having an additive effect on ERK1/2 activation, cotreatment with IGF-1 and LHRH also had an additive effect on cell proliferation. The LHRH-induced inhibition of Akt stimulated by IGF-1 was completely blocked by Safingol, a protein kinase C (PKC) alpha-specific inhibitor, and by a dominant negative form of PKCalpha. Finally, we showed that the inhibitory effect of LHRH on IGF-1-induced PKCalpha-mediated Akt activation was associated with a marked reduction in Bad phosphorylation and a substantial decrease in the ability of IGF-1 to rescue alphaT3 cells from apoptosis induced by serum starvation. Our results demonstrate for the first time that several interactions take place between IGF-1 and LHRH receptors in gonadotrope cells.	NCCAM, Diabet Unit, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; INRA, Unite Physiol Reprod & Comportements, F-37380 Nouzilly, France; Univ Lyon 1, UMR INSERM U449 INRA 1235, RTH Laennec, Sch Med, F-69372 Lyon, France; NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; Centre National de la Recherche Scientifique (CNRS); Universite de Tours; INRAE; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite de Franche-Comte; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Dupont, J (corresponding author), INRA, Unite Physiol Reprod & Comportements, F-37380 Nouzilly, France.	jdupont@tours.inra.fr	Quon, Michael/B-1970-2008	QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000002, ZIAAT000002] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Alarid ET, 1996, DEVELOPMENT, V122, P3319; ALBERTI VN, 1991, PATHOL RES PRACT, V187, P541, DOI 10.1016/S0344-0338(11)80138-X; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BACH MA, 1992, ENDOCRINOLOGY, V131, P2588, DOI 10.1210/en.131.6.2588; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Baker DM, 2000, BIOL REPROD, V63, P865, DOI 10.1095/biolreprod63.3.865; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; BORGEAT P, 1972, P NATL ACAD SCI USA, V69, P2677, DOI 10.1073/pnas.69.9.2677; BOURNE GA, 1988, MOL CELL ENDOCRINOL, V58, P155, DOI 10.1016/0303-7207(88)90149-9; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; Childs GV, 2001, ENDOCRINOLOGY, V142, P847, DOI 10.1210/en.142.2.847; Conn P M, 1995, Vitam Horm, V50, P151, DOI 10.1016/S0083-6729(08)60656-1; CONN PM, 1994, ANNU REV MED, V45, P391, DOI 10.1146/annurev.med.45.1.391; Daftary SS, 2003, ENDOCRINOLOGY, V144, P2034, DOI 10.1210/en.2002-221025; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Dondi D, 1998, BIOL SIGNAL RECEPT, V7, P55; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUFOURNY B, 1995, J BIOL CHEM, V272, P23589; Dupont J, 2000, J BIOL CHEM, V275, P35893, DOI 10.1074/jbc.M006741200; Dupont J, 2003, RECENT PROG HORM RES, V58, P325, DOI 10.1210/rp.58.1.325; Emons G, 1998, J STEROID BIOCHEM, V65, P199, DOI 10.1016/S0960-0760(97)00189-1; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hashizume T, 2002, ANIM REPROD SCI, V70, P13, DOI 10.1016/S0378-4320(01)00190-7; HAWES BE, 1993, ENDOCRINOLOGY, V132, P2124, DOI 10.1210/en.132.5.2124; Hiney JK, 1996, ENDOCRINOLOGY, V137, P3717, DOI 10.1210/en.137.9.3717; Imai A, 2000, Vitam Horm, V59, P1, DOI 10.1016/S0083-6729(00)59002-5; Johnson CM, 1997, J NEUROSCI, V17, P6189; Jungwirth A, 1997, PROSTATE, V32, P164; KAKAR SS, 1994, MOL CELL ENDOCRINOL, V106, P145, DOI 10.1016/0303-7207(94)90196-1; KANEMATSU T, 1991, ACTA ENDOCRINOL-COP, V125, P227, DOI 10.1530/acta.0.1250227; Kang SK, 2000, MOL CELL ENDOCRINOL, V162, P157, DOI 10.1016/S0303-7207(00)00196-9; Kiley SC, 2003, KIDNEY INT, V63, P33, DOI 10.1046/j.1523-1755.2003.00706.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kratzmeier M, 1996, MOL CELL ENDOCRINOL, V118, P103, DOI 10.1016/0303-7207(96)03788-4; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Kuemmerle JF, 1998, AM J PHYSIOL-GASTR L, V275, pG151, DOI 10.1152/ajpgi.1998.275.1.G151; Kuemmerle JF, 2003, AM J PHYSIOL-GASTR L, V284, pG411, DOI 10.1152/ajpgi.00310.2002; LeHoux JG, 2001, J BIOL CHEM, V276, P8021, DOI 10.1074/jbc.M009495200; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; Lewy H, 2003, MOL CELL ENDOCRINOL, V203, P25, DOI 10.1016/S0303-7207(03)00119-9; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Liu FJ, 2002, J BIOL CHEM, V277, P32099, DOI 10.1074/jbc.M203639200; Longo KM, 1998, ENDOCRINOLOGY, V139, P1125, DOI 10.1210/en.139.3.1125; Marelli MM, 1999, ENDOCRINOLOGY, V140, P329; MITCHELL R, 1994, J ENDOCRINOL, V140, pR15, DOI 10.1677/joe.0.140R015; Moretti RM, 1996, J CLIN ENDOCR METAB, V81, P3930, DOI 10.1210/jc.81.11.3930; Motley ED, 2001, CELL MOL BIOL, V47, P1059; Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Naor Z, 1998, FRONT NEUROENDOCRIN, V19, P1, DOI 10.1006/frne.1997.0162; Oomizu S, 1998, J ENDOCRINOL, V157, P53, DOI 10.1677/joe.0.1570053; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PERRIN MH, 1993, BIOCHEM BIOPH RES CO, V191, P1139, DOI 10.1006/bbrc.1993.1335; REINHART J, 1992, J BIOL CHEM, V267, P21281; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; Roberson MS, 1999, ENDOCRINOLOGY, V140, P1310, DOI 10.1210/en.140.3.1310; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; SHAH BH, 1994, MOL PHARMACOL, V46, P1; SIM PJ, 1995, MOL CELL ENDOCRINOL, V112, P257, DOI 10.1016/0303-7207(95)03616-F; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOLDANI R, 1995, FERTIL STERIL, V64, P634, DOI 10.1016/S0015-0282(16)57804-2; SOLDANI R, 1994, EUR J ENDOCRINOL, V131, P641, DOI 10.1530/eje.0.1310641; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Wang Y, 2002, EUR J ENDOCRINOL, V146, P447, DOI 10.1530/eje.0.1460447; Weil C, 1999, ENDOCRINOLOGY, V140, P2054, DOI 10.1210/en.140.5.2054; Wells A, 2002, CLIN CANCER RES, V8, P1251; Wen HC, 2003, CELL SIGNAL, V15, P37, DOI 10.1016/S0898-6568(02)00047-5; WHITLEY NC, 1995, BIOL REPROD, V53, P1359, DOI 10.1095/biolreprod53.6.1359; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; Xia YX, 2001, EUR J ENDOCRINOL, V144, P73, DOI 10.1530/eje.0.1440073; Zhen SJ, 1997, MOL ENDOCRINOL, V11, P1145, DOI 10.1210/me.11.8.1145; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377	86	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52500	52516		10.1074/jbc.M404571200	http://dx.doi.org/10.1074/jbc.M404571200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15448167	hybrid			2022-12-25	WOS:000225493400096
J	Trosky, JE; Mukherjee, S; Burdette, DL; Roberts, M; McCarter, L; Siegel, RM; Orth, K				Trosky, JE; Mukherjee, S; Burdette, DL; Roberts, M; McCarter, L; Siegel, RM; Orth, K			Inhibition of MAPK signaling pathways by VopA from Vibrio parahaemolyticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YERSINIA EFFECTOR YOPJ	During infection, bacterial pathogens utilize a type III secretion system to inject effectors into the cytoplasm of a target cell where they disrupt the defense system of the host cell. Vibrio parahaemolyticus, a causative agent of gastroenteritis endemic in Southeast Asia, has a type III secretion system that encodes a novel member of the YopJ-like protein effector family, VopA ( Vibrio outer protein A). Our studies revealed that Vibrio VopA encodes an evolutionarily conserved activity that is extremely potent and requires an intact catalytic site to abrogate signaling pathways in a manner distinct from that of other YopJ-like effectors. We observed that VopA efficiently inhibits the MAPK signaling pathways but not the NFkappaB pathway in mammalian cells. When expressed in yeast, VopA induces a growth arrest phenotype and also blocks yeast MAPK signaling pathways. Our observations provide insight into the immense diversity of targets utilized by YopJ-like effectors to manipulate eukaryotic signaling machineries that are important for the response and survival of the host cell during infection and/or symbiosis.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; NIAMS, Immunoregulat Unit, Autoimmun Branch, NIH, Bethesda, MD 20892 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Iowa	Orth, K (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd,Room NA5-320, Dallas, TX 75390 USA.	kimorth@hamon.swmed.edu	Dinalo, Jennifer/AAN-8708-2020; Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620; Dinalo, Jennifer/0000-0001-5174-5756	NIAID NIH HHS [Y2-AI-3739, AI056404] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056404] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akeda Y, 2002, INFECT IMMUN, V70, P970, DOI 10.1128/IAI.70.2.970-973.2002; BEG AA, 1996, SCIENCE, V274, P784; Collier-Hyams LS, 2002, J IMMUNOL, V169, P2846, DOI 10.4049/jimmunol.169.6.2846; Cornelis GR, 2002, J CELL BIOL, V158, P401, DOI 10.1083/jcb.200205077; Hotson A, 2003, MOL MICROBIOL, V50, P377, DOI 10.1046/j.1365-2958.2003.03730.x; Makino K, 2003, LANCET, V361, P743, DOI 10.1016/S0140-6736(03)12659-1; McCarter Linda, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P51; NISHIBUCHI M, 1995, INFECT IMMUN, V63, P2093, DOI 10.1128/IAI.63.6.2093-2099.1995; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Orth K, 2002, CURR OPIN MICROBIOL, V5, P38, DOI 10.1016/S1369-5274(02)00283-7; Prager R, 2003, J CLIN MICROBIOL, V41, P4270, DOI 10.1128/JCM.41.9.4270-4278.2003; Staskawicz BJ, 2001, SCIENCE, V292, P2285, DOI 10.1126/science.1062013; Sun J, 2004, AM J PHYSIOL-GASTR L, V287, pG220, DOI 10.1152/ajpgi.00498.2003; VAN AD, 1996, SCIENCE, V274, P787; Yoon S, 2003, J BIOL CHEM, V278, P2131, DOI 10.1074/jbc.M209905200	16	96	100	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51953	51957		10.1074/jbc.M407001200	http://dx.doi.org/10.1074/jbc.M407001200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459200	hybrid			2022-12-25	WOS:000225493400030
J	Chang, TS; Jeong, W; Woo, HA; Lee, SM; Park, S; Rhee, SG				Chang, TS; Jeong, W; Woo, HA; Lee, SM; Park, S; Rhee, SG			Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; HYDROGEN-PEROXIDE; THIOREDOXIN; PROTEIN; FAMILY; IDENTIFICATION; OVEROXIDATION; LOCALIZATION; INACTIVATION; MECHANISM	Peroxiredoxins (Prxs) are a family of peroxidases that reduce hydroperoxides. The cysteine residue in the active site of certain eukaryotic Prx enzymes undergoes reversible oxidation to sulfinic acid (Cys-SO2H) during catalysis, and sulfiredoxin (Srx) has been identified as responsible for reversal of the resulting enzyme inactivation in yeast. We have now characterized mammalian orthologs of yeast Srx with an assay based on monitoring of the reduction of sulfinic Prx by immunoblot analysis with antibodies specific for the sulfinic state. Sulfinic reduction by mammalian Srx was found to be a slow process (k(cat) = 0.18/min) that requires ATP hydrolysis. ATP could be efficiently replaced by GTP, dATP, or dGTP but not by CTP, UTP, dCTP, or dTTP. Both glutathione and thioredoxin are potential physiological electron donors for the Srx reaction, given that their K-m values (1.8 mM and 1.2 muM, respectively) are in the range of their intracellular concentrations, and the V-max values obtained with the two reductants were similar. Although its pK(a) is relatively low ( similar to 7.3), the active site cysteine of Srx remained reduced even when the active site cysteine of most Prx molecules became oxidized. Finally, depletion of human Srx by RNA interference suggested that Srx is largely responsible for reduction of the Cys-SO2H of Prx in A549 human cells.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University; Ewha Womans University	Rhee, SG (corresponding author), NIH, Bldg 50,Rm 3523,South Dr,MSC 8015, Bethesda, MD 20892 USA.	sgrhee@nih.gov	Woo, Hyun Ae/AAT-9586-2021					Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Georgiou G, 2003, SCIENCE, V300, P592, DOI 10.1126/science.1084976; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HALLIWELL B, 2000, FREE RADICAL BIO MED, P86; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jeong W, 2004, J BIOL CHEM, V279, P3142, DOI 10.1074/jbc.M307932200; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Miranda-Vizuete A, 2001, J BIOL CHEM, V276, P31567, DOI 10.1074/jbc.M101760200; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; RHEE SG, 2000, SCI STKE, V53, P1; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; WOO JR, 2004, J BIOL CHEM; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	30	285	304	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50994	51001		10.1074/jbc.M409482200	http://dx.doi.org/10.1074/jbc.M409482200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448164	hybrid			2022-12-25	WOS:000225355800044
J	Choi, YB; Ko, JK; Shin, J				Choi, YB; Ko, JK; Shin, J			The transcriptional corepressor, PELP1, recruits HDAC2 and masks Histones using two separate domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; INTERACTING PROTEIN; CHROMATIN-STRUCTURE; ACETYLATION; DEACETYLASE; ACTIVATION; COMPLEXES; PHOSPHORYLATION; COOPERATION; REPRESSION	PELP1 (proline-, glutamic acid-, and leucine-rich protein 1) has been recognized as a coactivator of estrogen receptor (ER)-recruiting p300/CREB-binding protein histone acetyltransferase to the target chromosome. The present study shows that PELP1 does indeed coactivate ER-mediated transcription but also serves as a corepressor of other nuclear hormone receptors (NR)- and non-NR sequence-specific transcription factors tested, including GR, Nur77, AP1, NF-kappaB, and TCF/SRF. PELP1 expression also retarded the proliferation of mouse fibroblast cell lines in which there was no detectable ER. This was due, at least in part, to the suppressed activation of serum-response genes such as c-fos that in turn resulted from the blocked histone hyperacetylation of nucleosomes containing the c-fos promoter region. The N-terminal leucine-abundant region of PELP1 was observed to interact with HDAC2 and exhibited repressive activity when tethered to the chromatin. In addition, the C-terminal glutamic acid- abundant region bound to the hypoacetylated histones H3 and H4 and prevented them from becoming substrates of histone acetyltransferase. Thus PELP1 promotes and maintains the hypoacetylated state of histones at the target genomic site, and ER binding reverses its role to hyperacetylate histones through an as yet unidentified mechanism.	Sungkyunkwan Univ, Sch Med, Suwon 440746, Kyonggi Do, South Korea; Samsung Biomed Res Inst, Suwon 440746, Kyonggi Do, South Korea	Sungkyunkwan University (SKKU)	Shin, J (corresponding author), Sungkyunkwan Univ, Sch Med, Suwon 440746, Kyonggi Do, South Korea.	jkshin@med.skku.ac.kr	Choi, Young Bong/J-4317-2019	Choi, Young Bong/0000-0002-2523-1441				Ahmad A, 2003, BIOCHEM BIOPH RES CO, V312, P1266, DOI 10.1016/j.bbrc.2003.11.073; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Balasenthil S, 2003, J BIOL CHEM, V278, P22119, DOI 10.1074/jbc.M212822200; Batova I, 1996, BIOL REPROD, V54, P1238, DOI 10.1095/biolreprod54.6.1238; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Flores-Saaib RD, 2000, NUCLEIC ACIDS RES, V28, P4189, DOI 10.1093/nar/28.21.4189; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Sambrook J, 2001, MOL CLONING LAB MANU; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326	43	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50930	50941		10.1074/jbc.M406831200	http://dx.doi.org/10.1074/jbc.M406831200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456770	hybrid			2022-12-25	WOS:000225355800036
J	Sanders, T; Hawrot, E				Sanders, T; Hawrot, E			A novel pharmatope tag inserted into the beta 4 subunit confers allosteric modulation to neuronal nicotinic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ALPHA-BUNGAROTOXIN; STRUCTURAL-ANALYSIS; BINDING; COMPLEX; SENSITIVITY; DIVERSITY; MECHANISM; REVEALS; PROTEIN	alpha-Bungarotoxin, the classic nicotinic antagonist, has high specificity for muscle type alpha1 subunits in nicotinic acetylcholine receptors. In this study, we show that an 11-amino-acid pharmatope sequence, containing residues important for alpha-bungarotoxin binding to alpha1, confers functional alpha-bungarotoxin sensitivity when strategically placed into a neuronal non-alpha subunit, normally insensitive to this toxin. Remarkably, the mechanism of toxin inhibition is allosteric, not competitive as with neuromuscular nicotinic receptors. Our findings argue that alpha-bungarotoxin binding to the pharmatope, inserted at a subunit-subunit interface diametrically distinct from the agonist binding site, interferes with subunit interface movements critical for receptor activation. Our results, taken together with the structural similarities between nicotinic and GABA(A) receptors, suggest that this allosteric mechanism is conserved in the Cys-loop ion channel family. Furthermore, as a general strategy, the engineering of allosteric inhibitory sites through pharmatope tagging offers a powerful new tool for the study of membrane proteins.	Brown Med Sch, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University	Hawrot, E (corresponding author), Brown Med Sch, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.	Edward_Hawrot@Brown.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034348, F32NS011027] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15578] Funding Source: Medline; NIGMS NIH HHS [GM32629] Funding Source: Medline; NINDS NIH HHS [NS34348, NS11027] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akaaboune M, 2002, NEURON, V34, P865, DOI 10.1016/S0896-6273(02)00739-0; ANAND R, 1991, J BIOL CHEM, V266, P11192; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Groot-Kormelink PJ, 1998, J BIOL CHEM, V273, P15317, DOI 10.1074/jbc.273.25.15317; Grutter T, 2001, TRENDS BIOCHEM SCI, V26, P459, DOI 10.1016/S0968-0004(01)01921-1; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Levandoski MM, 2003, EUR J PHARMACOL, V471, P9, DOI 10.1016/S0014-2999(03)01796-5; Levandoski MM, 1999, J BIOL CHEM, V274, P26113, DOI 10.1074/jbc.274.37.26113; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moise L, 2002, J TOXICOL-TOXIN REV, V21, P293, DOI 10.1081/TXR-120014407; Moise L, 2002, J BIOL CHEM, V277, P12406, DOI 10.1074/jbc.M110320200; Pereira EFR, 2002, J NEUROBIOL, V53, P479, DOI 10.1002/neu.10146; ROGERS CJ, 1994, J PHYSIOL-LONDON, V475, P69, DOI 10.1113/jphysiol.1994.sp020050; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; Samson AO, 2002, NEURON, V35, P319, DOI 10.1016/S0896-6273(02)00773-0; Sixma TK, 2003, ANNU REV BIOPH BIOM, V32, P311, DOI 10.1146/annurev.biophys.32.110601.142536; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; Trudell JR, 2002, BBA-BIOMEMBRANES, V1565, P91, DOI 10.1016/S0005-2736(02)00512-6; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; WEBER M, 1974, MOL PHARMACOL, V10, P15; Whiting PJ, 2003, CURR OPIN DRUG DISC, V6, P648; Whiting PJ, 2003, DRUG DISCOV TODAY, V8, P445, DOI 10.1016/S1359-6446(03)02703-X; Zeng HY, 2002, J BIOL CHEM, V277, P37439, DOI 10.1074/jbc.M205483200; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200	35	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51460	51465		10.1074/jbc.M409533200	http://dx.doi.org/10.1074/jbc.M409533200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448163	hybrid			2022-12-25	WOS:000225355800098
J	Vidali, M; Hidestrand, M; Eliasson, E; Mottaran, E; Reale, E; Rolla, R; Occhino, G; Albano, E; Ingelman-Sundberg, M				Vidali, M; Hidestrand, M; Eliasson, E; Mottaran, E; Reale, E; Rolla, R; Occhino, G; Albano, E; Ingelman-Sundberg, M			Use of molecular simulation for mapping conformational CYP2E1 epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM AUTOANTIBODIES; INDUCED AUTOIMMUNE HEPATITIS; HUMAN CYTOCHROME-P450 2E1; HALOTHANE HEPATITIS; ANTI-LIVER; ESCHERICHIA-COLI; ADDISONS-DISEASE; PLASMA-MEMBRANE; RAT HEPATOCYTES; ANTIBODIES	The identification of the epitopes recognized by autoantibodies against cytochrome P450s (CYPs) associated with drug-induced hepatotoxicity is difficult because of their conformational nature. In the present investigation, we used a novel approach based on the analysis of the whole molecule antigenic capacity following single amino acid substitutions to identify the conformational epitopes on CYP2E1. A molecular model of CYP2E1 was generated based on the CYP2C5 crystal structure, and potential motifs for amino acid exchanges were selected by computer simulation in the surface of alpha helices and beta sheets. Fourteen modified, apparently correctly folded CYP2E1 variants were produced in Escherichia coli and evaluated in immunoprecipitation experiments using sera with anti-CYP2E1 autoreactivity from 10 patients with halothane hepatitis and 12 patients with alcoholic liver disease. Ala substitution of Glu-248 and Lys-251 as well as of Lys-324, Lys-342, Lys-420, and Phe-421 severely decreased or abolished CYP2E1 recognition by the majority of both the halothane hepatitis and alcoholic liver disease sera, whereas the other substitutions had only minor effects. Based on the structural model, these substitutions identified two distinct epitopes on the CYP2E1 surface corresponding to the G-helix and an area formed by juxtaposition of the J' and K" helices, respectively. The combined use of molecular modeling and single amino acid mutagenesis is thus a useful approach for the characterization of conformational epitopes recognized by autoantibodies.	Univ Amedeo Avogadro E Piedmont, Dept Med Sci, I-28100 Novara, Italy; IRCAD, I-28100 Novara, Italy; Karolinska Inst, Inst Environm Med, Div Mol Toxicol, SE-17177 Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Lab Sci, Div Clin Pharmacol, SE-14186 Huddinge, Sweden	University of Eastern Piedmont Amedeo Avogadro; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Albano, E (corresponding author), Univ Amedeo Avogadro E Piedmont, Dept Med Sci, Via Solaroli 17, I-28100 Novara, Italy.	albano@med.unipmn.it	Ingelman-Sundberg, Magnus/ABD-9302-2021; Roberta, Rolla/ABH-5361-2020; Albano, Emanuele/K-2580-2016; Vidali, Matteo/T-2621-2019	Roberta, Rolla/0000-0003-0805-8285; Albano, Emanuele/0000-0003-4738-7049; Vidali, Matteo/0000-0001-9991-7502; Eliasson, Erik/0000-0002-4707-4256				Barnes HJ, 1996, METHOD ENZYMOL, V272, P3, DOI 10.1016/S0076-6879(96)72003-7; BEAUNE P, 1987, P NATL ACAD SCI USA, V84, P551, DOI 10.1073/pnas.84.2.551; Belloc C, 1997, PHARMACOGENETICS, V7, P181, DOI 10.1097/00008571-199706000-00002; Bourdi M, 1996, CHEM RES TOXICOL, V9, P1159, DOI 10.1021/tx960083q; BOURDI M, 1990, J CLIN INVEST, V85, P1967, DOI 10.1172/JCI114660; Clot P, 1997, GASTROENTEROLOGY, V113, P265, DOI 10.1016/S0016-5085(97)70104-5; DUCLOSVALLEE JC, 1995, GASTROENTEROLOGY, V108, P470, DOI 10.1016/0016-5085(95)90076-4; Eliasson E, 1996, MOL PHARMACOL, V50, P573; GILLAM EMJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P59, DOI 10.1006/abbi.1994.1280; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KENNA JG, 1988, HEPATOLOGY, V8, P1635, DOI 10.1002/hep.1840080627; Kerkar N, 2003, J IMMUNOL, V170, P1481, DOI 10.4049/jimmunol.170.3.1481; Lecoeur S, 1996, MOL PHARMACOL, V50, P326; LEEDER JS, 1992, J PHARMACOL EXP THER, V263, P360; Leeder JS, 1996, MOL PHARMACOL, V49, P234; Lewis DFV, 2003, TOXICOL IN VITRO, V17, P93, DOI 10.1016/S0887-2333(02)00098-X; Lytton SD, 1999, MOL PHARMACOL, V55, P223, DOI 10.1124/mol.55.2.223; Lytton SD, 2002, CLIN EXP IMMUNOL, V127, P293, DOI 10.1046/j.1365-2249.2002.01754.x; Ma Y, 2002, J IMMUNOL, V169, P277, DOI 10.4049/jimmunol.169.1.277; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; Manns MP, 1997, HEPATOLOGY, V26, P1054; Neve EPA, 2003, BIOCHEMISTRY-US, V42, P14566, DOI 10.1021/bi035193s; Njorku DB, 2002, ANESTH ANALG, V94, P243; OMURA T, 1964, J BIOL CHEM, V239, P2370; Ronis MJJ, 1996, CYTOCHROMES P450 MET, P211; SCHWEDE T, NUCL ACIDS RES, V31, P3381; SMITH GCM, 1993, LANCET, V342, P963, DOI 10.1016/0140-6736(93)92005-E; Stewart SF, 2004, J HEPATOL, V40, P176, DOI 10.1016/S0168-8278(04)90602-2; UIBO R, 1994, J CLIN ENDOCR METAB, V78, P323, DOI 10.1210/jc.78.2.323; Vidali M, 2003, HEPATOLOGY, V37, P410, DOI 10.1053/jhep.2003.50049; Williams D, 2000, PERFORM RES, V5, P131; WINQVIST O, 1993, J CLIN INVEST, V92, P2377, DOI 10.1172/JCI116843; WU DF, 1992, HEPATOLOGY, V15, P515, DOI 10.1002/hep.1840150326; YAMAMOTO AM, 1993, GASTROENTEROLOGY, V104, P1762, DOI 10.1016/0016-5085(93)90657-X	34	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50949	50955		10.1074/jbc.M407329200	http://dx.doi.org/10.1074/jbc.M407329200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456790	hybrid			2022-12-25	WOS:000225355800038
J	Hanford, LE; Enghild, JJ; Valnickova, Z; Petersen, SV; Schaefer, LM; Schaefer, TM; Reinhart, TA; Oury, TD				Hanford, LE; Enghild, JJ; Valnickova, Z; Petersen, SV; Schaefer, LM; Schaefer, TM; Reinhart, TA; Oury, TD			Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTOR; SIGNALING PATHWAYS; NEURITE OUTGROWTH; KAPPA-B; RAGE; EXPRESSION; PROTEIN; ACTIVATION; BLOCKADE; CLONING	The receptor for advanced glycation end products ( RAGE) is a member of the immunoglobulin superfamily of cell surface proteins that has been implicated as a progression factor in a number of pathologic conditions from chronic inflammation to cancer to Alzheimer's disease. In such conditions, RAGE acts to facilitate pathogenic processes. Its secreted isoform, soluble RAGE or sRAGE, has the ability to prevent RAGE signaling by acting as a decoy. sRAGE has been used successfully in animal models of a range of diseases to antagonize RAGE-mediated pathologic processes. In humans, sRAGE results from alternative splicing of RAGE mRNA. This study was aimed to determine whether the same holds true for mouse sRAGE and, in addition, to biochemically characterize mouse sRAGE. The biochemical characteristics examined include glycosylation and disulfide patterns. In addition, sRAGE was found to bind heparin, which may mediate its distribution in the extracellular matrix and cell surfaces of tissues. Finally, our data indicated that sRAGE in the mouse is likely produced by carboxyl-terminal truncation, in contrast to the alternative splicing mechanism reported in humans.	Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA 15261 USA; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA; Dartmouth Coll Sch Med, Dept Physiol, Lebanon, NH 03756 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Aarhus University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Dartmouth College	Oury, TD (corresponding author), Univ Pittsburgh, Dept Pathol, Med Ctr, 3550 Terrace St,Scaife Hall S740, Pittsburgh, PA 15261 USA.	tdoury@pitt.edu		Vang Petersen, Steen/0000-0002-9338-911X; Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063700] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL063700, R01-HL-063700] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arumugam T, 2004, J BIOL CHEM, V279, P5059, DOI 10.1074/jbc.M310124200; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Devaux Y, 2004, AM J RESP CRIT CARE, V169, pA456; Fattman CL, 2000, BIOCHEM BIOPH RES CO, V275, P542, DOI 10.1006/bbrc.2000.3327; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Hanford LE, 2003, AM J RESP CELL MOL, V29, pS77; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; JENDRISAK J, 1987, PROTEIN PURIFICATION, P75; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Kuniyasu H, 2002, J PATHOL, V196, P163, DOI 10.1002/path.1031; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; Malherbe P, 1999, MOL BRAIN RES, V71, P159, DOI 10.1016/S0169-328X(99)00174-6; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Oury TD, 2002, AM J PHYSIOL-LUNG C, V283, pL777, DOI 10.1152/ajplung.00011.2002; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Petersen SV, 2003, BIOCHEM J, V374, P199, DOI 10.1042/BJ20030313; Renard C, 1997, MOL PHARMACOL, V52, P54, DOI 10.1124/mol.52.1.54; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; SCHMIDT AM, 1994, J BIOL CHEM, V269, P9882; Srikrishna G, 2002, J NEUROCHEM, V80, P998, DOI 10.1046/j.0022-3042.2002.00796.x; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Wear-Maggitti K, 2004, ANN PLAS SURG, V52, P519, DOI 10.1097/01.sap.0000122857.49274.8c; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371	28	182	194	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50019	50024		10.1074/jbc.M409782200	http://dx.doi.org/10.1074/jbc.M409782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15381690	Green Accepted, hybrid			2022-12-25	WOS:000225229500059
J	Park, SW; Moon, YA; Horton, JD				Park, SW; Moon, YA; Horton, JD			Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; MODULAR ADAPTER PROTEIN; HAMSTER OVARY CELLS; LDL-RECEPTOR; SITE-1 PROTEASE; MEDIATED ENDOCYTOSIS; KNOCKOUT MICE; CHOLESTEROL; SREBP; HYPERCHOLESTEROLEMIA	Lipid homeostasis is transcriptionally regulated by three DNA-binding proteins, designated sterol regulatory element-binding protein (SREBP)-1a, - 1c, and -2. Oligonucleotide arrays hybridized with RNA made from livers of transgenic SREBP-1a, transgenic SREBP-2, and SREBP cleavage-activating protein knockout mice recently identified 33 genes regulated by SREBPs in liver, four of which had no known connection to lipid metabolism. One of the four genes was PCSK9, which encodes proprotein convertase subtilisin/kexin type 9a, a protein that belongs to the proteinase K subfamily of subtilases. Mutations in PCSK9 are associated with an autosomal dominant form of hypercholesterolemia. Here, we demonstrate that hepatic overexpression of either wild-type or mutant PCSK9 in mice results in hypercholesterolemia. The hypercholesterolemia is due to a post-transcriptional event causing a reduction in low density lipoprotein (LDL) receptor protein prior to the internalization and recycling of the receptor. Overexpression of PCSK9 in primary hepatocytes and in mice lacking the LDL receptor does not alter apolipoprotein B secretion. These data are consistent with PCSK9 affecting plasma LDL cholesterol levels by altering LDL receptor protein levels via a post-transcriptional mechanism.	Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Horton, JD (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75390 USA.	jay.horton@utsouthwestern.edu		Park, Sahng Wook/0000-0002-9594-7074	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL038049] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20948, HL-38049] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; *APPL BIOS, 2001, US B, V2; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; Engelking LJ, 2004, J CLIN INVEST, V113, P1168, DOI 10.1172/JCI200420978; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Green M, 1979, Methods Enzymol, V58, P425; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; HERZ J, 1991, J BIOL CHEM, V266, P21232; Horton JD, 1999, J CLIN INVEST, V103, P1067, DOI 10.1172/JCI6246; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Leren TP, 2004, CLIN GENET, V65, P419, DOI 10.1111/j.0009-9163.2004.0238.x; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; Michaely P, 2004, J BIOL CHEM, V279, P34023, DOI 10.1074/jbc.M405242200; Moon YA, 2003, J BIOL CHEM, V278, P7335, DOI 10.1074/jbc.M211684200; Norman D, 1999, J CLIN INVEST, V104, P619, DOI 10.1172/JCI6677; Nyberg-Hoffman C, 1999, NAT MED, V5, P955, DOI 10.1038/11400; Ouguerram K, 2004, ARTERIOSCL THROM VAS, V24, P1448, DOI 10.1161/01.ATV.0000133684.77013.88; Rader DJ, 2003, J CLIN INVEST, V111, P1795, DOI 10.1172/JCI200318925; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Sambrook J, 2001, MOL CLONING LAB MANU; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Timms KM, 2004, HUM GENET, V114, P349, DOI 10.1007/s00439-003-1071-9; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Wilund KR, 2002, HUM MOL GENET, V11, P3019, DOI 10.1093/hmg/11.24.3019; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	46	410	481	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50630	50638		10.1074/jbc.M410077200	http://dx.doi.org/10.1074/jbc.M410077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15385538	hybrid			2022-12-25	WOS:000225229500127
J	Serafino, A; Vallebona, PS; Lazzarino, G; Tavazzi, B; Rasi, G; Pierimarchi, P; Andreola, F; Moroni, G; Galvano, G; Galvano, F; Garaci, E				Serafino, A; Vallebona, PS; Lazzarino, G; Tavazzi, B; Rasi, G; Pierimarchi, P; Andreola, F; Moroni, G; Galvano, G; Galvano, F; Garaci, E			Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside	FASEB JOURNAL			English	Article						anthocyanin; melanoma differentiation; electron microscopy; confocal microscopy	MALIGNANT-MELANOMA; RETINOIC ACID; VITAMIN-C; IN-VITRO; INHIBITION; ANTHOCYANINS; EXPRESSION; CYANIDIN; PROLIFERATION; MELANOCYTES	Great attention has been recently given to a flavonoid of the anthocyanin class, cyanidin-3-O-beta-glucopyranoside (C-3-G), which is widely spread throughout the plant kingdom, and is present in both fruits and vegetables of human diets. In this study, we investigated the effect of C-3-G on proliferation and differentiation of human melanoma cells. Both morphological and functional parameters were evaluated, using electron and confocal microscopy, cytofluorometric analysis, HPLC assay, Western blot analysis, and enzymatic assay, as appropriate. A treatment with a single dose of C-3-G decreased cell proliferation without affecting cell viability and without inducing apoptosis or necrosis. The mitotic index and cell percentage in S phase were significantly lower in C-3-G treated cells compared with untreated control. C-3-G treatment induced, in a dose- and time-dependent manner, melanoma cell differentiation characterized by a strong increase in dendrite outgrowth accompanied with a remodeling of the microtubular network, a dramatic increase of focal adhesion and an increased expression of "brain specific" cytoskeletal components such as NF-160 and NF-200 neurofilament proteins. C-3-G treatment also induced increase of cAMP levels and up-regulation of tyrosinase expression and activity resulting in an enhanced melanin synthesis and melanosome maturation. Up-regulation of the melanoma differentiation antigen Melan-A/MART-1 in treated cells respect to the untreated control was also recorded. Data obtained provide evidence that a single treatment with C-3-G is able to revert the human melanoma cells from the proliferating to the differentiated state. We conclude that C-3-G is a very promising molecule to include in the strategies for treatment of melanoma; also because of its nutritional relevance.	CNR, Inst Neurobiol & Mol Med, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy; Univ Catania, Dept Chem Sci, Biochem Lab, Catania, Italy; Catholic Univ Rome Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; Univ Catania, Dept Agron Agrochem & Anim Prod Sci, Catania, Italy; Univ Reggio Calabria, Dept Agroforestry & Environm Sci, I-89100 Reggio Di Calabria, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata; University of Catania; Catholic University of the Sacred Heart; University of Catania; Universita Mediterranea di Reggio Calabria	Serafino, A (corresponding author), CNR, Inst Neurobiol & Mol Med, Via Fosso del Cavaliere 100, I-00133 Rome, Italy.	annalucia.serafino@ims.rm.cnr.it	Galvano, Fabio/F-8122-2010; Serafino, Annalucia/AAC-1719-2019; Rasi, Guido/AAC-8172-2021; Pierimarchi, Pasquale/AAX-2833-2020; TAVAZZI, BARBARA/AAB-9830-2019; GARACI, ENRICO/AAB-3349-2021; lazzarino, giuseppe/K-2277-2015	Galvano, Fabio/0000-0003-0644-0755; Serafino, Annalucia/0000-0002-1142-4752; Rasi, Guido/0000-0002-2191-1386; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279; Moroni, Gabriella/0000-0002-1215-423X				Amorini AM, 2001, FREE RADICAL RES, V35, P953, DOI 10.1080/10715760100301451; Bialy TL, 2002, DERMATOL SURG, V28, P1143, DOI 10.1046/j.1524-4725.2002.02114.x; Bishop JAN, 1997, CANCER METAST REV, V16, P141, DOI 10.1023/A:1005752510012; Briviba K, 2001, NUTR CANCER, V41, P172, DOI 10.1207/S15327914NC41-1&amp;2_24; Burton RC, 2000, CA-CANCER J CLIN, V50, P209, DOI 10.3322/canjclin.50.4.209; Busam KJ, 1998, AM J SURG PATHOL, V22, P976, DOI 10.1097/00000478-199808000-00007; Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Cal C., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P77, DOI 10.2174/1568011033353443; Chen YT, 1996, P NATL ACAD SCI USA, V93, P5915, DOI 10.1073/pnas.93.12.5915; Demary K, 2001, CANCER LETT, V163, P103, DOI 10.1016/S0304-3835(00)00676-5; DIPIERRO D, 1995, ANAL BIOCHEM, V231, P407, DOI 10.1006/abio.1995.0071; Fang D, 2001, AM J PATHOL, V158, P2107, DOI 10.1016/S0002-9440(10)64682-2; Fimognari C, 2004, BIOCHEM PHARMACOL, V67, P2047, DOI 10.1016/j.bcp.2004.02.021; Fitzpatrick TB, 1979, DERMATOLOGY GENERAL, P131; Hagiwara A, 2001, CANCER LETT, V171, P17, DOI 10.1016/S0304-3835(01)00510-9; HOLZMANN B, 1987, INT J CANCER, V39, P466, DOI 10.1002/ijc.2910390410; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; Ichikawa Haruyo, 2001, J Med Food, V4, P211, DOI 10.1089/10966200152744481; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Kahkonen MP, 2003, J AGR FOOD CHEM, V51, P628, DOI 10.1021/jf025551i; Kirkin AF, 1998, APMIS, V106, P665, DOI 10.1111/j.1699-0463.1998.tb00210.x; Koide T, 1997, CANCER BIOTHER RADIO, V12, P277, DOI 10.1089/cbr.1997.12.277; Kosala Raymond, 2000, SIGKDD EXPLORATIONS, V2, P1, DOI DOI 10.1145/360402.360406; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; Le Douarin N.M., 1982, NEURAL CREST; Lee HS, 2002, J AGR FOOD CHEM, V50, P1243, DOI 10.1021/jf011205+; Lee KW, 2002, LANCET, V359, P172, DOI 10.1016/S0140-6736(02)07358-0; Lopez-Lazaro M, 2002, Curr Med Chem Anticancer Agents, V2, P691; Martinez-Esparza M, 2001, INT J BIOCHEM CELL B, V33, P971, DOI 10.1016/S1357-2725(01)00068-1; Matsumoto H, 2001, J AGR FOOD CHEM, V49, P1546, DOI 10.1021/jf001246q; Melino G, 1993, CLIN CHEM ENZYM COMM, V6, P105; Meyskens FL, 2001, PIGM CELL RES, V14, P148, DOI 10.1034/j.1600-0749.2001.140303.x; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nagao N, 2000, J CANCER RES CLIN, V126, P511, DOI 10.1007/s004320000120; Niles RM, 2003, J NUTR, V133, p282S, DOI 10.1093/jn/133.1.282S; Oberley TD, 2002, AM J PATHOL, V160, P403, DOI 10.1016/S0002-9440(10)64857-2; Pantazis Panayotis, 1999, Neoplasia (New York), V1, P231, DOI 10.1038/sj.neo.7900025; Pereda MP, 1999, BRIT J CANCER, V81, P381, DOI 10.1038/sj.bjc.6690705; Reed JA, 1999, AM J PATHOL, V155, P549, DOI 10.1016/S0002-9440(10)65150-4; Savouret JF, 2002, BIOMED PHARMACOTHER, V56, P84, DOI 10.1016/S0753-3322(01)00158-5; Seeram NP, 2003, J AGR FOOD CHEM, V51, P1948, DOI 10.1021/jf025993u; Sovak Milos, 2001, J Med Food, V4, P93, DOI 10.1089/109662001300341752; TAKAHASHI H, 1992, J INVEST DERMATOL, V98, P481, DOI 10.1111/1523-1747.ep12499862; Tsuda T, 1999, FEBS LETT, V449, P179, DOI 10.1016/S0014-5793(99)00407-X; Wang HB, 2003, J AGR FOOD CHEM, V51, P1839, DOI 10.1021/jf0260747; Waxman S, 2000, LEUKEMIA, V14, P491, DOI 10.1038/sj.leu.2401714	48	49	59	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1940	+		10.1096/fj.04-1925fje	http://dx.doi.org/10.1096/fj.04-1925fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15451888				2022-12-25	WOS:000224243200008
J	Ahuja, A; Purcarea, C; Ebert, R; Sadecki, S; Guy, HI; Evans, DR				Ahuja, A; Purcarea, C; Ebert, R; Sadecki, S; Guy, HI; Evans, DR			Aquifex aeolicus Dihydroorotase - Association with aspartate transcarbamoylase switches on catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; EHRLICH ASCITES-CARCINOMA; ESCHERICHIA-COLI; HAMSTER DIHYDROOROTASE; SUBUNIT STRUCTURE; MAMMALIAN DIHYDROOROTASE; PYRIMIDINE BIOSYNTHESIS; CARBAMOYL-PHOSPHATE; DOMAIN; PURIFICATION	Dihydroorotase (DHOase) catalyzes the reversible condensation of carbamoyl aspartate to form dihydroorotate in de novo pyrimidine biosynthesis. The enzyme from Aquifex aeolicus, a hyperthermophilic organism of ancient lineage, was cloned and expressed in Escherichia coli. The purified protein was found to be a 45-kDa monomer containing a single zinc ion. Although there is no other DHOase gene in the A. aeolicus genome, the recombinant protein completely lacked catalytic activity at any temperature tested. However, DHOase formed an active complex with aspartate transcarbamoylase ( ATCase) from the same organism. Whereas the k(cat) of 13.8 +/- 0.03 s(-1) was close to the value observed for the mammalian enzyme, the Km for dihydroorotate, 3.03 +/- 0.05 mM was 433-fold higher. Gel filtration and chemical cross-linking showed that the complex exists as a 240-kDa hexamer (DHO3-ATC(3)) and a 480-kDa duo-decamer (DHO6-ATC(6)) probably in rapid equilibrium. Complex formation protects both DHOase and ATCase against thermal degradation at temperatures near 100 degreesC where the organism grows optimally. These results lead to the reclassification of both enzymes: ATCase, previously considered a Class C homotrimer, now falls into Class A, whereas the DHOase is a Class 1B enzyme. CD spectroscopy indicated that association with ATCase does not involve a significant perturbation of the DHOase secondary structure, but the visible absorption spectrum of a Co2+-substituted DHOase is appreciably altered upon complex formation suggesting a change in the electronic environment of the active site. The association of DHOase with ATCase probably serves as a molecular switch that ensures that free, uncomplexed DHOase in the cell remains inactive. At pH 7.4, the equilibrium ratio of carbamoyl aspartate to dihydroorotate is 17 and complex formation may drive the reaction in the biosynthetic direction.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Evans, DR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield St, Detroit, MI 48201 USA.	devans@cmb.biosci.wayne.edu		Purcarea, Cristina/0000-0001-5784-8545	NIGMS NIH HHS [GM/CA60371, GM/CA47399, R01 GM060371] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060371, R01GM047399] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahuja A, 2001, J BIOL CHEM, V276, P45694, DOI 10.1074/jbc.M106382200; BERGH ST, 1993, P NATL ACAD SCI USA, V90, P9818, DOI 10.1073/pnas.90.21.9818; CHRISTOPHERSON RI, 1979, J BIOL CHEM, V254, P2506; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P3358; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Fields C., 1999, PATHS PYRIMIDINES, V7, P49; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Huang DTC, 1999, BIOCHEMISTRY-US, V38, P9964, DOI 10.1021/bi990859x; Hughes LE, 1999, CURR MICROBIOL, V39, P175, DOI 10.1007/s002849900441; Jones M E, 1980, Mol Biol Biochem Biophys, V32, P165; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KELLY RE, 1986, J BIOL CHEM, V261, P6073; Kim GJ, 1998, BIOCHEM J, V330, P295, DOI 10.1042/bj3300295; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; KRUNGKRAI J, 1990, BIOCHEMISTRY-US, V29, P6270, DOI 10.1021/bi00478a023; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; LOLLIER M, 1995, CURR GENET, V28, P138, DOI 10.1007/BF00315780; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MUSMANNO LA, 1991, GENE, V99, P211, DOI 10.1016/0378-1119(91)90129-Y; OGAWA J, 1995, EUR J BIOCHEM, V229, P284, DOI 10.1111/j.1432-1033.1995.tb20467.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; Purcarea C, 2003, J BIOL CHEM, V278, P52924, DOI 10.1074/jbc.M309383200; Purcarea C, 2002, ACTA CRYSTALLOGR D, V58, P154, DOI 10.1107/S0907444901017528; SANDER EG, 1965, J BIOL CHEM, V240, P3628; SCHURR MJ, 1995, J BACTERIOL, V177, P1751, DOI 10.1128/jb.177.7.1751-1759.1995; SHEPHERDSON M, 1993, FEMS MICROBIOL LETT, V114, P201, DOI 10.1111/j.1574-6968.1993.tb06574.x; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; TAYLOR WH, 1976, J BACTERIOL, V127, P863, DOI 10.1128/JB.127.2.863-873.1976; Thoden JB, 2001, BIOCHEMISTRY-US, V40, P6989, DOI 10.1021/bi010682i; Vickrey JF, 2002, J BIOL CHEM, V277, P24490, DOI 10.1074/jbc.M200009200; WASHABAUGH MW, 1984, J BIOL CHEM, V259, P3293; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILLIAMS NK, 1993, PROTEIN ENG, V6, P333, DOI 10.1093/protein/6.3.333; WILLIAMS NK, 1995, BIOCHEMISTRY-US, V34, P11344, DOI 10.1021/bi00036a007; ZIMMERMANN BH, 1993, BIOCHEMISTRY-US, V32, P1519, DOI 10.1021/bi00057a016; ZIMMERMANN BH, 1995, BIOCHEMISTRY-US, V34, P7038, DOI 10.1021/bi00021a015	39	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53136	53144		10.1074/jbc.M403009200	http://dx.doi.org/10.1074/jbc.M403009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15381710	hybrid			2022-12-25	WOS:000225680600042
J	Correia, IJ; Paquete, CM; Coelho, A; Almeida, CC; Catarino, T; Louro, RO; Frazao, C; Saraiva, LM; Carrondo, MA; Turner, DL; Xavier, AV				Correia, IJ; Paquete, CM; Coelho, A; Almeida, CC; Catarino, T; Louro, RO; Frazao, C; Saraiva, LM; Carrondo, MA; Turner, DL; Xavier, AV			Proton-assisted two-electron transfer in natural variants of tetraheme cytochromes from Desulfomicrobium Sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; ENERGY TRANSDUCTION; ELECTRON-TRANSFER; DESULFURICANS NORWAY; REDOX POTENTIALS; STRUCTURAL BASIS; 4 HEMES; C(3); COOPERATIVITY; ANGSTROM	The tetraheme cytochrome c(3) isolated from Desulfomicrobium baculatum (DSM 1743) (Dsmb) was cloned, and the sequence analysis showed that this cytochrome differs in just three amino acid residues from the cytochrome c(3) isolated from Desulfomicrobium norvegicum (Dsmn): (DsmnXXDsmb) Thr-37 --> Ser, Val-45 --> Ala, and Phe-88 --> Tyr. X-ray crystallography was used to determine the structure of cytochrome c(3) from Dsmb, showing that it is very similar to the published structure of cytochrome c(3) from Dsmn. A detailed thermodynamic and kinetic characterization of these two tetraheme cytochromes c(3) was performed by using NMR and visible spectroscopy. The results obtained show that the network of cooperativities between the redox and protonic centers is consistent with a synergetic process to stimulate the hydrogen uptake activity of hydrogenase. This is achieved by increasing the affinity of the cytochrome for protons through binding electrons and, reciprocally, by favoring a concerted two-electron transfer assisted by the binding of proton(s). The data were analyzed within the framework of the differences in the primary and tertiary structures of the two proteins, showing that residue 88, close to heme I, is the main cause for the differences in the microscopic thermodynamic parameters obtained for these two cytochromes c(3). This comparison reveals how replacement of a single amino acid can tune the functional properties of energy-transducing proteins, so that they can be optimized to suit the bioenergetic constraints of specific habitats.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Univ Beira Interior, Fac Ciencias Saude, Ctr Invest Ciencias Saude, P-6201001 Covilha, Portugal; Univ Evora, Dept Quim, P-7000 Evora, Portugal; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, P-2829516 Caparica, Portugal; Univ Southampton, Sch Chem, Southampton SO17 1BJ, Hants, England	Universidade Nova de Lisboa; Universidade da Beira Interior; University of Evora; Universidade Nova de Lisboa; University of Southampton	Xavier, AV (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande 6, P-2780156 Oeiras, Portugal.	xavier@itqb.unl.pt	Correia, Ilidio/S-8295-2016; Saraiva, Ligia M/H-8537-2012; Catarino, Teresa/A-9267-2012; Louro, Ricardo O./AAB-4601-2020; Correia, I. J./AAE-2400-2020; Coelho, Ana V/H-8885-2012; Turner, David/B-8267-2009; Coelho, Ana V Varela/O-3977-2014; Turner, David L/B-9061-2011; Paquete, Catarina M./A-6615-2016; DE ALMEIDA, CARLOS CAETANO/K-4265-2016; Frazao, Carlos/C-1965-2008	Correia, Ilidio/0000-0003-1613-9675; Saraiva, Ligia M/0000-0002-0675-129X; Catarino, Teresa/0000-0003-3782-4014; Louro, Ricardo O./0000-0002-2392-6450; Correia, I. J./0000-0003-1613-9675; Coelho, Ana V/0000-0002-6143-4203; Coelho, Ana V Varela/0000-0002-6143-4203; Turner, David L/0000-0002-3754-6459; Paquete, Catarina M./0000-0002-1511-3732; DE ALMEIDA, CARLOS CAETANO/0000-0002-3215-5731; Carrondo, Maria Armenia/0000-0002-1261-1162; Frazao, Carlos/0000-0002-7725-1671				Aubert C, 2000, BBA-PROTEIN STRUCT M, V1476, P85, DOI 10.1016/S0167-4838(99)00221-6; Ausubel F., 1999, CURRENT PROTOCOLS MO; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brennan L, 2000, J MOL BIOL, V298, P61, DOI 10.1006/jmbi.2000.3652; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR SYSTEM PROTEIN; CAPEILLEREBLANDIN C, 1986, BIOCHIM BIOPHYS ACTA, V848, P279, DOI 10.1016/0005-2728(86)90202-1; Catarino T, 2001, CHEMBIOCHEM, V2, P416, DOI 10.1002/1439-7633(20010601)2:6<416::AID-CBIC416>3.3.CO;2-Q; CATARINO T, 1998, THESIS U NOVA LISBOA; CHRISTENSEN HEM, 1994, J PHOTOCH PHOTOBIO A, V82, P103, DOI 10.1016/1010-6030(94)87009-8; COLETTA M, 1991, EUR J BIOCHEM, V202, P1101, DOI 10.1111/j.1432-1033.1991.tb16476.x; Correia IJ, 2002, EUR J BIOCHEM, V269, P5722, DOI 10.1046/j.1432-1033.2002.03286.x; COUTINHO IB, 1995, EUR J BIOCHEM, V230, P1007, DOI 10.1111/j.1432-1033.1995.tb20649.x; COUTINHO IB, 1993, BIOCHEM J, V294, P899, DOI 10.1042/bj2940899; COUTINHO IB, 1994, METHOD ENZYMOL, V243, P119; Cruickshank D.W.J, 1996, P CCP4 STUD WEEK, P11; CZJZEK M, 1994, J MOL BIOL, V243, P653, DOI 10.1016/0022-2836(94)90039-6; DELGADO R, 1991, ANAL CHIM ACTA, V245, P271, DOI 10.1016/S0003-2670(00)80232-9; DIXON M, 1971, BIOCHIM BIOPHYS ACTA, V226, P241, DOI 10.1016/0005-2728(71)90092-2; Dutton P L, 1978, Methods Enzymol, V54, P411; FREY M, 1976, J MOL BIOL, V104, P741, DOI 10.1016/0022-2836(76)90134-0; GAYDA JP, 1988, EUR J BIOCHEM, V177, P199, DOI 10.1111/j.1432-1033.1988.tb14362.x; Genthner BRS, 1997, INT J SYST BACTERIOL, V47, P889; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Louro RO, 1998, BIOCHEMISTRY-US, V37, P15808, DOI 10.1021/bi981505t; Louro RO, 1998, J AM CHEM SOC, V120, P13240, DOI 10.1021/ja983102m; Louro RO, 2004, FEBS LETT, V576, P77, DOI 10.1016/j.febslet.2004.08.066; Louro RO, 1997, J BIOL INORG CHEM, V2, P488, DOI 10.1007/s007750050160; Louro RO, 2001, J BIOL CHEM, V276, P44044, DOI 10.1074/jbc.M107136200; Louro RO, 2001, CHEMBIOCHEM, V2, P831, DOI 10.1002/1439-7633(20011105)2:11<831::AID-CBIC831>3.0.CO;2-W; Louro RO, 1996, J BIOL INORG CHEM, V1, P34, DOI 10.1007/s007750050020; LOURO RO, 1998, THESIS U NOVA LISBOA; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MATIAS PM, 1993, J MOL BIOL, V234, P680, DOI 10.1006/jmbi.1993.1620; Matias PM, 2001, J BIOL INORG CHEM, V6, P63, DOI 10.1007/s007750000167; MCKENNA CE, 1991, BIOCHIM BIOPHYS ACTA, V1075, P109, DOI 10.1016/0304-4165(91)90082-R; Messias AC, 1998, J MOL BIOL, V281, P719, DOI 10.1006/jmbi.1998.1974; MILLER JDA, 1964, J GEN MICROBIOL, V37, P419, DOI 10.1099/00221287-37-3-419; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MOURA I, 1988, EUR J BIOCHEM, V176, P365, DOI 10.1111/j.1432-1033.1988.tb14290.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NETA P, 1987, J PHYS CHEM-US, V91, P1606, DOI 10.1021/j100290a063; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P71; Park JS, 1996, BBA-PROTEIN STRUCT M, V1293, P45, DOI 10.1016/0167-4838(95)00239-1; PFENNIG N, 1976, ARCH MICROBIOL, V110, P3, DOI 10.1007/BF00416962; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROUSSEL A, 1990, 15 IUCR C BORD FRANC, pC66; Salgueiro CA, 2001, BIOCHEMISTRY-US, V40, P9709, DOI 10.1021/bi010330b; Salgueiro CA, 1997, EUR J BIOCHEM, V244, P721, DOI 10.1111/j.1432-1033.1997.00721.x; SALGUEIRO CA, 1992, FEBS LETT, V314, P155, DOI 10.1016/0014-5793(92)80963-H; SANTOS H, 1984, EUR J BIOCHEM, V141, P283, DOI 10.1111/j.1432-1033.1984.tb08190.x; Saraiva LM, 1996, J BIOL INORG CHEM, V1, P542, DOI 10.1007/s007750050090; Saraiva LM, 1998, BIOCHEMISTRY-US, V37, P12160, DOI 10.1021/bi981001v; SHAPOSHNIKOV VV, 1960, NATURE, V187, P167, DOI 10.1038/187167a0; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Tickle IJ, 1998, ACTA CRYSTALLOGR D, V54, P547, DOI 10.1107/S0907444997013875; TURNER DL, 1994, BBA-BIOENERGETICS, V1187, P232, DOI 10.1016/0005-2728(94)90117-1; Turner DL, 1998, EUR BIOPHYS J BIOPHY, V27, P367, DOI 10.1007/s002490050144; Turner DL, 1996, EUR J BIOCHEM, V241, P723, DOI 10.1111/j.1432-1033.1996.00723.x; Valente FMA, 2001, CHEMBIOCHEM, V2, P895, DOI 10.1002/1439-7633(20011203)2:12<895::AID-CBIC895>3.0.CO;2-V; Xavier AV, 2004, BBA-BIOENERGETICS, V1658, P23, DOI 10.1016/j.bbabio.2004.03.017; XAVIER AV, 1986, J INORG BIOCHEM, V28, P239, DOI 10.1016/0162-0134(86)80087-3; Xavier AV, 2002, FEBS LETT, V532, P261, DOI 10.1016/S0014-5793(02)03692-X; YAGI T, 1968, BIOCHIM BIOPHYS ACTA, V153, P699, DOI 10.1016/0005-2728(68)90197-7	65	22	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52227	52237		10.1074/jbc.M408763200	http://dx.doi.org/10.1074/jbc.M408763200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456779	hybrid			2022-12-25	WOS:000225493400063
J	Pekkala, M; Hieta, R; Bergmann, U; Kivirikko, KI; Wierenga, RK; Myllyharju, J				Pekkala, M; Hieta, R; Bergmann, U; Kivirikko, KI; Wierenga, RK; Myllyharju, J			The peptide-substrate-binding domain of collagen prolyl 4-hydroxylases is a tetratricopeptide repeat domain with functional aromatic residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; PROLINE; ENZYMES; IDENTIFICATION; RECOGNITION; MECHANISM; COMPLEX; DESIGN	Collagen prolyl 4-hydroxylases catalyze the formation of 4-hydroxyproline in -X-Pro-Gly- sequences and have an essential role in collagen synthesis. The vertebrate enzymes are alpha(2)beta(2) tetramers in which the catalytic alpha-subunits contain separate peptide-substrate-binding and catalytic domains. We report on the crystal structure of the peptide-substrate-binding domain of the human type I enzyme refined at 2.3 resolution. It was found to belong to a family of tetratricopeptide repeat domains that are involved in many protein-protein interactions and consist of five alpha-helices forming two tetratricopeptide repeat motifs plus the solvating helix. A prominent feature of its concave surface is a deep groove lined by tyrosines, a putative binding site for proline-rich peptides. Solvent-exposed side chains of three of the tyrosines have a repeat distance similar to that of a poly-L-proline type II helix. The aromatic surface ends at one of the tyrosines, where the groove curves almost 90 away from the linear arrangement of the three tyrosine side chains, possibly inducing a bent conformation in the bound peptide. This finding is consistent with previous suggestions by others that a minimal structural requirement for proline 4-hydroxylation may be a sequence in the poly-L-proline type II conformation followed by a beta-turn in the Pro-Gly segment. Site-directed mutagenesis indicated that none of the tyrosines was critical for tetramer assembly, whereas most of them were critical for the binding of a peptide substrate and inhibitor both to the domain and the alpha(2)beta(2) enzyme tetramer.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu	Myllyharju, J (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi		Hieta, Reija/0000-0001-5724-6253				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; ATREYA PL, 1991, J BIOL CHEM, V266, P2852; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; Bhattacharyya R, 2003, J MOL BIOL, V331, P925, DOI 10.1016/S0022-2836(03)00759-9; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Dijkstra K, 1999, J BIOMOL NMR, V14, P195, DOI 10.1023/A:1008331225208; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freund C, 2002, EMBO J, V21, P5985, DOI 10.1093/emboj/cdf602; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mahoney NM, 1999, NAT STRUCT BIOL, V6, P666, DOI 10.1038/10722; Main ERG, 2003, STRUCTURE, V11, P497, DOI 10.1016/S0969-2126(03)00076-5; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; MYLLYLA R, 1977, EUR J BIOCHEM, V80, P349, DOI 10.1111/j.1432-1033.1977.tb11889.x; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Nodelman IM, 1999, J MOL BIOL, V294, P1271, DOI 10.1006/jmbi.1999.3318; Pekkala M, 2003, ACTA CRYSTALLOGR D, V59, P940, DOI 10.1107/S0907444903005420; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Rucker AL, 2003, PROTEINS, V53, P68, DOI 10.1002/prot.10477; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891; ZARRINPAR A, 2003, SCI STKE	50	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52255	52261		10.1074/jbc.M410007200	http://dx.doi.org/10.1074/jbc.M410007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456751	hybrid			2022-12-25	WOS:000225493400066
J	Smith, AMO; Ratcliffe, RG; Sweetlove, LJ				Smith, AMO; Ratcliffe, RG; Sweetlove, LJ			Activation and function of mitochondrial uncoupling protein in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE; MATRIX; METABOLISM; GLYCOLYSIS; HOMOLOGS; STRESS	Plant mitochondrial uncoupling protein (UCP) is activated by superoxide suggesting that it may function to minimize mitochondrial reactive oxygen species (ROS) formation. However, the precise mechanism of superoxide activation and the exact function of UCP in plants are not known. We demonstrate that 4-hydroxy-2-nonenal (HNE), a product of lipid peroxidation, and a structurally related compound, trans-retinal, stimulate a proton conductance in potato mitochondria that is inhibitable by GTP ( a characteristic of UCP). Proof that the effects of HNE and trans-retinal are mediated by UCP is provided by examination of proton conductance in transgenic plants overexpressing UCP. These experiments demonstrate that the mechanism of activation of UCP is conserved between animals and plants and imply a conservation of function. Mitochondria from transgenic plants overexpressing UCP were further studied to provide insight into function. Experimental conditions were designed to mimic a bioenergetic state that might be found in vivo ( mitochondria were supplied with pyruvate as well as tricarboxylic cycle acids at in vivo cytosolic concentrations and an exogenous ATP sink was established). Under such conditions, an increase in UCP protein content resulted in a modest but significant decrease in the rate of superoxide production. In addition, C-13-labeling experiments revealed an increase in the conversion of pyruvate to citrate as a result of increased UCP protein content. These results demonstrate that under simulated in vivo conditions, UCP is active and suggest that UCP may influence not only mitochondrial ROS production but also tricarboxylic acid cycle flux.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	University of Oxford	Sweetlove, LJ (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	lee.sweetlove@plants.ox.ac.uk		Ratcliffe, R. George/0000-0001-8394-1575	Biotechnology and Biological Sciences Research Council [JF16984] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aubert S, 2001, J EXP BOT, V52, P37, DOI 10.1093/jexbot/52.354.37; Brand M. D., 1995, BIOENERGETICS, V154, P62; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; Brandalise M, 2003, PLANT SCI, V165, P329, DOI 10.1016/S0168-9452(03)00159-6; Brandalise M, 2003, J BIOENERG BIOMEMBR, V35, P203, DOI 10.1023/A:1024603530043; Calegario FF, 2003, J BIOENERG BIOMEMBR, V35, P211, DOI 10.1023/A:1024655514113; Considine MJ, 2003, J BIOL CHEM, V278, P22298, DOI 10.1074/jbc.M301075200; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Farre EM, 2001, PLANT PHYSIOL, V127, P685, DOI 10.1104/pp.127.2.685; Fernie AR, 2004, CURR OPIN PLANT BIOL, V7, P254, DOI 10.1016/j.pbi.2004.03.007; FOX GG, 1989, J MAGN RESON, V82, P360, DOI 10.1016/0022-2364(89)90039-5; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Heazlewood JL, 2003, PLANT PHYSIOL, V132, P230, DOI 10.1104/pp.102.018986; Hourton-Cabassa U, 2004, PLANT PHYSIOL BIOCH, V42, P283, DOI 10.1016/j.plaphy.2004.01.007; Jenner HL, 2001, PLANT PHYSIOL, V126, P1139, DOI 10.1104/pp.126.3.1139; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; Miwa S, 2003, BIOCHEM SOC T, V31, P1300; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Picault N, 2004, TRENDS PLANT SCI, V9, P138, DOI 10.1016/j.tplants.2004.01.007; Rasmusson AG, 2004, ANNU REV PLANT BIOL, V55, P23, DOI 10.1146/annurev.arplant.55.031903.141720; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Schwender J, 2003, J BIOL CHEM, V278, P29442, DOI 10.1074/jbc.M303432200; Sluse FE, 2002, FEBS LETT, V510, P117, DOI 10.1016/S0014-5793(01)03229-X; Talbot DA, 2004, FEBS LETT, V556, P111, DOI 10.1016/S0014-5793(03)01386-3; Thimm O, 2004, PLANT J, V37, P914, DOI 10.1111/j.1365-313X.2004.02016.x; Trono D, 2004, PLANT CELL ENVIRON, V27, P437, DOI 10.1111/j.1365-3040.2003.01162.x; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643	31	121	126	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51944	51952		10.1074/jbc.M408920200	http://dx.doi.org/10.1074/jbc.M408920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456782	hybrid			2022-12-25	WOS:000225493400029
J	Yang, WR; Moore, IF; Koteva, KP; Bareich, DC; Hughes, DW; Wright, GD				Yang, WR; Moore, IF; Koteva, KP; Bareich, DC; Hughes, DW; Wright, GD			TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENES; DETERMINANTS; DEGRADATION	The tetracycline antibiotics block microbial translation and constitute an important group of antimicrobial agents that find broad clinical utility. Resistance to this class of antibiotics is primarily the result of active efflux or ribosomal protection; however, a novel mechanism of resistance has been reported to be oxygen-dependent destruction of the drugs catalyzed by the enzyme TetX. Paradoxically, the tetX genes have been identified on transposable elements found in anaerobic bacteria of the genus Bacteroides. Overexpression of recombinant TetX in Escherichia coli followed by protein purification revealed a stoichiometric complex with flavin adenine dinucleotide. Reconstitution of in vitro enzyme activity demonstrated a broad tetracycline antibiotic spectrum and a requirement for molecular oxygen and NADPH in antibiotic degradation. The tetracycline products of TetX activity were unstable at neutral pH, but mass spectral and NMR characterization under acidic conditions supported initial monohydroxylation at position 11a followed by intramolecular cyclization and non-enzymatic breakdown to other undefined products. TetX is therefore a FAD-dependent monooxygenase. The enzyme not only catalyzed efficient degradation of a broad range of tetracycline analogues but also conferred resistance to these antibiotics in vivo. This is the first molecular characterization of an antibiotic-inactivating monooxygenase, the origins of which may lie in environmental bacteria.	McMaster Univ, Antimicrobial Res Ctr, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Wright, GD (corresponding author), McMaster Univ, Antimicrobial Res Ctr, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada.	wrightge@mcmaster.ca	Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131; Koteva, Kalinka/0000-0002-6446-9567				ASLESON GL, 1975, J AM CHEM SOC, V97, P6246, DOI 10.1021/ja00854a051; BENVENISTE R, 1973, P NATL ACAD SCI USA, V70, P2276, DOI 10.1073/pnas.70.8.2276; BLACKWOOD RK, 1963, J AM CHEM SOC, V85, P3943, DOI 10.1021/ja00907a010; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001; GUINEY DG, 1984, PLASMID, V11, P248, DOI 10.1016/0147-619X(84)90031-3; LEATHERBARROW RJ, 2000, GRAFIT; Marshall CG, 1998, ANTIMICROB AGENTS CH, V42, P2215, DOI 10.1128/AAC.42.9.2215; McManus PS, 2002, ANNU REV PHYTOPATHOL, V40, P443, DOI 10.1146/annurev.phyto.40.120301.093927; McMurry LM, 2000, GRAM-POSITIVE PATHOGENS, P660; PARK BH, 1988, ANTIMICROB AGENTS CH, V32, P1797, DOI 10.1128/AAC.32.12.1797; Schmidt AS, 2001, APPL ENVIRON MICROB, V67, P5675, DOI 10.1128/AEM.67.12.5675-5682.2001; Schnappinger D, 1996, ARCH MICROBIOL, V165, P359, DOI 10.1007/s002030050339; Sengelov G, 2003, VET MICROBIOL, V95, P91, DOI 10.1016/S0378-1135(03)00123-8; SPEER BS, 1991, J BACTERIOL, V173, P176, DOI 10.1128/jb.173.1.176-183.1991; SPEER BS, 1988, J BACTERIOL, V170, P1423, DOI 10.1128/jb.170.4.1423-1429.1988; Sum PE, 1999, BIOORG MED CHEM LETT, V9, P1459, DOI 10.1016/S0960-894X(99)00216-4; Whittle G, 2001, APPL ENVIRON MICROB, V67, P3488, DOI 10.1128/AEM.67.8.3488-3495.2001	18	197	207	4	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52346	52352		10.1074/jbc.M409573200	http://dx.doi.org/10.1074/jbc.M409573200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452119	hybrid			2022-12-25	WOS:000225493400077
J	Yu, WF; Liang, XQ; Ensenauer, RE; Vockley, J; Sweetman, L; Schulz, H				Yu, WF; Liang, XQ; Ensenauer, RE; Vockley, J; Sweetman, L; Schulz, H			Leaky beta-oxidation of a trans-fatty acid - Incomplete beta-oxidation of elaidic acid is due to the accumulation of 5-trans-tetradecenoyl-CoA and its hydrolysis and conversion to 5-trans-tetradecenoylcarnitine in the matrix of rat mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; HEART-MITOCHONDRIA; LIVER MITOCHONDRIA; METABOLISM; PURIFICATION; ACYLATION; FAMILY; ENZYME; ESTERS	The degradation of elaidic acid (9-trans-octadecenoic acid), oleic acid, and stearic acid by rat mitochondria was studied to determine whether the presence of a trans double bond in place of a cis double bond or no double bond affects beta-oxidation. Rat mitochondria from liver or heart effectively degraded the coenzyme A derivatives of all three fatty acids. However, with elaidoyl-CoA as a substrate, a major metabolite accumulated in the mitochondrial matrix. This metabolite was isolated and identified as 5-trans-tetradecenoyl-CoA. In contrast, little or none of the corresponding metabolites were detected with oleoyl-CoA or stearoyl-CoA as substrates. A kinetic study of long-chain acyl-CoA dehydrogenase (LCAD) and very long-chain acyl-CoA dehydrogenase revealed that 5-trans-tetradecenoyl-CoA is a poorer substrate of LCAD than is 5-cis-tetradecenoyl-CoA, while both unsaturated acyl-CoAs are poor substrates of very long-chain acyl-CoA dehydrogenase when compared with myristoyl-CoA. Tetradecenoic acid and tetradecenoylcarnitine were detected by gas chromatography/ mass spectrometry and tandem mass spectrometry, respectively, when rat liver mitochondria were incubated with elaidoyl-CoA but not when oleoyl-CoA was the substrate. These observations support the conclusion that 5-trans-tetradecenoyl-CoA accumulates in the mitochondrial matrix, because it is less efficiently dehydrogenated by LCAD than is its cis isomer and that the accumulation of this beta-oxidation intermediate facilitates its hydrolysis and conversion to 5-trans-tetradecenoylcarnitine thereby permitting a partially degraded fatty acid to escape from mitochondria. Analysis of this compromised but functional process provides insight into the operation of beta-oxidation in intact mitochondria.	CUNY City Coll, Dept Chem, New York, NY 10031 USA; CUNY, Grad Ctr, New York, NY 10031 USA; Mayo Clin, Dept Med Genet, Rochester, MN 55905 USA; Baylor Univ, Med Ctr, Inst Metab Dis, Dallas, TX 75226 USA	City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System; Mayo Clinic; Baylor University; Baylor University Medical Center	Schulz, H (corresponding author), CUNY City Coll, Dept Chem, Convent Ave & 138th St, New York, NY 10031 USA.	hoschu@sci.ccny.cuny.edu	Vockley, Jerry/AAF-8523-2020; Vockley, Jerry/B-5210-2016	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NCRR NIH HHS [RR03060] Funding Source: Medline; NHLBI NIH HHS [HL30847] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARO A, 1998, T FATTY ACIDS HUMAN, P235; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAIGSCHMIDT MC, 1998, T FATTY ACIDS HUMAN, P59; DAVIDSON B, 1982, ARCH BIOCHEM BIOPHYS, V213, P155, DOI 10.1016/0003-9861(82)90450-7; DeMar JC, 1999, PROG LIPID RES, V38, P49, DOI 10.1016/S0163-7827(98)00020-4; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; IZAI K, 1992, J BIOL CHEM, V267, P1027; KLER RS, 1991, J BIOL CHEM, V266, P22932; LAWSON LD, 1979, LIPIDS, V14, P501, DOI 10.1007/BF02533469; Le WP, 2000, BBA-MOL CELL BIOL L, V1485, P121, DOI 10.1016/S1388-1981(00)00034-2; Liang X, 2001, BIOCHEM SOC T, V29, P279, DOI 10.1042/BST0290279; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; Lindwasser OW, 2002, P NATL ACAD SCI USA, V99, P13037, DOI 10.1073/pnas.212409999; LINESTEAD RP, 1931, J CHEM SOC, P740; MOHSEN AWA, 1995, BIOCHEMISTRY-US, V34, P10146, DOI 10.1021/bi00032a007; MOORE KH, 1982, J MOL CELL CARDIOL, V14, P451, DOI 10.1016/0022-2828(82)90151-1; NADA MA, 1995, J BIOL CHEM, V270, P530, DOI 10.1074/jbc.270.2.530; NEDERGAARD MM, 1979, METHOD ENZYMOL, V69, P390; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; Rashed MS, 1997, CLIN CHEM, V43, P1129; Ren Y, 2003, J BIOL CHEM, V278, P111, DOI 10.1074/jbc.M209261200; ROZEN R, 1994, GENOMICS, V24, P280, DOI 10.1006/geno.1994.1617; SCHULZ H, 1994, J NUTR, V124, P165, DOI 10.1093/jn/124.2.165; STEINMAN H, 1965, METHOD ENZYMOL, V35, P136; THORPE C, 1986, ANAL BIOCHEM, V155, P391, DOI 10.1016/0003-2697(86)90452-5; Ventura FV, 1998, EUR J BIOCHEM, V253, P614, DOI 10.1046/j.1432-1327.1998.2530614.x; WILLEBRA.AF, 1966, BIOCHIM BIOPHYS ACTA, V116, P583, DOI 10.1016/0005-2760(66)90130-5; Zhang DY, 2001, J BIOL CHEM, V276, P13622, DOI 10.1074/jbc.M011315200	30	23	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52160	52167		10.1074/jbc.M409640200	http://dx.doi.org/10.1074/jbc.M409640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466478	hybrid			2022-12-25	WOS:000225493400055
J	Chang, WY; Bryce, DM; D'Souza, SJA; Dagnino, L				Chang, WY; Bryce, DM; D'Souza, SJA; Dagnino, L			The DP-1 transcription factor is required for keratinocyte growth and epidermal stratification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIR FOLLICLE MORPHOGENESIS; CELL-CYCLE PROGRESSION; DNA-REPLICATION; E2F FAMILY; TARGET GENES; IN-VIVO; S-PHASE; DEREGULATED EXPRESSION; DIFFERENTIATION; PROLIFERATION	The epidermis is a stratified epithelium constantly replenished through the ability of keratinocytes in its basal layer to proliferate and self-renew. The epidermis arises from a single-cell layer ectoderm during embryogenesis. Large proliferative capacity is central to ectodermal cell and basal keratinocyte function. DP-1, a heterodimeric partner of E2F transcription factors, is highly expressed in the ectoderm and all epidermal layers during embryogenesis. To investigate the role of DP-1 in epidermal morphogenesis, we inhibited DP-1 activity through exogenous expression of a dominant-negative mutant (dnDP-1). Expression of the dnDP-1 mutant interferes with binding of E2F/DP-1 heterodimers to DNA and inhibits DNA replication, as well as cyclin A mRNA and protein expression. Chromatin immunoprecipitation analysis demonstrated that the cyclin A promoter is predominantly bound in proliferating keratinocytes by complexes containing E2F-3 and E2F-4. Thus, the mechanisms of decreased expression of cyclin A in the presence of dnDP-1 seem to involve inactivation of DP-1 complexes containing E2F-3 and E2F-4. To assess the consequences on epidermal morphogenesis of inhibiting DP-1 activity, we expressed dnDP-1 in rat epithelial keratinocytes in organotypic culture and observed that DP-1 inhibition negatively affected stratification of these cells. Likewise, expression of dnDP-1 in embryonic ectoderm explants produced extensive disorganization of subsequently formed epidermal basal and suprabasal layers, interfering with normal epidermal formation. We conclude that DP-1 activity is required for normal epidermal morphogenesis and ectoderm-to-epidermis transition.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Pediat, London, ON N6A 5C1, Canada; Child Hlth Res Inst, London, ON N6A 5C1, Canada; Lawson Hlth Res Inst, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol, Med Sci Bldg, London, ON N6A 5C1, Canada.	ldagnino@uwo.ca		Bryce, Dawn/0000-0002-7403-2940; Dagnino, Lina/0000-0003-1483-5159				BADEN HP, 1983, J INVEST DERMATOL, V80, P124, DOI 10.1111/1523-1747.ep12532899; BONEKO VM, 1988, ACTA ANAT, V133, P325; Botchkarev VA, 1999, NAT CELL BIOL, V1, P158, DOI 10.1038/11078; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Byrne C, 2003, J ANAT, V202, P113, DOI 10.1046/j.1469-7580.2003.00142.x; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Chuong CM, 2002, EXP DERMATOL, V11, P159; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Foitzik K, 1999, DEV BIOL, V212, P278, DOI 10.1006/dbio.1999.9325; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gopalkrishnan RV, 1996, ONCOGENE, V13, P2671; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HIRAI Y, 1989, DEVELOPMENT, V105, P271; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; Humbert PO, 2000, GENE DEV, V14, P690; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; JACKSON BW, 1981, DIFFERENTIATION, V20, P203, DOI 10.1111/j.1432-0436.1981.tb01177.x; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; Kulessa H, 2000, EMBO J, V19, P6664, DOI 10.1093/emboj/19.24.6664; La Thangue NB, 2003, NAT CELL BIOL, V5, P587, DOI 10.1038/ncb0703-587; Lania L, 1999, J CELL PHYSIOL, V179, P134, DOI 10.1002/(SICI)1097-4652(199905)179:2<134::AID-JCP3>3.0.CO;2-O; Lavia P, 1999, BIOESSAYS, V21, P221; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; MACCALLUM D K, 1990, Skin Pharmacology, V3, P86; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Niemann C, 2002, TRENDS CELL BIOL, V12, P185, DOI 10.1016/S0962-8924(02)02263-8; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Pasonen-Seppanen S, 2001, HISTOCHEM CELL BIOL, V116, P287, DOI 10.1007/s004180100312; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Tammi RH, 2000, HISTOCHEM CELL BIOL, V113, P265, DOI 10.1007/s004180000128; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vespa A, 2003, J BIOL CHEM, V278, P11528, DOI 10.1074/jbc.M208337200; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wang DW, 2001, MOL CARCINOGEN, V31, P90, DOI 10.1002/mc.1044; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU CL, 1995, MOL CELL BIOL, V15, P2536; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamada M, 2002, CYTOKINE, V17, P91, DOI 10.1006/cyto.2001.0992; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	71	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51343	51353		10.1074/jbc.M408635200	http://dx.doi.org/10.1074/jbc.M408635200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448153	hybrid			2022-12-25	WOS:000225355800085
J	Davis, TH; Chen, CL; Isom, LL				Davis, TH; Chen, CL; Isom, LL			Sodium channel beta 1 subunits promote neurite outgrowth in cerebellar granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; CELL-ADHESION; FGF RECEPTOR; GENERALIZED EPILEPSY; EXTRACELLULAR DOMAIN; AUXILIARY SUBUNIT; FEBRILE SEIZURES; N-CADHERIN; TENASCIN-R; EXPRESSION	Many immunoglobulin superfamily members are integral in development through regulation of processes such as growth cone guidance, cell migration, and neurite outgrowth. We demonstrate that homophilic interactions between voltage-gated sodium channel beta1 subunits promote neurite extension in cerebellar granule neurons. Neurons isolated from wild-type or beta1(-/-) mice were plated on top of parental, mock-, or beta1-transfected fibroblasts. Wild-type neurons consistently showed increased neurite length when grown on beta1-transfected monolayers, whereas beta1(-/-) neurons showed no increase compared with control conditions. beta1-Mediated neurite extension was mimicked using a soluble beta1 extracellular domain and was blocked by antibodies directed against the beta1 extracellular domain. Immunohistochemical analysis suggests that the beta1 and beta4 subunits, but not beta2 and beta3, are expressed in cerebellar Bergmann glia as well as granule neurons. These results suggest a novel role for beta1 during neuronal development and are the first demonstration of a functional role for sodium channel beta subunit-mediated cell adhesive interactions.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Isom, LL (corresponding author), Univ Michigan, Dept Pharmacol, 1150 W Med Ctr Dr,1301 MSRB 3, Ann Arbor, MI 48109 USA.	lisom@umich.edu		Isom, Lori/0000-0002-9479-6729	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS043062] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07767] Funding Source: Medline; NIMH NIH HHS [R01MH59980] Funding Source: Medline; NINDS NIH HHS [F31NS43062] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altman J, 1997, DEV CEREBELLAR SYSTE; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BIXBY JL, 1994, J CELL BIOL, V127, P1461, DOI 10.1083/jcb.127.5.1461; BOVOLENTA P, 1984, DEV BIOL, V102, P248, DOI 10.1016/0012-1606(84)90189-1; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Buttiglione M, 1996, MOL CELL NEUROSCI, V8, P53, DOI 10.1006/mcne.1996.0043; Chen CL, 2004, J NEUROSCI, V24, P4030, DOI 10.1523/JNEUROSCI.4139-03.2004; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Kamiguchi H, 1998, MOL CELL NEUROSCI, V12, P48, DOI 10.1006/mcne.1998.0702; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Kolkova K, 2000, J NEUROSCI, V20, P2238; Levy-Mozziconacci A, 1998, EUR J NEUROSCI, V10, P2757, DOI 10.1046/j.1460-9568.1998.00283.x; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Malhotra JD, 2004, J BIOL CHEM, V279, P40748, DOI 10.1074/jbc.M407243200; Malhotra JD, 2002, J BIOL CHEM, V277, P26681, DOI 10.1074/jbc.M202354200; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; Meadows LS, 2002, J NEUROSCI, V22, P10699; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Rolf B, 2002, J NEUROSCI, V22, P8357; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Schaller KL, 2003, CEREBELLUM, V2, P2, DOI 10.1080/14734220309424; Shah BS, 2001, J PHYSIOL-LONDON, V534, P763, DOI 10.1111/j.1469-7793.2001.t01-1-00763.x; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; Skaper SD, 2001, PROG NEUROBIOL, V65, P593, DOI 10.1016/S0301-0082(01)00017-X; Soha JM, 1997, J COMP NEUROL, V389, P642, DOI 10.1002/(SICI)1096-9861(19971229)389:4<642::AID-CNE7>3.0.CO;2-0; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TONG JF, 1993, BIOCHEM BIOPH RES CO, V195, P679, DOI 10.1006/bbrc.1993.2099; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; Yu FH, 2003, J NEUROSCI, V23, P7577	42	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51424	51432		10.1074/jbc.M410830200	http://dx.doi.org/10.1074/jbc.M410830200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452131	hybrid			2022-12-25	WOS:000225355800094
J	Kapyla, J; Jaalinoja, J; Tulla, M; Ylostalo, J; Nissinen, L; Viitasalo, T; Vehvilainen, P; Marjomaki, V; Nykvist, P; Saamanen, AM; Farndale, RW; Birk, DE; Ala-Kokko, L; Heino, J				Kapyla, J; Jaalinoja, J; Tulla, M; Ylostalo, J; Nissinen, L; Viitasalo, T; Vehvilainen, P; Marjomaki, V; Nykvist, P; Saamanen, AM; Farndale, RW; Birk, DE; Ala-Kokko, L; Heino, J			The fibril-associated collagen IX provides a novel mechanism for cell adhesion to cartilaginous matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; INTEGRINS ALPHA(1)BETA(1); 3-DIMENSIONAL COLLAGEN; RECOGNITION SITE; GENE-EXPRESSION; V COLLAGEN; BINDING; DOMAIN; IDENTIFICATION; RECEPTOR	Collagen IX is the prototype fibril-associated collagen with interruptions in triple helix. In human cartilage it covers collagen fibrils, but its putative cellular receptors have been unknown. The reverse transcription-PCR analysis of human fetal tissues suggested that based on their distribution all four collagen receptor integrins, namely alpha(1)beta(1), alpha(2)beta(1), alpha(10)beta(1), and alpha(11)beta(1), are possible receptors for collagen IX. Furthermore primary chondrocytes and chondrosarcoma cells express the four integrins simultaneously. Chondrosarcoma cells, as well as Chinese hamster ovary cells transfected to express alpha(1)beta(1), alpha(2)beta(1), or alpha(10)beta(1) integrin as their only collagen receptor, showed fast attachment and spreading on human recombinant collagen IX indicating that it is an effective cell adhesion protein. To further study the recognition of collagen IX we produced recombinant alphaI domains in Escherichia coli. For each of the four alphaI domains, collagen IX was among the best collagenous ligands, making collagen IX exceptional compared with all other collagen subtypes tested so far. Rotary shadowing electron microscopy images of both alpha(1)I- and alpha(2)I-collagen IX complexes unveiled only one binding site located in the COL3 domain close to the kink between it and the COL2 domain. The recognition of collagen IX by alpha(2)I was considered to represent a novel mechanism for two reasons. First, collagen IX has no GFOGER motif, and the identified binding region lacks any similar sequences. Second, the alpha(2)I domain mutations D219R and H258V, which both decreased binding to collagen I and GFOGER, had very different effects on its binding to collagen IX. D219R had no effect, and H258V prevented type IX binding. Thus, our results indicate that collagen IX has unique cell adhesion properties when compared with other collagens, and it provides a novel mechanism for cell adhesion to cartilaginous matrix.	Univ Turku, Dept Biochem & Food Chem, FI-20014 Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm Sci, FI-40014 Jyvaskyla, Finland; Univ Oulu, Bioctr, Collagen Res Unit, FL-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FL-90014 Oulu, Finland; Univ Turku, Dept Med Biochem, FI-20520 Turku, Finland; Univ Turku, Med Res Lab, FI-20520 Turku, Finland; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA; Univ Turku, Dept Biochem & Food Chem, FI-20014 Turku, Finland	University of Turku; University of Jyvaskyla; University of Oulu; University of Oulu; University of Turku; University of Turku; University of Cambridge; Jefferson University; Tulane University; Tulane University; University of Turku	Heino, J (corresponding author), Univ Turku, Dept Biochem & Food Chem, Arcanum Vatselankatu2, FI-20014 Turku, Finland.	jyrki.heino@utu.fi	Birk, David/I-4072-2012; Ylostalo, Joni/AAH-9457-2019	Birk, David/0000-0002-4865-9088; Ylostalo, Joni/0000-0001-9746-1994; Marjomaki, Varpu/0000-0002-4592-5926; Kapyla, Jarmo/0000-0003-3036-713X; Nissinen, Liisa/0000-0002-6743-6736				BIRK DE, 1990, J CELL SCI, V95, P649; Bonnemann CG, 2000, P NATL ACAD SCI USA, V97, P1212, DOI 10.1073/pnas.97.3.1212; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Camper L, 2001, CELL TISSUE RES, V306, P107, DOI 10.1007/s004410100385; Chen JC, 2002, AM J PATHOL, V161, P337, DOI 10.1016/S0002-9440(10)64185-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Czarny-Ratajczak M, 2001, AM J HUM GENET, V69, P969, DOI 10.1086/324023; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Ekholm E, 2002, AM J PATHOL, V160, P1779, DOI 10.1016/S0002-9440(10)61124-8; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Eyre DR, 2004, J BIOL CHEM, V279, P2568, DOI 10.1074/jbc.M311653200; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Golbik R, 2000, J MOL BIOL, V297, P501, DOI 10.1006/jmbi.2000.3575; HEINO J, 1989, J BIOL CHEM, V264, P380; Herouy Y, 1998, J INVEST DERMATOL, V111, P822, DOI 10.1046/j.1523-1747.1998.00369.x; Holden P, 1999, AM J HUM GENET, V65, P31, DOI 10.1086/302440; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Jokinen J, 2004, J BIOL CHEM, V279, P31956, DOI 10.1074/jbc.M401409200; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KERN A, 1994, J BIOL CHEM, V269, P22811; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Li SH, 2003, AM J PATHOL, V163, P1045, DOI 10.1016/S0002-9440(10)63464-5; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277; Lohiniva J, 2000, AM J MED GENET, V90, P216, DOI 10.1002/(SICI)1096-8628(20000131)90:3<216::AID-AJMG6>3.0.CO;2-1; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; Nishida N, 2003, NAT STRUCT BIOL, V10, P53, DOI 10.1038/nsb876; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; NORO A, 1983, J BIOL CHEM, V258, P9323; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Nykvist P, 2001, J BIOL CHEM, V276, P38673, DOI 10.1074/jbc.M102589200; Olsen BR, 1997, INT J BIOCHEM CELL B, V29, P555, DOI 10.1016/S1357-2725(96)00100-8; Paassilta P, 1999, AM J HUM GENET, V64, P1036, DOI 10.1086/302328; Pihlajamaa T, 1999, J BIOL CHEM, V274, P22464, DOI 10.1074/jbc.274.32.22464; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Sacca B, 2003, BIOCHEMISTRY-US, V42, P3429, DOI 10.1021/bi0206762; SANTALA P, 1994, J BIOL CHEM, V269, P1276; Siljander PRM, 2004, J BIOL CHEM, V279, P47763, DOI 10.1074/jbc.M404685200; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; Spayde EC, 2000, MATRIX BIOL, V19, P121, DOI 10.1016/S0945-053X(00)00055-X; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; VOIGT S, 1995, HISTOCHEM J, V27, P123; VUORIO E, 1984, FEBS LETT, V174, P238, DOI 10.1016/0014-5793(84)81165-5; WU JJ, 1992, J BIOL CHEM, V267, P23007; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zemmyo M, 2003, ARTHRITIS RHEUM-US, V48, P2873, DOI 10.1002/art.11246; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200; ZUTTER MM, 1990, AM J PATHOL, V137, P113	67	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51677	51687		10.1074/jbc.M409412200	http://dx.doi.org/10.1074/jbc.M409412200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15383545	hybrid			2022-12-25	WOS:000225355800124
J	Yu, S; Michie, SA; Lowe, AW				Yu, S; Michie, SA; Lowe, AW			Absence of the major zymogen granule membrane protein, GP2, does not affect pancreatic morphology or secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAMM-HORSFALL PROTEIN; RAT PANCREAS; ACINAR-CELLS; EXOCRINE PANCREAS; ESCHERICHIA-COLI; GP-2; GLYCOPROTEIN; MICE; UROMODULIN; IDENTIFICATION	The majority of digestive enzymes in humans are produced in the pancreas where they are stored in zymogen granules before secretion into the intestine. GP2 is the major membrane protein present in zymogen granules of the exocrine pancreas. Numerous studies have shown that GP2 binds digestive enzymes such as amylase, thereby supporting a role in protein sorting to the zymogen granule. Other studies have suggested that GP2 is important in the formation of zymogen granules. A knock-out mouse was generated for GP2 to study the impact of the protein on pancreatic function. GP2-deficient mice displayed no gross signs of nutrient malabsorption such as weight loss, growth retardation, or diarrhea. Zymogen granules in the GP2 knock-out mice appeared normal on electron microscopy and contained the normal complement of proteins excluding GP2. Primary cultures of pancreatic acini appropriately responded to secretagogue stimulation with the secretion of digestive enzymes. The course of experimentally induced pancreatitis was also examined in the knock-out mice because proteins known to associate with GP2 have been found to possess a protective role. When GP2 knock-out mice were subjected to two different models of pancreatitis, no major differences were detected. In conclusion, GP2 is not essential for pancreatic exocrine secretion or zymogen granule formation. It is unlikely that GP2 serves a major intracellular role within the pancreatic acinar cell and may be functionally active after it is secreted from the pancreas.	Stanford Univ, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Ctr Digest Dis, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Lowe, AW (corresponding author), Alway Bldg,Rm M211,300 Pasteur Dr, Stanford, CA 94305 USA.	lowe@stanford.edu			NIDDK NIH HHS [DK43294] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043294, R01DK043294] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Antonin W, 2002, MOL CELL BIOL, V22, P1545, DOI 10.1128/MCB.22.5.1545-1554.2002; Bates JM, 2004, KIDNEY INT, V65, P791, DOI 10.1111/j.1523-1755.2004.00452.x; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; COLOMER V, 1994, EMBO J, V13, P3711, DOI 10.1002/j.1460-2075.1994.tb06680.x; Dartsch H, 1998, EUR J CELL BIOL, V75, P211, DOI 10.1016/S0171-9335(98)80115-5; Demols A, 2000, PANCREAS, V20, P161, DOI 10.1097/00006676-200003000-00009; DITTIE A, 1992, EUR J CELL BIOL, V58, P243; FREEDMAN SD, 1993, BIOCHEM BIOPH RES CO, V197, P992, DOI 10.1006/bbrc.1993.2577; Fritz B.A., 1996, AM J PHYSIOL, V270, P176; FUKUOKA SI, 1991, P NATL ACAD SCI USA, V88, P2898, DOI 10.1073/pnas.88.7.2898; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Hao Y, 2004, ARCH PATHOL LAB MED, V128, P668; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; Imamura T, 2002, J BIOL CHEM, V277, P50725, DOI 10.1074/jbc.M204159200; JACOB M, 1992, BIOCHEM CELL BIOL, V70, P1105, DOI 10.1139/o92-156; Kalus I, 2002, BIOCHEM J, V362, P433, DOI 10.1042/0264-6021:3620433; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPEL M, 1977, VIRCHOWS ARCH A, V373, P97, DOI 10.1007/BF00432156; LEBLOND FA, 1993, BIOCHEM J, V291, P289, DOI 10.1042/bj2910289; LOMBARDI B, 1975, AM J PATHOL, V81, P87; LOMBARDI B, 1975, AM J PATHOL, V79, P465; LOWE AW, 1994, GASTROENTEROLOGY, V107, P1819, DOI 10.1016/0016-5085(94)90826-5; MACDONAL.RJ, 1972, BIOCHEM BIOPH RES CO, V49, P377, DOI 10.1016/0006-291X(72)90421-4; MENOZZI D, 1990, METHOD ENZYMOL, V192, P271; Mo L, 2004, AM J PHYSIOL-RENAL, V286, pF795, DOI 10.1152/ajprenal.00357.2003; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; RINDLER MJ, 1990, J BIOL CHEM, V265, P20784; RONZIO RA, 1978, BIOCHIM BIOPHYS ACTA, V508, P65, DOI 10.1016/0005-2736(78)90189-X; SCHEELE GA, 1994, PANCREAS, V9, P139, DOI 10.1097/00006676-199403000-00001; Schmidt K, 2001, J BIOL CHEM, V276, P14315, DOI 10.1074/jbc.M006221200; Schmidt K, 2000, J CELL SCI, V113, P2233; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Yu S, 2004, BIOCHEM BIOPH RES CO, V322, P320, DOI 10.1016/j.bbrc.2004.07.120	36	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50274	50279		10.1074/jbc.M410599200	http://dx.doi.org/10.1074/jbc.M410599200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15385539	hybrid			2022-12-25	WOS:000225229500089
J	Volanti, C; Gloire, G; Vanderplasschen, A; Jacobs, N; Habraken, Y; Piette, J				Volanti, C; Gloire, G; Vanderplasschen, A; Jacobs, N; Habraken, Y; Piette, J			Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy	ONCOGENE			English	Article						NF-kappa B; pyropheophorbide; photodynamic therapy; endothelial cells; oxidative stress; adhesion molecules	NF-KAPPA-B; PYROPHEOPHORBIDE-A; OXIDATIVE STRESS; IN-VIVO; CHOROIDAL NEOVASCULARIZATION; TUMOR; MATRIX-METALLOPROTEINASE-9; ACTIVATION; PHOTOSENSITIZATION; PHARMACOKINETICS	Photodynamic therapy (PDT) is a treatment for cancer and several noncancerous proliferating cell diseases that depends on the uptake of a photosensitizing compound followed by selective irradiation with visible light. In the presence of oxygen, irradiation leads to the production of reactive oxygen species (ROS). A large production of ROS induces the death of cancer cells by apoptosis or necrosis. A small ROS production can activate various cellular pathways. Here, we show that PDT by pyropheophorbide-a methyl ester (PPME) induces the activation of nuclear factor kappa B (NF-kappaB) in HMEC-1 cells. NF-kappaB is active since it binds to the NF-kappaB sites of both ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1) promoters and induces the transcription of several NF-kappaB target genes such as those of IL-6, ICAM-1, VCAM-I. In contrast, expression of ICAM-1 and VCAM-I at the protein level was not observed, although we measured an IL-6 secretion. Using specific chemical inhibitors, we showed that the lack of ICAM-1 and VCAM-I expression is the consequence of their degradation by lysosomal proteases. The proteasome and calpain pathways were not involved. All these observations were consistent with the fact that no adhesion of granulocytes was observed in these conditions.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Dept Immunol & Vaccinol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol B23, Dept Pathol, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be		Jacobs, Nathalie/0000-0002-9895-8465				Aiello L P, 1997, Curr Opin Ophthalmol, V8, P19; Arkell J, 2003, CELL BIOCHEM FUNCT, V21, P381, DOI 10.1002/cbf.1037; BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cecic I, 2001, PHOTOCHEM PHOTOBIOL, V74, P712, DOI 10.1562/0031-8655(2001)074<0712:IOSNRI>2.0.CO;2; Chen B, 2002, INT J CANCER, V98, P284, DOI 10.1002/ijc.10175; deVree WJA, 1996, CANCER RES, V56, P2908; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864; Gollnick SO, 1997, CANCER RES, V57, P3904; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; HENDERSON BW, 1995, PHOTOCHEM PHOTOBIOL, V62, P780, DOI 10.1111/j.1751-1097.1995.tb08730.x; Henderson BW, 1997, CANCER RES, V57, P4000; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kolev K, 2003, THROMB HAEMOSTASIS, V90, P528, DOI 10.1160/TH03-02-0070; Korbelik M, 1996, J Clin Laser Med Surg, V14, P329; Krammer B, 2001, ANTICANCER RES, V21, P4271; KROSL G, 1995, BRIT J CANCER, V71, P549, DOI 10.1038/bjc.1995.108; Lee JM, 2003, ANN NEUROL, V54, P379, DOI 10.1002/ana.10671; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; Marcinkowska A, 2001, FOLIA HISTOCHEM CYTO, V39, P177; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Niziolek M, 2003, PHOTOCHEM PHOTOBIOL, V78, P262, DOI 10.1562/0031-8655(2003)078<0262:CAACAO>2.0.CO;2; Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Rousset N, 1999, J PHOTOCH PHOTOBIO B, V52, P65, DOI 10.1016/S1011-1344(99)00104-9; Santos CF, 2003, AM J PHYSIOL-HEART C, V285, pH775, DOI 10.1152/ajpheart.00818.2002; Schmidt-Erfurth U, 1998, OPHTHALMOLOGE, V95, P725, DOI 10.1007/s003470050343; Schreiber S, 2002, INT J CANCER, V99, P279, DOI 10.1002/ijc.10299; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Wagner JG, 2000, PHARMACOL REV, V52, P349; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	42	40	42	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8649	8658		10.1038/sj.onc.1207871	http://dx.doi.org/10.1038/sj.onc.1207871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467759				2022-12-25	WOS:000224988800011
J	Paz, K; Socci, ND; van Nimwegen, E; Viale, A; Darnell, JE				Paz, K; Socci, ND; van Nimwegen, E; Viale, A; Darnell, JE			Transformation fingerprint: induced STAT3-C, v-Src and Ha-Ras cause small initial changes but similar established profiles in mRNA	ONCOGENE			English	Article						STAT3-C; Src; transformation	MAP KINASE KINASE; MAMMALIAN-CELLS; GENE-EXPRESSION; TRANSCRIPTION; ACTIVATION; PROTEIN; P53; IDENTIFICATION; SYSTEM; SIGNAL	Induced transformation of mouse fibroblasts was carried out by releasing tetracycline-repressed expression of an oncogenic mutant of STAT3, STAT3-C, or of v-Src or Ha-Ras. At 15 days after derepression of each oncogene, DNA microarrays showed elevation (> 3-fold) of a similar group of similar to25 mRNAs compared to untransformed cells. RT - PCR confirmed a number of these mRNA elevations. RNA samples were then analysed at intervals during the first 24 h after doxycycline removal to determine the time of early changes. Extensive changes were not observed by array analysis, except in v-Src-expressing cells where about 10 mRNAs were elevated threefold or more. However, RT - PCR did uncover changes in each derepressed cell type that included some of the changes observed after the 15-day transformation period. In addition, STAT3-C target genes such as BclXI and cyclin D1, which were not observed on array analysis, were elevated by RT - PCR analysis. We conclude, therefore, that early after oncogene induction, transcriptional changes, including those initiated by STAT3-C, may occur only in scarce mRNA and/or to a limited extent. However, with additional time and probably additional cell division, a new epigenetic state is established that is mirrored by a changed transcriptional pro. le emblematic of transformation by each of three oncogenes.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center; Rockefeller University	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.	darnell@rockefeller.edu	van Nimwegen, Erik/ABF-1085-2021	van Nimwegen, Erik/0000-0001-6338-1312	NIAID NIH HHS [AI32489, AI34420] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489, R01AI034420, R37AI034420] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOURNE HR, 1990, NATURE, V348, P678, DOI 10.1038/348678a0; BOYNTON AL, 1984, CANCER LETT, V21, P293, DOI 10.1016/0304-3835(84)90008-9; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; CHEN YC, 1977, CELL, V11, P513, DOI 10.1016/0092-8674(77)90069-1; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DUZGUNES N, 1993, METHOD ENZYMOL, V221, P303, DOI 10.1016/0076-6879(93)21025-4; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Freundlieb S, 1999, J GENE MED, V1, P4, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y; GEIGER B, 1979, P NATL ACAD SCI USA, V76, P2833, DOI 10.1073/pnas.76.6.2833; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Naef F, 2003, BIOINFORMATICS, V19, P178, DOI 10.1093/bioinformatics/19.2.178; Naef F, 2002, GENOME BIOL, V3; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Staudt LM, 2003, NEW ENGL J MED, V348, P1777, DOI 10.1056/NEJMra020067; STJOHNSTON D, 1992, CELL, V68, P201; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VARMUS HE, 1987, SCIENCE, V238, P1337, DOI 10.1126/science.2825348; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	40	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8455	8463		10.1038/sj.onc.1207803	http://dx.doi.org/10.1038/sj.onc.1207803			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378015				2022-12-25	WOS:000224870700006
J	Naaz, A; Holsberger, DR; Iwamoto, GA; Nelson, A; Kiyokawa, H; Cooke, PS				Naaz, A; Holsberger, DR; Iwamoto, GA; Nelson, A; Kiyokawa, H; Cooke, PS			Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity	FASEB JOURNAL			English	Article						p27; p21; adipogenesis; insulin resistance; transgenic; cell cycle	ADIPOSE-TISSUE CELLULARITY; INSULIN-RECEPTOR; GLUCOSE-INTOLERANCE; KNOCKOUT MICE; ADIPOGENESIS; CHILDHOOD; MUSCLE; DIFFERENTIATION; DEGRADATION; OVERWEIGHT	Adipocyte hyperplasia is characteristic of some forms of human obesity, but the role of adipocyte number in obesity and how normal adipocyte number is established are unclear. Preadipocytes proliferate and then differentiate to become mitotically quiescent adipocytes. This involves exit from the cell cycle, a process regulated by cell cycle inhibitors such as the cyclin-dependent kinase inhibitors (CDKIs) p27 and p21. 3T3-L1 preadipocytes show marked changes in p27 and p21 during differentiation, suggesting CDKIs may regulate establishment of adipocyte number in vivo. To study the role of these CDKIs in adipogenesis, we analyzed adult p27 knockout (p27KO), p21 knockout (p21KO), p27/p21 double knockout (DBKO), and wildtype (WT) mice. Adult DBKO mice weighed 100% more and had fourfold increases in body fat percentage compared with WT. Fat pad weights were increased 80, 90, and 500% in p27KO, p21KO, and DBKO mice, respectively, compared with WT. Adipocyte numbers of p27KO, p21KO, and DBKO mice were 1.9-, 1.7-, and 6.1-fold, respectively, that of WT; adipocyte size was not increased. DBKO mice showed glucose intolerance, insulin insensitivity, hepatic steatosis and dyslipidemia; gradations of these effects occurred in p27KO and p21KO mice. In conclusion, p27KO and p21KO mice are obese because of adipocyte hyperplasia, and DBKO mice have further increases in obesity and adipocyte hyperplasia, indicating that their functions in establishing adipocyte number are not redundant. p27 and p21 are major regulators of adipocyte number in vivo, and knockouts lacking one or both of these proteins provide models for producing adipocyte hyperplasia and understanding its metabolic consequences.	Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA; Univ Illinois, Dept Kinesiol, Urbana, IL 61802 USA; Univ Illinois, Div Nutr Sci, Urbana, IL 61802 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cooke, PS (corresponding author), Univ Illinois, Dept Vet Biosci, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	p-cooke@uiuc.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NIA NIH HHS [AG024387] Funding Source: Medline; NICHD NIH HHS [HD38085] Funding Source: Medline; NIEHS NIH HHS [ES11590] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG024387] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arner P, 2003, TRENDS ENDOCRIN MET, V14, P137, DOI 10.1016/S1043-2760(03)00024-9; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cariou B, 2004, ENDOCRINOLOGY, V145, P1926, DOI 10.1210/en.2003-0882; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Ebbeling CB, 2002, LANCET, V360, P473, DOI 10.1016/S0140-6736(02)09678-2; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; HAGER A, 1977, METABOLISM, V26, P607, DOI 10.1016/0026-0495(77)90082-8; Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467-789X.2001.00042.x; HIRSCH J, 1976, CLIN ENDOCRINOL META, V5, P299, DOI 10.1016/S0300-595X(76)80023-0; Jirawatnotai S, 2003, J BIOL CHEM, V278, P17021, DOI 10.1074/jbc.M301206200; JOHNSON PR, 1972, J LIPID RES, V13, P2; KIRKLAND JL, 1990, AM J PHYSIOL, V258, pC206, DOI 10.1152/ajpcell.1990.258.2.C206; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Lin J, 2003, BIOCHEM BIOPH RES CO, V300, P938, DOI 10.1016/S0006-291X(02)02949-2; Marques BG, 1998, AM J PHYSIOL-REG I, V275, pR1898, DOI 10.1152/ajpregu.1998.275.6.R1898; Martorell R, 2001, J NUTR, V131, p874S, DOI 10.1093/jn/131.3.874S; MERSMANN HJ, 1986, J ANIM SCI, V62, P980, DOI 10.2527/jas1986.624980x; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; MOSSBERG HO, 1989, LANCET, V2, P491; Ortenblad A, 2002, INT J MANAG REV, V4, P87, DOI 10.1111/1468-2370.00078; Patel YM, 1999, P NATL ACAD SCI USA, V96, P1279, DOI 10.1073/pnas.96.4.1279; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHNEIDER BS, 1981, AM J PHYSIOL, V240, pE358, DOI 10.1152/ajpendo.1981.240.4.E358; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Strauss RS, 2001, JAMA-J AM MED ASSOC, V286, P2845, DOI 10.1001/jama.286.22.2845; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Turnbull A, 2004, J PAEDIATR CHILD H, V40, P33, DOI 10.1111/j.1440-1754.2004.00286.x; Vanhala M, 1998, BRIT MED J, V317, P319, DOI 10.1136/bmj.317.7154.319; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	34	110	111	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1925	+		10.1096/fj.04-2631fje	http://dx.doi.org/10.1096/fj.04-2631fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15469964				2022-12-25	WOS:000224849900024
J	Broedl, UC; Jin, WJ; Fuki, IV; Glick, JM; Rader, DJ				Broedl, UC; Jin, WJ; Fuki, IV; Glick, JM; Rader, DJ			Structural basis of endothelial lipase tropism for HDL	FASEB JOURNAL			English	Article						lipoprotein lipase; lipoprotein hydrolysis; lipoprotein binding	LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; HEPATIC LIPASE; TRIGLYCERIDE LIPASE; PANCREATIC LIPASE; ENHANCES BINDING; CHIMERIC LIPASE; CATALYTIC SITE; GENE FAMILY	Lipoprotein lipase (LPL) and endothelial lipase (EL), the most closely related enzymes among the members of the triglyceride lipase gene family with regard to primary sequence, have distinct lipolytic properties ( triglyceride lipase vs. phospholipase) as well as different preferences for specific types of lipoproteins [triglyceride-rich lipoproteins vs. high density lipoprotein (HDL)] Lipid substrate specificity is believed to be conferred by the lid region located in the amino-terminal domain of the enzymes, whereas surprisingly little work has been done to identify the region mediating lipoprotein substrate specificity. To determine the domain responsible for lipoprotein preference within each enzyme, we generated the domain chimeric enzyme LPL-EL. The heterologous carboxy-terminal ( C terminal) domain did not change lipid substrate preference ( triglyceride vs. phospholipase) as determined by using artificial substrates. The EL C-terminal domain, however, enabled LPL-EL to bridge HDL particles like wild-type EL, whereas LPL only mediated binding of very low density lipoprotein. Unlike wild-type LPL, LPL-EL had substantial ability to hydrolyze HDL lipids similar to that of wild-type EL. Overexpression of LPL-EL in wild-type mice resulted in significantly reduced levels of HDL cholesterol and phospholipids by 93 and 85%, respectively, similar to the extent seen in EL-expressing mice, whereas no reduction of these parameters was observed in LPL-expressing mice. We conclude that the C-terminal domain of EL is crucial for the ability of EL to bind and to hydrolyze HDL and converts LPL to an enzyme fully capable of hydrolyzing HDL, highlighting the importance of the C-terminal lipase domain in lipoprotein substrate preference.	Univ Penn, Med Ctr, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Rader, DJ (corresponding author), Univ Penn, Med Ctr, Sch Med, Dept Med, 654 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	rader@mail.med.upenn.edu			NHLBI NIH HHS [HL55323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055323, R37HL055323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Broedl UC, 2004, CIRC RES, V94, P1554, DOI 10.1161/01.RES.0000130657.00222.39; Broedl UC, 2003, J BIOL CHEM, V278, P40688, DOI 10.1074/jbc.M304367200; Chahinian H, 2000, CURR PROTEIN PEPT SC, V1, P91, DOI 10.2174/1389203003381487; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DICHEK HL, 1993, J LIPID RES, V34, P1393; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; DUGI KA, 1992, J BIOL CHEM, V267, P25086; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Jin WJ, 2002, GENOMICS, V80, P268, DOI 10.1006/geno.2002.6837; Kobayashi J, 1996, J BIOL CHEM, V271, P26296, DOI 10.1074/jbc.271.42.26296; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; Lookene A, 1997, J BIOL CHEM, V272, P766, DOI 10.1074/jbc.272.2.766; Maugeais C, 2003, CIRCULATION, V108, P2121, DOI 10.1161/01.CIR.0000092889.24713.DC; McCoy MG, 2002, J LIPID RES, V43, P921; Nielsen MS, 1997, J BIOL CHEM, V272, P5821, DOI 10.1074/jbc.272.9.5821; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; Rader DJ, 2000, CURR OPIN LIPIDOL, V11, P141, DOI 10.1097/00041433-200004000-00006; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005; Sato T, 1997, J BIOL CHEM, V272, P2192; Sonoda H, 2002, J BIOL CHEM, V277, P34254, DOI 10.1074/jbc.M201659200; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R., 1984, LIPASES, P84; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WONG H, 1994, J BIOL CHEM, V269, P10319; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290	36	11	11	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1891	+		10.1096/fj.03-1307fje	http://dx.doi.org/10.1096/fj.03-1307fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456739				2022-12-25	WOS:000224243200006
J	Karmakar, S; Dhar, R; Das, C				Karmakar, S; Dhar, R; Das, C			Inhibition of cytotrophoblastic (JEG-3) cell invasion by interleukin 12 involves an interferon gamma-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; MATRIX METALLOPROTEINASES; TISSUE INHIBITORS; IV COLLAGENASE; HUMAN PLACENTA; E-CADHERIN; IN-VITRO; TRANSCRIPTIONAL SUPPRESSION; TROPHOBLAST INVASION; IMPLANTATION SITE	Trophoblast invasion, like tumor invasion, shares common biochemical mechanisms. However, in contrast to tumor invasion of a host tissue, trophoblastic invasion during implantation is strictly regulated, temporospatially. Factors responsible for these important regulatory processes are presently unknown; however, studies indicate that cytokines and growth factors present in the peri-implantation uterine milieu as the possible candidates. In this study we investigated the role of interleukin (IL) 12 in regulating trophoblast invasion and the expression of trophoblast proteases ( matrix metalloprotease (MMP)-2, MMP-9, and urokinase-type plasminogen activators) and their inhibitors ( tissue inhibitors of metalloprotease (TIMP) 1, TIMP-2, and plasminogen activator inhibitor (PAI)-1) using an in vitro tissue culture system of human choriocarcinoma cell line JEG-3. Our major findings show an anti-invasive role of IL-12, associated with an inhibitory effect on the proteases but with an opposite up-regulating influence on the protease inhibitor, TIMP-1, whereas TIMP-2 and plasminogen activator inhibitor 1 remained unaltered. Stimulation of JEG-3 cells with IL-12 also induced interferon (IFN)-gamma production, which when neutralized using a monoclonal anti-IFN-gamma antibody, F12, abrogates its ability to down-regulate the MMPs. IL-12 also mediates an IFN-gamma-dependent up-regulation of E-cadherin, thereby implying that alteration in cell-cell adhesion besides regulating the proteases and the inhibitors possibly contributes to the observed anti-invasive role of this cytokine. TIMP-1, although stimulated by IL-12, was found to be unaltered by antibody F12, thereby implying a possibility of an IL-12-dependent- IFN-gamma independent regulation. These findings thereby suggest an important role of IL-12 in modulation of trophoblast proteases and their inhibitors besides regulating cell-cell interactions and invasion during implantation, with far reaching possibilities for understanding the mechanism(s) and regulations of invasion and metastasis.	All India Inst Med Sci, Dept Biochem, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Karmakar, S (corresponding author), All India Inst Med Sci, Dept Biochem, Rm 3024, New Delhi 110029, India.	subhradipaiims@hotmail.com						Abraham M, 2002, INT IMMUNOL, V14, P1449, DOI 10.1093/intimm/dxf108; ALBINI A, 1987, CANCER RES, V47, P3239; Barber A, 2001, FASEB J, V15, P1158, DOI 10.1096/fj.00-0376com; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bischof P, 2002, J REPROD IMMUNOL, V55, P3, DOI 10.1016/S0165-0378(01)00142-5; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; CARMEN G, 1999, CLIN CANCER RES, V5, P3603; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chakraborty C, 2002, CAN J PHYSIOL PHARM, V80, P116, DOI 10.1139/Y02-016; Chaouat G, 2002, J REPROD IMMUNOL, V53, P241, DOI 10.1016/S0165-0378(01)00119-X; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Colombo MP, 2002, CYTOKINE GROWTH F R, V13, P155, DOI 10.1016/S1359-6101(01)00032-6; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Das SK, 1997, DEV GENET, V21, P44, DOI 10.1002/(SICI)1520-6408(1997)21:1&lt;44::AID-DVG5&gt;3.0.CO;2-8; Dey SK, 2004, ENDOCR REV, V25, P341, DOI 10.1210/er.2003-0020; Dias S, 1998, INT J CANCER, V75, P151, DOI 10.1002/(SICI)1097-0215(19980105)75:1<151::AID-IJC23>3.0.CO;2-I; Dias S, 1998, INT J CANCER, V78, P361, DOI 10.1002/(SICI)1097-0215(19981029)78:3<361::AID-IJC17>3.0.CO;2-9; Durand MK, 2004, THROMB HAEMOSTASIS, V91, P438, DOI 10.1160/TH03-12-0784; FEINBERG RF, 1989, LAB INVEST, V61, P20; FERNANDEZ PL, 1992, LAB INVEST, V66, P572; Franchimont D, 2000, J IMMUNOL, V164, P1768, DOI 10.4049/jimmunol.164.4.1768; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Gao F, 2001, ENDOCRINE, V16, P47, DOI 10.1385/ENDO:16:1:47; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Goodman RH, 2000, GENE DEV, V14, P1553; GRAHAM CH, 1992, BIOCHEM CELL BIOL, V70, P867, DOI 10.1139/o92-135; Halin C, 2002, NAT BIOTECHNOL, V20, P264, DOI 10.1038/nbt0302-264; Han XY, 2003, J BIOL CHEM, V278, P47785, DOI 10.1074/jbc.M309482200; HARMAINEN A, 1992, LAB INVEST, V67, P191; Herrler Andreas, 2003, Reprod Biomed Online, V6, P244; Hiscox S, 1999, J CELL SCI, V112, P3081; HOFMANN GE, 1994, AM J OBSTET GYNECOL, V170, P671, DOI 10.1016/S0002-9378(94)70246-2; Hohn HP, 1998, EXP CELL RES, V244, P249, DOI 10.1006/excr.1998.4184; Isaka K, 2003, PLACENTA, V24, P53, DOI 10.1053/plac.2002.0867; Karmakar S, 2002, AM J REPROD IMMUNOL, V48, P210, DOI 10.1034/j.1600-0897.2002.01151.x; KARMAKAR S, 2004, IN PRESS J REPROD IM; Kauma SW, 2000, J REPROD FERTIL, P31; KLIMAN HJ, 1990, P NATL ACAD SCI USA, V87, P3057, DOI 10.1073/pnas.87.8.3057; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LALA PK, 1990, CANCER METAST REV, V9, P369, DOI 10.1007/BF00049525; Lala PK, 1996, PLACENTA, V17, P545, DOI 10.1016/S0143-4004(96)80071-3; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Lee SC, 2003, J BIOMED SCI, V10, P73, DOI 10.1159/000068082; LIBRACH CL, 1994, J BIOL CHEM, V269, P17125; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LIOTTA LA, 1984, AM J PATHOL, V117, P339; Lucas ML, 2002, MOL THER, V5, P668, DOI 10.1006/mthe.2002.0601; Luo J, 1999, CANCER RES, V59, P3552; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; MARTIN O, 1982, AM J OBSTET GYNECOL, V142, P402, DOI 10.1016/S0002-9378(16)32380-8; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Nelissen I, 2002, J LEUKOCYTE BIOL, V71, P89; OKA H, 1993, CANCER RES, V53, P1696; Petraglia F, 1998, J REPROD IMMUNOL, V39, P221, DOI 10.1016/S0165-0378(98)00024-2; Pilka R, 2003, Ceska Gynekol, V68, P179; Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008; POLETTE M, 1994, LAB INVEST, V71, P838; Qin HW, 1998, J IMMUNOL, V161, P6664; Ruck P, 1996, PLACENTA, V17, P263, DOI 10.1016/S0143-4004(96)90047-8; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Shih IM, 2002, PLACENTA, V23, P706, DOI 10.1053/plac.2002.0864; SHIMONOVITZ S, 1994, AM J OBSTET GYNECOL, V171, P832, DOI 10.1016/0002-9378(94)90107-4; SOUNDARARAJAN R, 2004, REPROD BIOL ENDOCRIN, V2, P1; Tannenbaum CS, 1998, J IMMUNOL, V161, P927; Tannenbaum CS, 1996, J IMMUNOL, V156, P693; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; von Rango U, 2003, FERTIL STERIL, V79, P1176, DOI 10.1016/S0015-0282(02)04829-X; Wu J, 2003, ADV CANCER RES, V90, P127, DOI 10.1016/S0065-230X(03)90004-2; YAGEL S, 1993, J CLIN ENDOCR METAB, V77, P1506, DOI 10.1210/jc.77.6.1506; Zourbas S, 2001, CLIN EXP IMMUNOL, V126, P519, DOI 10.1046/j.1365-2249.2001.01607.x; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437; Zygmunt M, 1998, AM J REPROD IMMUNOL, V40, P326; Zygmunt M, 1998, PLACENTA, V19, P587, DOI 10.1016/S0143-4004(98)90019-4	76	55	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55297	55307		10.1074/jbc.M407013200	http://dx.doi.org/10.1074/jbc.M407013200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15448160	hybrid			2022-12-25	WOS:000225960800041
J	Behm-Ansmant, I; Grosjean, H; Massenet, S; Motorin, Y; Branlant, C				Behm-Ansmant, I; Grosjean, H; Massenet, S; Motorin, Y; Branlant, C			Pseudouridylation at position 32 of mitochondrial and cytoplasmic tRNAs requires two distinct enzymes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA; ESCHERICHIA-COLI; U2 SNRNA; GENETIC CLASSIFICATION; CRYSTAL-STRUCTURE; NORMAL GROWTH; SYNTHASE; YEAST; PROTEIN; PURIFICATION	Cytoplasmic and mitochondrial tRNAs contain several pseudouridylation sites, and the tRNA:Psi-synthase acting at position 32 had not been identified in Saccharomyces cerevisiae. By combining genetic and biochemical analyses, we demonstrate that two enzymes, Rib2/Pus8p and Pus9p, are required for Psi32 formation in cytoplasmic and mitochondrial tRNAs, respectively. Pus9p acts mostly in mitochondria, and Rib2/Pus8p is strictly cytoplasmic. This is the first case reported so far of two distinct tRNA modification enzymes acting at the same position but present in two different compartments. This peculiarity may be the consequence of a gene fusion that occurred during yeast evolution. Indeed, Rib2/Pus8p displays two distinct catalytic activities involved in completely unrelated metabolism: its C-terminal domain has a DRAP-deaminase activity required for riboflavin biogenesis in the cytoplasm, whereas its N-terminal domain carries the tRNA:Psi32-synthase activity. Pus9p has only a tRNA:Psi32-synthase activity and contains a characteristic mitochondrial targeting sequence at its N terminus. These results are discussed in terms of RNA:Psi-synthase evolution.	UHP Nancy 1, Fac Sci, UMR 7567 CNRS, Lab Maturat Acides Ribonucle, F-54506 Vandoeuvre Les Nancy, France; CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Motorin, Y (corresponding author), UHP Nancy 1, Fac Sci, UMR 7567 CNRS, Lab Maturat Acides Ribonucle, BP 239, F-54506 Vandoeuvre Les Nancy, France.	Yuri.Motorin@maem.uhp-nancy.fr	MOTORIN, Yuri/E-2499-2011; MOTORIN, Yuri/AAQ-9527-2020; BEHM-ANSMANT, Isabelle/B-1406-2012	MOTORIN, Yuri/0000-0002-8018-334X; Branlant, Christiane/0000-0003-4728-5499; Severine, Massenet/0000-0001-5187-8356; Motorin, Alexandr/0000-0001-9622-4591; Behm-Ansmant, Isabelle/0000-0001-8909-0660				Ansmant I, 2000, NUCLEIC ACIDS RES, V28, P1941, DOI 10.1093/nar/28.9.1941; Ansmant I, 2001, J BIOL CHEM, V276, P34934, DOI 10.1074/jbc.M103131200; ARNEZ JG, 1994, BIOCHEMISTRY-US, V33, P7560, DOI 10.1021/bi00190a008; Auffinger P, 1997, J MOL BIOL, V269, P326, DOI 10.1006/jmbi.1997.1022; Bacher A, 2001, VITAM HORM, V61, P1; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; Behm-Ansmant I, 2003, RNA, V9, P1371, DOI 10.1261/rna.5520403; Bonnerot C, 2003, MOL CELL, V12, P1309, DOI 10.1016/S1097-2765(03)00435-0; Conrad J, 1999, RNA, V5, P751, DOI 10.1017/S1355838299990167; Conrad J, 1998, J BIOL CHEM, V273, P18562, DOI 10.1074/jbc.273.29.18562; Del Campo M, 2004, RNA, V10, P231, DOI 10.1261/rna.5187404; Del Campo M, 2001, RNA, V7, P1603; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Jiang HQ, 1997, NUCLEIC ACIDS RES, V25, P2694, DOI 10.1093/nar/25.14.2694; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; LUE PF, 1969, BIOCHEM BIOPH RES CO, V34, P426, DOI 10.1016/0006-291X(69)90399-4; Ma XJ, 2003, EMBO J, V22, P1889, DOI 10.1093/emboj/cdg191; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; Massenet S, 1999, MOL CELL BIOL, V19, P2142; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NISHIMURA H, 1979, TRNASFER RNA STRUCTU, P547; NOSAKA K, 1994, J BIOL CHEM, V269, P30510; NURSE K, 1995, RNA, V1, P102; Ofengand J, 2002, FEBS LETT, V514, P17, DOI 10.1016/S0014-5793(02)02305-0; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; OLTMANNS O, 1969, MOL GEN GENET, V105, P306, DOI 10.1007/BF00277585; Raychaudhuri S, 1998, RNA, V4, P1407, DOI 10.1017/S1355838298981146; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; ROSE AM, 1995, BIOCHIMIE, V77, P45, DOI 10.1016/0300-9084(96)88103-X; Schaub M, 2002, BIOCHIMIE, V84, P791, DOI 10.1016/S0300-9084(02)01446-3; SHAVLOVSKII G M, 1982, Mikrobiologiya, V51, P96; SHAVLOVSKY GM, 1979, GENETIKA+, V15, P1561; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Urban A, 2003, J CHROMATOGR B, V786, P187, DOI 10.1016/S1570-0232(02)00742-0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437	45	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52998	53006		10.1074/jbc.M409581200	http://dx.doi.org/10.1074/jbc.M409581200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466869	Green Published, hybrid			2022-12-25	WOS:000225680600025
J	Christensen, RA; Shtifman, A; Allen, PD; Lopez, JR; Querfurth, HW				Christensen, RA; Shtifman, A; Allen, PD; Lopez, JR; Querfurth, HW			Calcium dyshomeostasis in beta-amyloid and Tau-bearing skeletal myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY MYOSITIS; NEURONAL CA2+ HOMEOSTASIS; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; TRANSGENIC MICE; SARCOPLASMIC-RETICULUM; MICROTUBULE-BINDING; PRECURSOR PROTEIN; MUSCLE FIBERS; IN-VIVO	The relative scarcity of inclusion-affected muscle cells or markers of cell death in inclusion body myositis (IBM) is in distinction to the specific and early intracellular deposition of several Alzheimer's Disease (AD)-related proteins. The current study examined the possible correlation between myotube beta-amyloid and/or Tau accumulations and a widespread mishandling of intracellular muscle calcium concentration that could potentially account for the unrelenting weakness in affected patients. Cultured myogenic cells (C2C12) expressed beta-amyloid-42 (Abeta(42)) and fetal Tau peptides, as human transgenes encoded by herpes simplex virus, either individually or concurrently. Co-expression of Abeta(42) in C2C12 myotubes resulted in hyperphosphorylation of Tau protein that was not observed when Tau was expressed alone. Resting calcium concentration and agonist-induced RyR-mediated Ca2+ release were examined using calcium-specific microelectrodes and Fluo-4 epifluorescence, respectively. Co-expression of Abeta(42) and Tau cooperatively elevated basal levels of myoplasmic- free calcium, an effect that was accompanied by depolarization of the plasma membrane. Sarcoplasmic reticulum (SR) calcium release, induced by KCl depolarization, was not affected by Abeta(42) or Tau. In contrast, expression of Abeta(42), Tau, or Abeta(42) together with Tau resulted in enhanced sensitivity of ryanodine receptors to activation by caffeine. Notably, expression of beta-amyloid, alone, was sufficient to result in an increased sensitivity to direct activation by caffeine. Current results indicate that amyloid proteins cooperate to raise resting calcium levels and that these effects are associated with a passive SR Ca2+ leak and Tau hyperphosphorylation in skeletal muscle.	Tufts Univ, Caritas St Elizabeths Med Ctr, Sch Med, Dept Neurol, Boston, MA 02135 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesia, Boston, MA 02115 USA	St. Elizabeth's Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Querfurth, HW (corresponding author), Tufts Univ, Caritas St Elizabeths Med Ctr, Sch Med, Dept Neurol, 736 Cambridge St, Boston, MA 02135 USA.	henry.querfurth@tufts.edu			NIAMS NIH HHS [5R01AR046513, 1F32AR049160-1] Funding Source: Medline; NINDS NIH HHS [R01 NS041373] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR049160, R01AR046513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041373] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARISPE N, 1994, MOL CELL BIOCHEM, V140, P119, DOI 10.1007/BF00926750; Askanas V, 2002, CURR OPIN NEUROL, V15, P525, DOI 10.1097/00019052-200210000-00002; Askanas V, 1998, ARCH NEUROL-CHICAGO, V55, P915, DOI 10.1001/archneur.55.7.915; ASKANAS V, 1998, INCLUSION BODY MYOSI, P3; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRION JP, 1993, J NEUROCHEM, V61, P2071, DOI 10.1111/j.1471-4159.1993.tb07444.x; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; Ferreira A, 1997, MOL CELL NEUROSCI, V9, P220, DOI 10.1006/mcne.1997.0615; Goedert M., 1997, MOL GENETIC BASIS NE, P613; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Gu YJ, 1996, J NEUROCHEM, V67, P1235; GUO G, 1997, J NEUROSCI, V17, P4212; HARTMANN H, 1993, BIOCHEM BIOPH RES CO, V194, P1216, DOI 10.1006/bbrc.1993.1952; Hartmann T, 1999, EUR ARCH PSY CLIN N, V249, P291, DOI 10.1007/s004060050102; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Hopf FW, 1996, J BIOL CHEM, V271, P22358, DOI 10.1074/jbc.271.37.22358; IANNACCONE ST, 1987, J CELL PHYSIOL, V133, P409, DOI 10.1002/jcp.1041330230; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; JAIMOVICH E, 1994, CELL CALCIUM, V15, P356, DOI 10.1016/0143-4160(94)90011-6; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; Kelliher M, 1999, NEUROSCIENCE, V92, P499, DOI 10.1016/S0306-4522(99)00042-1; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Le WD, 1997, J NEUROCHEM, V69, P978; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Leissring MA, 2001, NEUROBIOL DIS, V8, P469, DOI 10.1006/nbdi.2001.0382; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; LOPEZ JR, 1983, BIOPHYS J, V43, P1, DOI 10.1016/S0006-3495(83)84316-1; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; MARK RJ, 1995, J NEUROSCI, V15, P6239; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MATTSON MP, 1991, MOL CHEM NEUROPATHOL, V15, P117, DOI 10.1007/BF03159951; Mattson MP, 2000, J NEUROSCI, V20, P1358; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Murakami N, 1998, J NEUROPATH EXP NEUR, V57, P664, DOI 10.1097/00005072-199807000-00003; Nagao SI, 1999, MUSCLE NERVE, V22, P61, DOI 10.1002/(SICI)1097-4598(199901)22:1<61::AID-MUS10>3.0.CO;2-Y; NEVE RL, 1999, CURRENT PROTOCOLS NE; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Querfurth HW, 2001, MOL CELL NEUROSCI, V17, P793, DOI 10.1006/mcne.2001.0972; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4450; Rizzuto R, 2003, NAT GENET, V34, P135, DOI 10.1038/ng0603-135; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; Saiki Y, 1999, BIOCHEMISTRY-US, V38, P3112, DOI 10.1021/bi982250m; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shea TB, 1997, J NEUROSCI RES, V49, P759, DOI 10.1002/(SICI)1097-4547(19970915)49:6<759::AID-JNR10>3.0.CO;2-N; Shtifman A, 2004, AM J PHYSIOL-CELL PH, V286, pC73, DOI 10.1152/ajpcell.00194.2003; Shtifman A, 2002, J GEN PHYSIOL, V119, P15, DOI 10.1085/jgp.119.1.15; Suhara T, 2003, NEUROBIOL AGING, V24, P437, DOI 10.1016/S0197-4580(02)00135-5; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Tawil R, 2002, CURR OPIN RHEUMATOL, V14, P653, DOI 10.1097/00002281-200211000-00004; Town T, 2002, J NEUROSCI RES, V69, P362, DOI 10.1002/jnr.10299; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; WATANABE A, 1993, J BIOL CHEM, V268, P25712; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Yang TZ, 2003, J BIOL CHEM, V278, P25722, DOI 10.1074/jbc.M302165200; YANO M, 1995, J BIOL CHEM, V270, P19936, DOI 10.1074/jbc.270.34.19936; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x; Zucchi R, 1997, PHARMACOL REV, V49, P1	78	24	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53524	53532		10.1074/jbc.M408473200	http://dx.doi.org/10.1074/jbc.M408473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15385569	hybrid			2022-12-25	WOS:000225680600088
J	De Sanctis, G; Ciaccio, C; Fasciglione, GF; Fiorucci, L; Gioia, M; Sinibaldi, F; Marini, S; Santucci, R; Coletta, M				De Sanctis, G; Ciaccio, C; Fasciglione, GF; Fiorucci, L; Gioia, M; Sinibaldi, F; Marini, S; Santucci, R; Coletta, M			Effect of axial coordination on the kinetics of assembly and folding of the two halves of horse heart cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-EXCHANGE; HEME; ISOMERIZATION; MECHANISMS	The kinetics of the assembly of two complementary fragments of oxidized horse heart cytochrome c (cyt c), namely the heme-containing fragment-(1-56) and the fragment-(57-104), have been characterized at different pH values. At neutral pH the fragment-(1-56) is hexacoordinated and has two histidines axially ligated to the heme-Fe(III) (Santucci, R., Fiorucci, L., Sinibaldi, F., Polizio, F., Desideri, A., and Ascoli, F. (2000) Arch. Biochem. Biophys. 379, 331-336), thus mimicking what occurs in the folding intermediate of cyt c. The kinetics of the formation of the complex between the two fragments are characterized at pH 7.0 by a slow rate constant that is independent of the concentration of the reactants; conversely, at a low pH the kinetics are much faster and depend on the concentration of the fragments. This behavior suggests that the rate-limiting step observed in the recombination process of the fragments at neutral pH (that leads to the final coordination of Met-80) has to be ascribed to the detachment of the "misligated" histidine. Thus, the faster recombination rate at a low pH can be related to the fact that histidine is protonated and not able to coordinate to the metal. Furthermore, the independence of the rate constant on the concentration of the reactants observed at pH 7.0 can be accounted for by the occurrence of a conformational transition, which takes place immediately after the two fragments collapse together, likely simulating what induces the detachment of the misligated histidine during cytochrome folding.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, Italy	University of Rome Tor Vergata; University of Camerino	Coletta, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.	coletta@seneca.uniroma2.it	Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022; Marini, Stefano/B-1161-2012; Fasciglione, Giovanni Francesco/ABF-7738-2020; Gioia, Magda/ABF-8909-2020; Fiorucci, Laura/I-4555-2017	Marini, Stefano/0000-0003-1299-6696; Gioia, Magda/0000-0003-0352-3547; COLETTA, Massimiliano/0000-0002-5489-9467				Akiyama S, 2000, NAT STRUCT BIOL, V7, P514; Bai YW, 1999, P NATL ACAD SCI USA, V96, P477, DOI 10.1073/pnas.96.2.477; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; Colon W, 1997, BIOCHEMISTRY-US, V36, P12535, DOI 10.1021/bi971697c; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Eaton WA, 2000, ANNU REV BIOPH BIOM, V29, P327, DOI 10.1146/annurev.biophys.29.1.327; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; FONTANA A, 1995, FEBS LETT, V362, P266, DOI 10.1016/0014-5793(95)00237-4; Hagen SJ, 1996, P NATL ACAD SCI USA, V93, P11615, DOI 10.1073/pnas.93.21.11615; JONES CM, 1993, P NATL ACAD SCI USA, V90, P11860, DOI 10.1073/pnas.90.24.11860; MOORE GR, 1990, CYTOCHROMES EVOLUTIO; Myers JK, 2002, ANNU REV BIOCHEM, V71, P783, DOI 10.1146/annurev.biochem.71.110601.135346; PIELAK GJ, 1986, J AM CHEM SOC, V108, P2724, DOI 10.1021/ja00270a035; Pierce MM, 2000, J MOL BIOL, V298, P955, DOI 10.1006/jmbi.2000.3700; Pierce MM, 1997, PROTEIN SCI, V6, P618; Santucci R, 2000, ARCH BIOCHEM BIOPHYS, V379, P331, DOI 10.1006/abbi.2000.1885; Shastry MCR, 1998, NAT STRUCT BIOL, V5, P385, DOI 10.1038/nsb0598-385; Sinibaldi F, 2001, EUR J BIOCHEM, V268, P4537, DOI 10.1046/j.1432-1327.2001.02373.x; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; STELLWAGEN E, 1974, BIOCHEM BIOPH RES CO, V60, P371, DOI 10.1016/0006-291X(74)90214-9; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51; Yeh SR, 1999, J BIOL CHEM, V274, P17853, DOI 10.1074/jbc.274.25.17853; Yeh SR, 1998, NAT STRUCT BIOL, V5, P222, DOI 10.1038/nsb0398-222	23	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52860	52868		10.1074/jbc.M403127200	http://dx.doi.org/10.1074/jbc.M403127200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15385558	hybrid			2022-12-25	WOS:000225680600010
J	Edqvist, J; Ronnberg, E; Rosenquist, S; Blomqvist, K; Viitanen, L; Salminen, TA; Nylund, M; Tuuf, J; Mattjus, P				Edqvist, J; Ronnberg, E; Rosenquist, S; Blomqvist, K; Viitanen, L; Salminen, TA; Nylund, M; Tuuf, J; Mattjus, P			Plants express a lipid transfer protein with high similarity to mammalian sterol carrier protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID; GLYCOLIPID TRANSFER; COMPLETE GENOME; DEHYDROGENASE FAMILY; GENE; SEQUENCE; LOCALIZATION; REVEALS; CLONING; CATABOLISM	This is the first report describing the cloning and characterization of sterol carrier protein-2 (SCP-2) from plants. Arabidopsis thaliana SCP-2 (AtSCP-2) consists of 123 amino acids with a molecular mass of 13.6 kDa. AtSCP-2 shows 35% identity and 56% similarity to the human SCP-2-like domain present in the human D-bifunctional protein (DBP) and 30% identity and 54% similarity to the human SCP-2 encoded by SCP-X. The presented structural models of apo-AtSCP-2 and the ligand-bound conformation of AtSCP-2 reveal remarkable similarity with two of the structurally known SCP-2s, the SCP-2-like domain of human DBP and the rabbit SCP-2, correspondingly. The AtSCP-2 models in both forms have a similar hydrophobic ligand-binding tunnel, which is extremely suitable for lipid binding. AtSCP-2 showed in vitro transfer activity of BODIPY-phosphatidylcholine (BODIPY-PC) from donor membranes to acceptor membranes. The transfer of BODIPY-PC was almost completely inhibited after addition of 1-palmitoyl 2-oleoyl phosphatidylcholine or ergosterol. Dimyristoyl phosphatidic acid, stigmasterol, steryl glucoside, and cholesterol showed a moderate to marginal ability to lower the BODIPY-PC transfer rate, and the single chain palmitic acid and stearoyl-coenzyme A did not affect transfer at all. Expression analysis showed that AtSCP-2 mRNA is accumulating in most plant tissues. Plasmids carrying fusion genes between green fluorescent protein and AtSCP-2 were transformed with particle bombardment to onion epidermal cells. The results from analyzing the transformants indicate that AtSCP-2 is localized to peroxisomes.	Swedish Univ Agr Sci, Dept Plant Biol & Forest Genet, S-75007 Uppsala, Sweden; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland	Swedish University of Agricultural Sciences; Abo Akademi University	Edqvist, J (corresponding author), Swedish Univ Agr Sci, Dept Plant Biol & Forest Genet, Box 7080, S-75007 Uppsala, Sweden.	Johan.Edqvist@vbsg.slu.se	Mattjus, Peter/AAQ-7531-2021; Salminen, Tiina A./AAM-5443-2021; Nylund, Matts/I-5604-2013; Edqvist, Johan/H-7803-2019; Ronnberg, Elin/ABA-8898-2020; Salminen, Tiina A/G-7492-2019; Mattjus, Peter/ABE-3596-2021	Salminen, Tiina A./0000-0002-4135-8020; Ronnberg, Elin/0000-0002-4628-9968; Salminen, Tiina A/0000-0002-4135-8020; Mattjus, Peter/0000-0001-8991-5933; Edqvist, Johan/0000-0002-8174-4540; Rosenquist, Sara/0000-0001-7648-9103; Blomqvist, Kristina/0000-0003-1364-5337				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Barnes TM, 1996, J NEUROCHEM, V67, P46; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; Choinowski T, 2000, BIOCHEMISTRY-US, V39, P1897, DOI 10.1021/bi992742e; Dansen TB, 1999, BIOCHEM J, V339, P193, DOI 10.1042/0264-6021:3390193; David S., 1996, WEEDS WORLD, V3, P43; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dyer DH, 2003, J BIOL CHEM, V278, P39085, DOI 10.1074/jbc.M306214200; Edqvist J, 2002, PLANTA, V215, P41, DOI 10.1007/s00425-001-0717-x; Eklund DM, 2003, PLANT PHYSIOL, V132, P1249, DOI 10.1104/pp.103.020875; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Fulda M, 2002, PLANT J, V32, P93, DOI 10.1046/j.1365-313X.2002.01405.x; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; Garcia FL, 2000, J MOL BIOL, V295, P595, DOI 10.1006/jmbi.1999.3355; Graham IA, 2002, PROG LIPID RES, V41, P156, DOI 10.1016/S0163-7827(01)00022-4; Haapalainen AM, 2001, J MOL BIOL, V313, P1127, DOI 10.1006/jmbi.2001.5084; HWANG CW, 1991, GENE, V106, P61, DOI 10.1016/0378-1119(91)90566-T; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; Johnson MS, 2000, BIOINFORMATICS; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LEENDERS F, 1994, MOL CELL ENDOCRINOL, V104, P127, DOI 10.1016/0303-7207(94)90114-7; Leenders F, 1996, J BIOL CHEM, V271, P5438, DOI 10.1074/jbc.271.10.5438; LEHTONEN JV, 2004, IN PRESS J COMPUTER; Lin X, 2000, J BIOL CHEM, V275, P5104, DOI 10.1074/jbc.275.7.5104; Matile P, 1999, ANNU REV PLANT PHYS, V50, P67, DOI 10.1146/annurev.arplant.50.1.67; Matsuoka S, 2003, EUKARYOT CELL, V2, P638, DOI 10.1128/EC.2.3.638-645.2003; Mattjus P, 2003, BIOCHEMISTRY-US, V42, P535, DOI 10.1021/bi026896x; Mattjus P, 2002, BIOCHEMISTRY-US, V41, P266, DOI 10.1021/bi015718l; Mattjus P, 1999, ANAL BIOCHEM, V268, P297, DOI 10.1006/abio.1998.3065; Mattjus P, 2000, BIOCHEMISTRY-US, V39, P1067, DOI 10.1021/bi991810u; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mukherji M, 2003, PROG LIPID RES, V42, P359, DOI 10.1016/S0163-7827(03)00016-X; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; Requena N, 1999, MOL PLANT MICROBE IN, V12, P934, DOI 10.1094/MPMI.1999.12.10.934; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scott A, 1999, BIOTECHNIQUES, V26, P1125, DOI 10.2144/99266st04; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Seidel G, 1998, GENE, V225, P23, DOI 10.1016/S0378-1119(98)00532-0; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; TAN H, 1994, YEAST, V10, P1065, DOI 10.1002/yea.320100808; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; Wu SH, 2001, PLANT PHYSIOL BIOCH, V39, P917, DOI 10.1016/S0981-9428(01)01322-5; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	53	26	32	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53544	53553		10.1074/jbc.M405099200	http://dx.doi.org/10.1074/jbc.M405099200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456765	hybrid			2022-12-25	WOS:000225680600090
J	He, YY; Huang, JL; Chignell, CF				He, YY; Huang, JL; Chignell, CF			Delayed and sustained activation of extracellular signal-regulated kinase in human keratinocytes by UVA - Implications in carcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; DOWN-REGULATION; SINGLET OXYGEN; ERK; APOPTOSIS; RAS; JNK; PHOSPHORYLATION; P38; ULTRAVIOLET	Exposure to the sun's UV radiation appears to be the most important environmental factor involved in the development of skin cancer. UVA is the major portion of UV radiation in sunlight and is considered to be a human carcinogen. In this study, we have investigated the delayed and sustained activation of ERK MAPK by UVA exposure. In parallel, a delayed Ras activation with a similar time course was observed after UVA exposure. The activated Ras was found to be localized in endomembranes such as the Golgi apparatus instead of plasma membranes. Expression of dominant negative Ras (N17Ras) abolished ERK activation by UVA. The presence of AG1478, an epidermal growth factor (EGF) receptor ( EGFR) kinase inhibitor, had no effect on ERK or Ras activation, indicating that EGFR kinase activity is not involved in ERK activation by UVA. In contrast, protein kinase C (PKC) depletion by chronic 12-O-tetradecanoylphorbol-13-acetate treatment nearly abolished UVA-induced ERK and Ras activation. The presence of the Ca2+-dependent-PKC inhibitor Go6976 had a similar effect. These findings suggest that ERK activation by UVA is mediated by PKC in a Ras-dependent pathway. In addition, a gradual increase in intracellular calcium level after UVA exposure was detected by flow cytometry. The presence of the PLC inhibitor U73122 or the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N, N, N',N'-tetraacetic acid tetrakis (acetoxymethyl ester) (BAPTA-AM) blocked both ERK and Ras activation, suggesting that both PLC and calcium are required for ERK activation. Our findings demonstrated that, different from UVC and UVB, UVA-induced delayed and sustained ERK activation is EGFR kinase activity-independent, but PLC/calcium/PKC-mediated. The delayed and sustained ERK activation provides a survival signal to human HaCaT keratinocytes, which may serve as an important mechanism for cell transformation and potential skin carcinogenesis in vivo caused by UVA exposure.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, YY (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, FO-06,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	he3@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050046, Z01ES050046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Buckley S, 1999, AM J PHYSIOL-LUNG C, V277, pL159, DOI 10.1152/ajplung.1999.277.1.L159; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COFFER PJ, 1995, ONCOGENE, V11, P561; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; JONES GA, 1993, J BIOL CHEM, V268, P20845; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Klotz LO, 1999, EUR J BIOCHEM, V260, P917, DOI 10.1046/j.1432-1327.1999.00255.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Pourzand C, 1999, PHOTOCHEM PHOTOBIOL, V70, P380, DOI 10.1111/j.1751-1097.1999.tb08239.x; Princen K, 2003, CYTOM PART A, V51A, P35, DOI 10.1002/cyto.a.10008; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Stadheim TA, 2001, CANCER RES, V61, P1533; Tong ZM, 2002, CANCER RES, V62, P5528; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	32	71	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53867	53874		10.1074/jbc.M405781200	http://dx.doi.org/10.1074/jbc.M405781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471881	hybrid			2022-12-25	WOS:000225680600125
J	Ilegems, E; Pick, HM; Deluz, C; Kellenberger, S; Vogel, H				Ilegems, E; Pick, HM; Deluz, C; Kellenberger, S; Vogel, H			Noninvasive imaging of 5-HT3 receptor trafficking in live cells - From biosynthesis to endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; NICOTINIC ACETYLCHOLINE-RECEPTOR; GATED ION CHANNELS; LIVING CELLS; PLASMA-MEMBRANE; LIGAND-BINDING; FUNCTIONAL EXPRESSION; SURFACE EXPRESSION; MAMMALIAN-CELLS; GENE-EXPRESSION	Sequential stages in the life cycle of the ionotropic 5-HT3 receptor (5-HT3R) were resolved temporally and spatially in live cells by multicolor fluorescence confocal microscopy. The insertion of the enhanced cyan fluorescent protein into the large intracellular loop delivered a fluorescent 5-HT3R fully functional in terms of ligand binding specificity and channel activity, which allowed for the first time a complete real- time visualization and documentation of intracellular biogenesis, membrane targeting, and ligand-mediated internalization of a receptor belonging to the ligand-gated ion channel superfamily. Fluorescence signals of newly expressed receptors were detectable in the endoplasmic reticulum about 3 h after transfection onset. At this stage receptor subunits assembled to form active ligand binding sites as demonstrated in situ by binding of a fluorescent 5-HT3R-specific antagonist. After novel protein synthesis was chemically blocked, the 5-HT3R populations in the endoplasmic reticulum and Golgi cisternae moved virtually quantitatively to the cell surface, indicating efficient receptor folding and assembly. Intracellular 5-HT3 receptors were trafficking in vesicle-like structures along microtubules to the cell surface at a velocity generally below 1 mum/s and were inserted into the plasma membrane in a characteristic cluster distribution overlapping with actin-rich domains. Internalization of cell surface 5-HT3 receptors was observed within minutes after exposure to an extracellular agonist. Our orchestrated use of spectrally distinguishable fluorescent labels for the receptor, its cognate ligand, and specific organelle markers can be regarded as a general approach allowing subcellular insights into dynamic processes of membrane receptor trafficking.	Swiss Fed Inst Technol, EPFL, LCPPM, Inst Chem Sci & Engn, CH-1015 Lausanne, Switzerland; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	Ecole Polytechnique Federale de Lausanne; University of Lausanne	Vogel, H (corresponding author), Swiss Fed Inst Technol, EPFL, LCPPM, Inst Chem Sci & Engn, CH-1015 Lausanne, Switzerland.	horst.vogel@epfl.ch	Vogel, Horst/AAJ-5490-2021; Ilegems, Erwin/F-3493-2010	Ilegems, Erwin/0000-0002-5873-1186; Kellenberger, Stephan/0000-0003-1755-6198				BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; Barnes EM, 2000, LIFE SCI, V66, P1063, DOI 10.1016/S0024-3205(99)00469-5; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BOESS FG, 1995, J NEUROCHEM, V64, P1401; Boyd GW, 2003, J BIOL CHEM, V278, P27681, DOI 10.1074/jbc.M304938200; Boyd GW, 2002, MOL CELL NEUROSCI, V21, P38, DOI 10.1006/mcne.2002.1160; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAVEZ RA, 1992, J BIOL CHEM, V267, P23028; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dutton JL, 2000, NEUROPHARMACOLOGY, V39, P2054, DOI 10.1016/S0028-3908(00)00058-7; Emerit MB, 2002, MOL CELL NEUROSCI, V20, P110, DOI 10.1006/mcne.2002.1133; GREEN T, 1995, J BIOL CHEM, V270, P6056, DOI 10.1074/jbc.270.11.6056; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Hovius R, 1998, J NEUROCHEM, V70, P824; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; John PAS, 2001, J NEUROBIOL, V49, P212, DOI 10.1002/neu.1076; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; Lauf U, 2002, P NATL ACAD SCI USA, V99, P10446, DOI 10.1073/pnas.162055899; Lippincott-Schwartz J, 2001, HISTOCHEM CELL BIOL, V116, P97; Maksay G, 2003, J RECEPT SIG TRANSD, V23, P255, DOI 10.1081/RRS-120025568; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Mitra M, 2001, J NEUROSCI, V21, P3000, DOI 10.1523/JNEUROSCI.21-09-03000.2001; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; NarayFejesToth A, 1996, J BIOL CHEM, V271, P15436, DOI 10.1074/jbc.271.26.15436; Nashmi R, 2003, J NEUROSCI, V23, P11554; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Pick H, 2003, BIOCHEMISTRY-US, V42, P877, DOI 10.1021/bi026576d; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; SACKETT DL, 1993, BIOCHEMISTRY-US, V32, P13560, DOI 10.1021/bi00212a023; Schreiter C, 2003, J BIOL CHEM, V278, P22709, DOI 10.1074/jbc.M301801200; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SHERLINE P, 1975, J BIOL CHEM, V250, P5481; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Tairi AP, 1998, BIOCHEMISTRY-US, V37, P15850, DOI 10.1021/bi981812z; Toomre D, 1999, J CELL SCI, V112, P21; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; WERNER P, 1994, MOL BRAIN RES, V26, P233, DOI 10.1016/0169-328X(94)90095-7; WETTSTEIN FO, 1964, BIOCHIM BIOPHYS ACTA, V87, P525, DOI 10.1016/0926-6550(64)90131-8; Wohland T, 1999, BIOCHEMISTRY-US, V38, P8671, DOI 10.1021/bi990366s	45	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53346	53352		10.1074/jbc.M407467200	http://dx.doi.org/10.1074/jbc.M407467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15452106	hybrid			2022-12-25	WOS:000225680600067
J	Koeppel, MA; McCarthy, CC; Moertl, E; Jakobi, R				Koeppel, MA; McCarthy, CC; Moertl, E; Jakobi, R			Identification and characterization of PS-GAP as a novel regulator of caspase-activated PAK-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE GAMMA-PAK; ANCHORAGE-INDEPENDENT GROWTH; P21-ACTIVATED KINASE; MOLECULAR-CLONING; PROTEIN-KINASES; ADAPTER PROTEIN; CLEAVAGE; DOMAIN; CELLS; CDC42	p21-activated protein kinase (PAK)-2 is a member of the PAK family of serine/threonine kinases. PAKs are activated by the p21 G-proteins Rac and Cdc42 in response to a variety of extracellular signals and act in pathways controlling cell growth, shape, motility, survival, and death. PAK-2 is unique among the PAK family members because it is also activated through proteolytic cleavage by caspase-3 or similar proteases to generate the constitutively active PAK-2p34 fragment. Activation of full-length PAK-2 by Rac or Cdc42 stimulates cell survival and protects cells from cell death, whereas caspase-activated PAK-2p34 induces a cell death response. Caspase-activated PAK-2p34 is rapidly degraded by the 26 S proteasome, but full-length PAK-2 is not. Stabilization of PAK-2p34 by preventing its polyubiquitination and degradation results in a dramatic stimulation of cell death. Although many proteins have been shown to interact with and regulate full-length PAK-2, little is known about the regulation of caspase-activated PAK-2p34. Here, we identify PS-GAP as a regulator of caspase-activated PAK-2p34. PS-GAP is a GTPase-activating protein for Cdc42 and RhoA that was originally identified by its interaction with the tyrosine kinase PYK-2. PS-GAP interacts specifically with caspase-activated PAK-2p34, but not active or inactive full-length PAK-2, through a region between the GAP and SH3 domains. The interaction with PS-GAP inhibits the protein kinase activity of PAK-2p34 and changes the localization of PAK-2p34 from the nucleus to the perinuclear region. Furthermore, PS-GAP decreases the stimulation of cell death induced by stabilization of PAK-2p34.	Kansas City Univ Med & Biosci, Dept Biochem, Kansas City, MO 64106 USA; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Kansas City University of Medicine & Biosciences; Medical College of Wisconsin	Jakobi, R (corresponding author), Kansas City Univ Med & Biosci, Dept Biochem, 1750 Independence Ave, Kansas City, MO 64106 USA.	rjakobi@kcumb.edu						Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Chan WH, 1998, J PROTEIN CHEM, V17, P485, DOI 10.1023/A:1022578820147; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; Hashimoto S, 2001, J BIOL CHEM, V276, P6037, DOI 10.1074/jbc.M005854200; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; JAKOBI R, 1992, J BIOL CHEM, V267, P23894; Jakobi R, 2004, DRUG RESIST UPDATE, V7, P11, DOI 10.1016/j.drup.2004.01.001; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Jakobi R, 2002, BIOTECHNIQUES, V33, P1218, DOI 10.2144/02336bm07; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; James P, 1996, GENETICS, V144, P1425; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KREBS EG, 1994, TRENDS BIOCHEM SCI, V19, P439, DOI 10.1016/0968-0004(94)90125-2; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Roig J, 2001, VITAM HORM, V62, P167, DOI 10.1016/S0083-6729(01)62004-1; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tang TK, 1998, J CELL BIOCHEM, V70, P442, DOI 10.1002/(SICI)1097-4644(19980915)70:4<442::AID-JCB2>3.3.CO;2-N; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tu H, 1999, MOL CELL BIOL, V19, P602; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	55	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53653	53664		10.1074/jbc.M410530200	http://dx.doi.org/10.1074/jbc.M410530200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471851	hybrid			2022-12-25	WOS:000225680600102
J	Xu, LJ; Deng, XM				Xu, LJ; Deng, XM			Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces phosphorylation of mu- and m-calpain in association with increased secretion, cell migration, and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY NEUROENDOCRINE CELLS; GREEN FLUORESCENT PROTEIN; LUNG-CARCINOMA CELLS; CANCER INVASION; TUMOR-CELLS; KINASE-C; METASTASIS; MOTILITY; ACTIVATION; TRANSFORMATION	Mounting evidence indicates that cigarette smoking not only promotes tumorigenesis but also may increase the spread of cancer cells in the body. However, the intracellular mechanism(s) by which cigarette smoking promotes metastasis of human lung cancer remains enigmatic. Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is an important component in cigarette smoke and is formed by nitrosation of nicotine. mu- and m-calpain (calpain I and calpain II) are major members of the calpain family, which are ubiquitously expressed in both small cell lung cancer and non-small cell lung cancer cells. Our findings indicated that NNK potently induces phosphorylation of both mu- and m-calpain in association with their activation and increased migration as well as invasion of lung cancer cells. Treatment of cells with PD98059 blocked phosphorylation of m- and mu-calpain and resulted in suppression of NNK-induced cell migration and invasion. p44 MAPK/extracellular signal-regulated kinase 1 (ERK1) and p42 MAPK/ERK2 were activated by NNK, co-localized with mu- and m-calpain in cytoplasm, and directly phosphorylated mu- and m-calpain in vitro. These findings suggest a role for the ERK1/2 kinases as NNK-activated physiological calpain kinases. Specific knock-down of mu- and/or m- calpain expression by RNA interference blocked NNK-stimulated migration and invasion, suggesting that mu- and m-calpain may act as required targets in a NNK-induced metastatic signaling pathway. Furthermore, NNK promotes secretion of active mu- and m-calpain from lung cancer cells through vesicles, which may have the potential to cleave substrates in the extracellular matrix. Thus, NNK-induced cell migration and invasion may occur, at least in part, through a novel mechanism involving phosphorylation of calpains that leads to their activation and secretion, which may contribute to metastasis and/or progression of lung cancer.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu						ALBINI A, 1987, CANCER RES, V47, P3239; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Condeelis JS, 2000, EUR J CANCER, V36, P1671, DOI 10.1016/S0959-8049(00)00155-6; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; Farina KL, 1998, CANCER RES, V58, P2528; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gomez DE, 1999, ONCOL REP, V6, P1363; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOPALAKRISHNA R, 1994, P NATL ACAD SCI USA, V91, P12233, DOI 10.1073/pnas.91.25.12233; Heino J, 2002, CELL INVASION MED IN, P1; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mamoune A, 2003, CANCER RES, V63, P4632; Murin S, 2001, CHEST, V119, P1635, DOI 10.1378/chest.119.6.1635; Nishihara H, 2001, BIOCHEM BIOPH RES CO, V285, P845, DOI 10.1006/bbrc.2001.5242; Palecek SP, 1998, J CELL SCI, V111, P929; REPESH LA, 1989, INVAS METAST, V9, P192; SAMET JM, 1994, EPIDEMIOLOGY LUNG CA, P437; Schoenwaelder SM, 1999, J BIOL CHEM, V274, P14359, DOI 10.1074/jbc.274.20.14359; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; Schuller HM, 2002, NAT REV CANCER, V2, P455, DOI 10.1038/nrc824; Schuller HM, 1998, BIOCHEM PHARMACOL, V55, P1377, DOI 10.1016/S0006-2952(97)00651-5; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Smith SD, 2003, FEBS LETT, V542, P115, DOI 10.1016/S0014-5793(03)00361-2; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Wells A, 2000, ADV CANCER RES, V78, P31; Wyckoff JB, 2000, CANCER RES, V60, P2504	39	74	79	5	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53683	53690		10.1074/jbc.M409889200	http://dx.doi.org/10.1074/jbc.M409889200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471877	hybrid			2022-12-25	WOS:000225680600105
J	Yarovinsky, F; Andersen, JF; King, LR; Caspar, P; Aliberti, J; Golding, H; Sher, A				Yarovinsky, F; Andersen, JF; King, LR; Caspar, P; Aliberti, J; Golding, H; Sher, A			Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYCLOPHILIN-A; CRYSTAL-STRUCTURE; CYCLOSPORINE-A; CELL LINE; INFECTION; RECEPTOR; BINDING; ENTRY; INHIBITION	The protozoan parasite Toxoplasma gondii possesses a protein, cyclophilin-18 (C-18), which binds to the chemokine receptor CCR5, induces interleukin-12 production from murine dendritic cells, and inhibits fusion and infectivity of human immunodeficiency virus 1 (HIV-1) R5 viruses by co-receptor antagonism. Site-directed mutagenesis was employed to identify the domains in C-18 responsible for its CCR5 binding and antiviral functions. To do so we focused on amino acid differences with Plasmodium falciparum cyclophilin, which, although 53% identical with C-18, has minimal binding activity for CCR5, and we generated 22 mutants with substitutions in the regions of non-homology located on the putative surface of the molecule. Two mutations situated on the face of C-18, predicted to be involved in its interaction with the ligand cyclosporin A, were shown to be critical for CCR5-binding and the inhibition of HIV-1 fusion and infectivity. In contrast, four mutations in C-18 specifically designed to abolish the peptidylprolyl cis-trans-isomerase activity of the protein failed to inactivate its CCR5 binding and HIV inhibitory activities. Interleukin-12 induction by C-18, on the other hand, was abrogated by mutations effecting either the CCR5 binding or enzymatic function of the molecule. These findings shed light on the structural basis of the molecular mimicry of the chemokine function by a pathogen-derived protein and provide a basis for further modification of C-18 into an antiviral agent.	NIAID, Parasit Dis Lab, Immunobiol Sect, NIH, Bethesda, MD 20892 USA; NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Div Viral Prod, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA)	Sher, A (corresponding author), NIAID, Parasit Dis Lab, Immunobiol Sect, NIH, Bethesda, MD 20892 USA.	asher@mail.nih.gov	Aliberti, Julio/I-7354-2013; Aliberti, Julio/G-4565-2012	Aliberti, Julio/0000-0003-3420-8478; Yarovinsky, Felix/0000-0001-5825-8002	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000579, Z01AI000579] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberti J, 2003, NAT IMMUNOL, V4, P485, DOI 10.1038/ni915; Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bondue A, 2002, BIOCHEMISTRY-US, V41, P13548, DOI 10.1021/bi026087d; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cooley LA, 2003, J CLIN VIROL, V26, P121, DOI 10.1016/S1386-6532(02)00111-7; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Davis CW, 2004, J EXP MED, V199, P1037, DOI 10.1084/jem.20040426; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Golding H, 2003, BLOOD, V102, P3280, DOI 10.1182/blood-2003-04-1096; HIGH KP, 1994, J BIOL CHEM, V269, P9105; HILLMAN K, 1990, J IMMUNOL, V144, P2131; Holst PJ, 2003, MICROBES INFECT, V5, P179, DOI 10.1016/S1286-4579(02)00081-3; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Minder D, 2002, ARCH VIROL, V147, P1531, DOI 10.1007/s00705-002-0826-2; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; Peterson MR, 2000, J MOL BIOL, V298, P123, DOI 10.1006/jmbi.2000.3633; Pierson TC, 2003, CURR TOP MICROBIOL, V281, P1; Pushkarsky T, 2001, P NATL ACAD SCI USA, V98, P6360, DOI 10.1073/pnas.111583198; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771; Sher A, 2003, IMMUNOL RES, V27, P521, DOI 10.1385/IR:27:2-3:521; Sherry B, 1998, P NATL ACAD SCI USA, V95, P1758, DOI 10.1073/pnas.95.4.1758; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Trkola A, 1999, J VIROL, V73, P8966, DOI 10.1128/JVI.73.11.8966-8974.1999; Yurchenko V, 2002, J BIOL CHEM, V277, P22959, DOI 10.1074/jbc.M201593200; Zhang YJ, 1998, J VIROL, V72, P9337, DOI 10.1128/JVI.72.11.9337-9344.1998; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	36	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53635	53642		10.1074/jbc.M410550200	http://dx.doi.org/10.1074/jbc.M410550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15469936	hybrid			2022-12-25	WOS:000225680600100
J	Gabrielsen, M; Bond, CS; Hallyburton, I; Hecht, S; Bacher, A; Eisenreich, W; Rohdich, F; Hunter, WN				Gabrielsen, M; Bond, CS; Hallyburton, I; Hecht, S; Bacher, A; Eisenreich, W; Rohdich, F; Hunter, WN			Hexameric assembly of the bifunctional methylerythritol 2,4-cyclodiphosphate synthase and protein-protein associations in the deoxy-xylulose-dependent pathway of isoprenoid precursor biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYXYLULOSE PHOSPHATE-PATHWAY; NON-MEVALONATE PATHWAY; X-RAY-DIFFRACTION; ESCHERICHIA-COLI; 2-C-METHYL-D-ERYTHRITOL 2,4-CYCLODIPHOSPHATE; NONMEVALONATE PATHWAY; ESSENTIAL ENZYME; 4-PHOSPHATE; TERPENOIDS; MAPS	The bifunctional methylerythritol 4-phosphate cytidylyltransferase methylerythritol 2,4-cyclodiphosphate synthase (IspDF) is unusual in that it catalyzes nonconsecutive reactions in the 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway of isoprenoid precursor biosynthesis. The crystal structure of IspDF from the bacterial pathogen Campylobacter jejuni reveals an elongated hexamer with D-3 symmetry compatible with the dimeric 2C-methyl-D-erythritol-4-phosphate cytidylyltransferase and trimeric 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase monofunctional enzymes. Complex formation of IspDF with 4-diphosphocytidyl-2C-methyl-D-erythritol kinase (IspE), the intervening enzyme activity in the pathway, has been observed in solution for the enzymes from C. jejuni and Agrobacterium tumefaciens. The monofunctional enzymes (2C-methyl-D-erythritol-4-phosphate cytidylyltransferase, IspE, and 2C-methyl-D-erythritol2,4-cyclodiphosphate synthase) involved in the DOXP biosynthetic pathway of Escherichia coli also show physical associations. We propose that complex formation of the three enzymes at the core of the DOXP pathway can produce an assembly localizing 18 catalytic centers for the early stages of isoprenoid biosynthesis.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	University of Dundee; Technical University of Munich	Hunter, WN (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dow St, Dundee DD1 5EH, Scotland.	w.n.hunter@dundee.ac.uk	Eisenreich, Wolfgang/A-1258-2013; Bond, Charles/AAF-9608-2020; Hunter, William/AAE-3947-2019; Bond, Charles S/B-4094-2011	Eisenreich, Wolfgang/0000-0002-9832-8279; Bond, Charles/0000-0002-9584-6783; Bond, Charles S/0000-0002-9584-6783; Gabrielsen, Mads/0000-0002-9848-2276; Hallyburton, Irene/0000-0003-4883-5560				Adam P, 2002, P NATL ACAD SCI USA, V99, P12108, DOI 10.1073/pnas.182412599; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEYTIA ED, 1976, ANNU REV BIOCHEM, V45, P113, DOI 10.1146/annurev.bi.45.070176.000553; Boucher Y, 2000, MOL MICROBIOL, V37, P703, DOI 10.1046/j.1365-2958.2000.02004.x; Campos N, 2001, BIOCHEM J, V353, P59, DOI 10.1042/bj3530059; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Eisenreich W, 1998, CHEM BIOL, V5, pR221, DOI 10.1016/S1074-5521(98)90002-3; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Enright AJ, 2001, GENOME BIOL, V2; Freiberg C, 2001, J MOL MICROB BIOTECH, V3, P483; GABRIELSEN M, 2004, EUR J BIOCHEM, V271, P1; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Herz S, 2000, P NATL ACAD SCI USA, V97, P2486, DOI 10.1073/pnas.040554697; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kemp LE, 2003, ACTA CRYSTALLOGR D, V59, P607, DOI 10.1107/S090744490202365X; Kemp LE, 2002, P NATL ACAD SCI USA, V99, P6591, DOI 10.1073/pnas.102679799; Kemp LE, 2001, ACTA CRYSTALLOGR D, V57, P1189, DOI 10.1107/S0907444901010137; Kishida H, 2003, ACTA CRYSTALLOGR D, V59, P23, DOI 10.1107/S0907444902017705; Kollas AK, 2002, FEBS LETT, V532, P432, DOI 10.1016/S0014-5793(02)03725-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzuyama T, 2003, NAT PROD REP, V20, P171, DOI 10.1039/b109860h; Kuzuyama T, 2000, J BIOL CHEM, V275, P19928, DOI 10.1074/jbc.M001820200; Kuzuyama T, 2000, TETRAHEDRON LETT, V41, P703, DOI 10.1016/S0040-4039(99)02143-7; Lange BM, 2000, P NATL ACAD SCI USA, V97, P13172, DOI 10.1073/pnas.240454797; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lell B, 2003, ANTIMICROB AGENTS CH, V47, P735, DOI 10.1128/AAC.47.2.735-738.2003; Luttgen H, 2000, P NATL ACAD SCI USA, V97, P1062, DOI 10.1073/pnas.97.3.1062; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miallau L, 2003, P NATL ACAD SCI USA, V100, P9173, DOI 10.1073/pnas.1533425100; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843; Richard SB, 2002, J BIOL CHEM, V277, P8667, DOI 10.1074/jbc.C100739200; Richard SB, 2001, NAT STRUCT BIOL, V8, P641, DOI 10.1038/89691; Rodriguez-Concepcion M, 2002, PLANT PHYSIOL, V130, P1079, DOI 10.1104/pp.007138; Rohdich F, 2003, PURE APPL CHEM, V75, P393, DOI 10.1351/pac200375020393; Rohdich F, 2003, P NATL ACAD SCI USA, V100, P1586, DOI 10.1073/pnas.0337742100; Rohdich F, 2001, EUR J BIOCHEM, V268, P3190, DOI 10.1046/j.1432-1327.2001.02204.x; Rohdich F, 1999, P NATL ACAD SCI USA, V96, P11758, DOI 10.1073/pnas.96.21.11758; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Steinbacher S, 2002, J MOL BIOL, V316, P79, DOI 10.1006/jmbi.2001.5341; Takagi M, 2000, TETRAHEDRON LETT, V41, P3395, DOI 10.1016/S0040-4039(00)00375-0; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Wolff M, 2003, FEBS LETT, V541, P115, DOI 10.1016/S0014-5793(03)00317-X	56	39	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52753	52761		10.1074/jbc.M408895200	http://dx.doi.org/10.1074/jbc.M408895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466439	hybrid			2022-12-25	WOS:000225493400122
J	Molina, MM; Belli, G; de la Torre, MA; Rodriguez-Manzaneque, MT; Herrero, E				Molina, MM; Belli, G; de la Torre, MA; Rodriguez-Manzaneque, MT; Herrero, E			Nuclear monothiol glutaredoxins of Saccharomyces cerevisiae can function as mitochondrial glutaredoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OXIDATIVE STRESS; THIOLTRANSFERASE GLUTAREDOXIN; ESCHERICHIA-COLI; PROTEIN-KINASE; REDOX STATE; THIOREDOXIN; GLUTATHIONE; EXPRESSION; DISULFIDE	Glutaredoxins are thiol oxidoreductases that regulate protein redox state. In Saccharomyces cerevisiae, Grx1 and Grx2 are cytosolic dithiol glutaredoxins, whereas Grx3, Grx4, and Grx5 are monothiol glutaredoxins. Grx5 locates at the mitochondrial matrix and is needed for iron/sulfur cluster biogenesis. Its absence causes phenotypes such as inactivation of iron/sulfur enzymes and sensitivity to oxidative stress. Whereas Grx5 contains a single glutaredoxin domain, in Grx3 and Grx4 a thioredoxin-like domain is fused to the glutaredoxin domain. Here we have shown that Grx3 locates at the nucleus and that the thioredoxin-like domain is required for such location. We have addressed the functional divergence among glutaredoxins by targeting Grx2/3/4 molecules to the mitochondrial matrix using the Grx5 targeting sequence. The mitochondrial forms of Grx3 and Grx4 partially rescue the defects of a grx5 null mutant. On the contrary, mitochondrially targeted Grx2 does not suppress the mutant phenotype. Both the thioredoxin-like and glutaredoxin domains are needed for the mitochondrial activity of Grx3, although none of the cysteine residues at the thioredoxin-like domain is required for rescue of the grx5 phenotypes. We have concluded that dithiol glutaredoxins are functionally divergent from monothiol ones, but the latter can interchange their biological activities when compartment barriers are surpassed.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25008, Spain	Universitat de Lleida	Herrero, E (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Montserrat Roig 2, Lleida 25008, Spain.	enric.herrero@cmb.udl.es	de la Torre, M Angeles/A-7357-2010; Rodriguez-Manzaneque Martinez, Maria Teresa/C-6449-2011; belli, gemma/A-7424-2011; Bellí, Gemma/AAD-5325-2019; Herrero, Enrique/B-5592-2009	de la Torre, M Angeles/0000-0002-6111-1359; belli, gemma/0000-0002-4161-3204; Bellí, Gemma/0000-0002-4161-3204; Herrero, Enrique/0000-0002-6763-111X; , Micaela/0000-0002-2103-0351				Arino J, 2003, METHOD ENZYMOL, V366, P347; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Babichev Y, 2001, ADV EXP MED BIOL, V495, P41; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Belli G, 2002, J BIOL CHEM, V277, P37590, DOI 10.1074/jbc.M201688200; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Cha MK, 2004, J BIOL CHEM, V279, P11035, DOI 10.1074/jbc.M312657200; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gerber J, 2004, MOL CELL BIOL, V24, P4848, DOI 10.1128/MCB.24.11.4848-4857.2004; Gietz RD., 1988, GENE, V74, P3065; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Greene NDE, 2002, J BIOL CHEM, V277, P41645, DOI 10.1074/jbc.M203607200; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hughes AL, 2003, GENOME RES, V13, P1258; Isakov N, 2000, TRENDS BIOCHEM SCI, V25, P537, DOI 10.1016/S0968-0004(00)01685-6; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Kenchappa RS, 2002, J NEUROSCI, V22, P8402; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Llorente B, 2000, FEBS LETT, V487, P122, DOI 10.1016/S0014-5793(00)02291-2; Lopreiato R, 2004, BIOCHEM J, V377, P395, DOI 10.1042/BJ20030638; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; Outten CE, 2004, J BIOL CHEM, V279, P7785, DOI 10.1074/jbc.M312421200; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Pedrajas JR, 2002, BIOCHEM J, V364, P617, DOI 10.1042/BJ20020570; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Pineda-Molina E, 2001, BIOCHEMISTRY-US, V40, P14134, DOI 10.1021/bi011459o; Porras P, 2002, BIOCHEM BIOPH RES CO, V295, P1046, DOI 10.1016/S0006-291X(02)00771-4; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Robinson JB., 1987, MITOCHONDRIA PRACTIC, P153, DOI DOI 10.1016/J.BBRC.2005.02.135; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rouhier N, 2002, ANN NY ACAD SCI, V973, P520, DOI 10.1111/j.1749-6632.2002.tb04693.x; Sadek CM, 2003, J BIOL CHEM, V278, P13133, DOI 10.1074/jbc.M300369200; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; Tatchell K, 2002, METHOD ENZYMOL, V351, P661; Toledano MB, 2003, TOP CURR GENET, V1, P241; Trotter EW, 2003, EMBO REP, V4, P184, DOI 10.1038/sj.embor.embor729; Vilella F, 2004, COMP FUNCT GENOM, V5, P328, DOI 10.1002/cfg.406; Weiner Michael P., 1995, P613; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Wheeler GL, 2004, PHYSIOL PLANTARUM, V120, P12, DOI 10.1111/j.0031-9317.2004.0193.x; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200	62	77	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51923	51930		10.1074/jbc.M410219200	http://dx.doi.org/10.1074/jbc.M410219200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456753	Green Published, hybrid			2022-12-25	WOS:000225493400026
J	Miller, AL; Suntharalingam, M; Johnson, SL; Audhya, A; Emr, SD; Wente, SR				Miller, AL; Suntharalingam, M; Johnson, SL; Audhya, A; Emr, SD; Wente, SR			Cytoplasmic inositol hexakisphosphate production is sufficient for mediating the Gle1-mRNA export pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA EXPORT; SACCHAROMYCES-CEREVISIAE; YEAST NUCLEOPORIN; NUCLEOCYTOPLASMIC TRANSPORT; FUNCTIONAL-CHARACTERIZATION; SIGNAL-TRANSDUCTION; CONDITIONAL ALLELE; PROTEOMIC ANALYSIS; BINDING-PROTEINS	Production of inositol hexakisphosphate (IP6) by Ipk1, the inositol-1,3,4,5,6-pentakisphosphate 2-kinase, is required for Gle1-mediated mRNA export in Saccharomyces cerevisiae cells. To examine the network of interactions that require IP6 production, an analysis of fitness defects was conducted in mutants harboring both an ipk1 null allele and a mutant allele in genes encoding nucleoporins or transport factors. Enhanced lethality was observed with a specific subset of mutants, including nup42, nup116, nup159, dbp5, and gle2, all of which had been previously connected to Gle1 function. Complementation of the nup116Deltaipk1Delta and nup42Deltaipk1Delta double mutants did not require the Phe-Gly repeat domains in the respective nucleoporins, suggesting that IP6 was acting subsequent to heterogeneous nuclear ribonucleoprotein targeting to the nuclear pore complex. With Nup42 and Nup159 localized exclusively to the nuclear pore complex cytoplasmic side, we speculated that IP6 may regulate a cytoplasmic step in mRNA export. To test this prediction, the spatial requirements for the production of IP6 were investigated. Restriction of Ipk1 to the cytoplasm did not block IP6 production. Moreover, coincident sequestering of both Ipk1 and Mss4 ( an enzyme required for phosphatidylinositol 4,5-bisphosphate production) to the cytoplasm also did not block IP6 production. Given that the kinase required for inositol 1,3,4,5,6-pentakisphosphate production (Ipk2) is localized in the nucleus, these results indicated that soluble inositides were diffusing between the nucleus and the cytoplasm. Additionally, the cytoplasmic production of IP6 by plasma membrane-anchored Ipk1 rescued a gle1-2 ipk1-4 synthetic lethal mutant. Thus, cytoplasmic IP6 production is sufficient for mediating the Gle1-mRNA export pathway.	Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Vanderbilt University; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Wente, SR (corresponding author), Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, 3120 MRBIII,465 21st Ave S, Nashville, TN 37232 USA.	susan.wente@vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051219, R01GM051219] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51219] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Albertini M, 1998, J CELL BIOL, V143, P1447, DOI 10.1083/jcb.143.6.1447; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Bai C, 1997, METHOD ENZYMOL, V283, P141; Bailer SM, 2000, J BIOL CHEM, V275, P23540, DOI 10.1074/jbc.M001963200; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Belgareh N, 1998, MOL BIOL CELL, V9, P3475, DOI 10.1091/mbc.9.12.3475; BERCY J, 1987, GENE, V55, P277, DOI 10.1016/0378-1119(87)90287-3; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; DelPriore V, 1996, MOL BIOL CELL, V7, P1601, DOI 10.1091/mbc.7.10.1601; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Divecha N, 2000, CELL MOL LIFE SCI, V57, P379, DOI 10.1007/PL00000700; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; Feldherr CM, 1997, J CELL SCI, V110, P3065; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Gilbert W, 2004, MOL CELL, V13, P201, DOI 10.1016/S1097-2765(04)00030-9; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Goldstein AL, 1996, MOL BIOL CELL, V7, P917, DOI 10.1091/mbc.7.6.917; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Ho AK, 1998, MOL BIOL CELL, V9, P355, DOI 10.1091/mbc.9.2.355; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Hood JK, 2000, J CELL SCI, V113, P1471; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Hurwitz ME, 1998, P NATL ACAD SCI USA, V95, P11241, DOI 10.1073/pnas.95.19.11241; HURWITZ ME, 1995, J CELL BIOL, V130, P1275, DOI 10.1083/jcb.130.6.1275; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Ives EB, 2000, J BIOL CHEM, V275, P36575, DOI 10.1074/jbc.M007586200; Izaurralde E, 2002, EUR J CELL BIOL, V81, P577, DOI 10.1078/0171-9335-00273; James P, 1996, GENETICS, V144, P1425; Keminer O, 1999, BIOPHYS J, V77, P217, DOI 10.1016/S0006-3495(99)76883-9; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Maraldi NM, 1999, J CELL PHYSIOL, V181, P203, DOI 10.1002/(SICI)1097-4652(199911)181:2<203::AID-JCP3>3.0.CO;2-O; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Rayala HJ, 2004, MOL CELL PROTEOMICS, V3, P145, DOI 10.1074/mcp.M300106-MCP200; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; SIKORSKI RS, 1989, GENETICS, V122, P19; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; Suntharalingam M, 2004, J BIOL CHEM, V279, P35384, DOI 10.1074/jbc.M402044200; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Vinciguerra P, 2004, CURR OPIN CELL BIOL, V16, P285, DOI 10.1016/j.ceb.2004.03.013; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002	92	42	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51022	51032		10.1074/jbc.M409394200	http://dx.doi.org/10.1074/jbc.M409394200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15459192	hybrid			2022-12-25	WOS:000225355800047
J	Skorvaga, M; DellaVecchia, MJ; Croteau, DL; Theis, K; Truglio, JJ; Mandavilli, BS; Kisker, C; Van Houten, B				Skorvaga, M; DellaVecchia, MJ; Croteau, DL; Theis, K; Truglio, JJ; Mandavilli, BS; Kisker, C; Van Houten, B			Identification of residues within UvrB that are important for efficient DNA binding and damage processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CRYSTAL-STRUCTURE; THERMUS-THERMOPHILUS; PROTEIN COMPLEX; RECOGNITION; HELICASE; ENZYME	The UvrB protein is the central recognition protein in bacterial nucleotide excision repair. We have shown previously that the highly conserved beta-hairpin motif in Bacillus caldotenax UvrB is essential for DNA binding, damage recognition, and UvrC-mediated incision, as deletion of the upper part of the beta-hairpin ( residues 97 112) results in the inability of UvrB to be loaded onto damaged DNA, defective incision, and the lack of strand-destabilizing activity. In this work, we have further examined the role of the beta-hairpin motif of UvrB by a mutational analysis of 13 amino acids within or in the vicinity of the beta-hairpin. These amino acids are predicted to be important for the interaction of UvrB with both damaged and non-damaged DNA strands as well as the formation of salt bridges between the beta-hairpin and domain 1b of UvrB. The resulting mutants were characterized by standard functional assays such as oligonucleotide incision, electrophoretic mobility shift, strand-destabilizing, and ATPase assays. Our data indicated a direct role of Tyr(96), Glu(99), and Arg(123) in damage-specific DNA binding. In addition, Tyr(93) plays an important but less essential role in DNA binding by UvrB. Finally, the formation of salt bridges between the beta-hairpin and domain 1b, involving amino acids Lys(111) bound to Glu(307) and Glu(99) bound to Arg(367) or Arg(289), are important but not essential for the function of UvrB.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Slovak Acad Sci, Canc Res Inst, Dept Mol Genet, Bratislava 83391, Slovakia; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Slovak Academy of Sciences; University of Massachusetts System; University of Massachusetts Amherst	Kisker, C (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	kisker@pharm.sunysb.edu; vanhout1@niehs.nih.gov	Skorvaga, Milan/AAO-2360-2021; Kisker, Caroline/T-1724-2019; Van Houten, Bennett/K-2284-2019; Croteau, Deb/AAP-5933-2020	Kisker, Caroline/0000-0002-0216-6026; Theis, Karsten/0000-0003-2697-6143; Croteau, Deborah/0000-0002-6094-4084	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES061060] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DellaVecchia MJ, 2004, J BIOL CHEM, V279, P45245, DOI 10.1074/jbc.M408659200; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; Gordienko I, 1997, EMBO J, V16, P889, DOI 10.1093/emboj/16.4.889; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; Moolenaar GF, 2000, J BIOL CHEM, V275, P8044, DOI 10.1074/jbc.275.11.8044; Moolenaar GF, 2001, EMBO J, V20, P6140, DOI 10.1093/emboj/20.21.6140; Nakagawa N, 1999, J BIOCHEM, V126, P986, DOI 10.1093/oxfordjournals.jbchem.a022566; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; Skorvaga M, 2002, J BIOL CHEM, V277, P1553, DOI 10.1074/jbc.M108847200; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Theis K, 2000, MUTAT RES-DNA REPAIR, V460, P277, DOI 10.1016/S0921-8777(00)00032-X; Truglio JJ, 2004, EMBO J, V23, P2498, DOI 10.1038/sj.emboj.7600263; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889; Zou Y, 2004, BIOCHEMISTRY-US, V43, P4196, DOI 10.1021/bi035992a	14	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51574	51580		10.1074/jbc.M409266200	http://dx.doi.org/10.1074/jbc.M409266200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456749	hybrid			2022-12-25	WOS:000225355800113
J	Michod, D; Yang, JY; Chen, JH; Bonny, C; Widmann, C				Michod, D; Yang, JY; Chen, JH; Bonny, C; Widmann, C			A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells	ONCOGENE			English	Article						cancer; RasGAP; cell permeable peptides; TAT; genotoxins	NF-KAPPA-B; APOPTOSIS; TRANSDUCTION; INHIBITOR; DELIVERY; PROTECTS; CLEAVAGE	Treatment of many cancers relies on the combined action of several genotoxins, but the detrimental effect of these drugs on normal cells can cause severe side effects. One major challenge in anticancer therapy is therefore to increase the selectivity of current treatments toward cancer cells in order to spare normal cells. We have recently demonstrated that a RasGAP caspase cleavage fragment is able to sensitize HeLa cells towards cisplatin-induced apoptosis. Here, we extend this observation by showing that this fragment also enhances cell death induced by adriamycin and mitoxantrone, two other widely used genotoxins. Furthermore, we have delineated a short sequence within this fragment that still bears the genotoxin-sensitization property. The peptide encoded by this sequence, when fused to the TAT cell permeation sequence, potently sensitized a number of tumors cells, but not normal cells, towards apoptosis induced by cisplatin, adriamycin and mitoxantrone. This sensitization effect was not mediated through modulation of NFkappaB activity or activation of the JNK and p38 MAPK pathways. Our results demonstrate the feasibility in enhancing the efficacy of currently used drugs to selectively kill cancer cells using peptides derived from pro-apoptotic caspase substrate fragments.	Univ Lausanne, DBCM, CH-1005 Lausanne, Switzerland; CHU Vaudois, Med Genet Unit, CH-1011 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Widmann, C (corresponding author), Univ Lausanne, DBCM, Bugnon 9, CH-1005 Lausanne, Switzerland.	Christian.Widmann@ibcm.unil.ch	Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Michod, David/0000-0002-4187-405X				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yang JY, 2002, EUR CYTOKINE NETW, V13, P404; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001	18	46	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8971	8978		10.1038/sj.onc.1207999	http://dx.doi.org/10.1038/sj.onc.1207999			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467750				2022-12-25	WOS:000225354600012
J	Rong, R; Surace, EI; Haipek, CA; Gutmann, DH; Ye, KQ				Rong, R; Surace, EI; Haipek, CA; Gutmann, DH; Ye, KQ			Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression	ONCOGENE			English	Article						neurofibromatosis; NF2; merlin; phosphorylation; PAK2	CELL EXTENSION ACTIVITY; N-TERMINAL DOMAIN; TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; P21-ACTIVATED KINASE; ERM PROTEINS; FERM DOMAIN; EZRIN; MEMBRANE	The neurofibromatosis 2 (NF2) tumor suppressor protein, merlin, functions as a negative growth regulator; however, the molecular mechanisms that underlie merlin regulation remain elusive. Recent studies have implicated merlin phosphorylation in regulating merlin subcellular localization and growth suppression. P21-activated kinase (PAK), a downstream target of Rac1/Cdc42, directly phosphorylates merlin at Serine 518. In this report, we show that PAK2 directly phosphorylates wild-type merlin, whereas merlin truncation mutants with impaired GST-amino-terminal domain ( N-term or NTD)/GST-carboxy-terminal domain ( C-term or CTD) intramolecular association exhibit impaired S518 phosphorylation. We directly demonstrate that PAK2 phosphorylation impairs merlin N-term/C-term binding in vitro and in vivo. Lastly, we show that PAK2 phosphorylation impairs the ability of merlin to bind to two interacting proteins, CD44 and hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), both critical for merlin growth suppression. These observations suggest that merlin S518 phosphorylation directly modulates merlin intramolecular and intermolecular associations important for the ability of merlin to function as a tumor suppressor.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Emory University; Washington University (WUSTL)	Ye, KQ (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035848] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35848] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533; Brault E, 2001, J CELL SCI, V114, P1901; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1998, HUM MOL GENET, V7, P335, DOI 10.1093/hmg/7.3.335; Gutmann DH, 2001, HUM MOL GENET, V10, P1519, DOI 10.1093/hmg/10.14.1519; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Meng JJ, 2000, J NEUROSCI RES, V62, P491, DOI 10.1002/1097-4547(20001115)62:4<491::AID-JNR3>3.0.CO;2-D; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Neill GW, 2001, BIOCHEM J, V358, P727, DOI 10.1042/0264-6021:3580727; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, HUM MOL GENET, V11, P3167, DOI 10.1093/hmg/11.25.3167; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7	36	90	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8447	8454		10.1038/sj.onc.1207794	http://dx.doi.org/10.1038/sj.onc.1207794			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378014				2022-12-25	WOS:000224870700005
J	Suzuki, J; Sukezane, T; Akagi, T; Georgescu, MM; Ohtani, M; Inoue, H; Jat, PS; Goff, SP; Hanafusa, H; Shishido, T				Suzuki, J; Sukezane, T; Akagi, T; Georgescu, MM; Ohtani, M; Inoue, H; Jat, PS; Goff, SP; Hanafusa, H; Shishido, T			Loss of c-abl facilitates anchorage-independent growth of p53- and RB-deficient primary mouse embryonic fibroblasts	ONCOGENE			English	Article						anchorage-independent growth; SV40 T antigen; c-Abl; p53; RB	CHRONIC MYELOGENOUS LEUKEMIA; LARGE TUMOR-ANTIGEN; T-ANTIGEN; TYROSINE KINASE; CELL-TRANSFORMATION; PHOSPHORYLATION; METHYLATION; MICE; P53; SUPPRESSOR	The c-abl tyrosine kinase is the proto-oncogene of the v-abl oncogene of the Abelson murine leukemia virus. Although mutational variants of c-Abl can exhibit gain of function and can produce a transformed phenotype, the function of c-Abl in transformation remained unclear. Here, we report that the loss of c-abl facilitates transformation. c-abl-knockout mouse embryonic fibroblasts (MEFs) immortalized by SV40 T antigen acquired anchorage-independent growth, and by constructing mutational variants of T antigen we showed that binding of large T antigen to p53 and RB was necessary to induce anchorage-independent growth. Although c-abl/p53 double-knockout MEFs did not undergo anchorage-independent growth, those expressing human papilloma virus 16 E7, which mainly inactivates RB, did. Our results show that the loss of c-abl facilitates anchorage-independent growth in the context of p53 and RB deficiency, and suggest that loss of function of c-abl facilitates some types of transformation.	Nara Inst Sci & Technol, Oncol Mol Lab, Nara 6300101, Japan; Osaka Biosci Inst, Oncol Mol Lab, Osaka 5650874, Japan; Osaka Univ, Grad Sch Med, Dept Mol Oncol, Suita, Osaka 5650871, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Shiga Univ Med Sci, Sch Med, Dept Microbiol, Shiga 5202192, Japan; Ludwig Inst Canc Res, London W1W 7BS, England; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Nara Institute of Science & Technology; Osaka University; University of Texas System; UTMD Anderson Cancer Center; Shiga University of Medical Science; Ludwig Institute for Cancer Research; Columbia University	Shishido, T (corresponding author), Nara Inst Sci & Technol, Oncol Mol Lab, 8916-5 Takayama, Nara 6300101, Japan.	shishid@bs.naist.jp	Georgescu, Maria-Magdalena/AAJ-6359-2020; Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547; Shishido, Tomoyuki/0000-0002-8944-2088				ABELSON HT, 1970, CANCER RES, V30, P2213; Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Asimakopoulos FA, 1999, BLOOD, V94, P1141, DOI 10.1182/blood.V94.3.1141.415a35d_1141_1142; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Hardin JD, 1996, ONCOGENE, V12, P2669; Issa JPJ, 1999, BLOOD, V93, P2075, DOI 10.1182/blood.V93.6.2075.406k29_2075_2080; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Miyoshi-Akiyama T, 2001, ONCOGENE, V20, P4058, DOI 10.1038/sj.onc.1204528; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Smith JM, 2002, FRONT BIOSCI, V7, pD31; Tani K, 2003, J BIOL CHEM, V278, P21685, DOI 10.1074/jbc.M301447200; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; Whang YE, 2000, P NATL ACAD SCI USA, V97, P5486, DOI 10.1073/pnas.97.10.5486; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722	44	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8527	8534		10.1038/sj.onc.1207894	http://dx.doi.org/10.1038/sj.onc.1207894			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378021				2022-12-25	WOS:000224870700013
J	Gururaj, A; Barnes, CJ; Vadlamudi, RK; Kumar, R				Gururaj, A; Barnes, CJ; Vadlamudi, RK; Kumar, R			Regulation of phosphoglucomutase 1 phosphorylation and activity by a signaling kinase	ONCOGENE			English	Article						signaling; PGM; glycolysis; cancer metabolism	BREAST-CANCER CELLS; P21-ACTIVATED KINASES; SACCHAROMYCES-CEREVISIAE; ESTROGEN-RECEPTOR; REORGANIZATION; EXPRESSION; APOPTOSIS; TARGETS; COMPLEX; GROWTH	We have identified a novel mechanism of cross-talk between cell signaling and metabolic pathways, whereby the signaling kinase p21-activated kinase 1 (Pak1) binds to, phosphorylates and enhances the enzymatic activity of phosphoglucomutase 1 (PGM), an important regulatory enzyme in cellular glucose utilization and energy homeostasis. Pak1 and PGM were colocalized in model cell systems and showed functional interactions in a physiological setting. Strong direct interaction of PGM with Pak1 but not Pak2, Pak3, or Pak4 was observed. PGM binding was within 75-149 amino acids (aa) of Pak1, while Pak1 binding to PGM was in the N-terminal 96 aa. Pak1-mediated phosphorylation of PGM selectively on threonine 466 significantly increased PGM enzymatic activity and could be blocked by transfection with a dominant-negative Pak1 expression vector and by Pak1-specific small inhibitory RNA. Stable transfection of PGM into PGM-deficient K-562 leukemia cells further demonstrated the role of Pak1 in regulating PGM activity. The results presented here provide new evidence that the cell signaling kinase Pak1 is a novel regulator of glucose metabolism through its phosphorylation and regulation of PGM activity. These findings suggest a new mechanism whereby growth factor signaling may coordinately integrate metabolic regulation with established signaling functions of cell cycle regulation and cell growth.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Barnes, Christopher/B-1545-2015	Barnes, Christopher/0000-0001-9682-0748	NATIONAL CANCER INSTITUTE [R01CA090970] Funding Source: NIH RePORTER; NCI NIH HHS [CA90970, CA80066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Barnes CJ, 2002, CANCER RES, V62, P1251; BARNES CJ, 2003, NAT STRUCT BIOL, V3, P30; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Boros LG, 2002, PANCREAS, V24, P26, DOI 10.1097/00006676-200201000-00004; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DEY NB, 1994, J BIOL CHEM, V269, P27143; Gao H, 2004, ANAL BIOCHEM, V329, P269, DOI 10.1016/j.ab.2004.03.011; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Lindahl M, 2003, P NATL ACAD SCI USA, V100, P16107, DOI 10.1073/pnas.2534397100; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; PUTT W, 1993, BIOCHEM J, V296, P417, DOI 10.1042/bj2960417; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; Shanmuganathan A, 2004, FEBS LETT, V556, P253, DOI 10.1016/S0014-5793(03)01428-5; Takahashi N, 2001, HUM BIOL, V73, P755, DOI 10.1353/hub.2001.0076; Tomkins J, 1997, ANN HUM GENET, V61, P99; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Zhai WG, 1999, MOL CELL BIOL, V19, P2791	27	75	79	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8118	8127		10.1038/sj.onc.1207969	http://dx.doi.org/10.1038/sj.onc.1207969			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15378030				2022-12-25	WOS:000224692500009
J	Sivendran, S; Patterson, D; Spiegel, E; McGown, I; Cowley, D; Colman, RF				Sivendran, S; Patterson, D; Spiegel, E; McGown, I; Cowley, D; Colman, RF			Two novel mutant human adenylosuccinate Lyases (ASLs) associated with autism and characterization of the equivalent mutant Bacillus subtilis ASL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INBORN ERROR; ACTIVE-SITE; DEFICIENCY; ENZYME; IDENTIFICATION; PURIFICATION; CATALYSIS; MUTATION; HIS(141); DISEASE	An Australian patient with autism was found to be heterozygous for two mutations in the gene encoding adenylosuccinate lyase (ASL), resulting in the protein mutations E80D and D87E. The patient's mother carried only the E80D mutation. The equivalent positions are 62 and 69 in Bacillus subtilis ASL. Although both human and B. subtilis enzymes normally have Asp at position 87 (or 69), the B. subtilis ASL has Ile and Asp at 62 and 65, respectively, whereas human ASL has Glu and Arg at the equivalent positions. We have constructed, expressed, and purified the double mutant I62E/D65R as a "humanized" normal B. subtilis enzyme to compare with enzymes with a single mutation at position 62 (I62D/D65R), at position 69 (I62E/D65R/D69E), or at both positions (I62D/D65R/D69E). V-max for conversion of adenylosuccinate to AMP and fumarate is 0.57 mumol/min/mg for I62E/D65R, 0.064 mumol/min/mg for I62D/D65R, 0.27 mumol/min/mg for I62E/D65R/D69E, and 0.069 mumol/min/mg for I62D/D65R/D69E. The K-m for adenylosuccinate is elevated in the X62D mutants, and I62D/D65R is the least stable of these ASLs at 37 degreesC. The CD spectra of mutant and wild type enzymes are similar; thus, there are no appreciable structural changes. Clearly the Asp(62) causes the most drastic effect on ASL function, whereas the Glu(69) mutation produces only modest change. These results emphasize the importance of expanding tests for ASL deficiency to individuals with developmental delay of any severity, including individuals with autistic spectrum disorder. This study further demonstrates the usefulness of the B. subtilis ASL as a model to mimic the defective enzyme in ASL deficiency.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Univ Denver, Eleanor Roosevelt Inst, Denver, CO 80206 USA; Mater Misericordiae Univ Hosp, Brisbane, Australia	University of Delaware; University of Denver; University College Dublin	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	rfcolman@chem.udel.edu	Cowley, David M/M-9674-2013	Cowley, David M/0000-0002-4153-934X	NIDDK NIH HHS [R01-DK60504] Funding Source: Medline; NIMH NIH HHS [R01-MH65431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065431] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosius JL, 2000, BIOCHEMISTRY-US, V39, P13336, DOI 10.1021/bi001488j; Brosius JL, 2002, BIOCHEMISTRY-US, V41, P2217, DOI 10.1021/bi011998t; Castro M, 2002, NEUROPEDIATRICS, V33, P186, DOI 10.1055/s-2002-34493; JAEKEN J, 1988, EUR J PEDIATR, V148, P126, DOI 10.1007/BF00445919; JAEKEN J, 1984, LANCET, V2, P1058; Kmoch S, 2000, HUM MOL GENET, V9, P1501, DOI 10.1093/hmg/9.10.1501; Kohler M, 1999, Eur J Paediatr Neurol, V3, P3, DOI 10.1053/ejpn.1999.0172; LAIKIND PK, 1986, ANAL BIOCHEM, V156, P81, DOI 10.1016/0003-2697(86)90158-2; Lee TT, 1999, BIOCHEMISTRY-US, V38, P22, DOI 10.1021/bi982299s; Lee TT, 1998, BIOCHEMISTRY-US, V37, P8481, DOI 10.1021/bi9805339; Lee TT, 1997, J BIOL CHEM, V272, P458; Marie S, 2002, AM J HUM GENET, V71, P14, DOI 10.1086/341036; Marie S, 2004, AM J HUM GENET, V74, P1276, DOI 10.1086/421475; Miller MP, 2001, HUM MOL GENET, V10, P2319, DOI 10.1093/hmg/10.21.2319; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Palenchar JB, 2003, PROTEIN SCI, V12, P1694, DOI 10.1110/ps.0303903; Palenchar JB, 2003, BIOCHEMISTRY-US, V42, P1831, DOI 10.1021/bi020640+; Race V, 2000, HUM MOL GENET, V9, P2159, DOI 10.1093/hmg/9.14.2159; Ratner S, 1972, ENZYMES, P167; Redinbo MR, 1996, PROTEIN SCI, V5, P786; Segall ML, 2004, BIOCHEMISTRY-US, V43, P7391, DOI 10.1021/bi0494774; Sivendran S, 2004, FASEB J, V18, pC241; Stathis SL, 2000, J AM ACAD CHILD PSY, V39, P274, DOI 10.1097/00004583-200003000-00007; STONE RL, 1993, J BIOL CHEM, V268, P19710; TORNHEIM K, 1972, J BIOL CHEM, V247, P162; Toth EA, 2000, STRUCT FOLD DES, V8, P163, DOI 10.1016/S0969-2126(00)00092-7; VANDENBERGH F, 1993, J INHERIT METAB DIS, V16, P415, DOI 10.1007/BF00710291; VANDENBERGHE G, 2001, METABOLIC MOL BASIS, V2, P2653; Vitkup D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-11-r72; WOODWARD DO, 1966, J BIOL CHEM, V241, P580; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	32	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53789	53797		10.1074/jbc.M409974200	http://dx.doi.org/10.1074/jbc.M409974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471876	hybrid			2022-12-25	WOS:000225680600117
J	Spiegel, PC; Murphy, P; Stoddard, BL				Spiegel, PC; Murphy, P; Stoddard, BL			Surface-exposed hemophilic mutations across the factor VIIIC2 domain have variable effects on stability and binding activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; COAGULATION-FACTOR-VIII; LINEAR EXTRAPOLATION METHOD; C2 DOMAIN; BLOOD-COAGULATION; MEMBRANE-BINDING; FACTOR-V; MONOCLONAL-ANTIBODY; MISSENSE MUTATIONS; CRYSTAL-STRUCTURE	Factor VIII (fVIII) is a plasma glycoprotein that functions as an essential cofactor in blood coagulation. Its carboxyl-terminal "C2" domain is responsible for binding to both activated platelet surfaces and von Willebrand factor. We characterized the effect of 20 hemophilia-associated missense mutations across this domain ( that all occur in patients in vivo) on its stability and its binding activities. At least six of these mutations were severely destabilizing, and another four caused moderate destabilization and corresponding reductions in both binding functions. One mutant (A2201P) displayed a significant reduction in its membrane binding activity but normal von Willebrand factor binding, while two others (P2300S and R2304H) caused the opposite effect. Several mutations (including L2210P, V2223M, M2238V, and R2304C) displayed near wild-type stabilities and binding activities and may instead affect mRNA splicing or alternative properties or functions of the protein. This study demonstrated that von Willebrand factor and membrane binding activities can be uncoupled and uniquely disrupted by different mutations and that either effect can lead to similar reductions in clotting activity. It also illustrated how a heterogeneous genetic disorder causes diverse molecular phenotypes that result in similar disease states.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Grad Program Biomol Struct & Design, Seattle, WA 98195 USA; Univ Washington, Med Sci Training Program, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stoddard, BL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Mailstop A3-025,1100 Fairview Ave N, Seattle, WA 98109 USA.	bstoddar@fhcrc.org						Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; d'Oiron R, 2004, BLOOD, V103, P155, DOI 10.1182/blood-2003-04-1321; Dantas G, 2003, J MOL BIOL, V332, P449, DOI 10.1016/S0022-2836(03)00888-X; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; Gilbert GE, 2002, J BIOL CHEM, V277, P6374, DOI 10.1074/jbc.M104732200; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; Jacquemin MG, 1998, BLOOD, V92, P496, DOI 10.1182/blood.V92.2.496.414k16_496_506; KANE WH, 1988, BLOOD, V71, P539; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; Lewis DA, 2001, THROMB HAEMOSTASIS, V85, P260, DOI 10.1055/s-0037-1615697; Liu ML, 2000, BLOOD, V96, P979, DOI 10.1182/blood.V96.3.979.015k42a_979_987; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; Nogami K, 2000, J BIOL CHEM, V275, P25774, DOI 10.1074/jbc.M002007200; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; Pellequer JL, 1998, BLOOD CELL MOL DIS, V24, P448, DOI 10.1006/bcmd.1998.0214; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Pipe SW, 1996, J BIOL CHEM, V271, P25671, DOI 10.1074/jbc.271.41.25671; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Saenko E, 1999, J CHROMATOGR A, V852, P59, DOI 10.1016/S0021-9673(99)00491-4; Saenko E, 2001, J CHROMATOGR A, V921, P49, DOI 10.1016/S0021-9673(01)00601-X; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; Saenko EL, 2002, BRIT J HAEMATOL, V119, P323, DOI 10.1046/j.1365-2141.2002.03793.x; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; Schatz SM, 2004, BRIT J HAEMATOL, V125, P629, DOI 10.1111/j.1365-2141.2004.04959.x; SHIMA M, 1995, BRIT J HAEMATOL, V91, P714, DOI 10.1111/j.1365-2141.1995.tb05374.x; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; Spiegel PC, 2004, CHEM BIOL, V11, P1413, DOI 10.1016/j.chembiol.2004.08.006; Spiegel PC, 2001, BLOOD, V98, P13, DOI 10.1182/blood.V98.1.13; Spiegel PC, 2002, BRIT J HAEMATOL, V119, P310, DOI 10.1046/j.1365-2141.2002.03845.x; Takeshima K, 2003, THROMB HAEMOSTASIS, V89, P788, DOI 10.1055/s-0037-1613463; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; Tuddenham E G, 1994, Nucleic Acids Res, V22, P4851, DOI 10.1093/nar/22.22.4851; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Wilson WW, 2003, J STRUCT BIOL, V142, P56, DOI 10.1016/S1047-8477(03)00038-8; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	46	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53691	53698		10.1074/jbc.M409389200	http://dx.doi.org/10.1074/jbc.M409389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471879	hybrid			2022-12-25	WOS:000225680600106
J	Westlake, CJ; Payen, L; Gao, M; Cole, SPC; Deeley, RG				Westlake, CJ; Payen, L; Gao, M; Cole, SPC; Deeley, RG			Identification and characterization of functionally important elements in the multidrug resistance protein 1 COOH-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAINS; CONJUGATE EXPORT PUMP; ABC-TRANSPORTER; ATP-BINDING; MEMBRANE TOPOLOGY; LEUKOTRIENE C-4; MRP GENE; CONGENITAL HYPERINSULINISM; VINCRISTINE TRANSPORT	The ATP binding cassette (ABC) transporter, multidrug resistance protein 1 (MRP1/ABCC1), transports a broad spectrum of conjugated and unconjugated compounds, including natural product chemotherapeutic agents. In this study, we have investigated the importance of the COOH-terminal region of MRP1 for transport activity and basolateral plasma membrane trafficking. The COOH-terminal regions of some ABCC proteins have been implicated in protein trafficking, but the function of this region of MRP1 has not been defined. In contrast to results obtained with other ABCC proteins, we found that the COOH-proximal 30 amino acids of MRP1 can be removed without affecting trafficking to basolateral membranes. However, the truncated protein is inactive. Furthermore, removal of as few as 4 COOH-terminal amino acids profoundly decreases transport activity. Although amino acid sequence conservation of the COOH-terminal regions of ABC proteins is low, secondary structure predictions indicate that they consist of a broadly conserved helix-sheet-sheet-helix-helix structure. Consistent with a conservation of secondary and tertiary structure, MRP1 hybrids containing the COOH-terminal regions of either the homologous MRP2 or the distantly related P-glycoprotein were fully active and trafficked normally. Using mutated proteins, we have identified structural elements containing five conserved hydrophobic amino acids that are required for activity. We show that these are important for binding and hydrolysis of ATP by nucleotide binding domain 2. Based on crystal structures of several ABC proteins, we suggest that the conserved amino acids may stabilize a helical bundle formed by the COOH-terminal three helices and may contribute to interactions between the COOH-terminal region and the protein's two nucleotide binding domains.	Queens Univ, Canc Res Inst, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; McMaster University; Queens University - Canada	Deeley, RG (corresponding author), Queens Univ, Canc Res Inst, Botterell Hall, Kingston, ON K7L 3N6, Canada.	deeleyr@post.queensu.ca	Cole, Susan P.C./I-6389-2017; Westlake, Christopher/AAG-1150-2019; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; Westlake, Christopher/0000-0001-7476-2014; 				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Babenko AP, 2003, J BIOL CHEM, V278, P41577, DOI 10.1074/jbc.C300363200; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BATES SE, 2003, ABC PROTEINS BACTERI, P359; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Campbell JD, 2003, EMBO REP, V4, P1038, DOI 10.1038/sj.embor.7400003; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Deeley RG, 2003, ABC PROTEINS BACTERI, P393; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Fernandez SBM, 2002, J BIOL CHEM, V277, P31048, DOI 10.1074/jbc.M204267200; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FLENS MJ, 1994, CANCER RES, V54, P4557; Flens MJ, 1996, AM J PATHOL, V148, P1237; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Gentzsch M, 2002, BIOCHEM J, V366, P541, DOI 10.1042/BJ20020511; Gentzsch M, 2001, J BIOL CHEM, V276, P1291, DOI 10.1074/jbc.M003672200; Grant CE, 1997, GENOMICS, V45, P368, DOI 10.1006/geno.1997.4950; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Huopio H, 2002, J CLIN ENDOCR METAB, V87, P4502, DOI 10.1210/jc.2002-020378; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 2001, J BIOL CHEM, V276, P38108; Jedlitschky G, 1996, CANCER RES, V56, P988; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; Leslie EM, 2003, BIOCHEMISTRY-US, V42, P5214, DOI 10.1021/bi027076n; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; Matsushita K, 2002, CIRC RES, V90, P554, DOI 10.1161/01.RES.0000012666.42782.30; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Nies AT, 2002, EUR J BIOCHEM, V269, P1866, DOI 10.1046/j.1432-1033.2002.02832.x; Norman BH, 2002, BIOORG MED CHEM LETT, V12, P883, DOI 10.1016/S0960-894X(02)00051-3; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Qian YM, 2002, J BIOL CHEM, V277, P35225, DOI 10.1074/jbc.M206058200; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Reimann F, 2003, DIABETOLOGIA, V46, P241, DOI 10.1007/s00125-002-1014-3; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Schmitt L, 2003, J MOL BIOL, V330, P333, DOI 10.1016/S0022-2836(03)00592-8; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Westlake CJ, 2003, BIOCHEMISTRY-US, V42, P14099, DOI 10.1021/bi035333y; Yabuuchi H, 2002, BIOCHEM BIOPH RES CO, V299, P410, DOI 10.1016/S0006-291X(02)02658-X; Yang RY, 2003, J BIOL CHEM, V278, P30764, DOI 10.1074/jbc.M304118200	60	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53571	53583		10.1074/jbc.M402528200	http://dx.doi.org/10.1074/jbc.M402528200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15459206	hybrid			2022-12-25	WOS:000225680600093
J	Yoo, HY; Shevchenko, A; Shevchenko, A; Dunphy, WG				Yoo, HY; Shevchenko, A; Shevchenko, A; Dunphy, WG			Mcm2 is a direct substrate of ATM and ATR during DNA damage and DNA replication checkpoint responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; CELL-FREE-EXTRACTS; EARLY EMBRYONIC LETHALITY; S-PHASE; ATAXIA-TELANGIECTASIA; DEPENDENT CHECKPOINT; PROTEINS; KINASE; CHK1; ACTIVATION	In vertebrates, ATM and ATR are critical regulators of checkpoint responses to damaged and incompletely replicated DNA. These checkpoint responses involve the activation of signaling pathways that inhibit the replication of chromosomes with DNA lesions. In this study, we describe the isolation of a cDNA encoding a full-length version of Xenopus ATM. Using antibodies against the regulatory domain of ATM, we have identified the essential replication protein Mcm2 as an ATM-binding protein in Xenopus egg extracts. Xenopus Mcm2 underwent phosphorylation at Ser(92) in response to the presence of double-stranded DNA breaks or DNA replication blocks in egg extracts. This phosphorylation involved both ATM and ATR, but the relative contribution of each kinase depended upon the checkpoint-inducing DNA signal. Furthermore, both ATM and ATR phosphorylated Mcm2 directly at Ser(92) in cell-free kinase assays. Immunodepletion of both ATM and ATR abrogated the checkpoint response that blocks chromosomal DNA replication in egg extracts containing double-stranded DNA breaks. These experiments indicate that ATM and ATR phosphorylate the functionally critical replication protein Mcm2 during both DNA damage and replication checkpoint responses in Xenopus egg extracts.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	California Institute of Technology; Max Planck Society	Dunphy, WG (corresponding author), CALTECH, Div Biol, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	dunphy@cco.caltech.edu			NIGMS NIH HHS [GM43974] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043974, R01GM043974] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bailis JM, 2004, CURR OPIN GENET DEV, V14, P17, DOI 10.1016/j.gde.2003.11.002; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Brown EJ, 2000, GENE DEV, V14, P397; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; Ishimi Y, 2003, J BIOL CHEM, V278, P24644, DOI 10.1074/jbc.M213252200; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kobayashi T, 2002, J CELL SCI, V115, P3159; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Laskey RA, 2003, EMBO REP, V4, P26, DOI 10.1038/sj.embor.embor706; Liang DT, 1999, J CELL SCI, V112, P559; Liu QH, 2000, GENE DEV, V14, P1448; Marheineke K, 2004, J BIOL CHEM, V279, P28071, DOI 10.1074/jbc.M401574200; Marheineke K, 2001, J BIOL CHEM, V276, P17092, DOI 10.1074/jbc.M100271200; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; MILLS AD, 1989, J CELL SCI, V94, P471; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Prokhorova TA, 2000, J BIOL CHEM, V275, P2491, DOI 10.1074/jbc.275.4.2491; Robertson K, 1999, ONCOGENE, V18, P7070, DOI 10.1038/sj.onc.1203194; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Thomas H, 2004, RAPID COMMUN MASS SP, V18, P923, DOI 10.1002/rcm.1427; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	50	105	107	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53353	53364		10.1074/jbc.M408026200	http://dx.doi.org/10.1074/jbc.M408026200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15448142	hybrid, Green Accepted			2022-12-25	WOS:000225680600068
J	Fujita, M; Yoko-o, T; Okamoto, M; Jigami, Y				Fujita, M; Yoko-o, T; Okamoto, M; Jigami, Y			GPI7 involved in glycosylphosphatidylinositol biosynthesis is essential for yeast cell separation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CANDIDA-ALBICANS; PROTEIN-KINASE; ANCHOR SYNTHESIS; PLASMA-MEMBRANE; BUDDING YEAST; WALL PROTEINS; GENE; PATHWAY	GPI7 is involved in adding ethanolaminephosphate to the second mannose in the biosynthesis of glycosylphosphatidylinositol (GPI) in Saccharomyces cerevisiae. We isolated gpi7 mutants, which have defects in cell separation and a daughter cell-specific growth defect at the non-permissive temperature. WSC1, RHO2, ROM2, GFA1, and CDC5 genes were isolated as multicopy suppressors of gpi7-2 mutant. Multicopy suppressors could suppress the growth defect of gpi7 mutants but not the cell separation defect. Loss of function mutations of genes involved in the Cbk1p-Ace2p pathway, which activates the expression of daughter-specific genes for cell separation after cytokinesis, bypassed the temperature-sensitive growth defect of gpi7 mutants. Furthermore, deletion of EGT2, one of the genes controlled by Ace2p and encoding a GPI-anchored protein required for cell separation, ameliorated the temperature sensitivity of the gpi7 mutant. In this mutant, Egt2p was displaced from the septal region to the cell cortex, indicating that GPI7 plays an important role in cell separation via the GPI-based modification of daughter-specific proteins in S. cerevisiae.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba	Jigami, Y (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan.	jigami.yoshi@aist.go.jp	Fujita, Morihisa/AAM-4142-2020; Yoko-o, Takehiko/L-7093-2018	Yoko-o, Takehiko/0000-0003-0291-8299; Okamoto, michiyo/0000-0003-4280-6048				Abe H, 2003, GLYCOBIOLOGY, V13, P87, DOI 10.1093/glycob/cwg014; Bagnat M, 2002, P NATL ACAD SCI USA, V99, P14183, DOI 10.1073/pnas.172517799; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Baladron V, 2002, EUKARYOT CELL, V1, P774, DOI 10.1128/EC.1.5.774-786.2002; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Bi E, 1998, J CELL BIOL, V142, P1301, DOI 10.1083/jcb.142.5.1301; Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; Cabib E, 2001, J BIOL CHEM, V276, P19679, DOI 10.1074/jbc.R000031200; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Cid VJ, 2002, MICROBIOL-SGM, V148, P2647, DOI 10.1099/00221287-148-9-2647; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; Hamada K, 1998, MOL GEN GENET, V258, P53, DOI 10.1007/s004380050706; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Horecka J, 2000, YEAST, V16, P967, DOI 10.1002/1097-0061(200007)16:10<967::AID-YEA597>3.0.CO;2-G; Imhof I, 2004, J BIOL CHEM, V279, P19614, DOI 10.1074/jbc.M401873200; Jacoby JJ, 1998, MOL GEN GENET, V258, P148, DOI 10.1007/s004380050717; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kovacech B, 1996, MOL CELL BIOL, V16, P3264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagorce A, 2002, EUR J BIOCHEM, V269, P1697, DOI 10.1046/j.1432-1327.2002.02814.x; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Martin SW, 2004, EUKARYOT CELL, V3, P675, DOI 10.1128/EC.3.3.675-684.2004; Morsomme P, 2003, J CELL BIOL, V162, P403, DOI 10.1083/jcb.200212101; MRSA V, 1993, J BACTERIOL, V175, P2102, DOI 10.1128/JB.175.7.2102-2106.1993; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Nelson B, 2003, MOL BIOL CELL, V14, P3782, DOI 10.1091/mbc.E03-01-0018; Racki WJ, 2000, EMBO J, V19, P4524, DOI 10.1093/emboj/19.17.4524; Richard M, 2002, MICROBIOL-SGM, V148, P2125, DOI 10.1099/00221287-148-7-2125; Richard M, 2002, MOL MICROBIOL, V44, P841, DOI 10.1046/j.1365-2958.2002.02926.x; Richard M, 2001, J BACTERIOL, V183, P3098, DOI 10.1128/JB.183.10.3098-3107.2001; Ross-Macdonald P, 1999, METHOD ENZYMOL, V303, P512; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schmidt M, 2002, J CELL SCI, V115, P293; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Tanaka S, 2004, J BIOL CHEM, V279, P14256, DOI 10.1074/jbc.M313755200; Taron CH, 2000, MOL BIOL CELL, V11, P1611, DOI 10.1091/mbc.11.5.1611; Toh-e A, 1998, GENES GENET SYST, V73, P365, DOI 10.1266/ggs.73.365; Toh-e A, 1999, GENES GENET SYST, V74, P241, DOI 10.1266/ggs.74.241; Toh-e A, 2002, GENES GENET SYST, V77, P309, DOI 10.1266/ggs.77.309; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Umemura M, 2003, J BIOL CHEM, V278, P23639, DOI 10.1074/jbc.M301044200; WATZELE G, 1989, J BIOL CHEM, V264, P8753; Weiss EL, 2002, J CELL BIOL, V158, P885, DOI 10.1083/jcb.200203094	64	34	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51869	51879		10.1074/jbc.M405232200	http://dx.doi.org/10.1074/jbc.M405232200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452134	hybrid			2022-12-25	WOS:000225493400020
J	Siligardi, G; Hu, B; Panaretou, B; Piper, PW; Pearl, LH; Prodromou, C				Siligardi, G; Hu, B; Panaretou, B; Piper, PW; Pearl, LH; Prodromou, C			Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK-PROTEIN 90; N-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONE; STRUCTURAL BASIS; CLIENT PROTEIN; BINDING-SITE; DIMERIZATION; P50(CDC37); COMPLEX	ATP hydrolysis by the Hsp90 molecular chaperone requires a connected set of conformational switches triggered by ATP binding to the N-terminal domain in the Hsp90 dimer. Central to this is a segment of the structure, which closes like a "lid" over bound ATP, promoting N-terminal dimerization and assembly of a competent active site. Hsp90 mutants that influence these conformational switches have strong effects on ATPase activity. ATPase activity is specifically regulated by Hsp90 co-chaperones, which directly influence the conformational switches. Here we have analyzed the effect of Hsp90 mutations on binding ( using isothermal titration calorimetry and difference circular dichroism) and ATPase regulation by the co-chaperones Aha1, Sti1 (Hop), and Sba1 (p23). The ability of Sti1 to bind Hsp90 and arrest its ATPase activity was not affected by any of the mutants screened. Sba1 bound in the presence of AMPPNP to wild-type and ATPase hyperactive mutants with similar affinity but only very weakly to hypoactive mutants despite their wild-type ATP affinity. Unexpectedly, in all cases Sba1 bound to Hsp90 with a 1: 2 molar stoichiometry. Aha1 binding to mutants was similar to wild-type, but the - fold activation of their ATPase varied substantially between mutants. Analysis of complex formation with co-chaperone mixtures showed Aha1 and p50(cdc37) able to bind Hsp90 simultaneously but without direct interaction. Sba1 and p50cdc37 bound independently to Hsp90-AMPPNP but not together. These data indicated that Sba1 and Aha1 regulate Hsp90 by influencing the conformational state of the "ATP lid" and consequent N-terminal dimerization, whereas Sti1 does not.	Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England; Kings Coll London, Pharmaceut Opt Spect Ctr, London SE1 9NN, England; Kings Coll London, Div Life Sci, Dept Pharm, London SE1 9NN, England; Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2UH, S Yorkshire, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London; University of London; King's College London; University of Sheffield	Prodromou, C (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	chris.prodromou@icr.ac.uk	Hu, Bin/GWZ-8912-2022; Prodromou, Chrisostomos/ABA-9133-2021; Siligardi, Giuliano/AAO-7024-2020	Hu, Bin/0000-0001-6316-2830; Prodromou, Chrisostomos/0000-0003-4320-1147; Pearl, Laurence/0000-0002-6910-1809; Piper, Peter William/0000-0003-4019-2329				Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Lotz GP, 2003, J BIOL CHEM, V278, P17228, DOI 10.1074/jbc.M212761200; Meyer P, 2004, EMBO J, V23, P511, DOI 10.1038/sj.emboj.7600060; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Richter K, 2003, J BIOL CHEM, V278, P10328, DOI 10.1074/jbc.M213094200; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100	33	152	158	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51989	51998		10.1074/jbc.M410562200	http://dx.doi.org/10.1074/jbc.M410562200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466438	hybrid			2022-12-25	WOS:000225493400035
J	Treiber, C; Simons, A; Strauss, M; Hafner, M; Cappai, R; Bayer, TA; Multhaup, G				Treiber, C; Simons, A; Strauss, M; Hafner, M; Cappai, R; Bayer, TA; Multhaup, G			Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; A-BETA; TRANSGENIC MICE; TRACE-ELEMENT; DOMAIN; BINDING; VITAMIN-B12; METABOLISM; EXPRESSION; REDUCTION	The key protein in Alzheimer's disease, the amyloid precursor protein (APP), is a ubiquitously expressed copper-binding glycoprotein that gives rise to the Abeta amyloid peptide. Whereas overexpression of APP results in significantly reduced brain copper levels in three different lines of transgenic mice, knock-out animals revealed increased copper levels. A provoked rise in peripheral levels of copper reduced concentrations of soluble amyloid peptides and resulted in fewer pathogenic Abeta plaques. Contradictory evidence has been provided by the efficacy of copper chelation treatment with the drug clioquinol. Using a yeast model system, we show that adding clioquinol to the yeast culture medium drastically increased the intracellular copper concentration but there was no significant effect observed on zinc levels. This finding suggests that clioquinol can act therapeutically by changing the distribution of copper or facilitating copper uptake rather than by decreasing copper levels. The overexpression of the human APP or APLP2 extracellular domains but not the extracellular domain of APLP1 decreased intracellular copper levels. The expression of a mutant APP deficient for copper binding increased intracellular copper levels several-fold. These data uncover a novel biological function for APP and APLP2 in copper efflux and provide a new conceptual framework for the formerly diverging theories of copper supplementation and chelation in the treatment of Alzheimer's disease.	Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany; ZMBH, Ctr Mol Biol, D-69120 Heidelberg, Germany; Hochschule Tech & Gestaltung, Fachhochschule Mannheim, D-68163 Mannheim, Germany; Univ Melbourne, Dept Pathol, Ctr Neurosci, Melbourne, Vic 3010, Australia; Mental Hlth Res Inst, Parkville, Vic 3052, Australia; Univ Saarland, Med Ctr, Dept Psychiat, Div Neurobiol, D-66421 Homburg, Germany	Free University of Berlin; Ruprecht Karls University Heidelberg; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Saarland University	Multhaup, G (corresponding author), Free Univ Berlin, Inst Chem Biochem, Thielallee 63, D-14195 Berlin, Germany.	multhaup@chemie.fu-berlin.de	Cappai, Roberto/B-3347-2010	Cappai, Roberto/0000-0002-9505-8496				Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Borchardt T, 1999, BIOCHEM J, V344, P461, DOI 10.1042/0264-6021:3440461; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Dulubova I, 2004, BIOCHEMISTRY-US, V43, P9583, DOI 10.1021/bi049041o; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Loonen AJM, 2003, INT J GERIATR PSYCH, V18, P540, DOI 10.1002/gps.882; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Phinney AL, 2003, P NATL ACAD SCI USA, V100, P14193, DOI 10.1073/pnas.2332851100; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; SAMUDRALWAR DL, 1995, J NEUROL SCI, V130, P139, DOI 10.1016/0022-510X(95)00018-W; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shim H, 2003, J NUTR, V133, p1527S, DOI 10.1093/jn/133.5.1527S; Simons A, 2002, BIOCHEMISTRY-US, V41, P9310, DOI 10.1021/bi0258647; Squitti R, 2002, NEUROLOGY, V59, P1153, DOI 10.1212/WNL.59.8.1153; SUGAWARA N, 1991, RES COMMUN CHEM PATH, V72, P97; Thiele DJ, 2003, J NUTR, V133, p1579S, DOI 10.1093/jn/133.5.1579S; THOMPSON CM, 1988, NEUROTOXICOLOGY, V9, P1; VANTIGGELEN CJM, 1984, AM J PSYCHIAT, V141, P136; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; White AR, 1998, J NEUROSCI, V18, P6207; White AR, 2002, J NEUROSCI, V22, P365, DOI 10.1523/JNEUROSCI.22-02-00365.2002; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Yassin MS, 2000, J NEUROL SCI, V173, P40, DOI 10.1016/S0022-510X(99)00297-X	35	120	127	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51958	51964		10.1074/jbc.M407410200	http://dx.doi.org/10.1074/jbc.M407410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465814	hybrid			2022-12-25	WOS:000225493400031
J	Tomaska, L; Willcox, S; Slezakova, J; Nosek, J; Griffith, JD				Tomaska, L; Willcox, S; Slezakova, J; Nosek, J; Griffith, JD			Taz1 binding to a fission yeast model telomere - Formation of telomeric loops and higher order structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; IN-VITRO; T-LOOPS; DNA-SEQUENCES; PROTEIN; TRF2; LENGTH; CHROMOSOMES; POLYMERASE; CHROMATIN	Similar to its human homologues TRF1 and TRF2, fission yeast Taz1 protein is a component of telomeric chromatin regulating proper telomere maintenance. As mammalian TRF1 and TRF2 proteins have been shown to directly bind telomeric DNA to form protein arrays and looped structures, termed t-loops, the ability of Taz1p to act on fission yeast telomeric DNA in similar ways was examined using purified protein and model DNA templates. When incubated with Taz1p, model telomeres containing 3' single-stranded telomeric overhangs formed t-loops at a frequency approaching 13%. Termini with blunt ends and non-telomeric overhangs were deficient in t-loop formation. In addition, we observed arrays of multiple Taz1p molecules bound to the telomeric regions, resembling the pattern of TRF1 binding. The presence of t-loops larger than the telomeric tract, a high frequency of end-bound DNAs and a donut shape of the Taz1p complex suggest that Taz1p binds the 3' overhang then extrudes a loop that grows in size as the donut slides along the duplex DNA. Based on these in vitro results we discuss possible general implications for fission yeast telomere dynamics.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Comenius Univ, Fac Nat Sci, Dept Genet, Bratislava 84215, Slovakia; Comenius Univ, Fac Nat Sci, Dept Biochem, Bratislava 84215, Slovakia; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Comenius University Bratislava; Comenius University Bratislava; University of North Carolina; University of North Carolina Chapel Hill	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Mason Farm Rd CB7095, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu	, Proteomics Core UNC/AFQ-7201-2022; Tomaska, Lubomir/I-3071-2014; Nosek, Jozef/A-7581-2008	Tomaska, Lubomir/0000-0003-4886-1910; Nosek, Jozef/0000-0002-1020-5451	FIC NIH HHS [TW05654-01] Funding Source: Medline; NCI NIH HHS [CA19014] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW005654] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Borchers C, 2000, ANAL CHEM, V72, P1163, DOI 10.1021/ac990937m; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Cesare AJ, 2003, PLANT J, V36, P271, DOI 10.1046/j.1365-313X.2003.01882.x; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; Chikashige Y, 2001, CURR BIOL, V11, P1618, DOI 10.1016/S0960-9822(01)00457-2; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; de Lange T, 2004, NAT REV MOL CELL BIO, V5, P323, DOI 10.1038/nrm1359; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Fotiadou P, 2004, CANCER RES, V64, P3830, DOI 10.1158/0008-5472.CAN-04-0136; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Hiraoka Y, 1998, TRENDS BIOCHEM SCI, V23, P126, DOI 10.1016/S0968-0004(98)01176-1; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; McEachern MJ, 2000, P NATL ACAD SCI USA, V97, P11409, DOI 10.1073/pnas.210388397; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Miller KM, 2003, MOL CELL, V11, P303, DOI 10.1016/S1097-2765(03)00041-8; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Murti KG, 1999, P NATL ACAD SCI USA, V96, P14436, DOI 10.1073/pnas.96.25.14436; Nikitina T, 2004, J CELL BIOL, V166, P161, DOI 10.1083/jcb.200403118; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Park MJ, 2002, MOL CELLS, V13, P327; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Rhodes D, 2002, EMBO REP, V3, P1139, DOI 10.1093/embo-reports/kvf246; Sadaie M, 2003, GENE DEV, V17, P2271, DOI 10.1101/gad.1112103; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Stansel RM, 2002, J BIOL CHEM, V277, P11625, DOI 10.1074/jbc.C100764200; Stansel RM, 2001, EMBO J, V20, P5532; Tomaska L, 2002, MITOCHONDRION, V1, P455, DOI 10.1016/S1567-7249(02)00009-0; Vassetzky NS, 1999, NUCLEIC ACIDS RES, V27, P4687, DOI 10.1093/nar/27.24.4687; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	51	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50764	50772		10.1074/jbc.M409790200	http://dx.doi.org/10.1074/jbc.M409790200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15383525	hybrid			2022-12-25	WOS:000225355800018
J	Burri, L; Vascotto, K; Fredersdorf, S; Tiedt, R; Hall, MN; Lithgow, T				Burri, L; Vascotto, K; Fredersdorf, S; Tiedt, R; Hall, MN; Lithgow, T			Zim17, a novel zinc finger protein essential for protein import into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; INNER MEMBRANE; DOMAIN; HSP70; DNAJ; TRANSLOCATION; FAMILY; HOMOLOG	Translocation of precursor proteins across the mitochondrial membranes requires the coordinated action of multisubunit translocases in the outer and inner membrane, and the driving force for translocation across the inner membrane is provided by the matrix-located heat shock protein 70 (mtHsp70). The central components of the protein import machinery are essential. Here we describe Zim17, an essential protein with a (ZI) under bar nc finger (M) under bar otif involved in protein import into mitochondria. Comparative genomics suggested a correction to the open reading frame of YNL310c, the gene encoding Zim17 in Saccharomyces cerevisiae. The revised open reading frame codes for a classic mitochondrial targeting signal, which is processed from Zim17 in the mitochondrial matrix. Loss of Zim17 selectively diminishes import of proteins into the matrix of mitochondria, but this loss of Zim17 is partially suppressed by overexpression of the J-protein Pam18/Tim14. We propose that Zim17 functions as an example of a "fractured" J-protein, where a protein like Zim17 contributes a zinc finger domain to Type III J-proteins, in toto providing for substrate loading onto Hsp70.	Univ Melbourne, Russell Grimwade Sch Biochem & Mol Biol, Parkville, Vic 3010, Australia; Univ Basel, Bioctr, CH-4056 Basel, Switzerland	University of Melbourne; University of Basel	Lithgow, T (corresponding author), Univ Melbourne, Russell Grimwade Sch Biochem & Mol Biol, Parkville, Vic 3010, Australia.	t.lithgow@unimelb.edu.au	Lithgow, Trevor J/H-5925-2017	Lithgow, Trevor J/0000-0002-0102-7884; Hall, Michael N/0000-0002-2998-0757				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Becker S, 2001, GENE, V262, P15, DOI 10.1016/S0378-1119(00)00548-5; Beilharz T, 1998, J BIOL CHEM, V273, P35268, DOI 10.1074/jbc.273.52.35268; Bohm S, 1997, NUCLEIC ACIDS RES, V25, P2464, DOI 10.1093/nar/25.12.2464; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BRUNELLI JP, 1993, YEAST, V9, P1299, DOI 10.1002/yea.320091203; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chacinska A, 2003, EMBO J, V22, P5370, DOI 10.1093/emboj/cdg532; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; D'Silva PD, 2003, P NATL ACAD SCI USA, V100, P13839, DOI 10.1073/pnas.1936150100; DAUM G, 1982, J BIOL CHEM, V257, P3075; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Frazier AE, 2004, NAT STRUCT MOL BIOL, V11, P226, DOI 10.1038/nsmb735; Gething MJ, 1996, CURR BIOL, V6, P1573, DOI 10.1016/S0960-9822(02)70775-6; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Jensen RE, 1999, CURR BIOL, V9, pR779, DOI 10.1016/S0960-9822(00)80012-3; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Kozany C, 2004, NAT STRUCT MOL BIOL, V11, P234, DOI 10.1038/nsmb734; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; Li YF, 2004, J BIOL CHEM, V279, P38047, DOI 10.1074/jbc.M404319200; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lucattini R, 2004, MOL BIOL EVOL, V21, P652, DOI 10.1093/molbev/msh058; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; Merlin A, 1999, J CELL BIOL, V145, P961, DOI 10.1083/jcb.145.5.961; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; Rehling P, 2003, J MOL BIOL, V326, P639, DOI 10.1016/S0022-2836(02)01440-7; Rospert S, 1996, EMBO J, V15, P764, DOI 10.1002/j.1460-2075.1996.tb00412.x; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Samanta MP, 2003, P NATL ACAD SCI USA, V100, P12579, DOI 10.1073/pnas.2132527100; Sambrook J, 2001, MOL CLONING LAB MANU; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1; Voos W, 2003, MOL CELL, V11, P1, DOI 10.1016/S1097-2765(03)00002-9; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; Westermann B, 1997, J MOL BIOL, V272, P477, DOI 10.1006/jmbi.1997.1267; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	59	43	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50243	50249		10.1074/jbc.M409194200	http://dx.doi.org/10.1074/jbc.M409194200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383543	hybrid, Green Accepted			2022-12-25	WOS:000225229500085
J	Eischen, CM; Alt, JR; Wang, P				Eischen, CM; Alt, JR; Wang, P			Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development	ONCOGENE			English	Article						Mdm2; ARF; lymphoma; apoptosis; Myc; p53	MYC-INDUCED LYMPHOMAGENESIS; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; TRANSGENIC MICE; CANCER-THERAPY; MAMMARY-GLAND; FEEDBACK LOOP; IN-VIVO	The tumor suppressor p19(ARF) inhibits Mdm2, which restricts the activity of p53. Complicated feedback and control mechanisms regulate ARF, Mdm2, and p53 interactions. Here we report that ARF haploinsufficiency completely rescued the p53-dependent effects of Mdm2 haploinsufficiency on B-cell development, survival, and transformation. In contrast to Mdm2(+/-) B cells, Mdm2(+/-) B cells deficient in ARF were similar to wild-type B cells in their rates of growth and apoptosis and activation of p53. Consequently, the profoundly reduced numbers of B cells in Mdm2(+/-) Emu-myc transgenic mice were restored to normal levels in ARF(+/-)Mdm(2+/-) Emu-myc transgenics. Additionally, ARF(+/-)Mdm2(+/-) Emu-myc transgenics developed lymphomas at rates analogous to those observed for wild-type Emu-myc transgenics, demonstrating that loss of one allele of ARF rescued the protracted lymphoma latency in Mdm2(+/-) Emu-myc transgenics. Importantly, in ARF(+/-)Mdm2(+/-) Emu-myc transgenic lymphomas, p53 was inactivated at the frequency observed in lymphomas of wild-type Emu-myc transgenics. Collectively, these results support a model whereby the stoichiometry of Mdm2 and ARF controls apoptosis and tumor development, which should have significant implications in the treatment of malignancies that have inactivated ARF.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Eischen, CM (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA.	ceischen@unmc.edu			NCI NIH HHS [CA098139, T32 CA09476] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098139, T32CA009476] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Foster CJ, 2002, ONCOGENE, V21, P3525, DOI 10.1038/sj.onc.1205441; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; O'Leary KA, 2004, MOL CELL BIOL, V24, P186, DOI 10.1128/MCB.24.1.186-191.2004; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun Y, 2003, CANCER BIOL THER, V2, P623; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wang H, 2001, CURR CANCER DRUG TAR, V1, P177, DOI 10.2174/1568009013334133; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	45	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	2004	23	55					8931	8940		10.1038/sj.onc.1208052	http://dx.doi.org/10.1038/sj.onc.1208052			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467748				2022-12-25	WOS:000225354600008
J	Killian, A; Le Meur, N; Sesboue, R; Bourguignon, J; Bougeard, G; Gautherot, J; Bastard, C; Frebourg, T; Flaman, JM				Killian, A; Le Meur, N; Sesboue, R; Bourguignon, J; Bougeard, G; Gautherot, J; Bastard, C; Frebourg, T; Flaman, JM			Inactivation of the RRB1-Pescadillo pathway involved in ribosome biogenesis induces chromosomal instability	ONCOGENE			English	Article						cell cycle; chromosomal instability; mitosis; ribosome; yeast	CELL-CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; DYSKERATOSIS-CONGENITA; DNA-REPLICATION; HUMAN CANCERS; PROTEIN; GENE; CHECKPOINT; PROLIFERATION; MUTATIONS	Since chromosomal instability (CIN) is a hallmark of most cancer cells, it is essential to identify genes whose alteration results into this genetic instability. Using a yeast CIN indicator strain, we show that inactivation of the YMR131c/RRB1 gene, which is involved in early ribosome assembly and whose expression is induced when the spindle checkpoint is activated, alters chromosome segregation and blocks mitosis at the metaphase/anaphase transition. We demonstrate that RRB1 interacts with YPH1 (yeast pescadillo homologue 1) and other members of the Yph1 complex, RPL3, ERB1 and ORC6, involved in ribosome biogenesis and DNA replication. Transient depletion of the human homologues GRWD, Pescadillo, Rp13, Bop1 and Orc6L resulted in an increase of abnormal mitoses with appearance of binucleate or hyperploid cells, of cells with multipolar spindles and of aberrant metaphase plates. If deregulation of proteins involved in ribosome biogenesis, commonly observed in malignant tumors, could contribute to cancer through an aberrant protein synthesis, our study demonstrates that alteration of proteins linking ribosome biogenesis and DNA replication may directly cause CIN.	INSERM, U614, IFRMP, Fac Med, F-76183 Rouen, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Frebourg, T (corresponding author), INSERM, U614, IFRMP, Fac Med, 22 Blvd Gambetta, F-76183 Rouen, France.	Thierry.Frebourg@chu-rouen.fr	Flaman, Jean-Michel/K-8415-2018; BOUGEARD, Gaëlle/ABI-6642-2020; Frebourg, Thierry/AAK-8390-2020	Flaman, Jean-Michel/0000-0003-3544-0199; BOUGEARD, Gaëlle/0000-0002-1475-0254; 				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bergoglio V, 2002, CANCER RES, V62, P3511; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DOKAL I, 1994, LEUKEMIA LYMPHOMA, V15, P1, DOI 10.3109/10428199409051671; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Iouk TL, 2001, MOL CELL BIOL, V21, P1260, DOI 10.1128/MCB.21.4.1260-1271.2001; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schaper S, 2001, CURR BIOL, V11, P1885, DOI 10.1016/S0960-9822(01)00584-X; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0	34	57	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8597	8602		10.1038/sj.onc.1207845	http://dx.doi.org/10.1038/sj.onc.1207845			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467761				2022-12-25	WOS:000224988800005
J	Nagy, N; Takahara, M; Nishikawa, J; Bourdon, JC; Kis, LL; Klein, G; Klein, E				Nagy, N; Takahara, M; Nishikawa, J; Bourdon, JC; Kis, LL; Klein, G; Klein, E			Wild-type p53 activates SAP expression in lymphoid cells	ONCOGENE			English	Article						SAP; XLP; p53; lymphoma	LINKED LYMPHOPROLIFERATIVE-DISEASE; BARR-VIRUS INFECTION; NF-KAPPA-B; MICE DEFICIENT; ENCODING GENE; SH2 DOMAIN; EBV; MUTATIONS; MUTANT; SLAM	SAP is an adaptor molecule with one SH2 domain and it is expressed in activated T and NK cells, where it is required for the appropriate signaling from the SLAM family of surface receptors. Deleted or mutated SAP genes that encode functionally defective protein are associated with the X-linked lymphoproliferative disease(XLP). This primary immunodeficiency is characterized by extreme sensitivity to Epstein-Barr virus (EBV) infection, dysgammaglobulinemia and a high rate of lymphoma development. The vigorous T- and B-cell proliferation that follows EBV infection and the high incidence of lymphomas (30%) in XLP patients might reflect functional defects in cell cycle and/or apoptosis control. Our experiments show that SAP is a target of p53. In Burkitt lymphoma (BL) lines transfected with a temperatur-sensitive (ts) p53, SAP mRNA and protein expression was dependent on wild-type (wt) p53. Activation of endogenous wt p53 in BLs and lymphoblastoid cell lines led to the induction of SAP and this was inhibited by the specific p53 inhibitor pifithrin-a. Cell lines that carried mutant p53 did not express SAP under similar conditions. Moreover, we have shown binding of wt p53 to the promoter region of SAP by ChIP assay. Our results suggest that SAP contributes to the execution of some p53 functions.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	Karolinska Institutet; University of Dundee	Nagy, N (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.	Noemi.Nagy@mtc.ki.se	Nagy, Noemi/J-2936-2012; JC, Bourdon/A-4439-2008; Nishikawa, Jun/AAE-5355-2020	JC, Bourdon/0000-0003-4623-9386; Nagy, Noemi/0000-0002-7800-3493				Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Chan B, 2003, NAT CELL BIOL, V5, P155, DOI 10.1038/ncb920; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; Fei PW, 2002, CANCER RES, V62, P7316; Gorgoulis VG, 2003, EMBO J, V22, P1567, DOI 10.1093/emboj/cdg157; GRIERSON H, 1987, ANN INTERN MED, V106, P538, DOI 10.7326/0003-4819-106-4-538; HARADA S, 1982, INT J CANCER, V30, P739, DOI 10.1002/ijc.2910300610; HARRINGTON DS, 1987, CANCER-AM CANCER SOC, V59, P1419, DOI 10.1002/1097-0142(19870415)59:8<1419::AID-CNCR2820590807>3.0.CO;2-P; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Latour S, 2003, NAT CELL BIOL, V5, P149, DOI 10.1038/ncb919; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Nagy N, 2000, INT J CANCER, V88, P439, DOI 10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#; Nagy N, 2002, INT J CANCER, V100, P433, DOI 10.1002/ijc.10498; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; OKAN I, 1995, ONCOGENE, V11, P1027; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SEEMAYER TA, 1995, PEDIATR RES, V38, P471, DOI 10.1203/00006450-199510000-00001; Shlapatska LM, 2001, J IMMUNOL, V166, P5480, DOI 10.4049/jimmunol.166.9.5480; Strahm B, 2000, BRIT J HAEMATOL, V108, P377; Sumegi J, 2000, BLOOD, V96, P3118; Sylla BS, 2000, P NATL ACAD SCI USA, V97, P7470, DOI 10.1073/pnas.130193097; VOELKERDING KV, 1995, ONCOGENE, V10, P515; WILLIAMS LL, 1993, LANCET, V342, P587, DOI 10.1016/0140-6736(93)91413-G; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; Yin L, 2003, J MED VIROL, V71, P446, DOI 10.1002/jmv.10504; Zhou XZ, 1999, J IMMUNOL, V162, P3957	30	15	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	2004	23	53					8563	8570		10.1038/sj.onc.1207908	http://dx.doi.org/10.1038/sj.onc.1207908			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15378026				2022-12-25	WOS:000224988800001
J	McManus, DC; Lefebvre, CA; Cherton-Horvat, G; St-Jean, M; Kandimalla, ER; Agrawal, S; Morris, SJ; Durkin, JP; LaCasse, EC				McManus, DC; Lefebvre, CA; Cherton-Horvat, G; St-Jean, M; Kandimalla, ER; Agrawal, S; Morris, SJ; Durkin, JP; LaCasse, EC			Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics	ONCOGENE			English	Article						XIAP; RNAi; antisense; apoptosis; IAPs	X-LINKED INHIBITOR; LIGAND-INDUCED APOPTOSIS; STRUCTURAL BASIS; SERINE-PROTEASE; DOWN-REGULATION; CYTOCHROME-C; IN-VITRO; CASPASE INHIBITION; GENE-TRANSFER; BCL-2 GENE	Stable expression of short-hairpin RNAs (shRNAs) directed against the X-linked inhibitor of apoptosis (XIAP) resulted in the generation of three MDA-MB-231 cell lines (XIAP shRNA cells) with reductions in XIAP mRNA and protein levels >85% relative to MDA-MB-231 cells stably transfected with the U6 RNA polymerase III promoter alone (U6 cells). This RNA interference (RNAi) approach dramatically sensitized these cells to killing by the (t) under bar umor necrosis factor-(r) under bar elated (a) under bar poptosis-(i) under bar nducing (l) under bar igand (TRAIL). Importantly, loss of XIAP also sensitized the cells to killing by taxanes but had no additional effects on killing by carboplatin and doxorubicin. The increased sensitivity of the XIAP shRNA cells to killing by TRAIL and taxanes correlated with enhanced caspase cleavage and activation, including caspase-8, and robust processing of poly(ADP-ribose) polymerase and BID compared to U6 cells. Additionally, increasing XIAP levels by adenovirus-mediated expression protected both XIAP shRNA and U6 cells from TRAIL killing in a dose-dependent manner. The effects observed by stable RNAi with respect to TRAIL sensitization were also achieved following downregulation of XIAP in Panc-1 cells treated with a second-generation, mixed-backbone antisense oligonucleotide, AEG 35156/GEM640. These data indicate that reducing XIAP protein expression by either RNAi or antisense approaches increases cancer cell susceptibility to functionally diverse chemotherapeutic agents and supports the notion that downregulation of XIAP in vivo may synergize with disease-relevant chemotherapeutic regimes, including TRAIL and taxanes, to increase the effectiveness of antineoplastic agents.	Univ Ottawa, Aegera Oncol Inc, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada; Hybridon Inc, Cambridge, MA 02139 USA; Aegera Therapeut Inc, Verdun, PQ H3E 1A8, Canada	University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario	LaCasse, EC (corresponding author), Univ Ottawa, Aegera Oncol Inc, Rm 306,401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	eric.lacasse@aegera.com		Agrawal, Sudhir/0000-0003-4275-2510				Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Carter BZ, 2003, BLOOD, V102, P4179, DOI 10.1182/blood-2003-03-0960; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; CHAWLASARKAR M, 2004, CELL DEATH DIFFER, V30, P1; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cummings BS, 2004, J PHARMACOL EXP THER, V310, P126, DOI 10.1124/jpet.104.065862; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Giodini A, 2002, CANCER RES, V62, P2462; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Hsu CKA, 1997, EXP CELL RES, V232, P17, DOI 10.1006/excr.1997.3509; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1997, APOPTOSIS, V2, P423, DOI 10.1023/A:1026465926478; Lo YMD, 1999, CANCER RES, V59, P3899; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sasaki H, 2000, CANCER RES, V60, P5659; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Shi J, 2003, CURR MOL MED, V3, P727, DOI 10.2174/1566524033479401; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tillman DM, 2003, CANCER RES, V63, P5118; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vilenchik M, 2002, CANCER RES, V62, P2175; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang L, 2003, CANCER RES, V63, P6815; Zhang XD, 2001, CANCER RES, V61, P7339	58	151	162	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8105	8117		10.1038/sj.onc.1207967	http://dx.doi.org/10.1038/sj.onc.1207967			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15378029				2022-12-25	WOS:000224692500008
J	Lee, YC; Lee, KS; Park, SJ; Park, HS; Lim, JS; Park, KH; Im, MJ; Choi, IW; Lee, HK; Kim, UH				Lee, YC; Lee, KS; Park, SJ; Park, HS; Lim, JS; Park, KH; Im, MJ; Choi, IW; Lee, HK; Kim, UH			Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid	FASEB JOURNAL			English	Article						eosinophilia; NF-kappa B; oxidative stress; signal transduction	NF-KAPPA-B; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; LUNG-DISEASES; GROWTH-FACTOR; T-CELLS; GLUTATHIONE; ACTIVATION; RESPONSES	Oxidative stress plays an important role in the pathogenesis of bronchial asthma. An excess production of reactive oxygen species (ROS) and defective endogenous antioxidant defense mechanisms may be present in asthma. Reduced glutathione (GSH) is one of the most important reducing agents against oxidant free radicals. A reducing agent, L-2-oxothiazolidine-4-carboxylic acid (OTC), a prodrug of cysteine, increases intracellular GSH. We have used a mouse model for asthma to determine effects of OTC on allergen-induced bronchial inflammation and airway hyper-responsiveness. The administration of OTC reduced bronchial inflammation and airway hyper-responsiveness. ROS generation in bronchoalveolar lavage fluids was increased by ovalbumin ( OVA) inhalation, but this increase was diminished by administration of OTC. The increased IL-4, IL-5, IL-13, and eosinophil cationic protein levels in lungs after OVA inhalation were significantly reduced by the administration of OTC. In addition, the increased expression of ICAM-1, VCAM-1, RANTES, and eotaxin in lungs after OVA inhalation was significantly reduced by the administration of OTC. We also showed that the increased NF-kappaB levels in nuclear protein extracts of lung tissues at 72 h after OVA inhalation were decreased by the administration of OTC. These findings suggest that OTC may reduce airway inflammation and hyper-responsiveness through regulation of NF-kappaB activity.	Chonbuk Natl Univ Med Sch, Dept Internal Med, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Res Ctr Allerg Immune Dis, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Dept Biochem, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Dept Immunol, Jeonju 561712, South Korea; Chonbuk Natl Univ Med Sch, Inst Cardiovasc Res, Jeonju 561712, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Lee, YC (corresponding author), Chonbuk Natl Univ Med Sch, Dept Internal Med, 634-18 Keumamdong, Jeonju 561712, South Korea.	leeyc@chonbuk.ac.kr						Adam L, 1999, J BIOL CHEM, V274, P26337, DOI 10.1074/jbc.274.37.26337; ASTI C, 1995, PHARMACOL RES, V31, P387, DOI 10.1016/1043-6618(95)80094-8; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; Blesa S, 2002, PHARMACOL RES, V45, P135, DOI 10.1006/phrs.2001.0917; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Cheng JJ, 1996, BIOCHEM BIOPH RES CO, V225, P100, DOI 10.1006/bbrc.1996.1136; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cortijo J, 1999, FREE RADICAL BIO MED, V27, P392, DOI 10.1016/S0891-5849(99)00070-2; Dworski R, 2000, THORAX, V55, pS51, DOI 10.1136/thorax.55.suppl_2.S51; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GinnPease ME, 1996, BIOCHEM BIOPH RES CO, V226, P695, DOI 10.1006/bbrc.1996.1416; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Han MK, 2002, J BIOL CHEM, V277, P5315, DOI 10.1074/jbc.M106439200; Han SJ, 2002, J BIOL CHEM, V277, P44715, DOI 10.1074/jbc.M202524200; Harper R, 2001, AM J RESP CELL MOL, V25, P178, DOI 10.1165/ajrcmb.25.2.4471; HAZELTON GA, 1986, J PHARMACOL EXP THER, V237, P341; Henderson WR, 2002, J IMMUNOL, V169, P5294, DOI 10.4049/jimmunol.169.9.5294; HULSMANN AR, 1994, AM J RESP CRIT CARE, V149, P519, DOI 10.1164/ajrccm.149.2.8306055; JUN DY, 1997, J BIOL CHEM, V272, P30952; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee M, 2002, BIOCHEM J, V366, P937, DOI 10.1042/BJ20020453; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6; MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7; Mori A, 1999, J ALLERGY CLIN IMMUN, V103, pS429, DOI 10.1016/S0091-6749(99)70158-2; MOSLEN MT, 1989, J PHARMACOL EXP THER, V248, P157; Nishida S, 2002, FREE RADICAL RES, V36, P601, DOI 10.1080/10715760210872; Oiry J, 1999, J MED CHEM, V42, P4733, DOI 10.1021/jm980289j; OWEN S, 1991, NEW ENGL J MED, V325, P586; PORTA P, 1991, J PHARMACOL EXP THER, V257, P331; Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; Rahman I, 1997, THORAX, V52, P565, DOI 10.1136/thx.52.6.565; Rahman I, 1998, THORAX, V53, P601, DOI 10.1136/thx.53.7.601; SANG F, 1997, J BIOL CHEM, V272, P23086; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stutz AM, 1999, J IMMUNOL, V163, P4383; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Verhasselt V, 1999, J IMMUNOL, V162, P2569; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155; WILLIAMSON JM, 1981, P NATL ACAD SCI-BIOL, V78, P936, DOI 10.1073/pnas.78.2.936; WILLIAMSON JM, 1982, P NATL ACAD SCI-BIOL, V79, P6246, DOI 10.1073/pnas.79.20.6246; Zhang MJ, 2002, FREE RADICAL BIO MED, V32, P454, DOI 10.1016/S0891-5849(01)00825-5	49	62	63	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1917	+		10.1096/fj.04-2212fje	http://dx.doi.org/10.1096/fj.04-2212fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15385436				2022-12-25	WOS:000224243200018
J	Walduck, A; Schmitt, A; Lucas, B; Aebischer, T; Meyer, TF				Walduck, A; Schmitt, A; Lucas, B; Aebischer, T; Meyer, TF			Transcription profiling analysis of the mechanisms of vaccine-induced protection against H-pylori	FASEB JOURNAL			English	Article						microarray; immunization; mouse; recombinant Salmonella; helicobacter	GASTRIC EPITHELIAL-CELLS; CD4(+) T-CELLS; SMALL-INTESTINE; MICE; EXPRESSION; RESPONSES; IMMUNITY; LEPTIN; HOST; PROLIFERATION	Development of a vaccine against H. pylori is regarded as desirable alternative to the current antibiotic therapy regimens. Mice immunized with an attenuated recombinant Salmonella typhimurium expressing H. pylori urease subunits A& B have dramatically reduced bacterial loads after a single dose. The mechanism(s) of protection against this largely extra-cellular pathogen are not fully understood. The aim of this study was to identify genes that were regulated specifically in response to immunization, in order to gain a broader picture of the immune response in the immunized gastric epithelium. Gene expression in RNA isolated from the gastric mucosa of immunized and infected Balb/c mice was compared with that in infected only mice at 1, 3, and 14 days after challenge with a mouse-adapted strain of H. pylori. We show that infection with H. pylori causes an immediate reaction in vivo, which was clearly divided into acute and chronic phases, and further that the transcriptional response in the H. pylori infected and immunized gastric mucosa is unique. Analysis of gene expression patterns at day 14 post-infection suggested not only the beginning of a lymphocytic infiltrate, but of an integrated epithelial response characterized by increased expression of genes controlling cell cycle and turnover. This observation was confirmed in independent experiments. The global approach has brought new insights to the effect of immunization on the gastric epithelium and has led us to propose a new multi-factorial model for the mechanisms underlying vaccine-induced protection.	Max Planck Inst Infect Biol, Dept Mol Biol, Berlin, Germany	Max Planck Society	Meyer, TF (corresponding author), Max Planck Inst Infect Biol, Dept Mol Biol, Schumanstr 21-22, Berlin, Germany.	meyer@mpiib-berlin.mpg.de	Meyer, Thomas F. F/J-2485-2013	Meyer, Thomas F. F/0000-0002-6120-8679; Aebischer, Toni/0000-0002-4875-8457; Walduck, Anna/0000-0002-9624-4370				Aebischer T, 2001, INFECT IMMUN, V69, P556, DOI 10.1128/IAI.69.1.556-558.2001; Aebischer T, 2000, J BIOTECHNOL, V83, P77, DOI 10.1016/S0168-1656(00)00301-1; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Blanchard AP, 1996, NAT BIOTECHNOL, V14, P1649, DOI 10.1038/nbt1296-1649; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; Braissant O, 1998, BIOCHEMICA, V1, P10; Court M, 2003, J PATHOL, V201, P303, DOI 10.1002/path.1422; Cox JM, 2001, INFECT IMMUN, V69, P6970, DOI 10.1128/IAI.69.11.6970-6980.2001; De Lisle RC, 1998, AM J PHYSIOL-GASTR L, V275, pG219, DOI 10.1152/ajpgi.1998.275.2.G219; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Ermak TH, 1998, J EXP MED, V188, P2277, DOI 10.1084/jem.188.12.2277; Gomez-Duarte OG, 1998, VACCINE, V16, P460, DOI 10.1016/S0264-410X(97)00247-8; Guillemin K, 2002, P NATL ACAD SCI USA, V99, P15136, DOI 10.1073/pnas.182558799; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; Kamal M, 2001, CLIN EXP IMMUNOL, V126, P117, DOI 10.1046/j.1365-2249.2001.01589.x; Koesling J, 2001, VACCINE, V20, P413, DOI 10.1016/S0264-410X(01)00355-3; Lucas B, 2001, INFECT IMMUN, V69, P1714, DOI 10.1128/IAI.69.3.1714-1721.2001; Madsen J, 2003, EUR J IMMUNOL, V33, P2327, DOI 10.1002/eji.200323972; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Mills JC, 2001, P NATL ACAD SCI USA, V98, P13687, DOI 10.1073/pnas.231332398; Mohammadi M, 1997, GASTROENTEROLOGY, V113, P1848, DOI 10.1016/S0016-5085(97)70004-0; Mueller A, 2003, P NATL ACAD SCI USA, V100, P12289, DOI 10.1073/pnas.1635231100; Murray E, 2002, INFECT IMMUN, V70, P1481, DOI 10.1128/IAI.70.3.1481-1487.2002; Pappo J, 1999, INFECT IMMUN, V67, P337, DOI 10.1128/IAI.67.1.337-341.1999; Parvin MN, 2002, BBA-MOL CELL RES, V1542, P116, DOI 10.1016/S0167-4889(01)00172-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raso GM, 2002, BRIT J PHARMACOL, V137, P799, DOI 10.1038/sj.bjp.0704903; Sawai N, 1999, INFECT IMMUN, V67, P279, DOI 10.1128/IAI.67.1.279-285.1999; Sepulveda AR, 2002, ALIMENT PHARM THERAP, V16, P145, DOI 10.1046/j.1365-2036.16.s2.4.x; Siegmund B, 2002, GASTROENTEROLOGY, V122, P2011, DOI 10.1053/gast.2002.33631; Sommi P, 2002, EXP CELL RES, V281, P128, DOI 10.1006/excr.2002.5629; Song Hong, 2002, Di Yi Jun Yi Da Xue Xue Bao, V22, P59; Sutton P, 2001, IMMUNOL CELL BIOL, V79, P67, DOI 10.1046/j.1440-1711.2001.00977.x; Thim L, 2000, REGUL PEPTIDES, V90, P61, DOI 10.1016/S0167-0115(00)00110-5; van Doorn NEM, 1999, INFECT IMMUN, V67, P3040, DOI 10.1128/IAI.67.6.3040-3046.1999; Walduck A, 2004, CURR OPIN MICROBIOL, V7, P33, DOI 10.1016/j.mib.2003.12.010; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113	37	21	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1955	+		10.1096/fj.04-2321fje	http://dx.doi.org/10.1096/fj.04-2321fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456742				2022-12-25	WOS:000224243200005
J	Wong, EY; Lin, J; Forget, BG; Bodine, DM; Gallagher, PG				Wong, EY; Lin, J; Forget, BG; Bodine, DM; Gallagher, PG			Sequences downstream of the erythroid promoter are required for high level expression of the human alpha-spectrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; MEMBRANE SKELETAL PROTEINS; DIMER-DIMER ASSOCIATION; BETA-GLOBIN PROMOTER; HEREDITARY PYROPOIKILOCYTOSIS; CHROMATIN STRUCTURE; FUNCTIONAL DOMAINS; MAMMALIAN-CELLS; TRANSGENIC MICE; GAMMA-GLOBIN	alpha-Spectrin is a membrane protein critical for the flexibility and stability of the erythrocyte. We are attempting to identify and characterize the molecular mechanisms controlling the erythroid-specific expression of the alpha-spectrin gene. Previously, we demonstrated that the core promoter of the human alpha-spectrin gene directed low levels of erythroid-specific expression only in the early stages of erythroid differentiation. We have now identified a region 3' of the core promoter that contains a DNase I hypersensitive site and directs high level, erythroid-specific expression in reporter gene/transfection assays. In vitro DNase I footprinting and electrophoretic mobility shift assays identified two functional GATA-1 sites in this region. Both GATA-1 sites were required for full activity, suggesting that elements binding to each site interact in a combinatorial manner. This region did not demonstrate enhancer activity in any orientation or position relative to either the alpha-spectrin core promoter or the thymidine kinase promoter in reporter gene assays. In vivo studies using chromatin immunoprecipitation assays demonstrated hyperacetylation of this region and occupancy by GATA-1 and CBP (cAMP-response element-binding protein (CREB)-binding protein). These results demonstrate that a region 3' of the alpha-spectrin core promoter contains a GATA-1-dependent positive regulatory element that is required in its proper genomic orientation. This is an excellent candidate region for mutations associated with decreased alpha-spectrin gene expression in patients with hereditary spherocytosis and hereditary pyropoikilocytosis.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; NHGRI, Hematopoiesis Sect, NIH, Bethesda, MD 20892 USA	Yale University; Yale University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Gallagher, PG (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,POB 208064, New Haven, CT 06520 USA.	patrick.gallagher@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065448] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 65448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1982, NEW ENGL J MED, V306, P1155, DOI 10.1056/NEJM198205133061906; AGRE P, 1986, NEW ENGL J MED, V315, P1579, DOI 10.1056/NEJM198612183152504; AGRE P, 1985, NATURE, V314, P380, DOI 10.1038/314380a0; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bieker J J, 1998, Curr Opin Hematol, V5, P145; BLOOM ML, 1993, BLOOD, V82, P2906, DOI 10.1182/blood.V82.9.2906.bloodjournal8292906; Boulanger L, 2002, J BIOL CHEM, V277, P41563, DOI 10.1074/jbc.M208184200; CALLAGHER PG, 1997, HEMATOLOGY INFANCY C, V1, P544; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; CHASIS JA, 1988, J CLIN INVEST, V82, P617, DOI 10.1172/JCI113640; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; COETZER T, 1990, BLOOD, V75, P2235; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Frazar TF, 2003, MOL CELL BIOL, V23, P4753, DOI 10.1128/MCB.23.14.4753-4763.2003; Gallagher PG, 2000, BLOOD, V96, P1136, DOI 10.1182/blood.V96.3.1136.015k48_1136_1143; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; GALLAGHER PG, 1991, T ASSOC AM PHYSICIAN, V104, P32; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; HANSPAL M, 1993, BLOOD, V82, P1652; HANSPAL M, 1987, J CELL BIOL, V105, P1417, DOI 10.1083/jcb.105.3.1417; HANSPAL M, 1992, BLOOD, V80, P530; Harju S, 2002, EXP BIOL MED, V227, P683, DOI 10.1177/153537020222700902; Hural JA, 2000, J IMMUNOL, V165, P3239, DOI 10.4049/jimmunol.165.6.3239; Hwang ES, 2002, J IMMUNOL, V169, P248, DOI 10.4049/jimmunol.169.1.248; Im H, 2003, J BIOL CHEM, V278, P18346, DOI 10.1074/jbc.M300890200; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kobayashi M, 2001, DEVELOPMENT, V128, P2341; KOURY MJ, 1987, J CELL PHYSIOL, V133, P438, DOI 10.1002/jcp.1041330304; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; LIN HJ, 1987, J CLIN INVEST, V80, P374, DOI 10.1172/JCI113082; LIU SC, 1981, J CLIN INVEST, V68, P597, DOI 10.1172/JCI110293; LIU SC, 1982, P NATL ACAD SCI-BIOL, V79, P2072, DOI 10.1073/pnas.79.6.2072; Lomvardas S, 2002, MOL CELL, V9, P209, DOI 10.1016/S1097-2765(02)00463-X; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MORROW JS, 1997, HDB PHYSIOL 14, P485; Nemeth MJ, 2001, BLOOD CELL MOL DIS, V27, P767, DOI 10.1006/bcmd.2001.0448; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PETERS LL, 1992, P NATL ACAD SCI USA, V89, P5749, DOI 10.1073/pnas.89.13.5749; Ronchi Antonella, 1997, Genes and Function, V1, P245; Sabatino DE, 2000, J BIOL CHEM, V275, P28549, DOI 10.1074/jbc.M004043200; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SAHR KE, 1989, J CLIN INVEST, V84, P1243, DOI 10.1172/JCI114291; Sahr KE, 1996, BLOOD, V88, P4500, DOI 10.1182/blood.V88.12.4500.bloodjournal88124500; Seshasayee D, 2000, J BIOL CHEM, V275, P22969, DOI 10.1074/jbc.M002931200; Sinha S, 2000, MOL CELL BIOL, V20, P2543, DOI 10.1128/MCB.20.7.2543-2555.2000; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tse WT, 1999, BRIT J HAEMATOL, V104, P2, DOI 10.1111/j.1365-2141.1999.01130.x; WALENSKY LD, 2003, BLOOD PRINCIPLES PRA, P1709; Wandersee N J, 2000, Hematol J, V1, P235, DOI 10.1038/sj.thj.6200030; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	62	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55024	55033		10.1074/jbc.M408886200	http://dx.doi.org/10.1074/jbc.M408886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15456760	hybrid			2022-12-25	WOS:000225960800007
J	Andrews, SR; Taylor, EJ; Pell, G; Vincent, F; Ducros, VMA; Davies, GJ; Lakey, JH; Gilbert, HJ				Andrews, SR; Taylor, EJ; Pell, G; Vincent, F; Ducros, VMA; Davies, GJ; Lakey, JH; Gilbert, HJ			The use of forced protein evolution to investigate and improve stability of family 10 xylanases - The production of Ca2+-independent stable xylanases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-FLUORESCENS; ALPHA-AMYLASE; THERMOSTABILITY; CALCIUM; BINDING; IDENTIFICATION; DELETION; DOMAINS; ENZYMES	Metal ions such as calcium often play a key role in protein thermostability. The inclusion of metal ions in industrial processes is, however, problematic. Thus, the evolution of enzymes that display enhanced stability, which is not reliant on divalent metals, is an important biotechnological goal. Here we have used forced protein evolution to interrogate whether the stabilizing effect of calcium in an industrially relevant enzyme can be replaced with amino acid substitutions. Our study has focused on the GH10 xylanase CjXyn10A from Cellvibrio japonicus, which contains an extended calcium binding loop that confers proteinase resistance and thermostability. Three rounds of error-prone PCR and selection identified a treble mutant, D262N/A80T/R347C, which in the absence of calcium is more thermostable than wild type CjXyn10A bound to the divalent metal. D262N influences the properties of the calcium binding site, A80T fills a cavity in the enzyme, increasing the number of hydrogen bonds and van der Waals interactions, and the R347C mutation introduces a disulfide bond that decreases the free energy of the unfolded enzyme. A derivative of CjXyn10A (CfCjXyn10A) in which the calcium binding loop has been replaced with a much shorter loop from Cellulomonas fimi CfXyn10A was also subjected to forced protein evolution to select for thermostablizing mutations. Two amino acid substitutions within the introduced loop and the A80T mutation increased the thermostability of the enzyme. This study demonstrates how forced protein evolution can be used to introduce enhanced stability into industrially relevant enzymes while removing calcium as a major stability determinant.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of York - UK; Newcastle University - UK	Gilbert, HJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	h.j.gilbert@ncl.ac.uk	Davies, Gideon J/A-9042-2011; Vincent, Florence/F-7137-2016	Davies, Gideon J/0000-0002-7343-776X; Taylor, Edward/0000-0003-4024-0976; vincent, Florence/0000-0002-8564-4184				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; Declerck N, 2000, J MOL BIOL, V301, P1041, DOI 10.1006/jmbi.2000.4025; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Emami K, 2002, J BACTERIOL, V184, P4124, DOI 10.1128/JB.184.15.4124-4133.2002; FERREIRA LMA, 1990, BIOCHEM J, V269, P261, DOI 10.1042/bj2690261; FONTES CMGA, 1995, BIOCHEM J, V307, P151, DOI 10.1042/bj3070151; FONTES CMGA, 1995, APPL MICROBIOL BIOT, V43, P52, DOI 10.1007/BF00170622; Fontes CMGA, 2000, MICROBIOL-SGM, V146, P1959, DOI 10.1099/00221287-146-8-1959; Fuxreiter M, 1997, PROTEINS, V28, P183, DOI 10.1002/(SICI)1097-0134(199706)28:2<183::AID-PROT7>3.0.CO;2-G; Georis J, 2000, PROTEIN SCI, V9, P466; GREPINET O, 1988, J BACTERIOL, V170, P4582, DOI 10.1128/jb.170.10.4582-4588.1988; GREPINET O, 1988, J BACTERIOL, V170, P4576, DOI 10.1128/jb.170.10.4576-4581.1988; Haki GD, 2003, BIORESOURCE TECHNOL, V89, P17, DOI 10.1016/S0960-8524(03)00033-6; HALL J, 1993, BIO-TECHNOL, V11, P376, DOI 10.1038/nbt0393-376; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V248, P372, DOI 10.1006/bbrc.1998.8970; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nemeth A, 2002, BIOPHYS CHEM, V96, P229, DOI 10.1016/S0301-4622(02)00027-3; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1988, J BIOL CHEM, V263, P11820; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Pell G, 2004, J BIOL CHEM, V279, P9597, DOI 10.1074/jbc.M312278200; PICKERSGILL RW, 1993, J MOL BIOL, V229, P246, DOI 10.1006/jmbi.1993.1023; Savchenko A, 2002, BIOCHEMISTRY-US, V41, P6193, DOI 10.1021/bi012106s; Silversides FG, 1999, POULTRY SCI, V78, P1184, DOI 10.1093/ps/78.8.1184; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; Spurway TD, 1997, J BIOL CHEM, V272, P17523, DOI 10.1074/jbc.272.28.17523; Ueda KI, 1952, J AGR CHEM SOC JAPAN, V26, P35, DOI DOI 10.1271/NOGEIKAGAKU1924.26.35; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	33	41	42	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54369	54379		10.1074/jbc.M409044200	http://dx.doi.org/10.1074/jbc.M409044200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15452124	hybrid			2022-12-25	WOS:000225793600059
J	van Waardenburg, RCAM; de Jong, LA; van Eijndhovan, MAJ; Verseyden, C; Pluim, D; Jansen, LET; Bjornsti, MA; Schellens, JHM				van Waardenburg, RCAM; de Jong, LA; van Eijndhovan, MAJ; Verseyden, C; Pluim, D; Jansen, LET; Bjornsti, MA; Schellens, JHM			Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRASTRAND CROSS-LINK; ANTICANCER AGENTS; MAJOR ADDUCT; SYNERGISTIC CYTOTOXICITY; CELLULAR PHARMACOLOGY; PHASE-I; ARA-C; TOPOTECAN; CISPLATIN; COMBINATION	Camptothecins constitute a novel class of chemotherapeutics that selectively target DNA topoisomerase I (Top1) by reversibly stabilizing a covalent enzyme-DNA intermediate. This cytotoxic mechanism contrasts with that of platinum drugs, such as cisplatin, which induce inter- and intrastrand DNA adducts. In vitro combination studies using platinum drugs combined with Top1 poisons, such as topotecan, showed a schedule-dependent synergistic activity, with promising results in the clinic. However, whereas the molecular mechanism of these single agents may be relatively well understood, the mode of action of these chemotherapeutic agents in combination necessitates a more complete understanding. Indeed, we recently reported that a functional homologous recombination pathway is required for cisplatin and topotecan synergy yet represses the synergistic toxicity of 1-beta-D-arabinofuranosyl cytidine in combination with topotecan ( van Waardenburg, R. C., de Jong, L. A., van Delft, F., van Eijndhoven, M. A., Bohlander, M., Bjornsti, M. A., Brouwer, J., and Schellens, J. H. ( 2004) Mol. Cancer Ther. 3, 393-402). Here we provide direct evidence for Pt-1,3-d(GTG) poisoning of Top1 in vitro and demonstrate that persistent Pt-DNA adducts correlate with increased covalent Top1-DNA complexes in vivo. This contrasts with a lack of persistent lesions induced by the alkylating agent bis[chloroethyl]nitrosourea, which exhibits only additive activity with topotecan in a range of cell lines. In human IGROV-1 ovarian cancer cells, the synergistic activity of cisplatin with topotecan requires processive DNA polymerization, whereas overexpression of Top1 enhances yeast cell sensitivity to cisplatin. These results indicate that the cytotoxic activity of cisplatin is due, in part, to poisoning of Top1, which is exacerbated in the presence of topotecan.	Netherlands Canc Inst, Dept Expt Therapy, Div Med Oncol, NL-1066 CX Amsterdam, Netherlands; St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Leiden Univ, Leiden Inst Chem, MGC Dept Mol Genet, NL-2300 RA Leiden, Netherlands; Univ Utrecht, Fac Pharmaceut Sci, NL-3508 TB Utrecht, Netherlands	Netherlands Cancer Institute; St Jude Children's Research Hospital; Leiden University; Leiden University - Excl LUMC; Utrecht University	Schellens, JHM (corresponding author), Netherlands Canc Inst, Dept Expt Therapy, Div Med Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	jhm@nki.nl		Jansen, Lars/0000-0002-2158-0345	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099, R01CA058755] Funding Source: NIH RePORTER; NCI NIH HHS [CA23099, CA58755, CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOMMAERT FA, 1995, BIOCHEMISTRY-US, V34, P8474, DOI 10.1021/bi00026a031; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Champoux JJ, 2000, METH MOL B, V95, P81; Chen AY, 1999, ONCOLOGY-NY, V13, P39; CHENG MF, 1994, ONCOL RES, V6, P269; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; Chreneik JE, 2003, J BIOL CHEM, V278, P12461, DOI 10.1074/jbc.M212930200; Coleman RL, 2002, ONCOLOGIST, V7, P46; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Fiorica JV, 2002, ONCOLOGIST, V7, P36; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; Goldwasser F, 1996, CLIN CANCER RES, V2, P687; Goldwasser F, 1999, ANTI-CANCER DRUG, V10, P195, DOI 10.1097/00001813-199902000-00008; Gross-Goupil M, 2002, EUR J CANCER, V38, P1888, DOI 10.1016/S0959-8049(02)00232-0; Ho YP, 2003, MED RES REV, V23, P633, DOI 10.1002/med.10038; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KANO Y, 1992, INT J CANCER, V50, P604, DOI 10.1002/ijc.2910500420; Kaufmann SH, 1996, J NATL CANCER I, V88, P734, DOI 10.1093/jnci/88.11.734; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Ma JG, 1998, CANCER CHEMOTH PHARM, V41, P307, DOI 10.1007/s002800050744; Peters GJ, 2000, PHARMACOL THERAPEUT, V87, P227, DOI 10.1016/S0163-7258(00)00086-3; Pluim D, 1999, ANAL BIOCHEM, V275, P30, DOI 10.1006/abio.1999.4302; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 2001, CANCER RES, V61, P53; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Rasheed ZA, 2003, ONCOGENE, V22, P7296, DOI 10.1038/sj.onc.1206935; Reedijk J, 2003, P NATL ACAD SCI USA, V100, P3611, DOI 10.1073/pnas.0737293100; Rixe O, 1996, BIOCHEM PHARMACOL, V52, P1855, DOI 10.1016/S0006-2952(97)81490-6; Rodriguez-Galindo C, 2000, MED PEDIATR ONCOL, V35, P385, DOI 10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E; Rowinsky EK, 1996, J CLIN ONCOL, V14, P3074, DOI 10.1200/JCO.1996.14.12.3074; ROWINSKY EK, 1997, SEMIN ONCOL, V24; Sabourin M, 2000, NUCLEIC ACIDS RES, V28, P1947, DOI 10.1093/nar/28.9.1947; Sandler AB, 2003, SEMIN ONCOL, V30, P9, DOI 10.1053/sonc.2003.50012; Shivji MKK, 1999, METH MOL B, V113, P373; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Subramanian D, 2000, METH MOL B, V95, P137; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; Teuben JM, 1999, BIOCHEMISTRY-US, V38, P12305, DOI 10.1021/bi9904757; van Waardenburg RCA, 2004, MOL CANCER THER, V3, P393; VANGARDEREN CJ, 1994, EUR J BIOCHEM, V225, P1169; Wall ME, 1998, MED RES REV, V18, P299; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wilke HJ, 2003, ANN ONCOL, V14, P49, DOI 10.1093/annonc/mdg730; Wilstermann AM, 2003, CURR TOP MED CHEM, V3, P321, DOI 10.2174/1568026033452519; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200; Zeghari-Squalli N, 1999, CLIN CANCER RES, V5, P1189	50	33	34	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54502	54509		10.1074/jbc.M410103200	http://dx.doi.org/10.1074/jbc.M410103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471886	hybrid			2022-12-25	WOS:000225793600074
J	Zhang, Y; Ma, K; Song, SL; Elam, MB; Cook, GA; Park, EA				Zhang, Y; Ma, K; Song, SL; Elam, MB; Cook, GA; Park, EA			Peroxisomal proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) enhances the thyroid hormone induction of carnitine palmitoyltransferase I (CPT-I alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PATTERNS; MESSENGER-RNA ABUNDANCE; HEPATIC GLUCONEOGENESIS; TRANSCRIPTIONAL COACTIVATOR; MITOCHONDRIAL BIOGENESIS; NUCLEAR RECEPTORS; BINDING PROTEIN; 1ST INTRON; RAT-LIVER; PGC-1	Carnitine palmitoyltransferase I (CPT-I) catalyzes the rate-controlling step in the pathway of mitochondrial fatty acid oxidation. Thyroid hormone will stimulate the expression of the liver isoform of CPT-I (CPT-Ialpha). This induction of CPT-Ialpha gene expression requires the thyroid hormone response element in the promoter and sequences within the first intron. The peroxisomal proliferator-activated receptor-gamma coactivator-1alpha(PGC-1alpha) is a coactivator that promotes mitochondrial biogenesis, mitochondrial fatty acid oxidation, and hepatic gluconeogenesis. In addition, PGC-1alpha will stimulate the expression of CPT-Ialpha in primary rat hepatocytes. Here we report that thyroid hormone will increase PGC-1alpha mRNA and protein levels in rat hepatocytes. In addition, overexpression of PGC-1alpha will enhance the thyroid hormone induction of CPT-Ialpha indicating that PGC-1alpha is a coactivator for thyroid hormone. By using chromatin immunoprecipitation assays, we show that PGC-1alpha is associated with both the thyroid hormone response element in the CPT-Ialpha gene promoter and the first intron of the CPT-Ialpha gene. Our data demonstrate that PGC-1alpha participates in the stimulation of CPT-Ialpha gene expression by thyroid hormone and suggest that PGC-1alpha is a coactivator for thyroid hormone.	Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Park, EA (corresponding author), Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.	epark@utmem.edu			NHLBI NIH HHS [HL-66924] Funding Source: Medline; NIDDK NIH HHS [DK-059368] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059368] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrero MJ, 2000, BIOCHEM BIOPH RES CO, V279, P81, DOI 10.1006/bbrc.2000.3893; Boustead JN, 2003, BIOCHEM J, V369, P17, DOI 10.1042/BJ20021382; Cook GA, 1999, AM J MED SCI, V318, P43, DOI 10.1097/00000441-199907000-00007; Cook GA, 2001, J MOL CELL CARDIOL, V33, P317, DOI 10.1006/jmcc.2000.1304; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Jackson-Hayes L, 2003, J BIOL CHEM, V278, P7964, DOI 10.1074/jbc.M211062200; Jansen MS, 2000, J BIOL CHEM, V275, P34989, DOI 10.1074/jbc.M001752200; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Lavrentyev EN, 2004, BIOCHEM BIOPH RES CO, V315, P174, DOI 10.1016/j.bbrc.2004.01.040; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; Louet JF, 2002, J BIOL CHEM, V277, P37991, DOI 10.1074/jbc.M205087200; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MYNATT RL, 1994, BIOCHEM BIOPH RES CO, V201, P932, DOI 10.1006/bbrc.1994.1791; PARK EA, 1995, BIOCHEM J, V310, P853, DOI 10.1042/bj3100853; Park EA, 1998, BIOCHEM J, V330, P217; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Song SL, 2004, BBA-GENE STRUCT EXPR, V1679, P164, DOI 10.1016/j.bbaexp.2004.06.006; Sorensen Annette, 2002, Brain Res Gene Expr Patterns, V1, P167; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Weitzel JM, 2003, J MOL ENDOCRINOL, V31, P291, DOI 10.1677/jme.0.0310291; Weitzel JM, 2003, EXP PHYSIOL, V88, P121, DOI 10.1113/eph8802506; Weitzel JM, 2001, NUCLEIC ACIDS RES, V29, P5148, DOI 10.1093/nar/29.24.5148; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	39	74	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					53963	53971		10.1074/jbc.M406028200	http://dx.doi.org/10.1074/jbc.M406028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15469941	hybrid			2022-12-25	WOS:000225793600010
J	Chou, CJ; Wisedchaisri, G; Monfeli, RR; Oram, DM; Holmes, RK; Hol, WGJ; Beeson, C				Chou, CJ; Wisedchaisri, G; Monfeli, RR; Oram, DM; Holmes, RK; Hol, WGJ; Beeson, C			Functional studies of the Mycobacterium tuberculosis iron-dependent regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN REPRESSOR; METAL ION-ACTIVATION; DNA COMPLEX REVEALS; CRYSTAL-STRUCTURE; 3RD DOMAIN; BINDING; IDER; DTXR; IDENTIFICATION; VIRULENCE	The iron-dependent regulator (IdeR) protein in Mycobacterium tuberculosis, and its better characterized homologue, the diphtheria toxin repressor (DtxR) from Corynebacterium diphtheriae, are iron-dependent regulatory proteins that control gene expression in response to iron availability in bacteria. IdeR regulates several genes required for iron uptake and storage including those involved in the synthesis of transition metal chelators called siderophores that are linked to the M. tuberculosis virulence. In this study, the metal ion and binding affinities for IdeR binding to an fxbA operator duplex DNA were estimated using fluorescence assays. The Fe2+, Co2+, and Ni2+ affinities of the two metal ion binding sites in IdeR that are involved in the activation of the regulator DNA binding process in vitro were independently estimated. Binding to the two metal ion binding sites is apparently cooperative and the two affinities differ significantly. Occupation of the first metal ion binding site causes dimerization of IdeR, and the metal ion affinity is about 4 muM for Ni2+ and much less for Fe2+ and Co2+. Binding of the second metal ion fully activates IdeR for binding to the fxbA operator. The equilibrium metal ion dissociation constants for IdeR-fxbA operator binding are similar to9 muM for Fe2+, 13 muM for Ni2+, and 23 muM for Co2+. Interestingly, the natural IdeR cofactor, Fe2+, shows high affinities toward both binding sites. These results provide insight into the possible roles for each metal binding site in IdeR activation.	Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem & Biomol Struct, Seattle, WA 98195 USA; Univ Washington, Biomol Struct & Design Grad Program, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	Medical University of South Carolina; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Beeson, C (corresponding author), Med Univ S Carolina, Dept Pharmaceut Sci, 280 Calhoun St,Box 250140, Charleston, SC 29425 USA.	beesonc@musc.edu	Chou, C. James/I-6563-2012	Oram, Diana/0000-0001-8546-6800; Wisedchaisri, Goragot/0000-0002-6967-5925	NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014107, R22AI014107, R01AI014107] Funding Source: NIH RePORTER; NCI NIH HHS [CA65656] Funding Source: Medline; NIAID NIH HHS [AI14107] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; Bullen J J, 1978, Curr Top Microbiol Immunol, V80, P1; Chen CSY, 2000, BIOCHEMISTRY-US, V39, P10397, DOI 10.1021/bi0009284; Dhople AM, 1996, MICROBIOS, V87, P77; Ding X, 1996, NAT STRUCT BIOL, V3, P382, DOI 10.1038/nsb0496-382; Dussurget O, 1999, J BACTERIOL, V181, P3402, DOI 10.1128/JB.181.11.3402-3408.1999; Feese MD, 2001, J BIOL CHEM, V276, P5959, DOI 10.1074/jbc.M007531200; FISS EH, 1994, MOL MICROBIOL, V14, P557, DOI 10.1111/j.1365-2958.1994.tb02189.x; Goranson-Siekierke J, 1999, INFECT IMMUN, V67, P1806; Horsburgh MJ, 2002, MOL MICROBIOL, V44, P1269, DOI 10.1046/j.1365-2958.2002.02944.x; Jobling MG, 2000, P NATL ACAD SCI USA, V97, P14662, DOI 10.1073/pnas.011442598; Kochan I, 1973, Curr Top Microbiol Immunol, V60, P1; Love JF, 2004, P NATL ACAD SCI USA, V101, P2506, DOI 10.1073/pnas.0303794101; MACHAM LP, 1975, J GEN MICROBIOL, V89, P379, DOI 10.1099/00221287-89-2-379; Manabe YC, 1999, P NATL ACAD SCI USA, V96, P12844, DOI 10.1073/pnas.96.22.12844; Pan J, 1999, P NATL ACAD SCI USA, V96, P6149, DOI 10.1073/pnas.96.11.6149; PAYNE SM, 1989, MOL MICROBIOL, V3, P1301, DOI 10.1111/j.1365-2958.1989.tb00281.x; Pohl E, 1998, J BIOL CHEM, V273, P22420, DOI 10.1074/jbc.273.35.22420; Pohl E, 1999, J MOL BIOL, V285, P1145, DOI 10.1006/jmbi.1998.2339; Pohl E, 1999, J MOL BIOL, V292, P653, DOI 10.1006/jmbi.1999.3073; Pohl E, 1997, PROTEIN SCI, V6, P1114, DOI 10.1002/pro.5560060519; Qiu XY, 1996, BIOCHEMISTRY-US, V35, P12292, DOI 10.1021/bi960861d; QIU XY, 1995, STRUCTURE, V3, P87, DOI 10.1016/S0969-2126(01)00137-X; RAGHU B, 1993, BIOCHEM MOL BIOL INT, V31, P341; Rodriguez G. Marcela, 1999, Tubercle and Lung Disease, V79, P287; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; SCHMITT MP, 1995, INFECT IMMUN, V63, P4284, DOI 10.1128/IAI.63.11.4284-4289.1995; SCHMITT MP, 1992, P NATL ACAD SCI USA, V89, P7576, DOI 10.1073/pnas.89.16.7576; Spiering MM, 2003, P NATL ACAD SCI USA, V100, P3808, DOI 10.1073/pnas.0737977100; Sritharan M, 2000, WORLD J MICROB BIOT, V16, P769, DOI 10.1023/A:1008995313232; TAO X, 1995, P NATL ACAD SCI USA, V92, P6803, DOI 10.1073/pnas.92.15.6803; TAO X, 1992, P NATL ACAD SCI USA, V89, P5897, DOI 10.1073/pnas.89.13.5897; Twigg PD, 2001, P NATL ACAD SCI USA, V98, P11259, DOI 10.1073/pnas.191354798; Wang G, 1999, P NATL ACAD SCI USA, V96, P6119, DOI 10.1073/pnas.96.11.6119; White A, 1998, NATURE, V394, P502, DOI 10.1038/28893; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; Wisedchaisri G, 2004, J MOL BIOL, V342, P1155, DOI 10.1016/j.jmb.2004.07.083; XU T, 1992, J BIOL CHEM, V267, P21761	38	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53554	53561		10.1074/jbc.M407385200	http://dx.doi.org/10.1074/jbc.M407385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456786	hybrid			2022-12-25	WOS:000225680600091
J	Day, PW; Tesmer, JJG; Sterne-Marr, R; Freeman, LC; Benovic, JL; Wedegaertner, PB				Day, PW; Tesmer, JJG; Sterne-Marr, R; Freeman, LC; Benovic, JL; Wedegaertner, PB			Characterization of the GRK2 binding site of G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SIGNALING PROTEINS; GTPASE-ACTIVATING PROTEINS; COUPLED RECEPTOR KINASE; BETA(2)-ADRENERGIC RECEPTOR; SELECTIVE REGULATION; POINT MUTATION; BETA-ARRESTIN; RGS; REGULATOR; DOMAIN	Heterotrimeric guanine nucleotide-binding proteins (G proteins) transmit signals from membrane bound G protein-coupled receptors (GPCRs) to intracellular effector proteins. The G(q) subfamily of Galpha subunits couples GPCR activation to the enzymatic activity of phospholipase C-beta (PLC-beta). Regulators of G protein signaling (RGS) proteins bind to activated Galpha subunits, including Galpha(q), and regulate Galpha signaling by acting as GTPase activating proteins (GAPs), increasing the rate of the intrinsic GTPase activity, or by acting as effector antagonists for Galpha subunits. GPCR kinases (GRKs) phosphorylate agonist-bound receptors in the first step of receptor desensitization. The amino termini of all GRKs contain an RGS homology ( RH) domain, and binding of the GRK2 RH domain to Galpha(q) attenuates PLC-beta activity. The RH domain of GRK2 interacts with Galpha(q/11) through a novel Galpha binding surface termed the "C" site. Here, molecular modeling of the Galpha(q).GRK2 complex and site-directed mutagenesis of Galpha(q) were used to identify residues in Galpha(q) that interact with GRK2. The model identifies Pro(185) in Switch I of Galpha(q) as being at the crux of the interface, and mutation of this residue to lysine disrupts Galpha(q) binding to the GRK2-RH domain. Switch III also appears to play a role in GRK2 binding because the mutations Galpha(q)-V240A, Galpha(q)-D243A, both residues within Switch III, and Galpha(q)-Q152A, a residue that structurally supports Switch III, are defective in binding GRK2. Furthermore, GRK2-mediated inhibition of Galpha(q)-Q152A-R183C-stimulated inositol phosphate release is reduced in comparison to Galpha(q)-R183C. Interestingly, the model also predicts that residues in the helical domain of Galpha(q) interact with GRK2. In fact, the mutants Galpha(q)-K77A, Galpha(q)-L78D, Galpha(q)-Q81A, and Galpha(q)-R92A have reduced binding to the GRK2-RH domain. Finally, although the mutant Galpha(q)-T187K has greatly reduced binding to RGS2 and RGS4, it has little to no effect on binding to GRK2. Thus the RH domain A and C sites for Galpha(q) interaction rely on contacts with distinct regions and different Switch I residues in Galpha(q).	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Siena Coll, Dept Biol, Loudonville, NY 12211 USA	Jefferson University; University of Texas System; University of Texas Austin	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St,839 Blumle Life Sci Bldg, Philadelphia, PA 19107 USA.	P_Wedegaertner@mail.jci.tju.edu		Tesmer, John/0000-0003-1125-3727	NIGMS NIH HHS [GM62884, R01 GM062884, GM44944, R01 GM044944] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944, R01GM062884] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1992, SHORT PROTOCOLS MOL, P8; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Day PW, 2003, BIOCHEMISTRY-US, V42, P9176, DOI 10.1021/bi034442+; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Usui K, 2000, INT J MOL MED, V5, P335; Vajda S, 2004, TRENDS BIOTECHNOL, V22, P110, DOI 10.1016/j.tibtech.2004.01.006; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wodak SJ, 2004, CURR OPIN STRUC BIOL, V14, P242, DOI 10.1016/j.sbi.2004.02.003; Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837	36	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53643	53652		10.1074/jbc.M401438200	http://dx.doi.org/10.1074/jbc.M401438200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471870	Green Accepted, hybrid			2022-12-25	WOS:000225680600101
J	Kinlough, CL; Poland, PA; Bruns, JB; Harkleroad, KL; Hughey, RP				Kinlough, CL; Poland, PA; Bruns, JB; Harkleroad, KL; Hughey, RP			MUC1 membrane trafficking is modulated by multiple interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; CARCINOMA-ASSOCIATED ANTIGEN; BREAST-CANCER; CYTOPLASMIC TAIL; BETA-CATENIN; LIPID RAFTS; CELL-ADHESION; EGF RECEPTORS; RING FINGER	MUC1 is a mucin-like transmembrane protein found on the apical surface of many epithelia. Because aberrant intracellular localization of MUC1 in tumor cells correlates with an aggressive tumor and a poor prognosis for the patient, experiments were designed to characterize the features that modulate MUC1 membrane trafficking. By following [S-35]Met/Cys-labeled MUC1 in glycosylation-defective Chinese hamster ovary cells, we found previously that truncation of O-glycans on MUC1 inhibited its surface expression and stimulated its internalization by clathrin-mediated endocytosis. To identify signals for MUC1 internalization that are independent of its glycosylation state, the ectodomain of MUC1 was replaced with that of Tac, and chimera endocytosis was measured by the same protocol. Endocytosis of the chimera was significantly faster than for MUC1, indicating that features of the highly extended ectodomain inhibit MUC1 internalization. Analysis of truncation mutants and tyrosine mutants showed that Tyr(20) and Tyr(60) were both required for efficient endocytosis. Mutation of Tyr(20) significantly blocked coimmunoprecipitation of the chimera with AP-2, indicating that (YHPM)-H-20 is recognized as a YXXphi motif by the mu2 subunit. The tyrosine-phosphorylated (YTNP)-T-60 was previously identified as an SH2 site for Grb2 binding, and we found that mutation of Tyr(60) blocked coimmunoprecipitation of the chimera with Grb2. This is the first indication that Grb2 plays a significant role in the endocytosis of MUC1.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hughey, RP (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, 930 Scaife Hall, Pittsburgh, PA 15261 USA.	hughey@msx.dept-med.pitt.edu			NCI NIH HHS [P50-CA9044] Funding Source: Medline; NIDDK NIH HHS [P50-DK56490, DK54787] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK056490, R01DK054787] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Arcasoy SM, 1997, AM J RESP CELL MOL, V17, P422, DOI 10.1165/ajrcmb.17.4.2714; ARCASOY SM, 1998, AM J RESP CRIT CARE, V157, pA582; Bieche I, 1997, THYROID, V7, P725, DOI 10.1089/thy.1997.7.725; Boehm M, 2002, GENE, V286, P175, DOI 10.1016/S0378-1119(02)00422-5; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Carraway KL, 2003, BIOESSAYS, V25, P66, DOI 10.1002/bies.10201; Chu JS, 1999, CANCER LETT, V142, P121, DOI 10.1016/S0304-3835(99)00161-5; Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069; Croce MV, 2003, J HISTOCHEM CYTOCHEM, V51, P781, DOI 10.1177/002215540305100609; Dalziel M, 2001, J BIOL CHEM, V276, P11007, DOI 10.1074/jbc.M006523200; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; FONTENOT JD, 1995, J BIOMOL STRUCT DYN, V13, P245, DOI 10.1080/07391102.1995.10508837; FONTENOT JD, 1993, CANCER RES, V53, P5386; Foster FM, 2003, J CELL SCI, V116, P3037, DOI 10.1242/jcs.00609; Fujita K, 1999, BRIT J CANCER, V80, P301, DOI 10.1038/sj.bjc.6690355; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Guddo F, 1998, ANTICANCER RES, V18, P1915; Guddo F, 1998, J CLIN PATHOL, V51, P667, DOI 10.1136/jcp.51.9.667; Handa K, 2001, BIOCHEM BIOPH RES CO, V285, P788, DOI 10.1006/bbrc.2001.5225; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Hudson MJH, 1996, AM J PATHOL, V148, P951; Hull S R, 1989, Cancer Commun, V1, P261; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Julian J, 2002, BIOCHEM BIOPH RES CO, V293, P1183, DOI 10.1016/S0006-291X(02)00352-2; Kam JL, 1998, CANCER RES, V58, P5577; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Lillehoj EP, 2002, AM J PHYSIOL-LUNG C, V282, pL751, DOI 10.1152/ajplung.00383.2001; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181, DOI 10.1152/ajplung.2001.280.1.L181; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Muller S, 2002, J BIOL CHEM, V277, P26103, DOI 10.1074/jbc.M202921200; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PANDEY P, 1995, CANCER RES, V55, P4000; Poland PA, 1997, GLYCOCONJUGATE J, V14, P89, DOI 10.1023/A:1018569100438; Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Xu XZ, 2000, ONCOGENE, V19, P3172, DOI 10.1038/sj.onc.1203645; Zhang K, 1996, J CELL BIOCHEM, V60, P538, DOI 10.1002/(SICI)1097-4644(19960315)60:4<538::AID-JCB10>3.3.CO;2-A	78	46	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53071	53077		10.1074/jbc.M409360200	http://dx.doi.org/10.1074/jbc.M409360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471854	hybrid			2022-12-25	WOS:000225680600034
J	Morais-de-Sa, E; Pereira, PJB; Saraiva, MJ; Damas, AM				Morais-de-Sa, E; Pereira, PJB; Saraiva, MJ; Damas, AM			The crystal structure of transthyretin in complex with diethylstilbestrol - A promising template for the design of amyloid inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-BINDING; 2.5 ANGSTROM RESOLUTION; RAT TRANSTHYRETIN; THYROXINE-BINDING; NATIVE-STATE; PROTEIN; DISEASE; PREALBUMIN; REVEALS; VARIANT	Transthyretin ( TTR) is a homotetrameric plasma protein that, in conditions not yet completely understood, may aggregate, forming the fibrillar material associated with TTR amyloidosis. A number of reported experiments indicate that dissociation of the TTR tetramer occurs prior to fibril formation, and therefore, studies aiming at the discovery of compounds that stabilize the protein quaternary structure, thereby acting as amyloid inhibitors, are being performed. The ability of diethylstilbestrol ( DES) to act as a competitive inhibitor for the thyroid hormone binding to TTR indicated a possible stabilizing effect of DES upon binding. Here we report the crystallographic study of DES binding to TTR. The structural data reveal two different binding modes, both located in the thyroxine binding channel. In both cases, DES binds deeply in the channel and establishes interactions with the equivalent molecule present in the adjacent binding site. The most remarkable features of DES interaction with TTR are its hydrophobic interactions within the protein halogen binding pockets, where its ethyl groups are snugly fitted, and the hydrogen bonds established at the center of the tetramer with Ser-117. Experiments concerning amyloid formation in vitro suggest that DES is effectively an amyloid inhibitor in acid-mediated fibrillogenesis and may be used for the design of more powerful drugs. The present study gave us further insight in the molecular mechanism by which DES competes with thyroid hormone binding to TTR and highlights key interactions between DES and TTR that oppose amyloid formation.	Univ Porto, Inst Biol Mol & Celular, P-4150 Oporto, Portugal; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Damas, AM (corresponding author), Univ Porto, Inst Biol Mol & Celular, Rua Campo Alegre 823, P-4150 Oporto, Portugal.	amdamas@ibmc.up.pt	Saraiva, Maria João/K-3907-2013; Pereira, Pedro/F-8972-2011; Morais-de-Sá, Eurico/I-2157-2013	Saraiva, Maria João/0000-0002-3360-6899; Pereira, Pedro/0000-0003-0969-5438; Morais-de-Sá, Eurico/0000-0003-3525-8231				Adamski-Werner SL, 2004, J MED CHEM, V47, P355, DOI 10.1021/jm030347n; Almeida MR, 2004, BIOCHEM J, V381, P351, DOI 10.1042/BJ20040011; Almeida MR, 1997, ENDOCRINE, V6, P309, DOI 10.1007/BF02820508; Alves IL, 1997, HUM MUTAT, V9, P226, DOI 10.1002/(SICI)1098-1004(1997)9:3<226::AID-HUMU3>3.3.CO;2-W; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAVALIERI RR, 1981, PHARMACOL REV, V33, P55; CHENG SY, 1977, BIOCHEMISTRY-US, V16, P3707, DOI 10.1021/bi00635a031; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; Damas AM, 1996, ACTA CRYSTALLOGR D, V52, P966, DOI 10.1107/S0907444996003307; Green NS, 2003, J AM CHEM SOC, V125, P13404, DOI 10.1021/ja030294z; Greschik H, 2004, J BIOL CHEM, V279, P33639, DOI 10.1074/jbc.M402195200; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Hammarstrom P, 2001, SCIENCE, V293, P2459, DOI 10.1126/science.1062245; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Hammarstrom P, 2001, BIOCHEMISTRY-US, V40, P11453, DOI 10.1021/bi010673+; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hornberg A, 2004, BBA-PROTEINS PROTEOM, V1700, P93, DOI 10.1016/j.bbapap.2004.04.004; Hornberg A, 2000, J MOL BIOL, V302, P649, DOI 10.1006/jmbi.2000.4078; Ishihara A, 2003, MOL CELL ENDOCRINOL, V199, P105, DOI 10.1016/S0303-7207(02)00302-7; Jury HH, 2000, J STEROID BIOCHEM, V75, P167, DOI 10.1016/S0960-0760(00)00168-0; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KORACH KS, 1978, P NATL ACAD SCI USA, V75, P468, DOI 10.1073/pnas.75.1.468; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, CRYSTALLOGRAPHIC COM, V5; Miller SR, 2004, LAB INVEST, V84, P545, DOI 10.1038/labinvest.3700059; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; Muziol T, 2001, ACTA BIOCHIM POL, V48, P885; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NILSSON SF, 1975, J BIOL CHEM, V250, P8554; PAZ PDL, 1992, DESIGN DRUGS MACROMO; Quintas A, 1999, J BIOL CHEM, V274, P32943, DOI 10.1074/jbc.274.46.32943; Redondo C, 2000, BIOCHEM J, V348, P167, DOI 10.1042/0264-6021:3480167; REID DG, 1989, J BIOL CHEM, V264, P2013; ROUSSEL A, 1989, TURBOFRODO SILICON G; Saraiva MJM, 2001, HUM MUTAT, V17, P493, DOI 10.1002/humu.1132; Sebastiao MP, 1998, J BIOL CHEM, V273, P24715, DOI 10.1074/jbc.273.38.24715; Sebastiao MP, 2001, J MOL BIOL, V306, P733, DOI 10.1006/jmbi.2000.4415; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sousa MM, 2001, AM J PATHOL, V159, P1993; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wojtczak A, 1996, ACTA CRYSTALLOGR D, V52, P758, DOI 10.1107/S0907444996003046; Wojtczak A, 1997, ACTA BIOCHIM POL, V44, P505, DOI 10.18388/abp.1997_4400; Wojtczak A, 2001, ACTA CRYSTALLOGR D, V57, P1061, DOI 10.1107/S0907444901007235; Wojtczak A, 2001, ACTA CRYSTALLOGR D, V57, P957, DOI 10.1107/S0907444901006047	52	39	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53483	53490		10.1074/jbc.M408053200	http://dx.doi.org/10.1074/jbc.M408053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15469931	hybrid			2022-12-25	WOS:000225680600083
J	Obach, M; Navarro-Sabate, A; Caro, J; Kong, XG; Duran, J; Gomez, M; Perales, JC; Ventura, F; Rosa, JL; Bartrons, R				Obach, M; Navarro-Sabate, A; Caro, J; Kong, XG; Duran, J; Gomez, M; Perales, JC; Ventura, F; Rosa, JL; Bartrons, R			6-phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; FRUCTOSE 2,6-BISPHOSPHATASE; ERYTHROPOIETIN GENE; PROTEIN-KINASE; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; EXPRESSION; GLYCOLYSIS; CELLS; PATHWAY; FAMILY	The up-regulation of glycolysis to enhance the production of energy under reduced pO(2) is a hallmark of the hypoxic response. A key regulator of glycolytic flux is fructose-2,6-bisphosphate, and its steady state concentration is regulated by the action of different isozymes product of four genes (pfkfb1-4). pfkfb3 has been found in proliferating cells and tumors, being induced by hypoxia. To understand the organization of cis-acting sequences that are responsible for the oxygen-regulated pfkfb3 gene, we have studied its 5'-flanking region. Extensive analysis of the 5' pfkfb3 promoter sequence revealed the presence of putative consensus binding sites for various transcription factors that could play an important role in pfkfb3 gene regulation. These DNA consensus sequences included estrogen receptor, hypoxia response element (HRE), early growth response, and specific protein 1 putative binding sites. Promoter deletion analysis as well as putative HREs sequences ( wild type and mutated) fused to a c-fos minimal promoter unit constructs demonstrate that the sequence located from -1269 to -1297 relative to the start site is required for hypoxia-inducible factor 1 (HIF-1) induction. The effective binding of HIF-1 transcription factor to the HREs at -1279 and -1288 was corroborated by electrophoretic mobility shift assay and biotinylated oligonucleotide pull-down. In addition, HIF-1alpha null mouse embryo fibroblasts transfected with a full-length pfkfb3 promoter-luciferase reporter construct further demonstrated that HIF-1 protein was critically involved for hypoxia transactivation of this gene. Altogether, these results demonstrate that pfkfb3 is a hypoxia-inducible gene that is stimulated through HIF interaction with the consensus HRE site in its promoter region.	Univ Barcelona, Dept Ciencies Fisiol 2, Unitat Bioquim & Biol Mol, E-08907 Pavello De Govern, Lhospitalet, Spain; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA	University of Barcelona; Jefferson University	Bartrons, R (corresponding author), Univ Barcelona, Dept Ciencies Fisiol 2, Unitat Bioquim & Biol Mol, Campus Bellvitge,Feixa Llarga S-N, E-08907 Pavello De Govern, Lhospitalet, Spain.	rbartrons@ub.edu	Ventura, Francesc/ABG-2285-2020; Rosa, Jose Luis/K-6685-2014; Ventura, Francesc/K-9700-2014; PERALES, JOSE C. C/D-5586-2012; Navarro-Sabaté, Aurea/K-6329-2018; PERALES, JOSE C./AAC-3156-2019; PERALES, JOSE C/J-7457-2017	Ventura, Francesc/0000-0001-9673-9405; Rosa, Jose Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405; PERALES, JOSE C. C/0000-0001-7363-2226; Navarro-Sabaté, Aurea/0000-0002-8286-9732; PERALES, JOSE C./0000-0001-7363-2226; PERALES, JOSE C/0000-0001-7363-2226; Bartrons, Ramon/0000-0001-9349-5847; Obach, Merce/0000-0002-2756-6181				Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Atsumi T, 2002, CANCER RES, V62, P5881; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; Ebert BL, 1999, BLOOD, V94, P1864; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Goren N, 2000, MOL BRAIN RES, V75, P138, DOI 10.1016/S0169-328X(99)00319-8; Hamilton JA, 1997, MOL ENDOCRINOL, V11, P490, DOI 10.1210/me.11.4.490; Hirata T, 1998, BIOCHEM BIOPH RES CO, V242, P680, DOI 10.1006/bbrc.1997.8024; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; HUE L, 1993, ADV ENZYME REGUL, V33, P97; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Krebs H A, 1972, Essays Biochem, V8, P1; Manzano A, 1998, CYTOGENET CELL GENET, V83, P214, DOI 10.1159/000015181; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Minchenko O, 2003, FEBS LETT, V554, P264, DOI 10.1016/S0014-5793(03)01179-7; Navarro-Sabate A, 2001, GENE, V264, P131, DOI 10.1016/S0378-1119(00)00591-6; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Perez JX, 2000, AM J PHYSIOL-CELL PH, V279, pC1359, DOI 10.1152/ajpcell.2000.279.5.C1359; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; Riera L, 2003, FEBS LETT, V550, P23, DOI 10.1016/S0014-5793(03)00808-1; Riera L, 2002, BBA-MOL CELL RES, V1589, P89, DOI 10.1016/S0167-4889(02)00169-6; Sakai A, 1996, J BIOCHEM-TOKYO, V119, P506; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VENTURA F, 1991, BIOCHEM J, V276, P455, DOI 10.1042/bj2760455; WANG GL, 1993, BLOOD, V82, P3610; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watanabe F, 1997, J NEUROCHEM, V69, P1	38	180	187	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53562	53570		10.1074/jbc.M406096200	http://dx.doi.org/10.1074/jbc.M406096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466858	Green Published, hybrid			2022-12-25	WOS:000225680600092
J	Peng, HM; Morishima, Y; Jenkins, GJ; Dunbar, AY; Lau, M; Patterson, C; Pratt, WB; Osawa, Y				Peng, HM; Morishima, Y; Jenkins, GJ; Dunbar, AY; Lau, M; Patterson, C; Pratt, WB; Osawa, Y			Ubiquitylation of neuronal nitric-oxide synthase by CHIP, a chaperone-dependent E3 ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; IN-VITRO; PROTEIN; IDENTIFICATION; TRAFFICKING; DEGRADATION; SYSTEM; TARGET; HSP90; HSC70	It is established that neuronal nitric-oxide synthase (nNOS) is ubiquitylated and proteasomally degraded. The proteasomal degradation of nNOS is enhanced by suicide inactivation of nNOS or by the inhibition of hsp90, which is a chaperone found in a native complex with nNOS. In the current study, we have examined whether CHIP, a chaperone-dependent E3 ubiquitin-protein isopeptide ligase that is known to ubiquitylate other hsp90-chaperoned proteins, could act as an ubiquitin ligase for nNOS. We found with the use of HEK293T or COS-7 cells and transient transfection methods that CHIP overexpression causes a decrease in immunodetectable levels of nNOS. The extent of the loss of nNOS is dependent on the amount of CHIP cDNA used for transfection. Lactacystin (10 muM), a selective proteasome inhibitor, attenuates the loss of nNOS in part by causing the nNOS to be found in a detergent-insoluble form. Immunoprecipitation of the nNOS and subsequent Western blotting with an anti-ubiquitin IgG shows an increase in nNOS-ubiquitin conjugates because of CHIP. Moreover, incubation of nNOS with a purified system containing an E1 ubiquitin-activating enzyme, an E2 ubiquitin carrier protein conjugating enzyme (UbcH5a), CHIP, glutathione S-transferase-tagged ubiquitin, and an ATP-generating system leads to the ubiquitylation of nNOS. The addition of purified hsp70 and hsp40 to this in vitro system greatly enhances the amount of nNOS-ubiquitin conjugates, suggesting that CHIP is an E3 ligase for nNOS whose action is facilitated by (and possibly requires) its interaction with nNOS-bound hsp70.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA	University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Osawa, Y (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	osawa@umich.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065619, R37HL065619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65619] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIEHS NIH HHS [ES08365] Funding Source: Medline; NIGMS NIH HHS [GM61728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bender AT, 2000, J BIOL CHEM, V275, P17407, DOI 10.1074/jbc.M000155200; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Billecke SS, 2004, J BIOL CHEM, V279, P30252, DOI 10.1074/jbc.M403864200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Noguchi S, 2000, J BIOL CHEM, V275, P2376, DOI 10.1074/jbc.275.4.2376; Osawa Y, 2003, J PHARMACOL EXP THER, V304, P493, DOI 10.1124/jpet.102.035055; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200	23	61	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52970	52977		10.1074/jbc.M406926200	http://dx.doi.org/10.1074/jbc.M406926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466472	Green Published, hybrid			2022-12-25	WOS:000225680600021
J	Sebulsky, MT; Speziali, CD; Shilton, BH; Edgell, DR; Heinrichs, DE				Sebulsky, MT; Speziali, CD; Shilton, BH; Edgell, DR; Heinrichs, DE			FhuD1, a ferric hydroxamate-binding lipoprotein in Staphylococcus aureus - A case of gene duplication and lateral transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TREPONEMA-PALLIDUM TROA; IRON TRANSPORT; STREPTOCOCCUS-PNEUMONIAE; OLIGOPEPTIDE TRANSPORT; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; MALTOSE-BINDING; ABC TRANSPORTER; PROTEIN; IDENTIFICATION	Staphylococcus aureus can utilize ferric hydroxamates as a source of iron under iron-restricted growth conditions. Proteins involved in this transport process are: FhuCBG, which encodes a traffic ATPase; FhuD2, a post-translationally modified lipoprotein that acts as a high affinity receptor at the cytoplasmic membrane for the efficient capture of ferric hydroxamates; and FhuD1, a protein with similarity to FhuD2. Gene duplication likely gave rise to fhuD1 and fhuD2. While the genomic locations of fhuCBG and fhuD2 in S. aureus strains are conserved, both the presence and the location of fhuD1 are variable. The apparent redundancy of FhuD1 led us to examine the role of this protein. We demonstrate that FhuD1 is expressed only under conditions of iron limitation through the regulatory activity of Fur. FhuD1 fractions with the cell membrane and binds hydroxamate siderophores but with lower affinity than FhuD2. Using small angle x-ray scattering, the solution structure of FhuD1 resembles that of FhuD2, and only a small conformational change is associated with ferrichrome binding. FhuD1, therefore, appears to be a receptor for ferric hydroxamates, like FhuD2. Our data to date suggest, however, that FhuD1 is redundant to FhuD2 and plays a minor role in hydroxamate transport. However, given the very real possibility that we have not yet identified the proper conditions where FhuD1 does provide an advantage over FhuD2, we anticipate that FhuD1 serves an enhanced role in the transport of untested hydroxamate siderophores and that it may play a prominent role during the growth of S. aureus in its natural environments.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Heinrichs, DE (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada.	david.heinrichs@fmd.uwo.ca	Edgell, David/AAJ-1971-2020; Shilton, Brian H/A-6667-2011; Heinrichs, David/ABD-5702-2021	Speziali, Craig/0000-0002-6401-0174; Heinrichs, David/0000-0002-7217-2456				ALLOING G, 1994, J MOL BIOL, V241, P44, DOI 10.1006/jmbi.1994.1472; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Braun V, 1998, MET IONS BIOL SYST, V35, P67; Byers BR, 1998, MET IONS BIOL SYST, V35, P37; Cockayne A, 1998, INFECT IMMUN, V66, P3767, DOI 10.1128/IAI.66.8.3767-3774.1998; Courcol RJ, 1997, INFECT IMMUN, V65, P1944, DOI 10.1128/IAI.65.5.1944-1948.1997; Dale SE, 2004, INFECT IMMUN, V72, P29, DOI 10.1128/IAI.72.1.29-37.2004; DRECHSEL H, 1993, BIOMETALS, V6, P185; Garault P, 2002, J BIOL CHEM, V277, P32, DOI 10.1074/jbc.M107002200; Guinier A., 1955, SMALL ANGLE SCATTERI; Hammersley A. P., 1997, ESRF97HA02T; HAMMERSLEY AP, 1998, ESRF97HA02T; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101; KONETSCHNYRAPP S, 1990, EUR J BIOCHEM, V191, P65, DOI 10.1111/j.1432-1033.1990.tb19094.x; Koster W, 2001, RES MICROBIOL, V152, P291, DOI 10.1016/S0923-2508(01)01200-1; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Lee YH, 2002, J BACTERIOL, V184, P2300, DOI 10.1128/JB.184.8.2300-2304.2002; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Lindsay JA, 2004, TRENDS MICROBIOL, V12, P378, DOI 10.1016/j.tim.2004.06.004; Meyer JM, 1997, MICROBIOL-UK, V143, P35, DOI 10.1099/00221287-143-1-35; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; Posey JE, 2000, SCIENCE, V288, P1651, DOI 10.1126/science.288.5471.1651; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; ROHRBACH MR, 1995, J BACTERIOL, V177, P7186, DOI 10.1128/jb.177.24.7186-7193.1995; ROHRBACH MR, 1995, MOL GEN GENET, V248, P33, DOI 10.1007/BF02456611; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEIDER R, 1993, MOL MICROBIOL, V8, P111, DOI 10.1111/j.1365-2958.1993.tb01208.x; Sebulsky MT, 2000, J BACTERIOL, V182, P4394, DOI 10.1128/JB.182.16.4394-4400.2000; Sebulsky MT, 2003, J BIOL CHEM, V278, P49890, DOI 10.1074/jbc.M305073200; Sebulsky MT, 2001, J BACTERIOL, V183, P4994, DOI 10.1128/JB.183.17.4994-5000.2001; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Sutcliffe IC, 2002, MICROBIOL-SGM, V148, P2065, DOI 10.1099/00221287-148-7-2065; Tai SS, 2003, FEMS MICROBIOL LETT, V220, P303, DOI 10.1016/S0378-1097(03)00135-6; Weinberg ED, 1997, PERSPECT BIOL MED, V40, P578	38	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53152	53159		10.1074/jbc.M409793200	http://dx.doi.org/10.1074/jbc.M409793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475351	hybrid			2022-12-25	WOS:000225680600044
J	Tardy, C; Autefage, H; Garcia, V; Levade, T; Andrieu-Abadie, N				Tardy, C; Autefage, H; Garcia, V; Levade, T; Andrieu-Abadie, N			Mannose 6-phosphorylated proteins are required for tumor necrosis factor-induced apoptosis - Defective response in I-cell disease fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL STORAGE DISEASES; NEURONAL CEROID-LIPOFUSCINOSIS; MEDIATED HEPATOCYTE APOPTOSIS; TRIPEPTIDYL PEPTIDASE-II; CYTOCHROME-C RELEASE; CATHEPSIN-D; 6-PHOSPHATE RECEPTORS; MICE DEFICIENT; TNF-ALPHA; ACID SPHINGOMYELINASE	Whereas caspases are essential components in apoptosis, other proteases seem to be involved in programmed cell death. This study investigated the role of lysosomal mannose 6-phosphorylated proteins in tumor necrosis factor (TNF)-induced apoptosis. We report that fibroblasts isolated from patients affected with inclusion-cell disease (ICD), having a deficient activity of almost all lysosomal hydrolases, are resistant to the toxic effect of TNF. These mutant cells exhibited a defect in TNF-induced caspase activation, Bid cleavage, and release of cytochrome c. In contrast, TNF-induced p42/p44 MAPK activation and CD54 expression remained unaltered. Human ICD lymphoblasts and fibroblasts derived from mice nullizygous for Igf2 and the two mannose 6-phosphate (M6P) receptors, Mpr300 and Mpr46, which develop an ICD-like phenotype, were also resistant to CD95 ligand and TNF, respectively. Moreover, correction of the lysosomal enzyme defect of ICD fibroblasts, using a medium enriched in M6P-containing proteins, enabled restoration of sensitivity to TNF. This effect was blocked by exogenous M6P but not by cathepsin B or L inhibitors. Altogether, these findings suggest that some M6P-bearing glycoproteins modulate the susceptibility to TNF-induced apoptosis. As a matter of fact, exogenous tripeptidyl peptidase 1, a lysosomal carboxypeptidase, could sensitize ICD fibroblasts to TNF. These observations highlight the hitherto unrecognized role of some mannose 6-phosphorylated proteins such as tripeptidyl peptidase 1 in the apoptotic cascade triggered by TNF.	Ctr Hosp Univ Rangueil, INSERM, U466, F-31059 Toulouse 9, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Andrieu-Abadie, N (corresponding author), Ctr Hosp Univ Rangueil, INSERM, U466, 1 Ave Jean Poulhes,TSA 50032, F-31059 Toulouse 9, France.	nandrieu@toulouse.inserm.fr	Levade, Thierry/O-8948-2014; Andrieu-Abadie, Nathalie/N-6793-2013; Tardy, Claudine/G-2737-2017; GARCIA, Virginie/W-8313-2019; Tardy, Claudine/AAE-5026-2019	Andrieu-Abadie, Nathalie/0000-0003-2698-1970; GARCIA, Virginie/0000-0002-9761-7036; Tardy, Claudine/0000-0002-5292-0672				Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Beyaert R, 2002, INT REV CYTOL, V214, P225; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Bosshard NU, 1996, VET PATHOL, V33, P1, DOI 10.1177/030098589603300101; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; Chatelut M, 1997, CLIN CHIM ACTA, V262, P61, DOI 10.1016/S0009-8981(97)06527-3; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cho SG, 2000, J NEUROCHEM, V74, P1478, DOI 10.1046/j.1471-4159.2000.0741478.x; Cho SG, 2000, J NEUROSCI RES, V62, P234, DOI 10.1002/1097-4547(20001015)62:2<234::AID-JNR8>3.0.CO;2-8; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Czaja MJ, 2001, HEPATOLOGY, V34, P844, DOI 10.1053/jhep.2001.0340844; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dittmer F, 1998, TRANSGENIC RES, V7, P473, DOI 10.1023/A:1008823315416; Dittmer F, 1999, J CELL SCI, V112, P1591; Dressel R, 2004, J BIOL CHEM, V279, P20200, DOI 10.1074/jbc.M313108200; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Golabek AA, 2003, J BIOL CHEM, V278, P7135, DOI 10.1074/jbc.M211872200; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Hilbi H, 2000, INFECT IMMUN, V68, P5502, DOI 10.1128/IAI.68.10.5502-5508.2000; Hishita T, 2001, CANCER RES, V61, P2878; Jeyakumar M, 2002, NEUROPATH APPL NEURO, V28, P343, DOI 10.1046/j.1365-2990.2002.00422.x; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Jones B, 1998, AM J PHYSIOL-GASTR L, V275, pG723, DOI 10.1152/ajpgi.1998.275.4.G723; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; KAPLAN A, 1977, J CLIN INVEST, V60, P1088, DOI 10.1172/JCI108860; Koike M, 2003, MOL CELL NEUROSCI, V22, P146, DOI 10.1016/S1044-7431(03)00035-6; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; Lane SC, 1996, J NEUROCHEM, V67, P677; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Lin L, 2001, BIOCHEM J, V357, P49, DOI 10.1042/0264-6021:3570049; LITTLE L, 1987, BIOCHEM J, V248, P151, DOI 10.1042/bj2480151; MA ZM, 1991, J BIOL CHEM, V266, P10589; MALAGARIECAZENA.S, 2002, EXPERT REV MOL MED, P1; Michallet MC, 2004, J IMMUNOL, V172, P5405, DOI 10.4049/jimmunol.172.9.5405; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nakanishi H, 2001, J NEUROSCI, V21, P7526, DOI 10.1523/JNEUROSCI.21-19-07526.2001; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Neuzil J, 2002, BIOCHEM J, V362, P709, DOI 10.1042/0264-6021:3620709; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Salvesen GS, 2001, J CLIN INVEST, V107, P21, DOI 10.1172/JCI11829; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Shimizu M, 1999, J IMMUNOL, V162, P7350; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; Stefanis DD, 2002, BIOL CHEM, V383, P989, DOI 10.1515/BC.2002.106; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Tardy C, 2003, CELL DEATH DIFFER, V10, P1090, DOI 10.1038/sj.cdd.4401272; Tardy C, 2004, NEUROCHEM RES, V29, P871, DOI 10.1023/B:NERE.0000021232.05175.38; TOMKINSON B, 1987, P NATL ACAD SCI USA, V84, P7508, DOI 10.1073/pnas.84.21.7508; Tyynela J, 2000, EMBO J, V19, P2786, DOI 10.1093/emboj/19.12.2786; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Vigneswaran N, 2003, ORAL ONCOL, V39, P559, DOI 10.1016/S1368-8375(03)00038-1; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; Vines DJ, 1999, FEBS LETT, V443, P131, DOI 10.1016/S0014-5793(98)01683-4; Welss T, 2003, BIOCHEMISTRY-US, V42, P7381, DOI 10.1021/bi027307q; Werneburg N, 2004, AM J PHYSIOL-GASTR L, V287, pG436, DOI 10.1152/ajpgi.00019.2004; WIESMANN U, 1971, NEW ENGL J MED, V285, P1090; Winchester B, 2000, BIOCHEM SOC T, V28, P150, DOI 10.1042/bst0280150; Wraith J E, 2002, Semin Neonatol, V7, P75, DOI 10.1053/siny.2001.0088; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x	80	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52914	52923		10.1074/jbc.M408261200	http://dx.doi.org/10.1074/jbc.M408261200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15452110	hybrid			2022-12-25	WOS:000225680600015
J	Thompson, T; Tovar, C; Yang, H; Carvajal, D; Vu, BT; Xu, QL; Wahl, GM; Heimbrook, DC; Vassilev, LT				Thompson, T; Tovar, C; Yang, H; Carvajal, D; Vu, BT; Xu, QL; Wahl, GM; Heimbrook, DC; Vassilev, LT			Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR PROTEIN P53; PROLYL ISOMERASE PIN1; DNA-DAMAGE; IN-VIVO; P53-DEPENDENT APOPTOSIS; MDM2; GROWTH; PATHWAY; SITES; ACETYLATION	The p53 tumor suppressor is a key mediator of the cellular response to stress. Phosphorylation induced by multiple stress-activated kinases has been proposed to be essential for p53 stabilization, interaction with transcriptional co-activators, and activation of p53 target genes. However, genetic studies suggest that stress-activated phosphorylation may not be essential for p53 activation. We therefore investigated the role of p53 phosphorylation on six key serine residues (Ser(6), Ser(15), Ser(20), Ser(37), Ser(46), and Ser(392)) for p53 activation using nutlin-3, a recently developed small molecule MDM2 antagonist. We show here that nutlin does not induce the phosphorylation of p53. Comparison of the activity of unphosphorylated and phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide in HCT116 and RKO cells revealed no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes and to induce p53-dependent apoptosis. We conclude that p53 phosphorylation on six major serine sites is not required for activation of p53 target genes or biological responses in vivo.	Hoffmann La Roche Inc, Roche Res Ctr, Discovery Oncol, Nutley, NJ 07110 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Roche Holding; Salk Institute	Vassilev, LT (corresponding author), Hoffmann La Roche Inc, Roche Res Ctr, Discovery Oncol, 340 Kingsland St, Nutley, NJ 07110 USA.	lyubomir.vassilev@roche.com						Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Jackson MW, 2004, ONCOGENE, V23, P4477, DOI 10.1038/sj.onc.1207575; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Perego P, 2001, CURR MED CHEM, V8, P31, DOI 10.2174/0929867013373994; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Schmitt CA, 2002, J MOL MED-JMM, V80, P137, DOI 10.1007/s00109-001-0293-3; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Sluss HK, 2004, MOL CELL BIOL, V24, P976, DOI 10.1128/MCB.24.3.976-984.2004; Steensma David P, 2003, Methods Mol Med, V85, P323, DOI 10.1385/1-59259-380-1:323; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yang H, 2003, MOL CANCER THER, V2, P1023; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	43	201	206	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53015	53022		10.1074/jbc.M410233200	http://dx.doi.org/10.1074/jbc.M410233200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471885	hybrid			2022-12-25	WOS:000225680600027
J	Wilson, SJ; Roche, AM; Kostetskaia, E; Smyth, EM				Wilson, SJ; Roche, AM; Kostetskaia, E; Smyth, EM			Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS NEOINTIMAL FORMATION; A(2) RECEPTOR; PROTEIN-KINASE; HUMAN PLATELETS; LIGAND-BINDING; DEFICIENT MICE; BETA ISOFORMS; IN-VIVO; PHOSPHORYLATION; PROSTAGLANDIN	Prostacyclin (PGI(2)) and thromboxane (TxA(2)) are biological opposites; PGI(2), a vasodilator and inhibitor of platelet aggregation, limits the deleterious actions of TxA(2), a vasoconstrictor and platelet activator. The molecular mechanisms involved in the counterregulation of PGI(2)/TxA(2) signaling are unclear. We examined the interaction of the receptors for PGI(2) (IP) and TxA(2) (TPalpha). IP-induced cAMP and TP-induced inositol phosphate generation were unaltered when the receptors were co-expressed in HEK 293 cells (IP/TPalpha-HEK). TP-cAMP generation, in response to TP agonists or a TP-dependent isoprostane, iPE(2)III, was evident in IP/TPalpha-HEK and in aortic smooth muscle cells, but not in cells expressing either receptor alone, or in IP-deficient aortic smooth muscle cells. Augmentation of TP-induced cAMP generation, with the IP agonist cicaprost, was ablated in IP-deficient cells and was independent of direct IP signaling. IP/TPalpha heterodimers were formed constitutively when the receptors were co-expressed, with no overt changes in ligand binding to the individual receptor sites. However, despite inefficient binding of iPE(2)III to either the IP or TPalpha, expressed alone or in combination, robust cAMP generation was evident in IP/TPalpha-HEK, suggesting the formation of an alternative receptor site. Thus, IP/TPalpha dimerization was coincident with TP-cAMP generation, promoting a "PGI(2)-like" cellular response to TP activation. This represents a previously unknown mechanism by which IP may limit the cellular effects of TP.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania	Smyth, EM (corresponding author), Univ Penn, Ctr Expt Therapeut, 808 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	emer@spirit.gcrc.upenn.edu						AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Audoly LP, 2000, CIRCULATION, V101, P2833, DOI 10.1161/01.CIR.101.24.2833; Belton OA, 2003, CIRCULATION, V108, P3017, DOI 10.1161/01.CIR.0000104565.78013.AD; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Cayatte AJ, 2000, ARTERIOSCL THROM VAS, V20, P1724, DOI 10.1161/01.ATV.20.7.1724; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Chiang N, 1998, ARCH BIOCHEM BIOPHYS, V352, P207, DOI 10.1006/abbi.1998.0620; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; DORN GW, 1987, CIRC RES, V60, P952, DOI 10.1161/01.RES.60.6.952; EGAN KM, 2004, IN PRESS SCIENCE; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FITZGERALD GA, 1991, AM J CARDIOL, V68, pB11, DOI 10.1016/0002-9149(91)90379-Y; FUNK CD, 1993, MOL PHARMACOL, V44, P934; Giguere V, 2004, EUR J PHARMACOL, V494, P11, DOI 10.1016/j.ejphar.2004.04.041; GRIMALDI M, 1994, J NEUROCHEM, V63, P344; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; Harada M, 1999, CARDIOVASC RES, V43, P481, DOI 10.1016/S0008-6363(99)00107-8; Hirata M, 1993, Nihon Rinsho, V51, P1586; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; Miggin SM, 1998, BBA-GEN SUBJECTS, V1425, P543, DOI 10.1016/S0304-4165(98)00109-3; MONCADA S, 1981, CLIN SCI, V61, P369, DOI 10.1042/cs0610369; MURRAY R, 1990, J BIOL CHEM, V265, P21670; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Numaguchi Y, 1999, ARTERIOSCL THROM VAS, V19, P727, DOI 10.1161/01.ATV.19.3.727; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OATES JA, 1988, NEW ENGL J MED, V319, P761, DOI 10.1056/NEJM198809223191206; OGAWA Y, 1995, GENOMICS, V27, P142, DOI 10.1006/geno.1995.1016; Pakala R, 1997, CIRCULATION, V96, P2280; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Pratico D, 1996, J BIOL CHEM, V271, P14916, DOI 10.1074/jbc.271.25.14916; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Ropero AB, 1999, J PHYSIOL-LONDON, V521, P397, DOI 10.1111/j.1469-7793.1999.00397.x; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Turek JW, 2002, J BIOL CHEM, V277, P16791, DOI 10.1074/jbc.M105872200; vanderVuurst H, 1997, ARTERIOSCL THROM VAS, V17, P1830, DOI 10.1161/01.ATV.17.9.1830; Vane J. R., 1995, AM J CARDIOL, V75, p3A; Walsh MT, 2000, BBA-MOL CELL RES, V1496, P164, DOI 10.1016/S0167-4889(00)00031-8; Walsh MT, 2000, J BIOL CHEM, V275, P20412, DOI 10.1074/jbc.M907881199; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200	51	74	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53036	53047		10.1074/jbc.M405002200	http://dx.doi.org/10.1074/jbc.M405002200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471868	hybrid			2022-12-25	WOS:000225680600030
J	Labrecque, L; Nyalendo, C; Langlois, S; Durocher, Y; Roghi, C; Murphy, G; Gingras, D; Beliveau, R				Labrecque, L; Nyalendo, C; Langlois, S; Durocher, Y; Roghi, C; Murphy, G; Gingras, D; Beliveau, R			Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; 1-MATRIX METALLOPROTEINASE; IN-VIVO; C-SRC; TRANSIENT TRANSFECTION; SIGNAL-TRANSDUCTION; CELL MIGRATION; UP-REGULATION; MT1-MMP; ACTIVATION	We have recently shown that stimulation of endothelial cells with vascular endothelial growth factor ( VEGF) induces dissociation of caveolin-1 from the VEGFR-2 receptor, followed by Src family kinase-dependent tyrosine phosphorylation of the protein (Labrecque, L., Royal, I., Surprenant, D. S., Patterson, C., Gingras, D., and Beliveau, R. (2003) Mol. Biol. Cell 14, 334 - 347). In this study, we provide evidence that the VEGF-dependent tyrosine phosphorylation of caveolin-1 induces interaction of the protein with the membrane-type 1 matrix metalloproteinase ( MT1-MMP). This interaction requires the phosphorylation of caveolin-1 on tyrosine 14 by members of the Src family of protein kinases, such as Src and Fyn, because it is completely abolished by expression of a catalytically inactive Src mutant or by site-directed mutagenesis of tyrosine 14 of caveolin-1. Most interestingly, the association of MT1-MMP with phosphorylated caveolin-1 induced the recruitment of Src and a concomitant inhibition of the kinase activity of the enzyme, suggesting that this complex may be involved in the negative regulation of Src activity. The association of MT1-MMP with phosphorylated caveolin-1 occurs in caveolae membranes and involves the cytoplasmic domain of MT1-MMP because it was markedly reduced by mutation of Cys(574) and Val(582) residues of the cytoplasmic tail of the enzyme. Most interestingly, the reduction of the interaction between MT1-MMP and caveolin-1 by using these mutants also decreases MT1-MMP-dependent cell locomotion. Overall these results indicate that MT1-MMP associates with tyrosine-phosphorylated caveolin-1 and that this complex may play an important role in MT1-MMP regulation and function.	Univ Montreal, Hop St Justine, Mol Med Lab, Ctr Canc Charles Bruneau, Montreal, PQ H3T 1C5, Canada; Anim Cell Technol Grp, Montreal, PQ H4P 2R2, Canada; Cambridge Inst Med Res, Dept Oncol, Cambridge CB2 2XY, England	Universite de Montreal; University of Cambridge	Beliveau, R (corresponding author), Univ Montreal, Hop St Justine, Mol Med Lab, Ctr Canc Charles Bruneau, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	molmed@justine.umontreal.ca	Durocher, Yves/K-8709-2019; Roghi, Christian/F-3228-2012	Roghi, Christian/0000-0002-4109-6382				Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Deryugina EI, 2002, CANCER RES, V62, P580; Duan LJ, 2004, BLOOD, V103, P1370, DOI 10.1182/blood-2003-05-1701; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Ellis V, 2001, FEBS LETT, V506, P1, DOI 10.1016/S0014-5793(01)02845-9; Fielding PE, 2004, BIOCHEMISTRY-US, V43, P2578, DOI 10.1021/bi035442c; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gingras D, 2000, BBA-MOL CELL RES, V1497, P341, DOI 10.1016/S0167-4889(00)00071-9; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Jeong J W, 1999, Angiogenesis, V3, P167, DOI 10.1023/A:1009065709676; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kadono Y, 1998, CANCER RES, V58, P2240; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; Koike T, 2002, J CELL BIOCHEM, V86, P748, DOI 10.1002/jcb.10257; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; Langlois S, 2004, BLOOD, V103, P3020, DOI 10.1182/blood-2003-08-2968; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Liu J, 2002, J BIOL CHEM, V277, P10661, DOI 10.1074/jbc.M110354200; Liu J, 1999, J BIOL CHEM, V274, P15781, DOI 10.1074/jbc.274.22.15781; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Parat MO, 2003, MOL BIOL CELL, V14, P3156, DOI 10.1091/mbc.e02-11-0761; Pham PL, 2003, BIOTECHNOL BIOENG, V84, P332, DOI 10.1002/bit.10774; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sounni NE, 2004, J BIOL CHEM, V279, P13564, DOI 10.1074/jbc.M307688200; Sounni NE, 2002, INT J CANCER, V98, P23, DOI 10.1002/ijc.10134; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Urena JM, 1999, J CELL SCI, V112, P773; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yamamoto M, 1999, EXP CELL RES, V247, P380, DOI 10.1006/excr.1998.4379; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	53	132	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52132	52140		10.1074/jbc.M409617200	http://dx.doi.org/10.1074/jbc.M409617200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466865	hybrid			2022-12-25	WOS:000225493400052
J	Morgan, HD; Dean, W; Coker, HA; Reik, W; Petersen-Mahrt, SK				Morgan, HD; Dean, W; Coker, HA; Reik, W; Petersen-Mahrt, SK			Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues - Implications for epigenetic reprogramming	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-SWITCH RECOMBINATION; SINGLE-STRANDED-DNA; PRIMORDIAL GERM-CELLS; RNA EDITING ENZYME; SOMATIC HYPERMUTATION; MAMMALIAN DEVELOPMENT; ANTIBODY DIVERSIFICATION; GLYCOSYLASE ACTIVITY; PATERNAL GENOME; GENE-EXPRESSION	DNA deaminases of the Aid/Apobec family convert cytosine into uracil and play key roles in acquired and innate immunity. The epigenetic modification by methylation of cytosine in CpG dinucleotides is also mutagenic, but this is thought to occur by spontaneous deamination. Here we show that Aid and Apobec1 are 5-methylcytosine deaminases resulting in a thymine base opposite a guanine. Their action can thus lead to C --> T transition mutations in methylated DNA, or in conjunction with repair of the T:G mismatch, to demethylation. The Aid and Apobec1 genes are located in a cluster of pluripotency genes including Nanog and Stella and are co-expressed with these genes in oocytes, embryonic germ cells, and embryonic stem cells. These results suggest that Aid and perhaps some of its family members may have roles in epigenetic reprogramming and cell plasticity. Transition in CpG dinucleotides is the most frequent mutation in human genetic diseases, and sequence context analysis of CpG transitions in the APC tumor suppressor gene suggests that DNA deaminases may play a significant role in tumor etiology.	Babraham Inst, Lab Dev Genet & Imprinting, Dev Genet Programme, Cambridge CB2 4AT, England; Imperial Canc Res Fund, Clare Hall Labs, DNA Editing Lab, S Mimms EN6 3LD, Herts, England; MRC, Mol Biol Lab, Prot & Nucl Acid Chem Div, Cambridge CB2 2QH, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; MRC Laboratory Molecular Biology	Reik, W (corresponding author), Babraham Inst, Lab Dev Genet & Imprinting, Dev Genet Programme, Cambridge CB2 4AT, England.	wolf.reik@bbsrc.ac.uk	Reik, Wolf/I-6794-2012	Dean, Wendy/0000-0001-9441-5044; Reik, Wolf/0000-0003-0216-9881; Coker, Heather/0000-0001-9570-944X				Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Beroud C, 1996, NUCLEIC ACIDS RES, V24, P121, DOI 10.1093/nar/24.1.121; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Cedar H, 1999, NATURE, V397, P568, DOI 10.1038/17492; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; COHEN SS, 1957, J BIOL CHEM, V226, P631; Dean W, 2001, P NATL ACAD SCI USA, V98, P13734, DOI 10.1073/pnas.241522698; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; Freitag M, 2002, P NATL ACAD SCI USA, V99, P8802, DOI 10.1073/pnas.132212899; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Hardeland U, 2003, NUCLEIC ACIDS RES, V31, P2261, DOI 10.1093/nar/gkg344; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Ito S, 2004, P NATL ACAD SCI USA, V101, P1975, DOI 10.1073/pnas.0307335101; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Lee J, 2002, DEVELOPMENT, V129, P1807; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; LINDAHL T, 1976, NATURE, V259, P64, DOI 10.1038/259064a0; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; McBride KM, 2004, J EXP MED, V199, P1235, DOI 10.1084/jem.20040373; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Payer B, 2003, CURR BIOL, V13, P2110, DOI 10.1016/j.cub.2003.11.026; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Petersen-Mahrt SK, 2003, J BIOL CHEM, V278, P19583, DOI 10.1074/jbc.C300114200; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Poltoratsky VP, 2004, J IMMUNOL, V172, P4308, DOI 10.4049/jimmunol.172.7.4308; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xiao WY, 2003, DEV CELL, V5, P891, DOI 10.1016/S1534-5807(03)00361-7; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yu KF, 2004, J BIOL CHEM, V279, P6496, DOI 10.1074/jbc.M311616200; Zhu B, 2000, P NATL ACAD SCI USA, V97, P5135, DOI 10.1073/pnas.100107597	55	397	440	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52353	52360		10.1074/jbc.M407695200	http://dx.doi.org/10.1074/jbc.M407695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15448152	hybrid			2022-12-25	WOS:000225493400078
J	Nonami, A; Kato, R; Taniguchi, K; Yoshiga, D; Taketomi, T; Fukuyama, S; Harada, M; Sasaki, A; Yoshimura, A				Nonami, A; Kato, R; Taniguchi, K; Yoshiga, D; Taketomi, T; Fukuyama, S; Harada, M; Sasaki, A; Yoshimura, A			Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; INDUCED PROLIFERATION; SPROUTY; RAS; ERYTHROPOIETIN; SUPPRESSES; PATHWAY; ANTAGONIST; RECEPTOR	Sprouty/Spred family proteins have been identified as negative regulators of growth factor-induced ERK/mitogen-activated protein (MAP) kinase activation. However, it has not been clarified whether these proteins regulate cytokine-induced ERK activity. We found that Spred-1 is highly expressed in interleukin-3 (IL-3)-dependent hematopoietic cell lines and bone marrow-derived mast cells. To investigate the roles of Spred-1 in hematopoiesis, we expressed wild-type Spred-1 and a dominant negative form of Spred-1, DeltaC-Spred, in IL-3- and stem cell factor (SCF)-dependent cell lines as well as hematopoietic progenitor cells from mouse bone marrow by retrovirus gene transfer. In IL-3- dependent Ba/F3 cells expressing c-kit, forced expression of Spred-1 resulted in a reduced proliferation rate and ERK activation in response to not only SCF but also IL-3. In contrast, DeltaC-Spred augmented IL-3- induced cell proliferation and ERK activation. Wild-type Spred-1 inhibited colony formation of bone marrow cells in the presence of cytokines, whereas DeltaC-Spred-1 expression enhanced colony formation. Augmentation of ERK activation and proliferation in response to IL-3 was also observed in Spred-1-deficient bone marrow-derived mast cells. These data suggest that Spred-1 negatively regulates hematopoiesis by suppressing not only SCF-induced but also IL-3- induced ERK activation.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med, Dept Internal Med 1, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013; YOSHIGA, Daigo/GZM-9352-2022	YOSHIGA, Daigo/0000-0001-9603-3138; Sasaki, Atsuo/0000-0003-2963-4501				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Fichelson S, 1999, BLOOD, V94, P1601, DOI 10.1182/blood.V94.5.1601.417k19_1601_1613; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; Kerkhoff E, 2001, ADV ENZYME REGUL, V41, P261, DOI 10.1016/S0065-2571(00)00023-6; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; METCALF D, 1977, HEMOPOIETIC COLONIES, P12; Minowada G, 1999, DEVELOPMENT, V126, P4465; Miyoshi K, 2004, ONCOGENE, V23, P5567, DOI 10.1038/sj.onc.1207759; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Nobuhisa I, 2004, J EXP MED, V199, P737, DOI 10.1084/jem.20030830; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; OKUDA K, 1992, BLOOD, V79, P2880; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Reich A, 1999, DEVELOPMENT, V126, P4139; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rojnuckarin P, 2001, J BIOL CHEM, V276, P41014, DOI 10.1074/jbc.M106508200; Sakamoto H, 2000, J BIOL CHEM, V275, P35857, DOI 10.1074/jbc.M006317200; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Secchiero P, 2004, BLOOD, V103, P517, DOI 10.1182/blood-2003-06-2137; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Takaki S, 2002, J EXP MED, V195, P151, DOI 10.1084/jem.20011170; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	47	70	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52543	52551		10.1074/jbc.M405189200	http://dx.doi.org/10.1074/jbc.M405189200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465815	hybrid			2022-12-25	WOS:000225493400100
J	Stewart, AK; Kerr, N; Chernova, MN; Alper, SL; Vaughan-Jones, RD				Stewart, AK; Kerr, N; Chernova, MN; Alper, SL; Vaughan-Jones, RD			Acute pH-dependent regulation of AE2-mediated anion exchange involves discrete local surfaces of the NH2-terminal cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANE BAND-3; CARBONIC-ANHYDRASE-II; INTRACELLULAR PH; HISTIDINE-RESIDUES; EXTRACELLULAR PH; GENE FAMILY; CELL-LINE; AE2; TRANSPORT; CHLORIDE	We have previously defined in the NH2-terminal cytoplasmic domain of the mouse AE2/SLC4A2 anion exchanger a critical role for the highly conserved amino acids (aa) 336-347 in determining wild-type pH sensitivity of anion transport. We have now engineered hexa-Ala ((A)(6)) and individual amino acid substitutions to investigate the importance to pH-dependent regulation of AE2 activity of the larger surrounding region of aa 312-578. 4,4'-Diisothiocyanostilbene-2,2'-disulfonic acid (DIDS)-sensitive Cl-36(-) efflux from AE2-expressing Xenopus oocytes was monitored during changes in pH(i) or pH(o) in HEPES-buffered and in 5% CO2/HCO3--buffered conditions. Wild-type AE2-mediated Cl-36(-) efflux was profoundly inhibited at low pH(o), with a pH(o(50)) value = 6.75 +/- 0.05 and was stimulated up to 10-fold by intracellular alkalinization. Individual mutation of several amino acid residues at non-contiguous sites preceding or following the conserved sequence aa 336-347 attenuated pHi and/or pHo sensitivity of Cl-36(-) efflux. The largest attenuation of pH sensitivity occurred with the AE2 mutant (A)(6)357-362. This effect was phenocopied by AE2 H360E, suggesting a crucial role for His(360). Homology modeling of the three-dimensional structure of the AE2 NH2-terminal cytoplasmic domain (based on the structure of the corresponding region of human AE1) predicts that those residues shown by mutagenesis to be functionally important define at least one localized surface region necessary for regulation of AE2 activity by pH.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Mol & Vasc Med Unit, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Renal Unit, Boston, MA 02215 USA; Univ Oxford, Physiol Lab, Burdon Sanderson Cardiac Sci Ctr, Oxford OX1 3PT, England	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Oxford	Alper, SL (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Mol & Vasc Med Unit, RW763 E Campus,330 Brookline Ave, Boston, MA 02215 USA.	salper@caregroup.harvard.edu			PHS HHS [34854, 43495] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alper SL, 2002, J NEPHROL, V15, pS41; ALPER SL, 1994, CELL PHYSIOL BIOCHEM, V4, P265, DOI 10.1159/000154730; Bevensee M. O., 2000, KIDNEY PHYSL PATHOPH, P391; Ch'en FFT, 2003, J PHYSIOL-LONDON, V552, P715, DOI 10.1113/jphysiol.2003.051888; Cha B, 2003, J MEMBRANE BIOL, V191, P49, DOI 10.1007/s00232-002-1044-2; Chanchevalap S, 2000, J BIOL CHEM, V275, P7811, DOI 10.1074/jbc.275.11.7811; Chang SH, 2003, J BIOL CHEM, V278, P6879, DOI 10.1074/jbc.M211137200; Chernova MN, 1997, BBA-BIOMEMBRANES, V1329, P111, DOI 10.1016/S0005-2736(97)00090-4; Chernova MN, 2003, AM J PHYSIOL-CELL PH, V284, pC1235, DOI 10.1152/ajpcell.00522.2002; Chow CW, 1999, J BIOL CHEM, V274, P10481, DOI 10.1074/jbc.274.15.10481; Flagg TP, 2002, J PHYSIOL-LONDON, V544, P351, DOI 10.1113/jphysiol.2002.027581; FUNDER J, 1976, J PHYSIOL-LONDON, V262, P679, DOI 10.1113/jphysiol.1976.sp011615; Gowen JA, 2002, BIOPHYS J, V83, P880, DOI 10.1016/S0006-3495(02)75215-6; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HUMPHREYS BD, 1994, AM J PHYSIOL-CELL PH, V267, pC1295, DOI 10.1152/ajpcell.1994.267.5.C1295; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; Jennings ML, 1992, KIDNEY PHYSL PATHOPH, P113; JIANG LW, 1994, AM J PHYSIOL, V267, pC845, DOI 10.1152/ajpcell.1994.267.3.C845; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; Kumar S, 2002, BIOPHYS J, V83, P1595, DOI 10.1016/S0006-3495(02)73929-5; LEE BS, 1991, J BIOL CHEM, V266, P11448; Leem CH, 1999, J PHYSIOL-LONDON, V517, P159, DOI 10.1111/j.1469-7793.1999.0159z.x; Morton MJ, 2003, PFLUG ARCH EUR J PHY, V445, P577, DOI 10.1007/s00424-002-0901-2; Parker MD, 2001, BIOCHEM BIOPH RES CO, V282, P1103, DOI 10.1006/bbrc.2001.4692; REINERTSEN KV, 1988, J BIOL CHEM, V263, P11117; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Stewart AK, 2003, J AM SOC NEPHROL, V14, p304A; Stewart AK, 2002, J GEN PHYSIOL, V120, P707, DOI 10.1085/jgp.20028641; Stewart AK, 2001, AM J PHYSIOL-CELL PH, V281, pC1344, DOI 10.1152/ajpcell.2001.281.4.C1344; VAUGHANJONES RD, 1979, J PHYSIOL-LONDON, V295, P111, DOI 10.1113/jphysiol.1979.sp012957; VAUGHANJONES RD, 1986, J PHYSIOL-LONDON, V379, P377, DOI 10.1113/jphysiol.1986.sp016259; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Wakabayashi S, 2003, J BIOL CHEM, V278, P11828, DOI 10.1074/jbc.M213243200; Weeks DL, 2004, J BIOL CHEM, V279, P9944, DOI 10.1074/jbc.M312680200; Zhang DC, 2000, BLOOD, V96, P2925; Zhang Y, 1996, J BIOL CHEM, V271, P5741, DOI 10.1074/jbc.271.10.5741	37	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52664	52676		10.1074/jbc.M408108200	http://dx.doi.org/10.1074/jbc.M408108200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452108	hybrid			2022-12-25	WOS:000225493400113
J	Wang, JL; Julin, DA				Wang, JL; Julin, DA			DNA helicase activity of the RecD protein from Deinococcus radiodurans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BACTERIOPHAGE-T4 DDA HELICASE; ESCHERICHIA-COLI; RECBCD ENZYME; CHLAMYDIA-TRACHOMATIS; IONIZING-RADIATION; SACCHAROMYCES-CEREVISIAE; GENOME SEQUENCE; BINDING-PROTEIN; IN-VITRO	The bacterium Deinococcus radiodurans is extremely resistant to high levels of DNA-damaging agents, including gamma rays and ultraviolet light that can lead to double-stranded DNA breaks. Surprisingly, the organism does not appear to have a RecBCD enzyme, an enzyme that is critical for double-strand break repair in many other bacteria. The D. radiodurans genome does encode a protein whose closest characterized homologues are RecD subunits of RecBCD enzymes in other bacteria. We have purified this novel D. radiodurans RecD protein and characterized its biochemical activities. The D. radiodurans RecD protein is a DNA helicase that unwinds short ( 20 base pairs) DNA duplexes with either a 5'-single-stranded tail or a forked end, but not blunt-ended or 3'-tailed duplexes. Duplexes with 10 - 12 nucleotide (nt) 5'-tails are good unwinding substrates and are bound tightly, while DNA with shorter tails ( 4 - 8 nt) are poor unwinding substrates and are bound much less tightly. The RecD protein is much less efficient at unwinding slightly longer substrates ( 52 or 76 base pairs, with 12 nt 5'-tails). Unwinding of the longer substrates is stimulated somewhat ( 4 - 5-fold) by the single-stranded DNA-binding protein from D. radiodurans. These results show that the D. radiodurans RecD protein is a DNA helicase with 5'-3' polarity and low processivity.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Julin, DA (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.	dj13@umail.umd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039777, R01GM039777] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39777] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AltMorbe J, 1996, J BACTERIOL, V178, P4248, DOI 10.1128/jb.178.14.4248-4257.1996; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMUNDSEN SK, 1990, GENETICS, V126, P25; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; Battista JR, 1999, TRENDS MICROBIOL, V7, P362, DOI 10.1016/S0966-842X(99)01566-8; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; Belland RJ, 2003, P NATL ACAD SCI USA, V100, P8478, DOI 10.1073/pnas.1331135100; Bessler JB, 2001, TRENDS CELL BIOL, V11, P60, DOI 10.1016/S0962-8924(00)01877-8; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Bianco PR, 2000, NATURE, V405, P368, DOI 10.1038/35012652; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Byrd DR, 1997, MOL MICROBIOL, V25, P1011, DOI 10.1046/j.1365-2958.1997.5241885.x; CHAUDHURY AM, 1984, J BACTERIOL, V160, P788, DOI 10.1128/JB.160.2.788-791.1984; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; Chedin F, 2002, MOL MICROBIOL, V43, P823, DOI 10.1046/j.1365-2958.2002.02785.x; Chen HW, 1997, J BIOL CHEM, V272, P10072; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Churchill JJ, 1999, GENE DEV, V13, P901, DOI 10.1101/gad.13.7.901; Courcelle J, 2001, GENETICS, V158, P41; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; Edwards JS, 2003, TRENDS BIOTECHNOL, V21, P381, DOI 10.1016/S0167-7799(03)00196-3; Eggington JM, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-2; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GUTMAN PD, 1994, GENE, V141, P31, DOI 10.1016/0378-1119(94)90124-4; Haft DH, 2003, NUCLEIC ACIDS RES, V31, P371, DOI 10.1093/nar/gkg128; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Ivessa AS, 2003, MOL CELL, V12, P1525, DOI 10.1016/S1097-2765(03)00456-8; Ivessa AS, 2002, GENE DEV, V16, P1383, DOI 10.1101/gad.982902; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; Kim JI, 2002, J BACTERIOL, V184, P1649, DOI 10.1128/JB.184.6.1649-1660.2002; KORANGY F, 1992, J BIOL CHEM, V267, P3088; KORANGY F, 1993, BIOCHEMISTRY-US, V32, P4873, DOI 10.1021/bi00069a024; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P5346, DOI 10.1021/bi00521a040; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; LAHAYE A, 1993, J BIOL CHEM, V268, P26155; LENNON E, 1990, J BACTERIOL, V172, P2955, DOI 10.1128/jb.172.6.2955-2961.1990; Lipton MS, 2002, P NATL ACAD SCI USA, V99, P11049, DOI 10.1073/pnas.172170199; Liu YQ, 2003, P NATL ACAD SCI USA, V100, P4191, DOI 10.1073/pnas.0630387100; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Nanduri B, 2001, NUCLEIC ACIDS RES, V29, P2829, DOI 10.1093/nar/29.13.2829; Noirot-Gros MF, 2002, MOL GENET GENOMICS, V267, P391, DOI 10.1007/s00438-002-0670-9; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Phillips RJ, 1997, MOL GEN GENET, V254, P319, DOI 10.1007/PL00008605; RANEY KD, 1995, J BIOL CHEM, V270, P22236, DOI 10.1074/jbc.270.38.22236; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; Sambrook J, 1989, MOL CLONING LAB MANU, V2; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Tada S, 2001, NUCLEIC ACIDS RES, V29, P3835, DOI 10.1093/nar/29.18.3835; Taneja P, 2002, J BIOL CHEM, V277, P40853, DOI 10.1074/jbc.M208067200; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Taylor AF, 2003, NATURE, V423, P889, DOI 10.1038/nature01674; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571	64	34	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52024	52032		10.1074/jbc.M408645200	http://dx.doi.org/10.1074/jbc.M408645200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466873	hybrid			2022-12-25	WOS:000225493400039
J	Kao, WC; Chen, YR; Yi, EC; Lee, H; Tian, Q; Wu, KM; Tsai, SF; Yu, SSF; Chen, YJ; Aebersold, R; Chan, SI				Kao, WC; Chen, YR; Yi, EC; Lee, H; Tian, Q; Wu, KM; Tsai, SF; Yu, SSF; Chen, YJ; Aebersold, R; Chan, SI			Quantitative proteomic analysis of metabolic regulation by copper ions in Methylococcus capsulatus (Bath)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICULATE METHANE MONOOXYGENASE; METHYLOBACTERIUM-EXTORQUENS AM1; TANDEM MASS-SPECTROMETRY; METHANOTROPHIC BACTERIA; NUCLEOTIDE-SEQUENCE; STATISTICAL-MODEL; PROTEIN DATABASE; GENERATION; CLONING; SEARCH	Copper ions switch the oxidation of methane by soluble methane monooxygenase to particulate methane monooxygenase in Methylococcus capsulatus ( Bath). Toward understanding the change in cellular metabolism related to this transcriptional and metabolic switch, we have undertaken genomic sequencing and quantitative comparative analysis of the proteome in M. capsulatus ( Bath) grown under different copper-to-biomass ratios by cleavable isotope-coded affinity tag technology. Of the 682 proteins identified, the expressions of 60 proteins were stimulated by at least 2-fold by copper ions; 68 proteins were down-regulated by 2-fold or more. The 60 proteins overexpressed included the methane and carbohydrate metabolic enzymes, while the 68 proteins suppressed were mainly responsible for cellular signaling processes, indicating a role of copper ions in the expression of the genes associated with the metabolism of the organism downstream of methane oxidation. The study has also provided a complete	Acad Sinica, Inst Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 106, Taiwan; Inst Syst Biol, Seattle, WA 98103 USA; Natl Yang Ming Univ, Inst Genet & Genome Res Ctr, Taipei 112, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Institute for Systems Biology (ISB); National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan	Chan, SI (corresponding author), Acad Sinica, Inst Chem, 128 Academia Rd,Sect 2, Taipei 115, Taiwan.	chans@chem.sinica.edu.tw	Chen, Yu-Ju/E-9481-2015; Tsai, Shih-Feng/E-3997-2010; Chan, Sunney I/F-2017-2015; Yu, Steve Sheng-Fa/E-4866-2015; Kao, Wei-Chun/AAJ-4068-2020	Chen, Yu-Ju/0000-0002-3178-6697; Yu, Steve Sheng-Fa/0000-0002-3462-065X; Kao, Wei-Chun/0000-0001-8687-6334; Lee, Hookeun/0000-0002-0696-8421				Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON DJ, 1990, GENE, V90, P173, DOI 10.1016/0378-1119(90)90457-3; ANTHONY C, 1982, BIOCH METHYLOTROPHS, P296; Baxter NJ, 2002, ARCH MICROBIOL, V177, P279, DOI 10.1007/s00203-001-0387-x; Chan SI, 2004, BIOCHEMISTRY-US, V43, P4421, DOI 10.1021/bi0497603; Chistoserdova L, 2003, J BACTERIOL, V185, P2980, DOI 10.1128/JB.185.10.2980-2987.2003; Cooper G, 2001, NATURE, V414, P879, DOI 10.1038/414879a; Csaki R, 2003, MICROBIOL-SGM, V149, P1785, DOI 10.1099/mic.0.26061-0; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fjellbirkeland A, 2001, ARCH MICROBIOL, V176, P197, DOI 10.1007/s002030100307; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; Hulo N, 2004, NUCLEIC ACIDS RES, V32, pD134, DOI 10.1093/nar/gkh044; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kerr RA, 2004, SCIENCE, V303, P1953, DOI 10.1126/science.303.5666.1953; Li JX, 2003, MOL CELL PROTEOMICS, V2, P1198, DOI 10.1074/mcp.M300070-MCP200; Li XJ, 2003, ANAL CHEM, V75, P6648, DOI 10.1021/ac034633i; MARK AS, 2001, NATURE, V414, P857; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Pomper BK, 2002, FEBS LETT, V523, P133, DOI 10.1016/S0014-5793(02)02962-9; QUAYLE JR, 1978, MICROBIOL REV, V42, P251, DOI 10.1128/MMBR.42.2.251-273.1978; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Stolyar S, 1999, MICROBIOL-UK, V145, P1235, DOI 10.1099/13500872-145-5-1235; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; TAKAGI M, 1990, J BACTERIOL, V172, P411, DOI 10.1128/JB.172.1.411-418.1990; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; TROTSENKO YA, 2001, MIKROBIOLOGIYA, V70, P725; Vorholt JA, 1999, J BACTERIOL, V181, P5750, DOI 10.1128/JB.181.18.5750-5757.1999; Whittington DA, 2001, J AM CHEM SOC, V123, P827, DOI 10.1021/ja003240n; Xiong JJ, 2000, BIOCHEMISTRY-US, V39, P5117, DOI 10.1021/bi992796o; YI EC, 2004, CURRENT PROTOCOL PRO; Yu SSF, 2003, J BACTERIOL, V185, P5915, DOI 10.1128/JB.185.20.5915-5924.2003	36	70	79	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51554	51560		10.1074/jbc.M408013200	http://dx.doi.org/10.1074/jbc.M408013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385566	hybrid, Green Published			2022-12-25	WOS:000225355800110
J	Yoshida, M; Aizawa, T; Nakamura, T; Shitara, K; Hayakawa, Y; Matsubara, K; Miura, K; Kouno, T; Clark, KD; Strand, MR; Mizuguchi, M; Demura, M; Nitta, K; Kawano, K				Yoshida, M; Aizawa, T; Nakamura, T; Shitara, K; Hayakawa, Y; Matsubara, K; Miura, K; Kouno, T; Clark, KD; Strand, MR; Mizuguchi, M; Demura, M; Nitta, K; Kawano, K			The Gly-Gly linker region of the insect cytokine growth-blocking peptide is essential for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMATOCYTE-SPREADING PEPTIDE; NUCLEAR-MAGNETIC-RESONANCE; MODEL-FREE APPROACH; BIOLOGICAL-ACTIVITY; PARALYTIC PEPTIDES; HEMOLYMPH; RELAXATION; RESIDUES; NMR; MACROMOLECULES	Growth-blocking peptide (GBP) is a 25-amino acid cytokine isolated from the lepidopteran insect Pseudaletia separata. GBP exhibits various biological activities such as regulation of larval growth of insects, proliferation of a few kinds of cultured cells, and stimulation of a class of insect immune cells called plasmatocytes. The tertiary structure of GBP consists of a well structured core domain and disordered N and C termini. Our previous studies revealed that, in addition to the structured core, specific residues in the unstructured N-terminal region (Glu1 and Phe(3)) are also essential for the plasmatocyte-stimulating activity. In this study, a number of deletion, insertion, and site-directed mutants targeting the unstructured N-terminal residues of GBP were constructed to gain more detailed insight into the mode of interaction between the N-terminal region and GBP receptor. Alteration of the backbone length of the linker region between the core structure and N-terminal domain reduced plasmatocyte-stimulating activity. The substitutions of Gly(5) or Gly(6) in this linker region with more bulky residues, such as Phe and Pro, also remarkably reduced this activity. We conclude that the interaction of GBP with its receptor depends on the relative position of the N-terminal domain to the core structure, and therefore the backbone flexibility of Gly residues in the linker region is necessary for adoption of a proper conformation suited to receptor binding. Additionally, antagonistic experiments using deletion mutants confirmed that not only the core domain but also the N-terminal region of GBP are required for "receptor-binding," and furthermore Phe(3) is a binding determinant of the N-terminal domain.	Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Saga Univ, Dept Agr, Saga 8408502, Japan; Univ Georgia, Dept Entomol, Athens, GA 30602 USA	University of Toyama; Hokkaido University; Saga University; University System of Georgia; University of Georgia	Kawano, K (corresponding author), Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan.	kawano@sci.hokudai.ac.jp	Kawano, Keiichi/F-5265-2011; Demura, Makoto/F-5272-2011; Clark, Kevin/GQA-9811-2022; Aizawa, Tomoyasu/F-5278-2011	Demura, Makoto/0000-0003-0912-9284; Aizawa, Tomoyasu/0000-0001-9134-7576				Aizawa T, 2001, J BIOL CHEM, V276, P31813, DOI 10.1074/jbc.M105251200; Aizawa T, 1999, J BIOL CHEM, V274, P1887, DOI 10.1074/jbc.274.4.1887; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 2001, J BIOL CHEM, V276, P37431, DOI 10.1074/jbc.M105235200; Clark KD, 2001, J BIOL CHEM, V276, P18491, DOI 10.1074/jbc.M100579200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Furuya K, 1999, PEPTIDES, V20, P53, DOI 10.1016/S0196-9781(98)00148-X; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Ha SD, 1999, PEPTIDES, V20, P561, DOI 10.1016/S0196-9781(99)00008-X; Hayakawa Y, 1998, BIOCHEM BIOPH RES CO, V250, P194, DOI 10.1006/bbrc.1998.8959; HAYAKAWA Y, 1995, J INSECT PHYSIOL, V41, P1, DOI 10.1016/0022-1910(94)00077-T; HAYAKAWA Y, 1990, J BIOL CHEM, V265, P10813; HAYAKAWA Y, 1991, J BIOL CHEM, V266, P7982; HAYAKAWA Y, 1994, J BIOCHEM-TOKYO, V115, P15, DOI 10.1093/oxfordjournals.jbchem.a124291; HAYAKAWA Y, 1993, INSECT BIOCHEM MOLEC, V23, P225, DOI 10.1016/0965-1748(93)90003-B; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Mine S, 1999, J MOL BIOL, V286, P1547, DOI 10.1006/jmbi.1999.2572; Ohnishi A, 2001, J BIOL CHEM, V276, P37974; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PARMER AG, 1991, J AM CHEM SOC, V133, P4371; PIATTO M, 1992, J BIOMOL NMR, V2, P661; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Seino Atsushi, 1998, Journal of Sericultural Science of Japan, V67, P473; SKINNER WS, 1991, J BIOL CHEM, V266, P12873; SKINNER WS, 1993, COMP BIOCHEM PHYS C, V104, P133, DOI 10.1016/0742-8413(93)90124-4; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; Tada M, 2003, J BIOL CHEM, V278, P10778, DOI 10.1074/jbc.M211251200	30	6	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51331	51337		10.1074/jbc.M409382200	http://dx.doi.org/10.1074/jbc.M409382200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385535	hybrid			2022-12-25	WOS:000225355800083
J	Atkins, AR; Gallin, WJ; Owens, GC; Edelman, GM; Cunningham, BA				Atkins, AR; Gallin, WJ; Owens, GC; Edelman, GM; Cunningham, BA			Neural cell adhesion molecule (N-CAM) homophilic binding mediated by the two N-terminal Ig domains is influenced by intramolecular domain-domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; STRUCTURAL BASIS; INTEGRIN RECOGNITION; EXTRACELLULAR DOMAIN; POLYSIALIC ACID; NCAM; MECHANISM; SURFACE; SUPERFAMILY; RECEPTOR	The mechanism by which the neural cell adhesion molecule, N-CAM, mediates homophilic interactions between cells has been variously attributed to an isologous interaction of the third immunoglobulin (Ig) domain, to reciprocal binding of the two N-terminal Ig domains, or to reciprocal interactions of all five Ig domains. Here, we have used a panel of recombinant proteins in a bead binding assay, as well as transfected and primary cells, to clarify the molecular mechanism of N-CAM homophilic binding. The entire extracellular region of N-CAM mediated bead aggregation in a concentration- and temperature-dependent manner. Interactions of the N-terminal Ig domains, Ig1 and Ig2, were essential for bead binding, based on deletion and mutation experiments and on antibody inhibition studies. These findings were largely in accord with aggregation experiments using transfected L cells or primary chick brain cells. Additionally, maximal binding was dependent on the integrity of the intramolecular domain-domain interactions throughout the extracellular region. We propose that these interactions maintain the relative orientation of each domain in an optimal configuration for binding. Our results suggest that the role of Ig3 in homophilic binding is largely structural. Several Ig3-specific reagents failed to affect N-CAM binding on beads or on cells, while an inhibitory effect of an Ig3-specific monoclonal antibody is probably due to perturbations at the Ig2-Ig3 boundary. Thus, it appears that reciprocal interactions between Ig1 and Ig2 are necessary and sufficient for N-CAM homophilic binding, but that maximal binding requires the quaternary structure of the extracellular region defined by intramolecular domain-domain interactions.	Scripps Res Inst, Dept Neurobiol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Inst Neurosci, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; University of Alberta	Cunningham, BA (corresponding author), Scripps Res Inst, Dept Neurobiol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bcunning@scripps.edu		Atkins, Annette/0000-0003-2558-7058	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016550, R37HD009635, R01HD009635] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16550, HD09635] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Atkins AR, 1999, FEBS LETT, V451, P162, DOI 10.1016/S0014-5793(99)00554-2; Atkins AR, 2001, J MOL BIOL, V311, P161, DOI 10.1006/jmbi.2001.4861; Bateman A, 1996, EMBO J, V15, P6050, DOI 10.1002/j.1460-2075.1996.tb00993.x; BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; BERTOLOTTI R, 1980, P NATL ACAD SCI-BIOL, V77, P4831, DOI 10.1073/pnas.77.8.4831; BRACKENBURY R, 1981, P NATL ACAD SCI-BIOL, V78, P387, DOI 10.1073/pnas.78.1.387; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Chen YT, 1996, ANAL BIOCHEM, V242, P276, DOI 10.1006/abio.1996.0466; Crossin KL, 2000, DEV DYNAM, V218, P260, DOI 10.1002/(SICI)1097-0177(200006)218:2<260::AID-DVDY3>3.0.CO;2-9; CUNNINGHAM BA, 1983, P NATL ACAD SCI-BIOL, V80, P3116, DOI 10.1073/pnas.80.10.3116; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; Freigang J, 2000, CELL, V101, P425, DOI 10.1016/S0092-8674(00)80852-1; GERARDYSCHAHN R, 1994, INT J CANCER, P38; HALL AK, 1987, J CELL BIOL, V104, P1579, DOI 10.1083/jcb.104.6.1579; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; Johnson CP, 2004, P NATL ACAD SCI USA, V101, P6963, DOI 10.1073/pnas.0307567100; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; Kiselyov VV, 2003, STRUCTURE, V11, P691, DOI 10.1016/S0969-2126(03)00096-0; LECKBAND DE, 1992, SCIENCE, V255, P1419, DOI 10.1126/science.1542789; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; Owens GC, 1998, CANCER RES, V58, P2020; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Pierres A, 1998, CELL ADHES COMMUN, V5, P375, DOI 10.3109/15419069809010783; Pierres A, 1997, FEBS LETT, V403, P239, DOI 10.1016/S0014-5793(97)00060-4; Polo-Parada L, 2004, J NEUROSCI, V24, P1852, DOI 10.1523/JNEUROSCI.4406-03.2004; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RAO Y, 1994, J BIOL CHEM, V269, P27540; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Soroka V, 2003, STRUCTURE, V11, P1291, DOI 10.1016/j.str.2003.09.006; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Suzuki M, 2003, J BIOL CHEM, V278, P49459, DOI 10.1074/jbc.M308316200; Tan K, 1998, STRUCTURE, V6, P793, DOI 10.1016/S0969-2126(98)00080-X; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x; Zhu B, 2003, BIOPHYS J, V84, P4033, DOI 10.1016/S0006-3495(03)75129-7	41	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49633	49643		10.1074/jbc.M409159200	http://dx.doi.org/10.1074/jbc.M409159200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15381695	hybrid			2022-12-25	WOS:000225229500013
J	Morishima, N; Nakanishi, K; Tsuchiya, K; Shibata, T; Seiwa, E				Morishima, N; Nakanishi, K; Tsuchiya, K; Shibata, T; Seiwa, E			Translocation of bim to the endoplasmic reticulum (ER) mediates ER stress signaling for activation of caspase-12 during ER stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; CELL-DEATH; BH3-ONLY PROTEINS; MITOCHONDRIAL DYSFUNCTION; BAX; MECHANISMS; RECEPTORS; BCL-X(L); PATHWAYS	Endoplasmic reticulum (ER) stress activates caspase-12 in murine cells, triggering the ER stress-specific cascade for implementation of apoptosis. In C2C12 murine myoblast cells, activation of the cascade occurs without release of cytochrome c from mitochondria, suggesting that the cascade is independent of mitochondrial damage. Stable overexpression of Bcl-xL in C2C12 cells suppressed activation of caspase-12 and apoptosis. In ER-stressed cells, but not in normal cells, Bcl-xL was co-immunoprecipitated with Bim, a pro-apoptotic member of the Bcl-2 family, suggesting that Bcl-xL sequesters Bim, thereby inhibiting the apoptotic signaling. Fractionation of C2C12 cells revealed that ER stress led to translocation of Bim from a dynein-rich compartment to the ER, while stable overexpression of Bcl-xL suppressed accumulation of Bim on the ER. Although the toxic effect of Bim had been previously observed only at the mitochondrial outer membrane, overexpression of a Bim derivative, Bim(ER), targeted at the surface of the ER led to apoptosis. A C2C12 transfectant overexpressing the caspase-12 suppressor protein was resistant to Bim(ER), suggesting that the toxic effect of Bim on the ER is dependent on activation of caspase-12. Knockdown of Bim by RNA interference provided cells resistant to ER stress. These results suggest that translocation of Bim to the ER in response to ER stress is an important step toward activation of caspase-12 and initiation of the ER stress-specific caspase cascade.	RIKEN, Inst Phys & Chem Res, Bioarchitect Res Grp, Wako, Saitama 3510198, Japan; RIKEN, Inst Phys & Chem Res, Cellular & Mol Biol Lab, Wako, Saitama 3510198, Japan; Saitama Univ, Dept Mol Biol, Fac Sci & Engn, Saitama 3388570, Japan	RIKEN; RIKEN; Saitama University	Morishima, N (corresponding author), RIKEN, Inst Phys & Chem Res, Bioarchitect Res Grp, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	morishim@postman.riken.jp	Morishima, Nobuhiro/D-3946-2017; Nakanishi, Keiko/B-9963-2013					Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Mehmet H, 2000, NATURE, V403, P29, DOI 10.1038/47377; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Ron D, 2002, J CLIN INVEST, V109, P443, DOI 10.1172/JC1200215020; Rudner J, 2001, J CELL SCI, V114, P4161; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	42	152	164	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50375	50381		10.1074/jbc.M408493200	http://dx.doi.org/10.1074/jbc.M408493200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15452118	hybrid			2022-12-25	WOS:000225229500102
J	Dai, JL; Wang, L; Sahin, AA; Broemeling, LD; Schutte, M; Pan, Y				Dai, JL; Wang, L; Sahin, AA; Broemeling, LD; Schutte, M; Pan, Y			NHERF (Na+/H+ Exchanger Regulatory Factor) gene mutations in human breast cancer	ONCOGENE			English	Article						spleen tyrosine kinase; NHERF; breast cancer; mutation; merlin; haploinsufficiency	TYROSINE KINASE; ALLELIC IMBALANCE; TUMOR; HAPLOINSUFFICIENCY; EZRIN; SYK; CARCINOGENESIS; SUPPRESSES; DELETION; REGIONS	Yeast two-hybrid screening was used to explore novel proteins that interact with a breast tumor or metastasis suppressor, SYK (spleen tyrosine kinase). The screening yielded NHERF (Na+/H+ exchanger regulatory factor, also known as NHERF1 or EBP-50) that binds to the interdomain B of SYK. NHERF is an estrogen-responsive gene that encodes an inhibitory factor for epithelial Na+/H+ exchanger isoform 3 (NHE3). We found intragenic mutation of the NHERF gene accompanied by loss of heterzygosity (LOH) in similar to3% (3/85) of breast cancer cell lines and primary breast tumors. Mutations occurred at the conserved PDZ domains at NHERF NH2-terminus that bound to SYK, or at its COOH-terminus motif that binds to MERLIN, the product of Neurofibromatosis 2 (NF2) tumor suppressor gene. NHERF tumorigenic mutations decreased or abolished its interaction with SYK or MERLIN, suggesting a pathway link among these three molecules that may play a critical role in mammary neoplastic progression. Primary breast tumors with LOH at the NHERF locus had clinical presentations of higher aggressiveness, indicating that deregulated NHERF signaling may be associated with disease progression. Moreover, the LOH was inversely correlated with SYK promoter methylation, suggesting that NHERF and SYK may transduce a common suppressive signal. Taken together, the results indicated NHERF to be a candidate tumor suppressor gene in human breast carcinoma that may be interconnected to the SYK and MERLIN suppressors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Erasmus MC, Josephine Nefkens Inst, Dept Med Oncol, Rotterdam, Netherlands	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Erasmus University Rotterdam; Erasmus MC	Dai, JL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Unit 089,1515 Holcombe Blvd, Houston, TX 77030 USA.	jldai@mdanderson.org			NCI NIH HHS [R01 CA100278] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100278] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Bartkova J, 1996, CANCER RES, V56, P5475; Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; COUCH FJ, 2002, GENETIC BASIS HUMAN, P549; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Harkes IC, 2003, BRIT J CANCER, V89, P2289, DOI 10.1038/sj.bjc.6601448; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LUPULESCU A, 1993, EXP CLIN ENDOCRINOL, V101, P204, DOI 10.1055/s-0029-1211234; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Orsetti B, 1999, ONCOGENE, V18, P6262, DOI 10.1038/sj.onc.1203006; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; RADFORD DM, 1995, CANCER RES, V55, P3399; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; REIFENBERGER G, 1993, CANCER RES, V53, P2736; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Srivastava M, 2003, P NATL ACAD SCI USA, V100, P14287, DOI 10.1073/pnas.2235927100; Staff S, 2003, CANCER RES, V63, P4978; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Wang L, 2003, CANCER RES, V63, P4724; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2003, FEBS LETT, V536, P141, DOI 10.1016/S0014-5793(03)00043-7; YAEGASHI S, 1995, JPN J CANCER RES, V86, P929, DOI 10.1111/j.1349-7006.1995.tb03003.x; Yuan YF, 2001, CANCER RES, V61, P5558	38	74	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8681	8687		10.1038/sj.onc.1207962	http://dx.doi.org/10.1038/sj.onc.1207962			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467753				2022-12-25	WOS:000224988800014
J	Sorensen, TLM; Clausen, JD; Jensen, AML; Vilsen, B; Moller, JV; Andersen, JP; Nissen, P				Sorensen, TLM; Clausen, JD; Jensen, AML; Vilsen, B; Moller, JV; Andersen, JP; Nissen, P			Localization of a K+-binding site involved in dephosphorylation of the sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; INTRAMOLECULAR COMMUNICATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; A-DOMAIN; TRANSPORT; CA2+; DISSOCIATION; ACTIVATION; MECHANISM	K+ plays an important role for the function of the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA), but its binding site within the molecule has remained unidentified. We have located the binding site for a K+ ion in the P-domain by means of x-ray crystallography using crystals prepared in the presence of the K+ congener Rb+. Backbone carbonyls from the loop containing residues 711-715 together with the side chain of Glu(732) define the K+/Rb+ site in the Ca2+-ATPase conformation with bound Ca2+, ADP, and AlF4-. Functional analysis of Ca2+-ATPase mutants with alterations to Glu(732) shows that this site is indeed important for the stimulatory effect of K+ on the dephosphorylation rate. Comparison with the Ca2+-ATPase in a dephosphorylated E2 conformation suggests that the K+ site is involved in the correct movement and positioning of the A-domain during translocation and dephosphorylation.	Univ Aarhus, Dept Biophys, Inst Physiol & Biophys, DK-8000 Aarhus C, Denmark; Univ Aarhus, Ctr Struct Biol, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University; Aarhus University	Moller, JV (corresponding author), Univ Aarhus, Dept Biophys, Inst Physiol & Biophys, Ole Worms Alle 158, DK-8000 Aarhus C, Denmark.	jvm@biophys.au.dk; jpa@fi.au.dk; nissen@bioxray.dk	Nissen, Poul/D-5774-2014; Sørensen, Thomas Lykke-Møller/AAA-7052-2020	Vilsen, Bente/0000-0002-4727-9382; Lund Winther, Anne-Marie/0000-0002-5776-0989; Sorensen, Thomas Lykke-Moller/0000-0003-3873-3499; Nissen, Poul/0000-0003-0948-6628; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buoninsegni FT, 2004, BIOPHYS J, V86, P3671, DOI 10.1529/biophysj.103.036608; Champeil P, 1997, BIOCHEMISTRY-US, V36, P12383, DOI 10.1021/bi9709699; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; LEE AG, 1995, BIOCHEM J, V305, P225, DOI 10.1042/bj3050225; Lenoir G, 2004, J BIOL CHEM, V279, P9156, DOI 10.1074/jbc.M311411200; MEIS LD, 1971, J BIOL CHEM, V246, P4759; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Montigny C, 2004, J BIOL CHEM, V279, P43971, DOI 10.1074/jbc.M407142200; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SHIGEKAWA M, 1976, J BIOL CHEM, V251, P6947; SHIGEKAWA M, 1985, J BIOL CHEM, V260, P1679; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VARA F, 1982, J BIOL CHEM, V257, P2826; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330	27	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46355	46358		10.1074/jbc.C400414200	http://dx.doi.org/10.1074/jbc.C400414200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15383548	hybrid			2022-12-25	WOS:000224832400002
J	Kirilovsky, D; Roncel, M; Boussac, A; Wilson, A; Zurita, JL; Ducruet, JM; Bottin, H; Sugiura, M; Ortega, JM; Rutherford, AW				Kirilovsky, D; Roncel, M; Boussac, A; Wilson, A; Zurita, JL; Ducruet, JM; Bottin, H; Sugiura, M; Ortega, JM; Rutherford, AW			Cytochrome c(550) in the cyanobacterium Thermosynechococcus elongatus - Study of redox mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; EVOLVING PHOTOSYSTEM-II; PHOTOSYNTHETIC OXYGEN EVOLUTION; SP. PCC 6803; SYNECHOCOCCUS-ELONGATUS; THERMOLUMINESCENCE BANDS; PHOTOCHEMICAL ACTIVITY; ISOLATED CHLOROPLASTS; DELETION MUTAGENESIS; ANGSTROM RESOLUTION	Cytochrome c(550) is one of the extrinsic Photosystem II subunits in cyanobacteria and red algae. To study the possible role of the heme of the cytochrome c(550) we constructed two mutants of Thermosynechococcus elongatus in which the residue His-92, the sixth ligand of the heme, was replaced by a Met or a Cys in order to modify the redox properties of the heme. The H92M and H92C mutations changed the midpoint redox potential of the heme in the isolated cytochrome by +125 mV and -30 mV, respectively, compared with the wild type. The binding-induced increase of the redox potential observed in the wild type and the H92C mutant was absent in the H92M mutant. Both modified cytochromes were more easily detachable from the Photosystem II compared with the wild type. The Photosystem II activity in cells was not modified by the mutations suggesting that the redox potential of the cytochrome c(550) is not important for Photosystem II activity under normal growth conditions. A mutant lacking the cytochrome c(550) was also constructed. It showed a lowered affinity for Cl- and Ca2+ as reported earlier for the cytochrome c(550)-less Synechocystis 6803 mutant, but it showed a shorter lived S(2)Q(B)(-) state, rather than a stabilized S-2 state and rapid deactivation of the enzyme in the dark, which were characteristic of the Synechocystis mutant. It is suggested that the latter effects may be caused by loss ( or weaker binding) of the other extrinsic proteins rather than a direct effect of the absence of the cytochrome c(550).	CEA Saclay, URA Consejo Super Invest Cient 2096, Dept Biol Joliot Curie, Serv Bioenerget, F-91191 Gif Sur Yvette, France; Univ Sevilla, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Seville 41092, Spain	CEA; UDICE-French Research Universities; Universite Paris Saclay; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC)	Kirilovsky, D (corresponding author), CEA Saclay, URA Consejo Super Invest Cient 2096, Dept Biol Joliot Curie, Serv Bioenerget, F-91191 Gif Sur Yvette, France.	diana.kirilovsky@cea.fr	Rutherford, Alfred W/A-7831-2019; RONCEL, MERCEDES/G-3035-2015; Ortega, José María/O-7697-2014; Kirilovsky, Diana/I-2359-2014	Rutherford, Alfred W/0000-0002-3124-154X; RONCEL, MERCEDES/0000-0001-8749-7432; Ortega, José María/0000-0002-7841-3687; Wilson, Adjele Flore/0000-0003-2622-3600; Kirilovsky, Diana/0000-0003-2146-3103				BERTHOMIEU C, 1992, BIOCHEMISTRY-US, V31, P11460, DOI 10.1021/bi00161a026; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; Boussac A, 2004, J BIOL CHEM, V279, P22809, DOI 10.1074/jbc.M401677200; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; Ducruet JM, 2003, J EXP BOT, V54, P2419, DOI 10.1093/jxb/erg268; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; GOLDEN JW, 1988, SCIENCE, V242, P1421, DOI 10.1126/science.3144039; HOGANSON CW, 1990, BIOCHIM BIOPHYS ACTA, V1016, P203, DOI 10.1016/0005-2728(90)90059-D; HOLTON RW, 1963, SCIENCE, V142, P234, DOI 10.1126/science.142.3589.234; JOHNSON GN, 1995, BBA-BIOENERGETICS, V1229, P202, DOI 10.1016/0005-2728(95)00003-2; JOHNSON GN, 1994, BBA-BIOENERGETICS, V1184, P85, DOI 10.1016/0005-2728(94)90157-0; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Katoh H, 2001, PLANT CELL PHYSIOL, V42, P599, DOI 10.1093/pcp/pce074; Kerfeld CA, 1998, ANNU REV PLANT PHYS, V49, P397, DOI 10.1146/annurev.arplant.49.1.397; Kerfeld CA, 2003, PLANT CELL PHYSIOL, V44, P697, DOI 10.1093/pcp/pcg084; Kimura A, 2002, PLANT CELL PHYSIOL, V43, P932, DOI 10.1093/pcp/pcf110; KIRILOVSKY D, 1991, BIOCHIM BIOPHYS ACTA, V1060, P37, DOI 10.1016/S0005-2728(05)80116-1; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KRIEGER A, 1993, BIOCHIM BIOPHYS ACTA, V1144, P411, DOI 10.1016/0005-2728(93)90128-3; LUMRY R, 1959, PLANT PHYSIOL, V34, P301, DOI 10.1104/pp.34.3.301; MIRANDA T, 1995, PHOTOSYNTH RES, V43, P251, DOI 10.1007/BF00029938; MIYAO M, 1987, BIOCHIM BIOPHYS ACTA, V890, P151, DOI 10.1016/0005-2728(87)90016-8; MOHANTY P, 1993, BIOCHIM BIOPHYS ACTA, V1144, P92, DOI 10.1016/0005-2728(93)90035-E; Muhlenhoff U, 1996, MOL GEN GENET, V252, P93, DOI 10.1007/s004389670011; NAVARRO JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P46, DOI 10.1006/abbi.1995.1202; NISHIYAMA Y, 1994, PLANT PHYSIOL, V105, P1313, DOI 10.1104/pp.105.4.1313; PAPAGEORGIOU GC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P361, DOI 10.1016/S0005-2728(05)80148-3; RIESKE JS, 1959, PLANT PHYSIOL, V34, P293, DOI 10.1104/pp.34.3.293; Roncel M, 2003, J BIOL INORG CHEM, V8, P206, DOI 10.1007/s00775-002-0406-7; RUTHERFORD AW, 1984, BIOCHIM BIOPHYS ACTA, V767, P548, DOI 10.1016/0005-2728(84)90054-9; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; SATOH K, 1972, PLANT CELL PHYSIOL, V13, P885, DOI 10.1093/oxfordjournals.pcp.a074800; Shen JR, 1997, J BIOL CHEM, V272, P17821, DOI 10.1074/jbc.272.28.17821; SHEN JR, 1995, BIOCHEMISTRY-US, V34, P12661, DOI 10.1021/bi00039a023; SHEN JR, 1995, J BIOL CHEM, V270, P6901, DOI 10.1074/jbc.270.12.6901; Shen JR, 1998, BIOCHEMISTRY-US, V37, P1551, DOI 10.1021/bi971676i; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; STYRING S, 1987, BIOCHEMISTRY-US, V26, P2401, DOI 10.1021/bi00383a001; Sugiura M, 1999, PLANT CELL PHYSIOL, V40, P1219, DOI 10.1093/oxfordjournals.pcp.a029510; VASS I, 1987, FEBS LETT, V211, P215, DOI 10.1016/0014-5793(87)81439-4; Vass I., 1992, TOPICS PHOTOSYNTHESI, P259; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	46	31	32	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52869	52880		10.1074/jbc.M408206200	http://dx.doi.org/10.1074/jbc.M408206200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15385568	Green Published, hybrid			2022-12-25	WOS:000225680600011
J	Azmi, S; Ozog, A; Taneja, R				Azmi, S; Ozog, A; Taneja, R			Sharp-1/DEC2 inhibits skeletal muscle differentiation through repression of myogenic transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; CELL-CYCLE; NEGATIVE REGULATOR; STRA13 EXPRESSION; GENE-EXPRESSION; MEF2 PROTEINS; DNA-BINDING; P19 CELLS; MYOD; ENHANCER	Skeletal muscle differentiation is regulated by the basic-helix-loop-helix (bHLH) family of transcription factors. The myogenic bHLH factors form heterodimers with the ubiquitously expressed bHLH E-proteins and bind E-box (CANNTG) sites present in the promoters of several muscle-specific genes. Our previous studies have shown that the bHLH factor Sharp-1 is expressed in skeletal muscle and interacts with MyoD and E-proteins. However, its role in regulation of myogenic differentiation remains unknown. We report here that endogenous Sharp-1 is expressed in proliferating C2C12 myoblasts and is down-regulated during myogenic differentiation. Constitutive expression of Sharp-1 in C2C12 myoblasts promotes cell cycle exit causing a decrease in cyclin D1 expression but blocks terminal differentiation. Although MyoD expression is not inhibited, the induction of differentiation-specific genes such as myogenin, MEF2C, and myosin heavy chain is impaired by Sharp-1 overexpression. We demonstrate that the interaction of Sharp-1 with MyoD and E-proteins results in reduced DNA binding and transactivation from MyoD-dependent E-box sites. Re-expression of MyoDsimilar toE47 rescues the differentiation defect imposed by Sharp-1, suggesting that myogenic bHLH factors function downstream of Sharp-1. Our data suggest that protein-protein interactions between Sharp-1, MyoD, and E47 resulting in interference with MyoD function underlies Sharp-1-mediated repression of myogenic differentiation.	Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Taneja, R (corresponding author), Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA.	reshma.taneja@mssm.edu	Taneja, Reshma/F-9658-2014	Taneja, Reshma/0000-0002-2151-2094; Reshma, Taneja/0000-0001-6214-6177				Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Azmi S, 2002, MECH DEVELOP, V114, P181, DOI 10.1016/S0925-4773(02)00049-7; Beadling C, 2001, ONCOGENE, V20, P1771, DOI 10.1038/sj.onc.1204212; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; Cossins J, 2002, DEVELOPMENT, V129, P2195; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; Dilworth FJ, 2004, P NATL ACAD SCI USA, V101, P11593, DOI 10.1073/pnas.0404192101; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; FILVAROFF EH, 1994, DEVELOPMENT, V120, P1085; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Heller H, 2001, J BIOL CHEM, V276, P37307, DOI 10.1074/jbc.M103195200; Hughes M, 2004, DEV BIOL, V271, P26, DOI 10.1016/j.ydbio.2004.03.029; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEDENT V, 2002, GENOME BIOL; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Li YX, 2002, BIOCHEM J, V367, P413, DOI 10.1042/BJ20020514; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Olson E N, 1992, Semin Cell Biol, V3, P127; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; Porcher C, 1999, DEVELOPMENT, V126, P4603; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Seimiya M, 2002, BIOCHEM BIOPH RES CO, V292, P121, DOI 10.1006/bbrc.2002.6605; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; St-Pierre B, 2002, J BIOL CHEM, V277, P46544, DOI 10.1074/jbc.M111652200; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Wang DZ, 2001, DEVELOPMENT, V128, P4623; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	61	64	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52643	52652		10.1074/jbc.M409188200	http://dx.doi.org/10.1074/jbc.M409188200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15448136	hybrid			2022-12-25	WOS:000225493400111
J	Isnardi, I; Lesourne, R; Bruhns, P; Fridman, WH; Cambier, JC; Daeron, M				Isnardi, I; Lesourne, R; Bruhns, P; Fridman, WH; Cambier, JC; Daeron, M			Two distinct tyrosine-based motifs enable the inhibitory receptor Fc gamma RIIB to cooperatively recruit the inositol phosphatases SHIP1/2 and the adapters Grb2/Grap	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL ACTIVATION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 5-PHOSPHATASE; B-CELLS; NEGATIVE REGULATION; ANTIGEN RECEPTOR; DEFICIENT MICE; CYTOPLASMIC DOMAIN; PROTEIN; IGG; SHC	FcgammaRIIB are low-affinity receptors for IgG that contain an immunoreceptor tyrosine-based inhibition motif (ITIM) and inhibit immunoreceptor tyrosine-based activation motif (ITAM)-dependent cell activation. When co-aggregated with ITAM-bearing receptors, FcgammaRIIB become tyrosyl-phosphorylated and recruit the Src homology 2 (SH2) domain-containing inositol 5'-phosphatases SHIP1 and SHIP2, which mediate inhibition. The FcgammaRIIB ITIM was proposed to be necessary and sufficient for recruiting SHIP1/2. We show here that a second tyrosine-containing motif in the intracytoplasmic domain of FcgammaRIIB is required for SHIP1/2 to be coprecipitated with the receptor. This motif functions as a docking site for the SH2 domain-containing adapters Grb2 and Grap. These adapters interact via their C-terminal SH3 domain with SHIP1/2 to form a stable receptor-phosphatase-adapter trimolecular complex. Both Grb2 and Grap are required for an optimal coprecipitation of SHIP with FcgammaRIIB, but one adapter is sufficient for the phosphatase to coprecipitate in a detectable manner with the receptors. In addition to facilitating the recruitment of SHIPs, the second tyrosine-based motif may confer upon FcgammaRIIB the properties of scaffold proteins capable of altering the composition and stability of the signaling complexes generated following receptor engagement.	Inst Pasteur, Dept Immunol, Unite Allergol Mol & Cellulaire, F-75015 Paris, France; Inst Rech Biomed Cordeliers, Lab Immunol Cellulaire & Clin, INSERM, U255, F-75006 Paris, France; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Denver, CO 80262 USA; Inst Pasteur, Unite Allergol Mol & Cellulaire, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Daeron, M (corresponding author), Inst Pasteur, Dept Immunol, Unite Allergol Mol & Cellulaire, 25 Rue Dr Roux, F-75015 Paris, France.	daeron@pasteur.fr	Lesourne, Renaud/M-1855-2014; Bruhns, Pierre/F-5567-2013	Bruhns, Pierre/0000-0002-4709-8936; fridman, wolf herman/0000-0002-1332-0973; Cambier, John/0000-0002-7803-242X; Lesourne, Renaud/0000-0003-3816-7087				Aman MJ, 2000, MOL CELL BIOL, V20, P3576, DOI 10.1128/MCB.20.10.3576-3589.2000; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Brauweiler A, 2000, J EXP MED, V191, P1545, DOI 10.1084/jem.191.9.1545; Brauweiler A, 2001, J IMMUNOL, V167, P204, DOI 10.4049/jimmunol.167.1.204; Bruhns P, 2000, J BIOL CHEM, V275, P37357, DOI 10.1074/jbc.M003518200; Bruhns P, 1999, J IMMUNOL, V162, P3168; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; Burshtyn DN, 1999, J IMMUNOL, V162, P897; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Harmer SL, 1999, J BIOL CHEM, V274, P12183, DOI 10.1074/jbc.274.17.12183; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Lesourne R, 2001, J BIOL CHEM, V276, P6327, DOI 10.1074/jbc.M006537200; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Malbec O, 1998, J IMMUNOL, V160, P1647; Malbec O, 2001, J BIOL CHEM, V276, P30381, DOI 10.1074/jbc.M011094200; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Nakamura A, 2000, J EXP MED, V191, P899, DOI 10.1084/jem.191.5.899; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Phee H, 2001, MOL CELL BIOL, V21, P8615, DOI 10.1128/MCB.21.24.8615-8625.2001; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Shen R, 2002, MOL CELL BIOL, V22, P3230, DOI 10.1128/MCB.22.10.3230-3236.2002; SINCLAIR NRS, 1971, ADV EXP MED BIOL, V12, P609; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Wernersson S, 1999, J IMMUNOL, V163, P618; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Yamasaki S, 2003, MOL CELL BIOL, V23, P2515, DOI 10.1128/MCB.23.7.2515-2529.2003; Yuasa T, 1999, J EXP MED, V189, P187, DOI 10.1084/jem.189.1.187	47	39	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51931	51938		10.1074/jbc.M410261200	http://dx.doi.org/10.1074/jbc.M410261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456754	hybrid, Green Submitted			2022-12-25	WOS:000225493400027
J	Rohloff, P; Montalvetti, A; Docampo, R				Rohloff, P; Montalvetti, A; Docampo, R			Acidocalcisomes and the contractile vacuole complex are involved in osmoregulation in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-PUMPING PYROPHOSPHATASE; MICROTUBULE-ASSOCIATED PROTEIN-2; DICTYOSTELIUM-DISCOIDEUM; PLASMA-MEMBRANE; ION CHANNELS; CYCLIC-AMP; CYTOSKELETON; TRAFFICKING; PHOSPHORYLATION; IDENTIFICATION	Trypanosoma cruzi, the etiologic agent of Chagas disease, resists extreme fluctuations in osmolarity during its life cycle. T. cruzi possesses a robust regulatory volume decrease mechanism that completely reverses cell swelling when submitted to hypo-osmotic stress. The efflux of amino acids and K+ release could account for only part for this volume reversal. In this work we demonstrate that swelling of acidocalcisomes mediated by an aquaporin and microtubule- and cyclic AMP-mediated fusion of acidocalcisomes to the contractile vacuole complex with translocation of this aquaporin and the resulting water movement are responsible for the volume reversal not accounted for by efflux of osmolytes. Contractile vacuole bladders were isolated by subcellular fractionation in iodixanol gradients, showed a high concentration of basic amino acids and inorganic phosphate, and were able to transport protons in the presence of ATP or pyrophosphate. Taken together, these results strongly support a role for acidocalcisomes and the contractile vacuole complex in osmoregulation and identify a functional role for aquaporin in protozoal osmoregulation.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Rohloff, Peter/P-8722-2017	Rohloff, Peter/0000-0001-7274-8315	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023259, R01AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen RD, 2000, BIOESSAYS, V22, P1035; Allen RD, 2002, INT REV CYTOL, V215, P351; Boassa D, 2002, TRENDS PHARMACOL SCI, V23, P558, DOI 10.1016/S0165-6147(02)02112-0; BONE G, 1969, NATURE, V178, P308; BOWERS B, 1973, J CELL BIOL, V59, P784, DOI 10.1083/jcb.59.3.784; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; Brown D, 1998, AM J PHYSIOL-RENAL, V275, pF328, DOI 10.1152/ajprenal.1998.275.3.F328; CRONKITE DL, 1991, J PROTOZOOL, V38, P565, DOI 10.1111/j.1550-7408.1991.tb06081.x; Diviani D, 2001, J CELL SCI, V114, P1431; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; FOK AK, 1995, J CELL SCI, V108, P3163; Garcia F, 2001, J BIOL CHEM, V276, P12147, DOI 10.1074/jbc.M009403200; Gull K, 1999, ANNU REV MICROBIOL, V53, P629, DOI 10.1146/annurev.micro.53.1.629; Gustafson CE, 1998, HISTOCHEM CELL BIOL, V110, P377, DOI 10.1007/s004180050298; Hansen M, 2002, J BIOL CHEM, V277, P4874, DOI 10.1074/jbc.M110683200; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Kollien AH, 2000, PARASITOL TODAY, V16, P381, DOI 10.1016/S0169-4758(00)01724-5; Kollien AH, 2001, J INSECT PHYSIOL, V47, P739, DOI 10.1016/S0022-1910(00)00170-0; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LeFurgey A, 2001, COMP BIOCHEM PHYS A, V128, P385, DOI 10.1016/S1095-6433(00)00319-6; Levi V, 2003, BIOCHEM SOC T, V31, P997; LINDER JC, 1979, J CELL BIOL, V83, P371, DOI 10.1083/jcb.83.2.371; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; Martinac B, 2004, J CELL SCI, V117, P2449, DOI 10.1242/jcs.01232; Martinez R, 2002, MOL BIOCHEM PARASIT, V120, P205, DOI 10.1016/S0166-6851(01)00456-X; MCKANNA JA, 1973, SCIENCE, V179, P88, DOI 10.1126/science.179.4068.88; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; Merzendorfer H, 1997, J EXP BIOL, V200, P225; MILLS I, 1990, BIOCHEM BIOPH RES CO, V171, P143, DOI 10.1016/0006-291X(90)91368-3; Montalvetti A, 2004, J BIOL CHEM, V279, P38673, DOI 10.1074/jbc.M406304200; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Niemietz CM, 2002, FEBS LETT, V531, P443, DOI 10.1016/S0014-5793(02)03581-0; NOLTA KV, 1994, J BIOL CHEM, V269, P2225; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; QUIVIGER B, 1978, J ULTRA MOL STRUCT R, V62, P228, DOI 10.1016/S0022-5320(78)80020-3; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RICHTERLANDSBERG C, 1985, J NEUROCHEM, V45, P1218, DOI 10.1111/j.1471-4159.1985.tb05545.x; Rohloff P, 2003, MOL BIOCHEM PARASIT, V126, P219, DOI 10.1016/S0166-6851(02)00277-3; ROHLOFF P, 2003, THESIS U ILLINOIS UR; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Schekman R, 1998, NATURE, V396, P514, DOI 10.1038/24986; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; Seufferheld M, 2003, J BIOL CHEM, V278, P29971, DOI 10.1074/jbc.M304548200; Steck TL, 1997, J EUKARYOT MICROBIOL, V44, P503, DOI 10.1111/j.1550-7408.1997.tb05731.x; Taylor MC, 1999, MOL BIOCHEM PARASIT, V104, P205, DOI 10.1016/S0166-6851(99)00154-1; Temesvari LA, 1996, J CELL SCI, V109, P1479; Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001; VANROSSUM GDV, 1987, CURR TOP MEMBR TRANS, V30, P45; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	57	91	93	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52270	52281		10.1074/jbc.M410372200	http://dx.doi.org/10.1074/jbc.M410372200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466463	hybrid			2022-12-25	WOS:000225493400068
J	Toro, R; Saadi, I; Kuburas, A; Nemer, M; Russo, AF				Toro, R; Saadi, I; Kuburas, A; Nemer, M; Russo, AF			Cell-specific activation of the atrial natriuretic factor promoter by PITX2 and MEF2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-RIGHT ASYMMETRY; TRANSCRIPTION FACTOR MEF2C; RIEGER-SYNDROME; GENE-EXPRESSION; HOMEODOMAIN PROTEIN; SIGNALING PATHWAY; NONMUSCLE CELLS; PEPTIDE SYSTEM; MUSCLE; ISOFORMS	The PITX2 homeodomain protein is mutated in patients with Axenfeld-Rieger syndrome and is involved in the development of multiple organ systems, including the heart. We have examined the interaction of PITX2 isoforms with myocyte-enhancing factor 2A (MEF2A), which is a known regulator of cardiac development. A direct interaction between PITX2a and MEF2A was demonstrated using yeast two-hybrid and GST pull-down assays. To study the functional significance of this interaction, we used the atrial natriuretic factor (ANF) promoter. Coexpression of MEF2A and PITX2a or Pitx2c resulted in a strong synergistic activation of the ANF promoter in LS8 oral epithelial cells but not in other cell lines (NIH/3T3, Chinese hamster ovary, or C2C12). The synergism was dependent on promoter context, because it required MEF2 binding sites and was not seen with two other PITX2 target promoters. DNA binding by MEF2A was required but not sufficient for synergism. Upstream activators of p38 MAP kinases, MKK3 and MKK6, increased PITX2a and Pitx2c activity to yield up to 90-fold activation of the ANF promoter in LS8 cells. Because Axenfeld-Rieger syndrome is autosomal dominant and affects development of the oral epithelium, we tested one of the known PITX2 mutants. The PITX2a-K88E mutant protein suppressed wild type PITX2a synergism with MEF2A. These results demonstrate a promoter- and cell-specific functional interaction between PITX2 and MEF2A and suggest the possibility of coordinate control by these factors in the oral epithelium.	Univ Iowa, Genet Program, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada	University of Iowa; University of Iowa; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Russo, AF (corresponding author), Univ Iowa, Genet Program, Iowa City, IA 52242 USA.	andrew-russo@uiowa.edu	Saadi, Irfan/I-5989-2019	Saadi, Irfan/0000-0002-6250-6651; Russo, Andrew/0000-0002-8156-5649	PHS HHS [E13076] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amendt BA, 1998, J BIOL CHEM, V273, P20066, DOI 10.1074/jbc.273.32.20066; Amendt BA, 2000, CELL MOL LIFE SCI, V57, P1652, DOI 10.1007/PL00000647; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1997, MOL CELL BIOL, V17, P2756, DOI 10.1128/MCB.17.5.2756; Cho ES, 2000, EXP EYE RES, V71, P333, DOI 10.1006/exer.2000.0885; Cox CJ, 2002, J BIOL CHEM, V277, P25001, DOI 10.1074/jbc.M201737200; DODOU E, 1995, NUCLEIC ACIDS RES, V23, P4267, DOI 10.1093/nar/23.21.4267; Essner JJ, 2000, DEVELOPMENT, V127, P1081; Gage PJ, 1999, MAMM GENOME, V10, P197, DOI 10.1007/s003359900970; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Ganga M, 2003, J BIOL CHEM, V278, P22437, DOI 10.1074/jbc.M210163200; Green PD, 2001, GENE EXPRESSION, V9, P265, DOI 10.3727/000000001783992515; GUTKOWSKA J, 1989, ENDOCR REV, V10, P519, DOI 10.1210/edrv-10-4-519; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Harris AN, 1997, J MOL CELL CARDIOL, V29, P515, DOI 10.1006/jmcc.1996.0295; Hjalt TA, 2000, DEV DYNAM, V218, P195, DOI 10.1002/(SICI)1097-0177(200005)218:1<195::AID-DVDY17>3.0.CO;2-C; Jankowski M, 1996, REGUL PEPTIDES, V62, P53, DOI 10.1016/0167-0115(96)00004-3; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lines MA, 2002, HUM MOL GENET, V11, P1177, DOI 10.1093/hmg/11.10.1177; LIU ML, 1994, J BIOL CHEM, V269, P28514; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Lu MF, 1999, NATURE, V401, P276, DOI 10.1038/45797; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Melo LG, 2000, PHYSIOL GENOMICS, V3, P45, DOI 10.1152/physiolgenomics.2000.3.1.45; MIKAMI Y, 1995, CURR EYE RES, V14, P391, DOI 10.3109/02713689508999937; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; Park BK, 1998, ARCH ORAL BIOL, V43, P611, DOI 10.1016/S0003-9969(98)00039-9; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Saadi I, 2003, MOL CELL BIOL, V23, P1968, DOI 10.1128/MCB.23.6.1968-1982.2003; Saadi I, 2001, J BIOL CHEM, V276, P23034, DOI 10.1074/jbc.M008592200; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; St Amand TR, 2000, DEV BIOL, V217, P323, DOI 10.1006/dbio.1999.9547; St Amand TR, 1998, BIOCHEM BIOPH RES CO, V247, P100; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; Tremblay JJ, 2000, NEUROENDOCRINOLOGY, V71, P277, DOI 10.1159/000054547; Tremblay JJ, 1999, EMBO J, V18, P3431, DOI 10.1093/emboj/18.12.3431; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; VOLLMAR AM, 1991, ANAT EMBRYOL, V184, P331, DOI 10.1007/BF00957894; Westmoreland JJ, 2001, J NEUROSCI, V21, P6810, DOI 10.1523/JNEUROSCI.21-17-06810.2001; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; YU Y, 1992, GENE DEV, V9, P1783	51	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52087	52094		10.1074/jbc.M404802200	http://dx.doi.org/10.1074/jbc.M404802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466416	hybrid			2022-12-25	WOS:000225493400047
J	Fernandez-Monreal, M; Lopez-Atalaya, JP; Benchenane, K; Cacquevel, M; Dulin, F; Le Caer, JP; Rossier, J; Jarrige, AC; MacKenzie, ET; Colloc'h, N; Ali, C; Vivien, D				Fernandez-Monreal, M; Lopez-Atalaya, JP; Benchenane, K; Cacquevel, M; Dulin, F; Le Caer, JP; Rossier, J; Jarrige, AC; MacKenzie, ET; Colloc'h, N; Ali, C; Vivien, D			Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR; NEURONAL DEGENERATION; PROTEASE INHIBITOR; MOUSE HIPPOCAMPUS; SERINE PROTEASES; SPLICE VARIANTS; LATE-PHASE; POTENTIATION; SEIZURE; MICE	Tissue-type plasminogen activator (tPA) has been involved in both physiological and pathological glutamatergic-dependent processes, such as synaptic plasticity, seizure, trauma, and stroke. In a previous study, we have shown that the proteolytic activity of tPA enhances the N-methyl-D-aspartate ( NMDA) receptor-mediated signaling in neurons (Nicole, O., Docagne, F., Ali, C., Margaill, I., Carmeliet, P., MacKenzie, E. T., Vivien, D., and Buisson, A. ( 2001) Nat. Med. 7, 59 - 64). Here, we show that tPA forms a direct complex with the amino-terminal domain (ATD) of the NR1 subunit of the NMDA receptor and cleaves this subunit at the arginine 260. Furthermore, point mutation analyses show that arginine 260 is necessary for both tPA-induced cleavage of the ATD of NR1 and tPA-induced potentiation of NMDA receptor signaling. Thus, tPA is the first binding protein described so far to interact with the ATD of NR1 and to modulate the NMDA receptor function.	Univ Caen, CNRS, UMR 6185, Ctr Cyceron, F-14074 Caen, France; Ecole Polytech, CNRS, UMR 7651, F-91128 Palaiseau, France; Ecole Super Phys & Chim Ind Ville Paris, CNRS, UMR 7637, F-75231 Paris 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie; Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Vivien, D (corresponding author), Univ Caen, CNRS, UMR 6185, Ctr Cyceron, Bd Henri Becquerel,BP 5229, F-14074 Caen, France.	d.vivien@neuro.unicaen.fr	Mackenzie, Eric Thomson/L-1938-2015; Lopez-Atalaya, Jose P/E-3983-2014; benchenane, karim/D-8023-2015; Colloc'h, Nathalie/L-1570-2015; Lopez-Atalaya, Jose P/M-3595-2018; Monreal, Monica Fernandez/P-6685-2019; LOPEZ-ATALAYA, JOSE P./ABC-6022-2020; Fernandez-Monreal, Mónica/I-7954-2012	benchenane, karim/0000-0001-7118-0748; Monreal, Monica Fernandez/0000-0001-7278-448X; Fernandez-Monreal, Mónica/0000-0001-7278-448X; MacKenzie, Eric T/0000-0003-1057-7033; LOPEZ-ATALAYA, JOSE P./0000-0001-6064-7584; Ali, Carine/0000-0001-8007-7910; VIVIEN, DENIS/0000-0002-7636-2185				Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Basham ME, 2001, J NEUROCHEM, V77, P318, DOI 10.1046/j.1471-4159.2001.t01-1-00239.x; Benchenane K, 2004, TRENDS NEUROSCI, V27, P155, DOI 10.1016/j.tins.2003.12.011; Buisson A, 1998, FASEB J, V12, P1683, DOI 10.1096/fasebj.12.15.1683; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cinelli P, 2001, MOL CELL NEUROSCI, V18, P443, DOI 10.1006/mcne.2001.1028; Davies BJ, 1998, J BIOL CHEM, V273, P23004, DOI 10.1074/jbc.273.36.23004; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; Fernandez-Monreal M, 2004, MOL CELL NEUROSCI, V25, P594, DOI 10.1016/j.mcn.2003.11.002; Frey U, 1996, J NEUROSCI, V16, P2057; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gualandris A, 1996, J NEUROSCI, V16, P2220; Gveric D, 2001, BRAIN, V124, P1978, DOI 10.1093/brain/124.10.1978; Hoffman KB, 1998, BRAIN RES, V811, P29, DOI 10.1016/S0006-8993(98)00906-8; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Liberatore GT, 2003, STROKE, V34, P537, DOI 10.1161/01.STR.0000049764.49162.76; Lu WQ, 2002, J NEUROSCI, V22, P10781; Madani R, 1999, EMBO J, V18, P3007, DOI 10.1093/emboj/18.11.3007; Matys T, 2003, NAT MED, V9, P371, DOI 10.1038/nm0403-371; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Muller CM, 1998, NAT NEUROSCI, V1, P47, DOI 10.1038/248; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; Nakagami Y, 2000, J NEUROSCI, V20, P2003; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Paoletti P, 2000, NEURON, V28, P911, DOI 10.1016/S0896-6273(00)00163-X; Pawlak R, 2003, NAT NEUROSCI, V6, P168, DOI 10.1038/nn998; Perin-Dureau F, 2002, J NEUROSCI, V22, P5955; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Rogove AD, 1998, CURR BIOL, V8, P19, DOI 10.1016/S0960-9822(98)70016-8; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; SEEDS NW, 1992, ANN NY ACAD SCI, V667, P32; Seeds NW, 2003, J NEUROSCI, V23, P7368; Sharon R, 2002, MOL BRAIN RES, V104, P170, DOI 10.1016/S0169-328X(02)00354-6; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SUMI Y, 1992, DEVELOPMENT, V116, P625; Traynelis SF, 1998, J NEUROSCI, V18, P6163; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; Traynelis SF, 2001, NAT MED, V7, P17, DOI 10.1038/83289; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Wu YP, 2000, J CELL BIOL, V148, P1295, DOI 10.1083/jcb.148.6.1295; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Zhang ZG, 2002, CIRCULATION, V106, P740, DOI 10.1161/01.CIR.0000023942.10849.41; Zheng F, 2001, NAT NEUROSCI, V4, P894, DOI 10.1038/nn0901-894; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	57	101	112	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50850	50856		10.1074/jbc.M407069200	http://dx.doi.org/10.1074/jbc.M407069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448144	hybrid			2022-12-25	WOS:000225355800027
J	Griffith, CL; Klutts, JS; Zhang, LJ; Levery, SB; Doering, TL				Griffith, CL; Klutts, JS; Zhang, LJ; Levery, SB; Doering, TL			UDP-glucose dehydrogenase plays multiple roles in the biology of the pathogenic fungus Cryptococcus neoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE DIPHOSPHOGLUCOSE DEHYDROGENASE; GLUCURONIC ACID DECARBOXYLASE; CELL-WALL POLYSACCHARIDES; MYOINOSITOL OXYGENASE; LIQUID-CHROMATOGRAPHY; FUNCTIONAL CLONING; SUBUNIT STRUCTURE; ESCHERICHIA-COLI; MUTANT STRAINS; O-ACETYLATION	Cryptococcus neoformans is a pathogenic fungus surrounded by an elaborate polysaccharide capsule that is strictly required for its virulence in humans and other mammals. Nearly half of the sugar residues in the capsule are derived from UDP-glucuronic acid or its metabolites. To examine the role of these nucleotide sugars in C. neoformans, the gene encoding UDP-glucose dehydrogenase was disrupted. Mass spectrometry analysis of nucleotide sugar pools showed that the resulting mutant lacked both UDP-glucuronic acid and its downstream product, UDP-xylose, thus confirming the effect of the knockout and indicating that an alternate pathway for UDP-glucuronic acid production was not used. The mutant was dramatically affected by the lack of specific sugar donors, demonstrating altered cell integrity, temperature sensitivity, lack of growth in an animal model of cryptococcosis, and morphological defects. Additionally, the polysaccharide capsule could not be detected on the mutant cells, although the possibility remains that abbreviated forms of capsule components are made, possibly without proper surface display. The capsule defect is largely independent of the other observed changes, as cells that are acapsular because of mutations in other genes show lack of virulence but do not exhibit alterations in cell integrity, temperature sensitivity, or cellular morphology. All of the observed alterations were reversed by correction of the gene disruption.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA	Washington University (WUSTL); Washington University (WUSTL); University System Of New Hampshire; University of New Hampshire	Doering, TL (corresponding author), Campus Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.	doering@wustl.edu		Klutts, James/0000-0003-3788-1940	NCRR NIH HHS [P20 RR16459] Funding Source: Medline; NIGMS NIH HHS [GM R01 069968, R01 GM066303, GM R01 066303, GM F32 072341] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM072341, R01GM066303, R01GM069968] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arner RJ, 2001, BIOCHEM J, V360, P313, DOI 10.1042/bj3600313; AUSUBEL FM, 2004, CURRENT PROTOCOLS MO, V1; Bar-Peled M, 2001, P NATL ACAD SCI USA, V98, P12003, DOI 10.1073/pnas.211229198; Belay T, 1997, INFECT IMMUN, V65, P718, DOI 10.1128/IAI.65.2.718-728.1997; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; CHANG YC, 1994, MOL CELL BIOL, V14, P4912, DOI 10.1128/MCB.14.7.4912; CHERNIAK R, 1991, INFECT IMMUN, V59, P59, DOI 10.1128/IAI.59.1.59-64.1991; Cherniak R, 1998, CLIN DIAGN LAB IMMUN, V5, P146; Cox GM, 1996, J MED VET MYCOL, V34, P385; Davidson RC, 2000, FUNGAL GENET BIOL, V29, P38, DOI 10.1006/fgbi.1999.1180; Davidson RC, 2002, MICROBIOL-SGM, V148, P2607, DOI 10.1099/00221287-148-8-2607; FRANZEN JS, 1983, BIOCHIM BIOPHYS ACTA, V746, P146, DOI 10.1016/0167-4838(83)90068-7; FRANZEN JS, 1980, BIOCHIM BIOPHYS ACTA, V614, P242, DOI 10.1016/0005-2744(80)90214-4; GAINEY PA, 1972, BIOCHEM J, V129, P821, DOI 10.1042/bj1290821; Harper AD, 2002, PLANT PHYSIOL, V130, P2188, DOI 10.1104/pp.009654; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14218, DOI 10.1073/pnas.172522199; JAENICKE R, 1986, BIOCHEMISTRY-US, V25, P7283, DOI 10.1021/bi00371a006; Janbon G, 2001, MOL MICROBIOL, V42, P453, DOI 10.1046/j.1365-2958.2001.02651.x; Kanter U, 2003, YEAST, V20, P1317, DOI 10.1002/yea.1050; Kozel TR, 2003, INFECT IMMUN, V71, P2868, DOI 10.1128/IAI.71.5.2868-2875.2003; LOEWUS FA, 1962, P NATL ACAD SCI USA, V48, P421, DOI 10.1073/pnas.48.3.421; Maor BP, 2004, BIOCHEM J, V381, P131, DOI 10.1042/BJ20031075; McDade HC, 2001, MED MYCOL, V39, P151, DOI 10.1080/714030997; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; Moyrand F, 2002, MOL MICROBIOL, V45, P837, DOI 10.1046/j.1365-2958.2002.03059.x; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Pierini LM, 2001, MOL MICROBIOL, V41, P105, DOI 10.1046/j.1365-2958.2001.02504.x; Rabina J, 2001, GLYCOCONJUGATE J, V18, P799, DOI 10.1023/A:1021107602535; REDDY CC, 1981, J BIOL CHEM, V256, P8519; REDDY CC, 1981, J BIOL CHEM, V256, P8510; SASAKI K, 1984, PLANT CELL PHYSIOL, V25, P989; SCHILLER JG, 1976, BIOCHIM BIOPHYS ACTA, V453, P418, DOI 10.1016/0005-2795(76)90137-9; Seifert GJ, 2004, CURR OPIN PLANT BIOL, V7, P277, DOI 10.1016/j.pbi.2004.03.004; Seitz B, 2000, PLANT J, V21, P537, DOI 10.1046/j.1365-313x.2000.00696.x; Sommer U, 2003, J BIOL CHEM, V278, P47724, DOI 10.1074/jbc.M307223200; TOFFALETTI DL, 1993, J BACTERIOL, V175, P1405, DOI 10.1128/JB.175.5.1405-1411.1993; Vaishnav VV, 1998, CARBOHYD RES, V306, P315, DOI 10.1016/S0008-6215(97)10058-1; ZABLACKIS E, 1995, PLANT PHYSIOL, V107, P1129, DOI 10.1104/pp.107.4.1129; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200	39	64	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51669	51676		10.1074/jbc.M408889200	http://dx.doi.org/10.1074/jbc.M408889200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15383535	hybrid			2022-12-25	WOS:000225355800123
J	Michlig, S; Mercier, A; Doucet, A; Schild, L; Horisberger, JD; Rossier, BC; Firsov, D				Michlig, S; Mercier, A; Doucet, A; Schild, L; Horisberger, JD; Rossier, BC; Firsov, D			ERK1/2 controls Na,K-ATPase activity and transepithelial sodium transport in the principal cell of the cortical collecting duct of the mouse kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL ALPHA-SUBUNIT; EPITHELIAL-CELLS; GLUCOCORTICOID HORMONE; SURFACE EXPRESSION; KINASE INHIBITORS; RAT-KIDNEY; ACTIVATION; PHOSPHORYLATION; ALDOSTERONE; PATHWAYS	The collecting duct of normal kidney exhibits significant activity of the MEK1/2-ERK1/2 pathway as shown in vivo by immunostaining of phosphorylated active ERK1/2 (pERK1/2). The MEK1/2-ERK1/2 pathway controls many different ion transports both in proximal and distal nephron, raising the question of whether this pathway is involved in the basal and/or hormone-dependent transepithelial sodium reabsorption in the principal cell of the cortical collecting duct (CCD), a process mediated by the apical epithelial sodium channel and the basolateral sodium pump (Na, K-ATPase). To answer this question we used ex vivo microdissected CCDs from normal mouse kidney or in vitro cultured mpkCCD(cl4) principal cells. Significant basal levels of pERK1/2 were observed ex vivo and in vitro. Aldosterone and vasopressin, known to up-regulate sodium reabsorption in CCDs, did not change ERK1/2 activity either ex vivo or in vitro. Basal and aldosterone- or vasopressin-stimulated sodium transport was down-regulated by the MEK1/2 inhibitor PD98059, in parallel with a decrease in pERK1/2 in vitro. The activity of Na, K-ATPase but not that of epithelial sodium channel was inhibited by MEK1/2 inhibitors in both unstimulated and aldosteroneor vasopressin-stimulated CCDs in vitro. Cell surface biotinylation showed that intrinsic activity rather than cell surface expression of Na, K-ATPase was controlled by pERK1/2. PD98059 also significantly inhibited the activity of Na, K-ATPase ex vivo. Our data demonstrate that the ERK1/2 pathway controls Na, K-ATPase activity and transepithelial sodium transport in the principal cell and indicate that basal constitutive activity of the ERK1/2 pathway is a critical component of this control.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Paris 06, Inst Cordeliers, CNRS, UMR 7134,Lab Physiol & Genom Cellules Renales, F-75270 Paris, France	University of Lausanne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Firsov, D (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.	dmitri.firsov@ipharm.unil.ch	Horisberger, Jean-Daniel/A-2538-2009					Al-Khalili L, 2004, J BIOL CHEM, V279, P25211, DOI 10.1074/jbc.M402152200; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andreucci M, 2003, KIDNEY INT, V64, P1189, DOI 10.1046/j.1523-1755.2003.00204.x; Auberson M, 2003, AM J PHYSIOL-RENAL, V285, pF459, DOI 10.1152/ajprenal.00071.2003; Bacic D, 2003, PFLUG ARCH EUR J PHY, V446, P52, DOI 10.1007/s00424-002-0969-8; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Campean V, 2003, AM J PHYSIOL-RENAL, V285, pF19, DOI 10.1152/ajprenal.00443.2002; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dechenes G, 2000, J AM SOC NEPHROL, V11, P604, DOI 10.1681/ASN.V114604; ELALOUF JM, 1993, J CLIN INVEST, V91, P264, DOI 10.1172/JCI116180; Feranchak AP, 2001, J CLIN INVEST, V108, P1495, DOI 10.1172/JCI200112190; Fujita H, 2004, AM J PHYSIOL-RENAL, V286, pF120, DOI 10.1152/ajprenal.00351.2002; Geering K, 1997, CURR OPIN NEPHROL HY, V6, P434, DOI 10.1097/00041552-199709000-00005; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Hendron E, 2002, MOL BIOL CELL, V13, P3042, DOI 10.1091/mbc.E02-05-0260; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; Hu HJ, 2003, J NEUROPHYSIOL, V90, P1671, DOI 10.1152/jn.00340.2003; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Khundmiri SJ, 2004, J BIOL CHEM, V279, P17418, DOI 10.1074/jbc.M311715200; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Laroche-Joubert N, 2003, AM J PHYSIOL-RENAL, V284, pF948, DOI 10.1152/ajprenal.00394.2002; Lin HH, 1999, J BIOL CHEM, V274, P21544, DOI 10.1074/jbc.274.31.21544; Masaki T, 2003, KIDNEY INT, V63, P1256, DOI 10.1046/j.1523-1755.2003.00874.x; Morisset S, 2000, NATURE, V408, P860, DOI 10.1038/35048583; Nicod M, 2002, EMBO J, V21, P5109, DOI 10.1093/emboj/cdf509; Omori S, 2000, KIDNEY INT, V58, P27, DOI 10.1046/j.1523-1755.2000.00137.x; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Shen JP, 2003, AM J PHYSIOL-RENAL, V284, pF57, DOI 10.1152/ajprenal.00028.2002; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; SILVER RB, 1993, AM J PHYSIOL, V264, pF557, DOI 10.1152/ajprenal.1993.264.3.F557; Summa V, 2001, J BIOL CHEM, V276, P47087, DOI 10.1074/jbc.M107165200; Tian W, 2000, AM J PHYSIOL-RENAL, V279, pF593, DOI 10.1152/ajprenal.2000.279.4.F593; Wang HC, 2000, J BIOL CHEM, V275, P8600, DOI 10.1074/jbc.275.12.8600; Watanabe S, 2002, P NATL ACAD SCI USA, V99, P8366, DOI 10.1073/pnas.122210599; Watts BA, 2002, AM J PHYSIOL-RENAL, V282, pF1056, DOI 10.1152/ajprenal.00133.2001; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770	40	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51002	51012		10.1074/jbc.M405674200	http://dx.doi.org/10.1074/jbc.M405674200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456767	hybrid			2022-12-25	WOS:000225355800045
J	Lungu, AO; Jin, ZG; Yamawaki, H; Tanimoto, T; Wong, C; Berk, BC				Lungu, AO; Jin, ZG; Yamawaki, H; Tanimoto, T; Wong, C; Berk, BC			Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FLUID SHEAR-STRESS; INDUCED HYPERTENSION; STIMULATES PHOSPHORYLATION; IN-SITU; DYSFUNCTION; MECHANISMS; CALCIUM; CELLS; AKT	Fluid shear stress generated by blood flowing over the endothelium is a major determinant of arterial tone, vascular remodeling, and atherogenesis. Nitric oxide (NO) produced by endothelial NO synthase (eNOS) plays an essential role in regulation of vascular function and structure by blood flow. Although cyclosporin A (CsA), an inhibitory ligand of cyclophilin A, is a widely used immunosuppressive drug, it causes arterial hypertension in part by impairing eNOS-dependent vasodilation. Here we show that CsA inhibits fluid shear stress-mediated eNOS activation in endothelial cells via decreasing cholesterol content in caveolae. Exposure of cultured bovine aortic endothelial cells to 1 muM CsA for 1 h significantly inhibited NO production and eNOS phosphorylation at Ser-1179 induced by flow (shear stress=12 dynes/cm(2)). The effect of CsA was not related to inhibition of two known eNOS kinases, protein kinase B (Akt) and protein kinase A, because CsA did not affect Akt or protein kinase A activation. In rabbit aorta perfused ex vivo, CsA also significantly inhibited flow-induced eNOS phosphorylation at Ser-1179 but had no effect on Akt measured by phosphorylation at Ser-473. However, CsA treatment decreased cholesterol content in caveolae and displaced eNOS from caveolae, which may be caused by CsA disrupting the association of caveolin-1 and cyclophilin A. The magnitude of the cholesterol depleting effect was similar to that of beta-cyclodextrin, a cholesterol-binding molecule, and beta-cyclodextrin had a similar inhibitory effect on flow-mediated eNOS activation. Treating bovine aortic endothelial cells for 24 h with 30 mug/ml cholesterol blocked the CsA effect and restored eNOS phosphorylation in response to flow. These data suggest that decreasing cholesterol content in caveolae by CsA is a potentially important pathogenic mechanism for CsA-induced endothelial dysfunction and hypertension.	Univ Rochester, Sch Med & Dent, Aab Inst Biomed Sci, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Aab Inst Biomed Sci, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Jin, ZG (corresponding author), Univ Rochester, Sch Med & Dent, Aab Inst Biomed Sci, Cardiovasc Res Ctr, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.	zheng-gen_jin@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080611, R01HL064839] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL080611, HL-64839] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aizawa T, 2003, CIRC RES, V93, P406, DOI 10.1161/01.RES.0000091074.33584.F0; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; Boo YC, 2003, AM J PHYSIOL-CELL PH, V285, pC499, DOI 10.1152/ajpcell.00122.2003; Boo YC, 2002, AM J PHYSIOL-HEART C, V283, pH1819, DOI 10.1152/ajpheart.00214.2002; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Curtis JJ, 2002, CURR HYPERTENS REP, V4, P377, DOI 10.1007/s11906-002-0067-5; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DEHOFF JL, 1978, CLIN CHEM, V24, P433; DIEDERICH D, 1994, HYPERTENSION, V23, P957, DOI 10.1161/01.HYP.23.6.957; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Fleming I, 2003, AM J PHYSIOL-REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furukawa K, 1997, J NEUROSCI, V17, P8178, DOI 10.1523/jneurosci.17-21-08178.1997; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Gargalovic P, 2003, J LIPID RES, V44, P11, DOI 10.1194/jlr.R200005-JLR200; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; Ito J, 2002, J BIOL CHEM, V277, P7929, DOI 10.1074/jbc.M103878200; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Nichelle L, 2002, TRANSPLANT P, V34, P2824, DOI 10.1016/S0041-1345(02)03530-3; Oriji GK, 1999, AM J HYPERTENS, V12, P1091, DOI 10.1016/S0895-7061(99)00089-8; Oriji GK, 2001, PROSTAG LEUKOTR ESS, V65, P259, DOI 10.1054/plef.2001.0323; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; Peterson TE, 1999, CIRC RES, V85, P29; Razani B, 2001, J BIOL CHEM, V276, P38121; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; ROULLET JB, 1994, J CLIN INVEST, V93, P2244, DOI 10.1172/JCI117222; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; Schwenger V, 2001, Curr Hypertens Rep, V3, P434, DOI 10.1007/s11906-001-0063-1; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Yamawaki H, 2003, CIRCULATION, V108, P1619, DOI 10.1161/01.CIR.0000089373.49941.C4; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	51	66	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48794	48800		10.1074/jbc.M313897200	http://dx.doi.org/10.1074/jbc.M313897200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15383526	hybrid			2022-12-25	WOS:000225098100039
J	Ziesche, R; Petkov, V; Lambers, C; Erne, P; Block, LH				Ziesche, R; Petkov, V; Lambers, C; Erne, P; Block, LH			The calcium channel blocker amlodipine exerts its anti-proliferative action via p21((Waf1/Cip1)) gene activation	FASEB JOURNAL			English	Article						VSMC; glucocorticoid receptor; intracellular calcium; CCB	SMOOTH-MUSCLE-CELLS; LOW-DENSITY-LIPOPROTEIN; NF-KAPPA-B; TRANSCRIPTION FACTORS; C/EBP FAMILY; INTERLEUKIN-6 GENE; NUCLEAR-FACTOR; PROLIFERATION; GROWTH; BINDING	Proliferation of vascular smooth muscle cells (VSMC) contributes to the progression of atherosclerotic plaques. Calcium channel blockers have been shown to reduce VSMC proliferation, but the underlying molecular mechanism remains unclear. p21((Waf1/Cip1)) is a potent inhibitor of cell cycle progression. Here, we demonstrate that amlodipine (10(-6) to 10(-8) M) activates de novo synthesis of p21((Waf1/Cip1)) in vitro. We show that amlodipine-dependent activation of p21((Waf1/Cip1)) involves the action of the glucocorticoid receptor (GR) and C/EBP-alpha. The underlying pathway apparently involves the action of mitogen-activated protein kinase or protein kinase C, but not of extracellular signal-related kinase or changes of intracellular calcium. Amlodipine-induced p21((Waf1/Cip1)) promoter activity and expression were abrogated by C/EBP-alpha antisense oligonucleotide or by the GR antagonist RU486. Amlodipine-dependent inhibition of cell proliferation was partially reversed by RU486 at 10(-8) M (58% +/- 29%), antisense oligonucleotides targeting C/EBP-alpha (91% +/- 26%), or antisense mRNAs targeting p21((Waf1/Cip1)) (96% +/- 32%, n = 6); scrambled antisense oligonucleotides or those directed against C/EBP-alpha were ineffective. The data suggest that the anti-proliferative action of amlodipine is achieved by induction of the p21((Waf1/Cip1)) gene, which may explain beneficial covert effects of this widely used cardiovascular therapeutic drug beyond a more limited role as a vascular relaxant.	Univ Vienna, Dept Internal Med 4, A-1010 Vienna, Austria; Kantonsspital Luzern, Dept Cardiol, Luzern, Switzerland	University of Vienna; Lucerne Cantonal Hospital	Block, LH (corresponding author), Univ Hosp Vienna, Dept Internal Med 4, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	lutz-henning.block@akh-wien.ac.at						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Cattaruzza M, 2001, J BIOL CHEM, V276, P36999, DOI 10.1074/jbc.M105158200; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; Condorelli G, 2001, FASEB J, V15, P2162, DOI 10.1096/fj.01-0032com; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Eickelberg O, 1999, CIRCULATION, V99, P2276, DOI 10.1161/01.CIR.99.17.2276; Faggioli L, 1996, EUR J BIOCHEM, V239, P624, DOI 10.1111/j.1432-1033.1996.0624u.x; George SJ, 2001, GENE THER, V8, P668, DOI 10.1038/sj.gt.3301431; Hamilton CA, 2002, ATHEROSCLEROSIS, V160, P345, DOI 10.1016/S0021-9150(01)00605-0; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; Koshiyama H, 1999, J CARDIOVASC PHARM, V33, P894, DOI 10.1097/00005344-199906000-00009; Lag M, 2000, EXP LUNG RES, V26, P383, DOI 10.1080/019021400408326; Lai YM, 2002, HYPERTENS RES, V25, P109, DOI 10.1291/hypres.25.109; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; Mason RP, 2001, PHARMACOTHERAPY, V21, p209S, DOI 10.1592/phco.21.14.209S.34600; Nathe TJ, 2002, ARTERIOSCL THROM VAS, V22, P1293, DOI 10.1161/01.ATV.0000023428.69244.49; Papakonstantinou E, 1998, GLYCOBIOLOGY, V8, P821, DOI 10.1093/glycob/8.8.821; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Rudiger JJ, 2002, FASEB J, V16, P177, DOI 10.1096/fj.01-0226com; Ruiz-Torres A, 2003, INT J CLIN PHARM TH, V41, P386; Sanz-Gonzalez SM, 2000, FRONT BIOSCI, V5, pD619, DOI 10.2741/sanz; Stepien O, 1998, J CARDIOVASC PHARM, V31, P786, DOI 10.1097/00005344-199805000-00019; Tsuda Y, 2002, EUR J PHARMACOL, V446, P15, DOI 10.1016/S0014-2999(02)01811-3; Velarde V, 2001, J APPL PHYSIOL, V91, P1412, DOI 10.1152/jappl.2001.91.3.1412; Vijayagopal P, 2001, ATHEROSCLEROSIS, V157, P353, DOI 10.1016/S0021-9150(00)00742-5; Yang CM, 2001, BRIT J PHARMACOL, V132, P1531, DOI 10.1038/sj.bjp.0703976; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhao M, 2002, ARCH BIOCHEM BIOPHYS, V400, P199, DOI 10.1016/S0003-9861(02)00028-0	31	6	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1516	1523		10.1096/fj.04-1662com	http://dx.doi.org/10.1096/fj.04-1662com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466360				2022-12-25	WOS:000224849900035
J	Steiner, AA; Dogan, MD; Ivanov, AI; Patel, S; Rudaya, AY; Jennings, DH; Orchinik, M; Pace, TWW; O'Connor, KA; Watkins, LR; Romanovsky, AA				Steiner, AA; Dogan, MD; Ivanov, AI; Patel, S; Rudaya, AY; Jennings, DH; Orchinik, M; Pace, TWW; O'Connor, KA; Watkins, LR; Romanovsky, AA			A new function of the leptin receptor: mediation of the recovery from lipopolysaccharide-induced hypothermia	FASEB JOURNAL			English	Article						fever; body temperature; systemic inflammation; cytokines; tumor necrosis factor; corticosterone; Koletsky rats	TUMOR-NECROSIS-FACTOR; BROWN ADIPOSE-TISSUE; PITUITARY-ADRENAL AXIS; OBESE ZUCKER RATS; NF-KAPPA-B; OB/OB MICE; ACUTE-INFLAMMATION; PLASMA LEPTIN; GENE-PRODUCT; FACTOR-ALPHA	Obese (f/f) Koletsky rats lack the leptin receptor (LR), whereas their lean (F/?) counterparts bear a fully functional LR. By using f/f and F/? rats, we studied whether the LR is involved in lipopolysaccharide (LPS)-induced fever and hypothermia. The body temperature responses to LPS (10 or 100 mug/kg iv) were measured in Koletsky rats exposed to a thermoneutral (28degreesC) or cool (22degreesC) environment. Rats of both genotypes responded to LPS with fever at 28degreesC and with dose-dependent hypothermia at 22degreesC. The fever responses of the f/f and F/? rats were identical. The hypothermic response of the f/f rats was markedly prolonged compared with that of the F/? rats. The prolonged hypothermic response to LPS in the f/f rats was accompanied by enhanced NF-kappaB signaling in the hypothalamus and an exaggerated rise in the plasma concentration of tumor necrosis factor (TNF)-alpha. The f/f rats did not respond to LPS with an increase in the plasma concentration of corticosterone or adrenocorticotropic hormone, whereas their F/? counterparts did. The hypothermic response to TNF-alpha (80 mug/kg iv) was markedly prolonged in the f/f rats. These data show that the LR is essential for the recovery from LPS hypothermia. LR-dependent mechanisms of the recovery from LPS hypothermia include activation of the anti-inflammatory hypothalamo-pituitary-adrenal axis, inhibition of both the production and hypothermic action of TNF-alpha, and suppression of inflammatory (via NF-kappaB) signaling in the hypothalamus.	St Josephs Hosp, Systemic Inflammat Lab, Phoenix, AZ 85013 USA; Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; Univ Colorado, Dept Psychol, Boulder, CO 80309 USA	St. Joseph's Hospital and Medical Center; Emory University; Arizona State University; Arizona State University-Tempe; University of Colorado System; University of Colorado Boulder	Steiner, AA (corresponding author), St Josephs Hosp, Systemic Inflammat Lab, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	aromano@chw.edu	Ivanov, Andrei/V-1672-2019; Steiner, Alexandre A/G-1288-2012; Güner, Müberra Devrim/U-9518-2019; Güner, Müberra Devrim/Q-1305-2015	Steiner, Alexandre A/0000-0002-0802-4619; Güner, Müberra Devrim/0000-0001-6982-9026; Güner, Müberra Devrim/0000-0001-6982-9026; Romanovsky, Andrej/0000-0003-3772-8575	NINDS NIH HHS [NS-41233] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041233] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE S, 1988, JPN J CANCER RES, V79, P305, DOI 10.1111/j.1349-7006.1988.tb01591.x; Agnello D, 1998, AM J PHYSIOL-REG I, V275, pR913, DOI 10.1152/ajpregu.1998.275.3.R913; Arnalich F, 1999, J INFECT DIS, V180, P908, DOI 10.1086/314963; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BIBBY DC, 1989, J PHYSIOL-LONDON, V410, P367, DOI 10.1113/jphysiol.1989.sp017538; Bik W, 2001, NEUROENDOCRINOL LETT, V22, P208; Bornstein SR, 1998, J CLIN ENDOCR METAB, V83, P280, DOI 10.1210/jc.83.1.280; BUTLER LD, 1989, J NEUROIMMUNOL, V24, P143, DOI 10.1016/0165-5728(89)90108-2; Cabot C, 1998, BRAIN RES BULL, V46, P529, DOI 10.1016/S0361-9230(98)00050-1; CLEMMER TP, 1992, CRIT CARE MED, V20, P1395, DOI 10.1097/00003246-199210000-00006; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Costa A, 2001, FUNCT NEUROL, V16, P205; Cusin I, 1996, DIABETES, V45, P1446, DOI 10.2337/diabetes.45.10.1446; DASCOMBE MJ, 1989, INT J OBESITY, V13, P367; El-Solh A, 2001, CHEST, V120, P1989, DOI 10.1378/chest.120.6.1989; Faggioni R, 2000, AM J PATHOL, V156, P1781, DOI 10.1016/S0002-9440(10)65049-3; Faggioni R, 1999, AM J PHYSIOL-REG I, V276, pR136, DOI 10.1152/ajpregu.1999.276.1.R136; FERRAN C, 1990, TRANSPLANTATION, V50, P642, DOI 10.1097/00007890-199010000-00023; Fox AS, 2000, HORM BEHAV, V37, P377, DOI 10.1006/hbeh.2000.1580; GIRARDIER L, 1995, J PHYSIOL-LONDON, V488, P779, DOI 10.1113/jphysiol.1995.sp021009; GORDON CJ, 1990, PHYSIOL BEHAV, V47, P963, DOI 10.1016/0031-9384(90)90025-Y; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Han SJ, 2002, J BIOL CHEM, V277, P44715, DOI 10.1074/jbc.M202524200; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; HOLT S, 1983, BIOCHEM J, V214, P215, DOI 10.1042/bj2140215; Huang QL, 1998, ENDOCRINOLOGY, V139, P1524, DOI 10.1210/en.139.4.1524; Ivanov AI, 2002, AM J PHYSIOL-REG I, V282, pR311, DOI 10.1152/ajpregu.00376.2001; Kelly JF, 2004, DIABETES, V53, P911, DOI 10.2337/diabetes.53.4.911; KOZAK W, 1995, AM J PHYSIOL-REG I, V269, pR23, DOI 10.1152/ajpregu.1995.269.1.R23; Laflamme N, 1999, J NEUROCHEM, V73, P309, DOI 10.1046/j.1471-4159.1999.0730309.x; Leon LR, 1998, AM J PHYSIOL-REG I, V275, pR269, DOI 10.1152/ajpregu.1998.275.1.R269; Liu YJ, 2003, DIABETES, V52, P1409, DOI 10.2337/diabetes.52.6.1409; Livingstone DEW, 2000, ENDOCRINOLOGY, V141, P560, DOI 10.1210/en.141.2.560; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Luheshi GN, 1999, P NATL ACAD SCI USA, V96, P7047, DOI 10.1073/pnas.96.12.7047; Maskrey M, 2001, AM J PHYSIOL-REG I, V281, pR1675, DOI 10.1152/ajpregu.2001.281.5.R1675; Nadeau S, 2002, J IMMUNOL, V169, P3370, DOI 10.4049/jimmunol.169.6.3370; NICHOLSON WE, 1984, CLIN CHEM, V30, P259; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PLOTSKY PM, 1992, ENDOCRINOLOGY, V130, P1931, DOI 10.1210/en.130.4.1931; Romanovsky AA, 1997, AM J PHYSIOL-REG I, V273, pR407, DOI 10.1152/ajpregu.1997.273.1.R407; Romanovsky AA, 1996, AM J PHYSIOL-REG I, V270, pR693, DOI 10.1152/ajpregu.1996.270.4.R693; Romanovsky AA, 1998, AM J PHYSIOL-REG I, V275, pR323, DOI 10.1152/ajpregu.1998.275.1.R323; Romanovsky AA, 1998, AM J PHYSIOL-REG I, V275, pR332, DOI 10.1152/ajpregu.1998.275.1.R332; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; SEYDOUX J, 1990, AM J PHYSIOL, V259, pR61, DOI 10.1152/ajpregu.1990.259.1.R61; Takahashi N, 1999, J EXP MED, V189, P207, DOI 10.1084/jem.189.1.207; Takaya K, 1996, NAT GENET, V14, P130, DOI 10.1038/ng1096-130; Tollner B, 2000, PFLUG ARCH EUR J PHY, V440, P925, DOI 10.1007/s004240000386; TRIANDAFILLOU J, 1983, AM J PHYSIOL, V244, pE145, DOI 10.1152/ajpendo.1983.244.2.E145; Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1; WuPeng XS, 1997, DIABETES, V46, P513, DOI 10.2337/diabetes.46.3.513; YORK D, 1984, AM J PHYSIOL, V246, pE391, DOI 10.1152/ajpendo.1984.246.5.E391; Zarkesh-Esfahani H, 2001, J IMMUNOL, V167, P4593, DOI 10.4049/jimmunol.167.8.4593; ZUCKERMAN SH, 1989, EUR J IMMUNOL, V19, P301, DOI 10.1002/eji.1830190213	57	37	37	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1949	+		10.1096/fj.04-2295fje	http://dx.doi.org/10.1096/fj.04-2295fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15388670				2022-12-25	WOS:000224243200014
J	Blatner, NR; Stahelin, RV; Diraviyam, K; Hawkins, PT; Hong, WJ; Murray, D; Cho, WH				Blatner, NR; Stahelin, RV; Diraviyam, K; Hawkins, PT; Hong, WJ; Murray, D; Cho, WH			The molecular basis of the differential subcellular localization of FYVE domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; SURFACE-PLASMON RESONANCE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; PROTEIN INTERACTIONS; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; EARLY ENDOSOMES; C2 DOMAINS; MEMBRANE; BINDING	This study systematically analyzed the structural and mechanistic basis of the regulation of subcellular membrane targeting using FYVE domains as a model. FYVE domains, which mediate the recruitment of signaling and membrane-trafficking proteins to phosphatidylinositol 3-phosphate-containing endosomes, exhibit distinct subcellular localization despite minor structural variations within the family. Biophysical measurements, cellular imaging, and computational analysis of various FYVE domains showed that the introduction of a single cationic residue and a hydrophobic loop into the membrane binding region of the FYVE domains dramatically enhanced their membrane interactions. The results indicated that there is a threshold affinity for endosomal localization and that endosomal targeting of FYVE domains is sensitive to small changes in membrane affinity about this threshold. Collectively these studies provide new insight into how subcellular localization of FYVE domains and other membrane targeting domains can be regulated by minimal structural and environmental changes.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Cornell Univ, Weill Med Coll, Dept Immunol & Microbiol, New York, NY 10021 USA; Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England; Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Cho, WH (corresponding author), Univ Illinois, Dept Chem, MC 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019; HONG, Wanjin/E-9927-2010	Stahelin, Robert/0000-0001-5443-7863; Hawkins, Phillip/0000-0002-6979-0464	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598, R01GM053987, R01GM068849] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53987, GM68849, GM52598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; Bates PA, 1999, PROTEINS, P47; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V558, P13, DOI 10.1016/0005-2736(79)90311-0; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; BRUZIK KS, 1995, TETRAHEDRON LETT, V36, P2415, DOI 10.1016/0040-4039(95)00317-6; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Carroll K, 2004, NAT REV MOL CELL BIO, V5, P55, DOI 10.1038/nrm1278; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Diraviyam K, 2003, J MOL BIOL, V328, P721, DOI 10.1016/S0022-2836(03)00325-5; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Estrada L, 2001, HUM MOL GENET, V10, P485, DOI 10.1093/hmg/10.5.485; Eswar N, 2003, NUCLEIC ACIDS RES, V31, P3375, DOI 10.1093/nar/gkg543; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Hayakawa A, 2004, J BIOL CHEM, V279, P5958, DOI 10.1074/jbc.M310503200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 2004, J BIOL CHEM, V279, P3050, DOI 10.1074/jbc.M309007200; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Lee EY, 2002, SCIENCE, V297, P1193, DOI 10.1126/science.1071362; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Petrey D, 2003, PROTEINS, V53, P430, DOI 10.1002/prot.10550; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Ridley SH, 2001, J CELL SCI, V114, P3991; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; Xiang ZX, 2002, P NATL ACAD SCI USA, V99, P7432, DOI 10.1073/pnas.102179699; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003; Zimmermann P, 2002, MOL CELL, V9, P1215, DOI 10.1016/S1097-2765(02)00549-X	55	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53818	53827		10.1074/jbc.M408408200	http://dx.doi.org/10.1074/jbc.M408408200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15452113	hybrid			2022-12-25	WOS:000225680600120
J	Kumar, S; Gupta, L; Han, YS; Barillas-Mury, C				Kumar, S; Gupta, L; Han, YS; Barillas-Mury, C			Inducible Peroxidases mediate nitration of Anopheles midgut cells undergoing apoptosis in response to Plasmodium invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; IN-VITRO; NITROTYROSINE FORMATION; EOSINOPHIL PEROXIDASE; OOKINETE INVASION; MYELOPEROXIDASE; PEROXYNITRITE; TYROSINE; MECHANISM; GAMBIAE	Plasmodium berghei invasion of Anopheles stephensi midgut cells causes severe damage, induces expression of nitric-oxide synthase, and leads to apoptosis. The present study indicates that invasion results in tyrosine nitration, catalyzed as a two-step reaction in which nitric-oxide synthase induction is followed by increased peroxidase activity. Ookinete invasion induced localized expression of peroxidase enzymes, which catalyzed protein nitration in vitro in the presence of nitrite and H2O2. Histochemical stainings revealed that when a parasite migrates laterally and invades more than one cell, the pattern of induced peroxidase activity is similar to that observed for tyrosine nitration. In Anopheles gambiae, ookinete invasion elicited similar responses; it induced expression of 5 of the 16 peroxidase genes predicted by the genome sequence and decreased mRNA levels of one of them. One of these inducible peroxidases has a C-terminal oxidase domain homologous to the catalytic moiety of phagocyte NADPH oxidase and could provide high local levels of superoxide anion (O-2(radical anion)), that when dismutated would generate the local increase in H2O2 required for nitration. Chemically induced apoptosis of midgut cells also activated expression of four ookinete-induced peroxidase genes, suggesting their involvement in general apoptotic responses. The two-step nitration reaction provides a mechanism to precisely localize and circumscribe the toxic products generated by defense reactions involving nitration. The present study furthers our understanding of the biochemistry of midgut defense reactions to parasite invasion and how these may influence the efficiency of malaria transmission by anopheline mosquitoes.	NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA; Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Colorado State University	Barillas-Mury, C (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, 12735 Twinbrook Pkwy, Rockville, MD 20852 USA.	cbarillas@niaid.nih.gov	Gupta, Lalita/R-1111-2019	Kumar, Sanjeev/0000-0003-3866-4593; GUPTA, LALITA/0000-0002-0712-8512	NIAID NIH HHS [R01AI45573] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045573, Z01AI000947] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGERMULLER S, 1981, HISTOCHEMISTRY, V71, P33, DOI 10.1007/BF00592568; Billker O, 1997, PARASITOLOGY, V115, P1, DOI 10.1017/S0031182097008895; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; Daiber A, 2000, EUR J BIOCHEM, V267, P6729, DOI 10.1046/j.1432-1033.2000.01768.x; Danielli A, 2005, CELL MICROBIOL, V7, P181, DOI 10.1111/j.1462-5822.2004.00445.x; Danielli A, 2003, J BIOL CHEM, V278, P4184, DOI 10.1074/jbc.M208187200; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; Ferret Pierre-Jacques, 2002, BMC Immunol, V3, P3; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; Gorren ACF, 1998, BIOCHEMISTRY-MOSCOW+, V63, P734; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; Han YS, 2002, INSECT BIOCHEM MOLEC, V32, P1311, DOI 10.1016/S0965-1748(02)00093-0; Jiao KS, 2001, ANAL BIOCHEM, V293, P43, DOI 10.1006/abio.2001.5118; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P305; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Kumar S, 2003, P NATL ACAD SCI USA, V100, P14139, DOI 10.1073/pnas.2036262100; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Luckhart S, 1998, P NATL ACAD SCI USA, V95, P5700, DOI 10.1073/pnas.95.10.5700; McElhinney B, 2003, J LEUKOCYTE BIOL, V74, P897, DOI 10.1189/jlb.0103028; Monzani E, 2004, EUR J BIOCHEM, V271, P895, DOI 10.1111/j.1432-1033.2004.03992.x; Moulian N, 2001, BLOOD, V97, P3521, DOI 10.1182/blood.V97.11.3521; Myzak MC, 2002, REDOX REP, V7, P47, DOI 10.1179/135100002125000181; Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200; Ribeiro JMC, 1999, J EXP BIOL, V202, P809; RIBEIRO JMC, 1993, J EXP BIOL, V179, P273; SALAZAR CE, 1993, NUCLEIC ACIDS RES, V21, P4147, DOI 10.1093/nar/21.17.4147; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Tsurubuchi T, 2001, J LEUKOCYTE BIOL, V70, P52; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Vlachou D, 2004, CELL MICROBIOL, V6, P671, DOI 10.1111/j.1462-5822.2004.00394.x; Zieler H, 2000, P NATL ACAD SCI USA, V97, P11516, DOI 10.1073/pnas.97.21.11516	33	98	102	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53475	53482		10.1074/jbc.M409905200	http://dx.doi.org/10.1074/jbc.M409905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456781	hybrid			2022-12-25	WOS:000225680600082
J	Uchida, T; Mogi, T; Nakamura, H; Kitagawa, T				Uchida, T; Mogi, T; Nakamura, H; Kitagawa, T			Role of Tyr-288 at the dioxygen reduction site of cytochrome bo studied by stable isotope labeling and resonance Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX METAL CENTERS; COPPER BINUCLEAR CENTER; ELECTRON PARAMAGNETIC RESONANCE; AMINO-ACID-RESIDUES; SUBUNIT-I PERTURB; C-OXIDASE; ESCHERICHIA-COLI; UBIQUINOL OXIDASE; HYDROGEN-PEROXIDE; ACTIVE-SITE	To explore the role of a cross-link between side chains of Tyr-288 and His-284 at the heme-copper binuclear center, we prepared cytochrome bo where d(4)-Tyr, 1-[C-13]Tyr, or 4-[C-13]Tyr has been biosynthetically incorporated. Unexpectedly, the d(4)-Tyr-labeled enzyme showed a large decrease in the ubiquinol-1 oxidase and CO binding activities. Optical absorption and resonance Raman spectra identified the defect in the distal side of the heme-copper binuclear center. In the CO-bound d(4)-Tyr-labeled enzyme, a large fraction of the nu((Fe-C)) mode was shifted from the normal 520-cm(-1) band to a broad band centered around 491 cm(-1), as found for the Y288F mutant. Our results suggested that the substitution of ring hydrogens of Tyr-288 with deuteriums slows down the formation of the His-Tyr cross-link essential for dioxygen reduction at the binuclear center.	Natl Inst Nat Sci, Okazuki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Org, ATP Syst Project, Exploratory Res Adv Technol, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Nagasuta 4259, Japan; RIKEN, Harima Inst, Mikazuki, Hyogo 6795148, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Yokohama, Kanagawa 2300045, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); University of Tokyo; Japan Science & Technology Agency (JST); Tokyo Institute of Technology; RIKEN; Yokohama City University	Mogi, T (corresponding author), Natl Inst Nat Sci, Okazuki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan.	tmogi@res.titech.ac.jp; teizo@ims.ac.jp	Uchida, Takeshi/A-6455-2017	Uchida, Takeshi/0000-0001-9270-8329				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Aki M, 2002, J PHYS CHEM A, V106, P3436, DOI 10.1021/jp012492n; Blomberg MRA, 2000, J INORG BIOCHEM, V80, P261, DOI 10.1016/S0162-0134(00)00080-5; Buse G, 1999, PROTEIN SCI, V8, P985, DOI 10.1110/ps.8.5.985; Cappuccio JA, 2002, J AM CHEM SOC, V124, P1750, DOI 10.1021/ja011852h; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Das TK, 1998, BIOCHEMISTRY-US, V37, P14471, DOI 10.1021/bi981500w; Das TK, 2001, BIOPHYS J, V80, P2039, DOI 10.1016/S0006-3495(01)76177-2; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P13802, DOI 10.1021/bi00042a011; Fabian M, 1999, P NATL ACAD SCI USA, V96, P13114, DOI 10.1073/pnas.96.23.13114; Fabian M, 1999, BIOCHEMISTRY-US, V38, P6270, DOI 10.1021/bi982541v; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HIROTA S, 1994, FEBS LETT, V352, P67, DOI 10.1016/0014-5793(94)00919-8; HOFFMAN BM, 1979, P NATL ACAD SCI USA, V76, P6132, DOI 10.1073/pnas.76.12.6132; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; HOSLER JP, 1994, J AM CHEM SOC, V116, P5515, DOI 10.1021/ja00091a084; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; Iwaki M, 2003, BIOCHEMISTRY-US, V42, P8809, DOI 10.1021/bi034522d; KAINOSHO M, 1982, BIOCHEMISTRY-US, V21, P6273, DOI 10.1021/bi00267a036; Kannt A, 1998, J BIOENERG BIOMEMBR, V30, P81, DOI 10.1023/A:1020563629032; Kawasaki M, 1997, J BIOCHEM, V122, P422; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; Matsuura K, 2004, BIOCHEMISTRY-US, V43, P2288, DOI 10.1021/bi0355490; McCauley KM, 2000, J AM CHEM SOC, V122, P2403, DOI 10.1021/ja993774s; Mogi T, 1998, BIOCHEMISTRY-US, V37, P1632, DOI 10.1021/bi971978k; MOGI T, 1995, FEBS LETT, V370, P259; Mogi T, 1999, FEBS LETT, V457, P61, DOI 10.1016/S0014-5793(99)01007-8; Mogi T., 1998, J BIOCH MOL BIOL BIO, V2, P79; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Ogura T, 2004, BBA-BIOENERGETICS, V1655, P290, DOI 10.1016/j.bbabio.2003.10.013; Ogura T, 1996, J AM CHEM SOC, V118, P5443, DOI 10.1021/ja951922i; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Pinakoulaki E, 2002, J BIOL CHEM, V277, P13563, DOI 10.1074/jbc.M112200200; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P76, DOI 10.1021/bi9511705; PROSHLYAKOV DA, 1994, J BIOL CHEM, V269, P29385; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; Sato-Watanabe M, 1998, BIOCHEMISTRY-US, V37, P5356, DOI 10.1021/bi9727592; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Sucheta A, 1998, BIOCHEMISTRY-US, V37, P17905, DOI 10.1021/bi981092w; THOMAS JW, 1994, BIOCHEMISTRY-US, V33, P13013, DOI 10.1021/bi00248a010; Tomson F, 2002, BIOCHEMISTRY-US, V41, P14383, DOI 10.1021/bi026370c; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1994, J BIOL CHEM, V269, P30861; Uchida T, 2000, BIOCHEMISTRY-US, V39, P6669, DOI 10.1021/bi992538r; UNO T, 1994, J BIOL CHEM, V269, P11912; VAROTSIS CA, 1995, J AM CHEM SOC, V117, P11260, DOI 10.1021/ja00150a025; VYGODINA TV, 1988, ANN NY ACAD SCI, V550, P124, DOI 10.1111/j.1749-6632.1988.tb35329.x; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; WANG JL, 1995, BIOCHEMISTRY-US, V34, P15504, DOI 10.1021/bi00047a016; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WATMOUGH NJ, 1994, BIOCHEM J, V300, P469, DOI 10.1042/bj3000469; Whittaker MM, 2003, J BIOL CHEM, V278, P22090, DOI 10.1074/jbc.M300112200; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; WITTENBERG BA, 1968, J BIOL CHEM, V243, P1863; Yamazaki Y, 1999, J BIOCHEM-TOKYO, V125, P1131, DOI 10.1093/oxfordjournals.jbchem.a022395; YONETANI T, 1966, J BIOL CHEM, V241, P3240; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	71	21	21	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53613	53620		10.1074/jbc.M409719200	http://dx.doi.org/10.1074/jbc.M409719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465820	hybrid			2022-12-25	WOS:000225680600097
J	Wu, Q; Burghardt, R; Safe, S				Wu, Q; Burghardt, R; Safe, S			Vitamin D-interacting protein 205 (DRIP205) coactivation of estrogen receptor alpha (ER alpha) involves multiple domains of both proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; TRANSCRIPTIONAL REGULATION; BREAST-CANCER; DEPENDENT TRANSCRIPTION; RESPONSIVE PROMOTERS; MAMMALIAN MEDIATOR; HORMONE-RECEPTORS; IN-VIVO; COMPLEX; ACTIVATION	Vitamin D-interacting protein 205 (DRIP205) is a mediator complex protein that anchors the complex to the estrogen receptor ( ER) and other nuclear receptors (NRs). In ZR-75 breast cancer cells treated with 17beta-estradiol (E2) and transfected with a construct containing three tandem estrogen responsive elements (pERE(3)), DRIP205 coactivates ERalpha-mediated transactivation. DRIP205Delta587-636 is a DRIP205 mutant in which both NR boxes within amino acids 587-636 have been deleted and, in parallel transfection studies, DRIP205Delta587-636 also coactivates ERalpha. Moreover, both wild-type and variant DRIP205 also colocalize with ERalpha in the nuclei of transfected cells. Extensive deletion analysis of DRIP205 shows that multiple domains of this protein play a role in coactivation of ERalpha and in interactions with ERalpha. Coactivation of ERalpha by DRIP205 does not require NR boxes, and variants with deletion of N-terminal (amino acids 1-639) and C-terminal (amino acids 576-1566) significantly coactivate ERalpha. DRIP205 resembles p160 coactivators that also interact with multiple regions of ERalpha; however, unlike p160 coactivators, DRIP205 coactivation of ERalpha does not require NR boxes.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, 4466 TAMU,Vet Res Bldg 409, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	Burghardt, Robert C./AAF-4847-2021	Burghardt, Robert C./0000-0003-1021-8444				Acevedo ML, 2004, MOL CELL, V13, P725, DOI 10.1016/S1097-2765(04)00121-2; Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003; Bai YL, 2003, MOL ENDOCRINOL, V17, P589, DOI 10.1210/me.2002-0351; Barletta F, 2002, MOL ENDOCRINOL, V16, P301, DOI 10.1210/me.16.2.301; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Coulthard VH, 2003, J BIOL CHEM, V278, P10942, DOI 10.1074/jbc.M212950200; Edwards DP, 1999, VITAM HORM, V55, P165; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Heimann R, 1996, JNCI-J NATL CANCER I, V88, P1764, DOI 10.1093/jnci/88.23.1764; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Klinge CM, 1999, MOL CELL ENDOCRINOL, V157, P105, DOI 10.1016/S0303-7207(99)00165-3; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; ONATE SA, 1995, SCIENCE, V270, P1354; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Yang W, 1999, J BIOL CHEM, V274, P16838, DOI 10.1074/jbc.274.24.16838; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	50	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53602	53612		10.1074/jbc.M409778200	http://dx.doi.org/10.1074/jbc.M409778200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471764	hybrid			2022-12-25	WOS:000225680600096
J	Hannah, BLA; Misenheimer, TM; Pranghofer, MM; Mosher, DF				Hannah, BLA; Misenheimer, TM; Pranghofer, MM; Mosher, DF			A polymorphism in thrombospondin-1 associated with familial premature coronary artery disease alters Ca2+ binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; MULTIPLE EPIPHYSEAL DYSPLASIA; C-TERMINAL REGION; MYOCARDIAL-INFARCTION; TYPE-3 REPEATS; PSEUDOACHONDROPLASIA; CALCIUM; MUTATIONS; GLYCOPROTEIN; PLATELETS	A single nucleotide polymorphism that results in substitution at residue 700 of a serine (Ser-700) for an asparagine (Asn-700) in thrombospondin-1 is associated with familial premature coronary artery disease. The polymorphism is located in the first of 13 Ca2+-binding motifs, within a consensus sequence in which Asn-700 likely coordinates Ca2+. Equilibrium dialysis of constructs comprised of the adjoining epidermal growth factor-like module and the Ca2+-binding region (E3Ca) demonstrated that E3Ca Ser-700 binds significantly less Ca2+ than E3Ca Asn-700 at low [Ca2+]. The hypothesis that this difference is due to loss of a binding site in Ser-700 protein was tested with truncations of E3Ca containing four (Tr4), three (Tr3), two (Tr2), or one (Tr1) N-terminal Ca2+-binding motifs. The Ser-700 truncation constructs bound 1 fewer Ca2+ than matching Asn-700 constructs and exhibited decreased binding affinities. Intrinsic fluorescence of a tryptophan at residue 698 (Trp-698) in the most N-terminal motif was cooperatively quenched by the addition of Ca2+ to Asn-700 Tr2, Tr3, and Tr4 constructs. In Ser-700 constructs, quenching of Trp-698 was incomplete in the Tr2 and Tr3 constructs and complete only in the Tr4 construct. Ca2+-induced quenching of Ser-700 constructs required higher [Ca2+] and was slower as shown in stopped-flow experiments than quenching of Asn-700 constructs. Such differences were not found with Tb3+, which quenched the fluorescence of Asn-700 and Ser-700 constructs equivalently. Thus, the Ser-700 polymorphism alters a rapidly filled, high affinity Ca2+-binding site in the first Ca2+-binding motif. Slower Ca2+ binding to adjoining motifs partly compensates for the change.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Mol & Cellular Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Med Sci Training Programs, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, Rm 4285 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	dfmosher@wisc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462] Funding Source: Medline; NIGMS NIH HHS [T32 GM08688] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2003, J MOL BIOL, V328, P479, DOI 10.1016/S0022-2836(03)00248-1; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Adolph KW, 2002, DNA SEQUENCE, V13, P277, DOI 10.1080/1042517021000019278; Adolph KW, 2001, GENE, V269, P177, DOI 10.1016/S0378-1119(01)00441-3; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; Boekholdt SM, 2002, ARTERIOSCL THROM VAS, V22, pE24, DOI 10.1161/01.ATV.0000046235.22451.66; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Demaurex N, 2003, CELL CALCIUM, V34, P109, DOI 10.1016/S0143-4160(03)00081-2; ELIN RJ, 1996, CECIL TXB MED, P2224; Groves P, 2001, ACTA BIOCHIM POL, V48, P113; Hannah BLA, 2003, J BIOL CHEM, V278, P8929, DOI 10.1074/jbc.M211185200; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Kleerekoper Q, 2002, J BIOL CHEM, V277, P10581, DOI 10.1074/jbc.M109944200; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; Mabuchi A, 2004, AM J MED GENET A, V129A, P35, DOI 10.1002/ajmg.a.30164; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; Misenheimer TM, 2003, BIOCHEMISTRY-US, V42, P5125, DOI 10.1021/bi026983p; Misenheimer TM, 2001, J BIOL CHEM, V276, P45882, DOI 10.1074/jbc.M104218200; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; Narizhneva NV, 2004, J BIOL CHEM, V279, P21651, DOI 10.1074/jbc.M311090200; Pimanda JE, 2002, BLOOD, V100, P2832, DOI 10.1182/blood-2002-03-0770; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; TURK JL, 1986, ARCH BIOCHEM BIOPHYS, V245, P446, DOI 10.1016/0003-9861(86)90236-5; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; Xie LJ, 2001, J EXP MED, V193, P1341, DOI 10.1084/jem.193.12.1341; YAMANO K, 2004, BIOL REPROD	34	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51915	51922		10.1074/jbc.M409632200	http://dx.doi.org/10.1074/jbc.M409632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456750	hybrid			2022-12-25	WOS:000225493400025
J	Kweon, GR; Marks, JD; Krencik, R; Leung, EH; Schumacker, PT; Hyland, K; Kang, UJ				Kweon, GR; Marks, JD; Krencik, R; Leung, EH; Schumacker, PT; Hyland, K; Kang, UJ			Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE-INDUCED ATP LOSS; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; MITOCHONDRIAL RESPIRATION; GLUTATHIONE-PEROXIDASE; TYROSINE-HYDROXYLASE; SUPEROXIDE-DISMUTASE; BRAIN MITOCHONDRIA; SUBSTANTIA-NIGRA; NEURONS	Chronic mitochondrial dysfunction, in particular of complex I, has been strongly implicated in the dopaminergic neurodegeneration in Parkinson's disease. To elucidate the mechanisms of chronic complex I disruption-induced neurodegeneration, we induced differentiation of immortalized midbrain dopaminergic (MN9D) and non-dopaminergic (MN9X) neuronal cells, to maintain them in culture without significant cell proliferation and compared their survivals following chronic exposure to nanomolar rotenone, an irreversible complex I inhibitor. Rotenone killed more dopaminergic MN9D cells than non-dopaminergic MN9X cells. Oxidative stress played an important role in rotenone-induced neurodegeneration of MN9X cells, but not MN9D cells: rotenone oxidatively modified proteins more in MN9X cells than in MN9D cells and antioxidants decreased rotenone toxicity only in MN9X cells. MN9X cells were also more sensitive to exogenous oxidants than MN9D cells. In contrast, disruption of bioenergetics played a more important role in MN9D cells: rotenone decreased mitochondrial membrane protential and ATP levels in MN9D cells more than in MN9X cells. Supplementation of cellular energy with a ketone body, D-beta-hydroxybutyrate, decreased rotenone toxicity in MN9D cells, but not in MN9X cells. MN9D cells were also more susceptible to disruption of oxidative phosphorylation or glycolysis than MN9X cells. These findings indicate that, during chronic rotenone exposure, MN9D cells die primarily through mitochondrial energy disruption, whereas MN9X cells die primarily via oxidative stress. Thus, intrinsic properties of individual cell types play important roles in determining the predominant mechanism of complex I inhibition-induced neurodegeneration.	Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA; Univ Chicago, Dept Physiol & Pharmacol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Baylor Univ, Med Ctr, Inst Metab Dis, Dallas, TX 75226 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; Baylor University; Baylor University Medical Center	Kang, UJ (corresponding author), Univ Chicago, Dept Neurol, MC2030, Chicago, IL 60637 USA.	unkang@uchicago.edu	Marks, Jeremy/W-2087-2019; Kang, Un/AAV-2858-2020	Marks, Jeremy/0000-0002-2644-5257; Kang, Un/0000-0002-5970-6839; Krencik, Robert/0000-0002-2968-3162; Schumacker, Paul T/0000-0001-9591-2034	NHLBI NIH HHS [HL66315] Funding Source: Medline; NIGMS NIH HHS [T32 GM07281] Funding Source: Medline; NINDS NIH HHS [R01 NS038547-05, R01 NS43286, R01 NS038547, R01 NS038547-03, R01 NS038547-04, NS32080, R01 NS038547-02, R01 NS038547-01A1, NS38547] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038547, R29NS032080, R01NS032080, R01NS043286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BATES TE, 1994, J NEUROCHEM, V63, P640; Beal MF, 2003, ANN NEUROL, V53, pS39, DOI 10.1002/ana.10479; Bencsics C, 1996, J NEUROSCI, V16, P4449; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castro DS, 2001, J BIOL CHEM, V276, P43277, DOI 10.1074/jbc.M107013200; CHAN P, 1993, J NEUROCHEM, V61, P610; CHOI HK, 1991, BRAIN RES, V552, P67, DOI 10.1016/0006-8993(91)90661-E; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; DIMONTE D, 1986, BIOCHEM BIOPH RES CO, V137, P310, DOI 10.1016/0006-291X(86)91211-8; Ferrante RJ, 1997, BRAIN RES, V753, P157, DOI 10.1016/S0006-8993(97)00008-5; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Han BS, 2003, J NEUROSCI, V23, P5069; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; HEIKKILA RE, 1985, NEUROSCI LETT, V58, P133, DOI 10.1016/0304-3940(85)90342-8; Hoglinger GU, 2003, J NEUROCHEM, V84, P491, DOI 10.1046/j.1471-4159.2003.01533.x; HOWELLS DW, 1987, CLIN CHIM ACTA, V167, P23, DOI 10.1016/0009-8981(87)90081-7; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144; Mazzio E, 2003, NEUROTOXICOLOGY, V24, P137, DOI 10.1016/S0161-813X(02)00110-9; Menegon A, 1998, LANCET, V352, P1344, DOI 10.1016/S0140-6736(98)03453-9; Nakamura K, 2001, J BIOL CHEM, V276, P34402, DOI 10.1074/jbc.M103766200; Nakamura K, 2000, J NEUROCHEM, V74, P2305, DOI 10.1046/j.1471-4159.2000.0742305.x; Nakamura K, 2000, MOL PHARMACOL, V58, P271, DOI 10.1124/mol.58.2.271; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Perier C, 2003, TRENDS NEUROSCI, V26, P345, DOI 10.1016/S0166-2236(03)00144-9; Pong K, 2000, BRAIN RES, V881, P182, DOI 10.1016/S0006-8993(00)02841-9; PRZEDBORSKI S, 1992, J NEUROCHEM, V58, P1760, DOI 10.1111/j.1471-4159.1992.tb10051.x; Royland JE, 1999, BRAIN RES, V839, P41, DOI 10.1016/S0006-8993(99)01689-3; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Sherer TB, 2002, J NEUROSCI, V22, P7006; Storch A, 2000, BRAIN RES, V855, P67, DOI 10.1016/S0006-8993(99)02272-6; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862	42	57	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51783	51792		10.1074/jbc.M407336200	http://dx.doi.org/10.1074/jbc.M407336200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15469939	hybrid			2022-12-25	WOS:000225493400011
J	Lazzell, DR; Belizaire, R; Thakur, P; Sherry, DM; Janz, R				Lazzell, DR; Belizaire, R; Thakur, P; Sherry, DM; Janz, R			SV2B regulates synaptotagmin 1 by direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PROTEIN; MOUSE RETINA; T-SNARE; NEUROTRANSMITTER RELEASE; BINDING; EXOCYTOSIS; ENDOCYTOSIS; SYNTAXIN; CYCLE; IDENTIFICATION	SV2 proteins are abundant synaptic vesicle proteins expressed in two major (SV2A and SV2B) and one minor (SV2C) isoform. SV2A and SV2B have been shown to be involved in the regulation of synaptic vesicle exocytosis. Previous studies found that SV2A, but not SV2B, can interact with the cytoplasmic domain of synaptotagmin 1, a Ca2+ sensor for synaptic vesicle exocytosis. To determine whether SV2B can interact with full-length synaptotagmin 1, we performed immunoprecipitations from brain protein extracts and found that SV2B interacts strongly with synaptotagmin 1 in a detergent-resistant, Ca2+-independent manner. In contrast, an interaction between native SV2A and synaptotagmin 1 was not detectable under these conditions. The SV2B-synaptotagmin 1 complex also contained the synaptic t-SNARE proteins, syntaxin 1 and SNAP-25, suggesting that SV2B may participate in exocytosis by modulating the interaction of synaptotagmin 1 with t-SNARE proteins. Analysis of retinae in SV2B knock-out mice revealed a strong reduction in the level of synaptotagmin 1 in rod photoreceptor synapses, which are unique in that they express only the SV2B isoform. In contrast, other synaptic vesicle proteins were not affected by SV2B knock out, indicating a specific role for SV2B in the regulation of synaptotagmin 1 levels at certain synapses. These experiments suggest that the SV2B-synaptotagmin 1 complex is involved in the regulation of synaptotagmin 1 stability and/or trafficking. This study has demonstrated a new role of SV2B as a regulator of synaptotagmin 1 that is likely mediated by direct interaction of these two synaptic proteins.	Univ Texas, WM Keck Ctr Learning & Memory, Dept Neurobiol & Anat, Sch Med, Houston, TX 77030 USA; Univ Houston, Coll Optometry, Houston, TX 77204 USA	University of Texas System; University of Houston System; University of Houston	Janz, R (corresponding author), Univ Texas, WM Keck Ctr Learning & Memory, Dept Neurobiol & Anat, Sch Med, Houston, TX 77030 USA.	Roger.Janz@uth.tmc.edu		Janz, Roger/0000-0002-9872-0596; Belizaire, Roger/0000-0001-8496-287X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007467] Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY07751] Funding Source: Medline; NINDS NIH HHS [5-T32-NS07467] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aravanis AM, 2003, NEUROPHARMACOLOGY, V45, P797, DOI 10.1016/S0028-3908(03)00310-1; Bai JH, 2004, NEURON, V41, P929, DOI 10.1016/S0896-6273(04)00117-5; BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BAJJALIEH SM, 1993, P NATL ACAD SCI USA, V90, P2150, DOI 10.1073/pnas.90.6.2150; BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; Belizaire R, 2004, J COMP NEUROL, V470, P266, DOI 10.1002/cne.20008; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; FEANY MB, 1993, J CELL BIOL, V123, P575, DOI 10.1083/jcb.123.3.575; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; Fergestad T, 2001, J NEUROSCI, V21, P1218; Fergestad T, 1999, J NEUROSCI, V19, P5847, DOI 10.1523/JNEUROSCI.19-14-05847.1999; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; Han WP, 2004, NEURON, V41, P85, DOI 10.1016/S0896-6273(03)00820-1; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Janz R, 1999, NEUROSCIENCE, V94, P1279, DOI 10.1016/S0306-4522(99)00370-X; Janz R, 1998, J NEUROSCI, V18, P9269; Janz R, 1999, NEURON, V24, P1003, DOI 10.1016/S0896-6273(00)81046-6; Jarousse N, 2001, J CELL BIOL, V154, P857, DOI 10.1083/jcb.200103040; Jeon CJ, 1998, J NEUROSCI, V18, P8936; Kee Y, 1996, J NEUROSCI, V16, P1975; Koh TW, 2003, TRENDS NEUROSCI, V26, P413, DOI 10.1016/S0166-2236(03)00195-4; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Paillart C, 2003, J NEUROSCI, V23, P4092; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Rea R, 2004, NEURON, V41, P755, DOI 10.1016/S0896-6273(04)00088-1; Rickman C, 2003, J BIOL CHEM, V278, P5501, DOI 10.1074/jbc.C200692200; Rieke F, 1996, J PHYSIOL-LONDON, V493, P1; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Sudhof TC, 2000, NEURON, V28, P317, DOI 10.1016/S0896-6273(00)00109-4; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tokuoka H, 2003, NEURON, V38, P521, DOI 10.1016/S0896-6273(03)00290-3; Verona M, 2000, J NEUROCHEM, V74, P209, DOI 10.1046/j.1471-4159.2000.0740209.x; Wang MM, 2003, J COMP NEUROL, V460, P106, DOI 10.1002/cne.10636; Xu T, 2001, NAT CELL BIOL, V3, P691, DOI 10.1038/35087000; Yoshihara M, 2003, CURR OPIN NEUROBIOL, V13, P315, DOI 10.1016/S0959-4388(03)00063-1; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2	46	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52124	52131		10.1074/jbc.M407502200	http://dx.doi.org/10.1074/jbc.M407502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466855	hybrid			2022-12-25	WOS:000225493400051
J	Mashhoon, N; Carroll, M; Pruss, C; Eberhard, J; Ishikawa, S; Estabrook, RA; Reich, N				Mashhoon, N; Carroll, M; Pruss, C; Eberhard, J; Ishikawa, S; Estabrook, RA; Reich, N			Functional characterization of Escherichia coli DNA adenine methyltransferase, a novel target for antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE; KINETIC MECHANISM; DAM METHYLASE; CYTOSINE-C-5 METHYLTRANSFERASE; FACILITATED DIFFUSION; CATALYTIC PROPERTIES; SECONDARY STRUCTURE; GATC SITES; ENZYME; BINDING	We have characterized Escherichia coli DNA adenine methyltransferase, a critical regulator of bacterial virulence. Steady-state kinetics, product inhibition, and isotope exchange studies are consistent with a kinetic mechanism in which the cofactor S-adenosylmethionine binds first, followed by sequence-specific DNA binding and catalysis. The enzyme has a fast methyl transfer step followed by slower product release steps, and we directly demonstrate the competence of the enzyme cofactor complex. Methylation of adjacent GATC sites is distributive with DNA derived from a genetic element that controls the transcription of the adjacent genes. This indicates that the first methylation event is followed by enzyme release. The affinity of the enzyme for both DNA and S-adenosylmethionine was determined. Our studies provide a basis for further structural and functional analysis of this important enzyme and for the identification of inhibitors for potential therapeutic applications.	EpiGenX Pharmaceut, Pacific Technol Ctr, Santa Barbara, CA 93111 USA; Univ Kiel, Dept Operat Dent & Periodontol, Kiel, Germany; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of Kiel; University of California System; University of California Santa Barbara	Reich, N (corresponding author), EpiGenX Pharmaceut, Pacific Technol Ctr, Santa Barbara, CA 93111 USA.	reich@chem.ucsb.edu	Eberhard, Joerg/AAY-9034-2020; Eberhard, Jörg/G-1103-2012; Pruss, Cynthia/P-2552-2019; Pruss, Cynthia/A-7945-2013	Eberhard, Joerg/0000-0001-8060-2893; Pruss, Cynthia/0000-0002-3841-8336; Pruss, Cynthia/0000-0002-3841-8336	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI048377] Funding Source: NIH RePORTER; NIAID NIH HHS [2 R43 AI48377-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allan BW, 1999, J BIOL CHEM, V274, P19269, DOI 10.1074/jbc.274.27.19269; BARRAS F, 1988, NUCLEIC ACIDS RES, V16, P9821, DOI 10.1093/nar/16.20.9821; Berdis AJ, 1998, P NATL ACAD SCI USA, V95, P2874, DOI 10.1073/pnas.95.6.2874; BERGERAT A, 1990, NUCLEIC ACIDS RES, V18, P4369, DOI 10.1093/nar/18.15.4369; BERGERAT A, 1991, P NATL ACAD SCI USA, V88, P6394, DOI 10.1073/pnas.88.15.6394; BERGERAT A, 1989, J BIOL CHEM, V264, P4064; Bhattacharya SK, 1999, J BIOL CHEM, V274, P14743, DOI 10.1074/jbc.274.21.14743; BRAATEN BA, 1994, CELL, V76, P577, DOI 10.1016/0092-8674(94)90120-1; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; Gowher H, 2000, J MOL BIOL, V303, P93, DOI 10.1006/jmbi.2000.4127; HALE WB, 1994, J BACTERIOL, V176, P3438, DOI 10.1128/jb.176.11.3438-3441.1994; HERMAN GE, 1982, J BIOL CHEM, V257, P2605; Hernday A, 2002, P NATL ACAD SCI USA, V99, P16470, DOI 10.1073/pnas.182427199; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kossykh VG, 2004, J BACTERIOL, V186, P2061, DOI 10.1128/JB.186.7.2061-2067.2004; KRIEBARDIS A, 1987, FEBS LETT, V213, P297, DOI 10.1016/0014-5793(87)81509-0; Liebert K, 2004, J MOL BIOL, V341, P443, DOI 10.1016/j.jmb.2004.05.033; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; MAEGLEY KA, 1992, J BIOL CHEM, V267, P18527; MARINUS MG, 1983, MOL GEN GENET, V192, P288, DOI 10.1007/BF00327681; RAO DN, 1989, J MOL BIOL, V209, P599, DOI 10.1016/0022-2836(89)90597-4; REICH NO, 1990, J BIOL CHEM, V265, P8966; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; Reisenauer A, 1999, J BACTERIOL, V181, P5135, DOI 10.1128/JB.181.17.5135-5139.1999; SPECTOR T, 1981, BIOCHEM PHARMACOL, V30, P1, DOI 10.1016/0006-2952(81)90277-X; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2201, DOI 10.1021/bi951883n; SZILAK L, 1993, EUR J BIOCHEM, V218, P727, DOI 10.1111/j.1432-1033.1993.tb18427.x; Urig S, 2002, J MOL BIOL, V319, P1085, DOI 10.1016/S0022-2836(02)00371-6; Wahnon DC, 2001, J AM CHEM SOC, V123, P976, DOI 10.1021/ja003285o; WU JC, 1987, J BIOL CHEM, V262, P4778	35	40	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52075	52081		10.1074/jbc.M408182200	http://dx.doi.org/10.1074/jbc.M408182200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456775	hybrid			2022-12-25	WOS:000225493400045
J	Granier, S; Terrillon, S; Pascal, R; Demene, H; Bouvier, M; Guillon, G; Mendre, C				Granier, S; Terrillon, S; Pascal, R; Demene, H; Bouvier, M; Guillon, G; Mendre, C			A cyclic peptide mimicking the third intracellular loop of the V-2 vasopressin receptor inhibits signaling through its interaction with receptor dimer and G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; COUPLED RECEPTOR; SYNTHETIC PEPTIDES; PSEUDO-PROLINES; HIGH-AFFINITY; ACTIVATION; DIMERIZATION; BINDING; OLIGOMERIZATION; MEMBRANES	In this study, we investigated the mechanism by which a peptide mimicking the third cytoplasmic loop of the vasopressin V2 receptor inhibits signaling. This loop was synthesized as a cyclic peptide (i3 cyc) that adopted defined secondary structure in solution. We found that i3 cyc inhibited the adenylyl cyclase activity induced by vasopressin or a nonhydrolyzable analog of GTP, guanosine 5'-O-(3-thio) triphosphate. This peptide also affected the specific binding of [H-3] AVP by converting vasopressin binding sites from a high to a low affinity state without any effect on the global maximal binding capacity. The inhibitory actions of i3 cyc could also be observed in the presence of maximally uncoupling concentration of guanosine 5'-O-(3-thio) triphosphate, indicating a direct effect on the receptor itself and not exclusively on the interaction between the Gs protein and the V-2 receptor (V-2-R). Bioluminescence resonance energy-transfer experiments confirmed this assumption, because i3 cyc induced a significant inhibition of the bioluminescence resonance energy-transfer signal between the Renilla reniformis luciferase and the enhanced yellow fluorescent protein fused V-2-R. This suggests that the proper arrangement of the dimer could be an important prerequisite for triggering Gs protein activation. In addition to its effect on the receptor itself, the peptide exerted some of its actions at the G protein level, because it could also inhibit guanosine 5'-O-(3-thio) triphosphate-stimulated AC activity. Taken together, the data demonstrate that a peptide mimicking V-2-R third intracellular loop affects both the dimeric structural organization of the receptor and has direct inhibitory action on Gs.	CCIPE, INSERM, U469, F-34094 Montpellier, France; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montpellier 2, UMR 5073, F-34095 Montpellier, France; Ctr Biochim Struct, CNRS, UMR 5048, INSERM,UMR 554,UM1, F-34060 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montreal; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Mendre, C (corresponding author), CCIPE, INSERM, U469, 141 Rue Cardonille, F-34094 Montpellier, France.	christiane.mendre@ccipe.cnrs.fr	Pascal, Robert/O-1559-2013; Bouvier, Michel/H-2758-2014; Granier, Sebastien/J-1089-2016; Déméné, Hélène/AAZ-1691-2021	Pascal, Robert/0000-0001-9579-2503; Bouvier, Michel/0000-0003-1128-0100; Déméné, Hélène/0000-0002-7531-4309				Andres M, 2002, BRIT J PHARMACOL, V135, P1828, DOI 10.1038/sj.bjp.0704634; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BUTLEN D, 1978, MOL PHARMACOL, V14, P1006; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Demene H, 2003, BIOCHEMISTRY-US, V42, P8204, DOI 10.1021/bi027358n; Erlenbach I, 1998, J BIOL CHEM, V273, P26549, DOI 10.1074/jbc.273.41.26549; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FROESTL W, 1995, J MED CHEM, V38, P3313, DOI 10.1021/jm00017a016; Galvez T, 2000, MOL PHARMACOL, V57, P419, DOI 10.1124/mol.57.3.419; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GUILLON G, 1984, MOL PHARMACOL, V26, P241; Hayashida W, 1996, J BIOL CHEM, V271, P21985, DOI 10.1074/jbc.271.36.21985; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; KONIG B, 1994, BBA-MOL CELL RES, V1223, P261, DOI 10.1016/0167-4889(94)90235-6; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Mukhopadhyay S, 2001, EUR J BIOCHEM, V268, P499, DOI 10.1046/j.1432-1327.2001.01810.x; MUTTER M, 1995, PEPTIDE RES, V8, P145; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; ORLOFF J, 1962, J CLIN INVEST, V41, P702, DOI 10.1172/JCI104528; RANSNAS LA, 1988, J BIOL CHEM, V263, P17239; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; VARRAULT A, 1994, J BIOL CHEM, V269, P16720; Wohr T, 1996, J AM CHEM SOC, V118, P9218, DOI 10.1021/ja961509q; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	39	22	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50904	50914		10.1074/jbc.M405089200	http://dx.doi.org/10.1074/jbc.M405089200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452133	hybrid			2022-12-25	WOS:000225355800033
J	Maas, R				Maas, R			Prereplicative purine methylation and postreplicative demethylation in each DNA duplication of the Escherichia coli replication cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID REPLICATION; REPA1 PROTEIN; METHYLTRANSFERASE; 7-METHYLGUANINE; GENE; 5-METHYLCYTOSINE; SENSITIVITY; MUTATIONS; REPLICON; INCREASE	Escherichia coli plasmid DNA activated for initiation of duplication is in a stable low linking number supercoiled conformation. Low linking number DNA is methylated at the internal purines of a frequent 5'-Pyr-Pyr-Pur- Pur tetramer with a 5'-Pyr-Pur-3' axis of symmetry and is cut at the axis of symmetry by pneumococcal restriction enzyme DpnI when methylated in both strands. Purine methylation is of adenine in one strand and guanine in the other. Methylation of one of the two purines is removed during the cell cycle, presumably before the reverse shift to the B-supercoiled conformation. The topological transition was reconstituted in vitro only with DNA unmethylated at purines. Methylation-restriction analyses coupled with the chemical properties of low-linking number DNA and B-DNA respectively, suggest that removal of guanine methylation is essential for the low-linking number to B-DNA transition and hence for the deactivation of replication. Demethylation of methylguanine could explain the presence in E. coli of the two-member inducible operon known as ada. Characteristics of ada suggest a cascade of chemical DNA modifications that reverse prereplicative guanine methylation. Guanine demethylation could provide a model for the pivotal role played by de novo methylation in replication and for the essential role of "repair" enzyme ExoIII in demethylation leading to the reversal of replicative DNA activation and other processes that affect DNA function.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Maas, R (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	maasr01@endeavor.med.nyu.edu						Bandaru B, 1996, J BIOL CHEM, V271, P7851, DOI 10.1074/jbc.271.13.7851; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DEMPLE B, 1986, NUCLEIC ACIDS RES, V14, P5575, DOI 10.1093/nar/14.14.5575; DEMPLE B, 1982, J BIOL CHEM, V257, P13776; Gonzalgo ML, 1997, MUTAT RES-REV MUTAT, V386, P107, DOI 10.1016/S1383-5742(96)00047-6; GRIGG G, 1994, BIOESSAYS, V16, P431, DOI 10.1002/bies.950160612; IMLAY JA, 1986, J BACTERIOL, V166, P519, DOI 10.1128/jb.166.2.519-527.1986; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KATAOKA H, 1983, J BACTERIOL, V153, P1301, DOI 10.1128/JB.153.3.1301-1307.1983; KATAOKA H, 1985, MOL GEN GENET, V198, P263, DOI 10.1007/BF00383004; Kornberg A., 1992, DNA REPLICATION; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LITTLE JW, 1967, J BIOL CHEM, V242, P679; Maas R, 1997, J BACTERIOL, V179, P3823, DOI 10.1128/jb.179.12.3823-3827.1997; Maas R, 2001, CELL, V105, P945, DOI 10.1016/S0092-8674(01)00402-0; Maas R, 1997, J BACTERIOL, V179, P2163, DOI 10.1128/jb.179.7.2163-2168.1997; MACKAY WJ, 1994, J BACTERIOL, V176, P3224, DOI 10.1128/jb.176.11.3224-3230.1994; Maxam A M, 1980, Methods Enzymol, V65, P499; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; MOLLER A, 1981, P NATL ACAD SCI-BIOL, V78, P4777, DOI 10.1073/pnas.78.8.4777; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PAEK KH, 1986, J BACTERIOL, V165, P763, DOI 10.1128/jb.165.3.763-770.1986; PALMER BR, 1994, GENE, V143, P1, DOI 10.1016/0378-1119(94)90597-5; PARK JW, 1988, P NATL ACAD SCI USA, V85, P7467, DOI 10.1073/pnas.85.20.7467; RIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P110; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; SAADI S, 1987, J BACTERIOL, V169, P1836, DOI 10.1128/jb.169.5.1836-1846.1987; SAMSON L, 1977, NATURE, V267, P281, DOI 10.1038/267281a0; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SCHENDEL PF, 1978, J BACTERIOL, V135, P466, DOI 10.1128/JB.135.2.466-475.1978; Sharath AN, 2000, BIOCHEMISTRY-US, V39, P14611, DOI 10.1021/bi001610e; TAN BH, 1990, MUTAT RES, V237, P229, DOI 10.1016/0921-8734(90)90004-B; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; YEBRA MJ, 1995, BIOCHEMISTRY-US, V34, P14752, DOI 10.1021/bi00045a016	36	1	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51568	51573		10.1074/jbc.M407394200	http://dx.doi.org/10.1074/jbc.M407394200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448156	hybrid			2022-12-25	WOS:000225355800112
J	Mesmin, B; Robbe, K; Geny, B; Luton, F; Brandolin, G; Popoff, MR; Antonny, B				Mesmin, B; Robbe, K; Geny, B; Luton, F; Brandolin, G; Popoff, MR; Antonny, B			A phosphatidylserine-binding site in the cytosolic fragment of Clostridium sordellii lethal toxin facilitates glucosylation of membrane-bound Rac and is required for cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-PROTEINS; HA-RAS; COMPLEX; DOMAIN; MONOGLUCOSYLATION; TRANSLOCATION; CONSEQUENCES; LOCALIZATION; PURIFICATION; REGION	Large clostridial toxins glucosylate some small G proteins on a threonine residue, thereby preventing their interactions with effector molecules and regulators. We show that the glucosyltransferase domain of lethal toxin from Clostridium sordellii (LTcyt; amino acids 1-546), which is released into the cytosol during cell infection, binds preferentially to liposomes containing phosphatidylserine as compared with other anionic lipids. The binding of LTcyt to phosphatidylserine increases by two orders of magnitude the rate of glucosylation of liposome-bound geranyl-geranylated Rac-GDP. Limited proteolysis and deletion studies show that the binding site for phosphatidylserine lies within the first 18 N-terminal residues of LTcyt. Deletion of these residues abolishes the effect of phosphatidylserine on the activity of LTcyt on liposome-bound geranyl-geranylated Rac-GDP and prevents the morphological effects induced by LTcyt microinjection into various cells, but it does not affect the intrinsic activity of LTcyt on non-geranyl-geranylated Rac-GDP in solution. We conclude that the avidity of LTcyt for phosphatidylserine facilitates its targeting to the cytosolic leaflet of cell membranes and, notably, the plasma membrane, where this anionic lipid is abundant and where several targets of lethal toxin reside.	Inst Pasteur, Unite Bacteries Anaerobies & Toxines, F-75724 Paris 15, France; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Grenoble 1, CNRS, CEA, UMR 5092,Lab Biochim & Biophys Syst Integres, F-38054 Grenoble 9, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Popoff, MR (corresponding author), Inst Pasteur, Unite Bacteries Anaerobies & Toxines, 28 Rue Dr Roux, F-75724 Paris 15, France.	mpopoff@pasteur.fr; antonny@ipmc.cnrs.fr	Antonny, Bruno/ABH-7434-2020; Mesmin, Bruno/N-9246-2017; Luton, Frederic/N-7673-2017; Robbe-Sermesant, Karine/Q-2253-2016	Antonny, Bruno/0000-0002-9166-8668; Robbe-Sermesant, Karine/0000-0003-0580-3817; Mesmin, Bruno/0000-0002-5437-3246				Barth H, 2001, J BIOL CHEM, V276, P10670, DOI 10.1074/jbc.M009445200; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Busch C, 2000, CURR OPIN STRUC BIOL, V10, P528, DOI 10.1016/S0959-440X(00)00126-3; Caccin P, 2003, FEBS LETT, V542, P132, DOI 10.1016/S0014-5793(03)00365-X; Fernandez-Salas E, 2004, P NATL ACAD SCI USA, V101, P3208, DOI 10.1073/pnas.0400229101; Genth H, 1999, J BIOL CHEM, V274, P29050, DOI 10.1074/jbc.274.41.29050; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hofmann F, 1998, INFECT IMMUN, V66, P1076, DOI 10.1128/IAI.66.3.1076-1081.1998; Hofmann F, 1997, J BIOL CHEM, V272, P11074; Just I, 2000, HANDB EXP PHARM, V145, P307; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Lee SY, 2004, NATURE, V430, P232, DOI 10.1038/nature02632; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Murray D, 2002, CURR TOP MEMBR, V52, P277; Pfeifer G, 2003, J BIOL CHEM, V278, P44535, DOI 10.1074/jbc.M307540200; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Qa'Dan M, 2000, INFECT IMMUN, V68, P2470, DOI 10.1128/IAI.68.5.2470-2474.2000; Qa'Dan M, 2001, INFECT IMMUN, V69, P5487, DOI 10.1128/IAI.69.9.5487-5493.2001; Read PW, 2000, METHOD ENZYMOL, V325, P15; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Vetter IR, 2000, J MOL BIOL, V301, P1091, DOI 10.1006/jmbi.2000.4045	33	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49876	49882		10.1074/jbc.M406903200	http://dx.doi.org/10.1074/jbc.M406903200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383551	hybrid			2022-12-25	WOS:000225229500041
J	Satoh, A; Toyota, M; Ikeda, H; Morimoto, Y; Akino, K; Mita, H; Suzuki, H; Sasaki, Y; Kanaseki, T; Takamura, Y; Soejima, H; Urano, T; Yanagihara, K; Endo, T; Hinoda, Y; Fujita, M; Hosokawa, M; Sato, N; Tokino, T; Imai, K				Satoh, A; Toyota, M; Ikeda, H; Morimoto, Y; Akino, K; Mita, H; Suzuki, H; Sasaki, Y; Kanaseki, T; Takamura, Y; Soejima, H; Urano, T; Yanagihara, K; Endo, T; Hinoda, Y; Fujita, M; Hosokawa, M; Sato, N; Tokino, T; Imai, K			Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells	ONCOGENE			English	Article						DNA methylation; chromatin; gene expression	CPG ISLAND HYPERMETHYLATION; GENE-EXPRESSION; DNA METHYLATION; TUMOR-CELLS; HISTONE MODIFICATIONS; GOOD PROGNOSIS; PROMOTER-IV; LARGE-BOWEL; CARCINOMAS; PROTEIN	Tightly regulated at the level of transcription, expression of MHC class II molecules varies significantly among gastrointestinal cancers. High levels of MHC class II expression are often associated with a better prognosis, which is indicative of the involvement of CD4(+) lymphocytes in tumor suppression, but the molecular mechanism by which MHC class II expression is regulated remains unclear. In the present study, we investigated the expression of one inducible MHC class II molecule, HLA-DR, and its coactivators in a panel of colorectal and gastric cancer cell lines. Interferon-gamma induced expression of HLA-DR in 14 of 20 cell lines tested; the remaining six cell lines did not express HLA-DR. Analysis of the expression of transcription factors and coactivators associated with HLA-DR revealed that the loss of CIITA expression was closely associated with the absence of HLA-DR induction. Moreover, DNA methylation of the 50 CpG island of CIITA-PIV was detected in all cancer cells that lacked CIITA. The methylation and resultant silencing of CIITA-PIV depended on the activities of two DNA methyltransferases, DNMT1 and DNMT3B, and their genetic inactivation restored CIITA-PIV expression. It thus appears that CIITA methylation is a key mechanism that enables some gastrointestinal cancer cells to escape immune surveillance.	Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Dept Mol Biol, Canc Res Inst, Sapporo, Hokkaido 0608543, Japan; PRESTO JST, Kawaguchi 3320012, Japan; Sapporo Med Univ, Dept Pathol, Sapporo, Hokkaido 0608556, Japan; Saga Med Sch, Div Mol Biol & Genet, Saga 8498501, Japan; Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan; Natl Canc Ctr, Res Inst, Cent Anim Lab, Tokyo 1040045, Japan; Yamaguchi Univ, Sch Med, Dept Clin Lab Sci, Yamaguchi 7558505, Japan; Keiyukai Sapporo Hosp, Sapporo, Hokkaido 0030027, Japan	Sapporo Medical University; Sapporo Medical University; Japan Science & Technology Agency (JST); Sapporo Medical University; Saga University; Nagoya University; National Cancer Center - Japan; Yamaguchi University	Toyota, M (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	mtoyota@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Sasaki, Yasushi/0000-0002-3500-8059; Soejima, Hidenobu/0000-0001-5076-6563; Urano, Takeshi/0000-0003-3383-3554; Kanaseki, Takayuki/0000-0001-7294-6880				Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; ANDERSEN SN, 1993, BRIT J CANCER, V68, P80, DOI 10.1038/bjc.1993.290; Armstrong TD, 1998, J IMMUNOL, V160, P661; Armstrong TD, 1997, P NATL ACAD SCI USA, V94, P6886, DOI 10.1073/pnas.94.13.6886; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Croce M, 2003, ONCOGENE, V22, P7848, DOI 10.1038/sj.onc.1207054; Fahrner JA, 2002, CANCER RES, V62, P7213; Garrido F, 2001, ADV CANCER RES, V83, P117, DOI 10.1016/S0065-230X(01)83005-0; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAKLAMANIS L, 1992, CANCER SURV, V13, P155; Kanaseki T, 2003, J IMMUNOL, V170, P4980, DOI 10.4049/jimmunol.170.10.4980; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202; Liang GN, 2000, CANCER RES, V60, P4907; Lovig T, 2002, BRIT J CANCER, V87, P756, DOI 10.1038/sj.bjc.6600507; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; MCDOUGALL CJ, 1990, CANCER RES, V50, P8023; Meazza R, 2003, EUR J IMMUNOL, V33, P1183, DOI 10.1002/eji.200323712; Morris AC, 2000, J IMMUNOL, V164, P4143, DOI 10.4049/jimmunol.164.8.4143; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Neugut AI, 1996, SEMIN ONCOL, V23, P281; Nguyen CT, 2002, CANCER RES, V62, P6456; Ossendorp F, 2000, IMMUNOL LETT, V74, P75, DOI 10.1016/S0165-2478(00)00252-2; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sengupta PK, 2003, CANCER RES, V63, P1789; Suzuki H, 2000, CANCER RES, V60, P4353; Takamura Y, 2004, GLIA, V45, P392, DOI 10.1002/glia.10343; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Toes REM, 1999, J EXP MED, V189, P753, DOI 10.1084/jem.189.5.753; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; van den Elsen PJ, 2001, J REPROD IMMUNOL, V52, P129, DOI 10.1016/S0165-0378(01)00115-2; Waldburger JM, 2001, J EXP MED, V194, P393, DOI 10.1084/jem.194.4.393; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yazawa T, 2002, AM J PATHOL, V161, P291, DOI 10.1016/S0002-9440(10)64181-8	39	84	92	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8876	8886		10.1038/sj.onc.1208144	http://dx.doi.org/10.1038/sj.onc.1208144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467734				2022-12-25	WOS:000225354600003
J	Carretero, M; del Rio, M; Garcia, M; Escamez, MJ; Mirones, I; Rivas, L; Balague, C; Jorcano, JL; Larcher, F				Carretero, M; del Rio, M; Garcia, M; Escamez, MJ; Mirones, I; Rivas, L; Balague, C; Jorcano, JL; Larcher, F			A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides	FASEB JOURNAL			English	Article						AMP; burn wounds; mulitdrug resistance	HUMAN BETA-DEFENSIN; ANTIBIOTIC LL-37/HCAP-18; HUMAN LUNG; SKIN; LL-37; SURFACE; DIFFERENTIATION; EPITHELIUM; WOUNDS; MODEL	Infection represents a major associated problem in severely burned patients, as it causes skin graft failure and increases the risk of mortality. Topical and systemic antibiotic treatment is limited by the appearance of resistant bacterial strains. Antimicrobial peptides (AMPs) are gene-encoded "natural antibiotics" that form part of the innate mechanism of defense and may be active against such antibiotic-resistant microorganisms. Several microbicidal peptides are expressed in human skin under inflammatory conditions, and their function is not only limited to microbial killing but also influences tissue repair and adaptive immunity. Protein delivery through cutaneous gene therapy is a promising therapeutic tool for both skin and nonskin diseases. Here we present a gene transfer approach aimed at delivering antimicrobial peptides from keratinocytes. Adenoviral vectors encoding antimicrobial peptide genes were used to infect human keratinocytes growing either on plastic or as part of cultured skin equivalents. Inhibition of bacterial growth occurred both in conditioned media and in direct contact with AMPs gene-transduced keratinocytes. In addition, we showed cooperative effects after transfer of combinations of genes encoding for AMPs with structural differences. Combined cutaneous tissue engineering in conjunction with ( microbicidal) gene therapy emerges as a tailored therapeutic approach that is useful for wound coverage and, in this case, concomitantly combating infection.	Fdn Marcelino Botin, CIEMAT, Madrid 28040, Spain; CSIC, Ctr Invest Biol, Madrid, Spain; Almirall Prodesfarma SA, Barcelona, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Almirall	Larcher, F (corresponding author), Fdn Marcelino Botin, CIEMAT, Ave Complutense 22,Edificio 7, Madrid 28040, Spain.	fernando.larcher@ciemat.es	Toledano, Maria José Escámez/F-5297-2016; Carretero, Marta/C-3842-2017; DEL RIO, MARCELA/H-2796-2015; Larcher, Fernando/J-1527-2016; Rivas, Luis/O-8657-2017; Escamez, Maria-José/AAF-6038-2020; Carretero, Marta/AAF-3380-2021	Toledano, Maria José Escámez/0000-0002-5434-1885; Carretero, Marta/0000-0001-6152-3102; DEL RIO, MARCELA/0000-0003-2910-7189; Larcher, Fernando/0000-0002-6771-3561; Rivas, Luis/0000-0002-2958-3233; Escamez, Maria-José/0000-0002-5434-1885; Mirones, Isabel/0000-0001-6921-4590				Bals R, 1999, J CLIN INVEST, V103, P1113, DOI 10.1172/JCI6570; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Davidson DJ, 2004, J IMMUNOL, V172, P1146, DOI 10.4049/jimmunol.172.2.1146; DELRIO M, 2002, EUROPEAN REV, V10, P369; Erdag G, 2002, ANN SURG, V235, P113, DOI 10.1097/00000658-200201000-00015; Gallo RL, 2002, J ALLERGY CLIN IMMUN, V110, P823, DOI 10.1067/mai.2002.129801; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Heilborn JD, 2003, J INVEST DERMATOL, V120, P379, DOI 10.1046/j.1523-1747.2003.12069.x; Huang GTJ, 2002, HUM GENE THER, V13, P2017, DOI 10.1089/10430340260395875; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Liu AY, 2002, J INVEST DERMATOL, V118, P275, DOI 10.1046/j.0022-202x.2001.01651.x; Llames SG, 2004, TRANSPLANTATION, V77, P350, DOI 10.1097/01.TP.0000112381.80964.85; Maas-Szabowski N, 2003, J CELL SCI, V116, P2937, DOI 10.1242/jcs.00474; Marshall SH, 2003, ELECTRON J BIOTECHN, V6, P271, DOI 10.4067/S0717-34582003000300011; Meana A, 1998, BURNS, V24, P621, DOI 10.1016/S0305-4179(98)00107-7; Nagaoka I, 2000, INFLAMM RES, V49, P73, DOI 10.1007/s000110050561; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ortega MR, 2000, BURNS, V26, P724, DOI 10.1016/S0305-4179(00)00052-8; Schmid P, 2001, J INVEST DERMATOL, V116, P471, DOI 10.1046/j.1523-1747.2001.01279.x; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Spirito F, 2001, J GENE MED, V3, P21, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM156>3.0.CO;2-I; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; Valerie EJ, 2003, BURNS, V29, P15, DOI 10.1016/S0305-4179(02)00203-6; Yan H, 2001, ANTIMICROB AGENTS CH, V45, P1558, DOI 10.1128/AAC.45.5.1558-1560.2001	28	48	49	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1931	+		10.1096/fj.04-1515fje	http://dx.doi.org/10.1096/fj.04-1515fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456737				2022-12-25	WOS:000224243200003
J	Abajian, C; Yatsunyk, LA; Ramirez, BE; Rosenzweig, AC				Abajian, C; Yatsunyk, LA; Ramirez, BE; Rosenzweig, AC			Yeast Cox17 solution structure and copper(I) binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SUPEROXIDE-DISMUTASE; CRYSTAL-STRUCTURE; METALLOCHAPERONE COX17; CU(I)-BINDING PROTEIN; UNSTRUCTURED PROTEINS; ATX1 METALLOCHAPERONE; BACILLUS-SUBTILIS; TERMINAL DOMAIN; NMR STRUCTURE	Cox17 is a 69-residue cysteine-rich, copper-binding protein that has been implicated in the delivery of copper to the Cu-A and Cu-B centers of cytochrome c oxidase via the copper-binding proteins Sco1 and Cox11, respectively. According to isothermal titration calorimetry experiments, fully reduced Cox17 binds one Cu(I) ion with a Ka of (6.15 +/- 5.83) x 10(6) M-1. The solution structures of both apo and Cu(I)-loaded Cox17 reveal two alpha helices preceded by an extensive, unstructured N-terminal region. This region is reminiscent of intrinsically unfolded proteins. The two structures are very similar overall with residues in the copper-binding region becoming more ordered in Cu(I)-loaded Cox17. Based on the NMR data, the Cu(I) ion has been modeled as two-coordinate with ligation by conserved residues Cys(23) and Cys(26). This site is similar to those observed for the Atx1 family of copper chaperones and is consistent with reported mutagenesis studies. A number of conserved, positively charged residues may interact with complementary surfaces on Sco1 and Cox11, facilitating docking and copper transfer. Taken together, these data suggest that Cox17 is not only well suited to a copper chaperone function but is specifically designed to interact with two different target proteins.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Struct Biol NMR Facil, Evanston, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University	Rosenzweig, AC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	amyr@northwestern.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058518] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58518] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Balatri E, 2003, STRUCTURE, V11, P1431, DOI 10.1016/j.str.2003.10.004; Banci L, 2004, J BIOL CHEM, V279, P34833, DOI 10.1074/jbc.M403655200; Banci L, 2003, J BIOL CHEM, V278, P50506, DOI 10.1074/jbc.M307389200; Banci L, 2003, BIOCHEMISTRY-US, V42, P13422, DOI 10.1021/bi0353326; Banci L, 2003, ACCOUNTS CHEM RES, V36, P215, DOI 10.1021/ar010120r; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; Brown K, 2000, J BIOL CHEM, V275, P41133, DOI 10.1074/jbc.M008617200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Cobine PA, 2004, J BIOL CHEM, V279, P14447, DOI 10.1074/jbc.M312693200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Elam JS, 2002, ADV PROTEIN CHEM, V60, P151; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Hamza I, 2002, J BIOENERG BIOMEMBR, V34, P381, DOI 10.1023/A:1021254104012; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krezel A, 2001, J INORG BIOCHEM, V84, P77, DOI 10.1016/S0162-0134(00)00212-9; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P1589, DOI 10.1021/bi992822i; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Palumaa P, 2004, BIOCHEM J, V382, P307, DOI 10.1042/BJ20040360; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Punter FA, 2003, J BIOL CHEM, V278, P30875, DOI 10.1074/jbc.M302358200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ralle M, 2003, J BIOL CHEM, V278, P23163, DOI 10.1074/jbc.M303474200; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350	58	90	92	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53584	53592		10.1074/jbc.M408099200	http://dx.doi.org/10.1074/jbc.M408099200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465825	hybrid			2022-12-25	WOS:000225680600094
J	Habelhah, H; Laine, A; Erdjument-Bromage, H; Tempst, P; Gershwin, ME; Bowtell, DDL; Ronai, Z				Habelhah, H; Laine, A; Erdjument-Bromage, H; Tempst, P; Gershwin, ME; Bowtell, DDL; Ronai, Z			Regulation of 2-oxoglutarate (alpha-ketoglutarate) dehydrogenase stability by the RING finger ubiquitin ligase Siah	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY BILIARY-CIRRHOSIS; PROTEASOME PATHWAY; PROTEIN; HOMOLOGS; STRESS; SINA; EPITHELIUM; RESPONSES; HYPOXIA; DISEASE	The 2-oxoglutarate dehydrogenase complex (OGHDC) (also known as the alpha-ketoglutarate dehydrogenase complex) is a rate-limiting enzyme in the mitochondrial Krebs cycle. Here we report that the RING finger ubiquitin-protein isopeptide ligase Siah2 binds to and targets OGDHC-E2 for ubiquitination-dependent degradation. OGDHC-E2 expression and activity are elevated in Siah2(-/-) cells compared with Siah2(-/-) cells. Deletion of the mitochondrial targeting sequence of OGDHC-E2 results in its cytoplasmic localization and rapid proteasome-dependent degradation in Siah2(-/-) but not in Siah2(-/-) cells. Significantly, because of its overexpression or disruption of the mitochondrial membrane potential, the release of OGDHC-E2 from mitochondria to the cytoplasm also results in its concomitant degradation. The role of the Siah family of ligases in the regulation of OGDHC-E2 stability is expected to take place under pathological conditions in which the levels of OGDHC-E2 are altered.	CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; University of California System; University of California Davis; Peter Maccallum Cancer Center	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	zeev.ronai@mssm.edu	Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525; RONAI, ZEEV/0000-0002-3859-0400; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Habelhah, Hasem/0000-0003-4097-1007	NCI NIH HHS [CA78419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Gershwin ME, 2000, IMMUNOL REV, V174, P210, DOI 10.1034/j.1600-0528.2002.017402.x; Gibson GE, 2000, NEUROCHEM INT, V36, P97, DOI 10.1016/S0197-0186(99)00114-X; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Habelhah H, 2001, J BIOL CHEM, V276, P18090, DOI 10.1074/jbc.M011396200; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Harada K, 1999, HEPATOLOGY, V30, P36, DOI 10.1002/hep.510300145; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; JOPLIN RE, 1994, HEPATOLOGY, V19, P1375, DOI 10.1002/hep.1840190610; Lai JCK, 2003, NEUROCHEM RES, V28, P933, DOI 10.1023/A:1023235712524; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Migliaccio C, 1998, J IMMUNOL, V161, P5157; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Sourisseau T, 2001, J CELL SCI, V114, P1409; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Tretter L, 1999, ANN NY ACAD SCI, V893, P412, DOI 10.1111/j.1749-6632.1999.tb07867.x; TSUNEYAMA K, 1995, HEPATOLOGY, V21, P1031, DOI 10.1016/0270-9139(95)90251-1; VandeWater J, 1996, HEPATOLOGY, V24, P1079; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	29	46	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53782	53788		10.1074/jbc.M410315200	http://dx.doi.org/10.1074/jbc.M410315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466852	hybrid			2022-12-25	WOS:000225680600116
J	Argyrou, A; Vetting, MW; Blanchard, JS				Argyrou, A; Vetting, MW; Blanchard, JS			Characterization of a new member of the flavoprotein disulfide reductase family of enzymes from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDINE-NUCLEOTIDE TRANSHYDROGENASE; ESCHERICHIA-COLI LACKING; REDOX-ACTIVE DISULFIDE; ELECTRON-DENSITY MAPS; X-RAY-STRUCTURE; LIPOAMIDE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; STAPHYLOCOCCUS-AUREUS; TRYPANOTHIONE REDUCTASE; AZOTOBACTER-VINELANDII	The lpdA (Rv3303c) gene from Mycobacterium tuberculosis encoding a new member of the flavoprotein disulfide reductases was expressed in Escherichia coli, and the recombinant LpdA protein was purified to homogeneity. LpdA is a homotetramer and co-purifies with one molecule of tightly but noncovalently bound FAD and NADP(+) per monomer. Although annotated as a probable lipoamide dehydrogenase in M. tuberculosis, LpdA cannot catalyze reduction of lipoyl substrates, because it lacks one of two cysteine residues involved in dithiol-disulfide interchange with lipoyl substrates and a His-Glu pair involved in general acid catalysis. The crystal structure of LpdA was solved by multiple isomorphous replacement with anomalous scattering, which confirmed the absence of these catalytic residues from the active site. Although LpdA cannot catalyze reduction of disulfide-bonded substrates, it catalyzes the NAD(P) H-dependent reduction of alternative electron acceptors such as 2,6-dimethyl-1,4-benzoquinone and 5-hydroxy-1,4-naphthaquinone. Significant primary deuterium kinetic isotope effects were observed with [4S-H-2]NADH establishing that the enzyme promotes transfer of the C-4-proS hydride of NADH. The absence of an isotope effect with [4S-H-2]NADPH, the low K-m value of 0.5 muM for NADPH, and the potent inhibition of the NADH-dependent reduction of 2,6-dimethyl-1,4-benzoquinone by NADP(+) (K-i similar to 6 nM) and 2'-phospho-ADP-ribose (K-i similar to 800 nM), demonstrate the high affinity of LpdA for 2'-phosphorylated nucleotides and that the physiological substrate/product pair is NADPH/NADP(+) rather than NADH/NAD(+). Modeling of NADP(+) in the active site revealed that LpdA achieves the high specificity for NADP(+) through interactions involving the 2'-phosphate of NADP(+) and amino acid residues that are different from those in glutathione reductase.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Argyrou, A (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	aargyrou@medusa.bioc.aecom.yu.edu; vetting@aecom.yu.edu	Argyrou, Argyrides/AAC-4156-2020	Argyrou, Argyrides/0000-0003-3141-9122	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033449] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33696] Funding Source: Medline; NIGMS NIH HHS [GM33449] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argyrou A, 2004, PROG NUCLEIC ACID RE, V78, P89, DOI 10.1016/S0079-6603(04)78003-4; Argyrou A, 2003, BIOCHEMISTRY-US, V42, P2218, DOI 10.1021/bi020654f; Argyrou A, 2002, BIOCHEMISTRY-US, V41, P14580, DOI 10.1021/bi020376k; Argyrou A, 2001, BIOCHEMISTRY-US, V40, P11353, DOI 10.1021/bi010575o; BENEN J, 1992, EUR J BIOCHEM, V207, P487, DOI 10.1111/j.1432-1033.1992.tb17075.x; Bohme CC, 2000, J BIOL CHEM, V275, P37317, DOI 10.1074/jbc.M007695200; Boonstra B, 1999, J BACTERIOL, V181, P1030, DOI 10.1128/JB.181.3.1030-1034.1999; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; CENAS NK, 1994, BIOCHEMISTRY-US, V33, P2509, DOI 10.1021/bi00175a021; CENAS NK, 1989, BIOCHIM BIOPHYS ACTA, V973, P399, DOI 10.1016/S0005-2728(89)80381-0; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOK PF, 1991, ENZYME MECH ISOTOPE, P207; Corran HS, 1939, BIOCHEM J, V33, P793, DOI 10.1042/bj0330793; delCardayre SB, 1998, J BIOL CHEM, V273, P5752, DOI 10.1074/jbc.273.10.5752; delCardayre SB, 1998, J BIOL CHEM, V273, P5744, DOI 10.1074/jbc.273.10.5744; DIXON M, 1979, ENZYMES, P53; Duax WL, 2003, PROTEINS, V53, P931, DOI 10.1002/prot.10512; French CE, 1997, J BACTERIOL, V179, P2761, DOI 10.1128/jb.179.8.2761-2765.1997; HOPKINS N, 1995, BIOCHEMISTRY-US, V34, P11757, DOI 10.1021/bi00037a013; HOPKINS N, 1995, BIOCHEMISTRY-US, V34, P11766, DOI 10.1021/bi00037a014; HORECKER BL, 1948, J BIOL CHEM, V175, P385; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P8764, DOI 10.1073/pnas.88.19.8764; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Luba J, 1999, BIOCHEMISTRY-US, V38, P2725, DOI 10.1021/bi9825899; Macheroux P, 1999, METH MOL B, V131, P1; MASSEY V, 1958, BIOCHIM BIOPHYS ACTA, V30, P205, DOI 10.1016/0006-3002(58)90270-1; MASSEY V, 1960, BIOCHIM BIOPHYS ACTA, V37, P314, DOI 10.1016/0006-3002(60)90239-0; ORR GA, 1984, ANAL BIOCHEM, V142, P232, DOI 10.1016/0003-2697(84)90544-X; OTTOLINA G, 1989, BIOCHIM BIOPHYS ACTA, V998, P173, DOI 10.1016/0167-4838(89)90270-7; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAR; Patel MP, 1999, BIOCHEMISTRY-US, V38, P11827, DOI 10.1021/bi991025h; RIETVELD P, 1994, BIOCHEMISTRY-US, V33, P13888, DOI 10.1021/bi00250a043; RydstroM J., 1976, ENZYME, V13, P51; SCHIERBEEK AJ, 1989, J MOL BIOL, V206, P365, DOI 10.1016/0022-2836(89)90486-5; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; SEGEL IH, 1975, ENZYME KINETICS, P143; SIEGEL JM, 1959, ARCH BIOCHEM BIOPHYS, V82, P288, DOI 10.1016/0003-9861(59)90124-9; STEHLE T, 1990, FEBS LETT, V267, P186, DOI 10.1016/0014-5793(90)80921-5; STEIN AM, 1963, BIOCHEMISTRY-US, V338, P1015; Sun PD, 2002, ACTA CRYSTALLOGR D, V58, P1092, DOI 10.1107/S0907444902006510; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; VEEGER C., 1960, BIOCHIM ET BIOPHYS ACTA, V37, P181, DOI 10.1016/0006-3002(60)90108-6; VIENOZINSKIS J, 1990, BIOCHEM J, V269, P101, DOI 10.1042/bj2690101; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121	51	11	14	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52694	52702		10.1074/jbc.M410704200	http://dx.doi.org/10.1074/jbc.M410704200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456792	hybrid			2022-12-25	WOS:000225493400116
J	Karlsson, C; Korayem, AM; Scherfer, C; Loseva, O; Dushay, MS; Theopold, U				Karlsson, C; Korayem, AM; Scherfer, C; Loseva, O; Dushay, MS; Theopold, U			Proteomic analysis of the Drosophila larval hemolymph clot	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; IMMUNE-RESPONSE; CROSS-LINKING; PROTEINS; IDENTIFICATION; MELANOGASTER; GELSOLIN; PHAGOCYTOSIS; COAGULATION; ACTIVATION	Components of the insect clot, an extremely rapid forming and critical part of insect immunity, are just beginning to be identified ( 1). Here we present a proteomic comparison of larval hemolymph before and after clotting to learn more about this process. This approach was supplemented by the identification of substrates for the enzyme transglutaminase, which plays a role in both vertebrate blood clotting ( as factor XIIIa) and hemolymph coagulation in arthropods. Hemolymph proteins present in lower amounts after clotting include CG8502 ( a protein with a mucin-type domain and a domain with similarity to cuticular components), CG11313 ( a protein with similarity to prophenoloxidase-activating proteases), and two phenoloxidases, lipophorin, a secreted gelsolin, and CG15825, which had previously been isolated from clots ( 2). Proteins whose levels increase after clotting include a ferritin-subunit and two members of the immunoglobulin family with a high similarity to the small immunoglobulin-like molecules involved in mammalian innate immunity. Our results correlate with findings from another study of coagulation ( 2) that involved a different experimental approach. Proteomics allows the isolation of novel candidate clotting factors, leading to a more complete picture of clotting. In addition, our two-dimensional protein map of cell-free Drosophila hemolymph includes many additional proteins that were not found in studies performed on whole hemolymph.	Univ Stockholm, Dept Mol Biol & Funct Genom, S-10691 Stockholm, Sweden; Assiut Univ, Fac Sci, Dept Zool, Assiut 71516, Egypt; Dept Nat Sci, S-14189 Huddinge, Sweden	Stockholm University; Egyptian Knowledge Bank (EKB); Assiut University	Theopold, U (corresponding author), Univ Stockholm, Dept Mol Biol & Funct Genom, S-10691 Stockholm, Sweden.	uli@molbio.su.se	Dushay, Mitchell/B-1029-2009; Theopold, Ulrich/P-7205-2015	Theopold, Ulrich/0000-0002-1009-8254				Andersen SO, 1998, INSECT BIOCHEM MOLEC, V28, P421, DOI 10.1016/S0965-1748(98)00028-9; ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; Asha H, 2003, GENETICS, V163, P203; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Engstrom Y, 2004, TRENDS BIOTECHNOL, V22, P600, DOI 10.1016/j.tibtech.2004.09.002; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Goto A, 2003, DEV BIOL, V264, P582, DOI 10.1016/j.ydbio.2003.06.001; Goto A, 2001, BIOCHEM J, V359, P99, DOI 10.1042/0264-6021:3590099; Guedes SD, 2003, BIOCHEM BIOPH RES CO, V312, P545, DOI 10.1016/j.bbrc.2003.10.156; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HEINTZELMAN MB, 1993, J MOL BIOL, V230, P709, DOI 10.1006/jmbi.1993.1191; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Ikura K, 1998, ARCH BIOCHEM BIOPHYS, V356, P280, DOI 10.1006/abbi.1998.0775; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Irving P, 2001, P NATL ACAD SCI USA, V98, P15119, DOI 10.1073/pnas.261573998; Kazmirski SL, 2002, NAT STRUCT BIOL, V9, P112, DOI 10.1038/nsb745; Korayem AM, 2004, INSECT BIOCHEM MOLEC, V34, P1297, DOI 10.1016/j.ibmb.2004.09.001; Levy F, 2004, MOL CELL PROTEOMICS, V3, P156, DOI 10.1074/mcp.M300114-MCP200; Li D, 2002, INSECT BIOCHEM MOLEC, V32, P919, DOI 10.1016/S0965-1748(02)00030-9; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Loseva O, 2004, MOL CELL PROTEOMICS, V3, P796, DOI 10.1074/mcp.M400028-MCP200; Naitza S, 2004, MOL IMMUNOL, V40, P887, DOI 10.1016/j.molimm.2003.10.008; Osaki T, 2002, J BIOL CHEM, V277, P40084, DOI 10.1074/jbc.M206773200; Pearson AM, 2003, MICROBES INFECT, V5, P815, DOI 10.1016/S1286-4579(03)00157-6; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Scherfer C, 2004, CURR BIOL, V14, P625, DOI 10.1016/j.cub.2004.03.030; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; Theopold U, 1996, J BIOL CHEM, V271, P12708, DOI 10.1074/jbc.271.22.12708; Theopold U, 2004, TRENDS IMMUNOL, V25, P289, DOI 10.1016/j.it.2004.03.004; Vierstraete E, 2004, BIOCHEM BIOPH RES CO, V317, P1052, DOI 10.1016/j.bbrc.2004.03.150; Vierstraete E, 2004, P NATL ACAD SCI USA, V101, P470, DOI 10.1073/pnas.0304567101; Vierstraete E, 2003, BIOCHEM BIOPH RES CO, V304, P831, DOI 10.1016/S0006-291X(03)00683-1; Xu YS, 2000, J BIOL CHEM, V275, P24645, DOI 10.1074/jbc.M001159200; Yan JX, 2000, ELECTROPHORESIS, V21, P3666, DOI 10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6	39	122	130	1	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52033	52041		10.1074/jbc.M408220200	http://dx.doi.org/10.1074/jbc.M408220200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466469	hybrid			2022-12-25	WOS:000225493400040
J	Korporaal, SJA; Relou, IAM; van Eck, M; Strasser, V; Bezemer, M; Gorter, G; van Berkel, TJC; Nimpf, J; Akkerman, JWN; Lenting, PJ				Korporaal, SJA; Relou, IAM; van Eck, M; Strasser, V; Bezemer, M; Gorter, G; van Berkel, TJC; Nimpf, J; Akkerman, JWN; Lenting, PJ			Binding of low density lipoprotein to platelet apolipoprotein E receptor 2 ' results in phosphorylation of p38(MAPK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); KNOCKOUT MICE; RECEPTOR; IDENTIFICATION; REELIN; SITES; LDL; ACTIVATION; FIBRINOGEN; SECRETION	Binding of low density lipoprotein (LDL) to platelets enhances platelet responsiveness to various aggregation-inducing agents. However, the identity of the platelet surface receptor for LDL is unknown. We have previously reported that binding of the LDL component apolipoprotein B100 to platelets induces rapid phosphorylation of p38 mitogen-activated protein kinase (p38(MAPK)). Here, we show that LDL-dependent activation of this kinase is inhibited by receptor-associated protein ( RAP), an inhibitor of members of the LDL receptor family. Confocal microscopy revealed a high degree of co-localization of LDL and a splice variant of the LDL receptor family member apolipoprotein E receptor-2 (apoER2') at the platelet surface, suggesting that apoER2' may contribute to LDL-induced platelet signaling. Indeed, LDL was unable to induce p38(MAPK) activation in platelets of apoER2-deficient mice. Furthermore, LDL bound efficiently to soluble apoER2', and the transient LDL-induced activation of p38(MAPK) was mimicked by an anti-apoER2 antibody. Association of LDL to platelets resulted in tyrosine phosphorylation of apoER2', a process that was inhibited in the presence of PP1, an inhibitor of Src-like tyrosine kinases. Moreover, phosphorylated but not native apoER2' co-precipitated with the Src family member Fgr. This suggests that exposure of platelets to LDL induces association of apoER2' to Fgr, a kinase that is able to activate p38(MAPK). In conclusion, our data indicate that apoER2' contributes to LDL-dependent sensitization of platelets.	Univ Utrecht, Dept Haematol, Lab Thrombosis & Haemostasis, Univ Med Ctr Utrecht, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands; Leiden Univ, Gorlaeus Labs, Div Biopharmaceut, Leiden Amsterdam Ctr Drug Res, NL-2300 RA Leiden, Netherlands; Univ Vienna, A-1030 Vienna, Austria; Bioctr, Div Mol Genet, Dept Med Biochem, A-1030 Vienna, Austria	Utrecht University; Utrecht University Medical Center; Utrecht University; Leiden University; Leiden University - Excl LUMC; University of Vienna	Lenting, PJ (corresponding author), Univ Utrecht, Dept Haematol, Lab Thrombosis & Haemostasis, Univ Med Ctr Utrecht, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	p.j.lenting@lab.azu.nl	Lenting, Peter/F-8269-2013; Van Berkel, Theo/ABD-7677-2021; Lenting, Peter/AAH-5663-2019	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429; Nimpf, Johannes/0000-0002-9273-3492; van Eck, Miranda/0000-0003-3936-3194				Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CHATTERTON JE, 1995, J LIPID RES, V36, P2027; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Hackeng CM, 1999, ARTERIOSCL THROM VAS, V19, P239, DOI 10.1161/01.ATV.19.2.239; Hackeng CM, 2000, BIOCHEM J, V349, P231, DOI 10.1042/0264-6021:3490231; Hackeng CM, 1999, THROMB HAEMOSTASIS, V82, P1749, DOI 10.1055/s-0037-1614909; HASSALL DG, 1983, ARTERIOSCLEROSIS, V3, P332, DOI 10.1161/01.ATV.3.4.332; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; HERZ J, 1991, J BIOL CHEM, V266, P21232; Horn IR, 1998, THROMB HAEMOSTASIS, V80, P822; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Hussain MM, 2001, FRONT BIOSCI, V6, pD417, DOI 10.2741/Hussain1; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Kamada N, 2001, J Atheroscler Thromb, V8, P1; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Koch S, 2002, EMBO J, V21, P5996, DOI 10.1093/emboj/cdf599; KOLLER E, 1989, J BIOL CHEM, V264, P12412; Korschineck I, 2001, J BIOL CHEM, V276, P13192, DOI 10.1074/jbc.M011795200; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; Lutters BCH, 2003, J BIOL CHEM, V278, P33831, DOI 10.1074/jbc.M212655200; Ma SL, 2002, NEUROSCI LETT, V332, P216, DOI 10.1016/S0304-3940(02)00942-4; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Nofer JR, 1997, CIRCULATION, V95, P1370; PEDRENO J, 1992, ARTERIOSCLER THROMB, V12, P1353, DOI 10.1161/01.ATV.12.11.1353; Pedreno J, 1997, ARTERIOSCL THROM VAS, V17, P156, DOI 10.1161/01.ATV.17.1.156; Relou IAM, 2003, J BIOL CHEM, V278, P32638, DOI 10.1074/jbc.M212675200; Relou IAM, 2003, BIOCHEM J, V369, P407, DOI 10.1042/BJ20020410; Relou IAM, 2002, THROMB HAEMOSTASIS, V87, P880; Rice DS, 1998, DEVELOPMENT, V125, P3719; Riddell DR, 1998, BIOCHEM SOC T, V26, pS244, DOI 10.1042/bst026s244; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Strasser V, 2004, MOL CELL BIOL, V24, P1378, DOI 10.1128/MCB.24.3.1378-1386.2004; Sun XM, 1999, EUR J BIOCHEM, V262, P230, DOI 10.1046/j.1432-1327.1999.00394.x; SURYA II, 1992, BIOCHIM BIOPHYS ACTA, V1165, P19, DOI 10.1016/0005-2760(92)90070-C; Terpstra V, 2000, ARTERIOSCL THROM VAS, V20, P1860, DOI 10.1161/01.ATV.20.8.1860; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; van der Geer P, 2002, TRENDS CARDIOVAS MED, V12, P160, DOI 10.1016/S1050-1738(02)00154-8; VANWILLIGEN G, 1994, ARTERIOSCLER THROMB, V14, P41, DOI 10.1161/01.ATV.14.1.41; Volf I, 1997, AM J PHYSIOL-CELL PH, V273, pC118, DOI 10.1152/ajpcell.1997.273.1.C118	45	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52526	52534		10.1074/jbc.M407407200	http://dx.doi.org/10.1074/jbc.M407407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459198	hybrid, Green Published			2022-12-25	WOS:000225493400098
J	McEwen, DP; Isom, LL				McEwen, DP; Isom, LL			Heterophilic interactions of sodium channel beta 1 subunits with axonal and glial cell adhesion molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; RAT-BRAIN; MYELINATED AXONS; ANKYRIN-G; STRUCTURAL REQUIREMENTS; FUNCTIONAL EXPRESSION; AUXILIARY SUBUNIT; RANVIER FORMATION; INITIAL SEGMENTS; ALPHA-SUBUNITS	Voltage-gated sodium channels localize at high density in axon initial segments and nodes of Ranvier in myelinated axons. Sodium channels consist of a pore-forming alpha subunit and at least one beta subunit. beta1 is a member of the immunoglobulin superfamily of cell adhesion molecules and interacts homophilically and heterophilically with contactin and Nf186. In this study, we characterized beta1 interactions with contactin and Nf186 in greater detail and investigated interactions of beta1 with NrCAM, Nf155, and sodium channel beta2 and beta3 subunits. Using Fc fusion proteins and immunocytochemical techniques, we show that beta1 interacts with the fibronectin-like domains of contactin. beta1 also interacts with NrCAM, Nf155, sodium channel beta2, and Nf186 but not with sodium channel beta3. The interaction of the extracellular domains of beta1 and beta2 requires the region (169)TEEEGKTDGEGNA(181) located in the intracellular domain of beta2. Interaction of beta1 with Nf186 results in increased Na(v)1.2 cell surface density over alpha alone, similar to that shown previously for contactin and beta2. We propose that beta1 is the critical communication link between sodium channels, nodal cell adhesion molecules, and ankyrin(G).	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Isom, LL (corresponding author), Univ Michigan, Dept Pharmacol, 1150 W Med Ctr Dr,1301 MSRB 3, Ann Arbor, MI 48109 USA.	lisom@umich.edu		Isom, Lori/0000-0002-9479-6729	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS043067, R01NS017965] Funding Source: NIH RePORTER; NIMH NIH HHS [R01MH59980] Funding Source: Medline; NINDS NIH HHS [R01NS17965-17, NS43067] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arroyo EJ, 1999, J NEUROCYTOL, V28, P333, DOI 10.1023/A:1007009613484; BERGLUND EO, 1994, GENOMICS, V21, P571, DOI 10.1006/geno.1994.1316; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen CL, 2004, J NEUROSCI, V24, P4030, DOI 10.1523/JNEUROSCI.4139-03.2004; Chen CL, 2002, P NATL ACAD SCI USA, V99, P17072, DOI 10.1073/pnas.212638099; Custer AW, 2003, J NEUROSCI, V23, P10032; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DUGANDZIJANOVAKOVIC S, 1995, J NEUROSCI, V15, P492; Dupree JL, 1999, J CELL BIOL, V147, P1145, DOI 10.1083/jcb.147.6.1145; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; Gollan L, 2003, J CELL BIOL, V163, P1213, DOI 10.1083/jcb.200309147; Gollan L, 2002, J CELL BIOL, V157, P1247, DOI 10.1083/jcb.200203050; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; Isom LL, 2002, FRONT BIOSCI, V7, P12; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Jenkins SM, 2002, P NATL ACAD SCI USA, V99, P2303, DOI 10.1073/pnas.042601799; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Kazen-Gillespie KA, 2000, J BIOL CHEM, V275, P1079, DOI 10.1074/jbc.275.2.1079; Lambert S, 1997, J NEUROSCI, V17, P7025; Lustig M, 2001, CURR BIOL, V11, P1864, DOI 10.1016/S0960-9822(01)00586-3; Lustig M, 2001, J COMP NEUROL, V434, P13, DOI 10.1002/cne.1161; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Malhotra JD, 2002, J BIOL CHEM, V277, P26681, DOI 10.1074/jbc.M202354200; McEwen DP, 2004, J BIOL CHEM, V279, P16044, DOI 10.1074/jbc.M400856200; Meadows L, 2001, J NEUROCHEM, V76, P1871, DOI 10.1046/j.1471-4159.2001.00192.x; MORALES G, 1993, NEURON, V11, P1113, DOI 10.1016/0896-6273(93)90224-F; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Poliak S, 2003, NAT REV NEUROSCI, V4, P968, DOI 10.1038/nrn1253; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Revest JM, 1999, EUR J NEUROSCI, V11, P1134, DOI 10.1046/j.1460-9568.1999.00521.x; Rios JC, 2003, J NEUROSCI, V23, P7001, DOI 10.1523/JNEUROSCI.23-18-07001.2003; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; Salzer JL, 2003, NEURON, V40, P297, DOI 10.1016/S0896-6273(03)00628-7; Scherer SS, 1999, ANN NY ACAD SCI, V883, P131, DOI 10.1111/j.1749-6632.1999.tb08576.x; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; Simmons DL, 1999, METH MOL B, V96, P39; Tait S, 2000, J CELL BIOL, V150, P657, DOI 10.1083/jcb.150.3.657; Vabnick I, 1996, J NEUROSCI, V16, P4914; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Yu FH, 2003, J NEUROSCI, V23, P7577; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	53	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52744	52752		10.1074/jbc.M405990200	http://dx.doi.org/10.1074/jbc.M405990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466474	hybrid			2022-12-25	WOS:000225493400121
J	Saerens, D; Kinne, J; Bosmans, E; Wernery, U; Muyldermans, S; Conrath, K				Saerens, D; Kinne, J; Bosmans, E; Wernery, U; Muyldermans, S; Conrath, K			Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ANTIBODIES; RIBOSOME DISPLAY; IN-VITRO; FRAGMENTS; COMPLEX; PROTEIN; IDENTIFICATION; INHIBITION; GENERATION; STABILITY	The importance of the lymphocyte source to generate hybridomas or to construct antibody gene libraries from which to identify potent monoclonal antibodies is understudied. However, the few comparative studies that exist seem to favor the lymph node tissue as a B-cell source. Here the peripheral blood and lymph node lymphocytes of a dromedary immunized with prostate-specific antigen (PSA) have been employed to clone two independent gene banks of the variable domains of heavy-chain antibodies (i.e. the VHHs). Several PSA-specific VHHs were retrieved after panning of these phage-displayed VHH libraries. Some of them were derived from the same B-cell lineage, possibly reflecting the restricted primary repertoire of heavy-chain antibodies. Other binders originated from different B-cell lineages and apparently converged toward a striking homologous amino acid sequence motif in their CDR3. This illustrates the strong somatic hypermutation and stringent antigen-driven selection ongoing in these animals. Although the various antigen binders exhibit a broad range of kinetic rate constants for their interaction with the PSA, leading to equilibrium constants from 70 pM to 100 nM, no significant difference existed between the binders from the two B-cell sources. The VHHs of both libraries were categorized in three groups based on non-overlapping epitopes. Some of these VHHs could inhibit and others could enhance the proteolytic activity of the antigen. Remarkably, VHHs seem to sense or induce conformational changes on different PSA isoforms, a feature that might be exploited to study the PSA conformational flexibility and to discriminate the stages of prostate cancer.	Free Univ Brussels VIB, Cellular Immunol Lab, Dept Cellular & Mol Interact, B-1050 Brussels, Belgium; Cent Vet Res Lab, Dubai, U Arab Emirates; DiaMed Eurogen NV, B-2300 Turnhout, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Saerens, D (corresponding author), Free Univ Brussels VIB, Cellular Immunol Lab, Dept Cellular & Mol Interact, Pleinlaan 2, B-1050 Brussels, Belgium.	dsaerens@vub.ac.be	Saerens, Dirk/B-9162-2008; Muyldermans, Serge/AAC-7374-2019; Muyldermans, Serge V/C-6418-2016	Muyldermans, Serge/0000-0002-3678-3575; Muyldermans, Serge V/0000-0002-3678-3575; Saerens, Dirk/0000-0001-8894-8039				Basalp A, 2003, HYBRIDOMA HYBRIDOM, V22, P329, DOI 10.1089/153685903322538863; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Carvalho AL, 2002, J MOL BIOL, V322, P325, DOI 10.1016/S0022-2836(02)00705-2; Conrath KE, 2003, DEV COMP IMMUNOL, V27, P87, DOI 10.1016/S0145-305X(02)00071-X; Conrath KE, 2001, ANTIMICROB AGENTS CH, V45, P2807, DOI 10.1128/AAC.45.10.2807-2812.2001; Conrath KE, 2001, J BIOL CHEM, V276, P7346, DOI 10.1074/jbc.M007734200; Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935; Desmyter A, 2002, J BIOL CHEM, V277, P23645, DOI 10.1074/jbc.M202327200; Desmyter A, 2001, J BIOL CHEM, V276, P26285, DOI 10.1074/jbc.M102107200; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Ledeboer AM, 2002, J DAIRY SCI, V85, P1376, DOI 10.3168/jds.S0022-0302(02)74204-5; Linton HJ, 2003, CLIN CHEM, V49, P253, DOI 10.1373/49.2.253; Lipovsek D, 2004, J IMMUNOL METHODS, V290, P51, DOI 10.1016/j.jim.2004.04.008; Michel S, 1999, CLIN CHEM, V45, P638; Mikolajczyk SD, 2004, CLIN BIOCHEM, V37, P519, DOI 10.1016/j.clinbiochem.2004.05.016; Mikolajczyk SD, 2002, UROLOGY, V59, P797, DOI 10.1016/S0090-4295(01)01605-3; Muruganandam A, 2001, FASEB J, V15, P240, DOI 10.1096/fj.01-0343fje; Nguyen VK, 2001, ADV IMMUNOL, V79, P261, DOI 10.1016/S0065-2776(01)79006-2; Pleschberger M, 2004, BIOCONJUGATE CHEM, V15, P664, DOI 10.1021/bc049964w; Sambrook J, 2001, MOL CLONING LAB MANU; Sieber V, 1998, NAT BIOTECHNOL, V16, P955, DOI 10.1038/nbt1098-955; Sinkora M, 2000, MOL IMMUNOL, V37, P1025, DOI 10.1016/S0161-5890(01)00022-0; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; Stijlemans B, 2004, J BIOL CHEM, V279, P1256, DOI 10.1074/jbc.M307341200; Thomassen YE, 2002, ENZYME MICROB TECH, V30, P273, DOI 10.1016/S0141-0229(01)00497-5; Wan XS, 2003, PROSTATE, V56, P131, DOI 10.1002/pros.10247; Wu P, 2000, EUR J BIOCHEM, V267, P6212, DOI 10.1046/j.1432-1327.2000.01696.x; Yau KYF, 2003, J IMMUNOL METHODS, V281, P161, DOI 10.1016/j.jim.2003.07.011; Yip YL, 1997, IMMUNOTECHNOLOGY, V3, P195, DOI 10.1016/S1380-2933(97)00013-4; Zhang JB, 2004, J MOL BIOL, V335, P49, DOI 10.1016/j.jmb.2003.09.034	36	113	141	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51965	51972		10.1074/jbc.M409292200	http://dx.doi.org/10.1074/jbc.M409292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459193	hybrid			2022-12-25	WOS:000225493400032
J	Ueda, T; Kato, A; Ogawa, Y; Torizawa, T; Kuramitsu, S; Iwai, S; Terasawa, H; Shimada, I				Ueda, T; Kato, A; Ogawa, Y; Torizawa, T; Kuramitsu, S; Iwai, S; Terasawa, H; Shimada, I			NMR study of repair mechanism of DNA photolyase by FAD-induced paramagnetic relaxation enhancement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SUBSTRATE COMPLEX; BLUE-LIGHT PHOTORECEPTOR; ABSOLUTE ACTION SPECTRUM; LONG-RANGE STRUCTURE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; STAPHYLOCOCCAL NUCLEASE; RECOGNITION MECHANISM; ANACYSTIS-NIDULANS; DENATURED STATE	Cyclobutane pyrimidine dimer (CPD) photolyases, which contain FAD as a cofactor, use light to repair CPDs. We performed structural analyses of the catalytic site of the Thermus thermophilus CPD photolyase-DNA complex, using FAD-induced paramagnetic relaxation enhancement (PRE). The distances between the tryptophan residues and the FAD calculated from the PRE agree well with those observed in the x-ray structure ( with an error of <3 angstrom). Subsequently, a single-stranded DNA containing C-13-labeled CPD was prepared, and the FAD-induced PRE of the NMR resonances from the CPD lesion in complex with the CPD photolyase was investigated. The distance between the FAD and the CPD calculated from the PRE is 16 +/- 3 angstrom. The FAD-induced PRE was also observed in the CPD photolyase-double-stranded DNA complex. Based on these results, a model of the CPD photolyase-DNA complex was constructed, and the roles of Arg-201, Lys-240, Trp-247, and Trp-353 in the CPD-repair reaction are discussed.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Biol Informat Consortium, Japan Biol Informat Res Ctr, Chuo Ku, Tokyo 1040032, Japan; Osaka Univ, Grad Sch Sci, Osaka 5600043, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan	University of Tokyo; Osaka University; National Institute of Advanced Industrial Science & Technology (AIST)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp						AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Antony J, 2000, J AM CHEM SOC, V122, P1057, DOI 10.1021/ja993784t; Battiste JL, 2000, BIOCHEMISTRY-US, V39, P5355, DOI 10.1021/bi000060h; Carell T, 1997, ANGEW CHEM INT EDIT, V36, P1461, DOI 10.1002/anie.199714611; Carell T, 1998, EUR J ORG CHEM, V1998, P1245; Christine KS, 2002, J BIOL CHEM, V277, P38339, DOI 10.1074/jbc.M206531200; Gillespie JR, 1997, J MOL BIOL, V268, P158, DOI 10.1006/jmbi.1997.0954; Gillespie JR, 1997, J MOL BIOL, V268, P170, DOI 10.1006/jmbi.1997.0953; Hahn J, 1999, J PHYS CHEM B, V103, P2001, DOI 10.1021/jp984197h; HARM H, 1970, MUTAT RES, V10, P307, DOI 10.1016/0027-5107(70)90045-X; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; Iwahara J, 2004, J AM CHEM SOC, V126, P5879, DOI 10.1021/ja031580d; Iwahara J, 2003, J AM CHEM SOC, V125, P6634, DOI 10.1021/ja034488q; Johnson PE, 1999, J MOL BIOL, V287, P609, DOI 10.1006/jmbi.1999.2627; Kato R, 1997, J BACTERIOL, V179, P6499, DOI 10.1128/jb.179.20.6499-6503.1997; KAVARNOS GJ, 1993, FUNDAMENTALS PHOTOIN, P185; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; KIM ST, 1994, J AM CHEM SOC, V116, P3115, DOI 10.1021/ja00086a048; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Langenbacher T, 1997, J AM CHEM SOC, V119, P10532, DOI 10.1021/ja9721024; Lietzow MA, 2002, J MOL BIOL, V322, P655, DOI 10.1016/S0022-2836(02)00847-1; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MacFarlane AW, 2001, BIOCHEMISTRY-US, V40, P15203, DOI 10.1021/bi0114224; Mal TK, 2002, J AM CHEM SOC, V124, P14002, DOI 10.1021/ja028109p; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SANCAR GB, 1987, J BIOL CHEM, V262, P492; SANCAR GB, 1987, J BIOL CHEM, V262, P478; Sanders DB, 1999, J AM CHEM SOC, V121, P5127, DOI 10.1021/ja982660y; Schelvis JPM, 2003, J PHYS CHEM B, V107, P12352, DOI 10.1021/jp034209l; SOLOMON I, 1956, J CHEM PHYS, V25, P261, DOI 10.1063/1.1742867; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; Torizawa T, 2004, J BIOL CHEM, V279, P32950, DOI 10.1074/jbc.M404536200; Weber S, 2001, BIOPHYS J, V81, P1195, DOI 10.1016/S0006-3495(01)75777-3; Weber S, 2001, J AM CHEM SOC, V123, P3790, DOI 10.1021/ja003426m	46	17	17	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52574	52579		10.1074/jbc.M409942200	http://dx.doi.org/10.1074/jbc.M409942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465818	hybrid			2022-12-25	WOS:000225493400104
J	Ling, JH; Ainol, L; Zhang, L; Yu, XP; Pi, WH; Tuan, D				Ling, JH; Ainol, L; Zhang, L; Yu, XP; Pi, WH; Tuan, D			HS2 enhancer function is blocked by a transcriptional terminator inserted between the enhancer and the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; RNA-POLYMERASE-II; BETA-GLOBIN GENE; HYPERSENSITIVE SITES; INTERGENIC TRANSCRIPTION; LAC OPERATOR; REPRESSOR; ACTIVATION; DISTANCE; EXPRESSION	The HS2 enhancer in the beta-globin locus control region regulates transcription of the globin genes 10 - 50 kb away. How the HS2 enhancer acts over this distance is not clearly understood. Earlier studies show that in erythroid cells the HS2 enhancer initiates synthesis of intergenic RNAs from sites within and downstream of the enhancer, and the enhancer-initiated RNAs are transcribed through the intervening DNA into the cis-linked promoter and gene. To investigate the functional significance of the enhancer-initiated transcription, here we inserted the lac operator sequence in the intervening DNA between the HS2 enhancer and the epsilon-globin promoter in reporter plasmids and integrated the plasmids into erythroid K562 cells expressing the lac repressor protein. We found that the interposed lac operator/repressor complex blocked the elongation of enhancer-initiated transcription through the intervening DNA and drastically reduced HS2 enhancer function as measured by the level of mRNA synthesized from the epsilon-globin promoter. The results indicate that the tracking and transcription mechanism of the HS2 enhancer-assembled transcriptional machinery from the enhancer through the intervening DNA into the cis-linked promoter can mediate enhancer-promoter interaction over a long distance.	Med Coll Georgia, Dept Biochem & Mol Biol, Sch Med, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Tuan, D (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Sch Med, Augusta, GA 30912 USA.	dtuanlo@mail.mcg.edu		Yu, Xiuping/0000-0003-2844-7026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062308, R01HL039948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62308, HL39948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN M, 1983, CELL, V35, P187; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bungert J, 1999, MOL CELL BIOL, V19, P3062; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; CHAO MV, 1980, BIOCHEMISTRY-US, V19, P3260, DOI 10.1021/bi00555a025; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; Drewell RA, 2002, P NATL ACAD SCI USA, V99, P16853, DOI 10.1073/pnas.222671199; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Gilbert W, 1972, Ciba Found Symp, V7, P245; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; Hogga I, 2002, DEVELOPMENT, V129, P4915; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; Kong SM, 1997, MOL CELL BIOL, V17, P3955, DOI 10.1128/MCB.17.7.3955; Leach KM, 2001, MOL CELL BIOL, V21, P2629, DOI 10.1128/MCB.21.8.2629-2640.2001; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; Ling JH, 2003, NUCLEIC ACIDS RES, V31, P4582, DOI 10.1093/nar/gkg646; Ling JH, 2002, J VIROL, V76, P2410, DOI 10.1128/JVI.76.5.2410-2423.2002; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; Plant KE, 2001, MOL CELL BIOL, V21, P6507, DOI 10.1128/MCB.21.19.6507-6514.2001; *PROM, 1989, B PROM, V80; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Ramchandran R, 2000, AM J HEMATOL, V65, P14, DOI 10.1002/1096-8652(200009)65:1<14::AID-AJH3>3.0.CO;2-F; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TUAN D, 1992, P NATL ACAD SCI USA, V89, P11219, DOI 10.1073/pnas.89.23.11219; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; Tuan D, 1987, DEV CONTROL GLOBIN G, P211; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554	39	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51704	51713		10.1074/jbc.M404039200	http://dx.doi.org/10.1074/jbc.M404039200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15465832	hybrid			2022-12-25	WOS:000225355800127
J	Liu, SY; Yu, SX; Hasegawa, Y; LaPushin, R; Xu, HJ; Woodgett, JR; Mills, GB; Fang, XJ				Liu, SY; Yu, SX; Hasegawa, Y; LaPushin, R; Xu, HJ; Woodgett, JR; Mills, GB; Fang, XJ			Glycogen synthase kinase 3 beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; BETA-CATENIN; LYSOPHOSPHATIDIC ACID; CELL-LINES; DIFFERENTIAL REGULATION; XENOPUS EMBRYOS; AXIS FORMATION; MAP KINASES; PHOSPHORYLATION	The c-Jun N-terminal kinase (JNK)/stress activated protein kinase is preferentially activated by stress stimuli. Growth factors, particularly ligands for G protein-coupled receptors, usually induce only modest JNK activation, although they may trigger marked activation of the related extracellular signal-regulated kinase. In the present study, we demonstrated that homozygous disruption of glycogen synthase kinase 3beta (GSK-3beta) dramatically sensitized mouse embryonic fibroblasts (MEFs) to JNK activation induced by lysophosphatidic acid (LPA) and sphingosine-1-phosphate, two prototype ligands for G protein-coupled receptors. To a lesser degree, a lack of GSK-3beta also potentiated JNK activation in response to epidermal growth factor. In contrast, the absence of GSK-3beta decreased UV light-induced JNK activation. The increased JNK activation induced by LPA in GSK-3beta null MEFs was insufficient to trigger apoptotic cell death or growth inhibition. Instead, the increased JNK activation observed in GSK-3beta-/- MEFs was associated with an increased proliferative response to LPA, which was reduced by the inhibition of JNK. Ectopic expression of GSK-3beta in GSK-3beta-negative MEFs restrained LPA-triggered JNK phosphorylation and induced a concomitant decrease in the mitogenic response to LPA compatible with GSK-3beta through the inhibition of JNK activation, thus limiting LPA-induced cell proliferation. Mutation analysis indicated that GSK-3beta kinase activity was required for GSK-3beta to optimally inhibit LPA-stimulated JNK activation. Thus GSK-3beta serves as a physiological switch to specifically repress JNK activation in response to LPA, sphingosine-1-phosphate, or the epidermal growth factor. These results reveal a novel role for GSK-3beta in signal transduction and cellular responses to growth factors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Liu, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, POB 0814,1515 Holcombe Blvd, Houston, TX 77030 USA.	sliu@mail.mdanderson.org	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797	NATIONAL CANCER INSTITUTE [R01CA082716, P30CA016672, P01CA064602] Funding Source: NIH RePORTER; Canadian Institutes of Health Research [12043] Funding Source: Medline; NCI NIH HHS [CA82716, P01 CA064602, P30 CA016672, R01 CA082716, CA64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bost F, 1999, MOL CELL BIOL, V19, P1938; Castillo SS, 2003, J NUTR, V133, P3343, DOI 10.1093/jn/133.11.3343; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cui H, 1998, DEV BRAIN RES, V111, P177, DOI 10.1016/S0165-3806(98)00136-9; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Goetzl EJ, 1999, ADV EXP MED BIOL, V469, P259; GOODE N, 1992, J BIOL CHEM, V267, P16878; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Jacobs-Helber SM, 2004, BLOOD, V104, P696, DOI 10.1182/blood-2003-05-1754; Kim JW, 2003, J BIOL CHEM, V278, P13995, DOI 10.1074/jbc.M300253200; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pear Warren S., 1997, P41; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Sasaki T, 1998, J BIOCHEM, V124, P934, DOI 10.1093/oxfordjournals.jbchem.a022210; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shin SY, 2002, EXP MOL MED, V34, P444, DOI 10.1038/emm.2002.62; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200	48	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51075	51081		10.1074/jbc.M408607200	http://dx.doi.org/10.1074/jbc.M408607200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15466414	Green Accepted, hybrid			2022-12-25	WOS:000225355800053
J	Roy, R; Wewer, UM; Zurakowski, D; Pories, SE; Moses, MA				Roy, R; Wewer, UM; Zurakowski, D; Pories, SE; Moses, MA			ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							12 MELTRIN ALPHA; CYSTEINE-RICH DOMAIN; CONVERTING-ENZYME; URINARY PROTEINS; CELL-MIGRATION; IN-VITRO; METALLOPROTEASE; ADAM12; TIMP-3; INHIBITORS	ADAM 12 is a member of a family of disintegrin-containing metalloproteases that have been implicated in a variety of diseases including Alzheimer's disease, arthritis, and cancer. We purified ADAM 12 from the urine of breast cancer patients via Q-Sepharose anion exchange and gelatin-Sepharose affinity chromatography followed by protein identification by matrix-assisted laser desorption/ ionization-time of flight mass spectrometry. Four peptides were identified that spanned the amino acid sequence of ADAM 12. Immunoblot analysis using ADAM 12-specific antibodies detected an similar to 68-kDa band identified as the mature form of ADAM 12. To characterize catalytic properties of ADAM 12, full-length ADAM 12-S was expressed in COS-7 cells and purified. Substrate specificity studies demonstrated that ADAM 12-S degrades gelatin, type IV collagen, and fibronectin but not type I collagen or casein. Gelatinase activity of ADAM 12 was completely abrogated by zinc chelators 1,10-phenanthroline and EDTA and was partially inhibited by the hydroxamate inhibitor Marimastat. Endogenous matrix metalloprotease inhibitor TIMP-3 inhibited activity. To validate our initial identification of this enzyme in human urine, 117 urine samples from breast cancer patients and controls were analyzed by immunoblot. The majority of samples from cancer patients were positive for ADAM 12 ( 67 of 71, sensitivity 0.94) compared with urine from controls in which ADAM 12 was detected with significantly lower frequency. Densitometric analyses of immunoblots demonstrated that ADAM 12 protein levels were higher in urine from breast cancer patients than in control urine. In addition, median levels of ADAM 12 in urine significantly increased with disease progression. These data demonstrate for the first time that ADAM 12 is a gelatinase, that it can be detected in breast cancer patient urine, and that increased urinary levels of this protein correlate with breast cancer progression. They further support the possibility that detection of urinary ADAM 12 may prove useful in the development of noninvasive diagnostic and prognostic tests for breast and perhaps other cancers.	Harvard Univ, Childrens Hosp, Program Vasc Biol, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Orthoped Surg & Biostat, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Cambridge, MA 02138 USA; Mt Auburn Hosp, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Copenhagen, Inst Mol Pathol, Copenhagen, Denmark	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Mount Auburn Hospital; Harvard University; Harvard Medical School; University of Copenhagen	Moses, MA (corresponding author), Harvard Univ, Childrens Hosp, Program Vasc Biol, Karp Family Res Bldg,Floor 12,300 Longwood Ave, Boston, MA 02115 USA.	marsha.moses@childrens.harvard.edu	Pories, Susan/AAB-1757-2019	Pories, Susan/0000-0001-7315-9993				Alfandari D, 2001, CURR BIOL, V11, P918, DOI 10.1016/S0960-9822(01)00263-9; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BEREK JS, 1995, CANCER-AM CANCER SOC, V76, P2092, DOI 10.1002/1097-0142(19951115)76:10+<2092::AID-CNCR2820761331>3.0.CO;2-T; Breslow N.E., 1980, STAT METHODS CANC RE, P192; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao Y, 2002, J BIOL CHEM, V277, P26403, DOI 10.1074/jbc.M110814200; Chubinskaya S, 2001, J HISTOCHEM CYTOCHEM, V49, P1165, DOI 10.1177/002215540104900910; Fernandez CA, 2003, J BIOL CHEM, V278, P40989, DOI 10.1074/jbc.M306176200; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Lochter A, 1998, ANN NY ACAD SCI, V857, P180, DOI 10.1111/j.1749-6632.1998.tb10116.x; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Martin J, 2002, J BIOL CHEM, V277, P33683, DOI 10.1074/jbc.M200988200; Millichip MI, 1998, BIOCHEM BIOPH RES CO, V245, P594, DOI 10.1006/bbrc.1998.8485; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; Moses MA, 1998, CANCER RES, V58, P1395; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; Pieper R, 2004, PROTEOMICS, V4, P1159, DOI 10.1002/pmic.200300661; Prestigiacomo AP, 1996, J UROLOGY, V156, P350, DOI 10.1016/S0022-5347(01)65847-6; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; Thongboonkerd V, 2002, KIDNEY INT, V62, P1461, DOI 10.1046/j.1523-1755.2002.00565.x; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Zou J, 2004, J BIOL CHEM, V279, P9818, DOI 10.1074/jbc.M309696200	32	189	203	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51323	51330		10.1074/jbc.M409565200	http://dx.doi.org/10.1074/jbc.M409565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15381692	hybrid			2022-12-25	WOS:000225355800082
J	Sankaranarayanan, K; Jaiswal, AK				Sankaranarayanan, K; Jaiswal, AK			Nrf3 negatively regulates antioxidant-response element-mediated expression and antioxidant induction of NAD(P)H : quinone oxidoreductase1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; FUNCTIONAL-CHARACTERIZATION; ACTIVATION; CARCINOGENESIS; SUSCEPTIBILITY; TRANSFERASES; DISRUPTION; DEFICIENCY; COMPLEXITY; RADICALS	Antioxidant-response element (ARE) and nuclear factor Nrf2-mediated expression and coordinated induction of genes encoding chemopreventive proteins, including NQO1, are critical mechanisms in chemoprotection. Recently, Nrf3, a new member of the Nrf family with substantial homology to Nrf2, was identified and cloned. In this report, we have investigated the role of Nrf3 in ARE-mediated gene expression and induction of NQO1 in response to antioxidants. Overexpression of Nrf3 in Hep-G2 cells led to a concentration-dependent decrease in transfected and endogenous NQO1 gene expression and induction in response to antioxidant tert-butylhydroquinone (t-BHQ). Deletion mutation analysis revealed that Nrf3 repression of NQO1 gene expression required heterodimerization and DNA binding domains but not transcriptional activation domain of Nrf3. Bandshift and supershift assays with in vitro transcribed and translated proteins and nuclear extracts from Hep-G2 cells treated with Me2SO and t-BHQ and immunoprecipitation assays demonstrated that Nrf3 associates with small Maf proteins to bind to the ARE. RNA interference specific to Nrf3 reduced intracellular Nrf3 leading to increased expression and induction of transfected and endogenous NQO1 gene expression in response to t-BHQ. These results combined suggest that Nrf3 is a negative regulator of ARE-mediated gene expression.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	AJAISWAL@BCM.TMC.EDU			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Derjuga A, 2004, MOL CELL BIOL, V24, P3286, DOI 10.1128/MCB.24.8.3286-3294.2004; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Jaiswal AK, 2004, METHOD ENZYMOL, V378, P221; JOSEPH P, 1994, P NATL ACAD SCI USA, V91, P8413, DOI 10.1073/pnas.91.18.8413; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kobayashi A, 2004, METHOD ENZYMOL, V378, P273; LAST JA, 1994, ENVIRON HEALTH PERSP, V102, P179, DOI 10.2307/3432236; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2002, CANCER RES, V62, P3030; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627	32	83	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50810	50817		10.1074/jbc.M404984200	http://dx.doi.org/10.1074/jbc.M404984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385560	hybrid			2022-12-25	WOS:000225355800023
J	Hong, Y; Sundaram, S; Shin, DJ; Stanley, P				Hong, Y; Sundaram, S; Shin, DJ; Stanley, P			The Lec23 Chinese hamster ovary mutant is a sensitive host for detecting mutations in alpha-glucosidase I that give rise to congenital disorder of glycosylation IIb (CDG IIb)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; SIALIC ACID TRANSPORTER; MAMMARY-GLAND; MASS-SPECTROMETRY; D-MANNOSIDASE; CHO CELLS; GLYCOPROTEINS; CALNEXIN; BIOSYNTHESIS; DEFICIENT	Lec23 Chinese hamster ovary cells are defective in alpha-glucosidase I activity, which removes the distal alpha(1,2)-linked glucose residue from Glc(3)Man(9)GlcNAc(2) moieties attached to glycoproteins in the endoplasmic reticulum. Mutations in the human GCS1 gene give rise to the congenital disorder of glycosylation termed CDG IIb. Lec23 mutant cells have been shown to alter lectin binding and to synthesize predominantly oligomannosyl N-glycans on endogenous glycoproteins. A single point mutation (TCC to TTC; Ser to Phe) was identified in Lec23 Gcs1 cDNA and genomic DNA. Serine at the analogous position is highly conserved in all GCS1 gene homologues. A human GCS1 cDNA reverted the Lec23 phenotype, whereas GCS1 cDNA carrying the lec23 mutation (S440F in human) did not. By contrast, GCS1 cDNA with an R486T or F652L CDG IIb mutation gave substantial rescue of the Lec23 phenotype. Nevertheless, in vitro assays of each enzyme gave no detectable alpha-glucosidase I activity. Clearly the R486T and F652L GCS1 mutations are only mildly debilitating in an intact cell, whereas the S440F mutation largely inactivates alpha-glucosidase I both in vitro and in vivo. However, the S440F alpha-glucosidase I may have a small amount of alpha-glucosidase I activity in vivo based on the low levels of complex N-glycans in Lec23. A sensitive test for complex N-glycans showed the presence of polysialic acid on the neural cell adhesion molecule. The Lec23 Chinese hamster ovary mutant represents a sensitive host for detecting a wide range of mutations in human GCS1 that give rise to CDG IIb.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Chonnam Natl Univ, Sch Med, Gen Res Ctr Enter Bacteria, Kwangju 501746, South Korea; Chonnam Natl Univ, Sch Med, Dept Microbiol, Kwangju 501746, South Korea	Yeshiva University; Albert Einstein College of Medicine; Chonnam National University; Chonnam National University	Stanley, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747	NCI NIH HHS [P01 CA13330, R01 CA34634] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boedeker JC, 1999, J LIPID RES, V40, P1627; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; Chen P, 1997, ANAL BIOCHEM, V244, P144, DOI 10.1006/abio.1996.9874; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; De Praeter CM, 2000, AM J HUM GENET, V66, P1744, DOI 10.1086/302948; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Endo T, 2003, BIOL PHARM BULL, V26, P1641, DOI 10.1248/bpb.26.1641; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Fenouillet E, 1996, VIROLOGY, V218, P224, DOI 10.1006/viro.1996.0182; Fenouillet E, 1997, VIROLOGY, V231, P89, DOI 10.1006/viro.1997.8505; Freeze HH, 2002, BBA-GEN SUBJECTS, V1573, P388, DOI 10.1016/S0304-4165(02)00408-7; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hong YJ, 2003, J BIOL CHEM, V278, P53045, DOI 10.1074/jbc.M309967200; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; Jaeken J, 2004, J Inherit Metab Dis, V27, P423, DOI 10.1023/B:BOLI.0000031221.44647.9e; Kojima N, 1998, J BIOCHEM-TOKYO, V124, P726, DOI 10.1093/oxfordjournals.jbchem.a022173; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Lee JH, 2001, J BIOL CHEM, V276, P13924, DOI 10.1074/jbc.M010046200; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; Martin PT, 2003, GLYCOBIOLOGY, V13, p67R, DOI 10.1093/glycob/cwg077; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Powell AK, 1996, RAPID COMMUN MASS SP, V10, P1027; PUKAZHENTHI BS, 1993, J BIOL CHEM, V268, P6445; RAY MK, 1991, J BIOL CHEM, V266, P22818; Romaniouk A, 1997, GLYCOBIOLOGY, V7, P399, DOI 10.1093/glycob/7.3.399; Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P9701; SHAILUBHAI K, 1991, J BIOL CHEM, V266, P16587; SHAILUBHAI K, 1987, BIOCHEM J, V247, P555, DOI 10.1042/bj2470555; Spiro MJ, 2000, GLYCOBIOLOGY, V10, P521, DOI 10.1093/glycob/10.5.521; Spiro RG, 2004, CELL MOL LIFE SCI, V61, P1025, DOI 10.1007/s00018-004-4037-8; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STANLEY P, 1984, ARCH BIOCHEM BIOPHYS, V230, P363, DOI 10.1016/0003-9861(84)90119-X; STANLEY P, 1990, SOMAT CELL MOLEC GEN, V16, P211, DOI 10.1007/BF01233357; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Volker C, 2002, GLYCOBIOLOGY, V12, P473, DOI 10.1093/glycob/cwf050; von der Ohe M, 2002, GLYCOBIOLOGY, V12, P47, DOI 10.1093/glycob/12.1.47	47	18	18	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49894	49901		10.1074/jbc.M410121200	http://dx.doi.org/10.1074/jbc.M410121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383536	hybrid			2022-12-25	WOS:000225229500044
J	Purvis, AR; Sadler, JE				Purvis, AR; Sadler, JE			A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; VONWILLEBRAND-FACTOR VWF; ENDOPLASMIC-RETICULUM; POLYPEPTIDE-CHAIN; PROTEIN; PROPOLYPEPTIDE; IDENTIFICATION; LOCALIZATION; DIMERIZATION; REQUIREMENTS	The assembly of von Willebrand factor multimers in the Golgi apparatus requires D1D2 domains of the von Willebrand factor propeptide, which may act as an oxidoreductase to promote disulfide bond formation or rearrangement between two D3 domains in the mature subunit. This mechanism predicts that the propeptide should form a transient intrachain disulfide bond with the D3 domain before multimerization. Such an intermediate was detected using truncated subunits that simplify the analysis of the multimerization process. When only the D1D2D'D3 region of von Willebrand factor was expressed in baby hamster kidney cells, the propeptide and D'D3 formed an intrachain disulfide-linked species in the endoplasmic reticulum that could be identified by two-dimensional gel electrophoresis after cleavage with thrombin or furin. This intermediate rearranged in the Golgi to form free propeptide and D'D3 dimers that were secreted. A similar intracellular disulfide-linked species was identified in cells expressing the propeptide and D'D3 as separate proteins and in cells expressing full-length von Willebrand factor. These results support a model in which the propeptide acts as an oxidoreductase to promote von Willebrand factor multimerization in the Golgi apparatus.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Biol & Biomed Sci, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.	esadler@im.wustl.edu	Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072917] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL72917] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bodo I, 2001, BLOOD, V98, P2973, DOI 10.1182/blood.V98.10.2973; FAY PJ, 1982, P NATL ACAD SCI-BIOL, V79, P7200, DOI 10.1073/pnas.79.23.7200; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Gitler C, 1997, ANAL BIOCHEM, V252, P48, DOI 10.1006/abio.1997.2294; JAFFE EA, 1974, P NATL ACAD SCI USA, V71, P1906, DOI 10.1073/pnas.71.5.1906; Katsumi A, 2000, J BIOL CHEM, V275, P25585, DOI 10.1074/jbc.M002654200; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; NACHMAN R, 1977, J CLIN INVEST, V60, P914, DOI 10.1172/JCI108846; REHEMTULLA A, 1992, BLOOD, V79, P2349; Rivera VM, 2000, SCIENCE, V287, P826, DOI 10.1126/science.287.5454.826; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; VISCHER UM, 1994, BLOOD, V83, P3536; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WAGNER DD, 1987, P NATL ACAD SCI USA, V84, P1955, DOI 10.1073/pnas.84.7.1955; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320; WAGNER DD, 1985, J CELL BIOL, V101, P112, DOI 10.1083/jcb.101.1.112; WAGNER DD, 1984, J CELL BIOL, V99, P2123, DOI 10.1083/jcb.99.6.2123; WAGNER DD, 1983, J BIOL CHEM, V258, P2065; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9	25	40	41	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49982	49988		10.1074/jbc.M408727200	http://dx.doi.org/10.1074/jbc.M408727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15385532	hybrid			2022-12-25	WOS:000225229500054
J	Solanas, G; Miravet, S; Casagolda, D; Castano, J; Raurell, I; Corrionero, A; de Herreros, AG; Dunach, M				Solanas, G; Miravet, S; Casagolda, D; Castano, J; Raurell, I; Corrionero, A; de Herreros, AG; Dunach, M			beta-catenin and plakoglobin N- and C-tails determine ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; BINDING; CADHERIN; PROTEINS; ASSOCIATION; DESMOSOMES; INTERACTS; PYGOPUS; REGION	beta-Catenin and plakoglobin are related proteins involved in the regulation of adherens junctions and desmosomes. Moreover, by binding to Tcf-4, they can act as transcriptional modulators of genes involved in embryonic development and tumorigenesis. However, they associate to distinct Tcf-4 subdomains causing opposing effects on Tcf-4 binding to DNA: whereas beta-catenin does not affect this binding, plakoglobin prevents it. Both proteins are composed by two N- and C-tails and a central armadillo repeat domain. Interaction of Tcf-4, as well as other desmosomal or adherens junction components, with beta-catenin or plakoglobin takes place through the central armadillo domain. Here we show that, as reported for beta-catenin, plakoglobin terminal tails also interact with the central domain and regulate the ability of this region to bind to different cofactors. Moreover the specificity of the interaction of beta-catenin and plakoglobin with different subdomains in Tcf-4 or with other junctional components resides within the terminal tails and not in the armadillo domain. For instance, a chimeric protein in which the central domain of beta-catenin was replaced by that of plakoglobin presented the same specificity as wild-type beta-catenin. Therefore, the terminal tails of these proteins are responsible for discerning among binding of factors to the armadillo domain. These results contribute to the understanding of the molecular basis of the interactions established by these key regulators of epithelial tumorigenesis.	Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Unitat Biofis, E-08193 Barcelona, Spain; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain	Autonomous University of Barcelona; University of Barcelona; Pompeu Fabra University	de Herreros, AG (corresponding author), Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Unitat Biofis, E-08193 Barcelona, Spain.	agarcia@imim.es; mireia.dunach@uab.es	de Herreros, A Garcia/H-3104-2014; Dunach, Mireia/E-3604-2015	de Herreros, A Garcia/0000-0001-5270-0808; Dunach, Mireia/0000-0001-9844-5603; Solanas, Guiomar/0000-0001-8388-8647; Castano Cardoso, Julio/0000-0002-0712-5856				Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Castano J, 2002, J BIOL CHEM, V277, P31541, DOI 10.1074/jbc.M204376200; Feng Y, 2003, CANCER RES, V63, P8726; Gaudry CA, 2001, J BIOL CHEM, V276, P24871, DOI 10.1074/jbc.M102731200; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hu PQ, 2001, J INVEST DERMATOL, V117, P1059, DOI 10.1046/j.0022-202x.2001.01523.x; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kolligs FT, 2000, GENE DEV, V14, P1319; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Miravet S, 2003, MOL CELL BIOL, V23, P7391, DOI 10.1128/MCB.23.20.7391-7402.2003; Miravet S, 2002, J BIOL CHEM, V277, P1884, DOI 10.1074/jbc.M110248200; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Polakis P, 2000, GENE DEV, V14, P1837; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Townsley FM, 2004, NAT CELL BIOL, V6, P626, DOI 10.1038/ncb1141; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Williams BO, 2000, ONCOGENE, V19, P5720, DOI 10.1038/sj.onc.1203921; Zhurinsky J, 2000, J CELL SCI, V113, P3127; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	35	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49849	49856		10.1074/jbc.M408685200	http://dx.doi.org/10.1074/jbc.M408685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15381698	hybrid			2022-12-25	WOS:000225229500038
J	Demuth, I; Digweed, M; Concannon, P				Demuth, I; Digweed, M; Concannon, P			Human SNM1B is required for normal cellular response to both DNA interstrand crosslink-inducing agents and ionizing radiation	ONCOGENE			English	Article						hSNM1B; DNA doublestrand break; Fanconi anemia; DNA interstrand crosslinks; PSO2; DCLRE1B	FANCONI-ANEMIA GENE; SACCHAROMYCES-CEREVISIAE; POSITIONAL CLONING; GENOME INSTABILITY; MAMMALIAN-CELLS; REPAIR GENE; MITOMYCIN-C; PSO GENES; PATHWAY; PROTEIN	DNA interstrand crosslinks (ICLs) are critical lesions for the mammalian cell since they affect both DNA strands and block transcription and replication. The repair of ICLs in the mammalian cell involves components of different repair pathways such as nucleotide-excision repair and the double-strand break/homologous recombination repair pathways. However, the mechanistic details of mammalian ICL repair have not been fully delineated. We describe here the complete coding sequence and the genomic organization of hSNM1B, one of at least three human homologs of the Saccharomyces cerevisiae PSO2 gene. Depletion of hSNM1B by RNA interference rendered cells hypersensitive to ICL-inducing agents. This requirement for hSNM1B in the cellular response to ICL has been hypothesized before but never experimentally verified. In addition, siRNA knockdown of hSNM1B rendered cells sensitive to ionizing radiation, suggesting the possibility of hSNM1B involvement in homologous recombination repair of double-strand breaks arising as intermediates of ICL repair. Monoubiquitination of FANCD2, a key step in the FANG/BRCA pathway, is not affected in hSNM1B-depleted HeLa cells, indicating that hSNM1B is probably not a part of the Fanconi anemia core complex. Nonetheless, similarities in the phenotype of hSNM1B-depleted cells and cultured cells from patients suffering from Fanconi anemia make hSNM1B a candidate for one of the as yet unidentified Fanconi anemia genes not involved in monoubiquitination of FANCD2.	Benaroya Res Inst, Mol Genet Program, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Humboldt Univ, Inst Humangenet, D-13353 Berlin, Germany	Benaroya Research Institute; University of Washington; University of Washington Seattle; Humboldt University of Berlin	Concannon, P (corresponding author), Benaroya Res Inst, Mol Genet Program, 1201 9th Ave, Seattle, WA 98101 USA.	patcon@benaroyaresearch.org	Demuth, Ilja/ABD-5352-2021	Demuth, Ilja/0000-0002-4340-2523; Concannon, Patrick/0000-0002-5801-1859	NATIONAL CANCER INSTITUTE [R01CA057569] Funding Source: NIH RePORTER; NCI NIH HHS [CA57569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; Brendel M, 2003, MUTAT RES-REV MUTAT, V544, P179, DOI 10.1016/j.mrrev.2003.06.018; Bruun D, 2003, DNA REPAIR, V2, P1007, DOI 10.1016/S1568-7864(03)00112-5; CALDECOTT K, 1991, MUTAT RES, V255, P111, DOI 10.1016/0921-8777(91)90046-R; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Carreau M, 1999, MUTAT RES-DNA REPAIR, V435, P103, DOI 10.1016/S0921-8777(99)00041-5; CASSIER C, 1980, GENETICS, V96, P841; CASSIERCHAUVAT C, 1988, CURR GENET, V13, P37, DOI 10.1007/BF00365754; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; Demuth I, 1998, MUTAT RES-DNA REPAIR, V409, P11, DOI 10.1016/S0921-8777(98)00037-8; Digweed M, 2002, ONCOGENE, V21, P4873, DOI 10.1038/sj.onc.1205616; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dronkert MLG, 2000, MOL CELL BIOL, V20, P4553, DOI 10.1128/MCB.20.13.4553-4561.2000; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Foe J R, 1996, Nat Genet, V14, P488; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatti RA, 2001, ACTA ONCOL, V40, P702, DOI 10.1080/02841860152619115; HENRIQUES JAP, 1980, GENETICS, V95, P273; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; LEVITUS M, 2003, BLOOD, V103, P298; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; McHugh PJ, 2001, LANCET ONCOL, V2, P483, DOI 10.1016/S1470-2045(01)00454-5; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moynahan ME, 2001, CANCER RES, V61, P4842; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Richie CT, 2002, MOL CELL BIOL, V22, P8635, DOI 10.1128/MCB.22.24.8635-8647.2002; RICHTER D, 1992, MOL GEN GENET, V231, P194, DOI 10.1007/BF00279791; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Rothfuss A, 2004, MOL CELL BIOL, V24, P123, DOI 10.1128/MCB.24.1.123-134.2004; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; WILBORN F, 1989, CURR GENET, V16, P331, DOI 10.1007/BF00340711	47	65	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8611	8618		10.1038/sj.onc.1207895	http://dx.doi.org/10.1038/sj.onc.1207895			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467758				2022-12-25	WOS:000224988800007
J	Kuphal, S; Poser, I; Jobin, C; Hellerbrand, C; Bosserhoff, AK				Kuphal, S; Poser, I; Jobin, C; Hellerbrand, C; Bosserhoff, AK			Loss of E-cadherin leads to upregulation of NF kappa B activity in malignant melanoma	ONCOGENE			English	Article						melanoma; E-cadherin; p-p38; NF kappa B	ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; LOBULAR BREAST CANCERS; CELL-CELL-ADHESION; BETA-CATENIN; EXPRESSION; P38; PATHWAY; GROWTH; GENE	Malignant transformation of melanocytes frequently coincides with loss of E-cadherin expression. Here, we show that loss of E-cadherin leads to induction of nuclear factor kappa B (NFkappaB) activity in melanoma cell lines. Melanoma cells show constitutively active NFkappaB, whereas no activity is found in primary melanocytes. After reexpression of E-cadherin in melanoma cells, strong downregulation of NFkappaB activity was found. Consistently, NFkappaB activity was induced in primary human melanocytes after inhibition of E-cadherin activity by functionally blocking anti-E-cadherin antibodies. Interestingly, reexpression of E-cadherin-blocked p38 MAPK activity and the p38 MAPK inhibitors SB203580 and SB202190 almost completely prevented NFkappaB activation in melanoma cells. Furthermore, cytoplasmatic beta-catenin induced p38 and NFkappaB activation in malignant melanoma. To our knowledge, this is the first report suggesting a correlation between E-cadherin and NFkappaB activity in melanocytes and melanoma cells. In summary, we conclude that loss of E-cadherin and cytoplasmatic beta-catenin induces p38-mediated NFkappaB activation, potentially revealing an important mechanism of tumorigenesis in malignant melanomas.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA	University of Regensburg; University of North Carolina; University of North Carolina Chapel Hill	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Denkert C, 2002, CLIN EXP METASTAS, V19, P79, DOI 10.1023/A:1013857325012; Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Huang S, 2000, CLIN CANCER RES, V6, P2573; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Li G, 2001, CANCER RES, V61, P3819; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; McNulty SE, 2001, PIGM CELL RES, V14, P456, DOI 10.1034/j.1600-0749.2001.140606.x; Melki JR, 2000, BLOOD, V95, P3208; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Orsulic S, 1999, J CELL SCI, V112, P1237; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; Tamura S, 1996, BRIT J SURG, V83, P1608, DOI 10.1002/bjs.1800831138; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Yang JM, 2001, CANCER RES, V61, P4901	41	108	111	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8509	8519		10.1038/sj.onc.1207831	http://dx.doi.org/10.1038/sj.onc.1207831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378016				2022-12-25	WOS:000224870700011
J	Soares-Da-Silva, P; Serrao, MP; Pinho, MJ; Bonifacio, MJ				Soares-Da-Silva, P; Serrao, MP; Pinho, MJ; Bonifacio, MJ			Cloning and gene silencing of LAT2, the L-3,4-dihydroxyphenylalanine (L-DOPA) transporter, in pig renal LLC-PK1 epithelial cells	FASEB JOURNAL			English	Article						LAT2; siRNA; LLC-PK1 cells; amino acid exchanger	AMINO-ACID TRANSPORTERS; CEREBRAL ENDOTHELIAL-CELLS; BLOOD-BRAIN-BARRIER; MOLECULAR-BIOLOGY; P-GLYCOPROTEIN; HEAVY-CHAIN; SALT INTAKE; KIDNEY; HYPERTENSION; SODIUM	Organ-specific overexpression of type 2 L-amino acid transporter (LAT2) in the kidney of the spontaneous hypertensive rat ( SHR), accompanied by an enhanced ability to take up L-DOPA, may constitute the basis for the enhanced renal production of dopamine in the SHR in an attempt overcome the deficient dopamine-mediated natriuresis. To understand the physiological role of LAT2-mediated L-DOPA handling, we used 21-nucleotide small interfering RNA duplexes ( siRNA) to specifically suppress LAT2 expression in LLC-PK1 cells, a cell line that retains several properties of proximal tubular epithelial cells and takes up L-DOPA largely through Na+-independent transporters. After cloning the LLC-PK1 LAT2 gene, one target region of LAT2 mRNA ( nt 97-117) was selected by scanning the length of the LAT2 gene for AA-dinucleotide sequences and downstream 19 nucleotides. Levels of LAT2 cDNA, determined by real-time quantitative RT-PCR, were markedly (P< 0.05) reduced by LAT2 siRNA but not by the mismatch LAT2 siRNA. The LAT2 siRNA but not the mismatch LAT2 siRNA, reduced by 85% [C-14]-L-DOPA accumulation, a time- and concentration-dependent effect. The efflux of intracellular [C-14]-L-DOPA was markedly increased ( P< 0.05) by L-DOPA and L-leucine. The [C-14]-L-DOPA outward transport was decreased 90% by LAT2 siRNA, but not by the mismatch LAT2 siRNA. However, treatment with the siRNA LAT2 did not affect the L-DOPA-induced fractional outflow of [C-14]-L-DOPA. The Na+-independent and pH-sensitive L-DOPA transporter may include the hetero amino acid exchanger LAT2, whose activation results in trans-stimulation of L-DOPA outward transfer.	Fac Med, Inst Pharmacol & Therapeut, P-4200 Oporto, Portugal	Universidade do Porto	Soares-Da-Silva, P (corresponding author), Fac Med, Inst Pharmacol & Therapeut, P-4200 Oporto, Portugal.	psoaresdasilva@netcabo.pt	Soares-da-Silva, Patricio/A-6704-2015	Soares-da-Silva, Patricio/0000-0002-2446-5078; Pinho, Maria Joao/0000-0001-8173-0379; Serrao, Paula/0000-0002-3663-7500				AUDUS KL, 1986, J NEUROCHEM, V47, P484; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fraga S, 2002, J NUTR, V132, P733, DOI 10.1093/jn/132.4.733; Gomes P, 1999, BRAIN RES, V829, P143, DOI 10.1016/S0006-8993(99)01387-6; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; Hussain T, 2003, EXP BIOL MED, V228, P134, DOI 10.1177/153537020322800202; Jose PA, 2002, CURR HYPERTENS REP, V4, P237, DOI 10.1007/s11906-002-0013-6; Jose PA, 2002, CURR OPIN NEPHROL HY, V11, P87, DOI 10.1097/00041552-200201000-00013; Kageyama T, 2000, BRAIN RES, V879, P115, DOI 10.1016/S0006-8993(00)02758-X; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; Lucas-Teixeira VA, 2000, CLIN EXP HYPERTENS, V22, P455, DOI 10.1081/CEH-100100084; Motulsky H., 1999, ANAL DATA GRAPHPAD P; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Pinho MJ, 2003, HYPERTENSION, V42, P613, DOI 10.1161/01.HYP.0000091822.00166.B1; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; RACZ K, 1985, CIRC RES, V57, P889, DOI 10.1161/01.RES.57.6.889; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Sampaio-Maia B, 2001, AM J PHYSIOL-CELL PH, V280, pC333, DOI 10.1152/ajpcell.2001.280.2.C333; Sanada H, 1995, Hypertens Res, V18 Suppl 1, pS179, DOI 10.1291/hypres.18.SupplementI_S179; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Soares-Da-Silva P, 2000, AM J PHYSIOL-RENAL, V279, pF736, DOI 10.1152/ajprenal.2000.279.4.F736; Soares-da-Silva P, 1998, BRIT J PHARMACOL, V123, P13, DOI 10.1038/sj.bjp.0701572; Soares-da-Silva P, 2000, J PHARMACOL EXP THER, V293, P697; Soares-da-Silva P, 1998, AM J PHYSIOL-RENAL, V274, pF243, DOI 10.1152/ajprenal.1998.274.2.F243; SOARESDASILVA P, 1993, J AM SOC NEPHROL, V3, P1591; SOARESDASILVA P, 1992, BRIT J PHARMACOL, V105, P811, DOI 10.1111/j.1476-5381.1992.tb09062.x; SOARESDASILVA P, 1993, J PHARMACOL EXP THER, V264, P406; Vieira-Coelho MA, 1999, HYPERTENSION, V34, P666, DOI 10.1161/01.HYP.34.4.666; WADE LA, 1975, J NEUROCHEM, V25, P837, DOI 10.1111/j.1471-4159.1975.tb04415.x; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; YOSHIMURA M, 1990, J AUTON PHARMACOL, V10, pS67, DOI 10.1111/j.1474-8673.1990.tb00230.x	36	19	20	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2004	18	13					1489	1498		10.1096/fj.04-1787com	http://dx.doi.org/10.1096/fj.04-1787com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466357				2022-12-25	WOS:000224849900032
J	Lu, HL; Macosko, J; Habel-Rodriguez, D; Keller, RW; Brozik, JA; Keller, DJ				Lu, HL; Macosko, J; Habel-Rodriguez, D; Keller, RW; Brozik, JA; Keller, DJ			Closing of the fingers domain generates motor forces in the HIV reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; DNA-POLYMERASES; COMPLEX; INHIBITION; FIDELITY; REPLICATION; RESISTANCE; MECHANISM; KINETICS	Using the force sensor of an atomic force microscope, motor forces of the human immunodeficiency virus-1 reverse transcriptase were measured during active replication of a short DNA transcript. At low load forces the polymerase is mechanically slowed, whereas at high force (similar to15 piconewton) it stalls. From recordings of estimated polymerase turnover velocity versus load force, an approximate force-velocity curve has been constructed. The shape of the curve suggests that load force strongly inhibits the rate-limiting step of the polymerase turnover cycle and that the combined effect of load on all steps involves an effective motion of about 1.6 nm. Earlier results from pre-steady-state kinetics experiments have identified the rate-limiting step as the closing of the fingers domain to form a tight catalytic complex. Together these findings indicate that the closing of the fingers domain is a major force-generating step for human immunodeficiency virus reverse transcriptase and, by extension, for all DNA polymerase machines.	Univ New Mexico, Dept Chem, Albuquerque, NM 87106 USA	University of New Mexico	Keller, DJ (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87106 USA.	dkeller@unm.edu	lu, hailong/C-7754-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063808] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63808] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; Furge LL, 1999, BIOCHEMISTRY-US, V38, P4818, DOI 10.1021/bi982163u; Furman PA, 2000, CURR PHARM DESIGN, V6, P547, DOI 10.2174/1381612003400777; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KATI WM, 1992, J BIOL CHEM, V267, P25988; Keller D, 2000, BIOPHYS J, V78, P541, DOI 10.1016/S0006-3495(00)76615-X; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Pop MP, 1996, BIOCHEMISTRY-US, V35, P5054, DOI 10.1021/bi9530292; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614	19	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54529	54532		10.1074/jbc.M407193200	http://dx.doi.org/10.1074/jbc.M407193200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15385563	hybrid			2022-12-25	WOS:000225793600077
J	Matsuda, N; Kobayashi, H; Katoh, H; Ogawa, T; Futatsugi, L; Nakamura, T; Bakker, EP; Uozumi, N				Matsuda, N; Kobayashi, H; Katoh, H; Ogawa, T; Futatsugi, L; Nakamura, T; Bakker, EP; Uozumi, N			Na+-dependent K+ uptake ktr system from the cyanobacterium Synechocystis sp PCC 6803 and its role in the early phases of cell adaptation to hyperosmotic shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POTASSIUM UPTAKE; HKT TRANSPORTERS; PHOSPHATE SYNTHASE; OSMOTIC ADJUSTMENT; STRUCTURAL MODELS; BACILLUS-SUBTILIS; GENE-CLUSTER; SODIUM; EXPRESSION	Transmembrane ion transport processes play a key role in the adaptation of cells to hyperosmotic conditions. Previous work has shown that the disruption of a ktrB/ntpJ-like putative Na+/K+ transporter gene in the cyanobacterium Synechocystis sp. PCC 6803 confers increased Na+ sensitivity, and inhibits HCO3- uptake. Here, we report on the mechanistic basis of this effect. Heterologous expression experiments in Escherichia coli show that three Synechocystis genes are required for K+ transport activity. They encode an NAD(+)-binding peripheral membrane protein ( ktrA; sll0493), an integral membrane protein, belonging to a superfamily of K+ transporters ( ktrB; formerly ntpJ; slr1509), and a novel type of ktr gene product, not previously found in Ktr systems (ktrE; slr1508). In E. coli, Synechocystis KtrABE-mediated K+ uptake occurred with a moderately high affinity (K-m of about 60 muM), and depended on both Na+ and a high membrane potential, but not on ATP. KtrABE neither mediated Na+ uptake nor Na+ efflux. In Synechocystis sp. PCC 6803, KtrB-mediated K+ uptake required Na+ and was inhibited by protonophore. A DeltaktrB strain was sensitive to long term hyperosmotic stress elicited by either NaCl or sorbitol. Hyperosmotic shock led initially to loss of net K+ from the cells. The DeltaktrB cells shocked with sorbitol failed to reaccumulate K+ up to its original level. These data indicate that in strain PCC 6803 K+ uptake via KtrABE plays a crucial role in the early phase of cell turgor regulation after hyperosmotic shock.	Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan; Niigata Univ Pharm & Appl Life Sci, Fac Pharm, Niigata 9502081, Japan; Univ Osnabruck, Abt Mikrobiol, D-49076 Osnabruck, Germany	Nagoya University; Chiba University; Niigata University; University Osnabruck	Uozumi, N (corresponding author), Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan.	uozumi@agr.nagoya-u.ac.jp	Uozumi, Nobuyuki/AAG-3252-2019	Uozumi, Nobuyuki/0000-0003-4268-1126				BAKKER EP, 1981, J BACTERIOL, V147, P820, DOI 10.1128/JB.147.3.820-826.1981; BAKKER EP, 1990, FEMS MICROBIOL LETT, V75, P319, DOI 10.1111/j.1574-6968.1990.tb04105.x; BAKKER EP, 1993, ALKALI CATION TRANSP, P00205; Berry S, 2003, FEBS LETT, V548, P53, DOI 10.1016/S0014-5793(03)00729-4; Berthomieu P, 2003, EMBO J, V22, P2004, DOI 10.1093/emboj/cdg207; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; Bray EA, 1997, TRENDS PLANT SCI, V2, P48, DOI 10.1016/S1360-1385(97)82562-9; Bremer E, 2000, BACTERIAL STRESS RESPONSES, P79; BUURMAN ET, 1995, J BIOL CHEM, V270, P6678, DOI 10.1074/jbc.270.12.6678; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; Durell SR, 2000, BIOPHYS J, V78, P188, DOI 10.1016/S0006-3495(00)76584-2; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Fairbairn DJ, 2000, PLANT MOL BIOL, V43, P515, DOI 10.1023/A:1006496402463; Ferjani A, 2003, PLANT PHYSIOL, V131, P1628, DOI 10.1104/pp.102.017277; Garciadeblas B, 2003, PLANT J, V34, P788, DOI 10.1046/j.1365-313X.2003.01764.x; Gassmann W, 1996, PLANT J, V10, P869, DOI 10.1046/j.1365-313X.1996.10050869.x; GOHMANN S, 1994, MICROB PATHOGENESIS, V16, P53, DOI 10.1006/mpat.1994.1005; Harms C, 2001, MICROBIOL-SGM, V147, P2991, DOI 10.1099/00221287-147-11-2991; Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463; Holtmann G, 2003, J BACTERIOL, V185, P1289, DOI 10.1128/JB.185.4.1289-1298.2003; Horie T, 2001, PLANT J, V27, P129, DOI 10.1046/j.1365-313x.2001.01077.x; Inaba M, 2001, J BACTERIOL, V183, P1376, DOI 10.1128/JB.183.4.1376-1384.2001; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kato Y, 2001, P NATL ACAD SCI USA, V98, P6488, DOI 10.1073/pnas.101556598; Katoh H, 2001, J BACTERIOL, V183, P2779, DOI 10.1128/JB.183.9.2779-2784.2001; Kawano M, 1999, FEMS MICROBIOL LETT, V176, P449; Kawano M, 2000, J BACTERIOL, V182, P2507, DOI 10.1128/JB.182.9.2507-2512.2000; Lee SJ, 2004, MOL CELL, V14, P153, DOI 10.1016/S1097-2765(04)00202-3; Liu WH, 2001, PLANT PHYSIOL, V127, P283, DOI 10.1104/pp.127.1.283; Marin K, 2002, J BACTERIOL, V184, P2870, DOI 10.1128/JB.184.11.2870-2877.2002; Marin K, 1998, J BACTERIOL, V180, P4843, DOI 10.1128/JB.180.18.4843-4849.1998; Maser P, 2002, P NATL ACAD SCI USA, V99, P6428, DOI 10.1073/pnas.082123799; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; Morbach S, 2002, CHEMBIOCHEM, V3, P385, DOI 10.1002/1439-7633(20020503)3:5<384::AID-CBIC384>3.0.CO;2-H; Nakamura T, 1998, J BACTERIOL, V180, P3491, DOI 10.1128/JB.180.13.3491-3494.1998; Ohkawa H, 2000, J BACTERIOL, V182, P2591, DOI 10.1128/JB.182.9.2591-2596.2000; OHYAMA T, 1994, J BACTERIOL, V176, P4311, DOI 10.1128/jb.176.14.4311-4315.1994; Oren A, 1999, MICROBIOL MOL BIOL R, V63, P334, DOI 10.1128/MMBR.63.2.334-348.1999; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; REED RH, 1985, MAR BIOL, V88, P1, DOI 10.1007/BF00393037; REED RH, 1985, FEMS MICROBIOL LETT, V28, P225, DOI 10.1016/0378-1097(85)90086-2; RHOADS DB, 1977, J BIOL CHEM, V252, P1394; Roosild TP, 2002, CELL, V109, P781, DOI 10.1016/S0092-8674(02)00768-7; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Rus A, 2001, P NATL ACAD SCI USA, V98, P14150, DOI 10.1073/pnas.241501798; Sakuma T, 1998, BBA-BIOENERGETICS, V1363, P231, DOI 10.1016/S0005-2728(97)00102-3; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; Shibata M, 2002, J BIOL CHEM, V277, P18658, DOI 10.1074/jbc.M112468200; Shinozaki K, 1997, PLANT PHYSIOL, V115, P327, DOI 10.1104/pp.115.2.327; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; STUMPE S, 1996, HDB BIOL PHYS, P473; Su H, 2003, PLANT MOL BIOL, V52, P967, DOI 10.1023/A:1025445612244; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tchernov D, 2001, J BIOL CHEM, V276, P23450, DOI 10.1074/jbc.M101973200; Tholema N, 1999, FEBS LETT, V450, P217, DOI 10.1016/S0014-5793(99)00504-9; Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249; Uozumi N, 2001, AM J PHYSIOL-CELL PH, V281, pC733, DOI 10.1152/ajpcell.2001.281.3.C733; Walderhaug M.O., 1987, ION TRANSPORT PROKAR, P85; Wang L, 2002, J BACTERIOL, V184, P2620, DOI 10.1128/JB.184.10.2620-2625.2002; WHATMORE AM, 1990, J GEN MICROBIOL, V136, P2521, DOI 10.1099/00221287-136-12-2521; WHATMORE AM, 1990, J GEN MICROBIOL, V136, P2527, DOI 10.1099/00221287-136-12-2527	65	72	76	1	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54952	54962		10.1074/jbc.M407268200	http://dx.doi.org/10.1074/jbc.M407268200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15459199	hybrid			2022-12-25	WOS:000225793600125
J	Fessenden, JD; Feng, W; Pessah, IN; Allen, PD				Fessenden, JD; Feng, W; Pessah, IN; Allen, PD			Mutational analysis of putative calcium binding motifs within the skeletal ryanodine receptor isoform, RyR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; SITES; IDENTIFICATION; ACTIVATION; PROTEIN; LOCALIZATION; INACTIVATION; SENSITIVITY; EXPRESSION; CAFFEINE	The functional relevance of putative Ca2+ binding motifs previously identified with Ca2+ overlay binding analysis within the skeletal muscle ryanodine receptor isoform (RyR1) was examined using mutational analysis. EF hands between amino acid positions 4081 and 4092 (EF1) and 4116 and 4127 (EF2) were scrambled singly or in combination within the full-length rabbit RyR1 cDNA. These cDNAs were expressed in 1B5 RyR-deficient myotubes and channel function assessed using Ca2+-imaging techniques, [H-3]ryanodine binding measurements, and single channel experiments. In intact myotubes, these mutations did not affect functional responses to either depolarization or RyR agonists (caffeine, 4-chloro-m-cresol) compared with wtRyR1. However, in [H-3]ryanodine binding measurements, both Ca2+ activation and inhibition of the EF1 mutant was significantly altered compared with wtRyR1. No high affinity [H-3]ryanodine binding was observed in membranes expressing the EF2 mutation, although in single channel measurements, the EF2-disrupted channel could be activated by micromolar Ca2+ concentrations. In addition, micromolar levels of ryanodine placed these channels into the classical half-conductance state, thus indicating that occupancy of high affinity ryanodine binding sites is not required for ryanodine-induced subconductance states in RyR1. Disruption of three additional putative RyR1 calcium binding motifs located between amino acid positions 4254 and 4265 (EF3), 4407 and 4418 (EF4), or 4490 and 4502 (EF5) either singly or in combination (EF3-5) did not affect functional responses in 1B5 myotubes except that the EC50 for caffeine activation for the EF3 construct was significantly increased compared with wtRyR1. However, in [H-3]ryanodine binding experiments, the Ca2+-dependent activation and inactivation of mutated RyRs containing EF3, EF4, or EF5 was unaffected when compared with wtRyR1.	Brigham & Womens Hosp, Dept Anesthesia Res, Boston, MA 02115 USA; Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis	Fessenden, JD (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	fessenden@bbri.org	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X				Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CHEN SRW, 1993, J BIOL CHEM, V268, P13414; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; Du GG, 1999, J BIOL CHEM, V274, P26120, DOI 10.1074/jbc.274.37.26120; Feng W, 1999, MOL PHARMACOL, V55, P821; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Fessenden JD, 2003, J BIOL CHEM, V278, P28727, DOI 10.1074/jbc.M303821200; Fessenden JD, 2001, P NATL ACAD SCI USA, V98, P2865, DOI 10.1073/pnas.041608898; HADAD N, 1994, J BIOL CHEM, V269, P24864; Hamada T, 2002, J MOL BIOL, V324, P123, DOI 10.1016/S0022-2836(02)01032-X; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Masumiya H, 2001, J BIOL CHEM, V276, P39727, DOI 10.1074/jbc.M106557200; Meissner G, 2002, FRONT BIOSCI, V7, pD2072, DOI 10.2741/meissner; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1999, FEBS LETT, V459, P154, DOI 10.1016/S0014-5793(99)01232-6; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tu HP, 2003, BIOPHYS J, V85, P290, DOI 10.1016/S0006-3495(03)74474-9; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Xiong H, 1998, BIOCHEMISTRY-US, V37, P4804, DOI 10.1021/bi971198b; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y	30	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53028	53035		10.1074/jbc.M411136200	http://dx.doi.org/10.1074/jbc.M411136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15469935	hybrid			2022-12-25	WOS:000225680600029
J	Paithoonrangsarid, K; Shumskaya, MA; Kanesaki, Y; Satoh, S; Tabata, S; Los, DA; Zinchenko, VV; Hayashi, H; Tanticharoen, M; Suzuki, I; Murata, N				Paithoonrangsarid, K; Shumskaya, MA; Kanesaki, Y; Satoh, S; Tabata, S; Los, DA; Zinchenko, VV; Hayashi, H; Tanticharoen, M; Suzuki, I; Murata, N			Five histidine kinases perceive osmotic stress and regulate distinct sets of genes in Synechocystis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT SIGNAL-TRANSDUCTION; SP PCC-6803; ESCHERICHIA-COLI; SALT STRESS; EXPRESSION; PROTEINS; PERCEPTION; PATHWAY; HIK33	Microorganisms respond to hyperosmotic stress via changes in the levels of expression of large numbers of genes. Such responses are essential for acclimation to a new osmotic environment. To identify factors involved in the perception and transduction of signals caused by hyperosmotic stress, we examined the response of Synechocystis sp. PCC 6803, which has proven to be a particularly useful microorganism in similar analyses. We screened knockout libraries of histidine kinases (Hiks) and response regulators (Rres) in Synechocystis by DNA microarray and slot-blot hybridization analyses, and we identified several two-component systems, which we designated Hik-Rre systems, namely, Hik33-Rre31, Hik34-Rre1, and Hik10-Rre3, as well as Hik16-Hik41-Rre17, as the transducers of hyperosmotic stress. We also identified Hik2-Rre1 as a putative additional two-component system. Each individual two-component system regulated the transcription of a specific group of genes that were responsive to hyperosmotic stress.	Natl Inst Basic Biol, Div Cellular Regulat, Okazaki, Aichi 4448585, Japan; Natl Ctr Genet Engn & Biotechnol, Bangkok 12120, Thailand; Russian Acad Sci, Inst Plant Physiol, Moscow 127276, Russia; Ehime Univ, Satellite Venture Business Lab, Matsuyama, Ehime 7908577, Japan; Kazusa DNA Res Inst, Dept Plant Gene Res, Chiba 2920818, Japan; Moscow MV Lomonosov State Univ, Dept Genet, Moscow 119899, Russia; Grad Univ Adv Studies, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); Russian Academy of Sciences; Timiryazev Institute of Plant Physiology; Ehime University; Kazusa DNA Research Institute; Lomonosov Moscow State University; Graduate University for Advanced Studies - Japan	Murata, N (corresponding author), Natl Inst Basic Biol, Div Cellular Regulat, Okazaki, Aichi 4448585, Japan.	murata@nibb.ac.jp	Shumskaya, Maria/P-5972-2017; Kanesaki, Yu/J-3817-2017; Murata, Norio/E-6569-2010; Zinchenko, Vladislav V/K-3363-2017; Murata, Norio/O-7945-2019; LOS, Dmitry A./C-6608-2013	Shumskaya, Maria/0000-0001-7916-462X; Kanesaki, Yu/0000-0003-3537-9789; Zinchenko, Vladislav V/0000-0003-1931-2509; Murata, Norio/0000-0002-6605-5800; LOS, Dmitry A./0000-0002-0142-7853; , Kalyanee/0000-0001-9121-3295				COMEAU DE, 1985, J BACTERIOL, V164, P578, DOI 10.1128/JB.164.2.578-584.1985; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; Glockner G, 2000, J MOL EVOL, V51, P382; Inaba M, 2003, J BIOL CHEM, V278, P12191, DOI 10.1074/jbc.M212204200; Jiang M, 2000, MOL MICROBIOL, V38, P535, DOI 10.1046/j.1365-2958.2000.02148.x; Kaneko T, 2003, DNA RES, V10, P221, DOI 10.1093/dnares/10.5.221; Kaneko T, 1996, DNA Res, V3, P109; Kanesaki Y, 2002, BIOCHEM BIOPH RES CO, V290, P339, DOI 10.1006/bbrc.2001.6201; Koretke KK, 2000, MOL BIOL EVOL, V17, P1956, DOI 10.1093/oxfordjournals.molbev.a026297; Los D A, 2000, Sci STKE, V2000, ppe1, DOI 10.1126/stke.2000.62.pe1; Los DA, 1997, MOL MICROBIOL, V25, P1167, DOI 10.1046/j.1365-2958.1997.5641912.x; Marin K, 2003, P NATL ACAD SCI USA, V100, P9061, DOI 10.1073/pnas.1532302100; Marin K, 1998, J BACTERIOL, V180, P4843, DOI 10.1128/JB.180.18.4843-4849.1998; Mary I, 2003, FEMS MICROBIOL LETT, V226, P135, DOI 10.1016/S0378-1097(03)00587-1; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; Poolman B, 2002, MOL MICROBIOL, V44, P889, DOI 10.1046/j.1365-2958.2002.02894.x; Postier BL, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-23; Raffa RG, 2002, MOL MICROBIOL, V45, P1599, DOI 10.1046/j.1365-2958.2002.03112.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; van Waasbergen LG, 2002, J BACTERIOL, V184, P2481, DOI 10.1128/JB.184.9.2481-2490.2002; WADA H, 1989, PLANT CELL PHYSIOL, V30, P971; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	26	101	110	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53078	53086		10.1074/jbc.M410162200	http://dx.doi.org/10.1074/jbc.M410162200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471853	Green Published, hybrid			2022-12-25	WOS:000225680600035
J	Diamond, TL; Roshal, M; Jamburuthugoda, VK; Reynolds, HM; Merriam, AR; Lee, KY; Balakrishnan, M; Bambara, RA; Planelles, V; Dewhurst, S; Kim, B				Diamond, TL; Roshal, M; Jamburuthugoda, VK; Reynolds, HM; Merriam, AR; Lee, KY; Balakrishnan, M; Bambara, RA; Planelles, V; Dewhurst, S; Kim, B			Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERFORMANCE LIQUID-CHROMATOGRAPHY; RIBONUCLEOTIDE REDUCTASE; DNA-SYNTHESIS; DEOXYRIBONUCLEOSIDE TRIPHOSPHATES; FIDELITY; CELLS; REPLICATION; PYRIMIDINE; DAMAGE	Retroviruses utilize cellular dNTPs to perform proviral DNA synthesis in infected host cells. Unlike oncoretroviruses, which replicate in dividing cells, lentiviruses, such as human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus, are capable of efficiently replicating in non-dividing cells ( terminally differentiated macrophages) as well as dividing cells (i.e. activated CD4+ T cells). In general, non-dividing cells are likely to have low cellular dNTP content compared with dividing cells. Here, by employing a novel assay for cellular dNTP content, we determined the dNTP concentrations in two HIV-1 target cells, macrophages and activated CD4+ T cells. We found that human macrophages contained 130 250- fold lower dNTP concentrations than activated human CD4+ T cells. Biochemical analysis revealed that, unlike oncoretroviral reverse transcriptases (RTs), lentiviral RTs efficiently synthesize DNA even in the presence of the low dNTP concentrations equivalent to those found in macrophages. In keeping with this observation, HIV-1 vectors containing mutant HIV-1 RTs, which kinetically mimic oncoretroviral RTs, failed to transduce human macrophages despite retaining normal infectivity for activated CD4+ T cells and other dividing cells. These results suggest that the ability of HIV-1 to infect macrophages, which is essential to establishing the early pathogenesis of HIV-1 infection, depends, at least in part, on enzymatic adaptation of HIV-1 RT to efficiently catalyze DNA synthesis in limited cellular dNTP substrate environments.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA	University of Rochester; University of Rochester; University of Rochester; Utah System of Higher Education; University of Utah	Kim, B (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14642 USA.	baek_kim@urmc.rochester.edu		Dewhurst, Stephen/0000-0001-7729-7920	NIAID NIH HHS [R56 AI049057, R01 AI087508, AI49057, R01 AI049781, T32 AI049815, AI49781, R01 AI049057, R56 AI049781, T32 AI49815] Funding Source: Medline; NIGMS NIH HHS [GM49573, R01 GM049573] Funding Source: Medline; NIMH NIH HHS [P01 MH64570, P01 MH064570] Funding Source: Medline; NINDS NIH HHS [S11 NS43499, S11 NS043499] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049781, R01AI049057, R56AI049057, R01AI087508, T32AI049815, R56AI049781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH064570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [S11NS043499] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Decosterd LA, 1999, ANAL BIOCHEM, V270, P59, DOI 10.1006/abio.1999.4066; DeFife KM, 1999, J HISTOCHEM CYTOCHEM, V47, P65, DOI 10.1177/002215549904700107; Diamond TL, 2003, J BIOL CHEM, V278, P29913, DOI 10.1074/jbc.M211754200; Diamond TL, 2001, J BIOL CHEM, V276, P23624, DOI 10.1074/jbc.M102496200; DIPIERRO D, 1995, ANAL BIOCHEM, V231, P407, DOI 10.1006/abio.1995.0071; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; FULLER SA, 1982, BIOCHEM J, V206, P131, DOI 10.1042/bj2060131; Gutierrez-Rivas M, 1999, J MOL BIOL, V290, P615, DOI 10.1006/jmbi.1999.2880; Hauschka P V, 1973, Methods Cell Biol, V7, P361; Huang D, 2003, J CHROMATOGR B, V784, P101, DOI 10.1016/S1570-0232(02)00780-8; JACKSON RC, 1980, CANCER RES, V40, P1286; Kaushik N, 2000, BIOCHEMISTRY-US, V39, P2912, DOI 10.1021/bi991376w; Kim B, 1997, METHODS, V12, P318, DOI 10.1006/meth.1997.0485; Kinter A, 2000, IMMUNOL REV, V177, P88, DOI 10.1034/j.1600-065X.2000.17708.x; Klimatcheva E, 2001, MOL THER, V3, P928, DOI 10.1006/mthe.2001.0344; Krombach F, 1997, ENVIRON HEALTH PERSP, V105, P1261, DOI 10.2307/3433544; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Malboeuf CM, 2001, BIOTECHNIQUES, V30, P1074, DOI 10.2144/01305rr06; MAYBAUM J, 1980, J CHROMATOGR, V188, P149, DOI 10.1016/S0021-9673(00)88425-3; Menendez-Arias L, 1998, BIOCHEMISTRY-US, V37, P16636, DOI 10.1021/bi981830g; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; MUNCHPETERSEN B, 1973, EXP CELL RES, V79, P249, DOI 10.1016/0014-4827(73)90442-4; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; Roy B, 1999, ANAL BIOCHEM, V269, P403, DOI 10.1006/abio.1999.4051; SKOOG L, 1974, J BIOL CHEM, V249, P6434; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Weiss KK, 2004, BIOCHEMISTRY-US, V43, P4490, DOI 10.1021/bi035258r; Weiss KK, 2002, J BIOL CHEM, V277, P22662, DOI 10.1074/jbc.M200202200; Yao RJ, 2003, P NATL ACAD SCI USA, V100, P6628, DOI 10.1073/pnas.1131932100; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 2002, P NATL ACAD SCI USA, V99, P3746, DOI 10.1073/pnas.062502299	40	218	221	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51545	51553		10.1074/jbc.M408573200	http://dx.doi.org/10.1074/jbc.M408573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452123	Green Accepted, hybrid			2022-12-25	WOS:000225355800109
J	Jirawatnotai, S; Aziyu, A; Osmundson, EC; Moons, DS; Zou, XH; Kineman, RD; Kiyokawa, H				Jirawatnotai, S; Aziyu, A; Osmundson, EC; Moons, DS; Zou, XH; Kineman, RD; Kiyokawa, H			Cdk4 is indispensable for postnatal proliferation of the anterior pituitary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELEASING-HORMONE; CYCLIN-DEPENDENT KINASE-4; GROWTH-HORMONE; CELL-PROLIFERATION; TRANSGENIC MICE; EXPRESSION; DEFICIENT; GLAND; TUMORIGENESIS; HYPERPLASIA	For proper development and tissue homeostasis, cell cycle progression is controlled by multilayered mechanisms. Recent studies using knock-out mice have shown that animals can develop relatively normally with deficiency for each of the G(1)/S-regulatory proteins, D-type and E-type cyclins, cyclin-dependent kinase 4 (Cdk4), and Cdk2. Although Cdk4-null mice show no embryonic lethality, they exhibit specific endocrine phenotypes, i.e. dwarfism, infertility, and diabetes. Here we have demonstrated that Cdk4 plays an essential non-redundant role in postnatal proliferation of the anterior pituitary. Pituitaries from wild-type and Cdk4-null embryos at embryonic day 17.5 are morphologically indistinguishable with similar numbers of cells expressing a proliferating marker, Ki67, and cells expressing a differentiation marker, growth hormone. In contrast, anterior pituitaries of Cdk4-null mice at postnatal 8 weeks are extremely hypoplastic with markedly decreased numbers of Ki67(+) cells, suggesting impaired cell proliferation. Pituitary hyperplasia induced by transgenic expression of human growth hormone-releasing hormone (GHRH) is significantly diminished in the Cdk4+/- genetic background and completely abrogated in the Cdk4-/- background. Small interfering RNA ( siRNA)mediated knockdown of Cdk4 inhibits GHRH-induced proliferation of GH3 somato/lactotroph cells with restored expression of GHRH receptors. Cdk4 siRNA also inhibits estrogen-dependent cell proliferation in GH3 cells and closely related GH4 cells. In contrast, Cdk6 siRNA does not diminish proliferation of these cells. Furthermore, Cdk4 siRNA does not affect GHRH-induced proliferation of mouse embryonic fibroblasts or estrogen-dependent proliferation of mammary carcinoma MCF-7 cells. Taken together, Cdk4 is dispensable for prenatal development of the pituitary or proliferation of other nonendocrine tissues but indispensable specifically for postnatal proliferation of somato/lactotrophs.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kiyokawa, H (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, 900 S Ashland Ave,M-C 669, Chicago, IL 60607 USA.	kiyokawa@uic.edu	Kineman, Rhonda D/H-2221-2011; zou, Xianghong/E-4374-2011	Kineman, Rhonda D/0000-0001-7322-1152; Kiyokawa, Hiroaki/0000-0002-7942-6455	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038085, U54HD040093] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA100204] Funding Source: NIH RePORTER; NCI NIH HHS [CA100204] Funding Source: Medline; NICHD NIH HHS [HD38085, U54 HD40093] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernard-Kargar C, 2001, DIABETES, V50, pS30, DOI 10.2337/diabetes.50.2007.S30; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; BRAR AK, 1989, ENDOCRINOLOGY, V125, P801, DOI 10.1210/endo-125-2-801; Burgess R, 2002, CURR OPIN GENET DEV, V12, P534, DOI 10.1016/S0959-437X(02)00337-4; Canavese G, 2001, HUM PATHOL, V32, P1094, DOI 10.1053/hupa.2001.28234; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Cohen LE, 2000, ENDOCRINE, V12, P99, DOI 10.1385/ENDO:12:2:99; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Frohman LA, 2002, TRENDS ENDOCRIN MET, V13, P299, DOI 10.1016/S1043-2760(02)00613-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; HAMMER RE, 1985, NATURE, V315, P413, DOI 10.1038/315413a0; HU NP, 1994, ONCOGENE, V9, P1021; JANSSON JO, 1987, ENDOCRINOLOGY, V120, P525, DOI 10.1210/endo-120-2-525; Kiaris H, 2002, P NATL ACAD SCI USA, V99, P196, DOI 10.1073/pnas.012590999; Lee EJ, 2001, ENDOCRINOLOGY, V142, P414, DOI 10.1210/en.142.1.414; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Martin J, 2003, ONCOGENE, V22, P5261, DOI 10.1038/sj.onc.1206506; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Melmed S, 2003, J CLIN INVEST, V112, P1603, DOI 10.1172/JCI200320401; Mettus RV, 2003, ONCOGENE, V22, P8413, DOI 10.1038/sj.onc.1206888; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; MURDOCH GH, 1982, NATURE, V300, P192, DOI 10.1038/300192a0; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; Teixeira LT, 2000, ONCOGENE, V19, P1875, DOI 10.1038/sj.onc.1203490; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; ZEYTIN FN, 1984, ENDOCRINOLOGY, V114, P2054, DOI 10.1210/endo-114-6-2054	39	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51100	51106		10.1074/jbc.M409080200	http://dx.doi.org/10.1074/jbc.M409080200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456744	hybrid			2022-12-25	WOS:000225355800056
J	Vooijs, M; Schroeter, EH; Pan, YH; Blandford, M; Kopan, R				Vooijs, M; Schroeter, EH; Pan, YH; Blandford, M; Kopan, R			Ectodomain shedding and intramembrane cleavage of mammalian notch proteins is not regulated through oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALPHA-SECRETASE CLEAVAGE; SIGNAL PEPTIDE PEPTIDASE; DISEASE GAMMA-SECRETASE; OF-FUNCTION MUTATIONS; TRANSMEMBRANE DOMAIN; ALZHEIMERS-DISEASE; DISINTEGRIN-METALLOPROTEASE; CAENORHABDITIS-ELEGANS; INTRACELLULAR DOMAIN	Intramembrane cleaving proteases such as site 2 protease, gamma-secretase, and signal peptide peptidase hydrolyze peptide bonds within the transmembrane domain (TMD) of signaling molecules such as SREBP, Notch, and HLA-E, respectively. All three enzymes require a prior cleavage at the juxtamembrane region by another protease. It has been proposed that removing the extracellular domain allows dissociation of substrate TMD, held together by the extracellular domain or loop. Using gamma-secretase as a model intramembrane cleaving protease and Notch as a model substrate, we investigated whether activating and inactivating mutations in Notch modulate gamma-secretase cleavage through changes in oligomerization. We find that although the Notch epidermal growth factor repeats can promote dimer formation, most surface Notch molecules in mammalian cells are monomeric as are constitutively active or inactive Notch1 proteins. Using a bacterial assay for TM dimerization, we find that the isolated TMD of Notch and amyloid precursor protein self-associate and that mutations affecting Notch cleavage by gamma-secretase cleavage do not alter TMD dimerization. Our results indicate that ligand-induced reversal of controlled TMD dimerization by the Notch extracellular domain is unlikely to underlie the regulatory mechanism of intramembranous cleavage.	Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Kopan, R (corresponding author), Washington Univ, Sch Med, Dept Med, Div Dermatol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	kopan@wustl.edu	Kopan, Raphael/AAF-1357-2022; Vooijs, Marc/K-3522-2019; Kopan, Raphael/AFG-3275-2022	Kopan, Raphael/0000-0002-0350-2730	NIGMS NIH HHS [GM55479] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR BD, 1994, BIOCHEMISTRY-US, V33, P5539, DOI 10.1021/bi00184a024; Aster JC, 1999, BIOCHEMISTRY-US, V38, P4736, DOI 10.1021/bi982713o; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; Berry LW, 1997, DEVELOPMENT, V124, P925; Blat Y, 2002, BIOCHEM BIOPH RES CO, V299, P569, DOI 10.1016/S0006-291X(02)02705-5; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cheng HT, 2003, DEVELOPMENT, V130, P5031, DOI 10.1242/dev.00697; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; DECELIS JF, 1993, P NATL ACAD SCI USA, V90, P4037, DOI 10.1073/pnas.90.9.4037; DECELIS JF, 1994, GENETICS, V136, P183; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Freeman M, 2004, NAT REV MOL CELL BIO, V5, P188, DOI 10.1038/nrm1334; GOLDE TE, 2003, SCI STKE, pRE4; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; Gridley T, 2003, HUM MOL GENET, V12, pR9, DOI 10.1093/hmg/ddg052; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092-8674(03)00810-9; Huber O, 1999, J CELL SCI, V112, P4415; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; KODOYIANNI V, 1992, MOL BIOL CELL, V3, P1199, DOI 10.1091/mbc.3.11.1199; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Le Borgne R, 2003, CURR BIOL, V13, pR273, DOI 10.1016/S0960-9822(03)00199-4; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Li YH, 2002, BIOCHEMISTRY-US, V41, P4921, DOI 10.1021/bi011894i; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lin MH, 2003, DEV BIOL, V263, P343, DOI 10.1016/j.ydbio.2003.07.007; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; MUMM JS, 2000, THESIS WASHINGTON U; Nakajima M, 2000, J NEUROSCI RES, V62, P311, DOI 10.1002/1097-4547(20001015)62:2<311::AID-JNR16>3.0.CO;2-G; Parks AL, 2000, DEVELOPMENT, V127, P1373; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rand MD, 1997, PROTEIN SCI, V6, P2059; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Raya A, 2004, NATURE, V427, P121, DOI 10.1038/nature02190; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Sakamoto K, 2002, DEV BIOL, V241, P313, DOI 10.1006/dbio.2001.0517; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Urban S, 2003, MOL CELL, V11, P1425, DOI 10.1016/S1097-2765(03)00181-3; Urban S, 2002, EMBO J, V21, P4277, DOI 10.1093/emboj/cdf434; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; Vardar D, 2003, BIOCHEMISTRY-US, V42, P7061, DOI 10.1021/bi034156y; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Ye J, 2000, P NATL ACAD SCI USA, V97, P5123, DOI 10.1073/pnas.97.10.5123; Zweifel ME, 2003, PROTEIN SCI, V12, P2622, DOI 10.1110/ps.03279003	72	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50864	50873		10.1074/jbc.M409430200	http://dx.doi.org/10.1074/jbc.M409430200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448134	hybrid			2022-12-25	WOS:000225355800029
J	Yahiro, K; Wada, A; Yamasaki, E; Nakayama, M; Nishi, Y; Hisatsune, J; Morinaga, N; Sap, J; Noda, M; Moss, J; Hirayama, T				Yahiro, K; Wada, A; Yamasaki, E; Nakayama, M; Nishi, Y; Hisatsune, J; Morinaga, N; Sap, J; Noda, M; Moss, J; Hirayama, T			Essential domain of receptor tyrosine phosphatase beta (RPTP beta) for interaction with Helicobacter pylori vacuolating cytotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACA TOXIN; NERVOUS-SYSTEM; ZETA/RPTP-BETA; MICE DEFICIENT; PTP-ALPHA; PROTEIN; BINDING; INDUCTION; PHOSPHORYLATION; IDENTIFICATION	Helicobacter pylori produces a potent exotoxin, VacA, which causes progressive vacuolation as well as gastric injury. Although VacA was able to interact with two receptor-like protein tyrosine phosphatases, RPTPbeta and RPTPalpha, RPTPbeta was found to be responsible for gastric damage caused by VacA. To define the region of RPTPbeta involved in VacA binding, we made mutants of human cDNA RPTPbeta-B, a short receptor form of RPTPbeta. Immunoprecipitation experiments to assess VacA binding to RPTPbeta-B mutants indicated that five residues (QTTQP) at positions 747 - 751 of the extracellular domain of RPTPbeta-B ( which is commonly retained in RPTPbeta-A, a long form of RPTPbeta) play a crucial role in its interaction with VacA, resulting in vacuolation as well as Git-1 phosphorylation. Transfected cells expressing deletion mutant Delta752, which lacks QTTQP, or the double point mutant Delta747 (T748A, T749A) had diminished vacuolation in response to VacA. Treatment of RPTPbeta-B and Delta747 ( which have QTTQP at 747 - 751) with neuraminidase and O-glycosidase diminished their VacA binding, whereas chondroitinase ABC did not have an effect. No inhibitory effect of pleiotrophin, a natural RPTPbeta ligand, on VacA binding to RPTPbeta-B or Delta747 was observed, supporting the conclusion that the extracellular region of RPTPbeta-B responsible for VacA binding is different from that involved in binding pleiotrophin. These data define the region in the RPTPbeta extracellular domain critical for VacA binding, in particular the sequence QTTQP at positions 747 - 751 with crucial threonines at positions 748 and 749 and are consistent with a role for terminal sialic acids possibly because of threonine glycosylation.	Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan; Chiba Univ, Grad Sch Med, Dept Mol Infectiol, Chiba 2608670, Japan; Japan Sci & Technol Corp, PRESTO, Saitama 3320012, Japan; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Chiba University; Japan Science & Technology Agency (JST); New York University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hirayama, T (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.	hirayama@net.nagasaki-u.ac.jp		Yahiro, Kinnosuke/0000-0002-9813-0780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621; Christlet THT, 2001, BIOPHYS J, V80, P952, DOI 10.1016/S0006-3495(01)76074-2; Cover TL, 2003, CANCER RES, V63, P951; COVER TL, 1992, HUM PATHOL, V23, P1004, DOI 10.1016/0046-8177(92)90261-Z; de Bernard M, 2000, EMBO J, V19, P48, DOI 10.1093/emboj/19.1.48; de Bernard M, 1998, INFECT IMMUN, V66, P6014, DOI 10.1128/IAI.66.12.6014-6016.1998; Del Giudice G, 2001, ANNU REV IMMUNOL, V19, P523, DOI 10.1146/annurev.immunol.19.1.523; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; Fujikawa A, 2003, NAT GENET, V33, P375, DOI 10.1038/ng1112; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Garwood J, 2003, J BIOL CHEM, V278, P24164, DOI 10.1074/jbc.M211721200; Garwood J, 2001, RESTOR NEUROL NEUROS, V19, P51; Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871; Harroch S, 2000, MOL CELL BIOL, V20, P7706, DOI 10.1128/MCB.20.20.7706-7715.2000; Haunso A, 1999, BRAIN RES, V834, P219, DOI 10.1016/S0006-8993(99)01596-6; Johnson KG, 2003, PHYSIOL REV, V83, P1, DOI 10.1152/physrev.00016.2002; Kimura M, 1999, MICROB PATHOGENESIS, V26, P45, DOI 10.1006/mpat.1998.0241; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; LEVY JB, 1993, J BIOL CHEM, V268, P10573; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; Massari P, 1998, INFECT IMMUN, V66, P3981, DOI 10.1128/IAI.66.8.3981-3984.1998; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; McGee DJ, 1999, CURR TOP MICROBIOL, V241, P155; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; MORINALI M, 1998, J EXP MED, V187, P135; Murai KK, 2002, CURR BIOL, V12, P181, DOI 10.1016/S0960-9822(02)00680-2; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Nakayama M, 2004, J BIOL CHEM, V279, P7024, DOI 10.1074/jbc.M308898200; Padilla PI, 2000, J BIOL CHEM, V275, P15200, DOI 10.1074/jbc.275.20.15200; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peek RM, 2003, NAT GENET, V33, P328, DOI 10.1038/ng0303-328; Prinz C, 2003, TRENDS MICROBIOL, V11, P134, DOI 10.1016/S0966-842X(03)00024-6; Ricci V, 2000, MOL BIOL CELL, V11, P3897, DOI 10.1091/mbc.11.11.3897; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SU J, 1994, J BIOL CHEM, V269, P18731; Sundrud MS, 2004, P NATL ACAD SCI USA, V101, P7727, DOI 10.1073/pnas.0401528101; Supajatura V, 2002, J IMMUNOL, V168, P2603, DOI 10.4049/jimmunol.168.6.2603; Suzuki J, 2001, J CLIN INVEST, V107, P363, DOI 10.1172/JCI10254; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Yahiro K, 1997, BIOCHEM BIOPH RES CO, V238, P629, DOI 10.1006/bbrc.1997.7345; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; Yahiro K, 2003, J BIOL CHEM, V278, P19183, DOI 10.1074/jbc.M300117200; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	51	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51013	51021		10.1074/jbc.M406473200	http://dx.doi.org/10.1074/jbc.M406473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15383529	hybrid			2022-12-25	WOS:000225355800046
J	Kurosaki, M; Terao, M; Barzago, MM; Bastone, A; Bernardinello, D; Salmona, M; Garattini, E				Kurosaki, M; Terao, M; Barzago, MM; Bastone, A; Bernardinello, D; Salmona, M; Garattini, E			The aldehyde oxidase gene cluster in mice and rats - Aldehyde oxidase homologue 3, a novel member of the molybdo-flavoenzyme family with selective expression in the olfactory mucosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER XANTHINE DEHYDROGENASE; MOLECULAR-CLONING; CDNA CLONING; COMAMONAS-ACIDOVORANS; FUNCTIONAL EXPRESSION; OXIDOREDUCTASE GENE; TISSUE DISTRIBUTION; RETINAL OXIDASE; MOUSE; PURIFICATION	Mammalian molybdo-flavoenzymes are oxidases requiring FAD and molybdopterin ( molybdenum cofactor) for their catalytic activity. This family of proteins was thought to consist of four members, xanthine oxidoreductase, aldehyde oxidase 1 (AOX1), and the aldehyde oxidase homologues 1 and 2 (AOH1 and AOH2, respectively). Whereas the first two enzymes are present in humans and various other mammalian species, the last two proteins have been described only in mice. Here, we report on the identification, in both mice and rats, of a novel molybdo-flavoenzyme, AOH3. In addition, we have cloned the cDNAs coding for rat AOH1 and AOH2, demonstrating that this animal species has the same complement of molybdo-flavoproteins as the mouse. The AOH3 cDNA is characterized by remarkable similarity to AOX1, AOH1, AOH2, and xanthine oxidoreductase cDNAs. Mouse AOH3 is selectively expressed in Bowman's glands of the olfactory mucosa, although small amounts of the corresponding mRNA are present also in the skin. In the former location, two alternatively spliced forms of the AOH3 transcript with different 3'-untranslated regions were identified. The general properties of AOH3 were determined by purification of mouse AOH3 from the olfactory mucosa. The enzyme possesses aldehyde oxidase activity and oxidizes, albeit with low efficiency, exogenous substrates that are recognized by AOH1 and AOX1. The Aoh3 gene maps to mouse chromosome 1 band c1 and rat chromosome 7 in close proximity to the Aox1, Aoh1, and Aoh2 loci and has an exon/intron structure almost identical to that of the other molybdo-flavoenzyme genes in the two species.	Mario Negri Inst Pharmacol Res, Ctr Catullo & Daniela Borgomainerio, Mol Biol Lab, I-20157 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Mol Pharmacol & Biochem, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Garattini, E (corresponding author), Mario Negri Inst Pharmacol Res, Ctr Catullo & Daniela Borgomainerio, Mol Biol Lab, Via Eritrea 62, I-20157 Milan, Italy.	egarattini@marionegri.it	Terao, Mineko/AAA-6415-2020; terao, mineko/AAU-8089-2020; Barzago, Maria Monica/AAA-6402-2020; salmona, mario/AAA-7116-2020; salmona, mario/ABI-4066-2020; KUROSAKI, Mami/ABG-2224-2020; Garattini, Enrico/AAI-1998-2019	Terao, Mineko/0000-0002-9976-9869; Barzago, Maria Monica/0000-0002-6952-0069; salmona, mario/0000-0002-9098-9873; KUROSAKI, Mami/0000-0001-8231-713X; Garattini, Enrico/0000-0001-8983-886X				AMAYA Y, 1990, J BIOL CHEM, V265, P14170; Ambroziak W, 1999, J BIOL CHEM, V274, P33366, DOI 10.1074/jbc.274.47.33366; BEEDHAM C, 1995, ARCH BIOCHEM BIOPHYS, V319, P481, DOI 10.1006/abbi.1995.1320; BERGER R, 1995, SOMAT CELL MOLEC GEN, V21, P121, DOI 10.1007/BF02255787; Berglund L, 1996, J DAIRY SCI, V79, P198, DOI 10.3168/jds.S0022-0302(96)76351-8; Calzi ML, 1995, J BIOL CHEM, V270, P31037, DOI 10.1074/jbc.270.52.31037; CAZZANIGA G, 1994, GENOMICS, V23, P390, DOI 10.1006/geno.1994.1515; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Demontis S, 1999, BBA-GENE STRUCT EXPR, V1489, P207, DOI 10.1016/S0167-4781(99)00174-8; EDMONDSON DE, 1989, BIOCHEMISTRY-US, V28, P5924, DOI 10.1021/bi00440a032; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Garattini E, 2003, BIOCHEM J, V372, P15, DOI 10.1042/BJ20030121; Godber Ben, 1997, Biochemical Society Transactions, V25, p519S; Gonzalez FJ, 2003, ARCH BIOCHEM BIOPHYS, V409, P153, DOI 10.1016/S0003-9861(02)00364-8; Harrison R, 2004, DRUG METAB REV, V36, P363, DOI 10.1081/DMR-120037569; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; Hatt H, 1999, CELL MOL BIOL, V45, P285; Hoff T, 1998, BBA-GENE STRUCT EXPR, V1398, P397, DOI 10.1016/S0167-4781(98)00085-2; HOLMES RS, 1979, BIOCHEM GENET, V17, P517, DOI 10.1007/BF00498887; Huang DY, 1999, ARCH BIOCHEM BIOPHYS, V364, P264, DOI 10.1006/abbi.1999.1129; Huard JMT, 1998, J COMP NEUROL, V400, P469; ICHIDA K, 1993, GENE, V133, P279; Ivanov NV, 2003, EUR J BIOCHEM, V270, P4744, DOI 10.1046/j.1432-1033.2003.03875.x; Kappl R, 2002, MET IONS BIOL SYST, V39, P481; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kurosaki M, 1999, BIOCHEM J, V341, P71, DOI 10.1042/0264-6021:3410071; Lake BG, 2002, XENOBIOTICA, V32, P835, DOI 10.1080/00498250210158915; Linder N, 1999, LAB INVEST, V79, P967; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; Mendel RR, 2002, J EXP BOT, V53, P1689, DOI 10.1093/jxb/erf038; Nishino T, 1997, J BIOL CHEM, V272, P29859, DOI 10.1074/jbc.272.47.29859; NISHINO T, 1989, J BIOL CHEM, V264, P5468; Piras E, 2003, J HISTOCHEM CYTOCHEM, V51, P1545, DOI 10.1177/002215540305101114; Rooseboom M, 2004, PHARMACOL REV, V56, P53, DOI 10.1124/pr.56.1.3; RYBCZYNSKI R, 1990, J BIOL CHEM, V265, P19712; RYTKONEN EMK, 1995, CYTOGENET CELL GENET, V68, P61, DOI 10.1159/000133890; Saksela M, 1996, BIOCHEM J, V315, P235, DOI 10.1042/bj3150235; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; Schindelin H, 2001, ADV PROTEIN CHEM, V58, P47; Seo M, 2000, P NATL ACAD SCI USA, V97, P12908, DOI 10.1073/pnas.220426197; SHAW S, 1990, BIOCHEM J, V268, P579, DOI 10.1042/bj2680579; TATSUMI K, 1986, CANCER RES, V46, P1089; Terao M, 1997, BIOCHEM SOC T, V25, P791, DOI 10.1042/bst0250791; Terao M, 2000, J BIOL CHEM, V275, P30690, DOI 10.1074/jbc.M005355200; Terao M, 1998, BIOCHEM J, V332, P383, DOI 10.1042/bj3320383; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; Terao M, 2001, J BIOL CHEM, V276, P46347, DOI 10.1074/jbc.M105744200; TOMITA S, 1993, FEBS LETT, V336, P272, DOI 10.1016/0014-5793(93)80818-F; Tsuchida S, 2001, J VET MED SCI, V63, P353, DOI 10.1292/jvms.63.353; VENTURA SM, 1981, HORM RES, V14, P250, DOI 10.1159/000179395; Vila R, 2004, J BIOL CHEM, V279, P8668, DOI 10.1074/jbc.M308137200; Vorbach C, 2002, GENE DEV, V16, P3223, DOI 10.1101/gad.1032702; Wittle AE, 1999, MOL GEN GENET, V261, P672, DOI 10.1007/s004380050010; Wright RM, 1999, J BIOL CHEM, V274, P3878, DOI 10.1074/jbc.274.6.3878; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; Xiang Q, 1996, BIOCHEMISTRY-US, V35, P5441, DOI 10.1021/bi952880d; Xu FQ, 2003, P NATL ACAD SCI USA, V100, P13734; XU P, 1994, BIOCHEM BIOPH RES CO, V199, P998, DOI 10.1006/bbrc.1994.1328; Yoshihara S, 1997, ARCH BIOCHEM BIOPHYS, V338, P29, DOI 10.1006/abbi.1996.9774	60	51	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50482	50498		10.1074/jbc.M408734200	http://dx.doi.org/10.1074/jbc.M408734200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383531	hybrid			2022-12-25	WOS:000225229500114
J	Sordet, O; Khan, QA; Plo, I; Pourquier, P; Urasaki, Y; Yoshido, A; Antony, S; Kohlhagen, G; Solary, E; Saparbaev, M; Laval, J; Pommier, Y				Sordet, O; Khan, QA; Plo, I; Pourquier, P; Urasaki, Y; Yoshido, A; Antony, S; Kohlhagen, G; Solary, E; Saparbaev, M; Laval, J; Pommier, Y			Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; MAMMALIAN-CELLS; FILTER ELUTION; HL-60 CELLS; INDUCTION; DAMAGE; CLEAVAGE; FRAGMENTATION; INHIBITORS; MECHANISM	Topoisomerase I (Top1), an abundant nuclear enzyme expressed throughout the cell cycle, relaxes DNA supercoiling by forming transient covalent DNA cleavage complexes. We show here that staurosporine, a ubiquitous inducer of apoptosis in mammalian cells, stabilizes cellular Top1 cleavage complexes. These complexes are formed indirectly as staurosporine cannot induce Top1 cleavage complexes in normal DNA with recombinant Top1 or nuclear extract from normal cells. In treated cells, staurosporine produces oxidative DNA lesions and generates reactive oxygen species (ROS). Quenching of these ROS by the antioxidant N-acetyl-L-cysteine or inhibition of the mitochondrial dependent production of ROS by the caspase inhibitor benzyloxycarbonyl-VAD prevents staurosporine-induced Top1 cleavage complexes. Down-regulation of Top1 by small interfering RNA decreases staurosporine-induced apoptotic DNA fragmentation. We propose that Top1 cleavage complexes resulting from oxidative DNA lesions generated by ROS in staurosporine-treated cells contribute to the full apoptotic response.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; CEA, Lab Recombinat Mech, F-92265 Fontenay Aux Roses, France; Inst Bergonie, INSERM, E347, Mol Pharmacol Grp, F-33076 Bordeaux, France; Fac Med, INSERM, U517, F-21033 Dijon, France; Inst Gustave Roussy, F-94805 Villejuif, France; Fukui Med Univ, Dept Med 1, Fukui, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Bergonie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Gustave Roussy; University of Fukui	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 5068, Bethesda, MD 20892 USA.	pommier@nih.gov	Plo, Isabelle/AAT-6742-2021; Sordet, Olivier/M-3271-2014; Pourquier, Philippe/O-8030-2018; Plo, Isabelle/C-9056-2017; Saparbaev, Murat K/N-3225-2015; Saparbaev, Murat/AAC-5478-2020	Sordet, Olivier/0000-0001-6027-4925; Pourquier, Philippe/0000-0001-5326-3005; Plo, Isabelle/0000-0002-5915-6910; Saparbaev, Murat K/0000-0002-4630-1074; Saparbaev, Murat/0000-0002-4630-1074; Solary, Eric/0000-0002-8629-1341	NATIONAL CANCER INSTITUTE [ZIABC006150, Z01BC006150] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Daroui P, 2004, J BIOL CHEM, V279, P14587, DOI 10.1074/jbc.M311370200; Duan S, 2003, J BIOL CHEM, V278, P1346, DOI 10.1074/jbc.M209269200; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Kessel M, 2002, MOL CELL BIOCHEM, V234, P301, DOI 10.1023/A:1015927406142; Kohn KW, 1996, BIOESSAYS, V18, P505, DOI 10.1002/bies.950180613; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; MATTERN MR, 1993, ONCOL RES, V5, P467; Meng LH, 2003, CURR TOP MED CHEM, V3, P305; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier Philippe, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P303; Reinhold WC, 2003, CANCER RES, V63, P1000; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Soe K, 2004, DNA REPAIR, V3, P387, DOI 10.1016/j.dnarep.2003.12.003; SOLARY E, 1993, BLOOD, V81, P1359; Sordet O, 2004, CELL CYCLE, V3, P1095; Sordet O, 2004, J BIOL CHEM, V279, P33968, DOI 10.1074/jbc.M404620200; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; Tafani M, 2001, CANCER RES, V61, P2459; Tainton KM, 2000, BIOCHEM BIOPH RES CO, V276, P231, DOI 10.1006/bbrc.2000.3459; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Yoshida A, 1998, CANCER RES, V58, P2576; Yoshida A, 2003, J BIOL CHEM, V278, P37768, DOI 10.1074/jbc.M304914200	40	56	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50499	50504		10.1074/jbc.M410277200	http://dx.doi.org/10.1074/jbc.M410277200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15448130	hybrid			2022-12-25	WOS:000225229500115
J	Asano, T; Yao, YX; Zhu, JJ; Li, DH; Abbruzzese, JL; Reddy, SAG				Asano, T; Yao, YX; Zhu, JJ; Li, DH; Abbruzzese, JL; Reddy, SAG			The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappa B and c-Myc in pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; PI 3-kinase; Akt; NF-kappa B; c-Myc; PTEN	TUMOR-SUPPRESSOR; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; DEPENDENT PHOSPHORYLATION; DUCTAL ADENOCARCINOMA; CARCINOMA CELLS; PROSTATE-CANCER; AKT ACTIVATION; GROWTH-FACTOR; INHIBITION	The persistent activation of signaling cascades results in dramatic consequences that include loss of cellular growth control and neoplastic transformation. We show here that phosphoinositide 3-kinase (PI 3-kinase) and its mediator Akt were constitutively activated in pancreatic cancer and that this might be due to the aberrant expression of their natural antagonist MMAC/PTEN. Indeed, our results show that MMAC/PTEN expression was either lost or significantly reduced in five of eight cell lines and in twelve of seventeen tumor specimens examined. That the poor expression of MMAC/PTEN in pancreatic cancer cells could be due to promoter methylation was indicated by methylation-specific PCR analysis. Our studies also indicated that PI 3-kinase targeted two important transcription factors in pancreatic cancer cells. The ability of constitutively activated NF-kappaB to induce gene expression and the stabilization of c-MYC protein by decreased phosphorylation of Thr58 were both dependent on PI 3-kinase activity. When pancreatic cancer cells were treated with a peptide antagonist of NF-kappaB nuclear translocation, or stably transfected with a dominant-negative mutant of MYC, their proliferation was markedly inhibited. Taken together, these data indicate that the aberrant expression of MMAC/PTEN contributes to the activation of the PI 3-kinase/Akt pathway and its transcription factor mediators in pancreatic cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Reddy, SAG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Unit 426,1515 Holcombe Blvd, Houston, TX 77030 USA.	sa08366@odin.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA016672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adsay NV, 1999, PANCREAS, V18, P111, DOI 10.1097/00006676-199903000-00001; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Bondar VM, 2002, MOL CANCER THER, V1, P989; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Davies MA, 1998, CANCER RES, V58, P5285; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Ebert MPA, 2002, BRIT J CANCER, V86, P257, DOI 10.1038/sj/bjc/6600031; Evans D B, 1997, Cancer Treat Res, V90, P109; Fahy BN, 2003, BRIT J CANCER, V89, P391, DOI 10.1038/sj.bjc.6601037; Friess H, 1999, DIGEST SURG, V16, P281, DOI 10.1159/000018737; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Grewe M, 1999, CANCER RES, V59, P3581; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Hilgers W, 1999, GENE CHROMOSOME CANC, V26, P1; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; Kolenko V, 1999, J IMMUNOL, V163, P590; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LILLEMOE KD, 1995, ANN SURG, V221, P133, DOI 10.1097/00000658-199502000-00003; Longnecker DS, 1999, ANN NY ACAD SCI, V880, P74, DOI 10.1111/j.1749-6632.1999.tb09511.x; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nagy A, 2001, ANTICANCER RES, V21, P1321; Ng SSW, 2000, CANCER RES, V60, P5451; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Okami K, 1998, CANCER RES, V58, P509; Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Reddy SAG, 2001, CANCER J, V7, P274; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakurada A, 1997, JPN J CANCER RES, V88, P1025, DOI 10.1111/j.1349-7006.1997.tb00324.x; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shah SA, 2001, J GASTROINTEST SURG, V5, P603, DOI 10.1016/S1091-255X(01)80102-5; Shi Q, 2001, CANCER RES, V61, P4143; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tanno S, 2001, CANCER RES, V61, P589; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang WX, 1999, CLIN CANCER RES, V5, P119; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yao Z, 2002, PANCREAS, V24, P42, DOI 10.1097/00006676-200201000-00006	56	252	268	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8571	8580		10.1038/sj.onc.1207902	http://dx.doi.org/10.1038/sj.onc.1207902			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467756				2022-12-25	WOS:000224988800002
J	Kim, CJ; Cho, YG; Park, CH; Jeong, SW; Nam, SW; Kim, SY; Lee, SH; Yoo, NJ; Lee, JY; Park, WS				Kim, CJ; Cho, YG; Park, CH; Jeong, SW; Nam, SW; Kim, SY; Lee, SH; Yoo, NJ; Lee, JY; Park, WS			Inactivating mutations of the Siah-1 gene in gastric cancer	ONCOGENE			English	Article						stomach; beta-catenin; p53; cyclin D1; expression	BETA-CATENIN; TUMOR SUPPRESSION; POLYPOSIS-COLI; HUMAN HOMOLOG; SINA GENE; P53; APOPTOSIS; ABSENTIA; PATHWAY; PROTEIN	Siah-1 is the mammalian homolog of Drosophila seven in absentia (sina) and has been identified as a p53-inducible gene. Siah-1 can induce cell cycle arrests, tumor suppression, and apoptosis through a novel beta-catenin degradation pathway. To determine whether genetic alterations of Siah-1 gene are involved in the development and/or progression of gastric cancer, we searched for mutation of the Siah-1 gene in 95 gastric cancers by single-strand conformational polymorphism and sequencing. The effect of Siah-1 on beta-catenin degradation was further examined in wild- and mutant-type Siah-1-transfected HEK 293T cells. We found two missense mutations of the Siah-1 gene. The cases with Siah-1 mutation showed nuclear translocation and cytoplasmic staining of beta-catenin. Interestingly, two mutants of Siah-1 stabilized cytoplasmic levels of beta-catenin, even after treatment of adriamycin. Furthermore, both mutants failed to suppress cyclin D1 expression and to induce apoptosis. These data suggest that inactivating mutations of the Siah-1 may contribute to the development of gastric cancer through beta-catenin stabilization and apoptosis block.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Park, WS (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	wonsang@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Park WS, 1999, CANCER RES, V59, P4257; Park WS, 2000, APMIS, V108, P195, DOI 10.1034/j.1600-0463.2000.d01-44.x; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Shtutman Michael, 2002, Cancer Research, V62, P5947; SIVAK MV, 1984, GASTROINTEST ENDOSC, V30, P102, DOI 10.1016/S0016-5107(84)72333-9; SUH CI, 2000, J KOREAN CANC ASS, V32, P827; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884	25	39	42	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8591	8596		10.1038/sj.onc.1208113	http://dx.doi.org/10.1038/sj.onc.1208113			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467739				2022-12-25	WOS:000224988800004
J	von Kobbe, C; May, A; Grandori, C; Bohr, VA				von Kobbe, C; May, A; Grandori, C; Bohr, VA			Werner syndrome cells escape hydrogen peroxide-induced cell proliferation arrest	FASEB JOURNAL			English	Article						DNA damage; premature senescence	NORMAL HUMAN FIBROBLASTS; DNA-DAMAGE; SYNDROME PROTEIN; MAMMALIAN-CELLS; EXONUCLEASE ACTIVITY; GENOMIC INSTABILITY; GROWTH ARREST; P53; SENESCENCE; REPAIR	Werner syndrome (WS) is a rare disease caused by the lack of a functional nuclear WS protein (WRN). WS is characterized by the early onset of premature aging signs and a high incidence of sarcomas. WS diploid fibroblasts have a short life span and extensive genomic instability. Mammalian cells are continuously exposed to reactive oxygen species (ROS), which represent human mutagens and are thought to be a major contributor to the aging process. Hydrogen peroxide (H2O2) is a common ROS intermediate generated by various forms of oxidative stress. In response to H2O2-induced DNA damage, normal human diploid fibroblasts follow a pathway leading to irreversible proliferation arrest and premature senescence. Here we show that in contrast to normal human fibroblasts, WS diploid fibroblasts continue proliferating after extensive H2O2-induced DNA damage and accumulate oxidative DNA lesions. A direct role of WRN in this abnormal cellular response to H2O2 is demonstrated by interfering with WRN expression in normal human fibroblasts. We propose a role for WRN in the detection and/or processing of oxidative DNA lesions and in cellular responses to H2O2 as they relate to some of the phenotypical aspects of WS cells.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Fred Hutchinson Cancer Center	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020	von Kobbe, Cayetano/0000-0003-3895-3790	NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000727, Z01AG000727, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Benitez-Bribiesca L, 1999, ANN NY ACAD SCI, V887, P133, DOI 10.1111/j.1749-6632.1999.tb07928.x; Blander G, 2000, FASEB J, V14, P2138; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen LS, 2003, AGING CELL, V2, P191, DOI 10.1046/j.1474-9728.2003.00052.x; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; CHENG WH, 2003, TOPICS CURRENT GENET, P239; Cobb JA, 2002, FEBS LETT, V529, P43, DOI 10.1016/S0014-5793(02)03269-6; Cooper MP, 2000, GENE DEV, V14, P907; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DUVIC M, 1995, DERMATOL CLIN, V13, P163, DOI 10.1016/S0733-8635(18)30119-0; Franchitto A, 2003, CANCER RES, V63, P3289; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hartwig A, 2003, INT J CANCER, V104, P1, DOI 10.1002/ijc.10911; Hattori H, 2004, PATHOL INT, V54, P26, DOI 10.1111/j.1440-1827.2004.01585.x; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lebel M, 2001, CANCER RES, V61, P1816; Li BM, 2000, J BIOL CHEM, V275, P39800; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Oshima J, 2002, CANCER RES, V62, P547; Poot M, 2002, FASEB J, V16, P757, DOI 10.1096/fj.01-0906fje; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Prince PR, 1999, HUM GENET, V105, P132, DOI 10.1007/s004390051075; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schulz VP, 1996, HUM GENET, V97, P750; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; te Poele RH, 2002, CANCER RES, V62, P1876; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; von Kobbe C, 2003, MOL CELL BIOL, V23, P8601, DOI 10.1128/MCB.23.23.8601-8613.2003; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	57	59	60	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1970	+		10.1096/fj.04-1895fje	http://dx.doi.org/10.1096/fj.04-1895fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15459124				2022-12-25	WOS:000224243200001
J	Held, MA; Tan, L; Kamyab, A; Hare, M; Shpak, E; Kieliszewski, MJ				Held, MA; Tan, L; Kamyab, A; Hare, M; Shpak, E; Kieliszewski, MJ			Di-isodityrosine is the intermolecular cross-link of isodityrosine-rich extensin analogs cross-linked in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL GLYCOPROTEIN; CONTIGUOUS HYDROXYPROLINE RESIDUES; O-GLYCOSYLATION CODES; TOMATO EXTENSIN; ARABINOGALACTAN-PROTEINS; SUSPENSION CULTURES; PURIFICATION; PEROXIDASE; PRECURSORS; ROOT	Extensins are cell wall hydroxyproline-rich glycoproteins that form covalent networks putatively involving tyrosyl and lysyl residues in cross-links catalyzed by one or more extensin peroxidases. The precise cross-links remain to be chemically identified both as network components in muro and as enzymic products generated in vitro with native extensin monomers as substrates. However, some extensin monomers contain variations within their putative cross-linking motifs that complicate cross-link identification. Other simpler extensins are recalcitrant to isolation including the ubiquitous P3-type extensin whose major repetitive motif, Ser(Hyp)(4)-Ser-Hyp-Ser-(Hyp)(4)-Tyr-Tyr-Tyr-Lys, is of particular interest, not least because its Tyr-Tyr-Tyr intramolecular isodityrosine cross-link motifs are also putative candidates for further intermolecular cross-linking to form di-isodityrosine. Therefore, we designed a set of extensin analogs encoding tandem repeats of the P3 motif, including Tyr --> Phe and Lys --> Leu variations. Expression of these P3 analogs in Nicotiana tabacum cells yielded glycoproteins with virtually all Pro residues hydroxylated and subsequently arabinosylated and with likely galactosylated Ser residues. This was consistent with earlier analyses of P3 glycopeptides isolated from cell wall digests and the predictions of the Hyp contiguity hypothesis. The tyrosine-rich P3 analogs also contained isodityrosine, formed in vivo. Significantly, these isodityrosine-containing analogs were further crosslinked in vitro by an extensin peroxidase to form the tetra-tyrosine intermolecular cross-link amino acid di-isodityrosine. This is the first identification of an intermolecular cross-link amino acid in an extensin module and corroborates earlier suggestions that di-isodityrosine represents one mechanism for cross-linking extensins in muro.	Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ Washington, Dept Biol, Seattle, WA 98125 USA	University System of Ohio; Ohio University; Oregon State University; University of Washington; University of Washington Seattle	Kieliszewski, MJ (corresponding author), Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA.	kielisze@helios.phy.ohiou.edu		Held, Michael/0000-0003-2604-8048	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 00210] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; An G., 1989, PLANT MOL BIOL MANUA, P1, DOI [DOI 10.1007/978-94-009-0951-9, 10.1007/978-94-017-5294-7_3]; Bergman T., 1986, ADV METHODS PROTEIN, P45; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Brady JD, 1996, BIOCHEM J, V315, P323, DOI 10.1042/bj3150323; Brady JD, 1998, PHYTOCHEMISTRY, V47, P349, DOI 10.1016/S0031-9422(97)00592-X; BROWNLEADER MD, 1995, PLANT PHYSIOL, V109, P1115, DOI 10.1104/pp.109.3.1115; CASSAB GI, 1986, PLANTA, V168, P441, DOI 10.1007/BF00392262; DELOOSE M, 1991, GENE, V99, P95, DOI 10.1016/0378-1119(91)90038-D; EPSTEIN L, 1984, PHYTOCHEMISTRY, V23, P1241, DOI 10.1016/S0031-9422(00)80433-1; ESQUERRETUGAYE MT, 1979, PLANT PHYSIOL, V64, P314, DOI 10.1104/pp.64.2.314; EVERDEEN DS, 1988, PLANT PHYSIOL, V87, P616, DOI 10.1104/pp.87.3.616; FRANSSEN HJ, 1987, P NATL ACAD SCI USA, V84, P4495, DOI 10.1073/pnas.84.13.4495; Frueauf JB, 2000, PHYTOCHEMISTRY, V55, P429, DOI 10.1016/S0031-9422(00)00336-8; FRY SC, 1982, BIOCHEM J, V204, P449, DOI 10.1042/bj2040449; GOODENOUGH UW, 1986, J CELL BIOL, V103, P405, DOI 10.1083/jcb.103.2.405; Hall Q, 2002, PLANT CELL, V14, P1161, DOI 10.1105/tpc.010477; KIELISZEWSKI MJ, 1995, J BIOL CHEM, V270, P2541, DOI 10.1074/jbc.270.6.2541; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Kieliszewski MJ, 2001, PHYTOCHEMISTRY, V57, P319, DOI 10.1016/S0031-9422(01)00029-2; KIELISZEWSKI MJ, 1988, SELF ASSEMBLING ARCH, V46, P61; Lamport D. T. A., 1977, RECENT ADV PHYTOCHEM, V11, P79; LAMPORT DTA, 1967, NATURE, V216, P1322, DOI 10.1038/2161322a0; LAMPORT DTA, 1973, BIOCHEM J, V133, P125, DOI 10.1042/bj1330125; LAMPORT DTA, 1971, PLANT PHYSIOL, V48, P454, DOI 10.1104/pp.48.4.454; LAMPORT DTA, 1963, J BIOL CHEM, V238, P1438; LAMPORT DTA, 1969, BIOCHEMISTRY-US, V8, P1155, DOI 10.1021/bi00831a049; LAMPORT DTA, 1983, CURRENT TOPICS PLANT, V2, P73; LAMPORT DTA, 1973, 1 INT PROT C, P27; Lewis RV, 1996, PROTEIN EXPRES PURIF, V7, P400, DOI 10.1006/prep.1996.0060; MCCORMICK S, 1986, PLANT CELL REP, V5, P81, DOI 10.1007/BF00269239; MCGRATH KP, 1990, BIOTECHNOL PROGR, V6, P186; NAKAJIMA R, 1979, J BIOL CHEM, V254, P872; Price NJ, 2003, J BIOL CHEM, V278, P41389, DOI 10.1074/jbc.M304519200; ROBERTS K, 1974, PHILOS T R SOC B, V268, P129, DOI 10.1098/rstb.1974.0021; SANGER MP, 1983, ANAL BIOCHEM, V128, P66, DOI 10.1016/0003-2697(83)90345-7; Schnabelrauch LS, 1996, PLANT J, V9, P477, DOI 10.1046/j.1365-313X.1996.09040477.x; Shirsat AH, 1996, PLANTA, V199, P618, DOI 10.1007/BF00195195; SHOWALTER AM, 1991, PLANT MOL BIOL, V16, P547, DOI 10.1007/BF00023421; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Shpak E, 1999, P NATL ACAD SCI USA, V96, P14736, DOI 10.1073/pnas.96.26.14736; Shpak E, 2001, J BIOL CHEM, V276, P11272, DOI 10.1074/jbc.M011323200; SMITH JJ, 1984, PHYTOCHEMISTRY, V23, P1233, DOI 10.1016/S0031-9422(00)80432-X; SMITH JJ, 1986, PHYTOCHEMISTRY, V25, P1021, DOI 10.1016/S0031-9422(00)81547-2; Tan L, 2003, PLANT PHYSIOL, V132, P1362, DOI 10.1104/pp.103.021766; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; Zhang SG, 2002, BIOTECHNOL ADV, V20, P321, DOI 10.1016/S0734-9750(02)00026-5; Zhao ZD, 2002, PLANT J, V31, P431, DOI 10.1046/j.1365-313X.2002.01365.x; ZHOU J, 1992, PLANT MOL BIOL, V20, P5, DOI 10.1007/BF00029144	49	85	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55474	55482		10.1074/jbc.M408396200	http://dx.doi.org/10.1074/jbc.M408396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15465824	hybrid			2022-12-25	WOS:000225960800062
J	Nevo, Y; Nelson, N				Nevo, Y; Nelson, N			The mutation F227I increases the coupling of metal ion transport in DCT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE PERMEASE; IRON UPTAKE; MEMBRANE; PROTEIN; NRAMP2; FAMILY; EXPRESSION; RESISTANCE; MECHANISM; BINDING	Metal ion transport by DCT1, a member of the natural resistance-associated macrophage protein family, is driven by protons. The stoichiometry of the proton to metal ion is variable, and under optimal transport conditions, more than 10 protons are co-transported with a single metal ion. To understand this phenomenon better, we used site-directed mutagenesis of DCT1 and analyzed the mutants by complementation of yeast suppressor of mitochondria import function-null mutants and electrophysiology with Xenopus oocytes. The mutation F227I resulted in an increase of up to 14-fold in the ratio between metal ions to protons transported. This observation suggests that low metal ion to proton transport of DCT1 resulting from a proton slippage is not a necessity of the transport mechanism in which positively charged protons are driving two positive charges of the metal ion in the same direction. It supports the idea that the proton slippage has a physiological advantage, and the proton slip was positively selected during the evolution of DCT1.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Nelson, N (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	nelson@post.tau.ac.il		Nelson, Nathan/0000-0003-3588-7265				Bers DM, 2002, ANN NY ACAD SCI, V976, P500; Blair DF, 2003, FEBS LETT, V545, P86, DOI 10.1016/S0014-5793(03)00397-1; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; Cohen A, 2003, P NATL ACAD SCI USA, V100, P10694, DOI 10.1073/pnas.1934572100; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; Goswami T, 2002, BIOCHEM CELL BIOL, V80, P679, DOI 10.1139/O02-159; Gu HH, 1996, J BIOL CHEM, V271, P6911, DOI 10.1074/jbc.271.12.6911; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Inoue K, 2004, BIOCHEM J, V378, P949, DOI 10.1042/BJ20031261; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; Lam-Yuk-Tseung S, 2003, BLOOD, V101, P3699, DOI 10.1182/blood-2002-07-2108; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Marciani P, 2004, J MEMBRANE BIOL, V197, P91, DOI 10.1007/s00232-003-0644-9; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Nelson N, 2002, NAT REV MOL CELL BIO, V3, P876, DOI 10.1038/nrm955; Nelson N, 1998, J NEUROCHEM, V71, P1785; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Sacher A, 2001, J EXP BIOL, V204, P1053; Sahin-Toth M, 2000, P NATL ACAD SCI USA, V97, P10729, DOI 10.1073/pnas.200351797; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; Tandy S, 2000, J BIOL CHEM, V275, P1023, DOI 10.1074/jbc.275.2.1023; UJWAL ML, 1994, MOL MEMBR BIOL, V11, P9, DOI 10.3109/09687689409161024; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Weinglass AB, 2003, EMBO J, V22, P1467, DOI 10.1093/emboj/cdg145; WRIGHT EM, 1994, J EXP BIOL, V196, P197	42	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53056	53061		10.1074/jbc.M408398200	http://dx.doi.org/10.1074/jbc.M408398200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475345	hybrid, Green Submitted			2022-12-25	WOS:000225680600032
J	Wang, K; Yamamoto, H; Chin, JR; Werb, Z; Vu, TH				Wang, K; Yamamoto, H; Chin, JR; Werb, Z; Vu, TH			Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; BONE-FORMATION; OSTEOBLAST DIFFERENTIATION; METALLOPROTEINASE MT1-MMP; TARGETED DISRUPTION; FACTOR-ALPHA; LONG BONES; EXPRESSION; MORPHOGENESIS; CARTILAGE	The epidermal growth factor receptor (EGFR) and its ligands function in diverse cellular functions including cell proliferation, differentiation, motility, and survival. EGFR signaling is important for the development of many tissues, including skin, lungs, intestines, and the craniofacial skeleton. We have now determined the role of EGFR signaling in endochondral ossification. We analyzed long bone development in EGFR-deficient mice. EGFR deficiency caused delayed primary ossification of the cartilage anlage and delayed osteoclast and osteoblast recruitment. Ossification of the growth plates was also abnormal resulting in an expanded area of growth plate hypertrophic cartilage and few bony trabeculae. The delayed osteoclast recruitment was not because of inadequate expression of matrix metalloproteinases, including matrix metalloproteinase-9, which have previously been shown to be important for osteoclast recruitment. EGFR was expressed by osteoclasts, suggesting that EGFR ligands may act directly to affect the formation and/or function of these cells. EGFR signaling regulated osteoclast formation. Inhibition of EGFR tyrosine kinase activity decreased the generation of osteoclasts from cultured bone marrow cells.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vu, TH (corresponding author), Univ Calif San Francisco, Dept Med, Box 2911, San Francisco, CA 94143 USA.	thiennu@itsa.ucsf.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046238] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR046238-06A2, R01 AR046238, AR46238] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albrecht U, 1997, MOL CELLULAR METHODS, P23; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; BLAVIER L, 1995, J CELL SCI, V108, P3649; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; CANOUN C, 1993, J SURG RES, V54, P638, DOI 10.1006/jsre.1993.1098; CAPLAN AI, 1988, CIBA F SYMP, V136, P3021; Chan SY, 2000, J BIOL CHEM, V275, P38693, DOI 10.1074/jbc.M004189200; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; Davideau JL, 1995, CONNECT TISSUE RES, V32, P47, DOI 10.3109/03008209509013705; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Fuller K, 2000, J CELL SCI, V113, P2445; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Irie K, 2001, TISSUE CELL, V33, P478; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kheradmand F, 2002, J CELL SCI, V115, P839; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOZA J, 1995, BONE, V16, pS341; MARIE PJ, 1990, AM J PHYSIOL, V258, pE275, DOI 10.1152/ajpendo.1990.258.2.E275; MARTINEAUDOIZE B, 1988, ENDOCRINOLOGY, V123, P841, DOI 10.1210/endo-123-2-841; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; Miettinen PJ, 1999, NAT GENET, V22, P69, DOI 10.1038/8773; NG KW, 1983, CALCIFIED TISSUE INT, V35, P624, DOI 10.1007/BF02405105; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PARTANEN AM, 1985, DEV BIOL, V111, P84, DOI 10.1016/0012-1606(85)90437-3; RAISZ LG, 1980, ENDOCRINOLOGY, V107, P270, DOI 10.1210/endo-107-1-270; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; Sasano Y, 2002, J HISTOCHEM CYTOCHEM, V50, P325, DOI 10.1177/002215540205000304; Sato T, 1997, J CELL SCI, V110, P589; SHUM L, 1993, DEVELOPMENT, V118, P903; Sibilia M, 2003, DEVELOPMENT, V130, P4515, DOI 10.1242/dev.00664; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; STEIN GS, 1989, CONNECT TISSUE RES, V20, P3, DOI 10.3109/03008208909049996; STERN PH, 1985, J CLIN INVEST, V76, P2016, DOI 10.1172/JCI112202; TAKAHASHI N, 1986, J CLIN INVEST, V78, P894, DOI 10.1172/JCI112677; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; WILEY LM, 1992, DEV BIOL, V149, P247, DOI 10.1016/0012-1606(92)90282-L; Wilson SE, 1999, EXP EYE RES, V68, P377, DOI 10.1006/exer.1998.0603	46	92	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53848	53856		10.1074/jbc.M403114200	http://dx.doi.org/10.1074/jbc.M403114200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456762	hybrid, Green Accepted			2022-12-25	WOS:000225680600123
J	Huang, ZH; Zhou, B; Zhong, YZ				Huang, ZH; Zhou, B; Zhong, YZ			Molecular determinants of substrate recognition in hematopoietic protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; MAP-KINASE; CATALYTIC ACTIVATION; ENZYMATIC-ACTIVITY; INTERACTION MOTIF; TRAPPING MUTANTS; STRUCTURAL BASIS; DOCKING SITE; IN-VIVO; PTP-SL	The extracellular signal-regulated protein kinase 2 (ERK2) plays a central role in cellular proliferation and differentiation. Full activation of ERK2 requires dual phosphorylation of Thr(183) and Tyr(185) in the activation loop. Tyr(185) dephosphorylation by the hematopoietic protein-tyrosine phosphatase (HePTP) represents an important mechanism for down-regulating ERK2 activity. The bisphosphorylated ERK2 is a highly efficient substrate for HePTP with a k(cat)/K-m of 2.6 x 10(6) M-1 s(-1). In contrast, the k(cat)/K-m values for the HePTP-catalyzed hydrolysis of Tyr(P) peptides are 3 orders of magnitude lower. To gain insight into the molecular basis for HePTP substrate specificity, we analyzed the effects of altering structural features unique to HePTP on the HePTP-catalyzed hydrolysis of p-nitrophenyl phosphate, Tyr( P) peptides, and its physiological substrate ERK2. Our results suggest that substrate specificity is conferred upon HePTP by both negative and positive selections. To avoid nonspecific tyrosine dephosphorylation, HePTP employs Thr(106) in the substrate recognition loop as a key negative determinant to restrain its protein-tyrosine phosphatase activity. The extremely high efficiency and fidelity of ERK2 dephosphorylation by HePTP is achieved by a bipartite protein-protein interaction mechanism, in which docking interactions between the kinase interaction motif in HePTP and the common docking site in ERK2 promote the HePTP-catalyzed ERK2 dephosphorylation (similar to20-fold increase in k(cat)/K-m) by increasing the local substrate concentration, and second site interactions between the HePTP catalytic site and the ERK2 substrate-binding region enhance catalysis (similar to20-fold increase in k(cat)/K-m) by organizing the catalytic residues with respect to Tyr(P)(185) for optimal phosphoryl transfer.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Zhong, YZ (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu			NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NCI NIH HHS [CA69202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Karim FD, 1999, MOL CELL, V3, P741, DOI 10.1016/S1097-2765(01)80006-X; Keng YF, 1999, EUR J BIOCHEM, V259, P809, DOI 10.1046/j.1432-1327.1999.00090.x; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Oh-hora M, 1999, J IMMUNOL, V163, P1282; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Pedersen AK, 2004, BIOCHEM J, V378, P421, DOI 10.1042/BJ20030565; Pettiford SM, 2000, ONCOGENE, V19, P858, DOI 10.1038/sj.onc.1203408; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Sohaskey ML, 1999, MOL BIOL CELL, V10, P3729, DOI 10.1091/mbc.10.11.3729; Szedlacsek SE, 2001, J MOL BIOL, V311, P557, DOI 10.1006/jmbi.2001.4890; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wang ZX, 2002, BIOCHEMISTRY-US, V41, P7849, DOI 10.1021/bi025776m; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; Yao Z, 2000, FEBS LETT, V468, P37, DOI 10.1016/S0014-5793(00)01191-1; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhang ZY, 2003, PROG NUCLEIC ACID RE, V73, P171, DOI 10.1016/S0079-6603(03)01006-7; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	53	25	27	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52150	52159		10.1074/jbc.M407820200	http://dx.doi.org/10.1074/jbc.M407820200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466470	hybrid			2022-12-25	WOS:000225493400054
J	Jaramillo, M; Godbout, M; Naccache, PH; Olivier, M				Jaramillo, M; Godbout, M; Naccache, PH; Olivier, M			Signaling events involved in macrophage chemokine expression in response to monosodium urate crystals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; INDUCED NEUTROPHIL ACTIVATION; INDUCED ACUTE-INFLAMMATION; NITRIC-OXIDE SYNTHASE; GENE-EXPRESSION; MESSENGER-RNA; INDUCED ARTHRITIS; ALVEOLAR MACROPHAGES	Chemokine production has been associated with leukocyte infiltration into the joint during gouty arthritis, and monosodium urate (MSU) crystals, the causative agent of this arthropathy, have been shown to modulate their expression. In the present study, we investigated the transductional mechanisms underlying this cellular regulation in the murine macrophage cell line B10R. We report that MSU crystals rapidly and transiently increase mRNA levels of various chemokines in a concentration-dependent manner. Examination of second messenger activation revealed that macrophage exposure to MSU crystals led to MEK1/2, ERK1/2, and inhibitory protein kappaBalpha phosphorylation as well as to NF-kappaB and AP-1 nuclear translocation. Of interest, specific blockage of the ERK1/2 pathway drastically reduced up-modulation of MSU crystal-mediated chemokine production and activation of nuclear factors. Similarly, selective inhibition of NF-kappaB suppressed NF-kappaB DNA binding activity and the induction of all chemokine transcripts. These findings indicate that ERK1/2-dependent signals seem to be required for AP-1 and NF-kappaB activation and subsequent mRNA expression of the various macrophage chemokines. In addition, transcription and stability assays performed in presence of actinomycin D showed that MSU crystal-mediated MIP-1alpha mRNA up-regulation resulted solely from transcriptional control, whereas that of MIP-1alpha, MIP-2, and MCP-1 was due to both gene transcription activation and mRNA posttranscriptional stabilization. Overall, the results of this study help to define the molecular events that govern macrophage chemokine regulation in response to MSU crystals, which is of paramount importance to better understand, and eventually to tame, the inflammatory response during acute gout.	McGill Univ, Dept Med, Ctr Study Host Resistance, McGill Univ Hlth Ctr,Res Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Immunol, Montreal, PQ H3A 2B4, Canada; Univ Laval, Fac Med, Dept Med Biol, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med, Ste Foy, PQ G1V 4G2, Canada; Ctr Hosp Univ Quebec, Ctr Rech Rhumatol & Immunol, Quebec City, PQ, Canada	McGill University; McGill University; McGill University; Laval University; Laval University; Laval University	Olivier, M (corresponding author), McGill Univ, Dept Microbiol & Immunol, 3775 Univ St,duff Med Bldg,Rm 600, Montreal, PQ H3A 2B4, Canada.	martin.olivier@staff.mcgill.ca	Jaramillo, Maritza/T-7467-2019	Jaramillo, Maritza/0000-0002-1910-5684				ABRAMSON S, 1982, ARTHRITIS RHEUM, V25, P174, DOI 10.1002/art.1780250210; Agudelo CA, 2001, CURR OPIN RHEUMATOL, V13, P234, DOI 10.1097/00002281-200105000-00015; Bhat NR, 1998, J NEUROSCI, V18, P1633; Blanchette J, 2003, IMMUNOLOGY, V108, P513, DOI 10.1046/j.1365-2567.2003.01620.x; BOMALASKI JS, 1990, J IMMUNOL, V145, P3391; Chan ED, 2001, INFECT IMMUN, V69, P2001, DOI 10.1128/IAI.69.4.2001-2010.2001; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen XL, 1998, CIRC RES, V83, P952; DIGIOVINE FS, 1991, J CLIN INVEST, V87, P1375, DOI 10.1172/JCI115142; DIGIOVINE FS, 1987, J IMMUNOL, V138, P3213; Fujiwara K, 2002, LAB INVEST, V82, P1297, DOI 10.1097/01.LAB.0000029206.27080.D2; GAUDRY M, 1993, J CLIN INVEST, V91, P1649, DOI 10.1172/JCI116373; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GUERNE PA, 1989, ARTHRITIS RHEUM-US, V32, P1443, DOI 10.1002/anr.1780321114; HACHICHA M, 1995, J EXP MED, V182, P2019, DOI 10.1084/jem.182.6.2019; HARIGAI M, 1993, CLIN IMMUNOL IMMUNOP, V69, P83, DOI 10.1006/clin.1993.1153; Jaramillo M, 2004, J IMMUNOL, V172, P5734, DOI 10.4049/jimmunol.172.9.5734; Jaramillo M, 2002, J IMMUNOL, V169, P7026, DOI 10.4049/jimmunol.169.12.7026; Jijon HB, 2002, AM J PHYSIOL-CELL PH, V283, pC31, DOI 10.1152/ajpcell.00113.2001; Kan H, 1999, AM J PHYSIOL-HEART C, V277, pH1641, DOI 10.1152/ajpheart.1999.277.4.H1641; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Liu R, 2001, J LEUKOCYTE BIOL, V70, P961; Liu R, 2000, ARTHRITIS RHEUM, V43, P1145, DOI 10.1002/1529-0131(200005)43:5<1145::AID-ANR25>3.0.CO;2-T; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARSHALL NJ, 1995, GROWTH REGULAT, V5, P69; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; Matsukawa A, 1998, LAB INVEST, V78, P973; Matsukawa A, 1998, LAB INVEST, V78, P559; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Murakami Y, 2003, ARTHRITIS RHEUM, V48, P2931, DOI 10.1002/art.11271; Murakami Y, 2002, ARTHRITIS RHEUM, V46, P2504, DOI 10.1002/art.10468; NACCACHE PH, 1993, ARTHRITIS RHEUM, V36, P117, DOI 10.1002/art.1780360119; Nishimura A, 1997, J LEUKOCYTE BIOL, V62, P444, DOI 10.1002/jlb.62.4.444; PALIT J, 1986, BR J RHEUMATOL S1, V25, pA21; PASCUAL E, 1995, BRIT J RHEUMATOL, V34, P724; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Poon M, 1999, MOL CELL BIOL, V19, P6471; Punzi L, 2002, CRIT REV CL LAB SCI, V39, P63, DOI 10.1080/10408360290795448; RADZIOCH D, 1991, J LEUKOCYTE BIOL, V50, P263, DOI 10.1002/jlb.50.3.263; ROBERGE CJ, 1994, J IMMUNOL, V152, P5485; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rouleau P, 2003, CLIN IMMUNOL, V107, P46, DOI 10.1016/S1521-6616(02)00043-8; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Ryckman C, 2003, ARTHRITIS RHEUM-US, V48, P2310, DOI 10.1002/art.11079; SHI MM, 1995, BIOCHEM BIOPH RES CO, V211, P289, DOI 10.1006/bbrc.1995.1809; Shi MM, 1996, J BIOL CHEM, V271, P5878, DOI 10.1074/jbc.271.10.5878; Shi MM, 1999, IMMUNOLOGY, V97, P309; TERKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894, DOI 10.1002/art.1780340716; TERKELTAUB R, 1996, ARTHRITIS ALLIED CON, P2085; TERKELTAUB RA, 1990, J IMMUNOL, V144, P2719; WIDMER U, 1993, J IMMUNOL, V150, P4996; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; Xiao YQ, 1999, BBA-MOL CELL RES, V1450, P155, DOI 10.1016/S0167-4889(99)00042-7	56	47	54	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52797	52805		10.1074/jbc.M403823200	http://dx.doi.org/10.1074/jbc.M403823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15471869	hybrid			2022-12-25	WOS:000225493400127
J	Siletsky, SA; Pawate, AS; Weiss, K; Gennis, RB; Konstantinov, AA				Siletsky, SA; Pawate, AS; Weiss, K; Gennis, RB; Konstantinov, AA			Transmembrane charge separation during the ferryl-oxo -> oxidized transition in a nonpumping mutant of cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-ELECTRON REDUCTION; PROTON-PUMPING MECHANISM; RHODOBACTER-SPHAEROIDES; PARACOCCUS-DENITRIFICANS; CATALYTIC CYCLE; ENERGY TRANSDUCTION; HISTIDINE CYCLE; TRANSLOCATION; MODEL; RESOLUTION	The N139D mutant of cytochrome c oxidase from Rhodobacter sphaeroides retains full steady state oxidase activity but completely lacks proton translocation coupled to turnover in reconstituted liposomes ( Pawate, A. S., Morgan, J., Namslauer, A., Mills, D., Brzezinski, P., Ferguson-Miller, S., and Gennis, R. B. ( 2002) Biochemistry 41, 13417 - 13423). Here, time-resolved electron transfer and vectorial charge translocation in the ferryl-oxo --> oxidized transition ( transfer of the 4th electron in the catalytic cycle) have been studied with the N139D mutant using ruthenium(II)-tris-bipyridyl complex as a photoactive single-electron donor. With the wild type oxidase, the flash-induced generation of Deltaphi in the ferryl-oxo 3 oxidized transition begins with rapid vectorial electron transfer from Cu-A to heme a (tau similar to 15 mus), followed by two protonic phases, referred to as the intermediate (0.4 ms) and slow electrogenic phases (1.5 ms). In the N139D mutant, only a single protonic phase (tau similar to 0.6 ms) is observed, which was associated with electron transfer from heme a to the heme a(3)/Cu-B site and decelerates similar to 4-fold in D2O. With the wild type oxidase, such a high H2O/D2O solvent isotope effect is characteristic of only the slow (1.5 ms) phase. Presumably, the 0.6-ms electrogenic phase in the N139D mutant reports proton transfer from the inner aqueous phase to Glu-286, replacing the "chemical" proton transferred from Glu-286 to the heme a(3)/Cu-B site. The transfer occurs through the D-channel, because it is observed also in the N139D/K362M double mutant in which the K-channel is blocked. It is concluded that the intermediate electrogenic phase observed in the wild type enzyme is missing in the N139D mutant and is because of translocation of the "pumped" proton from Glu-286 to the D-ring propionate of heme a(3) or to release of this proton to the outer aqueous phase. Significantly, with the wild type oxidase, the protonic electrogenic phase associated with proton pumping ( similar to 0.4 ms) precedes the electrogenic phase associated with the oxygen chemistry ( similar to 1.5 ms).	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119992, Russia; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	Lomonosov Moscow State University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Konstantinov, AA (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Khokhlova 4, Moscow 119992, Russia.	konst@genebee.msu.su	Pawate, Ashtamurthy S/B-6843-2008; Siletsky, Sergey A./D-8076-2012	Pawate, Ashtamurthy S/0000-0002-0700-9871; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016101, R01HL016101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026916] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16101] Funding Source: Medline; NIGMS NIH HHS [R01 GM026916] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTZATBANOV VY, 1978, FEBS LETT, V87, P180, DOI 10.1016/0014-5793(78)80327-5; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; Bloch D, 2004, P NATL ACAD SCI USA, V101, P529, DOI 10.1073/pnas.0306036101; Brzezinski P, 2004, TRENDS BIOCHEM SCI, V29, P380, DOI 10.1016/j.tibs.2004.05.008; Fabian M, 2001, BIOCHEMISTRY-US, V40, P1867, DOI 10.1021/bi002373i; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Hinkle P C, 1979, Methods Enzymol, V55, P748; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Iwaki M, 2002, BBA-BIOENERGETICS, V1555, P116, DOI 10.1016/S0005-2728(02)00265-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Junemann S, 1997, BIOCHEMISTRY-US, V36, P14456, DOI 10.1021/bi971458p; Konstantinov AA, 1998, J BIOENERG BIOMEMBR, V30, P121, DOI 10.1023/A:1020571930850; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; KONSTANTINOV AA, 1977, DOKL AKAD NAUK SSSR+, V237, P713; Liao GL, 1996, BBA-BIOENERGETICS, V1274, P109, DOI 10.1016/0005-2728(96)00014-X; Ludwig B, 2001, CHEMBIOCHEM, V2, P392, DOI 10.1002/1439-7633(20010601)2:6<392::AID-CBIC392>3.3.CO;2-E; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; MITCHELL DM, 1995, FEBS LETT, V368, P148, DOI 10.1016/0014-5793(95)00626-K; MITCHELL P, 1988, ANN NY ACAD SCI, V550, P185, DOI 10.1111/j.1749-6632.1988.tb35335.x; MITCHELL P, 1968, CHEMIOSMOTIC COUPLIN, P1; MORGAN JE, 1994, J BIOENERG BIOMEMBR, V26, P599, DOI 10.1007/BF00831534; Namslauer A, 2003, P NATL ACAD SCI USA, V100, P15543, DOI 10.1073/pnas.2432106100; NILSSON T, 1992, P NATL ACAD SCI USA, V89, P6497, DOI 10.1073/pnas.89.14.6497; Pawate AS, 2002, BIOCHEMISTRY-US, V41, P13417, DOI 10.1021/bi026582+; Pfitzner U, 2000, BIOCHEMISTRY-US, V39, P6756, DOI 10.1021/bi992235x; Popovic DM, 2004, FEBS LETT, V566, P126, DOI 10.1016/j.febslet.2004.04.016; Popovic DM, 2004, J AM CHEM SOC, V126, P1858, DOI 10.1021/ja038267w; PROVENCHER SW, 1976, BIOPHYS J, V16, P27, DOI 10.1016/S0006-3495(76)85660-3; Puustinen A, 1999, P NATL ACAD SCI USA, V96, P35, DOI 10.1073/pnas.96.1.35; RICH P, 1997, BIOENERGETICS, V4, P419; RICH PR, 1995, AUST J PLANT PHYSIOL, V22, P479, DOI 10.1071/PP9950479; Ruitenberg M, 2000, P NATL ACAD SCI USA, V97, P4632, DOI 10.1073/pnas.080079097; Ruitenberg M, 2002, NATURE, V417, P99, DOI 10.1038/417099a; Siegbahn PEM, 2004, BBA-BIOENERGETICS, V1655, P45, DOI 10.1016/j.bbabio.2003.07.003; Siletsky S, 1999, BIOCHEMISTRY-US, V38, P4853, DOI 10.1021/bi982614a; SILETSKY SA, 1998, THESIS MOSCOW STATE; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; Tsukihara T, 2003, P NATL ACAD SCI USA, V100, P15304, DOI 10.1073/pnas.2635097100; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; Wikstrom M, 2000, BBA-BIOENERGETICS, V1458, P188, DOI 10.1016/S0005-2728(00)00068-2; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; Wikstrom M, 2003, BBA-BIOENERGETICS, V1604, P61, DOI 10.1016/S0005-2728(03)00041-0; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; Xavier AV, 2004, BBA-BIOENERGETICS, V1658, P23, DOI 10.1016/j.bbabio.2004.03.017; Xavier AV, 2002, FEBS LETT, V532, P261, DOI 10.1016/S0014-5793(02)03692-X; ZASLAVSKY D, 1993, FEBS LETT, V336, P389, DOI 10.1016/0014-5793(93)80843-J; Zaslavsky D, 1998, BIOCHEMISTRY-US, V37, P14910, DOI 10.1021/bi981490z; Zheng XH, 2003, BBA-BIOENERGETICS, V1557, P99, DOI 10.1016/S0005-2728(03)00002-1	50	69	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52558	52565		10.1074/jbc.M407549200	http://dx.doi.org/10.1074/jbc.M407549200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15385565	hybrid			2022-12-25	WOS:000225493400102
J	Hu, HT; Sheehan, JH; Chazin, WJ				Hu, HT; Sheehan, JH; Chazin, WJ			The mode of action of centrin - Binding of Ca2+ and a peptide fragment of Kar1p to the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; CALCIUM-FREE CALMODULIN; EF-HAND PROTEIN; CONFORMATIONAL-CHANGE; YEAST CALMODULIN; APO-CALMODULIN; TROPONIN-C; DUPLICATION; CALTRACTIN; SITES	Centrin is an EF-hand calcium-binding protein closely related to the prototypical calcium sensor protein calmodulin. It is found in microtubule-organizing centers of organisms ranging from algae and yeast to man. In vitro, the C-terminal domain of centrin binds to the yeast centrosomal protein Kar1p in a calcium-dependent manner, whereas the N-terminal domain does not show any appreciable affinity for Kar1p. To obtain deeper insights into the structural basis for centrin's function, we have characterized the affinities of the C-terminal domain of Chlamydomonas reinhardtii centrin for calcium and for a peptide fragment of Kar1p using CD, fluorescence, and NMR spectroscopy. Calcium binding site IV in C. reinhardtii centrin was found to bind Ca2+ similar to 100-fold more strongly than site III. In the absence of Ca2+, the protein occupies a mixture of closed conformations. Binding of a single ion in site IV is sufficient to radically alter the conformational equilibrium, promoting occupancy of an open conformation. However, an exchange between closed and open conformations remains even at saturating levels of Ca2+. The population of the open conformation is substantially stabilized by the presence of the target peptide Kar1p-(239 - 257) to a point where a single ion bound in site IV is sufficient to completely shift the conformational equilibrium to the open conformation. This is reflected in the enhancement of the Ca2+ affinity in this site by more than an order of magnitude. These data confirm the direct coupling of the Ca2+ binding-induced shift in the equilibrium between the closed and open conformations to the binding of the peptide. Combined with the common localization of the two proteins in the microtubule organizing center, our results suggest that centrin is constitutively bound to Kar1p through its C-terminal domain and that centrin's calcium sensor activities are mediated by the N-terminal domain.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Phys, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Chazin, WJ (corresponding author), Vanderbilt Univ, Dept Biol Struct, 5142 BIOSCI MRBIII, Nashville, TN 37232 USA.	walter.chazin@vanderbilt.edu		Hu, Haitao/0000-0002-0312-1954; Sheehan, Jonathan/0000-0002-9641-7577	NCI NIH HHS [P30 CA68485] Funding Source: Medline; NIEHS NIH HHS [P50 ES00267] Funding Source: Medline; NIGMS NIH HHS [T32 GM-08240, R01 GM-40120] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ababou A, 2001, BIOCHEMISTRY-US, V40, P12719, DOI 10.1021/bi010405b; Akyol Z, 2004, J BIOL CHEM, V279, P2166, DOI 10.1074/jbc.M302542200; Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; Biekofsky RR, 1998, BIOCHEMISTRY-US, V37, P7617, DOI 10.1021/bi9800449; BIGGINS S, 1994, J CELL BIOL, V125, P843, DOI 10.1083/jcb.125.4.843; CARLSTROM G, 1993, J MOL BIOL, V231, P415, DOI 10.1006/jmbi.1993.1291; Evenas J, 1998, BIOCHEMISTRY-US, V37, P13744, DOI 10.1021/bi9806448; Evenas J, 1997, BIOCHEMISTRY-US, V36, P3448, DOI 10.1021/bi9628275; FARAH CS, 1994, J BIOL CHEM, V269, P5230; Geier BM, 1996, J BIOL CHEM, V271, P28366, DOI 10.1074/jbc.271.45.28366; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hu HT, 2003, J MOL BIOL, V330, P473, DOI 10.1016/S0022-2836(03)00619-3; Ivanovska I, 2001, GENETICS, V157, P503; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; LINSE S, 1995, PROTEIN SCI, V4, P1038, DOI 10.1002/pro.5560040602; LINSE S, 1991, J BIOL CHEM, V266, P8050; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; MARTIN SR, 1986, BIOCHEM J, V238, P485, DOI 10.1042/bj2380485; Martin SR, 1999, PROTEIN SCI, V8, P2444; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; OHYA Y, 1994, GENETICS, V138, P1041; OLWIN BB, 1984, J BIOL CHEM, V259, P949; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; She MD, 1998, J MOL BIOL, V281, P445, DOI 10.1006/jmbi.1998.1933; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; STEINER RF, 1984, BIOPOLYMERS, V23, P1121, DOI 10.1002/bip.360230612; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Szczesna D, 1996, J BIOL CHEM, V271, P8381, DOI 10.1074/jbc.271.14.8381; TAILLON BE, 1992, J CELL BIOL, V119, P1613, DOI 10.1083/jcb.119.6.1613; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; Veeraraghavan S, 2002, J BIOL CHEM, V277, P28564, DOI 10.1074/jbc.M112232200; WEBER C, 1994, J BIOL CHEM, V269, P15795; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; YAZAWA M, 1992, BIOCHEMISTRY-US, V31, P3171, DOI 10.1021/bi00127a018; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	42	52	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50895	50903		10.1074/jbc.M404233200	http://dx.doi.org/10.1074/jbc.M404233200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452116	hybrid			2022-12-25	WOS:000225355800032
J	Joseph, JW; Koshkin, V; Saleh, MC; Sivitz, WI; Zhang, CY; Lowell, BB; Chan, CB; Wheeler, MB				Joseph, JW; Koshkin, V; Saleh, MC; Sivitz, WI; Zhang, CY; Lowell, BB; Chan, CB; Wheeler, MB			Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLET CELLS; INSULIN-SECRETION; COMMON POLYMORPHISM; ENERGY-METABOLISM; GENE-EXPRESSION; OBESITY; APOPTOSIS; PROMOTER; MICE; UCP2	Chronic exposure to elevated free fatty acids (lipotoxicity) induces uncoupling protein (UCP2) in the pancreatic beta-cell, and therefore a causal link between UCP2 and beta-cell defects associated with obesity may exist. Recently, we showed that lipid treatment in vivo and in vitro in UCP2(-/-) mice/islets does not result in any loss in beta-cell glucose sensitivity. We have now assessed the mechanism of maintained beta-cell function in UCP2(-/-) mice by exposing islets to 0.4 mM palmitate for 48 h. Palmitate treatment increased triglyceride concentrations in wild type (WT) but not UCP2(-/-) islets because of higher palmitate oxidation rates in the UCP2(-/-) islets. Dispersed beta-cells from the palmitate-exposed WT islets had reduced glucose-stimulated hyperpolarization of the mitochondrial membrane potential compared with both control WT and palmitate-exposed UCP2(-/-) beta-cells. The glucose-stimulated increases in the ATP/ADP ratio and cytosolic Ca2+ are attenuated in palmitate-treated WT but not UCP2(-/-) beta-cells. Exposure to palmitate reduced glucose-stimulated insulin secretion (GSIS) in WT islets, whereas UCP2(-/-) islets had enhanced GSIS. Overexpression of recombinant UCP2 but not enhanced green fluorescent protein in beta-cells resulted in a loss of glucose-stimulated hyperpolarization of the mitochondrial membrane potential and GSIS similar to that seen in WT islets exposed to palmitate. Reactive oxygen species (ROS) are known to increase the activity of UCP2. We showed that ROS levels were elevated in control UCP2(-/-) islets as compared with WT and UCP2(-/-) islets overexpressing UCP2 and that palmitate increased ROS in WT and UCP2(-/-) islets overexpressing UCP2 but not in UCP2(-/-) islets. Thus, UCP2(-/-) islets resisted the toxic effects of palmitate by maintaining glucose-dependent metabolism-secretion coupling. We propose that higher free fatty acid oxidation rates prevent accumulation of triglyceride in UCP2(-/-) islets, such accumulation being a phenomenon associated with lipotoxicity.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Iowa, Dept Internal Med, Div Endocrinol, Iowa City, IA 52246 USA; Univ Iowa, Dept Internal Med, Div Metab, Iowa City, IA 52246 USA; Univ Prince Edward Isl, Atlantic Vet Coll, Dept Biomed Sci, Charlottetown, PE C1A 4P3, Canada; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	University of Toronto; University of Toronto; University of Iowa; University of Iowa; University of Prince Edward Island; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle,Rm 3352, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca	Chan, Catherine/C-1162-2011	Chan, Catherine/0000-0003-3882-0592; Sivitz, William/0000-0002-7829-0189; Wheeler, Michael B./0000-0002-7480-7267				Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Barbu A, 2002, MOL CELL ENDOCRINOL, V190, P75, DOI 10.1016/S0303-7207(02)00009-6; BERTS A, 1995, BIOCHEM BIOPH RES CO, V208, P644, DOI 10.1006/bbrc.1995.1387; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; BRUBAKER PL, 1989, ENDOCRINOLOGY, V124, P3003, DOI 10.1210/endo-124-6-3003; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; Carlsson C, 1999, ENDOCRINOLOGY, V140, P3422, DOI 10.1210/en.140.8.3422; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Chandra J, 2001, DIABETES, V50, pS44, DOI 10.2337/diabetes.50.2007.S44; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; Dhamrait SS, 2004, EUR HEART J, V25, P468, DOI 10.1016/j.ehj.2004.01.007; DRUCKER DJ, 1991, ENDOCRINOLOGY, V128, P394, DOI 10.1210/endo-128-1-394; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; ERECINSKA M, 1992, BIOCHIM BIOPHYS ACTA, V1101, P273, DOI 10.1016/0167-4838(92)90555-R; Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hong Y, 2001, ENDOCRINOLOGY, V142, P249, DOI 10.1210/en.142.1.249; Joseph JW, 2002, DIABETES, V51, P3211, DOI 10.2337/diabetes.51.11.3211; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Koshkin V, 2003, J BIOL CHEM, V278, P19709, DOI 10.1074/jbc.M209709200; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; Sasahara M, 2004, DIABETES, V53, P482, DOI 10.2337/diabetes.53.2.482; SCHULTZ V, 1993, ANAL BIOCHEM, V215, P302, DOI 10.1006/abio.1993.1591; Sesti G, 2003, DIABETES, V52, P1280, DOI 10.2337/diabetes.52.5.1280; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Smukler SR, 2002, DIABETES, V51, P3450, DOI 10.2337/diabetes.51.12.3450; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	36	154	163	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51049	51056		10.1074/jbc.M409189200	http://dx.doi.org/10.1074/jbc.M409189200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448158	hybrid			2022-12-25	WOS:000225355800050
J	Kao, HI; Campbell, JL; Bambara, RA				Kao, HI; Campbell, JL; Bambara, RA			Dna2p helicase/nuclease is a tracking protein, like FEN1, for flap cleavage during Okazaki fragment maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; REPLICATION-PROTEIN; HELICASE ACTIVITY; CRYSTAL-STRUCTURE; POLYMERASE-DELTA; IN-VIVO; YEAST; ENDONUCLEASE-1	During cellular DNA replication the lagging strand is generated as discontinuous segments called Okazaki fragments. Each contains an initiator RNA primer that is removed prior to joining of the strands. Primer removal in eukaryotes requires displacement of the primer into a flap that is cleaved off by flap endonuclease 1 (FEN1). FEN1 employs a unique tracking mechanism that requires the recognition of the free 5' terminus and then movement to the base of the flap for cleavage. Abnormally long flaps are coated by replication protein A (RPA), inhibiting FEN1 cleavage. A second nuclease, Dna2p, is needed to cleave an RPA-coated flap producing a short RPA-free flap, favored by FEN1. Here we show that Dna2p is also a tracking protein. Annealed primers or conjugated biotin-streptavidin complex block Dna2p entry and movement. Single-stranded binding protein-coated flaps inhibit Dna2p cleavage. Like FEN1, Dna2p can track over substrates with a non-Watson Crick base, such as a biotin, or a missing base within a chain. Unlike FEN1, Dna2p shows evidence of a "threading-like" mechanism that does not support tracking over a branched substrate. We propose that the two nucleases both track, Dna2p first and then FEN1, to remove initiator RNA via long flap intermediates.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; CALTECH, Braun Labs, Pasadena, CA 91125 USA	University of Rochester; California Institute of Technology	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1979, J BIOL CHEM, V254, P1495; Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bae KH, 2003, NUCLEIC ACIDS RES, V31, P3006, DOI 10.1093/nar/gkg422; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Bae SH, 2002, J BIOL CHEM, V277, P26632, DOI 10.1074/jbc.M111026200; Bae SH, 2001, NUCLEIC ACIDS RES, V29, P3069, DOI 10.1093/nar/29.14.3069; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Budd ME, 2000, MUTAT RES-DNA REPAIR, V459, P173, DOI 10.1016/S0921-8777(99)00072-5; Callahan JL, 2003, MOL CELL BIOL, V23, P7849, DOI 10.1128/MCB.23.21.7849-7860.2003; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Choe W, 2002, MOL CELL BIOL, V22, P4202, DOI 10.1128/MCB.22.12.4202-4217.2002; Driscoll HC, 2003, J BIOL CHEM, V278, P41126, DOI 10.1074/jbc.M304798200; Formosa T, 1999, GENETICS, V151, P1459; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Imamura O, 2003, P NATL ACAD SCI USA, V100, P8193, DOI 10.1073/pnas.1431624100; Kang HY, 2000, GENETICS, V155, P1055; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; Kao HI, 2003, CRIT REV BIOCHEM MOL, V38, P433, DOI 10.1080/10409230390259382; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KORNBERG A, 1992, DNA REPLICATION, P140; Kunkel TA, 1997, CELL, V88, P155, DOI 10.1016/S0092-8674(00)81832-2; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lesur I, 2004, MOL BIOL CELL, V15, P1297, DOI 10.1091/mbc.E03-10-0742; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NETHANEL T, 1992, J VIROL, V66, P6634, DOI 10.1128/JVI.66.11.6634-6640.1992; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; Sibenaller ZA, 1998, BIOCHEMISTRY-US, V37, P12496, DOI 10.1021/bi981110+; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Weitao T, 2003, MUTAT RES-FUND MOL M, V532, P157, DOI 10.1016/j.mrfmmm.2003.08.015; Weitao T, 2003, J BIOL CHEM, V278, P22513, DOI 10.1074/jbc.M301610200; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001; Yong YQ, 1996, CHEM RES TOXICOL, V9, P179, DOI 10.1021/tx950112h; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	47	65	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50840	50849		10.1074/jbc.M409231200	http://dx.doi.org/10.1074/jbc.M409231200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448135	Green Accepted, hybrid			2022-12-25	WOS:000225355800026
J	Garrigue-Antar, L; Francois, V; Kadler, KE				Garrigue-Antar, L; Francois, V; Kadler, KE			Deletion of epidermal growth factor-like domains converts mammalian tolloid into a chordinase and effective procollagen C-proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; DORSAL-VENTRAL PATTERN; X-RAY-STRUCTURE; DROSOPHILA EMBRYO; ACTIVITY GRADIENT; CRYSTAL-STRUCTURE; ASTACIN FAMILY; BINDING; MEMBER; METALLOPROTEINASES	Bone morphogenetic protein (BMP)-1 and mammalian tolloid (mTld) are Ca2+-dependent metalloproteinases that result from alternative splicing of the bmp1 gene. They have different proteinase activities, e.g. BMP-1 effectively cleaves procollagen (an extracellular matrix protein) and chordin (a BMP antagonist), whereas mTld is a poor procollagen proteinase and will not cleave chordin in the absence of twisted gastrulation. This is perplexing because mTld (being the longer variant) might be expected to cleave all substrates cleaved by BMP-1. Studies have shown that the minimal structure for procollagen proteinase activity is proteinase-CUB1-CUB2 (BMP-1DeltaEC3) and therefore lacking the epidermal growth factor (EGF)-like domain thought to account for the Ca2+ dependence of BMP-1. In this study we generated three deletion mutants of mTld that lacked either one or both EGF-like domains (referred to as "mTld-DeltaEGF"). The mutated proteins were poorly but sufficiently secreted from 293-EBNA cells for in vitro assays of procollagen and chordin cleavage. Most surprisingly, the mTld-DeltaEGF mutants required Ca2+ for proteolytic activity, thereby showing that the EGF-like domains do not account for the Ca2+ dependence of BMP-1/mTld. Moreover, the mTld-DeltaEGFs are effective procollagen proteinases and cleave chordin. Furthermore, BMP-1DeltaEC3 cleaves chordin and requires Ca2+ for activity. Studies using nondenaturing gels showed that mTld molecules lacking EGF-like domains have a loose conformation such that in the presence of Ca2+ binding sites for chordin and procollagen on the "BMP-1-part" of the molecule are exposed. We propose that the EGF-like domains could hold CUB4/5 domains in locations that exclude substrates cleavable by BMP-1.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; CNRS, UPR 1142, Inst Genet Humaine, F-34396 Montpellier 5, France	University of Manchester; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Kadler, KE (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	karl.kadler@man.ac.uk	KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Garrigue-Antar, Laure/0000-0001-6331-8882				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Bernocco S, 2003, J BIOL CHEM, V278, P7199, DOI 10.1074/jbc.M210857200; Bersch B, 1998, BIOCHEMISTRY-US, V37, P1204, DOI 10.1021/bi971851v; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DALE L, 1992, DEVELOPMENT, V115, P573; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Gagne SM, 1998, J MOL BIOL, V278, P667, DOI 10.1006/jmbi.1998.1723; Garrigue-Antar L, 2001, J BIOL CHEM, V276, P26237, DOI 10.1074/jbc.M010814200; GOMISRUTH FX, 1994, J BIOL CHEM, V269, P17111; Gregory LA, 2004, J BIOL CHEM, V279, P29391, DOI 10.1074/jbc.M402687200; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Jones CM, 1996, DEVELOPMENT, V122, P1545; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Larrain J, 2000, DEVELOPMENT, V127, P821; Leighton M, 2003, J BIOL CHEM, V278, P18478, DOI 10.1074/jbc.M213021200; Lhomond G, 1996, EUR J BIOCHEM, V238, P744, DOI 10.1111/j.1432-1033.1996.0744w.x; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Millet C, 2001, MECH DEVELOP, V106, P85, DOI 10.1016/S0925-4773(01)00423-3; Neul JL, 1998, CELL, V95, P483, DOI 10.1016/S0092-8674(00)81616-5; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; Suzuki N, 1996, DEVELOPMENT, V122, P3587; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Varela PF, 1997, J MOL BIOL, V274, P635, DOI 10.1006/jmbi.1997.1424; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; Werner JM, 2000, J MOL BIOL, V296, P1065, DOI 10.1006/jmbi.1999.3513; WHARTON KA, 1993, DEVELOPMENT, V117, P807; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	52	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49835	49841		10.1074/jbc.M408134200	http://dx.doi.org/10.1074/jbc.M408134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15381708	Green Published, hybrid			2022-12-25	WOS:000225229500036
J	Viney, TJ; Schmidt, TW; Gierasch, W; Sattar, AW; Yaggie, RE; Kuburas, A; Quinn, JP; Coulson, JM; Russo, AF				Viney, TJ; Schmidt, TW; Gierasch, W; Sattar, AW; Yaggie, RE; Kuburas, A; Quinn, JP; Coulson, JM; Russo, AF			Regulation of the cell-specific calcitonin/calcitonin gene-related peptide enhancer by USF and the Foxa2 forkhead protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM STIMULATORY FACTOR; HELIX-LOOP-HELIX; TRIGEMINAL GANGLIA NEURONS; ACID DECARBOXYLASE GENE; HUMAN CALCITONIN GENE; NUCLEAR FACTOR 3-BETA; TRANSCRIPTION FACTORS; DNA-BINDING; E-BOX; WINGED-HELIX	An 18-bp enhancer controls cell-specific expression of the calcitonin/calcitonin gene-related peptide gene. The enhancer is bound by a heterodimer of the bHLH-Zip protein USF-1 and -2 and a cell-specific factor from thyroid C cell lines. In this report we have identified the cell-specific factor as the forkhead protein Foxa2 (previously HNF-3beta). Binding of Foxa2 to the 18-bp enhancer was demonstrated using electrophoretic mobility shift assays. The cell-specific DNA-protein complex was selectively competed by a series of Foxa2 DNA binding sites, and the addition of Foxa2 antiserum supershifted the complex. Likewise, a complex similar to that seen with extracts from thyroid C cell lines was generated using an extract from heterologous cells expressing recombinant Foxa2. Interestingly, overexpression of Foxa2 activated the 18-bp enhancer in heterologous cells but only in the presence of the adjacent helix-loop-helix motif. Likewise, coexpression of USF proteins with Foxa2 yielded greater activation than by Foxa2 alone. Unexpectedly, Foxa2 overexpression repressed activity in the CA77 thyroid C cell line, suggesting that Foxa2 may interact with additional cofactors. The stimulatory role of Foxa2 at the calcitonin/calcitonin gene-related peptide gene enhancer was confirmed by short interfering RNA-mediated knockdown of Foxa2. As seen with Foxa2 overexpression, the effect of Foxa2 knockdown also required the adjacent helix-loop-helix motif. These results provide the first evidence for combinatorial control of gene expression by bHLH-Zip and forkhead proteins.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Liverpool, Dept Human Anat & Cell Biol, Liverpool L69 3GE, Merseyside, England	University of Iowa; University of Liverpool	Russo, AF (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	andrew-russo@uiowa.edu	; Quinn, John/A-2972-2010	Viney, Tim/0000-0001-6444-1188; Coulson, Judy/0000-0003-2191-2001; Russo, Andrew/0000-0002-8156-5649; Quinn, John/0000-0003-3551-7803	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025969] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 25969] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGUANNO A, 1995, J NEUROCHEM, V65, P1944; Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; BALL DW, 1992, NUCLEIC ACIDS RES, V20, P117, DOI 10.1093/nar/20.1.117; BRACQ S, 1993, FEBS LETT, V331, P15, DOI 10.1016/0014-5793(93)80288-6; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Chen WG, 2003, J NEUROSCI, V23, P2572; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COPP DH, 1992, ENDOCRINOLOGY, V131, P1007, DOI 10.1210/en.131.3.1007; COSTA RH, 1991, NUCLEIC ACIDS RES, V19, P4139, DOI 10.1093/nar/19.15.4139; Coulson JM, 2003, BIOCHEM J, V369, P549, DOI 10.1042/BJ20021176; Dacquin R, 2004, J CELL BIOL, V164, P509, DOI 10.1083/jcb.200312135; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Durham PL, 2000, MOL ENDOCRINOL, V14, P1570, DOI 10.1210/me.14.10.1570; Durham PL, 2004, BRAIN RES, V997, P103, DOI 10.1016/j.brainres.2003.11.005; Durham PL, 2003, J NEUROSCI, V23, P807; Durham PL, 1998, MOL ENDOCRINOL, V12, P1002, DOI 10.1210/me.12.7.1002; Edvinsson L, 2003, EXPERT OPIN THER TAR, V7, P377, DOI 10.1517/eott.7.3.377.22440; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; Foucher I, 2003, DEVELOPMENT, V130, P1867, DOI 10.1242/dev.00414; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Heckert LL, 2001, MOL ENDOCRINOL, V15, P704, DOI 10.1210/me.15.5.704; Hoff AO, 2002, J CLIN INVEST, V110, P1849, DOI 10.1172/JCI200214218; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Jacob A, 1997, EXP CELL RES, V234, P277, DOI 10.1006/excr.1997.3622; Kaestner KH, 2000, GENE DEV, V14, P142; Labosky PA, 1998, MECH DEVELOP, V76, P185, DOI 10.1016/S0925-4773(98)00105-1; Lanigan TM, 1997, J BIOL CHEM, V272, P18316, DOI 10.1074/jbc.272.29.18316; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; LILLYCROP KA, 1993, VIROLOGY, V196, P888, DOI 10.1006/viro.1993.1552; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Martin CC, 2003, BIOCHEM J, V371, P675, DOI 10.1042/BJ20021585; MCCULLOCH J, 1986, P NATL ACAD SCI USA, V83, P5731, DOI 10.1073/pnas.83.15.5731; MCMAHON AP, 1994, CURR BIOL, V4, P903, DOI 10.1016/S0960-9822(00)00200-1; METZ R, 1991, ONCOGENE, V6, P2165; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PELEG S, 1990, MOL ENDOCRINOL, V4, P1750, DOI 10.1210/mend-4-11-1750; PHILIPPE J, 1995, MOL ENDOCRINOL, V9, P368, DOI 10.1210/me.9.3.368; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; PREIBISZ JJ, 1993, AM J HYPERTENS, V6, P434, DOI 10.1093/ajh/6.5.434; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Raynal JF, 1998, MOL BRAIN RES, V56, P227, DOI 10.1016/S0169-328X(98)00048-5; Ribeiro A, 1999, J BIOL CHEM, V274, P1216, DOI 10.1074/jbc.274.3.1216; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; STOLARSKYFREDMAN L, 1990, MOL ENDOCRINOL, V4, P497, DOI 10.1210/mend-4-3-497; Tsay W, 1997, DNA CELL BIOL, V16, P569, DOI 10.1089/dna.1997.16.569; TVERBERG LA, 1993, J BIOL CHEM, V268, P15965; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1; Waeber C, 2003, NEUROLOGY, V61, pS9, DOI 10.1212/WNL.61.8_suppl_4.S9; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Zaidi M, 2002, J CLIN INVEST, V110, P1769, DOI 10.1172/JCI200217425	57	16	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49948	49955		10.1074/jbc.M406659200	http://dx.doi.org/10.1074/jbc.M406659200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15385550	hybrid			2022-12-25	WOS:000225229500050
J	Kim, SH; Yin, YI; Li, YM; Sisodia, SS				Kim, SH; Yin, YI; Li, YM; Sisodia, SS			Evidence that assembly of an active gamma-secretase complex occurs in the early compartments of the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; BETA-APP; PRESENILIN-1; APH-1; NICASTRIN; NOTCH; PEN-2; RECONSTITUTION; SUBCOMPLEX; CLEAVAGE	The gamma-secretase complex, consisting of presenilins (PS), nicastrin (NCT), APH-1, and PEN-2, catalyzes the intramembranous proteolysis of truncated beta-amyloid precursor protein (APP) and Notch derivatives to generate the APP intracellular domain ( AICD) and Notch intracellular domain (NICD), respectively. To examine the intracellular sites in which active gamma-secretase resides, we expressed NCT variants harboring either an endoplasmic reticulum (ER) retention signal (NCT-ER) or a trans-Golgi network (TGN) targeting motif (NCT-TGN) along with PS1, APH-1, and PEN-2 and examined gamma-secretase activity in these settings. In cells expressing NCT- ER and the other components, PS1 fragments hyperaccumulated, but AICD levels were not elevated. On the other hand, upon coexpression of an ER-retained APP variant or a constitutionally active Notch mutant, NDeltaE, we observed enhanced production of AICD or NICD, respectively, in cells expressing NCT- ER. Moreover, we show that membranes from cells expressing NCT- ER, NCT- TGN, or NCT-WT contain identical levels of PS1 derivatives that can be photoaffinity cross-linked to a biotinylated, benzophenone-derivatized gamma-secretase inhibitor. Finally, our cell-free gamma-secretase assays revealed nearly equivalent gamma-secretase activities in cells expressing PS1, APH-1, PEN-2, and either NCT-WT or NCT-ER. Taken together, we interpret these findings as suggesting that active gamma-secretase complex is generated in the early compartments of the secretory pathway but that these complexes are transported to late compartments in which substrates are encountered and subsequently processed within respective transmembrane segments.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA	University of Chicago; Memorial Sloan Kettering Cancer Center	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.	ssisodia@bsd.uchicago.edu			NATIONAL INSTITUTE ON AGING [R01AG021494] Funding Source: NIH RePORTER; NIA NIH HHS [AG021494] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; Peraus GC, 1997, J NEUROSCI, V17, P7714; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	26	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48615	48619		10.1074/jbc.C400396200	http://dx.doi.org/10.1074/jbc.C400396200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15456788	hybrid			2022-12-25	WOS:000225098100017
J	De Genst, E; Handelberg, F; Van Meirhaeghe, A; Vynck, S; Loris, R; Wyns, L; Muyldermans, S				De Genst, E; Handelberg, F; Van Meirhaeghe, A; Vynck, S; Loris, R; Wyns, L; Muyldermans, S			Chemical basis for the affinity maturation of a camel single domain antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ANTIBODIES; PROTEIN-PROTEIN INTERACTIONS; SOMATIC HYPERMUTATION; EXPERIMENTAL-DESIGN; COMBINING SITE; FREE-ENERGY; ANTIGEN; BINDING; CRYSTALLOGRAPHY; RECOGNITION	Affinity maturation of classic antibodies supposedly proceeds through the pre-organization of the reactive germ line conformational isomer. It is less evident to foresee how this can be accomplished by camelid heavy-chain antibodies lacking light chains. Although these antibodies are subjected to somatic hypermutation, their antigen-binding fragment consists of a single domain with restricted flexibility in favor of binding energy. An antigen-binding domain derived from a dromedary heavy-chain antibody, cAb-Lys3, accumulated five amino acid substitutions in CDR1 and CDR2 upon maturation against lysozyme. Three of these residues have hydrophobic side chains, replacing serines, and participate in the hydrophobic core of the CDR1 in the mature antibody, suggesting that conformational rearrangements might occur in this loop during maturation. However, transition state analysis of the binding kinetics of mature cAb-Lys3 and germ line variants show that the maturation of this antibody relies on events late in the reaction pathway. This is reflected by a limited perturbation of k(a) and a significantly decreased k(d) upon maturation. In addition, binding reactions and the maturation event are predominantly enthalpically driven. Therefore, maturation proceeds through the increase of favorable binding interactions, or by the reduction of the enthalpic penalty for desolvation, as opposed to large entropic penalties associated with conformational changes and structural plasticity. Furthermore, the crystal structure of the mutant with a restored germ line CDR2 sequence illustrates that the matured hydrophobic core of CDR1 in cAb-Lys3 might be compensated in the germ line precursor by burying solvent molecules engaged in a stable hydrogen-bonding network with CDR1 and CDR2.	Free Univ Brussels VIB, Dept Mol & Cellular Interact, B-1050 Brussels, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	De Genst, E (corresponding author), Free Univ Brussels VIB, Dept Mol & Cellular Interact, Pleinlaan 2, B-1050 Brussels, Belgium.	edegenst@vub.ac.be	Muyldermans, Serge V/C-6418-2016; Loris, Remy/GPG-0894-2022; Muyldermans, Serge/AAC-7374-2019	Muyldermans, Serge V/0000-0002-3678-3575; Muyldermans, Serge/0000-0002-3678-3575; Loris, Remy/0000-0002-8862-3338				Bond CJ, 2003, J MOL BIOL, V332, P643, DOI 10.1016/S0022-2836(03)00967-7; Boniface JJ, 1999, P NATL ACAD SCI USA, V96, P11446, DOI 10.1073/pnas.96.20.11446; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cauerhff A, 2004, P NATL ACAD SCI USA, V101, P3539, DOI 10.1073/pnas.0400060101; Chong LT, 1999, P NATL ACAD SCI USA, V96, P14330, DOI 10.1073/pnas.96.25.14330; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; De Genst E, 2002, J BIOL CHEM, V277, P29897, DOI 10.1074/jbc.M202359200; Decanniere K, 2001, J MOL BIOL, V313, P473, DOI 10.1006/jmbi.2001.5075; Decanniere K, 2000, J MOL BIOL, V300, P83, DOI 10.1006/jmbi.2000.3839; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; ITO W, 1995, J MOL BIOL, V248, P729, DOI 10.1006/jmbi.1995.0255; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kabat EA, 1991, SEQUENCES PROTEINS I; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Li YL, 2003, NAT STRUCT BIOL, V10, P482, DOI 10.1038/nsb930; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Manivel V, 2000, IMMUNITY, V13, P611, DOI 10.1016/S1074-7613(00)00061-3; Milstein C, 1996, ADV PROTEIN CHEM, V49, P451, DOI 10.1016/S0065-3233(08)60494-5; Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuberger MS, 1998, IMMUNOL REV, V162, P107, DOI 10.1111/j.1600-065X.1998.tb01434.x; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; Weill JC, 1996, IMMUNOL TODAY, V17, P92, DOI 10.1016/0167-5699(96)80586-X; Yang PL, 1999, J MOL BIOL, V294, P1191, DOI 10.1006/jmbi.1999.3197	33	56	64	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53593	53601		10.1074/jbc.M407843200	http://dx.doi.org/10.1074/jbc.M407843200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15383540	hybrid			2022-12-25	WOS:000225680600095
J	Drees, JC; Lusetti, SL; Cox, MM				Drees, JC; Lusetti, SL; Cox, MM			Inhibition of RecA protein by the Escherichia coli RecX protein - Modulation by the RecA C terminus and filament functional state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; STALLED REPLICATION FORKS; BINDING-PROTEIN; RECOMBINATIONAL REPAIR; GENETIC-RECOMBINATION; ATP HYDROLYSIS; EXCHANGE; COMPLEXES; DINI; EXPRESSION	The RecX protein is a potent inhibitor of RecA activities. We identified several factors that affect RecX-RecA interaction. The interaction is enhanced by the RecA C terminus and by significant concentrations of free Mg2+ ion. The interaction is also enhanced by an N-terminal His(6) tag on the RecX protein. We conclude that RecX protein interacts most effectively with a RecA functional state designated A(o) and that the RecA C terminus has a role in modulating the interaction. We further identified a C-terminal point mutation in RecA protein (E343K) that significantly alters the interaction between RecA and RecX proteins.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NIGMS NIH HHS [GM 52725] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DEMOT R, 1994, NUCLEIC ACIDS RES, V22, P1313, DOI 10.1093/nar/22.7.1313; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; Haruta N, 2003, J BIOL CHEM, V278, P52710, DOI 10.1074/jbc.M308563200; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2004, J BIOL CHEM, V279, P30037, DOI 10.1074/jbc.M403064200; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; Pages V, 2003, DNA REPAIR, V2, P273, DOI 10.1016/S1568-7864(02)00217-3; Papavinasasundaram KG, 1998, MOL MICROBIOL, V30, P525, DOI 10.1046/j.1365-2958.1998.01083.x; Papavinasasundaram KG, 1997, MOL MICROBIOL, V24, P141, DOI 10.1046/j.1365-2958.1997.3441697.x; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; Robu ME, 2004, J BIOL CHEM, V279, P10973, DOI 10.1074/jbc.M312184200; SANO Y, 1993, J BACTERIOL, V175, P2451, DOI 10.1128/JB.175.8.2451-2454.1993; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Stohl EA, 2003, J BIOL CHEM, V278, P2278, DOI 10.1074/jbc.M210496200; Stohl EA, 2001, MOL MICROBIOL, V40, P1301, DOI 10.1046/j.1365-2958.2001.02463.x; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Sukchawalit R, 2001, FEMS MICROBIOL LETT, V205, P83, DOI 10.1111/j.1574-6968.2001.tb10929.x; UMEZU K, 1994, J BIOL CHEM, V269, P30005; VanLoock MS, 2003, J MOL BIOL, V333, P345, DOI 10.1016/j.jmb.2003.08.053; Venkatesh R, 2002, P NATL ACAD SCI USA, V99, P12091, DOI 10.1073/pnas.192178999; Vierling S, 2000, J BACTERIOL, V182, P4005, DOI 10.1128/JB.182.14.4005-4011.2000; Voloshin ON, 2001, GENE DEV, V15, P415, DOI 10.1101/gad.862901; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; Yang MK, 2001, CURR MICROBIOL, V42, P257, DOI 10.1007/s002840010214; Yasuda T, 1998, EMBO J, V17, P3207, DOI 10.1093/emboj/17.11.3207; Yasuda T, 2001, EMBO J, V20, P1192, DOI 10.1093/emboj/20.5.1192; Yoshimasu M, 2003, NUCLEIC ACIDS RES, V31, P1735, DOI 10.1093/nar/gkg256; Yu VPCC, 2000, GENE DEV, V14, P1400	47	52	54	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52991	52997		10.1074/jbc.M409050200	http://dx.doi.org/10.1074/jbc.M409050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466870	hybrid			2022-12-25	WOS:000225680600024
J	Holst, B; Holliday, ND; Bach, A; Elling, CE; Cox, HM; Schwartz, TW				Holst, B; Holliday, ND; Bach, A; Elling, CE; Cox, HM; Schwartz, TW			Common structural basis for constitutive activity of the ghrelin receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-HORMONE SECRETAGOGUE; DEPENDENT GENE-EXPRESSION; CANNABINOID CB1 RECEPTORS; SERUM RESPONSE FACTOR; LIGAND-BINDING SITES; NEURITE RETRACTION; SIGNALING PATHWAYS; INVERSE AGONISM; ENDOCYTOSIS	Three members of the ghrelin receptor family were characterized in parallel: the ghrelin receptor, the neurotensin receptor 2 and the orphan receptor GPR39. In transiently transfected COS-7 and human embryonic kidney 293 cells, all three receptors displayed a high degree of ligand-independent signaling activity. The structurally homologous motilin receptor served as a constitutively silent control; upon agonist stimulation, however, it signaled with a similar efficacy to the three related receptors. The constitutive activity of the ghrelin receptor and of neurotensin receptor 2 through the G(q), phospholipase C pathway was similar to50% of their maximal capacity as determined through inositol phosphate accumulation. These two receptors also showed very high constitutive activity in activation of cAMP response element-driven transcription. GPR39 displayed a clear but lower degree of constitutive activity through the inositol phosphate and cAMP response element pathways. In contrast, GPR39 signaled with the highest constitutive activity in respect of activation of serum response element-dependent transcription, in part, possibly, through G(12/13) and Rho kinase. Antibody feeding experiments demonstrated that the epitope-tagged ghrelin receptor was constitutively internalized but could be trapped at the cell surface by an inverse agonist, whereas GPR39 remained at the cell surface. Mutational analysis showed that the constitutive activity of both the ghrelin receptor and GPR39 could systematically be tuned up and down depending on the size and hydrophobicity of the side chain in position VI: 16 in the context of an aromatic residue at VII:09 and a large hydrophobic residue at VII:06. It is concluded that the three ghrelin-like receptors display an unusually high degree of constitutive activity, the structural basis for which is determined by an aromatic cluster on the inner face of the extracellular ends of TMs VI and VII.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; Kings Coll London, Ctr Res Neurosci, London SE1 1UL, England; 7TM Pharma AS, DK-2970 Horsholm, Denmark	University of Copenhagen; University of London; King's College London	Holst, B (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	b.holst@molpharm.dk	Cox, Helen M/F-2783-2015; Holliday, Nicholas/A-3607-2009	Holst, Birgitte/0000-0001-7432-097X; Cox, Helen/0000-0001-9024-1497; Schwartz, Thue W./0000-0002-0261-6904; Bach, Anders/0000-0003-4305-9910; Holliday, Nicholas/0000-0002-2900-828X				Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Brighton PJ, 2004, PHARMACOL REV, V56, P231, DOI 10.1124/pr.56.2.3; Burdyga G, 2004, J NEUROSCI, V24, P2708, DOI 10.1523/JNEUROSCI.5404-03.2004; Camina JP, 2004, ENDOCRINOLOGY, V145, P930, DOI 10.1210/en.2003-0974; Chang SH, 2004, J NEUROSCI, V24, P2277, DOI 10.1523/JNEUROSCI.4868-03.2004; Choi KC, 2003, ENDOCRINOLOGY, V144, P754, DOI 10.1210/en.2002-220783; Dobner PR, 2003, LIFE SCI, V73, P801, DOI 10.1016/S0024-3205(03)00411-9; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Elmquist JK, 2004, SCIENCE, V304, P63, DOI 10.1126/science.1096746; FARRENS DL, 1996, SCIENCE, V274, P468; Filipek S, 2003, ANNU REV BIOPH BIOM, V32, P375, DOI 10.1146/annurev.biophys.32.110601.142520; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Holst B, 1998, MOL PHARMACOL, V53, P166, DOI 10.1124/mol.53.1.166; Holst B, 2004, TRENDS PHARMACOL SCI, V25, P113, DOI 10.1016/j.tips.2004.01.010; Holst B, 2003, ANN NY ACAD SCI, V994, P1, DOI 10.1111/j.1749-6632.2003.tb03156.x; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Inui A, 2004, FASEB J, V18, P439, DOI 10.1096/fj.03-0641rev; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kim MS, 2003, NEUROREPORT, V14, P1317, DOI [10.1097/01.wnr.0000078703.79393.d2, 10.1097/00001756-200307180-00006]; Kim MS, 2004, MOL ENDOCRINOL, V18, P2291, DOI 10.1210/me.2003-0459; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Krebs A, 2003, J BIOL CHEM, V278, P50217, DOI 10.1074/jbc.M307995200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; Nagle DL, 1999, NATURE, V398, P148, DOI 10.1038/18210; Niu JX, 2003, CIRC RES, V93, P848, DOI 10.1161/01.RES.0000097607.14733.0C; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; Richard F, 2001, MOL PHARMACOL, V60, P1392, DOI 10.1124/mol.60.6.1392; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; ROSENKILDE MM, 2004, HDB CELL SIGNALING; Savinainen JR, 2003, BRIT J PHARMACOL, V140, P1451, DOI 10.1038/sj.bjp.0705577; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 2002, NATURE, V418, P595, DOI 10.1038/418595a; Schwartz T.W., 2002, TXB RECEPTOR PHARM, P81; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Singh LP, 2001, DIABETES, V50, P2355, DOI 10.2337/diabetes.50.10.2355; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Smith RG, 2001, ENDOCRINE, V14, P9, DOI 10.1385/ENDO:14:1:009; Sodhi A, 2000, CANCER RES, V60, P4873; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Waldhoer M, 2003, J BIOL CHEM, V278, P19473, DOI 10.1074/jbc.M213179200; Whistler JL, 2002, TRAFFIC, V3, P866, DOI 10.1034/j.1600-0854.2002.31203.x; Wilbanks AM, 2002, BIOCHEMISTRY-US, V41, P11981, DOI 10.1021/bi020275m	61	271	280	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53806	53817		10.1074/jbc.M407676200	http://dx.doi.org/10.1074/jbc.M407676200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15383539	hybrid			2022-12-25	WOS:000225680600119
J	O'Leary, JM; Hamilton, JM; Deane, CM; Valeyev, NV; Sandell, LJ; Downing, AK				O'Leary, JM; Hamilton, JM; Deane, CM; Valeyev, NV; Sandell, LJ; Downing, AK			Solution structure and dynamics of a prototypical chordin-like cysteine-rich repeat (von Willebrand factor type c module) from collagen IIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; EARLY MOUSE DEVELOPMENT; GROWTH-FACTOR BINDING; AMINO-PROPEPTIDE; DIFFERENTIAL EXPRESSION; MESSENGER-RNAS; EXTRACELLULAR-MATRIX; STRUCTURE PREDICTION; COUPLING-CONSTANTS; CHEMICAL-EXCHANGE	Chordin-like cysteine-rich (CR) repeats ( also referred to as von Willebrand factor type C (VWC) modules) have been identified in similar to200 extracellular matrix proteins. These repeats, named on the basis of amino acid conservation of 10 cysteine residues, have been shown to bind members of the transforming growth factor-beta (TGF-beta) superfamily and are proposed to regulate growth factor signaling. Here we describe the intramolecular disulfide bonding, solution structure, and dynamics of a prototypical chordin-like CR repeat from procollagen IIA (CRColIIA), which has been previously shown to bind TGF-beta1 and bone morphogenetic protein-2. The CRColIIA structure manifests a two sub-domain architecture tethered by a flexible linkage. Initial structures were calculated using RosettaNMR, a de novo prediction method, and final structure calculations were performed using CANDID within CYANA. The N-terminal region contains mainly beta-sheet and the C-terminal region is more irregular with the fold constrained by disulfide bonds. Mobility between the N- and C-terminal sub-domains on a fast time-scale was confirmed using NMR relaxation measurements. We speculate that the mobility between the two sub-domains may decrease upon ligand binding. Structure and sequence comparisons have revealed an evolutionary relationship between the N- terminal sub-domain of the CR module and the fibronectin type 1 domain, suggesting that these domains share a common ancestry. Based on the previously reported mapping of fibronectin binding sites for vascular endothelial growth factor to regions containing fibronectin type 1 domains, we discuss the possibility that this structural homology might also have functional relevance.	Univ Oxford, Dept Biochem, Div Struct Biol, Oxford OX1 3QU, England; Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA	University of Oxford; University of Oxford; Washington University (WUSTL)	Downing, AK (corresponding author), Univ Oxford, Dept Biochem, Div Struct Biol, South Pks Rd, Oxford OX1 3QU, England.	kristy.downing@bioch.ox.ac.uk		Deane, Charlotte/0000-0003-1388-2252				Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Aigner T, 1999, ARTHRITIS RHEUM, V42, P1443, DOI 10.1002/1529-0131(199907)42:7<1443::AID-ANR18>3.0.CO;2-A; Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; Bachiller D, 2000, NATURE, V403, P658, DOI 10.1038/35001072; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BISHOP PN, 1994, BIOCHEM BIOPH RES CO, V203, P289, DOI 10.1006/bbrc.1994.2180; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; Chivian D, 2003, PROTEINS, V53, P524, DOI 10.1002/prot.10529; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Crennell S, 2000, NAT STRUCT BIOL, V7, P1068; Diao JS, 1997, ACTA CRYSTALLOGR D, V53, P507, DOI 10.1107/S0907444997004034; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Foley SF, 2003, EUR J BIOCHEM, V270, P3610, DOI 10.1046/j.1432-1033.2003.03749.x; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Goerges AL, 2004, J BIOL CHEM, V279, P2307, DOI 10.1074/jbc.M308482200; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; Harrison PM, 1996, J MOL BIOL, V264, P603, DOI 10.1006/jmbi.1996.0664; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Innis CA, 2000, PROTEIN ENG, V13, P839, DOI 10.1093/protein/13.12.839; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Larrain J, 2000, DEVELOPMENT, V127, P821; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUI VCH, 1995, DEV DYNAM, V203, P198, DOI 10.1002/aja.1002030208; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Meissner A, 1997, J BIOMOL NMR, V10, P89, DOI 10.1023/A:1018331001961; Mizuguchi K, 1998, PROTEIN SCI, V7, P2469, DOI 10.1002/pro.5560071126; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; Oganesian A, 1997, J HISTOCHEM CYTOCHEM, V45, P1469, DOI 10.1177/002215549704501104; OLEARY JM, 2004, IN PRESS PROTEIN EXP; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Reardon A, 2000, MATRIX BIOL, V19, P169, DOI 10.1016/S0945-053X(00)00058-5; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SANDBERG MM, 1993, BIOCHEM J, V294, P595, DOI 10.1042/bj2940595; SANDELL LJ, 1994, DEV DYNAM, V199, P129, DOI 10.1002/aja.1001990206; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SATTLER M, 1995, J BIOMOL NMR, V5, P97, DOI 10.1007/BF00227475; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Shakhnovich BE, 2003, J MOL BIOL, V326, P1, DOI 10.1016/S0022-2836(02)01362-1; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; SWIDERSKI RE, 1994, DEV DYNAM, V200, P294, DOI 10.1002/aja.1002000404; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Werner JM, 2000, J MOL BIOL, V296, P1065, DOI 10.1006/jmbi.1999.3513; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; WILLIAMS RW, 1984, BIOCHEMISTRY-US, V23, P6796, DOI 10.1021/bi00321a080; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	77	70	81	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53857	53866		10.1074/jbc.M409225200	http://dx.doi.org/10.1074/jbc.M409225200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466413	hybrid			2022-12-25	WOS:000225680600124
J	Cassera, MB; Gozzo, FC; D'Alexandri, FL; Merino, EF; del Portillo, HA; Peres, VJ; Almeida, IC; Eberlin, MN; Wunderlich, G; Wiesner, J; Jomaa, H; Kimura, EA; Katzin, AM				Cassera, MB; Gozzo, FC; D'Alexandri, FL; Merino, EF; del Portillo, HA; Peres, VJ; Almeida, IC; Eberlin, MN; Wunderlich, G; Wiesner, J; Jomaa, H; Kimura, EA; Katzin, AM			The methylerythritol phosphate pathway is functionally active in all intraerythrocytic stages of Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; MEVALONATE-INDEPENDENT PATHWAY; ISOPRENOID BIOSYNTHESIS; ESCHERICHIA-COLI; NONMEVALONATE PATHWAY; HETEROLOGOUS EXPRESSION; ISOPENTENYL DIPHOSPHATE; EARLY STEPS; COENZYME-Q	Two genes encoding the enzymes 1-deoxy-D-xylulose-5-phosphate synthase and 1-deoxy-D-xylulose-5-phosphate reductoisomerase have been recently identified, suggesting that isoprenoid biosynthesis in Plasmodium falciparum depends on the methylerythritol phosphate ( MEP) pathway, and that fosmidomycin could inhibit the activity of 1-deoxy-D-xylulose-5-phosphate reductoisomerase. The metabolite 1-deoxy-D-xylulose-5-phosphate is not only an intermediate of the MEP pathway for the biosynthesis of isopentenyl diphosphate but is also involved in the biosynthesis of thiamin (vitamin B-1) and pyridoxal (vitamin B-6) in plants and many microorganisms. Herein we report the first isolation and characterization of most downstream intermediates of the MEP pathway in the three intraerythrocytic stages of P. falciparum. These include, 1-deoxy-D-xylulose-5-phosphate, 2-C-methyl-D-erythritol-4-phosphate, 4-(cytidine-5-diphospho)-2-C-methyl-D-erythritol, 4-(cytidine-5-diphospho)-2-C-methyl-D-erythritol-2-phosphate, and 2-C-methyl-D-erythritol-2,4-cyclodiphosphate. These intermediates were purified by HPLC and structurally characterized via biochemical and electrospray mass spectrometric analyses. We have also investigated the effect of fosmidomycin on the biosynthesis of each intermediate of this pathway and isoprenoid biosynthesis (dolichols and ubiquinones). For the first time, therefore, it is demonstrated that the MEP pathway is functionally active in all intraerythrocytic forms of P. falciparum, and de novo biosynthesis of pyridoxal in a protozoan is reported. Its absence in the human host makes both pathways very attractive as potential new targets for antimalarial drug development.	Univ Sao Paulo, Dept Parasitol, Inst Biomed Sci, BR-05508900 Sao Paulo, Brazil; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Univ Estadual Campinas, Inst Chem, Thomson Mass Spectrometry Lab, BR-13083970 Campinas, SP, Brazil	Universidade de Sao Paulo; Justus Liebig University Giessen; Universidade Estadual de Campinas	Katzin, AM (corresponding author), Univ Sao Paulo, Dept Parasitol, Inst Biomed Sci, Av Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.	amkatzin@icb.usp.br	Cassera, Maria/L-1572-2013; Almeida, Igor C./AAF-9409-2019; Gozzo, Fabio/F-8123-2010; Katzin, Alejandro/E-9862-2013; del Portillo, Hernando A/L-2131-2014; Eberlin, Marcos N/B-8106-2012; Wunderlich, Gerhard/G-8245-2012	Almeida, Igor C./0000-0002-2443-8213; Katzin, Alejandro/0000-0002-4782-2162; del Portillo, Hernando A/0000-0002-5278-3452; Wunderlich, Gerhard/0000-0003-1724-0337				Adam P, 2002, P NATL ACAD SCI USA, V99, P12108, DOI 10.1073/pnas.182412599; Aubouy A, 2003, ANTIMICROB AGENTS CH, V47, P231, DOI 10.1128/AAC.47.1.231-237.2003; Barkovich R, 2001, METAB ENG, V3, P27, DOI 10.1006/mben.2000.0168; Bauer JA, 2004, J BIOL CHEM, V279, P2704, DOI 10.1074/jbc.M310311200; Bouvier F, 1998, PLANT PHYSIOL, V117, P1423, DOI 10.1104/pp.117.4.1423; BRAUNBRETON C, 1986, MOL BIOCHEM PARASIT, V20, P33, DOI 10.1016/0166-6851(86)90140-4; Cane DE, 1999, J AM CHEM SOC, V121, P7722, DOI 10.1021/ja9914947; Cane DE, 2000, J AM CHEM SOC, V122, P4213, DOI 10.1021/ja000224h; Couto AS, 1999, BIOCHEM J, V341, P629, DOI 10.1042/0264-6021:3410629; CRANMER SL, 1995, J BIOL CHEM, V270, P15045, DOI 10.1074/jbc.270.25.15045; de Macedo CS, 2002, FEMS MICROBIOL LETT, V207, P13, DOI 10.1111/j.1574-6968.2002.tb11021.x; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Ehrenshaft M, 2001, J BACTERIOL, V183, P3383, DOI 10.1128/JB.183.11.3383-3390.2001; Eisenreich W, 2001, TRENDS PLANT SCI, V6, P78, DOI 10.1016/S1360-1385(00)01812-4; Eisenreich W, 1998, CHEM BIOL, V5, pR221, DOI 10.1016/S1074-5521(98)90002-3; Elliott JL, 2001, BIOCHEM J, V355, P733, DOI 10.1042/bj3550733; Ershov YV, 2002, J BACTERIOL, V184, P5045, DOI 10.1128/JB.184.18.5045-5051.2002; Fellermeier M, 2003, PHYTOCHEMISTRY, V64, P199, DOI 10.1016/S0031-9422(03)00197-3; Fellermeier MA, 1998, FEBS LETT, V437, P278, DOI 10.1016/S0014-5793(98)01250-2; Fevre EM, 1999, ANN TROP MED PARASIT, V93, P549, DOI 10.1080/00034989958050; FLESCH G, 1988, EUR J BIOCHEM, V175, P405, DOI 10.1111/j.1432-1033.1988.tb14210.x; Galperin MY, 1997, MOL MICROBIOL, V24, P443, DOI 10.1046/j.1365-2958.1997.3671706.x; Giner JL, 1998, CHEM COMMUN, P1857, DOI 10.1039/a804461i; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hecht S, 2001, P NATL ACAD SCI USA, V98, P14837, DOI 10.1073/pnas.201399298; Herz S, 2000, P NATL ACAD SCI USA, V97, P2486, DOI 10.1073/pnas.040554697; Hill RE, 1996, J BIOL CHEM, V271, P30426, DOI 10.1074/jbc.271.48.30426; Hintz M, 2001, FEBS LETT, V509, P317, DOI 10.1016/S0014-5793(01)03191-X; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kimura EA, 1996, J BIOL CHEM, V271, P14452, DOI 10.1074/jbc.271.24.14452; KIRCHMEIER RL, 1978, J PHARM SCI, V67, P1444, DOI 10.1002/jps.2600671032; Kitajima J, 2003, PHYTOCHEMISTRY, V62, P115, DOI 10.1016/S0031-9422(02)00438-7; Kuzuyama T, 2000, J BACTERIOL, V182, P891, DOI 10.1128/JB.182.4.891-897.2000; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P4509, DOI 10.1016/S0040-4039(98)00802-8; LAM HM, 1990, J BACTERIOL, V172, P6518, DOI 10.1128/jb.172.11.6518-6528.1990; LAM HM, 1992, J BACTERIOL, V174, P6033, DOI 10.1128/JB.174.19.6033-6045.1992; LAM HM, 1992, J BACTERIOL, V174, P1554, DOI 10.1128/jb.174.5.1554-1567.1992; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lange BM, 1999, ARCH BIOCHEM BIOPHYS, V365, P170, DOI 10.1006/abbi.1999.1168; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; Lell B, 2003, ANTIMICROB AGENTS CH, V47, P735, DOI 10.1128/AAC.47.2.735-738.2003; Lichtenthaler HK, 1997, PHYSIOL PLANTARUM, V101, P643, DOI 10.1111/j.1399-3054.1997.tb01049.x; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; Luttgen H, 2000, P NATL ACAD SCI USA, V97, P1062, DOI 10.1073/pnas.97.3.1062; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Monkkonen H, 2000, J CHROMATOGR B, V738, P395, DOI 10.1016/S0378-4347(99)00559-9; Moore SA, 2002, LANCET INFECT DIS, V2, P737, DOI 10.1016/S1473-3099(02)00451-6; OKAMOTO T, 1985, J CHROMATOGR, V342, P35, DOI 10.1016/S0378-4347(00)84487-4; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; Poliquin K, 2004, J BACTERIOL, V186, P4685, DOI 10.1128/JB.186.14.4685-4693.2004; Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843; Rioli V, 2003, J BIOL CHEM, V278, P8547, DOI 10.1074/jbc.M212030200; ROA BB, 1989, J BACTERIOL, V171, P4767, DOI 10.1128/jb.171.9.4767-4777.1989; Rodriguez-Concepcion M, 2002, PLANT PHYSIOL, V130, P1079, DOI 10.1104/pp.007138; Rohdich F, 2002, P NATL ACAD SCI USA, V99, P1158, DOI 10.1073/pnas.032658999; Rohdich F, 2001, EUR J BIOCHEM, V268, P3190, DOI 10.1046/j.1432-1327.2001.02204.x; Rohdich F, 1999, P NATL ACAD SCI USA, V96, P11758, DOI 10.1073/pnas.96.21.11758; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Sabino AA, 2004, ANGEW CHEM INT EDIT, V43, P2514, DOI 10.1002/anie.200353076; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Schwender J, 1999, FEBS LETT, V455, P140, DOI 10.1016/S0014-5793(99)00849-2; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Wetzel DK, 2004, FEBS LETT, V564, P143, DOI 10.1016/S0014-5793(04)00329-1; WHITE RH, 1978, BIOCHEMISTRY-US, V17, P3833, DOI 10.1021/bi00611a024; Wiesner J, 2002, ANTIMICROB AGENTS CH, V46, P2889, DOI 10.1128/AAC.46.9.2889-2894.2002; Wolff M, 2002, TETRAHEDRON LETT, V43, P2555, DOI 10.1016/S0040-4039(02)00293-9	73	98	99	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51749	51759		10.1074/jbc.M408360200	http://dx.doi.org/10.1074/jbc.M408360200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452112	hybrid			2022-12-25	WOS:000225493400007
J	Pandey, RR; Ceribelli, M; Singh, PB; Ericsson, J; Mantovani, R; Kanduri, C				Pandey, RR; Ceribelli, M; Singh, PB; Ericsson, J; Mantovani, R; Kanduri, C			NF-Y regulates the antisense promoter, bidirectional silencing, and differential epigenetic marks of the Kcnq1 imprinting control region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BECKWITH-WIEDEMANN-SYNDROME; DE-NOVO METHYLATION; BINDING PROTEINS; RNA; DNA; TRANSCRIPTION; COMPONENTS; MOUSE; H19	Antisense transcription has been shown to be one of the hierarchies that control gene expression in eukaryotes. Recently, we have documented that the mouse Kcnq1 imprinting control region (ICR) harbors bidirectional silencing property, and this feature is linked to an antisense RNA, Kcnq1ot1. In this investigation, using genomic footprinting, we have identified three NF-Y transcription factor binding sites appearing in a methylation-sensitive manner in the Kcnq1ot1 promoter. By employing a dominant negative mutant to the NF-Y transcription factor, we have shown that the NF-Y transcription factor positively regulates antisense transcription. Selective mutation of the conserved nucleotides in the NF-Y binding sites resulted in the loss of antisense transcription. The loss of antisense transcription from the Kcnq1ot1 promoter coincides with an enrichment in the levels of deacetylation and methylation at the lysine 9 residue of histone H3 and DNA methylation at the CpG residues, implying a crucial role for the NF-Y transcription factor in organizing the parent of origin-specific chromatin conformation in the Kcnq1 ICR. Parallel to the loss of antisense transcription, the loss of silencing of the flanking reporter genes was observed, suggesting that NF-Y-mediated Kcnq1ot1 transcription is critical in the bidirectional silencing process of the Kcnq1 ICR. These data highlight the NF-Y transcription factor as a crucial regulator of antisense promoter-mediated bidirectional silencing and the parent of origin-specific epigenetic marks at the Kcnq1 ICR. More importantly, for the first time, we document that NF-Y is involved in maintaining the antisense promoter activity against strong silencing conditions.	Uppsala Univ, Evolutionary Biol Centrum, Dept Genet & Dev, SE-75236 Uppsala, Sweden; Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy; Roslin Inst, Div Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland; Ludwig Inst Canc Res, Ctr Biomed, Gene Express Lab, S-75124 Uppsala, Sweden	Uppsala University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Ludwig Institute for Cancer Research	Kanduri, C (corresponding author), Uppsala Univ, Evolutionary Biol Centrum, Dept Genet & Dev, Norbyvagen 18A, SE-75236 Uppsala, Sweden.	kanduri.chandrasekhar@ebc.uu.se	Ericsson, Johan/AAA-6664-2020; Pandey, Radha Raman/AAQ-8593-2020; Singh, Prim/G-1088-2014	Ericsson, Johan/0000-0003-1186-6574; Pandey, Radha Raman/0000-0002-4439-8386; Singh, Prim/0000-0002-9571-0974; Kanduri, Chandrasekhar/0000-0001-6271-9078				Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Chandrasekhar K, 1997, MOL REPROD DEV, V48, P421; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Du MJ, 2004, GENOMICS, V84, P288, DOI 10.1016/j.ygeno.2004.03.008; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Grange T, 1997, METHODS, V11, P151, DOI 10.1006/meth.1996.0401; INAMDAR NM, 1991, PLANT MOL BIOL, V17, P111, DOI 10.1007/BF00036811; Jeffery L, 2004, J BIOL CHEM, V279, P49479, DOI 10.1074/jbc.M409070200; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; Kanduri C, 2002, CANCER RES, V62, P4545; Kanduri C, 2002, J BIOL CHEM, V277, P18106, DOI 10.1074/jbc.M200031200; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lavorgna G, 2004, TRENDS BIOCHEM SCI, V29, P88, DOI 10.1016/j.tibs.2003.12.002; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Thakur N, 2004, MOL CELL BIOL, V24, P7855, DOI 10.1128/MCB.24.18.7855-7862.2004; Thakur N, 2003, J BIOL CHEM, V278, P9514, DOI 10.1074/jbc.M212203200; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808	23	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52685	52693		10.1074/jbc.M408084200	http://dx.doi.org/10.1074/jbc.M408084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459184	hybrid			2022-12-25	WOS:000225493400115
J	Torban, E; Wang, HJ; Groulx, N; Gros, P				Torban, E; Wang, HJ; Groulx, N; Gros, P			Independent mutations in mouse Vangl2 that cause neural tube defects in looptail mice impair interaction with members of the Dishevelled family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR CELL-POLARITY; DROSOPHILA TISSUE POLARITY; PDZ DOMAINS; CONVERGENT EXTENSION; SIGNALING PATHWAYS; NATURAL-RESISTANCE; GENE; STRABISMUS; PROTEIN; GASTRULATION	Mammalian Vangl1 and Vangl2 are highly conserved membrane proteins that have evolved from a single ancestral protein Strabismus/Van Gogh found in Drosophila. Mutations in the Vangl2 gene cause a neural tube defect (craniorachischisis) characteristic of the looptail (Lp) mouse. Studies in model organisms indicate that Vangl proteins play a key developmental role in establishing planar cell polarity (PCP) and in regulating convergent extension (CE) movements during embryogenesis. The role of Vangl1 in these processes is virtually unknown, and the molecular function of Vangl1 and Vangl2 in PCP and CE is poorly understood. Using a yeast two-hybrid system, glutathione S-transferase pull-down and co-immunoprecipitation assays, we show that both mouse Vangl1 and Vangl2 physically interact with the three members of the cytoplasmic Dishevelled (Dvl) protein family. This interaction is shown to require both the predicted cytoplasmic C-terminal half of Vangl1/2 and a portion of the Dvl protein containing PDZ and DIX domains. In addition, we show that the two known Vangl2 loss-of-function mutations identified in two independent Lp alleles associated with neural tube defects impair binding to Dvl1, Dvl2, and Dvl3. These findings suggest a molecular mechanism for the neural tube defect seen in Lp mice. Our observations indicate that Vangl1 biochemical properties parallel those of Vangl2 and that Vangl1 might, therefore, participate in PCP and CE either in concert with Vangl2 or independently of Vangl2 in discrete cell types.	McGill Univ, Dept Biochem, Ctr Host Resistance, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Gros, P (corresponding author), McGill Univ, Dept Biochem, Ctr Host Resistance, 3655 Drummond St,Rm 907, Montreal, PQ H3G 1Y6, Canada.	philippe.gros@mcgill.ca						Axelrod JD, 2001, GENE DEV, V15, P1182; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bastock R, 2003, DEVELOPMENT, V130, P3007, DOI 10.1242/dev.00526; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Carreira-Barbosa F, 2003, DEVELOPMENT, V130, P4037, DOI 10.1242/dev.00567; Chae J, 1999, DEVELOPMENT, V126, P5421; Copp AJ, 2003, NAT REV GENET, V4, P784, DOI 10.1038/nrg1181; Courville P, 2004, J BIOL CHEM, V279, P3318, DOI 10.1074/jbc.M309913200; Curtin JA, 2003, CURR BIOL, V13, P1129, DOI 10.1016/S0960-9822(03)00374-9; Darken RS, 2002, EMBO J, V21, P976, DOI 10.1093/emboj/21.5.976; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fanto M, 2004, J CELL SCI, V117, P527, DOI 10.1242/jcs.00973; Frey L, 2003, EPILEPSIA, V44, P4, DOI 10.1046/j.1528-1157.44.s3.2.x; Goto T, 2002, DEV BIOL, V247, P165, DOI 10.1006/dbio.2002.0673; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Gubb D, 1999, GENE DEV, V13, P2315, DOI 10.1101/gad.13.17.2315; Hamblet NS, 2002, DEVELOPMENT, V129, P5827, DOI 10.1242/dev.00164; Jenny A, 2003, EMBO J, V22, P4409, DOI 10.1093/emboj/cdg424; Jessen JR, 2004, GENE EXPR PATTERNS, V4, P339, DOI 10.1016/j.modgep.2003.09.012; Jessen JR, 2002, NAT CELL BIOL, V4, P610, DOI 10.1038/ncb828; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; Katoh M, 2002, INT J MOL MED, V10, P11; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Kibar Z, 2003, GENOMICS, V82, P397, DOI 10.1016/S0888-7543(03)00113-7; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Kibar Z, 2001, GENOMICS, V72, P331, DOI 10.1006/geno.2000.6493; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Penton A, 2002, GENETICS, V161, P747; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Takeuchi M, 2003, CURR BIOL, V13, P674, DOI 10.1016/S0960-9822(03)00245-8; Taylor J, 1998, GENETICS, V150, P199; THEISEN H, 1994, DEVELOPMENT, V120, P347; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; van Ham M, 2003, MOL BIOL REP, V30, P69, DOI 10.1023/A:1023941703493; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vidal SM, 1996, J IMMUNOL, V157, P3559; Wallingford JB, 2002, DEVELOPMENT, V129, P5815, DOI 10.1242/dev.00123; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wolff T, 1998, DEVELOPMENT, V125, P1149	50	131	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52703	52713		10.1074/jbc.M408675200	http://dx.doi.org/10.1074/jbc.M408675200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456783	hybrid			2022-12-25	WOS:000225493400117
J	Engel, K; Zhou, MY; Wang, J				Engel, K; Zhou, MY; Wang, J			Identification and characterization of a novel monoamine transporter in the human brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRANSPORTER; NUCLEUS-ACCUMBENS; SEROTONIN; DOPAMINE; CLONING; EXPRESSION; PLASTICITY; COCAINE; KIDNEY; OCT3	Precise control of monoamine neurotransmitter levels in the extracellular fluids of the brain is critical in maintaining efficient and robust neurotransmission. High affinity transporters in the solute carrier SLC6A family function in removing monoamines from the neurosynaptic cleft. Emerging evidence suggests that these transporters are only one part of a system of transporters that work in concert to maintain brain homeostasis of monoamines. Here we report the cloning and characterization of a new human plasma membrane monoamine transporter, PMAT. The PMAT cDNA encodes a protein of 530 amino acid residues with 10 - 12 transmembrane segments. PMAT is not homologous to known neurotransmitter transporters but exhibits low homology to members of the equilibrative nucleoside transporter family. When expressed in Madin-Darby canine kidney cells and Xenopus laevis oocytes, PMAT efficiently transports serotonin (K-m = 114 muM), dopamine (K-m = 329 muM), and the neurotoxin 1-methyl-4-phenylpyridinium (K-m = 33 muM). In contrast, there is no significant interaction of PMAT with nucleosides or nucleobases. PMAT-mediated monoamine transport does not require Na+ or Cl- but appears to be sensitive to changes in membrane potential. Northern blot analysis showed that PMAT is predominantly expressed in the human brain and widely distributed in the central nervous system. These studies demonstrate that PMAT may be a novel low affinity transporter for biogenic amines, which, under certain conditions, might supplement the role of the high affinity transporters in the brain.	Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Wang, J (corresponding author), Univ Washington, Dept Pharmaceut, H272J,Hlth Sci Bldg, Seattle, WA 98195 USA.	jowang@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066233] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066233, GM66233] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; BLAKELY RD, 1994, J EXP BIOL, V196, P263; Brown P, 2000, J NEUROSCI, V20, P1952; Bunin MA, 1998, J NEUROSCI, V18, P4854; CARLSSON A, 1987, ANNU REV NEUROSCI, V10, P19; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Grundemann D, 1998, NAT NEUROSCI, V1, P349, DOI 10.1038/1557; GU H, 1994, J BIOL CHEM, V269, P7124; Inazu M, 1999, LIFE SCI, V64, P2239, DOI 10.1016/S0024-3205(99)00175-7; IZENWASSER S, 1990, BRAIN RES, V520, P303, DOI 10.1016/0006-8993(90)91719-W; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Koepsell H, 2004, PFLUG ARCH EUR J PHY, V447, P666, DOI 10.1007/s00424-003-1089-9; Kong W, 2004, CURR DRUG METAB, V5, P63, DOI 10.2174/1389200043489162; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; MIREYLEES SE, 1986, BIOCHEM PHARMACOL, V35, P4065, DOI 10.1016/0006-2952(86)90029-8; Pan YJ, 2001, DEV BRAIN RES, V126, P125, DOI 10.1016/S0165-3806(00)00145-0; PAULMICHL M, 1985, PFLUG ARCH EUR J PHY, V405, P102, DOI 10.1007/BF00584529; Ravary A, 2001, EUR J NEUROSCI, V13, P1349, DOI 10.1046/j.0953-816x.2001.1511.x; Reyes-Haro D, 2003, J NEUROSCI RES, V74, P97, DOI 10.1002/jnr.10724; Sora I, 2001, P NATL ACAD SCI USA, V98, P5300, DOI 10.1073/pnas.091039298; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; Wayment HK, 2001, J NEUROSCI, V21, P35, DOI 10.1523/JNEUROSCI.21-01-00035.2001; Wu X, 1998, J BIOL CHEM, V273, P32776, DOI 10.1074/jbc.273.49.32776; Wu XA, 2000, AM J PHYSIOL-RENAL, V279, pF449, DOI 10.1152/ajprenal.2000.279.3.F449; Wu XH, 1999, GENE, V233, P163, DOI 10.1016/S0378-1119(99)00143-2	31	206	213	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50042	50049		10.1074/jbc.M407913200	http://dx.doi.org/10.1074/jbc.M407913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15448143	hybrid			2022-12-25	WOS:000225229500062
J	Liao, P; Yu, DJ; Lu, SQ; Tang, ZZ; Liang, MC; Zeng, SH; Lin, WM; Soong, TW				Liao, P; Yu, DJ; Lu, SQ; Tang, ZZ; Liang, MC; Zeng, SH; Lin, WM; Soong, TW			Smooth muscle-selective alternatively spliced exon generates functional variation in Ca(v)1.2 calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; CA2+ CHANNELS; ALPHA(1C) SUBUNIT; ALPHA-1 SUBUNIT; CURRENT-DENSITY; N-TERMINUS; INACTIVATION; MODULATION; EXPRESSION; LOCALIZATION	Voltage-gated calcium channels play a major role in many important processes including muscle contraction, neurotransmission, excitation-transcription coupling, and hormone secretion. To date, 10 calcium channel alpha(1)-subunits have been reported, of which four code for L-type calcium channels. In our previous work, we uncovered by transcript-scanning the presence of 19 alternatively spliced exons in the L-type Ca(v)1.2 alpha(1)-subunit. Here, we report the smooth muscle-selective expression of alternatively spliced exon 9* in Ca(v)1.2 channels found on arterial smooth muscle. Specific polyclonal antibody against exon 9* localized the intense expression of 9*-containing Ca(v)1.2 channels on the smooth muscle wall of arteries, but the expression on cardiac muscle was low. Whole-cell patch clamp recordings of the 9*-containing Ca(v)1.2 channels in HEK293 cells demonstrated -9 and -11-mV hyperpolarized shift in voltage-dependent activation and current-voltage relationships, respectively. The steady-state inactivation property and sensitivity to blockade by nifedipine of the +/-exon 9* splice variants were, however, not significantly different. Such cell-selective expression of an alternatively spliced exon strongly indicates the customization and fine tuning of calcium channel functions through alternative splicing of the pore-forming alpha(1)-subunit. The generation of proteomic variations by alternative splicing of the calcium channel Ca(v)1.2 alpha(1)-subunit can potentially provide a flexible mechanism for muscle or neuronal cells to respond to various physiological signals or to diseases.	Natl Univ Singapore, Dept Physiol, Fac Med, Singapore 117597, Singapore; Natl Inst Neurosci, Singapore 308433, Singapore; Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; Ngee Ann Polytech, Singapore 599489, Singapore	National University of Singapore; National Neuroscience Institute (NNI); Johns Hopkins University	Soong, TW (corresponding author), Natl Univ Singapore, Dept Physiol, Fac Med, Blk MD9,2 Med Dr, Singapore 117597, Singapore.	phsstw@nus.edu.sg		Soong, Tuck Wah/0000-0002-0876-0325; Liang, Mui Cheng/0000-0003-1208-0733				Abernethy DR, 2002, J PHARMACOL EXP THER, V300, P724, DOI 10.1124/jpet.300.3.724; Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Bielefeldt K, 1999, J LAB CLIN MED, V133, P469, DOI 10.1016/S0022-2143(99)90024-0; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; HADLEY RW, 1991, J GEN PHYSIOL, V98, P265, DOI 10.1085/jgp.98.2.265; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Jaggar JH, 1998, ACTA PHYSIOL SCAND, V164, P577; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Kollmar R, 1997, P NATL ACAD SCI USA, V94, P14889, DOI 10.1073/pnas.94.26.14889; Ludwig A, 1997, J NEUROSCI, V17, P1339; MA WJ, 1992, J BIOL CHEM, V267, P22728; Mankodi A, 2002, MOL CELL, V10, P35, DOI 10.1016/S1097-2765(02)00563-4; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mittman S, 1999, NEUROSCI LETT, V269, P121, DOI 10.1016/S0304-3940(99)00319-5; Mittman S, 1999, NEUROSCI LETT, V274, P143, DOI 10.1016/S0304-3940(99)00716-8; NELSON MT, 1988, NATURE, V336, P382, DOI 10.1038/336382a0; Perets T, 1996, FEBS LETT, V384, P189, DOI 10.1016/0014-5793(96)00303-1; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Safa P, 2001, J BIOL CHEM, V276, P38727, DOI 10.1074/jbc.M103724200; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; Sinnegger-Brauns MJ, 2004, J CLIN INVEST, V113, P1430, DOI 10.1172/JCI200420208; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Soong TW, 2002, J NEUROSCI, V22, P10142; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; Tang ZZ, 2004, J BIOL CHEM, V279, P44335, DOI 10.1074/jbc.M407023200; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; Yang YB, 2000, J MOL CELL CARDIOL, V32, P973, DOI 10.1006/jmcc.2000.1138; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	44	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50329	50335		10.1074/jbc.M409436200	http://dx.doi.org/10.1074/jbc.M409436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15381693	hybrid			2022-12-25	WOS:000225229500096
J	Masri, B; Morin, N; Cornu, M; Knibiehler, B; Audigier, Y				Masri, B; Morin, N; Cornu, M; Knibiehler, B; Audigier, Y			Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells	FASEB JOURNAL			English	Article						G protein-coupled receptor; transduction; mouse	PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSLATIONAL CONTROL; SIGNALING PATHWAYS; HUMAN APJ; IN-VITRO; X-MSR	We report here that apelin (65-77) activates p70 S6 kinase (p70S6K), not only in CHO cells that have been stably transfected with the apelin receptor, but also in umbilical endothelial cells ( HUVEC), which express it endogenously. Apelin (65-77) induces a time-dependent phosphorylation of p70S6K at residues T421/S424 and T389. This dual phosphorylation is associated with two transduction cascades, involving a PI3K pathway and an ERK pathway, respectively. The PI3K pathway, which can be blocked by wortmannin, leads to phosphorylation of Akt at residues T308 or S473, which then promotes the phosphorylation of p70S6K at T421/S424 and T389. The ERK pathway is blocked by PD 098059, a MEK inhibitor, and results in the phosphorylation of p70S6K at T421/S424. Phosphorylation both of Akt and p70S6K is abrogated by pretreatment with pertussis toxin (PTX) and an inhibitor of atypical PKCs. In addition, we demonstrate that apelin (65-77) also increases the enzymatic activity of p70S6K and that the effects of the previously mentioned inhibitors on the level of T389 phosphorylation correlate with their action on enzyme activity. Interestingly, the main findings were reproduced in umbilical endothelial cells and apelin (65-77) promoted thymidine incorporation into DNA of these cells, revealing that apelin is a new mitogenic peptide for the endothelial cell.	CHU Rangueil, TSA 50032, INSERM, U589, F-31059 Toulouse 9, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Audigier, Y (corresponding author), CHU Rangueil, TSA 50032, INSERM, U589, 1 Ave Jean Poulhes, F-31059 Toulouse 9, France.	yaudig@toulouse.inserm.fr	Masri, Bernard/N-9856-2018	Masri, Bernard/0000-0002-4027-2604				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Devic E, 1996, MECH DEVELOP, V59, P129, DOI 10.1016/0925-4773(96)00585-0; Devic E, 1999, MECH DEVELOP, V84, P199, DOI 10.1016/S0925-4773(99)00081-7; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; Lehman JA, 2002, BIOCHEM BIOPH RES CO, V293, P463, DOI 10.1016/S0006-291X(02)00238-3; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Masri B, 2002, BIOCHEM BIOPH RES CO, V290, P539, DOI 10.1006/bbrc.2001.6230; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Sahni A, 1999, J BIOL CHEM, V274, P14936, DOI 10.1074/jbc.274.21.14936; Saint-Geniez M, 2002, MECH DEVELOP, V110, P183, DOI 10.1016/S0925-4773(01)00558-5; Saitoh M, 1998, BIOCHEM BIOPH RES CO, V253, P470, DOI 10.1006/bbrc.1998.9784; Seibenhener M L, 1999, Mol Cell Biol Res Commun, V2, P28, DOI 10.1006/mcbr.1999.0140; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wang GY, 2004, ENDOCRINOLOGY, V145, P1342, DOI 10.1210/en.2003-1116; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	54	174	191	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1909	+		10.1096/fj.04-1930fje	http://dx.doi.org/10.1096/fj.04-1930fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15385434				2022-12-25	WOS:000224243200015
J	Weinmann, M; Jendrossek, V; Guner, D; Goecke, B; Belka, C				Weinmann, M; Jendrossek, V; Guner, D; Goecke, B; Belka, C			Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways	FASEB JOURNAL			English	Article						apoptosis; selection; radiotherapy; chemotherapy	CYTOCHROME-C; DEATH; BCL-2; OXYGENATION; ACTIVATION; RADIATION; CASPASE-8; PROTEASE; CANCER; FADD	The negative influence of hypoxia on the outcome of malignant tumors may be caused by direct oxygen effects, and potentially, the selection of resistant tumor cells under repetitive hypoxia. To evaluate whether cyclic hypoxia selects for resistant cells and to analyze the underlying mechanisms, the influence of cyclic hypoxia on intracellular death pathways was determined in tumor cells. It could be demonstrated that cyclic hypoxia selects for cells with increased resistance against hypoxia-induced apoptosis. These cells exhibited a cross-resistance against paradigmatic triggers of mitochondrial apoptotic pathways (ionizing radiation/etoposide). In contrast, TRAIL-receptor mediated apoptosis remained unaffected. Thus, cyclic hypoxia selects for cells with defects of the mitochondrial rather than receptor-mediated pathways. Selection of p53-defective cells has been described as a consequence of cyclic hypoxia; therefore, we evaluated the impact of hypoxic selection on activation of p21 and downstream mediators of p53-dependent apoptosis. p53 function and protein levels of key mediators of mitochondrial apoptosis remained unaffected by hypoxic selection. However, radiation-induced conformational changes of Bax were reduced after cyclic hypoxia. In summary, it could be demonstrated that hypoxic stress confers a selection pressure on mitochondrial apoptotic pathways and, consecutively, to an increased resistance toward mitochondrial death triggers.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Charite, Dept Radiat Oncol, Berlin, Germany	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seylerstr 3, D-72076 Tubingen, Germany.	claus.belka@uni-uebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Belka C, 2003, STRAHLENTHER ONKOL, V179, P141, DOI 10.1007/s00066-003-1047-7; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; Brizel DM, 1996, CANCER RES, V56, P941; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 1996, CANCER RES, V56, P4509; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Kim CY, 1997, CANCER RES, V57, P4200; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; KISCHKEL FC, 2001, J BIOL CHEM, V2, P2; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Maecker HL, 2000, CANCER RES, V60, P4638; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Vaupel P, 1998, STRAHLENTHER ONKOL, V174, P6; VAUPEL P, 1987, CANCER RES, V47, P3496; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walenta S, 2000, CANCER RES, V60, P916; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; Weinmann M, 2004, ONCOGENE, V23, P3757, DOI 10.1038/sj.onc.1207481; Weinmann M, 2002, BRIT J CANCER, V86, P1355, DOI 10.1038/sj.bjc.6600237; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	45	52	52	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1906	+		10.1096/fj.04-1918fje	http://dx.doi.org/10.1096/fj.04-1918fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456741				2022-12-25	WOS:000224243200007
J	Firlej, V; Bocquet, B; Desbiens, X; de Launoit, Y; Chotteau-Lelievre, A				Firlej, V; Bocquet, B; Desbiens, X; de Launoit, Y; Chotteau-Lelievre, A			Pea3 transcription factor cooperates with USF-1 in regulation of the murine bax transcription without binding to an Ets-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND DEVELOPMENT; DUCT-LIKE STRUCTURES; ONCOGENE FAMILY; MOLECULAR-CLONING; EPITHELIAL-CELLS; BREAST-CANCER; DNA-BINDING; EXPRESSION PATTERNS; TUMOR-SUPPRESSOR; PROTEIN-PROTEIN	The Pea3 transcription factor (which belongs to the PEA3 group) from the Ets family has been shown to be involved in mammary embryogenesis and oncogenesis. However, except for proteinases, only few of its target genes have been reported. In the present report, we identified bax as a Pea3 up-regulated gene. We provide evidence of this regulation by using Pea3 overexpression and Pea3 silencing in a mammary cell line. Both Pea3 and Erm, another member of the PEA3 group, are able to transactivate bax promoter fragments. Although the minimal Pea3-regulated bax promoter does not contain an Ets-binding site, two functional upstream stimulatory factor-regulated E boxes are present. We further demonstrate the ability of Pea3 and USF-1 to cooperate for the transactivation of the bax promoter, mutation of the E boxes dramatically reducing the Pea3 transactivation potential. Although Pea3 did not directly bind to the minimal bax promoter, we provide evidence that USF-1 could form a ternary complex with Pea3 and DNA. Taken together, our results suggest that Pea3 may regulate bax transcription via the interaction with USF-1 but without binding to DNA.	Univ Sci & Technol Lille, Lab Biol Dev UPRES EA1033, F-59655 Villeneuve Dascq, France; Inst Pasteur, Inst Biol Lille, USTL, CNRS,UMR 8117, F-59021 Lille, France; ULB, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite Libre de Bruxelles	Chotteau-Lelievre, A (corresponding author), Univ Sci & Technol Lille, Lab Biol Dev UPRES EA1033, F-59655 Villeneuve Dascq, France.	anne.chotteau@ibl.fr	Bocquet, Beatrice/AAY-8447-2020; Firlej, Virginie/AFQ-6362-2022; Firlej, Virginie/R-2065-2018	Bocquet, Beatrice/0000-0002-6369-4818; Firlej, Virginie/0000-0003-4132-0695; 				Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bieche I, 2004, CARCINOGENESIS, V25, P405, DOI 10.1093/carcin/bgh024; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; Chen YL, 1999, MECH DEVELOP, V80, P67, DOI 10.1016/S0925-4773(98)00194-4; Chotteau-Lelievre A, 2004, CLIN CANCER RES, V10, P7297, DOI 10.1158/1078-0432.CCR-04-0593; Chotteau-Lelievre A, 2001, MECH DEVELOP, V108, P191, DOI 10.1016/S0925-4773(01)00480-4; Chotteau-Lelievre A, 2003, DEV BIOL, V259, P241, DOI 10.1016/S0012-1606(03)00182-9; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; COGNET M, 1991, J BIOL CHEM, V266, P7368; Coletta RD, 2004, J MAMMARY GLAND BIOL, V9, P39, DOI 10.1023/B:JOMG.0000023587.40966.f6; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Drevet JR, 1998, MOL REPROD DEV, V49, P131, DOI 10.1002/(SICI)1098-2795(199802)49:2<131::AID-MRD4>3.0.CO;2-Q; Egan BS, 1999, J BIOL CHEM, V274, P9098, DOI 10.1074/jbc.274.13.9098; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Habelhah H, 1999, ONCOGENE, V18, P1771, DOI 10.1038/sj.onc.1202465; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Irvin BJ, 2003, J BIOL CHEM, V278, P46378, DOI 10.1074/jbc.M305189200; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kurpios NA, 2003, J MAMMARY GLAND BIOL, V8, P177, DOI 10.1023/A:1025948823955; Laget MP, 1996, ONCOGENE, V12, P1325; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Liu YM, 2004, J BIOL CHEM, V279, P18694, DOI 10.1074/jbc.M308136200; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; Lynch CC, 2004, INT J ONCOL, V24, P1565; MIYASHITA T, 1995, CELL, V80, P293; MONTE D, 1994, ONCOGENE, V9, P1397; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Perez A, 2003, J BIOL CHEM, V278, P36942, DOI 10.1074/jbc.M300264200; Roehl H, 2001, CURR BIOL, V11, P503, DOI 10.1016/S0960-9822(01)00143-9; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Soriano JV, 1996, BIOCHEM BIOPH RES CO, V220, P879, DOI 10.1006/bbrc.1996.0499; SORIANO JV, 1995, J CELL SCI, V108, P413; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Wick W, 2001, J NEUROSCI, V21, P3360, DOI 10.1523/JNEUROSCI.21-10-03360.2001; Wick W, 1998, FEBS LETT, V440, P419, DOI 10.1016/S0014-5793(98)01494-X; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yan SQ, 2003, BIOL CHEM, V384, P1421, DOI 10.1515/BC.2003.157	66	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2005	280	2					887	898		10.1074/jbc.M408017200	http://dx.doi.org/10.1074/jbc.M408017200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	885ZF	15466854	hybrid			2022-12-25	WOS:000226195200007
J	Barney, BM; Igarashi, RY; Dos Santos, PC; Dean, DR; Seefeldt, LC				Barney, BM; Igarashi, RY; Dos Santos, PC; Dean, DR; Seefeldt, LC			Substrate interaction at an iron-sulfur face of the FeMo-cofactor during nitrogenase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; MOFE-PROTEIN; CLOSTRIDIUM-PASTEURIANUM; ACETYLENE-REDUCTION; MOLYBDENUM; DINITROGEN; BINDING; INTERMEDIATE; LOCALIZATION; CHROOCOCCUM	Nitrogenase catalyzes biological dinitrogen fixation, the reduction of N-2 to 2NH(3). Recently, the binding site for a non-physiological alkyne substrate (propargyl alcohol, HCequivalent toC-CH2OH) was localized to a specific Fe-S face of the FeMo-cofactor approached by the MoFe protein amino acid alpha-70(Val). Here we provide evidence to indicate that the smaller alkyne substrate acetylene (HCequivalent toCH), the physiological substrate dinitrogen, and its semi-reduced form hydrazine (H2N-NH2) interact with the same Fe-S face of the FeMo-cofactor. Hydrazine is a relatively poor substrate for the wild-type (alpha-70(Val)) MoFe protein. Substitution of the alpha-70(Val) residue by an amino acid having a smaller side chain (alanine) dramatically enhanced hydrazine reduction activity. Conversely, substitution of alpha-70(Val) by an amino acid having a larger side chain (isoleucine) significantly lowered the capacity of the MoFe protein to reduce dinitrogen, hydrazine, or acetylene.	Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Virginia Polytechnic Institute & State University; Utah System of Higher Education; Utah State University	Dean, DR (corresponding author), Virginia Tech, Dept Biochem, Blacksburg, VA 24061 USA.	deandr@vt.edu; seefeldt@cc.usu.edu	Barney, Brett M/A-6125-2013	Barney, Brett M/0000-0002-5976-5492; Seefeldt, Lance/0000-0002-6457-9504; Dos Santos, Patricia/0000-0002-3364-0931	NIGMS NIH HHS [GM-59087] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benton PMC, 2003, BIOCHEMISTRY-US, V42, P9102, DOI 10.1021/bi034595x; Benton PMC, 2001, J AM CHEM SOC, V123, P1822, DOI 10.1021/ja003662x; Benton PMC, 2001, BIOCHEMISTRY-US, V40, P13816, DOI 10.1021/bi011571m; Betley TA, 2003, J AM CHEM SOC, V125, P10782, DOI 10.1021/ja036687f; Chan JM, 1999, BIOCHEMISTRY-US, V38, P5779, DOI 10.1021/bi982866b; Christiansen J, 2000, PROKARYOTIC NITROGEN FIXATION, P101; Christiansen J, 2000, J BIOL CHEM, V275, P36104, DOI 10.1074/jbc.M004889200; Christiansen J, 2000, J BIOL CHEM, V275, P11459, DOI 10.1074/jbc.275.15.11459; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Cui Z, 2003, INORG CHEM, V42, P6252, DOI 10.1021/ic030108q; Dance I, 2003, CHEM COMMUN, P324, DOI 10.1039/b211036a; DAVIS LC, 1980, ARCH BIOCHEM BIOPHYS, V204, P270, DOI 10.1016/0003-9861(80)90033-8; DILWORTH MJ, 1991, BIOCHEM J, V277, P465, DOI 10.1042/bj2770465; DILWORTH MJ, 1966, BIOCHIM BIOPHYS ACTA, V127, P285, DOI 10.1016/0304-4165(66)90383-7; DILWORTH MJ, 1993, BIOCHEM J, V289, P395, DOI 10.1042/bj2890395; Durrant MC, 2002, BIOCHEMISTRY-US, V41, P13934, DOI 10.1021/bi025623z; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; Fisher K, 2000, BIOCHEMISTRY-US, V39, P15570, DOI 10.1021/bi0017834; HWANG JC, 1973, BIOCHIM BIOPHYS ACTA, V292, P256, DOI 10.1016/0005-2728(73)90270-3; Igarashi RY, 2004, J BIOL CHEM, V279, P34770, DOI 10.1074/jbc.M403194200; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; Lee HI, 2004, J AM CHEM SOC, V126, P9563, DOI 10.1021/ja048714n; Mayer SM, 2002, J CHEM SOC DALTON, P802, DOI 10.1039/b107336b; RIVERAORTIZ JM, 1975, J BACTERIOL, V123, P537, DOI 10.1128/JB.123.2.537-545.1975; Seefeldt LC, 2004, BIOCHEMISTRY-US, V43, P1401, DOI 10.1021/bi036038g; Smith JM, 2001, J AM CHEM SOC, V123, P9222, DOI 10.1021/ja016094+; THORNELEY RNF, 1978, NATURE, V272, P557, DOI 10.1038/272557a0; Vela J, 2004, J AM CHEM SOC, V126, P4522, DOI 10.1021/ja049417l; Yandulov DV, 2003, SCIENCE, V301, P76, DOI 10.1126/science.1085326	33	114	115	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53621	53624		10.1074/jbc.M410247200	http://dx.doi.org/10.1074/jbc.M410247200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465817	hybrid			2022-12-25	WOS:000225680600098
J	Chien, WW; Kumagai, T; Miller, CW; Desmond, JC; Frank, JM; Said, JW; Koeffler, HP				Chien, WW; Kumagai, T; Miller, CW; Desmond, JC; Frank, JM; Said, JW; Koeffler, HP			Cyr61 suppresses growth of human endometrial cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; CCN FAMILY; BREAST-CANCER; LUNG-CANCER; C-MYC; ENDOTHELIAL-CELLS; BCL-2 FAMILY; APOPTOSIS; DEATH; EXPRESSION	Cyr61 (CCN1) is a member of the CCN protein family; these secreted proteins are involved in diverse biological processes such as cell adhesion, angiogenesis, apoptosis, and either growth arrest or growth stimulation depending on the cellular context. We studied the role of Cyr61 in endometrial tumorigenesis. Levels of Cyr61 were decreased in endometrial tumors compared with normal endometrium. Knockdown of Cyr61 expression by RNA interference in a well differentiated endometrial adenocarcinoma cell line (Ishikawa) stimulated its cellular growth. Conversely, overexpression of the protein in the undifferentiated AN3CA endometrial cancer cell line decreased their growth concurrently with increased apoptosis in liquid culture. These same cells had decreased clonogenic capacity and a nearly complete loss of tumorigenicity in vivo. Furthermore, partially purified Cyr61 suppressed growth of endometrial cancer cells. The increased apoptosis in these endometrial cancer cells with forced overexpression of Cyr61 was associated with elevated expression of the pro-apoptotic proteins Bax, Bad, and TRAIL (tumor necrosis factor receptor-associated ligand). Cyr61-induced caspase-3 activation and depolarization of mitochondrial membrane. In summary, endometrial cancer cells have decreased expression of Cyr61 compared with normal endometrium, and this lowered expression may provide the transformed cells a growth advantage over their normal counterpart.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Hematol Oncol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chien, WW (corresponding author), Cedars Sinai Med Ctr, Dept Hematol Oncol, 110 George Burns Rd,D5065, Los Angeles, CA 90048 USA.	chienw@ucla.edu						Ahmed MS, 2004, J MOL CELL CARDIOL, V36, P393, DOI 10.1016/j.yjmcc.2003.12.004; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Brunelle JK, 2004, J BIOL CHEM, V279, P4305, DOI 10.1074/jbc.M312241200; Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Genini M, 1996, INT J CANCER, V66, P571; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hishikawa K, 2000, EUR J PHARMACOL, V392, P19, DOI 10.1016/S0014-2999(00)00115-1; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; KIHANA T, 1995, CANCER, V76, P72, DOI 10.1002/1097-0142(19950701)76:1<72::AID-CNCR2820760110>3.0.CO;2-3; Kim KH, 2003, J BIOL CHEM, V278, P13847, DOI 10.1074/jbc.M210128200; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Latinkic BV, 2001, ENDOCRINOLOGY, V142, P2549, DOI 10.1210/en.142.6.2549; Lea RG, 1999, AM J REPROD IMMUNOL, V42, P100; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Matias-Guiu X, 2001, HUM PATHOL, V32, P569, DOI 10.1053/hupa.2001.25929; McLaren J, 1997, HUM REPROD, V12, P146, DOI 10.1093/humrep/12.1.146; Muramatsu Y, 2002, KIDNEY INT, V62, P1601, DOI 10.1046/j.1523-1755.2002.00633.x; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Pilarsky CP, 1998, PROSTATE, V36, P85; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Sampath D, 2001, J CLIN ENDOCR METAB, V86, P1707, DOI 10.1210/jc.86.4.1707; Sasaki T, 2003, CANCER RES, V63, P801; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Secombe J, 2004, CELL, V117, P153, DOI 10.1016/S0092-8674(04)00336-8; Sheets EE, 1997, ANN MED, V29, P121, DOI 10.3109/07853899709113697; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; Spencer S J, 1996, Obstet Gynecol Surv, V51, P314, DOI 10.1097/00006254-199605000-00023; Tao XJ, 1997, J CLIN ENDOCR METAB, V82, P2738, DOI 10.1210/jc.82.8.2738; Tong XJ, 2004, ONCOGENE, V23, P4847, DOI 10.1038/sj.onc.1207628; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Xu LF, 2000, GENE DEV, V14, P585; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	47	83	98	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53087	53096		10.1074/jbc.M410254200	http://dx.doi.org/10.1074/jbc.M410254200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471875	hybrid			2022-12-25	WOS:000225680600036
J	Wachter, T; Sprick, M; Hausmann, D; Kerstan, A; McPherson, K; Stassi, G; Brocker, EB; Walczak, H; Leverkus, M				Wachter, T; Sprick, M; Hausmann, D; Kerstan, A; McPherson, K; Stassi, G; Brocker, EB; Walczak, H; Leverkus, M			cFLIP(L) inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappa B activation at the death-inducing signaling complex in human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN KINASE RIP; TNF RECEPTOR; CASPASE-8 ACTIVATION; GENE INDUCTION; CD95 LIGAND; C-FLIP; TRAIL; PROTEIN; FAS; EXPRESSION	Human keratinocytes undergo apoptosis following treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via surface-expressed TRAIL receptors 1 and 2. In addition, TRAIL triggers nonapoptotic signaling pathways including activation of the transcription factor NF-kappaB, in particular when TRAIL-induced apoptosis is blocked. The intracellular protein cFLIP(L) interferes with TRAIL-induced apoptosis at the death-inducing signaling complex (DISC) in many cell types. To study the role of cFLIP(L) in TRAIL signaling, we established stable HaCaT keratinocyte cell lines expressing varying levels of cFLIP(L). Functional analysis revealed that relative cFLIP(L) levels correlated with apoptosis resistance to TRAIL. Surprisingly, cFLIP(L) specifically blocked TRAIL-induced NF-kappaB activation and TRAIL-dependent induction of the proinflammatory target gene interleukin-8. Biochemical characterization of the signaling pathways involved showed that apoptosis signaling was inhibited at the DISC in cFLIP(L)-overexpressing keratinocytes, although cFLIP(L) did not significantly impair enzymatic activity of the receptor complex. In contrast, recruitment and modification of receptor-interacting protein was blocked in cFLIP(L)-overexpressing cells. Taken together, our data demonstrate that cFLIP(L) is not only a central antiapoptotic modulator of TRAIL-mediated apoptosis but also an inhibitor of TRAIL-induced NF-kappaB activation and subsequent proinflammatory target gene expression. Hence, cFLIP(L) modulation in keratinocytes may not only influence apoptosis sensitivity but may also lead to altered death receptor-dependent skin inflammation.	Univ Wurzburg, Sch Med, Dept Dermatol, D-97080 Wurzburg, Germany; Deutsch Krebsforschungszentrum, Dept Apoptosis Regulat D040, D-69120 Heidelberg, Germany; Univ Palermo, Lab Cellular & Mol Pathophysiol, Dept Surg & Oncol Sci, I-90127 Palermo, Italy	University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Palermo	Leverkus, M (corresponding author), Univ Wurzburg, Sch Med, Dept Dermatol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	leverkus_m@klinik.uni-wuerzburg.de	Stassi, Giorgio/AAC-1175-2022; Walczak, Henning/AAV-2214-2020; McPherson, Kirsty G/E-6331-2017; Sprick, Martin R./I-7995-2019; Sprick, Martin R./A-8611-2008	Walczak, Henning/0000-0002-6312-4591; McPherson, Kirsty G/0000-0003-3083-6303; Sprick, Martin R./0000-0001-9691-7574; Sprick, Martin R./0000-0001-9691-7574				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bachmann F, 2001, J INVEST DERMATOL, V117, P59, DOI 10.1046/j.0022-202x.2001.01380.x; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Fang LW, 2004, J BIOL CHEM, V279, P13, DOI 10.1074/jbc.M303860200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giannetti L, 2004, ONCOL REP, V11, P401; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grignani F, 1998, CANCER RES, V58, P14; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Koeplinger KA, 2000, PROTEIN EXPRES PURIF, V18, P378, DOI 10.1006/prep.2000.1205; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lavrik I, 2003, CELL DEATH DIFFER, V10, P144, DOI 10.1038/sj.cdd.4401156; Lee SH, 2003, APMIS, V111, P309, DOI 10.1034/j.1600-0463.2003.1110203.x; Leverkus M, 2000, BLOOD, V96, P2628; Leverkus M, 2000, CANCER RES, V60, P553; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; Li JH, 2003, J IMMUNOL, V171, P1526, DOI 10.4049/jimmunol.171.3.1526; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacFarlane M, 2003, TOXICOL LETT, V139, P89, DOI 10.1016/S0378-4274(02)00422-8; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Qin JZ, 2002, EXP DERMATOL, V11, P573, DOI 10.1034/j.1600-0625.2002.110610.x; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Sprick MR, 2004, BBA-MOL CELL RES, V1644, P125, DOI 10.1016/j.bbamcr.2003.11.002; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stassi G, 2000, NAT IMMUNOL, V1, P483, DOI 10.1038/82725; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Wajant H, 2004, VITAM HORM, V67, P101; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Weisfelner Michelle Emily, 2003, J Drugs Dermatol, V2, P385; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	71	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52824	52834		10.1074/jbc.M409554200	http://dx.doi.org/10.1074/jbc.M409554200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15459191	hybrid			2022-12-25	WOS:000225680600006
J	Yu, Q; Chen, D; Konig, R; Mariani, R; Unutmaz, D; Landau, NR				Yu, Q; Chen, D; Konig, R; Mariani, R; Unutmaz, D; Landau, NR			APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRION INFECTIVITY FACTOR; ANTIVIRAL ACTIVITY; VIF PROTEIN; HIV-1 VIF; CYTIDINE DEAMINASE; ENZYME APOBEC3G; IN-VIVO; DNA; HYPERMUTATION; DETERMINANT	In the human genome the apolipoprotein B mRNA-editing enzyme catalytic polypeptide ( APOBEC) 3 gene has expanded into a tandem array of genes termed APOBEC3A-G. Two members of this family, APOBEC3G and APOBEC3F, have been found to have potent activity against virion infectivity factor deficient (Deltavif) human immunodeficiency virus 1 (HIV-1). These enzymes become encapsidated in Deltavif HIV-1 virions and in the next round of infection deaminate the newly synthesized reverse transcripts. The lentiviral Vif protein prevents the deamination by inducing the degradation of APOBEC3G and APOBEC3F. We report here that two additional APOBEC3 family members, APOBEC3B and APOBEC3C, have potent antiviral activity against simian immunodeficiency virus (SIV), but not HIV-1. Both enzymes were encapsidated in HIV-1 and SIV virions and were active against Deltavif SIVmac and SIVagm. SIV Vif neutralized the antiviral activity of APOBEC3C, but not that of APOBEC3B. APOBEC3B induced abundant G --> A mutations in both wild-type and Deltavif SIV reverse transcripts. APOBEC3C induced substantially fewer mutations. APOBEC3F was found to be active against SIV and sensitive to SIVmac Vif. These findings raise the possibility that the different APOBEC3 family members function to neutralize specific lentiviruses.	Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA	Salk Institute; Vanderbilt University	Landau, NR (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Landau@salk.edu	König, Renate/AAB-8918-2019	König, Renate/0000-0003-4882-9179	NIAID NIH HHS [AI49131, AI58864] Funding Source: Medline; NIDA NIH HHS [DA14494] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058864, R01AI049131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014494] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Li JL, 2004, J CELL BIOCHEM, V92, P560, DOI 10.1002/jcb.20082; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Navarro F, 2004, CURR OPIN IMMUNOL, V16, P477, DOI 10.1016/j.coi.2004.05.006; Onishi M, 1996, EXP HEMATOL, V24, P324; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400; SAKAI H, 1993, J VIROL, V67, P1663, DOI 10.1128/JVI.67.3.1663-1666.1993; Schrofelbauer B, 2004, AIDS REV, V6, P34; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Sundrud MS, 2003, J IMMUNOL, V171, P3542, DOI 10.4049/jimmunol.171.7.3542; Suspene R, 2004, NUCLEIC ACIDS RES, V32, P2421, DOI 10.1093/nar/gkh554; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang JZ, 2004, HUM MOL GENET, V13, P1785, DOI 10.1093/hmg/ddh183; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	36	247	259	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53379	53386		10.1074/jbc.M408802200	http://dx.doi.org/10.1074/jbc.M408802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466872	hybrid			2022-12-25	WOS:000225680600071
J	Zhao, H; Russell, P				Zhao, H; Russell, P			DNA binding domain in the replication checkpoint protein Mrc1 of Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; FISSION YEAST; KINASES CDS1; IN-VITRO; DAMAGE; PHOSPHORYLATION; CLASPIN; ACTIVATION; REPAIR; CHK1	The replication checkpoint is activated when replication forks are obstructed by DNA lesions or protein complexes bound to DNA or when DNA synthesis is restrained by the limited availability of deoxyribonucleotides. This checkpoint preserves genome integrity by stabilizing stalled forks and delaying the onset of mitosis. In the fission yeast Schizosaccharomyces pombe, Mrc1 is a replication checkpoint adaptor protein that allows the sensor kinase Rad3-Rad26 to activate the effector kinase Cds1. In Saccharomyces cerevisiae, Mrc1 associates with replication forks and co-precipitates with the DNA replication protein Cdc45. Whether or not Mrc1 interacts directly with DNA is unknown. Here we define a similar to150 amino acid DNA binding domain (DBD) in the N-terminal region of S. pombe Mrc1. The DBD interacts preferentially with branched DNA structures in vitro. Deletion of the DBD or point mutations that diminish its DNA binding activity render cells sensitive to the replication inhibitor hydroxyurea. These mutations also impair the replication checkpoint arrest. The DBD has a helix-loop-helix motif that is predicted to bind DNA. This motif is conserved in the recently identified N-terminal DBD of human Claspin, a presumptive homolog of yeast Mrc1 proteins.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Russell, P (corresponding author), Scripps Res Inst, Dept Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	prussell@scripps.edu			NIGMS NIH HHS [GM59477] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Heyer WD, 2004, CURR BIOL, V14, pR56, DOI 10.1016/j.cub.2003.12.043; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Murakami H, 2002, NAT CELL BIOL, V4, P384, DOI 10.1038/ncb789; Nakamura TM, 2004, MOL CELL BIOL, V24, P6215, DOI 10.1128/MCB.24.14.6215-6230.2004; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Rhind N, 2001, MOL CELL BIOL, V21, P1499, DOI 10.1128/MCB.21.5.1499-1508.2001; Rhind N, 2000, J CELL SCI, V113, P3889; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; Tanaka K, 2004, J BIOL CHEM, V279, P32079, DOI 10.1074/jbc.M404834200; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tanaka K, 2001, MOL CELL BIOL, V21, P3398, DOI 10.1128/MCB.21.10.3398-3404.2001; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Willson J, 1997, NUCLEIC ACIDS RES, V25, P2138, DOI 10.1093/nar/25.11.2138; Xu H, 2004, MOL CELL BIOL, V24, P7082, DOI 10.1128/MCB.24.16.7082-7090.2004; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao H, 2003, MOL CELL BIOL, V23, P8395, DOI 10.1128/MCB.23.22.8395-8403.2003	34	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53023	53027		10.1074/jbc.M410449200	http://dx.doi.org/10.1074/jbc.M410449200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471884	hybrid			2022-12-25	WOS:000225680600028
J	Lamkanfi, M; Denecker, G; Kalai, M; D'hondt, K; Meeus, A; Declercq, W; Saelens, X; Vandenabeele, P				Lamkanfi, M; Denecker, G; Kalai, M; D'hondt, K; Meeus, A; Declercq, W; Saelens, X; Vandenabeele, P			INCA, a novel human caspase recruitment domain protein that inhibits interleukin-1 beta generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; GENE-EXPRESSION; MICE DEFICIENT; INFLAMMATORY CASPASES; CONVERTING-ENZYME; STRUCTURAL BASIS; SEPTIC SHOCK; ACTIVATION; APOPTOSIS; IL-1-BETA	Using in silico methods for screening the human genome for new caspase recruitment domain (CARD) proteins, we have identified INCA ( Inhibitory CARD) as a protein that shares 81% identity with the prodomain of caspase-1. The INCA gene is located on chromosome 11q22 between the genes of COP/Pseudo-ICE and ICEBERG, two other CARD proteins that arose from caspase-1 gene duplications. We show that INCA mRNA is expressed in many tissues. INCA is specifically upregulated by interferon-gamma in the monocytic cell lines THP-1 and U937. INCA physically interacts with procaspase-1 and blocks the release of mature IL-1beta from LPS-stimulated macrophages. Unlike COP/Pseudo-ICE and procaspase-1, INCA does not interact with RIP2 and does not induce NF-kappaB activation. Our data show that INCA is a novel intracellular regulator of procaspase-1 activation, involved in the regulation of pro-IL-1beta processing and its release during inflammation.	State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signalling & Cell Death, B-9052 Zwijnaarde, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Vandenabeele, P (corresponding author), State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signalling & Cell Death, Technol Pk 927, B-9052 Zwijnaarde, Belgium.	Peter.Vandenabeele@dmbr.UGent.be	Denecker, Geertrui/E-8134-2010; Vandenabeele, Peter/AAD-5793-2022; Vandenabeele, Peter/C-8597-2009; Saelens, Xavier/N-5728-2015	Vandenabeele, Peter/0000-0002-6669-8822; Denecker, Geertrui/0000-0002-2515-2911; , Xavier/0000-0002-3861-6965				Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Freeman BD, 2000, EXPERT OPIN INV DRUG, V9, P1651, DOI 10.1517/13543784.9.7.1651; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; HOPKINS SJ, 1989, J IMMUNOL METHODS, V120, P271, DOI 10.1016/0022-1759(89)90252-4; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lamkanfi M, 2004, J BIOL CHEM, V279, P24785, DOI 10.1074/jbc.M400985200; Lamkanfi M, 2004, CELL DEATH DIFFER, V11, P365, DOI 10.1038/sj.cdd.4401364; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; LAMKANFI M, 2003, CASPASES THEIR ROLE, P1; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; Netea MG, 2000, J IMMUNOL, V164, P2644, DOI 10.4049/jimmunol.164.5.2644; O'Reilly M, 1999, SHOCK, V12, P411, DOI 10.1097/00024382-199912000-00001; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Razmara M, 2002, J BIOL CHEM, V277, P13952, DOI 10.1074/jbc.M107811200; Sakao Y, 1999, INT IMMUNOL, V11, P471, DOI 10.1093/intimm/11.3.471; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Shornick LP, 1996, J EXP MED, V183, P1427, DOI 10.1084/jem.183.4.1427; Stehlik C, 2003, J BIOL CHEM, V278, P31941, DOI 10.1074/jbc.M300009200; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; VanCriekinge W, 1996, J BIOL CHEM, V271, P27245, DOI 10.1074/jbc.271.44.27245; VANDENABEELE P, 1990, LYMPHOKINE RES, V9, P381; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265	42	80	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51729	51738		10.1074/jbc.M407891200	http://dx.doi.org/10.1074/jbc.M407891200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15383541	hybrid			2022-12-25	WOS:000225493400004
J	Li, Q; Ching, AKK; Chan, BCL; Chow, SKY; Lim, PL; Ho, TCY; Ip, WK; Wong, CK; Lam, CWK; Lee, KKH; Chan, JYH; Chui, YL				Li, Q; Ching, AKK; Chan, BCL; Chow, SKY; Lim, PL; Ho, TCY; Ip, WK; Wong, CK; Lam, CWK; Lee, KKH; Chan, JYH; Chui, YL			A death receptor-associated anti-apoptotic protein, BRE, inhibits mitochondrial apoptotic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TRAIL-INDUCED APOPTOSIS; STRESS-MODULATING GENE; PROGRAMMED CELL-DEATH; MEDIATED APOPTOSIS; SIGNALING PATHWAYS; CD95 FAS/APO-1; BHRF1 PROTEIN; VIRUS ENCODES	BRE, brain and reproductive organ-expressed protein, was found previously to bind the intracellular juxtamembrane domain of a ubiquitous death receptor, tumor necrosis factor receptor 1 (TNF-R1), and to downregulate TNF-alpha-induced activation of NF-kappaB. Here we show that BRE also binds to another death receptor, Fas, and upon overexpression conferred resistance to apoptosis induced by TNF-alpha, anti-Fas agonist antibody, cycloheximide, and a variety of stress-related stimuli. However, down-regulation of the endogenous BRE by small interfering RNA increased apoptosis to TNF-alpha, but nottoetoposide, indicating that the physiological antiapoptotic role of this protein is specific to death receptor-mediated apoptosis. We further demonstrate that BRE mediates antiapoptosis by inhibiting the mitochondrial apoptotic machinery but without translocation to the mitochondria or nucleus or down-regulation of the cellular level of truncated Bid. Dissociation of BRE rapidly from TNF-R1, but not from Fas, upon receptor ligation suggests that this protein interacts with the death inducing signaling complex during apoptotic induction. Increased association of BRE with phosphorylated, sumoylated, and ubiquitinated proteins after death receptor stimulation was also detected. We conclude that in contrast to the truncated Bid that integrates mitochondrial apoptosis to death receptor-triggered apoptotic cascade, BRE inhibits the integration. We propose that BRE inhibits, by ubiquitination-like activity, components in or proximal to the death-inducing signaling complexes that are necessary for activation of the mitochondria.	Chinese Univ Hong Kong, Clin Immunol Unit, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Chem Pathol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Texas System; UTMD Anderson Cancer Center	Chui, YL (corresponding author), Chinese Univ Hong Kong, Clin Immunol Unit, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	yiuloonchui@cuhk.edu.hk	Wong, CK/H-3256-2016; Lee, Kenneth Ka Ho/H-6698-2013	Wong, CK/0000-0002-5637-8331; Lee, Kenneth Ka Ho/0000-0002-6520-304X; Chui, Yiu-Loon/0000-0002-3441-9729				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baier A, 2003, CURR OPIN RHEUMATOL, V15, P274, DOI 10.1097/00002281-200305000-00015; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Ching AKK, 2003, DNA CELL BIOL, V22, P497, DOI 10.1089/10445490360708900; Ching AKK, 2001, BIOCHEM BIOPH RES CO, V288, P535; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHINNAIYAN AM, 1995, CELL, V81, P512; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Dive C, 1992, Semin Cancer Biol, V3, P417; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Everett H, 2000, J EXP MED, V191, P1487, DOI 10.1084/jem.191.9.1487; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Foghsgaard L, 1997, J VIROL, V71, P7509, DOI 10.1128/JVI.71.10.7509-7517.1997; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gu CH, 1998, FASEB J, V12, P1101, DOI 10.1096/fasebj.12.12.1101; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kawanishi M, 1997, J VIROL, V71, P3319, DOI 10.1128/JVI.71.4.3319-3322.1997; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lee JC, 2003, IMMUNOL REV, V193, P39, DOI 10.1034/j.1600-065X.2003.00043.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI L, 1995, BIOCHEM BIOPH RES CO, V206, P764, DOI 10.1006/bbrc.1995.1108; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marshall WL, 1999, J VIROL, V73, P5181, DOI 10.1128/JVI.73.6.5181-5185.1999; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Miao J, 2001, J HISTOCHEM CYTOCHEM, V49, P491, DOI 10.1177/002215540104900409; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Okura T, 1996, J IMMUNOL, V157, P4277; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shchepina LA, 2002, ONCOGENE, V21, P8149, DOI 10.1038/sj.onc.1206053; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tollefson AE, 2001, J VIROL, V75, P8875, DOI 10.1128/JVI.75.19.8875-8887.2001; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XD, 2001, GENE DEV, V15, P2922; Wasilenko ST, 2003, P NATL ACAD SCI USA, V100, P14345, DOI 10.1073/pnas.2235583100; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	65	40	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52106	52116		10.1074/jbc.M408678200	http://dx.doi.org/10.1074/jbc.M408678200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465831	hybrid			2022-12-25	WOS:000225493400049
J	Wang, G; Conover, RC; Benoit, S; Olczak, AA; Olson, JW; Johnson, MK; Maier, RJ				Wang, G; Conover, RC; Benoit, S; Olczak, AA; Olson, JW; Johnson, MK; Maier, RJ			Role of a bacterial organic hydroperoxide detoxification system in preventing catalase inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI CATALASE; OXIDATIVE-STRESS RESISTANCE; UNSATURATED FATTY-ACIDS; NEUTROPHIL-ACTIVATING PROTEIN; THIOL-SPECIFIC ANTIOXIDANT; KATA-ASSOCIATED PROTEIN; HYDROGEN-PEROXIDE; HOST COLONIZATION; PSEUDOMONAS-AERUGINOSA; OXYGEN RADICALS	In the gastric pathogen Helicobacter pylori, catalase (KatA) and alkyl hydroperoxide reductase (AhpC) are two highly abundant enzymes that are crucial for oxidative stress resistance and survival of the bacterium in the host. Here we report a connection unidentified previously between the two stress resistance enzymes. We observed that the catalase in ahpC mutant cells in comparison with the parent strain is inactivated partially ( approximately 50%). The decrease of catalase activity is well correlated with the perturbation of the heme environment in catalase, as detected by electron paramagnetic resonance spectroscopy. To understand the reason for this catalase inactivation, we examined the inhibitory effects of hydroperoxides on H. pylori catalase ( either present in cell extracts or added to the purified enzyme) by monitoring the enzyme activity and the EPR signal of catalase. H. pylori catalase is highly resistant to its own substrate, without the loss of enzyme activity by treatment with a molar ratio of 1:3000 H2O2. However, it is inactivated by lower concentrations of organic hydroperoxides (the substrate of AhpC). Treatment with a molar ratio of 1:400 t-butyl hydroperoxide resulted in an inactivation of catalase by approximately 50%. UV-visible absorption spectra indicated that the catalase inactivation by organic hydroperoxides is caused by the formation of a catalytically incompetent compound II species. To further support the idea that organic hydroperoxides, which accumulate in the ahpC mutant cells, are responsible for the inactivation of catalase, we compared the level of lipid peroxidation found in ahpC mutant cells with that found in wild type cells. The results showed that the total amount of extractable lipid hydroperoxides in the ahpC mutant cells is approximately three times that in the wild type cells. Our findings reveal a novel role of the organic hydroperoxide detoxification system in preventing catalase inactivation.	Univ Georgia, Dept Microbiol, Athens, GA 30602 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Maier, RJ (corresponding author), Univ Georgia, Dept Microbiol, 805 Biol Sci Bldg, Athens, GA 30602 USA.	rmaier@uga.edu		Benoit, Stephane/0000-0002-9314-8586	NIDDK NIH HHS [1-R01-DK30061] Funding Source: Medline; NIGMS NIH HHS [GM62545] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; Bagchi D, 1996, FREE RADICAL RES, V24, P439, DOI 10.3109/10715769609088043; Baillon MLA, 1999, J BACTERIOL, V181, P4798, DOI 10.1128/JB.181.16.4798-4804.1999; Baker LMS, 2001, J BACTERIOL, V183, P1961, DOI 10.1128/JB.183.6.1961-1973.2001; Bereswill S, 1998, MICROBIOL-SGM, V144, P2505, DOI 10.1099/00221287-144-9-2505; BICOUT DJ, 1995, BBA-PROTEIN STRUCT M, V1252, P172, DOI 10.1016/0167-4838(95)00123-C; BIELSKI BHJ, 1983, J BIOL CHEM, V258, P4759; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Cooksley C, 2003, J MED MICROBIOL, V52, P461, DOI 10.1099/jmm.0.05070-0; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Harris AG, 2003, FEMS MICROBIOL LETT, V229, P283, DOI 10.1016/S0378-1097(03)00850-4; Harris AG, 2003, MICROBIOL-SGM, V149, P665, DOI 10.1099/mic.0.26012-0; Harris AG, 2002, MICROBIOL-SGM, V148, P3813, DOI 10.1099/00221287-148-12-3813; HAZELL SL, 1991, J GEN MICROBIOL, V137, P57, DOI 10.1099/00221287-137-1-57; HAZELL SL, 1990, J CLIN MICROBIOL, V28, P1060, DOI 10.1128/JCM.28.5.1060-1061.1990; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; Jungblut PR, 2000, MOL MICROBIOL, V36, P710, DOI 10.1046/j.1365-2958.2000.01896.x; KHULUSI S, 1995, J MED MICROBIOL, V42, P276, DOI 10.1099/00222615-42-4-276; Loewen PC, 2004, BIOCHEMISTRY-US, V43, P3089, DOI 10.1021/bi035663i; LOWEN P, 1997, OXIDATIVE STRESS MOL, P273; Lundstrom AM, 2000, MICROB PATHOGENESIS, V29, P257, DOI 10.1006/mpat.2000.0388; Ma JF, 1999, J BACTERIOL, V181, P3730, DOI 10.1128/JB.181.12.3730-3742.1999; Maniatis T., 1982, MOL CLONING LAB MANU; Miller RA, 1997, CLIN MICROBIOL REV, V10, P1; MOORE GR, 1994, BIOCHEM J, V304, P493, DOI 10.1042/bj3040493; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Nicholls P, 2001, ADV INORG CHEM, V51, P51; Odenbreit S, 1996, J BACTERIOL, V178, P6960, DOI 10.1128/jb.178.23.6960-6967.1996; Olczak AA, 2003, INFECT IMMUN, V71, P580, DOI 10.1128/IAI.71.1.580-583.2003; Olczak AA, 2002, J BACTERIOL, V184, P3186, DOI 10.1128/JB.184.12.3186-3193.2002; Radcliff FJ, 1997, INFECT IMMUN, V65, P4668, DOI 10.1128/IAI.65.11.4668-4674.1997; Ramarao N, 2000, MOL MICROBIOL, V38, P103, DOI 10.1046/j.1365-2958.2000.02114.x; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Seyler RW, 2001, INFECT IMMUN, V69, P4034, DOI 10.1128/IAI.69.6.4034-4040.2001; Storz G, 2000, BACTERIAL STRESS RESPONSES, P47; Tonello F, 1999, MOL MICROBIOL, V34, P238, DOI 10.1046/j.1365-2958.1999.01584.x; Wang G, 2004, INFECT IMMUN, V72, P1391, DOI 10.1128/IAI.72.3.1391-1396.2004; Windle HJ, 2000, J BIOL CHEM, V275, P5081, DOI 10.1074/jbc.275.7.5081; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zanotti G, 2002, J MOL BIOL, V323, P125, DOI 10.1016/S0022-2836(02)00879-3; [No title captured]	43	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51908	51914		10.1074/jbc.M408450200	http://dx.doi.org/10.1074/jbc.M408450200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456778	hybrid			2022-12-25	WOS:000225493400024
J	Zelenina, M; Tritto, S; Bondar, AA; Zelenin, S; Aperia, A				Zelenina, M; Tritto, S; Bondar, AA; Zelenin, S; Aperia, A			Copper inhibits the water and glycerol permeability of aquaporin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRINKING-WATER; CHANNEL; PROTEIN; ZINC; LOCALIZATION; TRANSPORT; AQP3	Aquaporin-3 (AQP3) is an aquaglyceroporin expressed in erythrocytes and several other tissues. Erythrocytes are, together with kidney and liver, the main targets for copper toxicity. Here we report that both water and glycerol permeability of human AQP3 is inhibited by copper. Inhibition is fast, dose-dependent, and reversible. If copper is dissolved in carbonic acid-bicarbonate buffer, the natural buffer system in our body, doses in the range of those observed in Wilson disease and in copper poisoning caused significant inhibition. AQP7, another aquaglyceroporin, was insensitive to copper. Three extracellular amino acid residues, Trp(128), Ser(152), and His(241), were identified as responsible for the effect of copper on AQP3. We have previously shown that Ser(152) is involved in regulation of AQP3 by pH. The fact that Ser(152) mediates regulation of AQP3 by copper may explain the phenomenon of exquisite sensitivity of human erythrocytes to copper at acidic pH. When AQP3 was co-expressed with another AQP, only glycerol but not water permeability was inhibited by copper. Our results provide a better understanding of processes that occur in severe copper metabolism defects such as Wilson disease and in copper poisoning.	Karolinska Inst, Dept Woman & Child Hlth, S-17177 Stockholm, Sweden; Russian Acad Sci, Inst Cytol & Genet, Lab Physiol Genet, Siberian Branch, Novosibirsk 630090, Russia; Univ Pavia, Dept Expt Med, Sect Human Physiol, I-27100 Pavia, Italy; Russian Acad Sci, Grp Funct Genom, Inst Chem Biol & Fundamental Med, Siberian Branch, Novosibirsk 630090, Russia	Karolinska Institutet; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; University of Pavia; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences	Aperia, A (corresponding author), Astrid Lindgren Childrens Hosp, Q2-09, S-17176 Stockholm, Sweden.	anita.aperia@kbh.ki.se	Tritto, Simona/A-5594-2013; Bondar, Alexander/AAA-7087-2020	Tritto, Simona/0000-0001-6629-3553; Bondar, Alexander/0000-0001-9181-0487				ALAM IA, 1989, ENVIRON POLLUT, V57, P167, DOI 10.1016/0269-7491(89)90008-0; Amancio OMS, 2003, EUR J CLIN NUTR, V57, P706, DOI 10.1038/sj.ejcn.1601601; Araya M, 2003, REGUL TOXICOL PHARM, V38, P389, DOI 10.1016/j.yrtph.2003.08.001; BAKER A, 1995, J HEPATOL, V23, P538, DOI 10.1016/0168-8278(95)80059-X; BASHIR NA, 1995, ANN TROP PAEDIATR, V15, P291, DOI 10.1080/02724936.1995.11747786; Bhattacharyya J, 2001, J PHYSIOL PHARMACOL, V52, P145; Bhowmik D, 2001, RENAL FAILURE, V23, P731, DOI 10.1081/JDI-100107371; Bremner I, 1998, AM J CLIN NUTR, V67, p1069S, DOI 10.1093/ajcn/67.5.1069S; CARLSEN A, 1976, ACTA PHYSIOL SCAND, V97, P501, DOI 10.1111/j.1748-1716.1976.tb10290.x; Coddou C, 2002, J NEUROCHEM, V80, P626, DOI 10.1046/j.0022-3042.2001.00732.x; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; Hoveyda N, 2003, J ENVIRON HEALTH, V66, P29; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Kajanachumpol Saowanee, 1997, Southeast Asian Journal of Tropical Medicine and Public Health, V28, P877; Kawahara S, 1998, Rinsho Ketsueki, V39, P665; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kuwahara M, 1997, BIOCHEMISTRY-US, V36, P13973, DOI 10.1021/bi9711442; Lee Je-Jung, 1998, Journal of Korean Medical Science, V13, P548; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; Liu JT, 2001, J TOXICOL-CLIN TOXIC, V39, P161, DOI 10.1081/CLT-100103832; Matsuzaki T, 1999, J HISTOCHEM CYTOCHEM, V47, P1275, DOI 10.1177/002215549904701007; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; Shim H, 2003, J NUTR, V133, p1527S, DOI 10.1093/jn/133.5.1527S; Tanner MS, 1998, AM J CLIN NUTR, V67, p1074S, DOI 10.1093/ajcn/67.5.1074S; Trombley PQ, 1996, J NEUROPHYSIOL, V76, P2536, DOI 10.1152/jn.1996.76.4.2536; Zelenina M, 2000, EUR BIOPHYS J BIOPHY, V29, P165, DOI 10.1007/PL00006645; Zelenina M, 2003, J BIOL CHEM, V278, P30037, DOI 10.1074/jbc.M302206200; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	33	106	113	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51939	51943		10.1074/jbc.M407645200	http://dx.doi.org/10.1074/jbc.M407645200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456785	hybrid			2022-12-25	WOS:000225493400028
J	Ishigaki, S; Hishikawa, N; Niwa, J; Iemura, S; Natsume, T; Hori, S; Kakizuka, A; Tanaka, K; Sobue, G				Ishigaki, S; Hishikawa, N; Niwa, J; Iemura, S; Natsume, T; Hori, S; Kakizuka, A; Tanaka, K; Sobue, G			Physical and functional interaction between Dorfin and Valosin-containing protein that are colocalized in ubiquitylated inclusions in neurodegenerative disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; RING-FINGER PROTEIN; ENDOPLASMIC-RETICULUM; ATPASE ACTIVITY; LEWY BODIES; UBIQUITIN; DISEASE; SYSTEM; GENE; VCP	Dorfin, a RING-IBR type ubiquitin ligase (E3), can ubiquitylate mutant superoxide dismutase 1, the causative gene of familial amyotrophic lateral sclerosis (ALS). Dorfin is located in ubiquitylated inclusions ( UBIs) in various neurodegenerative disorders, such as ALS and Parkinson's disease (PD). Here we report that Valosin-containing protein (VCP) directly binds to Dorfin and that VCP ATPase activity profoundly contributes to the E3 activity of Dorfin. High through-put analysis using mass spectrometry identified VCP as a candidate of Dorfin-associated protein. Glycerol gradient centrifugation analysis showed that endogenous Dorfin consisted of a 400 - 600-kDa complex and was co-immunoprecipitated with endogenous VCP. In vitro experiments showed that Dorfin interacted directly with VCP through its C-terminal region. These two proteins were colocalized in aggresomes in HEK293 cells and UBIs in the affected neurons of ALS and PD. VCPK524A, a dominant negative form of VCP, reduced the E3 activity of Dorfin against mutant superoxide dismutase 1, whereas it had no effect on the autoubiquitylation of Parkin. Our results indicate that VCPs functionally regulate Dorfin through direct interaction and that their functional interplay may be related to the process of UBI formation in neurodegenerative disorders, such as ALS or PD.	Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4668500, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Tokyo 1138613, Japan; Natl Inst Adv Sci & Technol, Biol Informat Res Ctr, Tokyo 1350064, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Funct Biol, Kyoto 6068502, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	Nagoya University; Tokyo Metropolitan Institute of Medical Science; National Institute of Advanced Industrial Science & Technology (AIST); Kyoto University; Japan Science & Technology Agency (JST)	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4668500, Japan.	sobueg@med.nagoya-u.ac.jp	ISHIGAKI, Shinsuke/I-7305-2014; Natsume, Tohru/M-7627-2018	Natsume, Tohru/0000-0002-1510-2582; Ishigaki, Shinsuke/0000-0002-9555-0659				Asai T, 2002, JPN J CANCER RES, V93, P296, DOI 10.1111/j.1349-7006.2002.tb02172.x; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dalal S, 2001, CELL, V104, P5, DOI 10.1016/S0092-8674(01)00186-6; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Hishikawa N, 2003, AM J PATHOL, V163, P609, DOI 10.1016/S0002-9440(10)63688-7; Ishigaki S, 2002, FEBS LETT, V531, P354, DOI 10.1016/S0014-5793(02)03546-9; Ishigaki S, 2002, J NEUROCHEM, V82, P576, DOI 10.1046/j.1471-4159.2002.00998.x; Ito T, 2003, J BIOL CHEM, V278, P29106, DOI 10.1074/jbc.M302763200; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kobayashi T, 2002, J BIOL CHEM, V277, P47358, DOI 10.1074/jbc.M207783200; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Matsuda N, 2001, J CELL SCI, V114, P1949; Matsumoto M, 2004, EMBO J, V23, P659, DOI 10.1038/sj.emboj.7600081; Mayer R J, 1989, Prog Clin Biol Res, V317, P809; Meyer HH, 1998, FEBS LETT, V437, P255, DOI 10.1016/S0014-5793(98)01232-0; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Mizuno Y, 2003, NEUROSCI LETT, V343, P77, DOI 10.1016/S0304-3940(03)00280-5; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a	41	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51376	51385		10.1074/jbc.M406683200	http://dx.doi.org/10.1074/jbc.M406683200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456787	hybrid			2022-12-25	WOS:000225355800089
J	Wang, XJ; Ikeguchi, Y; McCloskey, DE; Nelson, P; Pegg, AE				Wang, XJ; Ikeguchi, Y; McCloskey, DE; Nelson, P; Pegg, AE			Spermine synthesis is required for normal viability, growth, and fertility in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED HYPOPHOSPHATEMIA; SYNTHASE GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TRANSGENIC MICE; CELL-GROWTH; PEX GENE; POLYAMINES; GY; DEFICIENCY	Spermidine is essential for viability in eukaryotes but the importance of the longer polyamine spermine has not been established. Spermine is formed from spermidine by the action of spermine synthase, an aminopropyltransferase, whose gene (SpmS) is located on the X chromosome. Deletion of part of the X chromosome that include SpmS in Gy mice leads to a striking phenotype in affected males that includes altered phosphate metabolism and symptoms of hypophosphatemic rickets, circling behavior, hyperactivity, head shaking, inner ear abnormalities, deafness, sterility, a profound postnatal growth retardation, and a propensity to sudden death. It was not clear to what extent these alterations were due to the loss of spermine synthase activity, since this chromosomal deletion extends well beyond the SpmS gene and includes at least one other gene termed Phex. We have bred the Gy carrier female mice with transgenic mice (CAG/SpmS mice) that express spermine synthase from the ubiquitous CAG promoter. The resulting Gy-CAG/SpmS mice had extremely high levels of spermine synthase and contained spermine in all tissues examined. These mice had a normal life span and fertility and a normal growth rate except for a reduction in body weight due to a loss of bone mass that was consistent with the observation that the derangement in phosphate metabolism is due to the loss of the Phex gene and was not restored. These results show that spermine synthesis is needed for normal growth, viability, and fertility in male mice and that regulation of spermine synthase content is not required.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Pegg, AE (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.	apegg@psu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM26290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carpinelli MR, 2002, AM J PATHOL, V161, P1925, DOI 10.1016/S0002-9440(10)64468-9; Cason AL, 2003, EUR J HUM GENET, V11, P937, DOI 10.1038/sj.ejhg.5201072; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P2261, DOI 10.1073/pnas.2627990100; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P13869, DOI 10.1073/pnas.1835918100; Chattopadhyay MK, 2002, P NATL ACAD SCI USA, V99, P10330, DOI 10.1073/pnas.162362899; Childs AC, 2003, CELL MOL LIFE SCI, V60, P1394, DOI 10.1007/s00018-003-2332-4; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; GERNER EW, 1988, CANCER RES, V48, P4881; Grieff M, 1997, GENOMICS, V44, P227, DOI 10.1006/geno.1997.4876; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HAKOVIRTA H, 1993, MOL ENDOCRINOL, V7, P1430, DOI 10.1210/me.7.11.1430; Hamasaki-Katagiri N, 1998, GENE, V210, P195, DOI 10.1016/S0378-1119(98)00027-4; Ikeguchi Y, 2004, BIOCHEM J, V381, P701, DOI 10.1042/BJ20040419; Ikeguchi Y, 2003, BIOCHEM J, V373, P885, DOI 10.1042/BJ20030246; Ivanov IP, 2000, P NATL ACAD SCI USA, V97, P4808, DOI 10.1073/pnas.070055897; Kato M, 1999, MOL REPROD DEV, V54, P43, DOI 10.1002/(SICI)1098-2795(199909)54:1&lt;43::AID-MRD6&gt;3.0.CO;2-N; Korhonen VP, 2001, MOL PHARMACOL, V59, P231, DOI 10.1124/mol.59.2.231; Korolev S, 2002, NAT STRUCT BIOL, V9, P27, DOI 10.1038/nsb737; Lopatin AN, 2000, J MOL CELL CARDIOL, V32, P2007, DOI 10.1006/jmcc.2000.1232; Lorenz B, 1998, HUM MOL GENET, V7, P541, DOI 10.1093/hmg/7.3.541; LYON MF, 1986, P NATL ACAD SCI USA, V83, P4899, DOI 10.1073/pnas.83.13.4899; Mackintosh CA, 2000, BIOCHEM J, V351, P439, DOI 10.1042/0264-6021:3510439; MEYER RA, 1995, J ORTHOPAED RES, V13, P30, DOI 10.1002/jor.1100130107; Meyer RA, 1998, GENOMICS, V48, P289, DOI 10.1006/geno.1997.5169; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nilsson J, 2000, BIOCHEM J, V352, P381, DOI 10.1042/0264-6021:3520381; Nishimura K, 2002, GENES CELLS, V7, P41, DOI 10.1046/j.1356-9597.2001.00494.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; Park MH, 1997, BIOL SIGNAL, V6, P115; PEGG AE, 1995, INT J BIOCHEM CELL B, V27, P425, DOI 10.1016/1357-2725(95)00007-C; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1985, BIOCHEM BIOPH RES CO, V133, P82, DOI 10.1016/0006-291X(85)91844-3; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; Phillips LR, 2003, J GEN PHYSIOL, V122, P795, DOI 10.1085/jgp.200308953; Rea G, 2004, IUBMB LIFE, V56, P167, DOI 10.1080/15216540410001673996; Sawicki JA, 1998, EXP CELL RES, V244, P367, DOI 10.1006/excr.1998.4175; Schipper RG, 2000, SEMIN CANCER BIOL, V10, P55, DOI 10.1006/scbi.2000.0308; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Strom TM, 1997, HUM MOL GENET, V6, P165, DOI 10.1093/hmg/6.2.165; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Tristani-Firouzi M, 2001, AM J MED, V110, P50, DOI 10.1016/S0002-9343(00)00623-9; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wang YL, 2002, BIOCHEM J, V366, P79, DOI 10.1042/bj20020211; Warters RL, 1999, RADIAT RES, V151, P354, DOI 10.2307/3579948; WIEST L, 1997, METHOD MOL BIOL, V79, P51; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; Yoshida M, 2004, J BIOL CHEM, V279, P46008, DOI 10.1074/jbc.M404393200	51	65	69	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51370	51375		10.1074/jbc.M410471200	http://dx.doi.org/10.1074/jbc.M410471200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15459188	hybrid			2022-12-25	WOS:000225355800088
J	Hii, CS; Anson, DS; Costabile, M; Mukaro, V; Dunning, K; Ferrante, A				Hii, CS; Anson, DS; Costabile, M; Mukaro, V; Dunning, K; Ferrante, A			Characterization of the MEK5-ERK5 module in human neutrophils and its relationship to ERK1/ERK2 in the chemotactic response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; ARACHIDONIC-ACID; POLYMORPHONUCLEAR LEUKOCYTES; POTENTIAL ROLE; NADPH-OXIDASE; GROWTH-FACTOR; TNF-ALPHA; ERK5; RECEPTOR	The role of the extracellular signal-regulated kinase (ERK) 1 and ERK2 in the neutrophil chemotactic response remains to be identified since a previously used specific inhibitor of MEK1 and MEK2, PD98059, that was used to provide evidence for a role of ERK1 and ERK2 in regulating chemotaxis, has recently been reported to also inhibit MEK5. This issue is made more critical by our present finding that human neutrophils express mitogen-activated protein (MAP) kinase/ERK kinase (MEK) 5 and ERK5 (Big MAP kinase), and that their activities were stimulated by the bacterial tripeptide, formyl methionyl-leucyl-phenylalanine (fMLP). Dose response studies demonstrated a bell-shaped profile of fMLP-stimulated MEK5 and ERK5 activation, but this was left-shifted when compared with the profile of fMLP-stimulated chemotaxis. Kinetics studies demonstrated increases in kinase activity within 2 min, peaking at 3-5 min, and MEK5 activation was more persistent than that of ERK5. There were some similarities as well as differences in the pattern of activation between fMLP-stimulated ERK1 and ERK2, and MEK5-ERK5 activation. The up-regulation of MEK5-ERK5 activities was dependent on phosphatidylinositol 3-kinase. Studies with the recently described specific MEK inhibitor, PD184352, at concentrations that inhibited ERK1 and ERK2 but not ERK5 activity demonstrate that the ERK1 and ERK2 modules were involved in regulating fMLP-stimulated chemotaxis and chemokinesis. Our data suggest that the MEK5-ERK5 module is likely to regulate neutrophil responses at very low chemoattractant concentrations whereas at higher concentrations, a shift to the ERK1/ERK2 and p38 modules is apparent.	Womens & Childrens Hosp, Dept Immunopathol, Adelaide, SA 5006, Australia; Womens & Childrens Hosp, Dept Med Genet, Adelaide, SA 5006, Australia; Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Pediat, Adelaide, SA 5000, Australia	Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia; University of South Australia; University of Adelaide	Hii, CS (corresponding author), Womens & Childrens Hosp, Dept Immunopathol, 72 King William Rd, Adelaide, SA 5006, Australia.	charles.hii@adelaide.edu.au	costabile, maurizio/AEN-4356-2022; Dunning, Kylie/GLU-0471-2022	costabile, maurizio/0000-0002-2162-6497; Dunning, Kylie/0000-0002-0462-6479; Mukaro, Violet/0000-0002-3968-6551				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dharmawardhane S, 1999, J LEUKOCYTE BIOL, V66, P521, DOI 10.1002/jlb.66.3.521; Doring G, 2000, Paediatr Respir Rev, V1, P101, DOI 10.1053/prrv.2000.0030; Drost EM, 2002, EUR J IMMUNOL, V32, P393, DOI 10.1002/1521-4141(200202)32:2<393::AID-IMMU393>3.0.CO;2-5; Dwivedi PP, 2002, J BIOL CHEM, V277, P29643, DOI 10.1074/jbc.M204561200; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; FERRANTE A, 1982, J IMMUNOL METHODS, V48, P81, DOI 10.1016/0022-1759(82)90212-5; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Heuertz RM, 1999, J BIOL CHEM, V274, P17968, DOI 10.1074/jbc.274.25.17968; Hii CST, 1999, INFECT IMMUN, V67, P1297, DOI 10.1128/IAI.67.3.1297-1302.1999; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Hii CST, 2001, J BIOL CHEM, V276, P27246, DOI 10.1074/jbc.M103250200; Huang ZH, 1997, BIOCHEM J, V325, P553, DOI 10.1042/bj3250553; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karlsson A, 2000, J LEUKOCYTE BIOL, V67, P396, DOI 10.1002/jlb.67.3.396; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lehman JA, 2001, AM J PHYSIOL-CELL PH, V280, pC183, DOI 10.1152/ajpcell.2001.280.1.C183; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Naccache PH, 2000, J BIOL CHEM, V275, P23636, DOI 10.1074/jbc.M001780200; Nagata T, 2001, BRIT J ANAESTH, V86, P853, DOI 10.1093/bja/86.6.853; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; NELSON RD, 1975, J IMMUNOL, V115, P1650; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Niggli V, 1997, EUR J PHARMACOL, V335, P43, DOI 10.1016/S0014-2999(97)01169-2; Pearson GW, 2002, J BIOL CHEM, V277, P48094, DOI 10.1074/jbc.M208535200; PILLINGER MH, 1995, RHEUM DIS CLIN N AM, V21, P691; POWIS G, 1994, CANCER RES, V54, P2419; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Suire S, 2002, CURR BIOL, V12, P1068, DOI 10.1016/S0960-9822(02)00933-8; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Takami M, 2002, J IMMUNOL, V168, P4559, DOI 10.4049/jimmunol.168.9.4559; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xythalis D, 2002, INFLAMMATION, V26, P83, DOI 10.1023/A:1014836211643; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zu YL, 1998, J IMMUNOL, V160, P1982	51	32	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49825	49834		10.1074/jbc.M406892200	http://dx.doi.org/10.1074/jbc.M406892200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15381709	Green Published, hybrid			2022-12-25	WOS:000225229500035
J	Saito, T; Oda, Y; Kawaguchi, K; Sugimachi, K; Yamamoto, H; Tateishi, N; Tanaka, K; Matsuda, S; Iwamoto, Y; Ladanyi, M; Tsuneyoshi, M				Saito, T; Oda, Y; Kawaguchi, K; Sugimachi, K; Yamamoto, H; Tateishi, N; Tanaka, K; Matsuda, S; Iwamoto, Y; Ladanyi, M; Tsuneyoshi, M			E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma	ONCOGENE			English	Article						E-cadherin; Snail; CpG methylation; mutation; ELF3; synovial sarcoma; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTIONAL REPRESSOR SNAIL; CPG ISLAND METHYLATION; SOFT-TISSUE SARCOMAS; CELL-CELL-ADHESION; SSX FUSION TYPE; GENE-EXPRESSION; BREAST-CANCER; GASTRIC-CANCER; BETA-CATENIN	We have recently reported frequent E-cadherin gene mutations in synovial sarcoma (SS), suggesting mutational inactivation of E-cadherin as a potential mechanism of spindle cell morphology in SS, a spindle cell sarcoma that shows areas of glandular epithelial differentiaton in some cases (biphasic SS) and only pure spindle cell morphology in most cases (monophasic SS). However, the mechanism of downregulation of E-cadherin in SS remains unknown. To further address this issue, we analysed the mechanisms of E-cadherin silencing in 40 SS. Genetic and epigenetic changes in the E-cadherin gene, and the expression level of its transcriptional repressor Snail were examined by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP), methylation-specific PCR, and real-time quantitative PCR, respectively. Expression of E-cadherin was examined by RT-PCR and immunohistochemistry. We also examined ELF3, a transcription factor associated with epithelial differentiation in SS in a previous cDNA microarray, by RT-PCR. E-cadherin and ELF3 transcripts were detected, respectively, in 27/40 (67.5%) and in 25/40 (62.5%) of SS, and these epithelial-related genes were almost always coexpressed. Hypermethylation of the promoter of the E-cadherin gene was detected in five cases (12.5%) in SS; however, E-cadherin was silenced at mRNA level in only one of the five cases. E-cadherin missense mutations were observed in five cases (12.5%) of SS. In SS, all five cases with E-cadherin missense mutations had the SYT-SSX1 fusion and were monophasic tumors, suggesting a relationship between the SYT-SSX fusion type and E-cadherin missense mutation (P = 0.07). E-cadherin mRNA expression in SS was associated with reduced Snail expression level (P = 0.03). E-cadherin membranous expression was observed in 14/40 (35.0%) of SS, and was also correlated with SYT-SSX1 fusion type and biphasic histology. ELF3 was confirmed to be more highly expressed in biphasic than monophasic SS by real-time quantitative PCR. These results suggest that in SS the loss of E-cadherin expression occurs either by Snail trans-repression or by inactivating mutations. Thus, E-cadherin downregulation is associated with the loss or absence of glandular epithelial differentiation in certain SS.	Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka 8128582, Japan; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Kyushu University; Kyushu University; Memorial Sloan Kettering Cancer Center	Tsuneyoshi, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	masazumi@surgpath.med.kyushu-u.ac.jp	Tanaka, Kazuhiro/Q-7387-2019; Ladanyi, Marc/AAG-8585-2019	Tanaka, Kazuhiro/0000-0002-5138-8952; Matsuda, Shuichi/0000-0003-0802-1255	NCI NIH HHS [CA47179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; Antonescu CR, 2000, DIAGN MOL PATHOL, V9, P1, DOI 10.1097/00019606-200003000-00001; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0; Brown DT, 2003, BIOCHEM CELL BIOL, V81, P221, DOI 10.1139/o03-049; Bukholm IK, 2000, J PATHOL, V190, P15; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Endo K, 2001, J PATHOL, V193, P310, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH816>3.0.CO;2-K; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gambarotta G, 1996, ONCOGENE, V13, P1911; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1998, CANCER RES, V58, P2063; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hajra KM, 2002, CANCER RES, V62, P1613; HENNIG G, 1995, ONCOGENE, V11, P475; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiraguri S, 1998, CANCER RES, V58, P1972; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Laskin WB, 2002, ARCH PATHOL LAB MED, V126, P425; Lee YF, 2003, BRIT J CANCER, V88, P510, DOI 10.1038/sj.bjc.6600766; Lewis JJ, 2000, J CLIN ONCOL, V18, P2087, DOI 10.1200/JCO.2000.18.10.2087; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; Machado JC, 1999, LAB INVEST, V79, P459; Machen SK, 1999, AM J SURG PATHOL, V23, P268, DOI 10.1097/00000478-199903000-00004; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; MAYER B, 1993, CANCER RES, V53, P1690; Melki JR, 2000, BLOOD, V95, P3208; Nagayama S, 2002, CANCER RES, V62, P5859; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Noguchi SI, 1997, INT J CANCER, V72, P995; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Saito A, 1999, JPN J CANCER RES, V90, P993, DOI 10.1111/j.1349-7006.1999.tb00847.x; Saito T, 2000, J PATHOL, V192, P342, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH705>3.0.CO;2-R; Saito T, 2002, LAB INVEST, V82, P97, DOI 10.1038/labinvest.3780399; Saito T, 2002, HISTOPATHOLOGY, V40, P279, DOI 10.1046/j.1365-2559.2002.01345.x; Saito T, 2001, AM J PATHOL, V159, P2117, DOI 10.1016/S0002-9440(10)63063-5; Sato H, 1999, HUM PATHOL, V30, P1344, DOI 10.1016/S0046-8177(99)90066-7; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; Sefton M, 1998, DEVELOPMENT, V125, P3111; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Soares P, 1997, INT J CANCER, V70, P32; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trassard M, 2001, J CLIN ONCOL, V19, P525, DOI 10.1200/JCO.2001.19.2.525; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEISS SW, 2001, ENZINGER WEISSS SOFT; Yakushiji T, 2000, J CLIN PATHOL, V53, P525, DOI 10.1136/jcp.53.7.525; Yoo J, 2002, ARCH PATHOL LAB MED, V126, P33	80	42	48	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8629	8638		10.1038/sj.onc.1207960	http://dx.doi.org/10.1038/sj.onc.1207960			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467754				2022-12-25	WOS:000224988800009
J	He, LS; Grammer, AC; Wu, XL; Lipsky, PE				He, LS; Grammer, AC; Wu, XL; Lipsky, PE			TRAF3 forms heterotrimers with TRAF2 and modulates its ability to mediate NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; RESONANCE ENERGY-TRANSFER; LYMPHOTOXIN-BETA-RECEPTOR; TERMINAL KINASE; C-JUN; SUBCELLULAR-LOCALIZATION; FLUORESCENT PROTEIN; SPLICE-VARIANT; SINGLE-LASER; RING FINGER	FRET experiments utilizing confocal microscopy or flow cytometry assessed homo- and heterotrimeric association of human tumor necrosis factor receptor-associated factors (TRAF) in living cells. Following transfection of HeLa cells with plasmids expressing CFP- or YFP-TRAF fusion proteins, constitutive homotypic association of TRAF2, -3, and -5 was observed, as well as heterotypic association of TRAF1-TRAF2 and TRAF3-TRAF5. A novel heterotypic association between TRAF2 and -3 was detected and confirmed by immunoprecipitation in Ramos B cells that constitutively express both TRAF2 and -3. Experiments employing deletion mutants of TRAF2 and TRAF3 revealed that this heterotypic interaction minimally involved the TRAF-C domain of TRAF3 as well as the TRAF-N domain and zinc fingers 4 and 5 of TRAF2. A novel flow cytometric FRET analysis utilizing a two-step approach to achieve linked FRET from CFP to YFP to HcRed established that TRAF2 and -3 constitutively form homo- and heterotrimers. The functional importance of TRAF2-TRAF3 heterotrimerization was demonstrated by the finding that TRAF3 inhibited spontaneous NF-kappaB, but not AP-1, activation induced by TRAF2. Ligation of CD40 on Ramos B cells by recombinant CD154 caused TRAF2 and TRAF3 to dissociate, whereas overexpression of TRAF3 in Ramos B cells inhibited CD154-induced TRAF2-mediated activation of NF-kappaB. Together, these results reveal a novel association between TRAF2 and TRAF3 that is mediated by unique portions of each protein and that specifically regulates activation of NF-kappaB, but not AP-1.	NIAMS, NIH, US Dept HHS, Bethesda, MD 20892 USA; NIH, Glow Cytometry Sect, Off Sci & Technol, US Dept HHS, Bethesda, MD 20892 USA; NIH, Cell Biol Grp B, Autoimmun Branch, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Lipsky, PE (corresponding author), NIAMS, NIH, US Dept HHS, 9000 Rockville Pike,Bldg 10,Rm 9N228, Bethesda, MD 20892 USA.	lipskyp@mail.nih.gov		Grammer, Amrie/0000-0001-7142-2284	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041140, Z01AR041128] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Annunziata CM, 2000, BLOOD, V96, P2841; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brink R, 1998, J BIOL CHEM, V273, P4129, DOI 10.1074/jbc.273.7.4129; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Cannons JL, 2002, J IMMUNOL, V169, P2828, DOI 10.4049/jimmunol.169.6.2828; Chang YH, 2002, EXP CELL RES, V278, P166, DOI 10.1006/excr.2002.5573; Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775; Dadgostar H, 2003, FEBS LETT, V553, P403, DOI 10.1016/S0014-5793(03)01072-X; Dadgostar H, 2000, J BIOL CHEM, V275, P2539, DOI 10.1074/jbc.275.4.2539; Ely KR, 2002, J MOL RECOGNIT, V15, P286, DOI 10.1002/jmr.589; Force WR, 2000, J BIOL CHEM, V275, P11121, DOI 10.1074/jbc.275.15.11121; Frew IJ, 2003, MOL CELL BIOL, V23, P9150, DOI 10.1128/MCB.23.24.9150-9161.2003; Gamper C, 2001, HUM IMMUNOL, V62, P1167, DOI 10.1016/S0198-8859(01)00284-1; Grammer A C, 2000, Adv Immunol, V76, P61; Grammer AC, 1998, J IMMUNOL, V161, P1183; Ha H, 2003, EXP MOL MED, V35, P279, DOI 10.1038/emm.2003.38; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Han SY, 2003, BIOCHEM BIOPH RES CO, V305, P789, DOI 10.1016/S0006-291X(03)00852-0; Hatzoglou A, 2000, J IMMUNOL, V165, P1322, DOI 10.4049/jimmunol.165.3.1322; He LS, 2003, CYTOM PART A, V55A, P71, DOI 10.1002/cyto.a.10073; He LS, 2003, CYTOM PART A, V53A, P39, DOI 10.1002/cyto.a.10037; Hong JW, 2003, P NATL ACAD SCI USA, V100, P12301, DOI 10.1073/pnas.2133048100; Hong X, 2001, FEBS LETT, V499, P133, DOI 10.1016/S0014-5793(01)02535-2; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lee ZH, 2001, J LEUKOCYTE BIOL, V69, P490; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Li CL, 2003, J BIOL CHEM, V278, P50523, DOI 10.1074/jbc.M309381200; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; Ni CZ, 2002, ACTA CRYSTALLOGR D, V58, P1340, DOI 10.1107/S0907444902008958; Oukka M, 2002, MOL CELL, V9, P121, DOI 10.1016/S1097-2765(01)00434-8; Oukka M, 2004, J EXP MED, V199, P15, DOI 10.1084/jem.20030421; Prell RA, 2003, J IMMUNOL, V171, P5997, DOI 10.4049/jimmunol.171.11.5997; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sharma N, 2001, AM J PATHOL, V159, P339, DOI 10.1016/S0002-9440(10)61700-2; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaori-Kondo A, 2000, BIOCHEM BIOPH RES CO, V272, P856, DOI 10.1006/bbrc.2000.2860; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tsao DHH, 2000, MOL CELL, V5, P1051, DOI 10.1016/S1097-2765(00)80270-1; van Eyndhoven WG, 1999, MOL IMMUNOL, V36, P647, DOI 10.1016/S0161-5890(99)00079-6; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	56	69	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55855	55865		10.1074/jbc.M407284200	http://dx.doi.org/10.1074/jbc.M407284200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15383523	hybrid			2022-12-25	WOS:000225960800109
J	Tng, E; Tan, SM; Ranganathan, S; Cheng, M; Law, SKA				Tng, E; Tan, SM; Ranganathan, S; Cheng, M; Law, SKA			The integrin alpha(L)beta(2) hybrid domain serves as a link for the propagation of activation signal from its stalk regions to the I-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION DEFICIENCY; CYSTEINE-RICH REGION; A-DOMAIN; LIGAND-BINDING; CR3-DEPENDENT ADHESION; EXTRACELLULAR SEGMENT; ELECTRON-MICROSCOPY; SURFACE EXPRESSION; AVIDITY REGULATION; MISSENSE MUTATION	Integrin activation involves global conformational changes as demonstrated by various functional and structural analyses. The integrin beta hybrid domain is proposed to be involved in the propagation of this activation signal. Our previous study showed that the integrin beta(2)-specific monoclonal antibody 7E4 abrogates monoclonal antibody KIM185-activated but not Mg2+/EGTA-activated leukocyte function-associated antigen-1 (LFA-1; alpha(L)beta(2))-mediated adhesion to ICAM-1. Here we investigated the allosteric inhibitory property of 7E4. By using human/mouse chimeras and substitution mutations, the epitope of 7E4 was mapped to Val(407), located in the mid-region of the beta(2) hybrid domain. Two sets of constitutively active LFA-1 variants were used to examine the effect of 7E4 on LFA-1/ICAM-1 binding. 7E4 attenuated the binding of variants that have modifications to regions membrane proximal with respect to the beta(2) hybrid domain. In contrast, the inhibitory effect was minimal on variants with alterations in the alpha(L)I- and beta(2) I-like domains preceding the hybrid domain. Furthermore, 7E4 abrogated LFA-1/ICAM-1 adhesion of phorbol 12-myristate 13-acetate-treated MOLT-4 cells. Our data demonstrate that interaction between the hybrid and I-like domain is critical for the regulation of LFA-1-mediated adhesion.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 117597, Singapore	University of Oxford; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore	Law, SKA (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	Alaw@ntu.edu.sg	Law, Alex/A-2212-2011; Tan, Suet/A-2224-2011	Tan, Suet-Mien/0000-0003-2371-8739; Ranganathan, Shoba/0000-0002-8290-813X				ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BASIL V, 1990, FOLIA BIOL-PRAGUE, V36, P41; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Douglass WA, 1998, FEBS LETT, V440, P414, DOI 10.1016/S0014-5793(98)01498-7; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; Hogg N, 1999, J CLIN INVEST, V103, P97, DOI 10.1172/JCI3312; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kijas JMH, 1999, GENOMICS, V61, P101, DOI 10.1006/geno.1999.5948; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luo BH, 2004, J BIOL CHEM, V279, P27466, DOI 10.1074/jbc.M404354200; Mathew EC, 2000, CLIN EXP IMMUNOL, V121, P133, DOI 10.1046/j.1365-2249.2000.01277.x; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; NELSON C, 1992, J BIOL CHEM, V267, P3351; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Shaw JM, 2001, CLIN EXP IMMUNOL, V126, P311, DOI 10.1046/j.1365-2249.2001.01661.x; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tan SM, 2001, FEBS LETT, V505, P27, DOI 10.1016/S0014-5793(01)02778-8; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tan SM, 2001, J BIOL CHEM, V276, P36370, DOI 10.1074/jbc.M102392200; Valmu L, 1999, EUR J IMMUNOL, V29, P2107, DOI 10.1002/(SICI)1521-4141(199907)29:07<2107::AID-IMMU2107>3.0.CO;2-T; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WRIGHT AH, 1995, EUR J IMMUNOL, V25, P717, DOI 10.1002/eji.1830250313; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	44	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54334	54339		10.1074/jbc.M407818200	http://dx.doi.org/10.1074/jbc.M407818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15456774	hybrid			2022-12-25	WOS:000225793600055
J	Hiromura, M; Okada, F; Obata, T; Auguin, D; Shibata, T; Roumestand, C; Noguchi, M				Hiromura, M; Okada, F; Obata, T; Auguin, D; Shibata, T; Roumestand, C; Noguchi, M			Inhibition of Akt kinase activity by a peptide spanning the beta A strand of the proto-oncogene TCL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CELL-SURVIVAL; HUMAN CANCER; ACTIVATION; BINDING; 3-KINASE	Akt plays a central role in the regulation of cellular anti-apoptosis underlying various human neoplastic diseases. We have demonstrated previously that TCL1 ( a proto-oncogene underlying human T cell prolymphocytic leukemia) interacts with Akt and functions as an Akt kinase co-activator. With the aim to develop an Akt kinase inhibitor, we hypothesized that a peptide, which spans the Akt-binding site, binds to Akt and modulates Akt kinase activity and its downstream biological responses. Indeed, we demonstrated that a peptide, named "Akt-in" (Akt inhibitor, NH2-AVTDHPDRLWAWEKFCOOH, encompassing the betaA strand of human TCL1), interacted with Akt and specifically inhibited its kinase activity. Nuclear magnetic resonance studies suggested that interaction of Akt-in with the pleckstrin homology domain (PH) of Akt caused conformational changes on the variable loop 1 of Akt, the locus mediating phosphoinositide binding. Consistently, interaction of Akt-in with the Akt PH domain prevented phosphoinositide binding and hence inhibited membrane translocation and activation of Akt. Moreover, Akt-in inhibited not only cellular proliferation and anti-apoptosis in vitro but also in vivo tumor growth without any adverse effect. The roles of Akt, which possesses a PH domain, in intracellular signaling were well established. Hence, Akt inhibitors create an attractive target for anticancer therapy. However, no effective inhibitors specific for Akt have been developed. Akt-in, which inhibits association of phosphatidylinositol with Akt, is the first molecule to demonstrate specific Akt kinase inhibition potency. This observation will facilitate the design of specific inhibitors for Akt, a core intracellular survival factor underlying various human neoplastic diseases.	Hokkaido Univ, Inst Med Genet, Div Canc Biol, Sapporo, Hokkaido, Japan; Yamagata Univ, Grad Sch Med, Dept Biomol Funct, Yamagata 990, Japan; Fac Pharm Montpellier, Ctr Biochim Struct, Montpellier, France; Univ Tokushima, Inst Enzyme Res, Div Mol Genet, Tokushima 770, Japan; Appl Biosyst Japan Ltd, Tokyo, Japan	Hokkaido University; Yamagata University; Universite de Montpellier; Tokushima University; Thermo Fisher Scientific; Applied Biosystems	Noguchi, M (corresponding author), N15,W7,Kita Ku, Sapporo, Hokkaido 0600815, Japan.	m_noguch@igm.hokudai.ac.jp	Auguin, Daniel/Y-2074-2019	Auguin, Daniel/0000-0003-4713-9096; ROUMESTAND, Christian/0000-0002-4082-3293; Okada, Futoshi/0000-0003-4733-1037				Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Auguin D, 2004, J BIOL CHEM, V279, P35890, DOI 10.1074/jbc.M400364200; Auguin D, 2004, J BIOMOL NMR, V28, P137, DOI 10.1023/B:JNMR.0000013836.62154.c2; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barr RK, 2004, J BIOL CHEM, V279, P36327, DOI 10.1074/jbc.M402181200; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Coffer PJ, 1998, BIOCHEM J, V335, P1; Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407; Datta K, 2001, CANCER RES, V61, P1768; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Egami K, 2003, J CLIN INVEST, V112, P67, DOI 10.1172/JCI200316645; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; French SW, 2002, BIOCHEMISTRY-US, V41, P6376, DOI 10.1021/bi016068o; Gold MR, 2003, TRENDS IMMUNOL, V24, P104, DOI 10.1016/S1471-4906(03)00022-X; Hoh F, 1998, STRUCTURE, V6, P147, DOI 10.1016/S0969-2126(98)00017-3; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lock RB, 2003, INT J BIOCHEM CELL B, V35, P1614, DOI 10.1016/S1357-2725(03)00146-8; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Narducci MG, 2002, P NATL ACAD SCI USA, V99, P11712, DOI 10.1073/pnas.182412399; Niv MY, 2004, J BIOL CHEM, V279, P1242, DOI 10.1074/jbc.M306723200; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; OKADA F, 1992, BRIT J CANCER, V66, P635, DOI 10.1038/bjc.1992.329; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2001, ONCOGENE, V20, P5638, DOI 10.1038/sj.onc.1204596; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; Reuveni H, 2000, J CELL BIOL, V151, P1179, DOI 10.1083/jcb.151.6.1179; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8	62	75	87	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53407	53418		10.1074/jbc.M403775200	http://dx.doi.org/10.1074/jbc.M403775200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15459205	hybrid			2022-12-25	WOS:000225680600074
J	Wang, W; Stock, RE; Gronostajski, RM; Wong, YW; Schachner, M; Kilpatrick, DL				Wang, W; Stock, RE; Gronostajski, RM; Wong, YW; Schachner, M; Kilpatrick, DL			A role for nuclear factor I in the intrinsic control of cerebellar granule neuron gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA 6 SUBUNIT; TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION; REGULATORY ELEMENT; CELLS; SPECIFICATION; NFI; VITRO; VIVO; DIFFERENTIATION	Nervous system formation requires the elaboration of a complex series of differentiation events in both a spatially and maturation-regulated manner. A fundamental question is how neuronal subtype specification and developmental gene expression are controlled within maturing neurons. The alpha6 subunit of the gamma-aminobutyric acid type A (GABA(A)) receptor (GABRA6) is preferentially expressed in cerebellar granule neurons and is part of an intrinsic program directing their differentiation. We have employed a lentiviral approach to examine the transcriptional mechanisms controlling neuronal subtype-selective expression of this gene. These studies demonstrated that nuclear factor I (NFI) proteins are required for both transgenic GABRA6 promoter activity as well as endogenous expression of this gene in cerebellar granule neurons. Chromatin immunoprecipitation also showed that NFI proteins are bound to the GABRA6 promoter in these cells in vivo. Furthermore, analyses of gene knockout mice revealed that Nfia is specifically required for normal expression of the GABRA6 gene in cerebellar granule neurons. NFI expression and DNA binding activity are highly enriched in granule neurons, implicating this transcription factor family in the neuronal subtype-selective expression of the GABRA6 gene. These studies define a new role for NFI proteins as neuronal subtype-enriched transcriptional regulators that participate in an intrinsic transcriptional program directing the differentiation of cerebellar granule neurons.	Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany; SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Hamburg; University Medical Center Hamburg-Eppendorf; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Kilpatrick, DL (corresponding author), Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, BSB S4-139,55 Lake Ave N, Worcester, MA 01655 USA.	daniel.kilpatrick@umassmed.edu		Gronostajski, Richard/0000-0003-4264-208X; , wei/0000-0002-5138-2892	NATIONAL CANCER INSTITUTE [R01CA079999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058401] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA79999] Funding Source: Medline; NIDDK NIH HHS [R01DK58401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; Bahn S, 1999, EUR J NEUROSCI, V11, P2194, DOI 10.1046/j.1460-9568.1999.00662.x; Bahn S, 1997, P NATL ACAD SCI USA, V94, P9417, DOI 10.1073/pnas.94.17.9417; Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; Behrens M, 2000, EUR J NEUROSCI, V12, P1372, DOI 10.1046/j.1460-9568.2000.00032.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Brickley SG, 2001, NATURE, V409, P88, DOI 10.1038/35051086; Carletti B, 2002, J NEUROSCI, V22, P7132; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; CONDIT RC, 2001, PRINCIPLES VIRUS STR, P31; das Neves L, 1999, P NATL ACAD SCI USA, V96, P11946, DOI 10.1073/pnas.96.21.11946; GAO B, 1995, DEV BRAIN RES, V88, P1, DOI 10.1016/0165-3806(95)00062-I; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Grunder A, 2002, MECH DEVELOP, V112, P69, DOI 10.1016/S0925-4773(01)00640-2; Hatten ME, 1997, CURR OPIN NEUROBIOL, V7, P40, DOI 10.1016/S0959-4388(97)80118-3; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; INOUE T, 1990, J BIOL CHEM, V265, P19065; Jankovski A, 1996, EUR J NEUROSCI, V8, P2308, DOI 10.1111/j.1460-9568.1996.tb01194.x; Jones A, 1996, J NEUROCHEM, V67, P907; KATO K, 1990, J MOL BIOL, V214, P619, DOI 10.1016/0022-2836(90)90276-R; Kessler DS, 1997, P NATL ACAD SCI USA, V94, P13017, DOI 10.1073/pnas.94.24.13017; Lin X, 1996, NEUROSCI LETT, V220, P81, DOI 10.1016/S0304-3940(96)13214-6; Liu F, 1997, J BIOL CHEM, V272, P5056, DOI 10.1074/jbc.272.8.5056; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; McLean PJ, 2000, J NEUROCHEM, V74, P1858, DOI 10.1046/j.1471-4159.2000.0741858.x; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; PUZIANOWSKAKUZNICK, 1996, J BIOL CHEM, V271, P6273; Reiser J, 2000, GENE THER, V7, P910, DOI 10.1038/sj.gt.3301188; Shu TZ, 2003, J NEUROSCI, V23, P203; Spitz F, 1997, MOL CELL BIOL, V17, P656, DOI 10.1128/MCB.17.2.656; Steele-Perkins G, 2003, MOL CELL BIOL, V23, P1075, DOI 10.1128/MCB.23.3.1075-1084.2003; Wisden W, 1996, NEUROPHARMACOLOGY, V35, P1139, DOI 10.1016/S0028-3908(96)00076-7; Yacubova E, 2002, J NEUROSCI, V22, P5966; Yamasaki T, 2001, DEVELOPMENT, V128, P3133; ZHENG T, 1993, DEV BRAIN RES, V75, P91, DOI 10.1016/0165-3806(93)90068-L; Zhou HP, 2001, GENE EXPRESSION, V9, P217, DOI 10.3727/000000001783992597; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	42	44	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53491	53497		10.1074/jbc.M410370200	http://dx.doi.org/10.1074/jbc.M410370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466411	hybrid			2022-12-25	WOS:000225680600084
J	Barth, A; Bezlyepkina, N				Barth, A; Bezlyepkina, N			P-O bond destabilization accelerates phosphoenzyme hydrolysis of sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED DIFFERENCE SPECTROSCOPY; TIME-RESOLVED FTIR; MOLECULAR INTERPRETATION; CONFORMATIONAL-CHANGES; PROTEIN-STRUCTURE; ACETYL PHOSPHATE; CATALYTIC CYCLE; ATP; PHOSPHORYLATION; ENZYME	The phosphate group of the ADP-insensitive phosphoenzyme (E2-P) of sarcoplasmic reticulum Ca2+-ATPase (SERCA1a) was studied with infrared spectroscopy to understand the high hydrolysis rate of E2-P. By monitoring an autocatalyzed isotope exchange reaction, three stretching vibrations of the transiently bound phosphate group were selectively observed against a background of 50,000 protein vibrations. They were found at 1194, 1137, and 1115 cm(-1). This information was evaluated using the bond valence model and empirical correlations. Compared with the model compound acetyl phosphate, structure and charge distribution of the E2-P aspartyl phosphate resemble somewhat the transition state in a dissociative phosphate transfer reaction; the aspartyl phosphate of E2-P has 0.02 Angstrom shorter terminal P-O bonds and a 0.09 Angstrom longer bridging P-O bond that is similar to20% weaker, the angle between the terminal P-O bonds is wider, and -0.2 formal charges are shifted from the phosphate group to the aspartyl moiety. The weaker bridging P-O bond of E2-P accounts for a 10(11)-10(15)-fold hydrolysis rate enhancement, implying that P-O bond destabilization facilitates phosphoenzyme hydrolysis. P-O bond destabilization is caused by a shift of noncovalent interactions from the phosphate oxygens to the aspartyl oxygens. We suggest that the relative positioning of Mg2+ and Lys(684) between phosphate and aspartyl oxygens controls the hydrolysis rate of the ATPase phosphoenzymes and related phosphoproteins.	Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Goethe Univ Frankfurt, Inst Biophys, D-60590 Frankfurt, Germany	Stockholm University; Goethe University Frankfurt	Bezlyepkina, N (corresponding author), Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	Andreas.Barth@dbb.su.se	Barth, Andreas/N-8872-2013	Barth, Andreas/0000-0001-5784-7673				ALBEN JO, 1968, BIOCHEMISTRY-US, V7, P175, DOI 10.1021/bi00841a022; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Barth A, 1999, J BIOL CHEM, V274, P22170, DOI 10.1074/jbc.274.32.22170; BARTH A, 1994, BBA-BIOMEMBRANES, V1194, P75, DOI 10.1016/0005-2736(94)90205-4; Barth A, 1998, BIOPHYS J, V75, P538, DOI 10.1016/S0006-3495(98)77543-5; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815; Barth A, 2002, BIOPOLYMERS, V67, P237, DOI 10.1002/bip.10085; BARTH A, 1990, FEBS LETT, V277, P147, DOI 10.1016/0014-5793(90)80830-C; Barth A, 2000, FEBS LETT, V477, P151, DOI 10.1016/S0014-5793(00)01782-8; BELASCO JG, 1980, BIOCHEMISTRY-US, V19, P472, DOI 10.1021/bi00544a012; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; Brown I. D., 2002, CHEM BOND INORGANIC, V12; BROWN ID, 1992, ACTA CRYSTALLOGR B, V48, P553, DOI 10.1107/S0108768192002453; BROWN ID, 1976, ACTA CRYSTALLOGR B, V32, P1957, DOI 10.1107/S0567740876006869; BROWN ID, 1973, ACTA CRYSTALLOGR A, VA 29, P266, DOI 10.1107/S0567739473000689; BYSTROM A, 1951, ACTA CHEM SCAND, V5, P1003, DOI 10.3891/acta.chem.scand.05-1003; Cepus V, 1998, BIOCHEMISTRY-US, V37, P10263, DOI 10.1021/bi973183j; CHALOUB RM, 1979, J BIOL CHEM, V254, P9464; Cheng H, 2001, BIOCHEMISTRY-US, V40, P4035, DOI 10.1021/bi0021131; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DEMEIS L, 1988, FEBS LETT, V232, P73, DOI 10.1016/0014-5793(88)80389-2; Deng H, 2001, PRACT SPECTROSC SERI, V24, P477; Deng H, 1998, J PHYS CHEM B, V102, P3617, DOI 10.1021/jp973314q; DISABATO G, 1961, J AM CHEM SOC, V83, P4400, DOI 10.1021/ja01482a025; Du XL, 2000, J BIOL CHEM, V275, P8492, DOI 10.1074/jbc.275.12.8492; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; Fershts A, 1999, STRUCTURE MECH PROTE, P330; GANS P, 1971, VIBRATING MOL; Gerwert K, 1999, BIOL CHEM, V380, P931, DOI 10.1515/BC.1999.115; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HASSELBACH W, 1981, MEMBRANE TRANSPORT, P183; HERSCHBACH D, 1961, J CHEM PHYS, V35, P458, DOI 10.1063/1.1731952; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P5172, DOI 10.1021/bi00473a025; HERZBERG G, 1950, MOL SPECTRA MOL STRU, V1, P100; HORVATH G, 1987, ACTA CHIM HUNG, V124, P819; INESI G, 1985, ENZYMES BIOL MEMBR, V3, P157; JENCKS WP, 1989, METHOD ENZYMOL, V171, P145; JOHNSTON HS, 1964, J AM CHEM SOC, V86, P1643, DOI 10.1021/ja01062a044; Jung C, 2000, J MOL RECOGNIT, V13, P325, DOI 10.1002/1099-1352(200011/12)13:6<325::AID-JMR507>3.0.CO;2-C; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; LAYTON EM, 1956, J CHEM PHYS, V25, P135, DOI 10.1063/1.1742805; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; LEHNINGER AL, 1993, PRINCIPLES BIOCH, P66; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; MANTELE W, 1993, TRENDS BIOCHEM SCI, V18, P197, DOI 10.1016/0968-0004(93)90186-Q; Martonosi A, 1985, Soc Gen Physiol Ser, V39, P57; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; MURRAYRUST P, 1975, J AM CHEM SOC, V97, P921, DOI 10.1021/ja00837a055; Narlikar GJ, 1997, ANNU REV BIOCHEM, V66, P19, DOI 10.1146/annurev.biochem.66.1.19; Pauling L, 1929, J AM CHEM SOC, V51, P1010, DOI 10.1021/ja01379a006; POHLE W, 1991, J MOL STRUCT, V242, P333, DOI 10.1016/0022-2860(91)87145-8; RAUCH B, 1977, Z NATURFORSCH C, V32, P828; Schulz G.E., 1979, PRINCIPLES PROTEIN S, P28; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P4157; SIEBERT F, 1995, METHOD ENZYMOL, V246, P501; Sigel H, 1999, J AM CHEM SOC, V121, P6248, DOI 10.1021/ja9904181; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VIEYRA A, 1979, BIOCHIM BIOPHYS ACTA, V568, P437, DOI 10.1016/0005-2744(79)90312-7; VILSEN B, 1991, J BIOL CHEM, V266, P16157; Wharton CW, 2000, NAT PROD REP, V17, P447, DOI 10.1039/b002066o; ZIOLKOWSKI J, 1985, J SOLID STATE CHEM, V57, P269, DOI 10.1016/0022-4596(85)90152-5; ZIOLKOWSKI J, 1985, J SOLID STATE CHEM, V57, P291, DOI 10.1016/0022-4596(85)90153-7; ZIOLKOWSKI J, 1983, J CATAL, V84, P317; Zscherp C, 2001, BIOCHEMISTRY-US, V40, P1875, DOI 10.1021/bi002567y	74	29	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51888	51896		10.1074/jbc.M410867200	http://dx.doi.org/10.1074/jbc.M410867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452115	hybrid			2022-12-25	WOS:000225493400022
J	Mullner, C; Broos, LAM; van den Maagdenberg, AMJM; Striessnig, J				Mullner, C; Broos, LAM; van den Maagdenberg, AMJM; Striessnig, J			Familial hemiplegic migraine type 1 mutations K1336E, W1684R, and V1696I alter Ca(v)2.1 Ca2+ channel gating - Evidence for beta-subunit isoform-specific effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CALCIUM-CHANNEL; EPISODIC ATAXIA TYPE-2; FUNCTIONAL CONSEQUENCES; SYNAPTIC-TRANSMISSION; PROGRESSIVE ATAXIA; EXPRESSION; BRAIN; IDENTIFICATION; HETEROGENEITY; HIPPOCAMPUS	Mutations in the Ca(v)2.1 alpha1-subunit of P/Q-type Ca2+ channels cause human diseases, including familial hemiplegic migraine type-1 (FHM1). FHM1 mutations alter channel gating and enhanced channel activity at negative potentials appears to be a common pathogenetic mechanism. Different beta-subunit isoforms (primarily beta(4) and beta(3)) participate in the formation of Ca(v)2.1 channel complexes in mammalian brain. Here we investigated not only whether FHM1 mutations K1336E (KE), W1684R (WR), and V1696I (VI) can affect Ca(v)2.1 channel function but focused on the important question whether mutation-induced changes on channel gating depend on the beta-subunit isoform. Mutants were co-expressed in Xenopus oocytes together with beta(1), beta(3), or beta(4) and alpha(2)delta(1) subunits, and channel function was analyzed using the two-electrode voltage-clamp technique. WR shifted the voltage dependence for steady-state inactivation of Ba2+ inward currents (I-Ba) to more negative voltages with all beta-subunits tested. In contrast, a similar shift was observed for KE only when expressed with beta(3). All mutations promoted IBa decay during pulse trains only when expressed with beta(1) or beta(3) but not with beta(4). Enhanced decay could be explained by delayed recovery from inactivation. KE accelerated I-Ba inactivation only when co-expressed with beta(3), and VI slowed inactivation only with beta(1) or beta(3). KE and WR shifted channel activation of I-Ba to more negative voltages. As the beta-subunit composition of Ca(v)2.1 channels varies in different brain regions, our data predict that the functional FHM1 phenotype also varies between different neuronal compartments.	Univ Innsbruck, Inst Pharm, Abt Pharmakol & Toxikol, A-6020 Innsbruck, Austria; Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, NL-2300 Leiden, Netherlands	University of Innsbruck; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Striessnig, J (corresponding author), Univ Innsbruck, Inst Pharm, Abt Pharmakol & Toxikol, Peter Mayrstr 1-I, A-6020 Innsbruck, Austria.	joerg.striessnig@uibk.ac.at	Striessnig, Joerg/S-9334-2017; van den Maagdenberg, Arn M.J.M./AAE-9052-2019	Striessnig, Joerg/0000-0002-9406-7120; 	Austrian Science Fund FWF [P 17109] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Bayliss DA, 1997, J NEUROPHYSIOL, V77, P1362, DOI 10.1152/jn.1997.77.3.1362; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Day NC, 1998, MOL BRAIN RES, V60, P259, DOI 10.1016/S0169-328X(98)00186-7; Ducros A, 2001, NEW ENGL J MED, V345, P17, DOI 10.1056/NEJM200107053450103; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; Guida S, 2001, AM J HUM GENET, V68, P759, DOI 10.1086/318804; Hans M, 1999, J NEUROSCI, V19, P1610; Jen J, 1999, NEUROLOGY, V53, P34, DOI 10.1212/WNL.53.1.34; Jen J, 2001, NEUROLOGY, V57, P1843, DOI 10.1212/WNL.57.10.1843; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jouvenceau A, 2001, LANCET, V358, P801, DOI 10.1016/S0140-6736(01)05971-2; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; Kors EE, 2003, ARCH NEUROL-CHICAGO, V60, P684, DOI 10.1001/archneur.60.5.684; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lie AA, 1999, NEUROSCIENCE, V93, P449, DOI 10.1016/S0306-4522(99)00162-1; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; Ludwig A, 1997, J NEUROSCI, V17, P1339; Mochida S, 2003, P NATL ACAD SCI USA, V100, P2819, DOI 10.1073/pnas.262787699; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; Pietrobon D, 2002, MOL NEUROBIOL, V25, P31, DOI 10.1385/MN:25:1:031; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; Spafford JD, 2003, CURR OPIN NEUROBIOL, V13, P308, DOI 10.1016/S0959-4388(03)00061-8; Tottene A, 2002, P NATL ACAD SCI USA, V99, P13284, DOI 10.1073/pnas.192242399; van den Maagdenberg AMJM, 2004, NEURON, V41, P701, DOI 10.1016/S0896-6273(04)00085-6; Wappl E, 2002, J BIOL CHEM, V277, P6960, DOI 10.1074/jbc.M110948200; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403	31	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51844	51850		10.1074/jbc.M408756200	http://dx.doi.org/10.1074/jbc.M408756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15448138	hybrid			2022-12-25	WOS:000225493400017
J	Nixon, JC; Rajaiya, J; Webb, CF				Nixon, JC; Rajaiya, J; Webb, CF			Mutations in the DNA-binding domain of the transcription factor bright act as dominant negative proteins and interfere with immunoglobulin transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; DEAD RINGER GENE; CELL DIFFERENTIATION; EXPRESSION; FAMILY; SEQUENCE; REGION; LIPOPOLYSACCHARIDE; INTERLEUKIN-5; INDUCTION	Bright, for B cell regulator of immunoglobulin heavy chain transcription, binds A + T-rich sequences in the intronic enhancer regions of the murine heavy chain locus and 5'-flanking sequences of some variable heavy chain promoters. Most resting B cells do not express Bright; however, it is induced after stimulation with antigen or polyclonal mitogens. Bright activation results in up-regulation of mu transcription; however, it is not clear whether Bright function is critical for normal B cell development. To begin to address Bright function during B cell development, seven mutated forms of Bright were produced. Five of the seven mutants revealed little or no DNA binding activity. Furthermore, because Bright binds DNA as a dimer, two of the mutants formed complexes with wild type Bright and acted in a dominant negative fashion. Dominant negative Bright prevented the up-regulation of mu transcription in transfected Chinese hamster ovary cells transfected with wild type Bright. These data identify regions within Bright that are required for the DNA binding activity of Bright and for its function as a transcription factor.	Oklahoma Med Res Fdn, Immunobiol & Canc Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Webb, CF (corresponding author), Oklahoma Med Res Fdn, Immunobiol & Canc Res Program, 825 NE 13th St,MS 36, Oklahoma City, OK 73104 USA.	carol-webb@omrf.ouhsc.edu		Rajaiya, Jaya/0000-0002-4559-5613	NIAID NIH HHS [T32 AI007633, AI44215, AI45864] Funding Source: Medline; PHS HHS [T32 07364] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUCHANAN KL, 1995, J IMMUNOL, V155, P4270; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Iwahara J, 1999, EMBO J, V18, P6084, DOI 10.1093/emboj/18.21.6084; Iwahara J, 2002, EMBO J, V21, P1197, DOI 10.1093/emboj/21.5.1197; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Kaplan MH, 2001, J BIOL CHEM, V276, P21325, DOI 10.1074/jbc.M100836200; KEARNEY JF, 1976, J IMMUNOL, V117, P1567; Kortschak RD, 1998, GENOMICS, V51, P288, DOI 10.1006/geno.1998.5259; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; Nixon JC, 2004, CELL IMMUNOL, V228, P42, DOI 10.1016/j.cellimm.2004.03.004; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shandala T, 1999, DEVELOPMENT, V126, P4341; Shandala T, 2003, DEVELOPMENT, V130, P1505, DOI 10.1242/dev.00377; Shandala T, 2002, INT J DEV BIOL, V46, P423; Suzuki M, 1998, ONCOGENE, V17, P853, DOI 10.1038/sj.onc.1202163; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang ZY, 1999, MOL CELL BIOL, V19, P284; Webb C, 1999, COLD SPRING HARB SYM, V64, P109, DOI 10.1101/sqb.1999.64.109; Webb CF, 1998, J IMMUNOL, V160, P4747; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; WEBB CF, 1991, MOL CELL BIOL, V11, P5197, DOI 10.1128/MCB.11.10.5197; WEBB CF, 1989, J IMMUNOL, V143, P3934; WEBB CF, 1983, EUR J IMMUNOL, V13, P556, DOI 10.1002/eji.1830130708; Webb CF, 2000, J IMMUNOL, V165, P6956, DOI 10.4049/jimmunol.165.12.6956; Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95	30	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52465	52472		10.1074/jbc.M403028200	http://dx.doi.org/10.1074/jbc.M403028200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456761	hybrid			2022-12-25	WOS:000225493400091
J	Rochais, F; Vandecasteele, G; Lefebvre, F; Lugnier, C; Lum, H; Mazet, JL; Cooper, DMF; Fischmeister, R				Rochais, F; Vandecasteele, G; Lefebvre, F; Lugnier, C; Lum, H; Mazet, JL; Cooper, DMF; Fischmeister, R			Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes - An in vivo study using adenovirus-mediated expression of CNG channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADENYLYL-CYCLASE ACTIVITY; GATED CHANNELS; AMP PHOSPHODIESTERASE; VENTRICULAR MYOCYTES; CALCIUM-CHANNELS; BETA-ARRESTINS; LIVING CELLS; CA2+ CURRENT; ACTIVATION	Intracardiac cAMP levels are modulated by hormones and neuromediators with specific effects on contractility and metabolism. To understand how the same second messenger conveys different information, mutants of the rat olfactory cyclic nucleotide-gated (CNG) channel alpha-subunit CNGA2, encoded into adenoviruses, were used to monitor cAMP in adult rat ventricular myocytes. CNGA2 was not found in native myocytes but was strongly expressed in infected cells. In whole cell patch-clamp experiments, the forskolin analogue L-858051 (L-85) elicited a non-selective, Mg2+-sensitive current observed only in infected cells, which was thus identified as the CNG current (I-CNG). The beta-adrenergic agonist isoprenaline (ISO) also activated I-CNG, although the maximal efficiency was approximate to 5 times lower than with L-85. However, ISO and L-85 exerted a similar maximal increase of the L-type Ca2+ current. The use of a CNGA2 mutant with a higher sensitivity for cAMP indicated that this difference is caused by the activation of a localized fraction of CNG channels by ISO. cAMP-dependent protein kinase (PKA) blockade with H89 or PKI, or phosphodiesterase (PDE) inhibition with IBMX, dramatically potentiated ISO- and L-85-stimulated I-CNG. A similar potentiation of beta-adrenergic stimulation occurred when PDE4 was blocked, whereas PDE3 inhibition had a smaller effect (by 2-fold). ISO and L-85 increased total PDE3 and PDE4 activities in cardiomyocytes, although this effect was insensitive to H89. However, in the presence of IBMX, H89 had no effect on ISO stimulation of I-CNG. This study demonstrates that subsarcolemmal cAMP levels are dynamically regulated by a negative feedback involving PKA stimulation of subsarcolemmal cAMP-PDE.	Univ Paris Sud, INSERM, Fac Pharm, U 446, F-92296 Chatenay Malabry, France; Univ Louis Pasteur Strasbourg 1, Lab Pharmacol & Physicochim Interact Cellulaires, UMR 7034, CNRS,Fac Pharm, F-67401 Illkirch Graffenstaden, France; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Cambridge	Vandecasteele, G (corresponding author), Univ Paris Sud, INSERM, Fac Pharm, U 446, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	gregoire.vandecasteele@cep.u-psud.fr	Rochais, Francesca/ABF-4675-2021; lugnier, claire/AAF-3911-2020; Rochais, Francesca/A-5326-2017; Fischmeister, Rodolphe/L-6061-2018; Vandecasteele, Gregoire/M-2922-2018	Rochais, Francesca/0000-0001-9355-8916; Rochais, Francesca/0000-0001-9355-8916; Fischmeister, Rodolphe/0000-0003-2086-9865; Vandecasteele, Gregoire/0000-0002-4046-4171; LEFEBVRE, florence/0000-0003-0133-5825				AHMAD I, 1990, BIOCHEM BIOPH RES CO, V173, P463, DOI 10.1016/S0006-291X(05)81081-2; Baillie GS, 2003, P NATL ACAD SCI USA, V100, P940, DOI 10.1073/pnas.262787199; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; Bolger GB, 2003, J BIOL CHEM, V278, P49230, DOI 10.1074/jbc.M303772200; BRUNTON LL, 1979, NATURE, V280, P78, DOI 10.1038/280078a0; Bushnik T, 1996, BIOCHEM SOC T, V24, P1014, DOI 10.1042/bst0241014; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cui H, 2003, BIOCHEM BIOPH RES CO, V307, P119, DOI 10.1016/S0006-291X(03)01130-6; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; EcklyMichel A, 1997, BRIT J PHARMACOL, V122, P158, DOI 10.1038/sj.bjp.0701339; ESPINASSE I, 1995, J MOL CELL CARDIOL, V27, P1789, DOI 10.1016/0022-2828(95)90002-0; Fagan KA, 2001, FEBS LETT, V500, P85, DOI 10.1016/S0014-5793(01)02564-9; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Geoffroy V, 1999, EUR J BIOCHEM, V259, P892, DOI 10.1046/j.1432-1327.1999.00123.x; Georget M, 2003, FASEB J, V17, P1380, DOI 10.1096/fj.02-0784com; Goaillard JM, 2001, J PHYSIOL-LONDON, V530, P79, DOI 10.1111/j.1469-7793.2001.0079m.x; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; HUNDAL SP, 1993, BIOCHEM SOC T, V21, P119; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; JUREVICIUS J, J PHYSL, V551, P239; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KERAVIS TM, 1980, BIOCHIM BIOPHYS ACTA, V613, P116, DOI 10.1016/0005-2744(80)90198-9; KIRSTEIN M, 1995, J CLIN INVEST, V95, P794, DOI 10.1172/JCI117729; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGNIER C, 1993, J PHARMACOL EXP THER, V265, P1142; Lum H, 1999, AM J PHYSIOL-CELL PH, V277, pC580, DOI 10.1152/ajpcell.1999.277.3.C580; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; MULLER B, 1990, J CARDIOVASC PHARM, V16, P796, DOI 10.1097/00005344-199011000-00016; MULLER B, 1992, EUR J PHARM-MOLEC PH, V225, P263, DOI 10.1016/0922-4106(92)90028-T; Murthy KS, 2002, AM J PHYSIOL-CELL PH, V282, pC508, DOI 10.1152/ajpcell.00373.2001; OCONNELL TD, 2003, AFCS RES REPORTS, V1; Oki N, 2000, J BIOL CHEM, V275, P10831, DOI 10.1074/jbc.275.15.10831; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Petroff MGV, 2001, CIRC RES, V89, P445, DOI 10.1161/hh1701.095716; Rich TC, 2000, J GEN PHYSIOL, V116, P147, DOI 10.1085/jgp.116.2.147; Rich TC, 2002, ANN BIOMED ENG, V30, P1088, DOI 10.1114/1.1511242; Rich TC, 2001, J GEN PHYSIOL, V118, P63, DOI 10.1085/jgp.118.1.63; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Ruiz ML, 1996, J MOL CELL CARDIOL, V28, P1453, DOI 10.1006/jmcc.1996.0136; Saucerman JJ, 2003, J BIOL CHEM, V278, P47997, DOI 10.1074/jbc.M308362200; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAHID M, 1990, N-S ARCH PHARMACOL, V342, P698, DOI 10.1007/BF00175715; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Stoclet J.C., 1995, EXPERT OPIN INV DRUG, V4, P1081; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Verde I, 1999, BRIT J PHARMACOL, V127, P65, DOI 10.1038/sj.bjp.0702506; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Wechsler J, 2002, J BIOL CHEM, V277, P38072, DOI 10.1074/jbc.M203647200; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; YU HJ, 1993, MOL PHARMACOL, V44, P689; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	68	109	113	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52095	52105		10.1074/jbc.M405697200	http://dx.doi.org/10.1074/jbc.M405697200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466415	Green Published, hybrid			2022-12-25	WOS:000225493400048
J	Garbarino-Pico, E; Carpentieri, AR; Contin, MA; Sarmiento, MI; Brocco, MA; Panzetta, P; Rosenstein, RE; Caputto, BL; Guido, ME				Garbarino-Pico, E; Carpentieri, AR; Contin, MA; Sarmiento, MI; Brocco, MA; Panzetta, P; Rosenstein, RE; Caputto, BL; Guido, ME			Retinal ganglion cells are autonomous circadian oscillators synthesizing N-acetylserotonin during the day	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLDEN-HAMSTER RETINA; EARLY GENE-EXPRESSION; CHICKEN PINEAL-GLAND; ACETYLTRANSFERASE ACTIVITY; SUPRACHIASMATIC NUCLEUS; MELATONIN SYNTHESIS; MESSENGER-RNA; CYCLIC-AMP; PHOTIC REGULATION; MAMMALIAN RETINA	Retinal ganglion cells send visual and circadian information to the brain regarding the environmental light-dark cycles. We investigated the capability of retinal ganglion cells of synthesizing melatonin, a highly reliable circadian marker that regulates retinal physiology, as well as the capacity of these cells to function as autonomous circadian oscillators. Chick retinal ganglion cells presented higher levels of melatonin assessed by radioimmunoassay during both the subjective day in constant darkness and the light phase of a light-dark cycle. Similar changes were observed in mRNA levels and activity of arylalkylamine N-acetyltransferase, a key enzyme in melatonin biosynthesis, with the highest levels of both parameters during the subjective day. These daily variations were preceded by the elevation of cyclic-AMP content, the second messenger involved in the regulation of melatonin biosynthesis. Moreover, cultures of immunopurified retinal ganglion cells at embryonic day 8 synchronized by medium exchange synthesized a [H-3] melatonin-like indole from [H-3] tryptophan. This [H-3] indole was rapidly released to the culture medium and exhibited a daily variation, with levels peaking 8 h after synchronization, which declined a few hours later. Cultures of embryonic retinal ganglion cells also showed self-sustained daily rhythms in arylalkylamine N-acetyltransferase mRNA expression during at least three cycles with a period near 24 h. These rhythms were also observed after the application of glutamate. The results demonstrate that chick retinal ganglion cells may function as autonomous circadian oscillators synthesizing a melatonin-like indole during the day.	Univ Nacl Cordoba, Fac Ciencias Quim, CIQUIBIC CONICET, Dept Quim Biol, RA-5000 Cordoba, Argentina; Univ Buenos Aires, Fac Med, Dept Bioquim Humana, RA-1121 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; University of Buenos Aires	Guido, ME (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, CIQUIBIC CONICET, Dept Quim Biol, RA-5000 Cordoba, Argentina.	mguido@dqb.fcq.unc.edu.ar	Agata, Carpentieri/AAE-4504-2022	Carpentieri, Agata/0000-0002-6426-0501; Garbarino Pico, Eduardo/0000-0002-2931-2038				ALONSOGOMEZ AL, 1995, J NEUROCHEM, V46, P33; ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11, DOI 10.1101/SQB.1960.025.01.004; AVENDANO G, 1990, NEUROCHEM INT, V17, P117, DOI 10.1016/0197-0186(90)90075-5; AXELROD J, 1961, J BIOL CHEM, V236, P211; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; Bayarri MJ, 2003, BRAIN RES, V969, P175, DOI 10.1016/S0006-8993(03)02297-2; Benyassi A, 2000, NEUROREPORT, V11, P255, DOI 10.1097/00001756-200002070-00006; Bernard M, 1997, J NEUROCHEM, V68, P213; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; BESHARSE JC, 1983, NATURE, V305, P133, DOI 10.1038/305133a0; BESHARSE JC, 1983, SCIENCE, V219, P1341, DOI 10.1126/science.6828862; BINKLEY S, 1979, NATURE, V281, P479, DOI 10.1038/281479a0; BINKLEY S, 1980, J COMP PHYSIOL, V139, P103, DOI 10.1007/BF00691023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandstatter R, 2000, P NATL ACAD SCI USA, V97, P12324, DOI 10.1073/pnas.200354997; Brocco MA, 2002, NEUROSCI LETT, V328, P221, DOI 10.1016/S0304-3940(02)00516-5; Brocco MA, 1999, DEV BRAIN RES, V118, P23, DOI 10.1016/S0165-3806(99)00120-0; Butowt R, 2000, J NEUROSCI METH, V95, P29, DOI 10.1016/S0165-0270(99)00149-1; CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S; *CAN WHOL DRUG ASS, 1999, GUID GOV REL PROGR, P1; Caputto BL, 2000, NEUROCHEM RES, V25, P153, DOI 10.1023/A:1007508020173; CASSONE VM, 1990, J COMP PHYSIOL A, V167, P187; CHAMPNEY TH, 1984, J NEUROSCI RES, V11, P59, DOI 10.1002/jnr.490110107; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chong NW, 1998, MOL BRAIN RES, V61, P243, DOI 10.1016/S0169-328X(98)00219-8; Coon SL, 1999, J BIOL CHEM, V274, P9076, DOI 10.1074/jbc.274.13.9076; David-Gray ZK, 1998, NAT NEUROSCI, V1, P655, DOI 10.1038/3656; DOWSING BJ, 1992, MOL BRAIN RES, V14, P250, DOI 10.1016/0169-328X(92)90180-J; DUBOCOVICH ML, 1983, NATURE, V306, P782, DOI 10.1038/306782a0; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Ebling FJP, 1996, PROG NEUROBIOL, V50, P109, DOI 10.1016/S0301-0082(96)00032-9; FAILLACE MP, 1995, NEUROREPORT, V6, P2093, DOI 10.1097/00001756-199510010-00033; Faillace MP, 1996, J NEUROCHEM, V67, P623; FAILLACE MP, 1994, J NEUROCHEM, V62, P1995; Falcon J, 2003, J NEUROENDOCRINOL, V15, P378, DOI 10.1046/j.1365-2826.2003.00993.x; FALCON J, 1991, CELL TISSUE RES, V265, P601, DOI 10.1007/BF00340884; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; FRENCH PW, 1986, J NEUROSCI RES, V16, P479, DOI 10.1002/jnr.490160304; Fukuhara C, 2004, J NEUROSCI, V24, P1803, DOI 10.1523/JNEUROSCI.4988-03.2004; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Gooley JJ, 2001, NAT NEUROSCI, V4, P1165, DOI 10.1038/nn768; Green CB, 1998, TRENDS CELL BIOL, V8, P224, DOI 10.1016/S0962-8924(98)01269-0; GREENBERGER LM, 1985, J COMP NEUROL, V239, P361, DOI 10.1002/cne.902390402; Guido ME, 1999, NEUROSCIENCE, V90, P555, DOI 10.1016/S0306-4522(98)00467-9; Guido ME, 2002, NEUROCHEM RES, V27, P1473, DOI 10.1023/A:1021696321391; Guido ME, 1999, MOL BRAIN RES, V67, P247, DOI 10.1016/S0169-328X(99)00074-1; Guido ME, 1999, BRAIN RES PROTOC, V4, P147, DOI 10.1016/S1385-299X(99)00013-6; Guido ME, 2001, J NEUROCHEM, V76, P835, DOI 10.1046/j.1471-4159.2001.00081.x; Guido ME, 1996, J NEUROSCI RES, V43, P93, DOI 10.1002/jnr.490430112; HAMM HE, 1983, BRAIN RES, V266, P287, DOI 10.1016/0006-8993(83)90660-1; HAMM HE, 1980, P NATL ACAD SCI-BIOL, V77, P4998, DOI 10.1073/pnas.77.8.4998; Haque R, 2002, NEUROREPORT, V13, P2247, DOI 10.1097/00001756-200212030-00016; Hastings J.W., 1991, NEURAL INTEGRATIVE A, P435; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; Higgs MH, 1999, J NEUROSCI, V19, P3691; Iigo M, 1997, NEUROREPORT, V8, P1631; IUVONE PM, 1991, J NEUROCHEM, V57, P615, DOI 10.1111/j.1471-4159.1991.tb03792.x; IUVONE PM, 1990, J NEUROCHEM, V55, P673, DOI 10.1111/j.1471-4159.1990.tb04186.x; Iuvone PM, 2002, INVEST OPHTH VIS SCI, V43, P564; IUVONE PM, 1990, J NEUROCHEM, V54, P1562, DOI 10.1111/j.1471-4159.1990.tb01205.x; IUVONE PM, 2000, MELATONIN 4 DECADES, P31; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1969, ANAL BIOCHEM, V31, P480, DOI 10.1016/0003-2697(69)90290-5; Larkin P, 1999, MOL BRAIN RES, V70, P253, DOI 10.1016/S0169-328X(99)00154-0; Liu CM, 2004, CELL TISSUE RES, V315, P197, DOI 10.1007/s00441-003-0822-1; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Matsui K, 1998, J NEUROSCI, V18, P4500; Mey J, 2000, BRAIN RES REV, V32, P343, DOI 10.1016/S0165-0173(99)00022-3; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; MORIN LP, 1994, BRAIN RES REV, V19, P102, DOI 10.1016/0165-0173(94)90005-1; Natesan AK, 2002, VISUAL NEUROSCI, V19, P265, DOI 10.1017/S0952523802192042; Niki T, 1998, BIOCHEM BIOPH RES CO, V248, P115, DOI 10.1006/bbrc.1998.8916; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; PIERCE ME, 1993, NEURON, V10, P579, DOI 10.1016/0896-6273(93)90161-J; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Reppert SM, 1997, J BIOL RHYTHM, V12, P528, DOI 10.1177/074873049701200606; Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701; RUSAK B, 1990, ANNU REV NEUROSCI, V13, P387, DOI 10.1146/annurev.ne.13.030190.002131; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; Selby CP, 2000, P NATL ACAD SCI USA, V97, P14697, DOI 10.1073/pnas.260498597; TAKAHASHI JS, 1979, FED PROC, V38, P2583; TAKAO M, 1988, VISION RES, V28, P471, DOI 10.1016/0042-6989(88)90169-1; TESSIERLAVIGNE M, 1991, PRINCIPLES NEURAL SC, P400; THOMAS KB, 1993, BRAIN RES, V601, P303; Tosini G, 2000, CHRONOBIOL INT, V17, P599, DOI 10.1081/CBI-100101067; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; UNDERWOOD H, 1990, J BIOL RHYTHM, V5, P257, DOI 10.1177/074873049000500307; VALENZUELA P, 1981, NATURE, V289, P650, DOI 10.1038/289650a0; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; YOSHIDA K, 1993, NEURON, V10, P1049, DOI 10.1016/0896-6273(93)90053-T; Yoshimura T, 2001, AM J PHYSIOL-REG I, V280, pR1185, DOI 10.1152/ajpregu.2001.280.4.R1185; ZACHMANN A, 1992, CAN J ZOOL, V70, P25, DOI 10.1139/z92-004; ZAWILSKA JB, 1992, NEUROSCI LETT, V135, P71, DOI 10.1016/0304-3940(92)90138-W	100	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51172	51181		10.1074/jbc.M309248200	http://dx.doi.org/10.1074/jbc.M309248200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448149	hybrid			2022-12-25	WOS:000225355800064
J	Park, SJ; Wu, CH; Gordon, JD; Zhong, XL; Emami, A; Safa, AR				Park, SJ; Wu, CH; Gordon, JD; Zhong, XL; Emami, A; Safa, AR			Taxol induces caspase-10-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PACLITAXEL-INDUCED APOPTOSIS; LEUKEMIA-CELL LINE; HUMAN NEUROBLASTOMA-CELLS; BREAST-CARCINOMA CELLS; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; CHEMOTHERAPEUTIC DRUGS; CASPASE ACTIVATION; OCCURS DOWNSTREAM; ANTICANCER DRUGS	Taxol ( paclitaxel) is known to inhibit cell growth and trigger significant apoptosis in various cancer cells. Although taxol induces apoptosis of cancer cells, its exact mechanism of action is not yet known. In this study we investigated death receptors, FAS-associated death domain protein (FADD), the activation of caspases-10 and - 8 as well as the downstream caspases, and reactive oxygen species (ROS) in taxol-induced apoptosis in the CCRF-HSB-2 human lymphoblastic leukemia cell line. Pretreating the cells with neutralizing antibodies to Fas, tumor necrosis factor (TNF)-alpha receptor 1, or TNF-related apoptosis-inducing ligand receptors (DR4 and DR5) did not affect taxol-induced apoptosis, but transfection of the cells with a dominant negative FADD plasmid resulted in inhibition of taxol-induced apoptosis, revealing that taxol induces apoptosis independently of these death receptors but dependently on FADD. Furthermore, the drug induced activation of caspases-10, - 8, - 6, and - 3, cleaved Bcl-2, Bid, poly(ADP-ribose) polymerase, and lamin B, and down-regulated cellular levels of FLICE-like inhibitory protein ( FLIP) and X-chromosome-linked inhibitor of apoptosis protein ( XIAP). However, despite the release of cytochrome c from the mitochondria in taxol-treated cells, caspase-9 was not activated. Inhibitors of caspases-8, - 6, or - 3 partially inhibited taxol-induced apoptosis, whereas the caspase-10 inhibitor totally abrogated this process. Taxol-induced apoptosis was also associated with decreased mitochondrial membrane potential (DeltaPsim) and a significant increase in ROS generation. However, increased ROS production was not directly involved in taxol-triggered apoptosis. Therefore, these results demonstrate for the first time that taxol induces FADD-dependent apoptosis primarily through activation of caspase-10 but independently of death receptors.	Indiana Univ, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Safa, AR (corresponding author), Indiana Univ, Dept Pharmacol & Toxicol, 1044 W Walnut R4-119, Indianapolis, IN 46202 USA.	asafa@iupui.edu		Zhong, Xiaoling/0000-0002-9458-5382; Gordon, John/0000-0002-9781-9842	NATIONAL CANCER INSTITUTE [R01CA090878, R01CA080734, R01CA101743] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90878, CA 080734, CA 101743] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; Andre N, 2000, CANCER RES, V60, P5349; Andre N, 2002, FEBS LETT, V532, P256, DOI 10.1016/S0014-5793(02)03691-8; Aronis A, 2003, CELL DEATH DIFFER, V10, P335, DOI 10.1038/sj.cdd.4401150; Boldt S, 2002, CARCINOGENESIS, V23, P1831, DOI 10.1093/carcin/23.11.1831; Boudny V, 2002, BRIT J CANCER, V86, P463, DOI 10.1038/sj.bjc.6600080; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; Chang DW, 2003, J BIOL CHEM, V278, P16466, DOI 10.1074/jbc.C300089200; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; Do Yoo Y, 1998, CLIN CANCER RES, V4, P3063; Fan WM, 1999, BIOCHEM PHARMACOL, V57, P1215; Ferreira CG, 2000, CANCER RES, V60, P7133; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gordon J, 2003, INT J CANCER, V103, P316, DOI 10.1002/ijc.10828; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Huisman C, 2002, CLIN CANCER RES, V8, P596; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Ibrado AM, 1997, CANCER RES, V57, P1109; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kidd JF, 2002, J BIOL CHEM, V277, P6504, DOI 10.1074/jbc.M106802200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin HL, 2000, CANCER-AM CANCER SOC, V89, P983, DOI 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.3.CO;2-7; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McGinnis KM, 2003, NEUROCHEM INT, V42, P517, DOI 10.1016/S0197-0186(02)00078-5; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nimmanapalli R, 2001, CANCER RES, V61, P759; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038/sj.cdd.4401012; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Salah-Eldin AE, 2003, INT J CANCER, V103, P53, DOI 10.1002/ijc.10782; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Stadheim TA, 2001, CANCER RES, V61, P1533; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Tudor G, 2000, CELL DEATH DIFFER, V7, P574, DOI 10.1038/sj.cdd.4400688; Varbiro G, 2001, FREE RADICAL BIO MED, V31, P548, DOI 10.1016/S0891-5849(01)00616-5; Vikhanskaya F, 1998, EXP CELL RES, V241, P96, DOI 10.1006/excr.1998.4018; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wolfson M, 1997, INT J CANCER, V70, P248, DOI 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Wu CH, 2002, ONCOGENE, V21, P5160, DOI 10.1038/sj.onc.1205639; Wu CH, 2001, ONCOGENE, V20, P7006, DOI 10.1038/sj.onc.1204893; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeung TK, 1999, BIOCHEM BIOPH RES CO, V263, P398, DOI 10.1006/bbrc.1999.1375; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	74	179	183	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51057	51067		10.1074/jbc.M406543200	http://dx.doi.org/10.1074/jbc.M406543200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452117	hybrid			2022-12-25	WOS:000225355800051
J	Rothblum, K; Stahl, RC; Carey, DJ				Rothblum, K; Stahl, RC; Carey, DJ			Constitutive release of alpha 4 type V collagen N-terminal domain by Schwann cells and binding to cell surface and extracellular matrix heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIGRATION; IDENTIFICATION; SYNDECAN-3; RECEPTORS; CHAIN	During peripheral nerve development, Schwann cells synthesize collagen type V molecules that contain alpha4(V) chains. This collagen subunit possesses an N-terminal domain (NTD) that contains a unique high affinity heparin binding site. The alpha4(V)-NTD is adhesive for Schwann cells and sensory neurons and is an excellent substrate for Schwann cell and axonal migration. Here we show that the alpha4(V)-NTD is released constitutively by Schwann cells both in culture and in vivo. In cultures of neonatal rat Schwann cells, alpha4(V)-NTD release is increased significantly by ascorbate treatment, which facilitates collagen post-translational modification and collagen trimer assembly. In peripheral nerve tissue, the alpha4(V)-NTD is localized to the region of the outer Schwann cell membrane and associated extracellular matrix. The released alpha4(V)-NTD binds to the cell surface and extracellular matrix heparan sulfate proteoglycans of Schwann cells. Pull-down assays and immunofluorescent staining showed that the major alpha4(V)-NTD-binding proteins are glypican-1 and perlecan. alpha4(V)-NTD binding occurs via a mechanism that requires the high affinity heparin binding site and that is blocked by soluble heparin, demonstrating that binding to proteoglycans is mediated by their heparan sulfate chains.	Geisinger Med Clin, Weis Ctr Res, Danville, PA 17822 USA	Geisinger Medical Center	Carey, DJ (corresponding author), Geisinger Med Clin, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.	djcarey@geisinger.edu			NINDS NIH HHS [NS21925] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTON ES, 1994, DEV BIOL, V164, P133, DOI 10.1006/dbio.1994.1186; Asundi VK, 2003, J NEUROSCI RES, V73, P593, DOI 10.1002/jnr.10699; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BUNGE RP, 1986, ANNU REV NEUROSCI, V9, P305; CAREY DJ, 1993, EXP CELL RES, V208, P10, DOI 10.1006/excr.1993.1217; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; Carey DJ, 1997, BIOCHEM J, V327, P1; CAREY DJ, 1986, J CELL BIOL, V102, P2224; Chernousov MA, 2000, J BIOL CHEM, V275, P28208; Chernousov MA, 1999, J NEUROSCI RES, V56, P284, DOI 10.1002/(SICI)1097-4547(19990501)56:3<284::AID-JNR8>3.3.CO;2-H; Chernousov MA, 1996, J BIOL CHEM, V271, P13844, DOI 10.1074/jbc.271.23.13844; Chernousov MA, 1998, J CELL SCI, V111, P2763; Chernousov MA, 2001, J NEUROSCI, V21, P6125, DOI 10.1523/JNEUROSCI.21-16-06125.2001; Chernousov MA, 2000, HISTOL HISTOPATHOL, V15, P593, DOI 10.14670/HH-15.593; ECCLESTON PA, 1992, EXP CELL RES, V199, P1, DOI 10.1016/0014-4827(92)90455-H; Erdman R, 2002, J BIOL CHEM, V277, P7619, DOI 10.1074/jbc.M111311200; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200	19	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51282	51288		10.1074/jbc.M408837200	http://dx.doi.org/10.1074/jbc.M408837200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15383532	hybrid			2022-12-25	WOS:000225355800077
J	Jacobs, CM; Boldingh, KA; Slagsvold, HH; Thoresen, GH; Paulsen, RE				Jacobs, CM; Boldingh, KA; Slagsvold, HH; Thoresen, GH; Paulsen, RE			ERK2 prohibits apoptosis-induced subcellular translocation of orphan nuclear receptor NGFI-B/TR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; CEREBELLAR GRANULE NEURONS; NGFI-B; MEMBRANE DEPOLARIZATION; GLUTAMATE NEUROTOXICITY; INDUCIBLE MEMBER; CELL-DEATH; PC12 CELLS; GENE	Transcription factor NGFI-B ( neuronal growth factor-induced clone B), also called Nur77 or TR3, is an immediate early gene and an orphan member of the nuclear receptor family. The NGFI-B protein also has a function distinct from that of a transcription factor; it translocates to mitochondria to initiate apoptosis. Recently, it was demonstrated that NGFI-B interacts with Bcl-2 by inducing a conformational change in Bcl-2, converting it from protector to a killer (Lin, B., Kolluri, S. K., Lin, F., Liu, W., Han, Y. H., Cao, X., Dawson, M. I., Reed, J. C., and Zhang, X. K. ( 2004) Cell 116, 527 - 540). After exposing rat cerebellar granule neurons to glutamate ( 100 muM, 15 min), NGFI-B translocated to the mitochondria. Growth factors such as the epidermal growth factor activate the MAP kinase ERK, the activity of which may determine whether a cell survives or undergoes apoptosis. In the present study we found that the epidermal growth factor activated ERK2 in cerebellar granule neurons and that this activation prohibited glutamate-induced subcellular translocation of NGFI-B. Likewise, overexpressed active ERK2 resulted in a predominant nuclear localization of green fluorescent protein-tagged NGFI-B. Thus, activation of ERK2 may overcome apoptosis-induced subcellular translocation of NGFI-B. This finding represents a novel and rapid growth factor survival pathway that is independent of gene regulation.	Univ Oslo, Inst Pharm, N-0316 Oslo, Norway	University of Oslo	Paulsen, RE (corresponding author), Univ Oslo, Inst Pharm, POB 1068 Blindern, N-0316 Oslo, Norway.	r.e.paulsen@farmasi.uio.no		Paulsen, Ragnhild Elisabeth/0000-0003-0154-8775				ABE K, 1992, NEUROSCI RES, V14, P117, DOI 10.1016/0168-0102(92)90087-S; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; CASPER D, 1995, J NEUROCHEM, V65, P1016; Castro-Obregon S, 2004, J BIOL CHEM, V279, P17543, DOI 10.1074/jbc.M312363200; Cheung NS, 1998, NEUROPHARMACOLOGY, V37, P1419, DOI 10.1016/S0028-3908(98)00123-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Ciani E, 1995, J MOL NEUROSCI, V6, P131, DOI 10.1007/BF02736772; Ciani E, 1996, BRAIN RES, V728, P1; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; GALLO V, 1987, J NEUROSCI, V7, P2203; Gunn-Moore FJ, 1998, NEUROSCI LETT, V250, P53, DOI 10.1016/S0304-3940(98)00438-8; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MAIESE K, 1993, J NEUROSCI, V13, P3034; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Olney J W, 1986, Adv Exp Med Biol, V203, P631; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Slagsvold HH, 2003, BRAIN RES, V984, P111, DOI 10.1016/S0006-8993(03)03119-6; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Thoresen GH, 1998, J CELL PHYSIOL, V175, P10, DOI 10.1002/(SICI)1097-4652(199804)175:1<10::AID-JCP2>3.3.CO;2-6; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	35	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50097	50101		10.1074/jbc.M409145200	http://dx.doi.org/10.1074/jbc.M409145200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15448159	hybrid			2022-12-25	WOS:000225229500068
J	Sisci, D; Aquila, S; Middea, E; Gentile, M; Maggiolini, M; Mastroianni, F; Montanaro, D; Ando, S				Sisci, D; Aquila, S; Middea, E; Gentile, M; Maggiolini, M; Mastroianni, F; Montanaro, D; Ando, S			Fibronectin and type IV collagen activate ER alpha AF-1 by c-Src pathway: effect on breast cancer cell motility	ONCOGENE			English	Article						estrogen receptor alpha; extracellular matrix; fibronectin; type IV collagen; c-Src	FOCAL ADHESION KINASE; MEDIATED SIGNAL-TRANSDUCTION; STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; GROWTH-FACTOR; MAP KINASE; PROTEIN-KINASE; TYROSINE KINASES; FAMILY KINASES; MAMMARY-TUMORS	The expression of estrogen receptor alpha (ERalpha) is generally associated with a less invasive and aggressive phenotype in breast carcinoma. In an attempt to understand the role of ERalpha in regulating breast cancer cells invasiveness, we have demonstrated that cell adhesion on fibronectin (Fn) and type IV Collagen (Col) induces ERalpha-mediated transcription and reduces cell migration in MCF-7 and in MDA-MB-231 cell lines expressing ERalpha. Analysis of deleted mutants of ERalpha indicates that the transcriptional activation function (AF)-1 is required for ERalpha-mediated transcription as well as for the inhibition of cell migration induced by cell adhesion on extracellular matrix(ECM) proteins. In addition, the nuclear localization signal region and some serine residues in the AF-1 of the ERalpha are both required for the regulation of cell invasiveness as we have observed in HeLa cells. It is worth noting that c-Src activation is coincident with adhesion of cells to ECM proteins and that the inhibition of c-Src activity by PP2 or the expression of a dominant-negative c-Src abolishes ERalpha-mediated transcription and partially reverts the inhibition of cell invasiveness in ERalpha-positive cancer cells. These findings address the integrated role of ECM proteins and ERalpha in influencing breast cancer cell motility through a mechanism that involves c-Src and seems not to be related to a specific cell type.	Univ Calabria, Ctr Sanitario, Dipartimento Biol Cellulare, I-87030 Cosenza, Italy; Univ Calabria, Dipartimento Farmacobiol, Arcavacata Di Rende, Italy	University of Calabria; University of Calabria	Ando, S (corresponding author), Univ Calabria, Ctr Sanitario, Dipartimento Biol Cellulare, I-87030 Cosenza, Italy.	sebastiano.ando@unical.it	Maggiolini, Marcello/Z-4729-2019; /AAD-9701-2019	/0000-0001-6577-1541; Maggiolini, Marcello/0000-0002-7485-854X; AQUILA, Saveria/0000-0003-4738-6927				Abidi SMA, 1997, CLIN EXP METASTAS, V15, P432, DOI 10.1023/A:1018458406797; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Aplin AE, 1999, J CELL SCI, V112, P695; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; CHEN Q, 1994, J BIOL CHEM, V6, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Couse JF, 1995, BIOCHEM SOC T, V23, P929, DOI 10.1042/bst0230929; Crowe David L., 1999, Neoplasia (New York), V1, P368, DOI 10.1038/sj.neo.7900041; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Feng WJ, 2001, MOL ENDOCRINOL, V15, P32, DOI 10.1210/me.15.1.32; FRAKER LD, 1984, CANCER RES, V44, P5757; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Hynes RO, 1990, FIBRONECTINS; IGNARTROWBRIDGE DM, 1995, ENVIRON HEALTH PERSP, V103, P35, DOI 10.2307/3432505; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; LEHRER S, 1989, MT SINAI J MED, V56, P83; Lin TH, 1997, J BIOL CHEM, V272, P8849; Liotta L A, 1991, Semin Cancer Biol, V2, P111; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MCGUIRE WL, 1986, CANCER SURV, V5, P527; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OSBORNE CK, 1985, CANCER RES, V45, P584; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; PRICE JE, 1990, CANCER RES, V50, P717; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Suen PW, 1999, J CELL SCI, V112, P4067; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	54	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8920	8930		10.1038/sj.onc.1208098	http://dx.doi.org/10.1038/sj.onc.1208098			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467744				2022-12-25	WOS:000225354600007
J	Bower, KE; Fritz, JM; McGuire, KL				Bower, KE; Fritz, JM; McGuire, KL			Transcriptional repression of MMP-1 by p21(SNFT) and reduced in vitro invasiveness of hepatocarcinoma cells	ONCOGENE			English	Article						AP-1; Ets; bZIP; Jun; collagen; matrix metalloproteinase	MATRIX METALLOPROTEINASE-1; GENE-EXPRESSION; COLLAGENASE GENE; POOR-PROGNOSIS; INHIBITORS; CARCINOMA; PROTEIN	p21(SNFT) (21 kDa small nuclear factor isolated from T cells) is a human basic leucine zipper transcription factor that can repress AP-1-mediated transcription. We show here that overexpression of p21(SNFT) in HepG2 cells leads to repression of matrix metalloproteinase-1 by 70-80%. p21(SNFT) interacted with Jun at the matrix metalloproteinase-1 promoter -88 Ets/AP-1 enhancer element, where Jun is known to activate transcription via interaction with Fos and Ets proteins. When p21(SNFT)/Jun dimers bound the element in the presence of Ets, DNA was protected differently than when Fos was paired with Jun. The data suggest a difference in overall conformation between p21(SNFT)-containing and Fos-containing complexes that may be involved in the repression of matrix metalloproteinase-1 by p21(SNFT). Overexpression of p21(SNFT) led to a reduction in invasiveness of HepG2 cells through type I collagen and reconstituted basement membrane, an effect similar to that obtained via direct immunodepletion of matrix metalloproteinase-1. The results indicate that the mechanism of repression of matrix metalloproteinase-1 by p21(SNFT) may be exploited in inhibiting pathological matrix remodeling during cancer progression in vivo.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Bower, KE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd BCC239, La Jolla, CA 92037 USA.	kbower@scripps.edu						ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Blanc JF, 2002, INT J ONCOL, V20, P1129; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; Bower KE, 2002, J BIOL CHEM, V277, P34967, DOI 10.1074/jbc.M205048200; Buttice G, 1996, ONCOGENE, V13, P2297; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Iacobelli M, 2000, J IMMUNOL, V165, P860, DOI 10.4049/jimmunol.165.2.860; Inoue T, 1999, INT J MOL MED, V4, P73; Ito T, 1999, MODERN PATHOL, V12, P669; Jonat C, 1992, Matrix Suppl, V1, P145; Kim JH, 2001, MOL CELLS, V12, P32; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; McGuire KL, 1997, J IMMUNOL, V159, P1319; Mengshol JA, 2002, ARTHRITIS RHEUM, V46, P13, DOI 10.1002/1529-0131(200201)46:1<13::AID-ART497>3.0.CO;2-S; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Murray GI, 1998, J PATHOL, V185, P256; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; Ozaki I, 2002, J HEPATOL, V36, P169, DOI 10.1016/S0168-8278(01)00245-8; Siller-Lopez F, 2000, J HEPATOL, V33, P758, DOI 10.1016/S0168-8278(00)80307-4; Sunami E, 2000, Oncologist, V5, P108, DOI 10.1634/theoncologist.5-2-108; Tini M, 2002, COMP BIOCHEM PHYS A, V131, P569, DOI 10.1016/S1095-6433(01)00508-6; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781	29	7	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8805	8814		10.1038/sj.onc.1208109	http://dx.doi.org/10.1038/sj.onc.1208109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467742				2022-12-25	WOS:000225165100010
J	von Haefen, C; Gillissen, B; Hemmati, PG; Wendt, J; Guner, D; Mrozek, A; Belka, C; Dorken, B; Daniel, PT				von Haefen, C; Gillissen, B; Hemmati, PG; Wendt, J; Guner, D; Mrozek, A; Belka, C; Dorken, B; Daniel, PT			Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway	ONCOGENE			English	Article						TRAIL; Bax; Bak; apoptosis; mitochondrial pathway; synergy	NEGATIVE PROGNOSTIC-FACTOR; DEATH LIGAND; CELL-DEATH; PROTEIN EXPRESSION; ANTITUMOR-ACTIVITY; OLIGOMERIZES BAK; BREAST-CANCER; ACTIVATION; RESISTANCE; CARCINOMA	The death ligand TRAIL synergizes with DNA-damaging therapies such as chemotherapeutic drugs or ionizing irradiation. Here, we show that the synergism of TRAIL and 5-fluorouracil (5-FU) and cross-sensitization between TRAIL and 5-FU for induction of apoptosis, entirely depend on Bax proficiency in human DU145 and HCT116 carcinoma cells. DU145 prostate carcinoma cells that have lost Bax protein expression due to mutation fail to release cytochrome c and to activate caspase-3 and -9 when exposed to TRAIL and 5-FU. In contrast, TRAIL sensitized for 5-FU-induced apoptosis and vice versa upon reconstitution of Bax expression. Isobolographic analyses of ED50 doses for 5-FU at increasing TRAIL concentrations showed a clear synergism of TRAIL and 5-FU in Bax-expressing cells. In contrast, the effect was merely additive in DU145 cells lacking Bax. Notably, both DU145 and HCT116 Bax-deficient cells still express Bak. This indicates that Bak is not sufficient to mediate cross-sensitization and synergism between 5-FU and TRAIL. Stable overexpression of Bak in DU145 sensitized for epirubicin-induced apoptosis but failed to confer synergy between TRAIL and 5-FU. Moreover, we show by the use of EGFP-tagged Bax and Bak that TRAIL and 5-FU synergistically trigger oligomerization and clustering of Bax but not Bak. These data clearly establish distinct roles for Bax and Bak in linking the TRAIL death receptor pathway to the mitochondrial apoptosis signaling cascade and delineate a higher degree of specificity in signaling for cell death by multidomain Bcl-2 homologs.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; Univ Tubingen, Fac Med, Dept Radiat Oncol, Tubingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Daniel, PT (corresponding author), Charite Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de		Gillissen, Bernhard/0000-0002-1815-2091				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bonavida B, 1999, INT J ONCOL, V15, P793; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; CONEY LR, 1994, INT J CANCER, V58, P562, DOI 10.1002/ijc.2910580419; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gessner PK, 1995, TOXICOLOGY, V105, P161, DOI 10.1016/0300-483X(95)03210-7; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gliniak B, 1999, CANCER RES, V59, P6153; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; JSCHMELZ K, 2004, ONCOGENE, DOI DOI 10.1038/SJ.ONC1207848; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Leverkus M, 2000, CANCER RES, V60, P553; LUCKINGFAMIRA KM, 1994, LEUKEMIA, V8, P1825; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Rudner J, 2001, J CELL SCI, V114, P4161; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; WIEDER T, 1995, BIOCHEM J, V311, P873, DOI 10.1042/bj3110873; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	50	69	71	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8320	8332		10.1038/sj.onc.1207971	http://dx.doi.org/10.1038/sj.onc.1207971			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15467752				2022-12-25	WOS:000224749500014
J	Jowsey, PA; Doherty, AJ; Rouse, J				Jowsey, PA; Doherty, AJ; Rouse, J			Human PTIP facilitates ATM-mediated activation of p53 and promotes cellular resistance to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; BRCT DOMAIN; PROTEIN; 53BP1; CHECKPOINT; PHOSPHORYLATION; REPAIR; PATHWAY; ARREST; CHK1	Mus musculus Pax2 transactivation domain-interacting protein (Ptip) is an essential gene required for the maintenance of genome stability, although its precise molecular role is unclear. Human PTIP (hPTIP) was recently isolated in a screen for proteins, translated from cDNA pools, capable of interacting with peptides phosphorylated by the ATM (ataxia telangiectasia-mutated)/ATR (ataxia telangiectasia-related) protein kinases. hPTIP was described as a 757-amino acid protein bearing four BRCT domains. Here we report that instead full-length endogenous hPTIP contains 1069 amino acids and six BRCT domains. hPTIP shows increased association with 53BP1 in response to ionizing radiation (IR) but not in response to other DNA-damaging agents. Whereas translocation of both 53BP1 and hPTIP to sites of IR-induced DNA damage occurs independently of ATM, IR-induced association of PTIP and 53BP1 requires ATM. Deletion analysis identified the domains of 53BP1 and hPTIP required for protein-protein interaction and focus formation. Data characterizing the cellular roles of hPTIP are also presented. Small interfering RNA was used to show that hPTIP is required for ATM-mediated phosphorylation of p53 at Ser(15) and for IR-induced up-regulation of the cyclin-dependent kinase inhibitor p21. Lowering hPTIP levels also increased cellular sensitivity to IR, suggesting that this protein plays a critical role in maintaining genome stability.	Univ Dundee, Wellcome Trust Bioctr, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Dundee; University of Sussex	Rouse, J (corresponding author), Univ Dundee, Wellcome Trust Bioctr, MRC, Prot Phosphorylat Unit, Med Sci Inst Complex,Dow St, Dundee DD1 5EH, Scotland.	j.rouse@dundee.ac.uk		Doherty, Aidan/0000-0002-6370-1109; Jowsey, Paul/0000-0003-2867-6857				Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Cho EA, 2003, MOL CELL BIOL, V23, P1666, DOI 10.1128/MCB.23.5.1666-1673.2003; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mochan TA, 2003, CANCER RES, V63, P8586; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Rouse J, 2004, EMBO J, V23, P1188, DOI 10.1038/sj.emboj.7600129; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shimizu K, 2001, MOL CELL BIOL, V21, P3901, DOI 10.1128/MCB.21.12.3901-3912.2001; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	23	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55562	55569		10.1074/jbc.M411021200	http://dx.doi.org/10.1074/jbc.M411021200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15456759	hybrid			2022-12-25	WOS:000225960800073
J	Blumenstein, L; Ahmadian, MR				Blumenstein, L; Ahmadian, MR			Models of the cooperative mechanism for Rho effector recognition - Implications for RhoA-mediated effector activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SERINE-THREONINE KINASE; GTP-BINDING PROTEINS; CELLULAR-TRANSFORMATION; PUTATIVE TARGET; INSERT REGION; CITRON-KINASE; SERINE/THREONINE KINASE; ACTIN CYTOSKELETON; CATALYTIC-ACTIVITY	Activated GTPases of the Rho family regulate a spectrum of functionally diverse downstream effectors, initiating a network of signal transduction pathways by interaction and activation of effector proteins. Although effectors are defined as proteins that selectively bind the GTP-bound state of the small GTPases, there have been also several indications for a nucleotide-independent binding mode. By characterizing the molecular mechanism of RhoA interaction with its effectors, we have determined the equilibrium dissociation constants of several Rho-binding domains of three different effector proteins ( Rhotekin, ROCKI/ROKbeta/p160ROCK, PRK1/ PKNalpha where ROK is RhoA-binding kinase) for both RhoA . GDP and RhoA . GTP using fluorescence spectroscopy. In addition, we have identified two novel Rho-interacting domains in ROCKI, which bind RhoA with high affinity but not Cdc42 or Rac1. Our results, together with recent structural data, support the notion of multiple effector-binding sites in RhoA and strongly indicate a cooperative binding mechanism for PRK1 and ROCKI that may be the molecular basis of Rho-mediated effector activation.	Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany	Max Planck Society	Ahmadian, MR (corresponding author), Max Planck Inst Mol Physiol, Dept Biol Struct, Otto Hahn Str 11, D-44227 Dortmund, Germany.	reza.ahmadian@mpi-dortmund.mpg.de						Ahmadian Mohammad Reza, 2002, Methods Mol Biol, V189, P45; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Bush EW, 2000, BIOCHEMISTRY-US, V39, P8480, DOI 10.1021/bi992142f; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; Di Cunto F, 2002, J CELL SCI, V115, P4819, DOI 10.1242/jcs.00163; Doran JD, 2004, BIOCHEM J, V384, P255, DOI 10.1042/BJ20040344; Dvorsky R, 2004, J BIOL CHEM, V279, P7098, DOI 10.1074/jbc.M311911200; Dvorsky R, 2004, EMBO REP, V5, P1130, DOI 10.1038/sj.embor.7400293; Eda M, 2001, J CELL SCI, V114, P3273; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fiegen D, 2004, J BIOL CHEM, V279, P4743, DOI 10.1074/jbc.M310281200; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Fujita A, 2000, J CELL SCI, V113, P103; Haeusler LC, 2003, FEBS LETT, V555, P556, DOI 10.1016/S0014-5793(03)01351-6; Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; JOHN J, 1993, J BIOL CHEM, V268, P923; Joneson T, 1997, FASEB J, V11, pA994; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Karnoub AE, 2001, MOL CELL BIOL, V21, P2847, DOI 10.1128/MCB.21.8.2847-2857.2001; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Liu HF, 2003, J BIOL CHEM, V278, P2541, DOI 10.1074/jbc.M210391200; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; Madaule P, 2000, MICROSC RES TECHNIQ, V49, P123, DOI 10.1002/(SICI)1097-0029(20000415)49:2<123::AID-JEMT3>3.0.CO;2-R; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mircescu H, 2002, EUR J BIOCHEM, V269, P6241, DOI 10.1046/j.1432-1033.2002.03343.x; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mukai H, 2003, J BIOCHEM, V133, P17, DOI 10.1093/jb/mvg019; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Nomanbhoy T, 1999, BIOCHEMISTRY-US, V38, P15878, DOI 10.1021/bi9916832; Owen D, 2003, J BIOL CHEM, V278, P50578, DOI 10.1074/jbc.M304313200; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Peck JW, 2002, J BIOL CHEM, V277, P43924, DOI 10.1074/jbc.M203569200; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Scheffzek K, 2001, STRUCTURE, V9, P1043, DOI 10.1016/S0969-2126(01)00674-8; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Walker SJ, 2002, J BIOL CHEM, V277, P26260, DOI 10.1074/jbc.M201811200; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551; Zong H, 2001, MOL CELL BIOL, V21, P5287, DOI 10.1128/MCB.21.16.5287-5298.2001	74	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53419	53426		10.1074/jbc.M409551200	http://dx.doi.org/10.1074/jbc.M409551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475352	hybrid			2022-12-25	WOS:000225680600075
J	Granja, AG; Nogal, ML; Hurtado, C; Vila, V; Carrascosa, AL; Salas, ML; Fresno, M; Revilla, Y				Granja, AG; Nogal, ML; Hurtado, C; Vila, V; Carrascosa, AL; Salas, ML; Fresno, M; Revilla, Y			The viral protein A238L inhibits cyclooxygenase-2 expression through a nuclear factor of activated T cell-dependent transactivation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWINE-FEVER-VIRUS; NF-KAPPA-B; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; TRANSCRIPTION FACTOR NFAT1; MESSENGER-RNA STABILITY; C-JUN; PHOSPHATASE CALCINEURIN; SIGNALING CASCADE; G/H SYNTHASE; TNF-ALPHA	Cyclooxygenase-2 is transiently induced upon cell activation or viral infections, resulting in inflammation and modulation of the immune response. Here we report that A238L, an African swine fever virus protein, efficiently inhibits cyclooxygenase-2 gene expression in Jurkat T cells and in virus-infected Vero cells. Transfection of Jurkat cells stably expressing A238L with cyclooxygenase-2 promoter-luciferase constructs containing 5'-terminal deletions or mutations in distal or proximal nuclear factor of activated T cell ( NFAT) response elements revealed that these sequences are involved in the inhibition induced by A238L. Overexpression of a constitutively active version of the calcium-dependent phosphatase calcineurin or NFAT reversed the inhibition mediated by A238L on cyclooxygenase-2 promoter activation, whereas overexpression of p65 NFkappaB had no effect. A238L does not modify the nuclear localization of NFAT after phorbol 12-myristate 13-acetate/calcium ionophore stimulation. Moreover, we show that the mechanism by which the viral protein down-regulates cyclooxygenase-2 activity does not involve inhibition of the binding between NFAT and its specific DNA sequences into the cyclooxygenase-2 promoter. Strikingly, A238L dramatically inhibited the transactivation mediated by a GAL4-NFAT fusion protein containing the N-terminal transactivation domain of NFAT1. Taken together, these data indicate that A238L down-regulates cyclooxygenase-2 transcription through the NFAT response elements, being NFAT-dependent transactivation implicated in this down-regulation.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Revilla, Y (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.	yrevilla@cbm.uam.es	Granja, Aitor/K-8102-2014; Carrascosa, Angel L/K-4439-2014; Hurtado-Marcos, Carolina/AAH-3586-2020	Hurtado-Marcos, Carolina/0000-0003-0364-7742; Vila-del Sol, Virginia/0000-0002-5606-2767; Yolanda, Revilla/0000-0001-6555-6331; Fresno Escudero, Manuel/0000-0002-9223-5477				APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Barrios-Rodiles M, 1998, J IMMUNOL, V161, P2441; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Bergqvist A, 2001, J VIROL, V75, P772, DOI 10.1128/JVI.75.2.772-781.2001; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; ENJUANES L, 1976, J GEN VIROL, V32, P471, DOI 10.1099/0022-1317-32-3-471; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, J BIOL CHEM, V266, P12508; GARCIA R, 1995, J BIOTECHNOL, V40, P121, DOI 10.1016/0168-1656(95)00037-Q; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Griswold DE, 1996, MED RES REV, V16, P181, DOI 10.1002/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.0.CO;2-X; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang ZF, 2000, BIOCHEM PHARMACOL, V59, P187, DOI 10.1016/S0006-2952(99)00312-3; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Janelle ME, 2002, J BIOL CHEM, V277, P30665, DOI 10.1074/jbc.M203041200; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Luo C, 1996, MOL CELL BIOL, V16, P3955; Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miskin JE, 2000, J VIROL, V74, P9412, DOI 10.1128/JVI.74.20.9412-9420.2000; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; Moriuchi M, 2001, J VIROL, V75, P192, DOI 10.1128/JVI.75.1.192-198.2001; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; Nogal ML, 2001, J VIROL, V75, P2535, DOI 10.1128/JVI.75.6.2535-2543.2001; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Parry RV, 2003, NAT IMMUNOL, V4, P821, DOI 10.1038/ni0903-821; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Revilla Y, 1998, J BIOL CHEM, V273, P5405, DOI 10.1074/jbc.273.9.5405; Rodriguez CI, 2002, J VIROL, V76, P3936, DOI 10.1128/JVI.76.8.3936-3942.2002; San-Antonio B, 2002, J BIOL CHEM, V277, P27073, DOI 10.1074/jbc.M106983200; Savard M, 2000, J IMMUNOL, V164, P6467, DOI 10.4049/jimmunol.164.12.6467; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Scott ES, 2001, J VIROL, V75, P9955, DOI 10.1128/JVI.75.20.9955-9965.2001; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Steer SA, 2003, J IMMUNOL, V170, P1070, DOI 10.4049/jimmunol.170.2.1070; STILLMAN DJ, 1984, J BIOL CHEM, V259, P7955; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VINUELA E, 1985, CURR TOP MICROBIOL, V116, P151; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; YOCUM DE, 1989, CELL IMMUNOL, V122, P131, DOI 10.1016/0008-8749(89)90154-8	62	32	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53736	53746		10.1074/jbc.M406620200	http://dx.doi.org/10.1074/jbc.M406620200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471864	hybrid, Green Published			2022-12-25	WOS:000225680600111
J	Im, YJ; Na, Y; Kang, GB; Rho, SH; Kim, MK; Lee, JH; Chung, CH; Eom, SH				Im, YJ; Na, Y; Kang, GB; Rho, SH; Kim, MK; Lee, JH; Chung, CH; Eom, SH			The active site of a Lon protease from Methanococcus jannaschii distinctly differs from the canonical catalytic dyad of Lon proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL SIGNAL PEPTIDASE; ATP-DEPENDENT PROTEASE; SER-LYS DYAD; MITOCHONDRIAL LON; CRYSTAL-STRUCTURE; 20S PROTEASOME; QUALITY; PROTEOLYSIS; PROTEINS; BINDING	ATP-dependent Lon proteases catalyze the degradation of various regulatory proteins and abnormal proteins within cells. Methanococcus jannaschii Lon (Mj-Lon) is a homologue of Escherichia coli Lon (Ec-Lon) but has two transmembrane helices within its N-terminal ATPase domain. We solved the crystal structure of the proteolytic domain of Mj-Lon using multiwavelength anomalous dispersion, refining it to 1.9-Angstrom resolution. The structure displays an overall fold conserved in the proteolytic domain of Ec-Lon; however, the active site shows uniquely configured catalytic Ser-Lys-Asp residues that are not seen in Ec-Lon, which contains a catalytic dyad. In Mj-Lon, the C-terminal half of the beta4-alpha2 segment is an alpha-helix, whereas it is a beta-strand in Ec-Lon. Consequently, the configurations of the active sites differ due to the formation of a salt bridge between Asp-547 and Lys-593 in Mj-Lon. Moreover, unlike Ec-Lon, Mj-Lon has a buried cavity in the region of the active site containing three water molecules, one of which is hydrogen-bonded to catalytic Ser-550. The geometry and environment of the active site residues in Mj-Lon suggest that the charged Lys-593 assists in lowering the pK(a) of the Ser-550 hydroxyl group via its electrostatic potential, and the water in the cavity acts as a proton acceptor during catalysis. Extensive sequence alignment and comparison of the structures of the proteolytic domains clearly indicate that Lon proteases can be classified into two groups depending on active site configuration and the presence of DGPSA or (D/E) GDSA consensus sequences, as represented by Ec-Lon and Mj-Lon.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Seoul Natl Univ, Sch Biol Sci, Natl Res Lab Prot Biochem, Seoul 151742, South Korea	Gwangju Institute of Science & Technology (GIST); Seoul National University (SNU)	Eom, SH (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.	eom@gist.ac.kr		Rho, Seong-Hwan/0000-0002-8650-8205				Birghan C, 2000, EMBO J, V19, P114, DOI 10.1093/emboj/19.1.114; Botos I, 2004, J BIOL CHEM, V279, P8140, DOI 10.1074/jbc.M312243200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V60, P760; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Fersht A. R., 1999, STRUCTURE MECH PROTE, P472; Fu GK, 1997, J BIOL CHEM, V272, P534; Fukui T, 2002, J BACTERIOL, V184, P3689, DOI 10.1128/JB.184.13.3689-3698.2002; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; Gottesman S, 1999, CURR OPIN MICROBIOL, V2, P142, DOI 10.1016/S1369-5274(99)80025-3; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Groll M, 2003, INT J BIOCHEM CELL B, V35, P606, DOI 10.1016/S1357-2725(02)00390-4; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LEE AY, 2004, J BIOL CHEM; Lee AYL, 2004, EUR J BIOCHEM, V271, P834, DOI 10.1111/j.1432-1033.2004.03988.x; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; MENARD R, 1992, BIOL CHEM H-S, V373, P393, DOI 10.1515/bchm3.1992.373.2.393; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Stahlberg H, 1999, P NATL ACAD SCI USA, V96, P6787, DOI 10.1073/pnas.96.12.6787; SWAMY KHS, 1981, NATURE, V292, P652, DOI 10.1038/292652a0; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; Ward Donald E., 2002, Archaea, V1, P63, DOI 10.1155/2002/503191; WATABE S, 1985, J BIOL CHEM, V260, P4498; Watanabe S, 1999, EUR J BIOCHEM, V266, P811, DOI 10.1046/j.1432-1327.1999.00907.x; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Yoo SJ, 1997, FEBS LETT, V412, P57, DOI 10.1016/S0014-5793(97)00742-4	35	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53451	53457		10.1074/jbc.M410437200	http://dx.doi.org/10.1074/jbc.M410437200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456757	hybrid			2022-12-25	WOS:000225680600079
J	Kobayashi, Y; Kobayashi, K; Umehara, K; Dohra, H; Murata, T; Usui, T; Kawagishi, H				Kobayashi, Y; Kobayashi, K; Umehara, K; Dohra, H; Murata, T; Usui, T; Kawagishi, H			Purification, characterization, and sugar binding specificity of an N-glycolylneuraminic acid-specific lectin from the mushroom Chlorophyllum molybdites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANGANUTZIU-DEICHER ANTIGEN; ASPARAGINE-LINKED OLIGOSACCHARIDES; GAS-LIQUID-CHROMATOGRAPHY; HUMAN-COLON CANCER; MASS-SPECTROMETRY; FRUITING BODIES; SIALIC-ACID; STRUCTURAL DETERMINANTS; AFFINITY-CHROMATOGRAPHY; POLYPORUS-SQUAMOSUS	A carbohydrate-binding protein was isolated from the carpophores of the mushrooms and designated the Chlorophyllum molybdites lectin (CML) based on its origin. The molecular mass of CML was 32 kDa, and it was composed of two 16-kDa monomers with no disulfide bonds. Monosaccharide analysis indicated that 12% of the mass of CML was carbohydrate and consisted of GlcNAc:GalNAc:Gal:Man:L-Fuc in a molar ratio of 1.5:1.9:4.4:4.8:1.0. In the hemagglutination inhibition assay, CML exhibited the strongest binding specificity toward N-glycolylneuraminic acid (NeuGc) among the monosaccharides tested, whereas NeuAc did not inhibit the hemagglutination at all. GalNAc and Mealpha-GalNAc were also inhibitory at much higher concentrations than NeuGc. Among the glycoproteins, asialobovine submaxillary mucin (BSM) and porcine stomach mucin (PSM) showed strong inhibitory effects. In surface plasmon resonance analysis, asialo-BSM and PSM exhibited the strongest binding affinity. After co-injection of CML and NeuGc or GalNAc onto the asialo-BSM- or PSM-immobilized chip, the dissociation of CML from the immobilized PSM was accelerated by NeuGc and GalNAc, but the dissociation of CML from the immobilized asialo-BSM was only promoted by GalNAc. These results and the other surface plasmon resonance experiments allowed us to conclude that the binding of asialo-BSM to CML was because of an interaction between the lectin and the GalNAc residues of asialo-BSM, and both the NeuGc and GalNAc residues were responsible for the binding of PSM to CML. The results also suggested that CML had two different carbohydrate binding domains, one specific for NeuGc and the other for GalNAc.	Shizuoka Univ, Fac Agr, Dept Appl Biol Chem, Shizuoka 4228529, Japan; Gifu Univ, United Grad Sch, Gifu 5011193, Japan; Shizuoka Univ, Inst Genet Res & Biotechnol, Shizuoka 4228529, Japan	Shizuoka University; Gifu University; Shizuoka University	Kawagishi, H (corresponding author), Shizuoka Univ, Fac Agr, Dept Appl Biol Chem, 836 Ohya, Shizuoka 4228529, Japan.	achkawa@agr.shizuoka.ac.jp		Dohra, Hideo/0000-0002-3919-3538				[Anonymous], INT J MED MUSH; BLAYNEY D, 1980, WESTERN J MED, V132, P74; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCHER HP, 1974, EUR J BIOCHEM, V50, P71, DOI 10.1111/j.1432-1033.1974.tb03873.x; CASALSSTENZEL J, 1975, ANAL BIOCHEM, V65, P507, DOI 10.1016/0003-2697(75)90536-9; CHAI WG, 1992, EUR J BIOCHEM, V203, P257, DOI 10.1111/j.1432-1033.1992.tb19855.x; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DAM TK, 1993, BIOCHEM BIOPH RES CO, V196, P422, DOI 10.1006/bbrc.1993.2266; DEICHER H., 1926, ZEITSCHR HYG U INFEKTIONSKR, V106, P561, DOI 10.1007/BF02176298; DEVINE PL, 1991, CANCER RES, V51, P5826; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Hanganutziu M, 1924, CR SOC BIOL, V91, P1457; HIGASHI H, 1985, CANCER RES, V45, P3796; HIGASHI H, 1988, JPN J CANCER RES, V79, P952, DOI 10.1111/j.1349-7006.1988.tb00060.x; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P614; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P251; Hodge JE, 1962, METHODS CARBOHYDRATE, V1, P338; KAWACHI S, 1988, INT ARCH ALLER A IMM, V85, P381, DOI 10.1159/000234536; KAWAGISHI H, 1994, J BIOL CHEM, V269, P1375; KAWAGISHI H, 1988, FEBS LETT, V227, P99, DOI 10.1016/0014-5793(88)80876-7; Kawagishi H, 2001, BIOSCI BIOTECH BIOCH, V65, P2437, DOI 10.1271/bbb.65.2437; Kawagishi H, 2001, PHYTOCHEMISTRY, V56, P53, DOI 10.1016/S0031-9422(00)00351-4; KAWAGISHI H, 1990, BIOCHIM BIOPHYS ACTA, V1034, P247, DOI 10.1016/0304-4165(90)90045-X; Kawagishi H, 2000, BBA-GEN SUBJECTS, V1474, P299, DOI 10.1016/S0304-4165(00)00027-1; Kawagishi H, 1997, PHYTOCHEMISTRY, V44, P7, DOI 10.1016/S0031-9422(96)00492-X; KAWAGISHI H, 1988, CARBOHYD RES, V183, P150, DOI 10.1016/0008-6215(88)80057-0; KAWAGISHI H, 1994, FEBS LETT, V340, P56, DOI 10.1016/0014-5793(94)80172-X; KAWAGISHI H, 2001, J APPL GLYCOSCI, V48, P99; KAWAI T, 1991, CANCER RES, V51, P1242; KAWANO T, 1995, J BIOL CHEM, V270, P16458, DOI 10.1074/jbc.270.27.16458; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; Kobayashi K, 1997, MACROMOLECULES, V30, P2016, DOI 10.1021/ma961681e; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT RD, 1977, J BIOL CHEM, V252, P2961; LEHMANN PF, 1992, MYCOPATHOLOGIA, V118, P3, DOI 10.1007/BF00472564; LEVITAN D, 1981, TOXICON, V19, P179, DOI 10.1016/0041-0101(81)90130-6; Malykh Yanina N., 2001, BIOCHIMIE PARIS, V83, P623; Marquina G, 1996, CANCER RES, V56, P5165; MERCY PD, 1993, EUR J BIOCHEM, V215, P697, DOI 10.1111/j.1432-1033.1993.tb18081.x; MERCY SPD, 1992, EXPERIENTIA, V48, P498, DOI 10.1007/BF01928173; MIYAKE M, 1990, CANCER, V65, P499, DOI 10.1002/1097-0142(19900201)65:3<499::AID-CNCR2820650321>3.0.CO;2-P; MIYOSHI I, 1986, MOL IMMUNOL, V23, P631, DOI 10.1016/0161-5890(86)90100-8; Mo HQ, 2000, J BIOL CHEM, V275, P10623, DOI 10.1074/jbc.275.14.10623; MOORE S, 1963, J BIOL CHEM, V238, P235; Ratanapo S, 2001, PLANT SCI, V160, P739, DOI 10.1016/S0168-9452(00)00454-4; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SARRIS AH, 1979, J BIOL CHEM, V254, P6724; SMITH CW, 1980, HAWAII MED J, V39, P13; STENKLYFT PH, 1990, J TOXICOL-CLIN TOXIC, V28, P159, DOI 10.3109/15563659008993488; SWARNAKAR S, 1991, BIOCHEM BIOPH RES CO, V178, P85, DOI 10.1016/0006-291X(91)91783-9; Tsuchida A, 1998, J BIOCHEM, V123, P715; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; Yasuno S, 1997, BIOSCI BIOTECH BIOCH, V61, P1944, DOI 10.1271/bbb.61.1944; Zeng XX, 1998, CARBOHYD RES, V312, P209, DOI 10.1016/S0008-6215(98)00259-6; Zhang BY, 2001, GLYCOBIOLOGY, V11, P141, DOI 10.1093/glycob/11.2.141	58	34	34	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53048	53055		10.1074/jbc.M407997200	http://dx.doi.org/10.1074/jbc.M407997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471858	hybrid			2022-12-25	WOS:000225680600031
J	Price, MP; Thompson, RJ; Eshcol, JO; Wemmie, JA; Benson, CJ				Price, MP; Thompson, RJ; Eshcol, JO; Wemmie, JA; Benson, CJ			Stomatin modulates gating of acid-sensing ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; CENTRAL-NERVOUS-SYSTEM; BRAIN NA+ CHANNEL; CAENORHABDITIS-ELEGANS; SENSORY NEURONS; HEREDITARY STOMATOCYTOSIS; MECHANOSENSORY TERMINALS; HIPPOCAMPAL-NEURONS; ACTIVATED CURRENTS; DEG/ENAC CHANNELS	Acid-sensing ion channels (ASICs) are H+-gated members of the degenerin/epithelial Na+ channel (DEG/ENaC) family in vertebrate neurons. Several ASICs are expressed in sensory neurons, where they play a role in responses to nociceptive, taste, and mechanical stimuli; others are expressed in central neurons, where they participate in synaptic plasticity and some forms of learning. Stomatin is an integral membrane protein found in lipid/protein-rich microdomains, and it is believed to regulate the function of ion channels and transporters. In Caenorhabditis elegans, stomatin homologs interact with DEG/ENaC channels, which together are necessary for normal mechanosensation in the worm. Therefore, we asked whether stomatin interacts with and modulates the function of ASICs. We found that stomatin co-immunoprecipitated and co-localized with ASIC proteins in heterologous cells. Moreover, stomatin altered the function of ASIC channels. Stomatin potently reduced acid-evoked currents generated by ASIC3 without changing steady state protein levels or the amount of ASIC3 expressed at the cell surface. In contrast, stomatin accelerated the desensitization rate of ASIC2 and heteromeric ASICs, whereas current amplitude was unaffected. These data suggest that stomatin binds to and alters the gating of ASICs. Our findings indicate that modulation of DEG/ENaC channels by stomatin-like proteins is evolutionarily conserved and may have important implications for mammalian nociception and mechanosensation.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Benson, CJ (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 200 Hawkins Dr,E314-1 GH, Iowa City, IA 52242 USA.	chris-benson@uiowa.edu		Eshcol, Jayasheel/0000-0002-1784-8513; Wemmie, John/0000-0001-7531-9065; Benson, Christopher/0000-0001-6600-8193	NHLBI NIH HHS [HL04349] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004349] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen NJ, 2002, J PHYSIOL-LONDON, V543, P521, DOI 10.1113/jphysiol.2002.020297; Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Baron A, 2002, J BIOL CHEM, V277, P50463, DOI 10.1074/jbc.M208848200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Benson CJ, 1999, CIRC RES, V84, P921; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; Chalfie M, 1997, BIOL BULL, V192, P125, DOI 10.2307/1542584; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; de la Rosa DA, 2003, J PHYSIOL-LONDON, V546, P77, DOI 10.1113/jphysiol.2002.030692; de la Rosa DA, 2002, P NATL ACAD SCI USA, V99, P2326, DOI 10.1073/pnas.042688199; Deval E, 2004, J BIOL CHEM, V279, P19531, DOI 10.1074/jbc.M313078200; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; EBER SW, 1989, BRIT J HAEMATOL, V72, P452, DOI 10.1111/j.1365-2141.1989.tb07731.x; Fricke B, 2003, BLOOD, V102, P2268, DOI 10.1182/blood-2002-06-1705; Fricke B, 2000, CELL TISSUE RES, V299, P327; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; Gu GQ, 1996, P NATL ACAD SCI USA, V93, P6577, DOI 10.1073/pnas.93.13.6577; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; Hille B, 2001, ION CHANNELS EXCITAB, P61; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Ji HJ, 2002, J BIOL CHEM, V277, P8395, DOI 10.1074/jbc.M109465200; LANDE WM, 1982, J CLIN INVEST, V70, P1273, DOI 10.1172/JCI110726; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Mamet J, 2002, J NEUROSCI, V22, P10662; Mannsfeldt AG, 1999, MOL CELL NEUROSCI, V13, P391, DOI 10.1006/mcne.1999.0761; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Paukert M, 2004, J BIOL CHEM, V279, P18783, DOI 10.1074/jbc.M401477200; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; Sedensky MM, 2004, AM J PHYSIOL-CELL PH, V287, pC468, DOI 10.1152/ajpcell.00182.2003; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Snyers L, 1997, EUR J CELL BIOL, V73, P281; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Ugawa S, 2002, J CLIN INVEST, V110, P1185, DOI 10.1172/JCI200215709; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2004, P NATL ACAD SCI USA, V101, P3621, DOI 10.1073/pnas.0308753101; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Xie JH, 2002, J NEUROPHYSIOL, V87, P2835, DOI 10.1152/jn.2002.87.6.2835; Zhang JZ, 2001, AM J PHYSIOL-CELL PH, V280, pC1277, DOI 10.1152/ajpcell.2001.280.5.C1277; Zhu YW, 1999, BLOOD, V93, P2404, DOI 10.1182/blood.V93.7.2404.407k13_2404_2410	66	97	105	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53886	53891		10.1074/jbc.M407708200	http://dx.doi.org/10.1074/jbc.M407708200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471860	hybrid			2022-12-25	WOS:000225680600127
J	Santos, SG; Powis, SJ; Arosa, FA				Santos, SG; Powis, SJ; Arosa, FA			Misfolding of major histocompatibility complex class I molecules in activated T cells allows cis-interactions with receptors and signaling molecules and is associated with tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; HEAVY-CHAINS; MONOCLONAL-ANTIBODY; CYTOPLASMIC DOMAIN; ALPHA-3 DOMAIN; HLA MOLECULES; SURFACE; LYMPHOCYTES; ANTIGEN; HLA-B27	Knowledge of the origin and biochemical status of beta(2)-microglobulin-free or misfolded major histocompatibility complex (MHC)-I molecules is essential for understanding their pleiotropic properties. Here we show that in normal human T cells, misfolding of MHC-I molecules is turned on upon activation and cell division and is proportional to the level of proliferation. Immunoprecipitation showed that a number of proteins are associated with MHC-I heavy chains at the surface of activated T cells, including the CD8alphabeta receptor and the chaperone tandem calreticulin/ERp57, associations that rely upon the existence of a pool of HC-10-reactive molecules. Biochemical analysis showed that misfolded MHC-I molecules present at the cell surface are fully glycosylated mature molecules. Importantly, misfolded MHC-I molecules are tyrosine phosphorylated and are associated with kinase activity. In vitro kinase assays followed by reprecipitation indicated that tyrosine phosphorylation of the class I heavy chain is probably mediated by a Src tyrosine kinase because Lck was found associated with HC-10 immunocomplexes. Finally, we show that inhibition of tyrosine phosphorylation by using the Src-family tyrosine kinase inhibitor PP2 resulted in enhanced release of MHC-I heavy chains from the cell surface of activated T cells and a slight down-regulation of cell surface W6/32-reactive molecules. This study provides new insights into the biology of MHC-I molecules and suggests that tyrosine phosphorylation may be involved in the regulation of MHC-I misfolding and expression.	Inst Mol & Cell Biol, Div Human Genet & Genet Disorders, P-4150180 Oporto, Portugal; Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal; Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	Universidade do Porto; Universidade do Porto; University of Dundee	Arosa, FA (corresponding author), Inst Mol & Cell Biol, Div Human Genet & Genet Disorders, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	farosa@ibmc.up.pt	Santos, Susana G/L-9351-2013; Arosa, Fernando A./E-5640-2010	Santos, Susana G/0000-0002-8604-2978; Arosa, Fernando A./0000-0002-7209-4507; Powis, Simon/0000-0003-4218-2984				Allen RL, 1999, J IMMUNOL, V162, P5045; Antoniou AN, 2004, J BIOL CHEM, V279, P8895, DOI 10.1074/jbc.M311757200; Antoniou AN, 2003, CURR OPIN IMMUNOL, V15, P75, DOI 10.1016/S0952-7915(02)00010-9; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; Bird LA, 2003, EUR J IMMUNOL, V33, P748, DOI 10.1002/eji.200323678; BLUE ML, 1988, CELL, V54, P413, DOI 10.1016/0092-8674(88)90204-8; Bodnar A, 2003, INT IMMUNOL, V15, P331, DOI 10.1093/intimm/dxg042; Bregenholt S, 1996, J IMMUNOL, V157, P993; BUSHKIN Y, 1986, J EXP MED, V164, P458, DOI 10.1084/jem.164.2.458; BUSHKIN Y, 1988, P NATL ACAD SCI USA, V85, P3985, DOI 10.1073/pnas.85.11.3985; CAPPS GG, 1993, J IMMUNOL, V151, P159; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CARRENO BM, 1994, EUR J IMMUNOL, V24, P1285, DOI 10.1002/eji.1830240607; Chang AH, 2001, EUR J IMMUNOL, V31, P2382, DOI 10.1002/1521-4141(200108)31:8<2382::AID-IMMU2382>3.0.CO;2-K; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; Colbert RA, 2004, CURR MOL MED, V4, P21, DOI 10.2174/1566524043479293; Damjanovich S, 2002, IMMUNOL LETT, V82, P93, DOI 10.1016/S0165-2478(02)00024-X; DASGUPTA JD, 1987, P NATL ACAD SCI USA, V84, P1094, DOI 10.1073/pnas.84.4.1094; DEFELICE M, 1987, J IMMUNOL, V139, P2683; DEMARIA S, 1993, INT J CLIN LAB RES, V23, P61, DOI 10.1007/BF02592285; DEMARIA S, 1992, CELL IMMUNOL, V142, P103, DOI 10.1016/0008-8749(92)90272-Q; Doucey MA, 2004, NAT IMMUNOL, V5, P328, DOI 10.1038/ni1043; Fonseca AM, 2003, CELL IMMUNOL, V224, P17, DOI 10.1016/S0008-8749(03)00170-9; GEPPERT TD, 1988, J IMMUNOL, V140, P2155; GILLILAND LK, 1989, HUM IMMUNOL, V25, P269, DOI 10.1016/0198-8859(89)90089-X; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; GUILD BC, 1984, J BIOL CHEM, V259, P3504; Gur H, 1997, MOL IMMUNOL, V34, P125, DOI 10.1016/S0161-5890(97)00007-2; GUR H, 1990, J EXP MED, V172, P1267, DOI 10.1084/jem.172.4.1267; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Jelonek MT, 1998, J IMMUNOL, V160, P2809; Kang SJ, 2002, J BIOL CHEM, V277, P44838, DOI 10.1074/jbc.M207831200; Le Gall S, 2000, J VIROL, V74, P9256, DOI 10.1128/JVI.74.19.9256-9266.2000; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Lizee G, 2003, NAT IMMUNOL, V4, P1065, DOI 10.1038/ni989; MADRIGAL JA, 1991, J EXP MED, V174, P1085, DOI 10.1084/jem.174.5.1085; MATKO J, 1994, J IMMUNOL, V152, P3353; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PARHAM P, 1979, J IMMUNOL, V123, P342; Pickl WF, 1996, IMMUNOLOGY, V88, P104, DOI 10.1046/j.1365-2567.1996.d01-644.x; Puppo F, 2000, INT IMMUNOL, V12, P195, DOI 10.1093/intimm/12.2.195; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SAMBHARA SR, 1991, SCIENCE, V252, P1424; Sanders CR, 2000, CURR OPIN STRUC BIOL, V10, P438, DOI 10.1016/S0959-440X(00)00112-3; SCHNABL E, 1990, J EXP MED, V171, P1431, DOI 10.1084/jem.171.5.1431; SHARON M, 1988, J IMMUNOL, V141, P3512; SKOV S, 1995, J IMMUNOL, V154, P1167; Skov S, 1997, J IMMUNOL, V158, P3189; SMITH DM, 1994, J IMMUNOL, V153, P1054; Solheim JC, 1999, IMMUNOL REV, V172, P11, DOI 10.1111/j.1600-065X.1999.tb01352.x; Spaggiari GM, 2002, BLOOD, V100, P4098, DOI 10.1182/blood-2002-04-1284; STAM NJ, 1986, J IMMUNOL, V137, P2299; TAYLOR DS, 1986, P NATL ACAD SCI USA, V83, P4446, DOI 10.1073/pnas.83.12.4446; THOR G, 1993, J IMMUNOL, V151, P211; WACHOLTZ MC, 1989, J IMMUNOL, V142, P4201; Wearsch PA, 2004, J BIOL CHEM, V279, P25112, DOI 10.1074/jbc.M401721200	56	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53062	53070		10.1074/jbc.M408794200	http://dx.doi.org/10.1074/jbc.M408794200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471856	hybrid			2022-12-25	WOS:000225680600033
J	Chiocco, MJ; Kulnane, LS; Younkin, L; Younkin, S; Evin, G; Lamb, BT				Chiocco, MJ; Kulnane, LS; Younkin, L; Younkin, S; Evin, G; Lamb, BT			Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE PATIENTS; PRECURSOR-PROTEIN; ARTIFICIAL CHROMOSOME; MOUSE MODEL; HUMAN BRAIN; EXPRESSION; BACE1; APP; DEFICITS; IDENTIFICATION	Amyloid-beta (Abeta) the primary component of the senile plaques found in Alzheimer's disease ( AD) is generated by the rate-limiting cleavage of amyloid precursor protein (APP) by beta-secretase followed by gamma-secretase cleavage. Identification of the primary beta-secretase gene, BACE1, provides a unique opportunity to examine the role this unique aspartyl protease plays in altering Abeta metabolism and deposition that occurs in AD. The current experiments seek to examine how modulating beta-secretase expression and activity alters APP processing and Abeta metabolism in vivo. Genomic-based BACE1 transgenic mice were generated that overexpress human BACE1 mRNA and protein. The highest expressing BACE1 transgenic line was mated to transgenic mice containing human APP transgenes. Our biochemical and histochemical studies demonstrate that mice overexpressing both BACE1 and APP show specific alterations in APP processing and age-dependent Abeta deposition. We observed elevated levels of Abeta isoforms as well as significant increases of Abeta deposits in these double transgenic animals. In particular, the double transgenics exhibited a unique cortical deposition profile, which is consistent with a significant increase of BACE1 expression in the cortex relative to other brain regions. Elevated BACE1 expression coupled with increased deposition provides functional evidence for beta-secretase as a primary effector in regional amyloid deposition in the AD brain. Our studies demonstrate, for the first time, that modulation of BACE1 activity may play a significant role in AD pathogenesis in vivo.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia	Case Western Reserve University; University Hospitals of Cleveland; Mayo Clinic; University of Melbourne	Lamb, BT (corresponding author), Case Western Reserve Univ, Dept Genet, 10900 Euclid Ave, Cleveland, OH 44106 USA.	btl@po.cwru.edu	Evin, Genevieve M/E-5891-2013		NCI NIH HHS [CA43703, P30 CA043703] Funding Source: Medline; NIA NIH HHS [P50 AG008012, AG08012, AG14451, R01 AG023012, R01 AG023012-01A1] Funding Source: Medline; NIGMS NIH HHS [GM08056-21] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008012, R29AG014451, R01AG023012, R01AG014451] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Christen-Zaech S, 2003, CAN J NEUROL SCI, V30, P20, DOI 10.1017/S0317167100002389; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Clarimon J, 2003, J NEUROL, V250, P956, DOI 10.1007/s00415-003-1127-8; Delatour B, 2004, NEUROBIOL DIS, V16, P41, DOI 10.1016/j.nbd.2004.01.008; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; DOTY RL, 1987, BRAIN RES BULL, V18, P597, DOI 10.1016/0361-9230(87)90129-8; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gold G, 2003, AM J MED GENET B, V119B, P44, DOI 10.1002/ajmg.b.10010; HOGAN B, 1994, MANIPULATING MOUSE E, P217; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Irizarry MC, 2001, AM J PATHOL, V158, P173, DOI 10.1016/S0002-9440(10)63955-7; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KANDEL ER, 2000, PRINCIPLES NEURAL SC, P625; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Kovacs T, 2004, AGEING RES REV, V3, P215, DOI 10.1016/j.arr.2003.10.003; Kovacs T, 2001, NEUROREPORT, V12, P285, DOI 10.1097/00001756-200102120-00021; Kulnane LS, 2001, NEUROBIOL DIS, V8, P982, DOI 10.1006/nbdi.2001.0446; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; Lamb BT, 1997, HUM MOL GENET, V6, P1535, DOI 10.1093/hmg/6.9.1535; Lehman EJH, 2003, NEUROBIOL AGING, V24, P645, DOI 10.1016/S0197-4580(02)00153-7; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Liu HC, 2003, BRAIN RES, V961, P88, DOI 10.1016/S0006-8993(02)03849-0; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mohajeri MH, 2004, J NEURAL TRANSM, V111, P413, DOI 10.1007/s00702-003-0057-z; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Nicolaou M, 2001, NEUROGENETICS, V3, P203; Nowotny P, 2001, NEUROREPORT, V12, P1799, DOI 10.1097/00001756-200107030-00008; PAXINOS GF, 2001, MOUSE BRAIN STEREOTA, P108; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; SAMBROOK J, 2001, MOL CLONING LAB MANU, V1, P23; Saunders A.J, 1999, SCIENCE, V286, P1255, DOI DOI 10.1126/SCIENCE.286.5443.1255A; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Serby M, 1996, BIOL PSYCHIAT, V39, P375, DOI 10.1016/0006-3223(95)00472-6; SERBY M, 1991, AM J PSYCHIAT, V148, P357; Sheng JG, 2003, EXP NEUROL, V184, P1053, DOI 10.1016/j.expneurol.2003.08.018; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sun AY, 2002, EXP NEUROL, V175, P10, DOI 10.1006/exnr.2002.7875; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tanzi RE, 1999, J CLIN INVEST, V104, P1175, DOI 10.1172/JCI8593; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Zohar O, 2003, MOL BRAIN RES, V115, P63, DOI 10.1016/S0169-328X(03)00182-7	55	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52535	52542		10.1074/jbc.M409680200	http://dx.doi.org/10.1074/jbc.M409680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15452128	hybrid, Green Accepted			2022-12-25	WOS:000225493400099
J	Friedmann, E; Lemberg, MK; Weihofen, A; Dev, KK; Dengler, U; Rovelli, G; Martoglio, B				Friedmann, E; Lemberg, MK; Weihofen, A; Dev, KK; Dengler, U; Rovelli, G; Martoglio, B			Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN BIOSYNTHESIS; GAMMA-SECRETASE; INTRAMEMBRANE PROTEOLYSIS; ALZHEIMERS-DISEASE; ACTIVE-SITE; IDENTIFICATION; RECONSTITUTION; GLYCOSYLATION; PREDICTIONS; CLEAVAGE	The human genome encodes seven intramembrane-cleaving GXGD aspartic proteases. These are the two presenilins that activate signaling molecules and are implicated in Alzheimer's disease, signal peptide peptidase (SPP), required for immune surveillance, and fourSPP-like candidate proteases (SPPLs), of unknown function. Here we describe a comparative analysis of the topologies of SPP and its human homologues, SPPL2a, - 2b, - 2c, and - 3. We demonstrate that their N-terminal extensions are located in the extracellular space and, except for SPPL3, are modified with N-glycans. Whereas SPPL2a, - 2b, and - 2c contain a signal sequence, SPP and SPPL3 contain a type I signal anchor sequence for initiation of protein translocation and membrane insertion. The hydrophilic loops joining the transmembrane regions, which contain the catalytic residues, are facing the exoplasm. The C termini of all these proteins are exposed toward the cytosol. Taken together, our study demonstrates that SPP and its homologues are all of the same principal structure with a catalytic domain embedded in the membrane in opposite orientation to that of presenilins. Other than presenilins, SPPL2a, - 2b, - 2c, and - 3 are therefore predicted to cleave type II-oriented substrate peptides like the prototypic protease SPP.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland; Novartis Pharma AG, Nervous Syst Res, Novartis Inst Biomed Res, CH-4002 Basel, Switzerland; Novartis Pharma AG, Funct Gen, Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Novartis; Novartis	Martoglio, B (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland.	bruno.martoglio@bc.biol.ethz.ch	Weihofen, Andreas/A-1566-2011; Lemberg, Marius K/B-8881-2016	Lemberg, Marius K/0000-0002-0996-1268; Dev, Kumlesh/0000-0003-4274-9119; Weihofen, Andreas/0000-0001-6265-9087				An FY, 1999, J BACTERIOL, V181, P5915, DOI 10.1128/JB.181.19.5915-5921.1999; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Green DH, 2000, J BACTERIOL, V182, P278, DOI 10.1128/JB.182.2.278-285.2000; Grigorenko AP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P826, DOI 10.1023/A:1016365227942; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; High S, 1999, BIOCHEM SOC T, V27, P883, DOI 10.1042/bst0270883; Kall L, 2002, FEBS LETT, V532, P415, DOI 10.1016/S0014-5793(02)03730-4; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; LAU JTY, 1983, J BIOL CHEM, V258, P5255; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Lemberg MK, 2004, FEBS LETT, V564, P213, DOI 10.1016/S0014-5793(04)00192-9; Lemberg MK, 2003, ANAL BIOCHEM, V319, P327, DOI 10.1016/S0003-2697(03)00298-7; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Martoglio B, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P265; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Nilsson J, 2000, FEBS LETT, V486, P267, DOI 10.1016/S0014-5793(00)02321-8; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ott CM, 2002, J CELL SCI, V115, P2003; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WADA I, 1991, J BIOL CHEM, V266, P19599; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Zelenski NG, 1999, J BIOL CHEM, V274, P21973, DOI 10.1074/jbc.274.31.21973	46	81	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50790	50798		10.1074/jbc.M407898200	http://dx.doi.org/10.1074/jbc.M407898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385547	Green Published, hybrid			2022-12-25	WOS:000225355800021
J	Walker, KA; Mallik, P; Pratt, TS; Osuna, R				Walker, KA; Mallik, P; Pratt, TS; Osuna, R			The Escherichia coli fis promoter is regulated by changes in the levels of its transcription initiation nucleotide CTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA TRANSCRIPTION; DEPENDENT REITERATIVE TRANSCRIPTION; SALMONELLA-TYPHIMURIUM-PYRC; THIN-LAYER-CHROMATOGRAPHY; GROWTH-RATE REGULATION; SENSITIVE SELECTION; STRINGENT CONTROL; START SITES; OPERON EXPRESSION; NUCLEOSIDE TRIPHOSPHATE	Expression of the Escherichia coli nucleoid-associated protein Fis ( factor for inversion stimulation) is controlled at the transcriptional level in accordance with the nutritional availability. It is highly expressed during early logarithmic growth phase in cells growing in rich medium but poorly expressed in late logarithmic and stationary phase. However, fis mRNA expression is prolonged at high levels throughout the logarithmic and early stationary phase when the preferred transcription initiation site (+1C) is replaced with A or G, indicating that initiation with CTP is a required component of the regulation pattern. We show that RNA polymerase-fis promoter complexes are short lived and that transcription is stimulated over 20-fold from linear or supercoiled DNA if CTP is present during formation of initiation complexes, which serves to stabilize these complexes. Use of fis promoter fusions to lacZ indicated that fis promoter transcription is sensitive to the intracellular pool of the predominant initiating NTP. Growth conditions resulting in increases in CTP pools also result in corresponding increases in fis mRNA levels. Measurements of NTP pools performed throughout the growth of the bacterial culture in rich medium revealed a dramatic increase in all four NTP levels during the transition from stationary to logarithmic growth phase, followed by reproducible oscillations in their levels during logarithmic growth, which later decrease during the transition from logarithmic to stationary phase. In particular, CTP pools fluctuate in a manner consistent with a role in regulating fis expression. These observations support a model whereby fis expression is subject to regulation by the availability of its initiating NTP.	SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; Washington University (WUSTL)	Osuna, R (corresponding author), SUNY Albany, Dept Biol Sci, 1400 Washington Ave, Albany, NY 12222 USA.	osuna@albany.edu		Walker, Kimberly A/0000-0002-6360-2792	NIGMS NIH HHS [GM52051] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052051, R29GM052051] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER MD, 1978, J BACTERIOL, V133, P149, DOI 10.1128/JB.133.1.149-157.1978; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; Barker MM, 2001, J BACTERIOL, V183, P6315, DOI 10.1128/JB.183.21.6315-6323.2001; Beach MB, 1998, J BACTERIOL, V180, P5932, DOI 10.1128/JB.180.22.5932-5946.1998; BECK C, 1973, J MOL BIOL, V78, P117, DOI 10.1016/0022-2836(73)90431-2; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; Cabrera JE, 2001, J BACTERIOL, V183, P6126, DOI 10.1128/JB.183.20.6126-6134.2001; Caramel A, 2000, MOL MICROBIOL, V36, P85, DOI 10.1046/j.1365-2958.2000.01827.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASE CC, 1988, GENE, V72, P219, DOI 10.1016/0378-1119(88)90147-3; Claret L, 1996, J MOL BIOL, V263, P126, DOI 10.1006/jmbi.1996.0564; DICKSON RR, 1989, J BACTERIOL, V171, P4862, DOI 10.1128/jb.171.9.4862-4870.1989; Falconi M, 1996, MOL MICROBIOL, V19, P965, DOI 10.1046/j.1365-2958.1996.436961.x; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Goldberg MD, 2001, MOL MICROBIOL, V41, P549, DOI 10.1046/j.1365-2958.2001.02526.x; GonzalezGil G, 1996, MOL MICROBIOL, V22, P21, DOI 10.1111/j.1365-2958.1996.tb02652.x; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; Green J, 1996, MOL MICROBIOL, V20, P1043, DOI 10.1111/j.1365-2958.1996.tb02545.x; Han XS, 1998, J BACTERIOL, V180, P705, DOI 10.1128/JB.180.3.705-713.1998; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; Hershberg R, 2001, NUCLEIC ACIDS RES, V29, P277, DOI 10.1093/nar/29.1.277; IRR J, 1969, J BIOL CHEM, V244, P2233; Jacobson BA, 1998, MOL MICROBIOL, V28, P1315, DOI 10.1046/j.1365-2958.1998.00897.x; JENSEN KF, 1979, J BACTERIOL, V138, P731, DOI 10.1128/JB.138.3.731-738.1979; JENSEN KF, 1979, ANAL BIOCHEM, V98, P254, DOI 10.1016/0003-2697(79)90138-6; JENSEN KF, 1989, J GEN MICROBIOL, V135, P805; JUSTESEN J, 1975, J BACTERIOL, V123, P851, DOI 10.1128/JB.123.3.851-854.1975; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; LIU CG, 1994, GENE DEV, V8, P2904, DOI 10.1101/gad.8.23.2904; LIU J, 1994, J BACTERIOL, V176, P2938, DOI 10.1128/JB.176.10.2938-2945.1994; Mallik P, 2004, J BACTERIOL, V186, P122, DOI 10.1128/JB.186.1.122-135.2004; Martin RG, 1997, J BACTERIOL, V179, P7410, DOI 10.1128/jb.179.23.7410-7419.1997; Miller JH., 1972, EXPT MOL GENETICS; Murray HD, 2004, MOL MICROBIOL, V52, P1375, DOI 10.1111/j.1365-2958.2004.04060.x; Murray HD, 2003, MOL CELL, V12, P125, DOI 10.1016/S1097-2765(03)00266-1; NEUHARD J, 1986, EUR J BIOCHEM, V157, P335, DOI 10.1111/j.1432-1033.1986.tb09673.x; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P445; NILSSON L, 1994, J BIOL CHEM, V269, P9460; NILSSON L, 1992, J BACTERIOL, V174, P921, DOI 10.1128/jb.174.3.921-929.1992; NINNEMANN O, 1992, EMBO J, V11, P1075, DOI 10.1002/j.1460-2075.1992.tb05146.x; OSUNA R, 1995, J BACTERIOL, V177, P2021, DOI 10.1128/jb.177.8.2021-2032.1995; Paul BJ, 2004, CELL, V118, P311, DOI 10.1016/j.cell.2004.07.009; POULSEN P, 1987, MOL GEN GENET, V208, P152, DOI 10.1007/BF00330436; Pratt TS, 1997, J BACTERIOL, V179, P6367, DOI 10.1128/jb.179.20.6367-6377.1997; QI FX, 1995, J MOL BIOL, V254, P552, DOI 10.1006/jmbi.1995.0638; RANDERATH E, 1964, J CHROMATOGR, V16, P126, DOI 10.1016/S0021-9673(01)82446-8; ROLAND KL, 1985, J BACTERIOL, V163, P991, DOI 10.1128/JB.163.3.991-999.1985; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider DA, 2004, J BIOL CHEM, V279, P8262, DOI 10.1074/jbc.M311996200; Schneider DA, 2003, J BACTERIOL, V185, P6185, DOI 10.1128/JB.185.20.6185-6191.2003; Schneider DA, 2002, P NATL ACAD SCI USA, V99, P8602, DOI 10.1073/pnas.132285199; Schneider R, 2000, MOL MICROBIOL, V38, P167, DOI 10.1046/j.1365-2958.2000.02129.x; Sheikh J, 2001, MOL MICROBIOL, V41, P983, DOI 10.1046/j.1365-2958.2001.02512.x; Shin D, 2003, J BIOL CHEM, V278, P14776, DOI 10.1074/jbc.M213248200; SILVER S, 1996, TRANSPORT INORGANIC, P1091; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SORENSEN KI, 1993, J BACTERIOL, V175, P4137; SORENSEN KI, 1991, MOL GEN GENET, V225, P249, DOI 10.1007/BF00269856; Tu AHT, 1997, J BACTERIOL, V179, P6665, DOI 10.1128/jb.179.21.6665-6673.1997; VOGEL U, 1991, J BACTERIOL, V173, P1168, DOI 10.1128/jb.173.3.1168-1174.1991; Walker KA, 2002, J BACTERIOL, V184, P4783, DOI 10.1128/JB.184.17.4783-4791.2002; Walker KA, 1999, J BACTERIOL, V181, P1269, DOI 10.1128/JB.181.4.1269-1280.1999; Weinstein-Fischer D, 2000, MOL MICROBIOL, V35, P1413, DOI 10.1046/j.1365-2958.2000.01805.x; WILSON HR, 1992, J BACTERIOL, V174, P514, DOI 10.1128/jb.174.2.514-524.1992; WU CW, 1969, BIOCHEMISTRY-US, V8, P4458, DOI 10.1021/bi00839a035; Wu HC, 1998, MOL MICROBIOL, V27, P493, DOI 10.1046/j.1365-2958.1998.00699.x; XU JM, 1995, J BACTERIOL, V177, P938, DOI 10.1128/jb.177.4.938-947.1995	70	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50818	50828		10.1074/jbc.M406285200	http://dx.doi.org/10.1074/jbc.M406285200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385561	hybrid			2022-12-25	WOS:000225355800024
J	Auty, R; Steen, H; Myers, LC; Persinger, J; Bartholomew, B; Gygi, SP; Buratowski, S				Auty, R; Steen, H; Myers, LC; Persinger, J; Bartholomew, B; Gygi, SP; Buratowski, S			Purification of active TFIID from Saccharomyces cerevisiae - Extensive promoter contacts and co-activator function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; RSP5 UBIQUITIN LIGASE; TRANSCRIPTION FACTOR; BINDING PROTEIN; AFFINITY PURIFICATION; CRYSTAL-STRUCTURE; GENE-EXPRESSION; TATA; COMPLEXES	The basal transcription factor TFIID is composed of the TATA-binding protein (TBP) and 14 TBP-associated factors (TAFs). Although TBP alone binds to the TATA box of DNA and supports basal transcription, the TAFs have essential functions that remain poorly defined. In order to study its properties, TFIID was purified from Saccharomyces cerevisiae using a newly developed affinity tag. Analysis of the final elution by mass spectrometry confirms the presence of all the known TAFs and TBP, as well as Rsp5, Bul1, Ubp3, Bre5, Cka1, and Cka2. Both Taf1 and Taf5 are ubiquitinated, and the ubiquitination pattern of TFIID changes when BUL1 or BRE5 is deleted. Purified TFIID binds specifically to promoter DNA in a manner stabilized by TFIIA, and these complexes can be analyzed by native gel electrophoresis. Phenanthroline-copper footprinting and photoaffinity cross-linking indicate that TFIID makes extensive contacts upstream and downstream of the TATA box. TFIID supports basal transcription and activated transcription, both of which are enhanced by TFIIA.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; So Illinois Univ, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Dartmouth College; Southern Illinois University System; Southern Illinois University	Buratowski, S (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	steveb@hms.harvard.edu		Steen, Hanno/0000-0003-0179-6648	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046498, R29GM046498, R01GM062483] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46498, GM62483] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andel F, 1999, SCIENCE, V286, P2153, DOI 10.1126/science.286.5447.2153; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; Bleichenbacher M, 2003, J MOL BIOL, V332, P783, DOI 10.1016/S0022-2836(03)00887-8; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; Chapman RD, 2004, NUCLEIC ACIDS RES, V32, P35, DOI 10.1093/nar/gkh172; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; HENRY NL, 1992, J BIOL CHEM, V267, P23388; Honey S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e24; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; Hu P, 2003, MOL CELL, V12, P699, DOI 10.1016/j.molcel.2003.08.011; Johnston IM, 2002, MOL CELL BIOL, V22, P3757, DOI 10.1128/MCB.22.11.3757-3768.2002; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; KUWABARA M, 1986, BIOCHEMISTRY-US, V25, P7401, DOI 10.1021/bi00371a023; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Leurent C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; Matangkasombut O, 2000, GENE DEV, V14, P951; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Palancade B, 2002, J BIOL CHEM, V277, P36061, DOI 10.1074/jbc.M205192200; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Saez-Vasquez J, 2001, PLANT MOL BIOL, V47, P449, DOI 10.1023/A:1011619413393; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Sawa C, 2004, MOL CELL BIOL, V24, P4734, DOI 10.1128/MCB.24.11.4734-4742.2004; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; Sengupta SM, 1999, METHODS, V19, P434, DOI 10.1006/meth.1999.0880; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Wu SY, 2003, MOL CELL BIOL, V23, P6229, DOI 10.1128/MCB.23.17.6229-6242.2003; Wu XY, 2001, CURR GENET, V40, P234, DOI 10.1007/s00294-001-0257-8; Yashiroda H, 1996, MOL CELL BIOL, V16, P3255	56	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49973	49981		10.1074/jbc.M409849200	http://dx.doi.org/10.1074/jbc.M409849200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15448131	hybrid			2022-12-25	WOS:000225229500053
J	Inoue, D; Kido, S; Matsumoto, T				Inoue, D; Kido, S; Matsumoto, T			Transcriptional induction of FosB/Delta FosB gene by mechanical stress in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ELEMENT-BINDING PROTEIN; DELTA-FOSB; BONE-FORMATION; C-FOS; TRANSGENIC MICE; SHEAR-STRESS; SPACE-FLIGHT; EXPRESSION; CELLS	Mechanical stress to bone plays a critical role in maintaining bone mass and strength. However, the molecular mechanism of mechanical stress-induced bone formation is not fully understood. In the present study, we demonstrate that FosB and its spliced variant DeltaFosB, which is known to increase bone mass by stimulating bone formation in vivo, is rapidly induced by mechanical loading in mouse hind limb bone in vivo and by fluid shear stress (FSS) in mouse calvarial osteoblasts in vitro both at the mRNA and protein levels. FSS induction of FosB/DeltaFosB gene expression was dependent on gadlinium-sensitive Ca2+ influx and subsequent activation of ERK1/2. Analysis of the mouse FosB/DeltaFosB gene upstream regulatory region with luciferase reporter gene assays revealed that the FosB/DeltaFosB induction by FSS occurred at the transcriptional level and was conferred by a short fragment from -603 to -327. DNA precipitation assays and DNA decoy experiments indicated that ERK-dependent activation of CREB binding to a CRE/AP-1 like element (designated "CRE2") at the position of -413 largely contributed to the transcriptional effects of FSS. These results suggest that DeltaFosB participates in mechanical stress-induced intracellular signaling cascades that activate the osteogenic program in osteoblasts.	Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan	Tokushima University	Inoue, D (corresponding author), Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	inoued@clin.med.tokushima-u.ac.jp						Ahn JD, 2003, BIOCHEM BIOPH RES CO, V310, P1048, DOI 10.1016/j.bbrc.2003.09.124; Burr DB, 2002, BONE, V30, P781, DOI 10.1016/S8756-3282(02)00707-X; Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Inoue D, 1997, J BIOL CHEM, V272, P25386, DOI 10.1074/jbc.272.40.25386; Inoue M, 2000, BONE, V26, P281, DOI 10.1016/S8756-3282(99)00282-3; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790; Kveiborg M, 2002, ENDOCRINOLOGY, V143, P4304, DOI 10.1210/en.2002-220420; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; Lean JM, 1996, AM J PHYSIOL-ENDOC M, V270, pE937, DOI 10.1152/ajpendo.1996.270.6.E937; Lee IK, 2003, CURR DRUG TARGETS, V4, P619, DOI 10.2174/1389450033490821; Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898-6568(00)00096-6; Matsumoto T, 1998, BONE, V22, p89S, DOI 10.1016/S8756-3282(98)00018-0; Matsushita M, 1997, INFLAMM RES, V46, P461, DOI 10.1007/s000110050225; Mikuni-Takagaki Y, 1999, J BONE MINER METAB, V17, P57, DOI 10.1007/s007740050065; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; Nashat AH, 2003, MOL CELL BIOL, V23, P4788, DOI 10.1128/MCB.23.14.4788-4795.2003; Nestler EJ, 1999, BRAIN RES, V835, P10, DOI 10.1016/S0006-8993(98)01191-3; Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698; Nomura S, 2000, MATRIX BIOL, V19, P91, DOI 10.1016/S0945-053X(00)00050-0; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; Ono K, 2002, J BONE MINER RES, V17, P774, DOI 10.1359/jbmr.2002.17.5.774; Peake MA, 2003, FEBS LETT, V537, P117, DOI 10.1016/S0014-5793(03)00108-X; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Sakai K, 1999, J BONE MINER RES, V14, P2089, DOI 10.1359/jbmr.1999.14.12.2089; Sakata T, 1999, J BONE MINER RES, V14, P1596, DOI 10.1359/jbmr.1999.14.9.1596; Schneider V, 1995, ACTA ASTRONAUT, V36, P463, DOI 10.1016/0094-5765(95)00131-X; Sims NA, 2002, BONE, V30, P32, DOI 10.1016/S8756-3282(01)00622-6; Song KS, 2003, J BIOL CHEM, V278, P34890, DOI 10.1074/jbc.M303911200; Takahashi M, 1997, J VASC RES, V34, P212, DOI 10.1159/000159225; Tate MLK, 2003, J BIOMECH, V36, P1409, DOI 10.1016/S0021-9290(03)00123-4; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Weinreb M, 1997, BONE, V20, P347, DOI 10.1016/S8756-3282(97)00011-2; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200	44	77	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49795	49803		10.1074/jbc.M404096200	http://dx.doi.org/10.1074/jbc.M404096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383527	hybrid			2022-12-25	WOS:000225229500032
J	Maestroni, GJM				Maestroni, GJM			The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein	FASEB JOURNAL			English	Article						innate immunity; dendritic cell precursor; cytokine; CB2 cannabinoid receptor; chemotaxis	IMMUNE-SYSTEM; MIGRATION; TOLERANCE; DIFFERENTIATION; ACTIVATION; PRECURSORS; RECEPTORS; MONOCYTES; IMPACT	The decision-making mechanisms that determine the choice of the appropriate effector immune response to a microbial challenge are poorly understood. The endocannabinoid 2-arachidonoylglycerol (2-AG), injected intradermally in mice together with a soluble protein and a T helper-2 (Th2) priming Toll-like receptors (TLRs) agonist during primary immunization, shifts the memory response to the Th1 type. This effect can be shown by the enhanced hypersensitivity response and by the Th1 pattern of cytokines production that was abolished by the specific cannabinoid receptor CB2 antagonist SR 144528. 2-AG seems to operate during the innate response by increasing the number of dendritic cells (DCs) migrating to the draining lymph nodes. Expression of CB2 mRNA but not of the protein was higher in immature vs. mature DCs. Consistently, in vitro, 2-AG exerted a potent chemotactic activity on both immature and mature DCs. In conclusion, we suggest that, in vivo, the endocannabinoid 2-AG may act as chemotactic substance capable of recruiting DCs and/or their precursors during the innate immune response that, in presence of a TLR agonist, consequently instruct a Th1-shifted adaptive response. As 2-AG may be induced in tissues by various stimuli at concentrations similar to that used in our study, this evidence might be of a wide-ranging pathophysiological relevance.	Ist Cantonale Patol, Ctr Expt Pathol, CH-6601 Locarno, Switzerland		Maestroni, GJM (corresponding author), Ist Cantonale Patol, Ctr Expt Pathol, CH-6601 Locarno, Switzerland.	georges.maestroni@ti.ch	Maestroni, Georges/AAG-9117-2019					Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Ardavin C, 2003, NAT REV IMMUNOL, V3, P582, DOI 10.1038/nri1127; BURSTEIN HJ, 1993, J EXP MED, V177, P457, DOI 10.1084/jem.177.2.457; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; Jorda MA, 2002, BLOOD, V99, P2786; Kalia R, 1999, COMPUT SCI ENG, V1, P2; Kishimoto S, 2004, J BIOCHEM, V135, P517, DOI 10.1093/jb/mvh063; Kishimoto S, 2003, J BIOL CHEM, V278, P24469, DOI 10.1074/jbc.M301359200; Klein T W, 2001, Pain Res Manag, V6, P95; Klein TW, 2004, J NEUROIMMUNOL, V147, P91, DOI 10.1016/j.jneuroim.2003.10.019; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Leon B, 2004, BLOOD, V103, P2668, DOI 10.1182/blood-2003-01-0286; Maestroni GJM, 2004, J INVEST DERMATOL, V122, P119, DOI 10.1046/j.0022-202X.2003.22132.x; Maestroni GJM, 2003, J NEUROIMMUNOL, V144, P91, DOI 10.1016/j.jneuroim.2003.08.039; Maestroni GJM, 2000, J IMMUNOL, V165, P6743, DOI 10.4049/jimmunol.165.12.6743; Matias I, 2002, EUR J BIOCHEM, V269, P3771, DOI 10.1046/j.1432-1033.2002.03078.x; Mondino A, 1996, P NATL ACAD SCI USA, V93, P2245, DOI 10.1073/pnas.93.6.2245; Niederhoffer N, 2003, N-S ARCH PHARMACOL, V367, P434, DOI 10.1007/s00210-003-0755-y; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parolaro D, 2002, PROSTAG LEUKOTR ESS, V66, P319, DOI 10.1054/plef.2001.0355; Pulendran B, 2001, SCIENCE, V293, P253, DOI 10.1126/science.1062060; Qi H, 2003, INFECT IMMUN, V71, P3337, DOI 10.1128/IAI.71.6.3337-3342.2003; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; Steinman RM, 2003, APMIS, V111, P675, DOI 10.1034/j.1600-0463.2003.11107802.x; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Van Parijs L, 1998, SCIENCE, V280, P243; Yuan M, 2002, J NEUROIMMUNOL, V133, P124, DOI 10.1016/S0165-5728(02)00370-3	27	58	58	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1914	+		10.1096/fj.04-2190fje	http://dx.doi.org/10.1096/fj.04-2190fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15385435				2022-12-25	WOS:000224243200019
J	Lee, I; Skinner, MA; Guo, HB; Sujan, A; Pierce, M				Lee, I; Skinner, MA; Guo, HB; Sujan, A; Pierce, M			Expression of the vacuolar H+-ATPase 16-kDa subunit results in the Triton X-100-insoluble aggregation of beta(1) integrin and reduction of its cell surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; GROWTH-FACTOR-BETA; QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; FIBRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; PAPILLOMAVIRUS E5; EPITHELIAL-CELLS; N-GLYCOSYLATION; V-ATPASE	Vacuolar H+-ATPase functions as a vacuolar proton pump and is responsible for acidification of intracellular compartments such as the endoplasmic reticulum, Golgi, lysosomes, and endosomes. Previous reports have demonstrated that a 16-kDa subunit (16K) of vacuolar H+-ATPase via one of its transmembrane domains, TMD4, strongly associates with beta(1) integrin, affecting beta(1) integrin N-linked glycosylation and inhibiting its function as a matrix adhesion receptor. Because of this dramatic inhibition of beta(1) integrin-mediated HEK-293 cell motility by 16K expression, we investigated the mechanism by which 16 kDa was having this effect. Using HT1080 cells whose alpha(5)beta(1) integrin-mediated adhesion to fibronectin has been extensively studied, the expression of 16 kDa also resulted in reduced cell spreading on fibronectin-coated substrates. A pulse-chase study of beta(1) integrin biosynthesis indicated that 16K expression down-regulated the level of the 110-kDa biosynthetic form of beta(1) integrin (premature form) and, consequently, the level of the 130-kDa form of beta(1) integrin (mature form). Further experiments showed that the normal levels of association between the premature beta(1) integrin form and calnexin were significantly decreased by the expression of either 16 kDa or TMD4. Expression of 16 kDa also resulted in a Triton X-100-insoluble aggregation of an unusual 87-kDa form of beta(1) integrin. Interestingly, both Western blotting and a pulse-chase experiment showed co-immunoprecipitation of calnexin and 16K. These results indicate that 16K expression inhibits beta(1) integrin surface expression and spreading on matrix by a novel mechanism that results in reduced levels of functional beta(1) integrin.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Guelph	Pierce, M (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	hawkeye@uga.edu		Lee, Intaek/0000-0003-1084-674X	NCI NIH HHS [R01CA64462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; ARAI H, 1988, J BIOL CHEM, V263, P8796; Cannon KS, 2001, EMBO J, V20, P2443, DOI 10.1093/emboj/20.10.2443; DELCOMMENNE M, 1995, J BIOL CHEM, V270, P26794, DOI 10.1074/jbc.270.45.26794; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FORGAC M, 1992, ANN NY ACAD SCI, V671, P273, DOI 10.1111/j.1749-6632.1992.tb43802.x; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; Gottfried C, 2003, NEUROSCIENCE, V121, P553, DOI 10.1016/S0306-4522(03)00557-8; Guo HB, 2002, CANCER RES, V62, P6837; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; HEINO J, 1989, J BIOL CHEM, V264, P380; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Koistinen P, 2002, J BIOL CHEM, V277, P24835, DOI 10.1074/jbc.M203149200; LENTER M, 1994, J BIOL CHEM, V269, P12263; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Milner R, 2002, MOL CELL NEUROSCI, V20, P616, DOI 10.1006/mcne.2002.1151; Miura K, 2001, J BIOL CHEM, V276, P46276, DOI 10.1074/jbc.M102387200; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Nishi T, 2001, J BIOL CHEM, V276, P34122, DOI 10.1074/jbc.M104682200; Perlino E, 2000, AM J PATHOL, V157, P1727, DOI 10.1016/S0002-9440(10)64809-2; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; Rubinstein E, 1997, EUR J IMMUNOL, V27, P1919, DOI 10.1002/eji.1830270815; Salicioni AM, 2004, J BIOL CHEM, V279, P10005, DOI 10.1074/jbc.M306625200; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; Skinner MA, 2001, J BIOL CHEM, V276, P48451, DOI 10.1074/jbc.M103569200; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; Vihinen P, 2000, MELANOMA RES, V10, P243, DOI 10.1097/00008390-200010030-00006; Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	39	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53007	53014		10.1074/jbc.M405717200	http://dx.doi.org/10.1074/jbc.M405717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466867	hybrid			2022-12-25	WOS:000225680600026
J	Wenstrup, RJ; Florer, JB; Brunskill, EW; Bell, SM; Chervoneva, I; Birk, DE				Wenstrup, RJ; Florer, JB; Brunskill, EW; Bell, SM; Chervoneva, I; Birk, DE			Type V collagen controls the initiation of collagen fibril assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS-SYNDROME; FIBRILLOGENESIS IN-SITU; LETHAL MUTATION; ORGANIZATION; COL5A1; MICE; EXPRESSION; SEGMENTS; MECHANISM; EVOLUTION	Vertebrate collagen fibrils are heterotypically composed of a quantitatively major and minor fibril collagen. In non-cartilaginous tissues, type I collagen accounts for the majority of the collagen mass, and collagen type V, the functions of which are poorly understood, is a minor component. Type V collagen has been implicated in the regulation of fibril diameter, and we reported recently preliminary evidence that type V collagen is required for collagen fibril nucleation (Wenstrup, R. J., Florer, J. B., Cole, W. G., Willing, M. C., and Birk, D. E. ( 2004) J. Cell. Biochem. 92, 113 - 124). The purpose of this study was to define the roles of type V collagen in the regulation of collagen fibrillogenesis and matrix assembly. Mouse embryos completely deficient in pro-alpha1(V) chains were created by homologous recombination. The col5a1-/- animals die in early embryogenesis, at approximately embryonic day 10. The type V collagen-deficient mice demonstrate a virtual lack of collagen fibril formation. In contrast, the col5a1+/- animals are viable. The reduced type V collagen content is associated with a 50% reduction in fibril number and dermal collagen content. In addition, relatively normal, cylindrical fibrils are assembled with a second population of large, structurally abnormal collagen fibrils. The structural properties of the abnormal matrix are decreased relative to the wild type control animals. These data indicate a central role for the evolutionary, ancient type V collagen in the regulation of fibrillogenesis. The complete dependence of fibril formation on type V collagen is indicative of the critical role of the latter in early fibril initiation. In addition, this fibril collagen is important in the determination of fibril structure and matrix organization.	Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45267 USA; Thomas Jefferson Univ, Dept Anat & Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Anat & Cell Biol, Philadelphia, PA 19107 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Jefferson University; Jefferson University	Wenstrup, RJ (corresponding author), Childrens Hosp Res Fdn, Div Human Genet, 3333 Burnet Ave,ML 4006, Cincinnati, OH 45229 USA.	richard.wenstrup@cchmc.org	Birk, David/I-4072-2012	Birk, David/0000-0002-4865-9088; Bell, Sheila/0000-0002-1946-0969	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047054] Funding Source: NIH RePORTER; NEI NIH HHS [EY05129] Funding Source: Medline; NIAMS NIH HHS [AR47054] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; Bell SM, 1998, MECH DEVELOP, V74, P41, DOI 10.1016/S0925-4773(98)00065-3; BERG RA, 1982, METHOD ENZYMOL, V82, P372; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1995, DEV DYNAM, V202, P229, DOI 10.1002/aja.1002020303; Birk DE, 1997, DEV DYNAM, V208, P291; Birk DE, 1996, MATRIX BIOL, V15, P111, DOI 10.1016/S0945-053X(96)90152-3; BIRK DE, 1984, J CELL BIOL, V99, P2024, DOI 10.1083/jcb.99.6.2024; BIRK DE, 1990, J CELL SCI, V95, P649; BONADIO J, 1985, J BIOL CHEM, V260, P1734; Canty EG, 2004, J CELL BIOL, V165, P553, DOI 10.1083/jcb.200312071; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Exposito JY, 2000, MATRIX BIOL, V19, P275, DOI 10.1016/S0945-053X(00)00067-6; FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0; FITCH JM, 1984, P NATL ACAD SCI-BIOL, V81, P2791, DOI 10.1073/pnas.81.9.2791; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HOAGLIN DC, 1986, J AM STAT ASSOC, V81, P991, DOI 10.2307/2289073; JAENISCH R, 1983, CELL, V32, P209, DOI 10.1016/0092-8674(83)90511-1; Jepsen KJ, 2002, J BIOL CHEM, V277, P35532, DOI 10.1074/jbc.M205398200; Kadler KE, 1996, BIOCHEM J, V316, P1; Kadler KE, 2000, MATRIX BIOL, V19, P359, DOI 10.1016/S0945-053X(00)00082-2; KRATOCHWIL K, 1989, CELL, V57, P807, DOI 10.1016/0092-8674(89)90795-2; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; Mao JR, 2002, NAT GENET, V30, P421, DOI 10.1038/ng850; Marchant JK, 1996, J CELL BIOL, V135, P1415, DOI 10.1083/jcb.135.5.1415; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; Nagy A., 2003, MANIPULATING MOUSE E; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; NIYIBIZI C, 1994, EUR J BIOCHEM, V224, P943, DOI 10.1111/j.1432-1033.1994.00943.x; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; Schwarze U, 2000, AM J HUM GENET, V66, P1757, DOI 10.1086/302933; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; TAKAHARA K, 1995, GENOMICS, V29, P588, DOI 10.1006/geno.1995.9961; Tillet E, 1996, COMP BIOCHEM PHYS B, V113, P239, DOI 10.1016/0305-0491(95)02014-4; Vonesh E.F., 1997, LINEAR NONLINEAR MOD; Wenstrup RJ, 1996, J BIOL CHEM, V271, P10271, DOI 10.1074/jbc.271.17.10271; Wenstrup RJ, 2004, J CELL BIOCHEM, V92, P113, DOI 10.1002/jcb.20024; Wenstrup RJ, 2000, AM J HUM GENET, V66, P1766, DOI 10.1086/302930	42	335	352	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53331	53337		10.1074/jbc.M409622200	http://dx.doi.org/10.1074/jbc.M409622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15383546	hybrid			2022-12-25	WOS:000225680600065
J	Allende, ML; Sasaki, T; Kawai, H; Olivera, A; Mi, YD; van Echten-Deckert, G; Hajdu, R; Rosenbach, M; Keohane, CA; Mandala, S; Spiegel, S; Proia, RL				Allende, ML; Sasaki, T; Kawai, H; Olivera, A; Mi, YD; van Echten-Deckert, G; Hajdu, R; Rosenbach, M; Keohane, CA; Mandala, S; Spiegel, S; Proia, RL			Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; FUNCTIONAL-CHARACTERIZATION; VASCULAR MATURATION; MOLECULAR-CLONING; IMMUNOSUPPRESSANT FTY720; 1-PHOSPHATE RECEPTOR; ENDOTHELIAL-CELLS; SPHINGOSINE-1-PHOSPHATE; GROWTH; S1P(1)	Sphingosine-1-phosphate (S1P), a lipid signaling molecule that regulates many cellular functions, is synthesized from sphingosine and ATP by the action of sphingosine kinase. Two such kinases have been identified, SPHK1 and SPHK2. To begin to investigate the physiological functions of sphingosine kinase and S1P signaling, we generated mice deficient in SPHK1. Sphk1 null mice were viable, fertile, and without any obvious abnormalities. Total SPHK activity in most Sphk1-/- tissues was substantially, but not completely, reduced indicating the presence of multiple sphingosine kinases. S1P levels in most tissues from the Sphk1 -/- mice were not markedly decreased. In serum, however, there was a significant decrease in the S1P level. Although S1P signaling regulates lymphocyte trafficking, lymphocyte distribution was unaffected in lymphoid organs of Sphk1 -/- mice. The immunosuppressant FTY720 was phosphorylated and elicited lymphopenia in the Sphk1 null mice showing that SPHK1 is not required for the functional activation of this sphingosine analogue prodrug. The results with these Sphk1 null mice reveal that some key physiologic processes that require S1P receptor signaling, such as vascular development and proper lymphocyte distribution, can occur in the absence of SPHK1.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NIAMSD, NIH, Bethesda, MD 20892 USA; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Virginia Commonwealth Univ, Dept Biochem, Sch Med, Richmond, VA 23298 USA; Merck & Co Inc, Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Bonn; Virginia Commonwealth University; Merck & Company	Proia, RL (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bldg 10,Rm 9N-314,10 Ctr Dr,MSC 1821, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Chiba K, 1998, J IMMUNOL, V160, P5037; Clair T, 2003, CANCER RES, V63, P5446; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Herr DR, 2004, J BIOL CHEM, V279, P12685, DOI 10.1074/jbc.M310647200; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Kluk MJ, 2003, FEBS LETT, V533, P25, DOI 10.1016/S0014-5793(02)03742-0; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Krueger LA, 2002, CURRENT PROTOCOLS CY; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Li GC, 2001, DEVELOPMENT, V128, P3473; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Mendel J, 2003, J BIOL CHEM, V278, P22341, DOI 10.1074/jbc.M302857200; Morio T, 1998, DNA Res, V5, P335, DOI 10.1093/dnares/5.6.335; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Nishiura H, 2000, BIOCHEM SOC T, V28, P747, DOI 10.1042/BST0280747; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; Yagi H, 2000, EUR J IMMUNOL, V30, P1435, DOI 10.1002/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	47	371	382	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52487	52492		10.1074/jbc.M406512200	http://dx.doi.org/10.1074/jbc.M406512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15459201	hybrid			2022-12-25	WOS:000225493400094
J	Raschle, M; Van Komen, S; Chi, P; Ellenberger, T; Sung, P				Raschle, M; Van Komen, S; Chi, P; Ellenberger, T; Sung, P			Multiple interactions with the Rad51 recombinase govern the homologous recombination function of Rad54	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; YEAST RAD51; PROTEIN; CHROMATIN; REPAIR; FAMILY	In eukaryotes, Rad51 and Rad54 functionally cooperate to mediate homologous recombination and the repair of damaged chromosomes by recombination. Rad51, the eukaryotic counterpart of the bacterial RecA recombinase, forms filaments on single-stranded DNA that are capable of pairing the bound DNA with a homologous double-stranded donor to yield joint molecules. Rad54 enhances the homologous DNA pairing reaction, and this stimulatory effect involves a physical interaction with Rad51. Correspondingly, the ability of Rad54 to hydrolyze ATP and introduce superhelical tension into covalently closed circular plasmid DNA is stimulated by Rad51. By controlled proteolysis, we show that the amino-terminal region of yeast Rad54 is rather unstructured. Truncation mutations that delete the N-terminal 113 or 129 amino acid residues of Rad54 attenuate or ablate physical and functional interactions with Rad51 under physiological ionic strength, respectively. Surprisingly, under less stringent conditions, the Rad54 Delta129 protein can interact with Rad51 in affinity pull-down and functional assays. These results highlight the functional importance of the N-terminal Rad51 interaction domain of Rad54 and reveal that Rad54 contacts Rad51 through separable epitopes.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Yale University	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	tome@hms.harvard.edu; Patrick.Sung@yale.edu	Chi, Peter/AAI-1580-2019; Huang, Wenchi/F-3981-2010	Chi, Peter/0000-0001-9229-8729; Huang, Wenchi/0000-0001-5556-1460	NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM52504, GM57814] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2004, J BIOL CHEM, V279, P27824, DOI 10.1074/jbc.M402648200; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Haber JE, 2004, PHILOS T ROY SOC B, V359, P79, DOI 10.1098/rstb.2003.1367; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Shivji MKK, 2004, DNA REPAIR, V3, P835, DOI 10.1016/j.dnarep.2004.03.008; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Wolner B, 2003, MOL CELL, V12, P221, DOI 10.1016/S1097-2765(03)00242-9	29	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51973	51980		10.1074/jbc.M410101200	http://dx.doi.org/10.1074/jbc.M410101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465810	hybrid			2022-12-25	WOS:000225493400033
J	Chen, H; Pan, YX; Dudenhausen, EE; Kilberg, MS				Chen, H; Pan, YX; Dudenhausen, EE; Kilberg, MS			Amino acid deprivation induces the transcription rate of the human asparagine synthetase gene through a timed program of expression and promoter binding of nutrient-responsive basic region/leucine zipper transcription factors as well as localized histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; STRESS-RESPONSE; KINASE; ACTIVATION; ATF4; RNA; BETA; PHOSPHORYLATION; PROLIFERATION; TRANSLATION	Expression of human asparagine synthetase (ASNS), which catalyzes asparagine and glutamate biosynthesis, is transcriptionally induced following amino acid deprivation. Previous overexpression and electrophoresis mobility shift analysis showed the involvement of the transcription factors ATF4, C/EBPbeta, and ATF3-FL through the nutrient-sensing response element-1 (NSRE-1) within the ASNS promoter. Amino acid deprivation caused an elevated mRNA level for ATF4, C/EBPbeta, and ATF3-FL, and the present study established that the nuclear protein content for ATF4 and ATF3-FL were increased during amino acid limitation, whereas C/EBPbeta-LIP declined slightly. The total amount of C/EBPbeta-LAP protein was unchanged, but changes in the distribution among multiple C/EBPbeta-LAP forms were observed. Overexpression studies established that ATF4, ATF3-FL, and C/EBPbeta-LAP could coordinately modulate the transcription from the human ASNS promoter. Chromatin immunoprecipitation demonstrated that amino acid deprivation increased ATF3-FL, ATF4, and C/EBPbeta binding to the ASNS promoter and enhanced promoter association of RNA polymerase II, TATA-binding protein, and TFIIB of the general transcription machinery. A time course revealed a markedly different temporal order of interaction between these transcription factors and the ASNS promoter. During the initial 2 h, there was a 20-fold increase in ATF4 binding and a rapid increase in histone H3 and H4 acetylation, which closely paralleled the increased transcription rate of the ASNS gene, whereas the increase in ATF3-FL and C/EBPbeta binding was considerably slower and more closely correlated with the decline in transcription rate between 2 and 6 h. The data suggest that ATF3-FL and C/EBPbeta act as transcriptional suppressors for the ASNS gene to counterbalance the transcription rate activated by ATF4 following amino acid deprivation.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC,Genet Inst, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC,Genet Inst, Box 100245, Gainesville, FL 32610 USA.	mkilberg@ufl.edu	Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367	NIDDK NIH HHS [DK-52064] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Buck M, 2003, HEPATOLOGY, V37, P731, DOI 10.1053/jhep.2003.50155; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; De Angelis R, 2003, FEBS LETT, V547, P15, DOI 10.1016/S0014-5793(03)00659-8; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fernandez J, 2003, J BIOL CHEM, V278, P50000, DOI 10.1074/jbc.M305903200; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Kilberg M, 2002, J NUTR, V132, P1801, DOI 10.1093/jn/132.7.1801; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; Marten NW, 1996, BIOCHEM J, V317, P361, DOI 10.1042/bj3170361; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; Palii SS, 2004, J BIOL CHEM, V279, P3463, DOI 10.1074/jbc.M310483200; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wang J, 2003, J BIOL CHEM, V278, P32899, DOI 10.1074/jbc.M305456200; Zhan K, 2002, MOL CELL BIOL, V22, P7134, DOI 10.1128/MCB.22.20.7134-7146.2002; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002	38	157	160	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50829	50839		10.1074/jbc.M409173200	http://dx.doi.org/10.1074/jbc.M409173200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385533	hybrid			2022-12-25	WOS:000225355800025
J	Huang, YS; Li, T; Sane, DC; Li, LW				Huang, YS; Li, T; Sane, DC; Li, LW			IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; TOLL-LIKE RECEPTORS; NF-KAPPA-B; PHOSPHORYLATION; ACTIVATION; FAMILY; MEMBER; TRANSCRIPTION; TYROSINE; RESPOND	Being one of the key kinases downstream of Toll-like receptors, IRAK1 has initially thought to be responsible for NFkappaB activation. Yet IRAK1 knock-out mice still exhibit NFkappaB activation upon lipopolysaccharide (LPS) challenge, suggesting that IRAK1 may play other uncharacterized function. In this report, we show that IRAK1 is mainly involved in Stat3 activation and subsequent interleukin-10 (IL-10) gene expression. Splenocytes from IRAK1-deficient mice fail to exhibit LPS-induced Stat3 serine phosphorylation and IL-10 gene expression yet still maintain normal IL-1beta gene expression upon LPS challenge. Mechanistically, we observe that IRAK1 modification upon LPS challenge leads to its modification, nuclear distribution, and interaction with Stat3. IRAK1 can directly use Stat3 as a substrate and cause Stat3 serine 727 phosphorylation. In addition, nuclear IRAK1 binds directly with IL-10 promoter in vivo upon LPS treatment. Atherosclerosis patients usually have elevated serum IL-10 levels. We document here that IRAK1 is constitutively modified and localized in the nucleus in the peripheral blood mononuclear cells from atherosclerosis patients. These observations reveal the mechanism for the novel role of IRAK1 in the complex Toll-like receptor signaling network and indicate that IRAK1 regulation may be intimately linked with the pathogenesis and/or resolution of atherosclerosis.	Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27157 USA	Wake Forest University	Li, LW (corresponding author), Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27157 USA.	lwli@wfubmc.edu	LI, TAO/AAL-5932-2020	LI, TAO/0000-0001-7343-9688; Li, Liwu/0000-0001-8870-5299	NIAID NIH HHS [AI50089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050089] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 2001, CRIT CARE MED, V29, pS16, DOI 10.1097/00003246-200107001-00008; Akira S, 2001, ADV IMMUNOL, V78, P1, DOI 10.1016/S0065-2776(01)78001-7; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Bol GF, 2000, FEBS LETT, V477, P73, DOI 10.1016/S0014-5793(00)01759-2; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Feldmann K, 2002, EUR J IMMUNOL, V32, P1393, DOI 10.1002/1521-4141(200205)32:5<1393::AID-IMMU1393>3.0.CO;2-M; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li T, 2004, MOL IMMUNOL, V41, P85, DOI 10.1016/j.molimm.2004.03.009; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Mallat Z, 1999, ARTERIOSCL THROM VAS, V19, P611, DOI 10.1161/01.ATV.19.3.611; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Mueller LP, 2001, SHOCK, V16, P430, DOI 10.1097/00024382-200116060-00005; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Qin JZ, 2004, J BIOL CHEM, V279, P26748, DOI 10.1074/jbc.M400785200; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Vogel Stefanie N, 2003, Mol Interv, V3, P466, DOI 10.1124/mi.3.8.466; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540	34	97	106	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51697	51703		10.1074/jbc.M410369200	http://dx.doi.org/10.1074/jbc.M410369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15465816	hybrid			2022-12-25	WOS:000225355800126
J	Lee, KS; You, KH; Choo, JK; Han, YM; Yu, K				Lee, KS; You, KH; Choo, JK; Han, YM; Yu, K			Drosophila short neuropeptide F regulates food intake and body size	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEEDING-BEHAVIOR; GENE-EXPRESSION; MUSHROOM BODIES; NERVOUS-SYSTEM; MELANOGASTER; PEPTIDES; RECEPTOR; PEPTIDOMICS; INTEGRATION; MUTANTS	Neuropeptides regulate a wide range of animal behavior including food consumption, circadian rhythms, and anxiety. Recently, Drosophila neuropeptide F, which is the homolog of the vertebrate neuropeptide Y, was cloned, and the function of Drosophila neuropeptide F in feeding behaviors was well characterized. However, the function of the structurally related short neuropeptide F (sNPF) was unknown. Here, we report the cloning, RNA, and peptide localizations, and functional characterizations of the Drosophila sNPF gene. The sNPF gene encodes the preprotein containing putative RLRF amide peptides and was expressed in the nervous system of late stage embryos and larvae. The embryonic and larval localization of the sNPF peptide in the nervous systems revealed the larval central nervous system neural circuit from the neurons in the brain to thoracic axons and to connective axons in the ventral ganglion. In the adult brain, the sNPF peptide was localized in the medulla and the mushroom body. However, the sNPF peptide was not detected in the gut. The sNPF mRNA and the peptide were expressed during all developmental stages from embryo to adult. From the feeding assay, the gain-of-function sNPF mutants expressed in nervous systems promoted food intake, whereas the loss-of-function mutants suppressed food intake. Also, sNPF overexpression in nervous systems produced bigger and heavier flies. These findings indicate that the sNPF is expressed in the nervous systems to control food intake and regulate body size in Drosophila melanogaster.	Korea Res Inst Biosci & Biotechnol, Lab Dev & Differentiat, Taejon 395333, South Korea; Chung Ang Univ, Dept Life Sci, Seoul 156756, South Korea; Chungnam Natl Univ, Sch Biol Sci, Taejon 305764, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chung Ang University; Chungnam National University	Yu, K (corresponding author), Korea Res Inst Biosci & Biotechnol, Lab Dev & Differentiat, 52 Eoun Dong, Taejon 395333, South Korea.	kweonyu@kribb.re.kr	Han, Yong-Mahn/C-1652-2011	Yu, Kweon/0000-0002-4942-2576				Allan DW, 2003, CELL, V113, P73, DOI 10.1016/S0092-8674(03)00204-6; ASHBURNER M, 1989, DROSOPHILA LAB HDB, P140; Baggerman G, 2002, J BIOL CHEM, V277, P40368, DOI 10.1074/jbc.M206257200; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broeck JV, 2001, PEPTIDES, V22, P241, DOI 10.1016/S0196-9781(00)00376-4; Brown MR, 1999, PEPTIDES, V20, P1035, DOI 10.1016/S0196-9781(99)00097-2; CARLSON J, 1991, TRENDS NEUROSCI, V14, P520, DOI 10.1016/0166-2236(91)90004-E; Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; EDGECOMB RS, 1994, J EXP BIOL, V197, P215; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Feng GP, 2003, EUR J NEUROSCI, V18, P227, DOI 10.1046/j.1460-9568.2003.02719.x; Fiala A, 2002, CURR BIOL, V12, P1877, DOI 10.1016/S0960-9822(02)01239-3; FISCHBACH KF, 1989, CELL TISSUE RES, V258, P441, DOI 10.1007/BF00218858; Garczynski SF, 2002, PEPTIDES, V23, P773, DOI 10.1016/S0196-9781(01)00647-7; Heisenberg M., 1989, Progress in Zoology, V37, P3; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; Huang YQ, 1998, INSECT BIOCHEM MOLEC, V28, P345, DOI 10.1016/S0965-1748(98)00007-1; Joiner MLA, 1999, LEARN MEMORY, V6, P177; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Lange AB, 1998, PEPTIDES, V19, P459, DOI 10.1016/S0196-9781(97)00465-8; MAULE AG, 1995, HYDROBIOLOGIA, V305, P297, DOI 10.1007/BF00036410; Meinertzhagen Ian A., 1993, P1363; Mertens I, 2002, BIOCHEM BIOPH RES CO, V297, P1140, DOI 10.1016/S0006-291X(02)02351-3; Predel R, 2004, J COMP NEUROL, V474, P379, DOI 10.1002/cne.20145; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Shen P, 2001, J NEUROBIOL, V47, P16, DOI 10.1002/neu.1012; SHON B, 2001, BIOCHEM J, V360, P31; Spittaels K, 1996, INSECT BIOCHEM MOLEC, V26, P375, DOI 10.1016/0965-1748(95)00104-2; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; STRAUSFELD NJ, 1976, ATLAS INSECT BRAIN, P5; WAHLESTEDT C, 1993, ANNU REV PHARMACOL, V33, P309, DOI 10.1146/annurev.pa.33.040193.001521; Wu Q, 2003, NEURON, V39, P147, DOI 10.1016/S0896-6273(03)00396-9; Yu K, 2000, DEVELOPMENT, V127, P2143; Yu K, 1996, DEVELOPMENT, V122, P4033; Zimanyi IA, 1998, CURR PHARM DESIGN, V4, P349; Zinke I, 2002, EMBO J, V21, P6162, DOI 10.1093/emboj/cdf600	39	242	248	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50781	50789		10.1074/jbc.M407842200	http://dx.doi.org/10.1074/jbc.M407842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15385546	hybrid			2022-12-25	WOS:000225355800020
J	Coombes, BK; Brown, NF; Valdez, Y; Brumell, JH; Finlay, BB				Coombes, BK; Brown, NF; Valdez, Y; Brumell, JH; Finlay, BB			Expression and secretion of Salmonella pathogenicity island-2 virulence genes in response to acidification exhibit differential requirements of a functional type III secretion apparatus and SsaL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; ESCHERICHIA-COLI; HOST-CELLS; ACTIN CYTOSKELETON; MURINE MACROPHAGES; SSRA-SSRB; SYSTEM; IDENTIFICATION; EFFECTORS; PROTEINS	Salmonella pathogenicity island (SPI)-2 is pivotal to the intracellular survival of Salmonella and for virulence in mammals. SPI-2 encodes virulence factors (called effectors) that are translocated into the host cell, a type III secretion apparatus and a two-component regulatory system that regulates intracellular expression of SPI-2. Salmonella SPI-2 secretion activity appears to be induced in response to acidification of the vacuole in which it replicates. Here we show that the expression of the SPI-2 proteins, SseB and SseD (filament and pore forming components of the secretion apparatus, respectively) in response to acidification requires an intact secretion system and SsaL, a Salmonella homologue of SepL, a regulator required for type III-dependent secretion of translocators but not effectors in attaching and effacing gastrointestinal pathogens. We show that the expression of SPI-2-encoded effectors is acid-regulated but can be uncoupled from the expression of filament and translocon components, thus showing a differential requirement of SsaL for expression. The secretion and translocation of SPI-2-encoded effectors requires SsaL, but SsaL is dispensable for the secretion of SPI-2 effectors encoded in other pathogenicity loci, suggesting a secretion regulation function for SsaL. Further, we demonstrate that the differential expression of adjacent genes within the sseA operon (sseD and sseE) occurs at the transcriptional level. These data indicate that a Salmonella SPI-2 activation state is achieved by an acid-regulated response that requires SsaL. These data also suggest the existence of a previously unrecognized regulatory element within SPI-2 for the "effector operon" region downstream of sseD that might demarcate the expression of translocators and effectors.	Univ British Columbia, Biotechnol Lab, Michael Smith Labs, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Finlay, BB (corresponding author), Univ British Columbia, Biotechnol Lab, Michael Smith Labs, 237-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	bfinlay@interchange.ubc.ca	Coombes, Brian K/A-1727-2009; Brown, Nat/HHN-8551-2022	Coombes, Brian/0000-0001-9883-1010				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Beuzon CR, 1999, MOL MICROBIOL, V33, P806, DOI 10.1046/j.1365-2958.1999.01527.x; Blocker A, 2003, P NATL ACAD SCI USA, V100, P3027, DOI 10.1073/pnas.0535335100; Brumell JH, 2003, TRAFFIC, V4, P36, DOI 10.1034/j.1600-0854.2003.40106.x; Brumell JH, 2002, TRAFFIC, V3, P407, DOI 10.1034/j.1600-0854.2002.30604.x; Brumell JH, 2001, CELL MICROBIOL, V3, P75, DOI 10.1046/j.1462-5822.2001.00087.x; Cirillo DM, 1998, MOL MICROBIOL, V30, P175, DOI 10.1046/j.1365-2958.1998.01048.x; Coombes BK, 2003, MICROBES INFECT, V5, P561, DOI 10.1016/S1286-4579(03)00094-7; Day JB, 2003, INFECT IMMUN, V71, P6680, DOI 10.1128/IAI.71.11.6680-6685.2003; Deiwick J, 1999, MOL MICROBIOL, V31, P1759, DOI 10.1046/j.1365-2958.1999.01312.x; Deng WY, 2004, P NATL ACAD SCI USA, V101, P3597, DOI 10.1073/pnas.0400326101; Deng WY, 2001, INFECT IMMUN, V69, P6323, DOI 10.1128/IAI.69.10.6323-6335.2001; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Feng XH, 2003, MOL MICROBIOL, V48, P1131, DOI 10.1046/j.1365-2958.2003.03502.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GALAN JE, 1991, INFECT IMMUN, V59, P2901; Garmendia J, 2003, MICROBIOL-SGM, V149, P2385, DOI 10.1099/mic.0.26397-0; Gavigan SA, 1999, J BIOL CHEM, V274, P16010, DOI 10.1074/jbc.274.23.16010; Guignot J, 2004, J CELL SCI, V117, P1033, DOI 10.1242/jcs.00949; Hansen-Wester I, 2002, INFECT IMMUN, V70, P1403, DOI 10.1128/IAI.70.3.1403-1409.2002; Ho TD, 2002, J BACTERIOL, V184, P5234, DOI 10.1128/JB.184.19.5234-5239.2002; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; JENNINGS MP, 1993, MOL MICROBIOL, V9, P155, DOI 10.1111/j.1365-2958.1993.tb01677.x; Kehres DG, 2000, MOL MICROBIOL, V36, P1085, DOI 10.1046/j.1365-2958.2000.01922.x; Knodler LA, 2002, MOL MICROBIOL, V43, P1089, DOI 10.1046/j.1365-2958.2002.02820.x; Kresse AU, 2000, J BACTERIOL, V182, P6490, DOI 10.1128/JB.182.22.6490-6498.2000; Kuhle V, 2002, CELL MICROBIOL, V4, P813, DOI 10.1046/j.1462-5822.2002.00234.x; Lee AK, 2000, J BACTERIOL, V182, P771, DOI 10.1128/JB.182.3.771-781.2000; Meresse S, 2001, CELL MICROBIOL, V3, P567, DOI 10.1046/j.1462-5822.2001.00141.x; Miao EA, 2003, MOL MICROBIOL, V48, P401, DOI 10.1046/j.1365-2958.2003.t01-1-03456.x; Miao EA, 2002, J BACTERIOL, V184, P1493, DOI 10.1128/JB.184.5.1493-1497.2002; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Nikolaus T, 2001, J BACTERIOL, V183, P6036, DOI 10.1128/JB.183.20.6036-6045.2001; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Pelicic V, 1996, MOL MICROBIOL, V20, P919, DOI 10.1111/j.1365-2958.1996.tb02533.x; Rappl C, 2003, FEMS MICROBIOL LETT, V226, P363, DOI 10.1016/S0378-1097(03)00638-4; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; Ruiz-Albert J, 2003, MICROBIOL-SGM, V149, P1103, DOI 10.1099/mic.0.26190-0; Salcedo SP, 2003, EMBO J, V22, P5003, DOI 10.1093/emboj/cdg517; Senear DF, 1998, METHOD ENZYMOL, V295, P403; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Worley MJ, 2000, MOL MICROBIOL, V36, P749, DOI 10.1046/j.1365-2958.2000.01902.x; Wulff-Strobel CR, 2002, MOL MICROBIOL, V43, P411, DOI 10.1046/j.1365-2958.2002.02752.x; Zurawski DV, 2003, MOL MICROBIOL, V47, P1341, DOI 10.1046/j.1365-2958.2003.03373.x	48	128	133	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49804	49815		10.1074/jbc.M404299200	http://dx.doi.org/10.1074/jbc.M404299200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383528	hybrid			2022-12-25	WOS:000225229500033
J	Dugast-Darzacq, C; Pirity, M; Blanck, JK; Scherl, A; Schreiber-Agus, N				Dugast-Darzacq, C; Pirity, M; Blanck, JK; Scherl, A; Schreiber-Agus, N			Mxi1-SR alpha: a novel Mxi1 isoform with enhanced transcriptional repression potential	ONCOGENE			English	Article						Mxi1; Myc; Sin3; transcriptional repression; isoforms	HISTONE DEACETYLASES; MEDIATES REPRESSION; GENE-EXPRESSION; MAX NETWORK; MYC; PROMOTERS; PROTEIN; DOMAIN; INTERACTS; HOMOLOG	Mxi1 belongs to the Myc/Max/Mad network of proteins that have been implicated in the control of multiple aspects of cellular behavior. Previously, we had reported that the mouse mxi1 gene gives rise to two distinct transcript forms that can encode proteins with dramatically different functional abilities. The Mxi1-SR protein (here termed Mxi1-SRb) can interact with Sin3/histone deacetylase and function as a potent transcriptional repressor and growth suppressor, while the Mxi1-WR protein lacks these activities. Here, we describe a new mxi1-derived transcript form (termed mxi1-SRa) whose expression is governed by its own promoter, resulting in a spatiotemporally distinct expression pro. le from that of the highly related mxi1-SRb form. Moreover, the Mxi1-SRa protein product, with its unique Sin3 interacting domain, has a greater affinity than its Mxi1-SRb counterpart for the Sin3 adapter proteins as well as an enhanced potential for transcriptional repression in transient reporter assays. Our identification of this novel Mxi1 isoform that results from alternative 50 exon usage adds an additional layer of complexity to the Mad/Mxi1 family. In addition, our findings warrant re-evaluation of mxi1 expression patterns on the cellular level and its status in human cancer samples, with a renewed focus on the distinct isoforms.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Schreiber-Agus, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave,Ullmann 809, Bronx, NY 10461 USA.	agus@aecom.yu.edu		Dugast-Darzacq, Claire/0000-0001-8602-3534	NCI NIH HHS [1 R01 CA92558] Funding Source: Medline; NIGMS NIH HHS [T32GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Ariyanayagam-Baksh SM, 2003, MODERN PATHOL, V16, P992, DOI 10.1097/01.MP.0000087421.44975.1C; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Benson LQ, 1999, J BIOL CHEM, V274, P28794, DOI 10.1074/jbc.274.40.28794; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; Boue S, 2003, BIOESSAYS, V25, P1031, DOI 10.1002/bies.10371; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cowley SM, 2004, MOL CELL BIOL, V24, P2698, DOI 10.1128/MCB.24.7.2698-2709.2004; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Eilers AL, 1999, J BIOL CHEM, V274, P32750, DOI 10.1074/jbc.274.46.32750; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; KINGSTON RE, 2004, CURRENT PROTOCOLS MO; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Krakauer DC, 1999, SEMIN CELL DEV BIOL, V10, P555, DOI 10.1006/scdb.1999.0337; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Lee C, 2003, NUCLEIC ACIDS RES, V31, P101, DOI 10.1093/nar/gkg029; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Luo Q, 2001, J UROLOGY, V166, P1071, DOI 10.1016/S0022-5347(05)65924-1; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; PIRITY M, IN PRESS CURRENT TOP; Prochownik EV, 1998, GENE CHROMOSOME CANC, V22, P295, DOI 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.0.CO;2-Q; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Resch A, 2004, J PROTEOME RES, V3, P76, DOI 10.1021/pr034064v; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; Skotheim RI, 2002, CANCER RES, V62, P2359; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Sun LX, 2004, ONCOGENE, V23, P4722, DOI 10.1038/sj.onc.1207589; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; van Ingen H, 2004, BIOCHEMISTRY-US, V43, P46, DOI 10.1021/bi0355645; Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606	51	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8887	8899		10.1038/sj.onc.1208107	http://dx.doi.org/10.1038/sj.onc.1208107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467743				2022-12-25	WOS:000225354600004
J	Grifoni, D; Garoia, F; Schimanski, CC; Schmitz, G; Laurenti, E; Galle, PR; Pession, A; Cavicchi, S; Strand, D				Grifoni, D; Garoia, F; Schimanski, CC; Schmitz, G; Laurenti, E; Galle, PR; Pession, A; Cavicchi, S; Strand, D			The human protein Hugl-1 substitutes for Drosophila Lethal giant larvae tumour suppressor function in vivo	ONCOGENE			English	Article						Hugl-1; Lethal giant larvae; tumour suppressor; cell polarity; epithelial cancers; Drosophila	II HEAVY-CHAIN; CELL POLARITY; GENE-EXPRESSION; HUMAN HOMOLOG; DISCS LARGE; NE-DLG; GROWTH; LGL; COMPLEX; LOCALIZATION	Drosophila lethal giant larvae (lgl), discs large (dlg) and scribble (scrib) are tumour suppressor genes acting in a common pathway, whose loss of function leads to disruption of cell polarity and tissue architecture, uncontrolled proliferation and growth of neoplastic lesions. Mammalian homologues of these genes are highly conserved and evidence is emerging concerning their role in cell proliferation control and tumorigenesis in humans. Here we investigate the functional conservation between Drosophila lethal giant larvae and its human homologue Hugl-1(Llgl1). We first show that Hugl-1 is lost in human solid malignancies, supporting its role as a tumour suppressor in humans. Hugl-1 expression in homozygous Igl Drosophila mutants is able to rescue larval lethality; imaginal tissues do not show any neoplastic features, with Dig and Scrib exhibiting the correct localization; animals undergo a complete metamorphosis and hatch as viable adults. These data demonstrate that Hugl-1 can act as a tumour suppressor in Drosophila and thus is the functional homologue of lgl. Furthermore, our data suggest that the genetic pathway including the tumour suppressors lgl, dlg and scrib may be conserved in mammals, since human scrib and mammalian dlg can also rescue their respective Drosophila mutations. Our results highlight the usefulness of fruit fly as a model system for investigating in vivo the mechanisms linking loss of cell polarity and cell proliferation control in human cancers.	Dipartimento Biol Evoluz Sperimentale, Alma Mater Studiorum, I-40126 Bologna, Italy; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55131 Mainz, Germany; Osped Bellaria, Sez Patol, Dipartimento Oncol, Alma Mater Studiorum, I-40139 Bologna, Italy	Johannes Gutenberg University of Mainz	Grifoni, D (corresponding author), Dipartimento Biol Evoluz Sperimentale, Alma Mater Studiorum, Via Selmi 3, I-40126 Bologna, Italy.	dgrifoni@alma.unibo.it	Garoia, Flavio/AAW-1313-2020; Pession, Annalisa/B-9014-2012; Garoia, Flavio/AAL-4528-2020; Galle, Peter R/T-5292-2018; Grifoni, Daniela/A-3954-2012; Galle, Peter/ABE-2872-2021	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992; Pession, Annalisa/0000-0001-9035-9698; GRIFONI, DANIELA/0000-0001-7429-4062; Garoia, Flavio/0000-0001-7849-0036; Laurenti, Elisa/0000-0002-9917-9092				AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boussioutas A, 2003, CANCER RES, V63, P2569; BRAND AH, 1993, DEVELOPMENT, V118, P401; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Hanada N, 2000, INT J CANCER, V86, P480, DOI 10.1002/(SICI)1097-0215(20000515)86:4<480::AID-IJC6>3.0.CO;2-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; Jakobs R, 1996, J MOL BIOL, V264, P484, DOI 10.1006/jmbi.1996.0656; Kalmes A, 1996, J CELL SCI, V109, P1359; Kim YS, 2003, INT J ONCOL, V23, P1515; Larsson K, 1998, J BIOL CHEM, V273, P33610, DOI 10.1074/jbc.273.50.33610; Liu LX, 2002, WORLD J GASTROENTERO, V8, P580, DOI 10.3748/wjg.v8.i4.580; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Stowers RS, 1999, GENETICS, V152, P1631; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; STRAND D, 1995, ONCOGENE, V11, P291; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; WATSON KL, 1994, J CELL SCI, P19; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Woods DF, 1997, DEV GENET, V20, P111, DOI 10.1002/(SICI)1520-6408(1997)20:2<111::AID-DVG4>3.3.CO;2-O; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	37	101	107	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8688	8694		10.1038/sj.onc.1208023	http://dx.doi.org/10.1038/sj.onc.1208023			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467749				2022-12-25	WOS:000224988800015
J	Yang, M; Huang, HC; Li, JZ; Li, DX; Wang, HY				Yang, M; Huang, HC; Li, JZ; Li, DX; Wang, HY			Tyrosine phosphorylation of the LDL receptor-related protein (LRP) and activation of the ERK pathway are required for connective tissue growth factor to potentiate myofibroblast differentiation	FASEB JOURNAL			English	Article						CTGF; TGF beta 1; Smad	FACTOR-BETA; TGF-BETA; FACTOR CTGF; EXPRESSION; FIBROSIS; CELLS; FIBRONECTIN; MECHANISM	Renal myofibroblasts play a crucial role in the accumulation of excess extracellular matrix during renal fibrosis. Both transforming growth factor-beta1 (TGFbeta1) and connective tissue growth factor (CTGF) are important profibrotic growth factors, which interact in the pathogenesis of fibrosis. In this study, we demonstrate that CTGF alone has no influence on myofibroblast transformation and fibronectin secretion in kidney interstitial fibroblasts, whereas incubation of CTGF in combination with TGFbeta1 enhanced TGFbeta1 responses, including myofibroblast activation, de novo expression of alpha-SMA, and extracellular accumulation of fibronectin. CTGF induced tryrosine phosphorylation of the cytoplasmic domain of the low-density lipoprotein receptor-associated protein (LRP) in fibroblasts, and the LRP-antagonist, receptor-associated protein (RAP) inhibited CTGF-induced tryrosine phosphorylation of LRP. Inhibition of LRP signaling reduced CTGF-mediated synergistic induction of alpha-SMA protein. Furthermore, the potentiating action of CTGF was neither dependent on modulation of TGFbeta1-induced Smad2 phosphorylation and its association with Smad4, nor did it result from nuclear accumulation of activated Smad2. When TGFbeta1-pretreated fibroblasts were incubated with CTGF, activation of ERK1/2 MAPK signaling was observed. Inhibition of ERK activation by the MEK1 inhibitor PD98059 was associated with a reduction of CTGF-promoted alpha-SMA protein expression. Our in vitro studies provide evidence that CTGF potentiates TGFbeta1-mediated myofibroblast differentiation and activates differentiated myofibroblasts.	Peking Univ, Hosp 1, Div Nephrol, Beijing 100034, Peoples R China; Peking Univ, Inst Nephrol, Beijing 100034, Peoples R China; FibroGen Inc, San Francisco, CA USA	Peking University; Peking University; FibroGen	Huang, HC (corresponding author), Peking Univ, Hosp 1, Div Nephrol, 8 Xi Shi Ku St, Beijing 100034, Peoples R China.	haichang@bjmu.edu.cn						Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Bakin AV, 2002, J CELL SCI, V115, P3193; Becker GJ, 2000, CURR OPIN NEPHROL HY, V9, P133, DOI 10.1097/00041552-200003000-00006; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Crean John KG, 2001, Expert Opin Ther Targets, V5, P519; De Heer E, 2000, NEPHROL DIAL TRANSPL, V15, P72, DOI 10.1093/ndt/15.suppl_6.72; Denton CP, 2001, CURR OPIN RHEUMATOL, V13, P505, DOI 10.1097/00002281-200111000-00010; Doolittle F, 2002, ENVIRON MICROBIOL, V4, P10, DOI 10.1046/j.1462-2920.2002.gtfb00257.x; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; ElNahas AM, 1996, KIDNEY INT, V49, pS23; Evans RA, 2003, EXP CELL RES, V282, P90, DOI 10.1016/S0014-4827(02)00015-0; Fogo AB, 2000, CURR OPIN NEPHROL HY, V9, P241, DOI 10.1097/00041552-200005000-00006; Folger PA, 2001, INVEST OPHTH VIS SCI, V42, P2534; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gao RP, 2003, HEPATOL RES, V27, P214, DOI 10.1016/S1386-6346(03)00241-9; Goldschmeding R, 2000, NEPHROL DIAL TRANSPL, V15, P296, DOI 10.1093/ndt/15.3.296; Gore-Hyer E, 2002, AM J PHYSIOL-RENAL, V283, pF707, DOI 10.1152/ajprenal.00007.2002; Goumenos DS, 2001, NEPHRON, V87, P240, DOI 10.1159/000045921; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; Grupp C, 2001, KIDNEY INT, V59, P543, DOI 10.1046/j.1523-1755.2001.059002543.x; Gupta S, 2000, KIDNEY INT, V58, P1389, DOI 10.1046/j.1523-1755.2000.00301.x; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Inkinen K, 2003, CONNECT TISSUE RES, V44, P19, DOI 10.1080/03008200390151918; Inoue T, 2002, FASEB J, V16, P268, DOI 10.1096/fj.02-0442fje; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Klahr S, 2001, SEMIN NEPHROL, V21, P133, DOI 10.1053/snep.2001.20942; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; MuchanetaKubara EC, 1997, NEPHROL DIAL TRANSPL, V12, P904, DOI 10.1093/ndt/12.5.904; Pan LH, 2001, EUR RESPIR J, V17, P1220, DOI 10.1183/09031936.01.00074101; Paradis V, 2002, LAB INVEST, V82, P767, DOI 10.1097/01.LAB.0000017365.18894.D3; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; Tang WW, 1997, KIDNEY INT, V51, P926, DOI 10.1038/ki.1997.131; Twigg SM, 2002, ENDOCRINOLOGY, V143, P1260, DOI 10.1210/en.143.4.1260; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Walker GA, 2001, CURR TOP DEV BIOL, V51, P91, DOI 10.1016/S0070-2153(01)51003-0; Yang JW, 2003, J AM SOC NEPHROL, V14, P3167, DOI 10.1097/01.ASN.0000099373.33259.B2; Yang JW, 2003, AM J PATHOL, V163, P621, DOI 10.1016/S0002-9440(10)63689-9; Yokoi H, 2002, AM J PHYSIOL-RENAL, V282, pF933, DOI 10.1152/ajprenal.00122.2001; Zeisberg M, 2001, CURR OPIN NEPHROL HY, V10, P315, DOI 10.1097/00041552-200105000-00004; ZHANG K, 1994, AM J PATHOL, V145, P114	46	83	96	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1920	+		10.1096/fj.04-2357fje	http://dx.doi.org/10.1096/fj.04-2357fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15469966				2022-12-25	WOS:000224849900026
J	Katakami, N; Kaneto, H; Hao, H; Umayahara, Y; Fujitani, Y; Sakamoto, K; Gorogawa, S; Yasuda, T; Kawamori, D; Kajimoto, Y; Matsuhisa, M; Yutani, C; Hori, M; Yamasaki, Y				Katakami, N; Kaneto, H; Hao, H; Umayahara, Y; Fujitani, Y; Sakamoto, K; Gorogawa, S; Yasuda, T; Kawamori, D; Kajimoto, Y; Matsuhisa, M; Yutani, C; Hori, M; Yamasaki, Y			Role of pim-1 in smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; C-MYC; PROTOONCOGENE EXPRESSION; ANTISENSE OLIGODEOXYNUCLEOTIDES; CYCLE PROGRESSION; MESSENGER-RNA; IN-VITRO; ANGIOPLASTY; GENES; ATHEROSCLEROSIS	The proliferation of vascular smooth muscle cells (VSMCs) and alterations of their phenotype are implicated in the pathogenesis of atherosclerosis. Arterial wall injury induces the expression of proto-oncogenes, leading to the proliferation of VSMCs. In particular, c-Myc and c-Myb play a central role in cell cycle progression and are essential for VSMC replication. The protooncogene Pim-1 cooperates with c-Myc and enhances the transcriptional activity of c-Myb in hematopoietic cells, suggesting that Pim-1 is involved in cell cycle regulation. The aim of this study was to examine the possible involvement of Pim-1 in VSMC proliferation. Pim-1 was substantially induced in neointimal VSMCs of balloon-injured rat carotid arteries, and in vivo infection with a dominant negative Pim-1-expressing adenovirus (Ad-DN-Pim-1) markedly suppressed neointima formation and cell cycle progression in the balloon-injured arteries. In cultured VSMCs, treatment with serum or H2O2 induced Pim-1 expression, and H2O2- or serum-stimulated cell cycle progression and DNA synthesis were almost completely inhibited by DN-Pim-1 overexpression. Furthermore, we performed immunohistochemical staining for Pim-1 in human thoracic aortas and coronary arteries obtained from six individuals at autopsy and found that Pim-1-positive cells are observed predominantly in the thickened intima of the aortas and coronary arteries. To the best of our knowledge, this is the first report showing Pim-1 expression in rodent and human arterial walls. To summarize, Pim-1 expression was observed in the neointima of balloon-injured rat carotid arteries and in human thoracic aortas and coronary arteries showing intimal thickening, and the specific inhibition of Pim-1 function markedly suppressed neointima formation after balloon injury and the proliferation of cultured VSMCs, suggesting that Pim-1 plays a role in VSMC proliferation.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Natl Cardiovasc Ctr, Dept Pathol, Osaka 5650873, Japan	Osaka University; National Cerebral & Cardiovascular Center - Japan	Yamasaki, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yamasaki@medone.med.osaka-u.ac.jp	Katakami, Naoto/AAM-8822-2021	Katakami, Naoto/0000-0001-9020-8320				Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; BAUTERS C, 1992, EUR HEART J, V13, P556, DOI 10.1093/oxfordjournals.eurheartj.a060213; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CUYPERS HT, 1984, CELL, V37, P141; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; EBBECKE M, 1992, BASIC RES CARDIOL, V87, P585, DOI 10.1007/BF00788668; GADEAU AP, 1991, J CELL PHYSIOL, V146, P356, DOI 10.1002/jcp.1041460304; Izumi Y, 2001, CIRC RES, V88, P1120, DOI 10.1161/hh1101.091267; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; LILLY M, 1992, ONCOGENE, V7, P727; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; MIANO JM, 1990, AM J PATHOL, V137, P761; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V17, P433, DOI 10.1016/S0735-1097(10)80111-1; Rahman Z, 2001, IMMUNOL LETT, V75, P199, DOI 10.1016/S0165-2478(00)00322-9; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Zippo A, 2004, BLOOD, V103, P4536, DOI 10.1182/blood-2003-11-3827	30	59	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54742	54749		10.1074/jbc.M409140200	http://dx.doi.org/10.1074/jbc.M409140200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471855	hybrid			2022-12-25	WOS:000225793600102
J	Aller, SG; Eng, ET; De Feo, CJ; Unger, VM				Aller, SG; Eng, ET; De Feo, CJ; Unger, VM			Eukaryotic CTR copper uptake transporters require two faces of the third transmembrane domain for helix packing, oligomerization, and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR CHARACTERIZATION; GXXXG MOTIF; PROTEIN-DEGRADATION; CRYSTAL-STRUCTURE; YEAST; AFFINITY; GENE; ASSOCIATION; SEQUENCE	Members of the copper uptake transporter (CTR) family from yeast, plants, and mammals including human are required for cellular uptake of the essential metal copper. Based on biochemical data, CTRs have three transmembrane domains and have been shown to oligomerize in the membrane. Among individual members of the family, there is little amino acid sequence identity, raising questions as to how these proteins adopt a common fold, oligomerize, and participate in copper transport. Using site-directed mutagenesis, tryptophan scanning, genetic complementation, subcellular localization, chemical cross-linking, and the yeast unfolded protein response, we demonstrated that at least half of the third transmembrane domain (TM3) plays a vital role in CTR structure and function. The results of our analysis showed that TM3 contains two functionally distinct faces. One face bears a highly conserved Gly-X-X-X-Gly (GG4) motif, which we showed to be essential for CTR oligomerization. Moreover, we showed that steric constraints reach past the GG4-motif itself including amino acid residues that are not conserved throughout the CTR family. A second face of TM3 contains three amino acid positions that, when mutated to tryptophan, cause predominantly abnormal localization but are still partially functional in growth complementation experiments. These mutations cluster on the face opposite to the GG4-bearing face of TM3 where they may mediate interactions with the remaining two transmembrane domains. Taken together, our data support TM3 as being buried within trimeric CTR where it plays an essential role in CTR assembly.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Unger, VM (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.	vinzenz.unger@yale.edu		Eng, Edward/0000-0002-8014-7269; Aller, Stephen/0000-0003-0379-5534	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007223, R01GM066145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS045550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA017088] Funding Source: NIH RePORTER; NIDA NIH HHS [DA017088, R21 DA017088] Funding Source: Medline; NIGMS NIH HHS [R01 GM066145, T32 GM07223, GM66145] Funding Source: Medline; NINDS NIH HHS [F31 NS045550, F32 NS455550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Brenner SE, 1998, P NATL ACAD SCI USA, V95, P6073, DOI 10.1073/pnas.95.11.6073; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DiDonato M, 1997, BBA-MOL BASIS DIS, V1360, P3, DOI 10.1016/S0925-4439(96)00064-6; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Guo Y, 2004, J BIOL CHEM, V279, P17428, DOI 10.1074/jbc.M401493200; Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Klomp AEM, 2003, BIOCHEM J, V370, P881, DOI 10.1042/BJ20021128; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Lin XJ, 2002, MOL PHARMACOL, V62, P1154, DOI 10.1124/mol.62.5.1154; Linder M, 1991, BIOCH COPPER; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Marvin ME, 2003, MICROBIOL-SGM, V149, P1461, DOI 10.1099/mic.0.26172-0; Melnyk RA, 2004, J BIOL CHEM, V279, P16591, DOI 10.1074/jbc.M313936200; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Riggio M, 2002, BBA-GENE STRUCT EXPR, V1576, P127, DOI 10.1016/S0167-4781(02)00337-8; Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG311, DOI 10.1152/ajpgi.1999.276.2.G311; Schneider D, 2003, J BIOL CHEM, V278, P3105, DOI 10.1074/jbc.M206287200; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Wilson CA, 2000, J MOL BIOL, V297, P233, DOI 10.1006/jmbi.2000.3550; Zanusso G, 2001, J BIOL CHEM, V276, P40377, DOI 10.1074/jbc.C100458200; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2003, J BIOL CHEM, V278, P48210, DOI 10.1074/jbc.M309820200; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	45	83	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53435	53441		10.1074/jbc.M409421200	http://dx.doi.org/10.1074/jbc.M409421200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15385536	Green Accepted, hybrid			2022-12-25	WOS:000225680600077
J	Okumura, F; Hatakeyama, S; Matsumoto, M; Kamura, T; Nakayama, KI				Okumura, F; Hatakeyama, S; Matsumoto, M; Kamura, T; Nakayama, KI			Functional regulation of FEZ1 by the U-box-type ubiquitin ligase E4B contributes to neuritogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; MULTIUBIQUITIN CHAIN; NEURITE OUTGROWTH; AXONAL OUTGROWTH; PC12H CELLS; PROTEIN; CHAPERONE; DEGRADATION; PATHWAY; FAMILY	E4B ( also known as UFD2a) is a mammalian homolog of Saccharomyces cerevisiae Ufd2, which was originally described as a ubiquitin chain assembly factor (E4). E4B is a U-box-type ubiquitin-protein isopeptide ligase (E3) and likely functions as either an E3 or an E4. With a yeast two-hybrid screen, we have now identified FEZ1 (fasciculation and elongation protein zeta 1) as a protein that interacts with E4B. FEZ1 is implicated in neuritogenesis when phosphorylated by protein kinase Czeta (PKCzeta). Interaction between E4B and FEZ1 in mammalian cells was enhanced by coexpression of constitutively active PKCzeta. E4B mediated the polyubiquitylation of FEZ1 but did not affect its intracellular stability, suggesting that such modification of FEZ1 is not a signal for its proteolysis. Polyubiquitylation of FEZ1 by E4B required Lys(27) of ubiquitin. Expression of a dominant-negative mutant of E4B in rat pheochromocytoma PC12 cells resulted in inhibition of neurite extension induced either by nerve growth factor or by coexpression of FEZ1 and constitutively active PKCzeta. These findings indicate that E4B serves as a ubiquitin ligase for FEZ1 and thereby regulates its function but not its degradation.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp	Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979; Matsumoto, Masaki/0000-0002-6987-0288				Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Cruciat CM, 1999, EMBO J, V18, P5226, DOI 10.1093/emboj/18.19.5226; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Espinet C, 2000, J NEUROSCI METH, V100, P63, DOI 10.1016/S0165-0270(00)00233-8; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gindhart JG, 2003, MOL BIOL CELL, V14, P3356, DOI 10.1091/mbc.E02-12-0800; Golbik R, 1999, BIOL CHEM, V380, P1049, DOI 10.1515/BC.1999.131; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kaneko C, 2003, BIOCHEM BIOPH RES CO, V300, P297, DOI 10.1016/S0006-291X(02)02834-6; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsumoto M, 2004, EMBO J, V23, P659, DOI 10.1038/sj.emboj.7600081; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Miyoshi K, 2003, MOL PSYCHIATR, V8, P685, DOI 10.1038/sj.mp.4001352; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; Ohtani-Kaneko R, 1998, NEUROCHEM RES, V23, P1435, DOI 10.1023/A:1020763009488; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shirane M, 1999, J BIOL CHEM, V274, P28169, DOI 10.1074/jbc.274.40.28169; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; TAKADA K, 1994, NEUROCHEM RES, V19, P391, DOI 10.1007/BF00967315; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	47	43	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53533	53543		10.1074/jbc.M402916200	http://dx.doi.org/10.1074/jbc.M402916200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466860	hybrid			2022-12-25	WOS:000225680600089
J	Davare, MA; Saneyoshi, T; Guire, ES; Nygaard, SC; Soderling, TR				Davare, MA; Saneyoshi, T; Guire, ES; Nygaard, SC; Soderling, TR			Inhibition of calcium/calmodulin-dependent protein kinase kinase by protein 14-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; 14-3-3 BINDING; T-CELLS; ACTIVATION; CAMP; BAD; SURVIVAL	Intracellular calcium concentrations regulate diverse cellular events including cytoskeletal dynamics, gene transcription, and synaptic plasticity. The calcium signal is transduced in part by the calcium/calmodulin-dependent protein kinase (CaMK) cascade that is comprised of CaMK kinase (CaMKK) and its primary downstream substrates, CaMKI and CaMKIV. The CaMK cascade also participates in cross-talk with other signaling pathways: CaMKK/CaMKI can activate the mitogen-activated protein kinase pathway and cAMP-dependent protein kinase (PKA) can directly phosphorylate two inhibitory sites (Thr(108) and Ser(458)) in CaMKK. Here we report an additional PKA-dependent regulation of CaMKK through its interaction with protein 14-3-3. CaMKK and 14-3-3 co-immunoprecipitated from co-transfected heterologous cells as well as from rat brain homogenate, and site-directed mutagenesis studies identified phospho-Ser74 in CaMKK as the primary 14-3-3 binding site. In cultured rat hippocampal neurons and acute hippocampal slices this interaction was robustly stimulated by activation of PKA through forskolin treatment and was blocked by inhibition of PKA. Interaction of 14-3-3 with CaMKK had two regulatory consequences in vitro. It directly inhibited CaMKK activity, and it also blocked dephosphorylation of Thr108, an inhibitory PKA phosphorylation site. In human embryonic kidney 293 cells transfected with CaMKK and stimulated with forskolin, co-transfection with 14-3-3 prevented dephosphorylation of Thr108 to the same extent as did inhibition of protein phosphatases with okadaic acid. We conclude that binding of 14-3-3 to CaMKK stabilizes its inhibition by PKA-mediated phosphorylation, which may have important consequences in the regulation of CaMKI, CaMKIV, protein kinase B, and ERK signaling pathways.	Oregon Hlth Sci Univ, Vollum Inst L474, Portland, OR 97239 USA	Oregon Health & Science University	Soderling, TR (corresponding author), Oregon Hlth Sci Univ, Vollum Inst L474, 3181 SW Same Jackson Pk Rd, Portland, OR 97239 USA.	soderlit@ohsu.edu	Saneyoshi, Takeo/AAF-5170-2019	Davare, Monika/0000-0003-1802-7597	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027037] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK007680] Funding Source: Medline; NIGMS NIH HHS [R01 GM41292] Funding Source: Medline; NINDS NIH HHS [NS27037] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Atkins CM, 2004, J NEUROSCI, V24, P5193, DOI 10.1523/JNEUROSCI.0854-04.2004; Baxter HC, 2002, NEUROSCIENCE, V109, P5, DOI 10.1016/S0306-4522(01)00492-4; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Cavet ME, 2003, J BIOL CHEM, V278, P18376, DOI 10.1074/jbc.M208475200; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Forrest A, 2001, ONCOGENE, V20, P4393, DOI 10.1038/sj.onc.1204574; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Kao HT, 2002, NAT NEUROSCI, V5, P431, DOI 10.1038/nn840; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Matsushita M, 1999, J BIOL CHEM, V274, P10086, DOI 10.1074/jbc.274.15.10086; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Okuno S, 2001, J BIOCHEM, V130, P503, DOI 10.1093/oxfordjournals.jbchem.a003013; PAYNE ME, 1983, J BIOL CHEM, V258, P2376; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; Qin H, 2003, J BIOL CHEM, V278, P48570, DOI 10.1074/jbc.M308781200; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Schmitt JM, 2004, J BIOL CHEM, V279, P24064, DOI 10.1074/jbc.M401501200; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Suizu F, 2002, BIOCHEM J, V367, P335, DOI 10.1042/BJ20020536; Takahashi Y, 2003, NEUROCHEM RES, V28, P1265, DOI 10.1023/A:1024296932670; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; WATANABE M, 1993, MOL BRAIN RES, V17, P135, DOI 10.1016/0169-328X(93)90082-Z; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	56	50	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52191	52199		10.1074/jbc.M409873200	http://dx.doi.org/10.1074/jbc.M409873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15469938	hybrid			2022-12-25	WOS:000225493400059
J	Jackers, P; Szalai, G; Moussa, O; Watson, DK				Jackers, P; Szalai, G; Moussa, O; Watson, DK			Ets-dependent regulation of target gene expression during megakaryopoiesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; GLYCOPROTEIN IX PROMOTER; MURINE LEUKEMIA-VIRUS; RNA-POLYMERASE-II; CELL-LINE CMK; FLI-1 GENE; HISTONE ACETYLATION; BINDING PROTEIN; FAMILY; DIFFERENTIATION	Megakaryopoiesis is the process by which hematopoietic stem cells in the bone marrow differentiate into mature megakaryocytes. The expression of megakaryocytic genes during megakaryopoiesis is controlled by specific transcription factors. Fli-1 and GATA-1 transcription factors are required for development of megakaryocytes and promoter analysis has defined in vitro functional binding sites for these factors in several megakaryocytic genes, including GPIIb, GPIX, and C-MPL. Herein, we utilize chromatin immunoprecipitation to examine the presence of Ets-1, Fli-1, and GATA-1 on these promoters in vivo. Fli-1 and Ets-1 occupy the promoters of GPIIb, GPIX, and C-MPL genes in both Meg-01 and CMK11-5 cells. Whereas GPIIb is expressed in both Meg-01 and CMK11-5 cells, GPIX and C-MPL are only expressed in the more differentiated CMK11-5 cells. Thus, in vivo occupancy by an Ets factor is not sufficient to promote transcription of some megakaryocytic genes. GATA-1 and Fli-1 are both expressed in CMK11-5 cells and co-occupy the GPIX and C-MPL promoters. Transcription of all three megakaryocytic genes is correlated with the presence of acetylated histone H3 and phosphorylated RNA polymerase II on their promoters. We also show that exogenous expression of GATA-1 in Meg-01 cells leads to the expression of endogenous c-mpl and gpIX mRNA. Whereas GPIIb, GPIX, and C-MPL are direct target genes for Fli-1, both Fli-1 and GATA-1 are required for formation of an active transcriptional complex on the C-MPL and GPIX promoters in vivo. In contrast, GPIIb expression appears to be independent of GATA-1 in Meg-01 cells.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, Charleston, SC 29403 USA	Medical University of South Carolina; Medical University of South Carolina	Watson, DK (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 165 Ashley Ave, Charleston, SC 29403 USA.	watsondk@musc.edu	Szalai, Gabor/ABA-4146-2021	Szalai, Gabor/0000-0002-9462-8602	NCI NIH HHS [P01 CA78582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1991, EXP HEMATOL, V19, P923; Alexander WS, 1999, INT J BIOCHEM CELL B, V31, P1027, DOI 10.1016/S1357-2725(99)00079-5; Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERGERON D, 1993, LEUKEMIA, V7, P954; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; BLOCK KL, 1995, STEM CELLS, V13, P135, DOI 10.1002/stem.5530130205; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; Denicourt C, 1999, J VIROL, V73, P4439, DOI 10.1128/JVI.73.5.4439-4442.1999; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Eisbacher M, 2003, MOL CELL BIOL, V23, P3427, DOI 10.1128/MCB.23.10.3427-3441.2003; Eisbacher M, 2001, CELL GROWTH DIFFER, V12, P435; FONG AM, 1994, J BIOL CHEM, V269, P18441; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Georgiou P, 1996, INT J ONCOL, V9, P9; Gottgens B, 2002, EMBO J, V21, P3039, DOI 10.1093/emboj/cdf286; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; Holmes ML, 2002, J BIOL CHEM, V277, P48333, DOI 10.1074/jbc.M206127200; Horak CE, 2002, P NATL ACAD SCI USA, V99, P2924, DOI 10.1073/pnas.052706999; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Kawada H, 2001, INT J HEMATOL, V73, P463, DOI 10.1007/BF02994008; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; KOMATSU N, 1989, BLOOD, V74, P42; Kubo M, 2003, AM J PATHOL, V163, P571, DOI 10.1016/S0002-9440(10)63685-1; Kwiatkowski BA, 2000, BLOOD CELL MOL DIS, V26, P84, DOI 10.1006/bcmd.2000.0282; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lepage A, 1999, BLOOD, V94, P3366, DOI 10.1182/blood.V94.10.3366.422k35_3366_3380; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; Lu J, 2004, MOL CELL BIOL, V24, P428, DOI 10.1128/MCB.24.1.428-441.2004; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; Minami T, 1998, EUR J BIOCHEM, V258, P879, DOI 10.1046/j.1432-1327.1998.2580879.x; OGURA M, 1985, BLOOD, V66, P1384; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; OTT DE, 1994, VIROLOGY, V205, P563, DOI 10.1006/viro.1994.1680; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; PHILLIPS DR, 1988, BLOOD, V71, P831; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sakurai T, 2003, INT J ONCOL, V22, P1327; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sato N, 2000, EXP HEMATOL, V28, P802, DOI 10.1016/S0301-472X(00)00176-4; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Seth A, 1999, CELL DEATH DIFFER, V6, P902, DOI 10.1038/sj.cdd.4400567; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 2003, MOL CELL BIOL, V23, P1390, DOI 10.1128/MCB.23.4.1390-1402.2003; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WATSON DK, 2002, ENCY CANC, V2, P189; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	75	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52183	52190		10.1074/jbc.M407489200	http://dx.doi.org/10.1074/jbc.M407489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466856	hybrid			2022-12-25	WOS:000225493400058
J	Katsafanas, GC; Moss, B				Katsafanas, GC; Moss, B			Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE MESSENGER-RNAS; GENE-EXPRESSION; LATE PROMOTER; ENDORIBONUCLEASE G3BP; IN-VITRO; PURIFICATION; POLYMERASE; IDENTIFICATION; CELLS; SUBUNIT	Transcription of the DNA genome of vaccinia virus occurs in the cytoplasm and is temporally programmed by early, intermediate, and late stage-specific transcription factors in conjunction with a viral multisubunit RNA polymerase. The RNA polymerase, capping enzyme, and three factors (VITF-1, VITF-2, and VITF-3) are sufficient for in vitro transcription of a DNA template containing an intermediate stage promoter. Vaccinia virus intermediate transcription factor (VITF)-1 and -3 are virus-encoded, whereas VITF-2 was partially purified from extracts of uninfected HeLa cells. Using purified and recombinant viral proteins, we showed that the HeLa cell factor was required for transcription of linear or nicked circular templates but not of super coiled DNA. HeLa cell polypeptides of similar to110 and 66 kDa co-purified with VITF-2 activity through multiple chromatographic steps. The polypeptides were separated by SDS-polyacrylamide gel electrophoresis and identified by mass spectrometry as Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and p137, recently named cytoplasmic activation/proliferation-associated protein-1. The co-purification of the two polypeptides with transcription-complementing activity was confirmed with specific antibodies, and their association with each other was demonstrated by affinity chromatography of tagged recombinant forms. Furthermore, recombinant G3BP and p137 expressed individually or together in mammalian or bacterial cells complemented the activity of the viral RNA polymerase and transcription factors. The involvement of cellular proteins in transcription of intermediate stage genes may regulate the transition between early and late phases of vaccinia virus replication.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Moss, B (corresponding author), NIAID, Viral Dis Lab, NIH, 4 Ctr Dr,MSC 0445, Bethesda, MD 20892 USA.	bmoss@nih.gov		Moss, Bernard/0000-0002-2154-8564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000307, Z01AI000307] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN BY, 1989, J VIROL, V63, P226, DOI 10.1128/JVI.63.1.226-232.1989; AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1994, J BIOL CHEM, V269, P7552; Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x; BALDICK CJ, 1993, J VIROL, V67, P3515, DOI 10.1128/JVI.67.6.3515-3527.1993; BERTHOLET C, 1987, CELL, V50, P153, DOI 10.1016/0092-8674(87)90211-X; Broyles SS, 1999, J BIOL CHEM, V274, P35662, DOI 10.1074/jbc.274.50.35662; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; Broyles SS, 2003, J GEN VIROL, V84, P2293, DOI 10.1099/vir.0.18942-0; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; DENG L, 1994, J BIOL CHEM, V269, P14323; EARL PL, 1998, CURRENT PROTOCOLS MO, V2; ELLIS JA, 1995, J BIOL CHEM, V270, P20717, DOI 10.1074/jbc.270.35.20717; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gessler M, 1996, GENOMICS, V32, P169, DOI 10.1006/geno.1996.0099; Grill B, 2004, J IMMUNOL, V172, P2389, DOI 10.4049/jimmunol.172.4.2389; Hubbs AE, 1996, J VIROL, V70, P327, DOI 10.1128/JVI.70.1.327-331.1996; Katsafanas GC, 1999, VIROLOGY, V258, P469, DOI 10.1006/viro.1999.9744; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; KECK JG, 1993, J VIROL, V67, P5740, DOI 10.1128/JVI.67.10.5740-5748.1993; KECK JG, 1993, J VIROL, V67, P5749, DOI 10.1128/JVI.67.10.5749-5753.1993; Kovacs GR, 1996, J VIROL, V70, P6796, DOI 10.1128/JVI.70.10.6796-6802.1996; MORITZ RL, 1995, TECH PROT CHEM, V6, P311, DOI 10.1016/S1080-8914(06)80039-6; Moss B, 2001, FIELDS VIROLOGY, P2849; Parker F, 1996, MOL CELL BIOL, V16, P2561; Passarelli AL, 1996, J VIROL, V70, P4444, DOI 10.1128/JVI.70.7.4444-4450.1996; PATEL DD, 1987, EMBO J, V6, P3787, DOI 10.1002/j.1460-2075.1987.tb02714.x; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSALES R, 1994, J BIOL CHEM, V269, P14260; Sanz P, 1999, P NATL ACAD SCI USA, V96, P2692, DOI 10.1073/pnas.96.6.2692; SCHWER B, 1987, CELL, V50, P163, DOI 10.1016/0092-8674(87)90212-1; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; WARD GA, 1995, P NATL ACAD SCI USA, V92, P6773, DOI 10.1073/pnas.92.15.6773; WRIGHT CF, 1993, J VIROL, V67, P7264, DOI 10.1128/JVI.67.12.7264-7270.1993; Wright CF, 2001, J BIOL CHEM, V276, P40680, DOI 10.1074/jbc.M102399200; ZHANG YF, 1992, J VIROL, V66, P6470, DOI 10.1128/JVI.66.11.6470-6479.1992	39	62	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52210	52217		10.1074/jbc.M411033200	http://dx.doi.org/10.1074/jbc.M411033200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15471883	hybrid			2022-12-25	WOS:000225493400061
J	Shan, Y; Lambrecht, RW; Ghaziani, T; Donohue, SE; Bonkovsky, HL				Shan, Y; Lambrecht, RW; Ghaziani, T; Donohue, SE; Bonkovsky, HL			Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells - Insights from studies with small interfering RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED INDUCTION; PRIMARY CULTURES; PHENYLARSINE OXIDE; EPITHELIAL-CELLS; HEPATOMA-CELLS; GENE; EXPRESSION; METALLOPORPHYRINS; TRANSCRIPTION; MECHANISM	Heme oxygenase-1 is an antioxidant defense enzyme that converts heme to biliverdin, iron, and carbon monoxide. Bach-1 is a bZip protein that forms heterodimers with small Maf proteins and was reported recently to down-regulate the HO-1 gene in mice. Using small interfering RNAs targeted to human Bach-1 mRNA, we investigated whether modulation of human hepatic Bach-1 expression by small interfering ( si) RNA technology influences heme oxygenase-1 gene expression. We found that Bach-1 siRNAs transfected into Huh-7 cells significantly reduced Bach-1 mRNA and protein levels similar to80%, compared with non siRNA-treated cells. In contrast, transfection with the same amounts of nonspecific control duplexes or LaminB2-duplex did not reduce Bach-1 mRNA or protein levels, confirming the specificity of Bach-1 siRNA. Expression of the heme oxygenase-1 gene in Bach-1 siRNA-transfected cells was up-regulated 7-fold, compared with cells without Bach-1 siRNA. The effect of increasing concentrations of heme to up-regulate levels of heme oxygenase-1 was more pronounced when Bach-1 siRNA was present. Taken together, these results indicated that Bach-1 has a specific and selective ability to repress expression of human hepatic heme oxygenase-1. Silencing of Bach-1 by siRNAs is a useful method for up-regulating HO-1 gene expression. Exogenous heme produces additional up-regulation, beyond that produced by Bach-1 siRNAs, suggesting that heme does not act solely through its effects on Bach-1.	Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Pharmacol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Gen Clin Res Ctr, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut	Shan, Y (corresponding author), 263 Farmington Ave,MC-1111, Farmington, CT 06030 USA.	Shan@uchc.edu			NCRR NIH HHS [MO1-RR06192] Funding Source: Medline; NIDDK NIH HHS [N0-1 DK 92326, UO-1 DK065193, R01-DK38825] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK065193, N01DK092326, R01DK038825] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM J, 1992, J BIOL CHEM, V267, P16379; Alam J, 2003, AM J PHYSIOL-RENAL, V284, pF743, DOI 10.1152/ajprenal.00376.2002; ALAM J, 1989, J BIOL CHEM, V264, P6371; Bonkovsky H. L., 2002, OXIDATIVE STRESS AGI, P690; CABLE E, 1990, BIOCHEM BIOPH RES CO, V168, P176, DOI 10.1016/0006-291X(90)91690-T; Cable EE, 1997, MOL CELL BIOCHEM, V169, P13, DOI 10.1023/A:1006817207166; CABLE JW, 1993, MOL CELL BIOCHEM, V129, P93, DOI 10.1007/BF00926580; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; ELBIRT KK, 1998, ROLE MAP KINASES IND, P102; Gildemeister OS, 2001, MOL CELL BIOCHEM, V226, P17; Hill-Kapturczak N, 2002, DNA CELL BIOL, V21, P307, DOI 10.1089/104454902753759726; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; LAMBRECHT RW, ASCITES RENAL DYSFUN; LINCOLN BC, 1988, BIOCHEM J, V250, P189, DOI 10.1042/bj2500189; Lu TH, 1997, BBA-GENE STRUCT EXPR, V1352, P293, DOI 10.1016/S0167-4781(97)00028-6; Lu TH, 1998, GENE, V207, P177, DOI 10.1016/S0378-1119(97)00623-9; Lu TH, 2000, MOL CELL BIOCHEM, V209, P17, DOI 10.1023/A:1007025505842; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; Nath KA, 2001, KIDNEY INT, V59, P106, DOI 10.1046/j.1523-1755.2001.00471.x; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Shan Y, 1999, HEPATOLOGY, V30, p512A; Shan Y, 2004, HEPATOLOGY, V40, p527A; Shan Y, 2004, BBA-GENE STRUCT EXPR, V1679, P87, DOI 10.1016/j.bbaexp.2004.05.003; Shan Y, 2002, ARCH BIOCHEM BIOPHYS, V399, P159, DOI 10.1006/abbi.2001.2742; Shan Y, 1999, ARCH BIOCHEM BIOPHYS, V372, P224, DOI 10.1006/abbi.1999.1490; Shan Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P219, DOI 10.1006/abbi.2000.1921; SHIBAHARA S, 1993, J BIOCHEM-TOKYO, V113, P214, DOI 10.1093/oxfordjournals.jbchem.a124028; SRIVASTAVA KK, 1993, EUR J BIOCHEM, V213, P909, DOI 10.1111/j.1432-1033.1993.tb17835.x; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748	39	64	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51769	51774		10.1074/jbc.M409463200	http://dx.doi.org/10.1074/jbc.M409463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465821	hybrid			2022-12-25	WOS:000225493400009
J	Smith, AJ; Sanders, MA; Thompson, BR; Londos, C; Kraemer, FB; Bernlohr, DA				Smith, AJ; Sanders, MA; Thompson, BR; Londos, C; Kraemer, FB; Bernlohr, DA			Physical association between the adipocyte fatty acid-binding protein and hormone-sensitive lipase - A fluorescence resonance energy transfer analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; DIFFERENTIATION-RELATED PROTEIN; A-MEDIATED LIPOLYSIS; INSULIN-RESISTANCE; 3T3-L1 ADIPOCYTES; LIPID DROPLETS; ADIPOSE-TISSUE; PERILIPIN-A; KINASE; CELLS	Previous in vitro studies have established that hormone sensitive lipase (HSL) and adipocyte fatty acid-binding protein (AFABP) form a physical complex that presumably positions the FABP to accept a product fatty acid generated during catalysis. To assess AFABP-HSL interaction within a cellular context, we have used lipocytes derived from 293 cells (C8PA cells) and examined physical association using fluorescence resonance energy transfer. Transfection of C8PA cells with cyan fluorescent protein (CFP)-HSL, yellow fluorescent protein (YFP)-adipocyte FABP, or YFP-liver FABP revealed that under basal conditions each protein was cytoplasmic. In the presence of 20 muM forskolin, CFP-HSL translocated to the triacylglycerol droplet, coincident with BODIPY-FA labeled depots. Fluorescence resonance energy transfer analysis demonstrated that CFP-HSL associated with YFP-adipocyte FABP in both basal and forskolin-treated cells. In contrast, little if any fluorescence resonance energy transfer could be detected between CFP-HSL and YFP-liver FABP. These results suggest that a pre-lipolysis complex containing at least AFABP and HSL exists and that the complex translocates to the surface of the lipid droplet.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Imaging Ctr, St Paul, MN 55108 USA; NIDDK, Membrane Regulat Sect, NIH, Bethesda, MD 20892 USA; Stanford Univ, Dept Med, Div Endocrinol, Stanford, CA 94305 USA; Vet Adm Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 321 Church St SE, Minneapolis, MN 55455 USA.	bern1001@umn.edu	Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807	NIDDK NIH HHS [DK 46942, DK 53189] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053189, R01DK046942] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; CASTLEMAN K. R., 1996, DIGITAL IMAGE PROCES, P207; Chamberlain CE, 2000, METHOD ENZYMOL, V325, P389; Coe NR, 1999, J LIPID RES, V40, P967; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Hatch GM, 2002, J LIPID RES, V43, P1380, DOI 10.1194/jlr.M200130-JLR200; Helledie T, 2000, J LIPID RES, V41, P1740; Hertzel AV, 2002, J LIPID RES, V43, P2105, DOI 10.1194/jlr.M200227-JLR200; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Jenkins-Kruchten AE, 2003, J BIOL CHEM, V278, P47636, DOI 10.1074/jbc.M307680200; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Maeda K, 2003, DIABETES, V52, P300, DOI 10.2337/diabetes.52.2.300; Nakamura N, 2003, BIOCHEM BIOPH RES CO, V306, P333, DOI 10.1016/S0006-291X(03)00979-3; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 2001, J BIOL CHEM, V276, P49443, DOI 10.1074/jbc.M104095200; Siegel R. M., 2000, SCI STKE, V2000, ppl1; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; TORNQVIST H, 1972, J LIPID RES, V13, P424; XU ZH, 1991, J BIOL CHEM, V266, P14367; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	33	49	52	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52399	52405		10.1074/jbc.M410301200	http://dx.doi.org/10.1074/jbc.M410301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456755	hybrid			2022-12-25	WOS:000225493400084
J	Bagriantsev, S; Liebman, SW				Bagriantsev, S; Liebman, SW			Specificity of prion assembly in vivo - [PSI+] and [PIN+] form separate structures in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO APPEARANCE; SACCHAROMYCES-CEREVISIAE; GUANIDINE-HYDROCHLORIDE; SUP35 PROTEIN; PROPAGATION; HSP104; STRAINS; SCRAPIE; PSI(+); VITRO	The yeast prions [PSI+] and [PIN+] are self-propagating amyloid aggregates of the Gln/Asn-rich proteins Sup35p and Rnq1p, respectively. Like the mammalian PrP prion "strains," [PSI+] and [PIN+] exist in different conformations called variants. Here, [PSI+] and [PIN+] variants were used to model in vivo interactions between co-existing heterologous amyloid aggregates. Two levels of structural organization, like those previously described for [PSI+], were demonstrated for [PIN+]. In cells with both [PSI+] and [PIN+] the two prions formed separate structures at both levels. Also, the destabilization of [PSI+] by certain [PIN+] variants was shown not to involve alterations in the [PSI+] prion size. Finally, when two variants of the same prion that have aggregates with distinct biochemical characteristics were combined in a single cell, only one aggregate type was propagated. These studies demonstrate the intracellular organization of yeast prions and provide insight into the principles of in vivo amyloid assembly.	Univ Illinois, Mol Biol Lab, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Liebman, SW (corresponding author), Univ Illinois, Mol Biol Lab, 900 S Ashland Ave,MC567 Mol Biol Res Bldg,Rm 4068, Chicago, IL 60607 USA.	sueL@uic.edu		Bagriantsev, Sviatoslav/0000-0002-6661-3403	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056350] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56350, R01 GM056350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balguerie A, 2004, J CELL SCI, V117, P2599, DOI 10.1242/jcs.01116; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Borchsenius AS, 2001, EMBO J, V20, P6683, DOI 10.1093/emboj/20.23.6683; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley ME, 2003, GENETICS, V165, P1675; Bradley ME, 2002, P NATL ACAD SCI USA, V99, P16392, DOI 10.1073/pnas.152330699; Bruce ME, 2003, BRIT MED BULL, V66, P99, DOI 10.1093/bmb/66.1.99; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Derkatch IL, 2004, P NATL ACAD SCI USA, V101, P12934, DOI 10.1073/pnas.0404968101; Derkatch IL, 1998, P NATL ACAD SCI USA, V95, P2400, DOI 10.1073/pnas.95.5.2400; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 1996, GENETICS, V144, P1375; Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5; Eaglestone SS, 2000, P NATL ACAD SCI USA, V97, P240, DOI 10.1073/pnas.97.1.240; Ferreira PC, 2001, MOL MICROBIOL, V40, P1357, DOI 10.1046/j.1365-2958.2001.02478.x; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Grimminger V, 2004, J BIOL CHEM, V279, P7378, DOI 10.1074/jbc.M312403200; Kim K, 2002, J CELL BIOL, V156, P101, DOI 10.1083/jcb.200107037; Kimura Y, 2003, CELL STRUCT FUNCT, V28, P187; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Kochneva-Pervukhova NV, 2001, YEAST, V18, P489, DOI 10.1002/yea.700; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; McCampbell A, 2001, NAT MED, V7, P528, DOI 10.1038/87842; Ness F, 2002, MOL CELL BIOL, V22, P5593, DOI 10.1128/MCB.22.15.5593-5605.2002; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Silveira JR, 2004, CURR TOP MICROBIOL, V284, P1; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Tuite MF, 2003, NAT REV MOL CELL BIO, V4, P878, DOI 10.1038/nrm1247; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner Reed B., 2004, VVolume 41, P305; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	46	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51042	51048		10.1074/jbc.M410611200	http://dx.doi.org/10.1074/jbc.M410611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15465809	hybrid			2022-12-25	WOS:000225355800049
J	Wang, P; Nie, J; Pei, DQ				Wang, P; Nie, J; Pei, DQ			The hemopexin domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) is not required for its activation of proMMP2 on cell surface but is essential for MT1-MMP-mediated invasion in three-dimensional type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; CATALYTIC-DOMAIN; GELATINASE-A; PROGELATINASE; PROTEOLYSIS; BINDING; OLIGOMERIZATION; (TIMP)-2; RECEPTOR; CLEAVAGE	Membrane-type matrix metalloproteinase-1 (MT1-MMP) plays a key role in tumor invasion and metastasis by degrading the extracellular matrix and activating proMMP2. Here we show that the conserved hemopexin domain is required for MT1-MMP-mediated invasion and growth in three-dimensional type I collagen matrix but not proMMP2 activation. Deletion of the hemopexin domains in MT1-, MT2-, MT3-, MT5-, and MT6-MMP does not impair their abilities to activate proMMP2. In fact, hemopexin-less MT5- and MT6-MMP activate proMMP2 better than their wild type counterparts. On the other hand, hemopexin-less MT1-MMP fails to promote cell invasion into type I collagen but retains the capacity to enhance the growth of Madin-Darby canine kidney cells as cysts in three-dimensional collagen matrix. Moreover, the hemopexin domain is also required for MT1-MMP-mediated invasion/scattering of MCF-7 cells in three-dimensional collagen matrix. Because growth and invasion in a three-dimensional model may correlate with tumor invasiveness in vivo, our data suggest that the hemopexin domains of MT-MMPs should be targeted for the development of anti-cancer therapies by employing screening assays developed for three-dimensional models rather than their enzymatic activity toward proMMP2.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.	peixx003@umn.edu			NCI NIH HHS [CA76308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076308, R01CA076308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hurst DR, 2004, BIOCHEM J, V377, P775, DOI 10.1042/bj20031067; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nie J, 2003, CANCER RES, V63, P6758; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Takino T, 2004, CANCER RES, V64, P1044, DOI 10.1158/0008-5472.CAN-03-1843; Takino T, 2003, BIOCHEM BIOPH RES CO, V304, P160, DOI 10.1016/S0006-291X(03)00544-8; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; Wang P, 2004, J BIOL CHEM, V279, P20461, DOI 10.1074/jbc.M400264200; Wang X, 1999, FEBS LETT, V462, P261, DOI 10.1016/S0014-5793(99)01534-3; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	45	38	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51148	51155		10.1074/jbc.M409074200	http://dx.doi.org/10.1074/jbc.M409074200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15381707	hybrid			2022-12-25	WOS:000225355800061
J	Lookene, A; Zhang, LY; Hultin, M; Olivecrona, G				Lookene, A; Zhang, LY; Hultin, M; Olivecrona, G			Rapid subunit exchange in dimeric lipoprotein lipase and properties of the inactive monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; MISSENSE MUTATIONS; MOLECULAR-WEIGHT; HEPARIN-BINDING; GENE; IDENTIFICATION; CONSEQUENCES; METABOLISM; PARAMETERS; PROTEINS	Lipoprotein lipase (LPL), a key enzyme in the metabolism of triglyceride-rich plasma lipoproteins, is a homodimer. Dissociation to monomers leads to loss of activity. Evidence that LPL dimers rapidly exchange subunits was demonstrated by fluorescence resonance energy transfer between lipase subunits labeled with Oregon Green and tetrametylrhodamine, respectively, and also by formation of heterodimers composed of radiolabeled and biotinylated lipase subunits captured on streptavidine-agarose. Compartmental modeling of the inactivation kinetics confirmed that rapid subunit exchange must occur. Studies of activity loss indicated the existence of a monomer that can form catalytically active dimers, but this intermediate state has not been possible to isolate and remains hypothetical. Differences in solution properties and conformation between the stable but catalytically inactive monomeric form of LPL and the active dimers were studied by static light scattering, intrinsic fluorescence, and probing with 4,4'-dianilino- 1,1'-binaphtyl-5,5'-disulfonic acid and acrylamide. The catalytically inactive monomer appeared to have a more flexible and exposed structure than the dimers and to be more prone to aggregation. By limited proteolysis the conformational changes accompanying dissociation of the dimers to inactive monomers were localized mainly to the central part of the subunit, probably corresponding to the region for subunit interaction.	Umea Univ, Dept Med Biosci Physiol Chem, SE-90187 Umea, Sweden; Tallinn Univ Technol, Dept Gen Technol, EE-12618 Tallinn, Estonia; Umea Univ, Dept Surg & Perioperat Sci, SE-90185 Umea, Sweden	Umea University; Tallinn University of Technology; Umea University	Olivecrona, G (corresponding author), Umea Univ, Dept Med Biosci Physiol Chem, Bldg 6M,3rd Fl, SE-90187 Umea, Sweden.	Gunilla.Olivecrona@medbio.umu.se	Hultin, Magnus/A-1321-2010	Hultin, Magnus/0000-0003-2935-7161				BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; Bergo M, 2002, J BIOL CHEM, V277, P11927, DOI 10.1074/jbc.M200325200; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EGELRUD T, 1972, J BIOL CHEM, V247, P6212; Hanyu O, 2004, ATHEROSCLEROSIS, V174, P385, DOI 10.1016/j.atherosclerosis.2004.01.034; HATA A, 1992, J BIOL CHEM, V267, P20132; Hubbard SJ, 1998, PROTEIN ENG, V11, P349, DOI 10.1093/protein/11.5.349; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; Keiper T, 2001, J LIPID RES, V42, P1180; KRAPP A, 1995, J LIPID RES, V36, P2362; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; Lookene A, 2003, J BIOL CHEM, V278, P37183, DOI 10.1074/jbc.M303894200; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; Lutz EP, 2004, J BIOL CHEM, V279, P238, DOI 10.1074/jbc.M310559200; Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9; Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015-JLR200; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; Olivecrona G, 1997, METHOD ENZYMOL, V286, P102; OLIVECRONA G, 1995, ATHEROSCLEROSIS, V10, P250; OLIVECRONA T, 1982, EUR J BIOCHEM, V124, P629, DOI 10.1111/j.1432-1033.1982.tb06640.x; Olivecrona T., 1984, P205; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; Pentikainen MO, 2000, J BIOL CHEM, V275, P5694, DOI 10.1074/jbc.275.8.5694; Peterson J, 2002, J LIPID RES, V43, P398; PETERSON J, 1992, J LIPID RES, V33, P1165; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; Stein Y, 2003, ATHEROSCLEROSIS, V170, P1, DOI 10.1016/S0021-9150(03)00014-5; TORNVALL P, 1995, ARTERIOSCL THROM VAS, V15, P1086, DOI 10.1161/01.ATV.15.8.1086; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VILELLA E, 1993, J LIPID RES, V34, P1555; Wong H, 2002, J LIPID RES, V43, P993, DOI 10.1194/jlr.R200007-JLR200; Wu GS, 2003, J BIOL CHEM, V278, P11925, DOI 10.1074/jbc.M212736200; Zhang LY, 2003, J BIOL CHEM, V278, P29344, DOI 10.1074/jbc.M300455200; [No title captured]	39	47	49	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49964	49972		10.1074/jbc.M407419200	http://dx.doi.org/10.1074/jbc.M407419200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15385564	hybrid			2022-12-25	WOS:000225229500052
J	Iuliano, R; Le Pera, I; Cristofaro, C; Baudi, F; Arturi, F; Pallante, P; Martelli, ML; Trapasso, F; Chiariotti, L; Fusco, A				Iuliano, R; Le Pera, I; Cristofaro, C; Baudi, F; Arturi, F; Pallante, P; Martelli, ML; Trapasso, F; Chiariotti, L; Fusco, A			The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis	ONCOGENE			English	Article						polymorphisms; tyrosine phosphatase; thyroid; carcinoma; loss of heterozygosity	CARCINOMA CELL-LINES; ETA SUPPRESSES; CANCER CELLS; PROTEIN; EXPRESSION; GROWTH; INHIBITION; TUMORS; PROLIFERATION; DIMERIZATION	We recently isolated the r-PTPeta gene, which encodes a receptor-type tyrosine phosphatase protein that suppresses the neoplastic phenotype of retrovirally transformed rat thyroid cells. The human homologue gene PTPRJ/DEP-1 is deleted in various tumors. Moreover, the Gln276Pro polymorphism, located in the extracellular region of the gene, seems to play a critical role in susceptibility to some human neoplasias. Here we report the loss of heterozygosity ( LOH) of PTPRJ in 11/76 (14.5%) informative thyroid tumors ( including adenomas and carcinomas). We also looked for the Gln276Pro, Arg326Gln and Asp872Glu polymorphisms in exons 5, 6 and 13 of PTPRJ in 88 patients with thyroid tumors and in 54 healthy individuals. We found that the PTPRJ genotypes homozygous for the Gln276Pro and Arg326Gln polymorphisms, and the Asp872 allele were more frequent in thyroid carcinoma patients than in healthy individuals ( P = 0.032). In addition, PTPRJ LOH was more frequent in thyroid carcinomas of heterozygotes for Gln276Pro and Arg326Gln compared with homozygotes ( P = 0.006). This suggests that the presence of hemizygosity for these polymorphisms in the tumor facilitates tumor progression. These results indicate that the genotypic pro. le of PTPRJ affects susceptibility to thyroid carcinomas, and that allelic loss of this gene is involved in thyroid carcinogenesis.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulaire & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro Magna Graecia, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulaire & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Pallante, Pierlorenzo/AAX-8758-2020; Chiariotti, Lorenzo/AAC-5262-2022	Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; ARTURI, Franco/0000-0002-1660-1228				Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chiappetta G, 1998, CANCER RES, V58, P4193; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Dumont JE, 2002, AM J PHYSIOL-CELL PH, V283, pC2, DOI 10.1152/ajpcell.00581.2001; Fiore L, 1997, J CLIN ENDOCR METAB, V82, P4094, DOI 10.1210/jc.82.12.4094; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; Iuliano R, 2003, CANCER RES, V63, P882; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Keane MM, 1996, CANCER RES, V56, P4236; Kitamura Y, 2001, J CLIN ENDOCR METAB, V86, P4268, DOI 10.1210/jc.86.9.4268; Kovalerchuk B, 2000, IEEE ENG MED BIOL, V19, P26, DOI 10.1109/51.853479; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Martelli ML, 2000, EUR J ENDOCRINOL, V143, P515, DOI 10.1530/eje.0.1430515; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tallini G, 2002, ENDOCR PATHOL, V13, P271, DOI 10.1385/EP:13:4:271; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	31	55	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8432	8438		10.1038/sj.onc.1207766	http://dx.doi.org/10.1038/sj.onc.1207766			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378013				2022-12-25	WOS:000224870700003
J	St-Pierre, SJG; Chakkalakal, JV; Kolodziejczyk, SM; Knudson, JC; Jasmin, BJ; Megeney, LA				St-Pierre, SJG; Chakkalakal, JV; Kolodziejczyk, SM; Knudson, JC; Jasmin, BJ; Megeney, LA			Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway	FASEB JOURNAL			English	Article						signaling; corticosteroid; MAPK	DUCHENNE MUSCULAR-DYSTROPHY; N-TERMINAL KINASE; MUSCLE-FIBERS; MDX MOUSE; INCREASED EXPRESSION; DOUBLE-BLIND; IN-VIVO; SKELETAL; DEFLAZACORT; PREDNISONE	Duchenne muscular dystrophy (DMD) is a progressive and ultimately fatal skeletal muscle disease. Currently, the most effective therapy is the administration of a subclass of glucocorticoids, most notably deflazacort. Although deflazacort treatment can attenuate DMD progression, extend ambulation, and maintain muscle strength, the mechanism of its action remains unknown. Prior observations have shown that activation of a JNK1-mediated signal transduction cascade contributes to the progression of the DMD phenotype, in part by phosphorylation and inhibition of a calcineurin sensitive NF-ATc1 transcription factor. Here, we observed that deflazacort treatment restored myocyte viability in muscle cells with constitutive activation of JNK1 and in dystrophic mdx mice. However, deflazacort treatment did not alter JNK1 activity itself, but rather led to an increase in the activity of the calcineurin phosphatase and an up-regulation of NF-ATc1-dependent gene expression. The prophylactic effect of deflazacort treatment was associated with increased expression of NF-ATc1 target genes such as the dystrophin homologue utrophin. Moreover, the muscle sparing effects of deflazacort were completely abolished when used in conjunction with the calcineurin inhibitor cyclosporine. Collectively, these results show that deflazacort attenuates loss of dystrophic myofiber integrity by up-regulating the activity of the phosphatase calcineurin, which in turn negates JNK1 inhibition of NF-ATc1- mediated phosphorylation and nuclear exclusion of NF-ATc1.	Ottawa Gen Hosp, Ottawa Hlth Res Inst, Program Mol Med, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Ctr Neuromuscular Dis, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Megeney, LA (corresponding author), Ottawa Gen Hosp, Ottawa Hlth Res Inst, Program Mol Med, Gen Campus, Ottawa, ON K1H 8L6, Canada.	lmegeney@ohri.ca	Chakkalakal, Joe/ABD-2865-2020	Chakkalakal, Joe/0000-0002-8440-7312; Megeney, Lynn/0000-0002-6824-8569				Adcock IM, 2001, IMMUNOL CELL BIOL, V79, P376, DOI 10.1046/j.1440-1711.2001.01025.x; Anderson JE, 2000, CELL TRANSPLANT, V9, P551, DOI 10.1177/096368970000900411; Anderson JE, 1996, MUSCLE NERVE, V19, P1576, DOI 10.1002/(SICI)1097-4598(199612)19:12<1576::AID-MUS7>3.0.CO;2-7; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; BAUMBACH LL, 1989, NEUROLOGY, V39, P465, DOI 10.1212/WNL.39.4.465; Biggar WD, 2001, J PEDIATR-US, V138, P45, DOI 10.1067/mpd.2001.109601; Bonifati MD, 2000, MUSCLE NERVE, V23, P1344, DOI 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3.3.CO;2-6; Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590; BURGHES AHM, 1987, NATURE, V328, P434, DOI 10.1038/328434a0; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chakkalakal JV, 2003, P NATL ACAD SCI USA, V100, P7791, DOI 10.1073/pnas.0932671100; Chan RYY, 1998, J BIOL CHEM, V273, P9727, DOI 10.1074/jbc.273.16.9727; Chen RB, 2000, J IMMUNOL, V164, P825, DOI 10.4049/jimmunol.164.2.825; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DESILVA S, 1987, ARCH NEUROL-CHICAGO, V44, P818, DOI 10.1001/archneur.1987.00520200022012; EMERY AEH, 1993, DUCHENNE MUSCULAR DY, P24; FENICHEL GM, 1991, NEUROLOGY, V41, P1874, DOI 10.1212/WNL.41.12.1874; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Gramolini AO, 2001, AM J PHYSIOL-CELL PH, V281, pC1300, DOI 10.1152/ajpcell.2001.281.4.C1300; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Hack AA, 1999, P NATL ACAD SCI USA, V96, P10723, DOI 10.1073/pnas.96.19.10723; Han ZN, 2002, ARTHRITIS RHEUM, V46, P818, DOI 10.1002/art.10104; Hedin KE, 1997, J IMMUNOL, V159, P5431; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; Khanna S, 2003, FASEB J, V17, P1370, DOI 10.1096/fj.02-1108fje; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; MARKHAM A, 1995, DRUGS, V50, P317, DOI 10.2165/00003495-199550020-00008; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; MENDELL JR, 1989, NEW ENGL J MED, V320, P1592, DOI 10.1056/NEJM198906153202405; Mesa L E, 1991, Neuromuscul Disord, V1, P261, DOI 10.1016/0960-8966(91)90099-E; METZINGER L, 1995, BRIT J PHARMACOL, V116, P2811, DOI 10.1111/j.1476-5381.1995.tb15930.x; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Oak SA, 2003, J BIOL CHEM, V278, P39287, DOI 10.1074/jbc.M305551200; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Porter JD, 2003, HUM MOL GENET, V12, P1813, DOI 10.1093/hmg/ddg197; Querfurth HW, 2001, MOL CELL NEUROSCI, V17, P793, DOI 10.1006/mcne.2001.0972; SANDRI M, 1995, FEBS LETT, V373, P291, DOI 10.1016/0014-5793(95)00908-R; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Sousa AR, 1999, J ALLERGY CLIN IMMUN, V104, P565, DOI 10.1016/S0091-6749(99)70325-8; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Wang ZM, 1999, J PHYSIOL-LONDON, V516, P331, DOI 10.1111/j.1469-7793.1999.0331v.x	56	68	73	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1937	+		10.1096/fj.04-1859fje	http://dx.doi.org/10.1096/fj.04-1859fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15456738				2022-12-25	WOS:000224243200002
J	Haegebarth, A; Heap, D; Bie, WJ; Derry, JJ; Richard, SP; Tyner, AL				Haegebarth, A; Heap, D; Bie, WJ; Derry, JJ; Richard, SP; Tyner, AL			The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-ASSOCIATED PROTEIN; MAMMARY EPITHELIAL-CELLS; KH-DOMAIN; GASTROINTESTINAL-TRACT; CYCLE PROGRESSION; HIV REPLICATION; REV FUNCTION; GSG DOMAIN; BRK; EXPRESSION	Expression of the intracellular tyrosine kinase BRK/Sik is epithelial-specific and regulated during differentiation. Only a few substrates have been identified for BRK/Sik, including the KH domain containing RNA-binding protein Sam68 and the novel adaptor protein BKS. Although the physiological role of Sam68 is unknown, it has been shown to regulate mRNA transport, pre-mRNA splicing, and polyadenylation. Here we demonstrate that the Sam68-like mammalian proteins SLM-1 and SLM-2 but not the related KH domain containing heterogeneous nuclear ribonucleoprotein K are novel substrates of BRK/Sik. The expression of active BRK/Sik results in increased SLM-1 and SLM-2 phosphorylation and increased retention of BRK/Sik within the nucleus. The phosphorylation of SLM-1 and SLM-2 has functional relevance and leads to inhibition of their RNA-binding abilities. We show that SLM-1, SLM-2, and BRK/Sik have restricted patterns of expression unlike the ubiquitously expressed Sam68. Moreover, BRK/Sik, SLM-1, and Sam68 transcripts were coexpressed in the mouse gastrointestinal tract and skin, suggesting that SLM-1 and Sam68 could be physiologically relevant BRK/Sik targets in vivo. The ability of BRK/Sik to negatively regulate the RNA-binding activities of the KH domain RNA binding proteins SLM-1 and Sam68 may have an impact on the posttranscriptional regulation of epithelial cell gene expression.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Med, Chicago, IL 60607 USA; McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res,Dept Oncol, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res,Dept Med, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Tyner, Angela/0000-0001-7448-8625	NIDDK NIH HHS [R01 DK044525, R01 DK044525-10, DK07788, DK44525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525, R55DK044525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Cans C, 2000, BIOCHEM PHARMACOL, V60, P1203, DOI 10.1016/S0006-2952(00)00434-2; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hong EM, 2004, J BIOL CHEM, V279, P29700, DOI 10.1074/jbc.M313185200; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; LASKO P, 2003, SCI STKE; Lee JS, 1999, GENE, V240, P133, DOI 10.1016/S0378-1119(99)00421-7; LEE ST, 1993, ONCOGENE, V8, P3403; Li JL, 2002, J VIROL, V76, P4526, DOI 10.1128/JVI.76.9.4526-4535.2002; Li JL, 2002, J VIROL, V76, P8374, DOI 10.1128/JVI.76.16.8374-8382.2002; Li QH, 2002, FEBS LETT, V525, P145, DOI 10.1016/S0014-5793(02)03103-4; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Llor X, 1999, CLIN CANCER RES, V5, P1767; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Mclaren M, 2004, RNA, V10, P1119, DOI 10.1261/rna.5263904; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Petro BJ, 2004, ORAL ONCOL, V40, P1040, DOI 10.1016/j.oraloncology.2004.05.010; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Rafalska I, 2004, HUM MOL GENET, V13, P1535, DOI 10.1093/hmg/ddh167; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Reddy TR, 2002, J BIOL CHEM, V277, P5778, DOI 10.1074/jbc.M106836200; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; Serfas MS, 2003, ONCOL RES, V13, P409; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Stoss O, 2004, MOL CELL NEUROSCI, V27, P8, DOI 10.1016/j.mcn.2004.04.011; Stoss O, 2001, J BIOL CHEM, V276, P8665, DOI 10.1074/jbc.M006851200; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	53	69	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54398	54404		10.1074/jbc.M409579200	http://dx.doi.org/10.1074/jbc.M409579200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471878	hybrid			2022-12-25	WOS:000225793600062
J	Liu, MF; Garges, S; Adhya, S				Liu, MF; Garges, S; Adhya, S			LacP1 promoter with an extended-10 motif - Pleiotropic effects of cyclic AMP protein at different steps of transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR PROTEIN; OPEN COMPLEX-FORMATION; COLI RNA-POLYMERASE; PHAGE-PHI-29 REGULATORY PROTEIN-P4; ESCHERICHIA-COLI; ACTIVATOR PROTEIN; ALPHA-SUBUNIT; GALACTOSE OPERON; 434 REPRESSOR; IN-VIVO	The cyclic AMP receptor protein (CRP), which activates transcription from the wild-type lacP1 promoter and most of its mutants, represses productive RNA synthesis from a lacP1 promoter variant that contains an extended -10 element, although CRP enhances RNA polymerase binding as well as open complex formation in both promoters. Moreover, abortive RNA synthesis, which is already higher in the extended -10 variant compared with the parent promoter, was further enhanced by CRP. These results, together with the observed decrease in productive RNA synthesis, indicate that CRP, while facilitating the earlier steps of initiation, inhibits transcription from the extended -10 lacP1 by hindering promoter clearance. We propose that CRP decreases energetic barriers to RNA polymerase binding, isomerization, and abortive RNA synthesis but stabilizes the abortive RNA initiating complex, which results in increasing the activation energy of the transition state before the elongation complex. The results demonstrate for the first time that a DNA-binding regulatory protein acts as an activator or a repressor in different steps of the transcription initiation pathway because of the energetic differences of the intermediate complex in the same promoter.	NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Adhya, S (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Rm 5138, Bethesda, MD 20892 USA.	sadhya@helix.nih.gov		liu, mo fang/0000-0003-1800-466X	NATIONAL CANCER INSTITUTE [ZIABC008751, Z01BC008751] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIBA H, 1985, J BIOL CHEM, V260, P3063; Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; Benoff B, 2002, SCIENCE, V297, P1562, DOI 10.1126/science.1076376; Burns HD, 1999, NUCLEIC ACIDS RES, V27, P2051, DOI 10.1093/nar/27.9.2051; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; CHOY HE, 1993, P NATL ACAD SCI USA, V90, P472, DOI 10.1073/pnas.90.2.472; CHOY HE, 1995, EMBO J, V14, P4523, DOI 10.1002/j.1460-2075.1995.tb00131.x; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; Eichenberger P, 1996, BIOCHEMISTRY-US, V35, P15302, DOI 10.1021/bi961377d; Eichenberger P, 1997, P NATL ACAD SCI USA, V94, P9022, DOI 10.1073/pnas.94.17.9022; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; HERBERT M, 1986, P NATL ACAD SCI USA, V83, P2807, DOI 10.1073/pnas.83.9.2807; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LAVIGNE M, 1992, J MOL BIOL, V224, P293, DOI 10.1016/0022-2836(92)90995-V; Liu MF, 2004, P NATL ACAD SCI USA, V101, P6911, DOI 10.1073/pnas.0401929101; Liu MF, 2003, J BIOL CHEM, V278, P39755, DOI 10.1074/jbc.M305995200; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; Monsalve M, 1996, EMBO J, V15, P383, DOI 10.1002/j.1460-2075.1996.tb00368.x; Monsalve M, 1997, MOL CELL, V1, P99, DOI 10.1016/S1097-2765(00)80011-8; Monsalve M, 1996, P NATL ACAD SCI USA, V93, P8913, DOI 10.1073/pnas.93.17.8913; MORI K, 1985, J BIOL CHEM, V260, P4838; Muller-Hill B, 1998, CURR OPIN MICROBIOL, V1, P145, DOI 10.1016/S1369-5274(98)80004-0; MUSSO RE, 1977, CELL, V12, P847, DOI 10.1016/0092-8674(77)90283-5; NUEZ B, 1992, P NATL ACAD SCI USA, V89, P11401, DOI 10.1073/pnas.89.23.11401; PTASHNE M, 1980, CELL, V19, P1, DOI 10.1016/0092-8674(80)90383-9; Rawlinson ELA, 2002, BIOCHIMIE, V84, P559, DOI 10.1016/S0300-9084(02)01420-7; REZNIKOFF WS, 1978, OPERON, P221; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; Roy S, 1998, J BIOL CHEM, V273, P14059, DOI 10.1074/jbc.273.23.14059; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; Ryu S, 1998, GENE, V223, P235, DOI 10.1016/S0378-1119(98)00237-6; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; Sukhodolets MV, 1998, J BIOL CHEM, V273, P7018, DOI 10.1074/jbc.273.12.7018; Sullivan JJ, 1997, BIOCHEMISTRY-US, V36, P8005, DOI 10.1021/bi970363k; TAGAMI H, 1995, NUCLEIC ACIDS RES, V23, P599, DOI 10.1093/nar/23.4.599; Tagami H, 1998, EMBO J, V17, P1759, DOI 10.1093/emboj/17.6.1759; ValentinHansen P, 1996, MOL MICROBIOL, V20, P461, DOI 10.1046/j.1365-2958.1996.5341056.x; XIONG XF, 1991, J BACTERIOL, V173, P4570, DOI 10.1128/jb.173.15.4570-4577.1991; Xu J, 2000, DNA CELL BIOL, V19, P621, DOI 10.1089/104454900750019380; Xu J, 2001, J MOL BIOL, V309, P573, DOI 10.1006/jmbi.2001.4702	44	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54552	54557		10.1074/jbc.M408609200	http://dx.doi.org/10.1074/jbc.M408609200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15385551	hybrid			2022-12-25	WOS:000225793600080
J	Winshell, J; Paulson, BA; Buelow, BD; Champoux, JJ				Winshell, J; Paulson, BA; Buelow, BD; Champoux, JJ			Requirements for DNA unpairing during displacement synthesis by HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DOUBLE-STRANDED DNA; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; AVIAN RETROVIRUS; TEMPLATE-PRIMER; THERMODYNAMIC PARAMETERS; FUNCTIONAL IMPLICATIONS; NUCLEIC-ACID; INITIATION	DNA displacement synthesis by reverse transcriptase during retroviral replication is required for the production of the linear precursor to integration. The sensitivity of unpaired thymines to KMnO4 oxidation was used to probe for the extent of DNA melting by human immunodeficiency virus, type 1 (HIV-1) reverse transcriptase in front of the primer terminus in model oligonucleotide-based displacement constructs. Unpairing of the two base pairs downstream of the primer (+1 and +2 positions) requires the presence of the next correct dNTP, indicating that DNA melting only occurs after the formation of the ternary complex with the enzyme tightly clamped around the DNA. The amount or extent of DNA melting is not significantly affected by the length of the already-displaced strand or the base composition of the DNA beyond the +2 position. The F61W mutant form of HIV-1 reverse transcriptase, which is partially impaired for displacement synthesis, exhibits a reduction in the amount of melting at the +1 and +2 positions. These results demonstrate the importance of the observed melting to displacement synthesis and suggest that the unpairing reaction is mediated by an intimate association between the fingers region of the enzyme and the DNA in the closed clamp conformation of the protein.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA051605, R37CA051605] Funding Source: NIH RePORTER; NCI NIH HHS [CA51605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; Bommarito S, 2000, NUCLEIC ACIDS RES, V28, P1929, DOI 10.1093/nar/28.9.1929; BOONE LR, 1981, J VIROL, V37, P109, DOI 10.1128/JVI.37.1.109-116.1981; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; DOKTYCZ MJ, 1990, BIOPOLYMERS, V30, P829, DOI 10.1002/bip.360300718; Fisher TS, 2003, J MOL BIOL, V325, P443, DOI 10.1016/S0022-2836(02)01225-1; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HANSLER U, 1993, J AM CHEM SOC, V115, P8554, DOI 10.1021/ja00072a005; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; Hou EW, 2004, PROTEIN EXPRES PURIF, V34, P75, DOI 10.1016/j.pep.2003.10.018; HSU TW, 1982, J VIROL, V44, P47, DOI 10.1128/JVI.44.1.47-53.1982; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Kelleher CD, 1998, J BIOL CHEM, V273, P9976, DOI 10.1074/jbc.273.16.9976; Kelleher CD, 2000, J BIOL CHEM, V275, P13061, DOI 10.1074/jbc.275.17.13061; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Lanchy JM, 1996, BIOCHIMIE, V78, P1087, DOI 10.1016/S0300-9084(97)86734-X; Lanciault C, 2004, J BIOL CHEM, V279, P32252, DOI 10.1074/jbc.M404117200; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Najmudin S, 2000, J MOL BIOL, V296, P613, DOI 10.1006/jmbi.1999.3477; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Ramaiah D, 1998, NUCLEIC ACIDS RES, V26, P3940, DOI 10.1093/nar/26.17.3940; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; SENIOR M, 1988, BIOCHEMISTRY-US, V27, P3879, DOI 10.1021/bi00410a053; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Sugimoto N, 1996, NUCLEIC ACIDS RES, V24, P4501, DOI 10.1093/nar/24.22.4501; TAYLOR JM, 1983, J VIROL, V48, P654, DOI 10.1128/JVI.48.3.654-659.1983; VARMUS H, 1989, MOBILE DNA, P53; Whiting SH, 1998, J MOL BIOL, V278, P559, DOI 10.1006/jmbi.1998.1720; WHITING SH, 1994, J VIROL, V68, P4747, DOI 10.1128/JVI.68.8.4747-4758.1994; Winshell J, 2001, J MOL BIOL, V306, P931, DOI 10.1006/jmbi.2001.4439; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	40	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52924	52933		10.1074/jbc.M409134200	http://dx.doi.org/10.1074/jbc.M409134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465813	hybrid			2022-12-25	WOS:000225680600016
J	Bonin, F; Ryan, SD; Migahed, L; Mo, F; Lallier, J; Franks, DJ; Arai, H; Bennett, SAL				Bonin, F; Ryan, SD; Migahed, L; Mo, F; Lallier, J; Franks, DJ; Arai, H; Bennett, SAL			Anti-apoptotic actions of the platelet-activating factor acetylhydrolase I alpha(2) catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PAF-ACETHER; FACTOR RECEPTOR; CELL-DEATH; TRANSBILAYER MOVEMENT; PHOSPHOLIPASE A(2); EXPRESSION; INHIBITION; ANTAGONISTS; METABOLISM; BINDING	Platelet-activating factor (PAF) is an important mediator of cell loss following diverse pathophysiological challenges, but the manner in which PAF transduces death is not clear. Both PAF receptor-dependent and - independent pathways are implicated. In this study, we show that extracellular PAF can be internalized through PAF receptor-independent mechanisms and can initiate caspase-3-dependent apoptosis when cytosolic concentrations are elevated by similar to 15 pM/cell for 60 min. Reducing cytosolic PAF to less than 10 pM/cell terminates apoptotic signaling. By pharmacological inhibition of PAF acetylhydrolase I and II (PAF-AH) activity and down-regulation of PAF-AH I catalytic subunits by RNA interference, we show that the PAF receptor-independent death pathway is regulated by PAF-AH I and, to a lesser extent, by PAF-AH II. Moreover, the anti-apoptotic actions of PAF-AH I are subunit-specific. PAF-AH I alpha(1) regulates intracellular PAF concentrations under normal physiological conditions, but expression is not sufficient to reduce an acute rise in intracellular PAF levels. PAF-AH I alpha(2) expression is induced when cells are deprived of serum or exposed to apoptogenic PAF concentrations limiting the duration of pathological cytosolic PAF accumulation. To block PAF receptor-independent death pathway, we screened a panel of PAF antagonists (CV-3988, CV-6209, BN 52021, and FR 49175). BN 52021 and FR 49175 accelerated PAF hydrolysis and inhibited PAF-mediated caspase 3 activation. Both antagonists act indirectly to promote PAF-AH I alpha(2) homodimer activity by reducing PAF-AH I alpha(1) expression. These findings identify PAF-AH I alpha(2) as a potent antiapoptotic protein and describe a new means of pharmacologically targeting PAF-AH I to inhibit PAF-mediated cell death.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Neural Regenerat Lab, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Pathol, Ottawa, ON K1H 8M5, Canada; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Ottawa; University of Ottawa; University of Tokyo	Bennett, SAL (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Neural Regenerat Lab, Ottawa, ON K1H 8M5, Canada.	sbennet@uottawa.ca		Ryan, Scott/0000-0001-9829-4649				Asano K, 1999, BIOCHEM BIOPH RES CO, V261, P511, DOI 10.1006/bbrc.1999.1066; Barber LA, 1998, J BIOL CHEM, V273, P18891, DOI 10.1074/jbc.273.30.18891; Bate C, 2004, NEUROREPORT, V15, P509, DOI 10.1097/00001756-200403010-00025; Bate C, 2004, J BIOL CHEM, V279, P36405, DOI 10.1074/jbc.M404086200; Bazan NG, 1998, PROG BRAIN RES, V118, P281; Bennett SAL, 1998, CELL DEATH DIFFER, V5, P867, DOI 10.1038/sj.cdd.4400434; BIRKLE DL, 1988, J NEUROCHEM, V51, P1900, DOI 10.1111/j.1471-4159.1988.tb01175.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRATTON DL, 1993, J BIOL CHEM, V268, P3364; BRATTON DL, 1992, J IMMUNOL, V148, P514; Brewer C, 2002, J NEUROCHEM, V82, P1502, DOI 10.1046/j.1471-4159.2002.01094.x; Chen CH, 2003, CIRCULATION, V107, P2102, DOI 10.1161/01.CIR.0000065220.70220.F7; Darst M, 2004, J IMMUNOL, V172, P6330, DOI 10.4049/jimmunol.172.10.6330; Dupre DJ, 2001, J PHARMACOL EXP THER, V299, P358; Fukuda Y, 2000, EUR J PHARMACOL, V390, P203, DOI 10.1016/S0014-2999(99)00920-6; GERARD NP, 1994, J IMMUNOL, V152, P793; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirashima Y, 2000, BRAIN RES, V885, P128, DOI 10.1016/S0006-8993(00)02852-3; Hostettler ME, 2002, GLIA, V38, P228, DOI 10.1002/glia.10065; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; LACHACHI H, 1985, BIOCHEM BIOPH RES CO, V132, P460, DOI 10.1016/0006-291X(85)91156-8; LAMANT V, 1987, BIOCHEM PHARMACOL, V36, P2749, DOI 10.1016/0006-2952(87)90259-0; Li T, 2003, J BIOL CHEM, V278, P16614, DOI 10.1074/jbc.M211287200; Lu J, 2004, AM J PHYSIOL-GASTR L, V286, pG340, DOI 10.1152/ajpgi.00182.2003; Ma X, 2001, CURR EYE RES, V23, P326, DOI 10.1076/ceyr.23.5.326.5445; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Manya H, 1999, J BIOL CHEM, V274, P31827, DOI 10.1074/jbc.274.45.31827; MARCHESELLI VL, 1990, J BIOL CHEM, V265, P9140; Marques M, 2002, J INVEST DERMATOL, V119, P913, DOI 10.1046/j.1523-1747.2002.01859.x; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; Min JH, 2001, BIOCHEMISTRY-US, V40, P4539, DOI 10.1021/bi002600g; Mori M, 1996, J NEUROSCI, V16, P3590; NUNEZ D, 1986, EUR J PHARMACOL, V123, P197, DOI 10.1016/0014-2999(86)90660-6; OFLAHERTY JT, 1987, BIOCHEM BIOPH RES CO, V147, P18, DOI 10.1016/S0006-291X(87)80081-5; Ogden F, 1998, J NEUROSCI RES, V53, P677, DOI 10.1002/(SICI)1097-4547(19980915)53:6<677::AID-JNR6>3.0.CO;2-2; Ohshima N, 2002, J BIOL CHEM, V277, P9722, DOI 10.1074/jbc.M112406200; OKAMOTO M, 1986, CHEM PHARM BULL, V34, P345; Perry SW, 1998, J BIOL CHEM, V273, P17660, DOI 10.1074/jbc.273.28.17660; Pietri S, 1997, J MOL CELL CARDIOL, V29, P733, DOI 10.1006/jmcc.1996.0316; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Southall MD, 2001, J BIOL CHEM, V276, P45548, DOI 10.1074/jbc.M105978200; TERASHITA ZI, 1987, J PHARMACOL EXP THER, V242, P263; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; Tokuoka SM, 2003, EUR J NEUROSCI, V18, P563, DOI 10.1046/j.1460-9568.2003.02778.x; Tong N, 2001, EUR J NEUROSCI, V13, P1913, DOI 10.1046/j.0953-816x.2001.01572.x; VALONE FH, 1985, BIOCHEM BIOPH RES CO, V126, P502, DOI 10.1016/0006-291X(85)90634-5; Yoshida K, 1988, Prog Biochem Pharmacol, V22, P66	51	33	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52425	52436		10.1074/jbc.M410967200	http://dx.doi.org/10.1074/jbc.M410967200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15456758	hybrid			2022-12-25	WOS:000225493400087
J	Chien, CH; Huang, LH; Chou, CY; Chen, YS; Han, YS; Chang, GG; Liang, PH; Chen, X				Chien, CH; Huang, LH; Chou, CY; Chen, YS; Han, YS; Chang, GG; Liang, PH; Chen, X			One site mutation disrupts dimer formation in human DPP-IV proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL-PEPTIDASE-IV; HUMAN CYTOMEGALOVIRUS PROTEASE; IMPROVED GLUCOSE-TOLERANCE; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; INSULIN-SECRETION; DIMERIZATION; PURIFICATION; INHIBITION; STABILITY	DPP-IV is a prolyl dipeptidase, cleaving the peptide bond after the penultimate proline residue. It is an important drug target for the treatment of type II diabetes. DPP-IV is active as a dimer, and monomeric DPP-IV has been speculated to be inactive. In this study, we have identified the C-terminal loop of DPP-IV, highly conserved among prolyl dipeptidases, as essential for dimer formation and optimal catalysis. The conserved residue His(750) on the loop contributes significantly for dimer stability. We have determined the quaternary structures of the wild type, H750A, and H750E mutant enzymes by several independent methods including chemical cross-linking, gel electrophoresis, size exclusion chromatography, and analytical ultracentrifugation. Wild-type DPP-IV exists as dimers both in the intact cell and in vitro after purification from human semen or insect cells. The H750A mutation results in a mixture of DPP-IV dimer and monomer. H750A dimer has the same kinetic constants as those of the wild type, whereas the H750A monomer has a 60-fold decrease in k(cat). Replacement of His(750) with a negatively charged Glu (H750E) results in nearly exclusive monomers with a 300-fold decrease in catalytic activity. Interestingly, there is no dynamic equilibrium between the dimer and the monomer for all forms of DPP-IVs studied here. This is the first study of the function of the C-terminal loop as well as monomeric mutant DPP-IVs with respect to their enzymatic activities. The study has important implications for the discovery of drugs targeted to the dimer interface.	Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 115, Taiwan; Natl Yang Ming Univ, Fac Life Sci, Taipei 112, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	National Health Research Institutes - Taiwan; National Defense Medical Center; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Chen, X (corresponding author), Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, Taipei 115, Taiwan.	xchen@nhri.org.tw	Chen, Xin/D-2073-2010; Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256; Chou, Chi-Yuan/0000-0002-3400-171X; HAN, YU-SAN/0000-0002-9236-9045				Aertgeerts K, 2004, PROTEIN SCI, V13, P412, DOI 10.1110/ps.03460604; Ahren B, 2000, EUR J PHARMACOL, V404, P239, DOI 10.1016/S0014-2999(00)00600-2; Batra R, 2001, NAT STRUCT BIOL, V8, P810, DOI 10.1038/nsb0901-810; Boggetto N, 2002, BIOL CHEM, V383, P1321, DOI 10.1515/BC.2002.150; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Chang HC, 2003, J BIOL CHEM, V278, P23996, DOI 10.1074/jbc.M213242200; Chen YS, 2004, PROTEIN EXPRES PURIF, V35, P142, DOI 10.1016/j.pep.2003.12.019; Cole JL, 1996, BIOCHEMISTRY-US, V35, P15601, DOI 10.1021/bi961719f; Conarello SL, 2003, P NATL ACAD SCI USA, V100, P6825, DOI 10.1073/pnas.0631828100; DADDONA PE, 1978, J BIOL CHEM, V253, P4617; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; DARKE PL, 1994, METHOD ENZYMOL, V241, P104; De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703; De Meester I, 2000, ADV EXP MED BIOL, V477, P67; Deacon CF, 2001, DIABETES, V50, P1588, DOI 10.2337/diabetes.50.7.1588; DeMeester I, 1996, J IMMUNOL METHODS, V189, P99, DOI 10.1016/0022-1759(95)00239-1; Drucker DJ, 2003, EXPERT OPIN INV DRUG, V12, P87, DOI 10.1517/13543784.12.1.87; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Ishima R, 2003, J BIOL CHEM, V278, P43311, DOI 10.1074/jbc.M307549200; KATO T, 1978, CLIN CHEM, V24, P1163; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; Khayat R, 2004, BIOCHEMISTRY-US, V43, P316, DOI 10.1021/bi035170d; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Lambeir AM, 1997, BBA-PROTEIN STRUCT M, V1340, P215, DOI 10.1016/S0167-4838(97)00045-9; Lee DF, 2000, J VIROL, V74, P11873, DOI 10.1128/JVI.74.24.11873-11880.2000; Liang PH, 1998, BIOCHEMISTRY-US, V37, P5923, DOI 10.1021/bi9726077; Margosiak SA, 1996, BIOCHEMISTRY-US, V35, P5300, DOI 10.1021/bi952842u; Marguet D, 2000, P NATL ACAD SCI USA, V97, P6874, DOI 10.1073/pnas.120069197; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Pauly RP, 1996, J BIOL CHEM, V271, P23222, DOI 10.1074/jbc.271.38.23222; Polgar L, 2002, CELL MOL LIFE SCI, V59, P349, DOI 10.1007/s00018-002-8427-5; Pospisilik JA, 2002, DIABETES, V51, P2677, DOI 10.2337/diabetes.51.9.2677; PUSCHEL G, 1982, EUR J BIOCHEM, V126, P359, DOI 10.1111/j.1432-1033.1982.tb06788.x; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; RIEMANN D, 1995, CLIN EXP IMMUNOL, V100, P277; Rosenblum JS, 2003, CURR OPIN CHEM BIOL, V7, P496, DOI 10.1016/S1367-5931(03)00084-X; SAISON M, 1983, BIOCHEM J, V216, P177, DOI 10.1042/bj2160177; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt U, 1997, J BIOL CHEM, V272, P7732, DOI 10.1074/jbc.272.12.7732; Sudre B, 2002, DIABETES, V51, P1461, DOI 10.2337/diabetes.51.5.1461; Thoma R, 2003, STRUCTURE, V11, P947, DOI 10.1016/S0969-2126(03)00160-6; Villhauer EB, 2002, J MED CHEM, V45, P2362, DOI 10.1021/jm025522z; YAMANAKA G, 1995, J BIOL CHEM, V270, P30168; Zutshi R, 1998, CURR OPIN CHEM BIOL, V2, P62, DOI 10.1016/S1367-5931(98)80036-7	48	71	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52338	52345		10.1074/jbc.M406185200	http://dx.doi.org/10.1074/jbc.M406185200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15448155	hybrid			2022-12-25	WOS:000225493400076
J	Fu, VX; Schwarze, SR; Kenowski, ML; LeBlanc, S; Svaren, J; Jarrard, DF				Fu, VX; Schwarze, SR; Kenowski, ML; LeBlanc, S; Svaren, J; Jarrard, DF			A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II GENE; BENIGN PROSTATIC HYPERPLASIA; BECKWITH-WIEDEMANN-SYNDROME; CPG-ISLAND METHYLATION; TUMOR SUPPRESSOR WT1; DNA METHYLATION; WILMS-TUMOR; COLORECTAL-CANCER; IGF2/H19 LOCUS; CTCF-BINDING	The imprinted insulin-like growth factor-2 (IGF2) gene is an auto/paracrine growth factor expressed only from the paternal allele in adult tissues. In tissues susceptible to aging-related cancers, including the prostate, a relaxation of IGF2 imprinting is found, suggesting a permissive role for epigenetic alterations in cancer development. To determine whether IGF2 imprinting is altered in cellular aging and senescence, human prostate epithelial and urothelial cells were passaged serially in culture to senescence. Allelic analyses using an IGF2 polymorphism demonstrated a complete conversion of the IGF2 imprint status from monoallelic to biallelic, in which the development of senescence was associated with a 10-fold increase in IGF2 expression. As a mechanism, a 2-fold decrease in the binding of the enhancer-blocking element CCCTC-binding factor (CTCF) within the intergenic IGF2-H19 region was found to underlie this switch to biallelic IGF2 expression in senescent cells. This decrease in CTCF binding was associated with reduced CTCF expression in senescent cells. No de novo increases in methylation at the IGF2 CTCF binding site were seen. The forced down-regulation of CTCF expression using small interfering RNA in imprinted prostate cell lines resulted in an increase in IGF2 expression and a relaxation of imprinting. Our data suggest a novel mechanism for IGF2 imprinting regulation, that is, the reduction of CTCF expression in the control of IGF2 imprinting. We also demonstrate that altered imprinting patterns contribute to changes in gene expression in aging cells.	Univ Wisconsin, Ctr Comprehens Canc, Dept Surg, Sch Vet Med, Madison, WI 53792 USA; Univ Wisconsin, Dept Environm & Mol Toxicol, Sch Vet Med, Madison, WI 53792 USA; Univ Wisconsin, Dept Comparat Biosci, Sch Vet Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jarrard, DF (corresponding author), Univ Wisconsin, Ctr Comprehens Canc, Dept Surg, Sch Vet Med, 600 Highland Ave,K6-530, Madison, WI 53792 USA.	jarrard@surgery.wisc.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921	NATIONAL CANCER INSTITUTE [K08CA076184, R01CA097131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA97131, K08CA76184] Funding Source: Medline; NIDDK NIH HHS [1P50DK065303] Funding Source: Medline; NIGMS NIH HHS [T32 GM08688] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDFORD MT, 1987, CANCER RES, V47, P5274; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BONNET P, 1993, J CLIN ENDOCR METAB, V77, P1203, DOI 10.1210/jc.77.5.1203; Campisi J, 2000, IN VIVO, V14, P183; CATANIA J, 1991, MUTAT RES, V256, P283, DOI 10.1016/0921-8734(91)90019-8; Catchpoole D, 2000, J MED GENET, V37, P212, DOI 10.1136/jmg.37.3.212; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; COHEN P, 1994, HORM METAB RES, V26, P81, DOI 10.1055/s-2007-1000777; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2001, CANCER RES, V61, P4947; Cui HM, 2002, CANCER RES, V62, P6442; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; Feinberg AP, 2000, CURR TOP MICROBIOL, V249, P87; Forne T, 1997, P NATL ACAD SCI USA, V94, P10243, DOI 10.1073/pnas.94.19.10243; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Jarrard DF, 1999, CANCER RES, V59, P2957; Jarrard DF, 1995, CLIN CANCER RES, V1, P1471; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Jones BK, 2002, HUM MOL GENET, V11, P411, DOI 10.1093/hmg/11.4.411; Kaffer CR, 2001, MOL CELL BIOL, V21, P8189, DOI 10.1128/MCB.21.23.8189-8196.2001; Lee YI, 1996, DNA CELL BIOL, V15, P99, DOI 10.1089/dna.1996.15.99; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lyons AB, 1999, IMMUNOL CELL BIOL, V77, P509, DOI 10.1046/j.1440-1711.1999.00864.x; Mazin A. L., 1993, Molekulyarnaya Biologiya (Moscow), V27, P895; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Pant V, 2003, GENE DEV, V17, P586, DOI 10.1101/gad.254903; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Reik W, 2000, INT J DEV BIOL, V44, P145; Reik W, 2001, ELECTROPHORESIS, V22, P2838, DOI 10.1002/1522-2683(200108)22:14&lt;2838::AID-ELPS2838&gt;3.0.CO;2-M; REZNIKOFF CA, 1983, IN VITRO CELL DEV B, V19, P326; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Sasaki H, 2000, J BIOCHEM, V127, P711, DOI 10.1093/oxfordjournals.jbchem.a022661; Schoenherr CJ, 2003, NAT GENET, V33, P66, DOI 10.1038/ng1057; Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; SINGHAL RP, 1987, MECH AGEING DEV, V41, P199, DOI 10.1016/0047-6374(87)90040-6; Slater M, 2000, HISTOCHEM J, V32, P357, DOI 10.1023/A:1004065630631; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tran CP, 2002, MOL CANCER RES, V1, P113; Ulaner GA, 2003, ENDOCRINOLOGY, V144, P4420, DOI 10.1210/en.2003-0681; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vu TH, 2000, GENOMICS, V64, P132, DOI 10.1006/geno.1999.6094; Zhan SL, 1998, BRAIN RES, V792, P283, DOI 10.1016/S0006-8993(98)00157-7; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	55	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52218	52226		10.1074/jbc.M405015200	http://dx.doi.org/10.1074/jbc.M405015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15471867	hybrid			2022-12-25	WOS:000225493400062
J	Uchida, T; Stevens, JM; Daltrop, O; Harvat, EM; Hong, L; Ferguson, SJ; Kitagawa, T				Uchida, T; Stevens, JM; Daltrop, O; Harvat, EM; Hong, L; Ferguson, SJ; Kitagawa, T			The interaction of covalently bound heme with the cytochrome c maturation protein CcmE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CHAPERONE CCME; SERRATIA-MARCESCENS; PROXIMAL HISTIDINE; LUCINA-PECTINATA; VINYL INFLUENCES; HEMOGLOBINS-M; M IWATE	The heme chaperone CcmE is a novel protein that binds heme covalently via a histidine residue as part of its essential function in the process of cytochrome c biogenesis in many bacteria as well as plant mitochondria. In the continued absence of a structure of the holoform of CcmE, identification of the heme ligands is an important step in understanding the molecular function of this protein and the role of covalent heme binding to CcmE during the maturation of c-type cytochromes. In this work, we present spectroscopic data that provide insight into the ligation of the heme iron in the soluble domain of CcmE from Escherichia coli. Resonance Raman spectra demonstrated that one of the heme axial ligands is a histidine residue and that the other is likely to be Tyr(134). In addition, the properties of the heme resonances of the holo-protein as compared with those of a form of CcmE with non-covalently bound heme provide evidence for the modification of one of the heme vinyl side chains by the protein, most likely the 2-vinyl group.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Aichi 4448787, Japan; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); University of Oxford	Kitagawa, T (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Aichi 4448787, Japan.	teizo@ims.ac.jp	Uchida, Takeshi/A-6455-2017	Uchida, Takeshi/0000-0001-9270-8329				ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; Agrawal V, 2003, CURR PROTEIN PEPT SC, V4, P195, DOI 10.2174/1389203033487207; Aki M, 2000, J PHYS CHEM B, V104, P10765, DOI 10.1021/jp000357p; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Arnesano F, 2002, BIOCHEMISTRY-US, V41, P13587, DOI 10.1021/bi026362w; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; BANGCHAROENPAURPONG O, 1987, J CHEM PHYS, V87, P4273, DOI 10.1063/1.452885; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; Cerda-Colon JF, 1998, J AM CHEM SOC, V120, P9312, DOI 10.1021/ja972654m; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; CHOI S, 1982, J AM CHEM SOC, V104, P4337, DOI 10.1021/ja00380a005; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P9703, DOI 10.1073/pnas.152120699; DESBOIS A, 1992, EUR BIOPHYS J BIOPHY, V20, P321, DOI 10.1007/BF00196591; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; Enggist E, 2003, J BACTERIOL, V185, P175, DOI 10.1128/JB.185.1.175-183.2003; Enggist E, 2002, STRUCTURE, V10, P1551, DOI 10.1016/S0969-2126(02)00885-7; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Fee JA, 2004, BIOCHEMISTRY-US, V43, P12162, DOI 10.1021/bi048968l; Gao F, 1998, BIOCHEMISTRY-US, V37, P9751, DOI 10.1021/bi9800653; Gao F, 1999, BBA-PROTEIN STRUCT M, V1430, P203, DOI 10.1016/S0167-4838(98)00284-2; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; HARADA I, 1986, SPECTROCHIM ACTA A, V42, P307, DOI 10.1016/0584-8539(86)80193-3; HARADA I, 1986, SPECTROSCOPY BIOL SY, V13; HU SH, 1992, FEBS LETT, V314, P293, DOI 10.1016/0014-5793(92)81492-5; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Jayaraman V, 1996, BIOSPECTROSCOPY, V2, P311, DOI 10.1002/(SICI)1520-6343(1996)2:5<311::AID-BSPY4>3.3.CO;2-L; Kincaid JR, 1996, J BIOL CHEM, V271, P28805, DOI 10.1074/jbc.271.46.28805; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; Ma JG, 1998, BIOCHEMISTRY-US, V37, P5118, DOI 10.1021/bi972375b; NAGAI K, 1983, BIOCHEMISTRY-US, V22, P1305, DOI 10.1021/bi00274a048; NAGAI M, 1989, BIOCHEMISTRY-US, V28, P2418, DOI 10.1021/bi00432a012; Nagai M, 2000, BIOCHEMISTRY-US, V39, P13093, DOI 10.1021/bi001029i; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Spielewoy N, 2001, J BIOL CHEM, V276, P5491, DOI 10.1074/jbc.M008853200; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Stevens JM, 2003, J BIOL CHEM, V278, P20500, DOI 10.1074/jbc.M212925200; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; TSUBAKI M, 1980, BIOCHEMISTRY-US, V19, P379, DOI 10.1021/bi00543a020; VERMA AL, 1988, J AM CHEM SOC, V110, P6617, DOI 10.1021/ja00228a004; Vu BC, 2002, J AM CHEM SOC, V124, P8544, DOI 10.1021/ja026569c; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	51	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51981	51988		10.1074/jbc.M408963200	http://dx.doi.org/10.1074/jbc.M408963200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465823	hybrid			2022-12-25	WOS:000225493400034
J	Kou, I; Ikegawa, S				Kou, I; Ikegawa, S			SOX9-dependent and -independent transcriptional regulation of human cartilage link protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; II COLLAGEN GENE; RETINOIC ACID; IN-VIVO; SOX9; CHONDROGENESIS; EXPRESSION; DIFFERENTIATION; COL2A1; TRANSACTIVATION	Cartilage link protein is a key component of the cartilage extracellular matrix. The transcriptional regulation of the gene encoding cartilage link protein (CRTL1) is largely unknown, however. Here, we investigated the regulation of CRTL1 by SOX9, a key regulator of cartilage matrix genes and chondrogenesis. Knockdown of SOX9 resulted in decreased CRTL1 expression. SOX9 induced CRTL1 expression effectively in human nonchondrocytic immortalized cell lines as well as in mesenchymal stem cell and adult dermal fibroblast. These results indicate that, like other cartilage matrix genes, SOX9 is a key regulator of CRTL1. Unlike other cartilage matrix genes, however, the activation of CRTL1 by SOX9 and its known transcriptional co-activators L-SOX5 and SOX6 was cell type-dependent. Two cis-acting enhancer elements resided in the 5'-untranslated region of CRTL1. One contained a heptameric SOX binding sequence and showed SOX9-dependent enhancer activity in several cell lines. The other showed cell type-specific SOX9-independent enhancer activity. These findings suggest that the enhancer elements may mediate differential expression of CRTL1 during chondrocyte differentiation and maturation.	Univ Tokyo, Inst Med Sci, RIKEN, SNP Res Ctr,Lab Bone & Joint Dis,Minato Ku, Tokyo 1088639, Japan	RIKEN; University of Tokyo	Ikegawa, S (corresponding author), Univ Tokyo, Inst Med Sci, RIKEN, SNP Res Ctr,Lab Bone & Joint Dis,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sikegawa@ims.u-tokyo.ac.jp	Ikegawa, Shiro/N-6895-2015	Ikegawa, Shiro/0000-0003-0316-2147				Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bernard P, 2003, HUM MOL GENET, V12, P1755, DOI 10.1093/hmg/ddg182; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BINETTE F, 1994, J BIOL CHEM, V269, P19116; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; Czipri M, 2003, J BIOL CHEM, V278, P39214, DOI 10.1074/jbc.M303329200; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDHIA J, 1994, BIOCHEM J, V303, P329, DOI 10.1042/bj3030329; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712; McKenna LA, 1998, ARTHRITIS RHEUM, V41, P157, DOI 10.1002/1529-0131(199801)41:1<157::AID-ART19>3.0.CO;2-J; MORGELIN M, 1988, BIOCHEM J, V253, P175; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; NEAME PJ, 1986, J BIOL CHEM, V261, P3519; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; RHODES C, 1995, NUCLEIC ACIDS RES, V23, P2305, DOI 10.1093/nar/23.12.2305; RHODES C, 1991, NUCLEIC ACIDS RES, V19, P1933, DOI 10.1093/nar/19.8.1933; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; Vornehm SI, 1996, MATRIX BIOL, V15, P91, DOI 10.1016/S0945-053X(96)90150-X; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; Zhang P, 2003, J BIOL CHEM, V278, P117, DOI 10.1074/jbc.M208049200; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	32	81	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50942	50948		10.1074/jbc.M406786200	http://dx.doi.org/10.1074/jbc.M406786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15456769	hybrid			2022-12-25	WOS:000225355800037
J	Maita, N; Hatakeyama, K; Okada, K; Hakoshima, T				Maita, N; Hatakeyama, K; Okada, K; Hakoshima, T			Structural basis of biopterin-induced inhibition of GTP cyclohydrolase I by GFRP, its feedback regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPA-RESPONSIVE DYSTONIA; CRYSTAL-STRUCTURE; TETRAHYDROBIOPTERIN; PURIFICATION; MUTATION; RAT; PHENYLALANINE; COMPLEXES; BINDING; CLONING	GTP cyclohydrolase I (GTPCHI) is the rate-limiting enzyme involved in the biosynthesis of tetrahydrobiopterin, a key cofactor necessary for nitric oxide synthase and for the hydroxylases that are involved in the production of catecholamines and serotonin. In animals, the GTPCHI feedback regulatory protein ( GFRP) binds GTPCHI to mediate feed-forward activation of GTPCHI activity in the presence of phenylalanine, whereas it induces feedback inhibition of enzyme activity in the presence of biopterin. Here, we have reported the crystal structure of the biopterin-induced inhibitory complex of GTPCHI and GFRP and compared it with the previously reported phenylalanine-induced stimulatory complex. The structure reveals five biopterin molecules located at each interface between GTPCHI and GFRP. Induced fitting structural changes by the biopterin binding expand large conformational changes in GTPCHI peptide segments forming the active site, resulting in inhibition of the activity. By locating 3,4-dihydroxyphenylalanine-responsive dystonia mutations in the complex structure, we found mutations that may possibly disturb the GFRP-mediated regulation of GTPCHI.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA; Jap Sci & Technol Agcy, CREST, Nara 6300192, Japan; Nara Inst Sci & Technol, Struct Biol Lab, Nara 6300192, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Japan Science & Technology Agency (JST); Nara Institute of Science & Technology	Hakoshima, T (corresponding author), Univ Pittsburgh, Dept Surg, 497 Scaife Hall, Pittsburgh, PA 15213 USA.	hakosima@bs.naist.jp	Maita, Nobuo/J-1443-2012	Maita, Nobuo/0000-0003-2260-5783	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051257] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51257] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auerbach G, 2000, P NATL ACAD SCI USA, V97, P13567, DOI 10.1073/pnas.240463497; Bader G, 2001, J MOL BIOL, V312, P1051, DOI 10.1006/jmbi.2001.5011; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brique S, 1999, NEUROREPORT, V10, P487, DOI 10.1097/00001756-199902250-00008; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cosentino F, 1998, J CLIN INVEST, V101, P1530, DOI 10.1172/JCI650; Erlandsen H, 2000, BIOCHEMISTRY-US, V39, P2208, DOI 10.1021/bi992531+; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; ICHINOSE H, 1995, J BIOL CHEM, V270, P10062, DOI 10.1074/jbc.270.17.10062; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Maita N, 2002, P NATL ACAD SCI USA, V99, P1212, DOI 10.1073/pnas.022646999; Maita N, 2001, ACTA CRYSTALLOGR D, V57, P1153, DOI 10.1107/S0907444901005558; Meininger CJ, 2000, BIOCHEM J, V349, P353, DOI 10.1042/0264-6021:3490353; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIEDERWIESER A, 1984, EUR J PEDIATR, V141, P208, DOI 10.1007/BF00572762; NYGAARD TG, 1995, CURR OPIN NEUROL, V8, P310, DOI 10.1097/00019052-199508000-00011; Pieper GM, 1997, J CARDIOVASC PHARM, V29, P8, DOI 10.1097/00005344-199701000-00002; Skrygan M, 2001, J INHERIT METAB DIS, V24, P345, DOI 10.1023/A:1010544316387; Steinberger D, 2000, NEUROLOGY, V55, P1735, DOI 10.1212/WNL.55.11.1735; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Tassin J, 2000, BRAIN, V123, P1112, DOI 10.1093/brain/123.6.1112; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Yoneyama T, 1997, J BIOL CHEM, V272, P9690; Yoneyama T, 2001, PROTEIN SCI, V10, P871, DOI 10.1110/ps.38501; Yoneyama T, 2001, ARCH BIOCHEM BIOPHYS, V388, P67, DOI 10.1006/abbi.2001.2288; Yoneyama T, 1998, J BIOL CHEM, V273, P20102, DOI 10.1074/jbc.273.32.20102	36	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51534	51540		10.1074/jbc.M409440200	http://dx.doi.org/10.1074/jbc.M409440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448133	hybrid			2022-12-25	WOS:000225355800107
J	Wang, W; Ungermannova, D; Chen, L; Liu, XD				Wang, W; Ungermannova, D; Chen, L; Liu, XD			Molecular and biochemical characterization of the Skp2-Cks1 binding interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27; BOX PROTEIN SKP2; CELL-CYCLE; DEPENDENT DEGRADATION; UBIQUITIN LIGASE; PHOSPHORYLATION; CANCER; CKS1; EXPRESSION; REGULATORS	SCFSkp2 is a multisubunit E3 ubiquitin ligase responsible for ubiquitination of cell cycle inhibitor p27. Ubiquitination of p27 requires an adapter protein, Cks1, to be in direct association with Skp2. The exact interface between Skp2 and Cks1 has not been elucidated. Here we have reported the definition of the critical functional interface between Skp2 and Cks1. We have identified eight amino acid residues in two discrete regions of Skp2 that are engaged in Cks1 binding. Mutation of any of these eight residues alone or in combination results in the loss of Cks1 association and negates Skp2-dependent p27 ubiquitination. These eight amino acid residues map on the same side of the Skp2 structure and likely constitute a functional binding surface for Cks1. Four of the eight amino acid residues are located in the largely unstructured carboxyl-terminal tail region of Skp2. These results uncovered the specificity of the Skp2-Cks1 interaction and reveal a critical function for the structurally flexible carboxyl-terminal tail region of Skp2 in Cks1 recognition and substrate ubiquitination.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Liu, XD (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	Xuedong.Liu@Colorado.edu		LIU, XUEDONG/0000-0001-7209-4964	NCI NIH HHS [CA107098-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Ganiatsas S, 2001, ONCOGENE, V20, P3641, DOI 10.1038/sj.onc.1204501; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hsiung YG, 2001, MOL CELL BIOL, V21, P2506, DOI 10.1128/MCB.21.7.2506-2520.2001; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang W, 2003, J BIOL CHEM, V278, P32390, DOI 10.1074/jbc.M305241200; Wang W, 2004, ONCOGENE, V23, P1064, DOI 10.1038/sj.onc.1207204; Xu K, 2003, BIOCHEM J, V371, P957, DOI 10.1042/BJ20021722; Yang G, 2002, CLIN CANCER RES, V8, P3419	29	13	14	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51362	51369		10.1074/jbc.M405944200	http://dx.doi.org/10.1074/jbc.M405944200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15452136	hybrid			2022-12-25	WOS:000225355800087
J	Wilkinson, SP; Grove, A				Wilkinson, SP; Grove, A			HucR, a novel uric acid-responsive member of the MarR family of transcriptional regulators from Deinococcus radiodurans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ANTIBIOTIC-RESISTANCE; PROTEIN SECONDARY STRUCTURE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CIRCULAR-DICHROISM SPECTRA; MULTIDRUG EFFLUX OPERON; MEXA-MEXB-OPRM; ESCHERICHIA-COLI; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; DNA-BINDING	The MarR family of transcriptional regulators comprises a subset of winged helix DNA-binding proteins and includes numerous members that function in environmental surveillance of aromatic compounds. We describe the characterization of HucR, a novel MarR homolog from Deinococcus radiodurans that demonstrates phenolic sensing capabilities. HucR binds as a homodimer to a single site within its promoter/operator region with K-d = 0.29 +/- 0.02 nM. The HucR binding site contains a pseudopalindromic sequence, composed of 8-bp half-sites separated by 2 bp. The location of the HucR binding site in the intergenic region between hucR and a putative uricase suggests a mechanism of simultaneous co-repression of these two genes. The substrate of uricase, uric acid, is an efficient antagonist of DNA binding, reducing HucR-DNA complex formation to 50% at 0.26 mM ligand, compared with 5.2 and 46 mM for the aromatic compounds salicylate and acetylsalicylate, respectively. Enhanced levels in vivo of hucR and uricase transcript and increased uricase activity under conditions of excess uric acid further indicate a novel regulatory mechanism of aromatic catabolism in D. radiodurans. Since uric acid is a scavenger of reactive oxygen species, we hypothesize that HucR is a participant in the intrinsic resistance of D. radiodurans to high levels of oxidative stress.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Wilkinson, SP (corresponding author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	swilki2@lsu.edu; agrove@lsu.edu	Grove, Anne/O-5998-2015	Grove, Anne/0000-0002-4390-0354; Wilkinson, Steven/0000-0002-8075-4448				Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067, DOI 10.1128/AAC.41.10.2067; Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Alekshun MN, 1999, J BACTERIOL, V181, P4669, DOI 10.1128/JB.181.15.4669-4672.1999; ARIZA RR, 1994, J BACTERIOL, V176, P143, DOI 10.1128/JB.176.1.143-148.1994; Ausubel F. M., 1998, CURRENT PROTOCOLS MO, V1; Battista JR, 1999, TRENDS MICROBIOL, V7, P362, DOI 10.1016/S0966-842X(99)01566-8; BONGAERTS GPA, 1976, J BACTERIOL, V125, P689, DOI 10.1128/JB.125.2.689-697.1976; Brooun A, 1999, J BACTERIOL, V181, P5131, DOI 10.1128/JB.181.16.5131-5133.1999; Buchmeier N, 1997, INFECT IMMUN, V65, P3725, DOI 10.1128/IAI.65.9.3725-3730.1997; CARBONNEAU MA, 1989, ARCH BIOCHEM BIOPHYS, V275, P244, DOI 10.1016/0003-9861(89)90370-6; Carra JH, 1997, BIOCHEMISTRY-US, V36, P526, DOI 10.1021/bi962206b; COHEN SP, 1993, J BACTERIOL, V175, P7856, DOI 10.1128/JB.175.24.7856-7862.1993; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; Dalrymple BP, 1997, MICROBIOL-SGM, V143, P1203, DOI 10.1099/00221287-143-4-1203; Diaz E, 2000, CURR OPIN BIOTECH, V11, P467, DOI 10.1016/S0958-1669(00)00126-9; Earl AM, 2002, J BACTERIOL, V184, P1003, DOI 10.1128/jb.184.4.1003-1009.2002; Egland PG, 1999, J BACTERIOL, V181, P2102, DOI 10.1128/JB.181.7.2102-2109.1999; Evans K, 2001, J BACTERIOL, V183, P807, DOI 10.1128/JB.183.3.807-812.2001; Felitsky DJ, 2003, BIOCHEMISTRY-US, V42, P2202, DOI 10.1021/bi0270992; Fuangthong M, 2001, J BACTERIOL, V183, P4134, DOI 10.1128/JB.183.14.4134-4141.2001; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Galan B, 2003, NUCLEIC ACIDS RES, V31, P6598, DOI 10.1093/nar/gkg851; HACHLER H, 1991, J BACTERIOL, V173, P5532; Hink HU, 2002, ARTERIOSCL THROM VAS, V22, P1402, DOI 10.1161/01.ATV.0000027524.86752.02; Imhoff RD, 2003, BIOCHEMISTRY-US, V42, P4094, DOI 10.1021/bi027377x; Kean RB, 2000, J IMMUNOL, V165, P6511, DOI 10.4049/jimmunol.165.11.6511; Kenney LJ, 2002, CURR OPIN MICROBIOL, V5, P135, DOI 10.1016/S1369-5274(02)00310-7; Lim D, 2002, J BIOL CHEM, V277, P29253, DOI 10.1074/jbc.M111381200; Lobley A, 2001, BIOPHYS J, V80, p373A; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Machin M, 2004, COMP BIOCHEM PHYS B, V137, P383, DOI 10.1016/j.cbpc.2004.01.002; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Markillie LM, 1999, J BACTERIOL, V181, P666, DOI 10.1128/JB.181.2.666-669.1999; MARTIN RG, 1995, P NATL ACAD SCI USA, V92, P5456, DOI 10.1073/pnas.92.12.5456; Meima R, 2001, J BACTERIOL, V183, P3169, DOI 10.1128/JB.183.10.3169-3175.2001; MISRA HP, 1976, ARCH BIOCHEM BIOPHYS, V176, P577, DOI 10.1016/0003-9861(76)90201-0; Moken MC, 1997, ANTIMICROB AGENTS CH, V41, P2770, DOI 10.1128/AAC.41.12.2770; Narumi I, 2001, J BACTERIOL, V183, P6951, DOI 10.1128/JB.183.23.6951-6956.2001; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; Ouhammouch M, 2001, EMBO J, V20, P146, DOI 10.1093/emboj/20.1.146; Poole K, 1996, ANTIMICROB AGENTS CH, V40, P2021, DOI 10.1128/AAC.40.9.2021; Providenti MA, 2001, APPL ENVIRON MICROB, V67, P3530, DOI 10.1128/AEM.67.8.3530-3541.2001; Rainey FA, 1997, INT J SYST BACTERIOL, V47, P510, DOI 10.1099/00207713-47-2-510; RAMSAY GD, 1994, METHOD ENZYMOL, V240, P615; Reverchon S, 2002, J BACTERIOL, V184, P654, DOI 10.1128/JB.184.3.654-665.2002; ROPER DI, 1993, MOL GEN GENET, V237, P241, DOI 10.1007/BF00282806; Rouanet C, 1999, J BACTERIOL, V181, P5948, DOI 10.1128/JB.181.19.5948-5957.1999; Sambrook J, 2001, MOL CLONING LAB MANU; Schultz AC, 2001, J BACTERIOL, V183, P3293, DOI 10.1128/JB.183.11.3293-3302.2001; Scott GS, 2002, P NATL ACAD SCI USA, V99, P16303, DOI 10.1073/pnas.212645999; SEOANE AS, 1995, J BACTERIOL, V177, P3414, DOI 10.1128/jb.177.12.3414-3419.1995; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Srikumar R, 2000, J BACTERIOL, V182, P1410, DOI 10.1128/JB.182.5.1410-1414.2000; SULAVIK MC, 1995, MOL MED, V1, P436, DOI 10.1007/BF03401581; SWEET DM, 1976, MUTAT RES, V34, P175, DOI 10.1016/0027-5107(76)90122-6; WANG P, 1995, CAN J MICROBIOL, V41, P170, DOI 10.1139/m95-023; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Xiong A, 2000, ANTIMICROB AGENTS CH, V44, P2905, DOI 10.1128/AAC.44.10.2905-2907.2000	59	92	99	7	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51442	51450		10.1074/jbc.M405586200	http://dx.doi.org/10.1074/jbc.M405586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15448166	Green Published, hybrid			2022-12-25	WOS:000225355800096
J	Ohali, A; Avigad, S; Zaizov, R; Ophir, R; Horn-Saban, S; Cohen, IJ; Meller, I; Kollender, Y; Issakov, J; Yaniv, I				Ohali, A; Avigad, S; Zaizov, R; Ophir, R; Horn-Saban, S; Cohen, IJ; Meller, I; Kollender, Y; Issakov, J; Yaniv, I			Prediction of high risk Ewing's sarcoma by gene expression profiling	ONCOGENE			English	Article						Ewing's sarcoma; high risk; gene expression signature; prediction; prognosis	METASTASIS-ASSOCIATED GENE; HUMAN MTA1 GENE; BREAST-CANCER; CADHERIN EXPRESSION; CELL-LINES; TUMORS; INVASION; DIFFERENTIATION; OVEREXPRESSION; CLASSIFICATION	Ewing's sarcoma (ES) is the second most common primary malignant bone tumor in children and adolescents. Currently accepted clinical prognostic factors fail to classify ES patients' risk to relapse at diagnosis. We aimed to find a new strategy to distinguish between poor and good prognosis ES patients already at diagnosis. We analysed the gene expression profiles of 14 primary tumor specimens and six metastases from ES patients, using oligonucleotide microarray analysis. The over-expression of two genes was validated by quantitative PCR using the LightCycler system. We identified two distinct gene expression signatures distinguishing high-risk ES patients that are likely to progress from low-risk ES patients with a favorable prognosis of long-term progression-free survival. The microarray-based classification was superior to currently used prognostic parameters. Over-expressed genes in the poor prognosis patients included genes regulating the cell cycle and genes associated with invasion and metastasis, while among the downregulated genes were tumor suppressor genes and inducers of apoptosis. Our results indicate the existence of a specific gene expression signature of outcome in ES already at diagnosis, and provide a strategy to select patients who would benefit from risk-adapted improved therapy.	Schneider Childrens Med Ctr Israel, Mol Oncol Lab, IL-49202 Petah Tiqwa, Israel; Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Biol Serv, DNA Array Unit, IL-76100 Rehovot, Israel; Sourasky Med Ctr, IL-64239 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Avigad, S (corresponding author), Schneider Childrens Med Ctr Israel, Mol Oncol Lab, 14 Kaplan St, IL-49202 Petah Tiqwa, Israel.	savigad@post.tau.ac.il	Cohen, Ian/H-3358-2013					Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fouts RL, 2003, CANCER-AM CANCER SOC, V97, P1447, DOI 10.1002/cncr.11201; GINSBERG JP, 2002, PRINCIPLES PRACTICE, P973; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Iguchi H, 2000, INT J ONCOL, V16, P1211; Im YH, 2000, CANCER RES, V60, P1536; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Markus MA, 1999, J PATHOL, V187, P164, DOI 10.1002/(SICI)1096-9896(199901)187:2<164::AID-PATH208>3.0.CO;2-3; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; NAWA A, 2000, INT J MED BIOL ENV, V28, P33; Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; OBERLENDER SA, 1994, CELL ADHES COMMUN, V2, P521, DOI 10.3109/15419069409014216; Park BW, 2003, BREAST CANCER RES TR, V80, P79, DOI 10.1023/A:1024406223619; Pishvaian MJ, 1999, CANCER RES, V59, P947; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schulz S, 2000, J PATHOL, V191, P162; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; Shin CS, 2000, J CELL BIOCHEM, V78, P566, DOI 10.1002/1097-4644(20000915)78:4<566::AID-JCB6>3.0.CO;2-K; Shing DC, 2003, CANCER RES, V63, P4568; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Terrier P, 1996, SEMIN DIAGN PATHOL, V13, P250; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	36	76	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8997	9006		10.1038/sj.onc.1208060	http://dx.doi.org/10.1038/sj.onc.1208060			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467746				2022-12-25	WOS:000225354600016
J	Hartman, J; Muller, P; Foster, JS; Wimalasena, J; Gustafsson, JA; Strom, A				Hartman, J; Muller, P; Foster, JS; Wimalasena, J; Gustafsson, JA; Strom, A			HES-1 inhibits 17 beta-estradiol and heregulin-beta 1-mediated upregulation of E2F-1	ONCOGENE			English	Article						all-trans retinoic acid; cell cycle; T47D; HES-6; HERP; NPAT; cyclin E	BREAST-CANCER CELLS; TRANSCRIPTION FACTOR E2F1; TRANS-RETINOIC ACID; CYCLE PROGRESSION; ESTROGEN-RECEPTOR; S-PHASE; EXPRESSION; GENE; DIFFERENTIATION; PROLIFERATION	We have previously shown that expression of the transcription factor HES-1 is required for the growth-inhibitory effect of all-trans retinoic acid on MCF-7 cells. In this study, we have used T47D cells with tetracyclin-regulated expression of wild-type or a dominant-negative form of HES-1. Expression of HES-1 in T47D cells inhibited G(1)/S-phase transition and activation of Cdk2 elicited by estrogen. Estrogen treatment of T47D cells caused increased expression of E2F-1, and this expression was inhibited by cotreatment with all-trans retinoic acid. We show that the effect is mediated through HES-1, which directly downregulates E2F-1 expression through a CACGAG-site within the E2F-1 promoter. Furthermore, proliferation caused by heregulin-beta1 treatment of T47D cells was inhibited by all-trans retinoic acid and this effect was mediated by HES-1. Interestingly, heregulin-beta1-mediated upregulation of E2F-1 expression was directly inhibited by HES-1 through the same CACGAG-site as seen with estrogen-stimulated induction. In addition, we found that two important downstream target genes of estrogen and heregulin-beta1 that are regulated through E2F-1, cyclin E and NPAT, were both regulated in a similar fashion by all-trans retinoic acid, and these effects were antagonized by dominant-negative HES-1. These findings establish that HES-1 inhibits both estrogen- and heregulin-beta1-stimulated growth of breast cancer cells, and further suggest that growth inhibition induced in these cells by all-trans retinoic acid occurs via HES-1-mediated downregulation of E2F-1 expression.	Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden; Univ Tennessee, Med Ctr, Grad Sch Med, Dept Obstet & Gynecol, Knoxville, TN 37920 USA; Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet; University of Tennessee System; University of Tennessee Health Science Center; Karolinska Institutet	Strom, A (corresponding author), Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.	anders.strom@biosci.ki.se	Hartman, Johan/N-1406-2015	Hartman, Johan/0000-0002-6500-8527				Bae SK, 2000, DEVELOPMENT, V127, P2933; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Gao G, 2003, MOL CELL BIOL, V23, P2821, DOI 10.1128/MCB.23.8.2821-2833.2003; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Jhabvala-Romero F, 2003, ONCOGENE, V22, P8178, DOI 10.1038/sj.onc.1206912; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MARTE BM, 1995, ONCOGENE, V10, P167; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Muller P, 2002, J BIOL CHEM, V277, P28376, DOI 10.1074/jbc.C200340200; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nygard M, 2003, MOL ENDOCRINOL, V17, P79, DOI 10.1210/me.2002-0107; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shen WH, 2004, J BIOL CHEM, V279, P7438, DOI 10.1074/jbc.M310264200; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Strom A, 2000, ONCOGENE, V19, P5951, DOI 10.1038/sj.onc.1203990; Swearingen ML, 2003, CANCER LETT, V198, P229, DOI 10.1016/S0304-3835(03)00313-6; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tang CK, 1996, CANCER RES, V56, P3350; TSUTSUI T, 1987, CARCINOGENESIS, V8, P1715, DOI 10.1093/carcin/8.11.1715; Wang Q, 2000, CANCER RES, V60, P2040; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	35	49	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8826	8833		10.1038/sj.onc.1208139	http://dx.doi.org/10.1038/sj.onc.1208139			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467735				2022-12-25	WOS:000225165100012
J	Chang, CH; Svedruzic, D; Ozarowski, A; Walker, L; Yeagle, G; Britt, RD; Angerhofer, A; Richards, NGJ				Chang, CH; Svedruzic, D; Ozarowski, A; Walker, L; Yeagle, G; Britt, RD; Angerhofer, A; Richards, NGJ			EPR spectroscopic characterization of the manganese center and a free radical in the oxalate decarboxylase reaction - Identification of a tyrosyl radical during turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; COLI RIBONUCLEOTIDE REDUCTASE; ELECTRON-SPIN-RESONANCE; BACILLUS-SUBTILIS YVRK; ESCHERICHIA-COLI; BIOCHEMICAL PATHWAYS; SUPEROXIDE-DISMUTASE; HAMMERHEAD RIBOZYME; PEROXYL RADICALS; LOW-TEMPERATURE	Several molecular mechanisms for cleavage of the oxalate carbon-carbon bond by manganese-dependent oxalate decarboxylase have recently been proposed involving high oxidation states of manganese. We have examined the oxalate decarboxylase from Bacillus subtilis by electron paramagnetic resonance in perpendicular and parallel polarization configurations to test for the presence of such species in the resting state and during enzymatic turnover. Simulation and the position of the half-field Mn(II) line suggest a nearly octahedral metal geometry in the resting state. No spectroscopic signature for Mn(III) or Mn(IV) is seen in parallel mode EPR for samples frozen during turnover, consistent either with a large zero-field splitting in the oxidized metal center or undetectable levels of these putative high-valent intermediates in the steady state. A narrow, featureless g = 2.0 species was also observed in perpendicular mode in the presence of substrate, enzyme, and dioxygen. Additional splittings in the signal envelope became apparent when spectra were taken at higher temperatures. Isotopic editing resulted in an altered line shape only when tyrosine residues of the enzyme were specifically deuterated. Spectral processing confirmed multiple splittings with isotopically neutral enzyme that collapsed to a single prominent splitting in the deuterated enzyme. These results are consistent with formation of an enzyme-based tyrosyl radical upon oxalate exposure. Modestly enhanced relaxation relative to abiological tyrosyl radicals was observed, but site-directed mutagenesis indicated that conserved tyrosine residues in the active site do not host the unpaired spin. Potential roles for manganese and a peripheral tyrosyl radical during steady-state turnover are discussed.	Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	State University System of Florida; University of Florida; University of California System; University of California Davis	Chang, CH (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.	cchang@chem.ufl.edu; richards@qtp.ufl.edu	Chang, Christopher H/A-1404-2012; Angerhofer, Alexander/E-3143-2010	Chang, Christopher H/0000-0003-3800-6021; Angerhofer, Alexander/0000-0002-8580-6024; Svedruzic, Drazenka/0000-0002-0229-7229	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK061193, R01DK053556, R56DK061666, R01DK061666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048242, R29GM048242] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK61193, DK61666, DK53556] Funding Source: Medline; NIGMS NIH HHS [GM48242] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAGAM A, 1970, ELECT PARAMAGNETIC R, P454; Adam W, 2000, J AM CHEM SOC, V122, P9685, DOI 10.1021/ja0005082; Adrait A, 2002, BIOCHEMISTRY-US, V41, P6510, DOI 10.1021/bi012043d; Anand R, 2002, BIOCHEMISTRY-US, V41, P7659, DOI 10.1021/bi0200965; BARRY BA, 1990, J BIOL CHEM, V265, P20139; Borodine A., 1861, LIEBIGS ANN CHEM, V119, P121, DOI 10.1002/jlac.18611190113; Campbell KA, 2001, J AM CHEM SOC, V123, P5710, DOI 10.1021/ja0027463; Campbell KA, 1999, J AM CHEM SOC, V121, P4714, DOI 10.1021/ja9902219; CHANDRA SK, 1990, INORG CHEM, V29, P2423, DOI 10.1021/ic00338a008; CHENBARRETT Y, 1995, BIOCHEMISTRY-US, V34, P7847, DOI 10.1021/bi00024a008; Dunwell JM, 1998, BIOTECHNOL GENET ENG, V15, P1; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Gerfen GJ, 1998, J AM CHEM SOC, V120, P3823, DOI 10.1021/ja972166e; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; Hunsdiecker H., 1942, CHEM BER, V75, P291, DOI DOI 10.1002/CBER.19420750309; JOHNSON RG, 1956, CHEM REV, V56, P219, DOI 10.1021/cr50008a002; Katterle B, 1997, J BIOL CHEM, V272, P10414; KESSISSOGLOU DP, 1987, INORG CHEM, V26, P2487, DOI 10.1021/ic00262a030; KIM HW, 1990, FEBS LETT, V272, P34, DOI 10.1016/0014-5793(90)80442-L; Kolbe H., 1849, LIEBIGS ANN CHEM, V69, P257, DOI DOI 10.1002/JLAC.18490690302; Krzystek J, 2003, INORG CHEM, V42, P4610, DOI 10.1021/ic020712l; Lassmann G, 2003, PHYS CHEM CHEM PHYS, V5, P2442, DOI 10.1039/b302601a; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; Lide D. R., 1997, CRC HDB CHEM PHYS, P5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Mendes P, 1998, BIOINFORMATICS, V14, P869, DOI 10.1093/bioinformatics/14.10.869; Morrissey SR, 2000, J AM CHEM SOC, V122, P3473, DOI 10.1021/ja992989z; PADMAKUMAR R, 1995, J BIOL CHEM, V270, P9295, DOI 10.1074/jbc.270.16.9295; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P5712, DOI 10.1021/bi00017a002; Rajendiran TM, 2002, INORG CHIM ACTA, V339, P497, DOI 10.1016/S0020-1693(02)00956-8; Reddy SG, 1998, BIOCHEMISTRY-US, V37, P558, DOI 10.1021/bi972086n; Reed G., 1984, BIOL MAGN RESON, V6, P73; REED GH, 1995, METHOD ENZYMOL, V258, P362; Reinhardt LA, 2003, J AM CHEM SOC, V125, P1244, DOI 10.1021/ja0286977; Rogers PA, 2001, J BIOL CHEM, V276, P30980, DOI 10.1074/jbc.M101037200; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; STALLINGS WC, 1985, J BIOL CHEM, V260, P6424; STOLL S, 2003, THESIS EIDGENOSSISCH; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; Svistunenko DA, 2001, BBA-PROTEIN STRUCT M, V1546, P365, DOI 10.1016/S0167-4838(01)00157-1; Tanner A, 2000, J BACTERIOL, V182, P5271, DOI 10.1128/JB.182.18.5271-5273.2000; Tanner A, 2001, J BIOL CHEM, V276, P43627, DOI 10.1074/jbc.M107202200; TOMMOS C, 1995, J AM CHEM SOC, V117, P10325, DOI 10.1021/ja00146a017; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; van der Donk WA, 1998, BIOCHEMISTRY-US, V37, P6419, DOI 10.1021/bi9729357; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003; VIJH AK, 1967, CHEM REV, V67, P623, DOI 10.1021/cr60250a003; Vogt M, 2003, ACS SYM SER, V858, P193; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WEIL JA, 1994, ELECT PARAMAGNETIC R, P321; Weyhermuller T, 2002, INORG CHIM ACTA, V337, P344, DOI 10.1016/S0020-1693(02)01000-9; Whiting AK, 1996, BIOCHEMISTRY-US, V35, P160, DOI 10.1021/bi951979h; Whittaker MM, 2002, J BIOL INORG CHEM, V7, P136, DOI 10.1007/s007750100281; YANEZ J, 1987, J PHYS CHEM-US, V91, P487, DOI 10.1021/j100286a044	58	38	39	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52840	52849		10.1074/jbc.M402345200	http://dx.doi.org/10.1074/jbc.M402345200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15475346	hybrid			2022-12-25	WOS:000225680600008
J	Codina, A; Benoit, G; Gooch, JT; Neuhaus, D; Perlmann, T; Schwabe, JWR				Codina, A; Benoit, G; Gooch, JT; Neuhaus, D; Perlmann, T; Schwabe, JWR			Identification of a novel co-regulator interaction surface on the ligand binding domain of Nurr1 using NMR footprinting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR ACTIVATION; COACTIVATOR RECRUITMENT; HORMONE-RECEPTORS; MEDIATES TRANSACTIVATION; MOLECULAR DETERMINANTS; COREPRESSOR BINDING; STRUCTURAL BASIS; SPECTROSCOPY; MECHANISM; ALPHA	The nuclear receptor Nurr1 is a transcription factor essential for the development of midbrain dopaminergic neurons in vertebrates. Recent crystal structures of the Nurr1 ligand binding domain (LBD) and the Drosophila orthologue dHR38 revealed that, although these receptors share the classical LBD architecture, they lack a ligand binding cavity. This volume is instead filled with bulky hydrophobic side chains. Furthermore the "canonical" non-polar co-regulator binding groove is filled with polar side chains; thus, the regulation of transcription by this sub-family of nuclear receptor LBDs may be mediated by some other interaction surface on the LBD. We report here the identification of a novel co-regulator interface on the LBD of Nurr1. We used an NMR footprinting strategy that facilitates the identification of an interaction surface without the need of a full assignment. We found that non-polar peptides derived from the co-repressors SMRT and NCoR bind to a hydrophobic patch on the LBD of Nurr1. This binding surface involves a groove between helices 11 and 12. Mutations in this site abolish activation by the Nurr1 LBD. These findings give insight into the unique mechanism of action of this class of nuclear receptors.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden	MRC Laboratory Molecular Biology; Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research	Schwabe, JWR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	john.schwabe@mrc-lmb.cam.ac.uk	Schwabe, John WR/A-9132-2008	Schwabe, John WR/0000-0003-2865-4383; BENOIT, Gerard/0000-0001-9462-6570				Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Benko S, 2003, J BIOL CHEM, V278, P43797, DOI 10.1074/jbc.M306199200; Buervenich S, 2000, AM J MED GENET, V96, P808, DOI 10.1002/1096-8628(20001204)96:6<808::AID-AJMG23>3.0.CO;2-E; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Codina A, 2002, J BIOMOL NMR, V22, P295, DOI 10.1023/A:1014988206967; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Escriva H, 2000, BIOESSAYS, V22, P717; Galleguillos D, 2004, J BIOL CHEM, V279, P2005, DOI 10.1074/jbc.M308113200; Goodford P, 1996, J CHEMOMETR, V10, P107; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Iannone MA, 2001, CYTOMETRY, V44, P326, DOI 10.1002/1097-0320(20010801)44:4<326::AID-CYTO1124>3.0.CO;2-4; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Johnson BA, 2000, J MOL BIOL, V298, P187, DOI 10.1006/jmbi.2000.3636; Kallenberger BC, 2003, NAT STRUCT BIOL, V10, P136, DOI 10.1038/nsb892; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maruyama K, 1998, INT J ONCOL, V12, P1237; Nagy L, 2004, TRENDS BIOCHEM SCI, V29, P317, DOI 10.1016/j.tibs.2004.04.006; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Reese ML, 2003, J AM CHEM SOC, V125, P14250, DOI 10.1021/ja037640x; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; SCHWABE J, 2004, SCI STKE; Sohn YC, 2001, J BIOL CHEM, V276, P43734, DOI 10.1074/jbc.M107208200; Thornton JW, 2003, SCIENCE, V301, P1714, DOI 10.1126/science.1086185; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	34	47	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53338	53345		10.1074/jbc.M409096200	http://dx.doi.org/10.1074/jbc.M409096200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15456745	hybrid			2022-12-25	WOS:000225680600066
J	Lee, JM; Kim, YS; Choi, DH; Bang, MS; Han, TR; Joh, TH; Kim, SY				Lee, JM; Kim, YS; Choi, DH; Bang, MS; Han, TR; Joh, TH; Kim, SY			Transglutaminase 2 induces nuclear factor-kappa B activation via a novel pathway in BV-2 microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-TYPE TRANSGLUTAMINASE; CROSS-LINKING; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; CELIAC-DISEASE; MESSENGER-RNA; EXTRACELLULAR MATRICES; INCREASED EXPRESSION; PARKINSONS-DISEASE; ELASTASE INHIBITOR	Transglutaminase 2 (TGase 2) expression is increased in inflammatory diseases. We demonstrated previously that inhibitors of TGase 2 reduce nitric oxide ( NO) generation in a lipopolysaccharide (LPS)-treated microglial cell line. However, the precise mechanism by which TGase 2 promotes inflammation remains unclear. We found that TGase 2 activates the transcriptional activator nuclear factor (NF)-kappaB and thereby enhances LPS-induced expression of inducible nitric-oxide synthase. TGase 2 activates NF-kappaB via a novel pathway. Rather than stimulating phosphorylation and degradation of the inhibitory subunit alpha of NF-kappaB (I-kappaBalpha), TGase2 induces its polymerization. This polymerization results in dissociation of NF-kappaB and its translocation to the nucleus, where it is capable of up-regulating a host of inflammatory genes, including inducible nitric-oxide synthase and tumor necrosis factor alpha (TNF-alpha). Indeed, TGase inhibitors prevent depletion of monomeric I-kappaBalpha in the cytosol of cells overexpressing TGase 2. In an LPS-induced rat brain injury model, TGase inhibitors significantly reduced TNF-alpha synthesis. The findings are consistent with a model in which LPS-induced NF-kappaB activation is the result of phosphorylation of I-kappaBalpha by I-kappaB kinase as well as I-kappaBalpha polymerization by TGase 2. Safe and stable TGase2 inhibitors may be effective agents in diseases associated with inflammation.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, White Plains, NY 10605 USA; Burke Med Res Inst, White Plains, NY 10605 USA; Seoul Natl Univ, Coll Med, Dept Rehabil Med, Seoul 110744, South Korea	Cornell University; Seoul National University (SNU)	Kim, SY (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, White Plains, NY 10605 USA.	tgase@hanmail.net	Han, Tai Ryoon/J-5712-2012; Bang, Moon Suk/J-5501-2012					Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; Andringa G, 2004, FASEB J, V18, P932, DOI 10.1096/fj.03-0829fje; Antonyak MA, 2003, J BIOL CHEM, V278, P15859, DOI 10.1074/jbc.M300037200; Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; BAKER H, 1993, BRAIN RES, V614, P109, DOI 10.1016/0006-8993(93)91023-L; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; Bowness JM, 1997, MOL CELL BIOCHEM, V169, P157, DOI 10.1023/A:1006846400478; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; BRUCE SE, 1985, CLIN SCI, V68, P573, DOI 10.1042/cs0680573; Campisi A, 2003, BRAIN RES, V978, P24, DOI 10.1016/S0006-8993(03)02725-2; Catania A, 1998, ANN NY ACAD SCI, V856, P62, DOI 10.1111/j.1749-6632.1998.tb08313.x; Choi YC, 2000, J BIOL CHEM, V275, P8703, DOI 10.1074/jbc.275.12.8703; Choi YC, 2004, EUR NEUROL, V51, P10, DOI 10.1159/000074911; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995; Dedeoglu A, 2002, J NEUROSCI, V22, P8942; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Dieterich W, 1999, J INVEST DERMATOL, V113, P133, DOI 10.1046/j.1523-1747.1999.00627.x; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; Fujita K, 1998, NEUROCHEM RES, V23, P557, DOI 10.1023/A:1022442904179; Fujita K, 1998, J NEUROL SCI, V158, P53, DOI 10.1016/S0022-510X(98)00088-4; Gibson GE, 2002, BBA-MOL BASIS DIS, V1586, P177, DOI 10.1016/S0925-4439(01)00091-6; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gross SR, 2003, J INVEST DERMATOL, V121, P412, DOI 10.1046/j.1523-1747.2003.12353.x; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; Isobe T, 1999, EUR J CELL BIOL, V78, P876, DOI 10.1016/S0171-9335(99)80089-2; Junn E, 2003, P NATL ACAD SCI USA, V100, P2047, DOI 10.1073/pnas.0438021100; Karpuj MV, 2002, NAT MED, V8, P143, DOI 10.1038/nm0202-143; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Kim SY, 2002, NEUROCHEM INT, V40, P85, DOI 10.1016/S0197-0186(01)00064-X; Kim SY, 2002, J INTERF CYTOK RES, V22, P677, DOI 10.1089/10799900260100169; Kim SY, 1997, BIOCHEM BIOPH RES CO, V233, P39, DOI 10.1006/bbrc.1997.6407; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; Lampasona V, 1999, DIABETOLOGIA, V42, P1195, DOI 10.1007/s001250051291; Lentsch AB, 1999, AM J PATHOL, V154, P239, DOI 10.1016/S0002-9440(10)65270-4; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; LEU RW, 1982, EXP CELL RES, V141, P191, DOI 10.1016/0014-4827(82)90081-7; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; LORAND L, 1976, P NATL ACAD SCI USA, V73, P4479, DOI 10.1073/pnas.73.12.4479; McGeer PL, 2001, ADV NEUROL, V86, P83; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; MIRZA A, 1997, AM J PHYSIOL, V272, P281; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; MURTAUGH MP, 1983, J BIOL CHEM, V258, P1074; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; NOVOGRODSKY A, 1978, P NATL ACAD SCI USA, V75, P1157, DOI 10.1073/pnas.75.3.1157; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; Park KC, 2004, BIOCHEM BIOPH RES CO, V323, P1055, DOI 10.1016/j.bbrc.2004.08.204; Piacentini M, 2002, J NEUROCHEM, V81, P1061; Picarelli A, 2003, CLIN CHEM, V49, P2091, DOI 10.1373/clinchem.2003.023234; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Quan N, 1997, P NATL ACAD SCI USA, V94, P10985, DOI 10.1073/pnas.94.20.10985; Roberts ES, 2003, AM J PATHOL, V162, P2041, DOI 10.1016/S0002-9440(10)64336-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sanchez D, 2000, J AUTOIMMUN, V15, P441, DOI 10.1006/jaut.2000.0452; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCOTT KFF, 1982, P NATL ACAD SCI-BIOL, V79, P4093, DOI 10.1073/pnas.79.13.4093; Shin DM, 2004, J BIOL CHEM, V279, P15032, DOI 10.1074/jbc.M308734200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937; Taggart CC, 2002, J BIOL CHEM, V277, P33648, DOI 10.1074/jbc.M203710200; Ueki S, 1996, J CELL SCI, V109, P2727; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; WEINBERG JB, 1991, ARTHRITIS RHEUM, V34, P996, DOI 10.1002/art.1780340809	75	148	152	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53725	53735		10.1074/jbc.M407627200	http://dx.doi.org/10.1074/jbc.M407627200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15471861	hybrid			2022-12-25	WOS:000225680600110
J	Li, QY; Kaneko, S; Yang, L; Feldman, RI; Nicosia, SV; Chen, JD; Cheng, JQ				Li, QY; Kaneko, S; Yang, L; Feldman, RI; Nicosia, SV; Chen, JD; Cheng, JQ			Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR PROTEIN P53; HUMAN OVARIAN-CANCER; CENTROSOME AMPLIFICATION; CELL-LINES; CHROMOSOME SEGREGATION; MESSENGER-RNA; HUMAN TUMORS; KINASE; ACTIVATION; MDM2	The tumor suppressor p53 is important in the decision to either arrest cell cycle progression or induce apoptosis in response to a variety of stimuli. p53 post-translational modifications and association with other proteins have been implicated in the regulation of its stability and transactivation activity. Here we show that p53 is phosphorylated by the mitotic kinase Aurora-A at serine 215. Unlike most identified phosphorylation sites of p53 that positively associate with p53 function (Brooks, C. L., and Gu, W. (2003) Curr. Opin. Cell Biol. 15, 164-171), the phosphorylation of p53 by Aurora-A at Ser-215 abrogates p53 DNA binding and transactivation activity. Downstream target genes of p53, such as p21(Cip/WAF1) and PTEN, were inhibited by Aurora-A in a Ser-215 phosphorylation-dependent manner (i.e. phosphomimic p53-S215D lost and non-phosphorylatable p53-S215A retained normal p53 function). As a result, Aurora-A overrides the apoptosis and cell cycle arrest induced by cisplatin and gamma-irradiation, respectively. However, the effect of Aurora-A on p53 DNA binding and transactivation activity was not affected by phosphorylation of Ser-315, a recently identified Aurora-A phosphorylation site of p53 (Katayama, H., Sasai, K., Kawai, H., Yuan, Z. M., Bondaruk, J., Suzuki, F., Fujii, S., Arlinghaus, R. B., Czerniak, B. A., and Sen, S. (2004) Nat. Genet. 36, 55-62). Our data indicate that phosphorylation of p53 at Ser-215 by Aurora-A is a major mechanism to inactivate p53 and can provide a molecular insight for Aurora-A function.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Berlex Labs Inc, Biosci, Dept Canc Res, Richmond, CA 94804 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Cheng, JQ (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC Box 11, Tampa, FL 33612 USA.	jcheng@hsc.usf.edu						Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Ausubel F., 1999, CURRENT PROTOCOLS MO; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Castro A, 2003, J BIOL CHEM, V278, P2236, DOI 10.1074/jbc.M207894200; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Fraser M, 2003, CANCER RES, V63, P7081; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Goepfert TM, 2002, CANCER RES, V62, P4115; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Higuchi T, 2003, NATURE, V426, P780, DOI 10.1038/426780a; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; LE GP, 1994, J BIOL CHEM, V269, P4458; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Scrittori L, 2001, J BIOL CHEM, V276, P30002, DOI 10.1074/jbc.M102701200; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	37	94	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52175	52182		10.1074/jbc.M406802200	http://dx.doi.org/10.1074/jbc.M406802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15469940	hybrid			2022-12-25	WOS:000225493400057
J	van der Sanden, MHM; Meems, H; Houweling, M; Helms, JB; Vaandrager, AB				van der Sanden, MHM; Meems, H; Houweling, M; Helms, JB; Vaandrager, AB			Induction of CCAAT/enhancer-binding protein (C/EBP)-homologous protein/growth arrest and DNA damage-inducible protein 153 expression during inhibition of phosphatidylcholine synthesis is mediated via activation of a C/EBP-activating transcription factor-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ENDOPLASMIC-RETICULUM STRESS; SIGNAL-TRANSDUCTION PATHWAYS; HAMSTER OVARY CELLS; N-TERMINAL KINASE; MESSENGER-RNA; PHOSPHOLIPID-METABOLISM; GENE-TRANSCRIPTION; CHOP EXPRESSION; APOPTOSIS	The gene for the proapoptotic transcription factor CCAAT/enhancer-binding protein (C/EBP)-homologous protein/growth arrest and DNA damage-inducible protein 153 (CHOP/GADD153) is induced by various cellular stresses. Previously, we described that inhibition of phosphatidylcholine (PC) synthesis in MT58 cells, which contain a temperature-sensitive mutation in CTP: phosphocholine cytidylyltransferase (CT), results in apoptosis preceded by the induction of CHOP. Here we report that prevention of CHOP induction, by expression of antisense CHOP, delays the PC depletion-induced apoptotic process. By mutational analysis of the conserved region in the promoter of the CHOP gene, we provide evidence that the C/EBP-ATF composite site, but not the ER stress-responsive element or the activator protein-1 site, is required for the increased expression of CHOP during PC depletion. Inhibition of PC synthesis in MT58 cells also led to an increase in phosphorylation of the stress-related transcription factor ATF2 and the stress kinase JNK after 8 and 16 h, respectively. In contrast, no phosphorylation of p38 MAPK was observed in MT58 cultured at the nonpermissive temperature. Treatment of MT58 cells with the JNK inhibitor SP600125 could rescue the cells from apoptosis but did not inhibit the phosphorylation of ATF2 or the induction of CHOP. Taken together, our results suggest that increased expression of CHOP during PC depletion depends on a C/EBP-ATF element in its promoter and might be mediated by binding of ATF2 to this element.	Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3508 TD Utrecht, Netherlands	Utrecht University; Utrecht University	Vaandrager, AB (corresponding author), Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, POB 80176, NL-3508 TD Utrecht, Netherlands.	A.B.Vaandrager@vet.uu.nl		Vaandrager, Arie/0000-0001-9394-9239				Alonso CR, 1996, J BIOL CHEM, V271, P22271, DOI 10.1074/jbc.271.36.22271; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BAN N, 2000, DIABETES, V49, P3819; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KISS Z, 1990, PROG LIPID RES, V29, P141, DOI 10.1016/0163-7827(90)90001-2; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Porter AC, 1999, ONCOGENE, V18, P7794, DOI 10.1038/sj.onc.1203214; PRICE BD, 1992, J CELL PHYSIOL, V152, P545, DOI 10.1002/jcp.1041520314; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; Sevilla A, 2004, J BIOL CHEM, V279, P27458, DOI 10.1074/jbc.M401009200; SHENG W, 2003, ONCOGENE, V22, P955; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Van der Sanden MHM, 2003, BIOCHEM J, V369, P643, DOI 10.1042/BJ20020285; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	62	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52007	52015		10.1074/jbc.M405577200	http://dx.doi.org/10.1074/jbc.M405577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15466475	hybrid			2022-12-25	WOS:000225493400037
J	Pierreux, CE; Vanhorenbeeck, V; Jacquemin, P; Lemaigre, FP; Rousseau, GG				Pierreux, CE; Vanhorenbeeck, V; Jacquemin, P; Lemaigre, FP; Rousseau, GG			The transcription factor hepatocyte nuclear factor-6/Onecut-1 controls the expression of its paralog Onecut-3 in developing mouse endoderm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN MEMBER; CELL LINES; LIVER; HOMEODOMAIN; GENE; DIFFERENTIATION; PANCREAS; HNF-6; ACTIVATOR; PROTEINS	During development, the endoderm gives rise to several organs, including the pancreas and liver. This differentiation process requires spatial and temporal regulation of gene expression in the endoderm by a network of tissue-specific transcription factors whose elucidation is far from complete. These factors include the Onecut protein hepatocyte nuclear factor-6 (HNF-6), which controls pancreas and liver development as shown in our previous work on Hnf6 knock-out embryos. In mammals, HNF-6 has two paralogs, Onecut-2 (OC-2) and OC-3, whose patterns of expression in the adult overlap with that of HNF-6. In the present work, we examine the expression profile of the three Onecut factors in the developing mouse endoderm. We show that HNF-6, OC-2, and OC-3 are expressed sequentially, which defines new steps in endoderm differentiation. By analyzing Hnf6 knock-out embryos we find that HNF-6 is required for expression of the Oc3 gene in the endoderm. We show that OC-3 colocalizes with HNF-6 in the endoderm and in embryonic pancreas and liver. Based on transfection, chromatin immunoprecipitation, and whole embryo electroporation experiments, we demonstrate that HNF-6 can bind to and stimulate the expression of the Oc3 gene. This study identifies a regulatory cascade between two paralogous transcription factors, sheds new light on the interpretation of the Hnf6 knock-out phenotype, and broadens the transcription factors network operating during development of the endoderm, liver, and pancreas.	Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium	Universite Catholique Louvain	Rousseau, GG (corresponding author), ICP URL, HORM Unit, Box 7529,75 Ave Hippocrate, B-1200 Brussels, Belgium.	christophe.pierreux@horm.ucl.ac.be	Jacquemin, Patrick/ABA-7932-2021	Lemaigre, Frederic/0000-0002-3609-434X				Briancon N, 2004, J BIOL CHEM, V279, P33398, DOI 10.1074/jbc.M405312200; Burke Z, 2002, MECH DEVELOP, V118, P147, DOI 10.1016/S0925-4773(02)00240-X; Clotman F, 2002, DEVELOPMENT, V129, P1819; Grapin-Botton A, 2000, TRENDS GENET, V16, P124, DOI 10.1016/S0168-9525(99)01957-5; Hong SK, 2002, MECH DEVELOP, V112, P199, DOI 10.1016/S0925-4773(01)00647-5; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jacquemin P, 2003, GENE EXPR PATTERNS, V3, P639, DOI 10.1016/S1567-133X(03)00110-8; Jacquemin P, 2003, DEV BIOL, V258, P105, DOI 10.1016/S0012-1606(03)00115-5; Jacquemin P, 1999, J BIOL CHEM, V274, P2665, DOI 10.1074/jbc.274.5.2665; Jensen J, 2004, DEV DYNAM, V229, P176, DOI 10.1002/dvdy.10460; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; Maestro MA, 2003, HUM MOL GENET, V12, P3307, DOI 10.1093/hmg/ddg355; Nguyen DNT, 2000, MECH DEVELOP, V97, P57, DOI 10.1016/S0925-4773(00)00431-7; Nowling T, 2003, J BIOL CHEM, V278, P13696, DOI 10.1074/jbc.M207567200; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; PLUMBRUDEWIEZ N, 2004, IN PRESS HEPATOLOGY; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Servitja JM, 2004, DIABETOLOGIA, V47, P597, DOI 10.1007/s00125-004-1368-9; Streeper RS, 2001, J BIOL CHEM, V276, P19111, DOI 10.1074/jbc.M101442200; Strick-Marchand H, 2004, P NATL ACAD SCI USA, V101, P8360, DOI 10.1073/pnas.0401092101; Strick-Marchand H, 2002, HEPATOLOGY, V36, P794, DOI 10.1053/jhep.2002.36123; van Eyll JM, 2004, J CELL SCI, V117, P2077, DOI 10.1242/jcs.01067; Vanhorenbeeck V, 2002, BIOCHEM BIOPH RES CO, V292, P848, DOI 10.1006/bbrc.2002.6760; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393	27	30	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51298	51304		10.1074/jbc.M409038200	http://dx.doi.org/10.1074/jbc.M409038200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15381696	hybrid			2022-12-25	WOS:000225355800079
J	Chauchereau, A; Mathieu, M; de Saintignon, J; Ferreira, R; Pritchard, LL; Mishal, Z; Dejean, A; Harel-Bellan, A				Chauchereau, A; Mathieu, M; de Saintignon, J; Ferreira, R; Pritchard, LL; Mishal, Z; Dejean, A; Harel-Bellan, A			HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF	ONCOGENE			English	Article						PLZF; HDAC; PLZF-RAR alpha	ACID RECEPTOR-ALPHA; II HISTONE DEACETYLASES; SERUM RESPONSE FACTOR; RAR-ALPHA; MUSCLE DIFFERENTIATION; NUCLEAR EXPORT; POZ DOMAIN; COREPRESSOR; COMPLEX; SMRT	PLZF, the promyelocytic leukaemia zinc-finger protein, is a transcriptional repressor essential to development. In some acute leukaemias, a chromosomal translocation fusing the PLZF gene to that encoding the retinoic acid receptor RARalpha gives rise to a fusion protein, PLZF RARa, thought to be responsible for constitutive repression of differentiation-associated genes in these cells. Repression by both PLZF and PLZF-RARalpha is sensitive to the histone deacetylase inhibitor TSA, and PLZF was previously shown to interact physically with HDAC1, a class I histone deacetylase. We here asked whether class II histone deacetylases, known to be generally involved in differentiation processes, participate in the repression mediated by PLZF and PLZF-RARalpha, and found that PLZF interacts with HDAC4 in both GST-pull-down and co-immunoprecipitation assays. Furthermore, HDAC4 is indeed involved in PLZF and PLZF-RARalpha-mediated repression, since an enzymatically dead mutant of HDAC4 released the repression, as did an siRNA that blocks HDAC4 expression. Taken together, our data indicate that recruitment of HDAC4 is necessary for PLZF-mediated repression in both normal and leukaemic cells.	Inst Andre Lwoff, CNRS, UPR 9079, F-94800 Villejuif, France; Inst Andre Lwoff, Lab Cytometrie, F-94800 Villejuif, France; Inst Pasteur, INSERM, U579, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Harel-Bellan, A (corresponding author), Inst Andre Lwoff, CNRS, UPR 9079, 7 Rue Guy Moquet, F-94800 Villejuif, France.	ahbellan@vjf.cnrs.fr	Chauchereau, Anne/N-8880-2016; Dejean, Anne/L-5145-2018; Harel-Bellan, Annick/M-9795-2015; CHAUCHEREAU, Anne/B-1074-2009	Chauchereau, Anne/0000-0001-9447-3797; MATHIEU, Marion/0000-0002-1815-2112; Harel-Bellan, Annick/0000-0002-2339-153X				AHMED N, 1993, BIOCHEM MOL BIOL INT, V29, P1055; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Borghi S, 2001, J CELL SCI, V114, P4477; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davis FJ, 2003, J BIOL CHEM, V278, P20047, DOI 10.1074/jbc.M209998200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Groisman R, 1996, J BIOL CHEM, V271, P5258; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Licht JD, 1996, ONCOGENE, V12, P323; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Senbonmatsu T, 2003, EMBO J, V22, P6471, DOI 10.1093/emboj/cdg637; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Watamoto K, 2003, ONCOGENE, V22, P9176, DOI 10.1038/sj.onc.1206902; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	47	62	65	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8777	8784		10.1038/sj.onc.1208128	http://dx.doi.org/10.1038/sj.onc.1208128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467736				2022-12-25	WOS:000225165100007
J	Ciais, D; Cherradi, N; Bailly, S; Grenier, E; Berra, E; Pouyssegur, J; LaMarre, J; Feige, JJ				Ciais, D; Cherradi, N; Bailly, S; Grenier, E; Berra, E; Pouyssegur, J; LaMarre, J; Feige, JJ			Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b	ONCOGENE			English	Article						VEGF; TIS11b; mRNA stability; AU-rich element	IN-VIVO; TRISTETRAPROLIN; STABILITY; CELLS; DEADENYLATION; STABILIZATION; DEGRADATION; HYPOXIA; PATHWAY; ELEMENT	Vascular endothelial growth factor (VEGF) is an angiogenic cytokine, which plays a major role in tumor angiogenesis. VEGF mRNA expression is controlled by hypoxia, growth factors and hormones through both transcriptional and post-transcriptional mechanisms. VEGF mRNA has a short half-life and its abundance is regulated by the binding of stabilizing (HuR, hRNP-L) and still uncharacterised destabilizing proteins to its 3'-untranslated region. Here, we report that the ACTH-regulated zinc-finger protein TIS11b and its homologs TIS11 and TIS11d interact with the 3'-untranslated region of VEGF mRNA and decrease its stability (half-life reduced from 130 to 60 min). Within the 2201 by 3'-untranslated region of VEGF mRNA, we identified a 75 by domain, containing two consensus AU-rich motifs, which binds TIS11b and mediates its destabilizing activity. Ribonucleoprotein (RNP) complex immunoprecipitation experiments allowed us to demonstrate that the interaction between TIS11b and VEGF 3'-untranslated region occurs in live cells. Knocking down TIS11b expression in primary adrenocortical cells with small interfering (si)RNAs clearly indicated that TIS11b participates in the control of both basal and, to a larger extent, ACTH-induced VEGF mRNA expression levels. TIS11b is the first VEGF mRNA-destabilizing protein identified so far and therefore appears as a new potential target in antiangiogenic therapies.	CEA, DRDC ANGIO, INSERM EMI 01 05, Dept Cellular Responses & Dynam, F-38054 Grenoble 9, France; Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signalling Dev Biol & Canc Res, F-06189 Nice, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Feige, JJ (corresponding author), CEA, DRDC ANGIO, INSERM EMI 01 05, Dept Cellular Responses & Dynam, 17 Rue Martyrs, F-38054 Grenoble 9, France.	jjfeige@cea.fr	bailly, sabine/G-3540-2013; Feige, Jean-Jacques/M-8905-2017; Ciais, Delphine/O-9435-2016; Berra, Edurne/F-9692-2011; Cherradi, Nadia/K-9695-2016	bailly, sabine/0000-0003-1043-7030; Feige, Jean-Jacques/0000-0002-1354-7692; Berra, Edurne/0000-0002-3820-5744; Cherradi, Nadia/0000-0002-4292-774X; Ciais, Delphine/0000-0002-1649-897X				Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; Brand C, 1998, J BIOL CHEM, V273, P6410, DOI 10.1074/jbc.273.11.6410; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chinn AM, 2002, MOL ENDOCRINOL, V16, P1417, DOI 10.1210/me.16.6.1417; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; NEGOESCU A, 1994, MOL CELL ENDOCRINOL, V105, P155, DOI 10.1016/0303-7207(94)90165-1; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; ROSS HJ, 1991, BLOOD, V77, P1787; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; Stoecklin G, 2003, ONCOGENE, V22, P3554, DOI 10.1038/sj.onc.1206418; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000	22	93	96	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8673	8680		10.1038/sj.onc.1207939	http://dx.doi.org/10.1038/sj.onc.1207939			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467755				2022-12-25	WOS:000224988800013
J	Saenz, DA; Goldin, AP; Minces, L; Chianelli, M; Sarmiento, MAK; Rosenstein, RE				Saenz, DA; Goldin, AP; Minces, L; Chianelli, M; Sarmiento, MAK; Rosenstein, RE			Effect of melatonin on the retinal glutamate/glutamine cycle in the golden hamster retina	FASEB JOURNAL			English	Article						glutamine synthetase; L-glutamine influx; glutaminase	AMINO-ACID-TRANSPORT; GLUTAMINE-SYNTHETASE; GANGLION-CELLS; RABBIT RETINA; NEUROHORMONE MELATONIN; NEURONAL DEGENERATION; SYNAPTIC TRANSMISSION; CIRCADIAN REGULATION; RECEPTORS; SYSTEM	Glutamate is the main excitatory neurotransmitter in the retina, but it is neurotoxic when present in excessive amounts. The metabolic dependence of glutamatergic neurons upon glia via the glutamate/glutamine cycle to provide the precursor for neurotransmitter glutamate is well established. Since melatonin has been shown to be neuroprotective in several systems, in the present report, its effect on the glutamate/glutamine cycle activity was examined in the golden hamster retina. Melatonin (0.1-10 nM) significantly increased retinal glutamine synthetase activity but it did not affect L-glutamine release. A characterization of the hamster retinal L-glutamine uptake mechanism was performed. This mechanism was partly Na+-dependent, and it was significantly inhibited by 2-aminobicyclo (2, 2, 1) heptane 2-carboxylic acid (BCH, a selective antagonists for the L-type system) and by alpha-(methylamino)-isobutyric acid ( MeAIB, substrate characteristic for the A -type transporter) suggesting the coexistence of these transport systems in the hamster retina. Melatonin (0.1-10 nM) significantly increased total glutamine uptake as well as the BCH and the MeAIB-insensitive transporters activity. On the other hand, melatonin significantly decreased retinal glutaminase activity. On the basis of these results, it might be presumed that hamster retinal glutamate/glutamine cycle activity is regulated by physiological concentrations of melatonin. Furthermore, these findings suggest that a treatment with melatonin could be considered as a new approach to handling glutamate-mediated neuronal degeneration.	Univ Buenos Aires, Fac Med, Dept Bioquim Humana, Lab Neuroquim Retiniana & Oftalmol Expt,Conicet, RA-1121 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Rosenstein, RE (corresponding author), Univ Buenos Aires, Fac Med, Dept Bioquim Humana, Lab Neuroquim Retiniana & Oftalmol Expt,Conicet, Paraguay 2155,5P, RA-1121 Buenos Aires, DF, Argentina.	ruthr@fmed.uba.ar		Goldin, Andrea/0000-0002-6402-0890				Acuna Castroviejo Dario, 2002, Curr Top Med Chem, V2, P133; BENITEZKING G, 1993, EXPERIENTIA, V49, P635; BESHARSE JC, 1983, SCIENCE, V219, P1341, DOI 10.1126/science.6828862; BLOOMFIELD SA, 1985, J NEUROPHYSIOL, V53, P699, DOI 10.1152/jn.1985.53.3.699; BLOOMFIELD SA, 1985, J NEUROPHYSIOL, V53, P714, DOI 10.1152/jn.1985.53.3.714; Bode BP, 2001, J NUTR, V131, p2475S, DOI 10.1093/jn/131.9.2475S; Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x; Celebi S, 2002, EUR J OPHTHALMOL, V12, P77, DOI 10.1177/112067210201200201; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DAVID P, 1988, EXP EYE RES, V46, P657, DOI 10.1016/S0014-4835(88)80054-X; Deitmer JW, 2003, J NEUROCHEM, V87, P127, DOI 10.1046/j.1471-4159.2003.01981.x; DUBOCOVICH ML, 1988, FASEB J, V2, P2765, DOI 10.1096/fasebj.2.12.2842214; DUBOCOVICH ML, 1983, NATURE, V204, P183; Espinar A, 2000, J PINEAL RES, V28, P81, DOI 10.1034/j.1600-079X.2001.280203.x; FAILLACE MP, 1995, NEUROREPORT, V6, P2093, DOI 10.1097/00001756-199510010-00033; Faillace MP, 1996, J NEUROCHEM, V67, P623; FAILLACE MP, 1994, J NEUROCHEM, V62, P1995; Faillace MP, 1995, NEUROREPORT, V7, P141, DOI 10.1097/00001756-199512290-00034; Faillace MP, 1996, BRAIN RES, V711, P112, DOI 10.1016/0006-8993(95)01405-5; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; Gu SM, 2001, J BIOL CHEM, V276, P24137, DOI 10.1074/jbc.M009003200; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Heckel T, 2003, NEUROCHEM INT, V43, P289, DOI 10.1016/S0197-0186(03)00014-7; HUERTODELGADILLO L, 1994, J PINEAL RES, V17, P55, DOI 10.1111/j.1600-079X.1994.tb00114.x; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KVAMME E, 1985, METHOD ENZYMOL, V113, P241; Lima ACP, 2003, NEUROTOX RES, V5, P323, DOI 10.1007/BF03033152; LOUZADAJUNIOR P, 1992, J NEUROCHEM, V59, P358, DOI 10.1111/j.1471-4159.1992.tb08912.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY SC, 1987, PROG NEUROBIOL, V28, P55, DOI 10.1016/0301-0082(87)90005-0; MASSEY SC, 1988, J PHYSIOL-LONDON, V405, P635, DOI 10.1113/jphysiol.1988.sp017353; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; Meister A., 1970, METHOD ENZYMOL, V17, P900, DOI 10.1016/0076-6879(71)17304-1; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; Morgan J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1524; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; Nagaraja TN, 1996, J NEUROCHEM, V66, P1665; Otis TS, 1998, J NEUROSCI, V18, P7099; PANG SF, 1991, NEUROENDOCRINOLOGY, V53, P2, DOI 10.1159/000125787; Pappolla MA, 1997, J NEUROSCI, V17, P1683; PATEL AJ, 1983, DEV BRAIN RES, V10, P83, DOI 10.1016/0165-3806(83)90123-2; PIERCE ME, 1985, J GEN PHYSIOL, V86, P671, DOI 10.1085/jgp.86.5.671; Poitry S, 2000, J NEUROSCI, V20, P1809; Rauen T, 2000, NEUROCHEM INT, V37, P179, DOI 10.1016/S0197-0186(00)00021-8; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; RIEPE RE, 1977, NATURE, V268, P654, DOI 10.1038/268654a0; ROSNER M, 1992, RES COMMUN CHEM PATH, V77, P299; Saenz DA, 2002, J NEUROCHEM, V80, P512, DOI 10.1046/j.0022-3042.2001.00723.x; Saenz DA, 2002, J PINEAL RES, V33, P31, DOI 10.1034/j.1600-079X.2002.01880.x; SARKAR PK, 1983, MOL CELL BIOCHEM, V53-4, P233; SARTHY PV, 1983, J NEUROSCI, V3, P2532; SARTHY PV, 1978, J CELL BIOL, V78, P675, DOI 10.1083/jcb.78.3.675; Shaked I, 2002, J NEUROCHEM, V83, P574, DOI 10.1046/j.1471-4159.2002.01168.x; Siu AW, 1999, J PINEAL RES, V27, P122, DOI 10.1111/j.1600-079X.1999.tb00606.x; Tanaka K, 2000, NEUROSCI RES, V37, P15, DOI 10.1016/S0168-0102(00)00104-8; Thoreson WB, 1999, PROG RETIN EYE RES, V18, P765, DOI 10.1016/S1350-9462(98)00031-7; Tosini G, 2003, J NEUROENDOCRINOL, V15, P364, DOI 10.1046/j.1365-2826.2003.00973.x; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; VivienRoels B, 1997, GEN COMP ENDOCR, V106, P85, DOI 10.1006/gcen.1996.6853; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; ZAWILSKA JB, 1992, NEUROCHEM INT, V20, P23, DOI 10.1016/0197-0186(92)90122-8	63	21	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1912	+		10.1096/fj.04-2062fje	http://dx.doi.org/10.1096/fj.04-2062fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15448109				2022-12-25	WOS:000224243200010
J	Asthana, N; Yadav, SP; Ghosh, JK				Asthana, N; Yadav, SP; Ghosh, JK			Dissection of antibacterial and toxic activity of melittin - A leucine zipper motif plays a crucial role in determining its hemolytic activity but not antibacterial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND MELITTIN; LIPID VESICLES; SOLID-PHASE; PHOSPHOLIPID-MEMBRANES; CONFORMATIONAL CHANGE; SELF-ASSOCIATION; PORE FORMATION; AMINO GROUPS; PEPTIDES; AGGREGATION	Melittin, a naturally occurring antimicrobial peptide, exhibits strong lytic activity against both eukaryotic and prokaryotic cells. Despite a tremendous amount of work done, very little is known about the amino acid sequence, which regulates its toxic activity. With the goal of understanding the basis of toxic activity and poor cell selectivity in melittin, a leucine zipper motif has been identified. To evaluate the possible structural and functional roles of this motif, melittin and its two analogs, after substituting the heptadic leucine by alanine, were synthesized and characterized. Functional studies indicated that alanine substitution in the leucine zipper motif resulted in a drastic reduction of the hemolytic activity of melittin. However, interestingly, both the designed analogs exhibited antibacterial activity comparable to melittin. Mutations caused a significant decrease in the membrane permeability of melittin in zwitterionic but not in negatively charged lipid vesicles. Although both the analogs exhibited similar secondary structures in the presence of negatively charged lipid vesicles as melittin, they failed to adopt a significant helical structure in the presence of zwitterionic lipid vesicles. Results suggest that the substitution of heptadic leucine by alanine impaired the assembly of melittin in an aqueous environment and its localization only in zwitterionic but not in negatively charged membrane. Altogether, the results suggest the identification of a structural element in melittin, which probably plays a prominent role in regulating its toxicity but not antibacterial activity. The results indicate that cell selectivity in some antimicrobial peptides can probably be introduced by modulating their assembly in an aqueous environment.	Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Ghosh, JK (corresponding author), Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India.	jighosh@yahoo.com						ALTENBACH C, 1988, PROTEINS, V3, P230, DOI 10.1002/prot.340030404; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BATENBURG AM, 1988, BIOSCIENCE REP, V8, P299, DOI 10.1007/BF01115220; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1989, FEBS LETT, V259, P103, DOI 10.1016/0014-5793(89)81505-4; BROWN LR, 1980, BIOCHIM BIOPHYS ACTA, V622, P231, DOI 10.1016/0005-2795(80)90034-3; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; DEGRADO WF, 1981, J AM CHEM SOC, V103, P679, DOI 10.1021/ja00393a035; DEGRADO WF, 1982, BIOPHYS J, V37, P329, DOI 10.1016/S0006-3495(82)84681-X; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GEVOD VS, 1984, BIOPHYS J, V45, P1079, DOI 10.1016/S0006-3495(84)84255-1; Ghosh AK, 1997, BIOCHEMISTRY-US, V36, P14291, DOI 10.1021/bi971933j; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; Ghosh JK, 1998, J BIOL CHEM, V273, P7252, DOI 10.1074/jbc.273.13.7252; Ghosh JK, 1997, BIOCHEMISTRY-US, V36, P15451, DOI 10.1021/bi971152i; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HABERMANN E, 1970, H-S Z PHYSIOL CHEM, V351, P884, DOI 10.1515/bchm2.1970.351.2.884; JOHN E, 1992, BIOPHYS J, V63, P1536, DOI 10.1016/S0006-3495(92)81737-X; Juvvadi P, 1996, J AM CHEM SOC, V118, P8989, DOI 10.1021/ja9542911; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; Ladokhin AS, 1997, BIOPHYS J, V72, P1762, DOI 10.1016/S0006-3495(97)78822-2; LADOKHIN AS, 1995, BIOPHYS J, V69, P506, DOI 10.1016/S0006-3495(95)79924-6; Ladokhin AS, 2001, BBA-BIOMEMBRANES, V1514, P253, DOI 10.1016/S0005-2736(01)00382-0; LANSCHULZ WH, 1988, SCIENCE, V240, P1759; LEIPPE M, 1994, P NATL ACAD SCI USA, V91, P2602, DOI 10.1073/pnas.91.7.2602; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Papo N, 2003, BIOCHEMISTRY-US, V42, P458, DOI 10.1021/bi0267846; PEREZPAYA E, 1995, J BIOL CHEM, V270, P1048, DOI 10.1074/jbc.270.3.1048; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; Rex S, 1998, BIOCHEMISTRY-US, V37, P2336, DOI 10.1021/bi971009p; SCHRODER E, 1971, EXPERIENTIA, V27, P764, DOI 10.1007/BF02136851; SEKHARAM KM, 1991, BIOCHIM BIOPHYS ACTA, V1063, P171, DOI 10.1016/0005-2736(91)90367-H; Shai Y, 1996, J BIOL CHEM, V271, P7305, DOI 10.1074/jbc.271.13.7305; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; Subbalakshmi C, 1999, FEBS LETT, V448, P62, DOI 10.1016/S0014-5793(99)00328-2; TALBOT JC, 1979, FEBS LETT, V102, P191, DOI 10.1016/0014-5793(79)80957-6; TATHAM AS, 1983, BIOCHEM J, V211, P683, DOI 10.1042/bj2110683; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; VOGEL H, 1986, BIOPHYS J, V50, P573, DOI 10.1016/S0006-3495(86)83497-X; VOJKOVSKY T, 1995, PEPTIDE RES, V8, P236; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Yadav SP, 2003, J BIOL CHEM, V278, P51023, DOI 10.1074/jbc.M310052200; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	53	174	183	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55042	55050		10.1074/jbc.M408881200	http://dx.doi.org/10.1074/jbc.M408881200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15475354	hybrid			2022-12-25	WOS:000225960800009
J	Janz, JM; Farrens, DL				Janz, JM; Farrens, DL			Role of the retinal hydrogen bond network in rhodopsin Schiff base stability and hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONE VISUAL PIGMENTS; PROTEIN-COUPLED-RECEPTOR; RESONANCE RAMAN-SPECTROSCOPY; NIGHT BLINDNESS MUTANT; BOVINE RHODOPSIN; METARHODOPSIN-II; TRANSDUCIN ACTIVATION; FLUORESCENCE SPECTROSCOPY; COUNTERION SWITCH; CRYSTAL-STRUCTURE	Little is known about the molecular mechanism of Schiff base hydrolysis in rhodopsin. We report here our investigation into this process focusing on the role of amino acids involved in a hydrogen bond network around the retinal Schiff base. We find conservative mutations in this network (T94I, E113Q, S186A, E181Q, Y192F, and Y268F) increase the activation energy (E-a) and abolish the concave Arrhenius plot normally seen for Schiff base hydrolysis in dark state rhodopsin. Interestingly, two mutants ( T94I and E113Q) show dramatically faster rates of Schiff base hydrolysis in dark state rhodopsin, yet slower hydrolysis rates in the active MII form. We find deuterium affects the hydrolysis process in wild-type rhodopsin, exhibiting a specific isotope effect of similar to2.5, and proton inventory studies indicate that multiple proton transfer events occur during the process of Schiff base hydrolysis for both dark state and MII forms. Taken together, our study demonstrates the importance of the retinal hydrogen bond network both in maintaining Schiff base integrity in dark state rhodopsin, as well as in catalyzing the hydrolysis and release of retinal from the MII form. Finally, we note that the dramatic alteration of Schiff base stability caused by mutation T94I may play a causative role in congenital night blindness as has been suggested by the Oprian and Garriga laboratories.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Farrens, DL (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Mail Code L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	farrensd@ohsu.edu			NEI NIH HHS [EY 12095, T32 EY 07123-09] Funding Source: Medline; NIDA NIH HHS [DA 14896] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007123, R01EY012095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014896] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Andres A, 2001, EUR J BIOCHEM, V268, P5696, DOI 10.1046/j.0014-2956.2001.02509.x; Babu KR, 2001, BIOCHEMISTRY-US, V40, P13760, DOI 10.1021/bi015584b; Baehr W, 2003, VISION RES, V43, P2957, DOI 10.1016/j.visres.2003.10.001; BAEHR W, 1982, J BIOL CHEM, V257, P6452; Birge RR, 2003, P NATL ACAD SCI USA, V100, P9105, DOI 10.1073/pnas.1733801100; BRUAULT M, 1976, J ORG CHEM, V41, P346; COOPER A, 1987, J AM CHEM SOC, V109, P7254, DOI 10.1021/ja00258a002; Das J, 2004, BIOCHEMISTRY-US, V43, P5532, DOI 10.1021/bi036097u; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DENG H, 1994, BIOPHYS J, V66, P1129, DOI 10.1016/S0006-3495(94)80893-8; DOUKAS AG, 1978, BIOCHEMISTRY-US, V17, P2430, DOI 10.1021/bi00605a028; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Ebrey TG, 2000, METHOD ENZYMOL, V315, P196; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FILIPEK S, 2002, ANNU REV PHYSIOL, V20, P20; Gross AK, 2003, BIOCHEMISTRY-US, V42, P2009, DOI 10.1021/bi020613j; Gross AK, 2003, BIOCHEMISTRY-US, V42, P2002, DOI 10.1021/bi020612r; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Imai H, 1997, P NATL ACAD SCI USA, V94, P2322, DOI 10.1073/pnas.94.6.2322; Janz JM, 2004, J BIOL CHEM, V279, P29767, DOI 10.1074/jbc.M402567200; Janz JM, 2003, VISION RES, V43, P2991, DOI 10.1016/j.visres.2003.08.010; Janz JM, 2003, J BIOL CHEM, V278, P16982, DOI 10.1074/jbc.M210567200; Janz JM, 2001, BIOCHEMISTRY-US, V40, P7219, DOI 10.1021/bi002937i; Lewis JW, 1997, VISION RES, V37, P1, DOI 10.1016/S0042-6989(96)00138-1; Lewis JW, 2000, METHOD ENZYMOL, V315, P164; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; Nagata T, 1997, BIOCHEMISTRY-US, V36, P6164, DOI 10.1021/bi962920t; Nagata T, 1998, BIOCHEMISTRY-US, V37, P17216, DOI 10.1021/bi9810149; Noorwez SM, 2004, J BIOL CHEM, V279, P16278, DOI 10.1074/jbc.M312101200; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OSEROFF AR, 1974, BIOCHEMISTRY-US, V13, P4243, DOI 10.1021/bi00717a027; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; Patel AB, 2004, P NATL ACAD SCI USA, V101, P10048, DOI 10.1073/pnas.0402848101; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Ramon E, 2003, J BIOL CHEM, V278, P6427, DOI 10.1074/jbc.M210929200; Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; SAKAMOTO T, 1995, P NATL ACAD SCI USA, V92, P249, DOI 10.1073/pnas.92.1.249; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SHICHIDA Y, 1994, BIOCHEMISTRY-US, V33, P9040, DOI 10.1021/bi00197a002; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; Starace DM, 1997, J BIOL CHEM, V272, P1095, DOI 10.1074/jbc.272.2.1095; STEINBERG G, 1993, BIOPHYS J, V64, P1499, DOI 10.1016/S0006-3495(93)81518-2; Stenkamp RE, 2002, BBA-BIOMEMBRANES, V1565, P168, DOI 10.1016/S0005-2736(02)00567-9; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3529, DOI 10.1021/bi016023n; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; Xie GF, 2003, BIOCHEMISTRY-US, V42, P1995, DOI 10.1021/bi020611z; Yan ECY, 2003, P NATL ACAD SCI USA, V100, P9262, DOI 10.1073/pnas.1531970100; Yan ECY, 2002, BIOCHEMISTRY-US, V41, P3620, DOI 10.1021/bi0160011; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	71	58	59	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55886	55894		10.1074/jbc.M408766200	http://dx.doi.org/10.1074/jbc.M408766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15475355	hybrid			2022-12-25	WOS:000225960800112
J	Kuo, PC; Liu, HF; Chao, JI				Kuo, PC; Liu, HF; Chao, JI			Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; DOWN-REGULATION; CANCER CELLS; DNA-DAMAGE; MUTANT P53; AURORA-B; PHOSPHORYLATION; CHECKPOINT; ARREST; CYCLE	Quercetin, a ubiquitous bioactive plant flavonoid, has been shown to inhibit the proliferation of cancer cells. However, the regulation of survivin and p53 on the quercetin-induced cell growth inhibition and apoptosis in cancer cells remains unclear. In this study, we investigated the roles of survivin and p53 in the quercetin-treated human lung carcinoma cells. Quercetin (20-80 muM for 24 h) induced the cytotoxicity and apoptosis in both A549 and H1299 lung carcinoma cells in a concentration-dependent manner. Additionally, quercetin inhibited the cell growth, increased the fractions of G(2)/M phase, and raised the levels of cyclin B1 and phospho-cdc2 (threonine 161) proteins. Moreover, quercetin induced abnormal chromosome segregation in H1299 cells. The survivin proteins were highly expressed in mitotic phase and were located on the midbody of cytokinesis; however, the survivin proteins were increased and concentrated on the nuclei following quercetin treatment in the lung carcinoma cells. Transfection of a survivin antisense oligodeoxynucleotide enhanced the quercetin-induced cell growth inhibition and cytotoxicity. Subsequently, quercetin increased the levels of total p53 (DO-1), phospho-p53 (serine 15), and p21 proteins, which were translocated to the nuclei in A549 cells. Treatment with a specific p53 inhibitor, pifithrin-alpha, or transfection of a p53 antisense oligodeoxynucleotide enhanced the cytotoxicity of the quercetin-treated cells. Furthermore, transfection of a small interfering RNA of p21 enhanced the quercetin-induced cell death in A549 cells. Together, our results suggest that survivin can reduce the cell growth inhibition and apoptosis, and p53 elevates the p21 level, which may attenuate the cell death in the quercetin-treated human lung carcinoma cells.	Tzu Chi Univ, Coll Life Sci, Mol Toxicol Lab, Inst Pharmacol & Toxicol, Hualien 970, Taiwan	Tzu Chi University	Chao, JI (corresponding author), Tzu Chi Univ, Coll Life Sci, Mol Toxicol Lab, Inst Pharmacol & Toxicol, 701,Sect 3,Chung Yang Rd, Hualien 970, Taiwan.	chaoji@mail.tcu.edu.tw						AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; AVILA MA, 1994, CANCER RES, V54, P2424; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Beniston RG, 2003, ONCOGENE, V22, P5504, DOI 10.1038/sj.onc.1206848; Beniston RG, 2001, CARCINOGENESIS, V22, P1069, DOI 10.1093/carcin/22.7.1069; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Chao JI, 2004, J BIOL CHEM, V279, P20267, DOI 10.1074/jbc.M312381200; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; CHEN JY, 1993, ONCOGENE, V8, P2159; Choi JA, 2001, INT J ONCOL, V19, P837; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Di Carlo G, 1999, LIFE SCI, V65, P337, DOI 10.1016/S0024-3205(99)00120-4; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gupta K, 2002, BIOCHEMISTRY-US, V41, P13029, DOI 10.1021/bi025952r; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kawamura K, 2003, DEV BIOL, V256, P331, DOI 10.1016/S0012-1606(02)00135-5; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LEA MA, 1993, CANCER LETT, V68, P231, DOI 10.1016/0304-3835(93)90151-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MIYASHITA T, 1995, CELL, V80, P293; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olie RA, 2000, CANCER RES, V60, P2805; Ong CS, 2004, ONCOL REP, V11, P727; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; Plaumann B, 1996, ONCOGENE, V13, P1605; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rodel C, 2003, INT J RADIAT ONCOL, V55, P1341, DOI 10.1016/S0360-3016(02)04618-7; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; SMITH ML, 1995, ONCOGENE, V10, P1053; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tsai CM, 1996, CANCER RES, V56, P206; Wall NR, 2003, CANCER RES, V63, P230; Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9; Yoshizumi M, 2001, MOL PHARMACOL, V60, P656	49	138	145	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	2004	279	53					55875	55885		10.1074/jbc.M407985200	http://dx.doi.org/10.1074/jbc.M407985200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	882TI	15456784	hybrid			2022-12-25	WOS:000225960800111
J	Graziani, S; Xia, YN; Gurnon, JR; Van Etten, JL; Leduc, D; Skouloubris, S; Myllykallio, H; Liebl, U				Graziani, S; Xia, YN; Gurnon, JR; Van Etten, JL; Leduc, D; Skouloubris, S; Myllykallio, H; Liebl, U			Functional analysis of FAD-dependent thymidylate synthase ThyX from Paramecium bursaria chlorella virus-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; SYNTHETASE; PROTEIN; PBCV-1; LIFE	Sequence analysis of the 330-kb double-stranded DNA genome of Paramecium bursaria chlorella virus-1 revealed an open reading frame A674R that encodes a protein with up to 53% amino acid identity to a recently discovered new class of thymidylate synthases, called ThyX. Unlike the traditional thymidylate synthase, ThyA, that uses methylenetetrahydrofolate (CH(2)H(4)folate) as both a source of the methylene group and the reductant, CH(2)H(4)folate only supplies the methylene group in ThyX-catalyzed reactions. Furthermore, ThyX only catalyzes thymidylate (dTMP) formation in the presence of reduced pyridine nucleotides and oxidized FAD. The distribution and transcription patterns of the a674r gene in Chlorella viruses were examined. The a674r gene was cloned, and the protein was expressed in Escherichia coli. Biochemical characterization of the P. bursaria chlorella virus-1 recombinant ThyX protein indicates that it is more efficient at converting dUMP to dTMP than previously studied ThyX enzymes, thus allowing more detailed mechanistic studies of the enzyme. The ThyX-dUMP complexes with bound FAD function as efficient NAD(P) H oxidases, indicating that dUMP binds to the enzyme prior to NAD(P) H. This oxidation activity is directly linked to FAD reduction. Our results indicate that ThyX-specific inhibitors can be designed that do not affect ThyA enzymes. Finally, a model is proposed for the early stages of ThyX catalysis.	Ecole Polytech, Lab Opt & Biosci, INSERM, U451,CNRS,UMR 7645, F-91128 Palaiseau, France; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA; Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68583 USA; Univ Paris 11, Inst Genet & Microbiol, Lab Genom & Microbial Physiol, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; UDICE-French Research Universities; Universite Paris Saclay	Liebl, U (corresponding author), Ecole Polytech, Lab Opt & Biosci, INSERM, U451,CNRS,UMR 7645, F-91128 Palaiseau, France.	Ursula.Liebl@polytechnique.fr	Myllykallio, Hannu/Y-5462-2019	Myllykallio, Hannu/0000-0002-0541-1197; LIEBL, Ursula/0000-0003-0869-4388; Skouloubris, Stephane/0000-0001-6660-0023	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032441] Funding Source: NIH RePORTER; NCRR NIH HHS [P20-RR15635] Funding Source: Medline; NIGMS NIH HHS [GM32441] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal N, 2004, BIOCHEMISTRY-US, V43, P10295, DOI 10.1021/bi0490439; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; Copeland R. A., 2004, ENZYMES PRACTICAL IN; DARON HH, 1978, J BIOL CHEM, V253, P940; Fortune JM, 2001, J BIOL CHEM, V276, P24401, DOI 10.1074/jbc.M101693200; Graves MV, 2001, VIROLOGY, V285, P332, DOI 10.1006/viro.2001.0937; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; KALMAN TI, 1981, BIOCHEM BIOPH RES CO, V102, P682, DOI 10.1016/S0006-291X(81)80186-6; Kuhn P, 2002, PROTEINS, V49, P142, DOI 10.1002/prot.10202; Leduc D, 2004, P NATL ACAD SCI USA, V101, P7252, DOI 10.1073/pnas.0401365101; Mathews II, 2003, STRUCTURE, V11, P677, DOI 10.1016/S0969-2126(03)00097-2; Myllykallio H, 2002, SCIENCE, V297, P105, DOI 10.1126/science.1072113; Myllykallio H, 2003, TRENDS MICROBIOL, V11, P220, DOI 10.1016/S0966-842X(03)00101-X; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P467, DOI 10.1021/bi00700a011; Sun LW, 2000, VIROLOGY, V276, P27, DOI 10.1006/viro.2000.0500; Van Etten JL, 2003, ANNU REV GENET, V37, P153, DOI 10.1146/annurev.genet.37.110801.143915; VANETTEN JL, 1984, VIROLOGY, V134, P443, DOI 10.1016/0042-6822(84)90311-8; VANETTEN JL, 1981, VIROLOGY, V113, P704, DOI 10.1016/0042-6822(81)90199-9; VANETTEN JL, 1983, VIROLOGY, V126, P117, DOI 10.1016/0042-6822(83)90466-X	19	57	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54340	54347		10.1074/jbc.M409121200	http://dx.doi.org/10.1074/jbc.M409121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15471872	hybrid			2022-12-25	WOS:000225793600056
J	Dodd, RB; Allen, MD; Brown, SE; Sanderson, CM; Duncan, LM; Lehner, PJ; Bycroft, M; Read, RJ				Dodd, RB; Allen, MD; Brown, SE; Sanderson, CM; Duncan, LM; Lehner, PJ; Bycroft, M; Read, RJ			Solution structure of the Kaposi's sarcoma-associated herpesvirus K3N-terminal domain reveals a novel E2-binding C4HC3-type RING domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX CLASS-I; MHC CLASS-I; E3 UBIQUITIN LIGASES; CRYSTAL-STRUCTURE; FINGER PROTEINS; DOWN-REGULATION; IMMUNE EVASION; PHD DOMAIN; FAMILY; MOLECULES	RING domains are found in a large number of eukaryotic proteins. Most function as E3 ubiquitin-protein ligases, catalyzing the terminal step in the ubiquitination process. Structurally, these domains have been characterized as binding two zinc ions in a stable cross-brace motif. The tumorigenic human gamma-herpesvirus Kaposi's sarcoma-associated herpesvirus encodes a ubiquitin-protein ligase termed K3, which functions as an immune evasion molecule by ubiquitinating major histocompatibility complex class I. K3 possesses at its N terminus a domain related to cellular RING domains but with an altered zinc ligand arrangement. This domain was initially characterized as a plant homeodomain, a structure not previously known to function as an E3. Here, it is conclusively demonstrated that the K3 N-terminal domain is a variant member of the RING domain family and not a plant homeodomain. The domain is found to interact with the cellular ubiquitin-conjugating enzymes UbcH5A to -C and UbcH13, which dock to the equivalent surface as on classical cellular RING domains. Interaction with UbcH13 suggests a possible role for K3 in catalyzing Lys(63)-linked ubiquitination.	Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England; MRC, Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England; MRC, Rosalind Franklin Ctr Gen Res, Funct Gen Grp, Cambridge CB10 1SB, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Read, RJ (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	rjr27@cam.ac.uk	Bycroft, Mark/D-9446-2017; Dodd, Roger/B-4917-2008; Read, Randy J/L-1418-2013	Read, Randy J/0000-0001-8273-0047; Lehner, Paul Joseph/0000-0001-9383-1054; Bycroft, Mark/0000-0002-0673-2216; Dodd, Roger/0000-0003-4268-1863				Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; Ashley C, 2002, GENE, V285, P183, DOI 10.1016/S0378-1119(02)00409-2; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; Bashford D, 1997, LECT NOTES COMPUTER, P233, DOI [10.1007/3-540-63827-X, DOI 10.1007/3-540-63827-X_66]; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Cesarman E, 1999, SEMIN CANCER BIOL, V9, P165, DOI 10.1006/scbi.1998.0118; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Coscoy L, 2003, TRENDS CELL BIOL, V13, P287, DOI 10.1016/S0962-8924(03)00103-X; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; DeLano WL, 2002, PYMOL USERS MANUAL; Estevez AM, 2003, J BIOL CHEM, V278, P34943, DOI 10.1074/jbc.M305333200; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Fruh K, 2002, VIRUS RES, V88, P55, DOI 10.1016/S0168-1702(02)00120-X; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Haque M, 2001, J GEN VIROL, V82, P1175, DOI 10.1099/0022-1317-82-5-1175; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ishido S, 2000, J VIROL, V74, P5300, DOI 10.1128/JVI.74.11.5300-5309.2000; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson ES, 2002, NAT CELL BIOL, V4, pE295, DOI 10.1038/ncb1202-e295; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; Scheel H, 2003, TRENDS CELL BIOL, V13, P285, DOI 10.1016/S0962-8924(03)00102-8; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Stevenson PG, 2000, P NATL ACAD SCI USA, V97, P8455, DOI 10.1073/pnas.150240097; Tanaka K, 1998, GENES CELLS, V3, P499, DOI 10.1046/j.1365-2443.1998.00207.x; Uchida D, 2004, J EXP MED, V199, P167, DOI 10.1084/jem.20031291; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Wilkinson Caroline R. M., 2002, Trends in Cell Biology, V12, P545, DOI 10.1016/S0962-8924(02)02397-8; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	50	78	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53840	53847		10.1074/jbc.M409662200	http://dx.doi.org/10.1074/jbc.M409662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15465811	hybrid			2022-12-25	WOS:000225680600122
J	Koga, H; Ohshima, T; Shimotohno, K				Koga, H; Ohshima, T; Shimotohno, K			Enhanced activation of tax-dependent transcription of human T-cell leukemia virus type I (HTLV-I) long terminal repeat by TORC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BINDING-PROTEIN; MOLECULAR-MECHANISM; CREB; TRANSACTIVATION; ONCOPROTEIN; INTERACTS; COACTIVATOR; ELEMENT; DOMAIN	Tax, a protein encoded by the env-pX gene of human T-cell leukemia virus type I (HTLV-I), interacts with various host cell transcription factors. Tax activates transcription from the long terminal repeat (LTR) of HTLV-I through association with cyclic AMP-responsive element-binding protein (CREB). Here, we present evidence that transducer of regulated cyclic AMP-response element-binding protein 3 (TORC3), a co-activator of CREB, is involved in Tax-induced transcriptional activation from the HTLV-I LTR. By using a luciferase assay system, we show that TORC3 alone can enhance transcription from the HTLV-I LTR, as well as from a cellular cyclic AMP-response element (CRE). Interestingly, we find that co-expression of TORC3 and Tax dramatically increased transcriptional activation at the HTLV-I LTR. We also show by glutathione S-transferase pull-down and co-immunoprecipitation experiments that TORC3 interacts with Tax. Using deletion mutant analysis, we identify the Tax interaction domain of TORC3 as a region spanning from amino acid 1 to 103, which contains a coiled-coil domain. These results provide important clues toward understanding the molecular mechanism of Tax-dependent transcriptional activation of the HTLV-I LTR.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068502, Japan.	kshimoto@virus.kyoto-u.ac.jp		OHSHIMA, Takayuki/0000-0002-1501-6430				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Connor LM, 2000, VIROLOGY, V270, P328, DOI 10.1006/viro.2000.0262; Datta S, 2000, J VIROL, V74, P8277, DOI 10.1128/JVI.74.18.8277-8285.2000; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; GESSAIN A, 1985, LANCET, V2, P407; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; OSAME M, 1986, LANCET, V1, P1031; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Watanabe T, 1997, INT J HEMATOL, V66, P257; YAMAOKA S, 1992, ONCOGENE, V7, P433; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; Youn HG, 2003, J VIROL, V77, P10015, DOI 10.1128/JVI.77.18.10015-10027.2003	33	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					52978	52983		10.1074/jbc.M409021200	http://dx.doi.org/10.1074/jbc.M409021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15466468	hybrid			2022-12-25	WOS:000225680600022
J	Banik, SSR; Counter, CM				Banik, SSR; Counter, CM			Characterization of interactions between PinX1 and human telomerase Subunits hTERT and hTR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; REVERSE-TRANSCRIPTASE; NUCLEOLAR LOCALIZATION; ENZYME-ACTIVITY; IN-VIVO; RNA; PROTEIN; DOMAIN; DNA; PROCESSIVITY	The addition of telomeric repeats to chromosome ends by the enzyme telomerase is a highly orchestrated process. Although much is known regarding telomerase catalytic activity in vitro, less is known about how this activity is regulated in vivo to ensure proper telomere elongation. One protein that appears to be involved in negatively regulating telomerase function in vivo is PinX1 because overexpression of PinX1 inhibits telomerase activity and causes telomere shortening. To understand the nature of this repression, we characterized the interactions among PinX1 and the core components of telomerase, the human telomerase reverse transcriptase ( hTERT) and associated human telomerase RNA (hTR). We now show that in vitro PinX1 binds directly to the hTERT protein subunit, primarily to the hTR-binding domain, as well as to the hTR subunit. However, in a cellular context, the association of PinX1 with hTR is dependent on the presence of hTERT. Taken together, we suggest that PinX1 represses telomerase activity in vivo by binding to the assembled hTERT.hTR complex.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; Duke University	Counter, CM (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	count004@mc.duke.edu		Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R01CA082481] Funding Source: NIH RePORTER; NCI NIH HHS [CA082481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P342, DOI 10.1016/S0968-0004(99)01437-1; Armbruster BN, 2004, MOL CELL BIOL, V24, P3552, DOI 10.1128/MCB.24.8.3552-3561.2004; Armbruster BN, 2003, MOL CELL BIOL, V23, P3237, DOI 10.1128/MCB.23.9.3237-3246.2003; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Banik SSR, 2002, MOL CELL BIOL, V22, P6234, DOI 10.1128/MCB.22.17.6234-6246.2002; Beattie TL, 2000, MOL BIOL CELL, V11, P3329, DOI 10.1091/mbc.11.10.3329; Cabuy E, 2001, VIRCHOWS ARCH, V439, P176, DOI 10.1007/s004280100466; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Etheridge KT, 2002, J BIOL CHEM, V277, P24764, DOI 10.1074/jbc.M201227200; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Guglielmi B, 2002, J BIOL CHEM, V277, P35712, DOI 10.1074/jbc.M205526200; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Huard S, 2003, NUCLEIC ACIDS RES, V31, P4059, DOI 10.1093/nar/gkg437; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Lin J, 2004, GENE DEV, V18, P387, DOI 10.1101/gad.1171804; Lustig AJ, 2001, NAT STRUCT BIOL, V8, P297, DOI 10.1038/86157; Moriarty TJ, 2004, MOL CELL BIOL, V24, P3720, DOI 10.1128/MCB.24.9.3720-3733.2004; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Narayanan A, 1999, EMBO J, V18, P5120, DOI 10.1093/emboj/18.18.5120; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; Song H, 2004, BIOCHEM BIOPH RES CO, V316, P1116, DOI 10.1016/j.bbrc.2004.02.166; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; Yang YH, 2002, EXP CELL RES, V277, P201, DOI 10.1006/excr.2002.5541; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	30	66	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51745	51748		10.1074/jbc.M408131200	http://dx.doi.org/10.1074/jbc.M408131200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15381700	hybrid			2022-12-25	WOS:000225493400006
J	Liang, XD; Young, JJ; Boone, SA; Waugh, DS; Duesbery, NS				Liang, XD; Young, JJ; Boone, SA; Waugh, DS; Duesbery, NS			Involvement of domain II in toxicity of anthrax lethal factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-ANTHRACIS; PROTECTIVE ANTIGEN; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; FACTOR CLEAVES; KINASE-KINASE; TOXIN; INHIBITORS; SEQUENCE; BINDING	Anthrax lethal factor (LF) is a Zn2+-metalloprotease that cleaves and inactivates mitogen-activated protein kinase kinases (MEKs). We have used site-directed mutagenesis to identify a cluster of residues in domain II of LF that lie outside the active site and are required for cellular proteolytic activity toward MEKs. Alanine substituted for Leu(293), Lys(294), Leu(514), Asn(516), or Arg(491) caused a 10-50-fold reduction in LF toxicity. Further, whereas pairwise substitution of alanine for Leu(514) and either Leu(293), Lys(294), or Arg(491) completely abrogated LF toxicity, pairwise mutation of Leu(514) and Asn(516) resulted in toxicity comparable with N516A alone. The introduction of these mutations reduced LF-mediated cleavage of MEK2 in cell-based assays but altered neither the ability of LF to bind protective antigen nor its ability to translocate across a membrane. Interestingly, direct in vitro measurement of LF activity indicated that decreased toxicity was not always accompanied by reduced proteolytic activity. However, mutations in this region significantly reduced the ability of LF to competitively inhibit B-Raf phosphorylation of MEK. These results provide evidence that elements of domain II are involved in the association of LF into productive complex with MEKs.	Van Andel Res Inst, Lab Canc & Dev Cell Biol, Grand Rapids, MI 49503 USA; NCI, Prot Engn Sect, Macromol Crystallog Lab, Ctr Canc Res, Ft Detrick, MD 21702 USA	Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Duesbery, NS (corresponding author), Van Andel Res Inst, Lab Canc & Dev Cell Biol, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	duesbery@vai.org		Young, John/0000-0001-5929-5315; Duesbery, Nicholas/0000-0002-5708-4984; DUESBERY, NICK/0000-0002-4258-5655				ARORA N, 1993, J BIOL CHEM, V268, P3334; Bardwell AJ, 2004, BIOCHEM J, V378, P569, DOI 10.1042/BJ20031382; BEALL FA, 1962, J BACTERIOL, V83, P1274, DOI 10.1128/JB.83.6.1274-1280.1962; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; BRAGG TS, 1989, GENE, V81, P45, DOI 10.1016/0378-1119(89)90335-1; CATALDI A, 1990, MOL MICROBIOL, V4, P1111, DOI 10.1111/j.1365-2958.1990.tb00685.x; Chopra AP, 2003, J BIOL CHEM, V278, P9402, DOI 10.1074/jbc.M211262200; Dell'Aica I, 2004, EMBO REP, V5, P418, DOI 10.1038/sj.embor.7400118; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; Lacy DB, 2002, J BIOL CHEM, V277, P3006, DOI 10.1074/jbc.M109997200; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Min DH, 2004, NAT BIOTECHNOL, V22, P717, DOI 10.1038/nbt973; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Park S, 2000, PROTEIN EXPRES PURIF, V18, P293, DOI 10.1006/prep.2000.1208; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PEZARD C, 1993, J GEN MICROBIOL, V139, P2459, DOI 10.1099/00221287-139-10-2459; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; QUINN CP, 1991, J BIOL CHEM, V266, P20124; QUINN CP, 1990, J GEN MICROBIOL, V136, P1211, DOI 10.1099/00221287-136-7-1211; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; SINGH Y, 1989, J BIOL CHEM, V264, P11099; SINGH Y, 1989, J BIOL CHEM, V264, P19103; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANLEY JL, 1961, J GEN MICROBIOL, V26, P49, DOI 10.1099/00221287-26-1-49; Tonello F, 2002, NATURE, V418, P386, DOI 10.1038/418386a; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671	39	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52473	52478		10.1074/jbc.M409105200	http://dx.doi.org/10.1074/jbc.M409105200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15465830	hybrid			2022-12-25	WOS:000225493400092
J	Marin-Esteban, V; Falk, K; Rotzschke, O				Marin-Esteban, V; Falk, K; Rotzschke, O			"Chemical analogues" of HLA-DM can induce a peptide-receptive state in HLA-DR molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MHC; MYELIN BASIC-PROTEIN; BINDING; COMPLEXES; EXCHANGE; ANTIGEN; HLA-DR1; DISSOCIATION; ASSOCIATION; STABILITY	We had recently identified small molecular compounds that are able to accelerate the ligand exchange reactions of HLA-DR molecules. Here we show that this acceleration is due to the induction of a "peptide-receptive" state. Dissociation experiments of soluble HLA-DR2.CLIP ( class II-associated invariant chain peptide) complex and peptide-binding studies with "nonreceptive" empty HLA-DR1 and -DR2 molecules revealed that the presence of a small phenolic compound carrying an H-bond donor group ( -OH) results in the drastic increase of both off- and on-rates. The rate-limiting step for ligand exchange, the transition of the major histocompatibility complex molecule from a nonreceptive into the receptive state, is normally mediated by interaction with the chaperone HLA-DM. In this respect, the effect of small molecules resembles that of the natural catalyst, except that they are still active at neutral pH. These "chemical analogues" of HLA-DM can therefore modulate the response of CD4+ T cells by editing the antigen composition of surface-bound class II major histocompatibility complex on living antigen-presenting cells.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Falk, K (corresponding author), Max Delbruck Ctr Mol Med, Robert Rosslestr 10, D-13125 Berlin, Germany.	falk@mdc-berlin.de; roetzsch@mdc-berlin.de	Marin-Esteban, Viviana/A-8856-2014; Roetzschke, Olaf/GXH-0012-2022					BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Busch R, 1996, EMBO J, V15, P418, DOI 10.1002/j.1460-2075.1996.tb00372.x; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; Doebele RC, 2000, IMMUNITY, V13, P517, DOI 10.1016/S1074-7613(00)00051-0; Falk K, 2000, J EXP MED, V191, P717, DOI 10.1084/jem.191.4.717; Falk K, 2002, J BIOL CHEM, V277, P2709, DOI 10.1074/jbc.M109098200; Gauthier L, 1998, P NATL ACAD SCI USA, V95, P11828, DOI 10.1073/pnas.95.20.11828; Joshi RV, 2000, BIOCHEMISTRY-US, V39, P3751, DOI 10.1021/bi9923656; KROPSHOFER H, 1995, P NATL ACAD SCI USA, V92, P8313, DOI 10.1073/pnas.92.18.8313; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; Marin-Esteban V, 2003, J AUTOIMMUN, V20, P63, DOI 10.1016/S0896-8411(02)00107-5; McFarland BJ, 1999, J IMMUNOL, V163, P3567; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; Natarajan SK, 1999, J IMMUNOL, V162, P4030; Natarajan SK, 1999, J IMMUNOL, V162, P3463; Pashine A, 2003, IMMUNITY, V19, P183, DOI 10.1016/S1074-7613(03)00200-0; Rabinowitz JD, 1998, IMMUNITY, V9, P699, DOI 10.1016/S1074-7613(00)80667-6; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; Rosloniec EF, 1998, J IMMUNOL, V160, P2573; Rotzschke O, 2002, P NATL ACAD SCI USA, V99, P16946, DOI 10.1073/pnas.212643999; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Stratikos E, 2002, J EXP MED, V196, P173, DOI 10.1084/jem.20020117; Vacchino JF, 2001, J IMMUNOL, V166, P6680, DOI 10.4049/jimmunol.166.11.6680; Vogt AB, 1996, P NATL ACAD SCI USA, V93, P9724, DOI 10.1073/pnas.93.18.9724; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0; Zarutskie JA, 2001, P NATL ACAD SCI USA, V98, P12450, DOI 10.1073/pnas.211439398	31	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50684	50690		10.1074/jbc.M407598200	http://dx.doi.org/10.1074/jbc.M407598200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15381703	hybrid			2022-12-25	WOS:000225355800009
J	Pan, QH; Gollapudi, AS; Dave, VP				Pan, QH; Gollapudi, AS; Dave, VP			Biochemical evidence for the presence of a single CD3 delta and CD3 gamma chain in the surface T cell receptor/CD3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; ALPHA-BETA; TCR/CD3 COMPLEX; TCR-ALPHA; MULTIVALENT STRUCTURE; CD3-EPSILON CHAINS; CD3 COMPLEX; GAMMA; ASSOCIATION; ACTIVATION	The T cell antigen receptor (TCR) consists of an alphabeta heterodimer and associated invariant CD3gamma, delta, epsilon, and zeta chains (TCR/CD3 complex). The general stoichiometry of the receptor complex, which is believed to be one molecule each of TCRalpha, TCRbeta, CD3gamma, and CD3delta and two molecules each of CD3epsilon and CD3zeta, is not clearly understood. Although it has been shown that there are two chains of CD3epsilon and CD3zeta, the stoichiometry of CD3gamma or CD3delta chains in the surface antigen receptor complex has not been determined. In the present study, transgenic mice expressing an altered form of mouse CD3delta and CD3gamma were employed to show that the surface TCR complexes contain one molecule each of CD3delta and CD3gamma. Thymocytes from wild type and CD3 chain transgenic mice on the appropriate knockout background were surface-biotinylated and immunoprecipitated using a specific antibody. The immunoprecipitates were resolved in two dimensions under nonreducing/reducing conditions to determine the stoichiometry of CD3delta and CD3gamma in the surface antigen receptor complex. Our data clearly show the presence of one molecule each of CD3delta and CD3gamma in the surface TCR/CD3 complex.	Inst Rech Clin Montreal, Lymphocyte Dev Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Dave, VP (corresponding author), Inst Rech Clin Montreal, Lymphocyte Dev Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	vibhuti.dave@ircm.qc.ca						BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Call ME, 2004, EMBO J, V23, P2348, DOI 10.1038/sj.emboj.7600245; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; Davis MM, 2002, CELL, V110, P285, DOI 10.1016/S0092-8674(02)00865-6; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; Doucey MA, 2003, J BIOL CHEM, V278, P3257, DOI 10.1074/jbc.M208119200; EXLEY M, 1995, MOL IMMUNOL, V32, P829, DOI 10.1016/0161-5890(95)00046-H; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Gil D, 2002, CELL, V109, P901, DOI 10.1016/S0092-8674(02)00799-7; Haks MC, 1998, EMBO J, V17, P1871, DOI 10.1093/emboj/17.7.1871; Hayes SM, 2002, J EXP MED, V196, P1355, DOI 10.1084/jem.20021196; Jacobs H, 1997, IMMUNOL TODAY, V18, P565; Jose ES, 1998, EUR J IMMUNOL, V28, P12; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10619, DOI 10.1073/pnas.88.23.10619; KEARSE KP, 1995, IMMUNITY, V2, P391; Malissen B, 1999, ADV IMMUNOL, V72, P103, DOI 10.1016/S0065-2776(08)60018-8; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; PUNT JA, 1994, J EXP MED, V180, P587, DOI 10.1084/jem.180.2.587; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SUZUKI S, 1992, EUR J IMMUNOL, V22, P2475, DOI 10.1002/eji.1830221002; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; THIBAULT G, 1995, J IMMUNOL, V154, P3814; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	31	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51068	51074		10.1074/jbc.M406145200	http://dx.doi.org/10.1074/jbc.M406145200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15459203	hybrid			2022-12-25	WOS:000225355800052
J	Gratschev, D; Blom, T; Bjorklund, S; Tornquist, K				Gratschev, D; Blom, T; Bjorklund, S; Tornquist, K			Phosphatase inhibition reveals a calcium entry pathway dependent on protein kinase A in thyroid FRTL-5 cells - Comparison with store-operated calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IODIDE EFFLUX; CA2+ CHANNELS; PHOSPHOLIPASE-C; MOLECULAR-BASIS; TRPC3 CHANNELS; ACTIVATION; RECEPTOR; CA-2; OSCILLATIONS; STIMULATION	Calcium entry through store-operated calcium channels is an important entry mechanism. In the present report we have described a novel calcium entry pathway that is independent of depletion of intracellular calcium stores. Treatment of the cells with the phosphatase inhibitor calyculin A (caly A), which blocked thapsigargin-evoked store-operated calcium entry (SOCE), induced a potent concentration-dependent calcium entry. In a calcium-free buffer, acute addition of caly A evoked a very modest increase in cytosolic free calcium ([Ca2+](i)). This increase was not from the agonist-mobilizable calcium stores, as the thapsigargin-evoked increase in [Ca2+](i) was unaltered in caly A-treated cells. The caly A-evoked calcium entry was not blocked by Gd3+ or 2-APB, whereas SOCE was. Caly A enhanced the entry of barium, indicating that the increase in intracellular calcium was not the result of a decreased extrusion of calcium from the cytosol. Jasplakinolide and cytochalasin D had only marginal effects on calcium entry. The protein kinase A (PKA) inhibitor H-89 and an inhibitory peptide for PKA abolished the caly A-evoked entry of both calcium and barium. The SOCE was, however, enhanced in cells treated with H-89. In cells grown in the absence of thyrotropin (TSH), the caly A-evoked entry of calcium was smaller compared with cells grown in TSH-containing buffer. Stimulation of cells grown without TSH with forskolin or TSH restored the calyculin A-evoked calcium entry to that seen in cells grown in TSH-containing buffer. SOCE was decreased in these cells. Our results thus suggest that TSH, through the production of cAMP and activation of PKA, regulates a calcium entry pathway in thyroid cells. The pathway is distinctly different from the SOCE. As TSH is the main regulator of thyroid cells, we suggest that the novel calcium entry pathway participates in the regulation of basal calcium levels in thyroid cells.	Abo Akad Univ, BioCity, Dept Biol, Turku 20520, Finland; Turku Grad Sch Biomed Sci, Turku 20520, Finland; Biomedicum Heslinki, Minerva Fdn, Inst Med Res, Helsinki 00250, Finland	Abo Akademi University; University of Turku; University of Helsinki	Tornquist, K (corresponding author), Abo Akad Univ, BioCity, Dept Biol, Artillerigatan 6, Turku 20520, Finland.	kid.tornqvist@abo.fi						Albert AP, 2002, J PHYSIOL-LONDON, V544, P113, DOI 10.1113/jphysiol.2002.022574; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BERMAN MI, 1987, MOL CELL ENDOCRINOL, V54, P151, DOI 10.1016/0303-7207(87)90152-3; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; CORDA D, 1985, J BIOL CHEM, V260, P9230; Ekokoski E, 2001, J CELL PHYSIOL, V187, P166, DOI 10.1002/jcp.1070; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Laglia G, 1996, ENDOCRINOLOGY, V137, P3170, DOI 10.1210/en.137.8.3170; Lalevee N, 2003, ENDOCRINOLOGY, V144, P4575, DOI 10.1210/en.2003-0268; Larsson O, 1997, SCIENCE, V278, P471, DOI 10.1126/science.278.5337.471; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma R, 2001, J BIOL CHEM, V276, P25759, DOI 10.1074/jbc.M011241200; Mignen O, 2003, J BIOL CHEM, V278, P40088, DOI 10.1074/jbc.M306365200; Mignen O, 2003, J BIOL CHEM, V278, P10174, DOI 10.1074/jbc.M212536200; MONTERO M, 1994, J BIOL CHEM, V269, P3963; NORSTEDT C, 1990, ANAL BIOCHEM, V189, P231; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 2001, J CELL SCI, V114, P2223; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; Rosado JA, 2001, J BIOL CHEM, V276, P15666, DOI 10.1074/jbc.M009217200; ROSADO JA, 2000, J BIOL CHEM, V275; Schuhmann K, 1997, J GEN PHYSIOL, V110, P503, DOI 10.1085/jgp.110.5.503; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Shuttleworth TJ, 2003, BIOCHEM SOC T, V31, P916; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; TORNQUIST K, 1993, BIOCHEM J, V290, P443; Tornquist K, 1996, J CELL PHYSIOL, V166, P241; TORNQUIST K, 1992, J CELL PHYSIOL, V150, P90, DOI 10.1002/jcp.1041500113; TORNQUIST K, 1994, CELL CALCIUM, V15, P153, DOI 10.1016/0143-4160(94)90054-X; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108	40	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49816	49824		10.1074/jbc.M406364200	http://dx.doi.org/10.1074/jbc.M406364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15381705	hybrid			2022-12-25	WOS:000225229500034
J	Kim, JH; Stallcup, MR				Kim, JH; Stallcup, MR			Role of the coiled-coil coactivator (CoCoA) in aryl hydrocarbon receptor-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATOR PROTEIN; ESTROGEN-RECEPTOR; AH RECEPTOR; GENE-EXPRESSION; CYTOCHROME P4501A1; ACTIVATION DOMAIN; CORE COMPLEX; CROSS-TALK; CELL-CYCLE; IN-VIVO	The aryl hydrocarbon receptor (AHR) and AHR nuclear translocator (ARNT) are DNA binding transcription factors with basic helix-loop-helix/Per-Arnt-Sim (bHLH-PAS) domains. These two proteins form a heterodimer that mediates the toxic and biological effects of the environmental contaminant and AHR ligand 2,3,7,8-tetrachlorodibenzo-pdioxin. The coiled-coil protein coiled-coil coactivator (CoCoA) is a secondary coactivator for nuclear receptors and enhances nuclear receptor function by interacting with the bHLH-PAS domain of p160 coactivators. We report here that CoCoA also binds the bHLH-PAS domains of AHR and ARNT and functions as a potent primary coactivator for them; i.e. CoCoA does not require p160 coactivators for binding to and serving as a coactivator for AHR and ARNT. Endogenous CoCoA was recruited to a natural AHR target gene promoter in a 2,3,7,8- tetrachlorodibenzo-p-dioxin-dependent manner. Moreover, reduction of CoCoA mRNA levels by small interfering RNA inhibited the transcriptional activation by AHR and ARNT. Our data support a physiological role for CoCoA as a transcriptional coactivator in AHR/ARNT-mediated transcription.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.	stallcup@usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43093] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLBORG UG, 1995, CRIT REV TOXICOL, V25, P463, DOI 10.3109/10408449509017924; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Brunnberg S, 2003, P NATL ACAD SCI USA, V100, P6517, DOI 10.1073/pnas.1136688100; Corton JC, 1996, TOXICOL APPL PHARM, V139, P272, DOI 10.1006/taap.1996.0166; Denison MS, 2002, CHEM-BIOL INTERACT, V141, P3, DOI 10.1016/S0009-2797(02)00063-7; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; Huffman JL, 2001, J BIOL CHEM, V276, P40537, DOI 10.1074/jbc.M105675200; Jones LC, 2002, J BIOL CHEM, V277, P22515, DOI 10.1074/jbc.M200740200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kharat I, 1996, J BIOL CHEM, V271, P10533, DOI 10.1074/jbc.271.18.10533; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Porter W, 2001, J MOL ENDOCRINOL, V26, P31, DOI 10.1677/jme.0.0260031; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; Rowlands JC, 1996, MOL PHARMACOL, V50, P538; Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Wormke M, 2003, MOL CELL BIOL, V23, P1843, DOI 10.1128/MCB.23.6.1843-1855.2003; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116	36	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49842	49848		10.1074/jbc.M408535200	http://dx.doi.org/10.1074/jbc.M408535200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15383530	hybrid			2022-12-25	WOS:000225229500037
J	Pop, SM; Kolarik, RJ; Ragsdale, SW				Pop, SM; Kolarik, RJ; Ragsdale, SW			Regulation of anaerobic dehalorespiration by the transcriptional activator CprK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE SULFINIC ACID; COLI FNR PROTEIN; DESULFITOBACTERIUM-DEHALOGENANS; ESCHERICHIA-COLI; REDUCTIVE DEHALOGENATION; REDOX REGULATION; MICROBIAL DEHALOGENATION; THIOREDOXIN REDUCTASE; TETRACHLOROETHENE; PEROXIREDOXINS	Desulfomonile, Desulfitobacterium, and Dehalobacter are anaerobic microbes that can derive energy from the reductive dehalogenation of chlorinated organic compounds, many of which are environmental pollutants. There is very little information about how anaerobic dehalorespiration is regulated. An open reading frame within the Desulfitobacterium dehalogenans chlorophenol reductase (cpr) gene cluster (cprK) was proposed to be a transcriptional regulatory protein (Smidt, H., van Leest, M., van der Oost, J., and deVos, W. M. (2000) J. Bacteriol. 182, 5683-5691). We have cloned, actively overexpressed in Escherichia coli, and purified to homogeneity the D. dehalogenans CprK. The results of electrophoretic mobility shift assays, DNA footprinting studies, and promoter-lac fusion experiments indicate that CprK is a transcriptional activator of the cpr gene cluster. CprK binds 3-chloro-4-hydroxyphenylacetate (CHPA) with high affinity (K-d=3.5 muM, determined by isothermal titration calorimetry), which promotes its specific interaction with a DNA sequence (TTAAT-N4-ACTAA) located upstream of the -35 and -10 promoter regions of several cpr genes and activates transcription of these genes. Binding to the upstream "box" sequence increases the affinity of CprK for CHPA by similar to10-fold (K-d=0.4 muM, determined by electrophoretic mobility shift assays). Chlorophenylacetate, which lacks the ortho-hydroxy group, and hydroxyphenylacetate, lacking the chlorine group, do not activate transcription or promote DNA binding, even at millimolar concentrations, at least 1000-fold higher than the K-d value for CHPA. Lacking metals, CprK is oxygen-sensitive. Oxidation by diamide, which converts thiols to the disulfide, inactivates CprK, and reduction of the oxidized protein by dithiothreitol fully restores DNA binding, indicating that CprK is redox-regulated and is active only when reduced. This is the first reported characterization of a transcriptional regulator of anaerobic dehalorespiration.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Ragsdale, SW (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA.	sragsdale1@unl.edu			NCRR NIH HHS [1P20RR17675] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Copley SD, 1998, CURR OPIN CHEM BIOL, V2, P613, DOI 10.1016/S1367-5931(98)80092-6; Copley SD, 1997, CHEM BIOL, V4, P169, DOI 10.1016/S1074-5521(97)90285-4; El Fantroussi S, 1998, BIOTECHNOL PROGR, V14, P167, DOI 10.1021/bp980011k; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; Georgiou G, 2002, CELL, V111, P607, DOI 10.1016/S0092-8674(02)01165-0; GREEN J, 1993, MOL MICROBIOL, V8, P61, DOI 10.1111/j.1365-2958.1993.tb01203.x; Green J, 2001, ADV MICROB PHYSIOL, V44, P1, DOI 10.1016/S0065-2911(01)44010-0; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Holliger C, 1998, ARCH MICROBIOL, V169, P313, DOI 10.1007/s002030050577; Janssen DB, 2001, CURR OPIN BIOTECH, V12, P254, DOI 10.1016/S0958-1669(00)00208-1; JONES JB, 1977, COMMUN SOIL SCI PLAN, V8, P349, DOI 10.1080/00103627709366727; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Krasotkina J, 2001, J BIOL CHEM, V276, P40991, DOI 10.1074/jbc.M106217200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee DJ, 2000, MOL MICROBIOL, V37, P1032, DOI 10.1046/j.1365-2958.2000.02086.x; Li B, 1998, NUCLEIC ACIDS RES, V26, P2075, DOI 10.1093/nar/26.9.2075; LI SF, 1988, J BIOL CHEM, V263, P13700; Lucana DOD, 2003, MOL GENET GENOMICS, V268, P618, DOI 10.1007/s00438-002-0776-0; MaymoGatell X, 1997, SCIENCE, V276, P1568, DOI 10.1126/science.276.5318.1568; Miller JH., 1972, EXPT MOL GENETICS; MOHN WW, 1992, MICROBIOL REV, V56, P482, DOI 10.1128/MMBR.56.3.482-507.1992; Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200; Rabinowitz J, 1972, Methods Enzymol, V24, P431; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Smidt H, 2000, J BACTERIOL, V182, P5683, DOI 10.1128/JB.182.20.5683-5691.2000; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; Staples CR, 1998, BIOCHEMISTRY-US, V37, P4612, DOI 10.1021/bi9729763; UTKIN I, 1995, APPL ENVIRON MICROB, V61, P346, DOI 10.1128/AEM.61.1.346-351.1995; van de Pas BA, 2001, ARCH MICROBIOL, V176, P165, DOI 10.1007/s002030100316; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; Villemur R, 2002, CAN J MICROBIOL, V48, P697, DOI 10.1139/w02-057; Vitvitsky V, 2003, REDOX REP, V8, P57, DOI 10.1179/135100003125001260; Wiegel J, 1999, APPL ENVIRON MICROB, V65, P2217; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; YE DY, 1992, APPL ENVIRON MICROB, V58, P1110, DOI 10.1128/AEM.58.4.1110-1114.1992; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	40	37	39	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49910	49918		10.1074/jbc.M409435200	http://dx.doi.org/10.1074/jbc.M409435200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15381694	hybrid			2022-12-25	WOS:000225229500046
J	Kayed, R; Sokolov, Y; Edmonds, B; McIntire, TM; Milton, SC; Hall, JE; Glabe, CG				Kayed, R; Sokolov, Y; Edmonds, B; McIntire, TM; Milton, SC; Hall, JE; Glabe, CG			Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; MEMBRANES; CHANNELS; AGGREGATION; MECHANISM; TOXICITY; PEPTIDE; IMPLIES	Amyloid fibrillization is multistep process involving soluble oligomeric intermediates, including spherical oligomers and protofibrils. Amyloid oligomers have a common, generic structure, and they are intrinsically toxic to cells, even when formed from non-disease related proteins, which implies they also share a common mechanism of pathogenesis and toxicity. Here we report that soluble oligomers from several types of amyloids specifically increase lipid bilayer conductance regardless of the sequence, while fibrils and soluble low molecular weight species have no effect. The increase in membrane conductance occurs without any evidence of discrete channel or pore formation or ion selectivity. The conductance is dependent on the concentration of oligomers and can be reversed by anti-oligomer antibody. These results indicate that soluble oligomers from many types of amyloidogenic proteins and peptides increase membrane conductance in a conformation-specific fashion and suggest that this may represent the common primary mechanism of pathogenesis in amyloid-related degenerative diseases.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	cglabe@uci.edu	Hall, James E/K-6306-2012		NATIONAL INSTITUTE ON AGING [P50AG016573] Funding Source: NIH RePORTER; NIA NIH HHS [AG16573, AG00538] Funding Source: Medline; NINDS NIH HHS [NS31230] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; Bodles AM, 2000, EUR J BIOCHEM, V267, P2186, DOI 10.1046/j.1432-1327.2000.01219.x; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; EHRING GR, 1992, J MEMBRANE BIOL, V126, P75; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; Kagan BL, 2002, PEPTIDES, V23, P1311, DOI 10.1016/S0196-9781(02)00067-0; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Mason RP, 1999, J BIOL CHEM, V274, P18801, DOI 10.1074/jbc.274.26.18801; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; Sokolov Y, 2000, J GEN PHYSIOL, V115, P571, DOI 10.1085/jgp.115.5.571	18	735	759	0	84	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46363	46366		10.1074/jbc.C400260200	http://dx.doi.org/10.1074/jbc.C400260200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15385542	hybrid			2022-12-25	WOS:000224832400004
J	Lynch, RG				Lynch, RG			Surfactant and RDS in premature infants	FASEB JOURNAL			English	Editorial Material																		AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; CLEMENTS JA, 1956, AM J PHYSIOL, V187, P592; GRUENWALD P, 1956, Bull N Y Acad Med, V32, P689; PATTLE RE, 1955, NATURE, V175, P1125, DOI 10.1038/1751125b0	4	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2004	18	13					1624	1624		10.1096/fasebj.18.13.1624	http://dx.doi.org/10.1096/fasebj.18.13.1624			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	867NS	15466362				2022-12-25	WOS:000224849900037
